pair_id,para_id,sent_id,complex,label,simple,simp_sent_id,doc_pos,doc_quint,doc_len
CD012936,0,0,Three studies (146 participants) met our selection criteria.,rephrase,['Three studies involving 146 participants were included in this review.'],0,0.09090909090909091,1,11
CD012936,0,1,"Two studies compared multidisciplinary, fast-track palliative care versus multidisciplinary standard care while on a waiting-list control, and one study compared a multidisciplinary palliative approach versus multidisciplinary standard care at different time points (12, 16, and 24 weeks).",delete,[],1,0.18181818181818182,1,11
CD012936,0,2,Two were RCTs with parallel design (total 94 participants) and one was a cross-over design (52 participants).,delete,[],1,0.2727272727272727,2,11
CD012936,0,3,The three studies assessed palliative care as a home-based intervention.,split,"['All three studies compared palliative care delivered in home visits versus usual care for people with MS. Two studies included only participants with MS.', 'In all three studies, interventions focused on assessment and management of symptoms and end-of-life planning.']",1,0.36363636363636365,2,11
CD012936,0,4,"One of the three studies included participants with 'neurodegenerative diseases', with MS people being a subset of the randomised population.",rephrase,['The third study (Ne-PAL) included participants with MS and other neurodegenerative diseases.'],3,0.45454545454545453,3,11
CD012936,0,5,We assessed the risk of bias of included studies using Cochrane's 'Risk of Bias' tool.,delete,[],4,0.5454545454545454,3,11
CD012936,1,6,"We found no evidence of differences between intervention and control groups in long-time follow-up (> six months post-intervention) for the following outcomes: mean change in health-related quality of life (SEIQoL - higher scores mean better quality of life; MD 4.80, 95% CI -12.32 to 21.92; participants = 62; studies = 1; very low-certainty evidence), serious adverse events (RR 0.97, 95% CI 0.44 to 2.12; participants = 76; studies = 1, 22 events, low-certainty evidence) and hospital admission (RR 0.78, 95% CI 0.24 to 2.52; participants = 76; studies = 1, 10 events, low-certainty evidence).",delete,[],4,0.6363636363636364,4,11
CD012936,2,7,"The three included studies did not assess the following outcomes at long term follow-up (> six months post intervention): fatigue, anxiety, depression, disability, cognitive function, relapse-free survival, and sustained progression-free survival.",rephrase,"['The included studies did not assess fatigue, cognitive function, relapse-free survival or sustained progression-free survival.']",4,0.7272727272727273,4,11
CD012936,3,8,We did not find any trial that compared different types of palliative care with each other.,ignore,['We did not find studies that compared different types of palliative care with each other.'],5,0.8181818181818182,5,11
CD012936,4,9,"Based on the findings of the RCTs included in this review, we are uncertain whether palliative care interventions are beneficial for people with MS.",rephrase,['We are uncertain whether palliative care interventions are beneficial for people with MS.'],6,0.9090909090909091,5,11
CD012936,4,10,"There is low- or very low-certainty evidence regarding the difference between palliative care interventions versus usual care for long-term health-related quality of life, adverse events, and hospital admission in patients with MS. For intermediate-term follow-up, we are also uncertain about the effects of palliative care for the outcomes: health-related quality of life (measured by different assessments: SEIQoL or MSIS), disability, anxiety, and depression.",rephrase,"['There is low- or very low-certainty evidence regarding the difference between palliative care interventions versus usual care for long-term health-related quality of life, adverse events and hospital admission.']",7,1.0,5,11
CD009102,0,0,"We included five trials, in which 1406 infants participated.",rephrase,['We found five studies that involved 1406 babies whose breathing was supported with a nasal interface compared to a face mask in the delivery room.'],0,0.07692307692307693,1,13
CD009102,0,1,They were conducted in 13 neonatal centres across Europe and Australia.,rephrase,['The studies were conducted in high-income countries across Europe and Australia; the largest study included 617 babies and the smallest included 36 babies.'],1,0.15384615384615385,1,13
CD009102,0,2,Each of these trials compared a nasal interface to a face mask for the delivery of respiratory support to newborn infants in the DR.,rephrase,"['We wanted to find out if giving breathing support to babies through their nose (using a nasal prong, a tube that fits into one or both nostrils, or a nasal mask, a mask placed over the nose) would result in less death, intubations, and complications after birth, compared with a face mask or a laryngeal mask airway; or if one type of nasal interface was better than another for the same results.']",2,0.23076923076923078,2,13
CD009102,0,3,Potential sources of bias were a lack of blinding to treatment allocation of the caregivers and investigators in all trials.,delete,[],3,0.3076923076923077,2,13
CD009102,1,4,"The evidence suggests that resuscitation with a nasal interface in the DR, compared with a face mask, may have little to no effect on reducing death before discharge (typical risk ratio (RR) 0.72, 95% CI 0.47 to 1.13; 3 studies, 1124 infants; low-certainty evidence).",rephrase,"['We found that giving breathing support with a nasal interface in the delivery room may have little to no effect on the rate of death before discharge, compared to a face mask.']",3,0.38461538461538464,2,13
CD009102,2,5,"Resuscitation with a nasal interface may reduce the rate of intubation in the DR, but the evidence is very uncertain (RR 0.68, 95% CI 0.54 to 0.85; 5 studies, 1406 infants; very low-certainty evidence).",rephrase,"['It may reduce the number of newborn babies who are intubated in the delivery room, but the evidence is very uncertain.']",4,0.46153846153846156,3,13
CD009102,2,6,"The evidence is very uncertain for the rate of intubation within 24 hours of birth (RR 0.97, 95% CI 0.85 to 1.09; 3 studies, 749 infants; very low-certainty evidence), endotracheal intubation outside the DR during hospitalisation (RR 1.15, 95% CI 0.93 to 1.42; 1 study, 144 infants; very low-certainty evidence) and cranial ultrasound abnormalities (intraventricular haemorrhage (IVH) grade ≥ 3, or periventricular leukomalacia; RR 0.94, 95% CI 0.55 to 1.61; 3 studies, 749 infants; very low-certainty evidence).",rephrase,"['The evidence is very uncertain about the effect of giving breathing support with a nasal interface on the rate of intubation within 24 hours of birth; the rate of intubation during hospitalisation, once they leave the delivery room; or bleeding inside the brain.']",5,0.5384615384615384,3,13
CD009102,2,7,"Resuscitation with a nasal interface in the DR, compared with a face mask, may have little to no effect on the incidence of air leaks (RR 1.09, 95% CI 0.85 to 1.09; 2 studies, 507 infants; low-certainty evidence), or the need for supplemental oxygen at 36 weeks' corrected gestational age (RR 1.06, 95% CI 0.8 to 1.40; 2 studies, 507 infants; low-certainty evidence).",rephrase,"['Using a nasal interface may have little to no effect on the rate of lung complications (e.g. chronic lung disease, or air leaks).']",6,0.6153846153846154,4,13
CD009102,3,8,"We identified one ongoing study, which compares a nasal mask to a face mask to deliver PPV to infants in the DR. We did not identify any completed trials that compared nasal interfaces to LMAs or one nasal interface to another.",rephrase,['We found one ongoing study comparing a nasal mask to a face mask to give breathing support to babies in the delivery room.'],7,0.6923076923076923,4,13
CD009102,4,9,"Nasal interfaces were found to offer comparable efficacy to face masks (low- to very low-certainty evidence), supporting resuscitation guidelines that state that nasal interfaces are a comparable alternative to face masks for providing respiratory support in the DR.
Resuscitation with a nasal interface may reduce the rate of intubation in the DR when compared with a face mask.",delete,[],8,0.7692307692307693,4,13
CD009102,4,10,"However, the evidence is very uncertain.",rephrase,"['As a result, we have little confidence in the evidence and the results of this outcome should be interpreted with caution.']",8,0.8461538461538461,5,13
CD009102,4,11,This uncertainty is attributed to the use of a new ventilation system in the nasal interface group in two of the five trials.,rephrase,['It is not clear if the effect on intubation rates in the delivery room is due to the nasal interface or a new breathing system that was used in two of the five studies included in our analysis.'],9,0.9230769230769231,5,13
CD009102,4,12,"As such, it is not possible to differentiate separate, specific effects related to the ventilation device or to the interface in these studies.",delete,[],10,1.0,5,13
CD011922,0,0,We included one randomized controlled trial (RCT) on pharmacological interventions; the trial included 95 participants.,rephrase,['We included and analyzed one randomized controlled trial (a clinical study where people are randomly put into one or two (or more) treatment groups) with 95 participants.'],0,0.1111111111111111,1,9
CD011922,0,1,No studies were found for non-pharmacological interventions.,delete,[],1,0.2222222222222222,2,9
CD011922,0,2,"Concerning the proportion of participants with seizure freedom, no significant differences were found for the comparisons of levetiracetam versus lamotrigine (RR) 1.20, 95% CI 0.53 to 2.71; 67 participants; very low-certainty evidence), levetiracetam versus phenobarbital (RR 1.01, 95% CI 0.47 to 2.19; 66 participants; very low-certainty evidence), or lamotrigine versus phenobarbital (RR 0.84, 95% CI 0.35 to 2.02; 57 participants; very low-certainty evidence).",rephrase,"['Concerning the proportion of participants with freedom from seizures, no significant differences were found between the antiepileptic drugs (levetiracetam versus lamotrigine, levetiracetam versus phenobarbital, and lamotrigine versus phenobarbital).']",1,0.3333333333333333,2,9
CD011922,0,3,"It seemed that levetiracetam could improve cognition and lamotrigine could relieve depression, while phenobarbital and lamotrigine could worsen cognition, and levetiracetam and phenobarbital could worsen mood.",ignore,"['It seemed that levetiracetam could improve cognition (thinking) and lamotrigine could relieve depression, while phenobarbital and lamotrigine could worsen cognition, and levetiracetam and phenobarbital could worsen mood.']",2,0.4444444444444444,3,9
CD011922,0,4,"The risk of bias relating to allocation, blinding and selective reporting was unclear.",delete,[],3,0.5555555555555556,3,9
CD011922,0,5,We judged the certainty of the evidence for all outcomes to be very low.,split,"['The certainty of the evidence for all the outcomes from the study were very low.', 'This means that we are very uncertain about the results and they should be interpreted with caution.']",3,0.6666666666666666,4,9
CD011922,1,6,"This review does not provide sufficient evidence to support levetiracetam, phenobarbital or lamotrigine for the treatment of epilepsy in people with Alzheimer's disease.",delete,[],5,0.7777777777777778,4,9
CD011922,1,7,"Regarding efficacy and tolerability, no significant differences were found between levetiracetam, phenobarbital and lamotrigine.",delete,[],5,0.8888888888888888,5,9
CD011922,2,8,"Large RCTs with a double-blind, parallel-group design are required to determine the efficacy and tolerability of treatment for epilepsy in people with Alzheimer's disease.",rephrase,"[""Large randomized controlled trials are required to determine how effective and well tolerated treatments are for epilepsy in people with Alzheimer's disease.""]",5,1.0,5,9
CD012318,0,0,"We identified 31 studies (44 reports) including 27,071 participants and two ongoing studies.",split,"['Our search yielded 31 eligible studies comparing the transradial approach to the transfemoral approach in people undergoing diagnostic or therapeutic (or both) coronary catheterisation procedures in different settings, whether urgent (during heart attacks (myocardial infarctions)) or elective (planned procedure).', 'We also identified two ongoing studies.']",0,0.14285714285714285,1,7
CD012318,0,1,The risk of bias in the studies was low or unclear for several domains.,delete,[],2,0.2857142857142857,2,7
CD012318,0,2,"Compared to the transfemoral approach, the transradial approach reduced short-term net adverse clinical events (NACE) (i.e. assessed during hospitalisation and up to 30 days of follow-up) (RR 0.76, 95% CI 0.61 to 0.94; 17,133 participants; 4 studies; moderate quality evidence), cardiac death (RR 0.69, 95% CI 0.54 to 0.88; 11,170 participants; 11 studies; moderate quality evidence).",rephrase,"['We rated short-term NACE, cardiac death, and success of the procedure as moderate quality evidence.']",2,0.42857142857142855,3,7
CD012318,0,3,"However, short-term myocardial infarction was similar between both groups (RR 0.91, 95% CI 0.81 to 1.02; 19,430 participants; 11 studies; high quality evidence).",rephrase,"['When assessing individual outcomes, the risk of myocardial infarction and stroke was similar between groups.']",3,0.5714285714285714,3,7
CD012318,0,4,"The transradial approach had a lower procedural success rate (RR 0.97, 95% CI 0.96 to 0.98; 25,920 participants; 28 studies; moderate quality evidence), but was associated with a lower risk of all-cause mortality (RR 0.77, 95% CI 0.62 to 0.95; 18,955 participants; 10 studies; high quality evidence), bleeding (RR 0.54, 95% CI 0.40 to 0.74; 23,043 participants; 20 studies; low quality evidence), and access site complications (RR 0.36, 95% CI 0.22 to 0.59; 16,112 participants; 24 studies; low quality evidence).",delete,[],4,0.7142857142857143,4,7
CD012318,1,5,"Transradial approach for diagnostic CA or PCI (or both) in CAD may reduce short-term NACE, cardiac death, all-cause mortality, bleeding, and access site complications.",rephrase,"['Transradial access reduced death from cardiac causes, death from all causes during the first 30 days following intervention, bleeding, and local complications at the access site.']",4,0.8571428571428571,5,7
CD012318,1,6,There is insufficient evidence regarding the long-term clinical outcomes (i.e. beyond 30 days of follow-up).,delete,[],5,1.0,5,7
CD010850,0,0,We included three studies (179 participants) comparing LESS-DN with laparoscopic donor nephrectomy.,rephrase,['We searched to literature up to January 2016 and found three studies (reported in 5 publications that involved 179 participants) that compared these two types of kidney donor surgeries.'],0,0.14285714285714285,1,7
CD010850,0,1,"There were no significant differences between LESS-DN and laparoscopic donor nephrectomy for mean operative time (2 studies, 79 participants: MD 6.36 min, 95% CI -11.85 to 24.57), intra-operative blood loss (2 studies, 79 participants: MD -8.31 mL, 95% CI -23.70 to 7.09), or complication rates (3 studies, 179 participants: RD 0.05, 95% CI -0.04 to 0.14).",delete,[],1,0.2857142857142857,2,7
CD010850,0,2,"Pain scores at discharge were significantly less in the LESS-DN group (2 studies, 79 participants: MD -1.19, 95% CI -2.17 to -0.21).",rephrase,"['LESS-DN was found to be as safe as standard keyhole surgical techniques; pain at discharge was significantly less with LESS-DN, however there were no other discernible benefits over the standard technique.']",1,0.42857142857142855,3,7
CD010850,0,3,For all other outcomes (length of hospital stay; length of time to return to normal activities; blood transfusions; conversion to another form of surgery; warm ischaemia time; total analgesic requirement; graft loss) there were no significant differences observed.,delete,[],2,0.5714285714285714,3,7
CD010850,1,4,"Although risk of bias was assessed as low overall, one study was assessed at high risk of attrition bias.",rephrase,"['Overall, we found there was a low risk of bias for all studies; however, funding sources were not reported in two or three studies, and there was high risk of attrition bias in one study.']",2,0.7142857142857143,4,7
CD010850,2,5,Given the small number and size of included studies it is uncertain whether LESS-DN is better than laparoscopic donor nephrectomy.,rephrase,['The small number of studies with few participants eligible for inclusion indicates a need for future research in this area.'],3,0.8571428571428571,5,7
CD010850,2,6,Well designed and adequately powered RCTs are needed to better define the role of LESS-DN as a minimally invasive option for kidney donor surgery.,delete,[],4,1.0,5,7
CD005129,0,0,Thirty seven studies (2185 participants) were included in this review.,rephrase,['Thirty seven studies (2185 participants) were identified.'],0,0.16666666666666666,1,6
CD005129,0,1,"There was no significant difference in the risk for CMV disease (16 studies, 770 patients: RR 0.80, 95% CI 0.61 to 1.05), CMV infection (14 studies, 775 patients: RR 0.94, 95% CI 0.80 to 1.10) or all-cause mortality (8 studies, 502 patients: RR 0.57, 95% CI 0.32 to 1.03) with IgG compared with placebo/no treatment.",rephrase,['This review shows that IgG did not reduce the risk of CMV disease or all-cause mortality compared with placebo or no treatment.'],1,0.3333333333333333,2,6
CD005129,0,2,"However IgG significantly reduced the risk of death from CMV disease (6 studies, 346 patients: RR 0.33, 95% CI 0.14 to 0.80).",rephrase,['The combination of IgG with antiviral medications (aciclovir or ganciclovir) were not more effective than antiviral medications alone in reducing the risk of CMV disease or all-cause mortality.'],2,0.5,3,6
CD005129,0,3,"There was no difference in the risk for CMV disease (4 studies, 298 patients: RR 1.17, 95% CI 0.74 to 1.86), CMV infection (4 studies, 298 patients: RR 1.16, 95% CI 0.89 to 1.52) or all-cause mortality (2 studies, 217 patients: RR 0.92, 95% CI 0.37 to 2.29) between antiviral medication combined with IgG and antiviral medication alone.",delete,[],3,0.6666666666666666,4,6
CD005129,0,4,There was no significant difference in the risk of CMV disease with anti CMV vaccine or interferon compared with placebo or no treatment.,split,"['This review looked at the benefits and harms of IgG, anti CMV vaccines and interferon to prevent CMV disease in solid organ transplant recipients.', 'Anti CMV vaccines and interferon did not reduce the risk of CMV disease compared with placebo or no treatment.']",3,0.8333333333333334,5,6
CD005129,1,5,Currently there are no indications for IgG in the prophylaxis of CMV disease in recipients of solid organ transplants.,ignore,['Currently there are no indications for IgG in the prevention of CMV disease in recipients of solid organ transplants.'],5,1.0,5,6
CD010472,0,0,"Eight studies met our inclusion criteria, of which seven were full-length journal articles and one was a conference abstract.",rephrase,['We found eight studies that met our inclusion criteria.'],0,0.05,1,20
CD010472,0,1,"The eight studies included 961 participants with glaucoma, and compared two types of devices implanted during trabeculectomy versus standard trabeculectomy.",rephrase,['These studies included 961 people with glaucoma and compared one of two types of device implanted during trabeculectomy versus standard trabeculectomy.'],1,0.1,1,20
CD010472,0,2,"Seven studies (462 eyes, 434 participants) used the Ex-PRESS, and one study (527 eyes, 527 participants) used the PreserFlo MicroShunt.",rephrase,"['Seven studies used the Ex-PRESS (434 participants), and one study used the PreserFlo MicroShunt (527 participants).']",2,0.15,1,20
CD010472,0,3,No studies using the XEN Gel Stent implantation met our criteria.,rephrase,['We found no studies using the XEN Gel Stent that met our criteria.'],3,0.2,1,20
CD010472,0,4,"The studies were conducted in North America, Europe, and Africa.",ignore,"['These studies were conducted in North America, Europe, and Africa.']",4,0.25,2,20
CD010472,0,5,Planned follow-up periods ranged from six months to five years.,ignore,['Planned follow-up periods ranged from six months to five years.'],5,0.3,2,20
CD010472,0,6,"The studies were reported poorly, which limited our ability to judge risk of bias for many domains.",delete,[],6,0.35,2,20
CD010472,0,7,None of the studies explicitly masked outcome assessment.,delete,[],6,0.4,2,20
CD010472,0,8,We rated seven studies at high risk of detection bias.,delete,[],6,0.45,3,20
CD010472,1,9,"Low-certainty of evidence from five studies showed that using the Ex-PRESS plus trabeculectomy compared with standard trabeculectomy may be associated with a slightly lower IOP at one year (mean difference (MD) −1.76 mmHg, 95% confidence interval (CI) −2.81 to −0.70; 213 eyes).",rephrase,['Five studies found that using the Ex-PRESS shunt during trabeculectomy may slightly reduce eye pressure by about 1.76 mmHg more than standard trabeculectomy.'],6,0.5,3,20
CD010472,1,10,"Moderate-certainty of evidence from one study showed that using the PreserFlo MicroShunt may be associated with a slightly higher IOP than standard trabeculectomy at one year (MD 3.20 mmHg, 95% CI 2.29 to 4.11).",rephrase,['Another study showed that using the PreserFlo MicroShunt may be associated with a slightly higher eye pressure by 3.20 mmHg than standard trabeculectomy.'],7,0.55,3,20
CD010472,1,11,"Participants who received standard trabeculectomy may have a higher risk of hypotony compared with those who received device-modified trabeculectomy, but the evidence is uncertain (RR 0.73, 95% CI 0.46 to 1.17; I² = 38%; P = 0.14).",delete,[],8,0.6,3,20
CD010472,1,12,"In the subgroup of participants who received the PreserFlo MicroShunt, there was a lower risk of developing hypotony or shallow anterior chamber compared with those receiving standard trabeculectomy (RR 0.44, 95% CI 0.25 to 0.79; 526 eyes).",delete,[],8,0.65,4,20
CD010472,1,13,"Device-modified trabeculectomy may lead to less subsequent cataract surgery within one year (RR 0.46, 95% CI 0.27 to 0.80; I² = 0%).",delete,[],8,0.7,4,20
CD010472,2,14,"Use of an Ex-PRESS plus trabeculectomy may produce greater IOP reduction at one-year follow-up than standard trabeculectomy; however, due to potential biases and imprecision in effect estimates, the certainty of evidence is low.",delete,[],8,0.75,4,20
CD010472,2,15,PreserFlo MicroShunt may be inferior to standard trabeculectomy in lowering IOP.,rephrase,['Use of PreserFlo MicroShunt reduces the risk of developing abnormally low eye pressure by about 50% compared with standard trabeculectomy.'],8,0.8,4,20
CD010472,2,16,"However, PreserFlo MicroShunt may prevent postoperative hypotony and bleb leakage.",delete,[],9,0.85,5,20
CD010472,2,17,"Overall, device-modified trabeculectomy appears associated with a lower risk of cataract surgery within five years compared with standard trabeculectomy.",rephrase,['Five studies found that the use of either device may lower the risk of subsequent cataract surgery (replacing a cloudy lens within the eye).'],9,0.9,5,20
CD010472,2,18,"Due to various limitations in the design and conduct of the included studies, the applicability of this evidence synthesis to other populations or settings is uncertain.",delete,[],10,0.95,5,20
CD010472,2,19,"Further research is needed to determine the effectiveness and safety of other devices in subgroup populations, such as people with different types of glaucoma, of various races and ethnicity, and with different lens types (e.g. phakic, pseudophakic).",delete,[],10,1.0,5,20
CD003216,0,0,We included 33 RCTs with 7920 participants.,rephrase,['We found 33 studies that involved 7920 people.'],0,0.045454545454545456,1,22
CD003216,0,1,Data for meta-analysis were available from 6993 participants.,delete,[],1,0.09090909090909091,1,22
CD003216,1,2,"Pressure ulcer prevention
Eleven studies (with 12 arms) compared six types of nutritional interventions for the prevention of pressure ulcers.",rephrase,['Eleven studies looked at the effects of nutritional interventions on preventing pressure ulcers and 24 studies evaluated nutritional interventions for treating pressure ulcers.'],1,0.13636363636363635,1,22
CD003216,2,3,"Compared to standard diet, energy, protein and micronutrient supplements may result in little to no difference in the proportion of participants developing a pressure ulcer (energy, protein and micronutrient supplements 248 per 1000, standard diet 269 per 1000; RR 0.92, 95% CI 0.71 to 1.19; 3 studies, 1634 participants; low-certainty evidence).",rephrase,"['• Energy, protein and micronutrient supplements may make little to no difference to the development of a pressure ulcer (3 studies, 1634 people).']",2,0.18181818181818182,1,22
CD003216,3,4,"Compared to standard diet, protein supplements may result in little to no difference in pressure ulcer incidence (protein 21 per 1000, standard diet 28 per 1000; RR 0.75, 95% CI 0.49 to 1.14; 4 studies, 4264 participants; low-certainty evidence).",rephrase,"['• A protein supplement may make little to no difference in pressure ulcer development (4 studies, 4264 people).']",3,0.22727272727272727,2,22
CD003216,3,5,"The evidence is very uncertain about the gastrointestinal side effects of these supplements (protein 109 per 1000, standard diet 155 per 1000; RR 0.70, 95% CI 0.06 to 7.96; 2 studies, 140 participants, very low-certainty evidence).",delete,[],4,0.2727272727272727,2,22
CD003216,4,6,"The evidence is very uncertain about the effects of protein, arginine, zinc and antioxidants; L-carnitine, L-leucine, calcium, magnesium and vitamin D; EPA, GLA and antioxidants; disease-specific supplements on pressure ulcer incidence when compared to standard diet (1 study each; very low-certainty evidence for all comparisons).",delete,[],4,0.3181818181818182,2,22
CD003216,5,7,"Pressure ulcer treatment
Twenty-four studies (with 27 arms) compared 10 types of nutritional interventions or supplements for treatment of pressure ulcers.",delete,[],4,0.36363636363636365,2,22
CD003216,6,8,"Compared to standard diet, energy, protein and micronutrient supplements may slightly increase the number of healed pressure ulcers (energy, protein and micronutrients 366 per 1000, standard diet 253 per 1000; RR 1.45, 95% CI 1.14 to 1.85; 3 studies, 577 participants, low-certainty evidence).",rephrase,"['• Energy, protein and micronutrient supplements may increase the number of people whose pressure ulcers healed, but we are very uncertain about this result (3 studies, 577 people).']",4,0.4090909090909091,3,22
CD003216,6,9,The evidence is very uncertain about the effect of these supplements on gastrointestinal side effects.,rephrase,['It is unclear if the protein supplement causes any unwanted effects.'],5,0.45454545454545453,3,22
CD003216,7,10,"Compared to standard diet, the evidence is very uncertain about the effect of protein, arginine, zinc and antioxidant supplements on pressure ulcer healing (pressure ulcer area: mean difference (MD) 2 cm² smaller, 95% CI 4.54 smaller to 0.53 larger; 2 studies, 71 participants, very low-certainty evidence).",rephrase,"['• Compared to a standard diet, we are uncertain whether protein, arginine, zinc and antioxidant supplements improve the healing of pressure ulcers, (2 studies, 71 people).']",6,0.5,3,22
CD003216,7,11,The evidence on side effects of these supplements is very uncertain.,rephrase,"['We do not know if protein, arginine, zinc and antioxidant supplements cause any unwanted effects.']",7,0.5454545454545454,3,22
CD003216,8,12,"Compared to standard diet, supplements with arginine and micronutrients may not increase the number of healed pressure ulcers, but the evidence suggests a slight reduction in pressure ulcer area (MD 15.8% lower, 95% CI 25.11 lower to 6.48 lower; 2 studies, 231 participants, low-certainty evidence).",rephrase,"['• Arginine and micronutrient supplements may not increase the number of pressure ulcers healed, but they may slightly increase pressure ulcer healing (2 studies, 231 people).']",8,0.5909090909090909,3,22
CD003216,8,13,"The evidence is very uncertain about changes in pressure ulcer scores, acceptability, and side effects of these supplements.",rephrase,['It is unclear if the intervention has an effect on acceptability and unwanted effects.'],9,0.6363636363636364,4,22
CD003216,9,14,"Compared to placebo, collagen supplements probably improve the mean change in pressure ulcer area (MD 1.81 cm² smaller, 95% CI 3.36 smaller to 0.26 smaller; 1 study, 74 participants, moderate-certainty evidence).",rephrase,"['• Collagen supplements probably increase pressure ulcer healing (1 study, 74 people).']",10,0.6818181818181818,4,22
CD003216,9,15,The evidence is very uncertain about the effect of these supplements on side effects.,rephrase,"['The intervention may increase unwanted effects, but we are very uncertain about this result.']",11,0.7272727272727273,4,22
CD003216,10,16,"The evidence is very uncertain about the effects of vitamin C, different doses of arginine; EPA, GLA (special dietary fatty acids) and antioxidants; protein; a specialized amino acid mixture; ornithine alpha-ketoglutarate and zinc supplements on pressure ulcer healing (1 or 2 studies each; very low-certainty evidence).",delete,[],12,0.7727272727272727,4,22
CD003216,11,17,The benefits of nutritional interventions with various compositions for pressure ulcer prevention and treatment are uncertain.,rephrase,['We wanted to know whether nutritional interventions help to prevent people developing pressure ulcers and to promote the healing of existing pressure ulcers.'],12,0.8181818181818182,5,22
CD003216,11,18,There may be little or no difference compared to standard nutrition or placebo.,rephrase,"['We searched for studies that investigated any form of nutritional intervention compared with a normal diet, placebo (dummy medicine) or another type of nutritional intervention.']",13,0.8636363636363636,5,22
CD003216,11,19,"Nutritional supplements may not increase gastrointestinal side effects, but the evidence is very uncertain.",delete,[],14,0.9090909090909091,5,22
CD003216,11,20,Larger studies with similar nutrient compositions would reduce these uncertainties.,delete,[],14,0.9545454545454546,5,22
CD003216,11,21,"No study investigated the effects of special diets (e.g. protein-enriched diet, vegetarian diet) on pressure ulcer incidence and healing.",delete,[],14,1.0,5,22
CD002213,0,0,"This update located nine new studies, which were added to the six studies from our last update in 2008.",merge,"['These studies were added to the six that we found the last time we updated the review, bringing the total to 15 studies.']",0,0.125,1,8
CD002213,0,1,"This review now includes 15 studies (eight RCTs, five CBA and two ITS studies).",none,[],0,0.25,2,8
CD002213,0,2,All of these studies measured the effectiveness of IPE interventions compared to no educational intervention.,split,"['All 15 studies compared outcomes following an IPE intervention to outcomes, either in similar clinical settings that did not receive the IPE intervention, or in the same clinical setting before the intervention was made.', 'Because no studies compared an interprofessional intervention to a profession-specific intervention, our understanding of interprofessional interventions is limited.', 'The small number of studies included in this review, and their varied nature, limit our understanding of the key components of IPE and its effectiveness.']",1,0.375,2,8
CD002213,0,3,"Seven studies indicated that IPE produced positive outcomes in the following areas: diabetes care, emergency department culture and patient satisfaction; collaborative team behaviour and reduction of clinical error rates for emergency department teams; collaborative team behaviour in operating rooms; management of care delivered in cases of domestic violence; and mental health practitioner competencies related to the delivery of patient care.",merge,[],4,0.5,3,8
CD002213,0,4,"In addition, four of the studies reported mixed outcomes (positive and neutral) and four studies reported that the IPE interventions had no impact on either professional practice or patient care.",none,"['Seven of these studies reported positive outcomes for healthcare processes or patient outcomes, or both, four studies reported mixed outcomes (positive and neutral) and four reported no effects of IPE.']",4,0.625,4,8
CD002213,1,5,This updated review reports on 15 studies that met the inclusion criteria (nine studies from this update and six studies from the 2008 update).,rephrase,['Nine studies met the inclusion criteria for the review.'],5,0.75,4,8
CD002213,1,6,"Although these studies reported some positive outcomes, due to the small number of studies and the heterogeneity of interventions and outcome measures, it is not possible to draw generalisable inferences about the key elements of IPE and its effectiveness.",delete,[],6,0.875,5,8
CD002213,1,7,"To improve the quality of evidence relating to IPE and patient outcomes or healthcare process outcomes, the following three gaps will need to be filled: first, studies that assess the effectiveness of IPE interventions compared to separate, profession-specific interventions; second, RCT, CBA or ITS studies with qualitative strands examining processes relating to the IPE and practice changes; third, cost-benefit analyses.",rephrase,"['In particular, these should include: first, studies that assess the effectiveness of IPE interventions compared to separate, profession-specific interventions; second, RCT, CBA or ITS studies with qualitative strands examining processes relating to the IPE and practice changes; third, cost-benefit analyses.']",6,1.0,5,8
CD012103,0,0,We included a total of 27 reviews in this overview.,split,"['We found a total of 27 Cochrane ART reviews of high quality that could be included for this overview.', 'We did not include reviews of intrauterine insemination and ovulation induction.']",0,0.045454545454545456,1,22
CD012103,0,1,"The reviews were generally of high quality according to AMSTAR ratings, and included studies provided evidence that ranged from very low to high in quality.",delete,[],2,0.09090909090909091,1,22
CD012103,0,2,Ten reviews had not been updated in the past three years.,rephrase,"['Of the 27 reviews included in this overview, 10 reviews had not been updated in the past three years.']",2,0.13636363636363635,1,22
CD012103,0,3,"Seven reviews described interventions that provided a beneficial effect in reducing OHSS rates, and we categorised one additional review as 'promising'.",ignore,"[""Seven reviews described interventions that provided a beneficial effect in reducing OHSS rates, and we categorised one additional review as 'promising'.""]",3,0.18181818181818182,1,22
CD012103,0,4,"Of the effective interventions, all except one had no detrimental effect on pregnancy outcomes.",ignore,"['Of the effective interventions, all except one had no detrimental effect on pregnancy outcomes.']",4,0.22727272727272727,2,22
CD012103,1,5,Evidence of at least moderate quality indicates that clinicians should consider the following interventions in ART cycles to reduce OHSS rates.,ignore,['Evidence of at least moderate quality evidence indicates that clinicians should consider the following interventions in ART cycles to reduce OHSS rates.'],5,0.2727272727272727,2,22
CD012103,2,6,• Metformin treatment before and during an ART cycle for women with PCOS (moderate-quality evidence).,ignore,['• Metformin treatment before and during an ART cycle in women with PCOS (moderate-quality evidence).'],6,0.3181818181818182,2,22
CD012103,3,7,• Gonadotrophin-releasing hormone (GnRH) antagonist protocol in ART cycles (moderate-quality evidence).,ignore,['• Gonadotrophin-releasing hormone (GnRH) antagonist protocol in ART cycles (moderate-quality evidence).'],7,0.36363636363636365,2,22
CD012103,4,8,• GnRH agonist (GnRHa) trigger in donor oocyte or 'freeze-all' programmes (moderate-quality evidence).,ignore,"[""• GnRH agonist (GnRHa) trigger in donor oocyte or 'freeze-all' programmes (moderate-quality evidence).""]",8,0.4090909090909091,3,22
CD012103,5,9,Evidence of low or very low quality suggests that clinicians should consider the following interventions in ART cycles to reduce OHSS rates.,ignore,['Evidence of low or very low quality evidence suggests that clinicians should consider the following interventions in ART cycles to reduce OHSS rates.'],9,0.45454545454545453,3,22
CD012103,6,10,• Clomiphene citrate for controlled ovarian stimulation in ART cycles (low-quality evidence).,ignore,['• Clomiphene citrate for controlled ovarian stimulation in ART cycles (low-quality evidence).'],10,0.5,3,22
CD012103,7,11,• Cabergoline around the time of human chorionic gonadotrophin (hCG) administration or oocyte pickup in ART cycles (low-quality evidence).,ignore,['• Cabergoline around the time of human chorionic gonadotrophin (hCG) administration or oocyte pickup in ART cycles (low-quality evidence).'],11,0.5454545454545454,3,22
CD012103,8,12,• Intravenous fluids (plasma expanders) around the time of hCG administration or oocyte pickup in ART cycles (very low-quality evidence).,ignore,['• Intravenous fluids (blood plasma expanders) around the time of hCG administration or egg pickup in ART cycles (very low-quality evidence).'],12,0.5909090909090909,3,22
CD012103,9,13,• Progesterone for luteal phase support in ART cycles (low-quality evidence).,ignore,['• Progesterone for luteal phase support in ART cycles (low-quality evidence).'],13,0.6363636363636364,4,22
CD012103,10,14,• Coasting (withholding gonadotrophins) - a promising intervention that needs to be researched further for reduction of OHSS.,rephrase,['A promising intervention that needs to be researched further is coasting (withholding gonadotrophins) for reduction of OHSS.'],14,0.6818181818181818,4,22
CD012103,11,15,"On the basis of this overview, we must conclude that evidence is currently insufficient to support the widespread practice of embryo cryopreservation.",rephrase,"['On the basis of this overview, we must conclude that evidence is currently insufficient to support the widespread practice of freezing all embryos and replacing them at a later time when OHSS has dissolved.']",15,0.7272727272727273,4,22
CD012103,12,16,"Currently, 27 reviews in the Cochrane Library were conducted to report on or to try to report on OHSS in ART cycles.",delete,[],16,0.7727272727272727,4,22
CD012103,12,17,We identified four review protocols but no new registered titles that can potentially be included in this overview in the future.,delete,[],16,0.8181818181818182,5,22
CD012103,12,18,This overview provides the most up-to-date evidence on prevention of OHSS in ART cycles from all currently published Cochrane reviews on ART.,merge,[],16,0.8636363636363636,5,22
CD012103,12,19,Clinicians can use the evidence summarised in this overview to choose the best treatment regimen for individual patients - a regimen that not only reduces the chance of developing OHSS but does not compromise other outcomes such as pregnancy or live birth rate.,none,['Clinicians can use the evidence summarised in this overview to choose the best treatment regimen for individual patients - a regimen that not only reduces the chance of developing OHSS but does not compromise pregnancy outcomes.'],16,0.9090909090909091,5,22
CD012103,12,20,"Review results, however, are limited by the lack of recent primary studies or updated reviews.",rephrase,"['However, results of this overview are limited by the lack of recent primary studies or updated reviews.']",17,0.9545454545454546,5,22
CD012103,12,21,"Furthermore, this overview can be used by policymakers in developing local and regional protocols or guidelines and can reveal knowledge gaps for future research.",ignore,"['Furthermore, this overview can be used by policymakers in developing local and regional protocols or guidelines and can reveal knowledge gaps for future research.']",18,1.0,5,22
CD003123,0,0,We included 19 studies (2256 participants).,rephrase,['Our systematic review found 19 studies involving 2256 children that use epinephrine for the treatment of bronchiolitis in acute care settings.'],0,0.09090909090909091,1,11
CD003123,0,1,Epinephrine versus placebo among outpatients showed a significant reduction in admissions at Day 1 (risk ratio (RR) 0.67; 95% confidence interval (CI) 0.50 to 0.89) but not at Day 7 post-emergency department visit.,delete,[],1,0.18181818181818182,1,11
CD003123,0,2,There was no difference in LOS for inpatients.,delete,[],1,0.2727272727272727,2,11
CD003123,0,3,Epinephrine versus salbutamol showed no differences among outpatients for admissions at Day 1 or 7.,delete,[],1,0.36363636363636365,2,11
CD003123,0,4,Inpatients receiving epinephrine had a significantly shorter LOS compared to salbutamol (mean difference -0.28; 95% CI -0.46 to -0.09).,delete,[],1,0.45454545454545453,3,11
CD003123,0,5,One large RCT showed a significantly shorter admission rate at Day 7 for epinephrine and steroid combined versus placebo (RR 0.65; 95% CI 0.44 to 0.95).,delete,[],1,0.5454545454545454,3,11
CD003123,0,6,There were no important differences in adverse events.,rephrase,['The evidence shows no important differences in adverse effects with epinephrine over the short-term with long-term safety not being assessed.'],1,0.6363636363636364,4,11
CD003123,1,7,"This review demonstrates the superiority of epinephrine compared to placebo for short-term outcomes for outpatients, particularly in the first 24 hours of care.",rephrase,"['When comparing epinephrine with placebo, no differences were found for length of hospital stay but there is some indication that epinephrine is effective for reducing hospital admissions.']",2,0.7272727272727273,4,11
CD003123,1,8,Exploratory evidence from a single study suggests benefits of epinephrine and steroid combined for later time points.,rephrase,"['Exploratory results from one large, high-quality trial suggest that combined treatment with systemic glucocorticoids (dexamethasone) and epinephrine may significantly reduce admissions.']",3,0.8181818181818182,5,11
CD003123,1,9,More research is required to confirm the benefits of combined epinephrine and steroids among outpatients.,rephrase,"['Further research is needed to confirm the efficacy, applicability and long-term safety of epinephrine as a treatment for bronchiolitis.']",4,0.9090909090909091,5,11
CD003123,1,10,There is no evidence of effectiveness for repeated dose or prolonged use of epinephrine or epinephrine and dexamethasone combined among inpatients.,split,"['In summary, our systematic review provides evidence that epinephrine is more effective than placebo for bronchiolitis in outpatients.', 'There is no evidence to support the use of epinephrine for inpatients.']",5,1.0,5,11
CD007492,0,0,We identified one new trial from the updated searches.,split,"['We searched for all relevant studies until 4 September 2015.', 'We found seven studies, six of which we identified previously and one retrieved for this update.']",0,0.058823529411764705,1,17
CD007492,1,1,Seven trials (347 participants) met the selection criteria.,delete,[],2,0.11764705882352941,1,17
CD007492,1,2,"The interventions varied but had common components: interventions that increased the intensity and frequency of service delivery (4 trials, 200 participants), community-based specialist behaviour therapy (1 trial, 63 participants), and outreach treatment (1 trial, 50 participants).",delete,[],2,0.17647058823529413,1,17
CD007492,1,3,"Another trial compared two active arms (traditional counselling and integrated intervention for bereavement, 34 participants).",delete,[],2,0.23529411764705882,2,17
CD007492,2,4,The included studies investigated interventions dealing with the mental health problems of persons with an intellectual disability; none focused on physical health problems.,split,"['All of the studies assessed the impact of the intervention on the mental health of persons with an intellectual disability; none considered the physical health.', 'Those studies used different interventions, including giving persons with an intellectual disability more health services, psychological support, and treating them at home, instead of at the hospital.']",2,0.29411764705882354,2,17
CD007492,2,5,"Four studies assessed the effect of organisational interventions on behavioural problems for persons with an intellectual disability, three assessed care giver burden, and three assessed the costs associated with the interventions.",rephrase,"['Studies mainly looked at how the interventions helped the behavioural problems of those with an intellectual disability, how much burden they caused the care givers, and how much they cost.']",4,0.35294117647058826,2,17
CD007492,2,6,None of the included studies reported data on the effect of organisational interventions on adverse events.,rephrase,['No study assessed adverse events.'],5,0.4117647058823529,3,17
CD007492,2,7,Most studies were assessed as having low risk of bias.,delete,[],6,0.47058823529411764,3,17
CD007492,3,8,"It is uncertain whether interventions that increase the frequency and intensity of delivery or outreach treatment decrease behavioural problems for persons with an intellectual disability (two and one trials respectively, very low certainty evidence).",delete,[],6,0.5294117647058824,3,17
CD007492,3,9,"Behavioural problems were slightly decreased by community-based specialist behavioural therapy (one trial, low certainty evidence).",rephrase,['Community-based behaviour therapy might decrease behavioural problems.'],6,0.5882352941176471,3,17
CD007492,3,10,"Increasing the frequency and intensity of service delivery probably makes little or no difference to care giver burden (MD 0.03, 95% CI -3.48 to 3.54, two trials, moderate certainty evidence).",delete,[],7,0.6470588235294118,4,17
CD007492,3,11,"It is uncertain whether outreach treatment makes any difference for care giver burden (one trial, very low certainty evidence).",rephrase,['We are uncertain whether other interventions make any difference in reducing behavioural problems.'],7,0.7058823529411765,4,17
CD007492,3,12,"There was very limited evidence regarding costs, with low to very low certainty evidence for the different interventions.",rephrase,"['There was limited evidence about how those interventions helped care givers to deal with the burden of caring for their relatives with an intellectual disability, or how much they might cost compared with the usual care already provided.']",8,0.7647058823529411,4,17
CD007492,4,13,There is very limited evidence on the organisation of healthcare services for persons with an intellectual disability.,rephrase,"[""uthors' conclusions\nThere is little information on different ways to organise services for people with intellectual disabilities.""]",9,0.8235294117647058,5,17
CD007492,4,14,There are currently no well-designed studies focusing on organising the health services of persons with an intellectual disability and concurrent physical problems.,split,"['Most studies focused on people who had intellectual disabilities and mental health problems.', 'There were no studies on people who had intellectual disabilities and physical problems.']",10,0.8823529411764706,5,17
CD007492,4,15,There are very few studies of organisational interventions targeting mental health needs and the results of those that were found need corroboration.,delete,[],12,0.9411764705882353,5,17
CD007492,4,16,There is an urgent need for high-quality health services research to identify optimal health services for persons with an intellectual disability and concurrent physical problem.,delete,[],12,1.0,5,17
CD012254,0,0,We included three trials (in five articles) with 385 opiate-using participants that measured outcomes at different follow-up periods in this review.,rephrase,['We included three studies in this review with 385 participants in total with follow-up periods of different length.'],0,0.1,1,10
CD012254,0,1,"Two studies with 150 individuals compared DHC with buprenorphine for detoxification, and one study with 235 participants compared DHC to methadone for maintenance substitution therapy.",rephrase,"['Two studies with 150 participants compared DHC to buprenorphine for detoxification (managing physical symptoms of withdrawal), while one study with 235 individuals compared DHC to methadone for maintenance substitution therapy (providing legal substance to reduce risk behaviour and other harm related to drug use over a longer period).']",1,0.2,1,10
CD012254,0,2,We downgraded the quality of evidence mainly due to risk of bias and imprecision.,delete,[],2,0.3,2,10
CD012254,1,3,"For the two studies that compared DHC to buprenorphine, we found low-quality evidence of no significant difference between DHC and buprenorphine for detoxification at six-month follow-up (risk ratio (RR) 0.59, 95% confidence interval (CI) 0.25 to 1.39; P = 0.23) in the meta-analysis for the primary outcome of abstinence from illicit opiates.",delete,[],2,0.4,2,10
CD012254,1,4,"Similarly, low-quality evidence indicated no difference for treatment retention (RR 1.29, 95% CI 0.99 to 1.68; P = 0.06).",delete,[],2,0.5,3,10
CD012254,2,5,"In the single trial that compared DHC to methadone for maintenance substitution therapy, the evidence was also of low quality, and there may be no difference in effects between DHC and methadone for reported abstinence from illicit opiates (mean difference (MD) −0.01, 95% CI −0.31 to 0.29).",delete,[],2,0.6,3,10
CD012254,2,6,"For treatment retention at six months' follow-up in this single trial, the RR calculated with an intention-to-treat analysis also indicated that there may be no difference between DHC and methadone (RR 1.04, 95% CI 0.94 to 1.16).",delete,[],2,0.7,4,10
CD012254,3,7,"The studies that compared DHC to buprenorphine reported no serious adverse events, while the DHC versus methadone study reported one death due to methadone overdose.",rephrase,['The only adverse event reported was one death from a methadone overdose in the study that compared DHC with methadone as maintenance therapy.'],2,0.8,4,10
CD012254,4,8,We found low-quality evidence that DHC may be no more effective than other commonly used pharmacological interventions in reducing illicit opiate use.,rephrase,"['Overall, the evidence was of low quality.']",3,0.9,5,10
CD012254,4,9,"It is therefore premature to make any conclusive statements about the effectiveness of DHC, and it is suggested that further high-quality studies are conducted, especially in low- to middle-income countries.",rephrase,"['However it is premature to make definitive statements about the efficacy of DHC for reducing illegal substance use, due to the low quality of evidence.']",4,1.0,5,10
CD006004,0,0,A total of 1831 participants were randomised to drain (915 participants) versus 'no drain' (916 participants) in 12 trials included in this review.,rephrase,"[""A total of 1831 participants received drain (915 patients) versus 'no drain' (916 patients) in 12 trials included in this review.""]",0,0.058823529411764705,1,17
CD006004,0,1,Only two trials including 199 participants were of low risk of bias.,rephrase,"['Only two trials including 199 patients were of low risk of bias (free from errors in study design that can result in wrong conclusions, leading to overestimation of benefits and to underestimation of harms of the drainage or no drainage).']",1,0.11764705882352941,1,17
CD006004,0,2,Nine trials included patients undergoing elective laparoscopic cholecystectomy exclusively.,merge,['Nine of the 12 trials included patients who underwent planned operations.'],2,0.17647058823529413,1,17
CD006004,0,3,One trial included patients undergoing laparoscopic cholecystectomy for acute cholecystitis exclusively.,merge,[],2,0.23529411764705882,2,17
CD006004,0,4,"One trial included patients undergoing elective and emergency laparoscopic cholecystectomy, and one trial did not provide this information.",none,[],2,0.29411764705882354,2,17
CD006004,0,5,The average age of participants in the trials ranged between 48 years and 63 years in the 10 trials that provided this information.,ignore,['The average age of participants in the trials ranged between 48 years and 63 years in the 10 trials that provided this information.'],3,0.35294117647058826,2,17
CD006004,0,6,The proportion of females ranged between 55.0% and 79.0% in the 11 trials that provided this information.,ignore,['The proportion of females ranged between 55.0% and 79.0% in the 11 trials that provided this information.'],4,0.4117647058823529,3,17
CD006004,0,7,There was no significant difference between the drain group (1/840) (adjusted proportion: 0.1%) and the 'no drain' group (2/841) (0.2%) (RR 0.41; 95% CI 0.04 to 4.37) in short-term mortality in the ten trials with 1681 participants reporting on this outcome.,merge,[],5,0.47058823529411764,3,17
CD006004,0,8,There was no significant difference between the drain group (7/567) (adjusted proportion: 1.1%) and the 'no drain' group (3/576) (0.5%) in the proportion of patients who developed serious adverse events in the seven trials with 1143 participants reporting on this outcome (RR 2.12; 95% CI 0.67 to 7.40) or in the number of serious adverse events in each group reported by eight trials with 1286 participants; drain group (12/646) (adjusted rate: 1.5 events per 100 participants) versus 'no drain' group (6/640) (0.9 events per 100 participants); rate ratio 1.60; 95% CI 0.66 to 3.87).,merge,[],5,0.5294117647058824,3,17
CD006004,0,9,There was no significant difference in the quality of life between the two groups (one trial; 93 participants; SMD 0.22; 95% CI -0.19 to 0.63).,none,"['There was no significant or clinically important differences in the short-term mortality, serious complications, quality of life, length of hospital stay, operating time, return to normal activity, or return to work in the trials that reported these outcomes.']",5,0.5882352941176471,3,17
CD006004,0,10,The proportion of patients who were discharged as day-procedure laparoscopic cholecystectomy seemed significantly lower in the drain group than the 'no drain' group (one trial; 68 participants; drain group (0/33) (adjusted proportion: 0.2%) versus 'no drain' group (11/35) (31.4%); RR 0.05; 95% CI 0.00 to 0.75).,rephrase,"[""The proportion of patients who were discharged as day-procedure laparoscopic cholecystectomy seemed significantly lower in the drain group than in the 'no drain' group in one trial of high risk of bias involving 68 participants.""]",6,0.6470588235294118,4,17
CD006004,0,11,There was no significant difference in the length of hospital stay between the two groups (five trials; 449 participants; MD 0.22 days; 95% CI -0.06 days to 0.51 days).,delete,[],7,0.7058823529411765,4,17
CD006004,0,12,The operating time was significantly longer in the drain group than the 'no drain' group (seven trials; 775 participants; MD 5.00 minutes; 95% CI 2.69 minutes to 7.30 minutes).,delete,[],7,0.7647058823529411,4,17
CD006004,0,13,There was no significant difference in the return to normal activity and return to work between the groups in one trial involving 100 participants.,delete,[],7,0.8235294117647058,5,17
CD006004,0,14,This trial did not provide any information from which the standard deviation could be imputed and so the confidence intervals could not be calculated for these outcomes.,delete,[],7,0.8823529411764706,5,17
CD006004,1,15,There is currently no evidence to support the routine use of drain after laparoscopic cholecystectomy.,rephrase,"['Currently, there is no evidence to support the use of drain after laparoscopic cholecystectomy.']",7,0.9411764705882353,5,17
CD006004,1,16,Further well designed randomised clinical trials are necessary.,ignore,['Further well-designed randomised clinical trials are necessary.'],8,1.0,5,17
CD004886,0,0,Seven low quality randomised trials were included.,ignore,['Seven low quality randomised trials were included.'],0,0.1111111111111111,1,9
CD004886,0,1,"All studies included a total of 310 patients, but due to selective outcome reporting bias, less patients could be included in our analyses.",ignore,"['All the seven studies included a total of 310 patients, but due to selective outcome reporting bias, less patients could be included in our analyses.']",1,0.2222222222222222,2,9
CD004886,0,2,"Pooled analysis of three homogenous trials showed that needle aspiration did not significantly increase the proportion of patients with fever resolution (RR 0.60, 95% confidence interval (CI) 0.22 to 1.61).",rephrase,['Pooled analysis of three homogenous trials showed that needle aspiration did not significantly increase the proportion of patients with fever resolution.'],2,0.3333333333333333,2,9
CD004886,0,3,Sensitivity analysis according to trial quality preserved these findings.,delete,[],3,0.4444444444444444,3,9
CD004886,0,4,"Trials that evaluated resolution of abdominal pain, days to resolution of fever, pain, resolution of abscess cavities, reduction in liver size, and duration of hospitalisation were heterogeneous.",delete,[],3,0.5555555555555556,3,9
CD004886,0,5,"The benefits in the number of days to resolution of pain (MD -1.59, 95%CI -2.73 to -0.42), number of days to resolution of abdominal tenderness (MD -1.70, 95%CI -2.86 to -0.54), and duration of hospitalisation (MD -1.31, 95%CI -2.05 to -0.57) were observed in the needle aspiration group only.",rephrase,['Benefits could be observed in resolution time of pain and tenderness.'],3,0.6666666666666666,4,9
CD004886,1,6,Therapeutic aspiration in addition to metronidazole to hasten clinical or radiologic resolution of uncomplicated amoebic liver abscesses cannot be supported or refuted by the present evidence.,rephrase,['No additional benefit has been found with percutaneous needle aspiration plus metronidazole versus metronidazole alone for uncomplicated amoebic liver abscesses in hastening clinical and radiologic resolution.'],4,0.7777777777777778,4,9
CD004886,1,7,The trials lack methodological rigour and adequate sample size to conclude on the presence of effectiveness of adjunctive image-guided aspiration plus metronidazole versus metronidazole alone.,merge,"['However, this conclusion is based on trials with methodological flaws and with insufficient sample sizes, and requires further confirmation in larger well-designed, randomised trials.']",5,0.8888888888888888,5,9
CD004886,1,8,Further randomised trials are necessary.,none,[],5,1.0,5,9
CD011749,0,0,"We screened 7674 citations, from which 14 trials with 1844 participants met our inclusion criteria.",rephrase,['We found 14 randomized controlled studies that enrolled a total of 1844 adult participants.'],0,0.06666666666666667,1,15
CD011749,0,1,"Ten RCTs were placebo-controlled, and four reported comparisons of different drugs.",rephrase,['Ten studies compared medicine to placebo - an inactive medicine also known as a sugar pill; four studies compared different drugs.'],1,0.13333333333333333,1,15
CD011749,0,2,"Drugs examined in these trials were the following: antipsychotics (n = 10), alpha2 agonists (n = 3; all dexmedetomidine), statins (n = 2), opioids (n = 1; morphine), serotonin antagonists (n = 1; ondansetron), and cholinesterase (CHE) inhibitors (n = 1; rivastigmine).",rephrase,"[""These were antipsychotic drugs used as tranquillizers in ten studies; the sedative alpha2 agonist dexmedetomidine in three studies; statins that reduce cholesterol in two studies; opioids as part of pain management in one study; serotonin antagonists for nausea and vomiting in one study; and cholinesterase inhibitors, which are medicines for Alzheimer's disease, in one study.""]",2,0.2,1,15
CD011749,0,3,Only one of these trials consistently used non-pharmacological interventions that are known to improve patient outcomes in both intervention and control groups.,delete,[],3,0.26666666666666666,2,15
CD011749,1,4,Eleven studies (n = 1153 participants) contributed to analysis of the primary outcome.,rephrase,['Eleven studies with 1153 participants reported on the main outcome of this review - duration of delirium.'],3,0.3333333333333333,2,15
CD011749,1,5,Results of the NMA showed that the intervention with the smallest ratio of means (RoM) (i.e. most preferred) compared with placebo was the alpha2 agonist dexmedetomidine (0.58; 95% credible interval (CrI) 0.26 to 1.27; surface under the cumulative ranking curve (SUCRA) 0.895; moderate-quality evidence).,delete,[],4,0.4,2,15
CD011749,1,6,"In order of descending SUCRA values (best to worst), the next best interventions were atypical antipsychotics (RoM 0.80, 95% CrI 0.50 to 1.11; SUCRA 0.738; moderate-quality evidence), opioids (RoM 0.88, 95% CrI 0.37 to 2.01; SUCRA 0.578; very-low quality evidence), and typical antipsychotics (RoM 0.96, 95% CrI 0.64 to1.36; SUCRA 0.468; high-quality evidence).",delete,[],4,0.4666666666666667,3,15
CD011749,2,7,"The NMAs of multiple secondary outcomes revealed that only the alpha2 agonist dexmedetomidine was associated with a shorter duration of mechanical ventilation (RoM 0.55, 95% CrI 0.34 to 0.89; moderate-quality evidence), and the CHE inhibitor rivastigmine was associated with a longer ICU stay (RoM 2.19, 95% CrI 1.47 to 3.27; moderate-quality evidence).",delete,[],4,0.5333333333333333,3,15
CD011749,2,8,"Adverse events often were not reported in these trials or, when reported, were rare; pair-wise analysis of QTc prolongation in seven studies did not show significant differences between antipsychotics, ondansetron, dexmedetomidine, and placebo.",rephrase,['Adverse events often were not reported in these trials or were rare when reported.'],4,0.6,3,15
CD011749,3,9,We identified trials of varying quality that examined six different drug classes for treatment of delirium in critically ill adults.,rephrase,['The Review authors used the statistical method of network meta-analysis to compare the six different drug classes.'],5,0.6666666666666666,4,15
CD011749,3,10,"We found evidence that the alpha2 agonist dexmedetomidine may shorten delirium duration, although this small effect (compared with placebo) was seen in pairwise analyses based on a single study and was not seen in the NMA results.",split,"['When drug classes were directly compared with placebo, only the alpha2 agonist dexmedetomidine was found to reduce the duration of delirium, and the cholinesterase inhibitor rivastigmine was found to prolong the duration of delirium.', 'The other drugs when compared to placebo did not change delirium duration.', 'The alpha2 agonist dexmedetomidine shortened time spent on a breathing machine.']",6,0.7333333333333333,4,15
CD011749,3,11,"Alpha2 agonists also ranked best for duration of mechanical ventilation and length of ICU stay, whereas the CHE inhibitor rivastigmine was associated with longer ICU stay.",delete,[],9,0.8,4,15
CD011749,3,12,"We found no evidence of a difference between placebo and any drug in terms of delirium-free and coma-free days, days with coma, physical restraint use, length of stay, long-term cognitive outcomes, or mortality.",rephrase,"['Using this method, we did not find that any drug improved the duration of coma, length of stay, long-term cognitive outcomes, or death.']",9,0.8666666666666667,5,15
CD011749,3,13,"No studies reported delirium relapse, resolution of symptoms, or quality of life.",delete,[],10,0.9333333333333333,5,15
CD011749,3,14,"The ten ongoing studies and the six studies awaiting classification that we identified, once published and assessed, may alter the conclusions of the review.",rephrase,"['We found 10 ongoing studies and six studies awaiting classification that, once published and assessed, may change the conclusions of this review.']",10,1.0,5,15
CD009006,0,0,We included 13 randomised trials (975 participants).,rephrase,"['Based on searches carried out in 2006 and 2011, this review includes 13 trials with a total of 975 participants.']",0,0.09090909090909091,1,11
CD009006,0,1,"These evaluated social skills programmes versus standard care, or discussion group.",rephrase,"['The main objective of this review is to investigate the effectiveness of social skills programmes, compared to standard care or discussion groups, for people with schizophrenia.']",1,0.18181818181818182,1,11
CD009006,0,2,We found evidence in favour of social skills programmes compared to standard care on all measures of social functioning.,split,"['The review found significant differences in favour of social skills programmes compared to standard care on all measures of social functioning.', 'Rates of relapse were lower for social skills compared to standard care and there was a significant difference in favour of social skills on people’s mental state.']",2,0.2727272727272727,2,11
CD009006,0,3,"We also found that rates of relapse and rehospitalisation were lower for social skills compared to standard care (relapse: 2 RCTs, n = 263, RR 0.52 CI 0.34 to 0.79, very low quality evidence), (rehospitalisation: 1 RCT, n = 143, RR 0.53 CI 0.30 to 0.93, very low quality evidence) and participants’ mental state results (1 RCT, n = 91, MD -4.01 CI -7.52 to -0.50, very low quality evidence) were better in the group receiving social skill programmes.",delete,[],4,0.36363636363636365,2,11
CD009006,0,4,"Global state was measured in one trial by numbers not experiencing a clinical improvement, results favoured social skills (1 RCT, n = 67, RR 0.29 CI 0.12 to 0.68, very low quality evidence).",delete,[],4,0.45454545454545453,3,11
CD009006,0,5,"Quality of life was also improved in the social skills programme compared to standard care (1 RCT, n = 112, MD -7.60 CI -12.18 to -3.02, very low quality evidence).",rephrase,['Quality of life was also improved in the social skills programme compared to standard care.'],4,0.5454545454545454,3,11
CD009006,0,6,"However, when social skills programmes were compared to a discussion group control, we found no significant differences in the participants social functioning, relapse rates, mental state or quality of life, again the quality of evidence for these outcomes was very low.",rephrase,"['However, when social skills programmes were compared to discussion groups, there were no significant differences in people’s social functioning, relapse rates, mental state or quality of life.']",5,0.6363636363636364,4,11
CD009006,1,7,"Compared to standard care, social skills training may improve the social skills of people with schizophrenia and reduce relapse rates, but at present, the evidence is very limited with data rated as very low quality.",split,"['Compared to standard care, social skills programmes may improve the social skills of people with schizophrenia and reduce relapse rates.', 'However, at the moment evidence is very limited with data only of very low quality available.']",6,0.7272727272727273,4,11
CD009006,1,8,When social skills training was compared to discussion there was no difference on patients outcomes.,delete,[],8,0.8181818181818182,5,11
CD009006,1,9,"Cultural differences might limit the applicability of the current results, as most reported studies were conducted in China.",rephrase,"['Cultural differences might also limit the relevance of current results, as most reported studies were conducted in China.']",8,0.9090909090909091,5,11
CD009006,1,10,Whether social skills training can improve social functioning of people with schizophrenia in different settings remains unclear and should be investigated in a large multi-centre randomised controlled trial.,ignore,['Whether social skills programmes or training can improve the social functioning of people with schizophrenia in different settings remains unclear and should be further investigated in a large multi-centre randomised controlled trial.'],9,1.0,5,11
CD009620,0,0,"Five trials, including 1476 participants, were included in the review.",ignore,"['Five trials, including 1476 participants, were included in the review.']",0,0.07142857142857142,1,14
CD009620,0,1,Two trials compared interferon with observation alone and three trials compared interferon plus chemotherapy with chemotherapy alone.,delete,[],1,0.14285714285714285,1,14
CD009620,0,2,"A meta-analysis of two trials involving 370 participants found no significant difference in both overall survival (HR 1.14, 95% CI 0.84 to 1.55) and progression free survival (HR 0.99, 95% CI 0.79 to 1.24) between the interferon and observation alone groups in post-surgical women who had undergone first-line chemotherapy for advanced EOC.",delete,[],1,0.21428571428571427,2,14
CD009620,0,3,"One trial with 293 participants found that while no significant difference was observed in incidence of nausea or vomiting between the two treatment groups, significantly more flu-like symptoms (RR 2.25, 95% CI 1.73 to 2.91) and fatigue (RR 1.54, 95% CI 1.27 to 1.88) were reported in the interferon group.",delete,[],1,0.2857142857142857,2,14
CD009620,0,4,"For the second comparison, a meta-analysis of two trials comprising 244 participants found that although there was no significant difference in overall survival between the interferon plus chemotherapy and the chemotherapy alone group (HR 1.14, 95% CI 0.74 to 1.76), women in the interferon plus chemotherapy group had worse progression free survival than those in the chemotherapy alone group (HR 1.43, 95% CI 1.02 to 2.00).",delete,[],1,0.35714285714285715,2,14
CD009620,0,5,"Compared to chemotherapy alone, adding interferon to chemotherapy did not alter the incidence of adverse events in post-surgical women with advanced EOC.",delete,[],1,0.42857142857142855,3,14
CD009620,1,6,"Implications for practice
Based on low quality evidence, the addition of interferon to first-line chemotherapy did not alter the overall survival in post-surgical women with advanced EOC compared with chemotherapy alone.",rephrase,['The evidence from the three trials suggested that the addition of interferon to first-line chemotherapy did not alter the overall survival in post-surgical women with advanced EOC compared with chemotherapy alone.'],1,0.5,3,14
CD009620,1,7,There is low quality evidence to suggest that interferon in combination with chemotherapy worsened the progression free survival in post-surgical women with advanced EOC compared with chemotherapy alone.,rephrase,"['On the contrary, there is evidence that interferon in combination with chemotherapy worsened progression free survival in post-surgical women with advanced EOC compared with chemotherapy alone.']",2,0.5714285714285714,3,14
CD009620,1,8,There is not enough evidence that interferon therapy alone alters overall survival or progression free survival compared to observation alone in post-surgical women who have undergone first-line chemotherapy.,rephrase,"['Furthermore, there is not enough evidence that interferon therapy alone improves overall survival or progression free survival in post-surgical women who have undergone first-line chemotherapy when compared with observation alone.']",3,0.6428571428571429,4,14
CD009620,2,9,"Implications for research
Three of the five trials included in this review were stopped early and were, therefore, underpowered to detect any true effect of the intervention.",split,"['Three of the five trials were stopped early.', 'Most of the trials were not large enough to detect any true effect of the intervention.']",4,0.7142857142857143,4,14
CD009620,2,10,"The trials did not report the results of important outcomes in a uniform manner, preventing statistical aggregation of the results.",rephrase,['Trials either did not report the results of important outcomes or the results of important outcomes were not uniform between the trials.'],6,0.7857142857142857,4,14
CD009620,2,11,Trial methodology was poorly reported resulting in unclear risk of bias.,rephrase,['The risk of bias of most of the trials was high or unclear due to incomplete reporting of methods and results.'],7,0.8571428571428571,5,14
CD009620,2,12,"For clear recommendations to be made regarding the effectiveness of interferon in the treatment of advanced EOC, long-term, well conducted and adequately powered RCTs would be needed.",delete,[],8,0.9285714285714286,5,14
CD009620,2,13,"However, the available data do not suggest that interferon has an adequately advantageous effect to warrant further investigation.",delete,[],8,1.0,5,14
CD003162,0,0,We included 11 trials in the review with a total of 745 patients.,rephrase,"['We included 11 studies in the review, with a total of 745 participants.']",0,0.05263157894736842,1,19
CD003162,1,1,"Five studies compared the efficacy of the Epley manoeuvre against a sham manoeuvre, three against other particle repositioning manoeuvres (Semont, Brandt-Daroff and Gans) and three against a control (no treatment, medication only, postural restriction).",ignore,"['Five studies (334 patients) compared the efficacy of the Epley manoeuvre against a sham manoeuvre, three against other particle repositioning manoeuvres (Semont, Brandt-Daroff and Gans) and three with a control (no treatment, medication only, postural restriction).']",1,0.10526315789473684,1,19
CD003162,1,2,Patients were treated in hospital otolaryngology departments in eight studies and family practices in two studies.,rephrase,"['Patients were treated in hospital otolaryngology (ear, nose and throat) departments in eight studies and family practices in two studies.']",2,0.15789473684210525,1,19
CD003162,1,3,"All patients were adults aged 18 to 90 years old, with a sex ratio of 1:1.5 male to female.",ignore,"['All patients were adults aged 18 to 90 years old, with a sex ratio of 1:1.5 male to female.']",3,0.21052631578947367,2,19
CD003162,2,4,There was a low risk of overall bias in the studies included.,ignore,['There was a low risk of overall bias in the studies included.'],4,0.2631578947368421,2,19
CD003162,2,5,All studies were randomised with six applying sealed envelope or external allocation techniques.,rephrase,"['All trials were randomised, with five studies applying sealed envelope or external allocation techniques.']",5,0.3157894736842105,2,19
CD003162,2,6,Eight of the trials blinded the assessors to the participants' treatment group and data on all outcomes for all participants were reported in eight of the 11 studies.,rephrase,"[""Seven of the trials blinded the assessors to the patients' treatment group and data on all outcomes for all participants were reported in most studies.""]",6,0.3684210526315789,2,19
CD003162,3,7,"Complete resolution of vertigo
Complete resolution of vertigo occurred significantly more often in the Epley treatment group when compared to a sham manoeuvre or control (odds ratio (OR) 4.42, 95% confidence interval (CI) 2.62 to 7.44; five studies, 273 participants); the proportion of patients resolving increased from 21% to 56%.",rephrase,['For resolution of vertigo the Epley manoeuvre was significantly more effective than a sham manoeuvre or control.'],7,0.42105263157894735,3,19
CD003162,3,8,None of the trials comparing Epley versus other particle repositioning manoeuvres reported vertigo resolution as an outcome.,ignore,['None of the trials that compared Epley versus other particle repositioning manoeuvres reported vertigo resolution as an outcome.'],8,0.47368421052631576,3,19
CD003162,4,9,"Conversion of Dix-Hallpike positional test result from positive to negative
Conversion from a positive to a negative Dix-Hallpike test significantly favoured the Epley treatment group when compared to a sham manoeuvre or control (OR 9.62, 95% CI 6.0 to 15.42; eight studies, 507 participants).",rephrase,"['When studies looked at the conversion from a positive to a negative Dix-Hallpike test (a test to diagnose BPPV) in the patients, the results significantly favoured the Epley treatment group when compared to a sham manoeuvre or control.']",9,0.5263157894736842,3,19
CD003162,4,10,"There was no difference when comparing the Epley with the Semont manoeuvre (two studies, 117 participants) or the Epley with the Gans manoeuvre (one study, 58 participants).",rephrase,['There was no difference when Epley was compared with the Semont or Gans manoeuvre.'],10,0.5789473684210527,3,19
CD003162,4,11,"In one study a single Epley treatment was more effective than a week of three times daily Brandt-Daroff exercises (OR 12.38, 95% CI 4.32 to 35.47; 81 participants).",rephrase,['In one study a single Epley treatment was more effective than a week of three times daily Brandt-Daroff exercises.'],11,0.631578947368421,4,19
CD003162,5,12,"Adverse effects
Adverse effects were infrequently reported.",rephrase,['Adverse effects were not often reported.'],12,0.6842105263157895,4,19
CD003162,5,13,There were no serious adverse effects of treatment.,ignore,['There were no serious adverse effects of treatment.'],13,0.7368421052631579,4,19
CD003162,5,14,Rates of nausea during the repositioning manoeuvre varied from 16.7% to 32%.,ignore,['Rates of nausea during the repositioning manoeuvre varied from 16.7% to 32%.'],14,0.7894736842105263,4,19
CD003162,5,15,Some patients were unable to tolerate the manoeuvres because of cervical spine problems.,ignore,['Some patients were unable to tolerate the manoeuvres because of cervical spine (neck) problems.'],15,0.8421052631578947,5,19
CD003162,6,16,"There is evidence that the Epley manoeuvre is a safe, effective treatment for posterior canal BPPV, based on the results of 11, mostly small, randomised controlled trials with relatively short follow-up.",rephrase,['The review of trials found that the Epley manoeuvre is safe and effective in the short term.'],16,0.8947368421052632,5,19
CD003162,6,17,There is a high recurrence rate of BPPV after treatment (36%).,delete,[],17,0.9473684210526315,5,19
CD003162,6,18,"Outcomes for Epley manoeuvre treatment are comparable to treatment with Semont and Gans manoeuvres, but superior to Brandt-Daroff exercises.",delete,[],17,1.0,5,19
CD005390,0,0,": With regards to the effect of adjuvant therapy on stage II colon cancer, the pooled relative risk ratio for overall survival was 0.96 (95% confidence interval 0.88, 1.05).",delete,[],0,0.14285714285714285,1,7
CD005390,0,1,"With regards to disease-free survival, the pooled relative risk ratio was 0.83 (95% confidence interval 0.75, 0.92).",delete,[],0,0.2857142857142857,2,7
CD005390,1,2,": Although there was no improvement in overall survival in the pooled analysis, we did find that disease-free survival in patients with stage II colon cancer was signficantly better with the use of adjuvant therapy.",rephrase,['We performed a systematic review looking at all randomized clinical trials evaluating stage II colon cancer patients and adjuvant therapy versus surgery alone.'],0,0.42857142857142855,3,7
CD005390,1,3,"It seems reasonable to discuss the benefits of adjuvant systemic chemotherapy with those stage II patients who have high risk features, including obstruction, perforation, inadequate lymph node sampling or T4 disease.",rephrase,['Our review found that adjuvant therapy -either systemic or regional chemotherapy or immunotherapy- can improve the outcomes of stage II patients.'],1,0.5714285714285714,3,7
CD005390,1,4,The co-morbidities and likelihood of tolerating adjuvant systemic chemotherapy should be considered as well.,delete,[],2,0.7142857142857143,4,7
CD005390,1,5,There exists a need to further define which high-risk features in stage II colon cancer patients should be used to select patients for adjuvant therapy.,split,"['In addition, the high risk features of the tumour should also be considered when contemplating the benefits of systemic therapy in patients with stage II colon cancer.', 'Further investigation is needed to elucidate which patient and tumour factors can be used to select stage II colon cancer patients for adjuvant therapy.']",2,0.8571428571428571,5,7
CD005390,1,6,"Also, researchers must continue to search for other therapies which might be more effective, shorter in duration and less toxic than those available today.",rephrase,"['There also exists a need to continue to search for other adjuvant therapies which might be more effective, shorter in duration and less toxic than those available today.']",4,1.0,5,7
CD007574,0,0,We included 19 studies with a total of 3793 participants.,rephrase,['We found 19 trials involving a total of 3793 participants.'],0,0.16666666666666666,1,6
CD007574,0,1,"The majority of participants had large artery occlusion in the anterior circulation, and were treated within six hours of symptom onset with endovascular thrombectomy.",rephrase,"[""Treatment with endovascular thrombectomy can improve patients' chance of survival with the ability to function well without increasing the risk of bleeding in the brain or death.""]",1,0.3333333333333333,2,6
CD007574,0,2,"Treatment increased the chance of achieving a good functional outcome, defined as a modified Rankin Scale score of 0 to 2: risk ratio (RR) 1.50 (95% confidence interval (CI) 1.37 to 1.63; 3715 participants, 18 RCTs; high-certainty evidence).",delete,[],2,0.5,3,6
CD007574,0,3,"Treatment also reduced the risk of death at end of follow-up: RR 0.85 (95% CI 0.75 to 0.97; 3793 participants, 19 RCTs; high-certainty evidence) without increasing the risk of symptomatic intracranial haemorrhage in the acute phase: RR 1.46 (95% CI 0.91 to 2.36; 1559 participants, 6 RCTs; high-certainty evidence) or by end of follow-up: RR 1.05 (95% CI 0.72 to 1.52; 1752 participants, 10 RCTs; high-certainty evidence); however, the wide confidence intervals preclude any firm conclusion.",delete,[],2,0.6666666666666666,4,6
CD007574,0,4,"Neurological recovery to National Institutes of Health Stroke Scale (NIHSS) score 0 to 1 and degree of recanalisation rates were better in the treatment group: RR 2.03 (95% CI 1.21 to 3.40; 334 participants, 3 RCTs; moderate-certainty evidence) and RR 8.25 (95% CI 1.63 to 41.90; 198 participants, 2 RCTs; moderate-certainty evidence), respectively.",delete,[],2,0.8333333333333334,5,6
CD007574,1,5,"In individuals with acute ischaemic stroke due to large artery occlusion in the anterior circulation, endovascular thrombectomy can increase the chance of survival with a good functional outcome without increasing the risk of intracerebral haemorrhage or death.",rephrase,"['Randomised controlled trials of endovascular thrombectomy or intra-arterial thrombolysis, or both, plus routine medical treatment compared with routine medical treatment alone in people with a definite acute ischaemic stroke.']",2,1.0,5,6
CD008996,0,0,"A total of 1437 adult patients participated in the five randomized parallel group studies, with treatment durations ranging from 8 to 16 weeks.",rephrase,['These studies followed patients for 8 to 16 weeks while on therapy.'],0,0.07692307692307693,1,13
CD008996,0,1,The daily doses of eplerenone ranged from 25 mg to 400 mg daily.,rephrase,['The doses of eplerenone used in these studies ranged from 25 mg to 400 mg daily.'],1,0.15384615384615385,1,13
CD008996,0,2,Meta-analysis of these studies showed a reduction in systolic blood pressure of 9.21 mmHg (95% CI −11.08 to −7.34; I2 = 58%) and a reduction of diastolic pressure of 4.18 mmHg (95% CI −5.03 to −3.33; I2 = 0%) (moderate quality evidence).,delete,[],2,0.23076923076923078,2,13
CD008996,1,3,There may be a dose response effect for eplerenone in the reduction in systolic blood pressure at doses of 400 mg/day.,delete,[],2,0.3076923076923077,2,13
CD008996,1,4,"However, this finding is uncertain, as it is based on a single included study with low quality evidence.",delete,[],2,0.38461538461538464,2,13
CD008996,1,5,Overall there does not appear to be a clinically important dose response in lowering systolic or diastolic blood pressure at eplerenone doses of 50 mg to 400 mg daily.,delete,[],2,0.46153846153846156,3,13
CD008996,1,6,There did not appear to be any differences in the number of patients who withdrew due to adverse events or the number of patients with at least one adverse event in the eplerenone group compared to placebo.,rephrase,"['None of the studies reported on the clinically meaningful outcomes of eplerenone, such as whether eplerenone can reduce heart attacks, stroke, or death compared to placebo.']",2,0.5384615384615384,3,13
CD008996,1,7,"However, only three of the five included studies reported adverse events.",rephrase,['Only three of the five studies reported on side effects.'],3,0.6153846153846154,4,13
CD008996,1,8,"Most of the included studies were of moderate quality, as we judged multiple domains as being at unclear risk in the 'Risk of bias' assessment.",rephrase,"['We judged the five included trials to be of moderate quality, as authors did not extensively describe portions of their methodology.']",4,0.6923076923076923,4,13
CD008996,2,9,"Eplerenone 50 to 200 mg/day lowers blood pressure in people with primary hypertension by 9.21 mmHg systolic and 4.18 mmHg diastolic compared to placebo, with no difference of effect between doses of 50 mg/day to 200 mg/day.",merge,['This meta-analysis shows that eplerenone 50 to 200 mg/day reduces systolic blood pressure by approximately 9 mmHg and diastolic blood pressure by 4 mmHg compared to taking no medication.'],5,0.7692307692307693,4,13
CD008996,2,10,A dose of 25 mg/day did not produce a statistically significant reduction in systolic or diastolic blood pressure and there is insufficient evidence for doses above 200 mg/day.,none,[],5,0.8461538461538461,5,13
CD008996,2,11,There is currently no available evidence to determine the effect of eplerenone on clinically meaningful outcomes such as mortality or morbidity in hypertensive patients.,rephrase,"['There is currently no evidence that eplerenone has a beneficial effect on life expectancy or complications rleated to hypertension (e.g. heart attack, stroke).']",6,0.9230769230769231,5,13
CD008996,2,12,"The evidence available on side effects is insufficient and of low quality, which makes it impossible to draw conclusions about potential harm associated with eplerenone treatment in hypertensive patients.",rephrase,['Evidence for risk of side effects with eplerenone is limited and of poor quality; it is difficult to tell the extent of possible harm with eplerenone versus placebo.'],7,1.0,5,13
CD003700,0,0,Six trials involving 1740 children were included.,rephrase,['We found six trials (1740 participants) that used vitamin A adjunctive therapy in children with non-measles pneumonia.'],0,0.125,1,8
CD003700,0,1,There was no significant reduction in mortality associated with pneumonia in children treated with vitamin A compared to those who were not (pooled odds ratio (OR) 1.29; 95% confidence interval (CI) 0.63 to 2.66).,merge,[],1,0.25,2,8
CD003700,0,2,"Also, there was no statistically significant difference in duration of hospital stay (mean difference (MD) 0.08; 95% CI -0.43 to 0.59).",none,['There was no significant reduction in mortality or duration of hospital stay.'],1,0.375,2,8
CD003700,0,3,Disease severity after supplementary high-dose vitamin A was significantly worse compared with placebo.,merge,"['Supplementary high-dose vitamin A may result in a worsening of the disease, and low-dose vitamin A significantly reduces the recurrence of bronchopneumonia.']",2,0.5,3,8
CD003700,0,4,"However, low-dose vitamin A significantly reduced the recurrence rate of bronchopneumonia (OR 0.12; 95% CI 0.03 to 0.46).",none,[],2,0.625,4,8
CD003700,0,5,Moderate vitamin A significantly reduced the time to remission of signs in children with normal serum retinol (> 200 ug/L).,rephrase,['Moderate-dose vitamin A significantly reduces the time to remission of signs in children with normal serum retinol.'],3,0.75,4,8
CD003700,1,6,"The evidence does not suggest a significant reduction in mortality, measures of morbidity, nor an effect on the clinical course of pneumonia with vitamin A adjunctive treatment in children with non-measles pneumonia.",rephrase,"['The possible reason of the lack of benefit of vitamin A in non-measles pneumonia is that the effects of vitamin A may be disease-specific, with vitamin A only being effective when pneumonia is complicated with measles.']",4,0.875,5,8
CD003700,1,7,"However, not all studies measured all outcomes, which limited the number of studies that could be incorporated into the meta-analyses, so that there may have been a lack of statistical power to detect statistically significant differences.",delete,[],5,1.0,5,8
CD007083,0,0,"In this updated version of the review, we found no new studies that met our inclusion criteria.",rephrase,"['In this second update of the Cochrane review, we searched the databases until April 2013 but found no new studies.']",0,0.07692307692307693,1,13
CD007083,0,1,We included in this review four studies that compared neuraxial anaesthesia with general anaesthesia.,split,"['This systematic review is important because review authors assessed the risk of important outcomes after lower-limb revascularization with the participant under neuraxial or general anaesthesia.', 'They performed this systematic review to answer a single research question: What are the rates of death and major complications with spinal and epidural anaesthesia as compared with other types of anaesthesia for lower-limb revascularization?']",1,0.15384615384615385,1,13
CD007083,0,2,"The total number of participants was 696, of whom 417 were allocated to neuraxial anaesthesia and 279 to general anaesthesia.",rephrase,"['The total number of participants in the four included studies was 696, of whom 417 received neuraxial anaesthesia and 279 received general anaesthesia.']",3,0.23076923076923078,2,13
CD007083,0,3,"Participants allocated to neuraxial anaesthesia had a mean age of 67 years, and 59% were men.",delete,[],4,0.3076923076923077,2,13
CD007083,0,4,"Participants allocated to general anaesthesia had a mean age of 67 years, and 66% were men.",delete,[],4,0.38461538461538464,2,13
CD007083,0,5,Four studies had an unclear risk of bias.,delete,[],4,0.46153846153846156,3,13
CD007083,0,6,"No difference was observed between participants allocated to neuraxial or general anaesthesia in mortality rate (OR 0.89, 95% CI 0.38 to 2.07; 696 participants; four trials), myocardial infarction (OR 1.23, 95% CI 0.56 to 2.70; 696 participants; four trials), and lower-limb amputation (OR 0.84, 95% CI 0.38 to 1.84; 465 participants; three trials).",delete,[],4,0.5384615384615384,3,13
CD007083,0,7,"Pneumonia was less common after neuraxial anaesthesia than after general anaesthesia (OR 0.37, 95% CI 0.15 to 0.89; 201 participants; two trials).",rephrase,['The risk of pneumonia was 9% after neuraxial anaesthesia and 20% after general anaesthesia.'],4,0.6153846153846154,4,13
CD007083,0,8,"Evidence was insufficient for cerebral stroke, duration of hospital stay, postoperative cognitive dysfunction, complications in the anaesthetic recovery room and transfusion requirements.",rephrase,"['Evidence was insufficient to show the effects of neuraxial anaesthesia compared with other types of anaesthesia on cerebral stroke, duration of hospital stay, postoperative cognitive dysfunction, complications in the anaesthetic recovery room and transfusion requirements.']",5,0.6923076923076923,4,13
CD007083,0,9,"No data described nerve dysfunction, postoperative wound infection, patient satisfaction, postoperative pain score, claudication distance and pain at rest.",ignore,"['No data described nerve dysfunction, postoperative wound infection, patient satisfaction, postoperative pain score, claudication distance and pain at rest.']",6,0.7692307692307693,4,13
CD007083,1,10,Available evidence from included trials that compared neuraxial anaesthesia with general anaesthesia was insufficient to rule out clinically important differences for most clinical outcomes.,delete,[],7,0.8461538461538461,5,13
CD007083,1,11,Neuraxial anaesthesia may reduce pneumonia.,rephrase,"['One study recruited more than 50% of all reported cases.This systematic review shows that neuraxial anaesthesia may reduce the risk of pneumonia after lower-limb revascularization, but evidence is insufficient to support other benefits or harms.']",7,0.9230769230769231,5,13
CD007083,1,12,"No conclusions can be drawn with regard to mortality, myocardial infarction and rate of lower-limb amputation, or less common outcomes.",delete,[],8,1.0,5,13
CD005620,0,0,"We included a total of eight studies in this updated review, all of which were RCTs.",delete,[],0,0.043478260869565216,1,23
CD005620,0,1,"Two studies used a parallel-group design, and six used a split-mouth design.",rephrase,"[""Participants in six studies received composite and amalgam fillings in different teeth (known as 'split-mouth design'), whilst participants in the other two studies received either composite or amalgam fillings ('parallel-group' design).""]",0,0.08695652173913043,1,23
CD005620,0,2,We judged all of the included studies to be at high risk of bias due to lack of blinding and issues related to unit of analysis.,delete,[],1,0.13043478260869565,1,23
CD005620,0,3,"We identified one new trial since the previous version of this review (2014), as well as eight additional papers that assessed safety, all of which related to the two parallel-group studies that were already included in the review.",delete,[],1,0.17391304347826086,1,23
CD005620,1,4,"For our primary meta-analyses, we combined data from the two parallel-group trials, which involved 1645 composite restorations and 1365 amalgam restorations in 921 children.",rephrase,['Our main analysis focused on the two parallel-group studies that treated 921 children (aged 6 to 12 years) who had their teeth restored with amalgam (1365) or composite resin (1645) fillings.'],1,0.21739130434782608,2,23
CD005620,1,5,"We found low-certainty evidence that composite resin restorations had almost double the risk of failure compared to amalgam restorations (risk ratio (RR) 1.89, 95% confidence interval (CI) 1.52 to 2.35; P < 0.001), and were at much higher risk of secondary caries (RR 2.14, 95% CI 1.67 to 2.74; P < 0.001).",merge,[],2,0.2608695652173913,2,23
CD005620,1,6,"We found low-certainty evidence that composite resin restorations were not more likely to result in restoration fracture (RR 0.87, 95% CI 0.46 to 1.64; P = 0.66).",none,['We found that composite resin fillings were significantly more likely to fail than\xa0amalgam\xa0fillings when used to fill cavities in permanent teeth at the back of the mouth.'],2,0.30434782608695654,2,23
CD005620,2,7,Six trials used a split-mouth design.,rephrase,"[""Six of the trials used a 'split-mouth' design, which means that each participant had both types of fillings in different teeth.""]",3,0.34782608695652173,2,23
CD005620,2,8,"We considered these studies separately, as their reliability was compromised due to poor reporting, unit of analysis errors, and variability in methods and findings.",delete,[],4,0.391304347826087,2,23
CD005620,2,9,Subgroup analysis showed that the findings were consistent with the results of the parallel-group studies.,split,"[""We analysed the split-mouth studies separately from the parallel-group studies, and undertook a statistical approach known as 'subgroup analysis'."", 'This showed that the findings of these studies were compatible with the results from the two parallel-group studies.']",4,0.43478260869565216,3,23
CD005620,3,10,Three trials investigated possible harms of dental restorations.,delete,[],6,0.4782608695652174,3,23
CD005620,3,11,"Higher urinary mercury levels were reported amongst children with amalgam restorations in two trials, but the levels were lower than what is known to be toxic.",delete,[],6,0.5217391304347826,3,23
CD005620,3,12,"Some differences between amalgam and composite resin groups were observed on certain measures of renal, neuropsychological, and psychosocial function, physical development, and postoperative sensitivity; however, no consistent or clinically important harms were found.",delete,[],6,0.5652173913043478,3,23
CD005620,3,13,We considered that the vast number of comparisons made false-positive results likely.,rephrase,"[""Although we found that there were some possible side effects with each material used, this information is unreliable because the study authors carried out so many analyses that 'false positive' results were likely to be found.""]",6,0.6086956521739131,4,23
CD005620,3,14,"There was no evidence of differences between the amalgam and composite resin groups in neurological symptoms, immune function, and urinary porphyrin excretion.",rephrase,['The current evidence suggests there are no important differences in the safety of amalgam compared with composite resin dental fillings.'],7,0.6521739130434783,4,23
CD005620,3,15,"The evidence is of very low certainty, with most harms outcomes reported in only one trial.",rephrase,"[""We judge the available evidence to be 'low certainty', which means that the results may change with future research.""]",8,0.6956521739130435,4,23
CD005620,4,16,Low-certainty evidence suggests that composite resin restorations may have almost double the failure rate of amalgam restorations.,rephrase,"['Overall, the evidence suggests that amalgam restorations are effective, enduring, and safe, while composite resin restorations are more likely to fail and lead to secondary caries.']",9,0.7391304347826086,4,23
CD005620,4,17,"The risk of restoration fracture does not seem to be higher with composite resin restorations, but there is a much higher risk of developing secondary caries.",delete,[],10,0.782608695652174,4,23
CD005620,4,18,Very low-certainty evidence suggests that there may be no clinically important differences in the safety profile of amalgam compared with composite resin dental restorations.,delete,[],10,0.8260869565217391,5,23
CD005620,5,19,"This review supports the utility of amalgam restorations, and the results may be particularly useful in parts of the world where amalgam is still the material of choice to restore posterior teeth with proximal caries.",delete,[],10,0.8695652173913043,5,23
CD005620,5,20,"Of note, however, is that composite resin materials have undergone important improvements in the years since the trials informing the primary analyses for this review were conducted.",rephrase,"['However, the studies in this review were quite old, and composite resin materials have\xa0likely improved since the included studies were conducted.']",10,0.9130434782608695,5,23
CD005620,5,21,The global phase-down of dental amalgam via the Minamata Convention on Mercury is an important consideration when deciding between amalgam and composite resin dental materials.,rephrase,"['Governments around the world are trying to reduce the use of dental amalgam (according to the Minamata Convention on Mercury), and so each local area will have their own\xa0regulations and guidance.']",11,0.9565217391304348,5,23
CD005620,5,22,"The choice of which dental material to use will depend on shared decision-making between dental providers and patients in the clinic setting, and local directives and protocols.",rephrase,['Patients and dental providers can discuss together which material they want to use when permanent teeth in the back of the mouth require fillings in the dental clinic.'],12,1.0,5,23
CD011157,0,0,We included only one small trial published as an abstract article.,rephrase,"['We included one trial with 91 adult patients, of whom only 42 were analysed.']",0,0.08333333333333333,1,12
CD011157,0,1,The included study investigated the effects of meditation practice on patients newly hospitalised with acute leukaemia.,rephrase,['The trial involved five one-hour meditation intervention sessions between admission and discharge of participants newly diagnosed with acute myeloid or lymphoid leukaemia.'],1,0.16666666666666666,1,12
CD011157,0,2,"Ninety-one participants enrolled in the study, but only 42 participants remained in the trial throughout the six-month follow-up period and were eligible for analysis.",delete,[],2,0.25,2,12
CD011157,0,3,There was no information provided about the average age and sex of the study population.,rephrase,['There was no information about the age of the participants included in the study.'],2,0.3333333333333333,2,12
CD011157,0,4,"We found a high risk for attrition bias and unclear risk for reporting bias, performance and detection bias because of missing data due to abstract publication only, thus we judged the overall risk of bias as high.",delete,[],3,0.4166666666666667,3,12
CD011157,0,5,"According to the GRADE criteria, we judged the overall quality of the body of evidence for all predefined outcomes as 'very low', due to the extent of missing data on the study population, and the small sample size.",rephrase,"[""We judge the quality of the evidence for the outcomes quality of life and depression as 'very low', due to high risk of bias (only 42 out 91 participants were evaluated) and very imprecise results.""]",3,0.5,3,12
CD011157,1,6,"As the abstract publication did not provide numbers and results except P values, we are not able to give more details.",rephrase,"['As the abstract of the publication did not provide numbers, it is not possible to describe the results in more detail.']",4,0.5833333333333334,3,12
CD011157,2,7,"Meditation practice might be beneficial for the quality of life of haematologically-diseased patients, with higher scores for participants in the mediation arms compared to the participants in the usual care control group (low quality of evidence).",delete,[],5,0.6666666666666666,4,12
CD011157,2,8,"Levels of depression decreased for those practising meditation in both the spiritually-framed meditation group and the secularly-focused meditation group in comparison to the usual care control group, whose levels of depression remained constant (low quality of evidence).",rephrase,['Participants practising meditation reported better physical health and levels of depression could be decreased.'],5,0.75,4,12
CD011157,2,9,"The influence of meditation practice on overall survival, fatigue, anxiety, quality of sleep and adverse events remained unclear, as these outcomes were not evaluated in the included trial.",rephrase,"['Most of our pre-defined outcomes (overall survival, anxiety, fatigue, quality of sleep, and adverse events) were not reported at all.']",6,0.8333333333333334,5,12
CD011157,3,10,"To estimate the effects of meditation practice for patients suffering from haematological malignancies, more high quality randomised controlled trials are needed.",rephrase,['More high-quality and larger randomised controlled trials are needed to validate possible positive effects of meditation practice for haematologically-diseased patients.'],7,0.9166666666666666,5,12
CD011157,3,11,At present there is not enough information available on the effects of meditation in haematologically-diseased patients to draw any conclusion.,rephrase,"['There were not enough data available to determine the effectiveness of meditation practice on haematologically-diseased patients, thus the role of meditation in the treatment of haematological malignancies remains unclear.']",8,1.0,5,12
CD012058,0,0,We included in this review a total of 17 studies with 1988 participants (evidence current until November 2017).,rephrase,['We included 17 studies that had a total of 1988 participants (evidence current until November 2017).'],0,0.05,1,20
CD012058,0,1,"Three studies limited their inclusion to people with intermittent claudication, 12 limited inclusion to people with varying levels of critical limb ischaemia, and two included people with either condition.",rephrase,['Most of the studies included people with critical limb ischaemia; three studies included people with intermittent claudication.'],1,0.1,1,20
CD012058,0,2,"Study investigators evaluated many different types of gene therapies, using different protocols.",rephrase,"['These studies used various types of gene therapy as well as different dosages, some providing single treatments and some repeated treatments.']",2,0.15,1,20
CD012058,0,3,"Most studies evaluated growth factor-encoding gene therapy, with six studies using vascular endothelial growth factor (VEGF)-encoding genes, four using hepatocyte growth factor (HGF)-encoding genes, and three using fibroblast growth factor (FGF)-encoded genes.",delete,[],3,0.2,1,20
CD012058,0,4,"Two studies evaluated hypoxia-inducible factor 1-alpha (HIF-1α) gene therapy, one study used a developmental endothelial locus-1 gene therapy, and the final study evaluated a stromal cell-derived factor-1 (SDF-1) gene therapy.",delete,[],3,0.25,2,20
CD012058,0,5,"Most studies reported outcomes after 12 months of follow-up, but follow-up ranged from three months to two years.",delete,[],3,0.3,2,20
CD012058,1,6,"Overall risk of bias varied between studies, with many studies not providing sufficient detail for adequate determination of low risk of bias for many domains.",rephrase,"['Risk of bias of the included studies varied greatly, and this was a concern because studies did not clearly report on their methods nor on follow-up of participants.']",3,0.35,2,20
CD012058,1,7,"Two studies did not utilise a placebo control, leading to risk of performance bias.",rephrase,"['Most studies used a placebo control, which increases the risk that outcomes may have been different if people knew they were given treatment or control.']",4,0.4,2,20
CD012058,1,8,"Several studies reported in previous protocols or in their Methods sections that they would report on certain outcomes for which no data were then reported, increasing risk of reporting bias.",delete,[],5,0.45,3,20
CD012058,1,9,All included studies reported sponsorships from corporate entities that led to unclear risk of other bias.,rephrase,['Corporations that produce the tested treatments sponsored all included trials.'],5,0.5,3,20
CD012058,1,10,"The overall quality of evidence ranged from moderate to very low, generally as the result of heterogeneity and imprecision, with few or no studies reporting on outcomes.",rephrase,['The quality of evidence varied from moderate to very low.'],6,0.55,3,20
CD012058,2,11,"Evidence suggests no clear differences for the outcomes of amputation-free survival, major amputation, and all-cause mortality between those treated with gene therapy and those not receiving this treatment (all moderate-quality evidence).",rephrase,"['When combining the data, we found no clear differences between people who received gene therapy and those who did not in terms of amputation-free survival (patients who did not have an amputation and did not die), major amputation (above the ankle), or death.']",7,0.6,3,20
CD012058,2,12,"Low-quality evidence suggests improvement in complete ulcer healing with gene therapy (odds ratio (OR) 2.16, 95% confidence interval (CI) 1.02 to 4.59; P = 0.04).",rephrase,['We did see improvement in complete ulcer healing in the gene therapy treatment group compared to the control group.'],8,0.65,4,20
CD012058,2,13,We could not combine data on quality of life and can draw no conclusions at this time regarding this outcome (very low-quality evidence).,rephrase,['We were not able to combine data on quality of life or pain-free walking distances (distances one can walk without experiencing leg pain).'],9,0.7,4,20
CD012058,2,14,"We included one study in the meta-analysis for ankle brachial index, which showed no clear differences between treatments, but we can draw no overall association (low-quality evidence).",rephrase,['The quality of evidence for the ankle brachial index was low because only one study with few participants reported this outcome.'],10,0.75,4,20
CD012058,2,15,We combined in a meta-analysis pain symptom scores as assessed by visual analogue scales from two studies and found no clear differences between treatment groups (very low-quality evidence).,rephrase,"['Studies show no clear differences in pain symptom scores, but we evaluated only two studies for this outcome.']",11,0.8,4,20
CD012058,2,16,"We carried out extensive subgroup analyses by PAD classification, dosage schedule, vector type, and gene used but identified no substantial differences.",delete,[],12,0.85,5,20
CD012058,3,17,"Moderate-quality evidence shows no clear differences in amputation-free survival, major amputation, and all-cause mortality between those treated with gene therapy and those not receiving gene therapy.",delete,[],12,0.9,5,20
CD012058,3,18,"Some evidence suggests that gene therapy may lead to improved complete ulcer healing, but this outcome needs to be explored with improved reporting of the measure, such as decreased ulcer area in cm², and better description of ulcer types and healing.",delete,[],12,0.95,5,20
CD012058,3,19,"Further standardised data that are amenable to meta-analysis are needed to evaluate other outcomes such as quality of life, ankle brachial index, symptom scores, and claudication distance.",delete,[],12,1.0,5,20
CD004142,0,0,"We included a total of 12 trials with 854 women in the review, with 10 trials and 754 women in the meta-analysis.",split,"['We found 12 studies including 854 women that examined the effect of exercise in women with period pain.', 'Two trials did not report data suitable to be included in the meta-analysis, so we included 10 trials with 754 women in our meta-analysis.']",0,0.0625,1,16
CD004142,0,1,"Nine of the 10 studies compared exercise with no treatment, and one study compared exercise with NSAIDs.",merge,['Eleven trials compared exercise with no treatment and one compared exercise with NSAIDs.'],2,0.125,1,16
CD004142,0,2,No studies compared exercise with attention control or with the oral contraceptive pill.,none,[],2,0.1875,1,16
CD004142,0,3,"Studies used low-intensity exercise (stretching, core strengthening or yoga) or high-intensity exercise (Zumba or aerobic training); none of the included studies used resistance training.",rephrase,"['Exercise, whether low-intensity, such as yoga, or high-intensity, such as aerobics, may provide a large reduction in the intensity of period pain, compared to not doing anything.']",3,0.25,2,16
CD004142,1,4,"Exercise versus no treatment
Exercise may have a large effect on reducing menstrual pain intensity compared to no exercise (standard mean difference (SMD) -1.86, 95% confidence interval (CI) -2.06 to -1.66; 9 randomised controlled trials (RCTs), n = 632; I2= 91%; low-quality evidence).",delete,[],4,0.3125,2,16
CD004142,1,5,This SMD corresponds to a 25 mm reduction on a 100 mm visual analogue scale (VAS) and is likely to be clinically significant.,delete,[],4,0.375,2,16
CD004142,1,6,We are uncertain if there is any difference in adverse event rates between exercise and no treatment.,delete,[],4,0.4375,3,16
CD004142,2,7,"We are uncertain if exercise reduces overall menstrual symptoms (as measured by the Moos Menstrual Distress Questionnaire (MMDQ)), such as back pain or fatigue compared to no treatment (mean difference (MD) -33.16, 95% CI -40.45 to -25.87; 1 RCT, n = 120; very low-quality evidence), or improves mental quality of life (MD 4.40, 95% CI 1.59 to 7.21; 1 RCT, n = 55; very low-quality evidence) or physical quality of life (as measured by the 12-Item Short Form Health Survey (SF-12)) compared to no exercise (MD 3.40, 95% CI -1.68 to 8.48; 1 RCT, n = 55; very low-quality evidence) when compared to no treatment.",delete,[],4,0.5,3,16
CD004142,2,8,No studies reported on any changes in restriction of daily life activities or on absence from work or school.,rephrase,['No studies reported on rates of being absent from work or school or on restrictions of daily life activities.'],4,0.5625,3,16
CD004142,3,9,"Exercise versus NSAIDs
We are uncertain if exercise, when compared with mefenamic acid, reduced menstrual pain intensity (MD -7.40, 95% CI -8.36 to -6.44; 1 RCT, n = 122; very low-quality evidence), use of rescue analgesic medication (risk ratio (RR) 1.77, 95% CI 1.21 to 2.60; 1 RCT, n = 122; very low-quality evidence) or absence from work or school (RR 1.00, 95% CI 0.49 to 2.03; 1 RCT, n = 122; very low-quality evidence).",rephrase,"['There was not enough evidence to determine if there was any benefit of exercise when compared to NSAIDs, a class of medications (like ibuprofen) commonly used to treat period pain, on menstrual pain intensity, need for additional pain-relieving medication, or absence from work or school.']",5,0.625,4,16
CD004142,3,10,"None of the included studies reported on adverse events, overall menstrual symptoms, restriction of daily life activities or quality of life.",rephrase,['No studies reported on quality of life or restriction of daily life activities'],6,0.6875,4,16
CD004142,4,11,"The current low-quality evidence suggests that exercise, performed for about 45 to 60 minutes each time, three times per week or more, regardless of intensity, may provide a clinically significant reduction in menstrual pain intensity of around 25 mm on a 100 mm VAS.",rephrase,"['Most studies asked women to exercise at least three times per week, for about 45 to 60 minutes of exercise each time.']",7,0.75,4,16
CD004142,4,12,"All studies used exercise regularly throughout the month, with some studies asking women not to exercise during menstruation.",rephrase,"['Exercise was performed regularly throughout the month, with some studies asking women not to perform exercise during the period itself.']",8,0.8125,5,16
CD004142,4,13,"Given the overall health benefits of exercise, and the relatively low risk of side effects reported in the general population, women may consider using exercise, either alone or in conjunction with other modalities, such as NSAIDs, to manage menstrual pain.",delete,[],9,0.875,5,16
CD004142,4,14,It is unclear if the benefits of exercise persist after regular exercise has stopped or if they are similar in women over the age of 25.,rephrase,"['It is unclear if exercising less frequently, or for a shorter duration would have the same results.']",9,0.9375,5,16
CD004142,4,15,"Further research is required, using validated outcome measures, adequate blinding and suitable comparator groups reflecting current best practice or accounting for the extra attention given during exercise.",delete,[],10,1.0,5,16
CD009477,0,0,We included seven small RCTs involving 691 participants aged 17 to 78 years in our meta analyses.,rephrase,"['After searching for all relevant studies to August 2015, we found seven small randomized controlled trials (considered the highest quality study design) involving 691 participants aged 17 to 78 years.']",0,0.125,1,8
CD009477,0,1,The primary result showed that periodontal therapy combined with H. pylori eradication treatment increased the eradication rate of gastric H. pylori compared with eradication treatment alone (OR 2.15; 95% CI 1.47 to 3.14; P < 0.0001) in people with H. pylori infection.,merge,[],1,0.25,2,8
CD009477,0,2,"In addition, periodontal therapy also had benefits on long-term gastric H. pylori eradication.",none,['The results indicated that periodontal therapy as an added treatment had some benefits on eradication of gastricH.'],1,0.375,2,8
CD009477,0,3,"After eradication of H. pylori, the non-recurrence rate of gastric H. pylori infection increased in participants treated with periodontal therapy compared with those who received eradication therapy alone (OR 3.60; 95% CI 2.11 to 6.15; P < 0.00001).",delete,[],2,0.5,3,8
CD009477,0,4,"According to the GRADE approach, the overall quality of the evidence was 'moderate' for eradication rate of gastric H.pylori and 'low' for non-recurrence rate of gastric H. pylori.",delete,[],2,0.625,4,8
CD009477,1,5,"Overall, periodontal therapy could increase the efficiency of H. pylori eradication and the non-recurrence rate of gastricH.",rephrase,"['The eradication (the reduction of the prevalence of H. pylori in stomach to normal range) and non-recurrence (the proportion of participants that remained free of gastric H. pylori after successful eradication therapy) rates increased in people who received periodontal therapy plus eradication treatment, when compared with those who received eradication treatment alone.']",2,0.75,4,8
CD009477,1,6,pylori.,rephrase,['pylori for short-term and long-term follow-up.'],3,0.875,5,8
CD009477,1,7,"In view of the limited number and quality of included studies, it will be necessary to conduct more well-designed, multicenter, and large-scale RCTs to determine the effects of periodontal therapy in eradicating gastric H. pylori and suppressing the recurrence of this bacterium in the stomach.",delete,[],4,1.0,5,8
CD008312,0,0,We included 20 studies reporting data on 2832 participants.,rephrase,['We identified 20 studies (2832 participants).'],0,0.07142857142857142,1,14
CD008312,0,1,"Thirteen studies targeted adults with epilepsy, one study included participants of all ages, one study included participants older than two years, one recruited pediatric patients aged between 1 month to 15 years, one study targeted caregivers of children with epilepsy, one targeted adolescents and caregivers, and two studies targeted families of children with epilepsy.",delete,[],1,0.14285714285714285,1,14
CD008312,0,2,We identified three ongoing studies.,delete,[],1,0.21428571428571427,2,14
CD008312,0,3,"Follow-up time was generally short in most studies, ranging from 1 to 12 months.",delete,[],1,0.2857142857142857,2,14
CD008312,0,4,"The studies examined three main types of interventions: educational interventions, behavioural interventions and mixed interventions.",rephrase,"['The studies examined three main types of interventions:\n1. education and counselling of participants about topics such as epilepsy and medication used to control epilepsy (4 studies);\n2. behavioural interventions, such as asking people with epilepsy to link the intention of taking their medication with a particular time, place and other routine activity (13 studies); and\n3. mixed interventions, which is the use of more than one intervention (4 studies).']",1,0.35714285714285715,2,14
CD008312,0,5,All but three studies compared treatment with usual care or 'no intervention'.,rephrase,['One study is counted twice because it compared a behavioural intervention with a mixed intervention.'],2,0.42857142857142855,3,14
CD008312,0,6,"Due to heterogeneity between studies in terms of interventions, methods used to measure adherence and the way the studies were reported, we did not pool the results and these findings were inappropriate to be included in a meta-analysis.",rephrase,"['Studies measured adherence to medication in various ways, for example, with questionnaires, blood samples or electronic bottle tops.']",3,0.5,3,14
CD008312,1,7,Education and counselling of participants with epilepsy had mixed success (moderate-certainty evidence).,delete,[],4,0.5714285714285714,3,14
CD008312,1,8,Behavioural interventions such as the use of intensive reminders provided more favourable effects on adherence (moderate-certainty evidence).,rephrase,['Behavioural and mixed interventions probably improve adherence to medication.'],4,0.6428571428571429,4,14
CD008312,1,9,The effect on adherence to antiepileptic drugs described by studies of mixed interventions showed improved adherence in the intervention groups compared to the control groups (high-certainty evidence).,rephrase,['People in the intervention groups showed improved adherence compared to the control groups.'],5,0.7142857142857143,4,14
CD008312,2,10,"Eleven studies described seizure frequency or seizure severity or both, with four of them, reporting improved adherence and decreased seizure frequency in the intervention groups (moderate-certainty evidence).",rephrase,"['Four studies showed that when adherence improved in the intervention groups, seizure frequency or seizure severity was decreased.']",6,0.7857142857142857,4,14
CD008312,2,11,"Findings related to self-efficacy and quality of life were mixed, with no clear pattern across types of intervention.",delete,[],7,0.8571428571428571,5,14
CD008312,3,12,"Behavioural interventions such as intensive reminders and the use of mixed interventions demonstrate some positive results, however, we need more reliable evidence on their efficacy, derived from carefully-designed RCTs before we can draw a firm conclusion.",delete,[],7,0.9285714285714286,5,14
CD008312,3,13,None of the newly included studies have provided additional information that would lead to significant changes in our conclusions.,delete,[],7,1.0,5,14
CD012930,0,0,We identified and included 22 RCTs randomly assigning 8641 people with COPD to either once-daily LABA/LAMA FDC (6252 participants) or placebo (3819 participants); nine studies had a cross-over design.,rephrase,['Twenty-two studies (including 8641 people with COPD) compared once-daily LABA/LAMA in a single inhaler with a dummy inhaler.'],0,0.08333333333333333,1,12
CD012930,0,1,Studies had a duration of between three and 52 weeks (median 12 weeks).,delete,[],1,0.16666666666666666,1,12
CD012930,0,2,"The mean age of participants across the included studies ranged from 59 to 65 years and in 21 of 22 studies, participants had GOLD stage II or III COPD.",rephrase,['The majority of people who took part in the studies had mild-to-moderate COPD and the average age of people in each study ranged from 59 to 65 years.'],1,0.25,2,12
CD012930,0,3,"Concomitant inhaled corticosteroid (ICS) use was permitted in all of the included studies (where stated); across the included studies, between 28% to 58% of participants were using ICS at baseline.",rephrase,['People were allowed to continue to use their inhaled corticosteroids (ICS) during the studies; approximately a third to a half of people were using their ICS at the beginning of each study.'],2,0.3333333333333333,2,12
CD012930,0,4,"Six studies evaluated the once-daily combination of IND/GLY (110/50 μg), seven studies evaluated TIO/OLO (2.5/5 or 5/5 μg), eight studies evaluated UMEC/VI (62.5/5, 125/25 or 500/25 μg) and one study evaluated ACD/FOR (200/6, 200/12 or 200/18 μg); all LABA/LAMA combinations were compared with placebo.",rephrase,"['Six studies evaluated the once-daily combination of indacaterol/glycopyrronium, seven studies evaluated tiotropium/olodaterol, eight studies evaluated umeclidinium/vilanterol and one study evaluated aclidinium/formoterol.']",3,0.4166666666666667,3,12
CD012930,1,5,"The risk of bias was generally considered to be low or unknown (insufficient detail provided), with only one study per domain considered to have a high risk of bias except for the domain 'other bias' which was determined to be at high risk of bias in four studies (in three studies, disease severity was greater at baseline in participants receiving LABA/LAMA compared with participants receiving placebo, which would be expected to shift the treatment effect in favour of placebo).",delete,[],4,0.5,3,12
CD012930,2,6,"Compared to the placebo, the pooled results for the primary outcomes for the once-daily LABA/LAMA arm were as follows: all-cause mortality, OR 1.88 (95% CI 0.81 to 4.36, low-certainty evidence); all-cause serious adverse events (SAEs), OR 1.06 (95% CI 0.88 to 1.28, high-certainty evidence); acute exacerbations of COPD (AECOPD), OR 0.53 (95% CI 0.36 to 0.78, moderate-certainty evidence); adjusted St George's Respiratory Questionnaire (SGRQ) score, MD -4.08 (95% CI -4.80 to -3.36, high-certainty evidence); proportion of SGRQ responders, OR 1.75 (95% CI 1.54 to 1.99).",delete,[],4,0.5833333333333334,3,12
CD012930,2,7,"Compared with placebo, the pooled results for the secondary outcomes for the once-daily LABA/LAMA arm were as follows: adjusted trough forced expiratory volume in one second (FEV1), MD 0.20 L (95% CI 0.19 to 0.21, moderate-certainty evidence); adjusted peak FEV1, MD 0.31 L (95% CI 0.29 to 0.32, moderate-certainty evidence); and all-cause AEs, OR 0.95 (95% CI 0.86 to 1.04; high-certainty evidence).",delete,[],4,0.6666666666666666,4,12
CD012930,2,8,No studies reported data for the 6-minute walk test.,rephrase,['One of the outcomes of interest (how far a person is able to walk in six minutes) was not reported by any of the included studies.'],4,0.75,4,12
CD012930,2,9,The results were generally consistent across subgroups for different LABA/LAMA combinations and doses.,rephrase,['The results were similar for the different LABA/LAMA combinations and doses that we evaluated.'],5,0.8333333333333334,5,12
CD012930,3,10,"Compared with placebo, once-daily LABA/LAMA (either IND/GLY, UMEC/VI or TIO/OLO) via a combination inhaler is associated with a clinically significant improvement in lung function and health-related quality of life in patients with mild-to-moderate COPD; UMEC/VI appears to reduce the rate of exacerbations in this population.",rephrase,['People who took once-daily LABA/LAMA using a single inhaler showed a greater improvement in quality of life than those taking placebo in a dummy inhaler; lung function was also improved in people taking once-daily LABA/LAMA.'],6,0.9166666666666666,5,12
CD012930,3,11,These conclusions are supported by moderate or high certainty evidence based on studies with an observation period of up to one year.,delete,[],7,1.0,5,12
CD002058,0,0,We included two trials that involved 294 infants.,split,"['We included two trials that involved 294 infants.', 'One study included 278 infants and the other study included 16 infants.']",0,0.058823529411764705,1,17
CD002058,0,1,No new studies were included for the 2017 update.,ignore,['No new studies were included for the 2017 update.'],2,0.11764705882352941,1,17
CD002058,0,2,"The incidence of death or BPD at 36 weeks' postmenstrual age was not statistically significantly different between infants who received inhaled or systemic steroids (RR 1.09, 95% CI 0.88 to 1.35; RD 0.05, 95% CI -0.07 to 0.16; 1 trial, N = 278).",delete,[],3,0.17647058823529413,1,17
CD002058,0,3,"The incidence of BPD at 36 weeks' postmenstrual age among survivors was not statistically significant between groups (RR 1.34, 95% CI 0.94 to 1.90; RD 0.11, 95% CI -0.02 to 0.24; 1 trial, N = 206).",delete,[],3,0.23529411764705882,2,17
CD002058,0,4,"There was no statistically significant difference in the outcomes of BPD at 28 days, death at 28 days or 36 weeks' postmenstrual age and the combined outcome of death or BPD by 28 days between groups (2 trials, N = 294).",delete,[],3,0.29411764705882354,2,17
CD002058,0,5,"The duration of mechanical ventilation was significantly longer in the inhaled steroid group compared with the systemic steroid group (typical MD 4 days, 95% CI 0.2 to 8; 2 trials, N = 294; I² = 0%) as was the duration of supplemental oxygen (typical MD 11 days, 95% CI 2 to 20; 2 trials, N = 294; I² = 33%).",delete,[],3,0.35294117647058826,2,17
CD002058,1,6,"The incidence of hyperglycaemia was significantly lower with inhaled steroids (RR 0.52, 95% CI 0.39 to 0.71; RD -0.25, 95% CI -0.37 to -0.14; 1 trial, N = 278; NNTB 4, 95% CI 3 to 7 to avoid 1 infant experiencing hyperglycaemia).",delete,[],3,0.4117647058823529,3,17
CD002058,1,7,"The rate of patent ductus arteriosus increased in the group receiving inhaled steroids (RR 1.64, 95% CI 1.23 to 2.17; RD 0.21, 95% CI 0.10 to 0.33; 1 trial, N = 278; NNTH 5, 95% CI 3 to 10).",rephrase,"['The rate of patent ductus arteriosus (failure for the ductus arteriosus, an arterial shunt in fetal life, to close after birth) was increased in the group receiving inhaled steroids.']",3,0.47058823529411764,3,17
CD002058,1,8,In a subset of surviving infants in the United Kingdom and Ireland there were no significant differences in developmental outcomes at 7 years of age.,rephrase,['In a sub-sample of 52 children at age 7 years there were no differences in long-term follow-up outcomes between the inhaled and the systemic steroid groups.'],4,0.5294117647058824,3,17
CD002058,1,9,"However, there was a reduced risk of having ever been diagnosed as asthmatic by 7 years of age in the inhaled steroid group compared with the systemic steroid group (N = 48) (RR 0.42, 95% CI 0.19 to 0.94; RD -0.31, 95% CI -0.58 to -0.05; NNTB 3, 95% CI 2 to 20).",rephrase,"[""in an even smaller sample of 48 infants the outcome of 'ever diagnosed as asthmatic by seven years of age' was significantly lower in the inhaled steroid group compared with the systemic steroid group.""]",5,0.5882352941176471,3,17
CD002058,2,10,According to GRADE the quality of the evidence was moderate to low.,ignore,['According to GRADE the quality of the evidence was moderate to low.'],6,0.6470588235294118,4,17
CD002058,2,11,"Evidence was downgraded on the basis of design (risk of bias), consistency (heterogeneity) and precision of the estimates.",delete,[],7,0.7058823529411765,4,17
CD002058,3,12,Both studies received grant support and the industry provided aero chambers and metered dose inhalers of budesonide and placebo for the larger study.,ignore,['Both studies received grant support and the industry provided aero chambers and metered dose inhalers of budesonide and placebo for the larger study.'],7,0.7647058823529411,4,17
CD002058,3,13,No conflict of interest was identified.,ignore,['No conflict of interest was identified.'],8,0.8235294117647058,5,17
CD002058,4,14,We found no evidence that early inhaled steroids confer important advantages over systemic steroids in the management of ventilator-dependent preterm infants.,merge,['There was no evidence that inhaling steroids compared to systemic steroids prevented the primary outcome of death or bronchopulmonary dysplasia.'],9,0.8823529411764706,5,17
CD002058,4,15,Based on this review inhaled steroids cannot be recommended over systemic steroids as a part of standard practice for ventilated preterm infants.,none,[],9,0.9411764705882353,5,17
CD002058,4,16,"Because they might have fewer adverse effects than systemic steroids, further randomised controlled trials of inhaled steroids are needed that address risk/benefit ratio of different delivery techniques, dosing schedules and long-term effects, with particular attention to neurodevelopmental outcome.",delete,[],10,1.0,5,17
CD001250,0,0,"Six trials were included, involving 606 participants.",split,"['Six trials were included in the review.', 'The six trials involved a total of 606 participants with acute ankle sprains of relatively short duration.']",0,0.1111111111111111,1,9
CD001250,0,1,Five trials included comparisons of ultrasound therapy with sham ultrasound; and three trials included single comparisons of ultrasound with three other treatments.,split,"['Five trials compared ultrasound therapy with sham ultrasound (machine turned off).', 'Three of the six trials included single comparisons of ultrasound with three other treatments.']",2,0.2222222222222222,2,9
CD001250,0,2,The assessment of risk of bias was hampered by poor reporting of trial methods and results.,rephrase,['Poor reporting of trial methods made it difficult to assess the risk of bias of the included studies.'],4,0.3333333333333333,2,9
CD001250,0,3,None of the five placebo-controlled trials (sham ultrasound) demonstrated statistically significant differences between true and sham ultrasound therapy for any outcome measure at one to four weeks of follow-up.,rephrase,['The main results were from the review of the five placebo-controlled trials (sham ultrasound).'],5,0.4444444444444444,3,9
CD001250,0,4,"The pooled risk ratio for general improvement at one week was 1.04 (random-effects model, 95% confidence interval 0.92 to 1.17) for active versus sham ultrasound.",delete,[],6,0.5555555555555556,3,9
CD001250,0,5,"The differences between intervention groups were generally small, between zero and six per cent, for most dichotomous outcomes.",delete,[],6,0.6666666666666666,4,9
CD001250,1,6,The evidence from the five small placebo-controlled trials included in this review does not support the use of ultrasound in the treatment of acute ankle sprains.,rephrase,['The review aimed to look at the evidence from studies testing the use of ultrasound in clinical practice.'],6,0.7777777777777778,4,9
CD001250,1,7,"The potential treatment effects of ultrasound appear to be generally small and of probably of limited clinical importance, especially in the context of the usually short-term recovery period for these injuries.",rephrase,"['While ultrasound may still improve recovery in a small way, this potential benefit is probably too small to be important.']",7,0.8888888888888888,5,9
CD001250,1,8,"However, the available evidence is insufficient to rule out the possibility that there is an optimal dosage schedule for ultrasound therapy that may be of benefit.",delete,[],8,1.0,5,9
CD004791,0,0,Nine trials were included in the review.,ignore,['Nine trials are included in the review.'],0,0.08333333333333333,1,12
CD004791,0,1,"Seven trials, comparing antibiotics to placebo or no treatment, were meta-analysed.",delete,[],1,0.16666666666666666,1,12
CD004791,0,2,Systematic bias in design or publication is suggested by trial results.,delete,[],1,0.25,2,12
CD004791,0,3,The randomisation results suggest that the probability that true randomisation took place in all trials is very small and the report of most trials regarding design was poor.,delete,[],1,0.3333333333333333,2,12
CD004791,0,4,The proportion of participants with spontaneous bacterial peritonitis varied between the trials from 15% to 50%.,rephrase,['This systematic review of randomised clinical trials assesses whether antibiotic prophylaxis prevents spontaneous bacterial peritonitis and mortality among cirrhotic patients with ascites (excess fluid in the abdominal cavity) and no gastrointestinal bleeding.'],1,0.4166666666666667,3,12
CD004791,0,5,The calculated relative risks (95% confidence interval) of spontaneous bacterial peritonitis and mortality among patients treated with antibiotics compared with no treatment/placebo were 0.20 (0.11 to 0.37) and 0.61 (0.43 to 0.87).,rephrase,['The pooled rates of spontaneous bacterial peritonitis and mortality indicate that antibiotic prophylaxis reduces both.'],2,0.5,3,12
CD004791,0,6,There were very few reports of adverse events.,ignore,['There are very few reports of adverse events.'],3,0.5833333333333334,3,12
CD004791,1,7,The pooled estimates suggest that antibiotic prophylaxis might be prudent among cirrhotic patients with ascites and no gastrointestinal bleeding.,rephrase,"['Thus, the recommendation to prescribe prophylactic antibiotics to cirrhotic patients without gastrointestinal bleeding is hampered by quality of the trials that generated the data.']",4,0.6666666666666666,4,12
CD004791,1,8,"However, poor trial methodology and report coupled with findings suggesting systematic bias in publication and design reflect the fragility of these findings.",rephrase,"['Reviewing these trials, we found poor methodology, evidence suggesting publication bias, and limited follow-up periods.']",5,0.75,4,12
CD004791,1,9,Potential hazard to society and the patients themselves from resistant pathogens should be considered when promoting long-lasting antibiotic prophylaxis.,merge,"['Due to potential hazards, both to society as a whole and the patients, as individuals, before antibiotic prophylaxis can be confidently recommended, trials of better design, well reported, and of longer follow-up are required.']",6,0.8333333333333334,5,12
CD004791,1,10,It seems that recommending antibiotic prophylaxis is still far from being a substantiated prevention strategy.,merge,[],6,0.9166666666666666,5,12
CD004791,1,11,"Trials of better design, well reported, and of longer follow-up are greatly needed.",none,[],6,1.0,5,12
CD000398,0,0,"We included five completed trials, involving 4197 participants; all tested transdermal glyceryl trinitrate (GTN), an NO donor.",rephrase,"['We included five trials involving 4197 people; all trials assessed glyceryl trinitrate, a drug that is given as a skin patch and which releases nitric oxide.']",0,0.1,1,10
CD000398,0,1,"The assessed risk of bias was low across the included studies; one study was double-blind, one open-label and three were single-blind.",delete,[],1,0.2,1,10
CD000398,0,2,All included studies had blinded outcome assessment.,delete,[],1,0.3,2,10
CD000398,0,3,"Overall, GTN did not improve the primary outcome of death or dependency at the end of trial (modified Rankin Scale (mRS) > 2, OR 0.97, 95% CI 0.86 to 1.10, 4195 participants, high-quality evidence).",rephrase,"['Overall, glyceryl trinitrate did not improve the rate of death or dependency compared with those who did not receive glyceryl trinitrate after acute stroke.']",1,0.4,2,10
CD000398,0,4,"GTN did not improve secondary outcomes, including death (OR 0.78, 95% CI 0.40 to 1.50) and quality of life (MD -0.01, 95% CI -0.17 to 0.15) at the end of trial overall (high-quality evidence).",rephrase,['Glyceryl trinitrate did not improve other outcomes including death and quality of life.'],2,0.5,3,10
CD000398,0,5,Systolic/diastolic blood pressure (BP) was lower in people treated with GTN (MD -7.2 mmHg (95% CI -8.6 to -5.9) and MD -3.3 (95% CI -4.2 to -2.5) respectively) and heart rate was higher (MD 2.0 beats per minute (95% CI 1.1 to 2.9)).,delete,[],3,0.6,3,10
CD000398,0,6,"Headache was more common in those randomised to GTN (OR 2.37, 95% CI 1.55 to 3.62).",delete,[],3,0.7,4,10
CD000398,0,7,"We did not find any trials assessing other nitrates, L-arginine, or NOS-I.",rephrase,"['We did not find any trials assessing other nitrate drugs, L-arginine, or nitric oxide synthase inhibitors.']",3,0.8,4,10
CD000398,1,8,"There is currently insufficient evidence to recommend the use of NO donors, L-arginine or NOS-I in acute stroke, and only one drug (GTN) has been assessed.",rephrase,['There is currently insufficient evidence to recommend the use of drugs affecting nitric oxide production in acute stroke.'],4,0.9,5,10
CD000398,1,9,"In people with acute stroke, GTN reduces blood pressure, increases heart rate and headache, but does not alter clinical outcome (all based on high-quality evidence).",rephrase,"['Glyceryl trinitrate lowers blood pressure, and increases heart rate and headache in people with acute stroke.']",5,1.0,5,10
CD009468,0,0,"Only one study met the inclusion criteria, an RCT conducted in Tanzania between May 2003 and October 2004.",rephrase,['The study was performed in 2003-2004 in Tanzania.'],0,0.1111111111111111,1,9
CD009468,0,1,"Women in the intervention group (n=760) received a letter for their male partners, which invited them to return together to receive Couple Voluntary Counselling and Testing (CVCT) for HIV.",rephrase,"['Pregnant women in the intervention group were provided with a letter inviting their male partners to accompany them to their next visit, in which they were offered voluntary HIV counselling and testing (VCT) together or separately.']",1,0.2222222222222222,2,9
CD009468,0,2,Women in the control group (n=761) received individual HIV VCT during their first ANC visit and then usual care.,rephrase,['Women in the control group received the VCT individually during their first visit.'],2,0.3333333333333333,2,9
CD009468,0,3,"The percentages of women who received HIV VCT and collected their results were 48%, 45% and 39% in the intervention group and 93%, 78% and 71% in the control group (p <0,001).",rephrase,['The proportions of women that received VCT and collected their HIV test results were significantly lower in the intervention group than in the control group.'],3,0.4444444444444444,3,9
CD009468,0,4,Only 33% of women in the intervention group returned with their male partners and only 47% of them went through the whole CVCT process.,rephrase,['Most of the women in the intervention group did not return to the clinic for the subsequent visit and most of those that returned accompanied refused to receive VCT together with their male partners.'],4,0.5555555555555556,3,9
CD009468,0,5,The proportion of women who received HIV prophylaxis at delivery was not different between the two arms (27% in the intervention and 22% in the control group).,delete,[],5,0.6666666666666666,4,9
CD009468,0,6,The study had a high risk of bias.,delete,[],5,0.7777777777777778,4,9
CD009468,1,7,"We found only one eligible study that assessed the effectiveness of male involvement in improving women’s uptake of PMTCT services, which only focused on one part of the perinatal PMTCT cascade.",merge,[],5,0.8888888888888888,5,9
CD009468,1,8,We urgently need more rigorously designed studies assessing the impact of male engagement interventions on women’s uptake of PMTCT services to know if this intervention can contribute to improve uptake of PMTCT services and reduce vertical transmission of HIV in children.,none,['We urgently need more studies assessing different interventions to improve male engagement in PMTCT to identify the most successful approach for women to safely access health care for their own health and to deliver HIV negative children.'],5,1.0,5,9
CD010784,0,0,"We included 14 studies with a total of 978 randomised participants in our review, informing eight comparisons.",rephrase,"['We included 14 studies with a total of 978 randomised children with stones in either the kidney or ureter, which connects the kidney to the bladder.']",0,0.05555555555555555,1,18
CD010784,0,1,The studies contributing to most comparisons were at high or unclear risk of bias for most domains.,delete,[],1,0.1111111111111111,1,18
CD010784,1,2,"Shock wave lithotripsy versus dissolution therapy for intrarenal stones: based on one study (87 participants) and consistently very low quality evidence, we are uncertain about the effects of SWL on stone-free rate (SFR), serious adverse events or complications of treatment and secondary procedures for residual fragments.",rephrase,"['Shock waves versus medication to dissolve stones: we are uncertain about the effect on successful removal of stones, serious complications and the need for a second procedure to treat the stones.']",1,0.16666666666666666,1,18
CD010784,2,3,"Slow shock wave lithotripsy versus rapid shock wave lithotripsy for renal stones: based on one study (60 participants) and consistently very low quality evidence, we are uncertain about the effects of SWL on SFR, serious adverse events or complications of treatment and secondary procedures for residual fragments.",rephrase,['Shock waves given slowly versus shock waves given fast: we are uncertain about the effect of slow shock waves on successful removal of stones.'],2,0.2222222222222222,2,18
CD010784,3,4,"Shock wave lithotripsy versus ureteroscopy with holmium laser or pneumatic lithotripsy for renal and distal ureteric stones: based on three studies (153 participants) and consistently very low quality evidence, we are uncertain about the effects of SWL on SFR, serious adverse events or complications of treatment and secondary procedures.",split,"['Shock waves versus treatment using a scope through the bladder to break up the stone: we are uncertain about the effect of shock waves on successful removal of stones compared to using a scope.', 'We are also uncertain about the effect on serious complications and the need for other procedures.']",3,0.2777777777777778,2,18
CD010784,4,5,"Shock wave lithotripsy versus mini-percutaneous nephrolithotripsy for renal stones: based on one study (212 participants), SWL likely has a lower SFR (RR 0.88, 95% CI 0.80 to 0.97; moderate quality evidence); this corresponds to 113 fewer stone-free patients per 1000 (189 fewer to 28 fewer).",delete,[],5,0.3333333333333333,2,18
CD010784,4,6,"SWL may reduce severe adverse events (RR 0.13, 95% CI 0.02 to 0.98; low quality evidence); this corresponds to 66 fewer serious adverse events or complications per 1000 (74 fewer to 2 fewer).",delete,[],5,0.3888888888888889,2,18
CD010784,4,7,"Rates of secondary procedures may be higher (RR 2.50, 95% CI 1.01 to 6.20; low-quality evidence); this corresponds to 85 more secondary procedures per 1000 (1 more to 294 more).",delete,[],5,0.4444444444444444,3,18
CD010784,5,8,"Percutaneous nephrolithotripsy versus tubeless percutaneous nephrolithotripsy for renal stones: based on one study (23 participants) and consistently very low quality evidence, we are uncertain about the effects of percutaneous nephrolithotripsy on SFR, serious adverse events or complications of treatment and secondary procedures.",delete,[],5,0.5,3,18
CD010784,6,9,"Percutaneous nephrolithotripsy versus tubeless mini-percutaneous nephrolithotripsy for renal stones: based on one study (70 participants), SFR are likely similar (RR 1.03, 95% CI 0.93 to 1.14; moderate-quality evidence); this corresponds to 28 more per 1,000 (66 fewer to 132 more).",delete,[],5,0.5555555555555556,3,18
CD010784,6,10,We did not find any data relating to serious adverse events.,ignore,['We did not find any data relating to serious adverse events.'],5,0.6111111111111112,4,18
CD010784,6,11,Based on very low quality evidence we are uncertain about secondary procedures.,rephrase,['We are uncertain about the effect on the need for another procedure.'],6,0.6666666666666666,4,18
CD010784,7,12,"Alpha-blockers versus placebo with or without analgesics for distal ureteric stones: based on six studies (335 participants), alpha-blockers may increase SFR (RR 1.34, 95% CI 1.16 to 1.54; low quality evidence); this corresponds to 199 more stone-free patients per 1000 (94 more to 317 more).",rephrase,['Alpha-blockers versus placebo with or without ibuprofen: alpha-blockers may increase successful removal of stones.'],7,0.7222222222222222,4,18
CD010784,7,13,Based on very low quality evidence we are uncertain about serious adverse events or complications and secondary procedures.,rephrase,['We are uncertain about serious complications and the need for more procedures.'],8,0.7777777777777778,4,18
CD010784,8,14,"Based on mostly very low-quality evidence for most comparisons and outcomes, we are uncertain about the effect of nearly all medical and surgical interventions to treat stone disease in children.Common reasons why we downgraded our assessments of the quality of evidence were: study limitations (risk of bias), indirectness, and imprecision.",rephrase,['The quality of evidence for most outcomes was very low.'],9,0.8333333333333334,5,18
CD010784,8,15,These issues make it difficult to draw clinical inferences.,delete,[],10,0.8888888888888888,5,18
CD010784,8,16,"It is important that affected individuals, clinicians, and policy-makers are aware of these limitations of the evidence.",delete,[],10,0.9444444444444444,5,18
CD010784,8,17,There is a critical need for better quality trials assessing patient-important outcomes in children with stone disease to inform future guidelines on the management of this condition.,delete,[],10,1.0,5,18
CD006895,0,0,We included 23 individual RCTs and one cluster-RCT.,delete,[],0,0.1111111111111111,1,9
CD006895,0,1,"As one of the individual RCTs did not report outcomes in a usable way, we could only meta-analyse data from 23 trials, involving a total of 6950 participants including children (aged from one month to 11 years old), adults (mean age 37.3), and older people (mean age 84.6 years).",rephrase,"['We analysed data from 6950 people, including children (aged from 1 month to 11 years old), adults (mean age 37.3 years), and older people (mean age 84.6 years) from Italy, Japan, the United States, Croatia, England, Finland, Sweden, Chile, China, Denmark, Germany, Thailand, and Turkey.']",0,0.2222222222222222,2,9
CD006895,0,2,"One trial reported 22.5% flu-vaccine participants within the last 12 months, and 25.4% flu-vaccine participants during the intervention.",delete,[],1,0.3333333333333333,2,9
CD006895,0,3,Probiotics were more likely to be given with milk-based food in children; administered in powder form in adults; and given with milk-based food or in capsules in the elderly.,ignore,"['Probiotics were more likely to be given with milk-based food in children, in powder form in adults, and with milk-based food or capsules in the elderly.']",1,0.4444444444444444,3,9
CD006895,0,4,"Most of the studies used one or two strains (e.g. Lactobacillus plantarum HEAL9, Lactobacillus paracasei (8700:2 or N1115)) and 109 or 1011 colony-forming units (CFU)/day of probiotics for more than three months.",rephrase,"['One or two strains (e.g. Lactobacillus plantarum HEAL9, Lactobacillus paracasei (8700:2 or N1115)) and 109 or 1011 colony-forming units (CFU)/day of probiotics were used in most of the studies.']",2,0.5555555555555556,3,9
CD006895,1,5,"We found that probiotics may reduce the number of participants diagnosed with URTIs (at least one event) (RR 0.76, 95% CI 0.67 to 0.87; P < 0.001; 16 studies, 4798 participants; low-certainty evidence); likely reduce the number of participants diagnosed with URTIs (at least three events) (RR 0.59, 95% CI 0.38 to 0.91; P = 0.02; 4 studies, 763 participants; moderate-certainty evidence); may reduce the incidence rate (number of cases/person year) of URTIs (rate ratio 0.82, 95% CI 0.73 to 0.92, P = 0.001; 12 studies, 4364 participants; low-certainty evidence); may reduce the mean duration of an episode of acute URTIs (MD −1.22 days, 95% CI −2.12 to −0.33; P = 0.007; 6 studies, 2406 participants; low-certainty evidence); likely reduce the number of participants who used prescribed antibiotics for acute URTIs (RR 0.58, 95% CI 0.42 to 0.81; P = 0.001; 6 studies, 1548 participants; moderate-certainty evidence); and may not increase the number of participants who experienced at least one adverse event (RR 1.02, 95% CI 0.90 to 1.15; P = 0.79; 8 studies, 2456 participants; low-certainty evidence).",rephrase,['Probiotics may reduce the number of people diagnosed with at least one URTI by about 24%; likely reduce the number of people diagnosed with at least three URTIs by about 41%; may reduce the incidence rate (number of new cases during a specified period of time) of acute URTIs by about 18%; may reduce the mean duration of an episode of acute URTIs by about 1.22 days; likely reduce the number of people who used antibiotics for URTIs by about 42%; and may not increase the number of people who experienced side effects (any harm).'],3,0.6666666666666666,4,9
CD006895,1,6,"Evidence showing a decrease in the number of people absent from childcare centre, school, or work due to acute URTIs with probiotics is very uncertain (RR 0.14, 95% CI 0.03 to 0.59; 1 study, 80 participants; very low-certainty evidence).",rephrase,"['Evidence showing a decrease in the number of people absent from childcare centre, school, or work due to acute URTIs with probiotics was very uncertain.']",4,0.7777777777777778,4,9
CD006895,1,7,"Adverse events from probiotics were minor, and most commonly gastrointestinal symptoms, such as vomiting, flatulence, diarrhoea, and bowel pain.",delete,[],5,0.8888888888888888,5,9
CD006895,2,8,"Overall, we found that probiotics were better than placebo or no treatment in preventing acute URTIs.",rephrase,['We wanted to find out if probiotics prevent acute URTIs in people of all ages with a healthy immune system.'],5,1.0,5,9
CD008987,0,0,"We included three randomised controlled trials, involving a total of 251 participants.",rephrase,['This review includes evidence from three randomised controlled trials with a total of 251 participants.'],0,0.06666666666666667,1,15
CD008987,0,1,All three trials were at high risk of performance bias reflecting the fact that surgeons could not be blinded.,merge,"['All three trials were at some risk of bias, which means that their results may not be reliable.']",1,0.13333333333333333,1,15
CD008987,0,2,"One trial was at low risk of selection bias but was undermined by a high attrition bias, in part resulting from post-randomisation exclusions.",merge,[],1,0.2,1,15
CD008987,0,3,"There were incomplete details of methodology for the other two trials, which usually resulted in unclear risk of bias judgements.",none,[],1,0.26666666666666666,2,15
CD008987,1,4,Two trials compared radial head replacement with open reduction and internal fixation (ORIF) for treating Mason type III radial head fractures.,rephrase,['Two trials compared radial head replacement with ORIF for treating highly fragmented radial head fractures.'],2,0.3333333333333333,2,15
CD008987,1,5,The trial authors reported outcomes at a mean of 2.8 years and 15 months respectively.,delete,[],3,0.4,2,15
CD008987,1,6,"There were significant differences between the two groups in favour of radial head replacement in the Broberg and Morrey elbow scores (92.1 versus 72.4, mean difference (MD) 19.70; 95% confidence interval (CI) 15.64 to 23.76; one trial, 45 participants), excellent or good Broberg and Morrey elbow scores (33/36 versus 16/31, risk ratio (RR) 1.88; 95% CI 1.27 to 2.77; two trials), and overall adverse events (6/36 versus 15/31, RR 0.33; 95% CI 0.14 to 0.77; two trials).",delete,[],3,0.4666666666666667,3,15
CD008987,1,7,No statistically significant difference was found between the two groups in any of the reported individual adverse events.,delete,[],3,0.5333333333333333,3,15
CD008987,2,8,One trial compared biodegradable pins with standard metal screws in treating radial head fractures of AO-classification 21 B2.,rephrase,['One trial compared biodegradable pins with standard metal screws in treating displaced radial head fractures.'],3,0.6,3,15
CD008987,2,9,"The two types of fixation devices yielded similar results, with no significant between-group differences in the Broberg and Morrey scores (93.3 versus 90.9, MD 2.40; 95% CI -0.10 to 4.90), excellent or good Broberg and Morrey elbow scores (72/74 versus 56/61, RR 1.06; 95% CI 0.97 to 1.15), and adverse events (13/82 versus 16/82, RR 0.81; 95% CI 0.42 to 1.58) at two-year follow-up.",rephrase,['It found similar results for the two types of materials in terms of elbow function and adverse events.'],4,0.6666666666666666,4,15
CD008987,3,10,Only tentative conclusions can be drawn from the available evidence in this review.,delete,[],5,0.7333333333333333,4,15
CD008987,3,11,"Compared with ORIF, there was some evidence that radial head replacement had better elbow function and fewer adverse events for Mason type III radial head fractures in the short term.",rephrase,"['Overall, there is some evidence to support radial head replacement for treating highly fragmented radial head fractures instead of attempting to fix the fractured bone back in place.']",5,0.8,4,15
CD008987,3,12,"However, the evidence is of low quality and it is unknown whether these results would apply in the longer term or more generally.",ignore,"['However, the evidence is low quality and it is unknown whether these results would apply in the longer term or more generally.']",6,0.8666666666666667,5,15
CD008987,3,13,Using biodegradable implants may be as good as metallic implants for fixation of some usually more stable fractures but more evidence is needed to confirm this.,ignore,['Using biodegradable implants may be as good as metallic implants for fixing some usually more stable fractures but more evidence is needed to confirm this.'],7,0.9333333333333333,5,15
CD008987,3,14,There is a need for good quality evidence for addressing the areas of uncertainty for the surgical treatment of radial head fractures.,delete,[],8,1.0,5,15
CD003763,0,0,"Three trials involving a total of 404, mainly female and older, people with displaced fractures of the distal radius were included.",rephrase,"['Three randomised controlled trials involving a total of 404, mainly female and older, people with displaced fractures of the distal radius are included in this review.']",0,0.08333333333333333,1,12
CD003763,0,1,"These failed to assess functional outcome, and only one trial reported on complications.",rephrase,"['None of the trials assessed functional outcome, and only one trial reported on complications.']",1,0.16666666666666666,1,12
CD003763,1,2,One trial found no statistically significant differences between mechanical reduction using finger trap traction and manual reduction in anatomical outcomes.,merge,[],2,0.25,2,12
CD003763,1,3,All participants of this trial were given intravenous regional anaesthesia.,none,"['One trial, in which all participants had intravenous regional anaesthesia, found no significant differences in anatomical outcomes between mechanical reduction using finger trap traction and manual reduction.']",2,0.3333333333333333,2,12
CD003763,2,4,One trial compared a novel method of manual reduction where the non-anaesthetised patient actively provided counter-traction versus traditional manual reduction under intravenous regional anaesthesia.,split,"['Each trial compared different methods of reduction.', 'The second trial compared two methods of manual reduction.', 'These were a novel method of manual reduction where participants actively provided counter-traction without being given anaesthesia versus traditional manual reduction under intravenous regional anaesthesia.']",3,0.4166666666666667,3,12
CD003763,2,5,"While participants of the novel method group suffered more, yet not intolerable, pain during the reduction procedure, the latter was shorter in duration.",ignore,"['The participants of the novel method group suffered more but not intolerable pain during the reduction procedure, which was shorter in duration.']",6,0.5,3,12
CD003763,2,6,No differences in anatomical outcome were detected.,ignore,['No differences in anatomical outcome were detected.'],7,0.5833333333333334,3,12
CD003763,3,7,The third study compared mechanical reduction involving a special device without anaesthesia versus manual reduction under haematoma block (local anaesthesia).,ignore,['The third trial compared mechanical reduction involving a special device without anaesthesia versus manual reduction under haematoma block (local anaesthesia).'],8,0.6666666666666666,4,12
CD003763,3,8,Less pain during the reduction procedure was recorded for the mechanical traction group.,ignore,['Less pain during the reduction procedure was recorded for the mechanical traction group.'],9,0.75,4,12
CD003763,3,9,Both methods yielded similar radiological results.,rephrase,['Both methods yielded similar anatomical results.'],10,0.8333333333333334,5,12
CD003763,3,10,"Fewer participants of the mechanical traction group had signs of neurological impairment, mainly finger numbness, at five weeks but this difference was not statistically significant by one year.",ignore,"['Fewer participants of the mechanical traction group had signs of neurological impairment, mainly finger numbness, at five weeks but this difference was not statistically significant by one year.']",11,0.9166666666666666,5,12
CD003763,4,11,There was insufficient evidence from comparisons tested within randomised controlled trials to establish the relative effectiveness of different methods of closed reduction used in the treatment of displaced fractures of the distal radius in adults.,rephrase,['The review concluded that there was not enough evidence to decide whether there was any difference between the various methods tested.'],12,1.0,5,12
CD007196,0,0,"Only one trial including 75 participants (average age: 43 years; females: 65% of participants), randomised to early laparoscopic cholecystectomy (less than 24 hours after diagnosis) (n = 35) or delayed laparoscopic cholecystectomy (mean waiting period of 4.2 months) (n = 40), contributed information to this review.",split,"['Only one trial including 75 participants (average age: 43 years; females: 65% of participants) provided information for this review.', 'In this trial, 35 participants underwent early laparoscopic cholecystectomy (less than 24 hours after diagnosis) and 40 participants underwent delayed laparoscopic cholecystectomy after an average waiting period of approximately four months.']",0,0.05263157894736842,1,19
CD007196,0,1,The trial had a high risk of bias.,rephrase,['This trial was at high risk of bias (systematic errors or errors in study design which may influence the conclusions).'],2,0.10526315789473684,1,19
CD007196,0,2,Information on the outcome mortality was available for the 75 participants.,delete,[],3,0.15789473684210525,1,19
CD007196,0,3,Information on serious adverse events was available for 68 participants (28 people in the early group and 40 people in the delayed group).,delete,[],3,0.21052631578947367,2,19
CD007196,0,4,The other outcomes were available for 28 participants in the early laparoscopic cholecystectomy group and 35 participants in the delayed laparoscopic cholecystectomy group.,delete,[],3,0.2631578947368421,2,19
CD007196,0,5,There were no deaths in the early group (0/35) (0%) versus 1/40 (2.5%) in the delayed laparoscopic cholecystectomy group (P > 0.9999).,rephrase,['There were no deaths in the early group (0 out of 35) (0%) and there was one death (1 out of 40) (2.5%) in the delayed laparoscopic cholecystectomy group.'],3,0.3157894736842105,2,19
CD007196,0,6,There was no bile duct injury in either group.,merge,[],4,0.3684210526315789,2,19
CD007196,0,7,There were no serious adverse events related to the surgery in either group.,none,['There were no serious complications related to the surgery in either group.'],4,0.42105263157894735,3,19
CD007196,0,8,"During the waiting period, complications developed in the delayed laparoscopic cholecystectomy group.",rephrase,"['During the waiting period, 9 out of 40 participants (22.5%) developed gallstone-related serious complications.']",5,0.47368421052631576,3,19
CD007196,0,9,"The complications that the participants suffered included pancreatitis (n = 1), empyema of the gallbladder (n = 1), gallbladder perforation (n = 1), acute cholecystitis (n = 2), cholangitis (n = 2), obstructive jaundice (n = 2), and recurrent biliary colic (requiring hospital visits) (n = 5).",delete,[],6,0.5263157894736842,3,19
CD007196,0,10,"In total, 14 participants required hospital admissions for the above symptoms.",ignore,"['In total, 14 participants required hospital admissions for the above symptoms.']",6,0.5789473684210527,3,19
CD007196,0,11,All of these admissions occurred in the delayed group as all the participants were operated on within 24 hours in the early group.,split,"['All of these participants were from the delayed group.', 'All the participants in the early group were operated on within 24 hours.']",7,0.631578947368421,4,19
CD007196,0,12,"The proportion of people who developed serious adverse events was 0/28 (0%) in the early group, which was significantly lower than in the delayed laparoscopic cholecystectomy group 9/40 (22.5%) (P = 0.0082).",rephrase,['The proportion of participants who developed serious complications was significantly lower in the early group than the proportion of participants in the delayed laparoscopic cholecystectomy group.'],9,0.6842105263157895,4,19
CD007196,0,13,This trial did not report quality of life or return to work.,rephrase,['Quality of life and return to work were not reported in this trial.'],10,0.7368421052631579,4,19
CD007196,0,14,There was no significant difference in the proportion of people who required conversion to open cholecystectomy in the early group 0/28 (0%) compared with the delayed group (6/35 or 17.1%) (P = 0.0743).,rephrase,['There was no significant difference in the proportion of participants who required conversion to open removal of the gallbladder.'],11,0.7894736842105263,4,19
CD007196,0,15,"There was a statistically significant shorter hospital stay in the early group than in the delayed group (MD -1.25 days, 95% CI -2.05 to -0.45).",rephrase,['The hospital stay was significantly shorter (by about one day) in the early group than the delayed group.'],12,0.8421052631578947,5,19
CD007196,0,16,"There was a statistically significant shorter operating time in the early group than the delayed group (MD -14.80 minutes, 95% CI -18.02 to -11.58).",rephrase,['The operating time was significantly shorter (by about 15 minutes) in the early group than the delayed group.'],13,0.8947368421052632,5,19
CD007196,1,17,"Based on evidence from only one high-bias risk trial, it appears that early laparoscopic cholecystectomy (less than 24 hours after diagnosis of biliary colic) decreases the morbidity during the waiting period for elective laparoscopic cholecystectomy (mean waiting time 4.2 months), the hospital stay, and operating time.",rephrase,"['Based on evidence from only one high-bias risk trial, it appears that early laparoscopic cholecystectomy performed within 24 hours of diagnosis of biliary colic decreases serious complications, hospital stay, and operating time compared with delayed laparoscopic cholecystectomy with an average waiting time of four months.']",14,0.9473684210526315,5,19
CD007196,1,18,"Further randomised clinical trials are necessary to confirm or refute these findings, and to determine if early laparoscopic cholecystectomy is better than the delayed laparoscopic cholecystectomy if the waiting time is shortened further.",rephrase,"['Further well designed, randomised clinical trials are necessary to confirm or refute these findings.']",15,1.0,5,19
CD003797,0,0,"Six studies met the inclusion criteria but were limited by small sample sizes, various treatment regimes used and outcomes assessed.",merge,[],0,0.08333333333333333,1,12
CD003797,0,1,The studies were overall of unclear quality.,none,['We found six small trials of unclear quality answering these two questions.'],0,0.16666666666666666,1,12
CD003797,0,2,Data could only be pooled for the outcomes of treatment failure and hospitalisation.,rephrase,['We were only able to combine data for treatment failure and hospitalisation.'],1,0.25,2,12
CD003797,0,3,Other data could not be combined due to divergent outcome measurements.,delete,[],2,0.3333333333333333,2,12
CD003797,0,4,Meta-analysis revealed that children who received anticholinergics alone were significantly more likely to have treatment failure compared to those who received beta2-agonists from four trials on 171 children (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75).,split,"['We found data from four trials on 171 children comparing anticholinergics with beta2-agonists.', 'Children on anticholinergics alone were significantly more likely to experience treatment failure than those on beta2-agonists (odds ratio (OR) 2.27; 95% CI 1.08 to 4.75).']",2,0.4166666666666667,3,12
CD003797,0,5,"Also, treatment failure on anticholinergics alone was more likely than when anticholinergics were combined with beta2-agonists from four trials on 173 children (OR 2.65; 95% CI 1.2 to 5.88).",split,"['We also found data from four trials on 173 children comparing children on anticholinergics alone with children on anticholinergics plus beta2-agonists.', 'In this case, treatment failure was more likely in children taking anticholinergics only than if they were combined with beta2-agonists (OR 2.65; 95% CI 1.2 to 5.88).']",4,0.5,3,12
CD003797,0,6,Data on clinical scores/symptoms that were measured on different scales were conflicting.,delete,[],6,0.5833333333333334,3,12
CD003797,0,7,Individual trials reported that lung function was superior in the combination group when compared with anticholinergic agents used alone.,delete,[],6,0.6666666666666666,4,12
CD003797,0,8,The use of anticholinergics was not found to be associated with significant side effects.,delete,[],6,0.75,4,12
CD003797,1,9,"In children over the age of two years with acute asthma exacerbations, inhaled anticholinergics as single agent bronchodilators were less efficacious than beta2-agonists.",delete,[],6,0.8333333333333334,5,12
CD003797,1,10,Inhaled anticholinergics were also less efficacious than inhaled anticholinergics combined with beta2-agonists.,rephrase,"['In summary, we found that inhaled anticholinergics used on their own are less effective than inhaled beta2-agonists used alone or in combination with anticholinergics.']",6,0.9166666666666666,5,12
CD003797,1,11,Inhaled anticholinergic drugs alone are not appropriate for use as a single agent in children with acute asthma exacerbations.,rephrase,"['Inhaled anticholinergics seem safe, with no significant side effects apparent.']",7,1.0,5,12
CD004624,0,0,"Seven studies were included, they were all parallel-group studies, two studies were assessed as at low risk of bias and three at high risk of bias; two were considered to have unclear bias in their methodology.",delete,[],0,0.1,1,10
CD004624,0,1,A total of 2241 participants were enrolled in these trials.,rephrase,['Seven studies with a total of 2241 participants all involving a direct comparison of ibuprofen to paracetamol or the combination of both were included in this review.'],0,0.2,1,10
CD004624,1,2,Ibuprofen was found to be a superior analgesic to paracetamol at several doses with high quality evidence suggesting that ibuprofen 400 mg is superior to 1000 mg paracetamol based on pain relief (estimated from TOTPAR data) and the use of rescue medication meta-analyses.,delete,[],1,0.3,2,10
CD004624,1,3,"The risk ratio for at least 50% pain relief (based on TOTPAR) at six hours was 1.47 (95% confidence interval (CI) 1.28 to 1.69; five trials) favouring 400 mg ibuprofen over 1000 mg paracetamol, and the risk ratio for not using rescue medication (also favouring ibuprofen) was 1.50 (95% CI 1.25 to 1.79; four trials).",delete,[],1,0.4,2,10
CD004624,2,4,"The combined drug showed promising results, with a risk ratio for at least 50% of the maximum pain relief over six hours of 1.77 (95% CI 1.32 to 2.39) (paracetamol 1000 mg and ibuprofen 400 mg) (one trial; moderate quality evidence), and risk ratio not using rescue medication 1.60 (95% CI 1.36 to 1.88) (two trials; moderate quality evidence).",rephrase,"['When comparing combined versus single drugs, the body of evidence for the proportion of patients with > 50% maximum pain relief (TOTPAR) over two and six hours, was assessed as of moderate quality due to imprecise estimates based on single studies.']",1,0.5,3,10
CD004624,3,5,"The information available regarding adverse events from the studies (including nausea, vomiting, headaches and dizziness) indicated that they were comparable between the treatment groups.",ignore,"['The information available regarding adverse events from the studies (including nausea, vomiting, headaches and dizziness) indicated that they were comparable between the treatment groups.']",2,0.6,3,10
CD004624,3,6,"However, we could not formally analyse the data as it was not possible to work out how many adverse events there were in total.",ignore,"['However, review authors could not formally analyse the data as it was not possible to work out how many adverse events there were in total.']",3,0.7,4,10
CD004624,4,7,There is high quality evidence that ibuprofen is superior to paracetamol at doses of 200 mg to 512 mg and 600 mg to 1000 mg respectively based on pain relief and use of rescue medication data collected at six hours postoperatively.,rephrase,['The body of evidence for the use of rescue medication was assessed as being of high quality.'],4,0.8,4,10
CD004624,4,8,"The majority of this evidence (five out of six trials) compared ibuprofen 400 mg with paracetamol 1000 mg, these are the most frequently prescribed doses in clinical practice.",rephrase,"['On limited evidence, the combination of ibuprofen and paracetamol appeared to be no more effective than the single drugs when measured two hours after surgery.']",5,0.9,5,10
CD004624,4,9,The novel combination drug is showing encouraging results based on the outcomes from two trials when compared to the single drugs.,delete,[],6,1.0,5,10
CD011745,0,0,"We included 15 trials (39,908 participants) that evaluated antihypertensive pharmacotherapy for a mean duration of follow-up of 4.2 years.",rephrase,"['We found 15 trials including 39,908 people that investigated whether blood pressure-lowering drugs reduce sudden death.']",0,0.16666666666666666,1,6
CD011745,0,1,"This review provides moderate-quality evidence to show that antihypertensive drugs do not reduce sudden death (risk ratio (RR) 0.96, 95% confidence interval (CI) 0.81 to 1.15) but do reduce both non-fatal myocardial infarction (RR 0.85, 95% CI 0.74, 0.98; absolute risk reduction (ARR) 0.3% over 4.2 years) and fatal myocardial infarction (RR 0.75, 95% CI 0.62 to 0.90; ARR 0.3% over 4.2 years).",rephrase,['This review presents moderate-quality evidence to show that blood pressure-lowering drugs reduce heart attacks but do not appear to reduce sudden cardiac death.'],1,0.3333333333333333,2,6
CD011745,0,2,"Withdrawals due to adverse effects were increased in the drug treatment group to 12.8%, as compared with 6.2% in the no treatment group.",delete,[],2,0.5,3,6
CD011745,1,3,"Although antihypertensive drugs reduce the incidence of fatal and non-fatal myocardial infarction, they do not appear to reduce the incidence of sudden death.",delete,[],2,0.6666666666666666,4,6
CD011745,1,4,This suggests that sudden cardiac death may not be caused primarily by acute myocardial infarction.,rephrase,['This suggests that sudden cardiac death may not be caused primarily by heart attack.'],2,0.8333333333333334,5,6
CD011745,1,5,Continued research is needed to determine the causes of sudden cardiac death.,ignore,['Continued research is needed to determine the causes of sudden cardiac death.'],3,1.0,5,6
CD003283,0,0,Only two trials of limited quality met our inclusion criteria.,rephrase,['We found only two trials that looked at two-phase versus three-phase birth control pills.'],0,0.08333333333333333,1,12
CD003283,0,1,"One study compared two biphasic pills and one triphasic pill, each containing levonorgestrel and ethinyl estradiol.",rephrase,['One study compared two types of two-phase pills with a three-phase pill.'],1,0.16666666666666666,1,12
CD003283,0,2,"No important differences emerged, and the frequency of discontinuation due to medical problems was similar with all three pills.",rephrase,"['The pills did not differ in any major ways, including the numbers of women who stopped using the pills due to health problems.']",2,0.25,2,12
CD003283,0,3,The other trial compared a biphasic pill containing norethindrone (Ortho 10/11) with a triphasic pill containing levonorgestrel (Triphasil) and with another triphasic containing norethindrone (Ortho 7/7/7).,rephrase,['The other trial compared a two-phase pill with two different three-phase pills.'],3,0.3333333333333333,2,12
CD003283,0,4,The biphasic pill had inferior cycle control compared with the levonorgestrel triphasic.,delete,[],4,0.4166666666666667,3,12
CD003283,0,5,The odds ratio of cycles with intermenstrual bleeding was 1.70 (95% confidence interval (CI) 1.29 to 2.24) for the biphasic compared with the triphasic levonorgestrel pill.,delete,[],4,0.5,3,12
CD003283,0,6,The odds ratio of cycles without withdrawal bleeding was 6.48 (95% CI 3.13 to 13.39).,delete,[],4,0.5833333333333334,3,12
CD003283,0,7,"In contrast, cycle control with the biphasic pill was comparable to that of the triphasic containing the same progestin (norethindrone).",rephrase,"['In contrast, bleeding with the two-phase pill was like that of the three-phase pill with the same hormone (norethindrone).']",4,0.6666666666666666,4,12
CD003283,1,8,The available evidence is limited and the internal validity of these trials is questionable.,delete,[],5,0.75,4,12
CD003283,1,9,"Given the high losses to follow up, these reports may even be considered observational.",delete,[],5,0.8333333333333334,5,12
CD003283,1,10,"Given that caveat, the biphasic pill containing norethindrone was associated with inferior cycle control compared with the triphasic pill containing levonorgestrel.",delete,[],5,0.9166666666666666,5,12
CD003283,1,11,The choice of progestin may be more important than the phasic regimen in determining bleeding patterns.,rephrase,['The type of hormone may be more important than the phases for cycle control.'],5,1.0,5,12
CD010882,0,0,We included in the review two studies with a total of 30 randomly assigned participants.,rephrase,['We identified two studies involving 30 participants up to April 2015.'],0,0.1,1,10
CD010882,0,1,"We rated the quality of the evidence as very low as the result of study limitations, small numbers of events, and small sample sizes, with imprecision in the confidence interval (CI).",delete,[],1,0.2,1,10
CD010882,0,2,We were not able to perform meta-analysis because of heterogeneity related to the different interventions evaluated between included studies.,rephrase,"['We are uncertain as to whether comparison of different pharmacological interventions (rivastigmine, transdermal nicotine)showed an important effect on (1) the ability of people to recognize their paralyzed limb, and (2) independence in daily life functions after stroke, because results were imprecise and included studies did not report most of the predefined outcomes (ie, falls, balance, depression or anxiety, poststroke fatigue, and quality of life).']",1,0.3,2,10
CD010882,0,3,"Very low-quality evidence from one trial (20 participants) comparing effects of rivastigmine plus rehabilitation versus rehabilitation on overall USN at discharge showed the following: Barrage (mean difference (MD) 0.30, 95% confidence interval (CI) -0.18 to 0.78); Letter Cancellation (MD 10.60, 95% CI 2.07 to 19.13); Sentence Reading (MD 0.20, 95% CI -0.69 to 1.09), and the Wundt-Jastrow Area Illusion Test (MD -4.40, 95% CI -8.28 to -0.52); no statistical significance was observed for the same outcomes at 30 days' follow-up.",delete,[],2,0.4,2,10
CD010882,0,4,"In another trial (10 participants), study authors showed statistically significant reduction in omissions in the three cancellation tasks under transdermal nicotine treatment (mean number of omissions 2.93 ± 0.5) compared with both baseline (4.95 ± 0.8) and placebo (5.14 ± 0.9) (main effect of treatment condition: F (2.23) = 11.06; P value < 0.0001).",delete,[],2,0.5,3,10
CD010882,0,5,"One major adverse event occurred in the transdermal nicotine treatment group, and treatment was discontinued in the affected participant.",delete,[],2,0.6,3,10
CD010882,0,6,"None of the included trials reported data on several of the prespecified outcomes (falls, balance, depression or anxiety, poststroke fatigue, and quality of life).",delete,[],2,0.7,4,10
CD010882,1,7,The quality of the evidence from available RCTs was very low.,rephrase,['The quality of the evidence obtained from available randomized controlled trials was very low.'],2,0.8,4,10
CD010882,1,8,The effectiveness and safety of pharmacological interventions for USN after stroke are therefore uncertain.,ignore,['The effectiveness and safety of pharmacological interventions for USN after stroke are therefore uncertain.'],3,0.9,5,10
CD010882,1,9,Additional large RCTs are needed to evaluate these treatments.,rephrase,['Additional large randomized controlled trials are needed to evaluate these treatments.'],4,1.0,5,10
CD011354,0,0,"We included one study, with 60 randomized participants, in the review.",delete,[],0,0.0625,1,16
CD011354,0,1,The study population had a range of ulcer types that were venous arteriolosclerotic and venous/arterial in origin.,delete,[],0,0.125,1,16
CD011354,0,2,Study participants had recalcitrant ulcers that had not healed after treatment over a six-month period.,rephrase,['The study was small with 60 participants who had hard-to-heal ulcers.'],0,0.1875,1,16
CD011354,0,3,Participants allocated to NPWT received continuous negative pressure until they achieved 100% granulation (wound preparation stage).,delete,[],1,0.25,2,16
CD011354,0,4,A punch skin-graft transplantation was conducted and the wound then exposed to further NPWT for four days followed by standard care.,rephrase,"['In the study, the ulcers were treated with NPWT or with normal (standard) care until the wounds were considered ready to have a skin graft applied.']",1,0.3125,2,16
CD011354,0,5,Participants allocated to the control arm received standard care with dressings and compression until 100% granulation was achieved.,delete,[],2,0.375,2,16
CD011354,0,6,These participants also received a punch skin-graft transplant and then further treatment with standard care.,delete,[],2,0.4375,3,16
CD011354,0,7,All participants were treated as in-patients until healing occurred.,rephrase,['Participants remained in hospitals during treatment and until their wounds healed.'],2,0.5,3,16
CD011354,1,8,"There was low quality evidence of a difference in time to healing that favoured the NPWT group: the study reported an adjusted hazard ratio of 3.2, with 95% confidence intervals (CI) 1.7 to 6.2.",rephrase,['There was low evidence from this study that ulcers treated with NPWT healed more quickly than those treated with standard care (dressings and compression).'],3,0.5625,3,16
CD011354,1,9,The follow-up period of the study was a minimum of 12 months.,delete,[],4,0.625,4,16
CD011354,1,10,There was no evidence of a difference in the total number of ulcers healed (29/30 in each group) over the follow-up period; this finding was also low quality evidence.,delete,[],4,0.6875,4,16
CD011354,2,11,"There was low quality evidence of a difference in time to wound preparation for surgery that favoured NPWT (hazard ratio 2.4, 95% CI 1.2 to 4.7).",delete,[],4,0.75,4,16
CD011354,3,12,Limited data on adverse events were collected: these provided low quality evidence of no difference in pain scores and Euroqol (EQ-5D) scores at eight weeks after surgery.,rephrase,['There were very limited results for other outcomes such as adverse events (harms) and it was not clear how information about adverse effects was collected.'],4,0.8125,5,16
CD011354,4,13,There is limited rigorous RCT evidence available concerning the clinical effectiveness of NPWT in the treatment of leg ulcers.,rephrase,"['The evidence for the effectiveness of NPWT in treating leg ulcers is very limited, and at present consists of only one study with 60 participants.']",5,0.875,5,16
CD011354,4,14,"There is some evidence that the treatment may reduce time to healing as part of a treatment that includes a punch skin graft transplant, however, the applicability of this finding may be limited by the very specific context in which NPWT was evaluated.",rephrase,['This study provided evidence that NPWT may reduce time to healing as part of a treatment that includes a skin graft.'],6,0.9375,5,16
CD011354,4,15,There is no RCT evidence on the effectiveness of NPWT as a primary treatment for leg ulcers.,rephrase,"['At present, no RCTs have investigated the effectiveness of NPWT as a main treatment for leg ulcers.']",7,1.0,5,16
CD010115,0,0,"We found 43 studies that met the inclusion criteria, and more evidence was provided for fluticasone (26 studies; n = 21,247) than for budesonide (17 studies; n = 10,150).",split,"['We found 43 studies including more than 30,000 people with COPD.', 'More studies used fluticasone (26 studies; 21,247 people) than budesonide (17 studies; 10,150 people).']",0,0.058823529411764705,1,17
CD010115,0,1,"Evidence from the budesonide studies was more inconsistent and less precise, and the studies were shorter.",rephrase,"['Results from the budesonide studies were generally less clear because they were based on fewer people, and the studies were shorter.']",2,0.11764705882352941,1,17
CD010115,0,2,"The populations within studies were more often male with a mean age of around 63, mean pack-years smoked over 40 and mean predicted forced expiratory volume of one second (FEV1) less than 50%.",delete,[],3,0.17647058823529413,1,17
CD010115,1,3,"High or uneven dropout was considered a high risk of bias in almost 40% of the trials, but conclusions for the primary outcome did not change when the trials at high risk of bias were removed in a sensitivity analysis.",delete,[],3,0.23529411764705882,2,17
CD010115,2,4,"Fluticasone increased non-fatal serious adverse pneumonia events (requiring hospital admission) (odds ratio (OR) 1.78, 95% confidence interval (CI) 1.50 to 2.12; 18 more per 1000 treated over 18 months; high quality), and no evidence suggested that this outcome was reduced by delivering it in combination with salmeterol or vilanterol (subgroup differences: I2 = 0%, P value 0.51), or that different doses, trial duration or baseline severity significantly affected the estimate.",split,"[""Fluticasone increased 'serious' pneumonias (requiring hospital admission)."", 'Over 18 months, 18 more people of every 1000 treated with fluticasone were admitted to hospital for pneumonia.']",3,0.29411764705882354,2,17
CD010115,2,5,"Budesonide also increased non-fatal serious adverse pneumonia events compared with placebo, but the effect was less precise and was based on shorter trials (OR 1.62, 95% CI 1.00 to 2.62; six more per 1000 treated over nine months; moderate quality).",rephrase,"[""Budesonide also increased pneumonias that were classed as 'serious'.""]",5,0.35294117647058826,2,17
CD010115,2,6,"Some of the variation in the budesonide data could be explained by a significant difference between the two commonly used doses: 640 mcg was associated with a larger effect than 320 mcg relative to placebo (subgroup differences: I2 = 74%, P value 0.05).",rephrase,['A lower dose of budesonide (320 mcg) was associated with fewer serious pneumonias than a higher dose (640 mcg).'],6,0.4117647058823529,3,17
CD010115,3,7,An indirect comparison of budesonide versus fluticasone monotherapy revealed no significant differences with respect to serious adverse events (pneumonia-related or all-cause) or mortality.,rephrase,"['We also conducted an indirect comparison of budesonide and fluticasone based on their effects against placebo, to explore whether one drug was safer than the other.']",7,0.47058823529411764,3,17
CD010115,3,8,"The risk of any pneumonia event (i.e. less serious cases treated in the community) was higher with fluticasone than with budesonide (OR 1.86, 95% CI 1.04 to 3.34); this was the only significant difference reported between the two drugs.",rephrase,['The risk of any pneumonia event (i.e. less serious cases that could be treated without going to hospital) was higher with fluticasone than with budesonide.'],8,0.5294117647058824,3,17
CD010115,3,9,"However, this finding should be interpreted with caution because of possible differences in the assignment of pneumonia diagnosis, and because no trials directly compared the two drugs.",delete,[],9,0.5882352941176471,3,17
CD010115,4,10,"No significant difference in overall mortality rates was observed between either of the inhaled steroids and the control interventions (both high-quality evidence), and pneumonia-related deaths were too rare to permit conclusions to be drawn.",rephrase,"['No more deaths overall were reported in the ICS groups compared with controls, and deaths related to pneumonia were too rare to tell either way.']",9,0.6470588235294118,4,17
CD010115,5,11,"Budesonide and fluticasone, delivered alone or in combination with a LABA, are associated with increased risk of serious adverse pneumonia events, but neither significantly affected mortality compared with controls.",rephrase,"['Budesonide and fluticasone, delivered alone or in combination with LABA, can increase serious pneumonias that result in hospitalisation of people.']",10,0.7058823529411765,4,17
CD010115,5,12,The safety concerns highlighted in this review should be balanced with recent cohort data and established randomised evidence of efficacy regarding exacerbations and quality of life.,rephrase,"['These concerns need to be balanced with the known benefits of ICS (e.g. fewer exacerbations, improved lung function and quality of life).']",11,0.7647058823529411,4,17
CD010115,5,13,"Comparison of the two drugs revealed no statistically significant difference in serious pneumonias, mortality or serious adverse events.",rephrase,['Comparison of the two drugs revealed no difference in serious pneumonias or risk of death.'],12,0.8235294117647058,5,17
CD010115,5,14,"Fluticasone was associated with higher risk of any pneumonia when compared with budesonide (i.e. less serious cases dealt with in the community), but variation in the definitions used by the respective manufacturers is a potential confounding factor in their comparison.",rephrase,"['Fluticasone was associated with a higher risk of any pneumonia (i.e. cases that could be treated in the community) than budesonide, but potential differences in the definition used by the respective drug manufacturers reduced our confidence in this finding.']",13,0.8823529411764706,5,17
CD010115,6,15,"Primary research should accurately measure pneumonia outcomes and should clarify both the definition and the method of diagnosis used, especially for new formulations and combinations for which little evidence of the associated pneumonia risk is currently available.",rephrase,['Researchers should remain aware of the risks associated with ICS and should make sure that pneumonia is properly diagnosed in studies.'],14,0.9411764705882353,5,17
CD010115,6,16,"Similarly, systematic reviews and cohorts should address the reliability of assigning 'pneumonia' as an adverse event or cause of death and should determine how this affects the applicability of findings.",delete,[],15,1.0,5,17
CD006623,0,0,We found no new studies.,rephrase,"['We found only four studies, which included a small total number of participants.']",0,0.1,1,10
CD006623,0,1,This updated review therefore includes four studies with 278 participants.,rephrase,['We included four studies in our review (278 participants).'],1,0.2,1,10
CD006623,0,2,"Most analyses were based on data from few participants and low-quality evidence, so our results should be interpreted with caution.",rephrase,"['The evidence from the studies were of moderate to very low quality, and therefore our results should be interpreted with caution.']",2,0.3,2,10
CD006623,0,3,"Deliberate hypotension with propofol did not decrease TBL (millilitres) when compared with inhalation anaesthetics in either children (1 study; 70 participants; very low-quality evidence), or adults (1 study; 88 participants; moderate-quality evidence).",rephrase,['We found that propofol did not reduce measured overall blood loss in either children or adults (2 studies; 158 participants).'],3,0.4,2,10
CD006623,0,4,"Propofol improved the quality of the surgical field by less than one category on a scale from 0 (no bleeding) to 5 (severe bleeding) (mean difference -0.64, 95% CI -0.91 to -0.37; 4 studies; 277 participants; low-quality evidence), but no difference in operation time was reported (3 studies; 214 participants; low-quality evidence).",rephrase,"['Propofol might improve the quality of the surgical field a little (4 studies; 277 participants), but there was no difference in operation time (3 studies; 214 participants).']",4,0.5,3,10
CD006623,0,5,"Failure to lower blood pressure to target was less common in the propofol group (risk ratio of failure with propofol 0.24, 95% CI 0.09 to 0.66; 1 study; 88 participants; moderate-quality evidence).",rephrase,['Propofol was more reliable in achieving induced hypotension (1 study; 88 participants).'],5,0.6,3,10
CD006623,1,6,"Using propofol to achieve deliberate hypotension probably improves the surgical field, but the effect is small.",delete,[],6,0.7,4,10
CD006623,1,7,Deliberate hypotension with propofol did not decrease TBL and the operation time.,delete,[],6,0.8,4,10
CD006623,1,8,"However, due to the very low quality of the evidence, this conclusion is not definitive.",delete,[],6,0.9,5,10
CD006623,1,9,Randomized controlled trials with good-quality methodology and large sample size are required to investigate the effectiveness of deliberate hypotension with propofol for FESS.,delete,[],6,1.0,5,10
CD013252,0,0,"We identified nine RCTs that met the inclusion criteria, but four were ongoing trials, and were not included in this analysis.",rephrase,"['We identified nine studies that compared NOACs with warfarin, four of which were ongoing studies.']",0,0.07142857142857142,1,14
CD013252,0,1,"We included five RCTs, with 8373 participants, in the NMA (two RCTs compared apixaban to a vitamin K antagonist, two RCTs compared rivaroxaban to a vitamin K antagonist, and one RCT compared dabigatran to a vitamin K antagonist).",rephrase,['We included five trials involving 8373 participants in this review.'],1,0.14285714285714285,1,14
CD013252,1,2,"Very low- to moderate-certainty evidence suggests little or no difference between NOACs and vitamin K antagonists in death from cardiovascular causes (not reported in the dabigatran trial), myocardial infarction, stroke, death from any cause, and stent thrombosis.",delete,[],2,0.21428571428571427,2,14
CD013252,1,3,"Apixaban (RR 0.85, 95% CI 0.77 to 0.95), high dose rivaroxaban (RR 0.86, 95% CI 0.74 to 1.00), and low dose rivaroxaban (RR 0.80, 95% CI 0.68 to 0.92) probably reduce the risk of recurrent hospitalisation compared with vitamin K antagonists.",delete,[],2,0.2857142857142857,2,14
CD013252,1,4,No studies looked at health-related quality of life.,delete,[],2,0.35714285714285715,2,14
CD013252,2,5,Very low- to moderate-certainty evidence suggests that NOACs may be safer than vitamin K antagonists in terms of bleeding.,rephrase,['NOACs may be safer than warfarin.'],2,0.42857142857142855,3,14
CD013252,2,6,"Both high dose dabigatran (RR 0.53, 95% CI 0.29 to 0.97), and low dose dabigatran (RR 0.38, 95% CI 0.21 to 0.70) may reduce major bleeding more than vitamin K antagonists.",rephrase,['One of NOACs drugs (dabigatran) may reduce the rate of both major and non-major bleeding.'],3,0.5,3,14
CD013252,2,7,"High dose dabigatran (RR 0.83, 95% CI 0.72 to 0.96), low dose dabigatran (RR 0.66, 95% CI 0.58 to 0.75), apixaban (RR 0.67, 95% Cl 0.51 to 0.88), high dose rivaroxaban (RR 0.66, 95% CI 0.52 to 0.83), and low dose rivaroxaban (RR 0.71, 95% CI 0.57 to 0.88) probably reduce non-major bleeding more than vitamin K antagonists.",delete,[],4,0.5714285714285714,3,14
CD013252,3,8,The results from the NMA were inconclusive between the different NOACs for all primary and secondary outcomes.,rephrase,['There was no significant difference between NOACs agents in any primary or secondary outcomes.'],4,0.6428571428571429,4,14
CD013252,4,9,Very low- to moderate-certainty evidence suggests no meaningful difference in efficacy outcomes between non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists following percutaneous coronary interventions (PCI) in people with non-valvular atrial fibrillation.,rephrase,"['The evidence ranged from Very low- to moderate-certainty, indicating the need for more research on this issue.']",5,0.7142857142857143,4,14
CD013252,4,10,NOACs probably reduce the risk of recurrent hospitalisation for adverse events compared with vitamin K antagonists.,rephrase,"['However, NOACs probably reduce the need for hospitalisation compared to warfarin.']",6,0.7857142857142857,4,14
CD013252,5,11,"Low- to moderate-certainty evidence suggests that dabigatran may reduce the rates of major and non-major bleeding, and apixaban and rivaroxaban probably reduce the rates of non-major bleeding compared with vitamin K antagonists.",rephrase,['Other NOAC drugs (apixaban and rivaroxaban) probably reduce the rate of non-major bleeding.'],7,0.8571428571428571,5,14
CD013252,6,12,Our network meta-analysis did not show superiority of one NOAC over another for any of the outcomes.,delete,[],8,0.9285714285714286,5,14
CD013252,6,13,"Head to head trials, directly comparing NOACs against each other, are required to provide more certain evidence.",delete,[],8,1.0,5,14
CD005199,0,0,"Due to the differences in the method of assessment, the variability of data and the heterogeneity of the participant groups it was difficult to pool some of the outcome data.",delete,[],0,0.125,1,8
CD005199,0,1,Despite these limitations and potentially significant biases related to methodological quality there was evidence to suggest that a transverse or oblique incision has less impact on pulmonary function particularly in the early post-operative period and is less prone to rupture (wound dehiscence/incisional hernia).,rephrase,"['Nevertheless a trend was seen toward less analgesic requirement, less effect on pulmonary function and lower wound dehiscence and incisional hernia rates with a transverse incision.']",0,0.25,2,8
CD005199,0,2,The data on pain is less clear and should be interpreted with caution but some data suggests a transverse incision is less painful.,delete,[],1,0.375,2,8
CD005199,0,3,There was no difference seen in other early or late post-operative complications and recovery times were similar although the transverse incision may be cosmetically more acceptable.,rephrase,"['However, a transverse incision may be superior to a midline incision in terms of recovery and complications.']",1,0.5,3,8
CD005199,1,4,The analgesia use and the pulmonary compromise may be reduced with a transverse/oblique incision but this does not seem to be significant clinically as pulmonary complication rates and recovery times were the same.,split,"['Outcomes included analgesic use, pulmonary function, complication rates and hospital stay.', 'However, the lower pain and reduced effect on pulmonary function were not translated into other clinical advantages as recovery times and other complication rates (except cosmetic appearance) were similar.']",2,0.625,4,8
CD005199,1,5,The likelihood of wound dehiscence and rupture appears to be reduced with a transverse incision and a transverse incision may look better.,delete,[],4,0.75,4,8
CD005199,1,6,The methodological and clinical diversity and the potential for bias also mean that the results in favour of a transverse/oblique incision (particularly with regard to analgesic use) should be treated with caution.,delete,[],4,0.875,5,8
CD005199,1,7,The optimal incision for abdominal surgery still remains the preference of the surgeon.,rephrase,['The choice of abdominal surgical incision is determined largely by access.'],4,1.0,5,8
CD004174,0,0,We identified 10 RCTs with a total of 2361 participants that evaluated compression therapy.,rephrase,['We identified 10 randomised controlled trials with a total of 2361 participants that evaluated compression therapy (current until March 2017).'],0,0.05555555555555555,1,18
CD004174,0,1,The overall methodological quality of these trials was low.,rephrase,"['Overall, the included studies were of poor methodological quality.']",1,0.1111111111111111,1,18
CD004174,0,2,We used only five studies in meta-analysis owing to differences in intervention types and lack of data.,delete,[],2,0.16666666666666666,1,18
CD004174,0,3,Three studies compared elastic compression stockings (pressure of 30 to 40 mmHg at the ankle) versus no intervention.,delete,[],2,0.2222222222222222,2,18
CD004174,0,4,Two studies compared elastic compression stockings (pressure 20 to 40 mmHg) versus placebo stockings.,delete,[],2,0.2777777777777778,2,18
CD004174,0,5,"Overall, use of elastic compression stockings led to a clinically significant reduction in the incidence of PTS (risk ratio (RR) 0.62, 95% confidence interval (CI) 0.38 to 1.01; P = 0.05; 1393 participants; 5 studies; low-quality evidence); no reduction in the incidence of severe PTS (RR 0.78, 95% CI 0.53 to 1.15; P = 0.21; 1224 participants; 4 studies; low-quality evidence); and no clear difference in DVT recurrence (RR 0.94, 95% CI 0.69 to 1.28; 1212 participants; 4 studies; P = 0.69; low-quality evidence).",delete,[],2,0.3333333333333333,2,18
CD004174,0,6,"We did not pool data on the incidence of pulmonary embolism because this information was poorly reported, but we observed no differences between groups included in individual studies (low-quality evidence).",rephrase,['We found no clear differences in occurrence of pulmonary embolism (blockage of the artery in the lung) nor in reports of recurrent DVT.'],2,0.3888888888888889,2,18
CD004174,1,7,"Two studies evaluated effects of compression in the acute phase versus no compression treatment and found no differences in the incidence of PTS (RR 0.76, 95% CI 0.49 to 1.16; P = 0.2; 101 participants).",rephrase,"['Compression in the acute phase of DVT compared with ""no compression"" treatment did not significantly lower PTS incidence.']",3,0.4444444444444444,3,18
CD004174,1,8,"One study reported that thigh-length stockings did not provide better protection against development of PTS than knee-length stockings (RR 0.92, 95% CI 0.66 to 1.28; P = 0.6; 267 participants).",rephrase,['Thigh-length stockings did not provide better protection against development of PTS than knee-length stockings.'],4,0.5,3,18
CD004174,1,9,Another trial reported that wearing compression stockings for two years seemed to be superior to wearing them for one year in terms of PTS incidence.,ignore,['One trial reported that wearing compression stockings for two years seemed to be superior to wearing them for one year in terms of PTS incidence.'],5,0.5555555555555556,3,18
CD004174,2,10,"Two of the 10 included studies described patient satisfaction and quality of life (moderate-quality evidence), using different measurement systems.",delete,[],6,0.6111111111111112,4,18
CD004174,2,11,"The first study showed significant improvement in well-being and DVT-related quality of life with compression treatment (P < 0.05) compared with bed rest, and the second study showed no differences in quality of life scores between compression and placebo groups.",rephrase,"['Compression treatment did not seem to improve quality of life, except during the first nine days after DVT, but we could draw no real conclusions regarding this outcome.']",6,0.6666666666666666,4,18
CD004174,2,12,"Four studies poorly reported side effects (low-quality evidence) that included itching, erythema, and other forms of allergic reaction and described no serious adverse events.",rephrase,"['Side effects included itching, erythema, and other forms of allergic reaction.']",7,0.7222222222222222,4,18
CD004174,2,13,Compliance with wearing of compression stockings was generally high but varied across studies.,rephrase,['The study investigators reported no serious adverse events and indicated that compliance with use of compression stockings was generally high but varied across studies.'],8,0.7777777777777778,4,18
CD004174,3,14,Low-quality evidence suggests that elastic compression stockings may reduce the occurrence of PTS after DVT.,delete,[],9,0.8333333333333334,5,18
CD004174,3,15,We downgraded the quality of evidence owing to considerable heterogeneity between studies and lack of or unclear risk of blinding due to clinical assessment scores.,delete,[],9,0.8888888888888888,5,18
CD004174,3,16,No serious adverse effects occurred in these studies.,delete,[],9,0.9444444444444444,5,18
CD004174,3,17,Large randomised controlled trials are needed to confirm these findings because of current lack of high-quality evidence and considerable heterogeneity.,delete,[],9,1.0,5,18
CD013714,0,0,"We included two RCTs, with a total of 122 participants.",rephrase,"['We included two RCTs, with a total of 122 people with HAEC.']",0,0.08333333333333333,1,12
CD013714,0,1,We judged the overall risk of bias as high.,delete,[],1,0.16666666666666666,1,12
CD013714,0,2,"We downgraded the evidence due to risk of bias (random sequence generation, allocation concealment, and blinding) and small sample size.",delete,[],1,0.25,2,12
CD013714,1,3,"The evidence is very uncertain about the effect of probiotics on the occurrence of HAEC (OR 0.58, 95% CI 0.10 to 3.43; I² = 74%; 2 studies, 120 participants; very low-certainty evidence).",rephrase,['We are very uncertain whether there was a difference in the occurrence of HAEC between the group receiving probiotics and the group receiving placebo.'],1,0.3333333333333333,2,12
CD013714,1,4,We found one included study that did not measure serious adverse events and one included study that reported no serious adverse events related to probiotics.,rephrase,['No serious adverse events were reported.'],2,0.4166666666666667,3,12
CD013714,1,5,"Probiotics may result in little to no difference between probiotics and placebo in relation to the severity of children with HAEC at Grade I (OR 0.66, 95% CI 0.14 to 3.16; I² = 25%; 2 studies, 120 participants; low-certainty evidence).",merge,[],3,0.5,3,12
CD013714,1,6,"The effects of probiotics on the severity of HAEC at Grade II are very uncertain (OR 1.14, 95% CI 0.01 to 136.58; I² = 86%; 2 studies, 120 participants; very low-certainty evidence).",merge,['We are very uncertain about the effect of probiotics on the severity of HAEC.'],3,0.5833333333333334,3,12
CD013714,1,7,"Similarly, the evidence suggests that probiotics results in little to no difference in relation to the severity of HAEC at Grade III (OR 0.43, 95% CI 0.05 to 3.45; I² = 0%; 2 studies, 120 participants; low-certainty evidence).",none,[],3,0.6666666666666666,4,12
CD013714,2,8,No overall mortality or withdrawals due to adverse events were reported.,ignore,['No overall mortality or withdrawals due to adverse events were reported.'],4,0.75,4,12
CD013714,2,9,"Probiotics may result in little to no difference in the recurrence of episodes of HAEC compared to placebo (OR 0.85, 95% CI 0.24 to 3.00; 1 study, 60 participants; low-certainty evidence).",rephrase,['There was little or no difference in the recurrence of HAEC between the two groups.'],5,0.8333333333333334,5,12
CD013714,3,10,There is currently not enough evidence to assess the efficacy or safety of probiotics for the prevention of Hirschsprung-associated enterocolitis when compared with placebo.,delete,[],6,0.9166666666666666,5,12
CD013714,3,11,The presence of low- to very-low certainty evidence suggests that further well-designed and sufficiently powered RCTs are needed to clarify the true efficacy of probiotics.,delete,[],6,1.0,5,12
CD008168,0,0,We included 12 RCTs (1600 infants) in the review.,rephrase,"['Of these, 12\xa0studies (involving a total of 1600 infants) were eligible for inclusion in this review.']",0,0.09090909090909091,1,11
CD008168,0,1,There is one ongoing study and four awaiting classification.,rephrase,['One study is currently ongoing and four are awaiting classification.'],1,0.18181818181818182,1,11
CD008168,0,2,"There was little or no difference between intermittent phototherapy and continuous phototherapy with respect to rate of decline of bilirubin in jaundiced newborn infants (MD -0.09 micromol/L/hr, 95% CI -0.21 to 0.03; I² = 61%; 10 studies; 1225 infants; low-certainty evidence).",delete,[],2,0.2727272727272727,2,11
CD008168,0,3,One study involving 60 infants reported no incidence of bilirubin induced brain dysfunction (BIND).,rephrase,['Our primary outcomes of interest were the rate of fall in the serum bilirubin levels and bilirubin-induced brain dysfunction (BIND).'],2,0.36363636363636365,2,11
CD008168,0,4,It is uncertain whether either intermittent or continuous phototherapy reduces BIND because the certainty of this evidence is very low.,delete,[],3,0.45454545454545453,3,11
CD008168,0,5,"There was little or no difference in treatment failure (RD 0.03, 95% CI 0.08 to 0.15; RR 1.63, 95% CI 0.29 to 9.17; 1 study; 75 infants; very low-certainty evidence) or infant mortality (RD -0.01, 95% CI -0.03 to 0.01; RR 0.69, 95% CI 0.37 to 1.31 I² = 0%; 10 studies, 1470 infants; low-certainty evidence).",delete,[],3,0.5454545454545454,3,11
CD008168,1,6,The available evidence detected little or no difference between intermittent and continuous phototherapy with respect to rate of decline of bilirubin.,rephrase,['We found\xa0little or no difference\xa0between intermittent phototherapy and continuous phototherapy in reducing bilirubin levels.'],3,0.6363636363636364,4,11
CD008168,1,7,"Continuous phototherapy appears to be more effective in preterm infants, however, the risks of continuous phototherapy and the potential benefits of a slightly lower bilirubin level are unknown.",rephrase,"['Continuous phototherapy was more effective in preterm infants, however, we do not know if this is a meaningful difference.']",4,0.7272727272727273,4,11
CD008168,1,8,Intermittent phototherapy is associated with a decrease in the total number of hours of phototherapy exposure.,ignore,['Intermittent phototherapy is associated with\xa0a decrease in the total number of hours of phototherapy exposure.'],5,0.8181818181818182,5,11
CD008168,1,9,There are theoretical benefits to intermittent regimens but there are important safety outcomes that were inadequately addressed.,ignore,['There are theoretical benefits to intermittent regimens but\xa0there are important safety outcomes that were inadequately addressed.'],6,0.9090909090909091,5,11
CD008168,1,10,"Large, well designed, prospective trials are needed in both preterm and term infants before it can be concluded that intermittent and continuous phototherapy regimens are equally effective.",rephrase,"['Large, high-quality trials are needed in both preterm and term infants before it can be concluded that intermittent and continuous phototherapy regimens are equally effective.']",7,1.0,5,11
CD008938,0,0,We included in the review seven studies with a total of 852 participants.,rephrase,['We found seven studies with a total of 852 participants.'],0,0.125,1,8
CD008938,0,1,"The methodological quality of the included studies was generally ranked as showing low risk of bias in most domains, with the exception of one study, which did not mask participants.",delete,[],1,0.25,2,8
CD008938,0,2,We were able to include data from 838 participants in the meta-analysis.,delete,[],1,0.375,2,8
CD008938,0,3,"We found no statistically significant differences between participants receiving air and those given saline in any of the outcomes evaluated: inability to locate the epidural space (three trials, 619 participants) (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.33 to 2.31, low-quality evidence); accidental intravascular catheter placement (two trials, 223 participants) (RR 0.90, 95% CI 0.33 to 2.45, low-quality evidence); accidental subarachnoid catheter placement (four trials, 682 participants) (RR 2.95, 95% CI 0.12 to 71.90, low-quality evidence); combined spinal epidural failure (two trials, 400 participants) (RR 0.98, 95% CI 0.44 to 2.18, low-quality evidence); unblocked segments (five studies, 423 participants) (RR 1.66, 95% CI 0.72 to 3.85); and pain measured by VAS (two studies, 395 participants) (mean difference (MD) -0.09, 95% CI -0.37 to 0.18).",merge,['We found no convincing evidence that results differed when air or saline was used.'],1,0.5,3,8
CD008938,0,4,"With regard to adverse effects, we found no statistically significant differences between participants receiving air and those given saline in the occurrence of paraesthesias (three trials, 572 participants) (RR 0.89, 95% CI 0.69 to 1.15); difficulty in advancing the catheter (two trials, 227 participants) (RR 0.91, 95% CI 0.32 to 2.56); catheter replacement (two trials, 501 participants) (RR 0.69, 95% CI 0.26 to 1.83); and postdural puncture headache (one trial, 110 participants) (RR 0.83, 95% CI 0.12 to 5.71).",none,[],1,0.625,4,8
CD008938,1,5,Low-quality evidence shows that results do not differ between air and saline in terms of the loss of resistance technique for identification of the epidural space and reduction of complications.,ignore,['Low-quality evidence shows that results do not differ between air and saline in using loss of resistance technique for identification of the epidural space and in reducing complications.'],2,0.75,4,8
CD008938,1,6,"Applicability might be compromised, as most of the results described in this review were obtained from parturient patients.",ignore,"['The applicability of findings might be compromised, as most of the results described in this review were obtained from parturient patients.']",3,0.875,5,8
CD008938,1,7,This review underlines the need to conduct well-designed trials in this field.,delete,[],4,1.0,5,8
CD013013,0,0,We identified only one randomised controlled trial (N = 30 women) that evaluated the effect of paracervical block on women undergoing manual removal of a retained placenta compared with intravenous pethidine and diazepam.,rephrase,['The study involved 30 women who were undergoing the manual removal of a retained placenta.'],0,0.07692307692307693,1,13
CD013013,0,1,The study was conducted in a hospital in Papua New Guinea.,rephrase,"['We found one small, randomised controlled study that took place in a hospital in Papua New Guinea.']",1,0.15384615384615385,1,13
CD013013,0,2,"The study was at high risk of bias of performance bias and detection bias, low risk of attrition bias, and an unclear risk of selection bias, reporting bias, and other bias.",delete,[],2,0.23076923076923078,2,13
CD013013,1,3,The included study did not measure this review's primary outcomes of pain intensity and adverse events.,rephrase,['This study did not report on pain intensity or adverse events.'],2,0.3076923076923077,2,13
CD013013,2,4,"The study reported that there were no women, in either group, who experienced an estimated postpartum blood loss of more than 500 mL.",rephrase,['The study did report that none of the women experienced a postpartum blood loss of more than 500 mL.'],3,0.38461538461538464,2,13
CD013013,3,5,"We are uncertain about the providers' satisfaction with the procedure, defined as their perception of achieving good pain relief during the procedure (risk ratio (RR) 1.50, 95% confidence interval (CI) 0.71 to 3.16, one study, 30 women; very low quality evidence).",rephrase,"[""We are uncertain about the providers' satisfaction with the procedure (defined as their perception of good pain relief during the procedure), and the women's satisfaction with the procedure (defined as their perception of good pain relief during the procedure).""]",4,0.46153846153846156,3,13
CD013013,4,6,"We are also uncertain about the women's satisfaction with the procedure, defined as their perception of achieving good pain relief during the procedure (RR 0.82, 95% CI 0.49 to 1.37; one study, 30 women; very low quality evidence).",delete,[],5,0.5384615384615384,3,13
CD013013,5,7,The included study did not report on any of our other outcomes of interest.,delete,[],5,0.6153846153846154,4,13
CD013013,6,8,There is insufficient evidence from one small study to evaluate the effectiveness and safety of anaesthesia or analgesia during the manual removal of a retained placenta.,rephrase,['We found insufficient evidence to determine the effectiveness and safety of anaesthesia or analgesia during manual removal of a retained placenta.'],5,0.6923076923076923,4,13
CD013013,7,9,The quality of the available evidence was very low.,delete,[],6,0.7692307692307693,4,13
CD013013,7,10,"We downgraded based on issues of limitations in study design (risk of bias) and imprecision (single study with small sample size, few or no events, and wide confidence intervals).",delete,[],6,0.8461538461538461,5,13
CD013013,8,11,"There is a need for well-designed, multi-centre, randomised, controlled trials to evaluate the effectiveness and safety of different types of anaesthesia and analgesia during manual removal of a retained placenta.",merge,"['There is a need for further well designed, randomised controlled trials that report on the important outcomes outlined in this review.']",6,0.9230769230769231,5,13
CD013013,8,12,These studies could report on the important outcomes outlined in this review.,none,[],6,1.0,5,13
CD010365,0,0,We included five RCTs with a total of 827 participants.,rephrase,['We identified five RCTs with a total of 827 participants.'],0,0.05,1,20
CD010365,0,1,Outcomes were available for 730 participants (384 participants randomised to continuous sutures and 346 participants to interrupted sutures).,rephrase,['Seven hundred thirty participants (384 received continuous sutures and 346 interrupted sutures) provided data for this review.'],1,0.1,1,20
CD010365,0,2,All the trials were of unclear or high risk of bias.,rephrase,"['Levels of bias across the studies were mostly high or unclear, so there may have been flaws in trial organisation that could produce erroneous results.']",2,0.15,1,20
CD010365,0,3,The participants underwent abdominal or groin operations.,rephrase,['Participants had abdominal or groin operations.'],3,0.2,1,20
CD010365,0,4,"The only outcomes reported in the trials were superficial surgical site infection, superficial wound dehiscence (breakdown) and length of hospital stay.",rephrase,"['The only outcomes reported were, superficial surgical site infection, superficial wound breakdown and length of hospital stay.']",4,0.25,2,20
CD010365,0,5,"Other important outcomes such as quality of life, long-term patient outcomes and use of healthcare resources were not reported in these trials.",rephrase,"['No other important outcomes, including quality of life, long-term patient outcomes and use of healthcare resources, were reported.']",5,0.3,2,20
CD010365,1,6,"Overall, 6.5% (39/602 participants, four trials) developed superficial surgical site infections.",merge,[],6,0.35,2,20
CD010365,1,7,There was no significant difference between the groups in the proportion of participants who developed superficial surgical site infections (RR 0.73; 95% CI 0.40 to 1.33).,none,"['Approximately 6% of participants developed superficial surgical site infection, but there was no significant difference between the two groups in the proportion of participants who developed these.']",6,0.4,2,20
CD010365,1,8,"A total of 23 participants (23/625 (3.7%), four trials) developed superficial wound dehiscence.",rephrase,['Approximately 4% of participants developed superficial wound breakdown.'],7,0.45,3,20
CD010365,1,9,Twenty-two of the 23 participants belonged to the interrupted suture group.The proportion of participants who developed superficial wound dehiscence was statistically significantly lower in the continuous suture group compared to the interrupted suture group (RR 0.08; 95% CI 0.02 to 0.35).,delete,[],8,0.5,3,20
CD010365,1,10,Most of these wound dehiscences were reported in two recent trials in which the continuous skin suture groups received absorbable subcuticular sutures while the interrupted skin suture groups received non-absorbable transcutaneous sutures.,rephrase,['Most wound breakdowns occurred in two trials that used absorbable sutures for continuous suturing and non-absorbable sutures for interrupted suturing.'],8,0.55,3,20
CD010365,1,11,"The non-absorbable sutures were removed seven to nine days after surgery in the interrupted sutures groups whilst sutures in the comparator groups were not removed, being absorbable.",merge,"['Non-absorbable sutures are removed seven to nine days after surgery, but absorbable sutures are not removed, and so support the wound for longer - which may account for the difference in distribution of this problem between groups.']",9,0.6,3,20
CD010365,1,12,The continuous suture technique with absorbable suture does not require suture removal and provides support for the wound for a longer period of time.,none,[],9,0.65,4,20
CD010365,1,13,This may have contributed to the difference between the two groups in the proportion of participants who developed superficial wound dehiscence.,delete,[],10,0.7,4,20
CD010365,1,14,There was no significant difference in the length of the hospital stay between the two groups (MD -1.40 days; 95% CI -7.14 to 4.34).,rephrase,['There was no significant difference between groups for length of hospital stay.'],10,0.75,4,20
CD010365,2,15,Superficial wound dehiscence may be reduced by using continuous subcuticular sutures.,rephrase,['Superficial wound breakdown is reduced by continuous subcuticular suturing.'],11,0.8,4,20
CD010365,2,16,"However, there is uncertainty about this because of the quality of the evidence.",delete,[],12,0.85,5,20
CD010365,2,17,"Besides, the nature of the suture material used may have led to this observation, as the continuous suturing technique used suture material that did not need to be removed, whereas the comparator used interrupted (non-absorbable) sutures that did need to be removed.",rephrase,"['However, the trials that contributed to this result had suture removal in only one group (interrupted sutures), which may have led to this observation.']",12,0.9,5,20
CD010365,2,18,Differences in the methods of skin closure have the potential to affect patient outcomes and use of healthcare resources.,delete,[],13,0.95,5,20
CD010365,2,19,Further well-designed trials at low risk of bias are necessary to determine which type of suturing is better.,delete,[],13,1.0,5,20
CD004592,0,0,Only one study fulfilled the criteria (Amato 1988).,rephrase,['Only one randomised trial fulfilled the criteria for inclusion in the analysis.'],0,0.125,1,8
CD004592,0,1,20 full term babies requiring exchange transfusion for hemolytic jaundice due to ABO incompatibility were randomly allocated to receive single or double volume exchange transfusion.,rephrase,['This study compared single and double volume exchange transfusion in jaundice due to ABO hemolytic jaundice.'],1,0.25,2,8
CD004592,0,2,"Base line characteristics of both groups were similar with regards to birth weight 3260 (SD 390) g vs. 3350 SD (410) g, gestational age 39 (SD 1) week vs. 40 (SD 0.8) week, immediate pre exchange bilirubin level 199 (SD 33) micromol/L vs. 216 (SD 55) micromol/L.",delete,[],2,0.375,2,8
CD004592,0,3,Both groups were treated equally apart from the volume of blood used for exchange transfusion.,delete,[],2,0.5,3,8
CD004592,0,4,Total bilirubin levels immediately after exchange transfusion were not significantly different in either group.,rephrase,['The study found no significant difference in bilirubin levels following exchange.'],2,0.625,4,8
CD004592,0,5,No long term neurodevelopmental outcome was examined in this study.,rephrase,['This study did not look at any long term neurodevelopmental outcome (brain damage).'],3,0.75,4,8
CD004592,1,6,There was insufficient evidence to support or refute the use of single volume exchange transfusion as opposed to double volume exchange transfusion in jaundiced newborns.,merge,"['Based on the available data, there is insufficient evidence to support or refute the use of single volume exchange transfusion as opposed to double volume exchange transfusion in jaundiced newborns.']",4,0.875,5,8
CD004592,1,7,"A change from the current practice of double volume exchange transfusions for severe jaundice in newborns infant, cannot be recommended on current evidence.",none,[],4,1.0,5,8
CD013376,0,0,"We included three recent cluster-RCTs reporting the effects of agricultural education plus post-harvest technologies, compared to usual agricultural support or no intervention.",delete,[],0,0.06666666666666667,1,15
CD013376,0,1,"The participants were pregnant women and their children, lactating women and their infants (< 6 months), women of childbearing age, and young children (< 59 months), from rural, subsistence maize-farming communities in Kenya, Zimbabwe, and Tanzania.",delete,[],0,0.13333333333333333,1,15
CD013376,1,2,"Two trials randomised villages to the intervention and control groups, including a total of at least 979 mother-child pairs from 60 villages.",delete,[],0,0.2,1,15
CD013376,1,3,"The third trial randomised 420 households, including 189 mother-child pairs and 231 women of childbearing age.",rephrase,"['We included three trials, conducted in pregnant and breastfeeding women (1168 mother-child pairs), women of childbearing age (N = 231), and infants and young children (< 59 months old), from rural, subsistence maize-farming communities in Kenya, Tanzania, and Zimbabwe.']",0,0.26666666666666666,2,15
CD013376,1,4,Duration of the intervention and follow-up ranged between five and nine months.,delete,[],1,0.3333333333333333,2,15
CD013376,1,5,"Due to risk of attrition bias, the overall risk of bias was unclear in one trial, and high in the other two trials.",delete,[],1,0.4,2,15
CD013376,2,6,None of the included studies addressed the effects of nutritional education on pre- and postnatal growth.,delete,[],1,0.4666666666666667,3,15
CD013376,3,7,"One trial reported outcomes not prespecified in our review, and we were unable to obtain unpublished growth data from the second trial, even after contacting the authors.",rephrase,"['One trial in Tanzania, at unclear risk of bias overall, provided data for this review, since one trial did not report any outcomes relevant to this review, and we were unable to obtain unpublished growth data for another, even after contacting the study authors.']",1,0.5333333333333333,3,15
CD013376,3,8,"The third trial, in lactating women and their infants in Tanzania, reported on the infants' weight-for-age z-score (WAZ) after six months.",merge,[],2,0.6,3,15
CD013376,3,9,"This trial found that providing agricultural education aimed at changing farmers' post-harvest practices to reduce aflatoxin exposure, by using demonstrations (e.g. handsorting, de-hulling of maize, drying sheets, and insecticides), may improve WAZ in infants from these farmers' households, on average, by 0.57 (95% confidence interval (CI) 0.16 to 0.98; 1 study; 249 participants; very low-certainty evidence), compared to infants from households where the farmers received routine agricultural extension services.",none,"[""The trial, conducted in breastfeeding women and their babies, studied the effects of agricultural education (demonstrations to change farmers' practices after harvesting their maize crops to reduce aflatoxins (for example, by handsorting and de-hulling the maize, using drying sheets and insecticides) on the babies' weight, standardised for age (weight-for-age z-score (WAZ)), after six months (the z-score measures the difference between these babies and the median of a population of similar babies).""]",2,0.6666666666666666,4,15
CD013376,4,10,Another way of reporting the effect on WAZ is to compare the proportion of underweight infants (WAZ > 2 SD below the reference median value) per group.,rephrase,"['Another way of measuring the effect is to compare the proportion of underweight infants (WAZ ≥ 2 standard deviations below the reference median value) per group, after the intervention.']",3,0.7333333333333333,4,15
CD013376,4,11,This trial found that the intervention may reduce the proportion of underweight infants in the intervention households by 6.7% (95% CI -12.6 to -1.4; 249 participants; very low-certainty evidence) compared to control households.,rephrase,"['In this case, agricultural education may reduce the proportion of underweight children, on average, by 6.7% (very low-certainty evidence), compared to routine services.']",4,0.8,4,15
CD013376,5,12,No studies reported on unintended effects of agricultural and nutritional education.,rephrase,"['None of the included studies addressed the effects of nutritional education on length of height, or on unintended effects of agricultural or nutritional education.']",5,0.8666666666666667,5,15
CD013376,6,13,Evidence on the effects on child growth in LMICs of agricultural or nutritional education interventions that reduce aflatoxin exposure was very limited; no included study reported on linear growth.,rephrase,['Evidence about the effects on child growth of agricultural or nutritional education interventions that reduce aflatoxin exposure in LMICs was very limited.'],6,0.9333333333333333,5,15
CD013376,6,14,"Very low-certainty evidence suggested that agricultural education aimed at changing farmers' post-harvest practices to reduce aflatoxin exposure by using demonstrations, may result in an increase in WAZ, when compared to usual or no education.",rephrase,"[""Very low-certainty evidence from one trial suggested that the WAZ of 128 children from farmers' households who received agricultural education may improve by a z-score of 0.57, compared to 121 children from households where farmers only received routine services.""]",7,1.0,5,15
CD004455,0,0,"Two studies, involving 3813 women undergoing either vacuum or forceps deliveries, were included.",rephrase,['A total of 3813 women undergoing operative vaginal delivery were included.'],0,0.058823529411764705,1,17
CD004455,0,1,One study involving 393 women compared the antibiotic intravenous cefotetan after cord clamping compared with no treatment.,rephrase,['The USA study involved 393 women and compared 2 g of intravenous cefotetan after cord clamping with no treatment.'],1,0.11764705882352941,1,17
CD004455,0,2,The other study involving 3420 women compared a single dose of intravenous amoxicillin and clavulanic acid with placebo using 20 mL of intravenous sterile 0.9% saline.,split,"['The other study involved 3420 women.', 'This study compared intravenous amoxicillin and clavulanic acid with placebo.']",2,0.17647058823529413,1,17
CD004455,1,3,"The evidence suggests that prophylactic antibiotics reduce superficial perineal wound infection (risk ratio (RR) 0.53, 95% confidence interval (CI) 0.40 to 0.69; women = 3420; 1 study; high-certainty evidence), deep perineal wound infection (RR 0.46, 95% CI 0.31 to 0.69; women = 3420; 1 study; high-certainty evidence) and probably reduce wound breakdown (RR 0.52, 95% CI 0.43 to 0.63; women = 2593; 1 study; moderate-certainty evidence).",delete,[],4,0.23529411764705882,2,17
CD004455,1,4,"We are unclear about the effect on organ or space perineal wound infection (RR 0.11, 95% CI 0.01 to 2.05; women = 3420; 1 study) and endometritis (average RR 0.32, 95% CI 0.04 to 2.64; 15/1907 versus 30/1906; women = 3813; 2 studies) based on low-certainty evidence with wide CIs that include no effect.",delete,[],4,0.29411764705882354,2,17
CD004455,1,5,"Prophylactic antibiotics probably lower serious infectious complications (RR 0.44, 95% CI 0.22 to 0.89; women = 3420; 1 study; high-certainty evidence).",split,"['These findings included superficial and deep perineal wound infections (one study, 3420 women; high-certainty evidence) or wound breakdown (one study, 2593 women; moderate-certainty evidence).', 'Serious infectious complications were also reduced (one study, 3420 women; high-certainty evidence).', 'Due to low-certainty evidence, prophylactic antibiotics had uncertain effects on endometritis, experienced as fever and uterine tenderness or heavy bleeding (two studies, 3813 women; low-certainty evidence) and infected episiotomy/laceration presenting with organ or space perineal infection (one study, 3420 women; low-certainty evidence).']",4,0.35294117647058826,2,17
CD004455,1,6,They also have an important effect on reduction of confirmed or suspected maternal infection.,delete,[],7,0.4117647058823529,3,17
CD004455,1,7,The two included studies did not report on fever or urinary tract infection.,rephrase,"['Neither study specifically measured fever, urinary tract infection or adverse reactions in babies.']",7,0.47058823529411764,3,17
CD004455,2,8,"It is unclear, based on low-certainty evidence, whether prophylactic antibiotics have any impact on maternal adverse reactions (RR 2.00, 95% CI 0.18 to 22.05; women = 2593; 1 study) and maternal length of stay (MD 0.09 days, 95% CI -0.23 to 0.41; women = 393; 1 study) as the CIs were wide and included no effect.",rephrase,"['The impact on maternal adverse reactions (one study, 2593 women; low-certainty evidence) and maternal length of stay in hospital (one study, 393 women; low-certainty evidence) was also unclear due to the low-certainty of the study.']",8,0.5294117647058824,3,17
CD004455,2,9,Prophylactic antibiotics slightly improve perineal pain and health consequences of perineal pain and probably reduce costs.,split,"['Perineal pain and health consequences of perineal pain were slightly reduced.', 'Costs were reduced with use of prophylactic antibiotics.']",9,0.5882352941176471,3,17
CD004455,2,10,Prophylactic antibiotics did not have an important effect on dyspareunia (difficult or painful sexual intercourse) or breastfeeding at six weeks.,rephrase,['Prophylactic antibiotics did not have a clear effect on pain during sex and breastfeeding at six weeks.'],11,0.6470588235294118,4,17
CD004455,2,11,Antibiotic prophylaxis may slightly improve maternal hospital re-admission and maternal health-related quality of life.,rephrase,['Maternal hospital re-admission and maternal health-related quality of life may be slightly improved.'],12,0.7058823529411765,4,17
CD004455,2,12,Neonatal adverse reactions were not reported in any included trials.,delete,[],13,0.7647058823529411,4,17
CD004455,3,13,Prophylactic intravenous antibiotics are effective in reducing infectious puerperal morbidities in terms of superficial and deep perineal wound infection or serious infectious complications in women undergoing operative vaginal deliveries without clinical indications for antibiotic administration after delivery.,rephrase,"['Prophylactic antibiotics into a vein are effective in reducing ill-health caused by infections in women undergoing operative vaginal deliveries, and who do not have clinical indications for antibiotic administration.']",13,0.8235294117647058,5,17
CD004455,3,14,"Prophylactic antibiotics slightly improve perineal pain and health consequences of perineal pain, probably reduce the costs, and may slightly reduce the maternal hospital re-admission and health-related quality of life.",delete,[],14,0.8823529411764706,5,17
CD004455,3,15,"However, the effect on reduction of endometritis, organ or space perineal wound infection, maternal adverse reactions and maternal length of stay is unclear due to low-certainty evidence.",delete,[],14,0.9411764705882353,5,17
CD004455,4,16,"As the evidence was mainly derived from a single multi-centre study conducted in a high-income setting, future well-designed randomised trials in other settings, particularly in low- and middle-income settings, are required to confirm the effect of antibiotic prophylaxis for operative vaginal delivery.",split,"['The evidence was mainly from a single study in a high-income country.', 'Well-designed randomised studies in other settings are required to confirm this finding.']",14,1.0,5,17
CD005000,0,0,Ten studies (3340 participants) were included in the review.,rephrase,['Ten studies are included (3340 participants).'],0,0.06666666666666667,1,15
CD005000,0,1,Seven studies compared aripiprazole monotherapy versus placebo (2239 participants); two of these included a third comparison arm—one study used lithium (485 participants) and the other used haloperidol (480 participants).,rephrase,"['Most studies compared aripiprazole versus placebo, but some researchers compared aripiprazole versus haloperidol (two studies) and versus lithium (one study).']",1,0.13333333333333333,1,15
CD005000,0,2,"Two studies compared aripiprazole as an adjunctive treatment to valproate or lithium versus placebo as an adjunctive treatment (754 participants), and one study compared aripiprazole versus haloperidol (347 participants).",rephrase,['Two studies examined the effect of adding aripiprazole to another treatment (valproate or lithium) and compared this combination versus placebo combined with these other treatments.'],2,0.2,1,15
CD005000,0,3,The overall risk of bias was unclear.,rephrase,['We assessed the overall risk of bias in the ten studies as unclear.'],3,0.26666666666666666,2,15
CD005000,0,4,A high dropout rate from most trials (> 20% for each intervention in eight of the trials) may have affected the estimates of relative efficacy.,delete,[],4,0.3333333333333333,2,15
CD005000,0,5,"Evidence shows that aripiprazole was more effective than placebo in reducing manic symptoms in adults and children/adolescents at three and four weeks but not at six weeks (Young Mania Rating Scale (YMRS); mean difference (MD) at three weeks (random effects) -3.66, 95% confidence interval (CI) -5.82 to -2.05; six studies; N = 1819, moderate quality evidence) - a modest difference.",rephrase,"['After three weeks of treatment, aripiprazole was better than placebo at reducing the severity of mania when used on its own or when added to other mood stabilisers.']",4,0.4,2,15
CD005000,0,6,Aripiprazole was compared with other drug treatments in three studies in adults—lithium was used in one study and haloperidol in two studies.,merge,['Aripiprazole was similarly effective in reducing the symptoms of mania when compared with other drug treatments (haloperidol and lithium).'],5,0.4666666666666667,3,15
CD005000,0,7,"No statistically significant differences between aripiprazole and other drug treatments in reducing manic symptoms were noted at three weeks (YMRS MD at three weeks (random effects) 0.07, 95% CI -1.24 to 1.37; three studies; N = 972, moderate quality evidence) or at any other time point up to and including 12 weeks.",none,[],5,0.5333333333333333,3,15
CD005000,0,8,"Compared with placebo, aripiprazole caused more movement disorders, as measured on the Simpson Angus Scale (SAS), on the Barnes Akathisia Scale (BAS) and by participant-reported akathisia (high quality evidence), with more people requiring treatment with anticholinergic medication (risk ratios (random effects) 3.28, 95% CI 1.82 to 5.91; two studies; N = 730, high quality evidence).",rephrase,['Aripiprazole caused fewer movement disorders and less raised prolactin (a hormone secreted by the pituitary gland) than haloperidol.'],6,0.6,3,15
CD005000,0,9,"Aripiprazole also led to more gastrointestinal disturbances (nausea (high quality evidence), and constipation) and caused more children/adolescents to have a prolactin level that fell below the lower limit of normal.",rephrase,"['However, aripiprazole caused more inner restlessness (akathisia), nausea, and constipation than placebo.']",7,0.6666666666666666,4,15
CD005000,0,10,Significant heterogeneity was present in the meta-analysis of movement disorders associated with aripiprazole and other treatments and was most likely due to the different side effect profiles of lithium and haloperidol.,rephrase,['People taking aripiprazole were more likely to remain on treatment than those taking haloperidol but were no more or less likely than those taking placebo or lithium.'],8,0.7333333333333333,4,15
CD005000,0,11,"At the three-week time point, meta-analysis was not possible because of lack of data; however, at 12 weeks, haloperidol resulted in significantly more movement disorders than aripiprazole, as measured on the SAS, the BAS and the Abnormal Involuntary Movement Scale (AIMS) and by participant-reported akathisia.",delete,[],9,0.8,4,15
CD005000,0,12,"By 12 weeks, investigators reported no difference between aripiprazole and lithium (SAS, BAS, AIMS), except in terms of participant-reported akathisia (RR 2.97, 95% CI 1.37 to 6.43; one study; N = 313).",delete,[],9,0.8666666666666667,5,15
CD005000,1,13,"Aripiprazole is an effective treatment for mania in a population that includes adults, children and adolescents, although its use leads to gastrointestinal disturbances and movement disorders.",rephrase,"['In summary, aripiprazole is an effective treatment for mania when compared with placebo.']",9,0.9333333333333333,5,15
CD005000,1,14,"Comparative trials with medicines other than haloperidol and lithium are few, so the precise place of aripiprazole in therapy remains unclear.",delete,[],10,1.0,5,15
CD011914,0,0,"We identified a total of 556 records, of which 486 records were excluded on the basis of title and abstract.",rephrase,['The search identified 556 records.'],0,0.1,1,10
CD011914,0,1,We retrieved the remaining 70 references in full to determine eligibility.,delete,[],1,0.2,1,10
CD011914,0,2,"No studies fulfilled the inclusion criteria of this review, and thus we found no evidence to support or oppose the use of codeine or derivatives as antitussive agents for chronic cough in children.",split,"['We reviewed and assessed all of these against predetermined inclusion/exclusion criteria.', 'We found no eligible studies to include in this review.', 'However, our search did find studies that investigated codeine (or medications produced from codeine) in the treatment of acute cough (two weeks or less) in children.', 'Another Cochrane review specifically for children with acute cough evaluated these studies and found no evidence to support or oppose use of codeine (or medications produced from codeine).']",1,0.3,2,10
CD011914,1,3,"While chronic cough is not the same as acute cough, systematic reviews on the use of codeine efficacy for acute cough in children conclude an overall lack of evidence to support or oppose the use of over-the-counter cough and cold medications containing codeine (or derivatives) for treatment of acute cough in children.",delete,[],5,0.4,2,10
CD011914,1,4,"The lack of sufficient evidence to support the use of these medications has been consistently reaffirmed by medical experts in international chronic cough guidelines and by governing medical and pharmaceutical authorities in the USA, Europe, Canada, New Zealand, and Australia.",split,"['This overall lack of evidence is consistent with international chronic cough guidelines, which recommend treating the cause of the cough.', 'Given the lack of supporting trials, the findings from trials of acute cough in children, and the known harmful side effects, we have concluded that codeine-based medications cannot be recommended in children with chronic cough.']",5,0.5,3,10
CD011914,1,5,"Due to the lack of sufficient evidence to support efficacy, and the known risks associated with use - in particular the increased risks for children - these medications are now not recommended for children less than 12 years of age and children between 12 to 18 years with respiratory conditions.",rephrase,"['Due to the known risks associated with use, in particular the increased risks for children, governing bodies in the USA, Europe, Canada, New Zealand, and Australia have stated these medications are now not recommended for children younger than 12 years of age and children between 12 to 18 years with respiratory conditions.']",7,0.6,3,10
CD011914,2,6,This review has highlighted the absence of any randomised controlled trials evaluating codeine-based medications in the treatment of childhood chronic cough.,rephrase,['We searched for any randomised controlled trial comparing either codeine (or medications produced from codeine) versus placebo in the treatment of chronic cough (4 weeks or longer) in children aged 18 years and younger.'],8,0.7,4,10
CD011914,2,7,"Given the potential adverse events of respiratory suppression and opioid toxicity, national therapeutic regulatory authorities recommend the contraindication of access to codeine in children less than 12 years of age.",delete,[],9,0.8,4,10
CD011914,2,8,We suggest that clinical practice adhere to clinical practice guidelines and thus refrain from using codeine or its derivatives to treat cough in children.,delete,[],9,0.9,5,10
CD011914,2,9,Aetiological-based management practices continue to be advocated for children with chronic cough.,delete,[],9,1.0,5,10
CD004325,0,0,"The four included studies involved 163 participants, mainly active young adult males.",rephrase,['This review included four trials that involved 163 participants who were mainly active young adult males.'],0,0.058823529411764705,1,17
CD004325,0,1,All had had a primary (first time) traumatic anterior shoulder dislocation.,rephrase,['All had had a primary (first time) anterior shoulder dislocation as a result of injury.'],1,0.11764705882352941,1,17
CD004325,0,2,Methodological quality was variable.,rephrase,['Methodological quality of the trials was variable.'],2,0.17647058823529413,1,17
CD004325,1,3,All participants of one trial returned to active military duty.,merge,[],3,0.23529411764705882,2,17
CD004325,1,4,Two trials respectively reported similar numbers with reduced sports participation or non return to previous activities.,none,['Three trials found similar numbers returning to previous activities such as active military duties and sports.'],3,0.29411764705882354,2,17
CD004325,1,5,"The other, an inadequately reported, trial found significantly fewer people in the surgical group failed to attain previous levels of sports activity.",rephrase,['The other trial found significantly fewer people in the surgical group failing to attain previous levels of sports activity.'],4,0.35294117647058826,2,17
CD004325,2,6,"Pooled results from all four trials showed that subsequent instability, either redislocation or subluxation, was statistically significantly less frequent in the surgical group (risk ratio 0.25, 95% confidence interval 0.14 to 0.44).",merge,"['Pooled results from the three trials that were reported in full (124 participants) showed that subsequent instability, either redislocation or subluxation (partial dislocation), was significantly less frequent in the surgical group.']",5,0.4117647058823529,3,17
CD004325,2,7,"This result remained statistically significant (risk ratio 0.32, 95% confidence interval 0.17 to 0.59) for the three trials reported in full.",none,[],5,0.47058823529411764,3,17
CD004325,2,8,Half (17/33) of the conservatively treated patients with shoulder instability in these three trials opted for subsequent surgery.,ignore,['Half (17/33) of the conservatively treated patients with shoulder instability in these three trials opted for subsequent surgery.'],6,0.5294117647058824,3,17
CD004325,3,9,"Different, mainly patient rated, functional assessment measures for the shoulder were recorded in these trials.",merge,[],7,0.5882352941176471,3,17
CD004325,3,10,"The results were more favourable, usually statistically significantly so, in those treated surgically.",none,"['Function, measured in different ways in the four trials, was usually better in those treated surgically.']",7,0.6470588235294118,4,17
CD004325,4,11,The only complication reported was a septic joint in a surgically treated patient.,rephrase,['The only complication of treatment reported was an infected joint in a surgically treated patient.'],8,0.7058823529411765,4,17
CD004325,4,12,"There was no information on shoulder pain, long-term complications or resource use.",delete,[],9,0.7647058823529411,4,17
CD004325,5,13,"Limited evidence supports primary surgery for young adults, usually male, engaged in highly demanding physical activities who have sustained their first acute traumatic shoulder dislocation.",delete,[],9,0.8235294117647058,5,17
CD004325,5,14,There is no evidence available to determine which treatment is better for other patient groups.,delete,[],9,0.8823529411764706,5,17
CD004325,6,15,"Sufficiently powered, good quality, well reported randomised trials are required that compare surgical treatment with conservative treatment for these injuries, including in people at lower risk of recurrence.",delete,[],9,0.9411764705882353,5,17
CD004325,6,16,"Long-term surveillance of outcome, looking at shoulder disorders including osteoarthritis is also required.",delete,[],9,1.0,5,17
CD008811,0,0,Three trials randomly allocating people with age-related cataract to MSICS or ECCE were included in this review (n = 953 participants).,rephrase,['A total of 953 people with age-related cataract in India and Nepal were randomly allocated to MSICS and ECCE in these trials.'],0,0.08333333333333333,1,12
CD008811,0,1,Two trials were conducted in India and one in Nepal.,delete,[],1,0.16666666666666666,1,12
CD008811,0,2,"Trial methods, such as random allocation and allocation concealment, were not clearly described; in only one trial was an effort made to mask outcome assessors.",delete,[],1,0.25,2,12
CD008811,0,3,The three studies reported follow-up six to eight weeks after surgery.,delete,[],1,0.3333333333333333,2,12
CD008811,0,4,"In two studies, more participants in the MSICS groups achieved unaided visual acuity of 6/12 or 6/18 or better compared to the ECCE group, but overall not more than 50% of people achieved good functional vision in the two studies.",rephrase,"['People whose lens was removed with MSICS were more likely to achieve good functional vision, however, overall not more than 50% of people achieved good functional vision in the two studies.']",1,0.4166666666666667,3,12
CD008811,0,5,"10/806 (1.2%) of people enrolled in two trials had a poor outcome after surgery (best-corrected vision less than 6/60) with no evidence of difference in risk between the two techniques (risk ratio (RR) 1.58, 95% confidence interval (CI) 0.45 to 5.55).",rephrase,['1.2% of people enrolled in two trials had a poor outcome after surgery with best-corrected vision less than 6/60.'],2,0.5,3,12
CD008811,0,6,Surgically induced astigmatism was more common with the ECCE procedure than MSICS in the two trials that reported this outcome.,ignore,['Surgically induced astigmatism was more common with the ECCE procedure than MSICS in the two trials that reported this outcome.'],3,0.5833333333333334,3,12
CD008811,0,7,In one study there were more intra- and postoperative complications in the MSICS group.,ignore,['In one study there were more intra- and postoperative complications in the MSICS group.'],4,0.6666666666666666,4,12
CD008811,0,8,One study reported that the costs of the two procedures were similar.,ignore,['One study reported that the costs of the two procedures were similar.'],5,0.75,4,12
CD008811,1,9,There are no other studies from other countries other than India and Nepal and there are insufficient data on cost-effectiveness of each procedure.,delete,[],6,0.8333333333333334,5,12
CD008811,1,10,Better evidence is needed before any change may be implemented.,delete,[],6,0.9166666666666666,5,12
CD008811,1,11,Future studies need to have longer-term follow-up and be conducted to minimize biases revealed in this review with a larger sample size to allow examination of adverse events.,delete,[],6,1.0,5,12
CD011941,0,0,"We included eight RCTs: six reported between-participant data (2035 participants; 1908 analysed), and two reported within-participant data (70 participants, 68 analysed; 140 limbs; 136 analysed).",rephrase,['We included eight trials (1976 analysed participants).'],0,0.038461538461538464,1,26
CD011941,0,1,One study reported data for the comparison salt bath with UVB versus other treatment without UVB; and eight studies reported data for salt bath with UVB versus other treatment with UVB or UVB only.,rephrase,['No study reported primary outcome data for the comparison salt bath with UVB versus other treatment without UVB; five studies reported primary outcome data for salt bath with UVB versus UVB only.'],1,0.07692307692307693,1,26
CD011941,0,2,"Of these eight studies, only five reported any of our pre-specified outcomes and assessed the comparison of salt bath with UVB versus UVB only.",delete,[],2,0.11538461538461539,1,26
CD011941,0,3,The one included trial that assessed salt bath plus UVB versus other treatment without UVB (psoralen bath + UVA) did not report any of our primary outcomes.,split,"['One included trial assessed salt bath plus UVB versus other treatment without UVB (psoralen bath + UVA), but it did not report our primary outcomes for this comparison.', 'Eight trials assessed our second comparison of interest: salt bath with UVB versus other treatment with UVB or UVB only, and those that reported any outcomes of interest (only five studies) specifically compared salt bath with UVB versus UVB only.']",2,0.15384615384615385,1,26
CD011941,0,4,The mean age of the participants ranged from 41 to 50 years of age in 75% of the studies.,rephrase,"['Participants were male or female, and their ages mostly ranged from 41 to 50 years.']",4,0.19230769230769232,1,26
CD011941,0,5,None of the included studies reported on the predefined secondary outcomes of this review.,rephrase,['No study reported our secondary outcomes.'],5,0.23076923076923078,2,26
CD011941,0,6,"We judged seven of the eight studies as at high risk of bias in at least one domain, most commonly performance bias.",delete,[],6,0.2692307692307692,2,26
CD011941,0,7,Total trial duration ranged between at least two months and up to 13 months.,rephrase,['The duration of trials in total ranged between at least two months and up to 13 months.'],6,0.3076923076923077,2,26
CD011941,1,8,"In five studies, the median participant PASI score at baseline ranged from 15 to 18 and was balanced between treatment arms.",ignore,"['In five studies, the median PASI score at baseline ranged from 15 to 18 and was balanced between treatment arms.']",7,0.34615384615384615,2,26
CD011941,1,9,Three studies did not report PASI score.,ignore,['Three studies did not report PASI score.'],8,0.38461538461538464,2,26
CD011941,1,10,Most studies were conducted in Germany; all were set in Europe.,rephrase,['Most of the studies were conducted in Germany; all were based in Europe.'],9,0.4230769230769231,3,26
CD011941,1,11,"Half of the studies were multi-centred (set in spa centres or outpatient clinics); half were set in a single centre in either an unspecified settings, a psoriasis daycare centre, or a spa centre.",rephrase,['Half of the studies were conducted in multiple centres; the remainder were conducted in single centres.'],10,0.46153846153846156,3,26
CD011941,1,12,"Commercial spa or salt companies sponsored three of eight studies, health insurance companies funded another, the association of dermatologists funded another, and three did not report on funding.",rephrase,"['Three studies were sponsored by commercial spa or salt companies, one by health insurance companies, one by an association of dermatologists, and three did not report on funding.']",11,0.5,3,26
CD011941,2,13,"When comparing salt bath plus UVB versus UVB only, two between-participant studies found that salt bath plus UVB may improve psoriasis when measured using PASI 75 (achieving a 75% or more reduction in PASI score from baseline) (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.24 to 2.35; 278 participants; low-certainty evidence).",delete,[],12,0.5384615384615384,3,26
CD011941,2,14,"Assessment was conducted at the end of treatment, which was equivalent to six to eight weeks after start of treatment.",rephrase,['Outcomes were assessed at the end of treatment.'],12,0.5769230769230769,3,26
CD011941,2,15,"The two trials which contributed data for the primary efficacy outcome were conducted by the same group, and did not blind outcome assessors.",delete,[],13,0.6153846153846154,4,26
CD011941,2,16,The German Spas Association funded one of the trials and the funding source was not stated for the other trial.,delete,[],13,0.6538461538461539,4,26
CD011941,3,17,"Two other between-participant studies found salt bath plus UVB may make little to no difference to outcome treatment-related adverse events requiring withdrawal compared with UVB only (RR 0.96, 95% CI 0.35 to 2.64; 404 participants; low-certainty evidence).",rephrase,"['When assessing treatment-related adverse events requiring withdrawal, data from three other studies showed there may be little to no difference between salt bath plus UVB and the comparator UVB only (low-certainty evidence).']",13,0.6923076923076923,4,26
CD011941,3,18,"One of the studies reported adverse events, but did not specify the type of events; the other study reported skin irritation.",merge,[],14,0.7307692307692307,4,26
CD011941,3,19,"One within-participant study found similar results, with one participant reporting severe itch immediately after Dead Sea salt soak in the salt bath and UVB group and two instances of inadequate response to phototherapy and conversion to psoralen bath + UVA reported in the UVB only group (low-certainty evidence).",none,"['The adverse events included skin irritation and severe itch immediately after Dead Sea salt soaks (salt bath + UVB group), and inadequate response to phototherapy and conversion to psoralen bath + UVA (UVB only group).']",14,0.7692307692307693,4,26
CD011941,4,20,"Salt bath with artificial ultraviolet B (UVB) light may improve psoriasis in people with chronic plaque psoriasis compared with UVB light treatment alone, and there may be no difference in the occurrence of treatment-related adverse events requiring withdrawal.",delete,[],15,0.8076923076923077,5,26
CD011941,4,21,"Both results are based on data from a limited number of studies, which provided low-certainty evidence, so we cannot draw any clear conclusions.",delete,[],15,0.8461538461538461,5,26
CD011941,5,22,"The reporting of our pre-specified outcomes was either non-existent or limited, with a maximum of two studies reporting a given outcome.",rephrase,['The reporting of our outcomes was non-existent or limited.'],15,0.8846153846153846,5,26
CD011941,6,23,"The same group conducted the two trials which contributed data for the primary efficacy outcome, and the German Spas Association funded one of these trials.",delete,[],16,0.9230769230769231,5,26
CD011941,6,24,"We recommend further RCTs that assess PASI-75, with detailed reporting of the outcome and time point, as well as treatment-related adverse events.",rephrase,['We judged the evidence for ‘PASI-75’ and ‘treatment-related adverse events requiring withdrawal’ as low certainty.'],16,0.9615384615384616,5,26
CD011941,6,25,Risk of bias was an issue; future studies should ensure blinding of outcome assessors and full reporting.,delete,[],17,1.0,5,26
CD011498,0,0,"Eight trials, which included 1132 participants in total, met the inclusion criteria of this Cochrane review.",rephrase,"['Eight studies met the inclusion criteria of this Cochrane review, and seven studies provided information for the review.']",0,0.047619047619047616,1,21
CD011498,0,1,These trials were at high risk of bias trials.,delete,[],1,0.09523809523809523,1,21
CD011498,0,2,"One trial (which included five participants) did not contribute any data to this Cochrane review, and we excluded 13 participants in the remaining trials after randomisation; this left a total of 1114 participants, 510 randomised to non-surgical treatment and 604 to surgical treatment for analysis.",rephrase,['We included a total of 1114 participants undergoing non-surgical treatment (510 participants) or surgical treatment (604 participants) in the various analysis in the seven studies that provided information.'],1,0.14285714285714285,1,21
CD011498,0,3,The non-surgical treatment was definitive chemoradiotherapy in five trials and definitive radiotherapy in three trials.,rephrase,['The non-surgical treatment was chemoradiotherapy only in five studies and radiotherapy only in three studies.'],2,0.19047619047619047,1,21
CD011498,0,4,All participants were suitable for major surgery.,delete,[],3,0.23809523809523808,2,21
CD011498,0,5,Most of the data were from trials that compared chemoradiotherapy with surgery.,rephrase,['Most information was from trials that compared chemoradiotherapy with surgery.'],3,0.2857142857142857,2,21
CD011498,0,6,"There was no difference in long-term mortality between chemoradiotherapy and surgery (HR 0.88, 95% CI 0.76 to 1.03; 602 participants; four studies; low quality evidence).",rephrase,['There was no difference in long-term deaths between chemoradiotherapy and surgery in people with oesophageal cancer who are fit for surgery.'],4,0.3333333333333333,2,21
CD011498,0,7,"The long-term mortality was higher in radiotherapy than surgery (HR 1.39, 95% CI 1.18 to 1.64; 512 participants; three studies; very low quality evidence).",rephrase,['More people died in radiotherapy than surgery in people with oesophageal cancer who are fit for surgery in the long-term.'],5,0.38095238095238093,2,21
CD011498,0,8,"There was no difference in long-term recurrence between non-surgical treatment and surgery (HR 0.96, 95% CI 0.80 to 1.16; 349 participants; two studies; low quality evidence).",rephrase,['There was no difference in long-term cancer recurrence between non-surgical treatment and surgery.'],6,0.42857142857142855,3,21
CD011498,0,9,"The difference between non-surgical and surgical treatments was imprecise for short-term mortality (RR 0.39, 95% CI 0.11 to 1.35; 689 participants; five studies; very low quality evidence), the proportion of participants with serious adverse in three months (RR 0.61, 95% CI 0.25 to 1.47; 80 participants; one study; very low quality evidence), and proportion of people with local recurrence at maximal follow-up (RR 0.89, 95% CI 0.70 to 1.12; 449 participants; three studies; very low quality evidence).",rephrase,"['The difference between non-surgical and surgical treatments were imprecise for short-term deaths, the percentage of participants with serious adverse in three months, and the percentage of participants who had recurrence of cancer in and around the food-pipe.']",7,0.47619047619047616,3,21
CD011498,0,10,"The health-related quality of life was higher in non-surgical treatment between four weeks and three months after treatment (Spitzer Quality of Life Index; MD 0.93, 95% CI 0.24 to 1.62; 165 participants; one study; very low quality evidence).",rephrase,"['The health-related quality of life (covering aspects such as activity, daily living, health, support of family and friends, and outlook) was higher in non-surgical treatment between four weeks and three months after treatment, although it is unclear what this difference means to the patient.']",8,0.5238095238095238,3,21
CD011498,0,11,"The difference between non-surgical and surgical treatments was imprecise for medium-term health-related quality of life (three months to two years after treatment) (Spitzer Quality of Life Index; MD −0.95, 95% CI −2.10 to 0.20; 62 participants; one study; very low quality of evidence).",rephrase,['The difference between non-surgical and surgical treatments were imprecise for medium-term health-related quality of life (three months to two years after treatment).'],9,0.5714285714285714,3,21
CD011498,0,12,"The proportion of people with dysphagia at the last follow-up visit prior to death was higher with definitive chemoradiotherapy compared to surgical treatment (RR 1.48, 95% CI 1.01 to 2.19; 139 participants; one study; very low quality evidence).",delete,[],10,0.6190476190476191,4,21
CD011498,1,13,"Based on low quality evidence, chemoradiotherapy appears to be at least equivalent to surgery in terms of short-term and long-term survival in people with oesophageal cancer (squamous cell carcinoma type) who are fit for surgery and are responsive to induction chemoradiotherapy.",rephrase,['Chemoradiotherapy only appears to be at least equivalent to surgery in terms of short-term and long-term survival in people with one type of oesophageal cancer called squamous cell cancer and who are fit for surgery.'],10,0.6666666666666666,4,21
CD011498,1,14,"However, there is uncertainty in the comparison of definitive chemoradiotherapy versus surgery for oesophageal cancer (adenocarcinoma type) and we cannot rule out significant benefits or harms of definitive chemoradiotherapy versus surgery.",rephrase,"['There is more uncertainty in the comparison of chemoradiotherapy only versus surgery for another type of oesophageal cancer called adenocarcinoma, and we cannot rule out significant benefits or harms of definitive chemoradiotherapy versus surgery in this type of oesophageal cancer.']",11,0.7142857142857143,4,21
CD011498,1,15,"Based on very low quality evidence, the proportion of people with dysphagia at the last follow-up visit prior to death was higher with definitive chemoradiotherapy compared to surgery.",rephrase,['More people had difficulty in swallowing prior to their death after chemoradiotherapy treatment compared to surgical treatment.'],12,0.7619047619047619,4,21
CD011498,1,16,"Based on very low quality evidence, radiotherapy results in less long-term survival than surgery in people with oesophageal cancer who are fit for surgery.",rephrase,['Radiotherapy only results in less long-term survival than surgery (about 40% increase risk of deaths).'],13,0.8095238095238095,5,21
CD011498,1,17,"However, there is a risk of bias and random errors in these results, although the risk of bias in the studies included in this systematic review is likely to be lower than in non-randomised studies.",delete,[],14,0.8571428571428571,5,21
CD011498,2,18,Further trials at low risk of bias are necessary.,rephrase,['Further well-designed studies that measure outcomes that are important for patients are necessary.'],14,0.9047619047619048,5,21
CD011498,2,19,"Such trials need to compare endoscopic treatment with surgical treatment in early stage oesophageal cancer (carcinoma in situ and Stage Ia), and definitive chemoradiotherapy with surgical treatments in other stages of oesophageal cancer, and should measure and report patient-oriented outcomes.",delete,[],15,0.9523809523809523,5,21
CD011498,2,20,Early identification of responders to chemoradiotherapy and better second-line treatment for non-responders will also increase the need and acceptability of trials that compare definitive chemoradiotherapy with surgery.,delete,[],15,1.0,5,21
CD006807,0,0,Three trials including 255 patients qualified for this review.,rephrase,['A total of three trials including 255 patients qualified for this review of randomised clinical trials.'],0,0.1111111111111111,1,9
CD006807,0,1,"In two of the trial, a total of 150 patients were randomised to absorbable clips (n = 75) and non-absorbable clips (n = 75).",rephrase,['Two trials randomised 150 patients in total to absorbable clips (n = 75) and non-absorbable clips (n = 75).'],1,0.2222222222222222,2,9
CD006807,0,2,"In the third trial, a total of 105 patients were randomised to absorbable ligatures (n = 53) and non-absorbable clips (n = 52).",rephrase,['A third trial randomised a total of 105 patients to absorbable ligatures (n = 53) and non-absorbable clips (n = 52).'],2,0.3333333333333333,2,9
CD006807,0,3,All three trials were of high risk of bias.,ignore,['All three trials were of high risk of bias.'],3,0.4444444444444444,3,9
CD006807,0,4,There was no difference in the morbidity between the groups.,ignore,['There was no difference in the morbidity between the groups.'],4,0.5555555555555556,3,9
CD006807,0,5,"There was statistically significant longer operating time (MD 12.00 minutes, 95% CI 1.59 to 22.41) in the absorbable ligature group than non-absorbable clips.",merge,[],5,0.6666666666666666,4,9
CD006807,0,6,The duration and method of follow-up were not adequate to determine the incidence of long-term complications.,none,['The operating time was 12 minutes longer in the absorbable ligature group than in the group randomised to non-absorbable clips.The duration and method of follow-up were not adequate to determine the incidence of long-term complications.'],5,0.7777777777777778,4,9
CD006807,1,7,"We are unable to determine the benefits and harms of different methods of cystic duct occlusion because of the small sample size, short period of follow-up, and lack of reporting of important outcomes in the included trials.",ignore,"['We are unable to determine the benefits and harms of different methods of cystic duct occlusion because of the small sample size, short period of follow-up, and lack of reporting of important outcomes in the included trials.']",6,0.8888888888888888,5,9
CD006807,1,8,Adequately powered randomised trials with low risk of bias and with long periods of follow-up and assessing all of the important outcomes for patients and professionals are necessary.,rephrase,['New trials with long periods of follow-up and assessing the important outcomes are necessary.'],7,1.0,5,9
CD007584,0,0,We found one RCT and one retrospective study that met our inclusion criteria.,rephrase,"['Due to its rarity, this review is based on only one very small RCT and one small retrospective study.']",0,0.1111111111111111,1,9
CD007584,0,1,The data from these studies were too sparse to adequately assess the effectiveness and safety of adjuvant chemotherapy in the treatment of malignant germ cell ovarian cancer.,ignore,['The data from these studies were too sparse to adequately assess the effectiveness and safety of chemotherapy after surgery (adjuvant chemotherapy) in the treatment of malignant germ cell ovarian cancer.'],1,0.2222222222222222,2,9
CD007584,0,2,"All comparisons were restricted to single study analyses and this review was only based on 32 women, so it was not adequately powered to detect differences in survival.",ignore,"['All comparisons were restricted to single study analyses and this review was only based on 32 women, so it was not adequately powered to detect differences in survival.']",2,0.3333333333333333,2,9
CD007584,0,3,Adverse effects of treatment and recurrence-free survival were incompletely documented and QoL was not reported in any of the studies.We did not find any studies that reported specifically on adults so there were problems in separating data on adults and children in many of the potentially relevant studies.,rephrase,"['Adverse effects of treatment and recurrence-free survival were incompletely documented and QoL was not reported in any of the studies.We did not find any studies that reported specifically on adults as this disease usually afflicts younger people as opposed to the older population, so there were problems in separating data on adults and children in many of the studies.']",3,0.4444444444444444,3,9
CD007584,1,4,We found only low quality evidence on the use of chemotherapy in malignant germ cell tumours of the ovaries.,rephrase,"['Due to the small number of patients with malignant germ cell cancer in the two studies, our review shows that there were no good quality studies assessing the role of chemotherapy in this disease, be it in early or late stages.']",4,0.5555555555555556,3,9
CD007584,1,5,Therefore we are unable to reach definite conclusions about the relative benefits and harms of chemotherapy use in this disease regardless of disease stage.,merge,[],5,0.6666666666666666,4,9
CD007584,1,6,"Due to the benefit of chemotherapy in germ cell cancer of the testis, a trial of chemotherapy versus best supportive care is unlikely to be feasible.",none,['There was insufficient evidence to conclude that any form of chemotherapy or best supportive care is superior over the other.'],5,0.7777777777777778,4,9
CD007584,1,7,"Despite this, good quality randomised studies are warranted in this disease to define the role of chemotherapy (type of chemotherapy, duration of treatment, benefit, short and long term toxicities).",delete,[],6,0.8888888888888888,5,9
CD007584,1,8,"Given the rarity of this disease, we feel a trans-global approach would be essential in order to perform such trials.",delete,[],6,1.0,5,9
CD007288,0,0,Our searches found no randomised controlled trials or quasi-randomised controlled trials that met the eligibility criteria for this review.,split,"[""We searched for evidence from randomised controlled trials on hyperbaric oxygen therapy in adults with moderate to severe Bell's palsy."", 'Our searches revealed no trials that met the inclusion criteria for the review.']",0,0.14285714285714285,1,7
CD007288,1,1,"There is very low quality evidence from one randomised trial involving 79 participants with acute Bell's palsy, but this study was excluded as the outcome assessor was not blinded to treatment allocation and thus did not meet pre-defined eligibility criteria.",rephrase,"[""We found very low quality evidence from one trial to suggest that hyperbaric oxygen therapy might be beneficial for moderate to severe Bell's palsy.""]",2,0.2857142857142857,2,7
CD007288,1,2,"The trial compared 42 people who received hyperbaric oxygen therapy (2.8 atmospheres for 60 minutes twice daily, five days per week until the facial palsy resolved; maximum 30 'dives') and placebo tablets with 37 people who received placebo hyperbaric oxygen therapy (achieving only a normal partial pressure of oxygen) and prednisone (40 mg twice daily, reducing over eight days).",rephrase,"['The trial involved 79 participants and compared hyperbaric oxygen therapy to prednisone, a corticosteroid, which is a proven active treatment.']",3,0.42857142857142855,3,7
CD007288,1,3,"Facial function recovered in more participants treated with hyperbaric oxygen therapy than with prednisone (hyperbaric oxygen therapy, 40/42 (95%); prednisone, 28/37 (76%); risk ratio 1.26, 95% CI 1.04 to 1.53).",rephrase,['Those treated with hyperbaric oxygen recovered more quickly and recovered normal facial movement more often (95% versus 76%).'],4,0.5714285714285714,3,7
CD007288,1,4,There were no reported major complications and all participants completed the trial.,rephrase,"['All participants tolerated the treatment well, and there were no major complications.']",5,0.7142857142857143,4,7
CD007288,2,5,"Very low quality evidence from one trial suggests that hyperbaric oxygen therapy may be an effective treatment for moderate to severe Bell's palsy, but this study was excluded as the outcome assessor was not blinded to treatment allocation.",split,"['The quality of evidence from this trial was very low because the assessors of facial function were aware of which treatment each participant had been given, which introduces a high risk of bias.', ""There is therefore no high quality evidence on which to base conclusions about the efficacy of hyperbaric oxygen therapy in Bell's palsy.""]",6,0.8571428571428571,5,7
CD007288,2,6,Further randomised controlled trials are needed.,delete,[],8,1.0,5,7
CD004503,0,0,"In five studies, recruiting a total of 694 infants, a long IT was associated with a significant increase in air leak [typical RR 1.56 (1.25, 1.94), RD 0.13 (0.07, 0.20), NNT 8 (5, 14)].",split,"['These trials recruited a total of 694 newborn infants with acute respiratory failure mainly caused by hyaline membrane disease.', 'A long inspiratory time was associated with a significant increase in air leak from the lungs (NNT 8).']",0,0.16666666666666666,1,6
CD004503,0,1,There was no significant difference in the incidence of BPD.,merge,['There was no significant difference in the incidence of BPD but an increase in mortality before hospital discharge reached borderline statistical significance.'],2,0.3333333333333333,2,6
CD004503,0,2,"Long IT was associated with an increase in mortality before hospital discharge that reached borderline statistical significance [typical RR 1.26 (1.00, 1.59), RD 0.07 (0.00, 0.13)].",none,[],2,0.5,3,6
CD004503,1,3,"Caution should be exercised in applying these results to modern neonatal intensive care, because the studies included in this review were conducted prior to the introduction of antenatal steroids, post natal surfactant and the use of synchronised modes of ventilatory support.",ignore,"['Caution should be exercised in applying these results to modern neonatal intensive care because these studies were conducted before the introduction of antenatal steroids, postnatal surfactant and the use of synchronised modes of ventilatory support.']",3,0.6666666666666666,4,6
CD004503,1,4,Most of the participants had single pathology (HMD) and no studies examined the effects of IT on newborns ventilated for other reasons such as meconium aspiration and congenital heart disease (lungs with normal compliance).,delete,[],4,0.8333333333333334,5,6
CD004503,1,5,"However, the increased rates of air leaks and deaths using long ITs are clinically important; thus, infants with poorly compliant lungs should be ventilated with a short IT.",delete,[],4,1.0,5,6
CD009692,0,0,"One study met our inclusion criteria (26 children with minimal change nephrotic syndrome) and 11 were excluded (nine cross-over studies, one where albumin was not used for nephrotic syndrome and one where authors did not state whether the children had oedema).",delete,[],0,0.1,1,10
CD009692,0,1,"Risk of bias for the included study was unclear for selection bias, high for performance and detection bias, low for attrition bias, and high for selective reporting.",delete,[],0,0.2,1,10
CD009692,0,2,The included study compared albumin plus furosemide with an equal volume of dextrose.,delete,[],0,0.3,2,10
CD009692,0,3,"Of our prespecified outcomes, the authors reported clinical improvement as weight change, serum sodium and adverse outcomes (blood pressure).",split,"['To find out whether there was any improvement after albumin, the study measured weight loss and serum sodium.', 'The adverse effect measured was blood pressure.']",0,0.4,2,10
CD009692,0,4,The authors reported a greater weight loss in the albumin treated group initially but no difference overall at 10 days.,rephrase,['Although the authors reported increased weight loss we were not able to confirm this due to inconsistency between the data reported in the table and the text.'],2,0.5,3,10
CD009692,0,5,"However, the data in the text and the figures were inconsistent so we could not confirm the authors statements (very low certainty evidence).",rephrase,['We judged the evidence to be very low certainty.'],3,0.6,3,10
CD009692,0,6,"It is uncertain whether albumin infusion improves serum sodium when compared with an equal volume of dextrose (MD 2.00 mEq/L, 95% CI -0.09 to 4.09), systolic blood pressure (MD 2.00 mmHg, 95% CI -3.52 to 7.52) or diastolic blood pressure (MD 2.00 mmHg, 95%CI -4.29 to 8.29).",delete,[],4,0.7,4,10
CD009692,0,7,"Death, quality of life, and kidney function were not reported.",ignore,"['Death, quality of life, and kidney function were not reported.']",4,0.8,4,10
CD009692,1,8,"We identified only one small study that was relevant to our review, therefore we are unable to draw any conclusions regarding the use of human albumin with or without diuretics in nephrotic syndrome.",rephrase,['Because there was only one small study found we cannot tell whether albumin is effective in people with nephrotic syndrome and we do not know from the studies we looked at whether it is safe.'],5,0.9,5,10
CD009692,1,9,More RCTs are needed.,rephrase,['Therefore RCTs are needed.'],6,1.0,5,10
CD010076,0,0,"We identified five studies (one cluster RCT, three RCTs and one NRCT), evaluating the effectiveness of dental auxiliaries compared with dentists in providing dental care traditionally provided by dentists, eligible for inclusion in this review.",rephrase,"['We searched the literature up to November 2013 and found five studies (involving 13 dental auxiliaries, six dentists, and more than 1156 participants) evaluating the effectiveness of dental auxiliaries compared with dentists in providing care traditionally delivered by dentists for inclusion in this review.']",0,0.06666666666666667,1,15
CD010076,0,1,"The included studies, which involved 13 dental auxiliaries, six dentists, and more than 1156 participants, evaluated two clinical tasks/techniques: placement of preventive resin fissure sealants and the atraumatic restorative technique (ART).",rephrase,"['These studies evaluated only two clinical tasks/techniques: placement of preventive resin sealants, which are designed to prevent dental decay in the pits and grooves of back teeth; and the atraumatic restorative technique (ART), which is a method of filling teeth that does not require motorised instruments (e.g. dental drills).']",1,0.13333333333333333,1,15
CD010076,0,2,"Two studies were conducted in the US, and one each in Canada, Gambia and Singapore.",ignore,"['Two studies were conducted in the US, and one in each of Canada, Gambia and Singapore.']",2,0.2,1,15
CD010076,1,3,"Of the four studies evaluating effectiveness in placing preventive resin fissure sealants, three found no evidence of a difference in retention rates of those placed by dental auxiliaries and dentists over a range of follow-up periods (six to 24 months).",rephrase,"['Of the four studies comparing dental auxiliaries and dentists in placing preventive sealants, three found no differences between the two groups in the proportion of sealants that were still intact over different time periods (six to 24 months).']",3,0.26666666666666666,2,15
CD010076,1,4,One study found that fissure sealants placed by a dental auxiliary had lower retention rates than one placed by a dentist after 48 months (9.0% with auxiliary versus 29.1% with dentist).,rephrase,['One study found that fewer sealants placed by a dental auxiliary were still intact after 48 months than those placed by a dentist.'],4,0.3333333333333333,2,15
CD010076,1,5,"The same study reported that the net reduction after 48 months in the number teeth exhibiting caries (dental decay) was lower for teeth treated by the dental auxiliary than the dentist (3 with auxiliary versus 60 with dentist, P value < 0.001).",delete,[],5,0.4,2,15
CD010076,2,6,One study showed no evidence of a difference in dental decay after treatment with fissure sealants between groups.,rephrase,"['The same study reported that dental decay was more likely to develop in teeth that had been sealed by the dental auxiliary than the dentist, whereas another study reported no evidence of a difference between the groups.']",5,0.4666666666666667,3,15
CD010076,2,7,The one study comparing the effectiveness of dental auxiliaries and dentists in performing ART reported no difference in survival rates of the restorations (fillings) after 12 months.,rephrase,['The one study comparing the effectiveness of dental auxiliaries and dentists in performing ART reported no evidence of a difference in the proportion that needed replacing or that had developed new decay after 12 months.'],6,0.5333333333333333,3,15
CD010076,3,8,"All studies were at high risk of bias and the overall quality of the evidence was very low, as assessed using the GRADE approach.",delete,[],7,0.6,3,15
CD010076,3,9,"In addition, four of the included studies were more than 20 years old; the materials used and the techniques assessed were out of date.",rephrase,"['The included studies, of which four were more than 20 years old, were of low quality, had few participants and only considered two clinical tasks.']",7,0.6666666666666666,4,15
CD010076,3,10,"We found no eligible studies comparing the effectiveness of dental auxiliaries and dentists in the diagnosis of oral diseases and conditions, in delivering oral health education and other aspects of health promotion, or studies assessing participants' perspectives including the acceptability of care received.",delete,[],8,0.7333333333333333,4,15
CD010076,3,11,None of the included studies reported adverse effects.,rephrase,['None of the studies reported adverse events.'],8,0.8,4,15
CD010076,3,12,"In addition, we found no studies comparing the costs and cost-effectiveness of dental auxiliaries and dentists, their impact on access and equity of access to care that met the pre-specified inclusion criteria.",rephrase,"['In addition, none of the studies compared the costs and cost effectiveness of dental auxiliaries and dentists, or considered any impacts on access to care.']",9,0.8666666666666667,5,15
CD010076,4,13,"We only identified five studies for inclusion in this review, all of which were at high risk of bias and four were published more than 20 years ago, highlighting the paucity of high-quality evaluations of the relative effectiveness, cost-effectiveness and safety of dental auxiliaries compared with dentists in performing clinical tasks.",rephrase,"['This review highlights the lack of high-quality studies comparing the effectiveness, and cost-effectiveness, of dental auxiliaries and dentists in performing dental care traditionally delivered by dentists.']",10,0.9333333333333333,5,15
CD010076,4,14,No firm conclusions could be drawn from the present review about the relative effectiveness of dental auxiliaries and dentists.,rephrase,['Too few studies were included in this review to draw any firm conclusions about the relative effectiveness of dental auxiliaries and dentists.'],11,1.0,5,15
CD008005,0,0,Two placebo-controlled trials were included.,delete,[],0,0.08333333333333333,1,12
CD008005,0,1,One trial administered 10 mg/kg/day sapropterin in 89 children and adults with phenylketonuria whose diets were not restricted and who had previously responded to saproterin.This trial measured change in blood phenylalanine concentration.,delete,[],0,0.16666666666666666,1,12
CD008005,0,2,"The second trial screened 90 children (4 to 12 years) with phenylketonuria whose diet was restricted, for responsiveness to sapropterin.",rephrase,['The review identified two trials of sapropterin dihydrochloride; one in children and adults with no restricted diet and one in just children whose diet was restricted.'],0,0.25,2,12
CD008005,0,3,Forty-six responders entered the placebo-controlled part of the trial and received 20 mg/kg/day sapropterin.,rephrase,['The trials used different doses of sapropterin dihydrochloride (10 mg/kg/day and 20 mg/kg/day).'],1,0.3333333333333333,2,12
CD008005,0,4,This trial measured change in both phenylalanine concentration and protein tolerance.,rephrase,['The trial with the higher dose also measured the outcome change in protein tolerance.'],2,0.4166666666666667,3,12
CD008005,0,5,Both trials reported adverse events.,delete,[],3,0.5,3,12
CD008005,0,6,The trials showed an overall low risk of bias; but both are Biomarin-sponsored.,delete,[],3,0.5833333333333334,3,12
CD008005,0,7,"One trial showed a significant lowering in blood phenylalanine concentration in the sapropterin group (10 mg/kg/day), mean difference -238.80 μmol/L (95% confidence interval -343.09 to -134.51); a second trial (20 mg/kg/day sapropterin) showed a non-significant difference, mean difference -51.90 μmol/L (95% confidence interval -197.27 to 93.47).",delete,[],3,0.6666666666666666,4,12
CD008005,0,8,"The second trial also reported a significant increase in phenylalanine tolerance, mean difference18.00 mg/kg/day (95% confidence interval 12.28 to 23.72) in the 20 mg/kg/day sapropterin group.",delete,[],3,0.75,4,12
CD008005,1,9,There is evidence of short-term benefit from using sapropterin in some people with sapropterin-responsive forms of phenylketonuria; blood phenylalanine concentration is lowered and protein tolerance increased.,rephrase,['We found evidence to show that some people with mild or moderate phenylketonuria can benefit from the use of sapropterin dihydrochloride in the short term; the concentration of blood phenylalanine was lowered after treatment in both trials.'],3,0.8333333333333334,5,12
CD008005,1,10,There are no serious adverse events associated with using sapropterin in the short term.,rephrase,['There were no adverse effects associated with the use of sapropterin dihydrochloride in the short term.'],4,0.9166666666666666,5,12
CD008005,2,11,There is no evidence on the long-term effects of sapropterin and no clear evidence of effectiveness in severe phenylketonuria.,split,"['We found no evidence on the effects of long-term treatment.', 'We could not draw any conclusions\xa0on its benefits in severe phenylketonuria.']",5,1.0,5,12
CD010734,0,0,"Eleven studies met the criteria, providing 14 comparisons, and capturing data on 4317 participants.",rephrase,"['Eleven studies, which captured data on 4317 participants (3636 children, 648 women of reproductive age, and 33 infants), met our inclusion criteria.']",0,0.05,1,20
CD010734,0,1,"Seven studies were RCTs, three were cluster non-RCTs, and one was a randomised cross-over design.",delete,[],1,0.1,1,20
CD010734,0,2,"Seven studies were carried out among school children (N = 3636), three among women of reproductive age (N = 648), and one among infants (N = 33).",delete,[],1,0.15,1,20
CD010734,0,3,"The studies used diverse types of food as vehicle for iodine delivery: biscuits, milk, fish sauce, drinking water, yoghourt, fruit beverage, seasoning powder, and infant formula milk.",rephrase,"['The type of foods used as vehicle to deliver iodine differed between the studies, and included biscuits, milk, fish sauce, drinking water, yoghourt, fruit beverage, seasoning powder, and infant formula milk.']",1,0.2,1,20
CD010734,0,4,Daily amounts of iodine provided ranged from 35 µg/day to 220 µg/day; trial duration ranged from 11 days to 48 weeks.,rephrase,"['The amount of iodine provided to participants ranged from 35 µg/day to 220 µg/day, and study duration ranged from 11 days to 48 weeks.']",2,0.25,2,20
CD010734,0,5,"Five studies examined the effect of iodine fortification alone, two against the same unfortified food, and three against no intervention.",merge,[],3,0.3,2,20
CD010734,0,6,Six studies evaluated the effect of cofortification of iodine with other micronutrients versus the same food without iodine but with different levels of other micronutrients.,none,"['Of the 11 studies included, five examined the effect of adding iodine alone to foods compared to either no intervention or the same foods without iodine; while six evaluated the effect of adding iodine plus other micronutrients to foods compared to the same foods without iodine, but with different levels of other micronutrients.']",3,0.35,2,20
CD010734,0,7,"We assessed one study to be at low risk of bias for all bias domains, three at low risk of bias for all domains apart from selective reporting, and seven at an overall rating of high risk of bias.",delete,[],4,0.4,2,20
CD010734,1,8,"No study assessed the primary outcomes of death, mental development, cognitive function, cretinism, or hypothyroidism, or secondary outcomes of TSH or serum thyroglobulin concentration.",rephrase,"['No study evaluated the effect of adding iodine to foods on death, mental development, cognitive function, cretinism (a condition characterized by impaired control of physical movement and intellectual disability), hypothyroidism (underactive thyroid), thyroid-stimulating hormone concentration, or serum thyroglobulin concentration (these are biological markers that indicate the presence of iodine deficiency when concentration in the blood is high).']",4,0.45,3,20
CD010734,1,9,"Two studies reported the effects on goitre, one on physical development measures, and one on adverse effects.",rephrase,"['Two studies reported on the effect of the intervention on goitre, one study assessed five physical development measures (weight, height, weight-for-age, height-for-age, and weight-for-height scores), and one examined adverse effects.']",5,0.5,3,20
CD010734,1,10,All studies assessed urinary iodine concentration.,rephrase,"['All studies assessed urinary iodine concentration (the concentration of iodine secreted in the urine, which indicates the presence of iodine deficiency when concentration is low in a population group, rather than in an individual).']",6,0.55,3,20
CD010734,2,11,"The effects of iodine fortification compared to control on goitre prevalence (OR 1.60, 95% CI 0.60 to 4.31; 1 non-RCT, 83 participants; very low-quality evidence), and five physical development measures were uncertain (1 non-RCT, 83 participants; very low-quality evidence): weight (MD 0.23 kg, 95% CI -6.30 to 6.77); height (MD -0.66 cm, 95% CI -4.64 to 3.33); weight-for-age (MD 0.05, 95% CI -0.59 to 0.69); height-for-age (MD -0.30, 95% CI -0.75 to 0.15); and weight-for-height (MD -0.21, 95% CI -0.51 to 0.10).",rephrase,"['We are uncertain of the effects of iodine fortification on the proportion of participants with goitre, or on any of the five physical development measures.']",7,0.6,3,20
CD010734,2,12,One study reported that there were no adverse events observed during the cross-over trial (low-quality evidence).,rephrase,['One study reported narratively that no adverse effects were observed during the trial.'],8,0.65,4,20
CD010734,3,13,"Pooled results from RCTs showed that urinary iodine concentration significantly increased following iodine fortification (SMD 0.59, 95% CI 0.37 to 0.81; 6 RCTs, 2032 participants; moderate-quality evidence).",delete,[],9,0.7,4,20
CD010734,3,14,This is equivalent to an increase of 38.32 µg/L (95% CI 24.03 to 52.61 µg/L).,rephrase,"['We found a significant increase of 38.32 µg/L in urinary iodine concentration after adding iodine to foods, compared to the groups that did not have iodine added, from studies of higher quality.']",9,0.75,4,20
CD010734,3,15,"This effect was not observed in the meta-analysis of non-RCTs (SMD 0.25, 95% CI -0.16 to 0.66; 3 non-RCTs, 262 participants; very low-quality evidence).",delete,[],10,0.8,4,20
CD010734,3,16,Sensitivity analyses did not change the effect observed in the primary analyses.,delete,[],10,0.85,5,20
CD010734,4,17,"The evidence on the effect of iodine fortification of foods, beverages, condiments, or seasonings other than salt on reducing goitre, improving physical development measures, and any adverse effects is uncertain.",rephrase,"['Overall, there is no clear evidence on the effect of the intervention on reducing the proportion of people with goitre, improving physical growth, or adverse events.']",10,0.9,5,20
CD010734,4,18,"However, our findings suggest that the intervention likely increases urinary iodine concentration.",rephrase,"['However, our results show that adding iodine to foods likely increases urinary iodine concentration.']",11,0.95,5,20
CD010734,4,19,"Additional, adequately powered, high-quality studies on the effects of iodine fortification of foods on these, and other important outcomes, as well as its efficacy and safety, are required.",rephrase,"['Additional studies to better quantify the effect of the intervention on these outcomes, as well as other outcomes, are needed.']",12,1.0,5,20
CD015187,0,0,We included three studies with a total of 209 participants.,rephrase,"['We found three studies, which included a total of 209 people (65% female).']",0,0.0625,1,16
CD015187,0,1,One evaluated beta-blockers and the other two evaluated calcium channel blockers.,delete,[],1,0.125,1,16
CD015187,0,2,We did not identify any evidence for the remaining interventions of interest.,rephrase,"['However, we did not identify enough information in this review to know whether these side effects are a problem when the treatments are used for vestibular migraine.']",1,0.1875,1,16
CD015187,1,3,"Beta-blockers versus placebo
One study (including 130 participants, 61% female) evaluated the use of 95 mg metoprolol once daily for six months, compared to placebo.",rephrase,"['Beta-blockers\nThe first study looked at the use of a medicine called metoprolol, a tablet taken once daily.']",2,0.25,2,16
CD015187,1,4,The proportion of people who reported improvement in vertigo was not assessed in this study.,rephrase,['It was very unclear whether people felt their symptoms had improved when taking this treatment and whether the frequency of their vertigo attacks changed.'],3,0.3125,2,16
CD015187,1,5,Some data were reported on the frequency of vertigo attacks at six months and the occurrence of serious adverse effects.,delete,[],4,0.375,2,16
CD015187,1,6,"However, this is a single, small study and for all outcomes the certainty of evidence was low or very low.",rephrase,['We used standard methods to assess the certainty of the evidence.'],4,0.4375,3,16
CD015187,1,7,We are unable to draw meaningful conclusions from the numerical results.,delete,[],5,0.5,3,16
CD015187,2,8,"Calcium channel blockers versus no treatment
Two studies, which included a total of 79 participants (72% female), assessed the use of 10 mg flunarizine once daily for three months, compared to no intervention.",rephrase,"['Calcium channel blockers\nTwo smaller studies assessed the use of flunarizine, a tablet taken once a day.']",5,0.5625,3,16
CD015187,2,9,All of the evidence for this comparison was of very low certainty.,delete,[],6,0.625,4,16
CD015187,2,10,"Most of our outcomes were only reported by a single study, therefore we were unable to conduct any meta-analysis.",delete,[],6,0.6875,4,16
CD015187,2,11,"Some data were reported on improvement in vertigo and change in vertigo, but no information was available regarding serious adverse events.",delete,[],6,0.75,4,16
CD015187,2,12,"We are unable to draw meaningful conclusions from the numerical results, as these data come from single, small studies and the certainty of the evidence was very low.",rephrase,['We have very little confidence in the evidence because the three studies conducted were small.'],6,0.8125,5,16
CD015187,3,13,There is very limited evidence from placebo-controlled randomised trials regarding the efficacy and potential harms of pharmacological interventions for prophylaxis of vestibular migraine.,delete,[],7,0.875,5,16
CD015187,3,14,We only identified evidence for two of our interventions of interest (beta-blockers and calcium channel blockers) and all evidence was of low or very low certainty.,delete,[],7,0.9375,5,16
CD015187,3,15,Further research is necessary to identify whether these treatments are effective at improving symptoms and whether there are any harms associated with their use.,rephrase,"['We wanted to find out:\n- whether there is evidence that any medications work to prevent attacks of vestibular migraine, or reduce the symptoms when an attack occurs;\n- whether the treatments might cause any harm.']",7,1.0,5,16
CD004815,0,0,"Eight RCTs with a total of 8915 participants (4545 invasive strategies, 4370 conservative strategies) were eligible for inclusion.",rephrase,"['Of the included participants with UA and NSTEMI, there were 4545 in the invasive strategy arm and 4370 in the conservative strategy arm.']",0,0.1,1,10
CD004815,0,1,We included three new studies and 1099 additional participants in this review update.,rephrase,"['We included eight studies with 8915 participants: five trials were in the review version published in 2010, and three were new trials.']",1,0.2,1,10
CD004815,0,2,"In the all-study analysis, evidence did not show appreciable risk reductions in all-cause mortality (RR 0.87, 95% CI 0.64 to 1.18; eight studies, 8915 participants; low quality evidence) and death or non-fatal MI (RR 0.93, 95% CI 0.71 to 1.2; seven studies, 7715 participants; low quality evidence) with invasive strategies compared to conservative (selective invasive) strategies at six to 12 months follow-up.",rephrase,['Evidence failed to show appreciable risk reduction in all-cause mortality and death or non-fatal myocardial infarction (MI) with routine invasive management strategy compared to conservative strategies.'],2,0.3,2,10
CD004815,0,3,"There was appreciable risk reduction in MI (RR 0.79, 95% CI 0.63 to 1.00; eight studies, 8915 participants; moderate quality evidence), refractory angina (RR 0.64, 95% CI 0.52 to 0.79; five studies, 8287 participants; moderate quality evidence) and re-hospitalisation (RR 0.77, 95% CI 0.63 to 0.94; six studies, 6921 participants; moderate quality evidence) with routine invasive strategies compared to conservative (selective invasive) strategies also at six to 12 months follow-up.",rephrase,"['There was appreciable risk reduction in MI, refractory angina and re-hospitalisation with routine invasive strategies compared to conservative strategies, but this was associated with an increased risk of procedure-related MI and bleeding complications.']",3,0.4,2,10
CD004815,1,4,"Evidence also showed increased risks in bleeding (RR 1.73, 95% CI 1.30 to 2.31; six studies, 7584 participants; moderate quality evidence) and procedure-related MI (RR 1.87, 95% CI 1.47 to 2.37; five studies, 6380 participants; moderate quality evidence) with routine invasive strategies compared to conservative (selective invasive) strategies.",delete,[],4,0.5,3,10
CD004815,2,5,The low quality evidence were as a result of serious risk of bias and imprecision in the estimate of effect while moderate quality evidence was only due to serious risk of bias.,split,"['The quality of the evidence in this review update ranged from low quality to moderate quality.', 'Low quality evidence was as a result of serious risk of bias and uncertainty surrounding the effect, while moderate quality evidence was only due to serious risk of bias.']",4,0.6,3,10
CD004815,3,6,"In the all-study analysis, the evidence failed to show appreciable benefit with routine invasive strategies for unstable angina and non-ST elevation MI compared to conservative strategies in all-cause mortality and death or non-fatal MI at six to 12 months.",delete,[],6,0.7,4,10
CD004815,3,7,"There was evidence of risk reduction in MI, refractory angina and re-hospitalisation with routine invasive strategies compared to conservative (selective invasive) strategies at six to 12 months follow-up.",delete,[],6,0.8,4,10
CD004815,3,8,"However, routine invasive strategies were associated with a relatively high risk (almost double the risk) of procedure-related MI, and increased risk of bleeding complications.",rephrase,"['However, the invasive strategy also is associated with double the risk of heart attack during or soon after initial treatment, as well as an increased risk of bleeding.']",6,0.9,5,10
CD004815,3,9,"This systematic analysis of published RCTs supports the conclusion that, in patients with UA/NSTEMI, a selectively invasive (conservative) strategy based on clinical risk for recurrent events is the preferred management strategy.",rephrase,"['In summary, the published scientific research suggests that the invasive strategy may have particular benefit in those patients who are at high risk for recurrent events, and that patients at low risk for a recurrent event may even suffer harm from such an approach.']",7,1.0,5,10
CD005154,0,0,We identified two new studies for inclusion in the review update; the review now includes seven trials with 622 participants who presented to an emergency department with SVT.,rephrase,['We included in the review seven trials involving 622 patients.'],0,0.125,1,8
CD005154,0,1,"All included studies were RCTs, but only three described the randomisation process, and none had blinded participants, personnel, or outcome assessors to the intervention given.",delete,[],1,0.25,2,8
CD005154,0,2,"Moderate-quality evidence shows no differences in the number of people reverting to sinus rhythm who were treated with adenosine or CCA (89.7% vs 92.9%; OR 1.51, 95% confidence interval (CI) 0.85 to 2.68; participants = 622; studies = 7; I2 = 36%).",rephrase,['This finding is based on moderate-quality evidence.'],1,0.375,2,8
CD005154,0,3,Low-quality evidence suggests no appreciable differences in major adverse event rates between CCAs and adenosine.,rephrase,"['A temporary drop in blood pressure that did not require treatment was reported in only one of 152 study participants treated with CCAs, and low-quality evidence suggests that no patients treated with adenosine experienced low blood pressure.']",2,0.5,3,8
CD005154,0,4,"Researchers reported only one case of hypotension in the CCA group and none in the adenosine group (0.66% vs 0%; OR 3.09, 95% CI 0.12 to 76.71; participants = 306; studies = 3; I2 = 0%).",delete,[],3,0.625,4,8
CD005154,0,5,Included trials did not report length of stay in hospital nor patient satisfaction.,rephrase,['We have no data on length of stay in hospital nor on patient satisfaction.'],3,0.75,4,8
CD005154,1,6,"Moderate-quality evidence shows no differences in effects of adenosine and calcium channel antagonists for treatment of SVT on reverting to sinus rhythm, and low-quality evidence suggests no appreciable differences in the incidence of hypotension.",ignore,"['Moderate-quality evidence shows no differences in effects of adenosine and calcium channel antagonists for treatment of SVT on reverting to sinus rhythm, and low-quality evidence suggests no differences in cases of hypotension.']",4,0.875,5,8
CD005154,1,7,A study comparing patient experiences and prospectively studied adverse events would provide evidence on which treatment is preferable for management of SVT.,delete,[],5,1.0,5,8
CD008261,0,0,We included 25 trials with 2505 participants randomised to the different pharmacological agents and inactive controls.,rephrase,['We identified 25 randomised clinical trials involving 2505 people undergoing laparoscopic cholecystectomy.'],0,0.0625,1,16
CD008261,0,1,All the trials were at unclear risk of bias.,delete,[],1,0.125,1,16
CD008261,0,2,Most trials included only low anaesthetic risk people undergoing elective laparoscopic cholecystectomy.,rephrase,['Most participants in the trials were low anaesthetic risk people undergoing planned laparoscopic cholecystectomy.'],1,0.1875,1,16
CD008261,0,3,Participants were allowed to take additional analgesics as required in 24 of the trials.,rephrase,['Participants were allowed to take additional painkillers as required in most of the trials.'],2,0.25,2,16
CD008261,0,4,The pharmacological interventions in all the included trials were aimed at preventing pain after laparoscopic cholecystectomy.,rephrase,['The treatments in all the included trials were aimed at decreasing the pain after laparoscopic cholecystectomy before the participants reported pain.'],3,0.3125,2,16
CD008261,0,5,There were considerable differences in the pharmacological agents used and the methods of administration.,delete,[],4,0.375,2,16
CD008261,0,6,"The estimated effects of the intervention on the proportion of participants who were discharged as day-surgery, the length of hospital stay, or the time taken to return to work were imprecise in all the comparisons in which these outcomes were reported (very low quality evidence).",delete,[],4,0.4375,3,16
CD008261,0,7,"There was no mortality in any of the groups in the two trials that reported mortality (183 participants, very low quality evidence).",rephrase,['There were no deaths in either group in three trials (183 participants) that reported deaths.'],4,0.5,3,16
CD008261,0,8,Differences in serious morbidity outcomes between the groups were imprecise across all the comparisons (very low quality evidence).,split,"['The differences in the serious complications between the groups was imprecise in all the comparisons.', 'The differences in length of hospital stay and the time taken to return to work was imprecise in all the comparisons that reported these.']",5,0.5625,3,16
CD008261,0,9,None of the trials reported patient quality of life or time taken to return to normal activity.,ignore,['None of the trials reported quality of life or the time taken to return to normal activity.'],7,0.625,4,16
CD008261,0,10,The pain at 4 to 8 hours was generally reduced by about 1 to 2 cm on the visual analogue scale of 1 to 10 cm in the comparisons involving the different pharmacological agents and inactive controls (low or very low quality evidence).,merge,['Pain was lower in the participants who received painkillers compared with those who received controls at 4 to 8 hours and at 9 to 24 hours as measured by the visual analogue scale (a chart that rates the amount of pain on a scale of 1 to 10).'],8,0.6875,4,16
CD008261,0,11,The pain at 9 to 24 hours was generally reduced by about 0.5 cm (a modest reduction) on the visual analogue scale of 1 to 10 cm in the comparisons involving the different pharmacological agents and inactive controls (low or very low quality evidence).,none,[],8,0.75,4,16
CD008261,1,12,"There is evidence of very low quality that different pharmacological agents including non-steroidal anti-inflammatory drugs, opioid analgesics, and anticonvulsant analgesics reduce pain scores in people at low anaesthetic risk undergoing elective laparoscopic cholecystectomy.",rephrase,['The overall quality of evidence was very low.'],9,0.8125,5,16
CD008261,1,13,"However, the decision to use these drugs has to weigh the clinically small reduction in pain against uncertain evidence of serious adverse events associated with many of these agents.",ignore,"['However, the decision to use these drugs has to weigh the clinically small reduction in pain against uncertain evidence of serious adverse events associated with many of these agents.']",10,0.875,5,16
CD008261,1,14,Further randomised clinical trials of low risk of systematic and random errors are necessary.,rephrase,['Further trials are necessary.'],11,0.9375,5,16
CD008261,1,15,Such trials should include important clinical outcomes such as quality of life and time to return to work in their assessment.,rephrase,"['Such trials should include outcomes such as quality of life, the time taken to return to normal activity, and the time taken to return to work, which are important for the person undergoing laparoscopic cholecystectomy and the people who provide funds for the treatment.']",12,1.0,5,16
CD011921,0,0,"We included six studies that compared early oropharyngeal colostrum versus water, saline, placebo, or donor, or versus no intervention, enrolling 335 preterm infants with gestational ages ranging from 25 to 32 weeks' gestation and birth weights of 410 to 2500 grams.",rephrase,"[""Six studies were eligible for inclusion, involving 335 preterm infants with gestational ages ranging from 25 to 32 weeks' gestation and birth weights of 410 to 2500 grams.""]",0,0.1111111111111111,1,9
CD011921,0,1,"Researchers found no significant differences between OPC and control for primary outcomes - incidence of NEC (typical risk ratio (RR) 1.42, 95% confidence interval (CI) 0.50 to 4.02; six studies, 335 infants; P = 0.51; I² = 0%; very low-quality evidence), incidence of late-onset infection (typical RR 0.86, 95% CI 0.56 to 1.33; six studies, 335 infants; P = 0.50; I² = 0%; very low-quality evidence), and death before hospital discharge (typical RR 0.76, 95% CI 0.34 to 1.71; six studies, 335 infants; P = 0.51; I² = 0%; very low-quality evidence).",rephrase,"['Reviewers noted no differences between OPC and control for rate of NEC, infection, or death before hospital discharge.']",1,0.2222222222222222,2,9
CD011921,0,2,"Similarly, meta-analysis showed no difference in length of hospital stay between OPC and control groups (mean difference (MD) 0.81, 95% CI -5.87 to 7.5; four studies, 293 infants; P = 0.65; I² = 49%).",rephrase,"['Similarly, they observed no difference in length of hospital stay between OPC and control babies.']",2,0.3333333333333333,2,9
CD011921,0,3,"Days to full enteral feeds were reduced in the OPC group with MD of -2.58 days (95% CI -4.01 to -1.14; six studies, 335 infants; P = 0.0004; I² = 28%; very low-quality evidence).",delete,[],3,0.4444444444444444,3,9
CD011921,1,4,The effect of OPC was uncertain because of small sample sizes and imprecision in study results (very low-quality evidence).,delete,[],3,0.5555555555555556,3,9
CD011921,2,5,"No adverse effects were associated with OPC; however, data on adverse effects were insufficient, and no numerical data were available from the included studies.",split,"['However, included studies were small, data were insufficient, and study designs were not ideal.', 'Five of the included studies reported no harms (adverse effects); however, no numerical data are available from these studies.']",3,0.6666666666666666,4,9
CD011921,3,6,Overall the quality of included studies was low to very low across all outcomes.,rephrase,['Included studies were of very low quality; therefore the effects of OPC remain uncertain.'],5,0.7777777777777778,4,9
CD011921,3,7,"We downgraded GRADE outcomes because of concerns about allocation concealment and blinding, reporting bias, small sample sizes with few events, and wide confidence intervals.",delete,[],6,0.8888888888888888,5,9
CD011921,4,8,"Large, well-designed trials would be required to evaluate more precisely and reliably the effects of oropharyngeal colostrum on important outcomes for preterm infants.",rephrase,"['Larger, better quality clinical trials would be needed to evaluate more precisely and reliably the effects of OPC on important outcomes for preterm infants.']",6,1.0,5,9
CD012510,0,0,Three trials that randomized a combined total of 263 participants met the review inclusion criteria.,rephrase,"['Our review included three clinical trials that randomized 263 participants (most recent search - November 28, 2017).']",0,0.058823529411764705,1,17
CD012510,0,1,All three trials examined the treatment of symptomatic in-stent restenosis within the femoropopliteal arteries.,delete,[],1,0.11764705882352941,1,17
CD012510,0,2,These trials were carried out in Germany and Austria and used paclitaxel as the agent in the drug-eluting balloons.,rephrase,"['Trials included leg arteries at and above the knee and were carried out in Europe; all used DEBs that contained the chemical known as ""paclitaxel.""']",1,0.17647058823529413,1,17
CD012510,0,3,Two of the three trials were industry sponsored.,delete,[],2,0.23529411764705882,2,17
CD012510,0,4,"Two companies manufactured the drug-eluting balloons (Eurocor, Bonn, Germany; Medtronic, Fridley, Minnesota, USA).",rephrase,['Two companies manufactured the DEBs: Eurocor and Medtronic.'],2,0.29411764705882354,2,17
CD012510,0,5,The trials examined both anatomical and clinical endpoints.,delete,[],3,0.35294117647058826,2,17
CD012510,0,6,We noted heterogeneity in the frequency of bailout stenting deployment between studies as well as in the dosage of paclitaxel applied by the DEBs.,delete,[],3,0.4117647058823529,3,17
CD012510,0,7,"Using GRADE assessment criteria, we determined that the certainty of evidence presented was very low for the outcomes of amputation, target lesion revascularization, binary restenosis, death, and improvement of one or more Rutherford categories.",delete,[],3,0.47058823529411764,3,17
CD012510,0,8,"Most participants were followed up to 12 months, but one trial followed participants for up to 24 months.",rephrase,"['Most study participants were followed for six or more months; this is called ""follow-up.""']",3,0.5294117647058824,3,17
CD012510,1,9,Trial results show no difference in the incidence of amputation between DEBs and uncoated balloon angioplasty.,rephrase,['Results showed that DEBs were not better for participants than uncoated balloon angioplasty with regard to the need for amputation.'],4,0.5882352941176471,3,17
CD012510,1,10,"DEBs showed better outcomes for up to 24 months for target lesion revascularization (odds ratio (OR) 0.05, 95% confidence Interval (CI) 0.00 to 0.92 at six months; OR 0.24, 95% CI 0.08 to 0.70 at 24 months) and at six and 12 months for binary restenosis (OR 0.28, 95% CI 0.14 to 0.56 at six months; OR 0.34, 95% CI 0.15 to 0.76 at 12 months).",rephrase,"['At 24 months of follow-up, DEBs were associated with fewer target lesion revascularizations, which refers to the need to perform a procedure on a stent that had already been treated with a DEB or an uncoated balloon angioplasty for in-stent restenosis.']",5,0.6470588235294118,4,17
CD012510,1,11,"Participants treated with DEBs also showed improvement of one or more Rutherford categories at six and 12 months (OR 1.81, 95% CI 1.02 to 3.21 at six months; OR 2.08, 95% CI 1.13 to 3.83 at 12 months).",rephrase,"['Finally, more people who were treated with DEBs described improvement in their leg symptoms, as measured by a change in their Rutherford category.']",6,0.7058823529411765,4,17
CD012510,1,12,Data show no clear differences in death between DEBs and uncoated balloon angioplasty.,rephrase,['DEBs were not found to be better for participants than uncoated balloon angioplasty with regard to patient death.'],7,0.7647058823529411,4,17
CD012510,1,13,Data were insufficient for subgroup or sensitivity analyses to be conducted.,delete,[],8,0.8235294117647058,5,17
CD012510,2,14,"Based on a meta-analysis of three trials with 263 participants, evidence suggests an advantage for DEBs compared with uncoated balloon angioplasty for anatomical endpoints such as target lesion revascularization (TLR) and binary restenosis, and for one clinical endpoint - improvement in Rutherford category post intervention for up to 24 months.",delete,[],8,0.8823529411764706,5,17
CD012510,2,15,"However, the certainty of evidence for all these outcomes is very low due to the small number of included studies and participants and the high risk of bias in study design.",rephrase,"['The certainty of the evidence presented was very low because we identified only three studies with small numbers of participants, and because many participants in those studies were lost to follow-up.']",8,0.9411764705882353,5,17
CD012510,2,16,Adequately powered and carefully constructed randomized controlled trials are needed to adequately investigate the role of drug-eluting technologies in the management of in-stent restenosis.,delete,[],9,1.0,5,17
CD007722,0,0,"This review included one RCT in which 38 women (41 pregnancies) were randomised, with only 26 women (28 pregnancies) being analysed.",ignore,"['This review included one controlled trial in which 38 women (41 pregnancies) were randomised, with only 26 women (28 pregnancies) being analysed.']",0,0.1,1,10
CD007722,1,1,"This RCT comparing the effect of betamethasone (1.5 mg/day) with no medication found no statistically significant difference in neonatal thrombocytopenia (risk ratio (RR) 1.12, 95% confidence interval (CI) 0.62 to 2.05) and neonatal bleeding (RR 1.00, 95% CI 0.24 to 4.13).",rephrase,['Giving the mother betamethasone (1.5 mg/day) did not result in a difference in the neonatal platelet count at birth and at the first week of life.'],1,0.2,1,10
CD007722,1,2,"Review authors conducted an intention-to-treat analysis which showed similar findings: RR 1.18, 95% CI 0.57 to 2.45 and RR 1.05, 95% CI 0.24 to 4.61, respectively.",delete,[],2,0.3,2,10
CD007722,1,3,"Maternal death, perinatal mortality, postpartum haemorrhage and neonatal intracranial haemorrhage were not studied by this RCT.",rephrase,['Maternal postpartum haemorrhage and neonatal intracranial haemorrhage were not studied.'],2,0.4,2,10
CD007722,2,4,"Current evidence indicates that compared to no medication, betamethasone did not reduce the risk of neonatal thrombocytopenia and neonatal bleeding in ITP during pregnancy.",merge,['Current evidence from one randomised controlled trial indicates that betamethasone does not reduce the risk of neonatal thrombocytopenia and neonatal bleeding in ITP during pregnancy when compared to no medication.'],3,0.5,3,10
CD007722,2,5,There is insufficient evidence to support the use of betamethasone for treating ITP.,none,[],3,0.6,3,10
CD007722,2,6,This Cohrane review does not provide evidence about other medical treatments for ITP during pregnancy.,merge,['We could not identify evidence on other medical treatments for ITP during pregnancy.'],4,0.7,4,10
CD007722,2,7,"This systematic review also identifies the need for well-designed, adequately powered randomised clinical trials for this medical condition during pregnancy.",none,[],4,0.8,4,10
CD007722,2,8,"Unless randomised clinical trials provide evidence of a treatment effect and the trade off between potential benefits and harms are established, policy-makers, clinicians, and academics should not use betamethasone for ITP in pregnant women.",delete,[],5,0.9,5,10
CD007722,2,9,"Any future trials on medical treatments for treating ITP during pregnancy should test a variety of important maternal, neonatal or both outcome measures, including maternal death, perinatal mortality, postpartum haemorrhage and neonatal intracranial haemorrhage.",delete,[],5,1.0,5,10
CD010825,0,0,"Two studies, comparing reablement with usual home-care services with 811 participants, met our eligibility criteria for inclusion; we also identified three potentially eligible studies, but findings were not yet available.",delete,[],0,0.07142857142857142,1,14
CD010825,0,1,One included study was conducted in Western Australia with 750 participants (mean age 82.29 years).,merge,"['The review included two studies, one each from Australia (750 participants) and Norway (61 participants).']",0,0.14285714285714285,1,14
CD010825,0,2,The second study was conducted in Norway (61 participants; mean age 79 years).,none,[],0,0.21428571428571427,2,14
CD010825,1,3,We are very uncertain as to the effects of reablement compared with usual care as the evidence was of very low quality for all of the outcomes reported.,rephrase,['The very low quality evidence for all of the results means that we are uncertain about the effects of reablement when compared with usual care.'],1,0.2857142857142857,2,14
CD010825,1,4,The main findings were as follows.,delete,[],2,0.35714285714285715,2,14
CD010825,2,5,Functional status: very low quality evidence suggested that reablement may be slightly more effective than usual care in improving function at nine to 12 months (lower scores reflect greater independence; standardised mean difference (SMD) -0.30; 95% confidence interval (CI) -0.53 to -0.06; 2 studies with 249 participants).,delete,[],2,0.42857142857142855,3,14
CD010825,3,6,Adverse events: reablement may make little or no difference to mortality at 12 months' follow-up (RR 0.97; 95% CI 0.74 to 1.29; 2 studies with 811 participants) or rates of unplanned hospital admission at 24 months (RR 0.94; 95% CI 0.85 to 1.03; 1 study with 750 participants).,rephrase,"['Reablement may help some older adults to improve their abilities to engage in everyday activities (functional status) to a small degree, but may make little or no difference to death rates or admissions to hospital.']",2,0.5,3,14
CD010825,4,7,"The very low quality evidence also means we are uncertain whether reablement may influence quality of life (SMD -0.23; 95% CI -0.48 to 0.02; 2 trials with 249 participants) or living arrangements (RR 0.92, 95% CI 0.62 to 1.34; 1 study with 750 participants) at time points up to 12 months.",rephrase,['The findings mean we are also uncertain whether reablement affects quality of life or living arrangements.'],3,0.5714285714285714,3,14
CD010825,4,8,"People receiving reablement may be slightly less likely to have been approved for a higher level of personal care than people receiving usual care over the 24 months' follow-up (RR 0.87; 95% CI 0.77 to 0.98; 1 trial, 750 participants).",delete,[],4,0.6428571428571429,4,14
CD010825,4,9,"Similarly, although there may be a small reduction in total aggregated home and healthcare costs over the 24-month follow-up (reablement: AUD 19,888; usual care: AUD 22,757; 1 trial with 750 participants), we are uncertain about the size and importance of these effects as the results were based on very low quality evidence.",delete,[],4,0.7142857142857143,4,14
CD010825,5,10,Neither study reported user satisfaction with the service.,rephrase,"['Reablement may lead to a small decrease in numbers of people needing higher levels of personal care, and may decrease care costs to a small degree, but neither study reported satisfaction of those using the reablement service.']",4,0.7857142857142857,4,14
CD010825,6,11,There is considerable uncertainty regarding the effects of reablement as the evidence was of very low quality according to our GRADE ratings.,rephrase,"['While there may be some small positive effects of reablement, the evidence was very low quality, meaning that we are very uncertain about how large or important these effects may be.']",5,0.8571428571428571,5,14
CD010825,6,12,"Therefore, the effectiveness of reablement services cannot be supported or refuted until more robust evidence becomes available.",delete,[],6,0.9285714285714286,5,14
CD010825,6,13,There is an urgent need for high quality trials across different health and social care systems due to the increasingly high profile of reablement services in policy and practice in several countries.,rephrase,['There is a need for more studies to be conducted in a range of countries and situations before the effectiveness and safety of reablement can be determined with certainty.'],6,1.0,5,14
CD013094,0,0,This review included eight studies (with a total of 590 participants).,rephrase,['Our review identified eight randomised controlled trials with 590 participants in total.'],0,0.045454545454545456,1,22
CD013094,0,1,"Seven studies investigated the effects of hearing aids, four combination hearing aids and three sound generators.",ignore,"['Seven studies looked at the effects of hearing aids, four combination hearing aids and three sound generators.']",1,0.09090909090909091,1,22
CD013094,0,2,Seven studies were parallel-group RCTs and one had a cross-over design.,rephrase,['Seven studies allocated participants into parallel groups and in one study participants tried each intervention in a random order.'],2,0.13636363636363635,1,22
CD013094,0,3,"In general, risk of bias was unclear due to lack of detail about sequence generation and allocation concealment.",rephrase,"['In general, the risk of bias in the studies was unclear.']",3,0.18181818181818182,1,22
CD013094,0,4,There was also little or no use of blinding.,ignore,['There was also little or no use of blinding.'],4,0.22727272727272727,2,22
CD013094,1,5,"No data for our outcomes were available for any of our three main comparisons (comparing hearing aids, sound generators and combination devices with a waiting list control group, placebo or education/information only).",ignore,"['We did not find any data for our outcomes for any of our three main comparisons (comparing hearing aids, sound generators and combination devices with a waiting list control group, placebo or education/information only).']",5,0.2727272727272727,2,22
CD013094,1,6,"Data for our additional comparisons (comparing these devices with each other) were also few, with limited potential for data pooling.",rephrase,['There were also few data for our additional comparisons (comparing these devices with each other) and it was difficult to pool (combine) the data.'],6,0.3181818181818182,2,22
CD013094,2,7,"Hearing aid only versus sound generator device only
One study compared patients fitted with sound generators versus those fitted with hearing aids and found no difference between them in their effects on our primary outcome, tinnitus symptom severity measured with the Tinnitus Handicap Inventory (THI) at 3, 6 or 12 months (low-quality evidence).",rephrase,"['One study compared patients fitted with sound generators with those fitted with hearing aids and found no difference between them in their effects on our primary outcome, tinnitus symptom severity, at 3, 6 or 12 months.']",7,0.36363636363636365,2,22
CD013094,2,8,The use of both types of device was associated with a clinically significant reduction in tinnitus symptom severity.,ignore,['The use of both types of device was associated with a clinically significant reduction in tinnitus symptom severity.'],8,0.4090909090909091,3,22
CD013094,3,9,"Combination hearing aid versus hearing aid only
Three studies compared combination hearing aids with hearing aids and measured tinnitus symptom severity using the THI or Tinnitus Functional Index.",rephrase,['Three studies compared combination hearing aids/sound generators with hearing aids alone and measured tinnitus symptom severity.'],9,0.45454545454545453,3,22
CD013094,3,10,"When we pooled the data we found no difference between them (standardised mean difference -0.15, 95% confidence interval -0.52 to 0.22; three studies; 114 participants) (low-quality evidence).",rephrase,['When we combined the data for tinnitus symptom severity we found no difference between them.'],10,0.5,3,22
CD013094,3,11,The use of both types of device was again associated with a clinically significant reduction in tinnitus symptom severity.,ignore,['The use of both types of device was again associated with a clinically significant reduction in tinnitus symptom severity.'],11,0.5454545454545454,3,22
CD013094,4,12,Adverse effects were not assessed in any of the included studies.,ignore,['Adverse effects were not assessed in any of the included studies.'],12,0.5909090909090909,3,22
CD013094,5,13,"None of the studies measured the secondary outcomes of depressive symptoms or depression, anxiety symptoms or generalised anxiety, or health-related quality of life as measured by a validated instrument, nor the newly developed core outcomes tinnitus intrusiveness, ability to ignore, concentration, quality of sleep and sense of control.",rephrase,"['None of the studies measured depressive symptoms or depression, anxiety symptoms or generalised anxiety, or other important outcomes of interest in this review.']",13,0.6363636363636364,4,22
CD013094,6,14,"There is no evidence to support the superiority of sound therapy for tinnitus over waiting list control, placebo or education/information with no device.",delete,[],14,0.6818181818181818,4,22
CD013094,6,15,"There is insufficient evidence to support the superiority or inferiority of any of the sound therapy options (hearing aid, sound generator or combination hearing aid) over each other.",delete,[],14,0.7272727272727273,4,22
CD013094,6,16,"The quality of evidence for the reported outcomes, assessed using GRADE, was low.",rephrase,"['Where outcomes that we were interested in for this review were reported, we assessed the quality of the evidence available as low.']",14,0.7727272727272727,4,22
CD013094,6,17,"Using a combination device, hearing aid or sound generator might result in little or no difference in tinnitus symptom severity.",rephrase,"['Using a hearing aid, sound generator or combination device might result in little or no difference in tinnitus symptom severity.']",15,0.8181818181818182,5,22
CD013094,7,18,Future research into the effectiveness of sound therapy in patients with tinnitus should use rigorous methodology.,delete,[],16,0.8636363636363636,5,22
CD013094,7,19,"Randomisation and blinding should be of the highest quality, given the subjective nature of tinnitus and the strong likelihood of a placebo response.",delete,[],16,0.9090909090909091,5,22
CD013094,7,20,The CONSORT statement should be used in the design and reporting of future studies.,delete,[],16,0.9545454545454546,5,22
CD013094,7,21,"We also recommend the use of validated, patient-centred outcome measures for research in the field of tinnitus.",delete,[],16,1.0,5,22
CD013494,0,0,We included three RCTs with 737 people compared a higher blood pressure target with a lower blood pressure target during cardiac surgery with CPB.,rephrase,['We found three studies including 737 people undergoing heart surgery.'],0,0.14285714285714285,1,7
CD013494,0,1,"A high blood pressure target may result in little to no difference in acute kidney injury (risk ratio (RR) 1.30, 95% confidence interval (CI) 0.81 to 2.08; I² = 72%; 2 studies, 487 participants; low-certainty evidence), cognitive deterioration (RR 0.82, 95% CI 0.45 to 1.50; I² = 0%; 2 studies, 389 participants; low-certainty evidence), and all-cause mortality (RR 1.33, 95% CI 0.30 to 5.90; I² = 49%; 3 studies, 737 participants; low-certainty evidence).",delete,[],1,0.2857142857142857,2,7
CD013494,0,2,No study reported haemorrhagic stroke.,delete,[],1,0.42857142857142855,3,7
CD013494,0,3,"Although a high blood pressure target may increase the length of hospital stay slightly, we found no differences between a higher and a lower blood pressure target for the other secondary outcomes.",rephrase,"['Although a high blood pressure target may increase the length of hospital stay slightly, there may be little to no differences in quality of life or complications during hospitalisation.']",1,0.5714285714285714,3,7
CD013494,1,4,We also identified one ongoing RCT which is comparing a higher versus a lower blood pressure target among the people who undergo cardiac surgery with CPB.,rephrase,['We searched medical databases for clinical trials comparing high versus low blood pressure targets during heart surgery while on CPB.'],2,0.7142857142857143,4,7
CD013494,2,5,A high blood pressure target may result in little to no difference in patient outcomes including acute kidney injury and mortality.,rephrase,"['There was little to no difference between a high and low blood pressure target in injury to the kidneys, cognition damage, or deaths.']",3,0.8571428571428571,5,7
CD013494,2,6,"Given the wide CIs, further studies are needed to confirm the efficacy of a higher blood pressure target among those who undergo cardiac surgery with CPB.",delete,[],4,1.0,5,7
CD012996,0,0,We included 10 studies with 753 people with stroke.,rephrase,"['The studies involved a total of 753 participants at all stages of care, including being in hospital or back to living at home.']",0,0.07692307692307693,1,13
CD012996,0,1,"Five studies used physical activity interventions, four studies used a multicomponent lifestyle intervention, and one study used an intervention to reduce and interrupt sedentary behaviour.",rephrase,"[""Studies included exercise alone (one study) or in combination with education and coaching (one study); physical activity alone (one study) or in combination with a mobile phone 'app' (one study), multi-component lifestyle interventions including physical activity (four studies), and additional inpatient physiotherapy (one study).""]",1,0.15384615384615385,1,13
CD012996,0,2,"In all studies, the risk of bias was high or unclear in two or more domains.",merge,"['Because of problems in the ways they were conducted, and in the ways they were reported by the research teams, all studies were at high or unclear risk of bias.']",2,0.23076923076923078,2,13
CD012996,0,3,Nine studies had high risk of bias in at least one domain.,none,[],2,0.3076923076923077,2,13
CD012996,1,4,"The interventions did not increase or reduce deaths (risk difference (RD) 0.00, 95% confidence interval (CI) -0.02 to 0.03; 10 studies, 753 participants; low-certainty evidence), the incidence of recurrent cardiovascular or cerebrovascular events (RD -0.01, 95% CI -0.04 to 0.01; 10 studies, 753 participants; low-certainty evidence), the incidence of falls (and injuries) (RD 0.00, 95% CI -0.02 to 0.02; 10 studies, 753 participants; low-certainty evidence), or incidence of other adverse events (moderate-certainty evidence).",rephrase,"['Currently, the evidence shows that interventions to reduce sedentary behaviour do not increase or reduce death, cardiovascular events, falls or other adverse events, or amount of time spent sitting.']",3,0.38461538461538464,2,13
CD012996,2,5,"Interventions did not increase or reduce the amount of sedentary behaviour time (mean difference (MD) +0.13 hours/day, 95% CI -0.42 to 0.68; 7 studies, 300 participants; very low-certainty evidence).",delete,[],4,0.46153846153846156,3,13
CD012996,2,6,There were too few data to examine effects on patterns of sedentary behaviour.,rephrase,['The certainty of the effects on sedentary behaviour itself is very low.'],4,0.5384615384615384,3,13
CD012996,3,7,The effect of interventions on cardiometabolic risk factors allowed very limited meta-analysis.,delete,[],5,0.6153846153846154,4,13
CD012996,4,8,"Sedentary behaviour research in stroke seems important, yet the evidence is currently incomplete, and we found no evidence for beneficial effects.",rephrase,['Interest in sedentary behaviour after stroke is relatively recent; the main problem with the evidence is that very few studies have examined this to date.'],5,0.6923076923076923,4,13
CD012996,4,9,"Current World Health Organization (WHO) guidelines recommend reducing the amount of sedentary time in people with disabilities, in general.",delete,[],6,0.7692307692307693,4,13
CD012996,4,10,The evidence is currently not strong enough to guide practice on how best to reduce sedentariness specifically in people with stroke.,rephrase,['The available evidence tends to be restricted to patients after stroke who are more mobile.'],6,0.8461538461538461,5,13
CD012996,5,11,"More high-quality randomised trials are needed, particularly involving participants with mobility limitations.",delete,[],7,0.9230769230769231,5,13
CD012996,5,12,"Trials should include longer-term interventions specifically targeted at reducing time spent sedentary, risk factor outcomes, objective measures of sedentary behaviour (and physical activity), and long-term follow-up.",delete,[],7,1.0,5,13
CD012762,0,0,One double-blind cross-over RCT with 22 participants with SCD (aged 12 to 27 years) was eligible for inclusion.,delete,[],0,0.05,1,20
CD012762,0,1,"Following stratification into four pain crises severity grades, participants were then randomised to receive TENS or placebo (sham TENS).",split,"['The participants were graded into four groups according to how severe their pain was.', 'On the first visit, the participants from different groups were chosen randomly to receive either TENS or ‘sham’ TENS treatment.']",0,0.1,1,20
CD012762,0,2,The trial was concluded after 60 treatment episodes (30 treatment episodes of each treatment group).,delete,[],2,0.15,1,20
CD012762,1,3,There is a lack of clarity regarding the trial design and the analysis of the cross-over data.,delete,[],2,0.2,1,20
CD012762,1,4,"If a participant was allocated to TENS treatment for an episode of pain and subsequently returned with a further episode of a similar degree of pain, they would then receive the sham TENS treatment (cross-over design).",delete,[],2,0.25,2,20
CD012762,1,5,"For those experiencing a pain episode of a different severity, it is not clear whether they were re-randomised or given the alternate treatment.",rephrase,"['For those experiencing a pain episode of a different severity, it is not clear which treatment they were given.']",2,0.3,2,20
CD012762,1,6,Reporting and analysis was based on the total number pain events and not on the number of participants.,rephrase,['The reporting and analysis was based on only the total number pain events and not the number of people reporting pain episodes.'],3,0.35,2,20
CD012762,1,7,It is unclear how many participants were crossed over from the TENS group to the sham TENS group and vice versa.,rephrase,"[""It is unclear from this report how many participants were crossed over from TENS to 'sham' TENS treatment group.""]",4,0.4,2,20
CD012762,1,8,The trial had a high risk of bias regarding random sequence generation and allocation concealment; an unclear risk regarding the blinding of participants and personnel; and a low risk regarding the blinding of the outcome assessors and selective outcome reporting.,rephrase,['Hence we conclude that the trial has a high risk of bias and the results are hard to interpret.'],5,0.45,3,20
CD012762,2,9,"The trial was small and of very low quality; furthermore, given the issue with trial design we were unable to quantitatively analyse the data.",rephrase,"['Due to low-quality data and issues with the trial design, we can only report in a descriptive way without any formal analysis.']",6,0.5,3,20
CD012762,2,10,"Therefore, we present only a narrative summary and caution is advised in interpreting the results.",rephrase,['Caution should be used in interpreting these results.'],7,0.55,3,20
CD012762,2,11,"In relation to our pre-defined primary outcomes, the included trial did not report pain relief at two to four weeks post intervention.",delete,[],8,0.6,3,20
CD012762,2,12,The trial authors reported that no difference was found in the changes in pain ratings (recorded at one hour and four hours post intervention) between the TENS and the placebo groups.,rephrase,"[""In the included trial no difference was found in the rating of pain on a scale of 1 to 10 at the end of one hour and four hours between the TENS and 'sham' TENS treatment groups.""]",8,0.65,4,20
CD012762,2,13,"In relation to our secondary outcomes, the analgesic usage during the trial also did not show any difference between groups.",rephrase,['There was no difference between groups as to how much pain medication was used.'],9,0.7,4,20
CD012762,2,14,"Given the quality of the evidence, we are uncertain whether TENS improves overall satisfaction as compared to sham TENS.",ignore,"[""Given the very low quality of the evidence, we are also uncertain whether TENS improves overall satisfaction as compared to 'sham' TENS.""]",10,0.75,4,20
CD012762,2,15,The ability to cope with activities of daily living was not evaluated.,delete,[],11,0.8,4,20
CD012762,2,16,"Regarding adverse events, although one case of itching was reported in the TENS group, the site and nature of itching was not clearly stated; hence it cannot be clearly attributed to TENS.",merge,[],11,0.85,5,20
CD012762,2,17,"Also, two participants receiving 'sham' TENS reported a worsening of pain with the intervention.",none,"[""A minor adverse effect of itching was reported by only one person receiving TENS, whereas two people receiving 'sham' TENS reported a worsening of pain with the intervention.""]",11,0.9,5,20
CD012762,3,18,"Since we have only included one small and very low-quality trial, with a high risk of bias across several domains, we are unable to conclude whether TENS is harmful or beneficial for managing pain in people with SCD.",rephrase,"['Since there is only one included trial with very low-quality evidence, we cannot state whether TENS makes any difference to managing pain in people with SCD.']",12,0.95,5,20
CD012762,3,19,"There is a need for a well-designed, adequately-powered, RCT to evaluate the role of TENS in managing pain in people with SCD.",rephrase,"[""We searched for well-designed trials to see the effect of TENS compared to 'sham' TENS in people with SCD for relieving pain, reducing the intensity of pain, reducing the frequency of pain episodes, making a difference to the use of painkillers, improving quality of life and for assessing any adverse effects.""]",13,1.0,5,20
CD009600,0,0,We included two trials (105 participants) comparing ergonomic versus placebo keyboards.,rephrase,['Only two studies were found (involving 105 participants).'],0,0.14285714285714285,1,7
CD009600,0,1,Neither trial assessed the primary outcome (short-term overall improvement) or adverse effects of interventions.,rephrase,"['Neither study assessed short-term overall improvement, adverse effects or need for surgery as outcomes.']",1,0.2857142857142857,2,7
CD009600,0,2,In one small trial (25 participants) an ergonomic keyboard significantly reduced pain after 12 weeks (MD -2.40; 95% CI -4.45 to -0.35) but not six weeks (MD -0.20; 95% CI -1.51 to 1.11).,rephrase,['One small study (25 participants) found an ergonomic keyboard reduced pain after 12 weeks but the second study reported no difference in pain severity between the keyboard groups at six months.'],2,0.42857142857142855,3,7
CD009600,0,3,"In this same study, there was no difference between ergonomic and standard keyboards in hand function at six or 12 weeks or palm-wrist sensory latency at 12 weeks.",rephrase,['Neither study found improvements in hand function or signs of CTS by people using ergonomic computer keyboards more than those experienced by people using standard keyboards.'],3,0.5714285714285714,3,7
CD009600,0,4,The second trial (80 participants) reported no significant difference in pain severity after six months when using either of the three ergonomic keyboards versus a standard keyboard.,delete,[],4,0.7142857142857143,4,7
CD009600,0,5,"No trials comparing (i) ergonomic positioning or equipment with no treatment, (ii) ergonomic positioning or equipment with another non-surgical treatment, or (iii) different ergonomic positioning or equipment regimes, were found.",delete,[],4,0.8571428571428571,5,7
CD009600,1,6,There is insufficient evidence from randomised controlled trials to determine whether ergonomic positioning or equipment is beneficial or harmful for treating carpal tunnel syndrome.,rephrase,"['Based on the two studies in this review, which represent all the available evidence of sufficient quality for inclusion, there is no strong evidence for or against the use of ergonomic keyboards for the treatment of CTS.']",4,1.0,5,7
CD006804,0,0,We included 12 trials with 734 patients randomised to miniport laparoscopic cholecystectomy (380 patients) versus standard laparoscopic cholecystectomy (351 patients).,rephrase,['We identified 12 randomised clinical trials involving 734 patients that compared miniport laparoscopic cholecystectomy (380) with standard port laparoscopic cholecystectomy (351).'],0,0.0625,1,16
CD006804,0,1,Only one trial which included 70 patients was of low risk of bias.,rephrase,"['Most of the trials were of high risk of bias, i.e. there is possibility of arriving at wrong conclusions overestimating benefits or underestimating harms because of study design.']",1,0.125,1,16
CD006804,0,2,Miniport laparoscopic cholecystectomy could be completed successfully in more than 80% of patients in most trials.,ignore,['Miniport laparoscopic cholecystectomy could be completed successfully in more than 80% of patients in most studies.'],2,0.1875,1,16
CD006804,0,3,The remaining patients were mostly converted to standard port laparoscopic cholecystectomy but some were also converted to open cholecystectomy.,rephrase,['The remaining patients were mostly converted to standard port laparoscopic cholecystectomy but some patients had to undergo open cholecystectomy.'],3,0.25,2,16
CD006804,0,4,These patients were included for the outcome conversion to open cholecystectomy but excluded from other outcomes.,merge,['These patients were excluded from the analysis by the study authors and so the results of these trials as well as the present systematic review have to be interpreted with extreme caution.'],4,0.3125,2,16
CD006804,0,5,"Accordingly, the results of the other outcomes are on 343 patients in the miniport laparoscopic cholecystectomy group and 351 patients in the standard port laparoscopic cholecystectomy group, and therefore the results have to be interpreted with extreme caution.",none,[],4,0.375,2,16
CD006804,1,6,There was no mortality in the seven trials that reported mortality (0/194 patients in miniport laparoscopic cholecystectomy versus 0/203 patients in standard port laparoscopic cholecystectomy).,rephrase,['There was no mortality in either group in the seven trials that reported mortality (0/226 patients versus 0/234 patients).'],5,0.4375,3,16
CD006804,1,7,There were no significant differences between miniport laparoscopic cholecystectomy and standard laparoscopic cholecystectomy in the proportion of patients who developed serious adverse events (eight trials; 460 patients; RR 0.33; 95% CI 0.04 to 3.08) (miniport laparoscopic cholecystectomy: 1/226 (adjusted proportion 0.4%) versus standard laparoscopic cholecystectomy: 3/234 (1.3%); quality of life at 10 days after surgery (one trial; 70 patients; SMD -0.20; 95% CI -0.68 to 0.27); or in whom the laparoscopic operation had to be converted to open cholecystectomy (11 trials; 670 patients; RR 1.23; 95% CI 0.44 to 3.45) (miniport laparoscopic cholecystectomy: 8/351 (adjusted proportion 2.3%) versus standard laparoscopic cholecystectomy 6/319 (1.9%)).,rephrase,"['There were no significant differences between the two operation types in the proportion of patients who developed serious complications, quality of life at 10 days after operation, or in whom the laparoscopic operation had to be converted to open cholecystectomy.']",6,0.5,3,16
CD006804,1,8,Miniport laparoscopic cholecystectomy took five minutes longer to complete than standard laparoscopic cholecystectomy (12 trials; 695 patients; MD 4.91 minutes; 95% CI 2.38 to 7.44).,rephrase,['Miniport laparoscopic cholecystectomy took five minutes longer to complete than standard port laparoscopic cholecystectomy.'],7,0.5625,3,16
CD006804,1,9,There were no significant differences between miniport laparoscopic cholecystectomy and standard laparoscopic cholecystectomy in the length of hospital stay (six trials; 351 patients; MD -0.00 days; 95% CI -0.12 to 0.11); the time taken to return to activity (one trial; 52 patients; MD 0.00 days; 95% CI -0.31 to 0.31); or in the time taken for the patient to return to work (two trials; 187 patients; MD 0.28 days; 95% CI -0.44 to 0.99) between the groups.,rephrase,"['There were no significant differences between the two operation types in the length of hospital stay, the time taken to return to activity, or in the time taken to return to work.']",8,0.625,4,16
CD006804,1,10,There was no significant difference in the cosmesis scores at six months to 12 months after surgery between the two groups (two trials; 152 patients; SMD 0.13; 95% CI -0.19 to 0.46).,rephrase,"['There was no significant cosmetic difference at six months to 12 months after surgery between the two groups, in the two trials that reported this outcome.']",9,0.6875,4,16
CD006804,2,11,Miniport laparoscopic cholecystectomy can be completed successfully in more than 80% of patients.,delete,[],10,0.75,4,16
CD006804,2,12,"There appears to be no advantage of miniport laparoscopic cholecystectomy in terms of decreasing mortality, morbidity, hospital stay, return to activity, return to work, or improving cosmesis.",ignore,"['There appears to be no advantage of miniport laparoscopic cholecystectomy in terms of decreasing surgical complications, hospital stay, return to activity, return to work, or improving cosmesis.']",10,0.8125,5,16
CD006804,2,13,"On the other hand, there is a modest increase in operating time after miniport laparoscopic cholecystectomy compared with standard port laparoscopic cholecystectomy and the safety of miniport laparoscopic cholecystectomy is yet to be established.",split,"['On the other hand, there is a modest increase in operating time after miniport laparoscopic cholecystectomy compared with standard port laparoscopic cholecystectomy.', 'The safety of miniport laparoscopic cholecystectomy is yet to be established.']",11,0.875,5,16
CD006804,2,14,Miniport laparoscopic cholecystectomy cannot be recommended routinely outside well-designed randomised clinical trials.,split,"['Miniport laparoscopic cholecystectomy cannot be recommended routinely outside well-designed randomised clinical trials.', 'Further well-designed randomised clinical trials are necessary to determine whether miniport laparoscopic cholecystectomy is safe and whether there is any advantage over standard port laparoscopic cholecystectomy.']",13,0.9375,5,16
CD006804,2,15,Further trials of low risks of bias and low risks of random errors are necessary.,delete,[],15,1.0,5,16
CD003544,0,0,"We identified two small trials (Alexander 1991and Nishikawa 1996 which fulfilled the inclusion criteria, (total n=17, duration 3-6 weeks).",rephrase,"['We found two short trials (n=17, duration 3-6 weeks) that were too small and short to be informative.']",0,0.14285714285714285,1,7
CD003544,0,1,"Few data were reported and, because of inappropriate use of crossover methodology, we could not include all of the data in this review.",delete,[],1,0.2857142857142857,2,7
CD003544,0,2,"For the few chronically ill people in these trials, neither the 'active' tetracycline bacteriostatic agent, oral demeclocycline, nor the opiate antagonist naloxone, nor placebo, gave any suggestion of serious adverse effects for a period of up to six weeks.",rephrase,['The only data available were for adverse effects and neither the active treatments nor placebo produced any serious side effects.'],1,0.42857142857142855,3,7
CD003544,0,3,"The studies did not report any useful data on measures of polydipsia, physical symptoms secondary to increased fluid intake, mental state, general functioning or economic outcomes.",ignore,"['The studies did not report any useful data on measures of polydipsia, physical symptoms secondary to increased fluid intake, mental state, general functioning or economic outcomes.']",2,0.5714285714285714,3,7
CD003544,1,4,"The trials offer little useful data to the clinician hoping to treat psychosis-related polydipsia with drugs, except that further evaluative studies need to be conducted in this area.",split,"['Clinicians hoping to treat people with psychosis-related polydipsia are unable to gain any useful information from these trials and treatment of any sort might only be informative within a well-designed study.', 'More research is needed and these two trials, although unable to provide much data, do show this type of research is possible.']",3,0.7142857142857143,4,7
CD003544,1,5,"Treatment of any sort for psychosis related polydipsia might only be informative within a well designed, conducted and reported randomised study.",rephrase,['We systematically searched and evaluated randomised controlled trials investigating the effectiveness of drug treatment for polydipsia.'],5,0.8571428571428571,5,7
CD003544,1,6,"The two pioneering studies suggest that larger trials, though difficult, would not be impossible with adequate support and co-ordination.",delete,[],6,1.0,5,7
CD007472,0,0,"We identified a total of 15 randomised trials evaluating 11 different pharmacological interventions (methylprednisolone, multivitamin antioxidant infusion, vitamin E infusion, amrinone, prostaglandin E1, pentoxifylline, mannitol, trimetazidine, dextrose, allopurinol, and OKY 046 (a thromboxane A2 synthetase inhibitor)).",ignore,"['We identified a total of 15 randomised trials evaluating 11 different pharmacological interventions (methylprednisolone, multivitamin antioxidant infusion, vitamin E infusion, amrinone, prostaglandin E1, pentoxifylline, mannitol, trimetazidine, dextrose, allopurinol, and OKY 046).']",0,0.1111111111111111,1,9
CD007472,0,1,All trials had high risk of bias.,rephrase,"[""All trials had risk of bias ('systematic errors') and risk of play of chance ('random errors').""]",1,0.2222222222222222,2,9
CD007472,0,2,"There were no significant differences between the groups in mortality, liver failure, or perioperative morbidity.",rephrase,"['There was no significant difference between the groups in mortality, liver failure, or post-operative complications.']",2,0.3333333333333333,2,9
CD007472,0,3,The trimetazidine group had a significantly shorter hospital stay than control (MD -3.00 days; 95% CI -3.57 to -2.43).,rephrase,"['The trimetazidine group had a significantly shorter hospital stay, and the vitamin E group had a significantly shorter intensive therapy unit stay than the respective controls.']",3,0.4444444444444444,3,9
CD007472,0,4,There were no significant differences in any of the clinically relevant outcomes in the remaining comparisons.,ignore,['There was no significant difference in any of the clinically relevant outcomes in the remaining comparisons.'],4,0.5555555555555556,3,9
CD007472,0,5,"Methylprednisolone improved the enzyme markers of liver function and trimetazidine, methylprednisolone, and dextrose reduced the enzyme markers of liver injury compared with controls.",ignore,"['Methylprednisolone improved the enzyme markers of liver function and trimetazidine, methylprednisolone, and dextrose reduced the enzyme markers of liver injury compared to controls.']",5,0.6666666666666666,4,9
CD007472,0,6,"However, there is a high risk of type I and type II errors because of the few trials included, the small sample size in each trial, and the risk of bias.",rephrase,"['However, there is a high risk of type I (erroneously concluding that an intervention is beneficial when it is actually not beneficial) and type II errors (erroneously concluding that an intervention is not beneficial when it is actually beneficial) because of the few trials included, the small sample size in each trial, and the risks of bias.']",6,0.7777777777777778,4,9
CD007472,1,7,"Trimetazidine, methylprednisolone, and dextrose may protect against ischaemia reperfusion injury in elective liver resections performed under vascular occlusion, but this is shown in trials with small sample sizes and high risk of bias.",rephrase,"['Three pharmacological drugs - trimetazidine, methylprednisolone, and dextrose - have potential for a protective role against liver injury in elective liver surgery involving blood supply occlusion.']",7,0.8888888888888888,5,9
CD007472,1,8,The use of these drugs should be restricted to well-designed randomised clinical trials before implementing them in clinical practice.,rephrase,"['However, based on the current evidence it is recommended that the use of these agents should be restricted to well-designed trials in patients undergoing resection.']",8,1.0,5,9
CD009296,0,0,Five studies on 588 adults and children were included concerning nurse-led care versus physician-led care.,rephrase,['We found five studies on 588 adults and children.'],0,0.1111111111111111,1,9
CD009296,0,1,"One study included 154 patients with uncontrolled asthma, while the other four studies including 434 patients with controlled or partly controlled asthma.",delete,[],1,0.2222222222222222,2,9
CD009296,0,2,The studies were of good methodological quality (although it is not possible to blind people giving or receiving the intervention to which group they are in).,rephrase,['The studies were of good methodological quality.'],1,0.3333333333333333,2,9
CD009296,0,3,There was no statistically significant difference in the number of asthma exacerbations and asthma severity after treatment (duration of follow-up from six months to two years).,rephrase,['The number of asthma exacerbations (flare-ups) and the level of asthma severity did not differ at the end of the study period between the intervention and the control group.'],2,0.4444444444444444,3,9
CD009296,0,4,"Only one study had healthcare costs as an outcome parameter, no statistical differences were found.",rephrase,['Only one study reported information about the costs associated with both kinds of care and there was no significant difference between them.'],3,0.5555555555555556,3,9
CD009296,0,5,"Although not a primary outcome, quality of life is a patient-important outcome and in the three trials on 380 subjects that reported on this outcome, there was no statistically significant difference (standardised mean difference (SMD) -0.03; 95% confidence interval (CI) -0.23 to 0.17).",rephrase,['There was also no difference in quality of life.'],4,0.6666666666666666,4,9
CD009296,1,6,We found no significant difference between nurse-led care for patients with asthma compared to physician-led care for the outcomes assessed.,split,"['We reviewed the medical literature to find randomised controlled trials on care delivered by specialised nurse compared to care by a doctor in the management of asthma.', 'We found no difference between nurse-led care and physician-led care.']",5,0.7777777777777778,4,9
CD009296,1,7,"Based on the relatively small number of studies in this review, nurse-led care may be appropriate in patients with well-controlled asthma.",ignore,"['Based on the relatively small number of studies in this review, nurse-led care may be appropriate in patients with well-controlled asthma.']",7,0.8888888888888888,5,9
CD009296,1,8,More studies in varied settings and among people with varying levels of asthma control are needed with data on adverse events and health-care costs.,ignore,['More studies in varied settings and among people with varying levels of asthma control are needed with data on adverse events and healthcare costs.'],8,1.0,5,9
CD010899,0,0,"We identified 18 potential studies, of which two, currently reported only as abstracts, met the inclusion criteria for this review.",delete,[],0,0.09090909090909091,1,11
CD010899,0,1,Too little information was available for us to present full results or adequately assess risk of bias.,delete,[],0,0.18181818181818182,1,11
CD010899,0,2,"The participants were children aged five to 15 years with DMD, ambulant and non-ambulant.",rephrase,['The participants were children aged from five to 15 years with DMD who were able to walk and not able to walk.'],0,0.2727272727272727,2,11
CD010899,0,3,The interventions were risedronate versus no treatment in one trial (13 participants) and whole-body vibration versus a placebo device in the second (21 participants).,rephrase,['The treatments were risedronate versus no treatment in one trial (with 13 participants) and whole-body vibration versus a placebo (inactive) device in the other (with 21 participants).'],1,0.36363636363636365,2,11
CD010899,0,4,"Both studies reported improved bone mineral density with the active treatments, with no improvement in the control groups, but the abstracts did not compare treatment and control conditions.",split,"['Both completed trials, presented as abstracts only, reported an improvement in bone mineral density in children who received active treatment and no improvement in children in the control (placebo or no treatment) groups.', 'However, the reports did not report results for the comparison of treatment versus control groups, which means that it is not possible to draw conclusions about the effectiveness of either treatment.']",2,0.45454545454545453,3,11
CD010899,0,5,All children tolerated whole-body vibration treatment.,ignore,['All children tolerated whole-body vibration treatment.'],4,0.5454545454545454,3,11
CD010899,0,6,No study provided information on adverse events.,ignore,['Neither study provided information on adverse events.'],5,0.6363636363636364,4,11
CD010899,0,7,"Two studies are ongoing: one investigating whole-body vibration, the other investigating zoledronic acid.",rephrase,"['These studies are looking at the effects of whole-body vibration (two studies), risedronate, and zoledronic acid.']",6,0.7272727272727273,4,11
CD010899,1,8,We know of no high-quality evidence from RCTs to guide use of treatments to prevent or treat corticosteroid-induced osteoporosis and reduce the risk of fragility fractures in children and adults with DMD; only limited results from two trials reported in abstracts were available.,rephrase,['We know of no evidence from randomised clinical trials to guide use of treatments to prevent or treat osteoporosis and prevent fragility fractures in people with DMD taking corticosteroids.'],7,0.8181818181818182,5,11
CD010899,1,9,We await formal trial reports.,delete,[],8,0.9090909090909091,5,11
CD010899,1,10,"Findings from two ongoing relevant studies and two trials, for which only abstracts are available, will be important in future updates of this review.",delete,[],8,1.0,5,11
CD003564,0,0,We included 53 trials consisting of 1139 participants.,rephrase,['We found 53 trials consisting of 1139 participants.'],0,0.07692307692307693,1,13
CD003564,0,1,"Forty-eight studies used a cross-over design, and five were performed in accordance with a parallel-group design.",rephrase,"['Forty-eight studies used a cross-over design, which meant that each person in the trial received two or more treatments－one or more active treatments, the beta-agonist and a placebo in random order.']",1,0.15384615384615385,1,13
CD003564,0,2,"Forty-five studies addressed the effect of a single beta2-agonist administration, and eight focused on long-term treatment.",split,"['Most of the studies addressed the effect of a giving a single beta2-agonist treatment before exercise and recorded the effect on lung function following exercise.', 'Only eight focused on longer treatment－longer treatments would be needed to assess whether these treatments were harmful over the longer term.']",2,0.23076923076923078,2,13
CD003564,0,3,We addressed these two different intervention regimens as different comparisons.,delete,[],4,0.3076923076923077,2,13
CD003564,1,4,"Among primary outcomes for short-term administration, data on maximum fall in forced expiratory volume in 1 second (FEV1) showed a significant protective effect for both short-acting beta-agonists (SABA) and long-acting beta-agonists (LABA) compared with placebo, with a mean difference of -17.67% (95% confidence interval (CI) -19.51% to -15.84%, P = 0.00001, 799 participants from 72 studies).",rephrase,['Studies in which people received a single administration of a beta-agonist showed that FEV1 (a measure of lung function) fell significantly less for people taking SABA or LABA compared with placebo (mean difference (MD) -17.67%; 95% confidence interval (CI) -19.51% to -15.84%).'],4,0.38461538461538464,2,13
CD003564,1,5,"The subgroup analysis of studies performed in adults compared with those performed in children showed high heterogeneity confined to children, despite the comparable mean bronchoprotective effect.",delete,[],5,0.46153846153846156,3,13
CD003564,2,6,Secondary outcomes on other pulmonary function parameters confirmed a more positive and protective effect of beta2-agonists on EIA compared with placebo.,rephrase,['Other lung function measures confirmed that beta2-agonists were more beneficial compared with placebo.'],5,0.5384615384615384,3,13
CD003564,2,7,Occurrence of side effects was not significantly different between beta2-agonists and placebo.,rephrase,['No significant difference in the number of side effects was noted in people taking SABA or LABA compared with people taking placebo.'],6,0.6153846153846154,4,13
CD003564,3,8,Overall evaluation of the included long-term studies suggests a beta2-agonist bronchoprotective effect for the first dose of treatment.,rephrase,['We found that included longer-term studies showed that beta2-agonists were helpful in terms of lung function for the first dose of treatment.'],7,0.6923076923076923,4,13
CD003564,3,9,"However, long-term use of both SABA and LABA induced the onset of tolerance and decreased the duration of drug effect, even after a short treatment period.",rephrase,"['However, studies that provided longer-term treatment with SABA or LABA showed that over time, people built up a tolerance to the effects of treatments, and the beneficial effects lasted for shorter periods of time.']",8,0.7692307692307693,4,13
CD003564,4,10,"Evidence of low to moderate quality shows that beta2-agonists, both SABA and LABA, when administered in a single dose, are effective and safe in preventing EIA.",rephrase,"['This review shows that beta2-agonists－both SABA and LABA－when administered in a single dose, are effective and safe in preventing the symptoms of EIA.']",9,0.8461538461538461,5,13
CD003564,5,11,Long-term regular administration of inhaled beta2-agonists induces tolerance and lacks sufficient safety data.,split,"['Longer-term administration of inhaled beta2-agonists induces tolerance and lacks sufficient safety data.', 'We recommend that more studies are needed to determine whether it is safe to administer inhaled beta2-agonists alone to people who experience asthma symptoms when exercising.']",10,0.9230769230769231,5,13
CD003564,5,12,"This finding appears to be of particular clinical relevance in view of the potential for prolonged regular use of beta2-agonists as monotherapy in the pretreatment of EIA, despite the warnings of drug agencies (FDA, EMA) regarding LABA.",delete,[],12,1.0,5,13
CD012264,0,0,We included 10 RCTs that involved a total of 300 participants whose mean age was 54.4 years.,rephrase,['We included 10 trials that studied 300 people who were heart transplant recipients.'],0,0.0625,1,16
CD012264,0,1,Women accounted for fewer than 25% of all study participants.,delete,[],1,0.125,1,16
CD012264,0,2,Nine trials which randomised 284 participants to receive exercise-based rehabilitation (151 participants) or no exercise (133 participants) were included in the main analysis.,rephrase,"['We searched for randomised controlled trials (experiments that randomly allocate participants to one of two or more treatment groups) looking at the effectiveness of exercise-based rehabilitation programmes compared with no exercise, or a different type or intensity of exercise, in people aged 18 years or over, who were heart transplant recipients.']",1,0.1875,1,16
CD012264,0,3,One cross-over RCT compared high-intensity interval training with continued moderate-intensity training in 16 participants.,rephrase,['Nine studies compared exercise with no exercise; one study compared high-intensity interval training with continuous moderate-intensity exercise.'],2,0.25,2,16
CD012264,0,4,We reported findings for all trials at their longest follow-up (median 12 weeks).,delete,[],3,0.3125,2,16
CD012264,1,5,"Exercise-based cardiac rehabilitation increased exercise capacity (VO2peak) compared with no exercise control (MD 2.49 mL/kg/min, 95% CI 1.63 to 3.36; N = 284; studies = 9; moderate quality evidence).",rephrase,['We found that exercise-based cardiac rehabilitation led to an increase in the exercise capacity of heart transplant recipients compared to not undertaking exercise.'],3,0.375,2,16
CD012264,1,6,"There was evidence from one trial that high-intensity interval exercise training was more effective in improving exercise capacity than continuous moderate-intensity exercise (MD 2.30 mL/kg/min, 95% CI 0.59 to 4.01; N = 16; 1 study).",rephrase,['There was evidence of better exercise capacity following high-intensity interval training compared to continuous moderate-intensity exercise.'],4,0.4375,3,16
CD012264,1,7,"Four studies reported health-related quality of life (HRQoL) measured using SF-36, Profile of Quality of Life in the Chronically Ill (PLC) and the World Health Organization Quality Of Life (WHOQoL) - BREF.",merge,"['Four studies reported health-related quality of life, but there was no evidence of differences between exercise training and no exercise training in most (18/21) aspects reported, or between high- and moderate-intensity exercise.']",5,0.5,3,16
CD012264,1,8,"Due to the variation in HRQoL outcomes and methods of reporting we were unable to meta-analyse results across studies, but there was no evidence of a difference between exercise-based cardiac rehabilitation and control in 18 of 21 HRQoL domains reported, or between high and moderate intensity exercise in any of the 10 HRQoL domains reported.",none,[],5,0.5625,3,16
CD012264,1,9,One adverse event was reported by one study.,ignore,['One adverse event was reported in one study.'],6,0.625,4,16
CD012264,2,10,"Exercise-based cardiac rehabilitation improves exercise capacity, but exercise was found to have no impact on health-related quality of life in the short-term (median 12 weeks follow-up), in heart transplant recipients whose health is stable.",delete,[],7,0.6875,4,16
CD012264,3,11,There was no evidence of statistical heterogeneity across trials for exercise capacity and no evidence of small study bias.,delete,[],7,0.75,4,16
CD012264,3,12,"The overall risk of bias in included studies was judged as low or unclear; more than 50% of included studies were assessed at unclear risk of bias with respect to allocation concealment, blinding of outcome assessors and declaration of conflicts of interest.",rephrase,['Risk of bias in the included studies was assessed as low or unclear; lack of reporting made assessment for more than half of included studies challenging.'],7,0.8125,5,16
CD012264,3,13,Evidence quality was assessed as moderate according to GRADE criteria.,rephrase,['Poor reporting or few participants in the analyses led to evidence quality being judged as moderate for both exercise capacity and health-related quality of life.'],8,0.875,5,16
CD012264,4,14,"We found moderate quality evidence suggesting that exercise-based cardiac rehabilitation improves exercise capacity, and that exercise has no impact on health-related quality of life in the short-term (median 12 weeks follow-up), in heart transplant recipients.",rephrase,"['Evidence suggested that exercise-based cardiac rehabilitation improves exercise capacity, and that exercise has no impact on health-related quality of life in the short-term (median 12 weeks follow-up), in heart transplant recipients whose health is stable.']",9,0.9375,5,16
CD012264,4,15,"Cardiac rehabilitation appears to be safe in this population, but long-term follow-up data are incomplete and further good quality and adequately-powered trials are needed to demonstrate the longer-term benefits of exercise on safety and impact on both clinical and patient-related outcomes, such as health-related quality of life, and healthcare costs.",rephrase,['Further research is needed to establish long-term impacts of exercise-based rehabilitation on important aspects such as risk of death and hospital admission.'],10,1.0,5,16
CD006967,0,0,"We included six publications, with 125 participants (106 aged under 18 years).",rephrase,['We found six trials representing 125 participants for the present review.'],0,0.1111111111111111,1,9
CD006967,0,1,Two different comparisons were available: melatonin versus placebo and melatonin 5 mg versus melatonin 10 mg.,rephrase,['They reported two different comparisons: melatonin versus placebo and melatonin 5 mg versus melatonin 10 mg.'],1,0.2222222222222222,2,9
CD006967,0,2,"Despite our primary intention, due to insufficient information on outcomes, we were unable to perform any meta-analyses, but summarized data narratively.",delete,[],2,0.3333333333333333,2,9
CD006967,0,3,"Four studies were randomized, double-blind, cross-over, placebo-controlled trials and two were randomized, double-blind, parallel, placebo-controlled trials.",delete,[],2,0.4444444444444444,3,9
CD006967,0,4,Only two studies provided the exact number of seizures during the trial compared to the baseline: none of the participants with seizures during the trial had a change in seizure frequency compared with the baseline.,rephrase,['Only one study reported seizure frequency and none of the participants had a change in frequency occurring during the trial compared to before the trial.'],2,0.5555555555555556,3,9
CD006967,0,5,Two studies systematically evaluated adverse effects (worsening of headache was reported in a child with migraine under melatonin treatment).,delete,[],3,0.6666666666666666,4,9
CD006967,0,6,"Only one study systematically evaluated quality of life, showing no statistically significant improvement in quality of life in the add-on melatonin group.",rephrase,['Only one trial evaluated the effect of melatonin on quality of life and found no improvement with add-on melatonin compared with add-on placebo.'],3,0.7777777777777778,4,9
CD006967,1,7,"Included studies were of poor methodological quality, and did not systematically evaluate seizure frequency and adverse events, so that it was impossible to summarize data in a meta-analysis.",rephrase,"['Included trials did not evaluate seizure frequency, seizure freedom, and adverse events in a methodical way.']",4,0.8888888888888888,5,9
CD006967,1,8,It is not possible to draw any conclusion about the role of melatonin in reducing seizure frequency or improving quality of life in people with epilepsy.,rephrase,['The included trials were of poor methodological quality and it was not possible to draw any definitive conclusions about the role of melatonin in reducing seizure frequency or improving the quality of life in people with epilepsy.'],5,1.0,5,9
CD007536,0,0,Four trials (2300 women) are included.,rephrase,['Four trials with 2300 women provided information for the review.'],0,0.1111111111111111,1,9
CD007536,0,1,The interventions ranged from brief advice through to education on health and lifestyle over several sessions.,rephrase,['The health promotion offered to women in these studies ranged from very brief advice on a specific topic through to more general advice and education on health and lifestyle over several sessions.'],1,0.2222222222222222,2,9
CD007536,0,2,"For most outcomes, data were only available from individual studies.",delete,[],2,0.3333333333333333,2,9
CD007536,0,3,"Only one study followed up through pregnancy and there was no strong evidence of a difference between groups for preterm birth, congenital anomalies or weight for gestational age; only one finding (mean birthweight) reached statistical significance (mean difference -97.00, 95% confidence interval (CI) -168.05 to -25.95).",rephrase,"['In only one study were women followed up through pregnancy and there was little evidence of any differences between groups, although the babies of women who had received the health promotion intervention had slightly lower birthweights.']",2,0.4444444444444444,3,9
CD007536,0,4,This finding needs to be interpreted with caution as pregnancy outcome data were available for only half of the women randomised.,delete,[],3,0.5555555555555556,3,9
CD007536,0,5,"There was some evidence that health promotion interventions were associated with positive maternal behavioural change including lower rates of binge drinking (risk ratio 1.24, 95% CI 1.06 to 1.44).",rephrase,"['There was some evidence that health promotion interventions encourage women to have more healthy lifestyles, such as lower rates of binge drinking.']",3,0.6666666666666666,4,9
CD007536,0,6,"Overall, there has been little research in this area and there is a lack of evidence on the effects of pre-pregnancy health promotion on pregnancy outcomes.",rephrase,"['Overall, there was little evidence on the effects of pre-pregnancy health promotion on the health of mothers and babies, and more evidence is needed before its widespread implementation can be recommended.']",4,0.7777777777777778,4,9
CD007536,1,7,There is little evidence on the effects of pre-pregnancy health promotion and much more research is needed in this area.,delete,[],5,0.8888888888888888,5,9
CD007536,1,8,"There is currently insufficient evidence to recommend the widespread implementation of routine pre-pregnancy health promotion for women of childbearing age, either in the general population or between pregnancies.",delete,[],5,1.0,5,9
CD008722,0,0,We included 38 studies involving 9445 participants.,rephrase,['We identified 38 studies involving 9445 participants examining several types of interventions for enhancing adherence to dietary advice for preventing and managing many chronic diseases.'],0,0.125,1,8
CD008722,0,1,"Among studies that measured diet adherence outcomes between an intervention group and a control/usual care group, 32 out of 123 diet adherence outcomes favoured the intervention group, 4 favoured the control group whereas 62 had no significant difference between groups (assessment was impossible for 25 diet adherence outcomes since data and/or statistical analyses needed for comparison between groups were not provided).",delete,[],1,0.25,2,8
CD008722,0,2,"Interventions shown to improve at least one diet adherence outcome are: telephone follow-up, video, contract, feedback, nutritional tools and more complex interventions including multiple interventions.",ignore,"['Interventions shown to improve at least one diet adherence outcome are: telephone follow-up, video, contract, feedback, nutritional tools and more complex interventions including multiple interventions.']",1,0.375,2,8
CD008722,0,3,"However, these interventions also shown no difference in some diet adherence outcomes compared to a control/usual care group making inconclusive results about the most effective intervention to enhance dietary advice.",ignore,"['However, these interventions also showed no difference in some diet adherence outcomes compared to a control/usual care group making the results inconclusive about the most effective intervention to enhance dietary advice.']",2,0.5,3,8
CD008722,0,4,The majority of studies reporting a diet adherence outcome favouring the intervention group compared to the control/usual care group in the short-term also reported no significant effect at later time points.,split,"['Interestingly, all studies including clients with renal diseases reported at least one diet adherence outcome showing a statistically significant difference favouring the intervention group, no matter which intervention was provided.', 'The majority of studies reporting a diet adherence outcome favouring the intervention group compared to the control/usual care group in the short-term also reported no significant effect at later time points.']",3,0.625,4,8
CD008722,0,5,"Studies investigating interventions such as a group session, individual session, reminders, restriction and behaviour change techniques reported no diet adherence outcome showing a statistically significant difference favouring the intervention group.",ignore,"['Studies investigating interventions such as a group session, individual session, reminders, restriction and behaviour change techniques reported no diet adherence outcome showing a statistically significant difference favouring the intervention group.']",5,0.75,4,8
CD008722,0,6,"Finally, studies were generally of short duration and low quality, and adherence measures varied widely.",rephrase,"['Finally, interventions were generally of short duration, studies used different methods for measuring adherence and the quality of the studies was generally low.']",6,0.875,5,8
CD008722,1,7,"There is a need for further, long-term, good-quality studies using more standardized and validated measures of adherence to identify the interventions that should be used in practice to enhance adherence to dietary advice in the context of a variety of chronic diseases.",delete,[],7,1.0,5,8
CD000081,0,0,"This updated review includes 12 studies (6177 women), 11 in women in labour for whom a vaginal birth was intended, and one in women where an assisted birth was anticipated.",rephrase,['The review now includes 11 randomised controlled trials (with 5977 women) that compared episiotomy as needed (selective episiotomy) with routine episiotomy in terms of benefits and harms for mother and baby in women at low risk of instrumental delivery.'],0,0.05,1,20
CD000081,0,1,"Two were trials each with more than 1000 women (Argentina and the UK), and the rest were smaller (from Canada, Germany, Spain, Ireland, Malaysia, Pakistan, Columbia and Saudi Arabia).",delete,[],1,0.1,1,20
CD000081,0,2,"Eight trials included primiparous women only, and four trials were in both primiparous and multiparous women.",delete,[],1,0.15,1,20
CD000081,0,3,"For risk of bias, allocation was adequately concealed and reported in nine trials; sequence generation random and adequately reported in three trials; blinding of outcomes adequate and reported in one trial, blinding of participants and personnel reported in one trial.",delete,[],1,0.2,1,20
CD000081,1,4,"For women where an unassisted vaginal birth was anticipated, a policy of selective episiotomy may result in 30% fewer women experiencing severe perineal/vaginal trauma (RR 0.70, 95% CI 0.52 to 0.94; 5375 women; eight RCTs; low-certainty evidence).",rephrase,"['In women where health staff were only conducting selective episiotomy, there may be 30% fewer with severe perineal trauma at birth compared with women where a policy of routine episiotomy was applied (eight trials, 5375 women, low-certainty evidence).']",1,0.25,2,20
CD000081,1,5,"We do not know if there is a difference for blood loss at delivery (an average of 27 mL less with selective episiotomy, 95% CI from 75 mL less to 20 mL more; two trials, 336 women, very low-certainty evidence).",rephrase,"['We do not know if there is a difference in average blood loss between the groups (two trials, very low-certainty evidence).']",2,0.3,2,20
CD000081,1,6,"Both selective and routine episiotomy have little or no effect on infants with Apgar score less than seven at five minutes (four trials, no events; 3908 women, moderate-certainty evidence); and there may be little or no difference in perineal infection (RR 0.90, 95% CI 0.45 to 1.82, three trials, 1467 participants, low-certainty evidence).",rephrase,"['There is probably no difference in Apgar less than seven at five minutes, with no events in either groups (moderate-certainty evidence).']",3,0.35,2,20
CD000081,2,7,"For pain, we do not know if selective episiotomy compared with routine results in fewer women with moderate or severe perineal pain (measured on a visual analogue scale) at three days postpartum (RR 0.71, 95% CI 0.48 to 1.05, one trial, 165 participants, very low-certainty evidence).",rephrase,"[""We do not know if there is a difference in the number of women with moderate or severe perineal pain three days after giving birth (one trial, 165 women, very low-certainty evidence) but careful assessment of women's pain was not well carried out in the included trials.""]",4,0.4,2,20
CD000081,2,8,"There is probably little or no difference for long-term (six months or more) dyspareunia (RR1.14, 95% CI 0.84 to 1.53, three trials, 1107 participants, moderate-certainty evidence); and there may be little or no difference for long-term (six months or more) urinary incontinence (average RR 0.98, 95% CI 0.67 to 1.44, three trials, 1107 participants, low-certainty evidence).",rephrase,"['There may be little or no difference in the number of women developing perineal infection (two trials, low-certainty evidence); and there is probably little or no difference in women reporting painful sexual intercourse six months or more after delivery (three trials, 1107 women, moderate-certainty evidence); for urinary incontinence six months or more after delivery, there may be little or no difference between the groups.']",5,0.45,3,20
CD000081,2,9,One trial reported genital prolapse at three years postpartum.,merge,['One study reported genital prolapse three years after the birth and there was no clear difference between groups (low-certainty evidence).'],6,0.5,3,20
CD000081,2,10,"There was no clear difference between the two groups (RR 0.30, 95% CI 0.06 to 1.41; 365 women; one trial, low certainty evidence).",none,[],6,0.55,3,20
CD000081,2,11,"Other outcomes relating to long-term effects were not reported (urinary fistula, rectal fistula, and faecal incontinence).",rephrase,"['Other important outcomes relating to long-term effects were not reported in these trials (urinary fistula, rectal fistula, and faecal incontinence).']",7,0.6,3,20
CD000081,2,12,Subgroup analyses by parity (primiparae versus multiparae) and by surgical method (midline versus mediolateral episiotomy) did not identify any modifying effects.,delete,[],8,0.65,4,20
CD000081,2,13,"Pain was not well assessed, and women's preferences were not reported.",delete,[],8,0.7,4,20
CD000081,3,14,"One trial examined selective episiotomy compared with routine episiotomy in women where an operative vaginal delivery was intended in 175 women, and did not show clear difference on severe perineal trauma between the restrictive and routine use of episiotomy, but the analysis was underpowered.",split,"['One trial examined selective episiotomy compared with routine episiotomy in women for whom an operative vaginal birth was intended.', 'The results showed no clear difference in severe perineal trauma between the restrictive and routine use of episiotomy.']",8,0.75,4,20
CD000081,4,15,"In women where no instrumental delivery is intended, selective episiotomy policies result in fewer women with severe perineal/vaginal trauma.",merge,"['Overall, the findings show that selective use of episiotomy in women (where a normal delivery without forceps is anticipated) means that fewer women have severe perineal trauma.']",10,0.8,4,20
CD000081,4,16,"Other findings, both in the short or long term, provide no clear evidence that selective episiotomy policies results in harm to mother or baby.",none,[],10,0.85,5,20
CD000081,5,17,The review thus demonstrates that believing that routine episiotomy reduces perineal/vaginal trauma is not justified by current evidence.,rephrase,"['Thus the rationale for conducting routine episiotomies to prevent severe perineal trauma is not justified by current evidence, and we could not identify any benefits of routine episiotomy for the baby or the mother.']",11,0.9,5,20
CD000081,5,18,Further research in women where instrumental delivery is intended may help clarify if routine episiotomy is useful in this particular group.,rephrase,['More research is needed in order to inform policy in women where an instrumental birth is planned and episiotomy is often advocated.'],12,0.95,5,20
CD000081,5,19,"These trials should use better, standardised outcome assessment methods.",rephrase,['Outcomes could be better standardised and measured.'],13,1.0,5,20
CD001019,0,0,Five trials (612 women) met the inclusion criteria.,rephrase,"['We found five trials, including 612 women, that met the inclusion criteria.']",0,0.05263157894736842,1,19
CD001019,0,1,Only three trials (404 women) provided data that were suitable for analysis.,delete,[],1,0.10526315789473684,1,19
CD001019,1,2,"Combined oral contraceptive pill versus placebo
Two trials compared COCP with a placebo.",rephrase,['Combined oral contraceptive pill versus placebo\nWe found two trials including 354 women that compared the COCP with a placebo (pretend treatment).'],1,0.15789473684210525,1,19
CD001019,1,3,These studies were at high risk of bias.,rephrase,['The evidence was at high risk of bias.'],2,0.21052631578947367,2,19
CD001019,1,4,"For GRADE outcomes (self-reported pain (dysmenorrhoea) at the end of treatment), the quality of the evidence very low.",split,"['There was very low quality evidence that treatment with the COCP was associated with an improvement in self-reported dysmenorrhoea (period pain) at the end of treatment measure on a verbal rating scale (where the woman rates her pain as (for example) ""no pain,"" ""slight pain,"" ""moderate pain,"" ""severe pain"" and ""unbearable pain"") and low quality evidence for an improvement in self-reported dysmenorrhoea pain at the end of treatment using a visual rating scale (where the woman marks her pain visually on a line) compared with placebo.', 'There was very low quality evidence that there was a reduction in menstrual pain from the beginning to the end of treatment in the COCP group compared with women having a placebo.']",3,0.2631578947368421,2,19
CD001019,1,5,"Evidence was downgraded for imprecision as it was based on a single, small trial and for the visual analogue scale data there were wide confidence intervals (CIs).",rephrase,['The main reasons for downgrading the evidence were because the data were based on a single small trial with wide variation in results and lack of details about how the study had been designed.'],5,0.3157894736842105,2,19
CD001019,1,6,There appeared to have been substantial involvement of the pharmaceutical company funding the trials.,rephrase,"['There were some concerns with two of the studies that were funded by a pharmaceutical company that also had input into the design of the trial, data collection and the analysis of data.']",6,0.3684210526315789,2,19
CD001019,2,7,"Treatment with the COCP was associated with an improvement in self-reported pain at the end of treatment as evidenced by a lower score on the Dysmenorrhoea verbal rating scale (scale 0 to 3) compared with placebo (mean difference (MD) -1.30 points, 95% CI -1.84 to -0.76; 1 RCT, 96 women; very low quality evidence), a lower score on the Dysmenorrhoea visual analogue scale (no details of scale) compared with placebo (MD -23.68 points, 95% CI -28.75 to -18.62, 2 RCTs, 327 women; very low quality evidence) and a reduction in menstrual pain from baseline to the end of treatment (MD 2.10 points, 95% CI 1.38 to 2.82; 1 RCT, 169 women; very low quality evidence).",delete,[],7,0.42105263157894735,3,19
CD001019,3,8,"Combined oral contraceptive pill versus medical therapies
One underpowered trial compared the COCP with another medical treatment (goserelin).",rephrase,['Combined oral contraceptive pill versus other medical treatment\nWe found one trial of 50 women that compared the COCP with another medical treatment (goserelin).'],7,0.47368421052631576,3,19
CD001019,3,9,The study was at high risk of bias; the trial was unblinded and there was insufficient detail to judge allocation concealment and randomisation.,rephrase,['The study was at high risk of bias.'],8,0.5263157894736842,3,19
CD001019,3,10,"For GRADE outcomes (self-reported pain (dysmenorrhoea) at the end of treatment), the quality of the evidence ranged from low to very low.",delete,[],9,0.5789473684210527,3,19
CD001019,4,11,"At the end of treatment, the women in the goserelin group were amenorrhoeic and therefore no comparisons could be made between the groups for the primary outcome.",rephrase,"['At the end of treatment, the women in the goserelin group were not having a period and therefore we could not compare the groups.']",9,0.631578947368421,4,19
CD001019,4,12,"At six months' follow-up, there was no clear evidence of a difference between women treated with the COCP and women treated with goserelin for measures of dysmenorrhoea on a visual analogue scale (scale 1 to 10) (MD -0.10, 95% CI -1.28 to 1.08; 1 RCT, 50 women; very low quality evidence) or a verbal rating scale (scale 0 to 3) (MD -0.10, 95% CI -0.99 to 0.79; 1 RCT, 50 women; very low quality evidence).",rephrase,"['Six months after the end of treatment, there was very low quality evidence that there was no clear difference between women treated with the COCP and women treated with goserelin for self-reported dysmenorrhoea, using a visual rating scale or a verbal rating scale.']",10,0.6842105263157895,4,19
CD001019,4,13,"At six months' follow-up, there was no clear evidence of a difference between the COCP and goserelin groups for reporting complete absence of pain as measured by the visual analogue scale (risk ratio (RR) 0.36, 95% CI 0.02 to 8.43; 1 RCT, 50 women; very low quality evidence) or the verbal rating scale (RR 1.00, 95% CI 0.93 to 1.08; 1 RCT, 49 women; low quality evidence).",rephrase,"['Six months after the end of treatment, there was very low quality evidence that there was no clear evidence of a difference between the COCP and goserelin groups for reporting complete absence of pain, as measured by a visual rating scale and low quality evidence using a verbal rating scale.']",11,0.7368421052631579,4,19
CD001019,5,14,"Based on the limited evidence from two trials at high risk of bias and limited data for the prespecified outcomes for this review, there is insufficient evidence to make a judgement on the effectiveness of the COCP compared with placebo and the findings cannot be generalised.",delete,[],12,0.7894736842105263,4,19
CD001019,6,15,"Based on the limited evidence from one small trial that was at high risk of bias, there is insufficient evidence to make a judgement on the effectiveness of the COCP compared with other medical treatments.",delete,[],12,0.8421052631578947,5,19
CD001019,6,16,"Only one comparison was possible, with the medical intervention being goserelin, and the findings cannot be generalised.",delete,[],12,0.8947368421052632,5,19
CD001019,7,17,Further research is needed to fully evaluate the role of COCPs in managing pain-related symptoms associated with endometriosis.,delete,[],12,0.9473684210526315,5,19
CD001019,7,18,"There are other formulations of the combined hormonal contraception such as the transdermal patch, vaginal ring or combined injectable contraceptives which this review did not cover but should be considered in future updates.",delete,[],12,1.0,5,19
CD012871,0,0,We identified two studies (involving a total of 73 women) comparing cervical cerclage alone to a different comparator.,merge,['We identified two trials involving a total of 73 women.'],0,0.07692307692307693,1,13
CD012871,0,1,"We also identified three ongoing studies (one investigating vaginal progesterone after cerclage, and two investigating cerclage plus pessary).",none,[],0,0.15384615384615385,1,13
CD012871,1,2,"One study (20 women), conducted in the UK, comparing cervical cerclage in combination with a tocolytic (salbutamol) with cervical cerclage alone in women with singleton pregnancy did not provide any useable data for this review.",delete,[],1,0.23076923076923078,2,13
CD012871,1,3,"The other study (involving 53 women, with data from 50 women) took place in the USA and compared cervical cerclage in combination with a tocolytic (indomethacin) and antibiotics (cefazolin or clindamycin) versus cervical cerclage alone - this study did provide useable data for this review (and the study authors also provided additional data on request) but meta-analyses were not possible.",delete,[],1,0.3076923076923077,2,13
CD012871,1,4,"This study was generally at a low risk of bias, apart from issues relating to blinding.",delete,[],1,0.38461538461538464,2,13
CD012871,1,5,"We downgraded the certainty of evidence for serious risk of bias and imprecision (few participants, few events and wide 95% confidence intervals).",delete,[],1,0.46153846153846156,3,13
CD012871,2,6,"Cervical cerclage in combination with an antibiotic and tocolytic versus cervical cerclage alone (one study, 50 women/babies)
We are unclear about the effect of cervical cerclage in combination with antibiotics and a tocolytic compared with cervical cerclage alone on the risk of serious neonatal morbidity (RR 0.62, 95% CI 0.31 to 1.24; very low-certainty evidence); perinatal loss (data for miscarriage and stillbirth only - data not available for neonatal death) (RR 0.46, 95% CI 0.13 to 1.64; very low-certainty evidence) or preterm birth < 34 completed weeks of pregnancy (RR 0.78, 95% CI 0.44 to 1.40; very low-certainty evidence).",rephrase,"['We are unclear about the effects of the intervention because we identified very low-certainty evidence for the main outcomes in this review: serious complications; loss of the baby (data for miscarriage and stillbirth only - data were not available for the numbers of babies who died within 28 days of being born), or preterm birth before 34 completed weeks of pregnancy.']",1,0.5384615384615384,3,13
CD012871,2,7,There were no stillbirths (intrauterine death at 24 or more weeks).,rephrase,['There were no stillbirths (death within the womb at 24 or more weeks).'],2,0.6153846153846154,4,13
CD012871,3,8,The trial authors did not report on the numbers of babies discharged home healthy (without obvious pathology) or on the risk of neonatal death.,rephrase,"['Data for death of the newborn baby at discharge, or the number of babies discharged home healthy were not available.']",3,0.6923076923076923,4,13
CD012871,4,9,"Currently, there is insufficient evidence to evaluate the effect of combining a tocolytic (indomethacin) and antibiotics (cefazolin/clindamycin) with cervical cerclage compared with cervical cerclage alone for preventing spontaneous PTB in women with singleton pregnancies.",rephrase,['We found insufficient evidence to evaluate the effect of combining a tocolytic (indomethacin) and antibiotics (cefazolin/clindamycin) with inserting a cervical stitch compared with inserting a cervical stitch alone for preventing spontaneous preterm labour in women with singleton pregnancies.'],4,0.7692307692307693,4,13
CD012871,5,10,"Future studies should recruit sufficient numbers of women to provide meaningful results and should measure neonatal death and numbers of babies discharged home healthy, as well as other important outcomes listed in this review.",rephrase,['Future studies should recruit sufficient numbers of women to provide meaningful results and should investigate the risk of death of the baby shortly after birth and the numbers of babies discharged home healthy.'],5,0.8461538461538461,5,13
CD012871,6,11,We did not identify any studies looking at other treatments in combination with cervical cerclage.,rephrase,['We did not identify any studies looking at other treatments in combination with inserting a cervical stitch.'],6,0.9230769230769231,5,13
CD012871,6,12,"Future research needs to focus on the role of other interventions such as vaginal support pessary, reinforcing or second cervical cerclage placement, 17-alpha-hydroxyprogesterone caproate or dydrogesterone or vaginal micronised progesterone, omega-3 long chain polyunsaturated fatty acid supplementation and bed rest.",ignore,"['Additional research needs to focus on the role of other interventions such as a vaginal support pessary (device), reinforcing or second cervical stitch placement, 17-alpha-hydroxyprogesterone caproate, dydrogesterone or vaginal micronised progesterone, omega-3 long chain polyunsaturated fatty acid supplementation and bed rest.']",7,1.0,5,13
CD008075,0,0,We included four randomized trials involving 200 participants.,rephrase,['We included four trials involving 205 participants.'],0,0.07692307692307693,1,13
CD008075,0,1,"Owing to small numbers of studies and participants, it was not possible to combine data for all outcomes.",delete,[],1,0.15384615384615385,1,13
CD008075,0,2,"Two trials reported 28-day mortality, and one trial reported hospital mortality; in the third trial, the number of deaths stated did not match the quoted mortality rates.",rephrase,"['Key results\nOutcome data were limited - two trials reported death rates at 28 days and one reported death rates in hospital; in the fourth study, the number of deaths stated did not match the quoted mortality rates.']",1,0.23076923076923078,2,13
CD008075,0,3,"The pooled risk ratio (95% confidence interval) for 28-day mortality associated with HVHF was 0.89 (0.60 to 1.32, two trials, 146 participants, low-quality evidence).",delete,[],2,0.3076923076923077,2,13
CD008075,0,4,"One study (137 participants, low-quality evidence) reported length of stay in the ICU.",rephrase,"['One study reported length of stay in the ICU, and one provided data on organ dysfunction.']",2,0.38461538461538464,2,13
CD008075,0,5,"Two trials (170 participants, low-quality evidence) reported organ dysfunction, but we could not pool results owing to reporting differences.",delete,[],3,0.46153846153846156,3,13
CD008075,0,6,"Three studies (189 participants, low-quality evidence) reported on haemodynamic changes, but we could not pool results owing to reporting differences.",delete,[],3,0.5384615384615384,3,13
CD008075,0,7,Investigators reported no adverse events.,rephrase,['Investigators described no complications.'],3,0.6153846153846154,4,13
CD008075,0,8,"Overall, the included studies had low risk of bias.",delete,[],4,0.6923076923076923,4,13
CD008075,1,9,Investigators reported no adverse effects of HVHF (low-quality evidence).,rephrase,"['Studies included in this review reported relatively small numbers of participants and measured different outcomes; therefore, we judged the quality of evidence with respect to the impact of HVHF as low.']",4,0.7692307692307693,4,13
CD008075,1,10,"The results of this meta-analysis show that very few studies have been conducted to investigate the use of HVHF in critically ill patients with severe sepsis or septic shock (four studies, 201 participants, low-quality evidence).",rephrase,['No clear evidence showed any benefit of HVHF in critically ill patients with severe sepsis or septic shock.'],5,0.8461538461538461,5,13
CD008075,1,11,Researchers should consider additional randomized controlled trials that are large and multi-centred and have clinically relevant outcome measures.,rephrase,"['Larger trials, carried out at many centres, are required for full assessment of clinically relevant outcomes and for evaluation of cost versus benefit.']",6,0.9230769230769231,5,13
CD008075,1,12,The cost-effectiveness of HVHF should also be studied..,delete,[],7,1.0,5,13
CD007110,0,0,Our search led to 5518 potentially relevant references.,delete,[],0,0.045454545454545456,1,22
CD007110,0,1,"From these, we included seven RCTs in the analyses involving 2564 patients.",rephrase,['This led to the inclusion of seven randomised controlled trials involving with 2564 patients.'],0,0.09090909090909091,1,22
CD007110,0,2,"In contrast to the first version of this review including five trials, we excluded trials randomising children.",delete,[],1,0.13636363636363635,1,22
CD007110,0,3,"As a result, we excluded one trial from the former analyses and we identified three new trials.",delete,[],1,0.18181818181818182,1,22
CD007110,1,4,"Five trials with 1388 patients compared the combination of chemotherapy alone and chemotherapy plus radiotherapy, with the same number of chemotherapy cycles in both arms.",delete,[],1,0.22727272727272727,2,22
CD007110,1,5,"The addition of radiotherapy to chemotherapy has probably little or no difference on OS (HR 0.48; 95% confidence interval (CI) 0.22 to 1.06; P = 0.07, moderate- quality evidence), however two included trials had potential other high risk of bias due to a high number of patients not receiving planned radiotherapy.",delete,[],1,0.2727272727272727,2,22
CD007110,1,6,"After excluding these trials in a sensitivity analysis, the results showed that the combination of chemotherapy and radiotherapy improved OS compared to chemotherapy alone (HR 0.31; 95% CI 0.19 to 0.52; P <0.00001, moderate- quality evidence).",delete,[],1,0.3181818181818182,2,22
CD007110,1,7,In contrast to chemotherapy alone the use of chemotherapy and radiotherapy improved PFS (HR 0.42; 95% CI 0.25 to 0.72; P = 0.001; moderate- quality evidence).,delete,[],1,0.36363636363636365,2,22
CD007110,1,8,"Regarding infection- related mortality (RR 0.33; 95% CI 0.01 to 8.06; P = 0.5; low- quality evidence), second cancer- related mortality (RR 0.53; 95% CI 0.07 to 4.29; P = 0.55; low- quality evidence) and cardiac disease- related mortality (RR 2.94; 95% CI 0.31 to 27.55; P = 0.35;low- quality evidence), there is no evidence for a difference between the use of chemotherapy alone and chemotherapy plus radiotherapy.",rephrase,"['For infection- related mortality, second cancer- related mortality and cardiac disease- related mortality, there was no evidence for a difference between treatment groups.']",1,0.4090909090909091,3,22
CD007110,1,9,"For complete response rate (CRR) (RR 1.08; 95% CI 0.93 to 1.25; P = 0.33; low- quality evidence), there is also no evidence for a difference between treatment groups.",rephrase,['For complete response rate (CRR) there was no evidence for a difference between treatment groups either.'],2,0.45454545454545453,3,22
CD007110,2,10,"Two trials with 1176 patients compared the combination of chemotherapy alone and chemotherapy plus radiotherapy, with different numbers of chemotherapy cycles in both arms.",rephrase,"['For the comparison of chemotherapy alone and chemotherapy plus radiotherapy with different numbers of chemotherapy cycles in the arms, OS was reported in one trial only.']",3,0.5,3,22
CD007110,2,11,"OS is reported in one trial only, the use of chemotherapy alone (more chemotherapy cycles) may improve OS compared to chemotherapy plus radiotherapy (HR 2.12; 95% CI 1.03 to 4.37; P = 0.04; low- quality evidence).",rephrase,['The use of chemotherapy alone may improve OS compared to chemotherapy plus radiotherapy.'],4,0.5454545454545454,3,22
CD007110,2,12,This trial also had a potential other high risk of bias due to a high number of patients not receiving planned therapy.,delete,[],5,0.5909090909090909,3,22
CD007110,2,13,There is no evidence for a difference between chemotherapy alone and chemotherapy plus radiotherapy regarding PFS (HR 0.42; 95% CI 0.14 to 1.24; P = 0.12; low- quality evidence).,rephrase,['There was no evidence for a difference between treatment groups regarding PFS.'],5,0.6363636363636364,4,22
CD007110,2,14,"After excluding the trial with patients not receiving the planned therapy in a sensitivity analysis, the results showed that the combination of chemotherapy and radiotherapy improved PFS compared to chemotherapy alone (HR 0.24; 95% CI 0.070 to 0.88; P = 0.03, based on one trial).",rephrase,['After excluding one trial with patients not receiving the planned therapy the results showed that chemotherapy plus radiotherapy improved PFS.'],6,0.6818181818181818,4,22
CD007110,2,15,"For infection- related mortality (RR 6.90; 95% CI 0.36 to 132.34; P = 0.2; low- quality evidence), second cancer- related mortality (RR 2.22; 95% CI 0.7 to 7.03; P = 0.18; low- quality evidence) and cardiac disease-related mortality (RR 0.99; 95% CI 0.14 to 6.90; P = 0.99; low-quality evidence), there is no evidence for a difference between the use of chemotherapy alone and chemotherapy plus radiotherapy.",rephrase,"['For infection- related mortality, second cancer- related mortality and cardiac disease- related mortality, there is no evidence for a difference between treatment groups.']",7,0.7272727272727273,4,22
CD007110,2,16,CRR rate was not reported.,rephrase,['CR was not reported.'],8,0.7727272727272727,4,22
CD007110,3,17,This systematic review compared the effects of chemotherapy alone and chemotherapy plus radiotherapy in adults with early stage HL .,ignore,['This systematic review compared the effects of chemotherapy alone and chemotherapy plus radiotherapy in adults with early stage HL .'],9,0.8181818181818182,5,22
CD007110,4,18,"For the comparison with same numbers of chemotherapy cycles in both arms, we found moderate- quality evidence that PFS is superior in patients receiving chemotherapy plus radiotherapy than in those receiving chemotherapy alone.",ignore,['For the comparison with same numbers of chemotherapy cycles in both arms we found moderate- quality evidence that PFS is superior in patients receiving chemotherapy plus radiotherapy than in those receiving chemotherapy alone.'],10,0.8636363636363636,5,22
CD007110,4,19,The addition of radiotherapy to chemotherapy has probably little or no difference on OS .,ignore,['The addition of radiotherapy to chemotherapy has probably little or no difference on OS.'],11,0.9090909090909091,5,22
CD007110,4,20,The sensitivity analysis without the trials with potential other high risk of bias showed that chemotherapy plus radiotherapy improves OS compared to chemotherapy alone.,rephrase,['A further analysis without the trials with potential other high risk of bias showed that chemotherapy plus radiotherapy improves OS (both analyses moderate- quality evidence).'],12,0.9545454545454546,5,22
CD007110,5,21,"For the comparison with different numbers of chemotherapy cycles between the arms there are no implications for OS and PFS possible, because of the low quality of evidence of the results.",rephrase,"['For the comparison of chemotherapy alone and chemotherapy plus radiotherapy with different numbers of chemotherapy cycles between the arms there were no implications for OS and PFS possible, because of the low quality of evidence of the results.']",13,1.0,5,22
CD007679,0,0,This review included three RCTs with a total of 228 eyes.,rephrase,['This review included three randomised controlled trials with a total of 228 eyes.'],0,0.09090909090909091,1,11
CD007679,0,1,The range of myopia of included patients was -6.0 D to -20.0 D of myopia with up to 4.0 D of myopic astigmatism.,ignore,['The range of myopia of included patients was -6.0 D to -20.0 D with up to 4.0 D of myopic astigmatism.'],1,0.18181818181818182,1,11
CD007679,0,2,The percentage of eyes with uncorrected visual acuity (UCVA) of 20/20 or better at 12 months postoperative was not significantly different between the two groups.,rephrase,['The results of this review showed that the chance of the uncorrected visual acuity being 20/20 or better was not different between the two groups.'],2,0.2727272727272727,2,11
CD007679,0,3,Phakic IOL surgery was safer than excimer laser surgical correction for moderate to high myopia as it results in significantly less loss of best spectacle corrected visual acuity (BSCVA) at 12 months postoperatively.,ignore,['Phakic IOL surgery was safer than excimer laser surgical correction for moderate to high myopia as it results in significantly less loss of best spectacle corrected visual acuity (BSCVA) at 12 months postoperatively.'],3,0.36363636363636365,2,11
CD007679,0,4,However there is a low risk of developing early cataract with phakic IOLs.,delete,[],4,0.45454545454545453,3,11
CD007679,0,5,Phakic IOL surgery appears to result in better contrast sensitivity than excimer laser correction for moderate to high myopia.,ignore,['Phakic IOL surgery appears to result in better contrast sensitivity than excimer laser correction for moderate to high myopia.'],4,0.5454545454545454,3,11
CD007679,0,6,Phakic IOL surgery also scored more highly on patient satisfaction/preference questionnaires.,ignore,['Phakic IOL surgery also scored more highly on patient satisfaction/preference questionnaires.'],5,0.6363636363636364,4,11
CD007679,1,7,"The results of this review suggest that, at one year post surgery, phakic IOLs are safer than excimer laser surgical correction for moderate to high myopia in the range of -6.0 to -20.0 D and phakic IOLs are preferred by patients.",rephrase,['This review showed that phakic IOLs for the treatment of high myopia were safer and preferred by patients when compared with excimer laser.'],6,0.7272727272727273,4,11
CD007679,1,8,"While phakic IOLs might be accepted clinical practice for higher levels of myopia (greater than or equal to 7.0 D of myopic spherical equivalent with or without astigmatism), it may be worth considering phakic IOL treatment over excimer laser correction for more moderate levels of myopia (less than or equal to 7.0 D of myopic spherical equivalent with or without astigmatism).",delete,[],7,0.8181818181818182,5,11
CD007679,1,9,Further RCTs adequately powered for subgroup analysis are necessary to further elucidate the ideal range of myopia for phakic IOLs.,delete,[],7,0.9090909090909091,5,11
CD007679,1,10,This data should be considered alongside comparative data addressing long-term safety as it emerges.,delete,[],7,1.0,5,11
CD013461,0,0,"We included two studies, contributing data from 181 participants to the analyses.",rephrase,"['After screening records, we included two studies in this review and 181 participants contributed data to the analyses.']",0,0.07692307692307693,1,13
CD013461,1,1,Both studies recruited participants from US hospital clinics; one included people who were recovering from a stroke and the other women with breast cancer.,split,"['Both studies recruited participants from US hospitals.', 'One study included participants recovering from a stroke and the other included women with breast cancer.']",1,0.15384615384615385,1,13
CD013461,1,2,"For both studies, the intervention consisted of eight weeks of face-to-face behavioural therapy, with one study comparing to poststroke treatment as usual and the other comparing to problem-solving therapy.",split,"['In both studies, participants received behavioural activation delivered in eight weekly, face-to-face sessions.', 'One study compared behavioural activation with poststroke treatment as usual, while the other compared behavioural activation with problem-solving therapy, a talking therapy.']",3,0.23076923076923078,2,13
CD013461,2,3,Both studies were at risk of performance bias and potential conflict of interest arising from author involvement in the development of the intervention.,rephrase,"['Also, researchers were involved in the design of the intervention in both studies, and may, therefore, have had an interest in a favourable outcome for behavioural activation.']",5,0.3076923076923077,2,13
CD013461,2,4,"For one study, risks of selection bias and reporting bias were unclear and the study was judged at high risk of attrition bias.",delete,[],6,0.38461538461538464,2,13
CD013461,3,5,"Treatment efficacy (remission) was greater for behavioural activation than for comparators in the short term (risk ratio (RR) 1.53, 95% confidence interval (CI) 0.98 to 2.38; low-certainty evidence) and medium term (RR 1.76, 95% CI 1.01 to 3.08; moderate-certainty evidence), but these estimates lacked precision and effects were reduced in the long term (RR 1.42, 95% CI 0.91 to 2.23; moderate-certainty evidence).",rephrase,"['Low to moderate-certainty evidence suggested that behavioural activation may be more effective in the treatment of depression than included comparators, but these estimates were imprecise and effects were reduced in the longer term.']",6,0.46153846153846156,3,13
CD013461,3,6,"We found no evidence of a difference in treatment acceptability in the short term (RR 1.81, 95% CI 0.68 to 4.82) and medium term (RR 0.88, 95% CI 0.25 to 3.10) (low-certainty evidence).",delete,[],7,0.5384615384615384,3,13
CD013461,4,7,"There was no evidence of a difference in depression symptoms between behavioural activation and comparators (short term: MD –1.15, 95% CI –2.71 to 0.41; low-certainty evidence).",merge,"['There was no evidence of any differences between groups in the number of people who dropped out of the studies, depression symptoms, quality of life, physical functioning, or anxiety symptoms.']",7,0.6153846153846154,4,13
CD013461,4,8,"One study found no difference for quality of life (short term: MD 0.40, 95% CI –0.16 to 0.96; low-certainty evidence), functioning (short term: MD 2.70, 95% CI –6.99 to 12.39; low-certainty evidence), and anxiety symptoms (short term: MD –1.70, 95% CI –4.50 to 1.10; low-certainty evidence).",none,[],7,0.6923076923076923,4,13
CD013461,5,9,Neither study reported data on adverse effects.,rephrase,['The studies did not report on side effects during the study period.'],8,0.7692307692307693,4,13
CD013461,6,10,Evidence from this review was not sufficient to draw conclusions on the efficacy and acceptability of behavioural activation for the treatment of depression in adults with NCDs.,merge,['We did not find enough evidence in this review to know whether behavioural activation should be used to treat depression in adults with long-term physical conditions.'],9,0.8461538461538461,5,13
CD013461,6,11,"A future review may wish to include, or focus on, studies of people with subthreshold depression or depression symptoms without a formal diagnosis, as this may inform whether behavioural activation could be used to treat mild or undiagnosed (or both) depressive symptoms in people with NCDs.",merge,[],9,0.9230769230769231,5,13
CD013461,6,12,"Evidence from low-resource settings including low- and middle-income countries, for which behavioural activation may offer a feasible alternative to other treatments for depression, would be of interest.",none,[],9,1.0,5,13
CD013836,0,0,We included five RCTs (580 participants).,rephrase,['We included five trials randomising 580 participants.'],0,0.1,1,10
CD013836,0,1,"All trials were at high risk of bias, and had very low-certainty evidence.",rephrase,['The five trials were at high risk of bias (i.e. the trials were conducted in a way that may have skewed results to the positive side).'],1,0.2,1,10
CD013836,1,2,The five included trials assessed five different comparisons of antibiotics.,rephrase,['The five trials compared five different antibiotic regimens.'],2,0.3,2,10
CD013836,2,3,We did not conduct a meta-analysis due to lack of relevant data.,delete,[],3,0.4,2,10
CD013836,3,4,Of the five included trials one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacillin plus amikacin with cefotaxime plus gentamicin; one trial compared meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin); and one trial compared vancomycin plus gentamicin with vancomycin plus aztreonam.,ignore,['We included five trials:\xa0one trial compared cefazolin plus amikacin with vancomycin plus amikacin; one trial compared ticarcillin plus clavulanic acid with flucloxacillin plus gentamicin; one trial compared cloxacillin plus amikacin with cefotaxime plus gentamicin; one trial compared meropenem with standard care (ampicillin plus gentamicin or cefotaxime plus gentamicin); and one trial compared vancomycin plus gentamicin with vancomycin plus aztreonam.'],3,0.5,3,10
CD013836,4,5,"None of the five comparisons found any evidence of a difference when assessing all-cause mortality, serious adverse events, circulatory support, nephrotoxicity, neurological developmental impairment, or necrotising enterocolitis; however, none of the trials were near an information size that could contribute significantly to the evidence of the comparative benefits and risks of any particular antibiotic regimen.",rephrase,"[""None of the five antibiotic comparisons showed that the choice of antibiotics influenced the effects on death from all-causes, serious adverse events (i.e. major complications), circulatory support, nephrotoxicity (toxicity in the kidneys), neurological developmental impairment (disabilities in the functioning of the brain that affect a child's behaviour, memory, or ability to learn), or necrotising enterocolitis (tissues in the gut become inflamed and start to die).""]",4,0.6,3,10
CD013836,5,6,None of the trials assessed respiratory support or ototoxicity.,delete,[],5,0.7,4,10
CD013836,6,7,The benefits and harms of different antibiotic regimens remain unclear due to the lack of well-powered trials and the high risk of systematic errors.,delete,[],5,0.8,4,10
CD013836,7,8,Current evidence is insufficient to support any antibiotic regimen being superior to another.,rephrase,"['Current evidence cannot confirm or reject, one antibiotic regimen being superior to another due to scarce data.']",5,0.9,5,10
CD013836,7,9,RCTs assessing different antibiotic regimens in late-onset neonatal sepsis with low risks of bias are warranted.,delete,[],6,1.0,5,10
CD005500,0,0,We included 31 trials (8019 participants) in the analysis.,rephrase,['This review included data from 31 clinical trials involving 8019 participants.'],0,0.1111111111111111,1,9
CD005500,0,1,"In short-term (≤ 6 weeks) trials, pimecrolimus cream was significantly more effective and well-tolerated than vehicle (cream base, but not containing pimecrolimus).",rephrase,"['In the short-term (less than six weeks) treatment of eczema, we found pimecrolimus was more effective and well-tolerated when compared against vehicle (cream base not containing any pimecrolimus).']",1,0.2222222222222222,2,9
CD005500,0,2,"In long-term trials (≥ 6 months), pimecrolimus was significantly better than vehicle in preventing flares (9 trials, 3091 participants, RR 1.47, 95% CI 1.32 to 1.64 at six months) and in improving quality of life.",rephrase,"['Likewise, pimecrolimus was better than vehicle cream in preventing deterioration in eczema based on data from 9 trials involving 3091 participants.']",2,0.3333333333333333,2,9
CD005500,1,3,"Pimecrolimus was significantly less effective than two topical corticosteroids, i.e. 0.1% triamcinolone acetonide for investigators' global assessment (1 trial, 658 participants, RR 0.75, 95% CI 0.67 to 0.83) and 0.1% betamethasone valerate for participants' global assessment (1 trial, 87 participants, RR 0.61, 95% CI 0.45 to 0.81) at three weeks.",rephrase,"['However, we found that 3 weeks treatment with pimecrolimus was less effective than a moderate (triamcinolone acetonide, data from 1 trial with 658 participants) and a potent topical corticosteroid (betamethasone valerate, data from 1 trial with 87 participants).']",3,0.4444444444444444,3,9
CD005500,1,4,Pimecrolimus was also associated with significantly more overall withdrawals and skin burning.,split,"['Pimecrolimus caused a similar rate of adverse events to vehicle cream but had a lower overall dropout rate.', 'In contrast, pimecrolimus had higher dropout rates and caused more skin burning than topical corticosteroids.', 'Pimecrolimus caused a similar rate of adverse events to tacrolimus.']",4,0.5555555555555556,3,9
CD005500,1,5,None of the trials reported on key adverse effects such as thinning of skin.,ignore,"['None of the trials reported on key adverse effects, such as thinning of skin.']",7,0.6666666666666666,4,9
CD005500,2,6,"Pimecrolimus was significantly less effective than 0.1% tacrolimus for investigators' global assessment at 6 weeks (RR 0.58, 95% CI 0.46 to 0.74) and led to more withdrawals due to lack of efficacy (RR 2.37, 95% CI 1.10 to 5.08) based on 2 trials involving 639 participants, but there was no significant difference in proportions of participants experiencing any adverse events.",rephrase,"['Furthermore, 6-weeks treatment with pimecrolimus was less effective and caused more participants to drop out of treatment due to lack of efficacy than tacrolimus based on 2 trials involving 639 participants.']",8,0.7777777777777778,4,9
CD005500,3,7,Topical pimecrolimus is less effective than moderate and potent corticosteroids and 0.1% tacrolimus.,rephrase,['This review did not find evidence to support the notion that pimecrolimus was better than moderate or potent corticosteroids or tacrolimus in treating eczema.'],9,0.8888888888888888,5,9
CD005500,3,8,The therapeutic role of topical pimecrolimus is uncertain due to the absence of key comparisons with mild corticosteroids.,rephrase,"['However, there is a distinct lack of trials comparing pimecrolimus against mild-potency corticosteroids.']",10,1.0,5,9
CD007170,0,0,"Ten prospective, parallel-group design, randomised controlled trials, involving a total of 577 participants with type 1 and type 2 diabetes mellitus, were identified.",rephrase,"['The authors identified 10 randomised controlled trials, which involved 577 participants with diabetes mellitus.']",0,0.08333333333333333,1,12
CD007170,0,1,"Risk of bias was high or unclear in all but two trials, which were assessed as having moderate risk of bias.",delete,[],1,0.16666666666666666,1,12
CD007170,0,2,Risk of bias in some domains was high in 50% of trials.,delete,[],1,0.25,2,12
CD007170,0,3,"Oral monopreparations of cinnamon (predominantly Cinnamomum cassia) were administered at a mean dose of 2 g daily, for a period ranging from 4 to 16 weeks.",rephrase,"['Cinnamon was administered in tablet or capsule form, at a mean dose of 2 g daily, for four to 16 weeks.']",1,0.3333333333333333,2,12
CD007170,0,4,The effect of cinnamon on fasting blood glucose level was inconclusive.,split,"['Cinnamon bark has been shown in a number of animal studies to improve blood sugar levels, though its effect in humans is not too clear.', 'Hence, the review authors set out to determine the effect of oral cinnamon extract on blood sugar and other outcomes.']",2,0.4166666666666667,3,12
CD007170,0,5,"No statistically significant difference in glycosylated haemoglobin A1c (HbA1c), serum insulin or postprandial glucose was found between cinnamon and control groups.",rephrase,"['The review authors found cinnamon to be no more effective than placebo, another active medication or no treatment in reducing glucose levels and glycosylated haemoglobin A1c (HbA1c), a long-term measurement of glucose control.']",4,0.5,3,12
CD007170,0,6,There were insufficient data to pool results for insulin sensitivity.,delete,[],5,0.5833333333333334,3,12
CD007170,0,7,"No trials reported health-related quality of life, morbidity, mortality or costs.",rephrase,"['None of the trials looked at health-related quality of life, morbidity, death from any cause or costs.']",5,0.6666666666666666,4,12
CD007170,0,8,Adverse reactions to oral cinnamon were infrequent and generally mild in nature.,rephrase,['Adverse reactions to cinnamon treatment were generally mild and infrequent.'],6,0.75,4,12
CD007170,1,9,There is insufficient evidence to support the use of cinnamon for type 1 or type 2 diabetes mellitus.,merge,['Further trials investigating long-term benefits and risks of the use of cinnamon for diabetes mellitus are required.'],7,0.8333333333333334,5,12
CD007170,1,10,"Further trials, which address the issues of allocation concealment and blinding, are now required.",none,[],7,0.9166666666666666,5,12
CD007170,1,11,"The inclusion of other important endpoints, such as health-related quality of life, diabetes complications and costs, is also needed.",rephrase,"['Rigorous study design, quality reporting of study methods, and consideration of important outcomes such as health-related quality of life and diabetes complications, are key areas in need of attention.']",8,1.0,5,12
CD009285,0,0,"This review included 22 studies of good methodological quality that had enrolled 23,309 participants with COPD.",rephrase,"['We found 22 studies including 23,309 participants, comparing the long-term effectiveness and side effects of tiotropium and placebo.']",0,0.058823529411764705,1,17
CD009285,0,1,"The studies used similar designs, however, the duration varied from three months to four years.",delete,[],1,0.11764705882352941,1,17
CD009285,0,2,"In 19 of the studies, 18 mcg tiotropium once daily via the Handihaler dry powder inhaler was evaluated, and in three studies, 5 or 10 mcg tiotropium once daily via the Respimat soft mist inhaler was evaluated.",delete,[],1,0.17647058823529413,1,17
CD009285,0,3,"Compared to placebo, tiotropium treatment significantly improved the mean quality of life (mean difference (MD) -2.89; 95% confidence interval (CI) -3.35 to -2.44), increased the number of participants with a clinically significant improvement (odds ratio (OR) 1.52; 95% CI 1.38 to 1.68), and reduced the number of participants with a clinically significant deterioration (OR 0.65; 95% CI 0.59 to 0.72) in quality of life (measured by the St George's Respiratory Questionnaire (SGRQ)).",rephrase,"['Compared with placebo, tiotropium treatment led to an improvement in quality of life, fewer people had an exacerbation (worsening of COPD symptoms), or exacerbations leading to hospital admissions.']",1,0.23529411764705882,2,17
CD009285,0,4,Tiotropium treatment significantly reduced the number of participants suffering from exacerbations (OR 0.78; 95% CI 0.70 to 0.87).,delete,[],2,0.29411764705882354,2,17
CD009285,0,5,"This corresponds to a need to treat 16 patients (95% CI 10 to 36) with tiotropium for a year in order to avoid one additional patient suffering exacerbations, based on the average placebo event rate of 44% from one-year studies.",rephrase,"['The number of people that needed to be treated for a year, for one person to avoid one additional exacerbation was 16 (95% confidence interval (CI) 10 to 36).']",2,0.35294117647058826,2,17
CD009285,0,6,"Tiotropium treatment led to fewer hospitalisations due to exacerbations (OR 0.85; 95% CI 0.72 to 1.00), but there was no statistically significant difference in all-cause hospitalisations (OR 1.00; 95% CI 0.88 to 1.13) or non-fatal serious adverse events (OR 1.03; 95% CI 0.97 to 1.10).",delete,[],3,0.4117647058823529,3,17
CD009285,0,7,"Additionally, there was no statistically significant difference in all-cause mortality between the tiotropium and placebo groups (Peto OR 0.98; 95% CI 0.86 to 1.11).",rephrase,"['We found no statistically significant difference between the tiotropium and placebo groups in terms of the number of hospital admissions for any cause, serious adverse events or deaths during the studies.']",3,0.47058823529411764,3,17
CD009285,0,8,"However, subgroup analysis found a significant difference between the studies using a dry powder inhaler and those with a soft mist inhaler (test for subgroup differences: P = 0.01).",rephrase,"['However, when we divided the data depending on whether a dry powder inhaler or a soft mist inhaler was used in the studies, these two subgroups were significantly different.']",4,0.5294117647058824,3,17
CD009285,0,9,"With the dry powder inhaler there were fewer deaths in the tiotropium group (Peto OR 0.92; 95% CI 0.80 to 1.05) than in the placebo group (yearly rate 2.8%), but with the soft mist inhaler there were significantly more deaths in the tiotropium group (Peto OR 1.47; 95% CI 1.04 to 2.08) than in the placebo group (yearly rate 1.8%).",rephrase,"['With the dry powder inhaler there were fewer deaths in the tiotropium group than in the placebo group, whereas with the soft mist inhaler there were significantly more deaths in the tiotropium group than in the placebo group.']",5,0.5882352941176471,3,17
CD009285,0,10,"It is noted that the rates of patients discontinuing study treatment were uneven, with significantly fewer participants withdrawing from tiotropium treatment than from placebo treatment (OR 0.66; 95% CI 0.59 to 0.73).",delete,[],6,0.6470588235294118,4,17
CD009285,0,11,Participants on tiotropium had improved lung function at the end of the study compared with those on placebo (trough forced expiratory volume in one second (FEV1) MD 118.92 mL; 95% CI 113.07 to 124.77).,delete,[],6,0.7058823529411765,4,17
CD009285,1,12,"This review shows that tiotropium treatment was associated with a significant improvement in patients' quality of life and it reduced the risk of exacerbations, with a number needed to treat to benefit (NNTB) of 16 to prevent one exacerbation.",rephrase,"[""This review shows that treatment with tiotropium improves patients' quality of life, and reduces the risk of exacerbations, including exacerbations leading to hospitalisation.""]",6,0.7647058823529411,4,17
CD009285,1,13,Tiotropium also reduced exacerbations leading to hospitalisation but no significant difference was found for hospitalisation of any cause or mortality.,rephrase,['But tiotropium does not reduce hospitalisations for all causes or the number of deaths.'],7,0.8235294117647058,5,17
CD009285,1,14,"Thus, tiotropium appears to be a reasonable choice for the management of patients with stable COPD, as proposed in guidelines.",merge,"['Based on the evidence in this review, tiotropium appears to be a reasonable treatment choice for patients with stable COPD.']",8,0.8823529411764706,5,17
CD009285,1,15,The trials included in this review showed a difference in the risk of mortality when compared with placebo depending on the type of tiotropium delivery device used.,none,[],8,0.9411764705882353,5,17
CD009285,1,16,"However, these results have not been confirmed in a recent trial when 2.5 mcg or 5 mcg of tiotropium via Respimat was used in a direct comparison to the 18 mcg Handihaler.",delete,[],9,1.0,5,17
CD004634,0,0,We included 15 studies with a total of 1643 women.,rephrase,['We included 15 studies that randomly assigned a total of 1643 women to follicular aspiration alone or follicular flushing after aspiration.'],0,0.07142857142857142,1,14
CD004634,0,1,"Fourteen studies reported outcomes per woman randomised, and one study reported outcomes per ovary.",delete,[],1,0.14285714285714285,1,14
CD004634,0,2,No studies were at low risk of bias across all domains; the main limitation was lack of blinding.,rephrase,"['The main limitations of included studies were lack of blinding (the process of preventing women participating in the trial and research staff from being aware of the intervention used), inconsistency (differences across studies), and imprecision (insufficient data).']",1,0.21428571428571427,2,14
CD004634,0,3,"The certainty of the evidence ranged from moderate to very low, and was downgraded for risk of bias, imprecision, and inconsistency.",split,"['The certainty of evidence for the main outcome of live birth rate was moderate.', 'The certainty of evidence for the other outcomes ranged from very low to low.']",2,0.2857142857142857,2,14
CD004634,1,4,"We are uncertain of the effect of follicular flushing on live birth rate compared to aspiration alone (OR 0.93, 95% CI 0.59 to 1.46; 4 RCTs; n = 467; I2 = 0%; moderate-certainty evidence).",rephrase,['It is uncertain whether follicular flushing has an impact on live birth rate compared with aspiration alone.'],4,0.35714285714285715,2,14
CD004634,1,5,"This suggests that with a live birth rate of approximately 30% with aspiration alone, the equivalent live birth rate with follicular flushing lies between 20% and 39%.",ignore,"['This suggests that if a live birth rate of approximately 30% is seen with aspiration alone, the equivalent live birth rate with follicular flushing lies between 20% and 39%.']",5,0.42857142857142855,3,14
CD004634,1,6,"We are uncertain of the effect of follicular flushing on miscarriage rate compared to aspiration alone (OR 1.98, 95% CI 0.18 to 22.22; 1 RCT; n = 164; low-certainty evidence).",rephrase,"['One study reported on miscarriage rate, although the certainty of the evidence was low, preventing us from drawing any conclusions with confidence.']",6,0.5,3,14
CD004634,1,7,"This suggests that with a miscarriage rate of approximately 1% with aspiration alone, the equivalent miscarriage rate with follicular flushing lies between 0% and 22%.",rephrase,"['Nevertheless, the data suggest that if the miscarriage rate is approximately 1% with aspiration alone, the equivalent rate with follicular flushing lies between 0% and 22%.']",7,0.5714285714285714,3,14
CD004634,2,8,"We are uncertain of the effect of follicular flushing on oocyte yield (MD −0.47 oocytes, 95% CI −0.72 to −0.22; 9 RCTs; n = 1239; I2 = 61%; very low-certainty evidence); total number of embryos (MD −0.10 embryos, 95% CI −0.34 to 0.15; 2 RCTs; n = 160; I2 = 58%; low-certainty evidence); and clinical pregnancy rate (OR 1.12, 95% CI 0.85 to 1.51; 7 RCTs; n = 939; I2 = 46%; low-certainty evidence).",delete,[],8,0.6428571428571429,4,14
CD004634,2,9,"The duration of the retrieval process may be longer with flushing (MD 175.44 seconds, 95% CI 152.57 to 198.30; 7 RCTs; n = 785; I2 = 87%; low-certainty evidence).",delete,[],8,0.7142857142857143,4,14
CD004634,2,10,"It was not possible to perform a meta-analysis for adverse events, although individual studies reported on outcomes ranging from depression and anxiety to pain and pelvic organ injury.",delete,[],8,0.7857142857142857,4,14
CD004634,3,11,The effect of follicular flushing on both live birth and miscarriage rates compared with aspiration alone is uncertain.,rephrase,"['We are also uncertain of the impact of follicular flushing on the number of eggs retrieved, the number of embryos, or the clinical pregnancy rate compared to aspiration alone.']",8,0.8571428571428571,5,14
CD004634,3,12,"Although the evidence does not permit any firm conclusions on the impact of follicular flushing on oocyte yield, total number of embryos, number of cryopreserved embryos, or clinical pregnancy rate, it may be that the procedure itself takes longer than aspiration alone.",rephrase,"['Although the certainty of evidence was low, it appears that follicular flushing takes longer to perform than aspiration alone.']",9,0.9285714285714286,5,14
CD004634,3,13,The evidence was insufficient to permit any firm conclusions with respect to adverse events or safety.,ignore,['The available evidence was insufficient to permit any firm conclusions with respect to adverse events or safety.'],10,1.0,5,14
CD009682,0,0,We only found one study eligible for this review (22 participants).,rephrase,"['We found one study comparing pregabalin versus placebo, involving 22 randomised participants with essential tremor.']",0,0.16666666666666666,1,6
CD009682,0,1,We assessed the risk of bias for most domains as unclear.,delete,[],1,0.3333333333333333,2,6
CD009682,0,2,We graded the overall quality of evidence as very low.,delete,[],1,0.5,3,6
CD009682,0,3,"Compared to placebo, patients treated with pregabalin showed no significant improvement of motor tasks on the 36-point subscale of the Fahn-Tolosa-Marin Tremor Rating Scale (TRS) (MD −2.15 points; 95% CI −9.16 to 4.86) or on the 32-point functional abilities subscale of the TRS (MD −0.66 points; 95% CI −2.90 to 1.58).The limited evidence showed no difference in study withdrawal (Mantel-Haenszel RD −0.09; 95% CI −0.48 to 0.30) and presentation of adverse events between pregabalin and placebo (Mantel-Haenszel RD 0.18; 95% CI −0.13 to 0.50).",delete,[],1,0.6666666666666666,4,6
CD009682,1,4,The effects of pregabalin for treating essential tremor are uncertain because the quality of the evidence is very low.,rephrase,['The impact of pregabalin on functional abilities and adverse effects is uncertain because the quality of the evidence is very low.'],1,0.8333333333333334,5,6
CD009682,1,5,"One small study did not highlight any effect of this treatment; however, the high risk of bias and the lack of other studies on this topic limit further conclusion.",rephrase,['The lack of studies and the significant limitations in the one included trial preclude firm conclusions about the risk-benefit profile of this treatment.'],2,1.0,5,6
CD015391,0,0,We identified two completed studies with a total of 1649 symptomatic participants.,delete,[],0,0.07692307692307693,1,13
CD015391,0,1,"One study was conducted in the USA (study with 152 participants, 80 and 72 participants per study arm) and the other study in Brazil (study with 1497 high-risk participants for progression to severe disease, 741 and 756 participants per study arm) among outpatients with mild COVID-19.",delete,[],0,0.15384615384615385,1,13
CD015391,0,2,"Both studies were double-blind, placebo-controlled trials in which participants were prescribed 100 mg fluvoxamine two or three times daily for a maximum of 15 days.",delete,[],0,0.23076923076923078,2,13
CD015391,1,3,"We identified five ongoing studies and two studies awaiting classification (due to translation issues, and due to missing published data).",rephrase,['We found five ongoing studies and two studies that are awaiting classification.'],0,0.3076923076923077,2,13
CD015391,1,4,We found no published studies comparing fluvoxamine to other pharmacological interventions of proven efficacy.,rephrase,['All studies compared fluvoxamine to placebo together with standard care.'],1,0.38461538461538464,2,13
CD015391,2,5,We assessed both included studies to have an overall high risk of bias.,rephrase,"['We compared and summarised the results of the studies and rated our confidence in the evidence, based on common criteria such as study methods and study sizes.']",2,0.46153846153846156,3,13
CD015391,3,6,"Fluvoxamine for the treatment of COVID-19 in inpatients
We did not identify any completed studies of inpatients.",rephrase,['We did not find any studies that investigated the effect of fluvoxamine on people in hospital with COVID-19.'],3,0.5384615384615384,3,13
CD015391,4,7,"Fluvoxamine for the treatment of COVID-19 in outpatients
Fluvoxamine in addition to standard care may slightly reduce all-cause mortality at day 28 (RR 0.69, 95% CI 0.38 to 1.27; risk difference (RD) 9 per 1000; 2 studies, 1649 participants; low-certainty evidence), and may reduce clinical deterioration defined as all-cause hospital admission or death before hospital admission (RR 0.55, 95% CI 0.16 to 1.89; RD 57 per 1000; 2 studies, 1649 participants; low-certainty evidence).",rephrase,"['• Compared to placebo, fluvoxamine may slightly reduce the number of people who die in the 28 days after starting treatment (2 studies, 1649 people).']",4,0.6153846153846154,4,13
CD015391,4,8,"We are very uncertain regarding the effect of fluvoxamine on serious adverse events (RR 0.56, 95% CI 0.15 to 2.03; RD 54 per 1000; 2 studies, 1649 participants; very low-certainty evidence) or adverse events of any grade (RR 1.06, 95% CI 0.82 to 1.37; RD 7 per 1000; 2 studies, 1649 participants; very low-certainty evidence).",delete,[],5,0.6923076923076923,4,13
CD015391,5,9,"Neither of the studies reported on symptom resolution (clinical improvement), quality of life or suicide/suicide attempt.",rephrase,"['•Neither of the studies reported on quality of life, the time needed until all initial symptoms resolved, or suicide attempts.']",5,0.7692307692307693,4,13
CD015391,6,10,"Based on a low-certainty evidence, fluvoxamine may slightly reduce all-cause mortality at day 28, and may reduce the risk of admission to hospital or death in outpatients with mild COVID-19.",delete,[],6,0.8461538461538461,5,13
CD015391,6,11,"However, we are very uncertain regarding the effect of fluvoxamine on serious adverse events, or any adverse events.",rephrase,"['We cannot be confident in the current evidence for fluvoxamine in treating people with COVID-19, mainly due to the lack of studies that are currently available and some flaws in study design.']",6,0.9230769230769231,5,13
CD015391,7,12,"In accordance with the living approach of this review, we will continually update our search and include eligible trials as they arise, to complete any gaps in the evidence.",rephrase,['We will continue to search for new studies to complete the current evidence gap.'],7,1.0,5,13
CD007897,0,0,"We included 12 studies (8028 participants): two RCTs (294 participants), one cRCT (4407 participants) and nine CBA studies (3327 participants).",rephrase,['We included 12 studies with 8028 participants.'],0,0.09090909090909091,1,11
CD007897,0,1,The interventions varied from thorough renovation to cleaning only.,delete,[],1,0.18181818181818182,1,11
CD007897,1,2,"Repairing houses decreased asthma-related symptoms in adults (among others, wheezing (odds ratio (OR) 0.64; 95% confidence interval (CI) 0.55 to 0.75) and respiratory infections (among others, rhinitis (OR 0.57; 95% CI 0.49 to 0.66), two studies, moderate-quality evidence).",delete,[],1,0.2727272727272727,2,11
CD007897,1,3,"For children, we did not find a difference between repaired houses and receiving information only, in the number of asthma days or emergency department visits because of asthma (one study, moderate-quality evidence).",delete,[],1,0.36363636363636365,2,11
CD007897,2,4,"One CBA study showed very low-quality evidence that after repairing a mould-damaged office building, asthma-related and other respiratory symptoms decreased.",rephrase,['The repair of an office damaged by mould also reduced asthma and respiratory symptoms compared to an office that was not repaired.'],1,0.45454545454545453,3,11
CD007897,2,5,"In another CBA study, there was no difference in symptoms between full or partial repair of houses.",rephrase,['Full or partial repair did not result in a difference in symptoms.'],2,0.5454545454545454,3,11
CD007897,3,6,"For children in schools, the evidence of an effect of mould remediation on respiratory symptoms was inconsistent and out of many symptom measures only respiratory infections might have decreased after the intervention.",split,"[""Out of many symptom measures only pupils' visits to physicians due to a common cold were less frequent after the building was repaired."", 'For other respiratory symptoms of the pupils, the results were inconsistent.']",3,0.6363636363636364,4,11
CD007897,3,7,"For staff in schools, there was very low-quality evidence that asthma-related and other respiratory symptoms in mould-damaged schools were similar to those of staff in non-damaged schools, both before and after intervention.",rephrase,"['However, the evidence was of low to very low quality.']",5,0.7272727272727273,4,11
CD007897,4,8,We found moderate to very low-quality evidence that repairing mould-damaged houses and offices decreases asthma-related symptoms and respiratory infections compared to no intervention in adults.,rephrase,['There was moderate-quality evidence that there was no clear benefit from repair of houses on asthma symptoms among asthmatic children.'],6,0.8181818181818182,5,11
CD007897,4,9,"There is very low-quality evidence that although repairing schools did not significantly change respiratory symptoms in staff, pupils' visits to physicians due to a common cold were less frequent after remediation of the school.",delete,[],7,0.9090909090909091,5,11
CD007897,4,10,"Better research, preferably with a cRCT design and with more validated outcome measures, is needed.",rephrase,"['Better research is needed, preferably with a cluster-randomised design and with better measurement of the symptoms.']",7,1.0,5,11
CD010980,0,0,The search retrieved 62 reports in total.,delete,[],0,0.047619047619047616,1,21
CD010980,0,1,"Of these, we assessed 12 reports in full, corresponding to six trials.",delete,[],0,0.09523809523809523,1,21
CD010980,0,2,We included three trials and excluded one; two trials are ongoing.,delete,[],0,0.14285714285714285,1,21
CD010980,1,3,The included trials were conducted in hospital settings.,rephrase,['All of the trials took place in hospital settings.'],0,0.19047619047619047,1,21
CD010980,1,4,"Two trials were conducted in India; the third trial was a large cluster-randomised trial, which took place in 13 European countries.",rephrase,"['Two trials took place in India, the other was conducted in 13 different European countries.']",1,0.23809523809523808,2,21
CD010980,1,5,"Overall, we judged the included trials to be at a low risk of bias.",delete,[],2,0.2857142857142857,2,21
CD010980,1,6,"One study evaluated the use of calibrated drapes versus visual estimation, another evaluated the use of calibrated drapes versus the gravimetric technique (weight of blood-soaked materials), therefore, we were unable to pool the data from the two studies.",merge,[],2,0.3333333333333333,2,21
CD010980,1,7,"The third study did not measure any of the outcomes of interest, so did not contribute data to the analyses.",none,['Two trials contributed data to our analyses; one study did not provide data for any of the outcomes of interest in this review.'],2,0.38095238095238093,2,21
CD010980,2,8,"Direct measurement using calibrated drapes versus visual estimation
One cluster-randomised controlled trial in 13 western European countries, with over 25,000 women, examined this comparison.",rephrase,"['One trial (conducted in 13 European countries, involving over 25,000 women) compared the use of a calibrated drape (direct estimation) to visual estimation (indirect estimation).']",3,0.42857142857142855,3,21
CD010980,3,9,"The trial did not report on postpartum anaemia (defined as Hb lower than 9 mg/dL), blood loss greater than 500 mL, or maternal infection.",rephrase,"['The trial did not report the number of women who had anaemia after birth, blood loss of at least 500 mL, or infection.']",4,0.47619047619047616,3,21
CD010980,4,10,"Moderate-quality evidence suggests there is probably little or no difference between groups in: severe morbidity (coagulopathy, organ failure, intensive care unit admission; adjusted risk ratio (RR) 0.82, 95% confidence interval (CI) 0.48 to 1.39); the risk of blood transfusion (adjusted RR 0.82, 95% CI 0.46 to 1.46); the use of plasma expanders (adjusted RR 0.77, 95% CI 0.42 to 1.42); and the use of therapeutic uterotonics (adjusted RR 0.87, 95% CI 0.42 to 1.76).",rephrase,"['Moderate-quality evidence showed there was probably little or no difference between the methods for the risk of women developing serious conditions (e.g. failure to form clots, poor functioning of the liver, kidneys, and brain, admission to intensive care); their need for blood transfusion; the use of fluids to maintain their blood pressure; or the use of drugs to help their uterus contract to stop the bleeding.']",5,0.5238095238095238,3,21
CD010980,5,11,"Direct measurement using calibrated drapes (Excellent BRASSS-V Drape™) versus gravimetric technique
One randomised controlled trial in India, with 900 women, examined this comparison.",rephrase,"['One trial (conducted in India, involving 900 women) compared the use of a calibrated drape (direct estimation) to weighing and measuring blood and blood-soaked materials (indirect method).']",6,0.5714285714285714,3,21
CD010980,6,12,"The trial did not report on postpartum anaemia (defined as Hb lower than 9 mg/dL), severe morbidity, or maternal infection.",rephrase,"['The trial did not report the number of women who had anaemia after birth or infection, or the risk of developing serious conditions (such as failure to form clots, poor functioning of the liver, kidneys, and brain, or being admitted to intensive care).']",7,0.6190476190476191,4,21
CD010980,7,13,"High-quality evidence showed that using calibrated drapes improved the detection of blood loss greater than 500 mL when compared with the gravimetric technique (RR 1.86, 95% CI 1.11 to 3.11).",rephrase,['High-quality evidence showed that calibrated drapes were better than measuring the blood and blood-soaked materials at detecting blood loss of at least 500 mL.'],8,0.6666666666666666,4,21
CD010980,7,14,"Low-quality evidence suggests there may be little or no difference in the risk of blood transfusion between the two groups (RR 1.00, 95% CI 0.06 to 15.94), or in the use of plasma expanders, reported as intravenous fluids given for PPH treatment (RR 0.67; 95% CI 0.19 to 2.35).",rephrase,['Low-quality evidence showed there may be little or no difference between methods in the need for blood transfusion or fluids to maintain blood pressure.'],9,0.7142857142857143,4,21
CD010980,7,15,"High-quality evidence showed little or no difference in the use of therapeutic uterotonics (RR 1.01, 95% CI 0.90 to 1.13), but the use of therapeutic uterotonics was extremely high in both arms of the study (57% and 56%).",rephrase,['High-quality evidence showed little or no difference in the use of drugs to help the uterus contract in order to stop bleeding.'],10,0.7619047619047619,4,21
CD010980,8,16,"Overall, the evidence in this review is insufficient to support the use of one method over another for blood loss estimation after vaginal birth.",rephrase,['There was insufficient evidence to support the use of one method over another to estimate blood loss after vaginal birth.'],11,0.8095238095238095,5,21
CD010980,8,17,"In general, the quality of evidence for our predefined outcomes ranged from low to high quality, with downgrading decisions due to imprecision.",delete,[],12,0.8571428571428571,5,21
CD010980,8,18,The included trials did not report on many of our primary and secondary outcomes.,delete,[],12,0.9047619047619048,5,21
CD010980,9,19,"In trials that evaluate methods for estimating blood loss during vaginal birth, we believe it is important to measure their impact on clinical maternal and neonatal outcomes, along with their diagnostic accuracy.",delete,[],12,0.9523809523809523,5,21
CD010980,9,20,"This body of knowledge needs further, well designed, appropriately powered, randomised controlled trials that correlate blood loss with relevant clinical outcomes, such as those listed in this review.",rephrase,"['There is a need for high quality trials that measure important outcomes, such as those listed in this review.']",12,1.0,5,21
CD009518,0,0,"We included five randomized trials (208 participants, 104 in the intervention group and 104 in the control group).",rephrase,"['To assess the effects of isoflavones for the treatment of hypercholesterolaemia, we examined five randomized controlled trials of isoflavones or soy protein containing isoflavones.']",0,0.08333333333333333,1,12
CD009518,0,1,Interventions ranged from three to six months.,rephrase,['The trials lasted three to six months and involved 208 participants.'],1,0.16666666666666666,1,12
CD009518,0,2,Four trials reported results in non-Asian populations published in English.,delete,[],2,0.25,2,12
CD009518,0,3,One trial reported results in Chinese people published in Chinese.,delete,[],2,0.3333333333333333,2,12
CD009518,0,4,"Overall, the risk of bias of included trials was high or unclear.",delete,[],2,0.4166666666666667,3,12
CD009518,0,5,"There were no outcome data on death from any cause, morbidity, complications, health-related quality of life and costs.",rephrase,"['There were no outcome data on death from any cause, cardiovascular events such as heart attack or stroke, morbidity, complications, health-related quality of life and costs.']",2,0.5,3,12
CD009518,0,6,"Two trials reported adverse effects, including gastrointestinal discomfort (bloating and constipation) and an increased number of hot flushes.",ignore,"['Two trials reported adverse effects, including gastrointestinal discomfort (bloating and constipation) and an increased number of hot flushes.']",3,0.5833333333333334,3,12
CD009518,0,7,None of the trials found serious adverse events.,rephrase,['They observed no serious adverse events.'],4,0.6666666666666666,4,12
CD009518,0,8,There was a slight significant effect on triglycerides in favour of isoflavones when compared with placebo (mean difference (MD) -0.46 mmol/L (95% confidence interval (CI) -0.84 to -0.09; P = 0.02; 52 participants; 2 trials).,delete,[],5,0.75,4,12
CD009518,0,9,"No statistically significant effects on total cholesterol, low-density lipoprotein cholesterol and high-density lipoprotein cholesterol were shown in favour of isoflavones.",delete,[],5,0.8333333333333334,5,12
CD009518,1,10,We found no evidence for effects of isoflavones on patient-important outcomes or lowering of cholesterol levels in people with hypercholesterolaemia.,rephrase,"['In our included studies, we found no cholesterol-lowering effect of isoflavones.']",5,0.9166666666666666,5,12
CD009518,1,11,"Our findings have to be interpreted with caution due to high or unclear risk of bias in several risk of bias domains, and low number of participants in trials.",delete,[],6,1.0,5,12
CD013265,0,0,We included 145 studies in the review and sampled 27 of these for our analysis.,rephrase,['We included 27 studies in our analysis.'],0,0.047619047619047616,1,21
CD013265,0,1,"Six studies were conducted in Africa, seven in the Americas, four in South-East Asia, nine in Europe, and one in the Western Pacific.",merge,[],1,0.09523809523809523,1,21
CD013265,0,2,"Studies included urban and rural settings, and high-, middle-, and low-income settings.",none,"['Studies were conducted in Africa, the Americas, South-East Asia, Europe, and the Western Pacific, and included urban and rural settings, as well as high-, middle-, and low-income settings.']",1,0.14285714285714285,1,21
CD013265,1,3,"Many complex factors were found to influence parents’ vaccination views and practices, which we divided into four themes.",ignore,"['Many complex factors were found to influence parents’ vaccination views and practices, which we divided into four themes.']",2,0.19047619047619047,1,21
CD013265,2,4,"Firstly, parents’ vaccination ideas and practices may be influenced by their broader ideas and practices surrounding health and illness generally, and specifically with regards to their children, and their perceptions of the role of vaccination within this context.",ignore,"['Firstly, parents’ vaccination ideas and practices may be influenced by their broader ideas and practices surrounding health and illness generally, and specifically with regards to their children, and their perceptions of the role of vaccination within this context.']",3,0.23809523809523808,2,21
CD013265,2,5,"Secondly, many parents’ vaccination ideas and practices were influenced by the vaccination ideas and practices of the people they mix with socially.",ignore,"['Secondly, many parents’ vaccination ideas and practices were influenced by the vaccination ideas and practices of the people they mix with socially.']",4,0.2857142857142857,2,21
CD013265,2,6,"At the same time, shared vaccination ideas and practices helped some parents establish social relationships, which in turn strengthened their views and practices around vaccination.",ignore,"['At the same time, shared vaccination ideas and practices helped some parents establish social relationships, which in turned strengthened their views and practices around vaccination.']",5,0.3333333333333333,2,21
CD013265,2,7,"Thirdly, parents' vaccination ideas and practices may be influenced by wider political issues and concerns, and particularly their trust (or distrust) in those associated with vaccination programmes.",ignore,"['Thirdly, parent’s vaccination ideas and practices may be influenced by wider political issues and concerns, and particularly their trust (or distrust) in those associated with vaccination programmes.']",6,0.38095238095238093,2,21
CD013265,2,8,"Finally, parents' vaccination ideas and practices may be influenced by their access to and experiences of vaccination services and their frontline healthcare workers.",ignore,"['Finally, parent’s vaccination ideas and practices may be influenced by their access to and experiences of vaccination services and their frontline healthcare workers.']",7,0.42857142857142855,3,21
CD013265,3,9,We developed two concepts for understanding possible pathways to reduced acceptance of childhood vaccination.,ignore,['We developed two concepts for understanding possible pathways to reduced acceptance of childhood vaccination.'],8,0.47619047619047616,3,21
CD013265,4,10,"The first concept, ‘neoliberal logic’, suggests that many parents, particularly from high-income countries, understood health and healthcare decisions as matters of individual risk, choice, and responsibility.",ignore,"['The first concept, ‘neoliberal logic’, suggests that many parents, particularly from high-income countries, understood health and healthcare decisions as matters of individual risk, choice, and responsibility.']",9,0.5238095238095238,3,21
CD013265,4,11,"Some parents experienced this understanding as in conflict with vaccination programmes, which emphasise generalised risk and population health.",ignore,"['Some parents experienced this understanding as in conflict with vaccination programmes, which emphasise generalised risk and population health.']",10,0.5714285714285714,3,21
CD013265,4,12,This perceived conflict led some parents to be less accepting of vaccination for their children.,ignore,['This perceived conflict led some parents to be less accepting of vaccination for their children.'],11,0.6190476190476191,4,21
CD013265,5,13,"The second concept, ‘social exclusion’, suggests that some parents, particularly from low- and middle-income countries, were less accepting of childhood vaccination due to their experiences of social exclusion.",ignore,"['The second concept, ‘social exclusion’, suggests that some parents, particularly from low- and middle-income countries, were less accepting of childhood vaccination due to their experiences of social exclusion.']",12,0.6666666666666666,4,21
CD013265,5,14,"Social exclusion may damage trustful relationships between government and the public, generate feelings of isolation and resentment, and give rise to demotivation in the face of public services that are poor quality and difficult to access.",ignore,"['Social exclusion may damage trustful relationships between government and the public, generate feelings of isolation and resentment, and give rise to demotivation in the face of public services that are poor quality and difficult to access.']",13,0.7142857142857143,4,21
CD013265,5,15,"These factors in turn led some parents who were socially excluded to distrust vaccination, to refuse vaccination as a form of resistance or a way to bring about change, or to avoid vaccination due to the time, costs, and distress it creates.",ignore,"['These factors in turn led some parents who were socially excluded to distrust vaccination, to refuse vaccination as a form of resistance or a way to bring about change, or to avoid vaccination due to the time, costs, and distress it creates.']",14,0.7619047619047619,4,21
CD013265,6,16,Many of the overarching factors our review identified as influencing parents' vaccination views and practices were underrepresented in the interventions tested in the four related Cochrane Reviews of intervention effectiveness.,delete,[],15,0.8095238095238095,5,21
CD013265,7,17,"Our review has revealed that parents’ views and practices regarding childhood vaccination are complex and dynamic social processes that reflect multiple webs of influence, meaning, and logic.",delete,[],15,0.8571428571428571,5,21
CD013265,7,18,"We have provided a theorised understanding of the social processes contributing to vaccination acceptance (or not), thereby complementing but also extending more individualistic models of vaccination acceptance.",delete,[],15,0.9047619047619048,5,21
CD013265,7,19,"Successful development of interventions to promote acceptance and uptake of childhood vaccination will require an understanding of, and then tailoring to, the specific factors influencing vaccination views and practices of the group(s) in the target setting.",delete,[],15,0.9523809523809523,5,21
CD013265,7,20,"The themes and concepts developed through our review could serve as a basis for gaining this understanding, and subsequent development of interventions that are potentially more aligned with the norms, expectations, and concerns of target users.",delete,[],15,1.0,5,21
CD011009,0,0,The review included four studies with 820 women.,rephrase,['We found four RCTs (with 820 women) that met our inclusion requirements.'],0,0.07142857142857142,1,14
CD011009,0,1,The included studies were of overall low risk of bias.,delete,[],1,0.14285714285714285,1,14
CD011009,0,2,"Using GRADE methodology, we assessed the quality of evidence for the primary outcomes of this review to be very low- to low-quality evidence.",delete,[],1,0.21428571428571427,2,14
CD011009,0,3,"Evidence was downgraded for imprecision as it was based on single, small trials with wide confidence intervals (CI).",rephrase,"['We downgraded the evidence as it was based on single, small trials with widely variable results.']",1,0.2857142857142857,2,14
CD011009,0,4,We were able to include data from three of the four included studies.,delete,[],2,0.35714285714285715,2,14
CD011009,1,5,"In one study of women with both subclinical hypothyroidism and positive or negative anti-TPO antibodies (autoimmune disease), the evidence suggested that thyroxine replacement may have improved live birth rate (RR 2.13, 95% CI 1.07 to 4.21; 1 RCT, n = 64; low-quality evidence) and it may have led to similar miscarriage rates (RR 0.11, 95% CI 0.01 to 1.98; 1 RCT, n = 64; low-quality evidence).",rephrase,"['In women with mildly underactive thyroids (with or without ATD), the evidence suggested that thyroxine replacement may have improved live birth rates (low-quality evidence from one study involving 64 women) and it may have led to similar miscarriage rates (low-quality evidence from one study involving 64 women).']",2,0.42857142857142855,3,14
CD011009,1,6,"The evidence suggested that women with both subclinical hypothyroidism and positive or negative anti-TPO antibodies would have a 25% chance of a live birth with placebo or no treatment, and that the chance of a live birth in these women using thyroxine would be between 27% and 100%.",rephrase,"['The evidence suggested that women with mildly underactive thyroid (with or without ATD) would have a 25% chance of a live birth with placebo or no treatment, and 27% to 100% with thyroxine.']",3,0.5,3,14
CD011009,2,7,"In women with normal thyroid function and thyroid autoimmunity (euthyroid ATD), treatment with thyroxine replacement compared with placebo or no treatment may have led to similar live birth rates (risk ratio (RR) 1.04, 95% CI 0.83 to 1.29; 2 RCTs, number of participants (n) = 686; I2 = 46%; low-quality evidence) and miscarriage rates (RR 0.83, 95% CI 0.47 to 1.46, 2 RCTs, n = 686, I2 = 0%; low-quality evidence).",rephrase,"['In women with ATD and normal thyroid function, treatment with thyroxine replacement compared with placebo or no treatment may have led to similar live birth rates (low-quality evidence from two studies involving 686 women) and miscarriage rates (low quality evidence from two studies involving 686 women).']",4,0.5714285714285714,3,14
CD011009,2,8,"The evidence suggested that women with normal thyroid function and thyroid autoimmunity would have a 31% chance of a live birth with placebo or no treatment, and that the chance of a live birth in these women using thyroxine would be between 26% and 40%.",rephrase,"['The evidence suggested that women with ATD and normal thyroid function would have a 31% chance of a live birth with placebo or no treatment, and 26% to 40% with thyroxine.']",5,0.6428571428571429,4,14
CD011009,3,9,Adverse events were rarely reported.,rephrase,['Side effects were rarely reported.'],6,0.7142857142857143,4,14
CD011009,3,10,One RCT reported 0/32 in the thyroxine replacement group and 1/32 preterm births in the control group in women diagnosed with subclinical hypothyroidism and positive or negative anti-TPO antibodies.,rephrase,['One study reported none out of 32 preterm births in the thyroxine replacement group and one out of 32 preterm births in the control group in women diagnosed with mildly underactive thyroid (with or without ATD).'],7,0.7857142857142857,4,14
CD011009,3,11,One RCT reported 21/300 preterm births in the thyroxine replacement group and 19/300 preterm births in the control group in women diagnosed with positive anti-TPO antibodies.,rephrase,['One study reported 21 out of 300 preterm births in the thyroxine replacement group and 19 out of 300 preterm births in the control group in women diagnosed with ATD and normal thyroid function.'],8,0.8571428571428571,5,14
CD011009,3,12,"None of the RCTs reported on other maternal pregnancy complications, foetal complications or adverse effects of thyroxine.",ignore,"['None of the studies reported on other maternal pregnancy complications, foetal complications or side effects of thyroxine.']",9,0.9285714285714286,5,14
CD011009,4,13,We could draw no clear conclusions in this systematic review due to the very low to low quality of the evidence reported.,delete,[],10,1.0,5,14
CD002317,0,0,Fourteen trials (590 participants) were included.,rephrase,['This review contained 14 trials (with 590 participants) and tested the effectiveness of tricyclic drugs against placebo.'],0,0.08333333333333333,1,12
CD002317,0,1,"No overall difference was found for the primary outcome of response to treatment compared with placebo (risk ratio (RR) 1.07, 95% confidence interval (CI) 0.91 to 1.26; 9 trials, N = 454).",rephrase,"['Based on nine trials (454 participants), there was no evidence that tricyclic drugs lead to higher rates of remission or response than placebo.']",1,0.16666666666666666,1,12
CD002317,0,2,"There was a small reduction in depression symptoms (standardised mean difference (SMD) -0.32, 95% CI -0.59 to -0.04; 13 trials, N = 533), but the evidence was of low quality.",rephrase,"['Based on 13 of the trials (533 participants), there was evidence that people treated with a tricyclic drug had lower depression severity scores than those on placebo, however, the size of this difference was small.']",2,0.25,2,12
CD002317,0,3,"Subgroup analyses suggested a small reduction in depression symptoms among adolescents (SMD -0.45, 95% CI -0.83 to -0.007), and negligible change among children (SMD 0.15, 95% CI -0.34 to 0.64).",rephrase,['Subgroup analyses of six trials involving only adolescents (239 participants) and two trials involving only children (77 participants) found no evidence of differential rates of remission or response between the age groups.'],3,0.3333333333333333,2,12
CD002317,0,4,"Treatment with a tricyclic antidepressant caused more vertigo (RR 2.76, 95% CI 1.73 to 4.43; 5 trials, N = 324), orthostatic hypotension (RR 4.86, 95% CI 1.69 to 13.97; 5 trials, N = 324), tremor (RR 5.43, 95% CI 1.64 to 17.98; 4 trials, N = 308) and dry mouth (RR 3.35, 95% CI 1.98 to 5.64; 5 trials, N = 324) than did placebo, but no differences were found for other possible adverse effects.",delete,[],4,0.4166666666666667,3,12
CD002317,0,5,Wide CIs and the probability of selective reporting mean that there was very low-quality evidence for adverse events.,delete,[],4,0.5,3,12
CD002317,1,6,"There was heterogeneity across the studies in the age of participants, treatment setting, tricyclic drug administered and outcome measures.",delete,[],4,0.5833333333333334,3,12
CD002317,1,7,"Statistical heterogeneity was identified for reduction in depressive symptoms, but not for rates of remission or response.",rephrase,"['Only two trials produced a definitive result for depressive symptoms, and no trial produced a definitive result for response or remission.']",4,0.6666666666666666,4,12
CD002317,1,8,"As such, the findings from analyses of pooled data should be interpreted with caution.",delete,[],5,0.75,4,12
CD002317,2,9,"We judged none of these trials to be at low risk of bias, with limited information about many aspects of risk of bias, high dropout rates, and issues regarding measurement instruments and the clinical usefulness of outcomes, which were often variously defined across trials.",delete,[],5,0.8333333333333334,5,12
CD002317,3,10,Data suggest tricyclic drugs are not useful in treating depression in children.,rephrase,"['Tricyclic drugs do not seem useful for treating children before puberty, and are, at most, of moderate benefit for adolescents.']",5,0.9166666666666666,5,12
CD002317,3,11,There is marginal evidence to support the use of tricyclic drugs in the treatment of depression in adolescents.,rephrase,"['With these limitations, it is difficult to answer questions about the effectiveness and safety of tricyclic drugs for treating depression in children and adolescents.']",6,1.0,5,12
CD004574,0,0,Four trials were included.,rephrase,['Four randomised trials were included in the review.'],0,0.07692307692307693,1,13
CD004574,0,1,"These involved a total of 278, mainly adult, participants with 283 mallet finger injuries.",ignore,"['These involved a total of 278, mainly adult, participants with 283 mallet finger injuries.']",1,0.15384615384615385,1,13
CD004574,0,2,"All four trials were methodologically flawed, including inadequate outcome assessment.",rephrase,['The methods of all four trials were flawed leading to concerns about bias.'],2,0.23076923076923078,2,13
CD004574,1,3,Three trials compared different types of finger splints versus a standard Stack splint.,ignore,['Three trials compared different types of finger splints versus a standard Stack splint.'],3,0.3076923076923077,2,13
CD004574,1,4,One trial found a lower incidence of treatment failure in participants treated with a perforated custom-made splint.,rephrase,['One trial found less treatment failure in participants treated with a perforated custom-made splint.'],4,0.38461538461538464,2,13
CD004574,1,5,"One trial found there were fewer complications in participants treated with a padded aluminium-alloy malleable finger splint; however, the incidence of treatment failure was similar in the two treatment groups.",split,"['A second trial found there were fewer complications in participants treated with a padded aluminium-alloy malleable finger splint.', 'However, the incidence of treatment failure was similar in the two treatment groups of this trial.']",5,0.46153846153846156,3,13
CD004574,1,6,One trial evaluating the Abouna splint found a similar incidence of treatment failure in the two groups.,rephrase,['The third trial evaluated the Abouna splint and found a similar incidence of treatment failure in the two groups.'],7,0.5384615384615384,3,13
CD004574,1,7,"However, the Abouna splint often needed replacing due to disintegration of its rubber cover and rusting of the exposed wires and was also less popular with participants.",ignore,"['However, the Abouna splint often needed replacing due to disintegration of its rubber cover and rusting of the exposed wires and was also less popular with participants.']",8,0.6153846153846154,4,13
CD004574,2,8,The fourth trial found no statistically significant differences between participants whose mallet finger was treated with Kirschner wire fixation and those with a Pryor and Howard splint.,ignore,['The fourth trial in the review found no significant differences between participants whose mallet finger was treated with Kirschner wire fixation and those with a Pryor and Howard splint.'],9,0.6923076923076923,4,13
CD004574,2,9,Similar numbers had complications in the two groups.,ignore,['Similar numbers had complications in the two groups.'],10,0.7692307692307693,4,13
CD004574,3,10,"There was insufficient evidence from comparisons tested within randomised controlled trials to establish the relative effectiveness of different, either custom-made or off-the-shelf, finger splints used for treating mallet finger injury.",delete,[],11,0.8461538461538461,5,13
CD004574,3,11,"There was a useful reminder that splints used for prolonged immobilisation should be robust enough for everyday use, and of the central importance of patient adherence to instructions for splint use.",rephrase,"['It noted, however, that splints used for prolonged immobilisation should be robust enough for everyday use.']",11,0.9230769230769231,5,13
CD004574,3,12,There was insufficient evidence to determine when surgery is indicated.,rephrase,['The review concluded that there was not enough evidence to show which is the best way to treat mallet finger injury.'],12,1.0,5,13
CD009298,0,0,We included only one small pilot study (involving 30 women).,rephrase,['We found only one small pilot trial involving 30 women that assessed the feasibility of manual rotation versus routine care (no manual rotation).'],0,0.1,1,10
CD009298,0,1,"The study, which we considered to be at low risk of bias, was conducted in a tertiary referral hospital in Australia, and involved women with cephalic, singleton pregnancies.",rephrase,"[""We considered the study at low risk of bias but it did not have sufficient participants to detect important clinical benefits or harms of manual rotation to correct the baby's position in second stage of labour.""]",1,0.2,1,10
CD009298,0,2,The primary outcome was operative delivery (instrumental delivery or caesarean section).,delete,[],2,0.3,2,10
CD009298,1,3,"In the manual rotation group, 13/15 women went on to have an instrumental delivery or caesarean section, whereas in the control group, 12/15 women had an operative delivery.",delete,[],2,0.4,2,10
CD009298,1,4,The estimated risk ratio was 1.08 (95% confidence interval 0.79 to 1.49).,delete,[],2,0.5,3,10
CD009298,1,5,"There were no maternal or fetal mortalities in either group
There were no clear differences for any of the secondary maternal or neonatal outcomes reported (e.g. perineal trauma, analgesia use duration of labour).",rephrase,"[""The study reported no clear difference for the review's primary outcomes of operative delivery (vacuum-assisted delivery or forceps delivery (or both), or caesarean section) and no mother or baby deaths.""]",2,0.6,3,10
CD009298,2,6,"In terms of adverse events, there were no reported cases of umbilical cord prolapse or cervical laceration and a single case of a non-reassuring or pathological cardiotocograph during the procedure.",ignore,"['In terms of adverse events, there were no reported cases of umbilical cord prolapse or cervical laceration and a single case of a non-reassuring or pathological cardiotocograph during the procedure.']",3,0.7,4,10
CD009298,3,7,"Currently, there is insufficient evidence to determine the efficacy of prophylactic manual rotation early in the second stage of labour for prevention of operative delivery.",rephrase,['Further research is needed to assess the effect of manual rotation in second stage of labour to reduce operative delivery rates.'],4,0.8,4,10
CD009298,3,8,One additional study is ongoing.,delete,[],5,0.9,5,10
CD009298,3,9,Further appropriately designed trials are required to determine the efficacy of manual rotation.,delete,[],5,1.0,5,10
CD012011,0,0,"Of 15 studies identified, we included 12 (1288 babies) in the review - 11 comparing phototherapy with reflective materials and phototherapy alone, and one comparing a single phototherapy light bank with reflective materials with double phototherapy.",rephrase,['We found 12 studies with a total of 1288 babies.'],0,0.058823529411764705,1,17
CD012011,0,1,"All reflective materials consisted of curtains on three or four sides of the cot and were made of white plastic (five studies), white linen (two studies), or aluminium (three studies); materials were not specified in two studies.",rephrase,"[""Types of reflective materials included white plastic, white linen, and aluminium draped on three or four sides of the baby's cot.""]",1,0.11764705882352941,1,17
CD012011,0,2,Only 11 studies (10 comparing reflective materials versus none and one comparing reflective curtains and a single bank of lights with a double (above and below) phototherapy unit) provided sufficient data to be included in the meta-analysis.,rephrase,"['Of these, 11 compared a single unit of light with or without reflective materials around the lights.']",2,0.17647058823529413,1,17
CD012011,0,3,"Two excluded studies used the reflective materials in a way that did not meet our inclusion criteria, and we excluded one study because it compared four different phototherapy interventions not including reflective materials.",delete,[],3,0.23529411764705882,2,17
CD012011,0,4,"The risk of bias of included studies was generally low, but all studies had high risk of performance bias due to lack of blinding of the intervention.",delete,[],3,0.29411764705882354,2,17
CD012011,1,5,"Three studies (281 participants) reported a decline in serum bilirubin (SB) (μmol/L) at four to eight hours (mean difference (MD) -14.61, 95% confidence interval (CI) -19.80 to -9.42; I² = 57%; moderate-certainty evidence).",split,"['Three studies reported a decline in bilirubin at four to eight hours.', 'Moderate-certainty evidence shows a small but clinically important difference favouring the use of curtains.']",3,0.35294117647058826,2,17
CD012011,1,6,"Nine studies (893 participants) reported a decline in SB over 24 hours and showed a faster decline in SB in the intervention group, but heterogeneity (I² = 97%) was too substantial to permit a meaningful estimate of the actual effect size (very low-certainty evidence).",split,"['Decline in bilirubin over 24 hours was measured in nine studies.', 'All studies showed a faster decline in bilirubin in the curtains group, but the decline varied so widely that it was not meaningful to estimate the size of the effect.']",5,0.4117647058823529,3,17
CD012011,1,7,Subgroup analysis by type of reflective material used did not explain the heterogeneity.,delete,[],7,0.47058823529411764,3,17
CD012011,1,8,Exchange transfusion was reported by two studies; both reported none in either group.,delete,[],7,0.5294117647058824,3,17
CD012011,1,9,"Four studies (466 participants) reported the mean duration of phototherapy, and in each of these studies, it was reduced in the intervention group but there was substantial heterogeneity (I² = 88%), precluding meaningful meta-analysis of data.",rephrase,"['Four studies reporting the duration of phototherapy showed that it was shorter when reflective curtains were used, but this is of very low certainty.']",7,0.5882352941176471,3,17
CD012011,1,10,"The only two studies that reported the mean duration of hospital stay in hours showed a meaningful reduction (MD -41.08, 95% CI -45.92 to -36.25; I² = 0; moderate-certainty evidence).",rephrase,['Moderate-certainty evidence from two studies shows that the intervention reduces hospital stay by almost two days.'],8,0.6470588235294118,4,17
CD012011,2,11,"No studies reported costs of the intervention, parental or medical staff satisfaction, breastfeeding outcomes, or neurodevelopmental follow-up.",rephrase,"['None of the studies reported parent or healthcare personnel satisfaction with the curtains, or whether the curtains had any effect on breastfeeding rates.']",9,0.7058823529411765,4,17
CD012011,3,12,The only study that compared use of curtains with double phototherapy reported similar results for both groups.,rephrase,['One trial compared use of one light unit with curtains to use of two light units without curtains and showed similar results for both intervention and control groups.'],10,0.7647058823529411,4,17
CD012011,4,13,"Studies that monitored adverse events did not report increased adverse events related to the use of curtains, including acute life-threatening events, but other rarer side effects could not be excluded.",rephrase,"['There were no reports of any important adverse events, such as temperature instability or acute life-threatening events due to curtains obscuring the baby, nor of other minor effects.']",11,0.8235294117647058,5,17
CD012011,5,14,Moderate-certainty evidence shows that the use of reflective curtains during phototherapy may result in greater decline in SB.,rephrase,['Evidence is of moderate certainty.'],12,0.8823529411764706,5,17
CD012011,5,15,"Very low-certainty evidence suggests that the duration of phototherapy is reduced, and moderate-certainty evidence shows that the duration of hospital stay is also reduced.",delete,[],13,0.9411764705882353,5,17
CD012011,5,16,"Available evidence does not show any increase in adverse events, but further studies are needed.",delete,[],13,1.0,5,17
CD009080,0,0,Three studies provided data on the comparison between vitrectomy and observation in eyes with macular hole and visual acuity less than 20/50.,merge,[],0,0.1,1,10
CD009080,0,1,"Two studies, conducted in the USA and published in 1996 and 1997, used a similar protocol and included participants with stage II macular hole (42 eyes randomised, 36 analysed, number of participants not reported) or participants with stage III/IV hole (129 eyes of 120 participants, 115 eyes in analyses).",merge,[],0,0.2,1,10
CD009080,0,2,"The third study, conducted in the UK and published in 2004, included 185 eyes of 174 participants with full-thickness macular hole (41 eyes with stage II holes and 74 eyes with stage III/IV holes in analyses).",none,"['We included three studies, published between 1996 and 2004 and conducted in the USA and the UK, including 270 eyes in analyses, comparing vitrectomy and observation after 6 or 12 months.']",0,0.3,2,10
CD009080,0,3,"Studies were of good quality for randomisation and allocation concealment, whereas visual acuity measurement was unmasked.",rephrase,"['The evidence was of moderate quality, as the visual acuity measurement was unmasked.']",1,0.4,2,10
CD009080,1,4,"At 6 to 12 months, visual acuity was improved by about 1.5 Snellen lines (-0.16 logMAR, 95% confidence intervals -0.23 to -0.09 logMAR, 270 eyes, moderate-quality evidence).",delete,[],2,0.5,3,10
CD009080,1,5,"The chances of macular hole closure at 6 to 12 months were greatly increased using vitrectomy, yielding an odds ratio of 31.4 (95% confidence intervals 14.9 to 66.3, 265 eyes, high-quality evidence; raw sum data: 76% vitrectomy, 11% observation).",rephrase,"['Macular hole closure was much more likely with vitrectomy compared to observation, with mean closure rates of 76% versus 11%, respectively.']",2,0.6,3,10
CD009080,1,6,Vitrectomy was beneficial both in smaller (stage II) and in larger (stage III/IV) macular holes.,delete,[],3,0.7,4,10
CD009080,2,7,The largest study reported that cataract surgery was needed in about half of cases at two years after operation and that retinal detachment occurred in about 5% of operated eyes.,split,"['Cataract surgery was common in operated eyes.', 'In the largest study, retinal detachment occurred in the months following vitrectomy in about 5% of cases.']",3,0.8,4,10
CD009080,3,8,"Vitrectomy is effective in improving visual acuity, resulting in a moderate visual gain, and in achieving hole closure in people with macular hole.",ignore,"['Vitrectomy is effective in improving visual acuity, resulting in a moderate visual gain, and in achieving hole closure in people with macular hole.']",5,0.9,5,10
CD009080,3,9,"However, these results may not apply to modern surgery due to technological improvements in vitrectomy techniques.",rephrase,"['However, as vitrectomy technology has improved since the included trials were conducted, with use of a smaller incision and outpatient care, the results of this review may not apply to modern surgery.']",6,1.0,5,10
CD000433,0,0,"We included six RCTs, involving 204 preterm infants.",rephrase,"['We found six randomised trials (trials in which each infant had an equal chance of being chosen to receive either treatment), involving 204 preterm infants.']",0,0.09090909090909091,1,11
CD000433,0,1,The risk of bias for most methodological domains was unclear as there was insufficient detail reported.,delete,[],1,0.18181818181818182,1,11
CD000433,0,2,"Low-quality evidence showed that protein supplementation of human milk may increase in-hospital rates of growth in weight (MD 3.82 g/kg/day, 95% CI 2.94 to 4.7; five RCTs, 101 infants; I² = 73%), length (MD 0.12 cm/wk, 95% CI 0.07 to 0.17; four RCTs, 68 infants; I² = 89%), and head circumference (MD 0.06 cm/wk, 95% CI 0.01 to 0.12; four RCTs, 68 infants; I² = 84%).",delete,[],1,0.2727272727272727,2,11
CD000433,0,3,"Protein supplementation may lead to longer hospital stays (MD 18.5 days, 95% CI 4.39 to 32.61; one RCT, 20 infants; very low-quality evidence).",delete,[],1,0.36363636363636365,2,11
CD000433,0,4,"Very low quality evidence means that the effect of protein supplementation on the risk of feeding intolerance (RR 2.70, 95% CI 0.13 to 58.24; one RCT, 17 infants), or necrotizing enterocolitis (RR 1.11, 95% CI 0.07 to 17.12; one RCT, 76 infants) remains uncertain.",rephrase,"['Very low-quality evidence from one trial suggested that adding extra protein to expressed breast milk did not clearly increase the risk of necrotising enterocolitis (inflammation of the intestine) or feeding intolerance, or clearly alter serum albumin concentrations (a measure of blood protein levels).']",1,0.45454545454545453,3,11
CD000433,0,5,No data were available about the effects of protein supplementation on neurodevelopmental outcomes.,rephrase,"['No data were available on the effects of adding extra protein to human milk on long-term growth, body fat, obesity, high blood sugar, or brain development.']",2,0.5454545454545454,3,11
CD000433,1,6,"Low-quality evidence showed that protein supplementation of human milk, fed to preterm infants, increased short-term growth.",split,"['Low-quality evidence showed that the addition of extra protein to breast milk increased short-term rates of weight gain (five trials), length gain (four trials), and head growth (four trials).', 'Low-quality evidence from one trial did not show a clear difference in the rate of growth of skin fold thickness (measure of fat under the skin) between the supplemented and unsupplemented groups.', 'Very low-quality evidence from one trial reported that infants who received additional protein stayed in hospital longer, while very low-quality evidence from four trials observed higher blood urea nitrogen concentrations (measure of kidney function and protein breakdown) in these infants, compared to those who received no additional protein.']",3,0.6363636363636364,4,11
CD000433,1,7,"However, the small sample sizes, low precision, and very low-quality evidence regarding duration of hospital stay, feeding intolerance, and necrotising enterocolitis precluded any conclusions about these outcomes.",rephrase,"['However, its effect on length of hospital stay, feeding intolerance, and necrotizing enterocolitis is uncertain, due to data limitations and very low-quality evidence.']",6,0.7272727272727273,4,11
CD000433,1,8,There were no data on outcomes after hospital discharge.,merge,"['There were no data about effects on later health and development, or effects in low resource settings.']",7,0.8181818181818182,5,11
CD000433,1,9,"Our findings may not be generalisable to low-resource settings, as none of the included studies were conducted in these settings.",none,[],7,0.9090909090909091,5,11
CD000433,2,10,"Since protein supplementation of human milk is now usually done as a component of multi-nutrient fortifiers, future studies should compare different amounts of protein in multi-component fortifiers, and be designed to determine the effects on duration of hospital stay and safety, as well as on long-term growth, body composition, cardio-metabolic, and neurodevelopmental outcomes.",rephrase,"['Since protein supplementation of human milk is now usually done as a component of multi-nutrient fortifiers, future studies should compare different amounts of protein in multi-component fortifiers, and be designed to determine the effects on length of hospital stay, safety, long-term growth, body fat, obesity, high blood sugar, and brain development.']",8,1.0,5,11
CD010963,0,0,No completed studies met the inclusion criteria for the review.,rephrase,['We found no completed studies that compared keyhole surgery and radiotherapy alone or combined with chemotherapy.'],0,0.1,1,10
CD010963,0,1,"Two ongoing trials fulfilled the selection criteria, however neither are complete.",rephrase,"['Two ongoing trials did fulfil our selection criteria, however neither are yet complete.']",1,0.2,1,10
CD010963,1,2,"'Early-stage squamous cell carcinoma of the oropharynx: radiotherapy versus trans-oral robotic surgery (ORATOR)' is a phase II randomised controlled trial comparing primary radiation therapy with primary transoral robotic surgery for small-volume primary (T1-2, N0-2) OPSCC.",delete,[],2,0.3,2,10
CD010963,1,3,It is currently in progress with an estimated completion date of June 2021.,rephrase,['One has an estimated completion date of June 2021 and the other planned to start recruiting patients mid-2016.'],2,0.4,2,10
CD010963,2,4,"'European Organisation for Research and Treatment of Cancer 1420 (EORTC 1420-HNCG-ROG)' is a phase III, randomised study assessing the ""best of"" radiotherapy compared to transoral robotic surgery/transoral laser microsurgery in patients with T1-T2, N0 squamous cell carcinoma of the oropharynx and base of tongue.",delete,[],3,0.5,3,10
CD010963,2,5,It was due to start accrual mid-2016.,delete,[],3,0.6,3,10
CD010963,3,6,The role of endoscopic head and neck surgery in the management of OPSCC is clearly expanding as evidenced by its more overt incorporation into the current National Comprehensive Cancer Network guidelines.,rephrase,['The role of keyhole surgery in the management of throat cancer is expanding as is demonstrated by its incorporation into the current national guidelines in the USA.'],3,0.7,4,10
CD010963,3,7,Data are mounting regarding its outcomes both in terms of survival and lower morbidity.,rephrase,['Evidence is mounting regarding its outcomes both in terms of survival and fewer side effects.'],4,0.8,4,10
CD010963,3,8,"As confidence increases, it is being used in the management of more advanced OPSCC.",delete,[],5,0.9,5,10
CD010963,4,9,"Based on this review, there is currently no high-quality evidence from randomised controlled trials regarding clinical outcomes for patients with oropharyngeal cancer receiving endoscopic head and neck surgery compared with primary chemoradiotherapy.",rephrase,"['Based on this review, there is currently no high-quality evidence from randomised controlled trials that compare keyhole surgery with radiotherapy and chemotherapy for patients with throat cancer.']",5,1.0,5,10
CD008929,0,0,We included nine studies in this review which involved 134 participants with TBI.,ignore,['We included nine studies in this review which involved 134 participants with TBI.'],0,0.07142857142857142,1,14
CD008929,0,1,"Only five studies reported between-group differences, yielding outcome data for 105 participants with TBI.",rephrase,"['Only five studies, including 105 people provided usable results.']",1,0.14285714285714285,1,14
CD008929,0,2,"These five studies assessed the effects of a range of pharmacological (baclofen, botulinum toxin A) and non-pharmacological (casting, physiotherapy, splints, tilt table standing and electrical stimulation) interventions, often in combination.",rephrase,"['These studies tested the effects of a range of treatments, including medicines (baclofen or botulinum toxin A), casting, physiotherapy, splints, a table that moves people from the lying position to standing and electrical stimulation (where electrical impulses are delivered to the muscles).']",2,0.21428571428571427,2,14
CD008929,0,3,The studies which tested the effect of baclofen and tizanidine did not report their results adequately.,rephrase,['Studies inadequately reporting results had tested the effect of medicines (baclofen or tizanidine).'],3,0.2857142857142857,2,14
CD008929,0,4,"Where outcome data were available, spasticity and adverse events were reported, in addition to some secondary outcome measures.",delete,[],4,0.35714285714285715,2,14
CD008929,1,5,"Of the five studies with results, three were funded by governments, charities or health services and two were funded by a pharmaceutical or medical technology company.",ignore,"['Of the five studies with results, three were funded by governments, charities or health services and two were funded by a drug manufacturer and medical technology company.']",4,0.42857142857142855,3,14
CD008929,1,6,The four studies without useable results were funded by pharmaceutical or medical technology companies.,rephrase,['The other four studies without useable results were funded by drug manufacturer or medical technology companies.'],5,0.5,3,14
CD008929,2,7,"It was difficult to draw conclusions about the effectiveness of these interventions due to poor reporting, small study size and the fact that participants with TBI were usually only a proportion of the overall total.",delete,[],6,0.5714285714285714,3,14
CD008929,2,8,Meta-analysis was not feasible due to the paucity of data and heterogeneity of interventions and comparator groups.,delete,[],6,0.6428571428571429,4,14
CD008929,2,9,"Some studies concluded that the intervention they tested had beneficial effects on spasticity, and others found no difference between certain treatments.",rephrase,"['For spasticity, some studies concluded that the treatment they tested made an improvement, and others found no difference between treatments.']",6,0.7142857142857143,4,14
CD008929,2,10,The most common adverse event was minor skin damage in people who received casting.,ignore,['The most common side effect was minor skin damage in people who received casting.'],7,0.7857142857142857,4,14
CD008929,2,11,We believe it would be misleading to provide any further description of study results given the quality of the evidence was very low for all outcomes.,ignore,['We believe it would be misleading to provide any further description of study results given the quality of the evidence was very low for all measurements.'],8,0.8571428571428571,5,14
CD008929,3,12,The very low quality and limited amount of evidence about the management of spasticity in people with TBI means that we are uncertain about the effectiveness or harms of these interventions.,rephrase,"['Because of this, we cannot draw any firm conclusions about the benefits and harms of different treatments for spasticity in people with TBI.']",9,0.9285714285714286,5,14
CD008929,3,13,Well-designed and adequately powered studies using functional outcome measures to test the interventions used in clinical practice are needed.,delete,[],10,1.0,5,14
CD008036,0,0,"Since only one small study (n = 40) was included, no meta-analysis could be performed.",delete,[],0,0.09090909090909091,1,11
CD008036,0,1,The included randomised controlled study was of parallel design and undertaken at two paediatric hospitals in Australia.,delete,[],0,0.18181818181818182,1,11
CD008036,0,2,"The study evaluated the effects of a singing program on the quality of life and respiratory muscle strength of hospitalised children with cystic fibrosis (mean age 11.6 years, 35% male).",rephrase,"['The study assessed the impact of singing on respiratory muscle strength, quality of life and lung function tests.']",0,0.2727272727272727,2,11
CD008036,0,3,"While the singing group received eight individual singing sessions, the control group participated in preferred recreational activities, such as playing computer games or watching movies.",delete,[],1,0.36363636363636365,2,11
CD008036,0,4,This study was limited by a small sample size (51 participants) and a high drop-out rate (21%).,rephrase,['The included study was limited by the small number of participants (only 51 participants enrolled and only 40 were analysed) and a high drop-out rate (21%).'],1,0.45454545454545453,3,11
CD008036,1,5,"There were no differences between the groups at either post-intervention or follow-up; although by the end of treatment there were some improvements in some of the domains of the quality of life questionnaire Cystic Fibrosis Questionnaire-Revised (e.g. emotional, social and vitality domains) for both singing and control groups.",rephrase,['Participants from both the singing and recreation groups reported some improvement in quality of life measurements.'],2,0.5454545454545454,3,11
CD008036,1,6,"For the respiratory muscle strength indices, maximal expiratory pressure at follow-up (six to eight weeks post-intervention) was higher in the singing group, mean difference 25.80 (95% confidence interval 5.94 to 45.66).",rephrase,"['Participants in the singing group showed a greater increase in maximal expiratory pressure (a substitute measure of respiratory muscle strength test), while there was no improvement in this outcome for those in the recreation group.']",3,0.6363636363636364,4,11
CD008036,1,7,"There was no difference between groups for any of the other respiratory function parameters (maximal inspiratory pressure, spirometry) at either post-intervention or follow-up.",delete,[],4,0.7272727272727273,4,11
CD008036,1,8,No adverse effects were observed in the singing group; adverse events for the control group were not reported in the paper.,rephrase,['No adverse events were reported.'],4,0.8181818181818182,5,11
CD008036,2,9,There is insufficient evidence to determine the effects of singing on quality of life or on the respiratory parameters in people with cystic fibrosis.,split,"['There is currently not enough evidence to assess the effect of singing on clinical outcomes in people with cystic fibrosis.', 'Future studies using robust methods are needed to assess the possible effects of singing for people with cystic fibrosis']",5,0.9090909090909091,5,11
CD008036,2,10,"However, there is growing interest in non-medical treatments for cystic fibrosis and researchers may wish to investigate the impact of this inexpensive therapy on respiratory function and psychosocial well-being further in the future.",delete,[],7,1.0,5,11
CD011541,0,0,"This review included only one trial (21 participants), which compared fish oil-derived (n-3) fatty acid-based lipid emulsion (50 mL per infusion (1.05 g eicosapentaenoic and 10.5 g docosahexaenoic acid)) (10 participants) to soya oil-derived (n-6) fatty acid-based lipid emulsion (50 mL per infusion (1.05 g eicosapentaenoic and 10.5 g docosahexaenoic acid)) (11 participants) administered intravenously twice daily for 10 days, with a total follow-up of 40 days.",delete,[],0,0.08333333333333333,1,12
CD011541,0,1,"The study was conducted in a single centre in Germany in 18 men and three women, aged between 21 and 65 years, who were in hospital with acute guttate psoriasis and had mean total body surface involvement of 25.7% ± 20.4% (range 10 to 90).",rephrase,"['The study was conducted in Germany in 21 adults (18 men and 3 women) aged 21 to 65 years, with a mean of involved skin surface of 25%, who were in hospital with acute guttate psoriasis.']",0,0.16666666666666666,1,12
CD011541,0,2,The study was funded by a company that produces the oil emulsions.,ignore,['The study was funded by the company that produces the oil emulsions.'],1,0.25,2,12
CD011541,0,3,"We found no other evidence regarding non-antistreptococcal interventions used in clinical practice for guttate psoriasis, such as topical treatments (corticosteroids, vitamin D₃ analogues), systemic drugs, biological therapy, and phototherapy.",rephrase,"['Treatments for which we found no evidence include phototherapy and topical, oral, and biological medicines.']",2,0.3333333333333333,2,12
CD011541,1,4,"The primary outcomes of the review were not measured, and only one of our secondary outcomes was measured: improvement in participant satisfaction measures and quality of life assessment measures.",rephrase,"[""Most of our secondary outcomes were also not measured, including worsening of guttate psoriasis or recurrence within a period of six months after the treatment has finished; and percentage of participants achieving a Psoriasis Area Severity Index 75 or Physician's Global Assessment of 1 or 2.""]",3,0.4166666666666667,3,12
CD011541,1,5,"However, the study authors did report that there was rare skin irritation at the site of peripheral intravenous route, but the number of affected participants was not provided.",rephrase,"['The included study did not report measuring any harms of the treatments; however, the study authors did report rare skin irritation at site of injection, but did not provide the number of affected participants.']",4,0.5,3,12
CD011541,2,6,"Improvement between baseline and day 10, using a non-validated score assessed by participants themselves daily based on five items (appearance of lesions, impairment of daily life, pruritus, burning, and pain), was greater in the group that received the fish oil-derived (n-3) fatty acid-based lipid emulsion (75%) than in the group receiving the soya oil-derived (n-6) fatty acid-based lipid emulsion (18%) (one trial, 21 participants).",rephrase,"['After 10 days of treatment, study participants who received the fish oil-derived lipid emulsion (75% of people in this group) rated greater improvements than those receiving the soya oil-derived lipid emulsion (18% of people in this group).']",5,0.5833333333333334,3,12
CD011541,2,7,"However, these results are uncertain as they are based on very low-quality evidence.",ignore,"['However, these results are uncertain as they are based on very low-quality evidence.']",6,0.6666666666666666,4,12
CD011541,3,8,"There is no evidence regarding topical and systemic drugs, biotherapy, or phototherapy in guttate psoriasis (we did not consider drugs that aimed to eradicate streptococcal infection because these are assessed in another Cochrane Review).",delete,[],7,0.75,4,12
CD011541,3,9,"We are uncertain of the effect of intravenously administered lipid emulsion on guttate psoriasis because the quality of the evidence is very low, due to risk of bias (unclear risk of bias for all domains), indirectness (the trial only included adults, and the follow-up from baseline was only 10 days), and imprecision (small number of participants).",delete,[],7,0.8333333333333334,5,12
CD011541,4,10,This review highlights the need for trials assessing the efficacy and safety of phototherapy and topical and systemic drugs for guttate psoriasis.,delete,[],7,0.9166666666666666,5,12
CD011541,4,11,"There is also a need for studies that clearly distinguish the specific population with guttate psoriasis from the larger group of people with chronic plaque psoriasis, and children and young adults should be assessed as a distinct group.",delete,[],7,1.0,5,12
CD009695,0,0,Eleven studies were included in the review (791 participants).,merge,"['We found eleven studies enrolling 791 amphetamine-dependent participants and assessing the effects of four different psychostimulants: dexamphetamine, bupropion, methylphenidate and modafinil.']",0,0.1111111111111111,1,9
CD009695,0,1,"Studied psychostimulants included dexamphetamine, bupropion, methylphenidate and modafinil.",none,[],0,0.2222222222222222,2,9
CD009695,0,2,No significant differences were found between psychostimulants and placebo for any of the studied efficacy outcomes.,delete,[],1,0.3333333333333333,2,9
CD009695,0,3,Overall retention in studies was low (50.4%).,rephrase,['Retention in treatment was similar and low with both treatments.'],1,0.4444444444444444,3,9
CD009695,0,4,"Psychostimulants did not reduce amphetamine use (mean difference (MD) -0.26, 95% confidence interval (CI) -0.85 to 0.33) or amphetamine craving (MD 0.07, 95% CI -0.44 to 0.59) and did not increase sustained abstinence (relative risk (RR) 1.12, 95% CI 0.84 to 1.49).",rephrase,['Psychostimulants did not reduce amphetamine use or amphetamine craving and also did not increase sustained abstinence in comparison with placebo.'],2,0.5555555555555556,3,9
CD009695,0,5,"The proportion of adverse events inducing dropout was similar for psychostimulants and placebo (risk difference (RD) 0.01, 95% CI -0.03 to 0.04).",delete,[],3,0.6666666666666666,4,9
CD009695,0,6,The main findings did not change in any subgroup analysis.,delete,[],3,0.7777777777777778,4,9
CD009695,1,7,Results of this review do not support the use of psychostimulant medications at the tested doses as a replacement therapy for amphetamine abuse or dependence.,rephrase,"['In this review, the efficacy and safety of psychostimulants for amphetamine abuse or dependence were studied.']",3,0.8888888888888888,5,9
CD009695,1,8,"Future research could change this conclusion, as the numbers of included studies and participants are limited and information on relevant outcomes, such as efficacy according to the severity of dependence or craving, is still missing.",rephrase,"['The design of future trials should consider the level of dependence at study entry, the potency and the dose of the psychostimulant administered, the length of the trial and the representativeness of included participants.']",4,1.0,5,9
CD009078,0,0,We found three RCTs with a total of 58 participants that were eligible for inclusion.,rephrase,['Three eligible studies with a total of 58 participants were included in this review.'],0,0.058823529411764705,1,17
CD009078,0,1,"There was significant variability between the trials in interventions, methodology and outcome measures and therefore we did not perform meta-analysis.",rephrase,"['These studies varied significantly in interventions, methodology and reported outcomes.']",1,0.11764705882352941,1,17
CD009078,1,2,One study reported on the use of 2% CsA in maize oil and two on the use of a commercial emulsion of 0.05% CsA.,rephrase,"['One study used 2% CsA in maize oil, and two used a commercial emulsion of 0.05% CsA.']",2,0.17647058823529413,1,17
CD009078,1,3,"Of these three studies, one showed a beneficial effect of topical CsA in controlling signs and symptoms of AKC, one in controlling signs of AKC and one did not show evidence of an improvement.",split,"['Of these three studies, two showed a beneficial effect of topical CsA in controlling signs of AKC, and one did not find evidence of this improvement.', 'One study showed a beneficial effect of topical CsA in controlling symptoms of AKC, but the other two did not find evidence of this improvement.']",3,0.23529411764705882,2,17
CD009078,1,4,"Only two studies analysed the effect of topical CsA in reducing topical steroid use; one showed a significant reduction in topical steroid use with CsA, but the other did not show evidence of this improvement.",ignore,"['Only two studies analysed the effect of topical CsA in reducing topical steroid use; one showed a significant reduction in topical steroid use with CsA, but the other could not find evidence of this improvement.']",5,0.29411764705882354,2,17
CD009078,1,5,No serious adverse events were reported in the trials.,delete,[],6,0.35294117647058826,2,17
CD009078,2,6,This systematic review highlights the relative scarcity of controlled clinical trials assessing the efficacy of topical CsA therapy in AKC and suggests that evidence on the efficacy and safety of topical CsA treatment in patients with CsA remains limited.,rephrase,"['However, this review has identified a need for more randomised controlled trials to provide further reliable evidence on the efficacy and safety of topical treatment with CsA eyedrops for patients with AKC.']",6,0.4117647058823529,3,17
CD009078,2,7,"However, the data suggest that topical CsA may provide clinical and symptomatic relief in AKC and may help to reduce topical steroid use in patients with steroid-dependent or steroid-resistant AKC.",ignore,['The data suggest that topical CsA may provide clinical and symptomatic relief in AKC and may help to reduce topical steroid use in patients with steroid-dependent or steroid-resistant AKC.'],7,0.47058823529411764,3,17
CD009078,2,8,No serious adverse events were reported.,rephrase,"['Moreover, no serious adverse events were detected.']",8,0.5294117647058824,3,17
CD009078,2,9,Reported adverse events in patients treated with topical CsA include intense stinging and eyelid skin maceration.,delete,[],9,0.5882352941176471,3,17
CD009078,2,10,One patient in the placebo group developed a severe allergic response to maize antigens.,delete,[],9,0.6470588235294118,4,17
CD009078,2,11,"However, the total number of patients in the trials was too small to assess the safety of this treatment.",delete,[],9,0.7058823529411765,4,17
CD009078,3,12,Additional well-designed and powered RCTs of topical CsA in AKC are needed.,delete,[],9,0.7647058823529411,4,17
CD009078,3,13,"Ideal study designs should include adequate randomisation and concealment of allocation; masking of participants, personnel and outcome assessors; adequate follow-up periods and minimisation of attrition bias; and comparison groups with similar clinical and epidemiologic characteristics.",delete,[],9,0.8235294117647058,5,17
CD009078,3,14,Samples should be large enough to provide sufficient statistical power to assess the safety of CsA and to detect clinically relevant treatment effect sizes of the primary outcomes.,rephrase,"['These trials should include larger samples of patients with AKC, and their follow-up periods should be long enough to draw conclusions on the long-term efficacy and safety of this therapy.']",9,0.8823529411764706,5,17
CD009078,3,15,Analyses should be appropriate to the study’s design and outcome measures.,delete,[],10,0.9411764705882353,5,17
CD009078,3,16,"Moreover, standardisation of outcome measures and follow-up periods across studies would be beneficial to maximise study comparability.",delete,[],10,1.0,5,17
CD003366,0,0,This review included 28 studies.,merge,['We included 28 studies that randomised 6871 women.'],0,0.06666666666666667,1,15
CD003366,0,1,"The updated analysis included 6871 randomised women, while the original review had 3643 women.",none,[],0,0.13333333333333333,1,15
CD003366,0,2,"Of the 28 included studies, we considered 19 studies to be at low risk of bias overall; however, some studies failed to report details on allocation concealment and methods of outcome assessment for those outcomes that are more likely to be influenced by a lack of blinding (for example tumour response rate).",split,"['We considered 19 out of the 28 studies to be at low risk of bias overall.', 'However, some studies failed to report details on concealing drug treatments and methods of outcome assessment for those outcomes more likely to be at risk of bias (for example tumour response rate).']",1,0.2,1,15
CD003366,0,3,"Studies varied in the taxane-containing chemotherapy backbone, and the comparator arms and were categorised into three groups: Regimen A plus taxane versus Regimen A (2 studies); Regimen A plus taxane versus Regimen B (14 studies); and single-agent taxane versus Regimen C (13 studies).",rephrase,['There were variations in the taxane-containing chemotherapy regimen and the non-taxane treatments.'],3,0.26666666666666666,2,15
CD003366,0,4,"Thirteen studies used paclitaxel, 14 studies used docetaxel, and 1 study allowed the investigator to decide on the type of taxane; the majority of studies delivered a taxane every 3 weeks.",rephrase,"['Approximately half of the studies used paclitaxel and the other half used docetaxel, and in the majority of cases, taxanes were administered every three weeks.']",4,0.3333333333333333,2,15
CD003366,0,5,"Twenty studies administered taxanes as first-line treatment, and 21 studies involved anthracycline naïve women in the metastatic setting.",rephrase,"['Of the 28 studies, 20 studies included women who received taxanes as their first treatment after their diagnosis of metastatic breast cancer, and 21 studies involved women who had not been previously treated with anthracyclines in the metastatic setting.']",5,0.4,2,15
CD003366,0,6,"The combined HR for overall survival and time to progression favoured the taxane-containing regimens (HR 0.93, 95% confidence interval (CI) 0.88 to 0.99, P = 0.002, deaths = 4477; and HR 0.92, 95% CI 0.87 to 0.97, P = 0.002, estimated 5122 events, respectively) with moderate to substantial heterogeneity across trials.",delete,[],6,0.4666666666666667,3,15
CD003366,0,7,"If the analyses were restricted to studies of first-line chemotherapy, this effect persisted for overall survival (HR 0.93, 95% CI 0.87 to 0.99, P = 0.03) but not for time to progression (HR 0.96, 95% CI 0.90 to 1.02, P = 0.22).",rephrase,"['If the analyses were restricted to those studies where women received taxanes as their first treatment after their diagnosis of metastatic breast cancer, the survival benefit persisted.']",6,0.5333333333333333,3,15
CD003366,0,8,"Tumour response rates appeared to be better with taxane-containing chemotherapy in assessable women (RR 1.20, 95% CI 1.14 to 1.27, P < 0.00001) with substantial heterogeneity across studies.",delete,[],7,0.6,3,15
CD003366,0,9,"Taxanes were associated with an increased risk of neurotoxicity (RR 4.84, 95% CI 3.18 to 7.35, P < 0.00001, 24 studies) and hair loss (RR 2.37, 95% CI 1.45 to 3.87, P = 0.0006, 11 studies) but less nausea/vomiting compared to non-taxane-containing regimens (RR 0.62, 95% CI 0.46 to 0.83, P = 0.001, 26 studies).",rephrase,"['However, less nausea/vomiting was observed with taxanes.']",7,0.6666666666666666,4,15
CD003366,0,10,"Leukopaenia and treatment-related death did not differ between the two groups (RR 1.07, 95% CI 0.97 to 1.17, P = 0.16, 28 studies; and RR 1.00, 95% CI 0.63 to 1.57, P = 0.99, 23 studies, respectively).",rephrase,['There was no difference in the rates of leukopaenia (low white blood cells) or treatment-related deaths between taxane and non-taxane chemotherapy.'],8,0.7333333333333333,4,15
CD003366,0,11,"For quality of life measures, none of the individual studies reported a difference in overall or any of quality of life subscales between taxane-containing and non-taxane chemotherapy regimens.",rephrase,"['Of the studies that reported quality of life measures, there did not appear to be any differences (overall or on subscales) in quality of life between the two groups.']",9,0.8,4,15
CD003366,1,12,"Taxane-containing regimens appear to improve overall survival, time to progression, and tumour response rate in women with metastatic breast cancer.",rephrase,['This review showed that chemotherapy regimens including taxanes improved survival and decreased the progression of metastatic breast cancer.'],10,0.8666666666666667,5,15
CD003366,1,13,Taxanes are also associated with an increased risk of neurotoxicity but less nausea and vomiting compared to non-taxane-containing regimens.,rephrase,['The risk of experiencing neurotoxicity (tingling of hands and feet) with taxanes increased compared to non-taxane chemotherapy.'],11,0.9333333333333333,5,15
CD003366,1,14,"The considerable heterogeneity encountered across studies probably reflects the varying efficacy of the comparator regimens used in these studies and indicates that taxane-containing regimens are more effective than some, but not all, non-taxane-containing regimens.",rephrase,"['The degree of variability seen across the included studies probably reflects the varying efficacy of the non-taxane chemotherapy regimens used in these studies and indicates that taxane-containing chemotherapies are more effective than some, but not all, non-taxane-containing regimens.']",12,1.0,5,15
CD009109,0,0,"We included one trial, which was judged to be at high risk of performance, detection and attrition bias.",rephrase,"['The study was of short duration (three years), included a relatively small number of participants, and was assessed to be at a high risk of bias due to missing results for people who dropped out of the study.']",0,0.125,1,8
CD009109,0,1,"The 117 participants with a root-filled, premolar tooth restored with a carbon fibre post, were randomised to either a full coverage metal-ceramic crown or direct adhesive composite restoration.",rephrase,"['This review includes one study with 117 participants in which a tooth (117 premolars) received a carbon fibre post, and was restored with either a fused porcelain to metal crown or a routine white filling.']",1,0.25,2,8
CD009109,0,2,"None experienced a catastrophic failure (i.e. when the restoration cannot be repaired), although only 104 teeth were included in the final, three-year assessment.",rephrase,"['The evidence produced from one study concluded that none of the 117 root-filled premolars experienced a catastrophic failure (i.e. one that cannot be repaired) after three years, although only 104 teeth were included in the final, three-year assessment.']",2,0.375,2,8
CD009109,0,3,There was no clear difference between the crown and composite group and the composite only group for non-catastrophic failures of the restoration (1/54 versus 3/53; RR 0.33; 95% CI 0.04 to 3.05) or failures of the post (2/54 versus 1/53; RR 1.96; 95% CI 0.18 to 21.01) at three years.,delete,[],3,0.5,3,8
CD009109,0,4,The quality of the evidence for these outcomes is very low.,rephrase,['The quality of the evidence is very low.'],3,0.625,4,8
CD009109,0,5,"There was no evidence available for any of our secondary outcomes: patient satisfaction and quality of life, incidence or recurrence of caries, periodontal health status, and costs.",ignore,"['There was no evidence available for any of our secondary outcomes: patient satisfaction and quality of life, incidence or recurrence of decay, periodontal health status, and costs.']",4,0.75,4,8
CD009109,1,6,There is insufficient evidence to assess the effects of crowns compared to conventional fillings for the restoration of root-filled teeth.,rephrase,"['As there is only a single study, which is at high risk of bias, there is insufficient reliable evidence to determine whether single crowns are better than routine fillings.']",5,0.875,5,8
CD009109,1,7,"Until more evidence becomes available, clinicians should continue to base decisions about how to restore root-filled teeth on their own clinical experience, whilst taking into consideration the individual circumstances and preferences of their patients.",rephrase,['Future research should aim to provide more reliable information that can help clinicians to decide on appropriate treatment whilst taking into consideration the individual circumstances and preferences of their patients.'],6,1.0,5,8
CD011298,0,0,Six studies met our inclusion criteria and included a total of 5143 women.,rephrase,['We found six studies with a total of 5143 women.'],0,0.058823529411764705,1,17
CD011298,0,1,"Of three studies with self-reported pregnancy data, two showed pregnancy to be less likely in the experimental group than in the comparison group (OR 0.48, 95% CI 0.27 to 0.87) (OR 0.60, 95% CI 0.41 to 0.87).",rephrase,"['Of three studies with pregnancy data, two showed fewer pregnancies in the treatment group compared to the control group.']",1,0.11764705882352941,1,17
CD011298,0,2,The interventions included a clinic-based counseling program and a community-based communication project.,rephrase,['The programs in those studies were clinic counseling and community education.'],2,0.17647058823529413,1,17
CD011298,1,3,All studies showed some association of the intervention with contraceptive use.,rephrase,['All studies showed the special program was related to more birth control use.'],3,0.23529411764705882,2,17
CD011298,1,4,Two showed that treatment-group women were more likely to use a modern method than the control group: ORs were 1.77 (95% CI 1.08 to 2.89) and 3.08 (95% CI 2.36 to 4.02).,rephrase,"['In two studies, more women in the treatment group used a modern method of birth control than those in the control group.']",4,0.29411764705882354,2,17
CD011298,1,5,"In another study, treatment-group women were more likely than control-group women to use pills (OR 1.78, 95% CI 1.26 to 2.50) or an intrauterine device (IUD) (OR 3.72, 95% CI 1.27 to 10.86) but less likely to use and injectable method (OR 0.23, 95% CI 0.05 to 1.00).",rephrase,"['In another study, women in the treatment group were more likely to use pills or an IUD but less likely to use an injectable method.']",5,0.35294117647058826,2,17
CD011298,1,6,One study used a score for method effectiveness.,rephrase,['One study used a score for how well the birth control method usually worked.'],6,0.4117647058823529,3,17
CD011298,1,7,"The methods of the special-intervention group scored higher than those of the comparison group at three months (MD 13.26, 95% CI 3.16 to 23.36).",rephrase,['The methods of the treatment group scored higher than those of the control group.'],7,0.47058823529411764,3,17
CD011298,1,8,"A study emphasizing IUDs showed women in the intervention group were more likely to use an IUD (OR 1.79, 95% CI 1.20 to 2.69) and less likely to use no method (OR 0.48, 95% CI 0.31 to 0.75).",rephrase,['A study focused on IUDs showed more IUDs in the treatment group and less use of no method.'],8,0.5294117647058824,3,17
CD011298,1,9,"In another study, contraceptive use was more likely among women in a health service intervention compared to women in a community awareness program at four months (OR 1.79, 95% CI 1.40 to 2.30) or women receiving standard care at 10 to 12 months (OR 2.08, 95% CI 1.58 to 2.74).",rephrase,['Women in a health service program used birth control more often than those in a community education program or those getting standard care.'],9,0.5882352941176471,3,17
CD011298,1,10,That study was the only one with a specific component on the lactational amenorrhea method (LAM) that had sufficient data on LAM use.,delete,[],10,0.6470588235294118,4,17
CD011298,1,11,"Women in the health service group were more likely than those in the community awareness group to use LAM (OR 41.36, 95% CI 10.11 to 169.20).",rephrase,"['Also, women in the health service group were more likely to use the lactation method.']",10,0.7058823529411765,4,17
CD011298,2,12,We considered the quality of evidence to be very low.,rephrase,['We believe the data were very low quality for pregnancy and birth control use.'],11,0.7647058823529411,4,17
CD011298,2,13,"The studies had limitations in design, analysis, or reporting.",rephrase,"['The studies had problems in design, analysis, and reporting.']",12,0.8235294117647058,5,17
CD011298,2,14,Three did not adjust for potential confounding and only two had sufficient information on intervention fidelity.,rephrase,['Some did not adjust for factors that could affect the results.'],13,0.8823529411764706,5,17
CD011298,2,15,Outcomes were self reported and definitions varied for contraceptive use.,rephrase,['They had self-reported outcomes and used different measures for the outcomes.'],14,0.9411764705882353,5,17
CD011298,2,16,"All studies had adequate follow-up periods but most had high losses, as often occurs in contraception studies.",rephrase,['All studies had good follow-up times but most lost many women to follow up.'],15,1.0,5,17
CD008449,0,0,We included 62 studies with a total of 1982 participants that compared mirror therapy with other interventions.,merge,[],0,0.1,1,10
CD008449,0,1,"Of these, 57 were randomised controlled trials and five randomised cross-over trials.",none,"['We found 62 relevant studies, of which 57 randomly allocated participants to receive either MT or a control therapy (randomised controlled trials) and five provided both therapies to all participants, but in random order (cross-over trials).']",0,0.2,1,10
CD008449,0,2,Participants had a mean age of 59 years (30 to 73 years).,rephrase,['The studies involved a total of 1982 participants with a mean age of 59 years (30 to 73 years) after stroke.'],1,0.3,2,10
CD008449,0,3,"Mirror therapy was provided three to seven times a week, between 15 and 60 minutes for each session for two to eight weeks (on average five times a week, 30 minutes a session for four weeks).When compared with all other interventions, we found moderate-quality evidence that mirror therapy has a significant positive effect on motor function (SMD 0.47, 95% CI 0.27 to 0.67; 1173 participants; 36 studies) and motor impairment (SMD 0.49, 95% CI 0.32 to 0.66; 1292 participants; 39 studies).",rephrase,"['Mirror therapy was provided three to seven times a week, between 15 and 60 minutes for each session for two to eight weeks (on average five times a week, 30 minutes a session for four weeks).']",2,0.4,2,10
CD008449,0,4,"However, effects on motor function are influenced by the type of control intervention.",delete,[],3,0.5,3,10
CD008449,0,5,"Additionally, based on moderate-quality evidence, mirror therapy may improve activities of daily living (SMD 0.48, 95% CI 0.30 to 0.65; 622 participants; 19 studies).",delete,[],3,0.6,3,10
CD008449,0,6,"We found low-quality evidence for a significant positive effect on pain (SMD −0.89, 95% CI −1.67 to −0.11; 248 participants; 6 studies) and no clear effect for improving visuospatial neglect (SMD 1.06, 95% CI −0.10 to 2.23; 175 participants; 5 studies).",rephrase,['We found no clear effect for visuospatial neglect.'],3,0.7,4,10
CD008449,0,7,No adverse effects were reported.,ignore,['No adverse effects were reported.'],4,0.8,4,10
CD008449,1,8,"The results indicate evidence for the effectiveness of mirror therapy for improving upper extremity motor function, motor impairment, activities of daily living, and pain, at least as an adjunct to conventional rehabilitation for people after stroke.",rephrase,"['The studies provide moderately-reliable evidence that MT improves movement (motor function, motor impairment) and the performance of daily activities.']",5,0.9,5,10
CD008449,1,9,"Major limitations are small sample sizes and lack of reporting of methodological details, resulting in uncertain evidence quality.",delete,[],6,1.0,5,10
CD009982,0,0,Two trials were included this review.,ignore,['Two trials were included this review.'],0,0.058823529411764705,1,17
CD009982,0,1,One (involving 213 women and 213 neonates) evaluated the impact of Hib vaccination during pregnancy and the other study (involving 2116 women and 2049 neonates) evaluated the impact of viral influenza vaccination during pregnancy.,rephrase,"['In one small study (involving 213 women, mainly Hispanic and with low income, and 213 neonates, conducted in the US), women were given either Hib vaccination or a placebo control at between 34 to 36 weeks gestation.']",1,0.11764705882352941,1,17
CD009982,0,2,"Overall, the HiB vaccination trial was judged to be at 'high risk of bias' due to inadequate randomisation while the other trial was judged to be at 'low risk of bias'.",delete,[],2,0.17647058823529413,1,17
CD009982,1,3,"Hib vaccination during pregnancy versus placebo
One trial involving 213 women and 213 neonates evaluating the impact of Hib vaccination during pregnancy was included under this comparison.",delete,[],2,0.23529411764705882,2,17
CD009982,1,4,"The study did not report on any of this review's prespecified primary outcomes (including mortality, respiratory tract infection and sepsis) or secondary outcomes (including adverse events) except preterm delivery.",split,"[""This trial did not report on any of this review's primary outcomes, including: mortality, respiratory tract infection or sepsis among the women or their babies."", ""Nor did the study report on any of this review's other secondary outcomes apart from preterm birth and there were no clear differences between the vaccination and placebo groups.""]",2,0.29411764705882354,2,17
CD009982,1,5,"There was no clear difference between the Hib vaccination and placebo control groups in terms of preterm delivery (risk ratio (RR) 1.28, 95% confidence interval (CI) 0.12 to 13.86, one study, 213 participants), fetal distress (RR 1.23, 95% CI 0.67 to 2.26, one study, 213 infants), intubation (RR 1.03, 95% CI 0.55 to 1.95, one study, 213 infants) and neonatal jaundice (RR 1.01, 95% CI 0.52 to 1.97, one study, 213 infants).",delete,[],4,0.35294117647058826,2,17
CD009982,1,6,We could not grade the evidence for quality due to lack of outcome data.,delete,[],4,0.4117647058823529,3,17
CD009982,2,7,"Viral influenza vaccination during pregnancy versus placebo
One trial involving 2116 women and 2049 infants evaluating the impact of trivalent inactivated influenza vaccine (IIV3) during pregnancy was included under this comparison.",rephrase,"['In one large trial (involving 2116 women and 2049 infants, conducted in Soweto, South Africa) pregnant women received either inactivated viral influenza vaccination or a placebo control.']",4,0.47058823529411764,3,17
CD009982,3,8,"There was no clear difference between the viral influenza and placebo control group in terms of most of this review's primary outcomes: maternal death (RR 4.96, 95% CI 0.24 to 103.24, moderate quality evidence), infant death up to 175 days after birth (RR 0.71, 95% CI 0.37 to 1.37, moderate quality evidence), perinatal death (stillbirth and death in the first week of life) (RR 1.32, 95% CI 0.73 to 2.38, moderate quality evidence), influenza-like illness in women (RR 0.96, 95% CI 0.79 to 1.16) or their babies (RR 1.02, 95% CI 0.94 to 1.09), any respiratory illness in women (RR 0.97, 95% CI 0.91 to 1.04, high quality evidence) or their babies (RR 1.01, 95% CI 0.95 to 1.07, high quality evidence).",delete,[],5,0.5294117647058824,3,17
CD009982,3,9,"There were also no clear differences between vaccination and placebo control groups in terms of maternal hospitalisation for any infection (RR 2.27, 95% CI 0.94 to 5.49; 2116 women, moderate quality evidence), and neonatal hospitalisation for sepsis (RR 1.60, 95% CI 0.73 to 3.50; 2049 infants, moderate quality evidence).",delete,[],5,0.5882352941176471,3,17
CD009982,3,10,"However, viral influenza vaccination during pregnancy was associated with a reduction in reverse-transcriptase–polymerase-chain-reaction (RT-PCR) confirmed influenza among infants (RR 0.51, 95% CI 0.30 to 0.88, one study, 2049 infants) and women (RR 0.50, 95% CI 0.29 to 0.86, one study, 2116 women).",rephrase,['Viral influenza vaccination was associated with a reduction in confirmed influenza among women and their babies.'],5,0.6470588235294118,4,17
CD009982,4,11,"In terms of this review's secondary outcomes, there were no clear differences in terms of the impact on pregnancy outcomes (miscarriage, preterm labour and stillbirth), hospitalisation for respiratory infection among women and infants.",rephrase,"['However, there was no clear difference between groups in terms of pregnancy outcomes (miscarriage, preterm labour and stillbirth), influenza-like illness in women or their babies (high quality evidence), any respiratory illness, hospitalisation for respiratory infections and deaths among women (moderate quality evidence) and their babies (moderate quality evidence), neonatal hospitalisation for sepsis (moderate quality evidence), or maternal hospitalisation for any infection (moderate quality evidence).']",6,0.7058823529411765,4,17
CD009982,4,12,"Similarly, there was no difference between the viral influenza vaccine and placebo control groups in terms of any adverse systemic reactions.",rephrase,"['Similarly, there was no clear difference in any adverse systemic reactions between the vaccine and placebo groups.']",7,0.7647058823529411,4,17
CD009982,5,13,"There is limited evidence (from one small trial at a high risk of bias) on the effectiveness on Hib during pregnancy for improving maternal, neonatal and infant health outcomes.",delete,[],8,0.8235294117647058,5,17
CD009982,6,14,"Evidence from one large high quality trial on the effectiveness of viral influenza vaccine during pregnancy suggests reduced RT-PCR confirmed influenza among women and their babies, suggesting the potential of this strategy for scale up but further evidence from varying contexts is required.",rephrase,"['Evidence from one large high quality trial on the effectiveness of viral influenza vaccine during pregnancy suggests reduced reverse-transcriptase–polymerase-chain-reaction (RT-PCR) ) confirmed influenza among women and their babies, suggesting the potential of this strategy for scale up but further evidence from varying contexts is required.']",8,0.8823529411764706,5,17
CD009982,7,15,Further trials for both Hib and viral influenza vaccines with appropriate study designs and suitable comparison groups are required.,ignore,['Further trials for both Hib and viral influenza vaccines with appropriate study designs and suitable comparison groups are required.'],9,0.9411764705882353,5,17
CD009982,7,16,There are currently two 'ongoing' studies - these will be incorporated into the review in future updates.,ignore,['There are currently two ongoing studies - these will be incorporated into this review in future updates.'],10,1.0,5,17
CD006577,0,0,We identified four new trials for this update.,ignore,['We identified four new trials for this update.'],0,0.05263157894736842,1,19
CD006577,0,1,"In total, the evidence for this review rests on 26 trials (1369 participants).",rephrase,['This review includes 26 trials with a total of 1369 participants.'],1,0.10526315789473684,1,19
CD006577,0,2,"Listening to music was the main intervention used, and 23 of the studies did not include a trained music therapist.",delete,[],2,0.15789473684210525,1,19
CD006577,1,3,"Results indicate that music interventions have a small beneficial effect on psychological distress in people with CHD and this effect is consistent across studies (MD = -1.26, 95% CI -2.30 to -0.22, P = 0.02, I² = 0%).",delete,[],2,0.21052631578947367,2,19
CD006577,1,4,"Listening to music has a moderate effect on anxiety in people with CHD; however results were inconsistent across studies (SMD = -0.70, 95% CI -1.17 to -0.22, P = 0.004, I² = 77%).",delete,[],2,0.2631578947368421,2,19
CD006577,1,5,"Studies that used music interventions in people with myocardial infarction found more consistent anxiety-reducing effects of music, with an average anxiety reduction of 5.87 units on a 20 to 80 point score range (95% CI -7.99 to -3.75, P < 0.00001, I² = 53%).",delete,[],2,0.3157894736842105,2,19
CD006577,1,6,"Furthermore, studies that used patient-selected music resulted in greater anxiety-reducing effects that were consistent across studies (SMD = -0.89, 95% CI -1.42 to -0.36, P = 0.001, I² = 48%).",delete,[],2,0.3684210526315789,2,19
CD006577,1,7,"Findings indicate that listening to music reduces heart rate (MD = -3.40, 95% CI -6.12 to -0.69, P = 0.01), respiratory rate (MD = -2.50, 95% CI -3.61 to -1.39, P < 0.00001) and systolic blood pressure (MD = -5.52 mmHg, 95% CI - 7.43 to -3.60, P < 0.00001).",delete,[],2,0.42105263157894735,3,19
CD006577,1,8,"Studies that included two or more music sessions led to a small and consistent pain-reducing effect (SMD = -0.27, 95% CI -0.55 to -0.00, P = 0.05).",delete,[],2,0.47368421052631576,3,19
CD006577,1,9,"The results also suggest that listening to music may improve patients' quality of sleep following a cardiac procedure or surgery (SMD = 0.91, 95% CI 0.03 to 1.79, P = 0.04).",rephrase,"[""Finally, listening to music appears to improve patients' quality of sleep following a cardiac procedure or surgery.""]",2,0.5263157894736842,3,19
CD006577,2,10,We found no strong evidence for heart rate variability and depression.,rephrase,"['We found no evidence of effect for depression or heart rate variability, and inconsistent results for mood.']",3,0.5789473684210527,3,19
CD006577,2,11,Only one study considered hormone levels and quality of life as an outcome variable.,delete,[],4,0.631578947368421,4,19
CD006577,2,12,"A small number of studies pointed to a possible beneficial effect of music on opioid intake after cardiac procedures or surgery, but more research is needed to strengthen this evidence.",delete,[],4,0.6842105263157895,4,19
CD006577,3,13,"This systematic review indicates that listening to music may have a beneficial effect on anxiety in persons with CHD, especially those with a myocardial infarction.",rephrase,['The findings suggest that listening to music may have a beneficial effect on systolic blood pressure and heart rate in people with coronary heart disease.'],4,0.7368421052631579,4,19
CD006577,3,14,Anxiety-reducing effects appear to be greatest when people are given a choice of which music to listen to.,rephrase,"['Listening to music also appears to be effective in reducing anxiety in people with myocardial infarction, especially when they are given a choice of which music to listen to.']",5,0.7894736842105263,4,19
CD006577,4,15,"Furthermore, listening to music may have a beneficial effect on systolic blood pressure, heart rate, respiratory rate, quality of sleep and pain in persons with CHD.",rephrase,['Listening to music may also reduce pain and respiratory rate.'],6,0.8421052631578947,5,19
CD006577,4,16,"However, the clinical significance of these findings is unclear.",rephrase,"['Therefore, its clinical importance is unclear.']",7,0.8947368421052632,5,19
CD006577,4,17,"Since many of the studies are at high risk of bias, these findings need to be interpreted with caution.",rephrase,"['Overall, the quality of the evidence is not strong thus the results should be interpreted with caution.']",8,0.9473684210526315,5,19
CD006577,4,18,More research is needed into the effects of music interventions offered by a trained music therapist.,ignore,['More research is needed on the effects of music interventions offered by a trained music therapist.'],9,1.0,5,19
CD006739,0,0,"Twenty-five studies of good quality were identified, 11 trials evaluated sitagliptin and 14 trials vildagliptin treatment.",delete,[],0,0.06666666666666667,1,15
CD006739,0,1,"Altogether, 6743 patients were randomised in sitagliptin and 6121 patients in vildagliptin studies, respectively.",delete,[],0,0.13333333333333333,1,15
CD006739,0,2,Sitagliptin and vildagliptin studies ranged from 12 to 52 weeks duration.,rephrase,"['Most studies lasted 24 weeks, the longest trials evaluated 52 weeks of treatment.']",0,0.2,1,15
CD006739,0,3,"No data were published on mortality, diabetic complications, costs of treatment and health-related quality of life.",rephrase,"['So far, no study reported on patient-oriented parameters like mortality, diabetic complications, costs of treatment and health-related quality of life.']",1,0.26666666666666666,2,15
CD006739,1,4,"Sitagliptin and vildagliptin therapy in comparison with placebo resulted in an HbA1c reduction of approximately 0.7% and 0.6%, respectively.",rephrase,['When compared to placebo treatment sitagliptin and vildagliptin improved metabolic control.'],2,0.3333333333333333,2,15
CD006739,1,5,Data on comparisons with active comparators were limited but indicated no improved metabolic control following DPP-4 intervention in contrast to other hypoglycaemic agents.,rephrase,['Comparison with other already established blood-glucose lowering drugs did not reveal advantages of DPP-4 treatment.'],3,0.4,2,15
CD006739,1,6,Sitagliptin and vildagliptin therapy did not result in weight gain but weight loss was more pronounced following placebo interventions.,rephrase,['Weight gain was not observed after sitagliptin and vildagliptin therapy.'],4,0.4666666666666667,3,15
CD006739,1,7,No definite conclusions could be drawn from published data on sitagliptin and vildagliptin effects on measurements of beta-cell function.,delete,[],5,0.5333333333333333,3,15
CD006739,1,8,"Overall, sitagliptin and vildagliptin were well tolerated, no severe hypoglycaemia was reported in patients taking sitagliptin or vildagliptin.",ignore,"['Overall, sitagliptin and vildagliptin were well tolerated, no severe hypoglycaemia was reported in patients taking sitagliptin or vildagliptin.']",5,0.6,3,15
CD006739,1,9,All-cause infections increased significantly after sitagliptin treatment but did not reach statistical significance following vildagliptin therapy.,ignore,"['However, all-cause infections increased significantly after sitagliptin treatment but did not reach statistical significance following vildagliptin therapy.']",6,0.6666666666666666,4,15
CD006739,1,10,All published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements,ignore,"['Unfortunately, all published randomised controlled trials of at least 12 weeks treatment with sitagliptin and vildagliptin only reported routine laboratory safety measurements.']",7,0.7333333333333333,4,15
CD006739,2,11,DPP-4 inhibitors have some theoretical advantages over existing therapies with oral antidiabetic compounds but should currently be restricted to individual patients.,rephrase,"['Until new information arrives, DPP-4 inhibitors should only be used under controlled conditions and in individual patients.']",8,0.8,4,15
CD006739,2,12,Long-term data especially on cardiovascular outcomes and safety are urgently needed before widespread use of these new agents.,rephrase,['Since the new DPP-4 inhibitors may influence immune function additional long-term data on the safety of these drugs are necessary.'],9,0.8666666666666667,5,15
CD006739,2,13,More information on the benefit-risk ratio of DPP-4 inhibitor treatment is necessary especially analysing adverse effects on parameters of immune function.,delete,[],10,0.9333333333333333,5,15
CD006739,2,14,"Also, long-term data are needed investigating patient-oriented parameters like health-related quality of life, diabetic complications and all-cause mortality.",delete,[],10,1.0,5,15
CD004711,0,0,We included 34 trials with 2848 participants; 26 studies were parallel-group design (2725 participants) and eight used a cross-over design (123 participants).,rephrase,"['We included 34 trials in the review, with 2848 participants from 12 countries.']",0,0.1,1,10
CD004711,0,1,Only three included studies reported data for infants or children.,rephrase,['Participants were infants in three studies with adults (average age of 40 to 69 years) in the remainder.'],1,0.2,1,10
CD004711,0,2,Two further studies (76 participants) are awaiting classification.,delete,[],2,0.3,2,10
CD004711,1,3,"There was no overall statistical difference in artificial airway occlusion (RR 1.59, 95% CI 0.60 to 4.19; participants = 2171; studies = 15; I2 = 54%), mortality (RR 1.03, 95% CI 0.89 to 1.20; participants = 1951; studies = 12; I2 = 0%) or pneumonia (RR 0.93, 95% CI 0.73 to 1.19; participants = 2251; studies = 13; I2 = 27%).",rephrase,"['There was no overall difference in the rates of airway blockage, pneumonia or death in adults who were ventilated through heat and moisture exchangers compared to adults ventilated through a heated humidifier.']",2,0.4,2,10
CD004711,1,4,"There was some evidence that hydrophobic HMEs may reduce the risk of pneumonia compared to HHs (RR 0.48, 95% CI 0.28 to 0.82; participants = 469; studies = 3; I2 = 0%)..",rephrase,['There was some evidence that the occurrence of pneumonia may be lowered by using heat and moisture exchangers that capture less moisture.'],3,0.5,3,10
CD004711,2,5,The overall GRADE quality of evidence was low.,delete,[],4,0.6,3,10
CD004711,2,6,"Although the overall methodological risk of bias was generally unclear for selection and detection bias and low risk for follow-up, the selection of study participants who were considered suitable for HME and in some studies removing participants from the HME group made the findings of this review difficult to generalize.",delete,[],4,0.7,4,10
CD004711,3,7,"The available evidence suggests no difference between HMEs and HHs on the primary outcomes of airway blockages, pneumonia and mortality.",delete,[],4,0.8,4,10
CD004711,3,8,"However, the overall low quality of this evidence makes it difficult to be confident about these findings.",rephrase,"['The overall low quality of this evidence was low, making it difficult to be confident about these findings.']",4,0.9,5,10
CD004711,3,9,"Further research is needed to compare HMEs to HHs, particularly in paediatric and neonatal populations, but research is also needed to more effectively compare different types of HME to each other as well as different types of HH.",delete,[],5,1.0,5,10
CD001021,0,0,The searches identified 410 citations to 125 trials; 18 trials (3042 participants aged between five and 45 years) met the inclusion criteria.,rephrase,['The review includes 18 trials with 3042 people with CF aged between five and 45 years of age.'],0,0.04,1,25
CD001021,0,1,Limited data were available for meta-analyses due to the variability of trial design and reporting of results.,delete,[],1,0.08,1,25
CD001021,0,2,A total of 11 trials (1130 participants) compared an inhaled antibiotic to placebo or usual treatment for a duration between three and 33 months.,split,"['The trials lasted from three to 33 months.', 'In 11 trials investigators compared inhaled antibiotics with a placebo (an inhaled substance without the medication in it) and people were selected for one treatment or the other randomly.']",1,0.12,1,25
CD001021,0,3,"Five trials (1255 participants) compared different antibiotics, two trials (585 participants) compared different regimens of tobramycin and one trial (90 participants) compared intermittent tobramycin with continuous tobramycin alternating with aztreonam.",delete,[],3,0.16,1,25
CD001021,0,4,One trial (18 participants) compared an antibiotic to placebo and also to a different antibiotic and so fell into both groups.,split,"['Eight trials compared one inhaled antibiotic with either a different inhaled antibiotic or a different schedule of the same inhaled antibiotic.', 'One of the trials compared an antibiotic both to placebo and to a different antibiotic and so fell into both groups.']",3,0.2,1,25
CD001021,0,5,The most commonly studied antibiotic was tobramycin which was studied in 12 trials.,delete,[],5,0.24,2,25
CD001021,1,6,"Inhaled antibiotics compared to placebo
We found that inhaled antibiotics may improve lung function measured in a variety of ways (4 trials, 814 participants).",merge,"['Results from four trials showed that when compared to placebo, inhaled antibiotics may improve lung function and reduce the number of times the people with CF had a worsening of symptoms (exacerbation).']",5,0.28,2,25
CD001021,1,7,"Compared to placebo, inhaled antibiotics may also reduce the frequency of exacerbations (risk ratio (RR) 0.66, 95% confidence interval (CI) 0.47 to 0.93; 3 trials, 946 participants; low-certainty evidence).",none,[],5,0.32,2,25
CD001021,1,8,"Inhaled antibiotics may lead to fewer days off school or work (quality of life measure) (mean difference (MD) -5.30 days, 95% CI -8.59 to -2.01; 1 trial, 245 participants; low-certainty evidence).",rephrase,['Inhaled antibiotics may also mean fewer days off school or work (a measure of quality of life).'],6,0.36,2,25
CD001021,1,9,There were insufficient data for us to be able to report an effect on nutritional outcomes and there was no effect on survival.,rephrase,['They did not seem to have an effect on survival.'],7,0.4,2,25
CD001021,1,10,There was no effect on antibiotic resistance seen in the two trials that were included in meta-analyses.,delete,[],8,0.44,3,25
CD001021,1,11,"We are uncertain of the effect of the intervention on adverse events (very low-certainty evidence), but tinnitus and voice alteration were the only events occurring more often in the inhaled antibiotics group.",rephrase,"['We are not sure of the side effects of inhaled antibiotics, but tinnitus and changes in voice were reported more often in people inhaling antibiotics rather than the placebo.']",8,0.48,3,25
CD001021,1,12,The overall certainty of evidence was deemed to be low for most outcomes due to risk of bias within the trials and imprecision due to low event rates.,rephrase,"['We thought the overall certainty of evidence was low for most outcomes, mainly due to risks of bias within the trials and low event rates meaning results were not precise.']",9,0.52,3,25
CD001021,2,13,"Different antibiotics or regimens compared
Of the eight trials comparing different inhaled antibiotics or different antibiotic regimens, there was only one trial for each unique comparison.",rephrase,"['Where the trials compared different inhaled antibiotics or schedules, there was only one trial in each of the eight different comparisons.']",10,0.56,3,25
CD001021,2,14,We found no differences between groups for any outcomes except for the following.,rephrase,['The only differences we found in all these comparisons were for two outcomes.'],11,0.6,3,25
CD001021,2,15,"Aztreonam lysine for inhalation probably improved forced expiratory volume at one second (FEV1) % predicted compared to tobramycin (MD -3.40%, 95% CI -6.63 to -0.17; 1 trial, 273 participants; moderate-certainty evidence).",delete,[],12,0.64,4,25
CD001021,2,16,"However, the method of defining the endpoint was different to the remaining trials and the participants were exposed to tobramycin for a long period making interpretation of the results problematic.",delete,[],12,0.68,4,25
CD001021,2,17,We found no differences in any measure of lung function in the remaining comparisons.,rephrase,"['In one trial we found that aztreonam lysine probably improved lung function more than tobramycin, but no important differences were found in the other trials with regard to lung function.']",12,0.72,4,25
CD001021,2,18,"Trials measured pulmonary exacerbations in different ways and showed no differences between groups except for aztreonam lysine probably leading to fewer people needing treatment with additional antibiotics than with tobramycin (RR 0.66, 95% CI 0.51 to 0.86; 1 trial, 273 participants; moderate-certainty evidence); and there were fewer hospitalisations due to respiratory exacerbations with levofloxacin compared to tobramycin (RR 0.62, 95% CI 0.40 to 0.98; 1 trial, 282 participants; high-certainty evidence).",rephrase,['Aztreonam lysine also probably led to fewer people needing additional courses of antibiotics than tobramycin and there were fewer hospitalisations after levofloxacin compared to placebo.'],13,0.76,4,25
CD001021,2,19,"Important treatment-related adverse events were not very common across comparisons, but were reported less often in the tobramycin group compared to both aztreonam lysine and colistimethate.",rephrase,"['We noted that important side effects that were related to the treatment were not very common in the trials, but they were less common with tobramycin than with other antibiotics.']",14,0.8,4,25
CD001021,2,20,We found the certainty of evidence for these comparisons to be directly related to the risk of bias within the individual trials and varied from low to high.,delete,[],15,0.84,5,25
CD001021,3,21,"Long-term treatment with inhaled anti-pseudomonal antibiotics probably improves lung function and reduces exacerbation rates, but pooled estimates of the level of benefit were very limited.",delete,[],15,0.88,5,25
CD001021,3,22,The best evidence available is for inhaled tobramycin.,delete,[],15,0.92,5,25
CD001021,3,23,More evidence from trials measuring similar outcomes in the same way is needed to determine a better measure of benefit.,delete,[],15,0.96,5,25
CD001021,3,24,"Longer-term trials are needed to look at the effect of inhaled antibiotics on quality of life, survival and nutritional outcomes.",delete,[],15,1.0,5,25
CD007672,0,0,Fifty-one studies were included.,delete,[],0,0.1111111111111111,1,9
CD007672,0,1,"They used three different models, namely case management, shared care, and interdisciplinary teams.",rephrase,"['Three main models of care (case management, shared care and interdisciplinary team) designed to improve continuity of care were identified in the 51 studies included in this review.']",0,0.2222222222222222,2,9
CD007672,0,2,"Six additional interventional strategies were used besides these models: (1) patient-held record, (2) telephone follow-up, (3) communication and case discussion between distant healthcare professionals, (4) change in medical record system, (5) care protocols, directives and guidelines, and (6) coordination of assessments and treatment.",delete,[],1,0.3333333333333333,2,9
CD007672,1,3,"Based on the median effect size estimates, no significant difference in patient health-related outcomes was found between patients assigned to interventions and those assigned to usual care.",delete,[],1,0.4444444444444444,3,9
CD007672,1,4,"A limited number of studies reported psychological health, satisfaction of providers, or process of care measures.",merge,[],1,0.5555555555555556,3,9
CD007672,1,5,"However, they could not be regrouped to calculate median effect size estimates because of a high heterogeneity among studies.",none,"['Few studies reported provider and informal caregiver outcomes, as well as process of care outcomes, so they could not be regrouped for analysis.']",1,0.6666666666666666,4,9
CD007672,2,6,"Results from this Cochrane review do not allow us to conclude on the effectiveness of included interventions to improve continuity of care on patient, healthcare provider or process of care outcomes.",split,"['According to our analysis, there was no clear evidence that the interventions assessed in this review either improved or worsened patient health-related outcomes.', 'Therefore, our analyses did not allow us to draw firm conclusions on the effectiveness of interventions designed to improve continuity of care in the follow-up of patients with cancer.']",2,0.7777777777777778,4,9
CD007672,2,7,Future research should evaluate interventions that target an improvement in continuity as their primary objective and describe these interventions with the categories proposed in this review.,rephrase,['Future research should identify which outcomes are the most sensitive to change and the most meaningful regarding continuity of care.'],4,0.8888888888888888,5,9
CD007672,2,8,"Also of importance, continuity measures should be validated with persons with cancer who have been followed in various settings.",rephrase,"['Also, it would be valuable to develop a standardised instrument to measure continuity of care in patients with cancer.']",5,1.0,5,9
CD006009,0,0,We included 35 placebo controlled and three active controlled RCTs (N = 7365).,delete,[],0,0.08333333333333333,1,12
CD006009,0,1,The mean reduction on the IRLS was −5.7 points lower in dopamine agonist treatment compared to placebo (95% confidence interval (CI) −6.7 to −4.7).,rephrase,['Dopamine agonists lead to a larger improvement on the International RLS Severity Rating Scale (IRLS) compared to placebo.'],0,0.16666666666666666,1,12
CD006009,0,2,Periodic limb movements in sleep per hour of sleep (PLMS-Index; PLMSI) were −22.4/h lower than in placebo (95% CI −27.8 to −16.9).,rephrase,['Also periodic limb movements in sleep were significantly reduced by dopamine agonists compared to placebo.'],1,0.25,2,12
CD006009,0,3,"Self rated quality of sleep and disease specific quality of life were improved by a standardised mean difference (SMD) of 0.40 (95% CI 0.33 to 0.47) and 0.34 (95% CI 0.23 to 0.44), respectively.",rephrase,['Patients rated their quality of sleep and quality of life as markedly improved.'],2,0.3333333333333333,2,12
CD006009,0,4,"Patients were more likely to drop out (odds ratio (OR) 1.82, 95% CI 1.35 to 2.45) and experienced more adverse events under dopamine agonist treatment than with placebo (OR 1.82, 95% CI 1.59 to 2.08).",rephrase,"['Patients were, however, more likely to discontinue dopamine agonist treatment and experienced more adverse events when treated with dopamine agonists compared to placebo.']",3,0.4166666666666667,3,12
CD006009,0,5,Visual inspection of forest plots showed the highest efficacy in three studies investigating cabergoline and pergolide (N = 3).,delete,[],4,0.5,3,12
CD006009,0,6,"Active controlled trials investigated effects of cabergoline, pergolide, and pramipexole in a number of outcomes.",delete,[],4,0.5833333333333334,3,12
CD006009,0,7,"The IRLS score was lower with cabergoline and pramipexole compared to levodopa (MD −5.3, 95% CI −8.4 to −2.1).",delete,[],4,0.6666666666666666,4,12
CD006009,0,8,Only four studies investigated treatment efficacy up to seven months.,rephrase,"['Treatment durations varied from one week to seven months, but most treatments had durations of one to 12 weeks.']",4,0.75,4,12
CD006009,0,9,"The most severe side effect, augmentation, was not assessed reliably.",rephrase,"['Augmentation, a serious adverse event in dopaminergic treatment, has not been sufficiently assessed.']",5,0.8333333333333334,5,12
CD006009,1,10,The meta-analyses show the superiority of dopamine agonists over placebo in RCTs up to seven months.,rephrase,['We could include 38 trials in the meta-analyses which investigated the efficacy and safety of dopamine agonist treatment compared to placebo or to other treatments for RLS.'],6,0.9166666666666666,5,12
CD006009,1,11,Cabergoline and pramipexole showed larger efficacy compared to levodopa in some but not all outcomes.,delete,[],7,1.0,5,12
CD012505,0,0,We included 83 SRs; 70 had outcome data.,rephrase,"[""We included 83 systematic reviews with evidence about whether or not the intervention was able to reduce pregnant women's chance of having a preterm birth or a baby death.""]",0,0.038461538461538464,1,26
CD012505,0,1,Below we highlight key results from a subset of 36 SRs of interventions intended to prevent PTB.,delete,[],1,0.07692307692307693,1,26
CD012505,1,2,"Outcome: preterm birth
Clear evidence of benefit
Four SRs reported clear evidence of benefit to prevent specific populations of pregnant women from giving birth early, including midwife-led continuity models of care versus other models of care for all women; screening for lower genital tract infections for pregnant women less than 37 weeks' gestation and without signs of labour, bleeding or infection; and zinc supplementation for pregnant women without systemic illness.",rephrase,['Clear benefit\nWe were confident that the following interventions were able to help specific populations of pregnant women avoid giving birth early: midwife-led continuity models of care versus other models of care for all women; screening for lower genital tract infections; and zinc supplementation for pregnant women without systemic illness.'],1,0.11538461538461539,1,26
CD012505,1,3,Cervical cerclage showed clear benefit for women with singleton pregnancy and high risk of PTB only.,rephrase,['Cervical stitch (cerclage) was of benefit only for women at high risk of preterm birth and with singleton pregnancy.'],2,0.15384615384615385,1,26
CD012505,2,4,"Clear evidence of harm
No included SR reported clear evidence of harm.",rephrase,['Clear harm\nWe found no treatment that increased women’s chance of giving birth preterm.'],3,0.19230769230769232,1,26
CD012505,3,5,"No effect or equivalence
For pregnant women at high risk of PTB, bedrest for women with singleton pregnancy and antibiotic prophylaxis during the second and third trimester were of no effect or equivalent to a comparator.",delete,[],4,0.23076923076923078,2,26
CD012505,4,6,"Possible benefit
Four SRs found possible benefit in: group antenatal care for all pregnant women; antibiotics for pregnant women with asymptomatic bacteriuria; pharmacological interventions for smoking cessation for pregnant women who smoke; and vitamin D supplements alone for women without pre-existing conditions such as diabetes.",rephrase,"['Possible benefit\nThe following interventions may have helped some groups of pregnant women avoid preterm birth, but we have less confidence in these results: group antenatal care for all pregnant women; antibiotics for pregnant women with asymptomatic bacteriuria; pharmacological interventions for smoking cessation; and vitamin D supplements alone for women without health problems.']",4,0.2692307692307692,2,26
CD012505,5,7,"Possible harm
One SR reported possible harm (increased risk of PTB) with intramuscular progesterone, but this finding is only relevant to women with multiple pregnancy and high risk of PTB.",merge,[],5,0.3076923076923077,2,26
CD012505,5,8,"Another review found possible harm with vitamin D, calcium and other minerals for pregnant women without pre-existing conditions.",none,"['Possible harm\nWe found two interventions that may have made things worse for some pregnant women: intramuscular progesterone for women at high risk of preterm birth with multiple pregnancy; and taking vitamin D supplements, calcium and other minerals for pregnant women without health problems.']",5,0.34615384615384615,2,26
CD012505,6,9,"Outcome: perinatal death
Clear evidence of benefit
Two SRs reported clear evidence of benefit to reduce pregnant women's risk of perinatal death: midwife-led continuity models of care for all pregnant women; and fetal and umbilical Doppler for high-risk pregnant women.",rephrase,"[""Clear benefit\nWe were confident in evidence for midwife-led continuity models of care for all pregnant women; and for fetal and umbilical Doppler for high-risk pregnant women; these interventions appeared to reduce women's chance of experiencing baby death.""]",6,0.38461538461538464,2,26
CD012505,7,10,"Clear evidence of harm
No included SR reported clear evidence of harm.",rephrase,['Clear harm\nWe found no intervention that increased women’s risk of baby death.'],7,0.4230769230769231,3,26
CD012505,8,11,"No effect or equivalence
For pregnant women at high risk of PTB, antibiotic prophylaxis during the second and third trimester was of no effect or equivalent to a comparator.",delete,[],8,0.46153846153846156,3,26
CD012505,9,12,"Possible benefit
One SR reported possible benefit with cervical cerclage for women with singleton pregnancy and high risk of PTB.",rephrase,['Possible benefit\nWe found a possible benefit with cervical stitch (cerclage) for women with singleton pregnancy and high risk of preterm birth.'],8,0.5,3,26
CD012505,10,13,"Possible harm
One SR reported possible harm associated with a reduced schedule of antenatal visits for pregnant women at low risk of pregnancy complications; importantly, these women already received antenatal care in settings with limited resources.",split,"['Possible harm\nOne review reported possible harm associated with having fewer antenatal visits, even for pregnant women at low risk of pregnancy problems.', 'The pregnant women in this review already received limited antenatal care.']",9,0.5384615384615384,3,26
CD012505,11,14,"Outcomes: preterm birth and perinatal death
Unknown benefit or harm
For pregnant women at high risk of PTB for any reason including multiple pregnancy, home uterine monitoring was of unknown benefit or harm.",rephrase,"['Unknown benefit or harm\nFor pregnant women at high risk of preterm birth for any reason including multiple pregnancy, home uterine monitoring was of unknown benefit or harm.']",11,0.5769230769230769,3,26
CD012505,11,15,"For pregnant women at high risk due to multiple pregnancy: bedrest, prophylactic oral betamimetics, vaginal progesterone and cervical cerclage were all of unknown benefit or harm.",rephrase,"['For high-risk pregnant women with multiple pregnancy: bedrest, prophylactic oral betamimetics, vaginal progesterone and cervical cerclage were all of unknown benefit or harm.']",12,0.6153846153846154,4,26
CD012505,12,16,"Implications for practice
The overview serves as a map and guide to all current evidence relevant to PTB prevention published in the Cochrane Library.",delete,[],13,0.6538461538461539,4,26
CD012505,12,17,"Of 70 SRs with outcome data, we identified 36 reviews of interventions with the aim of preventing PTB.",delete,[],13,0.6923076923076923,4,26
CD012505,12,18,"Just four of these SRs had evidence of clear benefit to women, with an additional four SRs reporting possible benefit.",delete,[],13,0.7307692307692307,4,26
CD012505,12,19,"No SR reported clear harm, which is an important finding for women and health providers alike.",delete,[],13,0.7692307692307693,4,26
CD012505,13,20,"The overview summarises no evidence for the clinically important interventions of cervical pessary, cervical length assessment and vaginal progesterone because these Cochrane Reviews were not current.",rephrase,"['Our overview found no up-to-date information in the Cochrane Library for the important treatments of cervical pessary, vaginal progesterone or cervical assessment with ultrasound.']",13,0.8076923076923077,5,26
CD012505,13,21,These are active areas for PTB research.,delete,[],14,0.8461538461538461,5,26
CD012505,14,22,The graphic icons we assigned to SR effect estimates do not constitute clinical guidance or an endorsement of specific interventions for pregnant women.,rephrase,['We organised our information in clear figures with graphic icons to represent how confident we were in the results and to point readers toward promising treatments for specific groups of pregnant women.'],14,0.8846153846153846,5,26
CD012505,14,23,"It remains critical for pregnant women and their healthcare providers to carefully consider whether specific strategies to prevent PTB will be of benefit for individual women, or for specific populations of women.",ignore,"['It remains important for pregnant women and their healthcare providers to carefully consider whether specific strategies to prevent preterm birth will be of benefit for individual women, or for specific populations of women.']",15,0.9230769230769231,5,26
CD012505,15,24,"Implications for research
Formal consensus work is needed to establish standard language for overviews of reviews and to define the limits of their interpretation.",delete,[],16,0.9615384615384616,5,26
CD012505,16,25,"Clinicians, researchers and funders must address the lack of evidence for interventions relevant to women at high risk of PTB due to multiple pregnancy.",rephrase,['We found no high-quality evidence relevant to women at high risk of preterm birth due to multiple pregnancy.'],16,1.0,5,26
CD001936,0,0,We retrieved 1111 publications of which 51 satisfied our inclusion criteria.,rephrase,['Fifty-one studies satisfied our inclusion criteria.'],0,0.09090909090909091,1,11
CD001936,0,1,"In total there were 2871 participants (1645 active, 1226 placebo), each receiving on average 18 injections.",rephrase,"['In total there were 2871 participants (1645 in the treatment groups and 1226 in the placebo), each receiving on average 18 injections.']",1,0.18181818181818182,1,11
CD001936,0,2,Duration of immunotherapy varied from three days to three years.,rephrase,['The duration of treatment varied from three days to three years.'],2,0.2727272727272727,2,11
CD001936,0,3,"Symptom score data from 15 trials were suitable for meta-analysis and showed an overall reduction in the immunotherapy group (SMD -0.73 (95% CI -0.97 to -0.50, P < 0.00001)).",delete,[],3,0.36363636363636365,2,11
CD001936,0,4,"Medication score data from 13 trials showed an overall reduction in the immunotherapy group (SMD of -0.57 (95% CI -0.82 to -0.33, p<0.00001)).",delete,[],3,0.45454545454545453,3,11
CD001936,0,5,Clinical interpretation of the effect size is difficult.,delete,[],3,0.5454545454545454,3,11
CD001936,0,6,Adrenaline was given in 0.13% (19 of 14085 injections) of those on active treatment and in 0.01% (1 of 8278 injections) of the placebo group for treatment of adverse events.,delete,[],3,0.6363636363636364,4,11
CD001936,0,7,There were no fatalities.,delete,[],3,0.7272727272727273,4,11
CD001936,1,8,This review has shown that specific allergen injection immunotherapy in suitably selected patients with seasonal allergic rhinitis results in a significant reduction in symptom scores and medication use.,rephrase,['This review has shown that injection immunotherapy in suitably selected patients with hay fever results in significant reductions in symptom scores and medication use.'],3,0.8181818181818182,5,11
CD001936,1,9,Injection immunotherapy has a known and relatively low risk of severe adverse events.,ignore,['Injection immunotherapy has a known and relatively low risk of severe adverse events.'],4,0.9090909090909091,5,11
CD001936,1,10,We found no long-term consequences from adverse events.,rephrase,['We found no long-term consequences from adverse events and no fatalities.'],5,1.0,5,11
CD013038,0,0,"Three trials involving a total of 161 preterm infants were included in this review, but only two trials (131 infants) contributed data for meta-analysis.",rephrase,"['In a search up to 1 June 2018, we identified three completed studies involving 161 preterm infants admitted to a neonatal intensive care unit (NICU) at a tertiary hospital.']",0,0.07692307692307693,1,13
CD013038,0,1,"There was no evidence of a clear effect of exposure to the smell and taste of milk with tube feedings on time taken to reach full sucking feeds (MD -2.57 days, 95% CI -5.15 to 0.02; I2 = 17%; 2 trials, 131 infants; very low-quality evidence).",rephrase,['We found that exposure to the smell and taste of milk with orogastric or nasogastric tube feedings had no clear effect on the time to reach full sucking feeds.'],1,0.15384615384615385,1,13
CD013038,0,2,One trial reported no adverse effects.,rephrase,['One study reported no adverse effects.'],2,0.23076923076923078,2,13
CD013038,0,3,"There was no evidence of a clear effect of exposure to the smell and taste of milk on the following outcomes: time taken to reach full enteral feeds (MD -1.57 days, 95% CI -6.25 to 3.11; 1 trial, 51 infants; very low-quality evidence), duration of parenteral nutrition (MD -2.20 days, 95% CI -9.49 to 5.09; 1 trial, 51 infants; very low-quality evidence), incidence of necrotising enterocolitis (RR 0.62, 95% CI 0.15 to 2.48; 1 trial, 51 infants; low-quality evidence), and late infection (RR 2.46, 95% CI 0.27 to 22.13; 1 trial, 51 infants; low-quality evidence).",rephrase,"['Exposure to the smell and taste of milk also had no clear effect on time to reach full tube feeding, feed tolerance, incidence of late infection and severe intestinal infection, duration of intravenous nutrition, and growth.']",3,0.3076923076923077,2,13
CD013038,0,4,"There was very low-quality evidence demonstrating that exposure to the smell and taste of milk decreased duration of hospitalisation by almost four days (MD -3.89 days, 95% CI -7.03 to -0.75; I2 = 51%; 2 trials, 131 infants).",rephrase,['Very low-quality evidence from two studies suggested that exposure to the smell and taste of milk decreased the length of hospital stay by almost four days compared to no exposure to the smell and taste of milk.'],4,0.38461538461538464,2,13
CD013038,0,5,"In two trials, an increased growth velocity was noted in infants exposed to the intervention, but we were unable to combine data to perform meta-analysis.",delete,[],5,0.46153846153846156,3,13
CD013038,0,6,No data were available to assess feed intolerance and rates of exclusive breastfeeding at discharge.,delete,[],5,0.5384615384615384,3,13
CD013038,0,7,"Included trials were small and had methodological limitations including lack of randomisation (one trial), lack of blinding, and different inclusion criteria and administration of the interventions.",rephrase,"['However, the included studies were small and had several limitations in terms of how they were done.']",5,0.6153846153846154,4,13
CD013038,1,8,"Evidence from two trials suggests that exposure to the smell and taste of milk with tube feedings has no clear effect on time taken to reach full sucking feeds, but it may decrease length of hospitalisation.",rephrase,['Exposure to the smell and taste of milk with orogastric or nasogastric tube feedings may decrease length of hospitalisation for preterm infants.'],6,0.6923076923076923,4,13
CD013038,1,9,"However, these results are uncertain due to the very low quality of the evidence.",rephrase,"['However, the effect of this treatment to accelerate feeding in preterm infants is uncertain due to limited and very low-quality evidence.']",7,0.7692307692307693,4,13
CD013038,1,10,There is also limited evidence about the impact on other important clinical outcomes and on safety.,delete,[],8,0.8461538461538461,5,13
CD013038,1,11,"Future research should examine the effect of exposure to the smell and taste of milk with tube feedings on clinical outcomes during hospitalisation, such as attainment of full enteral and sucking feeds, safety, feed tolerance, incidence of infection, and infant growth.",merge,"['Future research needs to explore the effect of exposure to the smell and taste of milk with tube feedings on important clinical outcomes, such as time to full sucking feeds, adverse effects, time to reach full tube feedings, feed tolerance, incidence of infection, and growth.']",8,0.9230769230769231,5,13
CD013038,1,12,"Additionally, future research should be sufficiently powered to evaluate the effect of the intervention in infants of different gestational ages, on each sex separately, and on the optimal frequency and duration of exposure.",none,[],8,1.0,5,13
CD013577,0,0,We included 25 clinical trials (from 29 publications) investigating the effects of epidural corticosteroid injections compared to placebo in patients with lumbosacral radicular pain.,merge,['We included 25 clinical trials (reported in 29 publications) enrolling a total of 2470 people with sciatica comparing injection of anti-inflammatory steroids into the lower spine to placebo injection.'],0,0.047619047619047616,1,21
CD013577,0,1,The included studies provided data for a total of 2470 participants with a mean age ranging from 37.3 to 52.8 years.,none,[],0,0.09523809523809523,1,21
CD013577,0,2,Seventeen studies included participants with lumbosacral radicular pain with a diagnosis based on clinical assessment and 15 studies included participants with mixed duration of symptoms.,rephrase,['Most studies included participants with sciatica detected through clinical findings and most studies included participants with mixed duration of symptoms.'],1,0.14285714285714285,1,21
CD013577,0,3,The included studies were conducted mainly in North America and Europe.,rephrase,['The included studies were carried out mainly in North America and Europe.'],2,0.19047619047619047,1,21
CD013577,0,4,"Fifteen studies did not report funding sources, five studies reported not receiving funding, and five reported receiving funding from a non-profit or government source.",rephrase,"['Fifteen studies did not report any information related to funding, five studies reported not receiving any funding for conducting the study, and five studies reported receiving funding from a non-profit source (e.g. research institute, university) or from government sources.']",3,0.23809523809523808,2,21
CD013577,0,5,"Eight trials reported data on pain intensity, 12 reported data on disability, and eight studies reported data on adverse events.",rephrase,"['Eight trials reported data on leg pain, 12 trials reported data on disability, and eight studies reported data on adverse events.']",4,0.2857142857142857,2,21
CD013577,0,6,The duration of the follow-up assessments ranged from 12 hours to 1 year.,ignore,['The duration of the follow-up assessments ranged from 12 hours to 1 year.'],5,0.3333333333333333,2,21
CD013577,0,7,We considered eight trials to be of high quality because we judged them as having low risk of bias in four out of the five bias domains.,rephrase,['We considered only eight trials to be at low risk of bias.'],6,0.38095238095238093,2,21
CD013577,0,8,We identified one ongoing trial in a trial registry.,rephrase,['We identified one ongoing trial in a registry of trial protocols.'],7,0.42857142857142855,3,21
CD013577,1,9,"Epidural corticosteroid injections were probably slightly more effective compared to placebo in reducing leg pain at short-term follow-up (mean difference (MD) −4.93, 95% confidence interval (CI) −8.77 to –1.09 on a 0 to 100 scale; 8 trials, n = 949; moderate-quality evidence (downgraded for risk of bias)).",merge,[],8,0.47619047619047616,3,21
CD013577,1,10,"For disability, epidural corticosteroid injections were probably slightly more effective compared to placebo in reducing disability at short-term follow-up (MD −4.18, 95% CI −6.04 to −2.17, on a 0 to 100 scale; 12 trials, n = 1367; moderate-quality evidence (downgraded for risk of bias)).",none,['Injections of anti-inflammatory steroids into the lower spine is probably slightly better than placebo in reducing leg pain and disability at short-term follow-up.'],8,0.5238095238095238,3,21
CD013577,1,11,"The treatment effects are small, however, and may not be considered clinically important by patients and clinicians (i.e. MD lower than 10%).",rephrase,"['However, the treatment effects were small and may not be considered clinically important by patients and clinicians (i.e. less than 10 points on a 0 to 100 scale).']",9,0.5714285714285714,3,21
CD013577,2,12,"Most trials provided insufficient information on how or when adverse events were assessed (immediate or short-term follow-up) and only reported adverse drug reactions — that is, adverse events that the trialists attributed to the study treatment.",rephrase,['Most studies provided insufficient information on how or when adverse events were assessed (immediate or short-term follow-up) and only reported adverse drug reactions (unexpected events that the authors attributed to the study treatment).'],10,0.6190476190476191,4,21
CD013577,2,13,"We are very uncertain that epidural corticosteroid injections make no difference compared to placebo injection in the frequency of minor adverse events (risk ratio (RR) 1.14, 95% CI 0.91 to 1.42; 8 trials, n = 877; very low quality evidence (downgraded for risk of bias, inconsistency and imprecision)).",rephrase,['We are very uncertain that the frequency of minor adverse events is different following injections of anti-inflammatory steroids compared to placebo injection.'],11,0.6666666666666666,4,21
CD013577,2,14,"Minor adverse events included increased pain during or after the injection, non-specific headache, post-dural puncture headache, irregular periods, accidental dural puncture, thoracic pain, non-local rash, sinusitis, vasovagal response, hypotension, nausea, and tinnitus.",rephrase,"['Adverse events included increased pain during or after the injection, non-specific headache, headache after accidental spinal puncture, irregular periods, accidental spinal puncture, thoracic pain, non-local rash, sinusitis, vasovagal response (brief loss of consciousness), hypotension, nausea, and tinnitus.']",12,0.7142857142857143,4,21
CD013577,2,15,One study reported a major drug reaction for one patient on anticoagulant therapy who had a retroperitoneal haematoma as a complication of the corticosteroid injection.,rephrase,['One study reported a major drug reaction: one patient on anticoagulant therapy had a retroperitoneal haematoma (bleeding in the abdominal space) as a complication of the injection of anti-inflammatory steroids.'],13,0.7619047619047619,4,21
CD013577,3,16,This study found that epidural corticosteroid injections probably slightly reduced leg pain and disability at short-term follow-up in people with lumbosacral radicular pain.,delete,[],14,0.8095238095238095,5,21
CD013577,3,17,"In addition, no minor or major adverse events were reported at short-term follow-up after epidural corticosteroid injections or placebo injection.",delete,[],14,0.8571428571428571,5,21
CD013577,3,18,"Although the current review identified additional clinical trials, the available evidence still provides only limited support for the use of epidural corticosteroid injections in people with lumbosacral radicular pain as the treatment effects are small, mainly evident at short-term follow-up and may not be considered clinically important by patients and clinicians (i.e. mean difference lower than 10%).",rephrase,"['Although the current review identified additional trials, the available evidence still provides only limited support for the use of injections of anti-inflammatory steroids into the lower spine for sciatica as the treatment benefits are small, mainly evident at short-term follow-up, and may not be considered clinically important by patients and clinicians.']",14,0.9047619047619048,5,21
CD013577,3,19,"According to GRADE, the quality of the evidence ranged from very low to moderate, suggesting that further studies are likely to play an important role in clarifying the efficacy and tolerability of this treatment.",rephrase,"['The quality of evidence was at best moderate, suggesting that further studies may change our conclusions.']",15,0.9523809523809523,5,21
CD013577,3,20,We recommend that further trials should attend to methodological features such as appropriate allocation concealment and blinding of care providers to minimise the potential for biased estimates of treatment and harmful effects.,delete,[],16,1.0,5,21
CD006421,0,0,We included two RCTs (with a total of 789 participants) comparing LMWH with 5-FU infusion and placebo.,delete,[],0,0.16666666666666666,1,6
CD006421,0,1,"However, we did not perform a meta-analysis because of significant heterogeneity between these studies.",delete,[],0,0.3333333333333333,2,6
CD006421,0,2,"One study found a significant beneficial effect of LMWH with 5-FU in reducing postoperative PVR compared to placebo (RR: 0.48, 95% confidence interval: 0.25 to 0.92), in 174 patients who were viewed at high-risk of developing postoperative PVR.",rephrase,"['One study focused on patients who are considered at high-risk of developing PVR after surgery because of pre-existing ocular features, and found beneficial effects of this treatment in this group.']",0,0.5,3,6
CD006421,0,3,"The other study included 615 unselected cases of rhegmatogenous retinal detachment and could not show a difference between LMWH with 5-FU infusion and placebo in reducing PVR rates (RR:1.45, 95% confidence interval: 0.76 to 2.76).",delete,[],1,0.6666666666666666,4,6
CD006421,1,4,Results from this review indicate that there is inconsistent evidence from two studies on patients at different risk of PVR on the effect of LMWH and 5-FU used during vitrectomy to prevent PVR.,rephrase,['The two studies included in this review looked at using LMWH with 5-FU during retinal detachment repair to see if there was an effect of reducing PVR levels after surgery.'],1,0.8333333333333334,5,6
CD006421,1,5,"Future research should be conducted on high risk patients only, until a benefit is confirmed at least in this patient subgroup.",rephrase,"['Due to the inconsistency of the evidence, until further data are available, future research on the use of LMWH with 5-FU should be conducted only in retinal detachment patients who are likely to develop considerable retinal scarring after surgery.']",2,1.0,5,6
CD011979,0,0,Eight trials with 316 participants met the inclusion criteria.,rephrase,['We included eight trials (316 participants).'],0,0.08333333333333333,1,12
CD011979,0,1,Most of the included studies were single-centre studies that were carried out in clinics or hospitals with a sample size ranging from 14 to 84.,rephrase,['Most studies were undertaken in clinics or hospitals and had small numbers of participants (14 to 84).'],1,0.16666666666666666,1,12
CD011979,0,2,"We generally considered the included studies to be at unclear or high risk of bias, as they had one domain at high risk of bias, or three or more domains at unclear risk of bias.",delete,[],2,0.25,2,12
CD011979,1,3,We did not identify any studies that reported valid data for time to complete wound healing.,delete,[],2,0.3333333333333333,2,12
CD011979,1,4,"Meta-analysis of four studies including 116 participants indicated that participants receiving phototherapy may experience a greater proportion of wounds completely healed during follow-up compared with those receiving no phototherapy/placebo (64.5% for the phototherapy group versus 37.0% for the no phototherapy/placebo group; risk ratio 1.57, 95% confidence interval 1.08 to 2.28; low-quality evidence, downgraded for study limitations and imprecision).",delete,[],2,0.4166666666666667,3,12
CD011979,1,5,"Two studies mentioned adverse events in the results; one study with 16 participants suggested that there were no device-related adverse events, and the other study with 14 participants suggested that there was no clear difference between phototherapy and placebo group.",delete,[],2,0.5,3,12
CD011979,2,6,"Four studies reported change in ulcer size, but primarily due to high heterogeneity, they were not combined.",delete,[],2,0.5833333333333334,3,12
CD011979,2,7,Results from individual trials (including 16 participants to 84 participants) generally suggested that after two to four weeks of treatment phototherapy may result in a greater reduction in ulcer size but the quality of the evidence was low due to unclear risk of bias in the original trial and small sample size.,delete,[],2,0.6666666666666666,4,12
CD011979,2,8,We based the analyses for quality of life and amputations on only one study each (28 participants and 23 participants respectively); both outcomes showed no clear difference between the phototherapy group and the no phototherapy/placebo group.,rephrase,['We did not find sufficient evidence that the potential harms or incidence of amputations differed between the phototherapy group and the no phototherapy/placebo group.'],2,0.75,4,12
CD011979,3,9,"This systematic review of randomised trials suggested that phototherapy, when compared to no phototherapy/placebo, may increase the proportion of wounds completely healed during follow-up and may reduce wound size in people with diabetes, but there was no evidence that phototherapy improves quality of life.",rephrase,"['The results suggested that phototherapy, when compared to no phototherapy or a placebo, may increase the proportion of wounds completely healed during follow-up and reduce wound size.']",3,0.8333333333333334,5,12
CD011979,3,10,"Due to the small sample size and methodological flaws in the original trials, the quality of the evidence was low, which reduces our confidence in these results.",rephrase,['We judged the quality of the evidence to be low due to a lack of data and risk of the study results being biased.'],4,0.9166666666666666,5,12
CD011979,3,11,"Large, well-designed randomised controlled trials are needed to confirm whether phototherapy could be an effective option for the treatment of foot ulcers in people with diabetes.",rephrase,['Further high-quality studies are needed to confirm the benefits and harms of phototherapy.'],5,1.0,5,12
CD001035,0,0,A total of 5271 references were screened and of these 23 RCTs met the inclusion criteria.,delete,[],0,0.07142857142857142,1,14
CD001035,0,1,Most were conducted in the USA and in health-care clinics (e.g. family planning).,rephrase,"['The trials were mostly conducted in the USA (21 trials) and in health-care (e.g. family planning) clinics (14 trials), with only four in educational settings.']",0,0.14285714285714285,1,14
CD001035,1,2,"The majority of interventions provided information about STIs and taught safer sex skills (e.g. communication), occasionally supplemented with provision of resources (e.g. free sexual health services).",rephrase,"['The interventions mostly provided information about STIs and taught safer sex skills (e.g. communication with partners), occasionally supplemented with provision of resources (e.g. free sexual health services).']",1,0.21428571428571427,2,14
CD001035,1,3,"They were heterogeneous in duration, contact time, provider, behavioural aims and outcomes.",rephrase,"['Interventions varied considerably in duration, contact time, provider, behavioural aims and outcomes.']",2,0.2857142857142857,2,14
CD001035,1,4,A variety of STIs were addressed including HIV and chlamydia.,rephrase,"['A variety of STIs were addressed including HIV and chlamydia, but not explicitly HPV.']",3,0.35714285714285715,2,14
CD001035,1,5,None of the trials explicitly mentioned HPV or cervical cancer prevention.,delete,[],4,0.42857142857142855,3,14
CD001035,2,6,"Statistically significant effects for behavioural outcomes (e.g. increasing condom use) were common, though not universal and varied according to the type of outcome.",rephrase,['The most common behavioural outcome (measured in 19 trials) was condom use for vaginal intercourse.'],4,0.5,3,14
CD001035,2,7,There were no statistically significant effects of abstaining from or reducing sexual activity.,rephrase,"['In terms of statistically significant effects, some interventions improved condom-related behaviour and reduced the number of sexual partners, but none affected the frequency of sexual episodes.']",5,0.5714285714285714,3,14
CD001035,2,8,There were few statistically significant effects on biological (STI) outcomes.,rephrase,['Effects of interventions on STIs were limited.'],6,0.6428571428571429,4,14
CD001035,2,9,Considerable uncertainty exists in the risk of bias due to incomplete or ambiguous reporting.,delete,[],7,0.7142857142857143,4,14
CD001035,3,10,"Behavioural interventions for young women which aim to promote sexual behaviours protective of STI transmission can be effective, primarily at encouraging condom use.",delete,[],7,0.7857142857142857,4,14
CD001035,3,11,"Future evaluations should include a greater focus on HPV and its link to cervical cancer, with long-term follow-up to assess impact on behaviour change, rates of HPV infection and progression to cervical cancer.",delete,[],7,0.8571428571428571,5,14
CD001035,3,12,Studies should use an RCT design where possible with integral process evaluation and cost-effectiveness analysis where appropriate.,delete,[],7,0.9285714285714286,5,14
CD001035,3,13,Given the predominance of USA studies in this systematic review evaluations conducted in other countries would be particularly useful.,delete,[],7,1.0,5,14
CD001765,0,0,"Seventeen studies were included in the review, involving 3097 participants.",merge,"['The review included 17 studies (3097 participants), and showed that SSRIs were effective in reducing the symptoms of OCD.']",0,0.1111111111111111,1,9
CD001765,0,1,"Based on all 17 studies, SSRIs as a group were more effective than placebo in reducing the symptoms of OCD between 6 and 13 weeks post-treatment, measured using the Yale-Brown Obsessive Compulsive Scale (YBOCS) (WMD -3.21, 95% CI -3.84 to -2.57).",none,[],0,0.2222222222222222,2,9
CD001765,0,2,The WMD for individual SSRI drugs were similar and not statistically different.,delete,[],1,0.3333333333333333,2,9
CD001765,0,3,"Based on 13 studies (2697 participants), SSRIs were more effective than placebo in achieving clinical response at post-treatment (RR 1.84, 95% CI 1.56 to 2.17).",rephrase,"['Based on 13 studies (2697 participants), the review showed that people receiving SSRIs were nearly twice as likely as those receiving placebo to achieve clinical response (defined as a 25% or more reduction in symptoms).']",1,0.4444444444444444,3,9
CD001765,0,4,The pooled RR was shown to be similar between individual SSRI drugs.,rephrase,"['Indirect comparisons of effectiveness suggested that although individual SSRI drugs were similar in their effectiveness, they differed in terms of their adverse effects.']",2,0.5555555555555556,3,9
CD001765,0,5,"Although reported adverse effects data were more limited, with few exceptions, the overall and individual adverse effects for the different SSRIs were always worse than for placebo and, in the majority of cases, the difference was statistically significant.",delete,[],3,0.6666666666666666,4,9
CD001765,0,6,"Nausea, headache and insomnia were always reported amongst the most common adverse effects in trials of each of the drugs.",rephrase,['The most common adverse effect reported by participants was nausea.'],3,0.7777777777777778,4,9
CD001765,1,7,"SSRIs are more effective than placebo for OCD, at least in the short-term, although there are differences between the adverse effects of individual SSRI drugs.",rephrase,"['Further studies involving head to head comparisons between different SSRI drugs are required to obtain more reliable information on differences between SSRIs, both in terms of effectiveness and adverse effects.']",4,0.8888888888888888,5,9
CD001765,1,8,The longer term efficacy and tolerability of different SSRI drugs for OCD has yet to be established.,delete,[],5,1.0,5,9
CD013566,0,0,Our search yielded 2030 records.,rephrase,['We found 2030\xa0records.'],0,0.058823529411764705,1,17
CD013566,0,1,We assessed a total of 89 full-text articles for eligibility.,ignore,['We assessed a total of 89 full-text articles for eligibility.'],1,0.11764705882352941,1,17
CD013566,0,2,One prospective cohort study met our inclusion criteria.,ignore,['One prospective cohort study met our inclusion criteria.'],2,0.17647058823529413,1,17
CD013566,1,3,The included study collected data on outcomes from 605 women who obtained a medical abortion in Nepal from either a clinic or pharmacy setting.,rephrase,"['In this study, 605 women in Nepal received medical abortions from the same\xa0health care providers (auxiliary nurse midwives)\xa0in either a clinic or pharmacy-based setting.']",3,0.23529411764705882,2,17
CD013566,1,4,Both sites of care were staffed by the same auxiliary nurse midwives.,delete,[],4,0.29411764705882354,2,17
CD013566,1,5,"Over all domains, the risk of bias was judged to be low for our primary outcome.",delete,[],4,0.35294117647058826,2,17
CD013566,1,6,"During the pre-intervention period, the study’s investigators identified a priori appropriate confounders, which were clearly measured and adjusted for in the final analysis.",delete,[],4,0.4117647058823529,3,17
CD013566,2,7,"For women who received medical abortion in a pharmacy setting, compared to a clinic setting, there may be little or no difference in complete abortion rates (adjusted risk difference (RD)) 1.5, 95% confidence interval (CI) -0.8 to 3.8; 1 study, 600 participants; low certainty evidence).",rephrase,['There was no difference in complete abortion rates between the two different abortion settings.'],4,0.47058823529411764,3,17
CD013566,2,8,"The study reported no cases of blood transfusion, and a composite outcome, comprised mainly of infection complications, showed there may be little or no difference between settings (adjusted RD 0.8, 95% CI -1.0 to 2.8; 1 study, 600 participants; very low certainty evidence).",delete,[],5,0.5294117647058824,3,17
CD013566,2,9,"The study reported no events for hospital admission for an abortion-related event or need for surgical intervention, and there may be no difference in women reporting being highly satisfied with the facility where they were seen (38% pharmacy versus 34% clinic, P = 0.87; 1 study, 600 participants; low certainty evidence).",rephrase,"['Additional secondary outcomes included hospital admission for an abortion-related event, additional surgical interventions needed\xa0(besides uterine aspiration),\xa0and measures of quality of care.']",5,0.5882352941176471,3,17
CD013566,3,10,Conclusions about the effectiveness and safety of pharmacy provision of medical abortion are limited by the lack of comparative studies.,rephrase,"['Conclusions about the effectiveness, safety and quality of care of pharmacist provision of medical abortion are limited by the lack of comparative studies.']",6,0.6470588235294118,4,17
CD013566,3,11,"One study, judged to provide low certainty evidence, suggests that the effectiveness of medical abortion may not be different between the pharmacy and clinic settings.",rephrase,['A single non-randomized study provides us with low certainty that the effectiveness of medical abortion probably does not differ between the pharmacy or clinic setting when the care is provided by the same clinicians.'],7,0.7058823529411765,4,17
CD013566,3,12,"However, evidence for safety is insufficient to draw any conclusions, and more research on factors contributing to potential differences in quality of care is needed.",delete,[],8,0.7647058823529411,4,17
CD013566,3,13,"It is important to note that this study included a care model where a clinician provided services in a pharmacy, not direct provision of care by pharmacists or pharmacy staff.",delete,[],8,0.8235294117647058,5,17
CD013566,3,14,Three ongoing studies are potentially eligible for inclusion in review updates.,rephrase,['Three ongoing studies are potentially eligible for inclusion in an update of this review.'],8,0.8823529411764706,5,17
CD013566,3,15,"More research is needed because pharmacy provision could expand timely access to medical abortion, especially in settings where clinic services may be more difficult to obtain.",ignore,"['More research is needed because pharmacy provision could expand timely access to medical abortion, especially in settings where clinic services may be more difficult to obtain.']",9,0.9411764705882353,5,17
CD013566,3,16,Evidence is particularly limited on the patient experience and how the care process and quality of services may differ across different types of settings.,delete,[],10,1.0,5,17
CD012622,0,0,"Overall, 10 RCTs with 565 participants which investigated different non-pharmacological interventions for the management of chronic pain in MS fulfilled the review inclusion criteria.",split,"['Overall, we found 10 studies evaluating different non-medication treatments to treat chronic pain in persons with MS.', 'These studies included 565 participants and used a range of different methods to measure pain and other outcomes.']",0,0.16666666666666666,1,6
CD012622,0,1,"The non-pharmacological interventions evaluated included: transcutaneous electrical nerve stimulation (TENS), psychotherapy (telephone self-management, hypnosis and electroencephalogram (EEG) biofeedback), transcranial random noise stimulation (tRNS), transcranial direct stimulation (tDCS), hydrotherapy (Ai Chi) and reflexology.",rephrase,"['The treatments evaluated included: transcutaneous electrical nerve stimulation, transcranial direct stimulation, transcranial random noise stimulation, reflexology, psychotherapy and hydrotherapy.']",2,0.3333333333333333,2,6
CD012622,1,2,"There is very low-level evidence for the use of non-pharmacological interventions for chronic pain such as TENS, Ai Chi, tDCS, tRNS, telephone-delivered self-management program, EEG biofeedback and reflexology in pain intensity in pwMS.",rephrase,['Results from these studies show a very low level of evidence for the use of any non-medication treatments for chronic pain in persons with MS.'],3,0.5,3,6
CD012622,1,3,"Although there were improved changes in pain scores and secondary outcomes (such as fatigue, psychological symptoms, spasm in some interventions), these were limited by methodological biases within the studies.",delete,[],4,0.6666666666666666,4,6
CD012622,2,4,"Despite the use of a wide range of non-pharmacological interventions for the treatment of chronic pain in pwMS, the evidence for these interventions is still limited or insufficient, or both.",delete,[],4,0.8333333333333334,5,6
CD012622,2,5,More studies with robust methodology and greater numbers of participants are needed to justify the effect of these interventions for the management of chronic pain in pwMS.,rephrase,['More research with good methodological quality and greater number of participants are needed to determine the effectiveness of such treatments.'],4,1.0,5,6
CD013090,0,0,"We included 10 randomised clinical trials with 934 participants, but only five trials with 490 participants provided data for analysis.",rephrase,['We included 10 randomised clinical trials (studies where people are randomly put into one of two or more treatment groups) with 934 participants.'],0,0.041666666666666664,1,24
CD013090,0,1,All the trials compared Xiao Chai Hu Tang formula with no intervention.,merge,['All trials compared Xiao Chai Hu Tang formula with no treatment.'],1,0.08333333333333333,1,24
CD013090,0,2,All trials appeared to have been conducted and published only in China.,none,[],1,0.125,1,24
CD013090,0,3,"The included trials assessed heterogeneous forms of Xiao Chai Hu Tang formula, administered for three to eight months.",rephrase,['The trials assessed different formulas and doses for three to eight months.'],2,0.16666666666666666,1,24
CD013090,0,4,"One trial included participants with hepatitis B and comorbid tuberculosis, and one trial included participants with hepatitis B and liver cirrhosis.",rephrase,"['One trial included participants with tuberculosis (a disease of the lungs that can make you cough mucous), and one trial included participants with liver cirrhosis (scarring).']",3,0.20833333333333334,2,24
CD013090,0,5,The remaining trials included participants with hepatitis B only.,delete,[],4,0.25,2,24
CD013090,0,6,"All the trials were at high risk of bias, and the certainty of evidence for all outcomes that provided data for analyses was very low.",rephrase,"['Caution is needed with this beneficial finding as the trials are at high risk of bias, and this outcome has not yet been proven relevant to patients.']",4,0.2916666666666667,2,24
CD013090,0,7,"We downgraded the evidence by one or two levels because of outcome risk of bias, inconsistency or heterogeneity of results (opposite direction of effect), indirectness of evidence (use of surrogate outcomes instead of clinically relevant outcomes), imprecision of results (the CIs were wide), and publication bias (small sample size of the trials).",delete,[],5,0.3333333333333333,2,24
CD013090,0,8,"Additionally, 47 trials lacked the necessary methodological information needed to ensure the inclusion of these trials in our review.",delete,[],5,0.375,2,24
CD013090,1,9,"None of the included trials aimed to assess clinically relevant outcomes such as all-cause mortality, serious adverse events, health-related quality of life, hepatitis B-related mortality, or hepatitis B-related morbidity.",rephrase,"[""None of the 10 included trials reported data on all-cause mortality (death from any cause), serious side effects (untoward medical occurrences that result in serious outcomes such as death or disability), health-related quality of life (a measure of physical, mental, emotional, and social functioning a measure of a person's satisfaction with their life and health), hepatitis B-related death, and hepatitis B-related morbidity.""]",5,0.4166666666666667,3,24
CD013090,1,10,"The effects of Xiao Chai Hu Tang formula on the proportion of participants with adverse events considered 'not to be serious' is uncertain (RR 0.43, 95% CI 0.02 to 11.98; I2 = 69%; very low-certainty evidence).",rephrase,"[""We are uncertain whether Xiao Chai Hu Tang formula versus no intervention has a positive or negative effect regarding side effects considered 'not to be serious', the proportion of people with detectable HBeAg (a hepatitis B viral protein that indicates active viral replication), and separately reported side effects considered 'not to be serious'.""]",6,0.4583333333333333,3,24
CD013090,1,11,"Only three trials with 222 participants reported the proportion of people with detectable hepatitis B virus DNA (HBV-DNA), but the evidence that Xiao Chai Hu Tang formula reduces the presence of HBV-DNA in the blood (a surrogate outcome) is uncertain (RR 0.62, 95% CI 0.45 to 0.85; I2 = 0%; very low-certainty evidence).",rephrase,['Xiao Chai Hu Tang formula compared with no intervention seems to reduce the proportion of people with detectable HBV-DNA (which is used to indicate how much hepatitis B virus is in the blood) but the reliability of this finding is low.'],7,0.5,3,24
CD013090,1,12,"Only two trials with 160 participants reported the proportion of people with detectable hepatitis B virus e-antigen (HBeAg; a surrogate outcome) (RR 0.72, 95% CI 0.50 to 1.02; I2 = 38%; very low-certainty evidence) and the evidence is uncertain.",delete,[],8,0.5416666666666666,3,24
CD013090,1,13,The evidence is also uncertain for separately reported adverse events considered 'not to be serious'.,delete,[],8,0.5833333333333334,3,24
CD013090,2,14,Funding: two of the 10 included trials received academic funding from government or hospital.,rephrase,['Two of the 10 included trials reported receiving academic funding.'],8,0.625,4,24
CD013090,2,15,None of the remaining eight trials reported information on funding.,rephrase,['None of the remaining eight trials reported information of support or funding.'],9,0.6666666666666666,4,24
CD013090,3,16,The clinical effects of Xiao Chai Hu Tang formula for chronic hepatitis B remain unclear.,rephrase,"['Accordingly, properly designed randomised clinical trials are needed before the benefits and harms of Xiao Chai Hu Tang formula for chronic hepatitis B can be determined.']",10,0.7083333333333334,4,24
CD013090,3,17,The included trials were small and of low methodological quality.,rephrase,['These assessments of the reliability of the evidence are due to the poor design and reporting of the included trials.'],11,0.75,4,24
CD013090,3,18,"Despite the wide use of Xiao Chai Hu Tang formula, we lack data on all-cause mortality, serious adverse events, health-related quality of life, hepatitis B-related mortality, and hepatitis B-related morbidity.",delete,[],12,0.7916666666666666,4,24
CD013090,3,19,The evidence in this systematic review comes from data obtained from a maximum three trials.,delete,[],12,0.8333333333333334,5,24
CD013090,3,20,We graded the certainty of evidence as very low for adverse events considered not to be serious and the surrogate outcomes HBeAg and HBV-DNA.,delete,[],12,0.875,5,24
CD013090,3,21,"We found a large number of trials which lacked clear description of their design and conduct, and hence, these trials are not included in the present review.",delete,[],12,0.9166666666666666,5,24
CD013090,3,22,"As all identified trials were conducted in China, there might be a concern about the applicability of this review outside China.",delete,[],12,0.9583333333333334,5,24
CD013090,3,23,"Large-sized, high-quality randomised sham-controlled trials with homogeneous groups of participants and transparent funding are lacking.",delete,[],12,1.0,5,24
CD009192,0,0,"Out of 14 717 citations, only one study met the inclusion criteria; an RCT conducted on homeless and high-risk youth between September 1998 and October 1999 in Portland, United States.",rephrase,['This study was performed in 1998-1999 in the United States on high-risk and homeless youth.'],0,0.07142857142857142,1,14
CD009192,0,1,Participants (n=351) were offered counselling and oral HIV testing and were randomised into face-to-face (n=187 participants) and telephone (n=167) notification groups.,delete,[],1,0.14285714285714285,1,14
CD009192,0,2,The telephone notification group had the option of receiving HIV test results either by telephone or face-to-face.,rephrase,"['They were then divided into two groups; one that had to return to the testing site to get their HIV test results, and another that had the option of receiving HIV test results either by telephone or face-to-face at the testing site.']",1,0.21428571428571427,2,14
CD009192,0,3,"Overall, only 48% (n=168) of participants received their HIV test results and post-test counselling.",rephrase,"['Overall, less than half of participants received their HIV test results.']",2,0.2857142857142857,2,14
CD009192,0,4,Significantly more participants received their HIV test results in the telephone notification group compared to the face-to-face notification group; 58% (n=106) vs. 37% (n=62) (p < 0.001).,merge,[],3,0.35714285714285715,2,14
CD009192,0,5,"In the telephone notification group, the majority of participants who received their HIV test results did so by telephone (88%, n=93).",none,['Most participants in the telephone notification group opted for telephone rather than in person delivery of HIV test results.The proportion of youth receiving their HIV test results in the telephone group was significantly higher compared to the face-to-face group.'],3,0.42857142857142855,3,14
CD009192,0,6,The study could not offer information about the effectiveness of telephone HIV test notification with HIV-positive participants because only two youth tested positive and both were assigned to the face-to-face notification group.,delete,[],4,0.5,3,14
CD009192,0,7,The study had a high risk of bias.,delete,[],4,0.5714285714285714,3,14
CD009192,1,8,We found only one eligible study.,delete,[],4,0.6428571428571429,4,14
CD009192,1,9,"Although this study showed the use of the telephone for HIV test results notification was more effective than face-to-face delivery, it had a high-risk of bias.",rephrase,"['The aim of this review was to assess effectiveness of the telephone for HIV test result delivery, compared with face-to-face or other methods of HIV test result notification.']",4,0.7142857142857143,4,14
CD009192,1,10,"The study was conducted about 13 years ago in a high-income country, on a high-risk population, with low HIV prevalence, and the applicability of its results to other settings and contexts is unclear.",delete,[],5,0.7857142857142857,4,14
CD009192,1,11,The study did not provide information about telephone HIV test results notification of HIV positive people since none of the intervention group participants were HIV positive.,rephrase,"['However, since none of the participants in the telephone group were HIV positive, the study could not provide information about the effectiveness of telephone HIV test result delivery in people with HIV.']",5,0.8571428571428571,5,14
CD009192,1,12,"We found no information about the acceptability of the intervention to patients’ and providers’, its economic outcomes or potential adverse effects.",rephrase,"['In addition, we could not find any information about other relevant outcomes such as participants’ and providers’ satisfaction with the telephone HIV test results delivery, cost or potential harmful effects of this intervention.']",6,0.9285714285714286,5,14
CD009192,1,13,There is a need for robust evidence from various settings on the effectiveness of telephone use for HIV test results notification.,rephrase,['We urgently need more studies conducted in various settings comparing the effectiveness of telephone to other ways of HIV test result delivery and providing other relevant information in addition to the proportion of people receiving their HIV test results.'],7,1.0,5,14
CD002020,0,0,"We included 48 studies that involved 4937 participants and covered three types of programme: behavioural, cognitive-behavioural and multimodal.",ignore,"['We included a total of 48 studies that involved 4937 participants and covered three types of programme: behavioural, cognitive-behavioural and multimodal.']",0,0.1,1,10
CD002020,0,1,"Overall, we found that group-based parenting programmes led to statistically significant short-term improvements in depression (standardised mean difference (SMD) -0.17, 95% confidence interval (CI) -0.28 to -0.07), anxiety (SMD -0.22, 95% CI -0.43 to -0.01), stress (SMD -0.29, 95% CI -0.42 to -0.15), anger (SMD -0.60, 95% CI -1.00 to -0.20), guilt (SMD -0.79, 95% CI -1.18 to -0.41), confidence (SMD -0.34, 95% CI -0.51 to -0.17) and satisfaction with the partner relationship (SMD -0.28, 95% CI -0.47 to -0.09).",rephrase,"['Overall, the results suggested statistically significant improvements in the short-term for parental depression, anxiety, stress, anger, guilt, confidence and satisfaction with the partner relationship.']",1,0.2,1,10
CD002020,0,2,"However, only stress and confidence continued to be statistically significant at six month follow-up, and none were significant at one year.",ignore,"['However, only stress and confidence continued to be statistically significant at six month follow-up, and none were significant at one year.']",2,0.3,2,10
CD002020,0,3,"There was no evidence of any effect on self-esteem (SMD -0.01, 95% CI -0.45 to 0.42).",rephrase,['There was no evidence of effectiveness for self-esteem at any time point.'],3,0.4,2,10
CD002020,0,4,None of the trials reported on aggression or adverse effects.,rephrase,['None of the studies reported aggression or adverse outcomes.'],4,0.5,3,10
CD002020,1,5,"The limited data that explicitly focused on outcomes for fathers showed a statistically significant short-term improvement in paternal stress (SMD -0.43, 95% CI -0.79 to -0.06).",split,"['Only four studies reported the outcomes for fathers separately.', 'These limited data showed a statistically significant short-term improvement in paternal stress but did not show whether the parenting programmes were helpful in terms of improving depressive symptoms, confidence or partner satisfaction.']",5,0.6,3,10
CD002020,1,6,"We were unable to combine data for other outcomes and individual study results were inconclusive in terms of any effect on depressive symptoms, confidence or partner satisfaction.",delete,[],7,0.7,4,10
CD002020,2,7,The findings of this review support the use of parenting programmes to improve the short-term psychosocial wellbeing of parents.,rephrase,"['This review shows evidence of the short-term benefits of parenting programmes on depression, anxiety, stress, anger, guilt, confidence and satisfaction with the partner relationship.']",7,0.8,4,10
CD002020,2,8,Further input may be required to ensure that these results are maintained.,rephrase,['The findings suggest that further input may be needed to support parents to maintain these benefits.'],8,0.9,5,10
CD002020,2,9,"More research is needed that explicitly addresses the benefits for fathers, and that examines the comparative effectiveness of different types of programme along with the mechanisms by which such programmes bring about improvements in parental psychosocial functioning.",rephrase,"['However, more research is needed that explicitly addresses the benefits for fathers, and that provides evidence of the comparative effectiveness of different types of programme and identifies the mechanisms involved in bringing about change.']",9,1.0,5,10
CD001158,0,0,Very few studies directly assessed the effectiveness of corticosteroids for RA treatment and many were of poor methodologic quality.,ignore,['Very few studies directly assessed the effectiveness of corticosteroids for RA treatment and many were of poor methodologic quality.'],0,0.14285714285714285,1,7
CD001158,0,1,Only seven of 34 studies identified by our search met criteria for inclusion.,ignore,['Only seven of 34 studies identified by our search met criteria for inclusion.'],1,0.2857142857142857,2,7
CD001158,0,2,"Our results indicated that corticosteroids were significantly more effective than placebo controls for four of six outcomes assessed [standardized mean difference for tender joints = -0.37 (95%CI: -0.59, -0.14), swollen joints = -0.41 (-0.67, -0.16), pain = -0.43 (-0.74, -0.12), and functional status = -0.57 (-0.92, -0.22)].",ignore,"['Our results indicated that corticosteroids were significantly more effective than placebo controls for four of six outcomes assessed [standardized mean difference for tender joints = -0.37 (95%CI: -0.59, -0.14), swollen joints = -0.41 (-0.67, -0.16), pain = -0.43 (-0.74, -0.12), and functional status = -0.57 (-0.92, -0.22)].']",2,0.42857142857142855,3,7
CD001158,0,3,"The results for grip strength and ESR were not significant [GS = +0.30 (-0.19, +0.80), weighted mean difference (WMD) for ESR = -7.03 (-18.06, +4.01)].",ignore,"['The results for grip strength and ESR were not significant [GS = +0.30 (-0.19, +0.80), weighted mean difference (WMD) for ESR = -7.03 (-18.06, +4.01)].']",3,0.5714285714285714,3,7
CD001158,0,4,"The single trial that compared prednisone to aspirin indicated no statistically significant difference between these groups for joint tenderness (0.10 (-0.35, +0.55) and for ESR [0.00 (-11.09, +11.09].",ignore,"['The single trial that compared prednisone to aspirin indicated no statistically significant difference between these groups for joint tenderness (0.10 (-0.35, +0.55) and for ESR [0.00 (-11.09, +11.09].']",4,0.7142857142857143,4,7
CD001158,0,5,"Overall, the four outcomes assessed in the single trial that compared prednisone to chloroquine suggested that there was no statistically significant differenece in the effectiveness of these two agents [SMD for joint tenderness = +0.23 (-0.30, +0.75), swollen joints = +0.43 (-0.11, +0.96), functional status = -0.27 (-0.80, +0.26), and WMD for ESR = -16.00 (-30.58, -1.42)].",ignore,"['Overall, the four outcomes assessed in the single trial that compared prednisone to chloroquine suggested that there was no statistically significant differenece in the effectiveness of these two agents [SMD for joint tenderness = +0.23 (-0.30, +0.75), swollen joints = +0.43 (-0.11, +0.96), functional status = -0.27 (-0.80, +0.26), and WMD for ESR = -16.00 (-30.58, -1.42)].']",5,0.8571428571428571,5,7
CD001158,1,6,"Based on the limited data available, moderate-term prednisone treatment of RA appears to be superior to placebo and comparable to treatment with aspirin or chloroquine in improving several common rheumatoid arthritis disease activity measures.",delete,[],6,1.0,5,7
CD012980,0,0,"We included one, open-label randomised trial involving 47 participants with severe frostbite injuries.",rephrase,['We found one randomised controlled trial (RCT) involving 47 people who were rescued by mountain rescue teams in the French Alps.'],0,0.06666666666666667,1,15
CD012980,0,1,"We judged this trial to be at high risk of bias for performance bias, and uncertain risk for attrition bias; all other risk of bias domains we judged as low.",delete,[],1,0.13333333333333333,1,15
CD012980,1,2,"All participants underwent rapid rewarming, received 250 mg of aspirin and 400 mg intravascular (IV) buflomedil (since withdrawn from practice), and were then randomised to one of three treatment groups for the following eight days.",rephrase,"['Everybody was treated with a dose of two medicines, aspirin and buflomedil, then allocated to one of three groups for further treatment.']",1,0.2,1,15
CD012980,1,3,Group 1 received additional IV buflomedil 400 mg for one hour per day.,rephrase,"['Group 1 received additional buflomedil (since this RCT took place, buflomedil was withdrawn from use because of reports of severe adverse events associated with its use);\nGroup 2 received another medicine called iloprost;\nGroup 3 received iloprost and a substance involved naturally in the breakdown of blood clots (recombinant tissue plasminogen activator (rtPA)).']",2,0.26666666666666666,2,15
CD012980,1,4,"Group 2 received the prostacyclin, iloprost, 0.5 ng to 2 ng/kg/min IV for six hours per day.",delete,[],3,0.3333333333333333,2,15
CD012980,1,5,Group 3 received IV iloprost 2 ng/kg/min for six hours per day plus fibrinolysis with 100 mg recombinant tissue plasminogen activator (rtPA) for the first day only.,delete,[],3,0.4,2,15
CD012980,2,6,"The results suggest that iloprost and iloprost plus rtPA may reduce the rate of amputations in people with severe frostbite compared to buflomedil alone, RR 0.05 (95% CI 0.00 to 0.78; P = 0.03; very low-quality evidence) and RR 0.31 (95% CI 0.10 to 0.94; P = 0.04; very low-quality evidence), respectively.",rephrase,['People who received iloprost or iloprost combined with rtPA had fewer amputations than those who received buflomedil.'],3,0.4666666666666667,3,15
CD012980,2,7,"Iloprost may be as effective as iloprost plus rtPA at reducing the amputation rate, RR 0.14 (95% CI 0.01 to 2.56; P = 0.19; very low-quality evidence).",delete,[],4,0.5333333333333333,3,15
CD012980,2,8,There were no reported deaths or withdrawals due to adverse events in any of the groups; we assessed evidence for both outcomes as being of very low quality.,rephrase,"['There were no withdrawals from the trial because of unwanted effects of treatment, and there were no deaths.']",4,0.6,3,15
CD012980,2,9,"Adverse events (including flushing, nausea, palpitations and vomiting) were common, but not reported separately by comparator arm (very low-quality evidence).",rephrase,"['Adverse effects included hot flushes, feeling sick (nausea), heart palpitations and vomiting.']",5,0.6666666666666666,4,15
CD012980,2,10,"The included study did not measure the outcomes of acute pain, chronic pain, ability to perform activities of daily living, quality of life or occupational effects.",rephrase,"['This RCT did not report on intense pain, long-lasting pain, activities of daily living, quality of life, time off work, or time until a full return to work.']",6,0.7333333333333333,4,15
CD012980,3,11,There is a paucity of evidence regarding interventions for frostbite injuries.,delete,[],7,0.8,4,15
CD012980,3,12,"Very low-quality evidence from a single small trial indicates that iloprost, and iloprost plus rtPA, in combination with buflomedil may reduce the need for amputation in people with severe frostbite compared to buflomedil alone.",delete,[],7,0.8666666666666667,5,15
CD012980,3,13,"However, buflomedil has been withdrawn from use.",delete,[],7,0.9333333333333333,5,15
CD012980,3,14,High quality randomised trials are needed to establish firm evidence for the treatment of frostbite injuries.,rephrase,"['High quality RCTs are needed to confirm the result of this study, and to establish the best way to treat frostbite injuries.']",7,1.0,5,15
CD008455,0,0,One small trial at high risk of bias met the inclusion criteria.,delete,[],0,0.0625,1,16
CD008455,0,1,"The trial randomised 49 participants, most of whom had cancer.",rephrase,"['There were 49 participants, most of whom had cancer.']",0,0.125,1,16
CD008455,0,2,"It compared standard care (defined as surgery, antibiotics and oral rinses at the discretion of the oral-maxillofacial surgeon) to standard care plus hyperbaric oxygen therapy (2 atmospheres twice a day for 40 treatments).",rephrase,"[""The completed study compared people with BRONJ being treated with surgery, antibiotics and mouth rinses to people receiving the same 'standard care' with an add-on treatment called hyperbaric oxygen therapy, which is thought to increase bone renewal.""]",1,0.1875,1,16
CD008455,0,3,"The trial measured the percentage of participants who improved or healed at three, six, 12 and 18 months and last contact.",delete,[],2,0.25,2,16
CD008455,0,4,It also measured mean weekly pain scores.,delete,[],2,0.3125,2,16
CD008455,1,5,"At three months, the study found that the participants in intervention group were more likely to have an improvement in their osteonecrosis than the standard care group participants (risk ratio (RR) 1.94, 95% confidence interval (CI) 1.01 to 3.74).",rephrase,"['The study found that the participants in intervention group were more likely than the standard care group participants to have an improvement in their osteonecrosis at three months, but there was no clear difference between the groups when they were evaluated at six, 12 and 18 months and last contact.']",2,0.375,2,16
CD008455,1,6,"There was no clear difference between the groups for the outcome 'healed' at three months (RR 3.60, 95% CI 0.87 to 14.82).",merge,[],3,0.4375,3,16
CD008455,1,7,"There was no clear difference between the groups for improvement or healing when they were evaluated at six, 12 and 18 months and last contact.",none,['There was no clear difference between the groups at any time point for complete healing.'],3,0.5,3,16
CD008455,2,8,The study did not give any information on adverse events.,rephrase,['The study did not assess whether there were any side effects of the treatment.'],4,0.5625,3,16
CD008455,3,9,"Although the findings suggest adjunctive hyperbaric oxygen improved BRONJ, the quality of the evidence is very low since the only study was underpowered and was at high risk of bias due to lack of blinding, cross-over of participants between groups and very high attrition (50% at 12 months and 80% at 18 months in this study, which was designed for an intended follow-up of 24 months).",delete,[],5,0.625,4,16
CD008455,4,10,There is a lack of evidence from randomised controlled trials to guide treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ).,delete,[],5,0.6875,4,16
CD008455,4,11,"One small trial at high risk of bias evaluated hyperbaric oxygen therapy (HBO) as an adjunct to ""standard"" care and could not confirm or refute the effectiveness of HBO.",rephrase,['There is insufficient evidence to conclude whether hyperbaric oxygen therapy is a useful add-on to standard care in the treatment of BRONJ.'],5,0.75,4,16
CD008455,4,12,There are two ongoing trials of teriparatide treatment for BRONJ.,rephrase,"['There are two ongoing trials of teriparatide, a hormonal treatment for BRONJ.']",6,0.8125,5,16
CD008455,4,13,We found no randomised controlled trials of any other BRONJ treatments.,rephrase,['We found no randomised controlled trials of any other treatments for BRONJ.'],7,0.875,5,16
CD008455,4,14,High quality randomised controlled trials are needed.,rephrase,"['As there is a lack of good quality scientific evidence to decide how best to treat BRONJ, high quality trials are needed.']",8,0.9375,5,16
CD008455,4,15,We provide recommendations for their focus and design.,delete,[],9,1.0,5,16
CD009966,0,0,"Ten studies (21 records, 603 randomised participants) were included - three additional studies (five records) since our last review.",rephrase,['We included ten studies (including three additional studies) with a total of 603 randomised people receiving kidney transplants.'],0,0.058823529411764705,1,17
CD009966,0,1,Four studies compared more intensive versus less intensive insulin therapy; two studies compared dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo; one study compared DPP-4 inhibitors to insulin glargine; one study compared sodium glucose co-transporter 2 (SGLT2) inhibitors to placebo; and two studies compared glitazones and insulin to insulin therapy alone.,ignore,['Four studies compared more intensive to less intensive insulin therapy; two studies compared dipeptidyl peptidase-4 (DPP-4) inhibitors to placebo; one study compared DPP-4 inhibitors to insulin glargine; one study compared sodium glucose co-transporter 2 (SGLT2) inhibitors to placebo; and two studies compared glitazones plus insulin to insulin therapy alone.'],1,0.11764705882352941,1,17
CD009966,0,2,The majority of studies had an unclear to a high risk of bias.,delete,[],2,0.17647058823529413,1,17
CD009966,0,3,"There were no studies examining the effects of biguanides, glinides, GLP-1 agonists, or sulphonylureas.",delete,[],2,0.23529411764705882,2,17
CD009966,1,4,"Compared to less intensive insulin therapy, it is unclear if more intensive insulin therapy has an effect on transplant or graft survival (4 studies, 301 participants: RR 1.12, 95% CI 0.32 to 3.94; I2 = 49%; very low certainty evidence), delayed graft function (2 studies, 153 participants: RR 0.63, 0.42 to 0.93; I2 = 0%; very low certainty evidence), HbA1c (1 study, 16 participants; very low certainty evidence), fasting blood glucose (1 study, 24 participants; very low certainty evidence), kidney function markers (1 study, 26 participants; very low certainty evidence), death (any cause) (3 studies, 208 participants"" RR 0.68, 0.29 to 1.58; I2 = 0%; very low certainty evidence), hypoglycaemia (4 studies, 301 participants; very low certainty evidence) and medication discontinuation due to adverse effects (1 study, 60 participants; very low certainty evidence).",rephrase,"['From these studies, the effects of more compared to less intensive insulin treatment on kidney transplant survival, blood glucose control, death, and treatment side-effects including hypoglycaemia, are not well understood.']",2,0.29411764705882354,2,17
CD009966,2,5,"Compared to placebo, it is unclear whether DPP-4 inhibitors have an effect on hypoglycaemia and medication discontinuation (2 studies, 51 participants; very low certainty evidence).",delete,[],3,0.35294117647058826,2,17
CD009966,2,6,"However, DPP-4 inhibitors may reduce HbA1c and fasting blood glucose but not kidney function markers (1 study, 32 participants; low certainty evidence).",rephrase,"['Based on one study, DPP-4 inhibitors may improve blood glucose control without affecting kidney function markers.']",3,0.4117647058823529,3,17
CD009966,3,7,"Compared to insulin glargine, it is unclear if DPP-4 inhibitors have an effect on HbA1c, fasting blood glucose, hypoglycaemia or discontinuation due to adverse events (1 study, 45 participants; very low certainty evidence).",rephrase,['The rate of side-effects of DPP-4 inhibitors compared to placebo or insulin is also not well understood.'],4,0.47058823529411764,3,17
CD009966,4,8,"Compared to placebo, SGLT2 inhibitors probably do not affect kidney graft survival (1 study, 44 participants; moderate certainty evidence), but may reduce HbA1c without affecting fasting blood glucose and eGFR long-term (1 study, 44 participants, low certainty evidence).",rephrase,"['Based on one study, SGLT2 inhibitors probably do not affect kidney transplant survival, but may improve long-term blood glucose control without affecting long-term kidney function.']",5,0.5294117647058824,3,17
CD009966,4,9,"SGLT2 inhibitors probably do not increase hypoglycaemia, and probably have little or no effect on medication discontinuation due to adverse events.",rephrase,['SGLT2 inhibitors probably do not cause low sugar levels and have little or no effect on people stopping the medication.'],6,0.5882352941176471,3,17
CD009966,4,10,"However, all participants discontinuing SGLT2 inhibitors had urinary tract infections (1 study, 44 participants, moderate certainty evidence).",rephrase,"['However, in the study, people who stop SGLT2 inhibitors had urinary tract infections.']",7,0.6470588235294118,4,17
CD009966,5,11,"Compared to insulin therapy alone, it is unclear if glitazones added to insulin have an effect on HbA1c or kidney function markers (1 study, 62 participants; very low certainty evidence).",merge,['Glitazones and insulin may not have an effect on blood glucose control or side-effects compared to insulin alone.'],8,0.7058823529411765,4,17
CD009966,5,12,"However, glitazones may make little or no difference to fasting blood glucose (2 studies, 120 participants; low certainty evidence), and medication discontinuation due to adverse events (1 study, 62 participants; low certainty evidence).",none,[],8,0.7647058823529411,4,17
CD009966,6,13,"No studies of DPP-4 inhibitors, or glitazones reported effects on transplant or graft survival, delayed graft function or death (any cause).",rephrase,"['The effects of using DPP-4 inhibitors compared to placebo or insulin, or glitazones and insulin compared to insulin alone, on survival of the kidney transplant and death is also unclear.']",9,0.8235294117647058,5,17
CD009966,7,14,The efficacy and safety of glucose-lowering agents in the treatment of pre-existing and new-onset diabetes in kidney transplant recipients is questionable.,rephrase,['Contemporary evidence concerning glucose-lowering treatment for diabetes in people who have received kidney transplants is limited.'],10,0.8823529411764706,5,17
CD009966,7,15,"Evidence from existing studies examining the effect of intensive insulin therapy, DPP-4 inhibitors, SGLT inhibitors and glitazones is mostly of low to very low certainty.",delete,[],11,0.9411764705882353,5,17
CD009966,7,16,"Appropriately blinded, larger, and higher quality RCTs are needed to evaluate and compare the safety and efficacy of contemporary glucose-lowering agents in the kidney transplant population.",rephrase,"['Larger, higher quality studies are needed to evaluate the safety and effectiveness of current glucose lowering treatments.']",11,1.0,5,17
CD011382,0,0,"Ten studies met the inclusion criteria for the review, and nine studies provided information on one or more outcomes for the review.",rephrase,"['Ten studies met the inclusion criteria for the review, and nine studies provided information for the review.']",0,0.08333333333333333,1,12
CD011382,0,1,A total of 1014 participants were randomly assigned to the enhanced recovery protocol (499 participants) or standard care (515 participants) in the nine RCTs.,split,"['A total of 1014 participants received an enhanced recovery protocol (499 participants) or standard care (515 participants) in the nine trials.', 'The decision on whether a participant received an enhanced recovery protocol or standard care was made using methods similar to the toss of a coin, ensuring that the participants in the two groups were similar.']",1,0.16666666666666666,1,12
CD011382,0,2,"Most of the trials included low anaesthetic risk participants with high performance status undergoing different upper gastrointestinal, liver and pancreatic surgeries.",rephrase,['Most of the trials included persons who were healthy in aspects other than the condition requiring surgery.'],3,0.25,2,12
CD011382,0,3,Eight trials incorporated more than one element of the enhanced recovery protocol.,ignore,['Eight trials incorporated more than one component of the enhanced recovery protocol.'],4,0.3333333333333333,2,12
CD011382,0,4,All of the trials were at high risk of bias.,delete,[],5,0.4166666666666667,3,12
CD011382,0,5,The overall quality of evidence was low or very low.,rephrase,['The quality of evidence was low or very low.'],5,0.5,3,12
CD011382,1,6,"None of the trials reported long-term mortality, medium-term health-related quality of life(three months to one year), time to return to normal activity, or time to return to work.",ignore,"['None of the trials reported long-term deaths, medium-term health-related quality of life (three months to one year), time to return to normal activity, or time to return to work.']",6,0.5833333333333334,3,12
CD011382,1,7,"The difference between the enhanced recovery protocol and standard care were imprecise for short-term mortality (enhanced recovery protocol: 4/425 (adjusted proportion = 0.6%); standard care: 1/443 (0.2%); seven trials; 868 participants; RR 2.79; 95% CI 0.44 to 17.73; very low quality evidence), proportion of people with serious adverse events (enhanced recovery protocol: 4/157 (adjusted proportion = 0.6%); standard care: 0/184 (0.0%); two trials; 341 participants; RR 5.57; 95% CI 0.68 to 45.89; very low quality evidence), number of serious adverse events (enhanced recovery protocol: 34/421 (8 per 100 participants); standard care: 46/438 (11 per 100 participants); seven trials; 859 participants; rate ratio 0.72; 95% CI 0.45 to 1.13; very low quality evidence), health-related quality of life (four trials; 373 participants; SMD 0.29; 95% CI -0.04 to 0.62; very low quality evidence) and hospital readmissions (enhanced recovery protocol: 14/355 (adjusted proportion = 3.3%); standard care: 9/378 (2.4%); seven trials; 733 participants; RR 1.4; 95% CI 0.69 to 2.87; very low quality evidence).",rephrase,"['The difference between enhanced recovery protocols and standard care was imprecise for short-term deaths, percentage of people with major complications, total number of major complications, health-related quality of life and hospital readmissions.']",7,0.6666666666666666,4,12
CD011382,1,8,"The enhanced recovery protocol group had a lower proportion of people with mild adverse events (enhanced recovery protocol: 31/254 (adjusted proportion = 10.9%); standard care: 51/271 (18.8%); four trials; 525 participants; RR 0.58; 95% CI 0.39 to 0.85; low quality evidence), fewer number of mild adverse events (enhanced recovery protocol: 69/499 (13 per 100 participants); standard care: 128/515 (25 per 100 participants); nine trials; 1014 participants; rate ratio 0.52; 95% CI 0.39 to 0.70; low quality evidence), shorter length of hospital stay (nine trials; 1014 participants; MD -2.19 days; 95% CI -2.53 to -1.85; low quality evidence) and lower costs (four trials; 282 participants; MD USD -6300; 95% CI -8400 to -4200; low quality evidence) than standard care group.",rephrase,"['Enhanced recovery protocols had a lower percentage of people with minor complications, fewer minor complications, shorter length of hospital stay (approximately two days shorter hospital stay per person) and lower costs (cost savings of approximately USD 6300 per person) compared to standard care.']",8,0.75,4,12
CD011382,2,9,"Based on low quality evidence, enhanced recovery protocols may reduce length of hospital stay and costs (primarily because of reduction in hospital stay) in people undergoing major upper gastrointestinal, liver and pancreatic surgeries.",delete,[],9,0.8333333333333334,5,12
CD011382,2,10,"However, the validity of the results is uncertain because of the risk of bias in the trials and the way the outcomes were measured.",rephrase,"['As a result, there is a lot of uncertainty regarding the results.']",9,0.9166666666666666,5,12
CD011382,2,11,"Future RCTs should be conducted with low risk of bias, and measure clinically important outcomes for including the three months to one year period.",delete,[],10,1.0,5,12
CD014823,0,0,We included 223 studies in the review and sampled 53 of these for our analysis.,rephrase,['We analysed 53 qualitative studies where patients received rehabilitation services in their own homes.'],0,0.034482758620689655,1,29
CD014823,0,1,"Forty-five studies were conducted in high-income countries, and eight in low-and middle-income countries.",delete,[],1,0.06896551724137931,1,29
CD014823,0,2,"Twenty studies addressed in-person home-based rehabilitation, 28 studies addressed home-based telerehabilitation services, and five studies addressed both modes of delivery.",delete,[],1,0.10344827586206896,1,29
CD014823,0,3,"The studies mainly explored the perspectives of healthcare providers, patients with a range of different health conditions, and their informal caregivers and family members.",rephrase,"['The studies explored the views and experiences of patients, families and healthcare providers.']",1,0.13793103448275862,1,29
CD014823,1,4,"Based on our GRADE-CERQual assessments, we had high confidence in eight of the findings, and moderate confidence in five, indicating that it is highly likely or likely respectively that these findings are a reasonable representation of the phenomenon of interest.",merge,[],2,0.1724137931034483,1,29
CD014823,1,5,There were two findings with low confidence.,none,['We have moderate to high confidence in the following findings.'],2,0.20689655172413793,2,29
CD014823,2,6,"High and moderate confidence findings
Home-based rehabilitation services delivered in-person or through telerehabilitation
Patients experience home-based services as convenient and less disruptive of their everyday activities.",rephrase,['Home-based rehabilitation services delivered in-person or through telerehabilitation\nPatients experience home-based services as convenient and less disruptive of their everyday activities.'],3,0.2413793103448276,2,29
CD014823,2,7,Patients and providers also suggest that these services can encourage patients' self-management and can make them feel empowered about the rehabilitation process.,ignore,"[""Patients and providers also suggest that these services can encourage patients' self-management and can make them feel empowered about the rehabilitation process.""]",4,0.27586206896551724,2,29
CD014823,2,8,"But patients, family members, and providers describe privacy and confidentiality issues when services are provided at home.",ignore,"['But patients,\xa0family members, and providers describe privacy and confidentiality issues when services are provided at home.']",5,0.3103448275862069,2,29
CD014823,2,9,These include the increased privacy of being able to exercise at home but also the loss of privacy when one’s home life is visible to others.,ignore,['These include the increased privacy of being able to exercise at home but also the loss of privacy when one’s home life is visible to others.'],6,0.3448275862068966,2,29
CD014823,3,10,Patients and providers also describe other factors that can affect the success of home-based rehabilitation services.,ignore,['Patients and providers also describe other factors that can affect the success of home-based rehabilitation services.'],7,0.3793103448275862,2,29
CD014823,3,11,"These include support from providers and family members, good communication with providers, the requirements made of patients and their surroundings, and the transition from hospital to home-based services.",ignore,"['These include support from providers and family members, good communication with providers, the requirements made of patients and their surroundings, and the transition from hospital to home-based services.']",8,0.41379310344827586,3,29
CD014823,4,12,"Telerehabilitation specifically
Patients, family members and providers see telerehabilitation as an opportunity to make services more available.",ignore,"['Telerehabilitation specifically\nPatients, family members and providers see telerehabilitation as an opportunity to make services more available.']",9,0.4482758620689655,3,29
CD014823,4,13,But providers point to practical problems when assessing whether patients are performing their exercises correctly.,ignore,['But providers point to practical problems when assessing whether patients are performing their exercises correctly.'],10,0.4827586206896552,3,29
CD014823,4,14,Providers and patients also describe interruptions from family members.,ignore,['Providers and patients also describe interruptions from family members.'],11,0.5172413793103449,3,29
CD014823,5,15,"In addition, providers complain of a lack of equipment, infrastructure and maintenance and patients refer to usability issues and frustration with digital technology.",ignore,"['In addition, providers complain of a lack of equipment, infrastructure and maintenance and patients refer to usability issues and frustration with digital technology.']",12,0.5517241379310345,3,29
CD014823,5,16,Providers have different opinions about whether telerehabilitation is cost-efficient for them.,ignore,['Providers have different opinions about whether telerehabilitation is cost-efficient for them.'],13,0.5862068965517241,3,29
CD014823,5,17,But many patients see telerehabilitation as affordable and cost-saving if the equipment and infrastructure have been provided.,ignore,['But many patients see telerehabilitation as affordable and cost-saving if the equipment and infrastructure has been provided.'],14,0.6206896551724138,4,29
CD014823,6,18,Patients and providers suggest that telerehabilitation can change the nature of their relationship.,ignore,['Patients and providers suggest that telerehabilitation can change the nature of their relationship.'],15,0.6551724137931034,4,29
CD014823,6,19,"For instance, some patients describe how telerehabilitation leads to easier and more relaxed communication.",ignore,"['For instance, some patients describe how telerehabilitation leads to easier and more relaxed communication.']",16,0.6896551724137931,4,29
CD014823,6,20,Other patients describe feeling abandoned when receiving telerehabilitation services.,ignore,['Other patients describe feeling abandoned when receiving telerehabilitation services.'],17,0.7241379310344828,4,29
CD014823,7,21,"Patients, family members and providers call for easy-to-use technologies and more training and support.",ignore,"['Patients, family members and providers call for easy-to-use technologies and more training and support.']",18,0.7586206896551724,4,29
CD014823,7,22,They also suggest that at least some in-person sessions with the provider are necessary.,ignore,['They also suggest that at least some in-person sessions with the provider are necessary.'],19,0.7931034482758621,4,29
CD014823,7,23,They feel that telerehabilitation services alone can make it difficult to make meaningful connections.,ignore,['They feel that telerehabilitation services alone can make it difficult to make meaningful connections.'],20,0.8275862068965517,5,29
CD014823,7,24,They also explain that some services need the provider’s hands.,ignore,['They also explain that some services need the provider’s hands.'],21,0.8620689655172413,5,29
CD014823,7,25,Providers highlight the importance of personalising the services to each person’s needs and circumstances.,ignore,['Providers highlight the importance of personalising the services to each person’s needs and circumstances.'],22,0.896551724137931,5,29
CD014823,8,26,This synthesis identified several factors that can influence the successful implementation of in-person home-based rehabilitation and telerehabilitation services.,delete,[],23,0.9310344827586207,5,29
CD014823,8,27,"These included factors that facilitate implementation, but also factors that can challenge this process.",delete,[],23,0.9655172413793104,5,29
CD014823,8,28,"Healthcare providers, program planners and policymakers might benefit from considering these factors when designing and implementing programmes.",delete,[],23,1.0,5,29
CD005266,0,0,We screened 4651 titles and abstracts identified by the search and assessed 92 full-texts/records for inclusion.,delete,[],0,0.07142857142857142,1,14
CD005266,0,1,"We included one cluster-randomised trial, the ADDITION-Cambridge study, which involved 20,184 participants from 33 general practices in Eastern England and assessed the effects of inviting versus not inviting high-risk individuals to screening for diabetes.",rephrase,"['We found one randomised controlled trial (a clinical study in which participants are assigned to one of two or more treatment groups using a random method) where 20,184 high-risk individuals from 33 general practices in Eastern England were either invited or not invited to screening for type 2 diabetes (the ADDITION-Cambridge study).']",0,0.14285714285714285,1,14
CD005266,0,2,"The diabetes risk score was used to identify high-risk individuals; it comprised variables relating to age, sex, body mass index, and the use of prescribed steroid and anti-hypertensive medication.",ignore,"['The diabetes risk score to identify high-risk individuals comprised variables relating to age, sex, body mass index, and the use of prescribed steroids and anti-hypertensive medication.']",1,0.21428571428571427,2,14
CD005266,0,3,"Twenty-seven practices were randomised to the screening group (11,737 participants actually attending screening) and 5 practices to the no-screening group (4137 participants).",rephrase,"['A total of 11,737 participants attended screening in actuality, and 4137 participants represented the no-screening group.']",2,0.2857142857142857,2,14
CD005266,0,4,"In both groups, 36% of participants were women; the average age of participants was 58.2 years in the screening group and 57.9 years in the no-screening group.",ignore,"['In both groups, 36% of participants were women; the average age of participants was 58.2 years in the screening group and 57.9 years in the no-screening group.']",3,0.35714285714285715,2,14
CD005266,0,5,Almost half of participants in both groups were on antihypertensive medication.,rephrase,['Almost half of participants in both groups were on medication for high blood pressure.'],4,0.42857142857142855,3,14
CD005266,0,6,"The findings from the first phase of this study indicate that screening compared to no screening for type 2 diabetes did not show a clear difference in all-cause mortality (hazard ratio (HR) 1.06, 95% confidence interval (CI) 0.90 to 1.25, low-certainty evidence).",delete,[],5,0.5,3,14
CD005266,0,7,"Screening compared to no screening for type 2 diabetes mellitus showed an HR of 1.26, 95% CI 0.75 to 2.12 (low-certainty evidence) for diabetes-related mortality (based on whether diabetes was reported as a cause of death on the death certificate).",delete,[],5,0.5714285714285714,3,14
CD005266,0,8,Diabetes-related morbidity and health-related quality of life were only reported in a subsample and did not show a substantial difference between the screening intervention and control.,merge,[],5,0.6428571428571429,4,14
CD005266,0,9,"The included study did not report on adverse events, incidence of type 2 diabetes, glycosylated haemoglobin A1c (HbA1c), and socioeconomic effects.",none,"['The included study did not report on side effects of screening, new cases of type 2 diabetes, health-related quality of life, glycosylated haemoglobin A1c (HbA1c) as a long-term measurement of glucose control, and socioeconomic effects (such as costs of screening, use of medication, number of consultations).']",5,0.7142857142857143,4,14
CD005266,1,10,We are uncertain about the effects of screening for type 2 diabetes on all-cause mortality and diabetes-related mortality.,rephrase,['We are uncertain about the effects on screening for type 2 diabetes mellitus on death from any cause and death from diabetes-related causes (the only outcomes of importance for our review for which study authors provided reliable data).'],6,0.7857142857142857,4,14
CD005266,1,11,Evidence was available from one study only.,rephrase,['We based the certainty of the evidence on only one study.'],7,0.8571428571428571,5,14
CD005266,1,12,We are therefore unable to draw any firm conclusions relating to the health outcomes of early type 2 diabetes mellitus screening.,delete,[],8,0.9285714285714286,5,14
CD005266,1,13,"Furthermore, the included study did not assess all of the outcomes prespecified in the review (diabetes-related morbidity, incidence of type 2 diabetes, health-related quality of life, adverse events, socioeconomic effects).",delete,[],8,1.0,5,14
CD007922,0,0,This updated review includes two new randomized trials.,delete,[],0,0.125,1,8
CD007922,0,1,"In total, 10 randomized trials with 432 participants and four comparisons are included in this review.",rephrase,['We found 10 randomized clinical trials involving 432 participants.'],0,0.25,2,8
CD007922,0,2,One trial had a low risk of bias.,delete,[],1,0.375,2,8
CD007922,0,3,"No differences were demonstrated in mortality, with risk ratio (RR) of 0.97 (95% confidence interval (CI) 0.20 to 4.59; P value 0.97; 268 participants, six trials, very low quality of evidence (grading of recommendations assessment, development and evaluation (GRADE)), and in pneumonia, with RR of 0.40 (95% CI 0.11 to 1.39; P value 0.15; 120 participants, three trials, very low quality of evidence (GRADE)).",rephrase,['Six trials reported mortality.'],1,0.5,3,8
CD007922,0,4,"Statistically significant results included the following: The PEEP group had higher arterial oxygen pressure (PaO2)/fraction of inspired oxygen (FiO2) on day one postoperatively, with a mean difference of 22.98 (95% CI 4.40 to 41.55; P value 0.02; 80 participants, two trials, very low quality of evidence (GRADE)), and postoperative atelectasis (defined as an area of collapsed lung, quantified by computerized tomography scan) was less in the PEEP group (standard mean difference -1.2, 95% CI -1.78 to -0.79; P value 0.00001; 88 participants, two trials, very low quality of evidence (GRADE)).",delete,[],2,0.625,4,8
CD007922,0,5,No adverse events were reported in the three trials that adequately measured these outcomes (barotrauma and cardiac complications).,delete,[],2,0.75,4,8
CD007922,0,6,"Using information size calculations, we estimated that a further 21,200 participants would have to be randomly assigned to allow a reliable conclusion about PEEP and mortality.",rephrase,['We performed calculations to predict how many more participants would be needed before reliable conclusions can be made about the effect on mortality of the application of PEEP.'],2,0.875,5,8
CD007922,1,7,Evidence is currently insufficient to permit conclusions about whether intraoperative PEEP alters risks of postoperative mortality and respiratory complications among undifferentiated surgical patients.,rephrase,['Evidence is currently insufficient to allow conclusions about how intraoperative PEEP affects postoperative mortality and respiratory complications.'],3,1.0,5,8
CD005125,0,0,"We identified and included one trial (147 women from a pre-planned sample size of 310 women) that compared the effect of prophylactic antibiotic (single-dose, second-generation cephalosporin - cefotetan or cefoxitin, 1 g intravenously) on postpartum perineal wound complications in third- or fourth-degree perineal tears compared with placebo.",split,"['The review identified one trial, involving 147 women.', 'This trial was conducted to explore the benefit of routine prophylactic antibiotics (intervention group) versus placebo (control group) for women with severe perineal tears.']",0,0.14285714285714285,1,7
CD005125,0,1,"Perineal wound complications (wound disruption and purulent discharge) at the two-week postpartum check up were 8.20% and 24.10% in the treatment and the control groups respectively (risk ratio (RR) 0.34, 95% confidence interval (CI) 0.12 to 0.96).",delete,[],2,0.2857142857142857,2,7
CD005125,0,2,"However, the high failed-appointment rate may limit the generalisability of the results.",delete,[],2,0.42857142857142855,3,7
CD005125,0,3,The overall risk of bias was low except for incomplete outcome data.,delete,[],2,0.5714285714285714,3,7
CD005125,0,4,"The quality of the evidence using GRADE was moderate for infection rate at two weeks' postpartum, and low for infection rate at six weeks' postpartum.",rephrase,"[""There was no statistically significant difference in perineal wound complications before discharge and at six weeks' postpartum.""]",2,0.7142857142857143,4,7
CD005125,1,5,"Although the data suggest that prophylactic antibiotics help to prevent perineal wound complications following third- or fourth-degree perineal tear, loss to follow-up was very high.",rephrase,['We assessed reduction of perineal wound infection in third- or fourth-degree tear by antibiotic prophylaxis as low to moderate quality of the evidence.'],3,0.8571428571428571,5,7
CD005125,1,6,The results should be interpreted with caution as they are based on one small trial.,rephrase,"['However, the results are based on one small trial and there was a high loss to follow-up.']",4,1.0,5,7
CD006390,0,0,Twelve randomised clinical trials (RCTs) met our predefined review protocol criteria for analysis.,delete,[],0,0.04,1,25
CD006390,0,1,"We found only one trial to be at low risk of bias, considering the remaining trials to be at high risk of bias.",delete,[],0,0.08,1,25
CD006390,0,2,"The risk of selection bias in nine studies was unclear due to poor reporting, leading to uncertainty in the pooled effect estimates.",delete,[],0,0.12,1,25
CD006390,0,3,"Five trials compared NSAIDs versus placebo, four trials compared NSAID versus opioids, and four trials compared NSAID versus spasmolytic drugs (one of the 12 trials was a three-arm study comparing NSAIDs versus both opioids and spasmolytic drugs).",merge,[],0,0.16,1,25
CD006390,0,4,"There were 828 randomised participants (minimum 30 and maximum 324 per trial), of whom 416 received NSAIDs and 412 received placebo, spasmolytic drugs, or opioids.",none,"['We included 12 randomised clinical trials with 828 participants, of whom 416 received NSAIDs and 412 received placebo, spasmolytic drugs, or opioids, in the review.']",0,0.2,1,25
CD006390,0,5,Twenty-four per cent of the participants were males.,ignore,['Twenty-four per cent of the participants were males.'],1,0.24,2,25
CD006390,0,6,The age of the participants in the trials ranged from 18 to 86 years.,rephrase,['The age of participants ranged from 18 to 86 years.'],2,0.28,2,25
CD006390,0,7,All people were admitted to emergency departments for acute biliary pain.,ignore,['All people were admitted to emergency department for acute biliary pain.'],3,0.32,2,25
CD006390,0,8,There was no mortality.,ignore,['There was no mortality.'],4,0.36,2,25
CD006390,0,9,"When compared with placebo, NSAIDs obtained a significantly lower proportion of participants without complete pain relief (RR 0.27, 95% confidence interval (CI) 0.19 to 0.40; I2 = 0%; 5 trials; moderate-quality evidence), which was confirmed by Trial Sequential Analysis, but not regarding participants with complications (RR 0.66, 95% CI 0.38 to 1.15; I2 = 26%; 3 trials; very low-quality evidence).",delete,[],5,0.4,2,25
CD006390,0,10,"NSAIDs showed more pain control than spasmolytic drugs (RR 0.51, 95% CI 0.37 to 0.71; I2 = 0%; 4 trials; low-quality evidence), which was not confirmed by Trial Sequential Analysis, and a significantly lower proportion of participants with complications (RR 0.27, 95% CI 0.12 to 0.57; I2 = 0%; 2 trials; low-quality evidence), which was also not confirmed by Trial Sequential Analysis.",delete,[],5,0.44,3,25
CD006390,0,11,"We found no difference in the proportions of participants without complete pain relief when comparing NSAIDs versus opioids (RR 0.98, 95% CI 0.47 to 2.07; I2 = 52%), suggesting moderate heterogeneity among trials (4 trials; very low-quality evidence).",delete,[],5,0.48,3,25
CD006390,0,12,"Only one trial comparing NSAIDs versus opioids reported results on complications, finding no significant difference between treatments.",ignore,"['One trial comparing NSAIDs versus opioids reported results on complications, finding no significant difference between treatments.']",5,0.52,3,25
CD006390,0,13,None of the included trials reported severe adverse events.,rephrase,['None of the trials reported major adverse events.'],6,0.56,3,25
CD006390,0,14,"Seven out of the 12 trials assessed non-severe adverse events: in two out of the seven trials, adverse events were not observed, and minor events were reported in the remaining five trials.",rephrase,"['Seven out of 12 trials reported minor adverse events; in two out of the eight trials adverse events were not observed, and minor events were reported in the remaining five trials.']",7,0.6,3,25
CD006390,1,15,"In addition, we found one ongoing RCT assessing the analgesic efficacy of intravenous ibuprofen in biliary colic.",rephrase,['We found one ongoing randomised clinical trial aimed at assessing the analgesic effectiveness of intravenous ibuprofen in biliary colic.'],8,0.64,4,25
CD006390,2,16,"NSAIDs have been assessed in relatively few trials including a limited number of participants for biliary colic, considering its common occurrence.",delete,[],9,0.68,4,25
CD006390,2,17,We found only one trial to be at low risk of bias.,delete,[],9,0.72,4,25
CD006390,2,18,There was no mortality.,delete,[],9,0.76,4,25
CD006390,2,19,None of the included trials reported quality of life.,ignore,['None of the included trials reported quality of life.'],9,0.8,4,25
CD006390,2,20,"The generalisability of the review is low as most of the RCTs included neither elderly people nor participants with comorbidities, who are more prone to complications as compared to others with biliary colic.",delete,[],10,0.84,5,25
CD006390,3,21,The beneficial effect of NSAIDs compared with placebo on pain relief was confirmed when we applied Trial Sequential Analysis.,rephrase,['We found that NSAIDs significantly reduced biliary pain when compared with placebo and spasmolytic drugs.'],10,0.88,5,25
CD006390,4,22,The quality of evidence according to GRADE criteria was moderate for the comparison of NSAIDs versus placebo regarding the outcome lack of pain relief and low or very low for the other outcomes and comparisons.,rephrase,['The quality of evidence according to GRADE criteria (a system developed to grade evidence and recommendations in health care) was moderate for the comparison NSAIDs versus placebo for the outcome lack of pain relief and low or very low for the other outcomes and comparisons.'],11,0.92,5,25
CD006390,5,23,"We found only one trial at low risk of bias, following the predefined 'Risk of bias' domains.",rephrase,"[""Only one of 12 trials was at low risk of bias following predefined 'Risk of bias' domains.""]",12,0.96,5,25
CD006390,5,24,"We found the risk of selection bias to be unclear in nine studies due to poor reporting, leading to uncertainty in the pooled effect estimates.",delete,[],13,1.0,5,25
CD012315,0,0,We included four studies involving a total of 773 randomised participants aged between 14 months and 16 years.,rephrase,['We found four studies that included 773 children aged 14 months to 16 years.'],0,0.058823529411764705,1,17
CD012315,0,1,"All four studies involved children with asthma, with the case-planning undertaken by a trained nurse educator.",rephrase,['All the studies involved children with asthma.'],1,0.11764705882352941,1,17
CD012315,0,2,"However, the discharge planning/education differed among the studies.",split,"['The programme used for the discharge plan differed among the studies, but all were delivered by a trained asthma educator (lay health worker or nurse specifically trained on educating patients with asthma).', 'The studies followed the children for 2 to 14 months after discharge.']",2,0.17647058823529413,1,17
CD012315,0,3,We could include data from only two studies (361 children) in the meta-analysis.,merge,"['We could only include data from two studies in a combined analysis (i.e. the meta-analysis), as the other two studies also enrolled children who were not hospitalised, and we could not obtain data specific to the children who were hospitalised and one of those studies included children with acute wheezing illness( no previous asthma diagnosis); the data specific to this review could not be obtained.']",4,0.23529411764705882,2,17
CD012315,0,4,"Two further studies enrolled children in both inpatient and outpatient settings, and one of these studies also included children with acute wheezing illness (no previous asthma diagnosis); the data specific to this review could not be obtained.",none,[],4,0.29411764705882354,2,17
CD012315,0,5,"For the primary outcome of exacerbations requiring hospitalisation, those in the intervention group were significantly less likely to be rehospitalised (odds ratio (OR) 0.29, 95% confidence interval (CI) 0.16 to 0.50) compared to controls.",delete,[],5,0.35294117647058826,2,17
CD012315,0,6,This equates to 189 (95% CI 124 to 236) fewer admissions per 1000 children.,delete,[],5,0.4117647058823529,3,17
CD012315,0,7,No adverse events were reported in any study.,delete,[],5,0.47058823529411764,3,17
CD012315,0,8,"In the context of substantial statistical heterogeneity between the two studies, there were no statistically significant effects on emergency department (OR 0.37, 95% CI 0.04 to 3.05) or general practitioner (OR 0.87, 95% CI 0.22 to 3.44) presentations.",delete,[],5,0.5294117647058824,3,17
CD012315,0,9,"There were no data on cost-effectiveness, length of stay of subsequent hospitalisations, or adherence to medications.",rephrase,"['Data on cost-effectiveness, length of stay of future hospitalisations, and adherence to discharge medications were not available.']",5,0.5882352941176471,3,17
CD012315,0,10,"One study reported quality of life, with no significant differences observed between the intervention and control groups.",rephrase,['One study reported quality of life and found no differences between the intervention and control group.'],6,0.6470588235294118,4,17
CD012315,1,11,"We considered three of the studies to have an unclear risk of bias, primarily due to inadequate description of the blinding of participants and investigators.",delete,[],7,0.7058823529411765,4,17
CD012315,1,12,The fourth study was assessed as at high risk of bias as a single unblinded investigator was used.,delete,[],7,0.7647058823529411,4,17
CD012315,1,13,"Using the GRADE system, we assessed the quality of the evidence as moderate for the outcome of hospitalisation and low for the outcomes of emergency department visits and general practitioner consultations.",rephrase,['We considered the quality of the evidence to be moderate for the outcome of hospital readmissions and low for the outcomes of future emergency department visits and general practitioner consultations for asthma flare-ups.'],7,0.8235294117647058,5,17
CD012315,2,14,"Current evidence suggests that individual caseworker-assigned discharge plans, as compared to non-caseworker-assigned plans, may be beneficial in preventing hospital readmissions for acute exacerbations in children with asthma.",split,"['Individual caseworker-assigned discharge planned management, as compared to non-caseworker-assigned management, may prevent readmissions to hospital for asthma flare-ups in children.', 'However, the current evidence is limited to only two studies in children with asthma.']",8,0.8823529411764706,5,17
CD012315,2,15,"There was no clear indication that the intervention reduces emergency department and general practitioner attendances for asthma, and there is an absence of data for children with other chronic respiratory conditions.",rephrase,['No clear benefit was seen on future emergency department or general practitioner visits for acute asthma.'],10,0.9411764705882353,5,17
CD012315,2,16,"Given the potential benefit and cost savings to the healthcare sector and families if hospitalisations and outpatient attendances can be reduced, there is a need for further randomised controlled trials encompassing different chronic respiratory illnesses, ethnicity, socio-economic settings, and cost-effectiveness, as well as defining the essential components of a complex intervention.",delete,[],11,1.0,5,17
CD006383,0,0,This review examined four trials lasting 24 to 52 weeks involving 2250 people randomised to either insulin detemir or glargine.,split,"['Four studies investigated a total of 2250 people.', 'Trials lasted between 24 and 52 weeks.']",0,0.07142857142857142,1,14
CD006383,0,1,"Overall, risk of bias of the evaluated studies was high.",ignore,"['Overall, risk of bias of the evaluated studies was high.']",2,0.14285714285714285,1,14
CD006383,0,2,Insulin glargine was dosed once-daily in the evening.,delete,[],3,0.21428571428571427,2,14
CD006383,0,3,Insulin detemir was initiated once-daily in the evening with the option of an additional dose in the morning in three studies and initiated twice-daily in one study.,delete,[],3,0.2857142857142857,2,14
CD006383,0,4,Of randomised patients 13.6% to 57.2% were injecting insulin detemir twice-daily at the end of trial.,delete,[],3,0.35714285714285715,2,14
CD006383,1,5,"Glycaemic control, measured by glycosylated haemoglobin A1c (HbA1c) and HbA1c equal to or less than 7% with or without hypoglycaemia, did not differ statistically significantly between treatment groups.",delete,[],3,0.42857142857142855,3,14
CD006383,2,6,"The results showed no significant differences in overall, nocturnal and severe hypoglycaemia between treatment groups.",rephrase,"['There were no differences in overall, nocturnal and severe hypoglycaemia when comparing insulin detemir to insulin glargine.']",3,0.5,3,14
CD006383,3,7,Insulin detemir was associated with less weight gain.,rephrase,['Insulin detemir was associated with significantly less weight gain (one study showing a difference of 0.9 kg).'],4,0.5714285714285714,3,14
CD006383,3,8,Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions.,rephrase,['Treatment with insulin glargine resulted in a lower daily basal insulin dose and a lower number of injection site reactions (1.8% of patients treated with insulin detemir compared to 0.4% of patients treated with insulin glargine had injection side reactions).'],5,0.6428571428571429,4,14
CD006383,4,9,There was no significant difference in the variability of FPG or glucose values in 24-hour profiles between treatment groups.,rephrase,['There was no difference in the variability of fasting glucose levels or the variability of glucose values of 24-hour profiles between the two treatment groups.'],6,0.7142857142857143,4,14
CD006383,4,10,"It was not possible to draw conclusions on quality of life, costs or mortality.",rephrase,"['From the retrieved trials it was not possible to draw conclusions on the effects of these two insulins on quality of life, their costs or on the number of fatalities.']",7,0.7857142857142857,4,14
CD006383,4,11,Only one trial reported results on health-related quality of life and showed no significant differences between treatment groups.,ignore,['Only one trial reported results on health-related quality of life and showed no significant differences between treatment groups.'],8,0.8571428571428571,5,14
CD006383,5,12,Our analyses suggest that there is no clinically relevant difference in efficacy or safety between insulin detemir and insulin glargine for targeting hyperglycaemia.,rephrase,['Our analyses suggest that there is no clinically relevant difference in the efficacy or the safety between the use of insulin detemir and insulin glargine for treating type 2 diabetes mellitus.'],9,0.9285714285714286,5,14
CD006383,5,13,"However, to achieve the same glycaemic control insulin detemir was often injected twice-daily in a higher dose but with less weight gain, while insulin glargine was injected once-daily, with somewhat fewer injection site reactions.",ignore,"['However, to achieve the same glycaemic control insulin detemir was often injected twice-daily in a higher dose but with less weight gain, while insulin glargine was only injected once-daily, with somewhat fewer injection site reactions.']",10,1.0,5,14
CD010537,0,0,We included 68 systematic reviews published in the Cochrane Library up to May 2018.,split,"['We included 68 Cochrane systematic reviews on various stages of the ART cycle.', 'We included in the overview reviews of in vitro fertilisation (IVF) and intracytoplasmic sperm injection (ICSI).']",0,0.1111111111111111,1,9
CD010537,0,1,All were of high quality.,ignore,['All were of high quality.'],2,0.2222222222222222,2,9
CD010537,0,2,"These reviews identified 38 interventions that were effective (n = 23) or promising (n = 15), and they identified 19 interventions that were ineffective (n = 2) or possibly ineffective (n = 17).",ignore,"['The reviews identified 38 interventions that were effective (n = 23) or promising (n = 15), and they identified 19 interventions that were ineffective (n = 2) or possibly ineffective (n = 17).']",3,0.3333333333333333,2,9
CD010537,0,3,"For 15 interventions, review authors were unable to draw conclusions owing to lack of evidence.",ignore,"['For 15 interventions, the reviews were unable to draw conclusions owing to lack of evidence.']",4,0.4444444444444444,3,9
CD010537,1,4,We identified an additional 11 protocols and four titles for future inclusion in this overview.,delete,[],5,0.5555555555555556,3,9
CD010537,2,5,This overview provides the most up-to-date evidence on ART cycles from systematic reviews of randomised controlled trials.,rephrase,['This overview provides the most up-to-date evidence from randomised controlled trials on ART cycles.'],5,0.6666666666666666,4,9
CD010537,2,6,"Fertility treatments are costly, and the stakes are high.",delete,[],6,0.7777777777777778,4,9
CD010537,2,7,Using the best available evidence to optimise outcomes is best practice.,delete,[],6,0.8888888888888888,5,9
CD010537,2,8,"Evidence from this overview could be used to develop clinical practice guidelines and protocols that can be applied in daily clinical practice to improve live birth rates and reduce rates of multiple pregnancy, cycle cancellation, and ovarian hyperstimulation syndrome.",rephrase,"['Use of evidence from this overview to guide clinical practice should help to improve live birth rates and reduce rates of multiple pregnancy, cycle cancellation, and ovarian hyperstimulation syndrome.']",6,1.0,5,9
CD005959,0,0,Five small trials comparing dynamic compression plates with locked intramedullary nailing were included in this review.,rephrase,['Five poor quality trials were included in this review.'],0,0.1,1,10
CD005959,0,1,These involved a total of 260 participants undergoing surgery for either acute fractures or after early failure of conservative treatment.,rephrase,['These involved a total of 260 participants who were randomly assigned to having their humerus fractures fixed with either a plate or a nail.'],1,0.2,1,10
CD005959,0,2,"All five trials had methodological flaws, such as the lack of assessor blinding, that could have influenced their findings.",delete,[],2,0.3,2,10
CD005959,0,3,"There was no significant difference in fracture union between plating and nailing (five trials, RR 1.05; 95% CI 0.97 to 1.13).",rephrase,['Both nailing and plating had similar fracture union rates.'],2,0.4,2,10
CD005959,0,4,"There was a statistically significant increase in shoulder impingement following nailing when compared with plating (five trials, RR 0.12; 95% CI 0.04 to 0.38).",rephrase,"['Compared with plating, nailing was associated with an increased risk of shoulder impingement involving shoulder pain and restrictions in shoulder range of movement.']",3,0.5,3,10
CD005959,0,5,"Intramedullary nails were removed significantly more frequently than plates (three trials, RR 0.17; 95% CI 0.04 to 0.76).",rephrase,"['Usually because of impingement, nails had to be removed more frequently than plates.']",4,0.6,3,10
CD005959,0,6,"There was no statistically significant difference between plating and nailing in operating time, blood loss during surgery, iatrogenic radial nerve injury, return to pre-injury occupation by six months or American Shoulder and Elbow Surgeons (ASES) scores.",delete,[],5,0.7,4,10
CD005959,1,7,Two further small trials are awaiting classification.,delete,[],5,0.8,4,10
CD005959,2,8,"The available evidence shows that intramedullary nailing is associated with an increased risk of shoulder impingement, with a related increase in restriction of shoulder movement and need for removal of metalwork.",delete,[],5,0.9,5,10
CD005959,2,9,"There was insufficient evidence to determine if there were any other important differences, including in functional outcome, between dynamic compression plating and locked intramedullary nailing for humeral shaft fractures.",rephrase,['The limited available evidence did not show important differences between the two surgical methods in the other outcomes reported by one or more trials.'],5,1.0,5,10
CD008523,0,0,Five studies (reported in 10 papers) were identified.,rephrase,['Five studies (reported in 10 papers) were found to be relevant.'],0,0.07692307692307693,1,13
CD008523,0,1,"However, three of the five studies provided un-usable data.",ignore,"['However, three of the five studies provided un-usable data.']",1,0.15384615384615385,1,13
CD008523,0,2,Thus the data from only two studies (reported in seven papers) with 105 participants were included for this review.,ignore,['Thus data from only two studies (reported in seven papers) with 105 participants was included for this review.'],2,0.23076923076923078,2,13
CD008523,0,3,"There was insufficient data to compare results on all-cause mortality, cost effectiveness, exercise capacity, Quality of life and Peak O2 consumption.",ignore,"['There was insufficient data to compare results on all-cause mortality, cost effectiveness, exercise capacity, Quality of life and Peak O2 consumption.']",3,0.3076923076923077,2,13
CD008523,1,4,"When comparing active pacing versus placebo pacing on exercise capacity, one study showed that exercise time decreased from (13.1 ± 4.4) minutes to (12.6 ± 4.3) minutes in the placebo group and increased from (12.1 ± 5.6) minutes to (12.9 ± 4.2) minutes in the treatment group (MD 0.30; 95% CI -1.54 to 2.14).",rephrase,['There was no difference in exercise capacity when comparing active pacing versus placebo pacing.'],4,0.38461538461538464,2,13
CD008523,1,5,Statistically significant data from the same study showed that left ventricular outflow tract obstruction decreased from (71 ± 32) mm Hg to (52 ± 34) mm Hg in the placebo group and from (70 ± 24) mm Hg to (33 ± 27) mm Hg in the active pacing group (MD -19.00; 95% CI -32.29 to -5.71).,rephrase,['However left ventricular outflow tract obstruction decreased significantly in the active pacing group compared to placebo.'],5,0.46153846153846156,3,13
CD008523,1,6,This study was also able to show that New York Heart Association (NYHA) functional class decreased from (2.5 ± 0.5) to (2.2 ± 0.6) in the inactive pacing group and decreased from (2.6 ± 0.5) to (1.7 ± 0.7) in the placebo group (MD -0.50; 95% CI -0.78 to -0.22).,rephrase,['New York Heart Association functional class increased in the active pacing group compared to the placebo group and this was also observed when comparing active pacing versus trancoronary ablation of septal hypertrophy.'],6,0.5384615384615384,3,13
CD008523,2,7,"When comparing active pacing versus trancoronary ablation of septal hypertrophy (TASH), data from one study showed that NYHA functional class decreased from (3.2 ± 0.7) to (1.5 ± 0.5) in the TASH group and decreased from (3.0 ± 0.1) to (1.9 ± 0.6) in the pacemaker group.",delete,[],7,0.6153846153846154,4,13
CD008523,2,8,This study also showed that LV wall thickness remained unchanged in the active pacing group compared to reduction from (22 ± 4) mm to (17 ± 3) mm in the TASH group (MD 0.60; 95% CI -5.65 to 6.85) and that LV outflow tract obstruction decreased from (80 ± 35.5) mm Hg in the TASH group to (49.3 ± 37.7) mm Hg in the pacemaker group.,delete,[],7,0.6923076923076923,4,13
CD008523,3,9,Trials published to date lack information on clinically relevant end-points.,delete,[],7,0.7692307692307693,4,13
CD008523,3,10,"Existing data is derived from small trials at high risk of bias, which concentrate on physiological measures.",rephrase,"['Interpretation of these data needs to be cautious because existing data is derived from small trials at high risk of bias, which concentrate on physiological measures.']",7,0.8461538461538461,5,13
CD008523,3,11,Their results are inconclusive.,ignore,['Their results are inconclusive.'],8,0.9230769230769231,5,13
CD008523,3,12,Further large and high quality trials with more appropriate outcomes are warranted.,ignore,['Further large and high quality trials with more appropriate outcomes are warranted.'],9,1.0,5,13
CD010640,0,0,We included in this systematic review 4745 participants who were randomly assigned in 21 trials.,rephrase,"['We included 4745 participants from 21 trials who received iron injections, iron tablets or no treatment.']",0,0.04,1,25
CD010640,0,1,Trials were conducted in a wide variety of clinical settings.,rephrase,"['Clinical settings of these trials included loss of blood, cancer, anaemia before surgery for various reasons and heart failure, among others.']",1,0.08,1,25
CD010640,0,2,Most trials included participants with mild to moderate anaemia and excluded participants who were allergic to iron therapy.,ignore,['Most trials included participants with mild to moderate anaemia and excluded participants who were allergic to iron therapy.'],2,0.12,1,25
CD010640,0,3,All trials were at high risk of bias for one or more domains.,delete,[],3,0.16,1,25
CD010640,0,4,We compared both oral iron and parenteral iron versus inactive controls and compared different iron preparations.,delete,[],3,0.2,1,25
CD010640,1,5,"The comparison between oral iron and inactive control revealed no evidence of clinical benefit in terms of mortality (RR 1.05, 95% CI 0.68 to 1.61; four studies, N = 659; very low-quality evidence).",rephrase,['Comparisons between iron tablets and no treatment revealed no evidence of clinical benefit in terms of a decrease in death or in quality of life.'],3,0.24,2,25
CD010640,1,6,The point estimate of the mean difference in haemoglobin levels in individual studies ranged from 0.3 to 3.1 g/dL higher in the oral iron group than in the inactive control group.,delete,[],4,0.28,2,25
CD010640,1,7,"The proportion of participants who required blood transfusion was lower with oral iron than with inactive control (RR 0.74, 95% CI 0.55 to 0.99; three studies, N = 546; very low-quality evidence).",rephrase,"['However, a reduction in the proportion of participants who required blood transfusion was noted among those who received iron tablets versus no treatment.']",4,0.32,2,25
CD010640,1,8,"Evidence was inadequate for determination of the effect of parenteral iron on mortality versus oral iron (RR 1.49, 95% CI 0.56 to 3.94; 10 studies, N = 2141; very low-quality evidence) or inactive control (RR 1.04, 95% CI 0.63 to 1.69; six studies, N = 1009; very low-quality evidence).",delete,[],5,0.36,2,25
CD010640,1,9,"Haemoglobin levels were higher with parenteral iron than with oral iron (MD -0.50 g/dL, 95% CI -0.73 to -0.27; six studies, N = 769; very low-quality evidence).",split,"['Haemoglobin levels were higher in participants receiving iron tablets versus no treatment.', 'With regards to iron injections, haemoglobin levels were higher after iron injections compared with levels reported after iron tablets or no treatment, but no evidence showed clinical benefit in terms of a decrease in death, in the number of participants requiring blood transfusion or in quality of life of participants.']",5,0.4,2,25
CD010640,1,10,The point estimate of the mean difference in haemoglobin levels in individual studies ranged between 0.3 and 3.0 g/dL higher in the parenteral iron group than in the inactive control group.,delete,[],7,0.44,3,25
CD010640,1,11,"Differences in the proportion of participants requiring blood transfusion between parenteral iron and oral iron groups (RR 0.61, 95% CI 0.24 to 1.58; two studies, N = 371; very low-quality evidence) or between parenteral iron groups and inactive controls (RR 0.84, 95% CI 0.66 to 1.06; eight studies, N = 1315; very low-quality evidence) were imprecise.",delete,[],7,0.48,3,25
CD010640,1,12,"Average blood volume transfused was less in the parenteral iron group than in the oral iron group (MD -0.54 units, 95% CI -0.96 to -0.12; very low-quality evidence) based on one study involving 44 people.",rephrase,"['Although the average amount of blood transfused was less in the iron injection group than in the iron tablet group, only one trial reported this outcome, introducing significant doubt about this finding.']",7,0.52,3,25
CD010640,1,13,Differences between therapies in quality of life or in the proportion of participants with serious adverse events were imprecise (very low-quality evidence).,rephrase,['Differences in serious complications between people who received iron versus no treatment were imprecise.'],8,0.56,3,25
CD010640,1,14,"No trials reported severe allergic reactions due to parenteral iron, suggesting that these are rare.",rephrase,"['No trials reported severe allergic reactions due to iron injections, suggesting that these are rare.']",9,0.6,3,25
CD010640,1,15,"Adverse effects related to oral iron treatment included nausea, diarrhoea and constipation; most were mild.",rephrase,"['Most of the adverse events related to iron tablet treatment were mild; effects such as nausea, diarrhoea and constipation were reported.']",10,0.64,4,25
CD010640,2,16,"Comparisons of one iron preparation over another for mortality, haemoglobin or serious adverse events were imprecise.",rephrase,['Comparisons of the clinical benefit of one iron preparation over another were imprecise.'],11,0.68,4,25
CD010640,2,17,No information was available on quality of life.,delete,[],12,0.72,4,25
CD010640,2,18,"Thus, little evidence was found to support the use of one preparation or regimen over another.",rephrase,"['In summary, no evidence is currently available to support the routine use of iron injections in adult anaemic men and or in adult non-pregnant anaemic women who have not just given birth to a baby.']",12,0.76,4,25
CD010640,3,19,"Subgroup analyses did not reveal consistent results; therefore we were unable to determine whether iron is useful in specific clinical situations, or whether iron therapy might be useful for people who are receiving erythropoietin.",rephrase,['We were unable to determine whether iron is useful in specific clinical situations because available information was not clearly presented.'],13,0.8,4,25
CD010640,4,20,"• Very low-quality evidence suggests that oral iron might decrease the proportion of people who require blood transfusion, and no evidence indicates that it decreases mortality.",delete,[],14,0.84,5,25
CD010640,4,21,"Oral iron might be useful in adults who can tolerate the adverse events, which are usually mild.",rephrase,['Iron tablets might be useful in anaemic adult men and adult women who can tolerate the side effects.'],14,0.88,5,25
CD010640,5,22,• Very low-quality evidence suggests that intravenous iron results in a modest increase in haemoglobin levels compared with oral iron or inactive control without clinical benefit.,delete,[],15,0.92,5,25
CD010640,6,23,• No evidence can be found to show any advantage of one iron preparation or regimen over another.,rephrase,['No evidence suggests any advantage of one iron preparation over another.'],15,0.96,5,25
CD010640,7,24,"• Additional randomised controlled trials with low risk of bias and powered to measure clinically useful outcomes such as mortality, quality of life and blood transfusion requirements are needed.",rephrase,['Additional randomised controlled trials are required to determine whether iron treatment decreases death and blood transfusion requirements and improves quality of life.'],16,1.0,5,25
CD007480,0,0,The review included 12 studies (reported in 22 publications).,delete,[],0,0.1,1,10
CD007480,0,1,"The included studies assigned 24,846 participants aged one to six months to vitamin A supplementation or control group.",rephrase,"['The search identified 12 studies that involved 24,846 infants.']",0,0.2,1,10
CD007480,0,2,"There was no effect of vitamin A supplementation for the primary outcome of all-cause mortality based on seven studies that included 21,339 (85%) participants (risk ratio (RR) 1.05, 95% confidence interval (CI) 0.89 to 1.25; I2 = 0%; test for heterogeneity: P = 0.79; quality of evidence: moderate).",delete,[],1,0.3,2,10
CD007480,0,3,"Also, there was no effect of vitamin A supplementation on mortality or morbidity due to diarrhoea and respiratory tract infection.",rephrase,['Supplementation had no beneficial effects to reduce death or illness due to diarrhoea or pneumonia.'],1,0.4,2,10
CD007480,0,4,"There was an increased risk of bulging fontanelle within 24 to 72 hours of supplementation in the vitamin A group compared to control (RR 3.10, 95% CI 1.89 to 5.09; I2 = 9%, test for heterogeneity: P = 0.36; quality of evidence: high).",delete,[],2,0.5,3,10
CD007480,0,5,"There was no reported subsequent increased risk of death, convulsions or irritability in infants who developed bulging fontanelle after vitamin A supplementation, and it resolved in most cases within 72 hours.",delete,[],2,0.6,3,10
CD007480,0,6,"There was no increased risk of other adverse effects such as vomiting, irritability, diarrhoea, fever and convulsions in the vitamin A supplementation group compared to control.",delete,[],2,0.7,4,10
CD007480,0,7,"Vitamin A supplementation did not have any statistically significant effect on vitamin A deficiency (RR 0.86, 95% CI 0.70 to 1.06; I2 = 27%; test for heterogeneity: P = 0.25; quality of evidence: moderate).",rephrase,"['Similarly, vitamin A supplementation did not reduce the proportion of children with vitamin A deficiency based on their blood levels of vitamin A (quality of evidence: moderate).']",2,0.8,4,10
CD007480,1,8,There is no convincing evidence that vitamin A supplementation for infants one to six months of age results in a reduction in infant mortality or morbidity in low- and middle-income countries.,rephrase,['The results of the studies provided no convincing evidence that vitamin A supplementation reduces death or illness in infants one to six months of age (quality of evidence: moderate).'],3,0.9,5,10
CD007480,1,9,"There is an increased risk of bulging fontanelle with vitamin A supplementation in this age group; however, there were no reported subsequent complications because of this adverse effect.",rephrase,['Infants who were given vitamin A had an increased risk of development of bulging of soft spot at the top of the head (called bulging fontanelle) and quality of evidence for this side effect was high.'],4,1.0,5,10
CD006088,0,0,There are no new trials to include in this review update.,delete,[],0,0.09090909090909091,1,11
CD006088,0,1,"Previously, four studies with a total of 224 participants were included; one was performed exclusively in children and three in adolescents or adults.",rephrase,['In this review we found four studies with a total of 224 participants that were suitable for inclusion; one was performed exclusively in children and three in adolescents or adults.'],0,0.18181818181818182,1,11
CD006088,0,2,One using an antitussive had no extractable pneumonia-specific data.,delete,[],1,0.2727272727272727,2,11
CD006088,0,3,"Three different mucolytics (bromhexine, ambroxol, neltenexine) were used in the remaining studies, of which only two had extractable data.",rephrase,"['However, data could only be obtained from two studies; both studies used mucolytics (ambroxol and bromhexine) in conjunction with antibiotics.']",1,0.36363636363636365,2,11
CD006088,0,4,They demonstrated no significant difference for the primary outcome of 'not cured or not improved' for mucolytics.,rephrase,"['Combining these two studies, the rate of cure or improvement in cough of people who received mucolytics was similar to those who did not.']",2,0.45454545454545453,3,11
CD006088,0,5,"A secondary outcome of 'not cured' was reduced (odds ratio (OR) for children 0.36, 95% confidence interval (CI) 0.16 to 0.77; number needed to treat to benefit (NNTB) at day 10 = 5 (95% CI 3 to 16) and OR 0.32 for adults (95% CI 0.13 to 0.75); NNTB at day 10 = 5 (95% CI 3 to 19)).",merge,"['However, in the secondary analysis, children who received a mucolytic were more likely to be cured of cough (the number needed to treat to benefit (NNTB) at day 10 was 5 for children and 4 for adults).']",3,0.5454545454545454,3,11
CD006088,0,6,"In a post hoc analysis combining data for children and adults, again there was no difference in the primary outcome of 'not cured or not improved' (OR 0.85, 95% CI 0.40 to 1.80) although mucolytics reduced the secondary outcome 'not cured' (OR 0.34, 95% CI 0.19 to 0.60; NNTB 4, 95% CI 3 to 8).",none,[],3,0.6363636363636364,4,11
CD006088,0,7,The risk of bias was low or unclear.,rephrase,['There were no obvious biases in the studies.'],4,0.7272727272727273,4,11
CD006088,1,8,There is insufficient evidence to decide whether OTC medications for cough associated with acute pneumonia are beneficial.,rephrase,"['Thus, there is insufficient evidence to draw any definitive conclusions on the role of OTC medications taken as an additional treatment for cough associated with acute pneumonia.']",5,0.8181818181818182,5,11
CD006088,1,9,Mucolytics may be beneficial but there is insufficient evidence to recommend them as an adjunctive treatment for acute pneumonia.,rephrase,['Mucolytics may be beneficial but the lack of consistent evidence precludes recommending the routine use of mucolytics as an addition in the treatment of troublesome cough associated with pneumonia in children or adults.'],6,0.9090909090909091,5,11
CD006088,1,10,This leaves only theoretical recommendations that OTC medications containing codeine and antihistamines should not be used in young children.,delete,[],7,1.0,5,11
CD012519,0,0,We included 12 eligible trials with a total of 1450 mothers and 1204 known infants.,rephrase,"['Twelve eligible trials with a total of 1450 mothers and 1204 known infants were included from searches, up to date as of March 2017.']",0,0.0625,1,16
CD012519,0,1,Eleven trials administered probiotics to mothers during pregnancy and one trial administered probiotics to mothers after birth of their preterm infants.,rephrase,['Eleven trials gave probiotics to mothers during pregnancy and one trial gave probiotics to mothers after the birth of their preterm infants.'],1,0.125,1,16
CD012519,0,2,No studies compared maternal probiotic administration directly with neonatal administration.,rephrase,['No studies compared maternal probiotic administration directly versus neonatal administration.The studies of pregnant women focused on various aspects of the studies with different probiotics given at different times.'],2,0.1875,1,16
CD012519,0,3,"Included prenatal trials were highly variable in the indication for the trial, the gestational age and duration of administration of probiotics, as well as the dose and formulation of the probiotics.",delete,[],3,0.25,2,16
CD012519,0,4,The pregnant women included in these trials were overall at low risk for preterm birth.,ignore,['The pregnant women included in these trials were overall at low risk for preterm birth.'],3,0.3125,2,16
CD012519,0,5,"In a meta-analysis of trial data, oral probiotic administration to pregnant women did not reduce the incidence of preterm birth < 37 weeks (typical risk ratio (RR) 0.92, 95% confidence interval (CI) 0.32 to 2.67; 4 studies, 518 mothers and 506 infants), < 34 weeks (typical risk difference (RD) 0.00, 95% CI -0.02 to 0.02; 2 studies, 287 mothers and infants), the incidence of infant mortality (typical RD 0.00, 95% CI -0.02 to 0.02; 2 studies, 309 mothers and 298 infants), or the gestational age at birth (mean difference (MD) 0.15, 95% CI -0.33 to 0.63; 2 studies, 209 mothers with 207 infants).",delete,[],4,0.375,2,16
CD012519,1,6,One trial studied administration of probiotics to mothers after preterm birth and included 49 mothers and 58 infants.,rephrase,['The one trial with mothers given probiotics after birth was to mothers of infants who weighed less than 1500 g at birth.'],4,0.4375,3,16
CD012519,1,7,"There were no significant differences in the risk of any NEC (RR 0.44, 95% CI 0.13 to 1.46; 1 study, 58 infants), surgery for NEC (RR 0.15, 95% CI 0.01 to 2.58; 1 study, 58 infants), death (RR 0.66, 95% CI 0.06 to 6.88; 1 study, 58 infants), and death or NEC (RR 0.53, 95% CI 0.19 to 1.49; 1 study, 58 infants).",delete,[],5,0.5,3,16
CD012519,1,8,"There was an improvement in time to reach 50% enteral feeds in infants whose mothers received probiotics, but the estimate is imprecise (MD -9.60 days, 95% CI -19.04 to -0.16 days; 58 infants).",delete,[],5,0.5625,3,16
CD012519,1,9,No other improvement in any neonatal outcomes were reported.,delete,[],5,0.625,4,16
CD012519,1,10,The estimates were imprecise and do not exclude the possibility of meaningful harms or benefits from maternal probiotic administration.,delete,[],5,0.6875,4,16
CD012519,1,11,There were no cases of culture-proven sepsis with the probiotic organism.,delete,[],5,0.75,4,16
CD012519,1,12,The GRADE quality of evidence was judged to be low to very low due to inconsistency and imprecision.,rephrase,"['In general, the evidence was of low to very low quality due to imprecision (small sample sizes) and indirectness (enrolled mothers were not necessarily at high risk for delivering their babies early).']",5,0.8125,5,16
CD012519,2,13,There is insufficient evidence to conclude whether there is appreciable benefit or harm to neonates of either oral supplementation of probiotics administered to pregnant women at low risk for preterm birth or oral supplementation of probiotics to mothers of preterm infants after birth.,ignore,['There is insufficient evidence to conclude whether there is appreciable benefit or harm to neonates of either oral supplementation of probiotics administered to pregnant women at low risk for preterm birth or oral supplementation of probiotics to mothers of preterm infants after birth.'],6,0.875,5,16
CD012519,2,14,"Oral supplementation of probiotics to mothers of preterm infants after birth may decrease time to 50% enteral feeds, however, this estimate is extremely imprecise.",delete,[],7,0.9375,5,16
CD012519,2,15,"More research is needed for post-natal administration of probiotics to mothers of preterm infants, as well as to pregnant mothers at high risk for preterm birth.",rephrase,"['More studies are needed to know if probiotics given to mothers of preterm infants decreases death, necrotizing enterocolitis, or other problems related to prematurity.']",7,1.0,5,16
CD004496,0,0,The updated search in June 2011 did not identify any new trials.,rephrase,['Only one trial was identified.'],0,0.125,1,8
CD004496,0,1,One study is included in the review.,delete,[],1,0.25,2,8
CD004496,0,2,This study assessed the effect of intraventricular gentamicin in a mixed population of neonates (69%) and older infants (31%) with gram-negative meningitis and ventriculitis.,delete,[],1,0.375,2,8
CD004496,0,3,Mortality was statistically significantly higher in the group that received intraventricular gentamicin in addition to intravenous antibiotics compared to the group receiving intravenous antibiotics alone (RR 3.43; 95% CI 1.09 to 10.74; RD 0.30; 95% CI 0.08 to 0.53); NNTH 3; 95% CI 2 to 13).,delete,[],1,0.5,3,8
CD004496,0,4,Duration of CSF culture positivity did not differ significantly (MD -1.20 days; 95% CI -2.67 to 0.27).,delete,[],1,0.625,4,8
CD004496,1,5,"In one trial that enrolled infants with gram-negative meningitis and ventriculitis, the use of intraventricular antibiotics in addition to intravenous antibiotics resulted in a three-fold increased RR for mortality compared to standard treatment with intravenous antibiotics alone.",ignore,"['In this trial enrolling infants with gram-negative meningitis and ventriculitis, the use of intraventricular antibiotics in addition to intravenous antibiotics resulted in a three-fold increased risk for mortality compared to standard treatment with intravenous antibiotics alone.']",1,0.75,4,8
CD004496,1,6,"Based on this result, intraventricular antibiotics as tested in this trial should be avoided.",rephrase,"['Based on this result, intraventricular antibiotics should be avoided.']",2,0.875,5,8
CD004496,1,7,Further trials comparing these interventions are not justified in this population.,rephrase,['Further trials comparing these interventions are not justified in newborn infants.'],3,1.0,5,8
CD006371,0,0,Six trials (553 participants) are included in this review.,ignore,['Six trials (553 participants) were included in this review.'],0,0.08333333333333333,1,12
CD006371,0,1,"Studies were varied in design, with significant heterogeneity in the evaluation of subjective tinnitus perception, with different scores, scales, tests and questionnaires as well as variance in the outcome measures used to assess the improvement in tinnitus sensation/quality of life.",delete,[],1,0.16666666666666666,1,12
CD006371,0,2,This precluded meta-analysis of the data.,delete,[],1,0.25,2,12
CD006371,0,3,There was no long-term follow-up.,delete,[],1,0.3333333333333333,2,12
CD006371,0,4,We assessed the risk of bias as medium in three and high in three studies.,delete,[],1,0.4166666666666667,3,12
CD006371,0,5,"Following analysis of the data, no significant change was seen in the loudness of tinnitus or the overall severity of tinnitus following the use of sound therapy compared to other interventions such as patient education, 'relaxation techniques', 'tinnitus coping strategies', counselling, 'tinnitus retraining' and exposure to environmental sounds.",ignore,"[""Following analysis of the data, no significant change was seen in the loudness of tinnitus or the overall severity of tinnitus following the use of sound therapy compared to other interventions such as patient education, 'relaxation techniques', 'tinnitus coping strategies', counselling, 'tinnitus retraining' and exposure to environmental sounds.""]",1,0.5,3,12
CD006371,0,6,No side effects or significant morbidity were reported from the use of sound-creating devices.,rephrase,['No side effects were reported from the use of sound-creating devices.'],2,0.5833333333333334,3,12
CD006371,1,7,The limited data from the included studies failed to show strong evidence of the efficacy of sound therapy in tinnitus management.,merge,"['The limited data from the studies included in the review failed to show strong evidence of the efficacy of sound therapy in tinnitus management, however the absence of conclusive evidence should not be interpreted as evidence of lack of effectiveness.']",3,0.6666666666666666,4,12
CD006371,1,8,The absence of conclusive evidence should not be interpreted as evidence of lack of effectiveness.,none,[],3,0.75,4,12
CD006371,1,9,"The lack of quality research in this area, in addition to the common use of combined approaches (hearing therapy plus counselling) in the management of tinnitus are, in part, responsible for the lack of conclusive evidence.",merge,['There is a lack of quality research in this area and also combined approaches (hearing therapy plus counselling) are commonly used in the management of tinnitus.'],4,0.8333333333333334,5,12
CD006371,1,10,"Other combined forms of management, such as tinnitus retraining therapy, have been subject to a Cochrane Review.",none,[],4,0.9166666666666666,5,12
CD006371,1,11,Optimal management may involve multiple strategies.,rephrase,['Optimal management of tinnitus may involve multiple strategies.'],5,1.0,5,12
CD014873,0,0,We synthesised 43 studies sampled from 170 eligible studies reported in 182 publications.,rephrase,"['We identified 170 eligible studies and included 43 of the most relevant studies, 39 from high-income countries and four from low- to middle-income countries.']",0,0.0625,1,16
CD014873,0,1,Included studies involved 633 participants.,rephrase,['The included studies involved a total of 633 participants.'],1,0.125,1,16
CD014873,0,2,"GRADE-CERQual assessments of findings were mostly high (n = 21, 58%) or moderate (n = 12, 33%) confidence with three (8%) low or very low confidence.",delete,[],2,0.1875,1,16
CD014873,0,3,"Poorly managed, moderate or severe chronic non-cancer pain had profound adverse impacts on family dynamics and relationships; family members’ emotions, well-being, autonomy and sense of self-identity; parenting strategies; friendships and socialising; children’s education and future employment prospects; and parental employment.",rephrase,"[""Moderate or severe chronic pain negatively affected a child or young person's whole family, family life and their social lives.""]",2,0.25,2,16
CD014873,0,4,Most children and parents understood chronic non-cancer pain as having an underlying biological cause and wanted curative treatment.,rephrase,['These studies primarily explored the views and experiences of adolescents with chronic non-cancer pain and their parents in the United Kingdom.'],3,0.3125,2,16
CD014873,0,5,"However, families had difficulties seeking and obtaining support from health services to manage their child’s pain and its impacts.",rephrase,"['Children and their families wanted to know the cause of the pain and have it resolved, but they found it difficult to get help and treatments that worked from health services.']",4,0.375,2,16
CD014873,0,6,"Children and parents felt that healthcare professionals did not always listen to their experiences and expertise, or believe the child's pain.",rephrase,['Sometimes healthcare professionals did not believe the child was in pain or listen to how pain affected them.'],5,0.4375,3,16
CD014873,0,7,Some families repeatedly visited health services seeking a diagnosis and cure.,rephrase,['Some families made many repeated visits to health services seeking a diagnosis and cure.'],6,0.5,3,16
CD014873,0,8,"Over time, some children and families gave up hope of effective treatment.",rephrase,"['Over time, some children and families realised their pain was unlikely to be cured and so focused on living well with pain or gave up hope of effective treatment.']",7,0.5625,3,16
CD014873,0,9,"Outcomes measured within trials and Cochrane Reviews of intervention effects did not include some outcomes of importance to children and families, including impacts of pain on the whole family and absence of pain.",delete,[],8,0.625,4,16
CD014873,0,10,"Cochrane Reviews have mainly neglected a holistic biopsychosocial approach, which specifies the interrelatedness of biological, psychological and social aspects of illness, when selecting outcome measures and considering how chronic pain management interventions work.",delete,[],8,0.6875,4,16
CD014873,1,11,We had high or moderate confidence in the evidence contributing to most review findings.,delete,[],8,0.75,4,16
CD014873,1,12,"Further research, especially into families' experiences of treatments and services, could strengthen the evidence for low or very low confidence findings.",delete,[],8,0.8125,5,16
CD014873,1,13,"Future research should also explore families' experiences in low- to middle-income contexts; of pain treatments including opioid use in children, which remains controversial; and of social care services.",delete,[],8,0.875,5,16
CD014873,1,14,We need development and testing of family-centred interventions and services acceptable to families.,delete,[],8,0.9375,5,16
CD014873,1,15,Future trials of children's chronic non-cancer pain interventions should include family-centred outcomes.,delete,[],8,1.0,5,16
CD012507,0,0,"This review included two randomised controlled trials involving 38 children (20 boys, 18 girls), aged 15 to 96 months, and their mothers.",rephrase,"['The studies involved 38 children (20 boys, 18 girls), aged 15 to 96 months, and their mothers.']",0,0.047619047619047616,1,21
CD012507,0,1,"All children had developmental disabilities; 10 had motor disorders, but it was unclear if these motor disorders affected their gestural, vocal or verbal communication.",rephrase,"['The studies involved children with a range of developmental difficulties; most had intellectual disability, 10 had movement disorders (cerebral palsy).']",1,0.09523809523809523,1,21
CD012507,0,2,Mothers attended eight group training sessions over 11 to 12 weeks and received two or three home visits.,rephrase,['Mothers attended eight group training sessions 11 to 12 weeks with two or three home visits.'],2,0.14285714285714285,1,21
CD012507,0,3,Outcomes were assessed immediately after training.,rephrase,['Results were assessed immediately after training.'],3,0.19047619047619047,1,21
CD012507,0,4,We found no report of longer-term follow-up.,rephrase,['We found no report of results at a later date (longer-term follow-up).'],4,0.23809523809523808,2,21
CD012507,0,5,One study took place at an intervention centre in Canada and the other in South Korea.,rephrase,"['We found only two studies that reported the effects of parent communication training; one study took place at an intervention centre in Canada, the other in South Korea.']",5,0.2857142857142857,2,21
CD012507,1,6,Both studies recruited small numbers of participants from single centres.,delete,[],6,0.3333333333333333,2,21
CD012507,1,7,"Since it is not possible to blind participants attending or therapists providing training to group allocation, we considered both studies to be at high risk of performance bias.",delete,[],6,0.38095238095238093,2,21
CD012507,1,8,"We also rated one study at high risk of attrition bias, and both studies at low risk of reporting bias.",delete,[],6,0.42857142857142855,3,21
CD012507,2,9,There was very low-quality evidence for all outcomes assessed.,delete,[],6,0.47619047619047616,3,21
CD012507,2,10,There was no evidence of an effect of training for children's initiation of conversation or engagement in joint attention during interaction with their mothers.,delete,[],6,0.5238095238095238,3,21
CD012507,2,11,"Mothers who received training became more responsive to their children's communication, but there were no differences in the extent to which they controlled conversation by directing their children.",delete,[],6,0.5714285714285714,3,21
CD012507,2,12,"Missing data meant that we were unable to evaluate the effects of training on children's frequency of communication, frequency of spoken language in conversation, speech production, or receptive or expressive language development.",rephrase,"[""We were not able to evaluate the effects of parent-mediated communication intervention and frequency of children's communication, their use of spoken language in conversation with their parents, their speech production or their language development because the data were not available.""]",6,0.6190476190476191,4,21
CD012507,2,13,There were no effects on maternal stress.,rephrase,"[""However, there was no associated reduction in mothers' directiveness (such as their use of commands) in conversation and no change in maternal stress.""]",7,0.6666666666666666,4,21
CD012507,2,14,"We found no reports of the effects of parent training on children's use of individual communication skills, such as asking questions or providing information, on their generic participation or adverse outcomes.",rephrase,"[""We have no reports of children's development of individual communication skills, such as learning to ask questions, and no reports of defects of the intervention on their generic participation or harms arising from the intervention.""]",8,0.7142857142857143,4,21
CD012507,2,15,"Neither did we find reports of mothers' satisfaction with treatment, its acceptability or their compliance with it.",rephrase,"['Finally, we found no reports of maternal satisfaction with the treatment.']",9,0.7619047619047619,4,21
CD012507,3,16,"There is only limited, very low quality evidence that parent-mediated communication interventions may be associated with improvements in interaction between mothers and their preschool children who have motor disorders.",merge,[],10,0.8095238095238095,5,21
CD012507,3,17,"The indirectness of the study samples and high risk of bias in the included the studies significantly limits our confidence in the evidence, as do issues with study design and lack of detail in results.",none,"[""We judged the evidence from the included studies to be of very low quality because of issues with study design and a lack of detail in the results presented, and because it was not clear whether children's movement disorders affected their communication.""]",10,0.8571428571428571,5,21
CD012507,3,18,It is not clear if training has been tested with children whose motor disorders limit the consistency and accuracy of movements underpinning spoken or gestural communication.,delete,[],11,0.9047619047619048,5,21
CD012507,3,19,Some speech and language therapists currently provide communication training for parents.,delete,[],11,0.9523809523809523,5,21
CD012507,3,20,"Further research, with larger numbers of children whose movement disorders affect their speech and gestures, coupled with detailed reporting of children's baseline skills, is needed to test whether communication training for parents can help them to promote the communication development of their young children with movement disorders.",rephrase,"['Research with larger numbers of families of children whose movement disorders affect their speech and gesture is needed, to test whether communication training for parents can help them to promote the communication development of their young children with movement disorders.']",11,1.0,5,21
CD006913,0,0,"Twenty-one studies were eligible for inclusion (1745 participants; 19 in adults, 2 in adolescents).",delete,[],0,0.08333333333333333,1,12
CD006913,0,1,Most studies used multimodular approaches.,rephrase,"['Most studies examined combination therapies, often aimed at improving stress management.']",0,0.16666666666666666,1,12
CD006913,0,2,The risk of bias was high for all studies.,delete,[],1,0.25,2,12
CD006913,0,3,"In adults, psychotherapy had no effect on quality of life at around 12 months (3 studies, 235 patients, SMD -0.07; 95% CI -0.33 to 0.19), emotional status (depression, 4 studies, 266 patients, SMD 0.03; 95% CI -0.22 to 0.27) or proportion of patients not in remission (5 studies, 287 patients, OR 0.85; 95% CI 0.48 to 1.48).",rephrase,"['In adults, psychotherapy was not effective at 6 and 12 months for all outcomes (quality of life, emotional status/depression and relapse/disease activity), based on 3 studies.']",1,0.3333333333333333,2,12
CD006913,0,4,Results were similar at 3 to 8 months.,delete,[],2,0.4166666666666667,3,12
CD006913,0,5,There was no evidence for statistical heterogeneity or subgroup effects based on type of disease or intensity of the therapy.,rephrase,"[""There was no difference by type of disease (Crohn's disease versus ulcerative colitis) or intensity of the therapy.""]",2,0.5,3,12
CD006913,0,6,"In adolescents, there were positive short term effects of psychotherapy on most outcomes assessed including quality of life (2 studies, 71 patients, SMD 0.70; 95% CI 0.21 to 1.18) and depression (1 study, 41 patients, SMD -0.62; 95% CI -1.25 to 0.01).",rephrase,"['In adolescents, there was a small positive effect for all outcomes (quality of life, coping, depression and anxiety), but only short term effects were reported in this group.']",3,0.5833333333333334,3,12
CD006913,0,7,"Educational interventions had no effect on quality of life at 12 months (5 studies, 947 patients, SMD 0.11; 95% CI -0.02 to 0.24), depression (3 studies, 378 patients, SMD -0.08; 95% CI -0.29 to 0.12) and proportion of patients not in remission (3 studies, 434 patients, OR 1.00; 95% CI 0.65 to 1.53).",rephrase,"['In adults, educational interventions were also not effective to improve quality of life and the course of the disease over 1 year, based on 5 studies.']",4,0.6666666666666666,4,12
CD006913,0,8,No adverse events were reported in any of the included studies.,rephrase,['None of the included studies reported any side effects of psychological interventions.'],5,0.75,4,12
CD006913,1,9,There is no evidence for efficacy of psychological therapy in adult patients with IBD in general.,delete,[],6,0.8333333333333334,5,12
CD006913,1,10,"In adolescents, psychological interventions may be beneficial, but the evidence is limited.",rephrase,"['We assume that adolescents, and patients with special needs (e.g. emotional problems) may benefit from psychological therapy.']",6,0.9166666666666666,5,12
CD006913,1,11,"Further evidence is needed to assess the efficacy of these therapies in subgroups identified as being in need of psychological interventions, and to identify what type of therapy may be most useful.",rephrase,['More research is needed to examine the effect of psychotherapy focusing on the individual psychological situation of IBD patients.'],7,1.0,5,12
CD001180,0,0,Eleven trials are included in this update; 10 of these we judged to be at an unclear or high risk of bias.,split,"['Seven out of the eleven studies were at high risk of bias and we could not assess the potential bias in three studies due to poor reporting.', 'One study was at low risk of bias.']",0,0.07692307692307693,1,13
CD001180,0,1,"The trials were clinically heterogeneous with differences in duration of follow-up, and ultrasound regimens.",rephrase,"['The trials were all different, for example in their duration of follow-up (three weeks to 12 months), and the strength of the ultrasound waves used (high or low frequency ultrasound).']",2,0.15384615384615385,1,13
CD001180,0,2,Nine trials evaluated high frequency ultrasound; seven studies provided data for ulcers healed and two provided data on change in ulcer size only.,rephrase,['Eight studies compared ultrasound with use of no ultrasound for venous leg ulcers and the other three compared ultrasound with sham ultrasound.'],3,0.23076923076923078,2,13
CD001180,0,3,Two trials evaluated low frequency ultrasound and both reported ulcers healed data.,rephrase,['The two studies that evaluated low-frequency ultrasound did not report whether participants experienced side effects.'],4,0.3076923076923077,2,13
CD001180,1,4,"It is uncertain whether high frequency ultrasound affects the proportion of ulcers healed compared with no ultrasound at any of the time points evaluated: at seven to eight weeks (RR 1.21, 95% CI 0.86 to 1.71; 6 trials, 678 participants; low quality evidence - downgraded once for risk of bias and once for imprecision); at 12 weeks (RR 1.26, 95% CI 0.92 to 1.73; 3 trials, 489 participants; moderate quality evidence - downgraded once for imprecision); and at 12 months (RR 0.93, 95% CI 0.73 to 1.18; 1 trial, 337 participants; low quality evidence - downgraded once for unclear risk of bias and once for imprecision).",split,"['It is not clear from this evidence whether ultrasound (high or low frequency) increases the healing of venous leg ulcers.', ""It is also uncertain whether either high- or low-frequency ultrasound affects participants' quality of life.""]",5,0.38461538461538464,2,13
CD001180,2,5,"One trial (92 participants) reported that a greater percentage reduction in ulcer area was achieved at four weeks with high-frequency ultrasound, while another (73 participants) reported no clear difference in change in ulcer size at seven weeks.",delete,[],7,0.46153846153846156,3,13
CD001180,2,6,"We downgraded the level of this evidence to very low, mainly for risk of bias (typically lack of blinded outcome assessment and attrition) and imprecision.",delete,[],7,0.5384615384615384,3,13
CD001180,3,7,"Data from one trial (337 participants) suggest that high frequency ultrasound may increase the risk of non-serious adverse events (RR 1.29, 95% CI 1.02 to 1.64; moderate quality evidence - downgraded once for imprecision) and serious adverse events (RR 1.21, 95% CI 0.78 to 1.89; moderate quality evidence downgraded once for imprecision).",rephrase,['The results of one study (337 participants) suggest that high-frequency ultrasound may be associated with more adverse events such as pain and skin redness (moderate quality evidence).'],7,0.6153846153846154,4,13
CD001180,4,8,"It is uncertain whether low frequency ultrasound affects venous ulcer healing at eight and 12 weeks (RR 3.91, 95% CI 0.47 to 32.85; 2 trials, 61 participants; very low quality evidence (downgraded for risk of bias and imprecision)).",delete,[],8,0.6923076923076923,4,13
CD001180,5,9,"High-frequency ultrasound probably makes little or no difference to quality of life (moderate quality evidence, downgraded for imprecision).",delete,[],8,0.7692307692307693,4,13
CD001180,5,10,"The outcomes of adverse effects, quality of life and cost were not reported for low-frequency ultrasound treatment.",delete,[],8,0.8461538461538461,5,13
CD001180,6,11,It is uncertain whether therapeutic ultrasound (either high or low frequency) improves the healing of venous leg ulcers.,rephrase,['In September 2016 we searched for randomised controlled trials (RCTs) that investigated whether ultrasound helps to heal or improves the symptoms of venous leg ulcers.'],8,0.9230769230769231,5,13
CD001180,6,12,We rated most of the evidence as low or very low quality due to risk of bias and imprecision.,rephrase,['We consider the available evidence to be low quality due to these risks of bias.'],9,1.0,5,13
CD004334,0,0,"Five studies involving 3,070 individuals met the criteria for inclusion in the meta-analysis.",rephrase,"['The authors found five studies involving a total of 3,070 participants.']",0,0.125,1,8
CD004334,0,1,All interventions for promoting use of booster seats among 4 to 8 year olds demonstrated a positive effect (relative risk (RR) 1.43; 95% confidence intervals (CI) 1.05 to 1.96).,rephrase,"['All interventions investigated by the studies were found to increase the use of booster seats, compared to the group receiving no intervention.']",1,0.25,2,8
CD004334,0,2,"Incentives combined with education demonstrated a beneficial effect (RR 1.32, 95% CI 1.12 to 1.55; n = 1,898).",delete,[],2,0.375,2,8
CD004334,0,3,Distribution of free booster seats combined with education also had a beneficial effect (RR 2.34; 95% CI 1.50 to 3.63; n = 380) as did education-only interventions (RR 1.32; 95% CI 1.16 to 1.49; n = 563).,split,"['The distribution of free booster seats combined with education on their use, had a marked beneficial effect, as did incentives (for example, booster seat discount coupons or gift certificates) combined with education.', 'Education-only interventions also produced beneficial outcomes.']",2,0.5,3,8
CD004334,0,4,"One study which evaluated enforcement of booster seat law met the criteria for inclusion in the meta-analysis, but demonstrated no marked beneficial effect.",rephrase,"['One of the studies evaluated the effectiveness of the enforcement of a booster seat law, but did not detect an effect on usage.']",4,0.625,4,8
CD004334,1,5,Available evidence suggests that interventions to increase use of booster seats among children age four to eight years are effective.,rephrase,"['The authors concluded that the current evidence suggests that several types of interventions aimed at increasing the use of booster seats among children aged four to eight years, are effective.']",5,0.75,4,8
CD004334,1,6,Combining incentives (booster seat discount coupons or gift certificates) or distribution of free booster seats with education demonstrated marked beneficial outcomes for acquisition and use of booster seats for four to eight year olds.,delete,[],6,0.875,5,8
CD004334,1,7,"There is some evidence of beneficial effect of legislation on acquisition and use of booster seats but this was mainly from uncontrolled before-and-after studies, which did not meet the criteria for inclusion in the meta-analysis.",delete,[],6,1.0,5,8
CD008824,0,0,"Four trials met the inclusion criteria, with a total of 3198 children under five years of age, and were conducted in Afghanistan, Spain, and the USA.",split,"['The review authors examined the available evidence up to 17 June 2016, and included four trials with a total of 3198 children under five years of age.', 'The included trials were conducted in Afghanistan, Spain and the USA.']",0,0.06666666666666667,1,15
CD008824,0,1,"Prevalence of vitamin D deficiency varied widely in these populations (range: 73.1% in Afghanistan, 10 to 12% in USA, and 6.2% in Spain).",delete,[],2,0.13333333333333333,1,15
CD008824,0,2,"The included trials evaluated mortality (two trials), pneumonia incidence (two trials), diarrhoea incidence (two trials), hospitalization (two trials), and mean serum vitamin D concentrations (four trials).",delete,[],2,0.2,1,15
CD008824,1,3,"We do not know whether vitamin D supplementation impacts on all-cause mortality because this outcome was underpowered due to few events (risk ratio (RR) 1.43, 95% confidence interval (CI) 0.54 to 3.74; one trial, 3046 participants, low quality evidence).",rephrase,['We do not know about whether Vitamin D influences hospital admissions as there was only one small study measuring this (very low quality evidence).'],2,0.26666666666666666,2,15
CD008824,2,4,"For pneumonia, episodes of 'radiologically confirmed' first or only episode of pneumonia were little different in the supplemented and unsupplemented group (Rate Ratio: 1.06, 95% confidence interval (CI) 0.89 to 1.26; two trials, 3134 participants, moderate quality evidence), and similarly for children with confirmed or unconfirmed pneumonia (RR 0.95, 95% CI 0.87 to 1.04; one trial, 3046 participants).",merge,[],3,0.3333333333333333,2,15
CD008824,2,5,In these two trials there were no obvious differences between supplemented and unsupplemented children regarding episodes of diarrhoea.,none,['Limited evidence showed that there was no obvious difference in the first or repeat episodes of diarrhoea between supplemented and unsupplemented children.'],3,0.4,2,15
CD008824,3,6,"In the single large trial from Afghanistan, the trial authors reported that vitamin D supplementation was associated with an increase in repeat episodes of pneumonia confirmed by chest radiograph (RR 1.69, 95% CI 1.28 to 2.21; one trial, 3046 participants), but not reflected in the outcome of confirmed or unconfirmed pneumonia (RR 1.06, 95% CI 1.00 to 1.13; one trial, 3046 participants).",rephrase,['One large trial from Afghanistan showed an increase in repeat episodes of confirmed pneumonia but not on confirmed and unconfirmed pneumonia.'],4,0.4666666666666667,3,15
CD008824,4,7,"For hospital admission measured in one small trial, there was no difference detected (RR 0.86, 95% CI 0.20 to 3.62; one trial, 88 participants; very low quality evidence).",delete,[],5,0.5333333333333333,3,15
CD008824,5,8,"The mean serum vitamin D concentrations were higher in supplemented compared to unsupplemented children at the end of supplementation (MD 7.72 ng/mL, 95% CI 0.50 to 14.93; four trials, 266 participants, low quality evidence).",rephrase,['The mean serum vitamin D concentrations were higher in the supplemented versus unsupplemented children at the end of supplementation period (low quality evidence).'],5,0.6,3,15
CD008824,5,9,These results were driven primarily by two smaller trials with large magnitudes of effect.,delete,[],6,0.6666666666666666,4,15
CD008824,5,10,"In the other two bigger trials, serum vitamin D concentrations were elevated in the intervention group for most of the trial duration but not at the end of supplementation.",delete,[],6,0.7333333333333333,4,15
CD008824,5,11,"This may be due to time elapsed at measurement from the last dose, incomplete compliance, or increased need of vitamin D with infant age.",delete,[],6,0.8,4,15
CD008824,6,12,"We did not find any trial that reported on the incidence of TB, malaria or febrile illness, duration of pneumonia, duration of diarrhoea, severity of infection, and cause-specific mortality (due to TB, diarrhoea, or malaria).",rephrase,['None of the included trials reported on TB or malaria as outcomes.'],6,0.8666666666666667,5,15
CD008824,7,13,Evidence from one large trial did not demonstrate benefit of vitamin D supplementation on the incidence of pneumonia or diarrhoea in children under five years.,rephrase,['One large trial has not demonstrated an effect of vitamin D on death or respiratory infections in children under five years of age.'],7,0.9333333333333333,5,15
CD008824,7,14,"To our knowledge, trials that evaluated supplementation for preventing other infections, including TB and malaria, have not been performed.",rephrase,['We did not find trials evaluating Vitamin D supplementation to prevent other infections such as TB and malaria.'],8,1.0,5,15
CD005547,0,0,We included a total of six trials (24 reports) that randomised 7873 pregnant women.,rephrase,['We searched for evidence in March 2021 and identified six randomised controlled studies (in 24 reports) that included 7873 pregnant women.'],0,0.06666666666666667,1,15
CD005547,0,1,"All of the included trials were conducted in antenatal clinics within hospitals in LMICs (Uganda, Nigeria, Peru, India, Sierra Leone and Tanzania).",ignore,"['All of the included studies were conducted in antenatal clinics within hospitals in LMICs (Uganda, Nigeria, Peru, India, Sierra Leone and Tanzania).']",1,0.13333333333333333,1,15
CD005547,0,2,"Among primary outcomes, five trials reported maternal anaemia, one trial reported preterm birth and three trials reported perinatal mortality.",delete,[],2,0.2,1,15
CD005547,0,3,"Among secondary outcomes, included trials reported maternal worm prevalence, low birthweight (LBW) and birthweight.",delete,[],2,0.26666666666666666,2,15
CD005547,0,4,None of the included studies reported maternal anthropometric measures or infant survival at six months.,delete,[],2,0.3333333333333333,2,15
CD005547,0,5,"Overall, we judged the included trials to be generally at low risk of bias for most domains, while the certainty of evidence ranged from low to moderate.",delete,[],2,0.4,2,15
CD005547,1,6,"Analysis suggests that administration of a single dose of antihelminthics in the second trimester of pregnancy may reduce maternal anaemia by 15% (average risk ratio (RR) 0.85, 95% confidence interval (CI) 0.72 to 1.00; I²= 86%; 5 trials, 5745 participants; low-certainty evidence).",rephrase,['Evidence from five trials (5745 women) suggests that deworming using a single dose of antihelminthics in the second trimester of pregnancy may reduce maternal anaemia (low-certainty evidence).'],2,0.4666666666666667,3,15
CD005547,1,7,"We are uncertain of the effect of antihelminthics during pregnancy on preterm birth (RR 0.84, 95% CI 0.38 to 1.86; 1 trial, 1042 participants; low-certainty evidence) or perinatal mortality (RR 1.01, 95% CI 0.67 to 1.52; 3 trials, 3356 participants; low-certainty evidence).",rephrase,"['We are uncertain about the effects on preterm birth (1042 women in 1 study) or perinatal mortality (3356 women in 3 studies), with low-certainty evidence for both outcomes.']",3,0.5333333333333333,3,15
CD005547,2,8,"We are uncertain of the effect of antihelminthics during pregnancy on hookworm (average RR 0.31, 95% CI 0.05 to 1.93; Tau² = 1.76, I² = 99%; 2 trials, 2488 participants; low-certainty evidence).",rephrase,['The number of women with worms was reduced (2488 women in 2 studies; low-certainty evidence).'],4,0.6,3,15
CD005547,2,9,"Among other secondary outcomes, findings suggest that administration of antihelminthics during pregnancy may reduce the prevalence of trichuris (average RR 0.68, 95% CI 0.48 to 0.98; I²=75%; 2 trials, 2488 participants; low-certainty evidence) and ascaris (RR 0.24, 95% CI 0.19 to 0.29; I²= 0%; 2 trials, 2488 participants; moderate-certainty evidence).",delete,[],5,0.6666666666666666,4,15
CD005547,2,10,"Antihelminthics during pregnancy probably make little or no difference to LBW (RR 0.89, 95% CI 0.69 to 1.16; 3 trials, 2960 participants; moderate-certainty evidence) and birthweight (mean difference 0.00 kg, 95% CI -0.03 kg to 0.04 kg; 3 trials, 2960 participants; moderate-certainty evidence).",rephrase,"['Antihelminthics probably make little or no difference to LBW babies (3301 women in 4 studies) or birthweight (3301 women in 4 studies), with moderate-certainty evidence for both outcomes.']",5,0.7333333333333333,4,15
CD005547,3,11,The evidence suggests that administration of a single dose of antihelminthics in the second trimester of pregnancy may reduce maternal anaemia and worm prevalence when used in settings with high prevalence of maternal helminthiasis.,rephrase,"['Antihelminthic drugs given during the second trimester of pregnancy may reduce maternal anaemia and the number of women with worms, but with no impact on other maternal or pregnancy outcomes.']",6,0.8,4,15
CD005547,3,12,Further data is needed to establish the benefit of antihelminthic treatment on other maternal and pregnancy outcomes.,rephrase,"['Further research is needed among particular groups of women and on the effectiveness of additional interventions with antihelminthics, including health education.']",7,0.8666666666666667,5,15
CD005547,4,13,Future research should focus on evaluating the effect of these antihelminthics among various subgroups in order to assess whether the effect varies.,delete,[],8,0.9333333333333333,5,15
CD005547,4,14,Future studies could also assess the effectiveness of co-interventions and health education along with antihelminthics for maternal and pregnancy outcomes.,delete,[],8,1.0,5,15
CD008704,0,0,A total of three studies involving 144 eligible participants were included in the review.,rephrase,"['The review included three studies, involving a total of 144 people.']",0,0.1,1,10
CD008704,0,1,"Two of the studies (56 participants) compared an early version of acceptance and commitment therapy (ACT) with CBT, and one study (88 eligible participants) compared extended behavioural activation with CBT.",rephrase,"['The studies examined two different forms of third wave CBT, consisting of acceptance and commitment therapy (ACT) (two studies) and extended behavioural activation (BA) (one study).']",1,0.2,1,10
CD008704,0,2,No other studies of third wave CBT were identified.,rephrase,['All three studies compared these third wave CBT approaches with CBT.'],2,0.3,2,10
CD008704,0,3,The two ACT studies were assessed as being at high risk of performance bias and researcher allegiance.,delete,[],3,0.4,2,10
CD008704,0,4,"Post-treatment results, which were based on dropout rates, showed no evidence of any difference between third wave CBT and other psychological therapies for the primary outcomes of efficacy (risk ratio (RR) of clinical response 1.14, 95% confidence interval (CI) 0.79 to 1.64; very low quality) and acceptability.",delete,[],3,0.5,3,10
CD008704,0,5,"Results at two-month follow-up showed no evidence of any difference between third wave CBT and other psychological therapies for clinical response (2 studies, 56 participants, RR 0.22, 95% CI 0.04 to 1.15).",delete,[],3,0.6,3,10
CD008704,0,6,Moderate statistical heterogeneity was indicated in the acceptability analyses (I2 = 41%).,delete,[],3,0.7,4,10
CD008704,1,7,Very low quality evidence suggests that third wave CBT and CBT approaches are equally effective and acceptable in the treatment of acute depression.,split,"['In this review, we focused on third wave CBT approaches, a group of psychological therapies that target the process of thoughts (rather than their content, as in CBT) to help people become aware of their thoughts and accept them in a non-judgemental way.', 'The aim of the review was to find out whether third wave CBT was more effective and acceptable than other psychological therapy approaches for people with acute depression.', 'The results suggested that third wave CBT and CBT approaches were equally effective in treating depression.', 'However, the quality of evidence was very low because of the small number of studies of poor quality that we included in the review; therefore it is not possible to conclude whether third wave CBT approaches might be more effective and acceptable than other psychological therapies in the short term or over a longer period of time.']",3,0.8,4,10
CD008704,1,8,"Evidence is limited in quantity, quality and breadth of available studies, precluding us from drawing any conclusions as to their short- or longer-term equivalence.",delete,[],7,0.9,5,10
CD008704,1,9,The increasing popularity of third wave CBT approaches in clinical practice underscores the importance of completing further studies to compare various third wave CBT approaches with other psychological therapy approaches to inform clinicians and policymakers on the most effective forms of psychological therapy in treating depression.,rephrase,"['Given the increasing popularity of third wave CBT approaches in clinical practice, further studies should be prioritised to establish whether third wave CBT approaches are more helpful than other psychological therapies in treating people with acute depression.']",7,1.0,5,10
CD008453,0,0,Two completed and one ongoing clinical trial met the inclusion criteria.,delete,[],0,0.1,1,10
CD008453,0,1,One trial (34 patients randomised) examined the effects of H pylori eradication on levodopa absorption and motor symptoms and found significant improvements in both.,rephrase,['One of the trials reported a significant increase in levodopa absorption and improvement in motor symptoms when antibiotics were used to eradicate H pylori.'],0,0.2,1,10
CD008453,0,2,The ongoing trial has similar objectives and aims to recruit 100 patients.,delete,[],1,0.3,2,10
CD008453,0,3,The other completed trial (20 patients analysed) sought to find a causal link between infection with H pylori and Parkinsonism and was non-contributory.,delete,[],1,0.4,2,10
CD008453,0,4,A worsening of symptoms was noted with eradication failure.,delete,[],1,0.5,3,10
CD008453,1,5,The prevalence of H pylori in Parkinson's disease was reported in four studies and ranged from 37% to 59% which is similar to that of the general population.,delete,[],1,0.6,3,10
CD008453,2,6,There is currently a lack of evidence on the effects of screening and treating H pylori in patients with Parkinson's disease.,rephrase,"[""It will be important also to look at the cost of both screening for H pylori and treatment of H pylori in Parkinson's disease patients to see if this is worthwhile.""]",1,0.7,4,10
CD008453,2,7,There is limited evidence to suggest that H Pylori eradication improves the absorption of levodopa and improves motor symptoms.,rephrase,"[""We used clinical trials to see if treatment of H pylori-positive Parkinson's disease patients with antibiotics improved the absorption of levodopa and improved their motor symptoms.""]",2,0.8,4,10
CD008453,2,8,Results from an ongoing trial will inform the evidence base and will be incorporated in an update of this review.,rephrase,"[""A further trial of H pylori eradication in Parkinson's disease is still underway and the results, which are due in 2010, will help inform further studies.""]",3,0.9,5,10
CD008453,2,9,There is a need for well-conducted randomised controlled trials with standard outcome measures for motor symptoms and incorporating the costs of screening and treatment.,rephrase,['More clinical trials are needed using standard measures of motor symptoms.'],4,1.0,5,10
CD010662,0,0,Seven studies met our eligibility criteria.,delete,[],0,0.05263157894736842,1,19
CD010662,0,1,All were randomized controlled trials; six assigned clusters and one randomized individuals.,split,"['We found seven randomized trials.', 'Six assigned groups (clusters) and one randomized individuals.']",0,0.10526315789473684,1,19
CD010662,0,2,"Sample sizes for the cluster-randomized trials ranged from 2157 to 15,614; the number of clusters ranged from 18 to 70.",delete,[],2,0.15789473684210525,1,19
CD010662,0,3,"Four trials took place in African countries, two in the USA, and one in England.",ignore,"['Four trials took place in African countries, two in the USA, and one in England.']",2,0.21052631578947367,2,19
CD010662,0,4,"Three were based mainly in schools, two were in community settings, one took place during military training, and one was clinic-based.",rephrase,"['The studies were based in schools, community settings, a clinic, and a military training setting.']",3,0.2631578947368421,2,19
CD010662,1,5,"Five studies provided data on pregnancy, either from pregnancy tests or national records of abortions and live births.",merge,[],4,0.3157894736842105,2,19
CD010662,1,6,Four trials assessed the incidence or prevalence of HIV and HSV-2.,merge,"['Five trials examined pregnancy, four studied HIV and HSV-2 (herpes), and three assessed other STI.']",4,0.3684210526315789,2,19
CD010662,1,7,Three trials examined other STI.,none,[],4,0.42105263157894735,3,19
CD010662,1,8,"The trials showed or reported no significant difference between study groups for pregnancy or HIV, but favorable effects were evident for some STI.",split,"['We found no major differences between study groups for pregnancy or HIV.', 'Some results were seen for STI outcomes.']",5,0.47368421052631576,3,19
CD010662,1,9,"Two showed a lower incidence of HSV-2 for the behavioral-intervention group compared to the usual-care group, with reported adjusted rate ratios (ARR) of 0.65 (95% CI 0.43 to 0.97) and 0.67 (95% CI 0.47 to 0.97), while HIV did not differ significantly.",rephrase,['Two studies showed fewer HSV-2 cases with the behavioral program compared to the control group.'],7,0.5263157894736842,3,19
CD010662,1,10,One also reported lower syphilis incidence and gonorrhea prevalence for the behavioral intervention plus STI management compared to the usual-care group.,rephrase,['One also reported fewer cases of syphilis and gonorrhea with the behavioral program plus STI management.'],8,0.5789473684210527,3,19
CD010662,1,11,"The reported ARR were 0.58 (95% CI 0.35 to 0.96) and 0.28 (95% CI 0.11 to 0.70), respectively.",delete,[],9,0.631578947368421,4,19
CD010662,1,12,Another study reported a negative effect on gonorrhea for young women in the intervention group versus the control group (ARR 1.93; 95% CI 1.01 to 3.71).,rephrase,['Another study reported a higher gonorrhea rate for the intervention group.'],9,0.6842105263157895,4,19
CD010662,1,13,The difference occurred among those with only one year of the intervention.,delete,[],10,0.7368421052631579,4,19
CD010662,2,14,We found few studies and little clinical evidence of effectiveness for interventions promoting condom use for dual protection.,rephrase,['We found little clinical effect of improving condom use.'],10,0.7894736842105263,4,19
CD010662,2,15,"We did not find favorable results for pregnancy or HIV, and only found some for other STI.",rephrase,"['The studies had a clinical outcome such as pregnancy, HIV, or STI tests.']",11,0.8421052631578947,5,19
CD010662,2,16,The overall quality of evidence was moderate to low; losses to follow up were high.,split,"['The studies provided moderate to low quality information.', 'Losses to follow up were high.']",12,0.8947368421052632,5,19
CD010662,2,17,Effective interventions for improving condom use are needed to prevent pregnancy and HIV/STI transmission.,rephrase,['We need good programs on condom use to prevent pregnancy and HIV/STI.'],14,0.9473684210526315,5,19
CD010662,2,18,Interventions should be feasible for resource-limited settings and tested using valid and reliable outcome measures.,split,"['Programs should be useful for settings with few resources.', 'Interventions should be tested with valid outcome measures.']",15,1.0,5,19
CD003211,0,0,Eight trials recruiting a total of 637 infants met the inclusion criteria for the systematic review.,rephrase,['We found 8 clinical trials recruiting 637 babies up to 6 months of age who presented with symptoms of GOR.'],0,0.08333333333333333,1,12
CD003211,0,1,The infants included in the review were mainly formula-fed term infants.,rephrase,"[""The recruited babies were mainly 'healthy' term babies (i.e. babies born within three weeks of the due date) who were bottle feeding.""]",1,0.16666666666666666,1,12
CD003211,0,2,The trials were of variable methodological quality.,delete,[],2,0.25,2,12
CD003211,0,3,"Formula-fed term infants with GOR on feed thickeners had nearly two fewer episodes of regurgitation per day (mean difference -1.97 episodes per day, 95% confidence interval (CI) -2.32 to -1.61; 6 studies, 442 infants, moderate-certainty evidence) and were 2.5 times more likely to be asymptomatic from regurgitation at the end of the intervention period (risk ratio 2.50, 95% CI 1.38 to 4.51; number needed to treat for an additional beneficial outcome 5, 95% CI 4 to 13; 2 studies, 186 infants, low-certainty evidence) when compared to infants with GOR on unthickened feeds.",split,"['We found that term babies with GOR given feed thickeners had nearly two fewer reflux episodes per day.', 'Babies with GOR were also 2.5 times more likely to have no reflux symptoms if feed thickeners were used.']",2,0.3333333333333333,2,12
CD003211,0,4,No studies reported failure to thrive as an outcome.,rephrase,['No studies reported information on failure to thrive (i.e. poor growth).'],4,0.4166666666666667,3,12
CD003211,0,5,"We found low-certainty evidence based on 2 studies recruiting 116 infants that use of feed thickeners improved the oesophageal pH probe parameters of reflux index (i.e. percentage of time pH < 4), number of reflux episodes lasting longer than 5 minutes, and duration of longest reflux episode.",split,"['We found that babies with GOR given feed thickeners showed an improvement in an important measure of acid reflux obtained from pH study.', 'Reflux index (i.e. percentage of time of acidic reflux of pH < 4) was 5% lower in babies given feed thickeners.']",5,0.5,3,12
CD003211,0,6,No major side effects were reported with the use of feed thickeners.,delete,[],7,0.5833333333333334,3,12
CD003211,0,7,Information was insufficient to conclude which type of feed thickener is superior.,delete,[],7,0.6666666666666666,4,12
CD003211,1,8,Gastro-oesophageal reflux is a physiological self resolving phenomenon in infants that does not necessarily require any treatment.,delete,[],7,0.75,4,12
CD003211,1,9,"However, we found moderate-certainty evidence that feed thickeners should be considered if regurgitation symptoms persist in term bottle-fed infants.",delete,[],7,0.8333333333333334,5,12
CD003211,1,10,The reduction of two episodes of regurgitation per day is likely to be of clinical significance to caregivers.,rephrase,"['Due to study design limitations, we are moderately confident in the evidence for the reduction of two reflux episodes per day.']",7,0.9166666666666666,5,12
CD003211,1,11,"Due to the limited information available, we were unable to assess the use of feed thickeners in infants who are breastfeeding or preterm nor could we conclude which type of feed thickener is superior.",rephrase,['Further research is needed to determine which type of feed thickener is better and whether feed thickeners are useful in babies with GOR who are breastfeeding or preterm.'],8,1.0,5,12
MR000026,0,0,"We included 12 studies (in 13 publications) in this review, but interpretability and generalizability of these studies is difficult and the study designs used were at high risk of bias.",rephrase,['We found 12 studies that explored whether or not checking reference lists was useful for systematic reviews.'],0,0.125,1,8
MR000026,0,1,The additional yield (calculated by dividing the additional 'unique' yield identified by checking reference lists by the total number of studies found to be eligible within the study) of relevant studies identified through checking reference lists ranged from 2.5% to 42.7%.,rephrase,"['These studies reported a range of results, from identifying only a few additional studies (2.5%: 2 of 79 included studies) to identifying many additional studies (42.7%: 111 of 260 included studies) through checking reference lists.']",1,0.25,2,8
MR000026,0,2,Only two studies reported yield information by publication type (dissertations and systematic reviews).,delete,[],2,0.375,2,8
MR000026,0,3,"No cost data were reported although one study commented that it was impossible to isolate the time spent on reference tracking since this was done in parallel with the critical appraisal of each paper, and for that particular study costs were not specifically estimated.",rephrase,"['Unfortunately, none of the studies looked at how much time or money were spent on the process of checking reference lists, and it was suggested this would be almost impossible to estimate.']",2,0.5,3,8
MR000026,1,4,There is some evidence to support the use of checking reference lists for locating studies in systematic reviews.,delete,[],3,0.625,4,8
MR000026,1,5,"However, this evidence is derived from weak study designs.",rephrase,['Unfortunately our findings are based on weak information.'],3,0.75,4,8
MR000026,1,6,"In situations where the identification of all relevant studies through handsearching and database searching is difficult, it would seem prudent that authors of reviews check reference lists to supplement their searching.",rephrase,"['The data do suggest that in situations where researchers may have difficulty locating information, checking through the reference lists may be an important way to reduce the risk of missing relevant information.']",4,0.875,5,8
MR000026,1,7,"The challenge, therefore, is for review authors to recognize those situations.",delete,[],5,1.0,5,8
CD011572,0,0,The screening process identified 61 included studies which encompass 58 induction phases (5111 patients randomised to placebo) and 12 maintenance phases (1579 patients randomised to placebo).,rephrase,['Sixty-one trials were included which evaluated 58 induction phases (5111 patients randomised to placebo) and 12 maintenance phases (1579 patients randomised to placebo).'],0,0.07142857142857142,1,14
CD011572,0,1,"For induction trials, the pooled estimate of placebo response was 33% (95% CI 30% to 36%) while the pooled estimate of placebo remission was 12% (95% CI 9% to 15%).",delete,[],1,0.14285714285714285,1,14
CD011572,0,2,"For maintenance trials, the pooled estimate of placebo response was 23% (95% CI 19% to 28%) while the pooled estimate of placebo remission was 17% (95% CI 10% to 27%).",delete,[],1,0.21428571428571427,2,14
CD011572,1,3,"Studies enrolling patients with more active disease confirmed objectively by endoscopy were associated with significantly lower placebo remission and response rates than trials enrolling patients with less active disease (27% versus 4%, OR 2.60, 95% CI 1.25 to 5.42, P = 0.01 for UCDAI endoscopy sub score ≥1 versus ≥ 2 for remission; and 27% versus 4%, OR 1.70, 95% CI 1.02 to 2.82, P = 0.02 for UCDAI endoscopy sub score greater than or equal to one versus greater than or equal to two for response).",rephrase,"['A key finding was that trials enrolling patients with more severe endoscopic disease (i.e. inflammation of the colon as confirmed by a colonoscopy) at trial entry were associated with lower placebo response and remission rates, which underpins the importance of objectively ensuring that patients enrolled into UC trials have sufficient disease severity.']",1,0.2857142857142857,2,14
CD011572,1,4,"With respect to drug class, the lowest placebo response and remission rates were observed in trials evaluating corticosteroids (23%; 95% CI 19 to 29%, and 5%; 95% CI 2 to 11%, respectively).",split,"['The researchers found that placebo response and remission rates varied according to which class of drug was being tested with the highest placebo response rates observed for biological drugs (genetically engineered medications made from living organisms).', 'The highest placebo remission rates were observed for trials evaluating aminosalicylates (a type of anti-inflammatory drug).', 'The lowest placebo response and remission rates were in trials that assessed corticosteroids (drugs that suppress inflammation and immunity).']",2,0.35714285714285715,2,14
CD011572,1,5,"Trials of biologics had the highest placebo response rate (35%; 95% CI 30 to 41%), while trials evaluating aminosalicylates had the highest placebo remission rate (18%; 95% CI 12 to 24%).",delete,[],5,0.42857142857142855,3,14
CD011572,1,6,"Disease duration of greater than five years prior to enrolment was associated with a significantly lower placebo response rate compared to disease duration of less than or equal to five years (29% versus 47%, respectively; OR 0.54, 95% CI 0.32 to 0.92, P = 0.02).",rephrase,['Disease duration of greater than five years prior to trial enrolment was associated with a significantly lower placebo response rate compared to disease duration of less than or equal to five years.'],5,0.5,3,14
CD011572,1,7,"The requirement of a minimum rectal bleeding score for study eligibility was associated with an increased placebo response rate compared to studies that did not use rectal bleeding for trial eligibility (37% versus 32%, respectively; OR 1.70, 95% CI 1.02 to 2.82, P = 0.02).",rephrase,['The requirement of a minimum rectal bleeding score for study eligibility was associated with an increased placebo response rate compared to studies that did not use rectal bleeding for trial eligibility.'],6,0.5714285714285714,3,14
CD011572,1,8,"Finally, the time point of primary outcome assessment was found to be significantly associated with placebo remission rates such that every one week increment in endpoint assessment was associated with a 6% increase in the placebo remission rate (OR 1.06, 95% CI 1.02 to 1.10, P = 0.01).",rephrase,['The time point of primary outcome assessment was found to be significantly associated with placebo remission rates such that every one week increment in endpoint assessment was associated with an increase in the placebo remission rate.'],7,0.6428571428571429,4,14
CD011572,2,9,"Cumulative meta-analysis indicated a consistent increase in the placebo response rate from 1987 to 2007 (from 13% to 33%), although rates have remained constant from 2008 to 2015 (32% to 34%).",merge,[],8,0.7142857142857143,4,14
CD011572,2,10,"Similarly, placebo remission rates increased from 1987 to 2007 (5% to 14%) but have remained constant from 2008 to 2015 (12 to 14%).",merge,['The researchers also found that placebo rates have remained stable from 2008 to 2015.'],8,0.7857142857142857,4,14
CD011572,2,11,"On meta-regression, there were no statistically significant differences between the 1987-2007 and 2008-2015 point estimates for both response (P = 0.81) and remission (P = 0.32).",none,[],8,0.8571428571428571,5,14
CD011572,3,12,"Placebo response and remission rates vary according to endoscopic disease severity and rectal bleeding score at trial entry, class of agent, disease duration, and the time point at which the primary outcome was measured.",ignore,"['In conclusion, placebo response and remission rates vary according to endoscopic disease severity and rectal bleeding score at trial entry, drug class, disease duration, and the time point at which the primary outcome was measured.']",9,0.9285714285714286,5,14
CD011572,3,13,"These observations have important implications for the design and conduct of future clinical trials in UC and will help researchers design trials, determine required sample sizes and also provide useful information about trial design features which should be considered when planning new trials.",rephrase,"['The overall findings will help researchers conducting trials to design their studies, determine the number of patients required for their planned trials and also provide useful information about trial design features which should be considered when planning new trials.']",10,1.0,5,14
CD008302,0,0,Altogether 223 patients with DTC participated in four trials.,rephrase,['Overall 223 patients with differentiated thyroid cancer participated in four studies.'],0,0.09090909090909091,1,11
CD008302,0,1,"Overall, studies had a high risk of bias.",delete,[],1,0.18181818181818182,1,11
CD008302,0,2,We found no statistically significant differences between rhTSH and THW treatment in terms of successful ablation rate but significant benefits in radiation exposure to blood and bone marrow.,rephrase,['We found no statistically significant differences between recombinant human thyrotropin and thyroid hormone withdrawal treatment in terms of successful reduction of thyroid remnants or cancer cells but significant benefits in radiation exposure to blood and bone marrow.'],1,0.2727272727272727,2,11
CD008302,0,3,One trial reported on benefits in some domains of health-related quality of life.,ignore,['One trial reported on benefits in some domains of health-related quality of life.'],2,0.36363636363636365,2,11
CD008302,0,4,There were no deaths and no serious adverse effects in DTC patients treated with either rhTSH or THW.,merge,"['There were no deaths and no serious adverse effects observed, however maximum follow up was only 12 months.']",3,0.45454545454545453,3,11
CD008302,0,5,Maximum follow up was 12 months.,none,[],3,0.5454545454545454,3,11
CD008302,0,6,"None of the included trials investigated complete or partial remission of metastatic tumour, secondary malignancies or economic outcomes.",ignore,"['None of the included trials investigated complete or partial remission of metastatic tumour, secondary malignancies or economic outcomes.']",4,0.6363636363636364,4,11
CD008302,0,7,We did not find sufficient data comparing rhTSH with THW-aided radioiodine treatment for metastatic DTC.,rephrase,['We did not find sufficient data comparing recombinant human thyrotropin with thyroid hormone withdrawal-aided radioiodine treatment for metastatic differentiated cancer.'],5,0.7272727272727273,4,11
CD008302,1,8,"Results from four randomised controlled clinical trials suggest that rhTSH is as effective as THW on iodine-131 thyroid remnant ablation, with limited data on significant benefits in decreased whole body radiation exposure and health-related quality of life.",delete,[],6,0.8181818181818182,5,11
CD008302,1,9,It is still uncertain whether lower iodine-131 doses (1110 MBq or 1850 MBq versus 3700 MBq) are equally effective for remnant ablation under rhTSH stimulation.,delete,[],6,0.9090909090909091,5,11
CD008302,1,10,Randomised controlled clinical trials are needed to guide treatment selection for metastatic differentiated thyroid cancer.,delete,[],6,1.0,5,11
CD005379,0,0,Information on cognitive function at the start of a study was available on 4080 participants randomised in three trials.,merge,['The authors included three randomised controlled trials involving 3536 participants.'],0,0.05555555555555555,1,18
CD005379,0,1,Cognitive function data were available on 3536 participants at final follow-up.,none,[],0,0.1111111111111111,1,18
CD005379,1,2,In two studies participants received gel capsules containing either omega-3 PUFA (the intervention) or olive or sunflower oil (placebo) for six or 24 months.,rephrase,['In two studies participants were randomly assigned to receive gel capsules containing omega-3 PUFA or olive or sunflower oil for six or 24 months.'],1,0.16666666666666666,1,18
CD005379,1,3,"In one study, participants received margarine spread for 40 months; the margarine for the intervention group contained omega-3 PUFA.",rephrase,"['In the third study, participants were randomly assigned to receive tubs of margarine spread for 40 months (regular margarine versus margarine fortified with omega-3 PUFA).']",2,0.2222222222222222,2,18
CD005379,1,4,Two studies had cognitive health as their primary outcome; one study of cardiovascular disease included cognitive health as an additional outcome.,delete,[],3,0.2777777777777778,2,18
CD005379,2,5,None of the studies examined the effect of omega-3 PUFA on incident dementia.,rephrase,['None of the studies examined the effect of omega-3 PUFA on new dementia cases over the study period.'],3,0.3333333333333333,2,18
CD005379,2,6,In two studies involving 3221 participants there was no difference between the omega-3 and placebo group in mini-mental state examination score at final follow-up (following 24 or 40 months of intervention); MD -0.07 (95% CI -0.25 to 0.10).,rephrase,['In two studies involving 3221 participants there was no difference between the omega-3 PUFA and placebo group in mini-mental state examination score at final follow-up.'],4,0.3888888888888889,2,18
CD005379,2,7,"In two studies involving 1043 participants, other tests of cognitive function such as word learning, digit span and verbal fluency showed no beneficial effect of omega-3 PUFA supplementation.",ignore,"['In two studies (1043 participants), other tests of cognitive function such as word learning, digit span and verbal fluency showed no beneficial effect of omega-3 PUFA supplementation.']",5,0.4444444444444444,3,18
CD005379,2,8,Participants in both the intervention and control groups experienced either small or no cognitive declines during the studies.,ignore,['Participants in both the intervention and control groups experienced little or no cognitive decline during the studies.'],6,0.5,3,18
CD005379,3,9,The main reported side-effect of omega-3 PUFA supplementation was mild gastrointestinal problems.,merge,"['The main reported side-effect of omega-3 PUFA supplementation was mild gastrointestinal problems, but overall minor symptoms were reported by fewer than 15% of participants, and people in the control group were just as likely to report symptoms as those receiving an omega-3 PUFA supplement.']",7,0.5555555555555556,3,18
CD005379,3,10,"Overall, minor adverse events were reported by fewer than 15% of participants, and reports were balanced between intervention groups.",none,[],7,0.6111111111111112,4,18
CD005379,3,11,Adherence to the intervention was on average over 90% among people who completed the trials.,rephrase,['Adherence to the supplementation protocol was high in all trials with on average over 90% of supplements being apparently consumed by trial participants.'],8,0.6666666666666666,4,18
CD005379,3,12,All three studies included in this review are of high methodological quality.,rephrase,"['All three studies included in this review were of high methodological quality, and so the findings are unlikely to be due to chance or bias.']",9,0.7222222222222222,4,18
CD005379,4,13,Direct evidence on the effect of omega-3 PUFA on incident dementia is lacking.,merge,[],10,0.7777777777777778,4,18
CD005379,4,14,The available trials showed no benefit of omega-3 PUFA supplementation on cognitive function in cognitively healthy older people.,none,['The results of the available studies show no benefit for cognitive function with omega-3 PUFA supplementation among cognitively healthy older people.'],10,0.8333333333333334,5,18
CD005379,4,15,Omega-3 PUFA supplementation is generally well tolerated with the most commonly reported side-effect being mild gastrointestinal problems.,rephrase,"['Omega-3 PUFA supplements may have other health benefits, and the authors comment that consumption of fish is recommended as part of a healthy diet.']",11,0.8888888888888888,5,18
CD005379,5,16,Further studies of longer duration are required.,merge,[],12,0.9444444444444444,5,18
CD005379,5,17,Longer-term studies may identify greater change in cognitive function in study participants which may enhance the ability to detect the possible effects of omega-3 PUFA supplementation in preventing cognitive decline in older people.,none,"['Longer studies are required, during which greater changes in cognitive function may occur, to enable researchers to identify possible benefits of omega-3 PUFA in preventing cognitive decline.']",12,1.0,5,18
CD008160,0,0,We identified 1995 references and included10 RCTs (2745 workers).,delete,[],0,0.08333333333333333,1,12
CD008160,0,1,Two studies were assessed with low risk of bias.,rephrase,['Two studies were rated as having low risk of bias.'],0,0.16666666666666666,1,12
CD008160,0,2,Most trials (N = 8) examined office workers.,delete,[],1,0.25,2,12
CD008160,0,3,Few workers were sick-listed.,rephrase,"['Neck pain is more common in the general population than previously known.This Cochrane review presents what we know from research about the effect of workplace interventions for workers with neck pain who, for the most part, are not sick-listed.']",1,0.3333333333333333,2,12
CD008160,0,4,"Thus, WIs were seldom designed to improve return-to-work.",delete,[],2,0.4166666666666667,3,12
CD008160,0,5,"Overall, there was low quality evidence that showed no significant differences between WIs and no intervention for pain prevalence or severity.",rephrase,['The present review found low quality evidence that those who received workplace interventions did not get more pain relief than those who received no interventions.'],2,0.5,3,12
CD008160,0,6,"If present, significant results in favour of WIs were not sustained across follow-up times.",delete,[],3,0.5833333333333334,3,12
CD008160,0,7,"There was moderate quality evidence (1 study, 415 workers) that a four-component WI was significantly more effective in reducing sick leave in the intermediate-term (OR 0.56, 95% CI 0.33 to 0.95), but not in the short- (OR 0.83, 95% CI 0.52 to 1.34) or long-term (OR 1.28, 95% CI 0.73 to 2.26).",rephrase,"['We found moderate quality evidence (1 trial, 415 workers) that workplace interventions reduced sick leave among the workers at six month-, but not at three- and 12-month follow-ups.']",3,0.6666666666666666,4,12
CD008160,0,8,These findings might be because only a small proportion of the workers were sick-listed.,rephrase,['This could be due to the fact that few participants in the study were sick-listed.'],4,0.75,4,12
CD008160,1,9,"Overall, this review found low quality evidence that neither supported nor refuted the benefits of any specific WI for pain relief and moderate quality evidence that a multiple-component intervention reduced sickness absence in the intermediate-term, which was not sustained over time.",delete,[],5,0.8333333333333334,5,12
CD008160,1,10,Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.,rephrase,['Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate for both pain and sickness absence.'],5,0.9166666666666666,5,12
CD008160,1,11,There is an urgent need for high quality RCTs with well designed WIs.,delete,[],6,1.0,5,12
CD011715,0,0,"Six studies including a total of 2100 participants met the inclusion criteria: we pooled four studies including 792 people in the main efficacy analyses, and presented the results of a cluster implementation study (n = 1213) and an oral steroid tapering study (n = 95) separately.",rephrase,"['We found a total of six studies including 2100 participants: four studies including 792 people could be pooled for the main results, and two other studies were looked at separately because their designs were very different (n = 1213 and n = 95).']",0,0.07142857142857142,1,14
CD011715,0,1,"Baseline characteristics relating to asthma severity were variable, but studies generally recruited people with asthma taking regular medications and excluded those with COPD or severe asthma.",rephrase,['People in the four pooled studies in general took regular medications and we excluded those with severe asthma or other lung diseases.'],1,0.14285714285714285,1,14
CD011715,0,2,One study compared the two types of check-up for oral steroid tapering in severe refractory asthma and we assessed it as a separate question.,rephrase,"['We looked at two other studies with very different designs to the main four separately: one compared a practice where people with asthma were given the option of a telephone check-up or a practice visit where they came to the clinic as usual, and one looked specifically at using technology to monitor people while cutting down their oral steroids dose.']",2,0.21428571428571427,2,14
CD011715,0,3,"The studies could not be blinded and dropout was high in four of the six studies, which may have biased the results.",delete,[],3,0.2857142857142857,2,14
CD011715,1,4,"We could not say whether more people who had a remote check-up needed oral corticosteroids for an asthma exacerbation than those who were seen face-to-face because the confidence intervals (CIs) were very wide (OR 1.74, 95% CI 0.41 to 7.44; 278 participants; one study; low quality evidence).",rephrase,"['We cannot say whether or not people who had a check-up over the phone or internet were more or less likely to need oral corticosteroids for an asthma attack than those seen face-to-face, and we were uncertain of the result for several reasons.']",3,0.35714285714285715,2,14
CD011715,1,5,"In the face-to-face check-up groups, 21 participants out of 1000 had exacerbations that required oral steroids over three months, compared to 36 (95% CI nine to 139) out of 1000 for the remote check-up group.",delete,[],4,0.42857142857142855,3,14
CD011715,1,6,"Exacerbations that needed treatment in the Emergency Department (ED), hospital admission or an unscheduled healthcare visit all happened too infrequently to detect whether remote check-ups are a safe alternative to face-to-face consultations.",rephrase,"['Too few people had asthma attacks that needed treatment in the Emergency Department or hospital, or an unscheduled visit to see their doctor to tell if remote check-ups were as good as face-to-face consultations.']",4,0.5,3,14
CD011715,1,7,Serious adverse events were not reported separately from the exacerbation outcomes.,delete,[],5,0.5714285714285714,3,14
CD011715,2,8,There was no difference in asthma control measured by the Asthma Control Questionnaire (ACQ) or in quality of life measured on the Asthma Quality of Life Questionnaire (AQLQ) between remote and face-to-face check-ups.,merge,"[""There didn't appear to be a difference in asthma control or quality of life, but we were able to rule out the possibility that remote check-ups are not as good as face-to-face consultations on these measures.""]",5,0.6428571428571429,4,14
CD011715,2,9,We could rule out significant harm of remote check-ups for these outcomes but we were less confident because these outcomes are more prone to bias from lack of blinding.,none,[],5,0.7142857142857143,4,14
CD011715,3,10,The larger implementation study that compared two general practice populations demonstrated that offering telephone check-ups and proactively phoning participants increased the number of people with asthma who received a review.,merge,"['The study that tested the possible benefit of giving people the option of a telephone check-up showed that this increased the number of people reviewed, but did not show an overall benefit on asthma outcomes.']",6,0.7857142857142857,4,14
CD011715,3,11,"However, we do not know whether the additional participants who had a telephone check-up subsequently benefited in asthma outcomes.",none,[],6,0.8571428571428571,5,14
CD011715,4,12,"Current randomised evidence does not demonstrate any important differences between face-to-face and remote asthma check-ups in terms of exacerbations, asthma control or quality of life.",delete,[],7,0.9285714285714286,5,14
CD011715,4,13,"There is insufficient information to rule out differences in efficacy, or to say whether or not remote asthma check-ups are a safe alternative to being seen face-to-face.",delete,[],7,1.0,5,14
CD005604,0,0,"Three included therapeutic studies had 182 randomised participants with 162 completing the trials although in one study, children with recurrent wheeze were also included.",rephrase,['We included three therapeutic studies with 182 randomised participants.'],0,0.08333333333333333,1,12
CD005604,0,1,The four included safety evaluation studies randomised 3166 participants with 2862 completing the trials.,delete,[],1,0.16666666666666666,1,12
CD005604,0,2,Clinical heterogeneity was evident and limited data prevented combining data for meta-analysis.,delete,[],1,0.25,2,12
CD005604,0,3,The two larger therapeutic studies described significant improvement in both the intervention and the placebo/placebo-like arms with no significant difference between the two groups.,rephrase,['Two studies found that chronic cough significantly improved in both treatment and placebo groups with no difference between the two groups.'],1,0.3333333333333333,2,12
CD005604,0,4,"In the study with the smallest sample size, cetirizine (a second generation anti-histamine) was significantly more efficacious than placebo in reducing chronic cough in children associated with seasonal allergic rhinitis, and the effect was seen within two weeks of therapy.",rephrase,['One small study however described that children who had chronic cough associated with seasonal allergic rhinitis treated with cetirizine improved significantly more than children on placebo and this difference was evident by two weeks.'],2,0.4166666666666667,3,12
CD005604,0,5,In contrast three of the larger evaluation studies that enrolled children with allergic rhinitis described a non-significant increase in cough as an adverse event.,merge,['Four studies that evaluated safety profiles included 3166 randomised participants and described a non significant increase in cough in participants who received the active medication.'],3,0.5,3,12
CD005604,0,6,"Combined data from the four safety evaluation studies revealed a non-significant difference between groups (OR 1.47 , 95% CI 0.86, 2.49) for cough as an adverse event but the trend favoured the placebo arm.",none,[],3,0.5833333333333334,3,12
CD005604,1,7,This review has significant limitations.,merge,[],4,0.6666666666666666,4,12
CD005604,1,8,"However, our finding of uncertain efficacy of anti-histamines for chronic cough are similar to that for acute cough in children.",none,"['Despite the limitations of this review, our findings are similar to the review on anti-histamines for acute cough which showed no good evidence for or against the use of anti-histamines.']",4,0.75,4,12
CD005604,1,9,"In contrast to recommendations in adults with chronic cough, anti-histamines cannot be recommended as empirical therapy for children with chronic cough.",ignore,"['In contrast to recommendations in adults with chronic cough, anti-histamines cannot be recommended as empirical therapy for children with chronic cough.']",5,0.8333333333333334,5,12
CD005604,1,10,"If anti-histamines were to be trialled in these children, current data suggest a clinical response (time to response) occurs within two weeks of therapy.",delete,[],6,0.9166666666666666,5,12
CD005604,1,11,However the use of anti-histamines in children with non-specific cough has to be balanced against the well known risk of adverse events especially in very young children.,delete,[],6,1.0,5,12
CD008253,0,0,One single-centred trial (46 participants) was identified comparing a topical steroid (betamethasone) given as nasal drops to placebo.,rephrase,['Our search found one trial with 46 adult volunteers with cystic fibrosis which compared nasal drops containing a steroid (betamethasone) to identical drops containing no active treatment.'],0,0.08333333333333333,1,12
CD008253,0,1,Treatment was given twice daily for six weeks; 22 participants received the active drug.,rephrase,['Two drops were applied directly to polyps twice a day for six weeks.'],1,0.16666666666666666,1,12
CD008253,1,2,"Subjective symptom scores, change in polyp size, and side effects were assessed.",delete,[],2,0.25,2,12
CD008253,1,3,There was no difference in nasal symptom scores between the treatment and placebo groups.,delete,[],2,0.3333333333333333,2,12
CD008253,1,4,"Betamethasone was effective in reducing the size of polyps, but was associated with increased reports of mild side effects, nasal bleeding and discomfort.",rephrase,"['There were no major side effects linked to using betamethasone, and only three volunteers reported increased nose bleeds and discomfort.']",2,0.4166666666666667,3,12
CD008253,2,5,Risk of bias was high since over 50% of people enrolled did not complete the study.,rephrase,"['However, over 50% of people enrolled did not complete the study and the reasons for dropping out were not very clearly explained.']",3,0.5,3,12
CD008253,2,6,Follow-up of participants was short (six weeks) also reducing the significance of the results for clinical practice.,rephrase,"[""Also, the trial only followed the volunteers for six weeks, which is a short time when evaluating a treatment that could be needed for the rest of a person's life.""]",4,0.5833333333333334,3,12
CD008253,3,7,This review suggests topical steroids for nasal polyposis in people with cystic fibrosis have no demonstrable effect on subjective nasal symptom scores.,delete,[],5,0.6666666666666666,4,12
CD008253,3,8,"They have some effect in reducing the size of the polyps, but due to the small sample size, poor completion rates and lack of follow-up, the trial is at high risk of bias and evidence for efficacy is limited.",delete,[],5,0.75,4,12
CD008253,3,9,Overall there is no clear evidence for using topical steroids in people with cystic fibrosis and nasal polyposis.,delete,[],5,0.8333333333333334,5,12
CD008253,4,10,A well-designed randomised controlled trial of adequate power and long-term follow-up is needed.,delete,[],5,0.9166666666666666,5,12
CD008253,4,11,Validated measures of symptoms and physical findings should be performed and quality of life issues addressed.,rephrase,['More trials are needed to confirm the findings and these trials should report on measures of symptoms and quality of life issues.'],5,1.0,5,12
CD009651,0,0,We included 11 small trials involving 564 adults (aged 16 to 76 years) with patella fractures.,split,"['We searched the scientific literature to January 2020 and found 11 relevant studies with 564 participants.', 'Participants in these studies were aged between 16 and 76 years.']",0,0.047619047619047616,1,21
CD009651,0,1,There were 340 men and 212 women; the gender of 12 participants was not reported.,ignore,['There were 340 men and 212 women; the gender of 12 participants was not reported.'],2,0.09523809523809523,1,21
CD009651,0,2,"Seven trials were conducted in China and one each in Finland, Mexico, Pakistan and Turkey.",ignore,"['Seven trials were conducted in China and one each in Finland, Mexico, Pakistan and Turkey.']",3,0.14285714285714285,1,21
CD009651,0,3,All 11 trials compared different surgical interventions for patella fractures.,rephrase,['All 11 studies compared different types of surgery or surgical devices.'],4,0.19047619047619047,1,21
CD009651,0,4,"All trials had design flaws, such as lack of assessor blinding, which put them at high risk of bias, potentially limiting the reliability of their findings.",rephrase,['This was mainly because all the trials had design flaws that put them at high risk of bias and the studies were also small with few events.'],5,0.23809523809523808,2,21
CD009651,0,5,"No trial reported on health-related quality of life, return to previous activity or cosmetic appearance.",ignore,"['None of the studies reported on health-related quality of life, return to previous activity or cosmetic appearance.']",6,0.2857142857142857,2,21
CD009651,0,6,The trials tested one of seven comparisons.,rephrase,['The 11 studies made seven comparisons.'],7,0.3333333333333333,2,21
CD009651,0,7,"In the following, we report those of the main outcomes for which evidence was available for the three most important comparisons.",rephrase,['We report here the findings for the three most important comparisons.'],8,0.38095238095238093,2,21
CD009651,1,8,Four trials (174 participants) compared percutaneous osteosynthesis versus open surgery.,rephrase,['Four studies compared methods of percutaneous fixation (surgery using small incisions to insert the fixation devices) with open surgery (involving wide incisions).'],9,0.42857142857142855,3,21
CD009651,1,9,"Very low-quality evidence means that we are uncertain of the findings of no clinically important difference between the two interventions in patient-rated knee function at 12 months (1 study, 50 participants) or in knee pain at intermediate-term follow-up at eight weeks to three months.",rephrase,['One study found no important difference between the two methods in patient-rated knee function at 12 months.'],10,0.47619047619047616,3,21
CD009651,1,10,"Furthermore, very low-quality evidence means we are uncertain whether, compared with open surgery, percutaneous fixation surgery reduces the incidence of major adverse outcomes, such as loss of reduction and hardware complications, or results in better observer-rated knee function scores.",delete,[],11,0.5238095238095238,3,21
CD009651,2,11,Two trials (112 participants) compared cable pin system (open or percutaneous surgery) versus tension band technique.,rephrase,['Two studies compared cable pin system (open or percutaneous surgery) with tension band technique.'],11,0.5714285714285714,3,21
CD009651,2,12,"The very low-quality evidence means we are uncertain of the findings at one year in favour of the cable pin system of slightly better patient-rated knee function, fewer adverse events and slightly better observer-rated measures of knee function.",rephrase,"['These found slightly better patient-rated knee function at one year, fewer adverse events and slightly better observer-rated measures of knee function in the cable pin group.']",12,0.6190476190476191,4,21
CD009651,2,13,There was very low-quality evidence of little clinically important between-group difference in knee pain at three months.,rephrase,['There was little important difference between the two groups in knee pain at three months.'],13,0.6666666666666666,4,21
CD009651,3,14,"Very low-quality evidence from two small trials (47 participants) means that we are uncertain of the findings of little difference between biodegradable versus metallic implants at two-year follow-up in the numbers of participants with occasional knee pain, incurring adverse events or with reduced knee motion.",rephrase,"['Two studies comparing biodegradable (non-metallic) versus metallic implants found little difference in reported outcomes (knee pain, adverse events and knee motion) between the two groups.']",14,0.7142857142857143,4,21
CD009651,4,15,There was very low-quality and incomplete evidence from single trials for four other comparisons.,ignore,['There was very low-quality and incomplete evidence from single trials for four other comparisons.'],15,0.7619047619047619,4,21
CD009651,4,16,This means we are uncertain of the results of one trial (28 participants) that compared patellectomy with advancement of vastus medialis obliquus surgery with simple patellectomy; of one quasi-RCT (56 participants) that compared a new intraoperative reduction technique compared with a standard technique; of one quasi-RCT (65 participants) that compared a modified tension band technique versus the conventional AO tension band wiring (TBW) technique; and of one trial (57 participants) that compared adjustable patella claws and absorbable suture versus Kirschner wire tension band.,delete,[],16,0.8095238095238095,5,21
CD009651,5,17,There is very limited evidence from nine RCTs and two quasi-RCTs on the relative effects of different surgical interventions for treating fractures of the patella in adults.,delete,[],16,0.8571428571428571,5,21
CD009651,5,18,There is no evidence from trials evaluating the relative effects of surgical versus conservative treatment or different types of conservative interventions.,delete,[],16,0.9047619047619048,5,21
CD009651,6,19,"Given the very low-quality evidence, we are uncertain whether methods of percutaneous osteosynthesis give better results than conventional open surgery; whether cable pin system (open or percutaneous surgery) gives better results than the tension band technique; and whether biodegradable implants are better than metallic implants for displaced patellar fractures.",delete,[],16,0.9523809523809523,5,21
CD009651,7,20,"Further randomised trials are needed, but, to optimise research effort, these should be preceded by research that aims to identify priority questions.",rephrase,['Further research is warranted and should be preceded by research to determine which questions should be prioritised.'],16,1.0,5,21
CD010550,0,0,Six randomised controlled trials with a total of 788 women were included.,rephrase,"['Six trials were included, with a total of 788 women undergoing an IVF treatment.']",0,0.07142857142857142,1,14
CD010550,0,1,The largest of these trials included 396 women eligible for this review.,rephrase,['The largest trial in the review (with 396 women) has not yet reported full results.'],1,0.14285714285714285,1,14
CD010550,1,2,"No evidence of a statistically significant difference was found between natural cycle and standard IVF in live birth rates (OR 0.68, 95% CI 0.46 to 1.01, two studies, 425 women, I2= 0%, moderate quality evidence).",delete,[],2,0.21428571428571427,2,14
CD010550,1,3,"The evidence suggests that for a woman with a 53% chance of live birth using standard IVF, the chance using natural cycle IVF would range from 34% to 53%.",ignore,"['The evidence suggested that for a woman with a 53% chance of live birth using standard IVF, the chance using natural cycle IVF ranges from 34% to 53%.']",2,0.2857142857142857,2,14
CD010550,1,4,"There was no evidence of a statistically significant difference between natural cycle and standard IVF in rates of OHSS (OR 0.19, 95% CI 0.01 to 4.06, one study, 60 women, very low quality evidence), clinical pregnancy (OR 0.52 95% CI 0.17 to 1.61, 4 studies, 351 women, I2=63%, low quality evidence), ongoing pregnancy (OR 0.72, 95% CI 0.50 to 1.05, three studies, 485 women, I2=0%, moderate quality evidence), multiple pregnancy (OR 0.76, 95% CI 0.25 to 2.31, 2 studies, 527 women, I2=0%, very low quality evidence), gestational abnormalities (OR 0.44 95% CI 0.03 to 5.93, 1 study, 18 women, very low quality evidence) or cycle cancellations (OR 8.98, 95% CI 0.20 to 393.66, 2 studies, 159 women, I2=83%, very low quality evidence).",rephrase,"['No significant difference was found in rates of clinical pregnancy, ongoing pregnancy, multiple pregnancy, incidence of ovarian hyperstimulation syndrome, gestational abnormalities or cancellations of treatment.']",3,0.35714285714285715,2,14
CD010550,1,5,"One trial reported that the oocyte retrieval rate was significantly lower in the natural cycle group (MD -4.40, 95% CI -7.87 to -0.93, 60 women, very low quality evidence).",delete,[],4,0.42857142857142855,3,14
CD010550,1,6,There were insufficient data to draw any conclusions about rates of treatment cancellation.,delete,[],4,0.5,3,14
CD010550,1,7,Findings on treatment costs were inconsistent and more data are awaited.,split,"['However findings were imprecise for all outcomes and further evidence from larger studies is awaited.', 'Findings on cost-effectiveness were inconsistent.']",4,0.5714285714285714,3,14
CD010550,1,8,The evidence was limited by imprecision.,rephrase,"['Quality ratings for the evidence ranged from very low to moderate, the main limitation being imprecision due to insufficient data.']",6,0.6428571428571429,4,14
CD010550,1,9,"Findings for pregnancy rate and for cycle cancellation were sensitive to the choice of statistical model: for these outcomes, use of a fixed effect model suggested a benefit for the standard IVF group.",rephrase,['When the review authors checked the effect of using an alternative method of analysis the findings suggested higher rates of clinical pregnancy with standard IVF than with natural cycle IVF.'],7,0.7142857142857143,4,14
CD010550,1,10,"Moreover the largest trial has not yet completed follow up, though data have been reported for over 95% of women.",delete,[],8,0.7857142857142857,4,14
CD010550,2,11,Further evidence from well conducted large trials is awaited on natural cycle IVF treatment.,delete,[],8,0.8571428571428571,5,14
CD010550,2,12,Future trials should compare natural cycle IVF with standard IVF.,delete,[],8,0.9285714285714286,5,14
CD010550,2,13,"Outcomes should include cumulative live birth and pregnancy rates, the number of treatment cycles necessary to reach live birth, treatment costs and adverse effects.",delete,[],8,1.0,5,14
CD004654,0,0,Fifteen trials involving 3781 participants were included.,delete,[],0,0.1,1,10
CD004654,0,1,No studies reported the effect of meglitinides on mortality or morbidity.,rephrase,['No studies reported the effect of meglitinides on mortality or diabetes related complications.'],0,0.2,1,10
CD004654,0,2,"In the eleven studies comparing meglitinides to placebo, both repaglinide and nateglinide resulted in a reductions in glycosylated haemoglobin (0.1% to 2.1% reduction in HbA1c for repaglinide; 0.2% to 0.6% for nateglinide).",rephrase,"['In the eleven studies comparing meglitinides to placebo, both repaglinide and nateglinide resulted in an improved blood sugar control.']",1,0.3,2,10
CD004654,0,3,"Only two trials compared repaglinide to nateglinide (342 participants), with greater reduction in glycosylated haemoglobin in those receiving repaglinide.",delete,[],2,0.4,2,10
CD004654,0,4,Repaglinide (248 participants in three trials) had a similar degree of effect in reducing glycosylated haemoglobin as metformin.,delete,[],2,0.5,3,10
CD004654,0,5,"Nateglinide had a similar or slightly less marked effect on glycosylated haemoglobin than metformin (one study, 355 participants).",delete,[],2,0.6,3,10
CD004654,0,6,Weight gain was generally greater in those treated with meglitinides compared with metformin (up to three kg in three months).,rephrase,"['Weight gain was generally greater in those treated with meglitinides compared with metformin (up to three kg in three months), another oral antidiabetic drug.']",2,0.7,4,10
CD004654,0,7,Diarrhoea occurred less frequently and hypoglycaemia occurred more frequently but rarely severely enough as to require assistance.,ignore,"['Here, diarrhoea occurred less frequently and hypoglycaemia occurred more frequently but rarely severely enough as to require assistance.']",3,0.8,4,10
CD004654,1,8,"Meglitinides may offer an alternative oral hypoglycaemic agent of similar potency to metformin, and may be indicated where side effects of metformin are intolerable or where metformin is contraindicated.",rephrase,"['Meglitinides may offer an alternative oral hypoglycaemic agent of similar potency to metformin, and may be indicated where side effects of metformin are intolerable (in particular persistent diarrhoea) or where metformin is contraindicated.']",4,0.9,5,10
CD004654,1,9,"However, there is no evidence available to indicate what effect meglitinides will have on important long-term outcomes, particularly mortality.",split,"['However, there is no evidence available yet to indicate what effect meglitinides will have on important long-term outcomes, in particular, on mortality.', 'As yet, the experience with meglitinides in terms of side effects is limited.']",5,1.0,5,10
CD006573,0,0,A total of 501 liver transplant recipients undergoing liver transplantation for chronic HCV infection were randomised in 12 trials to various experimental interventions and control interventions.,delete,[],0,0.08333333333333333,1,12
CD006573,0,1,The proportion of genotype I varied between 49% and 100% in the seven trials that reported the genotype.,delete,[],0,0.16666666666666666,1,12
CD006573,0,2,Only one or two trials were included under each comparison.,delete,[],0,0.25,2,12
CD006573,0,3,All the trials were of high risk of bias.,rephrase,"['All the trials were at high risk of systematic errors (ie, there was potential to arrive at wrong conclusions because of the way the trial was conducted) and random errors (there was potential to arrive at the wrong conclusions because of the play of chance).']",0,0.3333333333333333,2,12
CD006573,0,4,Ten trials including 441 liver transplant recipients provided data for this review.,ignore,['Ten trials including 441 liver transplant recipients provided data for this review.'],1,0.4166666666666667,3,12
CD006573,1,5,There were no significant differences in the 90-day mortality (1 trial; 81 participants; 5/35 (adjusted proportion: 14.2%) in interferon group versus 5/46 (10.9%) in control group; RR 1.31; 95% CI 0.41 to 4.19); mortality at maximal follow-up (2 trials; 105 participants; 7/47 (adjusted proportion: 14.8%) in interferon group versus 10/58 (17.2%) in control group; RR 0.86; 95% CI 0.36 to 2.08); long-term mortality (1 trial; 81 participants; HR 0.45; 95% CI 0.13 to 1.56); mortality at maximal follow-up (1 trial; 54 participants; 1/26 (3.9%) in pegylated interferon group versus 2/28 (7.1%) in control group; RR 0.54; 95% CI 0.05 to 5.59); 90-day mortality (1 trial; 115 participants; 5/55 (9.1%) in pegylated interferon plus ribavirin group versus 3/60 (5.0%) in control group; RR 1.82; 95% 0.46 to 7.25); 90-day mortality (3 trials; 53 participants; 3/37 (adjusted proportion: 4.3%) in HCV antibody group versus 1/16 (6.3%) in placebo group; RR 0.69; 95% CI 0.15 to 3.11); or 90-day mortality (2 trials; 31 participants; 2/14 (adjusted proportion: 16.2%) in HCV antibody high-dose group versus 1/17 (5.9%) in HCV antibody low-dose group; RR 2.75; 95% CI; 0.30 to 25.35).,merge,[],2,0.5,3,12
CD006573,1,6,There were no significant differences in the retransplantation at maximal follow-up (2 trials; 105 participants; 2/47 (adjusted proportion: 4.0%) in interferon group versus 2/58 (3.4%) in control group; RR 1.17; 95% CI 0.22 to 6.2); 90-day retransplantation (1 trial; 18 participants; 1/12 (8.3%) in HCV antibody group versus 0/6 (0%) in control group; RR 1.71; 95% CI 0.09 to 32.93); or 90-day retransplantation (1 trial; 12 participants; 1/6 (17.7%) in HCV antibody high-dose group versus 0/6 (0%) in HCV antibody low-dose group; RR 3.00; 95% CI 0.15 to 61.74).,none,['There were no significant differences in the proportion of patients who died or required retransplantation within 90 days or at maximal follow-up between the different treatment groups for any of the comparisons.'],2,0.5833333333333334,3,12
CD006573,1,7,"There were no significant differences in serious adverse events, graft rejection, worsening of fibrosis, or HCV recurrence between intervention and control groups in any of the comparisons that reported these outcomes.",rephrase,"['There were no significant differences in serious complications, graft rejection, microscopic features of liver damage, or evidence of chronic hepatitis C recurrence between the different treatment groups or no treatment in any of the comparisons that reported these outcomes.']",3,0.6666666666666666,4,12
CD006573,1,8,"None of the trials reported quality of life, liver decompensation, intensive therapy unit stay, or hospital stay.",ignore,"['None of the trials reported quality of life, liver failure, intensive therapy unit stay, or hospital stay.']",4,0.75,4,12
CD006573,1,9,Life-threatening adverse events were not reported in either group in any of the comparisons.,rephrase,['Life-threatening adverse events were not reported in any of the comparisons.'],5,0.8333333333333334,5,12
CD006573,2,10,There is currently no evidence to recommend prophylactic antiviral treatment to prevent recurrence of HCV infection either in primary liver transplantation or retransplantation.,ignore,['There is currently no evidence to recommend preventive antiviral treatment to prevent recurrence of chronic HCV infection either in primary liver transplantation or retransplantation.'],6,0.9166666666666666,5,12
CD006573,2,11,Further randomised clinical trials with adequate trial methodology and adequate duration of follow-up are necessary.,rephrase,['Further randomised clinical trials with low risk of random errors and systematic errors are necessary to assess the long-term survival benefits for various treatment options in these patients.'],7,1.0,5,12
CD004567,0,0,"Nine trials involving 117,272 individuals of age 35 years or older are included in this review.",ignore,"['Nine trials involving 117,272 adults of age 35 years or older were included in this review.']",0,0.1111111111111111,1,9
CD004567,0,1,"The trials were conducted in Australia, Finland, India, Italy, the United Kingdom and the United States, with duration of follow-up ranging from 2.1 to 12 years.",rephrase,"['The trials were conducted in Australia, Finland, India, Italy, the United Kingdom and the United States and were of high methodological quality.']",1,0.2222222222222222,2,9
CD004567,0,2,The doses of antioxidant vitamins were higher than the recommended daily allowance.,rephrase,['The doses of antioxidants given in each trial were higher than the recommended daily allowances.'],2,0.3333333333333333,2,9
CD004567,0,3,"There was no evidence of effect of antioxidant vitamin supplementation in reducing the risk of cataract, cataract extraction, progression of cataract or in slowing the loss of visual acuity.",merge,"['The trials provided no evidence of effect of the antioxidant vitamins beta-carotene, vitamin E and vitamin C given alone or in combination on the incidence of cataract, its extraction or progression and on the loss of visual acuity.']",3,0.4444444444444444,3,9
CD004567,0,4,"In the pooled analyses, there was no evidence of effect of beta-carotene supplementation in reducing the risk of cataract (two trials) (relative risk (RR) 0.99, 95% confidence interval (CI) 0.91 to 1.08; n = 57,703) or in reducing the risk of cataract extraction (three trials) (RR 1.00, 95% CI 0.91 to 1.10; n = 86,836) or of vitamin E supplementation in reducing the risk of cataract (three trials) (RR 0.97, 95% CI 0.91 to 1.04; n = 50,059) or of cataract extraction (five trials) (RR 0.98, 95% CI 0.91 to 1.05; n = 83,956).",none,[],3,0.5555555555555556,3,9
CD004567,0,5,The proportion of participants developing hypercarotenodermia (yellowing of skin) while on beta-carotene ranged from 7.4% to 15.8%.,rephrase,['Some participants (7% to 16%) on beta-carotene developed yellowing of the skin (hypercarotenodermia).'],4,0.6666666666666666,4,9
CD004567,1,6,"There is no evidence from RCTs that supplementation with antioxidant vitamins (beta-carotene, vitamin C or vitamin E) prevents or slows the progression of age-related cataract.",delete,[],5,0.7777777777777778,4,9
CD004567,1,7,"We do not recommend any further studies to examine the role of antioxidant vitamins beta-carotene, vitamin C and vitamin E in preventing or slowing the progression of age-related cataract.",delete,[],5,0.8888888888888888,5,9
CD004567,1,8,Costs and adverse effects should be weighed carefully with unproven benefits before recommending their intake above recommended daily allowances.,delete,[],5,1.0,5,9
CD008888,0,0,"The search identified 1178 potentially relevant titles; however, there were no published studies that were specifically designed to answer this question.",delete,[],0,0.14285714285714285,1,7
CD008888,0,1,Two studies met criteria for inclusion in the review and 98 children were included in the meta-analysis.,rephrase,"['Data from two small studies were available for inclusion in this review; however, both studies were in infants following hospitalisation for an acute bronchiolitis illness (98 infants in total).']",0,0.2857142857142857,2,7
CD008888,0,2,"There was no significant difference between groups in the proportion of children 'not cured' at follow-up (primary outcome measure), with a pooled odds ratio (OR) of 0.61 (95% confidence interval (CI) 0.24 to 1.55).",rephrase,"[""There was no difference between groups in the proportion of children 'not cured' at follow-up.""]",1,0.42857142857142855,3,7
CD008888,0,3,"However, the included studies were limited in their ability to answer the review question by the fact that all participants were infants, post acute bronchiolitis illness, and cough duration at the start of study medication was ill-defined.",delete,[],2,0.5714285714285714,3,7
CD008888,1,4,There is currently no evidence to support the use of ICS for treatment of subacute cough in children.,rephrase,"['Without further available evidence, recommendations for the use of inhaled corticosteroids for the treatment of subacute cough in children cannot be made.']",2,0.7142857142857143,4,7
CD008888,1,5,"However, this systematic review is limited by the small number of studies available for analysis and the size, quality and design of these studies.",delete,[],3,0.8571428571428571,5,7
CD008888,1,6,Further well-designed RCTs are required to support or refute the efficacy of treatment with ICS in children with subacute cough.,rephrase,"['Further well-designed studies, including children over 12 months of age, are required to determine whether treatment with inhaled corticosteroids can safely and effectively reduce the severity of subacute cough in children.']",3,1.0,5,7
CD006362,0,0,"We included nine RCTs with 1069 participants, describing 37 comparisons: six were NSAIDs versus placebo and three were NSAIDs versus NSAIDs.",rephrase,"['This review found nine studies (1069 participants of both genders, including children, adults and older people from the USA, Japan, Belgium and Denmark) that compared various NSAIDs either with each other or with an inactive substance that has no treatment value (placebo).']",0,0.1,1,10
CD006362,0,1,The overall risk of bias in the included studies was mixed.,delete,[],1,0.2,1,10
CD006362,0,2,"In a pooled analysis, NSAIDs did not significantly reduce the total symptom score (SMD -0.40, 95% CI -1.03 to 0.24, three studies, random-effects model), or duration of colds (MD -0.23, 95% CI -1.75 to 1.29, two studies, random-effects model).",delete,[],1,0.3,2,10
CD006362,0,3,"For respiratory symptoms, cough did not improve (SMD -0.05, 95% CI -0.66 to 0.56, two studies, random-effects model) but the sneezing score significantly improved (SMD -0.44, 95% CI -0.75 to -0.12, two studies, random-effects model).",delete,[],1,0.4,2,10
CD006362,0,4,"For outcomes related to the analgesic effects of NSAIDs (headache, ear pain, and muscle and joint pain) the treatment produced significant benefits.",rephrase,"['Our findings suggest that NSAIDs may improve most analgesia-related symptoms caused by the common cold (headache, ear pain, and muscle and joint pain), but there is no clear evidence that NSAIDs are effective in improving coughs and runny noses caused by the common cold.']",1,0.5,3,10
CD006362,0,5,"The risk of adverse effects was not high with NSAIDs (RR 2.94, 95% CI 0.51 to 17.03, two studies, random-effects model) but it is difficult to conclude that such drugs are no different from placebo.",delete,[],2,0.6,3,10
CD006362,0,6,The quality of the evidence may be estimated as 'moderate' because of imprecision.,ignore,"[""The quality of the evidence may be estimated as 'moderate' because of imprecision.""]",2,0.7,4,10
CD006362,0,7,The major limitations of this review are that the results of the studies are quite diverse and the number of studies for one result is quite small.,ignore,['The major limitations of this review are that the results of the studies are quite diverse and the number of studies for each outcome is quite small.'],3,0.8,4,10
CD006362,1,8,NSAIDs are somewhat effective in relieving the discomfort caused by a cold but there is no clear evidence of their effect in easing respiratory symptoms.,ignore,['NSAIDs are somewhat effective in relieving the discomfort caused by a cold but there is no clear evidence of their effect in easing respiratory symptoms.'],4,0.9,5,10
CD006362,1,9,The balance of benefit and harms needs to be considered when using NSAIDs for colds.,ignore,['The balance of benefit and harms needs to be considered when using NSAIDs for colds.'],5,1.0,5,10
CD011314,0,0,Nine randomised clinical trials with 879 participants fulfilled our inclusion criteria.,split,"['We searched the medical literature for randomised clinical trials (where people are allocated at random to one of two or more treatment groups) in order to perform an analysis of the role of radiotherapy administered externally for advanced liver cancer.', 'We found nine randomised clinical trials including a total of 879 people with advanced liver cancer.', 'We also identified seven ongoing randomised clinical trials.']",0,0.07142857142857142,1,14
CD011314,0,1,"All trials were at high risk of bias, and we rated the evidence as low to very low quality.",ignore,"['All trials were at high risk of bias, and we rated the evidence as low to very low quality.']",3,0.14285714285714285,1,14
CD011314,0,2,"All of the included trials compared combined external beam radiotherapy plus chemoembolisation versus chemoembolisation alone in people with unresectable hepatocellular carcinoma; moreover, three of the trials compared external beam radiotherapy alone versus chemoembolisation alone.",rephrase,['Most of the included trials compared combined radiotherapy and chemoembolisation versus chemoembolisation alone.'],4,0.21428571428571427,2,14
CD011314,0,3,All trials were conducted in China.,rephrase,['All of the included trials were conducted in China.'],5,0.2857142857142857,2,14
CD011314,0,4,"The median age in most of the included trials was around 52 years, and most trial participants were male.",ignore,"['The average age in most of the included studies was around 52 years, and most trial participants were male.']",6,0.35714285714285715,2,14
CD011314,0,5,The median follow-up duration ranged from one to three years.,ignore,['The average follow-up duration ranged from one to three years.'],7,0.42857142857142855,3,14
CD011314,0,6,"None of the trials reported data on cancer-related mortality, quality of life, serious adverse events, or time to progression of the tumour.",delete,[],8,0.5,3,14
CD011314,0,7,"For the comparison of radiotherapy plus chemoembolisation versus chemoembolisation alone, the risk ratio for one-year all-cause mortality was 0.51 (95% confidence interval (CI) 0.41 to 0.62; P < 0.001; 9 trials; low-quality evidence); for complete response rate was 2.14 (95% CI 1.47 to 3.13; P < 0.001; 7 trials; low-quality evidence); and for overall response rate defined as complete response plus partial response was 1.58 (95% CI 1.40 to 1.78; P < 0.001; 7 trials; low-quality evidence), all in favour of combined treatment with external beam radiotherapy plus transarterial chemoembolisation and seemingly supported by our Trial Sequential Analysis.",delete,[],8,0.5714285714285714,3,14
CD011314,0,8,"Additionally, the combined treatment was associated with a higher risk of elevated total bilirubin and elevated alanine aminotransferase.",delete,[],8,0.6428571428571429,4,14
CD011314,0,9,"The risk ratio for the risk of elevated alanine aminotransferase was 1.41 (95% CI 1.08 to 1.84; P = 0.01; very low-quality evidence), while for elevated total bilirubin it was 2.69 (95% CI 1.34 to 5.40; P = 0.005; very low-quality evidence).",delete,[],8,0.7142857142857143,4,14
CD011314,0,10,"For the comparison of radiotherapy versus chemoembolisation, the risk ratio for one-year all-cause mortality was 1.21 (95% CI 0.97 to 1.50; 3 trials; I2 = 0%; very low-quality evidence) which was not supported by our Trial Sequential Analysis.",delete,[],8,0.7857142857142857,4,14
CD011314,1,11,"In addition, we found seven ongoing randomised clinical trials evaluating different external beam radiotherapy techniques for people with unresectable hepatocellular carcinoma.",delete,[],8,0.8571428571428571,5,14
CD011314,2,12,"We found very low- and low-quality evidence suggesting that combined external beam radiotherapy and chemoembolisation may be associated with lower mortality and increased complete and overall response rates, despite an increased toxicity as expressed by a higher rise of bilirubin and alanine aminotransferase.",rephrase,"['When compared with chemoembolisation alone, combined radiotherapy plus chemoembolisation may be associated with fewer deaths and more tumour size reduction, despite being associated with an increased risk for non-life-threatening adverse effects such as a higher rise of bilirubin and alanine aminotransferase.']",8,0.9285714285714286,5,14
CD011314,2,13,A high risk of systematic errors (bias) as well as imprecision and inconsistency suggest that these findings should be considered cautiously and that high-quality trials are needed to assess further the role of external beam radiotherapy for unresectable hepatocellular carcinoma.,rephrase,['The low quality of evidence suggests that these results should be considered cautiously and that high-quality randomised trials should be performed to assess further the role of external beam radiotherapy for unresectable hepatocellular carcinoma.'],9,1.0,5,14
CD009458,0,0,We included one RCT (153 women) comparing the LNG-IUS administering 20 micrograms (μu) levonorgestrel per day versus 10 milligrams of continuous or cyclical oral medroxyprogesterone (MPA) for treating any type of endometrial hyperplasia.,delete,[],0,0.06666666666666667,1,15
CD009458,0,1,Only 19 women in this study were histologically confirmed with atypical complex hyperplasia before treatment.,rephrase,"['It was conducted in Norway and included 153 women, but only 19 of the women had a confirmed histological diagnosis of atypical endometrial hyperplasia; the other women had other types of endometrial hyperplasia.']",0,0.13333333333333333,1,15
CD009458,0,2,The evidence was of low or very low quality.,rephrase,['The quality of the evidence was low or very low for all outcomes.'],1,0.2,1,15
CD009458,0,3,"The included study was at low risk of bias, but the quality of the evidence was very seriously limited by imprecision and indirectness.",ignore,"['The included study was at low risk of bias, but the quality of the evidence was very seriously limited by imprecision and indirectness.']",2,0.26666666666666666,2,15
CD009458,0,4,We did not find any RCTS comparing the LNG-IUS or oral progestogens versus placebo in women with atypical endometrial hyperplasia.,rephrase,['The included RCT compared LNG-IUS versus oral continuous or cyclic medroxyprogesterone (MPA) for treating endometrial hyperplasia.'],3,0.3333333333333333,2,15
CD009458,1,5,"Among the 19 women with atypical complex hyperplasia, after six months of treatment there was insufficient evidence to determine whether there was a difference in regression rates between the LNG-IUS group and the progesterone group (odds ratio (OR) 2.76, 95% confidence interval (CI) 0.26 to 29.73; 1 RCT subgroup, 19 women, very low-quality evidence).",rephrase,"['After six months of treatment, there was insufficient evidence to determine whether there was a difference in regression rates between the LNG-IUS group and the MPA group.']",4,0.4,2,15
CD009458,1,6,The rate of regression was 100% in the LNG-IUS group (n = 6/6) and 77% in the progesterone group (n = 10/13).,ignore,['The rate of regression was 100% in the LNG-IUS group (n = 6/6) and 77% in the MPA group (n = 10/13).'],5,0.4666666666666667,3,15
CD009458,2,7,"Among the total study population (N = 153), over the six months' treatment the main adverse effects were nausea and vaginal bleeding.",ignore,"[""Among the total study population (N = 153), over the six months' treatment the main adverse effects were nausea and vaginal bleeding.""]",6,0.5333333333333333,3,15
CD009458,2,8,"There was no evidence of a difference between the groups in rates of nausea (OR 0.58, 95% CI 0.28 to 1.18; 1 RCT, 153 women, very low-quality evidence).",merge,"['There was no evidence of a difference between the groups in rates of nausea, but vaginal bleeding was more common in the LNG-IUS group.']",7,0.6,3,15
CD009458,2,9,"Vaginal bleeding was more common in the LNG-IUS group (OR 2.89, 95% CI 1.11 to 7.52; 1 RCT, 153 women, low-quality evidence).",none,[],7,0.6666666666666666,4,15
CD009458,2,10,"Except for nausea and vaginal bleeding, no other adverse effects were reported.",delete,[],8,0.7333333333333333,4,15
CD009458,3,11,"We did not find any RCTS of women with atypical endometrial hyperplasia, and our findings derive from a subgroup of 19 women in a larger RCT.",delete,[],8,0.8,4,15
CD009458,3,12,"All six women who used the LNG-IUS system achieved regression of atypical hyperplasia, but there was insufficient evidence to draw any conclusions regarding the relative efficacy of LNG-IUS versus oral progesterone (MPA) in this group of women.",delete,[],8,0.8666666666666667,5,15
CD009458,3,13,"When assessed in a population of women with any type of endometrial hyperplasia, there was no clear evidence of a difference between LNG-IUS and oral progesterone (MPA) in risk of nausea, but vaginal bleeding was more likely to occur in women using the LNG-IUS.",delete,[],8,0.9333333333333333,5,15
CD009458,3,14,Larger studies are necessary to assess the efficacy and safety of oral and intrauterine progestogens in treating atypical endometrial hyperplasia.,delete,[],8,1.0,5,15
CD011429,0,0,"We retrieved 2398 citations: 30 studies were eligible for further examination of their full text, and we found one registered clinical trial in progress.",split,"['We identified 2398 potential studies, 30 of which we looked at in detail.', 'We found one registered trial that is investigating our review question, but it is still ongoing and not yet completed or published.']",0,0.14285714285714285,1,7
CD011429,0,1,No studies could be included in the analysis or review.,rephrase,['We did not analyse the quality of the evidence as we did not find any suitable studies to include in our review.'],2,0.2857142857142857,2,7
CD011429,0,2,"We assigned one study as awaiting classification, as it has not been accepted for publication.",split,"['We found one suitable study, however although the study is complete the manuscript has not yet been accepted for publication, and so we were unable to analyse the data.', 'We have assigned the study as awaiting classification; once its results are published we will evaluate it again and decide if it is eligible for inclusion in the review.']",3,0.42857142857142855,3,7
CD011429,1,3,This systematic review failed to locate relevant published RCTs to support or refute the assertion that vascular access specialist teams are superior to the generalist model.,merge,['We failed to locate any published randomized controlled trials (RCTs) to support or refute the assertion that vascular access specialist teams are superior to the generalist model for device insertion and prevention of failure.'],5,0.5714285714285714,3,7
CD011429,1,4,"A vascular access specialist team has advanced knowledge with regard to insertion techniques, clinical care, and management of vascular access devices, whereas a generalist model comprises nurses, doctors, or other designated healthcare professionals in the healthcare facility who may have less advanced insertion techniques and who care for vascular access devices amongst other competing clinical tasks.",none,[],5,0.7142857142857143,4,7
CD011429,1,5,"However, this conclusion may change once the one study awaiting classification and one ongoing study are published.",ignore,"['However, this conclusion may change once the one study awaiting classification and the one ongoing study are published.']",6,0.8571428571428571,5,7
CD011429,1,6,There is a need for good-quality RCTs to evaluate the efficacy of a vascular access specialist team approach for vascular access device insertion and care for the prevention of failure.,rephrase,['There is a need for good-quality RCTs to evaluate the efficacy of a VAST approach for VAD insertion and prevention of failure.'],7,1.0,5,7
CD011424,0,0,We included 22 RCTs (3703 women).,rephrase,"['Twenty-two randomised controlled trials, including a total of 3703\xa0women, met the inclusion criteria of this review.']",0,0.05263157894736842,1,19
CD011424,0,1,Most of these studies included women with unexplained infertility.,rephrase,"['Most women had a type of infertility known as unexplained infertility, which means that after all routine tests were done, there was no obvious explanation for why the couple had not become pregnant so far.']",1,0.10526315789473684,1,19
CD011424,1,2,"Intentional endometrial injury versus either no intervention or a sham procedure
The primary analysis was restricted to studies at low risk of bias, which left only one study included.",delete,[],2,0.15789473684210525,1,19
CD011424,1,3,"We are uncertain whether endometrial injury has an effect on the probability of live birth, as only one study is included in the analysis and the confidence interval is wide (risk ratio (RR) 1.11, 95% confidence interval (CI) 0.78 to 1.59; 1 RCT, 210 participants).",delete,[],2,0.21052631578947367,2,19
CD011424,1,4,"Evidence suggests that if the chance of live birth with no intervention/a sham procedure is assumed to be 34%, then the chance with endometrial injury would be 27% to 55%.",delete,[],2,0.2631578947368421,2,19
CD011424,1,5,"When all studies were included in the sensitivity analysis, we were uncertain whether endometrial injury improves live birth/ongoing pregnancy, as the evidence was of very low quality (RR 1.71, 95% CI 1.32 to 2.21; 8 RCTs, 1522 participants; I² = 16%).",delete,[],2,0.3157894736842105,2,19
CD011424,1,6,"Evidence suggests that if the chance of live birth/ongoing pregnancy with no intervention/a sham procedure is assumed to be 13%, then the chance with endometrial injury would be 17% to 28%.",rephrase,"['Evidence suggests that if the chance of live birth with no intervention/a placebo procedure is assumed to be 34%, then the chance with endometrial injury would be 27% to 55%.']",2,0.3684210526315789,2,19
CD011424,2,7,"A narrative synthesis conducted for the other primary outcome of pain during the procedure included studies measuring pain on a zero-to-ten visual analogue scale (VAS) or grading pain as mild/moderate/severe, and showed that most often mild to moderate pain was reported (6 RCTs, 911 participants; very low-quality evidence).",delete,[],3,0.42105263157894735,3,19
CD011424,3,8,"Timing of intentional endometrial injury
Four trials compared endometrial injury performed in the cycle before IUI to that performed in the same cycle as IUI.",rephrase,['Four trials compared endometrial injury performed in the cycle before IUI to such injury performed in the same cycle as IUI.'],3,0.47368421052631576,3,19
CD011424,3,9,None of these studies reported the primary outcomes of live birth/ongoing pregnancy and pain during the procedure.,rephrase,['Live birth/ongoing pregnancy or pain during the procedure was not reported.'],4,0.5263157894736842,3,19
CD011424,4,10,"One study compared endometrial injury in the early follicular phase (EFP; Day 2 to 4) to endometrial injury in the late follicular phase (LFP; Day 7 to 9), both in the same cycle as IUI.",rephrase,"['One trial compared endometrial injury performed early in the first half of the menstrual cycle (Day 2 to 4) to endometrial injury performed late in the first half of the menstrual cycle (Day 7 to 9), both in the same cycle as IUI.']",5,0.5789473684210527,3,19
CD011424,4,11,"The primary outcome live birth/ongoing pregnancy was not reported, but the study did report the other primary outcome of pain during the procedure assessed by a zero-to-ten VAS.",split,"['Live birth/ongoing pregnancy was not reported.', 'This study reported pain assessed by a zero-to-ten visual scale, where 0 is pain-free and 10 is unbearable pain, and showed that the pain score on average was 0.17 points lower after endometrial injury early in the first half of the menstrual cycle compared to such injury late in the first half of the menstrual cycle.']",6,0.631578947368421,4,19
CD011424,4,12,The average pain score was 3.67 (standard deviation (SD) 0.7) when endometrial injury was performed in the EFP and 3.84 (SD 0.96) when endometrial injury was performed in the LFP.,delete,[],8,0.6842105263157895,4,19
CD011424,4,13,"The mean difference was -0.17, suggesting that on average, women undergoing endometrial injury in the EFP scored 0.17 points lower on the VAS as compared to women undergoing endometrial injury in the LFP (95% CI -0.48 to 0.14; 1 RCT, 110 participants; very low-quality evidence).",delete,[],8,0.7368421052631579,4,19
CD011424,5,14,Evidence is insufficient to show whether there is a difference in live birth/ongoing pregnancy between endometrial injury and no intervention/a sham procedure in women undergoing IUI or attempting to conceive via sexual intercourse.,delete,[],8,0.7894736842105263,4,19
CD011424,5,15,"The pooled results should be interpreted with caution, as the evidence was of low to very low quality due to high risk of bias present in most included studies and an overall low level of precision.",rephrase,['The quality of the evidence was assessed as low to very low.'],8,0.8421052631578947,5,19
CD011424,5,16,"Furthermore, studies investigating the effect of timing of endometrial injury did not report the outcome live birth/ongoing pregnancy; therefore no conclusions could be drawn for this outcome.",rephrase,"['Furthermore, no conclusions could be drawn about whether timing of endometrial injury affects the probability of having a baby.']",9,0.8947368421052632,5,19
CD011424,5,17,Further well-conducted RCTs that recruit large numbers of participants and minimise bias are required to confirm or refute these findings.,rephrase,"['This means that results must be treated cautiously, and further studies are needed to confirm findings.']",10,0.9473684210526315,5,19
CD011424,5,18,Current evidence is insufficient to support routine use of endometrial injury in women undergoing IUI or attempting to conceive via sexual intercourse.,ignore,['Current evidence is insufficient to support routine use of endometrial injury in women undergoing IUI or attempting to conceive via sexual intercourse.'],11,1.0,5,19
CD000230,0,0,"For this update, we included 25 randomised controlled trials (RCTs) involving over 18,000 women and their babies.",rephrase,"['This updated review now includes\xa025\xa0randomised controlled trials, involving over 18,000 women and their babies.']",0,0.1111111111111111,1,9
CD000230,0,1,The overall risk of bias was low in half of the studies.,delete,[],1,0.2222222222222222,2,9
CD000230,0,2,"The evidence suggests that zinc supplementation may result in little or no difference in reducing preterm births (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.74 to 1.03; 21 studies, 9851 participants; low-certainty evidence).",rephrase,"['We found that zinc supplementation in pregnancy may make little to no difference in reducing the risk of preterm births, stillbirths, or deaths around the time of birth, when compared to no zinc supplementation or placebo.']",1,0.3333333333333333,2,9
CD000230,0,3,"Further, zinc supplementation may make little or no difference in reducing the risk of stillbirth (RR 1.22, 95% CI 0.80 to 1.88; 7 studies, 3295 participants; low-certainty evidence), or perinatal deaths (RR 1.10, 95% CI 0.81 to 1.51; 2 studies, 2489 participants; low-certainty evidence).",rephrase,"['Zinc supplementation may make little or no difference to the birthweight of babies, and probably makes little or no difference to the number of babies born either with a low birthweight or small for their gestational age, when compared with no zinc supplementation, or with giving a placebo.']",2,0.4444444444444444,3,9
CD000230,0,4,"It is unclear whether zinc supplementation reduces neonatal death, because the certainty of the evidence is very low.",rephrase,"['We cannot be sure whether zinc supplementation reduces death in newborns, because the certainty of the evidence is very low.']",3,0.5555555555555556,3,9
CD000230,0,5,"Finally, for other birth outcomes, zinc supplementation may make little or no difference to mean birthweight (MD 13.83, 95% CI -15.81 to 43.46; 22 studies, 7977 participants; low-certainty evidence), and probably makes little or no difference in reducing the risk of low birthweight (RR 0.94, 95% CI 0.79 to 1.13; 17 studies, 7399 participants; moderate-certainty evidence) and small-for-gestational age babies when compared to placebo or no zinc supplementation (RR 1.02, 95% CI 0.92 to 1.12; 9 studies, 5330 participants; moderate-certainty evidence).",delete,[],4,0.6666666666666666,4,9
CD000230,0,6,"We did not conduct subgroup analyses, as very few studies used normal zinc populations.",delete,[],4,0.7777777777777778,4,9
CD000230,1,7,There is not enough evidence that zinc supplementation during pregnancy results in improvements in maternal or neonatal outcomes.,rephrase,['There is not enough evidence that zinc supplementation during pregnancy results in better outcomes for women and their babies.'],4,0.8888888888888888,5,9
CD000230,1,8,"Future research to address ways of improving the overall nutritional status of pregnant women, particularly in low-income regions, and not looking at zinc in isolation, should be an urgent priority.",split,"[""Finding ways to improve women's overall nutritional status, particularly in low-income areas, will do more to improve the health of mothers and babies than supplementing pregnant women with zinc alone."", 'This should be an urgent research priority for the future.']",5,1.0,5,9
CD003310,0,0,This is an update of a 2001 review that identified no eligible trials.,delete,[],0,0.08333333333333333,1,12
CD003310,0,1,One trial including 40 infants met the inclusion criteria for this review.,delete,[],0,0.16666666666666666,1,12
CD003310,0,2,"Using GRADE criteria, we judged the quality of the evidence as low owing to risk of bias (inadequate reporting of methods of randomisation, allocation concealment and/or blinding) and imprecision (wide confidence intervals and data from a single small trial).",delete,[],0,0.25,2,12
CD003310,0,3,"We found no evidence of a difference between calcium and phosphorus supplementation versus no supplementation for neonatal growth outcomes (weight, length, head circumference) at any time point reported (two, four or six weeks postnatal age).",rephrase,['We found no difference in growth between infants who had been given human milk supplemented with extra calcium and phosphorus and infants who had received no supplementation.'],0,0.3333333333333333,2,12
CD003310,0,4,"At six weeks postnatal age, supplementation with calcium/phosphorus was associated with a decrease in serum alkaline phosphatase concentration (MD -56.85 IU/L, 95% CI -101.27 to -12.43; one randomised controlled trial (RCT); n = 40 infants).",delete,[],1,0.4166666666666667,3,12
CD003310,0,5,"Investigators provided no data on growth at 12 to 18 months, neonatal fractures, feed intolerance, breastfeeding or any of the prespecified childhood outcomes for this review (fractures, growth, neurodevelopmental outcomes).",delete,[],1,0.5,3,12
CD003310,1,6,We identified one small trial including only 40 infants that compared supplementation of human milk with calcium and phosphorus versus no supplementation in hospitalised preterm infants.,rephrase,['We searched for evidence in April 2016 and identified one randomised controlled trial including 40 babies.'],1,0.5833333333333334,3,12
CD003310,1,7,We judged the evidence to be of low quality and found no evidence of differences between groups for clinically important outcomes including growth and fractures.,rephrase,"['One small trial provided the evidence, and we judged the evidence to be of low quality.']",2,0.6666666666666666,4,12
CD003310,1,8,"Although serum alkaline phosphatase concentration was reduced in the group receiving supplementation at six weeks postnatal age, this difference is unlikely to be of clinical significance.",delete,[],3,0.75,4,12
CD003310,1,9,We conclude that evidence is insufficient to determine whether benefit or harm ensues when human milk is supplemented with calcium and/or phosphorus for the hospitalised preterm infant.,rephrase,['Evidence is insufficient to allow a judgement as to whether extra calcium and/or phosphorus provided to preterm babies confers benefit for their bones and growth.'],3,0.8333333333333334,5,12
CD003310,1,10,"We see no advantage of conducting further trials of this intervention because with the advent of multi-component human milk fortifier, supplementation of human milk with calcium and/or phosphorus alone is no longer common practice.",rephrase,"['It is no longer very common to give calcium and phosphorus supplements alone, as human milk fortifiers now available include many other components as well as minerals to support the growth and development of preterm babies.']",4,0.9166666666666666,5,12
CD003310,1,11,Future trials should consider assessing effects of multi-component fortifiers with different mineral compositions on clinically important outcomes during the neonatal period and in later childhood.,rephrase,['We therefore suggest that future trials conducted to examine effects of mineral supplements in preterm babies include them in multi-component human milk fortifiers and assess clinically important outcomes into childhood.'],5,1.0,5,12
CD005610,0,0,"Eight studies met our inclusion criteria: three RCTs and five ITS studies involving a total of 135 general practices/primary care clinics, seven hospitals and one outpatient clinic.",rephrase,"['We found eight eligible studies (three randomised controlled trials and five interrupted time series studies) involving 135 primary care clinics, seven hospitals and one outpatient clinic.']",0,0.09090909090909091,1,11
CD005610,0,1,"The studies were heterogeneous in terms of types of interventions, elective procedures and clinical conditions; this made meta-analysis unfeasible.",rephrase,"['Different interventions, elective procedures and clinical conditions across included studies made pooling of data unfeasible.']",1,0.18181818181818182,1,11
CD005610,1,2,"One ITS study evaluating prioritisation of demand through a system for streamlining elective surgery services reduced the number of semi-urgent participants waiting longer than the recommended time (< 90 days) by 28 participants/mo, while no effects were found for urgent (< 30 days) versus non-urgent participants (< 365 days).",rephrase,"['The single study that evaluated an intervention aimed at prioritising demand showed that introducing a system for streamlining elective surgery reduced the number of semi-urgent patients waiting longer than recommended, but did not affect urgent or non-urgent groups.']",2,0.2727272727272727,2,11
CD005610,2,3,Interventions aimed at restructuring the intake assessment/referral process were evaluated in seven studies.,rephrase,['Seven studies evaluated interventions aimed at restructuring the intake assessment/referral process.'],3,0.36363636363636365,2,11
CD005610,2,4,"Four studies (two RCTs and two ITSs) evaluated open access, or direct booking/referral: One RCT, which showed that open access to laparoscopic sterilisation reduced waiting times, had very high attrition (87%); the other RCT showed that open access to investigative services reduced waiting times (30%) for participants with lower urinary tract syndrome (LUTS) but had no effect on waiting times for participants with microscopic haematuria.",rephrase,['Three of four studies evaluating effects of open access or direct booking/referral showed beneficial effects: One study showed reduced waiting times for open access to sterilisation through keyhole surgery; another showed that open access to investigative services may lead to reduced waiting times for patients with urinary symptoms (but not for patients with microscopic blood in urine); and one study reported that same-day scheduling reduced waiting times for those seeking child health outpatient services.'],4,0.45454545454545453,3,11
CD005610,2,5,"In one ITS study, same-day scheduling for paediatric health clinic appointments reduced waiting times (direct reduction of 25.2 days, and thereafter a decrease of 3.03 days per month), while another ITS study showed no effect of a direct booking system on proportions of participants receiving a colposcopy appointment within the recommended time.",rephrase,['One study showed no effect of a direct booking system on the proportion of patients reported to have moderate or severe cell changes on the neck of the womb who received an appointment for further investigation within four weeks.'],5,0.5454545454545454,3,11
CD005610,2,6,One RCT and one ITS showed no effect of distant consultancy (instant photography for dermatological conditions and telemedicine for ear nose throat (ENT) conditions) on waiting times; another ITS study showed no effect of a pooled waiting list on the number of participants waiting for uncomplicated spinal surgery.,split,"['Two studies of distant consultancy (instant photography for skin conditions and telemedicine for ear, nose and throat conditions) showed no effect on waiting times to see a specialist.', 'One study reported that using a pooled waiting list did not change the number of patients waiting for routine back surgery within the recommended time.']",6,0.6363636363636364,4,11
CD005610,3,7,"Overall quality of the evidence for all outcomes, assessed using the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) tool, ranged from low to very low.",delete,[],8,0.7272727272727273,4,11
CD005610,4,8,We found no studies evaluating interventions to increase capacity or to ration demand.,rephrase,['We found no studies evaluating interventions aimed at increasing capacity or rationing demand.'],8,0.8181818181818182,5,11
CD005610,5,9,"As only a handful of low-quality studies are presently available, we cannot draw any firm conclusions about the effectiveness of the evaluated interventions in reducing waiting times.",ignore,"['As only a handful of low-quality studies are presently available, we cannot draw any firm conclusions about the effectiveness of the evaluated interventions in reducing waiting times.']",9,0.9090909090909091,5,11
CD005610,5,10,"However, interventions involving the provision of more accessible services (open access or direct booking/referral) show some promise.",ignore,"['However, interventions involving the provision of more accessible services (open access or direct booking/referral) show some promise.']",10,1.0,5,11
CD012964,0,0,"Three trials (20,412 women) met our inclusion criteria.",split,"['We searched for evidence on 28 May 2017 and found three trials which met the inclusion criteria for the review.', 'We identified three trials (involving 20,412 women).']",0,0.05555555555555555,1,18
CD012964,0,1,"Two trials (20,212 women) compared intravenous (IV) TXA with placebo or standard care and were conducted in acute hospital settings (labour ward, emergency department) (in high-, middle- and low-income countries).",split,"['However, one of the trials (based in Iran) did not report important outcomes, therefore, our findings are based on two trials (involving 20,212 women) conducted in hospital settings in high-, middle- and low-income countries.', 'One was a large trial that included more than 20,000 women, and both studies looked at the effectiveness and safety of intravenous (IV) TXA compared with placebo (dummy treatment) or no treatment.']",2,0.1111111111111111,1,18
CD012964,1,2,"One other trial (involving 200 women) was conducted in Iran and compared IV TXA with rectal misoprostol, but did not report on any of this review's primary or GRADE outcomes.",delete,[],4,0.16666666666666666,1,18
CD012964,1,3,"There were no trials that assessed EACA, aprotinin or aminomethylbenzoic acid.",delete,[],4,0.2222222222222222,2,18
CD012964,2,4,"Standard care plus IV TXA for the treatment of primary PPH compared with placebo or standard care alone
Two trials (20,212 women) assessed the effect of TXA for the treatment of primary PPH compared with placebo or standard care alone.",delete,[],4,0.2777777777777778,2,18
CD012964,2,5,The larger of these (The WOMAN trial) contributed over 99% of the data and was assessed as being at low risk of bias.,rephrase,['The trial contributing most of the information to the review was at low risk of bias.'],4,0.3333333333333333,2,18
CD012964,2,6,"The quality of the evidence varied for different outcomes, Overall, evidence was mainly graded as moderate to high quality.",delete,[],5,0.3888888888888889,2,18
CD012964,3,7,"The data show that IV TXA reduces the risk of maternal death due to bleeding (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.65 to 1.00; two trials, 20,172 women; quality of evidence: moderate).",rephrase,['Our results show that TXA reduces the risk of maternal death due to bleeding (quality of evidence: moderate).'],5,0.4444444444444444,3,18
CD012964,3,8,The quality of evidence was rated as moderate due to imprecision of effect estimate.,delete,[],6,0.5,3,18
CD012964,3,9,"The effect was more evident in women given treatment between one and three hours after giving birth with no apparent reduction when given after three hours (< one hour = RR 0.80, 95% CI 0.55 to 1.16; one to three hours = RR 0.60, 95% CI 0.41 to 0.88; > three hours = RR 1.07, 95% 0.76 to 1.51; test for subgroup differences: Chi² = 4.90, df = 2 (P = 0.09), I² = 59.2%).",delete,[],6,0.5555555555555556,3,18
CD012964,3,10,"There was no heterogeneity in the effect by mode of birth (test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.91), I² = 0%).",delete,[],6,0.6111111111111112,4,18
CD012964,3,11,"There were fewer deaths from all causes in women receiving TXA, although the 95% CI for the effect estimate crosses the line of no effect (RR 0.88, 95% CI 0.74 to 1.05; two trials, 20,172 women, quality of evidence: moderate).",rephrase,['There were fewer deaths from all causes but the findings were uncertain (quality of evidence: moderate).'],6,0.6666666666666666,4,18
CD012964,3,12,"Results from one trial with 151 women suggest that blood loss of ≥ 500 mL after randomisation may be reduced (RR 0.50, 95% CI 0.27 to 0.93; one trial, 151 women; quality of evidence: low).",rephrase,['In one trial with a small sample size additional blood loss of 500 mL or more was also reduced (151 women; quality of evidence: low).'],7,0.7222222222222222,4,18
CD012964,3,13,"TXA did not reduce the risk of serious maternal morbidity (RR 0.99, 95% CI 0.83 to 1.19; one trial, 20,015 women; quality of evidence: high), hysterectomy to control bleeding (RR 0.95, 95% CI 0.81 to 1.12; one trial, 20,017 women; quality of evidence: high) receipt of blood transfusion (any) (RR 1.00, 95% CI 0.97 to 1.03; two trials, 20,167 women; quality of evidence: moderate) or maternal vascular occlusive events (any), although results were imprecise for this latter outcome (RR 0.88, 95% CI 0.54 to 1.43; one trial, 20,018 women; quality of evidence: moderate).",split,"['TXA had little or no effect on the risk of serious maternal illness (quality of evidence: high), or complications such as stroke or deep venous thrombosis (quality of evidence: moderate).', 'Rates of hysterectomy to control bleeding (quality of evidence: high) and blood transfusion (quality of evidence: moderate) were similar for women receiving TXA versus placebo.']",8,0.7777777777777778,4,18
CD012964,3,14,"There was an increase in the use of brace sutures in the TXA group (RR 1.19, 95% CI 1.01, 1.41) and a reduction in the need for laparotomy for bleeding (RR 0.64, 95% CI 0.49, 0.85).",rephrase,['There was an increase in one surgical intervention (brace sutures) in the TXA group and a reduction in another (laparotomy to control bleeding) but there were no clear differences between groups for other surgical and invasive procedures.'],10,0.8333333333333334,5,18
CD012964,4,15,"TXA when administered intravenously reduces mortality due to bleeding in women with primary PPH, irrespective of mode of birth, and without increasing the risk of thromboembolic events.",rephrase,['TXA when administered intravenously was effective in reducing mortality due to bleeding when given within three hours in women with primary postpartum haemorrhage without increasing the risk of other complications.'],11,0.8888888888888888,5,18
CD012964,4,16,"Taken together with the reliable evidence of the effect of TXA in trauma patients, the evidence suggests that TXA is effective if given as early as possible.",delete,[],12,0.9444444444444444,5,18
CD012964,5,17,"Facilities for IV administration may not be available in non-hospital settings therefore, alternative routes to IV administration need to be investigated.",rephrase,['Facilities for IV administration is not available in some settings so future research could look at whether TXA is effective and safe if given by other methods.'],12,1.0,5,18
CD010026,0,0,We included six RCTs with 527 participants.,rephrase,['We found six studies with 527 participants.'],0,0.08333333333333333,1,12
CD010026,0,1,Only one RCT was judged to be at low risk of bias.,delete,[],1,0.16666666666666666,1,12
CD010026,0,2,The remaining five RCTs were at unclear or high risk of bias.,delete,[],1,0.25,2,12
CD010026,0,3,"No trial mentioned the primary outcomes of longest follow-up mortality, Glasgow Outcome Scale score at three months or any adverse events related to mannitol or hypertonic saline.",rephrase,"['No study reported on the effects of mannitol and hypertonic saline on mortality, the condition of the patient three months after the operation or patient quality of life.']",1,0.3333333333333333,2,12
CD010026,0,4,"Three trials mentioned the secondary outcomes of intraoperative brain relaxation, hospital stay and ICU stay; quality of life was not reported in any of the trials.",rephrase,['Three studies reported the level of brain relaxation.'],2,0.4166666666666667,3,12
CD010026,0,5,Brain relaxation was inadequate in 42 of 197 participants in the hypertonic saline group and in 68 of 190 participants in the mannitol group.,rephrase,"['Based on our results, we would expect that of 100 patients who received hypertonic saline during surgery, around 22 patients would fail to have adequate brain relaxation compared with 36 patients given mannitol.']",3,0.5,3,12
CD010026,0,6,"The risk ratio for brain bulge or tense brain in the hypertonic saline group was 0.60 (95% confidence interval (CI) 0.44 to 0.83, low-quality evidence).",delete,[],4,0.5833333333333334,3,12
CD010026,0,7,One trial reported ICU and hospital stay.,rephrase,['The length of intensive care unit stay and hospital stay was reported by one study.'],4,0.6666666666666666,4,12
CD010026,0,8,"The mean (standard deviation (SD)) duration of ICU stay in the mannitol and hypertonic saline groups was 1.28 (0.5) and 1.25 (0.5) days (P value 0.64), respectively; the mean (SD) duration of hospital stay in the mannitol and hypertonic saline groups was 5.7 (0.7) and 5.7 (0.8) days (P value 1.00), respectively",delete,[],5,0.75,4,12
CD010026,1,9,"From the limited data available on the use of mannitol and hypertonic saline for brain relaxation during craniotomy, it is suggested that hypertonic saline significantly reduces the risk of tense brain during craniotomy.",rephrase,['The quality of evidence for brain relaxation with use of hypertonic saline is low.'],5,0.8333333333333334,5,12
CD010026,1,10,A single trial suggests that ICU stay and hospital stay are comparable with the use of mannitol or hypertonic saline.,delete,[],6,0.9166666666666666,5,12
CD010026,1,11,"However, focus on other related important issues such as long-term mortality, long-term outcome, adverse events and quality of life is needed.",rephrase,"['Further research is needed to assess more important issues such as long-term mortality, long-term outcomes, adverse events and quality of life with use of the two fluids.']",6,1.0,5,12
CD010288,0,0,Only one study enrolling 14 participants was eligible for inclusion in the review.,rephrase,['We could only include one small study in the review (14 participants) and this was stopped early because not enough people agreed to join the study as volunteers.'],0,0.14285714285714285,1,7
CD010288,0,1,"The double-blind study compared a daily dose of 600 mg omalizumab or placebo along with twice daily itraconazole and oral corticosteroids, with a maximum daily dose of 400 mg.",rephrase,"['Volunteers were given of 600 mg of omalizumab or placebo daily along with itraconazole (an antifungal drug) twice daily and oral corticosteroids, with a maximum daily dose of 400 mg.']",1,0.2857142857142857,2,7
CD010288,0,2,Treatment lasted six months but the study was terminated prematurely and complete data were not available.,rephrase,['The study lasted six months and compared omalizumab (Xolair®) injections under the skin of the upper arm or the thigh to placebo injections (dummy treatment containing no active medication).'],2,0.42857142857142855,3,7
CD010288,0,3,We contacted the study investigator and were told that the study was terminated due to the inability to recruit participants into the study despite all reasonable attempts.,delete,[],3,0.5714285714285714,3,7
CD010288,0,4,One or more serious side effects were encountered in six out of nine (66.67%) and one out of five (20%) participants in omalizumab group and placebo group respectively.,rephrase,['Six out of nine volunteers (66.67%) in the omalizumab group and one out of five volunteers (20%) in the placebo group reported one or more serious side effects.'],3,0.7142857142857143,4,7
CD010288,1,5,There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis.,merge,"['Due to the lack of evidence, we are not able to make recommendations either in favour of, or against the use of, anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis.']",4,0.8571428571428571,5,7
CD010288,1,6,"There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function.",none,[],4,1.0,5,7
CD011052,0,0,We included 15 studies.,ignore,['We included 15 studies.'],0,0.07142857142857142,1,14
CD011052,0,1,The total number of participants included in the analyses was 3520.,rephrase,['The studies covered 3520 people.'],1,0.14285714285714285,1,14
CD011052,0,2,"Most studies were small with fewer than 120 participants, although two larger studies with 2012 and 671 participants were included.",rephrase,"['Although most studies were small with fewer than 120 participants, there were two larger studies with 2012 and 671 participants included.']",2,0.21428571428571427,2,14
CD011052,0,3,"There was considerable variation in many of the study characteristics, including the anaesthetics used.",merge,"['There was a great variation in many of the important elements among the studies, including the type of anaesthetics used and the levels of nitrous oxide used.']",3,0.2857142857142857,2,14
CD011052,0,4,"The concentrations of nitrous oxide varied between 50% and 70%, and half of the studies used clinical signs and haemodynamic changes to monitor depth of anaesthesia.",none,[],3,0.35714285714285715,2,14
CD011052,1,5,"As it was not possible to blind the anaesthetist to the anaesthetic used, we rated all studies at high risk of performance bias and we therefore downgraded the quality of evidence by one level for risk of bias using the GRADE approach.",delete,[],4,0.42857142857142855,3,14
CD011052,1,6,"Other types of bias were generally low, or were rated unclear due to missing information.",rephrase,"['Other indicators suggested a low risk of bias, or an unclear risk because of missing information.']",4,0.5,3,14
CD011052,2,7,"No studies were designed to measure AAGA as the primary outcome, and were therefore statistically underpowered to answer this review question.",rephrase,"['No study was designed to measure accidental awareness, but rather they measured it as a secondary outcome.']",5,0.5714285714285714,3,14
CD011052,2,8,"Despite the inclusion of 3520 participants, only three awareness events were reported by two studies.",rephrase,"['Although there were 3520 participants included in the studies, there were only three reports of a participant becoming aware.']",6,0.6428571428571429,4,14
CD011052,2,9,In one study the event was due to technical failure.,delete,[],7,0.7142857142857143,4,14
CD011052,2,10,"Due to the rarity of the events, we did not consider it appropriate to pool the data, and we therefore downgraded the quality of evidence by a further level for imprecision using GRADE.",delete,[],7,0.7857142857142857,4,14
CD011052,3,11,It is not possible to draw any conclusions from this review.,split,"['It is not possible to draw any conclusions from this review.', 'The review question is inadequately supported by the lack of strong evidence.']",7,0.8571428571428571,5,14
CD011052,3,12,"The included studies were mainly small (fewer than 120 participants) and there were limited estimates of effect, with only two studies reporting any events.",rephrase,"['The included studies were mainly too small, and only two studies reported any events.']",9,0.9285714285714286,5,14
CD011052,3,13,"We cannot therefore determine whether the use of nitrous oxide in general anaesthesia increases, decreases or has no effect on the risk of accidental awareness.",delete,[],10,1.0,5,14
CD005278,0,0,"Only three trials tested the efficacy of interferon (IFN) beta including a total of 1160 participants (639 treatment, 521 placebo); no trial tested the efficacy of glatiramer acetate (GA).",split,"['IFN and GA demonstrated only\xa0partial efficacy that could be ascribed to the fact that in the studies that lead to their approval they have been initiated in patients with a disease history of several years.', 'Among the pertinent literature, only three studies\xa0were found to test the efficacy of IFN beta including a total of 1160 participants (639 under treatment, 521 under placebo); while no published study testing the efficacy of GA was found.']",0,0.16666666666666666,1,6
CD005278,0,1,"The metanalyses showed that the proportion of patients converting to CDMS was significantly lower in IFN beta-treated than in placebo-treated patients both after one year (pooled OR 0.53; 95% CI, 0.40 to 0.71; p <0.0001) as well as after two years of follow-up (pooled OR 0.52; 95% CI, 0.38 to 0.70; p <0.0001).",delete,[],2,0.3333333333333333,2,6
CD005278,0,2,Early treatment with IFN beta was associated with the side effect profile reported by the randomised controlled trials with this drug.,merge,[],2,0.5,3,6
CD005278,0,3,"Since side effects were reported with some heterogeneity in the three studies the metanalysis was possible only for the frequency of serious adverse events, not significantly different in IFN beta-treated or placebo-treated patients.",none,['Side effects and adverse events occurrence was the same as reported by the many studies on IFN beta treatments in\xa0MS patients with different levels of the disease.'],2,0.6666666666666666,4,6
CD005278,1,4,The efficacy of IFN beta treatment on preventing the conversion from CIS to CDMS was confirmed over two years of follow-up.,rephrase,['The review found that early interferon beta-1a treatment is effective in preventing the conversion of the first\xa0isolated demyelinating episodes into clinically definite MS both after one year and two years of follow-up.'],3,0.8333333333333334,5,6
CD005278,1,5,"Since patients had some clinical heterogeneity (length of follow-up, clinical findings of initial attack), it could be useful for the clinical practice to further analyse the efficacy of IFN beta treatment in different patient subgroups.",delete,[],4,1.0,5,6
CD010312,0,0,"We included three trials, involving 244 women.",rephrase,['The review identified three randomised controlled studies (involving 244 women) that compared the use of prostaglandins with placebo.'],0,0.07692307692307693,1,13
CD010312,0,1,The studies were considered to be at high risk of bias.,delete,[],1,0.15384615384615385,1,13
CD010312,1,2,The prostaglandins used were PG E2 analogue (sulprostone) in 50 participants and PG E1 analogue (misoprostol) in 194 participants at a dose of 250 mcg and 800 mcg respectively.,rephrase,['The prostaglandin was administered by intravenous infusion (E2 analogue sulprostone) in one study including 50 women and was orally or sublingually administered (E1 analogue misoprostol) in the other two studies including 194 women.'],1,0.23076923076923078,2,13
CD010312,1,3,"The prostaglandins compared with placebo, were not superior in reducing the rate of manual removal of placenta (average risk ratio (RR) 0.82; 95% confidence interval (CI) 0.54 to 1.27), severe postpartum haemorrhage (RR 0.80; 95% CI 0.55 to 1.15), need for blood transfusion (RR 0.72; 95% CI 0.43 to 1.22), mean blood loss (mean difference (MD) -205.26 mL; 95% CI -536.31 to 125.79, random-effects) and the mean time from injection to placental removal (MD -7.00 minutes; 95% CI -21.20 to 7.20).",delete,[],2,0.3076923076923077,2,13
CD010312,1,4,"Side-effects were no different between groups (vomiting, headache, pain and nausea between injection and discharge from the labour ward), with the exception of shivering, which was more frequent in women receiving prostaglandins (RR 10.00; 95% CI 1.40 to 71.49).",rephrase,"['Shivering was more frequent in women receiving the prostaglandin but there were no clear differences in vomiting, headache, maternal pain or nausea compared with placebo.']",2,0.38461538461538464,2,13
CD010312,1,5,We did not obtain any data for the primary outcomes of maternal mortality and the need to add another therapeutic uterotonic.,delete,[],3,0.46153846153846156,3,13
CD010312,2,6,"Currently there is limited, very low-quality evidence relating to the effectiveness and the safety using prostaglandins for the management of retained placenta.",ignore,"['Currently there is limited, very low-quality evidence relating to the effectiveness and the safety using prostaglandins for the management of retained placenta.']",3,0.5384615384615384,3,13
CD010312,2,7,"Use of prostaglandins resulted in less need for manual removal of placenta, severe postpartum haemorrhage and blood transfusion but none of the differences reached statistical significance.",ignore,"['Use of prostaglandins resulted in less need for manual removal of placenta, severe postpartum haemorrhage and need for blood transfusion but none of the differences reached statistical significance.']",4,0.6153846153846154,4,13
CD010312,2,8,"Much larger, adequately powered studies are needed to confirm that these clinically important beneficial effects are not just chance findings.",ignore,"['Much larger, adequately powered studies are needed to confirm that these clinically important beneficial effects are not just chance findings.']",5,0.6923076923076923,4,13
CD010312,3,9,"Similarly, no differences were detected between prostaglandins and placebo in mean blood loss or the mean time from injection to placental removal (minutes) or side-effects (vomiting, headache, pain and nausea between injection and discharge from the labour ward) except for 'shivering' which was more frequent in women who received prostaglandin.",rephrase,"['Similarly, no differences were detected between prostaglandins and placebo in mean blood loss or the mean time from injection to placental removal (minutes).']",6,0.7692307692307693,4,13
CD010312,3,10,The included studies were of poor quality and there is little confidence in the effect estimates; the true effect is likely to be substantially different.,delete,[],7,0.8461538461538461,5,13
CD010312,3,11,We can not make any recommendations about changes to clinical practice.,delete,[],7,0.9230769230769231,5,13
CD010312,3,12,More high-quality research in this area is needed.,delete,[],7,1.0,5,13
CD004610,0,0,Twenty-two studies (3215 participants) were included.,rephrase,['Results\nTwenty-two studies (total 3215 participants) were included.'],0,0.037037037037037035,1,27
CD004610,0,1,The majority of studies enrolled patients with mild to moderate CDI who could tolerate oral antibiotics.,ignore,['The majority of studies enrolled participants with mild to moderate CDI who could tolerate oral antibiotics.'],1,0.07407407407407407,1,27
CD004610,0,2,Sixteen of the included studies excluded patients with severe CDI and few patients with severe CDI were included in the other six studies.,ignore,['Sixteen of the included studies excluded participants with severe CDI and few participants with severe CDI were included in the other studies.'],2,0.1111111111111111,1,27
CD004610,0,3,"Twelve different antibiotics were investigated: vancomycin, metronidazole, fusidic acid, nitazoxanide, teicoplanin, rifampin, rifaximin, bacitracin, cadazolid, LFF517, surotomycin and fidaxomicin.",rephrase,['Twelve different antibiotics were assessed.'],3,0.14814814814814814,1,27
CD004610,0,4,Most of the studies were active comparator studies comparing vancomycin with other antibiotics.,rephrase,['Most of the studies compared vancomycin or metronidazole with other antibiotics.'],4,0.18518518518518517,1,27
CD004610,0,5,One small study compared vancomycin to placebo.,rephrase,['One small study compared vancomycin to placebo (e.g. sugar pill).'],5,0.2222222222222222,2,27
CD004610,0,6,There were no other studies that compared antibiotic treatment to a placebo or a 'no treatment' control group.,ignore,['There were no other studies that compared antibiotic treatment to a placebo or a no treatment control group.'],6,0.25925925925925924,2,27
CD004610,0,7,The risk of bias was rated as high for 17 of 22 included studies.,rephrase,['Seventeen of the 22 included studies had quality issues.'],7,0.2962962962962963,2,27
CD004610,0,8,Vancomycin was found to be more effective than metronidazole for achieving symptomatic cure.,rephrase,"['In four studies, vancomycin was found to be superior to metronidazole for achieving sustained symptomatic cure (defined as resolution of diarrhoea and no recurrence of CDI).']",8,0.3333333333333333,2,27
CD004610,0,9,"Seventy-two per cent (318/444) of metronidazole patients achieved symptomatic cure compared to 79% (339/428) of vancomycin patients (RR 0.90, 95% CI 0.84 to 0.97; moderate quality evidence).",delete,[],9,0.37037037037037035,2,27
CD004610,0,10,Fidaxomicin was found to be more effective than vancomycin for achieving symptomatic cure.,delete,[],9,0.4074074074074074,3,27
CD004610,0,11,"Seventy-one per cent (407/572) of fidaxomicin patients achieved symptomatic cure compared to 61% (361/592) of vancomycin patients (RR 1.17, 95% CI 1.04 to 1.31; moderate quality evidence).",delete,[],9,0.4444444444444444,3,27
CD004610,0,12,Teicoplanin may be more effective than vancomycin for achieving a symptomatic cure.,delete,[],9,0.48148148148148145,3,27
CD004610,0,13,"Eightly-seven per cent (48/55) of teicoplanin patients achieved symptomatic cure compared to 73% (40/55) of vancomycin patients (RR 1.21, 95% CI 1.00 to 1.46; very low quality evidence).",delete,[],9,0.5185185185185185,3,27
CD004610,0,14,For other comparisons including the one placebo-controlled study the quality of evidence was low or very low due to imprecision and in many cases high risk of bias because of attrition and lack of blinding.,delete,[],9,0.5555555555555556,3,27
CD004610,0,15,"One hundred and forty deaths were reported in the studies, all of which were attributed by study authors to the co-morbidities of the participants that lead to acquiring CDI.",rephrase,"['One hundred and forty deaths were reported in the studies, all of which were attributed to participants preexisting health problems.']",9,0.5925925925925926,3,27
CD004610,0,16,"Although many other adverse events were reported during therapy, these were attributed to the participants' co-morbidities.",delete,[],10,0.6296296296296297,4,27
CD004610,0,17,The only adverse events directly attributed to study medication were rare nausea and transient elevation of liver enzymes.,rephrase,['The only side effects attributed to antibiotics were rare nausea and temporary elevation of liver enzymes.'],10,0.6666666666666666,4,27
CD004610,0,18,Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13 (Health Warehouse).,ignore,['Recent cost data (July 2016) for a 10 day course of treatment shows that metronidazole 500 mg is the least expensive antibiotic with a cost of USD 13.'],11,0.7037037037037037,4,27
CD004610,0,19,"Vancomycin 125 mg costs USD 1779 (Walgreens for 56 tablets) compared to fidaxomicin 200 mg at USD 3453.83 or more (Optimer Pharmaceuticals) and teicoplanin at approximately USD 83.67 (GBP 71.40, British National Formulary).",rephrase,['Vancomycin 125 mg costs USD 1779 compared to fidaxomicin 200 mg at USD 3453.83 or more and teicoplanin at approximately USD 83.67.'],12,0.7407407407407407,4,27
CD004610,1,20,No firm conclusions can be drawn regarding the efficacy of antibiotic treatment in severe CDI as most studies excluded patients with severe disease.,rephrase,['Conclusion\nNo firm conclusions can be drawn regarding the effectiveness of antibiotic treatment in severe CDI as most studies excluded these patients.'],13,0.7777777777777778,4,27
CD004610,1,21,The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the initiating antibiotic.,ignore,"[""The lack of any 'no treatment' control studies does not allow for any conclusions regarding the need for antibiotic treatment in patients with mild CDI beyond withdrawal of the antibiotic that caused CDI.""]",14,0.8148148148148148,5,27
CD004610,1,22,"Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin.",ignore,"['Nonetheless, moderate quality evidence suggests that vancomycin is superior to metronidazole and fidaxomicin is superior to vancomycin.']",15,0.8518518518518519,5,27
CD004610,1,23,The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other two antibiotics.,ignore,['The differences in effectiveness between these antibiotics were not too large and the advantage of metronidazole is its far lower cost compared to the other antibiotics.'],16,0.8888888888888888,5,27
CD004610,1,24,The quality of evidence for teicoplanin is very low.,ignore,['The quality of evidence for teicoplanin is very low.'],17,0.9259259259259259,5,27
CD004610,1,25,Adequately powered studies are needed to determine if teicoplanin performs as well as the other antibiotics.,rephrase,['Larger studies are needed to determine if teicoplanin performs as well as the other antibiotics.'],18,0.9629629629629629,5,27
CD004610,1,26,"A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin, would be of interest.",ignore,"['A trial comparing the two cheapest antibiotics, metronidazole and teicoplanin would be of interest.']",19,1.0,5,27
CD007978,0,0,We included nine trials enrolling 1733 patients; all trials were judged to be at risk of bias.,delete,[],0,0.0625,1,16
CD007978,0,1,Seven were randomised controlled trials; two were cluster-randomised controlled designs.,delete,[],0,0.125,1,16
CD007978,0,2,Eight examined email as compared to standard methods of communication.,rephrase,['Eight of the trials looked at email compared with standard methods of communication.'],0,0.1875,1,16
CD007978,0,3,One compared email with telephone for the delivery of counselling.,rephrase,['One of the trials looked at email counselling compared with telephone counselling.'],1,0.25,2,16
CD007978,0,4,"When email was compared to standard methods, for the majority of patient/caregiver outcomes it was not possible to adequately assess whether email had any effect.",rephrase,"['Where email was compared to standard methods of communication we found that we could not properly determine what effect email was having on patient/caregiver outcomes, as there were missing data and the results of the different studies varied.']",2,0.3125,2,16
CD007978,0,5,"For health service use outcomes it was not possible to adequately assess whether email has any effect on resource use, but some results indicated that an email intervention leads to an increased number of emails and telephone calls being received by healthcare professionals.",rephrase,"['For health service use outcomes the situation was the same, but some results seemed to show that an email intervention may lead to an increased number of emails and telephone calls being received by healthcare professionals.']",3,0.375,2,16
CD007978,0,6,Three studies reported some type of adverse event but it was not clear if the adverse event had any impact on the health of the patient or the quality of health care.,delete,[],4,0.4375,3,16
CD007978,0,7,"When email counselling was compared to telephone counselling only patient outcomes were measured, and for the majority of measures there was no difference between groups.",rephrase,"['We found that it only looked at patient outcomes, and found few differences between groups.']",4,0.5,3,16
CD007978,0,8,Where there were differences these showed that telephone counselling leads to greater change in lifestyle modification factors than email counselling.,ignore,['Where there were differences these showed that telephone counselling leads to greater changes in lifestyle than email counselling.'],5,0.5625,3,16
CD007978,0,9,"There was one outcome relating to harm, which showed no difference between the email and the telephone counselling groups.",delete,[],6,0.625,4,16
CD007978,0,10,There were no primary outcomes relating to healthcare professionals for either comparison.,delete,[],6,0.6875,4,16
CD007978,1,11,"The evidence base was found to be limited with variable results and missing data, and therefore it was not possible to adequately assess the effect of email for clinical communication between patients/caregivers and healthcare professionals.",delete,[],6,0.75,4,16
CD007978,1,12,Recommendations for clinical practice could not be made.,rephrase,['The nature of the results means that we cannot make any recommendations for how email might best be used in clinical practice.'],6,0.8125,5,16
CD007978,1,13,Future research should ideally address the issue of missing data and methodological concerns by adhering to published reporting standards.,merge,"['Future research should make allowances for how quickly technology changes, and should consider how much email would cost to introduce and what effect it has on the use of healthcare resources.']",7,0.875,5,16
CD007978,1,14,The rapidly changing nature of technology should be taken into account when designing and conducting future studies and barriers to trial development and implementation should also be tackled.,merge,[],7,0.9375,5,16
CD007978,1,15,Potential outcomes of interest for future research include cost-effectiveness and health service resource use.,none,[],7,1.0,5,16
CD004925,0,0,Seven RCTs (1154 patients) of low or moderate quality were identified.,rephrase,['Seven studies (1154 patients) were identified.'],0,0.125,1,8
CD004925,0,1,"The incidence of MUCs was significantly reduced (RR 0.24, 95% CI 0.07 to 0.77, P = 0.02, NNT 13) by universal prophylactic stenting.",rephrase,['The incidence of MUCs were significantly reduced by the use of prophylactic stenting.'],1,0.25,2,8
CD004925,0,2,"This was dependent on whether the same surgeon performed, or was in attendance, during the operations.",delete,[],2,0.375,2,8
CD004925,0,3,Two patients lost their grafts to infective urinary tract complications in the stented group.,delete,[],2,0.5,3,8
CD004925,0,4,"UTIs, in general, were more common in stented patients (RR 1.49, 95% CI 1.04 to 2.15) unless the patients were prescribed cotrimoxazole 480 mg/d: in which case the incidence was equivalent (RR 0.97, 95% CI 0.71 to 1.33).",rephrase,['Urinary tract infections (UTIs) were more common in stented patients however the addition of antibiotic prophylaxis resulted in no difference in the incidence of UTIs between the two groups.'],2,0.625,4,8
CD004925,0,5,"Stents appeared generally well tolerated, although studies using longer stents (≥ 20 cm) for longer periods (> 6 weeks) had more problems with encrustation and migration.",delete,[],3,0.75,4,8
CD004925,1,6,Routine prophylactic stenting reduces the incidence of MUCs.,delete,[],3,0.875,5,8
CD004925,1,7,"Studies comparing selective stenting and universal prophylactic stenting, whilst difficult to design and analyse, would address the unresolved quality of life and economic issues.",rephrase,['More studies are needed to investigate the use of selective versus universal prophylactic stenting for the unresolved issues of quality of life and cost.'],3,1.0,5,8
CD003885,0,0,"Nine trials were identified in the searches and five trials, with a total of 547 participants, met the inclusion criteria.",rephrase,['The review includes five trials with a total of 547 participants.'],0,0.09090909090909091,1,11
CD003885,0,1,"Only one trial reported incidence of pneumococcal infection, and this demonstrated that the polysaccharide pneumococcal vaccine used (PPV14) failed to reduce significantly the risk of infection in children under three years of age, but was associated with only minor adverse events.",rephrase,"['One trial showed that the polysaccharide vaccine did not reduce the risk of infection very much in children younger than three years old, but it was linked with only minor adverse events.']",1,0.18181818181818182,1,11
CD003885,0,2,"Three trials of conjugate pneumococcal vaccines found that antibody responses were increased compared to control groups, including those in infants, although clinical outcomes were not measured in these trials.",rephrase,"['Three trials of conjugate vaccines showed increased antibody responses compared to control groups in people of all ages, although clinical outcomes were not measured in these trials.']",2,0.2727272727272727,2,11
CD003885,1,3,"Previous trials have shown that conjugate pneumococcal vaccines are safe and effective in normal healthy individuals, including those under the age of two years.",delete,[],3,0.36363636363636365,2,11
CD003885,1,4,"The controlled trials included in this review have demonstrated immunogenicity (the ability to induce the body's immune response, without which there is no protection) of these vaccines, and observational studies in people with sickle cell disease support these findings.",delete,[],3,0.45454545454545453,3,11
CD003885,1,5,We therefore recommend that conjugate pneumococcal vaccines are used in people with sickle cell disease.,split,"['We searched for trials which compared a polysaccharide or conjugate pneumococcal vaccine schedule with a different schedule or no vaccination in people with sickle cell disease.', 'We recommend that conjugate pneumococcal vaccines are used in people with sickle cell disease.']",3,0.5454545454545454,3,11
CD003885,1,6,"Randomised trials in people with sickle cell disease will be needed to determine the optimal vaccination regimen when further, potentially more effective vaccines become available.",rephrase,"['Randomised trials will be needed to determine the best vaccination schedule when further, potentially more effective vaccines become available.']",5,0.6363636363636364,4,11
CD003885,1,7,Such trials should measure clinical outcomes of effectiveness.,ignore,['Such trials should measure clinical outcomes of effectiveness.'],6,0.7272727272727273,4,11
CD003885,1,8,The trials included in this review were published between 1983 and 2003.,delete,[],7,0.8181818181818182,5,11
CD003885,1,9,We have not identified any further relevant trials up to December 2011.,delete,[],7,0.9090909090909091,5,11
CD003885,1,10,We therefore do not plan to update this review until new trials are published.,delete,[],7,1.0,5,11
CD008693,0,0,Three trials involving 104 people were included.,rephrase,['This review identified three randomized controlled trials involving 104 patients.'],0,0.06666666666666667,1,15
CD008693,0,1,We classified one study as having low risk of bias; the others had some limitations and we classified them as having high risk of bias.,delete,[],1,0.13333333333333333,1,15
CD008693,1,2,Two studies (one with low risk of bias and the other with high risk of bias) applied progressive resistance training (PRT) combined with range of motion exercises and stretching; the comparison group received standard care.,rephrase,['Two studies compared progressive resistance training with standard care (usual treatment process).'],1,0.2,1,15
CD008693,1,3,"Pooled data demonstrated that PRT can improve shoulder pain (mean difference (MD) -6.26; 95% confidence interval (CI) -12.20 to -0.31) and shoulder disability (MD -8.48; 95% CI -15.07 to -1.88), both measured using the Shoulder Pain and Disability Index (SPADI) (range 0 to 100).",delete,[],2,0.26666666666666666,2,15
CD008693,1,4,"Similarly, secondary outcomes were also improved: active range of motion for external rotation (MD 14.51 degrees; 95% CI 7.87 to 21.14), passive range of motion for abduction (MD 7.65 degrees; 95% CI 0.64 to 14.66), forward flexion (MD 6.20 degrees; 95% CI 0.69 to 11.71), external rotation (MD 7.17 degrees; 95% CI 2.20 to 12.14) and horizontal abduction (MD 7.34 degrees; 95% CI 2.86 to 11.83).",rephrase,"['When we combined their results we found that progressive resistance training improved shoulder pain, shoulder disability, active range of motion for external rotation, passive range of motion for abduction, forward flexion, external rotation and horizontal abduction.']",2,0.3333333333333333,2,15
CD008693,1,5,Strength and resistance of scapular muscles was assessed in one study and the results showed a statistically significant benefit of PRT.,delete,[],3,0.4,2,15
CD008693,1,6,The studies did not demonstrate a statistically significant difference in quality of life.,ignore,['The studies did not demonstrate a statistically significant difference in quality of life.'],3,0.4666666666666667,3,15
CD008693,1,7,Only two non-serious adverse events were described in the PRT group compared with none in the standard care group.,rephrase,['Two non-serious adverse events were reported in the progressive resistance training group and none in the standard care group.'],4,0.5333333333333333,3,15
CD008693,2,8,"One study with high risk of bias used a broad spectrum of techniques including free active exercises, stretching and postural care for a period of three months following surgery.",rephrase,"['Another study compared a broad spectrum of techniques, including free active exercises, stretching, postural care, re-education of scapulothoracic postural muscles, and strength of shoulder muscles, with routine postoperative physiotherapy care for three months following surgery.']",5,0.6,3,15
CD008693,2,9,"This study did not demonstrate a difference between the exercise group and routine postoperative physiotherapy care in shoulder function and quality of life, but serious methodological limitations could explain this.",rephrase,['This study did not demonstrate a difference between the exercise group and the routine physiotherapy care group in shoulder function or quality of life.'],6,0.6666666666666666,4,15
CD008693,2,10,No serious adverse events were reported.,rephrase,['No adverse effects were reported.'],7,0.7333333333333333,4,15
CD008693,3,11,"Limited evidence from two RCTs demonstrated that PRT is more effective than standard physiotherapy treatment for shoulder dysfunction in patients treated for head and neck cancer, improving pain, disability and range of motion of the shoulder joint, but it does not improve quality of life.",delete,[],8,0.8,4,15
CD008693,3,12,"However, although statistically significant the measured benefits of the intervention may be small.",delete,[],8,0.8666666666666667,5,15
CD008693,3,13,Other exercise regimes were not shown to be effective compared to routine postoperative physiotherapy.,delete,[],8,0.9333333333333333,5,15
CD008693,3,14,"Further studies which apply other exercise interventions in head and neck cancer patients in the early postoperative and radiotherapy period are needed, with long-term follow-up.",ignore,"['Further studies which apply other exercise interventions in head and neck cancer patients in the early postoperative period and after radiotherapy are needed, with long-term follow-up.']",8,1.0,5,15
CD001518,0,0,Cabergoline has been compared with placebo in two phase II (6 - 12 weeks) and one phase III randomised controlled trials (24 weeks).,rephrase,"['Cabergoline has been compared with inactive placebo in two smaller and shorter (6 - 12 weeks) studies and one larger, medium term trial (24 weeks).']",0,0.08333333333333333,1,12
CD001518,0,1,"These were double-blind, parallel group, multicentre studies including 268 patients with Parkinson's disease and motor complications.",rephrase,"[""These trials included 268 patients with Parkinson's disease and motor complications.""]",1,0.16666666666666666,1,12
CD001518,0,2,"The reduction of 1.14 hours (WMD; 95% CI -0.06, 2.33; p = 0.06) in off time in favour of cabergoline was not statistically significant.",rephrase,"['The average reduction in the time patients spent in the immobile off state was 1.1 hours greater with cabergoline compared with placebo, although this was not statistically significant.']",2,0.25,2,12
CD001518,0,3,Inadequate data on dyskinesia was collected either on rating scales or as adverse event reporting to allow a conclusion to be drawn.,rephrase,['Inadequate data on dyskinesia was collected to allow a conclusion to be drawn.'],3,0.3333333333333333,2,12
CD001518,0,4,A small but statistically significant advantage of cabergoline over placebo was seen in one study for UPDRS ADL (part II) score and UPDRS motor score.,rephrase,['A small but significant advantage of cabergoline over placebo was seen in one study for activities of daily living and physical functioning.'],4,0.4166666666666667,3,12
CD001518,0,5,No such advantage was seen in one other study due to small numbers of patients and the comparatively low doses of cabergoline used.,ignore,['No such advantage was seen in one other study due to small numbers of patients and the comparatively low doses of cabergoline used.'],5,0.5,3,12
CD001518,0,6,No significant differences in Schwab and England scale were seen in two studies.,delete,[],6,0.5833333333333334,3,12
CD001518,0,7,"Levodopa dose reduction was significantly greater with cabergoline (WMD 149.6 mg/d; 95% CI 94.1, 205.1; p < 0.00001).",rephrase,['Levodopa dose reduction was greater with cabergoline by 145 mg per day.'],6,0.6666666666666666,4,12
CD001518,0,8,There was a trend towards more dopaminergic adverse events with cabergoline but this did not reach statistical significance at the p < 0.01 level.,merge,[],7,0.75,4,12
CD001518,0,9,"However, there was a trend towards fewer withdrawals from cabergoline.",none,['There was a trend towards more side effects with cabergoline but towards fewer withdrawals from cabergoline treatment.'],7,0.8333333333333334,5,12
CD001518,1,10,"In the management of the motor complications seen in Parkinson's disease, cabergoline can be used to reduce levodopa dose and modestly improve motor impairment and disability with an acceptable adverse event profile.",rephrase,"[""In the management of the motor complications seen in Parkinson's disease, cabergoline can be used to reduce levodopa dose and modestly improve motor function and activities of daily living with an acceptable side effect profile.""]",8,0.9166666666666666,5,12
CD001518,1,11,"These conclusions are based on, at best, medium term evidence.",rephrase,"['This is based on, at best, medium term evidence.']",9,1.0,5,12
CD007849,0,0,We included 10 trials that involved 390 children with ASD.,delete,[],0,0.0625,1,16
CD007849,0,1,The age range was three to 18 years and the treatment duration ranged from four weeks to nine months.,delete,[],0,0.125,1,16
CD007849,0,2,"The studies were carried out in Hong Kong, mainland China and Egypt.",rephrase,"['These studies, which were carried out in Hong Kong, mainland China and Egypt, involved 390 children aged between three and 18 years.']",0,0.1875,1,16
CD007849,1,3,"Two trials compared needle acupuncture with sham acupuncture and found no difference in the primary outcome of core autistic features (RFRLRS total score: MD 0.09; 95% CI -0.03 to 0.21, P = 0.16), although results suggested needle acupuncture might be associated with improvement in some aspects of the secondary outcomes of communication and linguistic ability, cognitive function and global functioning.",split,"['Two studies compared needle acupuncture with sham acupuncture and found no difference in core autistic features.', 'Results did suggest that needle acupuncture might be associated with improvement in other areas of communication and linguistic ability, cognitive function and global functioning.']",1,0.25,2,16
CD007849,2,4,Six trials compared needle acupuncture plus conventional treatment with conventional treatment alone.,ignore,['Six studies compared needle acupuncture plus conventional treatment with conventional treatment alone.'],3,0.3125,2,16
CD007849,2,5,"The trials used different primary outcome measures and most could not demonstrate effectiveness of acupuncture in improving core autistic features in general, though one trial reported patients in the acupuncture group were more likely to have improvement on the Autism Behavior Checklist (RR 1.53; 95% CI 1.09 to 2.16, P = 0.02) and had slightly better post-treatment total scores (MD -5.53; 95% CI -10.76 to -0.31, P = 0.04).",split,"['They used a range of tools to measure core autistic features and most could not show that acupuncture led to improvement in these.', 'One trial did report, though, that needle acupuncture led to an improvement in scores on Autism Behavior Checklist.']",4,0.375,2,16
CD007849,2,6,"There was no evidence that acupuncture was effective for the secondary outcome of communication and linguistic ability, though there seemed to be some benefit for the secondary outcomes of cognitive function and global functioning.",rephrase,['There was no evidence for improvement due to acupuncture on communication and linguistic ability but it might be beneficial for cognitive function and global functioning.'],6,0.4375,3,16
CD007849,3,7,Two trials compared acupressure plus conventional treatment with conventional treatment alone and did not report on the primary outcome.,rephrase,"['Two studies compared acupressure plus conventional treatment with conventional treatment alone and found no difference in core autistic features, although acupressure seemed to improve some aspects of the secondary outcomes.']",7,0.5,3,16
CD007849,3,8,"Individual study results suggested there may be some benefit from acupressure for certain aspects of the secondary outcomes of communication and linguistic ability, cognitive function and global functioning.",delete,[],8,0.5625,3,16
CD007849,4,9,"Four trials reported some adverse effects, though there was little quantitative information, and at times both intervention and control groups experienced them.",rephrase,['Half of the trials reported some negative effects but did not report how often or how severe these were and sometimes the problems occurred in both the treatment and control groups.'],8,0.625,4,16
CD007849,4,10,"Adverse effects noted included bleeding, crying due to fear or pain, irritability, sleep disturbance and increased hyperactivity.",rephrase,"['Problems that were noted by parents of study participants included crying due to fear or pain, bleeding, sleep disturbance and increased hyperactivity.']",9,0.6875,4,16
CD007849,4,11,None of the trials reported on quality of life.,rephrase,['None of the studies used measures of quality of life.'],10,0.75,4,16
CD007849,5,12,"There are a number of problems with the evidence base: the trials were few in number and included only children; six of the trials were at high risk of bias; they were heterogeneous in terms of participants and intervention; they were of short duration and follow-up; they reported inconsistent and imprecise results, and, due to carrying out large numbers of analyses, they were at risk of false positivity.",rephrase,"['Moreover, there is a high likelihood that they may have been biased due to the methods used not being rigorous enough, the wide variety in the people and interventions in the studies, the inconsistent and imprecise reporting of results and the large number of analyses carried out, which make it more likely a significant result will be found just by chance.']",11,0.8125,5,16
CD007849,6,13,Current evidence does not support the use of acupuncture for treatment of ASD.,merge,"['In conclusion, current evidence does not support the use of acupuncture for the treatment of ASD.']",12,0.875,5,16
CD007849,6,14,There is no conclusive evidence that acupuncture is effective for treatment of ASD in children and no RCTs have been carried out with adults.,none,[],12,0.9375,5,16
CD007849,6,15,Further high quality trials of larger size and longer follow-up are needed.,rephrase,['We need high quality trials of larger size and longer follow-up as the evidence base at present has many limitations.'],13,1.0,5,16
CD011045,0,0,"The current version of this review includes 72 studies, published between 1978 and July 2013, assessed as being at overall unclear or high risk of bias with respect to selection and consumption outcomes.",rephrase,"['This review includes 72 randomised controlled trials (RCTs) published up to July 2013 that compared at least two groups of participants, each presented with a different size of a portion, package or item of tableware.']",0,0.058823529411764705,1,17
CD011045,0,1,Ninety-six per cent of included studies (69/72) manipulated food products and 4% (3/72) manipulated cigarettes.,delete,[],1,0.11764705882352941,1,17
CD011045,0,2,No included studies manipulated alcohol products.,split,"['Included studies measured the amounts of food, alcohol or tobacco selected and/or consumed by participants, typically over a period of one day or less.', 'Almost all of the included studies investigated food, with only three tobacco studies and no alcohol studies found.']",1,0.17647058823529413,1,17
CD011045,0,3,"Forty-nine per cent (35/72) manipulated portion size, 14% (10/72) package size and 21% (15/72) tableware size or shape.",delete,[],3,0.23529411764705882,2,17
CD011045,0,4,More studies investigated effects among adults (76% (55/72)) than children and all studies were conducted in high-income countries - predominantly in the USA (81% (58/72)).,rephrase,"['The average age of participants in the different studies ranged from three to 55 years, with more studies involving adults than children and most conducted in the USA.']",3,0.29411764705882354,2,17
CD011045,0,5,"Sources of funding were reported for the majority of studies, with no evidence of funding by agencies with possible commercial interests in their results.",rephrase,['Sources of funding were reported for the majority of studies and there was no evidence of study funding by agencies with commercial interests in their results.'],4,0.35294117647058826,2,17
CD011045,1,6,"A meta-analysis of 86 independent comparisons from 58 studies (6603 participants) found a small to moderate effect of portion, package, individual unit or tableware size on consumption of food (SMD 0.38, 95% CI 0.29 to 0.46), providing moderate quality evidence that exposure to larger sizes increased quantities of food consumed among children (SMD 0.21, 95% CI 0.10 to 0.31) and adults (SMD 0.46, 95% CI 0.40 to 0.52).",delete,[],5,0.4117647058823529,3,17
CD011045,1,7,"The size of this effect suggests that, if sustained reductions in exposure to larger-sized food portions, packages and tableware could be achieved across the whole diet, this could reduce average daily energy consumed from food by between 144 and 228 kcal (8.5% to 13.5% from a baseline of 1689 kcal) among UK children and adults.",rephrase,['If an effect of this size were sustained across the whole diet it would be equivalent to around a 12% to 16% change in average daily energy intake from food among UK adults.'],5,0.47058823529411764,3,17
CD011045,1,8,"A meta-analysis of six independent comparisons from three studies (108 participants) found low quality evidence for no difference in the effect of cigarette length on consumption (SMD 0.25, 95% CI -0.14 to 0.65).",rephrase,"['From three tobacco studies, we found no effect of longer compared with shorter cigarettes on the amounts of tobacco consumed.']",6,0.5294117647058824,3,17
CD011045,2,9,"One included study (50 participants) estimated a large effect on consumption of exposure to differently shaped tableware (SMD 1.17, 95% CI 0.57 to 1.78), rated as very low quality evidence that exposure to shorter, wider bottles (versus taller, narrower bottles) increased quantities of water consumed by young adult participants.",split,"['One study found that adults provided with shorter, wider bottles drank larger amounts of water from them, having already poured more, compared with those provided with taller, narrower bottles.', 'However, we rated the quality of this evidence as very low, due to very serious concerns about study limitations and not having enough evidence (only one study with outcome data from 50 participants).']",7,0.5882352941176471,3,17
CD011045,3,10,"A meta-analysis of 13 independent comparisons from 10 studies (1164 participants) found a small to moderate effect of portion or tableware size on selection of food (SMD 0.42, 95% CI 0.24 to 0.59), rated as moderate quality evidence that exposure to larger sizes increased the quantities of food people selected for subsequent consumption.",delete,[],9,0.6470588235294118,4,17
CD011045,3,11,"This effect was present among adults (SMD 0.55, 95% CI 0.35 to 0.75) but not children (SMD 0.14, 95% CI -0.06 to 0.34).",delete,[],9,0.7058823529411765,4,17
CD011045,4,12,"In addition, a meta-analysis of three independent comparisons from three studies (232 participants) found a very large effect of exposure to differently shaped tableware on selection of non-alcoholic beverages (SMD 1.47, 95% CI 0.52 to 2.43), rated as low quality evidence that exposure to shorter, wider (versus taller, narrower) glasses or bottles increased the quantities selected for subsequent consumption among adults (SMD 2.31, 95% CI 1.79 to 2.83) and children (SMD 1.03, 95% CI 0.41 to 1.65).",rephrase,"['Evidence from three studies suggested that adults and children provided with shorter, wider bottles or glasses selected increased quantities of non-alcoholic beverages for subsequent consumption, compared with those provided with taller, narrower bottles or glasses.']",9,0.7647058823529411,4,17
CD011045,5,13,"This review found that people consistently consume more food and drink when offered larger-sized portions, packages or tableware than when offered smaller-sized versions.",rephrase,"['We found evidence that people consistently ate more food or drank more non-alcoholic drinks when offered larger-sized portions, packages or items of tableware than when offered smaller-sized versions.']",10,0.8235294117647058,5,17
CD011045,5,14,"This suggests that policies and practices that successfully reduce the size, availability and appeal of larger-sized portions, packages, individual units and tableware can contribute to meaningful reductions in the quantities of food (including non-alcoholic beverages) people select and consume in the immediate and short term.",rephrase,"['Overall, this review provides the most conclusive evidence to date that acting to reduce the size, availability and appeal of larger-sized portions, packages and tableware has potential to reduce the quantities of food that people select and consume by meaningful amounts.']",11,0.8823529411764706,5,17
CD011045,5,15,"However, it is uncertain whether reducing portions at the smaller end of the size range can be as effective in reducing food consumption as reductions at the larger end of the range.",ignore,"['However, it is uncertain whether reducing portions at the smaller end of the size range can be as effective in reducing food consumption as reductions at the larger end of the range.']",12,0.9411764705882353,5,17
CD011045,5,16,We are unable to highlight clear implications for tobacco or alcohol policy due to identified gaps in the current evidence base.,rephrase,"['Our findings highlight the need for further research that aims to reduce uncertainties about these effects and address identified gaps in the evidence base, including not having enough evidence for longer-term effects and the absence of evidence about alcohol products.']",13,1.0,5,17
CD002968,0,0,Fourteen randomised controlled trials comparing exercise against no exercise in type 2 diabetes were identified involving 377 participants.,rephrase,['These included 377 participants and compared groups that differed only with respect to an exercise programme intervention.'],0,0.1,1,10
CD002968,0,1,Trials ranged from eight weeks to twelve months duration.,rephrase,['The duration of the interventions in the studies ranged from eight weeks to one year.'],1,0.2,1,10
CD002968,0,2,"Compared with the control, the exercise intervention significantly improved glycaemic control as indicated by a decrease in glycated haemoglobin levels of 0.6% (-0.6 % HbA1c, 95% confidence interval (CI) -0.9 to -0.3; P < 0.05).",delete,[],2,0.3,2,10
CD002968,0,3,This result is both statistically and clinically significant.,delete,[],2,0.4,2,10
CD002968,0,4,"There was no significant difference between groups in whole body mass, probably due to an increase in fat free mass (muscle) with exercise, as reported in one trial (6.3 kg, 95% CI 0.0 to 12.6).",delete,[],2,0.5,3,10
CD002968,0,5,"There was a reduction in visceral adipose tissue with exercise (-45.5 cm2, 95% CI -63.8 to -27.3), and subcutaneous adipose tissue also decreased.",delete,[],2,0.6,3,10
CD002968,0,6,No study reported adverse effects in the exercise group or diabetic complications.,split,"['No adverse effects with exercise were reported.', 'The effect of exercise on diabetic complications was not assessed in any of the studies.']",2,0.7,4,10
CD002968,0,7,"The exercise intervention significantly increased insulin response (131 AUC, 95% CI 20 to 242) (one trial), and decreased plasma triglycerides (-0.25 mmol/L, 95% CI -0.48 to -0.02).",rephrase,"[""Exercise improved the body's reaction to insulin and decreased blood lipids.""]",4,0.8,4,10
CD002968,0,8,"No significant difference was found between groups in quality of life (one trial), plasma cholesterol or blood pressure.",split,"['Quality of life was only assessed in one study, which found no difference between the two groups.', 'No significant difference was found between groups in blood levels of cholesterol or blood pressure.']",5,0.9,5,10
CD002968,1,9,"The meta-analysis shows that exercise significantly improves glycaemic control and reduces visceral adipose tissue and plasma triglycerides, but not plasma cholesterol, in people with type 2 diabetes, even without weight loss.",rephrase,['This review found that exercise improves blood sugar control and that this effect is evident even without weight loss.'],7,1.0,5,10
CD005315,0,0,"Overall, 102 studies have been included in this review.",rephrase,"['The review identified 102 relevant studies, 85 of which were on the use of music in hospital.']",0,0.14285714285714285,1,7
CD005315,0,1,"Interventions explored were: 'positive distracters', to include aromas (two studies), audiovisual distractions (five studies), decoration (one study), and music (85 studies); interventions to reduce environmental stressors through physical changes, to include air quality (three studies), bedroom type (one study), flooring (two studies), furniture and furnishings (one study), lighting (one study), and temperature (one study); and multifaceted interventions (two studies).",rephrase,"['Other environmental aspects considered were: aromas (two studies), audiovisual distractions (five studies), decoration (one study), air quality (three studies), bedroom type (one study), flooring (two studies), furniture and furnishings (one study), lighting (one study), temperature (one study), and multiple design changes (two studies).']",1,0.2857142857142857,2,7
CD005315,0,2,"We did not find any studies meeting the inclusion criteria to evaluate: art, access to nature for example, through hospital gardens, atriums, flowers, and plants, ceilings, interventions to reduce hospital noise, patient controls, technologies, way-finding aids, or the provision of windows.",ignore,"['No studies meeting the inclusion criteria were found to evaluate: art, access to nature for example through hospital gardens, atriums, flowers, and plants, ceilings, interventions to reduce hospital noise, patient controls, technologies, way-finding aids, or the provision of windows.']",2,0.42857142857142855,3,7
CD005315,0,3,"Overall, it appears that music may improve patient-reported outcomes such as anxiety; however, the benefit for physiological outcomes, and medication consumption has less support.",rephrase,"['Overall, it appears that music in hospital may help improve patient-reported outcomes such as anxiety; however, there is less evidence to support the use of music for physiological outcomes (such as reducing heart rate and blood pressure) and for reducing the use of medications.']",3,0.5714285714285714,3,7
CD005315,0,4,"There are few studies to support or refute the implementation of physical changes, and except for air quality, the included studies demonstrated that physical changes to the hospital environment at least did no harm.",delete,[],4,0.7142857142857143,4,7
CD005315,1,5,"Music may improve patient-reported outcomes in certain circumstances, so support for this relatively inexpensive intervention may be justified.",delete,[],4,0.8571428571428571,5,7
CD005315,1,6,"For some environmental interventions, well designed research studies have yet to take place.",delete,[],4,1.0,5,7
CD008537,0,0,"Five reviews, 114 studies, 7333 participants, satisfied criteria for inclusions.",rephrase,"['Five reviews, 114 studies, 7333 participants, were included.']",0,0.09090909090909091,1,11
CD008537,0,1,"The outcomes considered were alcohol withdrawal seizures, adverse events and dropouts.",rephrase,"['We considered the efficacy of the medication on alcohol withdrawal seizures, adverse events as a measure of safety and acceptability of the treatment as dropouts from the study.']",1,0.18181818181818182,1,11
CD008537,0,2,"Comparing the five treatments with placebo, benzodiazepines performed better for seizures, three studies, 324 participants, RR 0.16 (95% CI 0.04 to 0.69), moderate quality of evidence.",rephrase,"['Comparing the five treatments with placebo, benzodiazepines performed better for seizures (three studies, 324 participants, moderate quality of evidence).']",2,0.2727272727272727,2,11
CD008537,0,3,"Comparing each of the five treatments versus specific class of drugs, benzodiazepines performed better than antipsychotics for seizures, 4 studies, 633 participants, RR 0.24 (95% CI 0.07 to 0.88) high quality of the evidence.",rephrase,"['Benzodiazepines also performed better than antipsychotics for seizures (4 studies, 633 participants, high quality of evidence).']",3,0.36363636363636365,2,11
CD008537,0,4,"Comparing different benzodiazepines and anticonvulsants among themselves, 28 comparisons, results never reached statistical significance but chlordiazepoxide performed better.",delete,[],4,0.45454545454545453,3,11
CD008537,1,5,"The quality of evidence was high for 3% of the results, moderate for 28%, low for 48% and very low for 20%.",delete,[],4,0.5454545454545454,3,11
CD008537,2,6,"Among the treatments considered, benzodiazepines showed a protective benefit against seizures, when compared to placebo and a potentially protective benefit for many outcomes when compared with antipsychotics.",delete,[],4,0.6363636363636364,4,11
CD008537,2,7,"Nevertheless, no definite conclusions about the effectiveness and safety of benzodiazepines were possible, because of the heterogeneity of the trials both in interventions and in the assessment of outcomes.",delete,[],4,0.7272727272727273,4,11
CD008537,2,8,Data on potential harms are sparse and fragmented.,rephrase,['Data on potential harms were sparse and fragmented in these studies.'],4,0.8181818181818182,5,11
CD008537,2,9,"Results do not provide sufficient evidence in favour of anticonvulsants for the treatment of AWS, but anticonvulsants seem to have limited side effects.",delete,[],5,0.9090909090909091,5,11
CD008537,2,10,"There is also not enough evidence of effectiveness and safety of baclofen, because only one study consider this treatment and of GHB for which no strong differences were observed in the comparisons with placebo, benzodiazepines and anticonvulsants.",rephrase,"['The treatments used were sedative benzodiazepines, anticonvulsants, baclofen, GHB and PAN.']",5,1.0,5,11
CD005384,0,0,"We included 17 trials, enrolling 1958 infants in this review.",rephrase,['We found 17 trials (enrolling 1958 infants) comparing NCPAP with NIPPV.'],0,0.1111111111111111,1,9
CD005384,0,1,"NIPPV likely reduces the rate of respiratory failure (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.54 to 0.78; risk difference (RD) -0.08, 95% CI -0.12 to -0.05; 17 RCTs, 1958 infants; moderate-certainty evidence) and needing endotracheal tube ventilation (RR 0.67, 95% CI 0.56 to 0.81; RD -0.07, 95% CI -0.11 to -0.04; 16 RCTs; 1848 infants; moderate-certainty evidence) amongst infants treated with early NIPPV compared with early NCPAP.",delete,[],1,0.2222222222222222,2,9
CD005384,1,2,"The meta-analysis demonstrated that NIPPV may reduce the risk of developing CLD compared to CPAP (RR 0.70, 95% CI 0.52 to 0.92; 12 RCTs, 1284 infants; low-certainty evidence) slightly.",delete,[],1,0.3333333333333333,2,9
CD005384,1,3,"NIPPV may result in little to no difference in mortality (RR 0.82, 95% CI 0.62 to 1.10; 17 RCTs; 1958 infants; I2 of 0%; low-certainty evidence), the incidence of pneumothorax (RR 0.92, 95% CI 0.60 to 1.41; 16 RCTs; 1674 infants; I2 of 0%; low-certainty evidence), and rates of severe IVH (RR 0.98, 95% CI 0.53 to 1.79; 8 RCTs; 977 infants; I2 of 0%; low-certainty evidence).",rephrase,"['Compared to NCPAP, NIPPV may result in little to no difference on the risk of dying, developing an air leak in the thoracic cage, or a severe brain bleed.']",1,0.4444444444444444,3,9
CD005384,2,4,"When applied within six hours after birth, NIPPV likely reduces the risk of respiratory failure and the need for intubation and endotracheal tube ventilation in very preterm infants (GA 28 weeks and above) with respiratory distress syndrome or at risk for RDS.",ignore,"['When applied within six hours after birth, NIPPV likely reduces the risk of respiratory failure and the need for intubation and endotracheal tube ventilation in very preterm infants (gestational age of 28 weeks and above) with respiratory distress syndrome (RDS) or at risk for RDS.']",2,0.5555555555555556,3,9
CD005384,2,5,It may also decrease the rate of CLD slightly.,rephrase,['It may also decrease the rate of chronic lung disease slightly.'],3,0.6666666666666666,4,9
CD005384,2,6,"However, most trials enrolled infants with a gestational age of approximately 28 to 32 weeks with an overall mean gestational age of around 30 weeks.",rephrase,"['However, there was a lack of data for the most premature infants that are born at less than 28 weeks of gestational age.']",4,0.7777777777777778,4,9
CD005384,2,7,"As such, the results of this review may not apply to extremely preterm infants that are most at risk of needing mechanical ventilation or developing CLD.",delete,[],5,0.8888888888888888,5,9
CD005384,2,8,Additional studies are needed to confirm these results and to assess the safety of NIPPV compared with NCPAP alone in a larger patient population.,rephrase,['Additional studies are needed to determine how NIPPV can be best delivered to infants.'],5,1.0,5,9
CD010792,0,0,We included one RCT (56 eyes of 55 participants) in this review.,rephrase,['We found one eligible study of 55 participants from the UK.'],0,0.07142857142857142,1,14
CD010792,0,1,The study compared two types of topical biguanides for the treatment of AK: chlorhexidine 0.02% and polyhexamethylene biguanide (PHMB) 0.02%.,rephrase,['The study randomly assigned people with AK to one of two medical treatment options: chlorhexidine eye drops or polyhexamethylene biguanide (PHMB) eye drops.'],1,0.14285714285714285,1,14
CD010792,0,2,All participants were contact lens wearers with a median age of 31 years.,rephrase,['All participants in the study had a history of contact lens wear.'],2,0.21428571428571427,2,14
CD010792,0,3,Treatment duration ranged from 51 to 145 days.,rephrase,['Participants in the study were treated for 51 to 145 days.'],3,0.2857142857142857,2,14
CD010792,0,4,"The study, conducted in the UK, was well-designed and had low risk of bias overall.",rephrase,"['Although the study was well-designed with no suggestion of bias, the results must be interpreted carefully because of the small number of participants.']",4,0.35714285714285715,2,14
CD010792,1,5,Outcome data were available for 51 (91%) of 56 eyes.,delete,[],5,0.42857142857142855,3,14
CD010792,1,6,Follow-up times for outcome measurements in the study were not reported.,delete,[],5,0.5,3,14
CD010792,1,7,"Resolution of infection, defined as control of ocular inflammation, relief of pain and photosensitivity, and recovery of vision, was 86% in the chlorhexidine group compared with 78% in the PHMB group (relative risk (RR) 1.10, 95% confidence intervals (CI) 0.84 to 1.42).",delete,[],5,0.5714285714285714,3,14
CD010792,1,8,"In the chlorhexidine group, 20 of 28 eyes (71%) had better visual acuity compared with 13 of 23 eyes (57%) in the PHMB group at final follow-up (RR 1.26, 95% CI 0.82 to 1.94).",delete,[],5,0.6428571428571429,4,14
CD010792,1,9,"Five participants required therapeutic keratoplasty: 2 in the chlorhexidine group compared with 3 in the PHMB group (RR 0.55, 95% CI 0.10 to 3.00).",delete,[],5,0.7142857142857143,4,14
CD010792,1,10,No serious adverse event related to drug toxicity was observed in the study.,rephrase,['No serious side effect was observed with either treatment in the study.'],5,0.7857142857142857,4,14
CD010792,2,11,There is insufficient evidence to evaluate the relative effectiveness and safety of medical therapy for the treatment of AK.,delete,[],6,0.8571428571428571,5,14
CD010792,2,12,Results from the one included study yielded no difference with respect to outcomes reported between chlorhexidine and PHMB.,rephrase,"['In the one study identified, similar results were seen between the chlorhexidine and PHMB groups in terms of resolution of infection, changes in vision, or need for surgery.']",6,0.9285714285714286,5,14
CD010792,2,13,"However, the sample size was inadequate to detect clinically meaningful differences between the two groups as indicated by the wide confidence intervals of effect estimates.",delete,[],7,1.0,5,14
CD004975,0,0,We included five studies with 1601 children in the review.,rephrase,['We identified five randomised clinical studies with 1601 children comparing two dosing schedules.'],0,0.2,1,5
CD004975,0,1,"Pooled analysis demonstrated that the following outcomes were comparable between the two groups: clinical cure at the end of therapy (RR 1.03, 95% CI 0.99 to 1.07); during therapy (RR 1.06, 95% CI 0.85 to 1.33) and at follow-up (RR 1.02, 95% CI 0.95 to 1.09); recurrent AOM (RR 1.21, 95% CI 0.52 to 2.81); compliance rate (RR 1.04, 95% CI 0.98 to 1.10) and overall adverse events (RR 0.92, 95% CI 0.52 to 1.63).",rephrase,"['The secondary outcomes were clinical cure rate in terms of middle ear effusion during therapy, clinical cure rate post-treatment (one to three months) in terms of resolution of middle ear infection, AOM complications and adverse events to medication.']",1,0.4,2,5
CD004975,0,2,"When we performed subgroup analysis separately for trials with amoxicillin only and amoxicillin/clavulanate only, it showed that all important outcomes were comparable between once or twice daily groups and the three times daily group.",delete,[],2,0.6,3,5
CD004975,0,3,"The risk of bias amongst the five included studies was as follows: for random sequence generation we graded two studies as low and three unclear risk of bias; for allocation concealment all studies were at unclear risk of bias; for blinding (performance and detection bias) we graded four as high and one as unclear risk of bias; for incomplete outcome data (attrition bias) we graded two low, two high and one as unclear risk of bias; for reporting bias four were at low and one at high risk; and for ‘other’ bias four were at low and one at unclear risk of bias.",delete,[],2,0.8,4,5
CD004975,1,4,"This review showed that the results of using once or twice daily doses of amoxicillin, with or without clavulanate, were comparable with three doses for the treatment of AOM.",rephrase,"['The results showed that treating acute middle ear infection with either once/twice daily or three times daily amoxicillin, with or without clavulanate, has the same results using our outcome measures, including adverse events such as diarrhoea and skin reactions.']",2,1.0,5,5
CD011670,0,0,We included two randomised controlled trials with a total of 80 participants in this review.,split,"['We searched for all relevant randomised controlled trials up to 23 August 2016.', 'We identified two trials involving 80 participants.']",0,0.043478260869565216,1,23
CD011670,1,1,1.,delete,[],2,0.08695652173913043,1,23
CD011670,1,2,"Early versus delayed open appendicectomy for appendiceal phlegmon
Forty participants (paediatric and adults) with appendiceal phlegmon were randomised either to early appendicectomy (appendicectomy as soon as appendiceal mass resolved within the same admission) (n = 20), or to delayed appendicectomy (initial conservative treatment followed by interval appendicectomy six weeks later) (n = 20).",rephrase,['One compared early versus delayed open appendicectomy in 40 children and adults with appendiceal phlegmon.'],2,0.13043478260869565,1,23
CD011670,1,3,The trial was at high risk of bias.,delete,[],3,0.17391304347826086,1,23
CD011670,1,4,There was no mortality in either group.,rephrase,['There were no deaths in the study.'],3,0.21739130434782608,2,23
CD011670,1,5,"There is insufficient evidence to determine the effect of using either early or delayed open appendicectomy onoverall morbidity (RR 13.00; 95% CI 0.78 to 216.39; very low-quality evidence), the proportion of participants who developed wound infection (RR 9.00; 95% CI 0.52 to 156.91; very low quality evidence) or faecal fistula (RR 3.00; 95% CI 0.13 to 69.52; very low quality evidence).",rephrase,"['From one trial in children and adults comparing open with delayed appendicectomy, there was insufficient evidence to show the effect of using either approach on the overall complication rate or the proportion of participants who developed wound infection.']",4,0.2608695652173913,2,23
CD011670,1,6,"The quality of evidence for increased length of hospital stay and time away from normal activities in the early appendicectomy group (MD 6.70 days; 95% CI 2.76 to 10.64, and MD 5.00 days; 95% CI 1.52 to 8.48, respectively) is very low quality evidence.",rephrase,['Our certainty in a longer stay in hospital stay and time away from normal activities with open appendicectomy is very low.'],5,0.30434782608695654,2,23
CD011670,1,7,The trial reported neither quality of life nor pain outcomes.,rephrase,"['Quality of life, and pain were not reported in this trial.']",6,0.34782608695652173,2,23
CD011670,2,8,2.,delete,[],7,0.391304347826087,2,23
CD011670,2,9,"Early versus delayed laparoscopic appendicectomy for appendiceal abscess
Forty paediatric participants with appendiceal abscess were randomised either to early appendicectomy (emergent laparoscopic appendicectomy) (n = 20) or to delayed appendicectomy (initial conservative treatment followed by interval laparoscopic appendicectomy 10 weeks later) (n = 20).",delete,[],7,0.43478260869565216,3,23
CD011670,2,10,The trial was at high risk of bias.,delete,[],7,0.4782608695652174,3,23
CD011670,2,11,The trial did not report on overall morbidity or complications.,rephrase,['The other trial in children with appendiceal abscess receiving either early or delayed keyhole appendicectomy did not report on overall complication rates.'],7,0.5217391304347826,3,23
CD011670,2,12,There was no mortality in either group.,delete,[],8,0.5652173913043478,3,23
CD011670,2,13,We do not have sufficient evidence to determine the effects of using either early or delayed laparoscopic appendicectomy for outcomes relating to hospital stay between the groups (MD −0.20 days; 95% CI −3.54 to 3.14; very low quality of evidence).,rephrase,['The trial did not provide enough evidence to show the effect of using either approach on the length of hospital stay among participants.'],8,0.6086956521739131,4,23
CD011670,2,14,Health-related quality of life was measured with the Pediatric Quality of Life Scale-Version 4.0 questionnaire (a scale of 0 to 100 with higher values indicating a better quality of life).,delete,[],9,0.6521739130434783,4,23
CD011670,2,15,Health-related quality of life score measured at 12 weeks after appendicectomy was higher in the early appendicectomy group than in the delayed appendicectomy group (MD 12.40 points; 95% CI 9.78 to 15.02) but the quality of evidence was very low.,delete,[],9,0.6956521739130435,4,23
CD011670,2,16,This trial reported neither the pain nor the time away from normal activities.,rephrase,"['The study did not report if there were any deaths, and did not provide information on pain, or time away from normal activities.']",9,0.7391304347826086,4,23
CD011670,3,17,It is unclear whether early appendicectomy prevents complications compared to delayed appendicectomy for people with appendiceal phlegmon or abscess.,delete,[],10,0.782608695652174,4,23
CD011670,3,18,The evidence indicating increased length of hospital stay and time away from normal activities in people with early open appendicectomy is of very low quality.,rephrase,"['Overall, we judged the quality of the evidence to be very low.']",10,0.8260869565217391,5,23
CD011670,3,19,The evidence for better health-related quality of life following early laparoscopic appendicectomy compared with delayed appendicectomy is based on very low quality evidence.,merge,['At present the benefits and harms of early versus delayed appendicectomy are not well understood because the current information is based upon very low quality evidence.'],11,0.8695652173913043,5,23
CD011670,3,20,"For both comparisons addressed in this review, data are sparse, and we cannot rule out significant benefits or harms of early versus delayed appendicectomy.",none,[],11,0.9130434782608695,5,23
CD011670,4,21,"Further trials on this topic are urgently needed and should specify a set of criteria for use of antibiotics, percutaneous drainage of the appendiceal abscess prior to surgery and resolution of the appendiceal phlegmon or abscess.",rephrase,"['Thus, further well-designed trials are urgently needed.']",12,0.9565217391304348,5,23
CD011670,4,22,"Future trials should include outcomes such as time away from normal activities, quality of life and the length of hospital stay.",delete,[],13,1.0,5,23
CD006060,0,0,Twenty-two trials which randomised approximately 6200 people to pioglitazone treatment were identified.,rephrase,['Twenty-two trials randomised approximately 6200 people to pioglitazone treatment.'],0,0.125,1,8
CD006060,0,1,Longest duration of therapy was 34.5 months.,rephrase,['The longest duration of pioglitazone therapy was 34.5 months.'],1,0.25,2,8
CD006060,0,2,"Published studies of at least 24 weeks pioglitazone treatment in people with type 2 diabetes mellitus did not provide convincing evidence that patient-oriented outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by this compound.",rephrase,"['Unfortunately, the published studies of at least 24 weeks pioglitazone treatment in people with type 2 diabetes mellitus did not provide convincing evidence that patient-oriented outcomes are positively influenced by this compound.']",2,0.375,2,8
CD006060,0,3,Metabolic control measured by glycosylated haemoglobin A1c (HbA1c) as a surrogate endpoint did not demonstrate clinically relevant differences to other oral antidiabetic drugs.,delete,[],3,0.5,3,8
CD006060,0,4,Occurrence of oedema was significantly raised.,ignore,['The occurrence of oedema was significantly raised.'],3,0.625,4,8
CD006060,0,5,The results of the single trial with relevant clinical endpoints (Prospective Pioglitazone Clinical Trial In Macrovascular Events - PROactive study) have to be regarded as hypothesis-generating and need confirmation.,rephrase,['The results of the single trial with relevant endpoints (Prospective Pioglitazone Clinical Trial In Macrovascular Events - PROactive study) have to be confirmed by other independent investigations.'],4,0.75,4,8
CD006060,1,6,"Until new evidence becomes available, the benefit-risk ratio of pioglitazone remains unclear.",rephrase,['Until new evidence becomes available (several large trials are ongoing) the place of pioglitazone in the treatment of type 2 diabetes mellitus remains unclear.'],5,0.875,5,8
CD006060,1,7,Different therapeutic indications for pioglitazone of the two big U.S. and European drug agencies should be clarified to reduce uncertainties amongst patients and physicians.,delete,[],6,1.0,5,8
CD007088,0,0,We included two trials with 156 participants for this review.,rephrase,['We identified two trials with 156 participants for this review.'],0,0.05555555555555555,1,18
CD007088,0,1,The comparisons included in these two trials were percutaneous cholecystostomy followed by early laparoscopic cholecystectomy versus delayed laparoscopic cholecystectomy (1 trial; 70 participants) and percutaneous cholecystostomy versus conservative treatment (1 trial; 86 participants).,rephrase,['The comparisons included in these two trials were 1) percutaneous cholecystostomy plus laparoscopic cholecystectomy (key hole removal of gallbladder) immediately after the general condition improves (percutaneous cholecystostomy followed by early laparoscopic cholecystectomy) versus planned delayed laparoscopic cholecystectomy performed routinely (1 trial; 70 participants) and 2) percutaneous cholecystostomy versus conservative treatment (supportive treatment and antibiotic treatment) (1 trial; 86 participants).'],1,0.1111111111111111,1,18
CD007088,0,2,Both trials had high risk of bias.,rephrase,['Both trials were at high risk of systematic error (prone to arrive at wrong conclusions because of the way the trials were designed and data were analysed).'],2,0.16666666666666666,1,18
CD007088,1,3,Percutaneous cholecystostomy with early laparoscopic cholecystectomy versus delayed laparoscopic cholecystectomy: There was no significant difference in mortality between the two intervention groups (0/37 versus 1/33; Fisher's exact test: P value = 0.47).,delete,[],3,0.2222222222222222,2,18
CD007088,1,4,There was no significant difference in overall morbidity between the two intervention groups (1/31 versus 2/30; Fisher's exact test: P value = 0.61).,rephrase,['There was no significant difference in the proportion of participants who died or developed complications between any of the comparison groups.'],3,0.2777777777777778,2,18
CD007088,1,5,This trial did not report on quality of life.,rephrase,['Quality of life was not reported in any of the trials.'],4,0.3333333333333333,2,18
CD007088,1,6,There was no significant difference in the proportion of participants requiring conversion to open cholecystectomy between the two intervention groups (2/31 percutaneous cholecystostomy followed by early laparoscopic cholecystectomy versus 4/30 delayed laparoscopic cholecystectomy; Fisher's exact test: P value = 0.43).,rephrase,['There was no significant difference in the proportion of participants requiring conversion to open cholecystectomy in the only comparison that reported this outcome (percutaneous cholecystostomy followed by early laparoscopic cholecystectomy versus delayed laparoscopic cholecystectomy).'],5,0.3888888888888889,2,18
CD007088,1,7,The mean total hospital stay was significantly lower in the percutaneous cholecystostomy followed by early laparoscopic cholecystectomy group compared with the delayed laparoscopic cholecystectomy group (1 trial; 61 participants; MD -9.90 days; 95% CI -12.31 to -7.49).,merge,['The mean total hospital stay and mean costs were significantly lower in the percutaneous cholecystostomy followed by early laparoscopic cholecystectomy group compared with the delayed laparoscopic cholecystectomy group.'],6,0.4444444444444444,3,18
CD007088,1,8,The mean total costs were significantly lower in the percutaneous cholecystostomy followed by early laparoscopic cholecystectomy group compared with the delayed laparoscopic cholecystectomy group (1 trial; 61 participants; MD -1123.00 USD; 95% CI -1336.60 to -909.40).,none,[],6,0.5,3,18
CD007088,2,9,Percutaneous cholecystostomy versus conservative treatment: Nine of the 44 participants underwent delayed cholecystectomy in the percutaneous cholecystostomy group.,delete,[],7,0.5555555555555556,3,18
CD007088,2,10,Seven of the 42 participants underwent delayed cholecystectomy in the conservative treatment group.,delete,[],7,0.6111111111111112,4,18
CD007088,2,11,There was no significant difference in mortality between the two intervention groups (6/44 versus 7/42; Fisher's exact test: P value = 0.77).,delete,[],7,0.6666666666666666,4,18
CD007088,2,12,There was no significant difference in overall morbidity between the two intervention groups (6/44 versus 3/42; Fisher's exact test: P value = 0.49).,delete,[],7,0.7222222222222222,4,18
CD007088,2,13,The number of participants who underwent laparoscopic cholecystectomy was not reported in this trial.,delete,[],7,0.7777777777777778,4,18
CD007088,2,14,"Therefore, we were unable to calculate the proportion of participants who underwent conversion to open cholecystectomy.",delete,[],7,0.8333333333333334,5,18
CD007088,2,15,"The other outcomes, total hospital stay, quality of life, and total costs, were not reported in this trial.",delete,[],7,0.8888888888888888,5,18
CD007088,3,16,"Based on the current available evidence from randomised clinical trials, we are unable to determine the role of percutaneous cholecystostomy in the clinical management of high-risk surgical patients with acute cholecystitis.",ignore,"['Based on the current available evidence, we are unable to determine the role of percutaneous cholecystostomy in the clinical management of high-risk surgical patients with acute cholecystitis.']",7,0.9444444444444444,5,18
CD007088,3,17,There is a need for adequately powered randomised clinical trials of low risk of bias on this issue.,rephrase,['There is a need for well-designed clinical trials with low risk of systematic error and random errors on this issue.'],8,1.0,5,18
CD010259,0,0,Four trials were identified for inclusion in this review.,rephrase,['We reviewed the medical literature up to July 2013 and identified four randomised controlled trials that investigated early (permanent removal of dressings within 48 hours of surgery) versus delayed removal of dressings (permanent removal of dressings after 48 hours of surgery with interim changes of dressing allowed) in people with surgical wounds.'],0,0.07692307692307693,1,13
CD010259,0,1,All the trials were at high risk of bias.,rephrase,"['The levels of bias across the studies were mostly high or unclear, i.e. flaws in the conduct of these trials could have resulted in the production of incorrect results.']",1,0.15384615384615385,1,13
CD010259,0,2,Three trials provided information for this review.,delete,[],2,0.23076923076923078,2,13
CD010259,0,3,"Overall, this review included 280 people undergoing planned surgery.",rephrase,['A total of 280 people undergoing planned surgery were included in this review.'],2,0.3076923076923077,2,13
CD010259,0,4,Participants were randomised to early dressing removal (removal of the wound dressing within the 48 hours following surgery) (n = 140) or delayed dressing removal (continued dressing of the wound beyond 48 hours) (n = 140) in the three trials.,rephrase,['The choice of whether the dressing was removed early (within 48 hours) or retained for more 48 hours was made randomly by a method similar to the toss of a coin.'],3,0.38461538461538464,2,13
CD010259,0,5,"There were no statistically significant differences between the early dressing removal group and delayed dressing removal group in the proportion of people who developed superficial surgical site infection within 30 days (RR 0.64; 95% CI 0.32 to 1.28), superficial wound dehiscence within 30 days (RR 2.00; 95% CI 0.19 to 21.16) or serious adverse events within 30 days (RR 0.83; 95% CI 0.28 to 2.51).",rephrase,"['No significant differences were reported between the two groups in terms of superficial surgical site infection (infection of the wound), superficial wound dehiscence (partial disruption of the wound that results in it reopening at the skin surface) or the number of people experiencing serious adverse events.']",4,0.46153846153846156,3,13
CD010259,0,6,No deep wound infection or deep wound dehiscence occurred in any of the participants in the trials that reported this outcome.,rephrase,"['There were no deep wound infections or complete wound dehiscence (complete disruption of wound healing, when the wound reopens completely) in the studies that reported these complications.']",5,0.5384615384615384,3,13
CD010259,0,7,None of the trials reported quality of life.,ignore,['None of the studies reported quality of life.'],6,0.6153846153846154,4,13
CD010259,0,8,The hospital stay was significantly shorter (MD -2.00 days; 95% CI -2.82 to -1.18) and the total cost of treatment significantly less (MD EUR -36.00; 95% CI -59.81 to -12.19) in the early dressing removal group than in the delayed dressing removal group in the only trial that reported these outcomes.,delete,[],7,0.6923076923076923,4,13
CD010259,1,9,The early removal of dressings from clean or clean contaminated surgical wounds appears to have no detrimental effect on outcomes.,delete,[],7,0.7692307692307693,4,13
CD010259,1,10,"However, it should be noted that the point estimate supporting this statement is based on very low quality evidence from three small randomised controlled trials, and the confidence intervals around this estimate were wide.",merge,[],7,0.8461538461538461,5,13
CD010259,1,11,"Early dressing removal may result in a significantly shorter hospital stay, and significantly reduced costs, than covering the surgical wound with wound dressings beyond the first 48 hours after surgery, according to very low quality evidence from one small randomised controlled trial.",none,"['Participants in the group that had early removal of dressings had significantly shorter hospital stays and incurred significantly lower treatment costs than those in the delayed removal of dressings group, but these results were based on very low quality evidence from one small randomised controlled trial.']",7,0.9230769230769231,5,13
CD010259,1,12,Further randomised controlled trials of low risk of bias are necessary to investigate whether dressings are necessary after 48 hours in different types of surgery and levels of contamination and investigate whether antibiotic therapy influences the outcome,rephrase,"['We recommend further randomised controlled trials are performed to investigate whether dressing of wounds beyond 48 hours after surgery is necessary, since the current evidence is based on very low quality evidence from three small randomised controlled trials.']",8,1.0,5,13
CD010636,0,0,We included five studies with a total of 1296 participants under two years of age hospitalised with bronchiolitis.,rephrase,['We identified five randomised controlled trials (1296 participants under two years of age) comparing montelukast (a leukotriene inhibitor) with placebo in infants and young children hospitalised with bronchiolitis.'],0,0.058823529411764705,1,17
CD010636,0,1,Two studies with low risk of bias compared 4 mg montelukast (a leukotriene inhibitor) daily use from admission until discharge with a matching placebo.,delete,[],1,0.11764705882352941,1,17
CD010636,0,2,Both selected length of hospital stay as a primary outcome and clinical severity score as a secondary outcome.,split,"['Our primary outcomes were length of hospital stay and all-cause mortality.', 'Secondary outcomes included clinical severity score, percentage of symptom-free days, percentage of children requiring ventilation, recurrent wheezing, oxygen saturation, respiratory rate and clinical adverse effects.']",1,0.17647058823529413,1,17
CD010636,0,3,"However, the effects of leukotriene inhibitors on length of hospital stay and clinical severity score were uncertain due to considerable heterogeneity between the study results and wide confidence intervals around the estimated effects (hospital stay: mean difference (MD) -0.95 days, 95% confidence interval (CI) -3.08 to 1.19, P value = 0.38, low quality evidence; clinical severity score on day two: MD -0.57, 95% CI -2.37 to 1.23, P value = 0.53, low quality evidence; clinical severity score on day three: MD 0.17, 95% CI -1.93 to 2.28, P value = 0.87, low quality evidence).",rephrase,['The effects of montelukast on length of hospital stay and clinical severity score were uncertain due to considerable heterogeneity (differences) between the study results and wide confidence intervals around the estimated effects.'],3,0.23529411764705882,2,17
CD010636,0,4,The other three studies compared montelukast for several weeks for preventing post-bronchiolitis symptoms with placebo.,delete,[],4,0.29411764705882354,2,17
CD010636,0,5,"We assessed one study as low risk of bias, whereas we assessed the other two studies as having a high risk of attrition bias.",delete,[],4,0.35294117647058826,2,17
CD010636,0,6,"Due to the significant clinical heterogeneity in severity of disease, duration of treatment, outcome measurements and timing of assessment, we did not pool the results.",delete,[],4,0.4117647058823529,3,17
CD010636,0,7,Individual analyses of these studies did not show significant differences between the leukotriene inhibitors group and the control group in symptom-free days and incidence of recurrent wheezing.,rephrase,['Data on symptom-free days and incidence of recurrent wheezing were from single studies only and individual analyses of these studies did not show significant differences between the intervention group and the control group.'],4,0.47058823529411764,3,17
CD010636,0,8,One study of 952 children reported two deaths in the leukotriene inhibitors group: neither was determined to be drug-related.,ignore,['One study of 952 children reported two deaths in the leukotriene inhibitors group: neither was determined to be drug-related.'],5,0.5294117647058824,3,17
CD010636,0,9,"No data were available on the percentage of children requiring ventilation, oxygen saturation and respiratory rate.",ignore,"['No data were available on the percentage of children requiring ventilation, oxygen saturation and respiratory rate.']",6,0.5882352941176471,3,17
CD010636,0,10,"Finally, three studies reported adverse events including diarrhoea, wheezing shortly after administration and rash.",ignore,"['Finally, three studies reported adverse events including diarrhoea, wheezing shortly after administration and rash.']",7,0.6470588235294118,4,17
CD010636,0,11,No differences were reported between the study groups.,ignore,['No differences were reported between the study groups.'],8,0.7058823529411765,4,17
CD010636,1,12,The current evidence does not allow definitive conclusions to be made about the effects of leukotriene inhibitors on length of hospital stay and clinical severity score in infants and young children with bronchiolitis.,rephrase,"['Overall, the current evidence does not allow definitive conclusions to be made about the effect and safety of leukotriene inhibitors in infants and young children with bronchiolitis.']",9,0.7647058823529411,4,17
CD010636,1,13,"The quality of the evidence was low due to inconsistency (unexplained high levels of statistical heterogeneity) and imprecision arising from small sample sizes and wide confidence intervals, which did not rule out a null effect or harm.",rephrase,"['We assessed the quality of the evidence for length of hospital stay and clinical severity score as low due to inconsistency and imprecision arising from small sample sizes and wide confidence intervals, which did not rule out no effect or harm.']",10,0.8235294117647058,5,17
CD010636,1,14,Data on symptom-free days and incidence of recurrent wheezing were from single studies only.,delete,[],11,0.8823529411764706,5,17
CD010636,1,15,Further large studies are required.,delete,[],11,0.9411764705882353,5,17
CD010636,1,16,"We identified one registered ongoing study, which may make a contribution in the updates of this review.",delete,[],11,1.0,5,17
CD004920,0,0,We included 22 studies (total of 2761 participants).,rephrase,['We included 22 randomized controlled trials (RCTs) (total of 2761 participants).'],0,0.038461538461538464,1,26
CD004920,0,1,"Of those 22 studies, 12 were included in the original published review and 10 were newly identified.",delete,[],1,0.07692307692307693,1,26
CD004920,0,2,Eleven trials compared the use of fluconazole to placebo or no antifungal treatment.,ignore,['Eleven trials compared the use of fluconazole to placebo or no antifungal treatment.'],1,0.11538461538461539,1,26
CD004920,0,3,Three trials compared ketoconazole versus placebo.,ignore,['Three trials compared ketoconazole versus placebo.'],2,0.15384615384615385,1,26
CD004920,0,4,One trial compared anidulafungin with placebo.,ignore,['One trial compared anidulafungin with placebo.'],3,0.19230769230769232,1,26
CD004920,0,5,One trial compared caspofungin to placebo.,ignore,['One trial compared caspofungin to placebo.'],4,0.23076923076923078,2,26
CD004920,0,6,Two trials compared micafungin to placebo.,ignore,['Two trials compared micafungin to placebo.'],5,0.2692307692307692,2,26
CD004920,0,7,One trial compared amphotericin B to placebo.,ignore,['One trial compared amphotericin B to placebo.'],6,0.3076923076923077,2,26
CD004920,0,8,"Two trials compared nystatin to placebo and one trial compared the effect of clotrimazole, ketoconazole, nystatin and no treatment.",ignore,"['Two trials compared nystatin to placebo and one trial compared the effect of clotrimazole, ketoconazole, nystatin and no treatment.']",7,0.34615384615384615,2,26
CD004920,0,9,We found two new ongoing studies and four new studies awaiting classification.,delete,[],8,0.38461538461538464,2,26
CD004920,0,10,"The RCTs included participants of both genders with wide age range, severity of critical illness and clinical characteristics.",rephrase,['The RCTs included participants of both genders with a wide age range and severity of critical illness.'],8,0.4230769230769231,3,26
CD004920,0,11,Funding sources from pharmaceutical companies were reported in 11 trials and one trial reported funding from a government agency.,rephrase,['Funding sources from drug manufacturers were reported in 11 out of 22 studies.'],9,0.46153846153846156,3,26
CD004920,0,12,"Most of the studies had an overall unclear risk of bias for key domains of this review (random sequence generation, allocation concealment, incomplete outcome data).",delete,[],10,0.5,3,26
CD004920,0,13,Two studies had a high risk of bias for key domains.,delete,[],10,0.5384615384615384,3,26
CD004920,0,14,"Regarding the other domains (blinding of participants and personnel, outcome assessment, selective reporting, other bias), most of the studies had a low or unclear risk but four studies had a high risk of bias.",delete,[],10,0.5769230769230769,3,26
CD004920,1,15,"There was moderate grade evidence that untargeted antifungal treatment did not significantly reduce or increase total (all-cause) mortality (RR 0.93, 95% CI 0.79 to 1.09, P value = 0.36; participants = 2374; studies = 19).",rephrase,['Results of 19 from 22 randomized trials involved 2374 participants and showed that antifungal medications given before definitive diagnosis of fungal infection did not reduce mortality from all causes.'],10,0.6153846153846154,4,26
CD004920,1,16,"With regard to the outcome of proven invasive fungal infection, there was low grade evidence that untargeted antifungal treatment significantly reduced the risk (RR 0.57, 95% CI 0.39 to 0.83, P value = 0.0001; participants = 2024; studies = 17).",rephrase,"['However, results from 17 randomized studies involving 2024 participants showed that antifungal drugs significantly reduced the risk of developing invasive fungal infections.']",11,0.6538461538461539,4,26
CD004920,1,17,"The risk of fungal colonization was significantly reduced (RR 0.71, 95% CI 0.52 to 0.97, P value = 0.03; participants = 1030; studies = 12) but the quality of evidence was low.",delete,[],12,0.6923076923076923,4,26
CD004920,1,18,"There was no difference in the risk of developing superficial fungal infection (RR 0.69, 95% CI 0.37 to 1.29, P value = 0.24; participants = 662; studies = 5; low grade of evidence) or in adverse events requiring cessation of treatment between the untargeted treatment group and the other group (RR 0.89, 95% CI 0.62 to 1.27, P value = 0.51; participants = 1691; studies = 11; low quality of evidence).",rephrase,['We also reviewed the evidence from five trials (662 participants) about the effect of antifungal treatment on the development of superficial fungal infections but we did not find any significant difference.'],12,0.7307692307692307,4,26
CD004920,1,19,The quality of evidence for the outcome of total (all-cause) mortality was moderate due to limitations in study design.,ignore,['The quality of evidence for the outcome of mortality (all-cause) was moderate due to limitations in study design.'],13,0.7692307692307693,4,26
CD004920,1,20,"The quality of evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization and adverse events requiring cessation of therapy was low due to limitations in study design, non-optimal total population size, risk of publication bias, and heterogeneity across studies.",rephrase,"['The quality of evidence for the outcome of invasive fungal infection, superficial fungal infection, fungal colonization and adverse events requiring cessation of therapy was low due to limitations in study design, non-optimal total number of patients studied and results inconsistent across studies.']",14,0.8076923076923077,5,26
CD004920,2,21,"There is moderate quality evidence that the use of untargeted antifungal treatment is not associated with a significant reduction in total (all-cause) mortality among critically ill, non-neutropenic adults and children compared to no antifungal treatment or placebo.",rephrase,['There is moderate quality evidence that the use of antifungal treatment given before definitive diagnosis of fungal infection is not associated with a significant reduction in mortality from all causes among critically ill adults and children with a normal number of neutrophils in the blood.'],15,0.8461538461538461,5,26
CD004920,2,22,"The untargeted antifungal treatment may be associated with a reduction of invasive fungal infections but the quality of evidence is low, and both the heterogeneity and risk of publication bias is high.",rephrase,['This type of antifungal treatment may be associated with a reduction of invasive fungal infections but the quality of evidence on this point is low.'],16,0.8846153846153846,5,26
CD004920,3,23,"Further high-quality RCTs are needed to improve the strength of the evidence, especially for more recent and less studied drugs (e.g. echinocandins).",rephrase,['Further studies with high-quality design are needed to improve the evidence.'],17,0.9230769230769231,5,26
CD004920,3,24,"Future trials should adopt standardized definitions for microbiological outcomes (e.g. invasive fungal infection, colonization) to reduce heterogeneity.",delete,[],18,0.9615384615384616,5,26
CD004920,3,25,Emergence of resistance to antifungal drugs should be considered as outcome in studies investigating the effects of untargeted antifungal treatment to balance risks and benefit.,delete,[],18,1.0,5,26
CD007457,0,0,We included four randomised controlled trials involving 1933 participants.,delete,[],0,0.0625,1,16
CD007457,1,1,"For the primary outcome category of health, there was moderate quality evidence from one study that women who received prenatal support via mobile phone messages had significantly higher satisfaction than those who did not receive the messages, both in the antenatal period (mean difference (MD) 1.25, 95% confidence interval (CI) 0.78 to 1.72) and perinatal period (MD 1.19, 95% CI 0.37 to 2.01).",rephrase,"['There was moderate quality evidence from one study which showed that pregnant women who received supportive, informative text messages experienced higher satisfaction and confidence, and lower anxiety levels in the antenatal period than women who did not receive these.']",0,0.125,1,16
CD007457,1,2,"Their confidence level was also higher (MD 1.12, 95% CI 0.51 to 1.73) and anxiety level was lower (MD -2.15, 95% CI -3.42 to -0.88) than in the control group in the antenatal period.",delete,[],1,0.1875,1,16
CD007457,1,3,"In this study, no further differences were observed between groups in the perinatal period.",delete,[],1,0.25,2,16
CD007457,1,4,"There was low quality evidence that the mobile phone messaging intervention did not affect pregnancy outcomes (gestational age at birth, infant birth weight, preterm delivery and route of delivery).",rephrase,['There was low quality evidence that there was no difference in pregnancy outcomes.'],1,0.3125,2,16
CD007457,2,5,"For the primary outcome category of health behaviour, there was moderate quality evidence from one study that mobile phone message reminders to take vitamin C for preventive reasons resulted in higher adherence (risk ratio (RR) 1.41, 95% CI 1.14 to 1.74).",delete,[],2,0.375,2,16
CD007457,2,6,"There was high quality evidence from another study that participants receiving mobile phone messaging support had a significantly higher likelihood of quitting smoking than those in a control group at 6 weeks (RR 2.20, 95% CI 1.79 to 2.70) and at 12 weeks follow-up (RR 1.55, 95% CI 1.30 to 1.84).",rephrase,"['We found one trial that provided high quality evidence that regular support messages sent by text message can help people to quit smoking, at least in the short-term.']",2,0.4375,3,16
CD007457,2,7,"At 26 weeks, there was only a significant difference between groups if, for participants with missing data, the last known value was carried forward.",delete,[],3,0.5,3,16
CD007457,2,8,"There was very low quality evidence from one study that mobile phone messaging interventions for self-monitoring of healthy behaviours related to childhood weight control did not have a statistically significant effect on physical activity, consumption of sugar-sweetened beverages or screen time.",split,"['One study assessing whether mobile phone messaging promoted use of preventive medication reported moderate quality evidence of higher self-reported adherence by people receiving the messages.', 'A fourth study on healthy behaviours in children found very low quality evidence showing that the interventions had no effect.']",3,0.5625,3,16
CD007457,3,9,"For the secondary outcome of acceptability, there was very low quality evidence from one study that user evaluation of the intervention was similar between groups.",rephrase,"[""There was very low quality evidence from one study that people's evaluation of the intervention was similar between groups.""]",5,0.625,4,16
CD007457,3,10,"There was moderate quality evidence from one study of no difference in adverse effects of the intervention, measured as rates of pain in the thumb or finger joints, and car crash rates.",ignore,"['There was moderate quality evidence from one study of no difference in harms of the intervention, measured as rates of pain in the thumb or finger joints, and car crash rates.']",6,0.6875,4,16
CD007457,4,11,None of the studies reported the secondary outcomes of health service utilisation or costs of the intervention.,rephrase,['There were no studies reporting outcomes related to health service utilisation or costs.'],7,0.75,4,16
CD007457,5,12,"We found very limited evidence that in certain cases mobile phone messaging interventions may support preventive health care, to improve health status and health behaviour outcomes.",rephrase,"['Although we find that, overall, mobile phone messaging can be helpful for some aspects of preventive health care, much is not yet known about the long-term effects or potential negative consequences.']",8,0.8125,5,16
CD007457,5,13,"However, because of the low number of participants in three of the included studies, combined with study limitations of risk of bias and lack of demonstrated causality, the evidence for these effects is of low to moderate quality.",delete,[],9,0.875,5,16
CD007457,5,14,The evidence is of high quality only for interventions aimed at smoking cessation.,delete,[],9,0.9375,5,16
CD007457,5,15,"Furthermore, there are significant information gaps regarding the long-term effects, risks and limitations of, and user satisfaction with, such interventions.",delete,[],9,1.0,5,16
CD004563,0,0,"We included six randomised controlled trials with moderate or high risk of bias, involving 2123 participants.",delete,[],0,0.1111111111111111,1,9
CD004563,0,1,"There is moderate quality evidence that involving consumers in the development of patient information material results in material that is more relevant, readable and understandable to patients, without affecting their anxiety.",ignore,"['There is moderate quality evidence from two trials that involving consumers in the development of patient information material results in material that is more relevant, readable and understandable, without affecting anxiety.']",0,0.2222222222222222,2,9
CD004563,0,2,This 'consumer-informed' material can also improve patients' knowledge.,ignore,"[""This 'consumer-informed' material can also improve knowledge.""]",1,0.3333333333333333,2,9
CD004563,0,3,There is low quality evidence that using consumer interviewers instead of staff interviewers in satisfaction surveys can have a small influence on the survey results.,rephrase,"['Two trials, which compared using consumer interviewers with staff interviewers as data collectors for patient satisfaction surveys, found small differences in satisfaction survey results, with less favourable results obtained when consumers were the interviewers.']",2,0.4444444444444444,3,9
CD004563,0,4,There is low quality evidence that an informed consent document developed with consumer input (potential trial participants) may have little if any impact on understanding compared to a consent document developed by trial investigators only.,rephrase,"['One trial comparing two informed consent documents, one developed with consumer input and the other developed by the trial investigators, showed that consumer input may have little if any impact on understanding of the trial described in the consent document.']",3,0.5555555555555556,3,9
CD004563,0,5,There is very low quality evidence that telephone discussions and face-to-face group meetings engage consumers better than mailed surveys in order to set priorities for community health goals.,rephrase,"['One trial, comparing two different methods for involving the public (telephone discussion and a face-to-face group meeting), showed that a face-to-face meeting is most likely to engage consumers and may result in different community health priorities.']",4,0.6666666666666666,4,9
CD004563,0,6,They also result in different priorities being set for these goals.,delete,[],5,0.7777777777777778,4,9
CD004563,1,7,There is little evidence from randomised controlled trials of the effects of consumer involvement in healthcare decisions at the population level.,merge,['This review shows that little research has been done to find the best ways of involving consumers in healthcare decisions at the population level.'],5,0.8888888888888888,5,9
CD004563,1,8,The trials included in this review demonstrate that randomised controlled trials are feasible for providing evidence about the effects of involving consumers in these decisions.,none,[],5,1.0,5,9
CD006559,0,0,"We included 13 studies: one cluster randomised controlled trial (CRCT) and 12 ITS studies, involving 40 hospitals, 51 intensive care units (ICUs), 27 wards, and more than 3504 patients and 1406 healthcare professionals.",rephrase,"['We identified 13 studies: one cluster randomised controlled trial (CRCT) and 12 interrupted time series (ITS) studies, involving 40 hospitals, 51 intensive care units (ICUs), 27 wards and more than 1406 healthcare professionals and 3504 patients, which assessed the impact of different interventions to reduce the occurrence of device-related infections for inclusion in this review.']",0,0.08333333333333333,1,12
CD006559,0,1,"Six of the included studies targeted adherence to guidelines to prevent central line-associated blood stream infections (CLABSIs); another six studies targeted adherence to guidelines to prevent ventilator-associated pneumonia (VAP), and one study focused on interventions to improve urinary catheter practices.",delete,[],1,0.16666666666666666,1,12
CD006559,0,2,We judged all included studies to be at moderate or high risk of bias.,rephrase,['We judged all studies to be at moderate to high risk of bias.'],1,0.25,2,12
CD006559,1,3,The largest median effect on rates of VAP was found at nine months follow-up with a decrease of 7.36 (-10.82 to 3.14) cases per 1000 ventilator days (five studies and 15 sites).,delete,[],2,0.3333333333333333,2,12
CD006559,1,4,"The one included cluster randomised controlled trial (CRCT) observed, improved urinary catheter practices five weeks after the intervention (absolute difference 12.2 percentage points), however, the statistical significance of this is unknown given a unit of analysis error.",delete,[],2,0.4166666666666667,3,12
CD006559,1,5,"It is worth noting that N = 6 interventions that did result in significantly decreased infection rates involved more than one active intervention, which in some cases, was repeatedly administered over time, and further, that one intervention involving specialised oral care personnel showed the largest step change (-22.9 cases per 1000 ventilator days (standard error (SE) 4.0), and also the largest slope change (-6.45 cases per 1000 ventilator days (SE 1.42, P = 0.002)) among the included studies.",delete,[],2,0.5,3,12
CD006559,1,6,"We attempted to combine the results for studies targeting the same indwelling medical device (central line catheters or mechanical ventilators) and reporting the same outcomes (CLABSI and VAP rate) in two separate meta-analyses, but due to very high statistical heterogeneity among included studies (I2 up to 97%), we did not retain these analyses.",delete,[],2,0.5833333333333334,3,12
CD006559,1,7,Six of the included studies reported post-intervention adherence scores ranging from 14% to 98%.,rephrase,['The results of six studies that reported adherence/non-adherence with infection control recommendations showed very varying adherence scores ranging from 14% to 98%.'],2,0.6666666666666666,4,12
CD006559,1,8,"The effect on rates of infection were mixed and the effect sizes were small, with the largest median effect for the change in level (interquartile range (IQR)) for the six CLABSI studies being observed at three months follow-up was a decrease of 0.6 (-2.74 to 0.28) cases per 1000 central line days (six studies and 36 sites).",rephrase,"['The effect sizes were small with the largest median effect for studies addressing central line associated blood stream infections (CLABSIs) occurring immediately after the implementation of an intervention to improve adherence to guidelines, in the majority of studies this change was not sustained over longer follow-up times.']",3,0.75,4,12
CD006559,1,9,This change was not sustained over longer follow-up times.,rephrase,['The median effect for studies aiming to reduce ventilator-associated pneumonia (VAP) was somewhat greater and was sustained up to 12 months follow-up.'],4,0.8333333333333334,5,12
CD006559,2,10,The low to very low quality of the evidence of studies included in this review provides insufficient evidence to determine with certainty which interventions are most effective in changing professional behaviour and in what contexts.,ignore,['The low to very low quality of the evidence of the studies included in this review provides insufficient evidence to determine with certainty which interventions are most effective in changing professional behaviour and in what contexts.'],5,0.9166666666666666,5,12
CD006559,2,11,"However, interventions that may be worth further study are educational interventions involving more than one active element and that are repeatedly administered over time, and interventions employing specialised personnel, who are focused on an aspect of care that is supported by evidence e.g. dentists/dental auxiliaries performing oral care for VAP prevention.",ignore,"['However, interventions that may be worth further study are educational interventions consisting of more than one active element and that are repeatedly administered over time, and interventions employing dedicated personnel, who are focused on a certain aspect of care that is supported by evidence e.g. dentists/dental auxiliaries providing oral care.']",6,1.0,5,12
CD009834,0,0,"In this review update, we added one study with 219 children.",rephrase,['This review update (up to 26 August 2016) includes two clinical trials that compared antibiotics with placebo for children in the post-acute bronchiolitis phase (> 14 days).'],0,0.09090909090909091,1,11
CD009834,0,1,A total of two RCTs with 249 children (n = 240 completed) were eligible for inclusion in this review.,rephrase,['This review update includes a total of two trials with 249 children (n = 240 completed).'],1,0.18181818181818182,1,11
CD009834,0,2,"Both studies contributed to our primary and secondary outcomes, but we assessed the quality of evidence for our three primary outcomes as low, owing to the small numbers of studies and participants; and high attrition in one of the studies.",rephrase,"['Both studies contributed to primary and secondary outcomes, but the quality of evidence was low.']",2,0.2727272727272727,2,11
CD009834,0,3,"Data show no significant differences between treatment groups for our primary outcomes: proportion of children (n = 249) who had persistent symptoms at follow-up (odds ratio (OR) 0.69, 95% confidence interval (CI) 0.37 to 1.28; fixed-effect model); and number of children (n = 240) rehospitalised with respiratory illness within six months (OR 0.54, 95% CI 0.05 to 6.21; random-effects model).",delete,[],3,0.36363636363636365,2,11
CD009834,0,4,We were unable to analyse exacerbation rate because studies used different methods to report this information.,delete,[],3,0.45454545454545453,3,11
CD009834,0,5,"Data showed no significant differences between treatment groups for our secondary outcome: proportion of children (n = 240) with wheeze at six months (OR 0.47, 95% CI 0.06 to 3.95; random-effects model).",rephrase,"['Review authors noted no significant differences between treatment groups for our primary outcomes: proportion of children (n = 249) who had persistent symptoms at follow-up, and number of children (n = 240) rehospitalised with respiratory illness within six months; nor for our secondary outcome: proportion of children (n = 240) with wheeze at six months.']",3,0.5454545454545454,3,11
CD009834,0,6,"One study reported bacterial resistance, but only at 48 hours (thus with limited applicability for this review).",rephrase,"['One study reported bacterial resistance, but only at 48 hours.']",4,0.6363636363636364,4,11
CD009834,0,7,Another study reported adverse events from which all children recovered and remained in the study.,ignore,['One study reported adverse events from which all children recovered and remained in the study.'],5,0.7272727272727273,4,11
CD009834,1,8,Current evidence is insufficient to inform whether antibiotics should be used to treat or prevent persistent respiratory symptoms in the post-acute bronchiolitis phase.,rephrase,"['Currently, not enough evidence is available to inform whether antibiotics should be used to treat or prevent persistent respiratory symptoms in the post-acute phase of bronchiolitis.']",6,0.8181818181818182,5,11
CD009834,1,9,Future RCTs are needed to evaluate the efficacy of antibiotics for reducing persistent respiratory symptoms.,merge,"['Clinical trials are needed to evaluate the efficacy of antibiotics for reducing persistent respiratory symptoms, especially in countries where morbidity of bronchiolitis is high (e.g. indigenous populations).']",7,0.9090909090909091,5,11
CD009834,1,10,"This is particularly important in populations with high acute and post-acute bronchiolitis morbidity (e.g. indigenous populations in Australia, New Zealand, and the USA).",none,[],7,1.0,5,11
CD001902,0,0,"Five trials were included in this review, representing 924 randomised children with epilepsy, all under 16 years of age at randomisation, with a median follow-up of 5.6 years.",rephrase,"['The same five trials were included in our analysis, comprising 924 epileptic children (all below 16 years old) who were randomly assigned to either early removal of AEDs (before completing two years without seizures); or late withdrawal of AEDs (after completing two years without seizures).']",0,0.07692307692307693,1,13
CD001902,0,1,No eligible trial evaluated adults or assessed mortality or status epilepticus as outcomes.,delete,[],1,0.15384615384615385,1,13
CD001902,0,2,"The pooled risk ratio for seizure relapse after AED withdrawal was 1.34 (95% CI 1.13 to 1.59, P = 0.0007).",rephrase,"['Considering all evidence, we found that stopping AED intake before completing two years without seizures increases the risk of seizure relapse by around 34%.']",1,0.23076923076923078,2,13
CD001902,0,3,"Conforming to this estimate, the number needed to harm, that is expose an individual to a higher risk of seizure relapse because of early withdrawal of AED, is 8 (95% CI 5 to 20).",delete,[],2,0.3076923076923077,2,13
CD001902,0,4,"Early discontinuation was associated with greater relapse rates in people with partial seizures with a pooled risk ratio of 1.51 (95% CI 0.97 to 2.35, P = 0.07).",delete,[],2,0.38461538461538464,2,13
CD001902,0,5,Absence type epilepsy showed a lower risk of relapse.,delete,[],2,0.46153846153846156,3,13
CD001902,0,6,"Variables associated with higher risk of seizure relapse were abnormal EEG findings (pooled RR 1.44, 95% CI 1.13 to 1.83, P = 0.003), especially epileptiform activity (RR 2.58, 95% CI 2.03 to 3.28, P < 0.0001); epilepsy onset before 2 years or after 10 years of age; history of status epilepticus; intellectual disability (IQ < 70); and high seizure frequency before and during treatment.",delete,[],2,0.5384615384615384,3,13
CD001902,0,7,Gender and family history did not show any significant influence over seizure relapse.,delete,[],2,0.6153846153846154,4,13
CD001902,0,8,"Overall, the included trials were classified as low or unclear risk of bias where methodological information was not reported and could not be provided by original study authors.",rephrase,"['Overall, the included trials provided a moderate quality of evidence.']",2,0.6923076923076923,4,13
CD001902,1,9,"There is evidence to support waiting for at least two seizure-free years before discontinuing AEDs in children, particularly if individuals have an abnormal EEG or partial seizures, or both.",rephrase,"['The review of trials found that there is evidence to support waiting at least two years or more seizure free before discontinuing AEDs in children, especially if they had partial seizures or abnormal EEG.']",3,0.7692307692307693,4,13
CD001902,1,10,There is insufficient evidence to establish when to withdraw AEDs in children with generalised seizures.,rephrase,"['There is not enough evidence that demonstrates the optimal time to remove antiepileptic drugs in people (children or adults) with generalised seizures (if the electrical discharges affect the whole brain, causing global symptoms).']",4,0.8461538461538461,5,13
CD001902,1,11,There is no evidence to guide the timing of withdrawal of AEDs in seizure-free adults.,rephrase,['There is not enough evidence to show the best time to withdraw antiepileptic drugs in adults with epilepsy who are free of seizures.'],5,0.9230769230769231,5,13
CD001902,1,12,"Further high-quality randomised controlled trials are needed, particularly recruiting adults and recruiting those with generalised seizure types, to identify the optimal timing of AED withdrawal and risk factors predictive of relapse.",rephrase,"['More research is needed, particularly involving adults and those with generalised seizure types.']",6,1.0,5,13
CD009832,0,0,We included three trials involving a total of 209 participants.,rephrase,['We included a total of three trials involving 209 participants who were treated with oral zinc pills or placebo.'],0,0.0625,1,16
CD009832,0,1,The studies were at moderate to high risk of bias.,delete,[],1,0.125,1,16
CD009832,0,2,"All included studies had differences in participant selection criteria, length of follow-up and outcome measurement, precluding a meta-analysis.",rephrase,"['All three included studies had differences in their participant selection, length of follow-up and outcome measurement, which prevented a meta-analysis (combining of results).']",1,0.1875,1,16
CD009832,0,3,"The participants were all adults over 18 years with subjective tinnitus, but one study conducted in 2013 (n = 109) included only elderly patients.",rephrase,['All patients were adults over 18 years who had subjective tinnitus.'],2,0.25,2,16
CD009832,1,4,"Improvement in tinnitus severity and disability
Only the study in elderly patients used a validated instrument (Tinnitus Handicap Questionnaire) for this primary outcome.",merge,['All three studies investigated improvement in tinnitus as their primary outcome.'],3,0.3125,2,16
CD009832,1,5,"The authors of this cross-over study did not report the results of the two phases separately and found no significant differences in the proportion of patients reporting tinnitus improvement at four months of follow-up: 5% (5/93) versus 2% (2/94) in the zinc and placebo groups, respectively (risk ratio (RR) 2.53, 95% confidence interval (CI) 0.50 to 12.70; very low-quality evidence).",none,[],3,0.375,2,16
CD009832,2,6,None of the included studies reported any significant adverse effects.,rephrase,['Three cases of mild adverse effects were reported in different participants (e.g. mild gastric symptoms).'],4,0.4375,3,16
CD009832,3,7,"Secondary outcomes
For the secondary outcome change in tinnitus loudness, one study reported no significant difference between the zinc and placebo groups after eight weeks: mean difference in tinnitus loudness -9.71 dB (95% CI -25.53 to 6.11; very low-quality evidence).",delete,[],5,0.5,3,16
CD009832,3,8,Another study also measured tinnitus loudness but used a 0- to 100-point scale.,delete,[],5,0.5625,3,16
CD009832,3,9,The authors of this second study reported no significant difference between the zinc and placebo groups after four months: mean difference in tinnitus loudness rating scores 0.50 (95% CI -5.08 to 6.08; very low-quality evidence).,rephrase,['The authors reported no significant difference between the groups.'],5,0.625,4,16
CD009832,4,10,Two studies used unvalidated instruments to assess tinnitus severity.,rephrase,['Two studies assessed change in the overall severity of tinnitus.'],6,0.6875,4,16
CD009832,4,11,"One (with 50 participants) reported the severity of tinnitus using a non-validated scale (0 to 7 points) and found no significant difference in subjective tinnitus scores between the zinc and placebo groups at the end of eight weeks of follow-up (mean difference (MD) -1.41, 95% CI -2.97 to 0.15; very low-quality evidence).",rephrase,"['Another study (2003) reported the severity of tinnitus using a non-validated scale (0 to 7) and found a significant difference in the subjective tinnitus scores, which favoured the zinc group.']",7,0.75,4,16
CD009832,4,12,A third trial (n = 50) also evaluated the improvement of tinnitus using a non-validated instrument (a 0 to 10 scale: 10 = severe and unbearable tinnitus).,rephrase,['A third study (1991) also evaluated improvement of tinnitus using a non-validated instrument (a scale of 0 to 10) and found no significant difference between groups.'],8,0.8125,5,16
CD009832,4,13,"In this study, after eight weeks there was no difference in the proportion of patients with improvement in their tinnitus, 8.7% (2/23) treated with zinc versus 8% (2/25) of those who received a placebo (RR 1.09, 95% CI 0.17 to 7.10, very low-quality evidence).",rephrase,['The quality of the evidence is very low.'],9,0.875,5,16
CD009832,5,14,"None of the included studies reported any of our other secondary outcomes (quality of life, change in socioeconomic impact associated with work, change in anxiety and depression disorders, change in psychoacoustic parameters or change in thresholds on pure tone audiometry).",delete,[],10,0.9375,5,16
CD009832,6,15,We found no evidence that the use of oral zinc supplementation improves symptoms in adults with tinnitus.,ignore,['We found no evidence that the use of oral zinc supplementation improves symptoms in adults with tinnitus.'],10,1.0,5,16
CD004877,0,0,We included 12 studies involving 1954 participants.,rephrase,"['In this updated review, we included a total of 12 studies (including five new studies), involving 1954 participants.']",0,0.125,1,8
CD004877,0,1,We identified ten studies as being of methodologically poor quality and two studies as being of medium quality.,rephrase,['We identified ten studies as being of poor methodological quality and only two studies as being of medium methodological quality.'],1,0.25,2,8
CD004877,0,2,We did not perform a meta-analysis but reported the results separately.,rephrase,['Two studies separately reported one case of diarrhoea and one case of mild nausea; two trials reported no adverse events in the treatment group; and other studies did not report any adverse events.'],2,0.375,2,8
CD004877,0,3,Six formulations were shown to be superior to the control in improving recovery: Ertong Qingyan Jiere Koufuye was more effective than Fufang Shuanghua Koufuye for acute pharyngitis (odds ratio (OR) 2.52; 95% confidence interval (Cl) 1.11 to 5.74); Yanhouling mixture  was more effective than gentamicin atomised inhalation for acute pharyngitis (OR 5.39; 95% CI 2.69 to 10.81); Qinganlan Liyan Hanpian was more effective than Fufang Caoshanhu Hanpian for acute pharyngitis (OR 2.25; 95% CI 1.08 to 4.67); sore throat capsules were more effective than antibiotics (intravenous cefalexin) for acute pharyngitis or acute tonsillitis (OR 2.36; 95% CI 1.01 to 5.51); compound dandelion soup was more effective than sodium penicillin for acute purulent tonsillitis (OR 5.06; 95% CI 1.70 to 15.05); and eliminating heat by nourishing yin and relieving sore-throat methods combined with Dikuiluqan Hanpian was more effective than Dikuiluqan Hanpian alone for children with chronic pharyngitis (OR 2.63; 95% CI 1.02 to 6.79).,delete,[],3,0.5,3,8
CD004877,0,4,Another six formulations were shown to be equally efficacious as the control.,delete,[],3,0.625,4,8
CD004877,1,5,"Based on the existing evidence in this review, some Chinese herbal medicines for treating sore throat appeared efficacious.",delete,[],3,0.75,4,8
CD004877,1,6,"However, due to the lack of high quality clinical trials, the efficacy of Chinese herbal medicine for treating sore throat is controversial and questionable.",delete,[],3,0.875,5,8
CD004877,1,7,Therefore we cannot recommend any kind of Chinese medical herbal formulation as an effective remedy for sore throat.,split,"['Chinese medicinal herbs may be the treatment choice for sore throat, but we cannot recommend any particular preparation or formulation over another as we did not find any well-designed studies to provide strong evidence to conclusively support or reject the use of Chinese traditional herbal medicines in the treatment of sore throat.', 'Enhancing the quality of research into Chinese medicinal herbs for sore throat is imperative, and stronger evidence from high quality, randomised controlled trials (RCTs) are needed.']",3,1.0,5,8
CD006930,0,0,A total of 1092 participants randomly assigned to the low pressure group (509 participants) and the standard pressure group (583 participants) in 21 trials provided information for this review on one or more outcomes.,split,"['A total of 1092 patients were studied in 21 trials.', 'Patients were assigned to a low pressure group (509 patients) or a standard pressure group (583 patients).']",0,0.0625,1,16
CD006930,0,1,Three additional trials comparing low pressure pneumoperitoneum with standard pressure pneumoperitoneum (including 179 participants) provided no information for this review.,delete,[],2,0.125,1,16
CD006930,0,2,Most of the trials included low anaesthetic risk participants undergoing elective laparoscopic cholecystectomy.,rephrase,['Most of the trials included low surgical risk patients undergoing planned laparoscopic cholecystectomy.'],2,0.1875,1,16
CD006930,0,3,One trial including 140 participants was at low risk of bias.,rephrase,['Only one trial including 140 participants was at low risk of bias (low chance of arriving at wrong conclusions because of study design).'],3,0.25,2,16
CD006930,0,4,The remaining 20 trials were at high risk of bias.,rephrase,['The remaining 20 trials were at high risk of bias (high chance of arriving at wrong conclusions because of trial design).'],4,0.3125,2,16
CD006930,0,5,The overall quality of evidence was low or very low.,ignore,['The overall quality of evidence was very low.'],5,0.375,2,16
CD006930,0,6,No mortality was reported in either the low pressure group (0/199; 0%) or the standard pressure group (0/235; 0%) in eight trials that reported mortality.,rephrase,['No deaths were reported in either low pressure or standard pressure groups in eight trials that reported deaths (total of 434 patients in both groups).'],6,0.4375,3,16
CD006930,0,7,"One participant experienced the outcome of serious adverse events (low pressure group 1/179, 0.6%; standard pressure group 0/215, 0%; seven trials; 394 participants; RR 3.00; 95% CI 0.14 to 65.90; very low quality evidence).",rephrase,"['One participant experienced the outcome of serious adverse events (low pressure group 1/179, 0.6%; standard pressure group 0/215, 0%).']",7,0.5,3,16
CD006930,0,8,"Quality of life, return to normal activity, and return to work were not reported in any of the trials.",ignore,"['Quality of life, return to normal activity, and return to work were not reported in any of the trials.']",8,0.5625,3,16
CD006930,0,9,"The difference between groups in the conversion to open cholecystectomy was imprecise (low pressure group 2/269, adjusted proportion 0.8%; standard pressure group 2/287, 0.7%; 10 trials; 556 participants; RR 1.18; 95% CI 0.29 to 4.72; very low quality evidence) and was compatible with an increase, a decrease, or no difference in the proportion of conversion to open cholecystectomy due to low pressure pneumoperitoneum.",rephrase,['The difference in the percentage of people undergoing conversion to open operation (from key-hole operation) between the low pressure group (2/269; 0.8%) and the standard pressure group (2/287; 0.7%) was imprecise.'],9,0.625,4,16
CD006930,0,10,No difference in the length of hospital stay was reported between the groups (five trials; 415 participants; MD -0.30 days; 95% CI -0.63 to 0.02; low quality evidence).,rephrase,['No difference was noted in the length of hospital stay between the groups.'],10,0.6875,4,16
CD006930,0,11,Operating time was about two minutes longer in the low pressure group than in the standard pressure group (19 trials; 990 participants; MD 1.51 minutes; 95% CI 0.07 to 2.94; very low quality evidence).,rephrase,['Operating time was about two minutes longer (very low quality evidence) in the low pressure group than in the standard pressure group.'],11,0.75,4,16
CD006930,1,12,Laparoscopic cholecystectomy can be completed successfully using low pressure in approximately 90% of people undergoing laparoscopic cholecystectomy.,merge,[],12,0.8125,5,16
CD006930,1,13,"However, no evidence is currently available to support the use of low pressure pneumoperitoneum in low anaesthetic risk patients undergoing elective laparoscopic cholecystectomy.",none,['Currently no evidence is available to support the use of low pressure pneumoperitoneum in low surgical risk patients undergoing planned laparoscopic cholecystectomy.'],12,0.875,5,16
CD006930,1,14,The safety of low pressure pneumoperitoneum has to be established.,ignore,['The safety of low pressure pneumoperitoneum has to be established.'],13,0.9375,5,16
CD006930,1,15,"Further well-designed trials are necessary, particularly in people with cardiopulmonary disorders who undergo laparoscopic cholecystectomy.",delete,[],14,1.0,5,16
CD007166,0,0,"Forty-four eligible trials, involving 8436 participants were identified.",rephrase,"['Forty-four randomised trials, involving 8436 participants were identified as suitable for this review.']",0,0.1,1,10
CD007166,0,1,"Compared to placebo, adjuvant therapy significantly reduced off-time (-1.05 hours/day, 95% confidence interval (CI) -1.19 to -0.90; P<0.00001), the required levodopa dose (-55.65 mg/day, CI -62.67 to -48.62; P<0.00001) and improved UPDRS scores (UPDRS ADL score: -1.31 points, CI -1.62 to -0.99; P<0.00001; UPDRS motor score: -2.84 points, CI -3.36 to -2.32; P<0.00001; UPDRS total score: -3.26 points, CI -4.52 to -2.00; P<0.00001).",delete,[],1,0.2,1,10
CD007166,0,2,"However, dyskinesia (odds ratio (OR) 2.50, CI 2.21 to 2.84; P<0.00001) and side-effects including constipation (OR 3.19, CI 2.17 to 4.68; P<0.00001), dizziness (OR 1.57, CI 1.30 to 1.90; P<0.00001), dry mouth (OR 2.33, CI 1.22 to 4.47; P=0.01), hallucinations (OR 2.16, CI 1.70 to 2.74; P<0.00001), hypotension (OR 1.47, CI 1.18 to 1.83; P=0.0007), insomnia (OR 1.38, CI 1.09 to 1.74; P=0.007), nausea (OR 1.78, CI 1.53 to 2.07; P<0.00001), somnolence (OR 1.87, CI 1.40 to 2.51; P<0.0001) and vomiting (OR 2.56, CI 1.67 to 3.93; P<0.0001) were all increased with adjuvant therapy.",delete,[],1,0.3,2,10
CD007166,1,3,Indirect comparisons of the three drug classes suggested that dopamine agonists were more efficacious in reducing off-time (dopamine agonist: -1.54 hours/day; COMTI: -0.83 hours/day; MAOBI: -0.93 hours/day; test for heterogeneity between drug classes P=0.0003) and levodopa dose (dopamine agonist: -116 mg/day; COMTI: -52 mg/day; MAOBI: -29 mg/day; test for heterogeneity between drug classes P<0.00001).,delete,[],1,0.4,2,10
CD007166,1,4,"UPDRS scores also improved more with dopamine agonists than with COMTI or MAOBI (UPDRS total scores - dopamine agonist: -10.01 points versus COMTI: -1.46 points versus MAOBI: -2.20 points; test for heterogeneity between drug classes P<0.00001), although more dyskinesia were seen with dopamine agonists (OR 2.70) and COMTI (OR 2.50) than with MAOBI (OR 0.94) (test for heterogeneity between drug classes P=0.009).",delete,[],1,0.5,3,10
CD007166,1,5,"Although the increase in the overall incidence of side-effects was generally more marked with dopamine agonists (OR 1.52) and COMTI (OR 2.0) than with MAOBI (OR 1.32), heterogeneity between drug classes was only of borderline significance (P=0.07).",delete,[],1,0.6,3,10
CD007166,2,6,"Compared to placebo, adjuvant therapy reduces off-time, levodopa dose, and improves UPDRS scores in PD patients who develop motor complications on levodopa therapy.",rephrase,"[""The review confirms reports from individual trials that, compared to placebo, add-on therapy (on a background of levodopa) significantly reduces patient off-time, reduces the required levodopa dose and improves overall disability scores (measured on the Unified Parkinson's Disease Rating Scale - UPDRS).""]",1,0.7,4,10
CD007166,2,7,"However, this is at the expense of increased dyskinesia and numerous other side-effects.",rephrase,"['However, dyskinesia and other side-effects such as constipation, hallucinations and vomiting are increased with adjuvant therapy.']",2,0.8,4,10
CD007166,2,8,"Indirect comparisons suggest that dopamine agonist therapy may be more effective than COMTI and MAOBI therapy, which have comparable efficacy.",split,"['Indirect comparisons of the three drug classes (dopamine agonists, COMTIs and MAOBIs) suggest that dopamine agonists may provide more effective symptomatic control than COMTI and MAOBI therapy.', 'COMTI and MAOBI have comparable efficacy.']",3,0.9,5,10
CD007166,2,9,"However, as indirect comparisons should be interpreted with caution, direct head-to-head randomised trials assessing the impact of these different drug classes on overall patient-rated quality of life are needed.",rephrase,"['However these observations are based on indirect comparisons between trials, so could be due to other factors, e.g. differences in the types of people included in the trials, and so should to be interpreted with caution.']",5,1.0,5,10
CD004808,0,0,"We included thirty trials, all conducted in high income countries, involving 4691 participants.",rephrase,"['We found 30 trials involving 4691 participants, examining several types of contracts.']",0,0.14285714285714285,1,7
CD004808,0,1,Median sample size per group was 21.,delete,[],1,0.2857142857142857,2,7
CD004808,0,2,"We examined the quality of each trial against eight standard criteria, and all trials were inadequate in relation to three or more of these standards.",delete,[],1,0.42857142857142855,3,7
CD004808,0,3,"Trials evaluated contracts in addiction (10 trials), hypertension (4 trials), weight control (3 trials) and a variety of other areas (13 trials).",rephrase,"['The main health problems targeted were substance addictions, hypertension and overweight.']",1,0.5714285714285714,3,7
CD004808,0,4,"Fifteen trials reported at least one outcome that showed statistically significant differences favouring the contracts group, six trials reported at least one outcome that showed differences favouring the control group and 26 trials reported at least one outcome without differences between groups.",split,"['In 15 of the trials there was at least one outcome showing statistically significant differences in favour of the contracts group (although some of the improvements in adherence did not remain when measured after a longer period).', 'In six trials at least one outcome showed such differences in favour of the control group.', 'In 26 trials there was at least one outcome for which there was no difference between the contract and control groups.']",2,0.7142857142857143,4,7
CD004808,0,5,Effects on adherence were not detected when measured over longer periods.,delete,[],5,0.8571428571428571,5,7
CD004808,1,6,"There is limited evidence that contracts can potentially contribute to improving adherence, but there is insufficient evidence from large, good quality studies to routinely recommend contracts for improving adherence to treatment or preventive health regimens.",rephrase,"[""There is not enough reliable evidence available to recommend the routine use of contracts in health services to improve patients' adherence to healthcare activities or other outcomes.""]",5,1.0,5,7
CD003491,0,0,"A total of 32 trials provided data for inclusion in the review in terms of efficacy, withdrawal and side effect analysis.",merge,[],0,0.125,1,8
CD003491,0,1,We were unable to find any differences in efficacy when comparing classes of antidepressants.,none,"['This review compared the efficacy, withdrawal rates and side effects of different antidepressant classes in the treatment of depression in older people.']",0,0.25,2,8
CD003491,0,2,"Tricyclic antidepressants (TCAs) compared less favourably with selective serotonin reuptake inhibitors (SSRIs) in terms of numbers of patients withdrawn irrespective of reason (RR: 1.23, CI 1.05 to 1.43) and number withdrawn due to side effects (RR: 1.36, CI 1.09 to 1.70).",delete,[],1,0.375,2,8
CD003491,0,3,"Further analyses demonstrated that TCA related antidepressants had similar withdrawal rates to SSRIs irrespective of reason of withdrawal (RR: 1.49, CI 0.74 to 2.98) or withdrawal due to side effects (RR: 1.07, CI 0.43 to 2.70).",delete,[],1,0.5,3,8
CD003491,0,4,The qualitative analysis of side effects showed a small increased profile of gastro-intestinal and neuropsychiatric side effects associated with classical TCAs.,delete,[],1,0.625,4,8
CD003491,1,5,Our findings suggest that SSRIs and TCAs are of the same efficacy.,rephrase,['Our main findings indicate that tricyclic antidepressants (classical and tricyclic related) and selective serotonin reuptake inhibitors (SSRIs) are equally efficacious.'],1,0.75,4,8
CD003491,1,6,"However, we have found some evidence suggesting that TCA related antidepressants and classical TCAs have different side effect profiles and are associated with differing withdrawal rates when compared with SSRIs.",split,"['However, when comparing the two tricyclic groups with SSRIs we found that tricyclic related antidepressants were similar to SSRIs in terms of overall withdrawal rate, and classical tricyclic antidepressants were associated with a higher withdrawal rate due to side effects.', 'These findings are reflected in the differing side effect profiles when comparing both tricyclic groups with SSRIs.']",2,0.875,5,8
CD003491,1,7,"The review suggests that classical TCAs are associated with a higher withdrawal rate due to side effect experience, although these results must be interpreted with caution due to the heterogeneity of the drugs and patient populations.",rephrase,['The findings of the review must be interpreted with some caution in view of the relatively low patient numbers and lack of side effect data.'],4,1.0,5,8
CD008864,0,0,We included six RCTs with a total of 248 participants; none of the trials were determined to have overall low risk of bias.,rephrase,"['We searched the databases to August 2013, we identified six randomized trials in cardiac and elective surgical settings that compared fibrinogen concentrate (248 participants) with placebo/other sources or no treatment.']",0,0.125,1,8
CD008864,0,1,"We found 12 ongoing trials, from which we were unable to retrieve any data.",rephrase,"['Additionally, we found 12 ongoing trials, but we were unable to retrieve any data from them.']",1,0.25,2,8
CD008864,0,2,"Only two trials provided data on mortality, and one was a zero event study; thus the meta-analysis showed no statistically significant effect on overall mortality (2.6% vs 9.5%, RR 0.28, 95% CI 0.03 to 2.33).",delete,[],2,0.375,2,8
CD008864,0,3,"Our analyses on blood transfusion data suggest a beneficial effect of fibrinogen concentrate in reducing the incidence of allogenic transfusions (RR 0.47, 95% CI 0.31 to 0.72) but show no effect on other predefined outcomes, including adverse events such as thrombotic episodes.",rephrase,['We could not identify beneficial effects of fibrinogen concentrate on patient survival.'],2,0.5,3,8
CD008864,1,4,"In the six available RCTs of elective surgery, fibrinogen concentrate appears to reduce transfusion requirements, but the included trials are of low quality with high risk of bias and are underpowered to detect mortality, benefit or harm.",delete,[],3,0.625,4,8
CD008864,1,5,"Furthermore, data on mortality are lacking, heterogeneity is high and acute or severe bleeding in a non-elective surgical setting remains unexplored.",delete,[],3,0.75,4,8
CD008864,1,6,"Currently, weak evidence supports the use of fibrinogen concentrate in bleeding patients, as tested here in primarily elective cardiac surgery.",rephrase,"['However, all trials were of low quality and were small, so evidence in support of fibrinogen concentrate in patients with bleeding remains weak.']",3,0.875,5,8
CD008864,1,7,More research is urgently needed.,delete,[],4,1.0,5,8
CD011383,0,0,We included eight RCTs with 311 participants in this review.,merge,"['Eight trials including 311 participants met the inclusion criteria for the review, of whom 306 participants were included in various comparisons.']",0,0.05263157894736842,1,19
CD011383,0,1,"After exclusion of five participants, we included 306 participants in one or more outcomes.",none,[],0,0.10526315789473684,1,19
CD011383,0,2,"Five trials (240 participants) investigated the three main treatments: open necrosectomy (121 participants), minimally invasive step-up approach (80 participants), and peritoneal lavage (39 participants) and were included in the network meta-analysis.",rephrase,"['The treatments compared in five trials included necrosectomy, peritoneal lavage, and the step-up approach.']",1,0.15789473684210525,1,19
CD011383,0,3,"Three trials (66 participants) investigated the variations in the main treatments: early open necrosectomy (25 participants), delayed open necrosectomy (11 participants), video-assisted minimally invasive step-up approach (12 participants), endoscopic minimally invasive step-up approach (10 participants), minimally invasive step-up approach (planned surgery) (four participants), and minimally invasive step-up approach (continued percutaneous drainage) (four participants).",rephrase,['Three other trials compared variations in timing of necrosectomy and methods of step-up approach.'],2,0.21052631578947367,2,19
CD011383,0,4,The trials included infected or sterile necrotising pancreatitis of varied aetiology.,rephrase,['The participants in the trials had infected or sterile pancreatic necrosis resulting from varying causes.'],3,0.2631578947368421,2,19
CD011383,1,5,All the trials were at unclear or high risk of bias and the overall quality of evidence was low or very low for all the outcomes.,delete,[],4,0.3157894736842105,2,19
CD011383,1,6,"Overall, short-term mortality was 30% and serious adverse events rate was 139 serious adverse events per 100 participants.",rephrase,"['Overall, the short-term death rate (mortality over a short time) was 30% and serious adverse events (side effects or complications) rate was 139 per 100 participants.']",4,0.3684210526315789,2,19
CD011383,1,7,The differences in short-term mortality and proportion of people with serious adverse events were imprecise in all the comparisons.,ignore,['The differences in short-term mortality and percentage of people with serious adverse events were imprecise in all the comparisons.'],5,0.42105263157894735,3,19
CD011383,1,8,"The number of serious adverse events and adverse events were fewer in the minimally invasive step-up approach compared to open necrosectomy (serious adverse events: rate ratio 0.41, 95% CI 0.25 to 0.68; 88 participants; 1 study; adverse events: rate ratio 0.41, 95% CI 0.25 to 0.68; 88 participants; 1 study).",rephrase,['The number of serious adverse events and adverse events were fewer in the minimally invasive step-up approach compared to open necrosectomy.'],6,0.47368421052631576,3,19
CD011383,1,9,"The proportion of people with organ failure and the mean costs were lower in the minimally invasive step-up approach compared to open necrosectomy (organ failure: OR 0.20, 95% CI 0.07 to 0.60; 88 participants; 1 study; mean difference in costs: USD -11,922; P value < 0.05; 88 participants; 1 studies).",rephrase,['The percentage of people with organ failure and the average costs were lower in the minimally invasive step-up approach compared to open necrosectomy.'],7,0.5263157894736842,3,19
CD011383,1,10,"There were more adverse events with video-assisted minimally invasive step-up approach group compared to endoscopic-assisted minimally invasive step-up approach group (rate ratio 11.70, 95% CI 1.52 to 89.87; 22 participants; 1 study), but the number of interventions per participant was less with video-assisted minimally invasive step-up approach group compared to endoscopic minimally invasive step-up approach group (difference in medians: 2 procedures; P value < 0.05; 20 participants; 1 study).",rephrase,['The number of adverse events were more with the video-assisted minimally invasive step-up approach compared to the endoscopic-assisted minimally invasive step-up approach but the total numbers of procedures performed were less with the video-assisted minimally invasive step-up approach compared to the endoscopic minimally invasive step-up approach.'],8,0.5789473684210527,3,19
CD011383,1,11,"The differences in any of the other comparisons for number of serious adverse events, proportion of people with organ failure, number of adverse events, length of hospital stay, and intensive therapy unit stay were either imprecise or were not consistent.",ignore,"['The differences in any of the other comparisons for number of serious adverse events, percentage of people with organ failure, number of adverse events, length of hospital stay, and intensive therapy unit stay were either imprecise or were not consistent.']",9,0.631578947368421,4,19
CD011383,1,12,"None of the trials reported long-term mortality, infected pancreatic necrosis (trials that included participants with sterile necrosis), health-related quality of life at any time frame, proportion of people with adverse events, requirement for additional invasive intervention, time to return to normal activity, and time to return to work.",rephrase,"['None of the trials reported long-term mortality, infected pancreatic necrosis (in trials that included participants with sterile necrosis), health-related quality of life (which measures physical, mental, emotional, and social functioning), percentage of people with adverse events, requirement for additional invasive intervention, time to return to normal activity, and time to return to work.']",10,0.6842105263157895,4,19
CD011383,2,13,"Low to very low quality evidence suggested that the minimally invasive step-up approach resulted in fewer adverse events, serious adverse events, less organ failure, and lower costs compared to open necrosectomy.",delete,[],11,0.7368421052631579,4,19
CD011383,2,14,Very low quality evidence suggested that the endoscopic minimally invasive step-up approach resulted in fewer adverse events than the video-assisted minimally invasive step-up approach but increased the number of procedures required for treatment.,delete,[],11,0.7894736842105263,4,19
CD011383,2,15,There is currently no evidence to suggest that early open necrosectomy is superior or inferior to peritoneal lavage or delayed open necrosectomy.,delete,[],11,0.8421052631578947,5,19
CD011383,2,16,"However, the CIs were wide and significant benefits or harms of different treatments cannot be ruled out.",delete,[],11,0.8947368421052632,5,19
CD011383,2,17,The TENSION trial currently underway in Netherlands is assessing the optimal way to perform the minimally invasive step-up approach (endoscopic drainage followed by endoscopic necrosectomy if necessary versus percutaneous drainage followed by video-assisted necrosectomy if necessary) and is assessing important clinical outcomes of interest for this review.,delete,[],11,0.9473684210526315,5,19
CD011383,2,18,Implications for further research on this topic will be determined after the results of this RCT are available.,rephrase,"['As a result, further studies are required on this topic.']",11,1.0,5,19
CD007910,0,0,The literature search yielded 359 reports of which only one study was identified that met our inclusion criteria and reported relevant clinical endpoints.,delete,[],0,0.16666666666666666,1,6
CD007910,0,1,This study randomised 4110 adult participants with a functioning kidney transplant and elevated homocysteine levels to folic acid plus high dose B multivitamins or low dose multivitamins who were followed for a mean 4.0 years.,rephrase,['A single study was identified that randomised 4110 adult participants with a functioning kidney transplant to homocysteine lowering with folic acid and high dose multivitamins or to low dose multivitamins and followed them for an average of four years.'],0,0.3333333333333333,2,6
CD007910,0,2,"Despite effectively lowering homocysteine levels) in homocysteine levels at follow-up (MD -4.40 μmol/L, 95% CI -5.98 to -2.82) there was no evidence the intervention impacted on any of the outcomes reported including cardiovascular mortality (RR 0.91, 95% CI 0.69 to 1.20), all-cause mortality (RR 1.04, 95% CI 0.88 to 1.22), myocardial infarction (RR 1.02, 95% CI 0.77 to 1.35), stroke (RR 1.08, 95% CI 0.69 to 1.71), commencement of renal replacement therapy (RR 1.12, 95% CI 0.91 to 1.37) or all reported adverse events (RR 1.02, 95% CI 0.87 to 1.20).",rephrase,"['Despite effectively lowering homocysteine levels, there was no evidence of benefit for any of a range of cardiovascular events.']",1,0.5,3,6
CD007910,0,3,"There was no evidence the intervention impacted on the primary endpoint of the study, a cardiovascular event composite (RR 0.99, 95% CI 0.85 to 1.15).",delete,[],2,0.6666666666666666,4,6
CD007910,0,4,The study was of high quality.,delete,[],2,0.8333333333333334,5,6
CD007910,1,5,There is no current evidence to support the use of homocysteine lowering therapy for cardiovascular disease prevention in kidney transplant recipients.,rephrase,['The aim of this review was to determine if homocysteine lowering therapies effectively reduce cardiovascular event rates in kidney transplant recipients.'],2,1.0,5,6
CD002232,0,0,This systematic review attempted to summarise evidence from randomised clinical trials on the treatment of spontaneous bacterial peritonitis.,split,"['This review aimed to evaluate the beneficial and harmful effects of different types and modes of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients.', 'Further randomised clinical trials with an adequate design, including a large number of participants and sufficient duration should be carefully planned to provide a more precise estimate of the beneficial and harmful effects of antibiotic treatment for spontaneous bacterial peritonitis.']",0,0.125,1,8
CD002232,0,1,Thirteen studies were included; each one of them compared different antibiotics in their experimental and control groups.,ignore,['Thirteen trials were included; each one of them compared different antibiotics in their experimental and control groups.'],2,0.25,2,8
CD002232,0,2,"No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial.",ignore,"['No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial.']",3,0.375,2,8
CD002232,0,3,"Currently, the evidence showing that lower dosage or short-term treatment with third generation cephalosporins is as effective as higher dosage or long-term treatment is weak.",delete,[],4,0.5,3,8
CD002232,0,4,Oral quinolones could be considered an option for those with less severe manifestations of the disease.,delete,[],4,0.625,4,8
CD002232,1,5,This review provides no clear evidence for the treatment of cirrhotic patients with spontaneous bacterial peritonitis.,split,"['Based on the identified evidence, we cannot suggest the most appropriate management to treat spontaneous bacterial peritonitis in regard to the type, dosage, duration, or administration route of the antibiotic therapy.', 'This review found no evidence that the effect or safety of one antibiotic is more beneficial than another.']",4,0.75,4,8
CD002232,1,6,"In practice, third generation cephalosporins have already been established as the standard treatment of spontaneous bacterial peritonitis, and it is clear, that empirical antibiotic therapy should be provided in any case.",delete,[],6,0.875,5,8
CD002232,1,7,"However, until large, well-conducted trials provide more information, practice will remain based on impression, not evidence.",delete,[],6,1.0,5,8
MR000056,0,0,We included 10 RCTs with a total of 1213 units of analysis.,merge,[],0,0.07142857142857142,1,14
MR000056,0,1,"The unit of analysis was the individual reviewer in seven studies (722 reviewers in total), and the reviewed manuscript in three studies (491 manuscripts in total).",none,['We found 10 studies that involved a total of 1213 units of analysis (722 reviewers and 491 manuscripts).'],0,0.14285714285714285,1,14
MR000056,1,2,"In eight RCTs, participants were journal peer reviewers.",rephrase,['Eight studies included only journal peer reviewers.'],1,0.21428571428571427,2,14
MR000056,1,3,"In two studies, the participants were grant peer reviewers.",rephrase,['The remaining two studies included grant peer reviewers.'],2,0.2857142857142857,2,14
MR000056,1,4,"The training interventions can be broadly divided into dialogue-based interventions (interactive workshop, face-to-face training, mentoring) and one-way communication (written information, video course, checklist, written feedback).",delete,[],3,0.35714285714285715,2,14
MR000056,1,5,Most studies were small.,delete,[],3,0.42857142857142855,3,14
MR000056,2,6,"We found moderate-certainty evidence that emails reminding peer reviewers to check items of reporting checklists, compared with standard journal practice, have little or no effect on the completeness of reporting, measured as the proportion of items (from 0.00 to 1.00) that were adequately reported (mean difference (MD) 0.02, 95% confidence interval (CI) −0.02 to 0.06; 2 RCTs, 421 manuscripts).",rephrase,"['Emails reminding peer reviewers to check items of reporting checklists, compared with standard journal practice, probably have little or no effect on the completeness of reporting (evidence from 2 studies with 421 manuscripts).']",3,0.5,3,14
MR000056,3,7,"There was low-certainty evidence that reviewer training, compared with standard journal practice, slightly improves peer reviewer ability to detect errors (MD 0.55, 95% CI 0.20 to 0.90; 1 RCT, 418 reviewers).",rephrase,"['Reviewer training, compared with standard journal practice, may slightly improve peer reviewer ability to detect errors (evidence from 1 study with 418 reviewers).']",4,0.5714285714285714,3,14
MR000056,4,8,"We found low-certainty evidence that reviewer training, compared with standard journal practice, has little or no effect on stakeholders' assessment of review quality in journal peer review (standardized mean difference (SMD) 0.13 standard deviations (SDs), 95% CI −0.07 to 0.33; 1 RCT, 418 reviewers), or change in stakeholders' assessment of review quality in journal peer review (SMD −0.15 SDs, 95% CI −0.39 to 0.10; 5 RCTs, 258 reviewers).",rephrase,"[""Reviewer training, compared with standard journal practice, may have little or no effect on stakeholders' assessment of review quality (evidence from 6 studies with 616 reviewers and 60 manuscripts).""]",5,0.6428571428571429,4,14
MR000056,5,9,"We found very low-certainty evidence that a video course, compared with no video course, has little or no effect on inter-reviewer agreement in grant peer review (MD 0.14 points, 95% CI −0.07 to 0.35; 1 RCT, 75 reviewers).",rephrase,"['We are unsure about the effect of a video course, compared with no video course, on agreement between reviewers (evidence from 1 study with 75 reviewers).']",6,0.7142857142857143,4,14
MR000056,6,10,"There was low-certainty evidence that structured individual feedback on scoring, compared with general information on scoring, has little or no effect on the change in inter-reviewer agreement in grant peer review (MD 0.18 points, 95% CI −0.14 to 0.50; 1 RCT, 41 reviewers, low-certainty evidence).",rephrase,"['Structured individual feedback on scoring, compared with general information on scoring, may have little or no effect on the change in agreement between reviewers (evidence from 1 study with 41 reviewers).']",7,0.7857142857142857,4,14
MR000056,7,11,Evidence from 10 RCTs suggests that training peer reviewers may lead to little or no improvement in the quality of peer review.,delete,[],8,0.8571428571428571,5,14
MR000056,7,12,There is a need for studies with more participants and a broader spectrum of valid and reliable outcome measures.,delete,[],8,0.9285714285714286,5,14
MR000056,7,13,Studies evaluating stakeholders' assessments of the quality of peer review should ensure that these instruments have sufficient levels of validity and reliability.,rephrase,"['Additionally, it is unclear whether the studies measured peer review quality in a valid and reliable way.']",8,1.0,5,14
CD014816,0,0,We included 13 studies (540 participants) in this review.,rephrase,['We found 13 studies that involved 540 participants with SLE that included a structured exercise programme that lasted up to 12 weeks in duration.'],0,0.045454545454545456,1,22
CD014816,0,1,"Studies compared exercise as an adjunct to usual pharmacological care (antimalarials, immunosuppressants, and oral glucocorticoids) with usual pharmacological care plus placebo (one study); usual pharmacological care (six studies); and another non-pharmacological treatment such as relaxation therapy (seven studies).",delete,[],1,0.09090909090909091,1,22
CD014816,0,2,"Most studies had selection bias, and all studies had performance and detection bias.",delete,[],1,0.13636363636363635,1,22
CD014816,0,3,We downgraded the evidence for all comparisons because of a high risk of bias and imprecision.,rephrase,"['We compared and summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes.']",1,0.18181818181818182,1,22
CD014816,1,4,"Exercise plus usual pharmacological care versus placebo plus usual pharmacological care
Evidence from a single small study (17 participants) that compared whole body vibration exercise to whole body placebo vibration exercise (vibrations switched off) indicated that exercise may have little to no effect on fatigue, functional capacity, and pain (low-certainty evidence).",rephrase,"['Whole body vibration exercise plus usual care may result in little to no effect on fatigue, functional capacity, and pain when compared to whole body placebo vibration exercise (vibration switched off) plus usual care (1 study, 17 participants).']",2,0.22727272727272727,2,22
CD014816,1,5,We are uncertain whether exercise results in fewer or more withdrawals (very low-certainty evidence).,delete,[],3,0.2727272727272727,2,22
CD014816,1,6,"The study did not report disease activity, quality of life, and serious adverse events.",rephrase,['The study did not measure disease activity or quality of life.'],3,0.3181818181818182,2,22
CD014816,2,7,"The study measured fatigue using the self-reported Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-Fatigue), scale 0 to 52; lower score means less fatigue.",rephrase,"['The study measured fatigue using the Functional Assessment of Chronic Illness Therapy – Fatigue domain (FACIT-Fatigue) (0 to 52 scale, where 0 means no fatigue) and, at 12 weeks, fatigue improved by 5 points in the exercise group compared to the group that did not exercise:\n– People who exercised rated their fatigue at 33 points.']",4,0.36363636363636365,2,22
CD014816,2,8,"People who did not exercise rated their fatigue at 38 points and those who did exercise rated their fatigue at 33 points (mean difference (MD) 5 points lower, 95% confidence interval (CI) 13.29 lower to 3.29 higher).",rephrase,['– People who did not exercise rated their fatigue at 38 points.'],5,0.4090909090909091,3,22
CD014816,3,9,"The study measured functional capacity using the self-reported 36-item Short Form health questionnaire (SF-36) Physical Function domain, scale 0 to 100; higher score means better function.",rephrase,"['The study measured functional capacity using the Functional Capacity domain in the 36-item Short Form health questionnaire (SF-36) (0 to 100 scale, where 100 means best function) and, at 12 weeks, function worsened by 2.5 points in the exercise group compared to the group that did not exercise:\n– People who exercised rated their functional capacity at 67.5 points.']",6,0.45454545454545453,3,22
CD014816,3,10,"People who did not exercise rated their functional capacity at 70 points and those who did exercise rated their functional capacity at 67.5 points (MD 2.5 points lower, 95% CI 23.78 lower to 18.78 higher).",rephrase,['– People who did not exercise rated their functional capacity at 70 points.'],7,0.5,3,22
CD014816,4,11,"The study measured pain using the SF-36 Pain domain, scale 0 to 100; lower scores mean less pain.",rephrase,"['The study measured pain on the Pain domain of the SF-36 (0 to 100 scale, where 0 means no pain) and, at 12 weeks, pain improved by 9 points in the exercise group compared to the group that did not exercise:\n– People who exercised rated their pain at 34 points.']",8,0.5454545454545454,3,22
CD014816,4,12,"People who did not exercise rated their pain at 43 points and those who did exercise rated their pain at 34 points (MD 9 points lower, 95% CI 28.88 lower to 10.88 higher).",rephrase,['– People who did not exercise rated their pain at 43 points.'],9,0.5909090909090909,3,22
CD014816,5,13,"More participants from the exercise group (3/11, 27%) withdrew from the study than the placebo group (1/10, 10%) (risk ratio (RR) 2.73, 95% CI 0.34 to 22.16).",rephrase,['More people from the exercise group (27%) withdrew from the study compared those in the placebo group (10%).'],10,0.6363636363636364,4,22
CD014816,6,14,"Exercise plus usual pharmacological care versus usual pharmacological care alone
The addition of exercise to usual pharmacological care may have little to no effect on fatigue, functional capacity, and disease activity (low-certainty evidence).",rephrase,"['Exercise plus usual care may result in little to no effect on fatigue, functional capacity, and disease activity when compared to usual care alone.']",11,0.6818181818181818,4,22
CD014816,6,15,"We are uncertain whether the addition of exercise improves pain (very low-certainty evidence), or results in fewer or more withdrawals (very low-certainty evidence).",rephrase,['And we are uncertain whether exercise improves pain when compared to usual care alone.'],12,0.7272727272727273,4,22
CD014816,6,16,Serious adverse events and quality of life were not reported.,delete,[],13,0.7727272727272727,4,22
CD014816,7,17,"Exercise plus usual care versus another non-pharmacological intervention such as receiving information about the disease or relaxation therapy
Compared with education or relaxation therapy, exercise may reduce fatigue slightly (low-certainty evidence), may improve functional capacity (low-certainty evidence), probably results in little to no difference in disease activity (moderate-certainty evidence), and may result in little to no difference in pain (low-certainty evidence).",rephrase,"['Exercise plus usual care may reduce fatigue, improve functional capacity, and probably results in little to no difference in disease activity, and may result in little to no difference in pain when compared to another non-medicine intervention plus usual care.']",13,0.8181818181818182,5,22
CD014816,7,18,We are uncertain whether exercise results in fewer or more withdrawals (very low-certainty evidence).,delete,[],14,0.8636363636363636,5,22
CD014816,7,19,Quality of life and serious adverse events were not reported.,delete,[],14,0.9090909090909091,5,22
CD014816,8,20,"Due to low- to very low-certainty evidence, we are not confident on the benefits of exercise on fatigue, functional capacity, disease activity, and pain, compared with placebo, usual care, or advice and relaxation therapy.",rephrase,"['We have little confidence in the evidence because the number of studies was very small, and it is possible that people in the studies were aware of which treatment they were getting.']",14,0.9545454545454546,5,22
CD014816,8,21,Harms data were not well reported.,delete,[],15,1.0,5,22
CD002295,0,0,We identified 24 eligible trials with a total of 7279 adult participants randomised.,rephrase,['We found 24 studies with a total of 7279 people.'],0,0.06666666666666667,1,15
CD002295,0,1,"Two studies focused on relapse prevention among smokers who had recently stopped smoking, and the remaining 22 studies were concerned with smoking cessation for smokers who wished to quit.",rephrase,['Two studies focused on helping those who had recently stopped smoking and the rest of the studies included current smokers who wished to quit.'],1,0.13333333333333333,1,15
CD002295,0,2,Eleven studies were with women only and one with men only.,split,"['All the studies were conducted with adults.', 'Eleven studies were with women only and one with men only.']",2,0.2,1,15
CD002295,0,3,Most studies recruited fairly inactive people.,ignore,['Most studies recruited fairly inactive people.'],4,0.26666666666666666,2,15
CD002295,0,4,"Most of the trials employed supervised, group-based cardiovascular-type exercise supplemented by a home-based exercise programme and combined with a multi-session cognitive behavioural smoking cessation programme.",rephrase,"['Most studies offered supervised and group-based, aerobic-type exercise.']",5,0.3333333333333333,2,15
CD002295,0,5,The comparator in most cases was a multi-session cognitive behavioural smoking cessation programme alone.,delete,[],6,0.4,2,15
CD002295,0,6,"Overall, we judged two studies to be at low risk of bias, 11 at high risk of bias, and 11 at unclear risk of bias.",delete,[],6,0.4666666666666667,3,15
CD002295,1,7,"Among the 21 studies analysed, we found low-certainty evidence, limited by potential publication bias and by imprecision, comparing the effect of exercise plus smoking cessation support with smoking cessation support alone on smoking cessation outcomes (RR 1.08, 95% CI 0.96 to 1.22; I2 = 0%; 6607 participants).",rephrase,"['When we combined the results of 21 studies (6607 participants) which compared exercise and smoking-cessation programmes to smoking cessation programmes alone, there was no evidence that exercise increased quit rates at six months or longer.']",6,0.5333333333333333,3,15
CD002295,1,8,We excluded one study from this analysis as smoking abstinence rates for the study groups were not reported.,delete,[],7,0.6,3,15
CD002295,1,9,"There was no evidence of subgroup differences according to the type of exercise promoted; the subgroups considered were: cardiovascular-type exercise alone (17 studies), resistance training alone (one study), combined cardiovascular-type and resistance exercise (one study) and type of exercise not specified (two studies).",rephrase,['There was no evidence that the effect was different for different types of exercise.'],7,0.6666666666666666,4,15
CD002295,1,10,"The results were not significantly altered when we excluded trials with high risk of bias, or those with special populations, or those where smoking cessation intervention support was not matched between the intervention and control arms.",delete,[],8,0.7333333333333333,4,15
CD002295,1,11,"Among the two relapse prevention studies, we found very low-certainty evidence, limited by risk of bias and imprecision, that adding exercise to relapse prevention did not improve long-term abstinence compared with relapse prevention alone (RR 0.98, 95% CI 0.65 to 1.47; I2 = 0%; 453 participants).",rephrase,"['We judged the evidence from two studies examining whether exercise helps people to avoid relapse to smoking to be of very low certainty, again suggesting that more research is needed.']",8,0.8,4,15
CD002295,2,12,"There is no evidence that adding exercise to smoking cessation support improves abstinence compared with support alone, but the evidence is insufficient to assess whether there is a modest benefit.",delete,[],9,0.8666666666666667,5,15
CD002295,2,13,"Estimates of treatment effect were of low or very low certainty, because of concerns about bias in the trials, imprecision and publication bias.",rephrase,['This is due to imprecision of the estimated effects and a high risk of bias in the methods used by one of the studies.'],9,0.9333333333333333,5,15
CD002295,2,14,"Consequently, future trials may change these conclusions.",rephrase,"['We judged the quality of evidence for whether exercise programmes help people quit smoking as low certainty, suggesting that future research could change these results.']",10,1.0,5,15
CD004372,0,0,We identified three new RCTs (480 participants).,rephrase,"['We found three studies, with a total of 480 participants with congenital heart disease, which looked at how psychological interventions (talking/counselling therapy) impacted depression.']",0,0.08333333333333333,1,12
CD004372,0,1,Participants were adults with congenital heart disease.,rephrase,['Our aim was to examine the effects (both harms and benefits) of psychological interventions for treating depression in young adults and adults with congenital heart disease.'],1,0.16666666666666666,1,12
CD004372,0,2,"Included studies varied in intervention length (90 minutes to 3 months) and follow-up (3 to 12 months), with depression assessed post-intervention and at follow-up.",rephrase,['The psychological interventions lasted between 90 minutes and 3 months.'],2,0.25,2,12
CD004372,0,3,Risk of bias assessment identified an overall low risk of bias for the main outcome of depression.,rephrase,"['We selected studies that met our criteria, assessed the risk of bias for depression, compared the results of these studies, and rated our confidence in the evidence based on these studies (e.g. assessment methods and size of the sample).']",3,0.3333333333333333,2,12
CD004372,1,4,"Psychological interventions (talking/counselling therapy) may reduce depression more than usual care at both three-month (mean difference (MD) -1.07, 95% confidence interval (CI) -1.84 to -0.30; P = 0.006; I2 = 0%; 2 RCTs, 156 participants; low-certainty evidence), and 12-month follow-up (MD -1.02, 95% CI -1.92 to -0.13; P = 0.02; I2 = 0%; 2 RCTs, 287 participants; low-certainty evidence).",delete,[],4,0.4166666666666667,3,12
CD004372,2,5,There was insufficient evidence to draw conclusions about the impact of psychological interventions on quality of life.,rephrase,['There was insufficient evidence to draw conclusions about the impact of psychological interventions (talking/counselling therapy) on quality of life.'],4,0.5,3,12
CD004372,3,6,None of the included studies reported on our other outcomes of interest.,delete,[],5,0.5833333333333334,3,12
CD004372,4,7,"Due to the low number of studies included, we did not undertake any subgroup analyses.",delete,[],5,0.6666666666666666,4,12
CD004372,4,8,One study awaits classification.,delete,[],5,0.75,4,12
CD004372,5,9,Psychological interventions may reduce depression in adults with congenital heart disease compared to usual care.,split,"['The results of our review suggest that a psychological intervention may help to reduce the symptoms of depression in adults with congenital heart disease.', 'However, the type and length of the intervention varied between studies, so it may be possible that some interventions may make little or no difference to reducing depression.']",5,0.8333333333333334,5,12
CD004372,5,10,"However, the certainty of the evidence is low.",rephrase,"['There were only three studies that met the criteria for the review, and the certainty of the evidence was low.']",7,0.9166666666666666,5,12
CD004372,6,11,"Further research is needed to establish the role of psychological interventions in this population, defining the optimal duration, method of administration, and number of sessions required to obtain the greatest benefit.",delete,[],8,1.0,5,12
CD008714,0,0,Only one randomised trial was identified and included in the review.,rephrase,"['The authors identified only one randomised trial, with 24 participants included.']",0,0.09090909090909091,1,11
CD008714,0,1,The bias risk in the trial was high.,rephrase,"['The trial is small and at a high risk of bias, which suggests that the results may not be reliable.']",1,0.18181818181818182,1,11
CD008714,0,2,The trial compared chlorambucil versus no intervention in 24 patients with primary biliary cirrhosis.,rephrase,['This trial compared chlorambucil with no intervention.'],2,0.2727272727272727,2,11
CD008714,0,3,Fisher's exact test did not show a significant reduction of mortality when comparing chlorambucil with no treatment (0/13 (0%) versus (2/11 (18.2%); P = 0.20).,split,"[""Fisher's exact test and t-test were used instead."", 'Chlorambucil was not associated with significantly lower mortality when compared with no intervention.']",3,0.36363636363636365,2,11
CD008714,0,4,"There was no significant difference regarding adverse events for chlorambucil compared with no treatment, but all patients receiving chlorambucil experienced adverse events (13/13 (100%) versus (3/11 (27%); P = 0.1).",rephrase,"['All patients on chlorambucil experienced adverse events, especially bone marrow suppression.']",5,0.45454545454545453,3,11
CD008714,0,5,"According to the authors of the trial, chlorambucil led to a significant improvement in mean serum levels of bilirubin (P < 0.05), albumin (P < 0.05), immunoglobulin M (P < 0.01), serum aspartate aminotransferase activity (P < 0.01), and hepatic inflammatory infiltrates (P < 0.01).",rephrase,"['Chlorambucil led to a significant improvement in mean serum levels of bilirubin, albumin, immunoglobulin M, serum aspartate aminotransferase activity, and hepatic inflammatory infiltrates.']",6,0.5454545454545454,3,11
CD008714,1,6,There is not sufficient evidence to support or reject the use of chlorambucil for patients with primary biliary cirrhosis.,split,"['This review aimed to assess the beneficial or harmful effects of chlorambucil for primary biliary cirrhosis.', 'It remains unclear whether chlorambucil can be supported or rejected for use in patients with primary biliary cirrhosis.']",7,0.6363636363636364,4,11
CD008714,1,7,"Chlorambucil may show benefit in some unvalidated surrogate outcome measures (for example, serum bilirubin and immunoglobulin M levels).",delete,[],9,0.7272727272727273,4,11
CD008714,1,8,"Chlorambucil is, however, connected with a number of adverse events.",delete,[],9,0.8181818181818182,5,11
CD008714,1,9,Bone marrow suppression should be noted in particular.,delete,[],9,0.9090909090909091,5,11
CD008714,1,10,Further randomised clinical trials are necessary to assess the benefits and harms of chlorambucil in this indication.,delete,[],9,1.0,5,11
CD005260,0,0,We identified no new studies for inclusion in this update.,delete,[],0,0.1111111111111111,1,9
CD005260,0,1,"In total we included one trial, excluded 18 trials, classed one trial as ongoing, and classed another as awaiting classification.",delete,[],0,0.2222222222222222,2,9
CD005260,0,2,"The total number of participants in the included trial was 10, and the methodological quality of this trial was moderate because of high risk of bias in relation to two domains (random sequence generation and allocation concealment) but low risk of bias for the four remaining domains (blinding, incomplete outcome data, selective reporting, and any other bias).",delete,[],0,0.3333333333333333,2,9
CD005260,0,3,"The included trial was a short-term cross-over randomised trial undertaken in Canada, which tested the effects of adding three seemingly identical prosthetic weights (150 g vs 770 g vs 1625 g) to the prostheses of a total of 10 participants with unilateral dysvascular transfemoral amputation.",rephrase,"['This trial had a cross-over design, and each of the 10 participants had three seemingly identical prosthetic weights added to the prosthesis below the knee in random order.']",0,0.4444444444444444,3,9
CD005260,0,4,Eight participants were over 60 years of age.,rephrase,"['The participants - nine men and one woman - were over 50 years of age, and eight were over 60 years old.']",1,0.5555555555555556,3,9
CD005260,0,5,"Trial authors found that four participants preferred the addition of the lightest weight (150 g), five preferred the middle weight (770 g), and one preferred the heaviest weight (1625 g).",rephrase,"['Over the few hours of the trial, four participants preferred the lightest weight (150 g), five preferred the medium weight (770 g), and one preferred the heaviest weight (1625 g).']",2,0.6666666666666666,4,9
CD005260,0,6,Researchers interpreted this as equating to user satisfaction (success) and reported no adverse effects.,rephrase,['Study authors reported no adverse effects.'],3,0.7777777777777778,4,9
CD005260,1,7,"The limited evidence presented in this review is of very low quality and is insufficient to inform the choice of prosthetic rehabilitation, including the optimum weight of the prosthesis, after unilateral transfemoral amputation in older dysvascular people.",ignore,"['The limited evidence included in this review is of very low quality and is insufficient to inform the choice of prosthetic rehabilitation, including optimum weight of the prosthesis, after unilateral transfemoral amputation in older dysvascular people.']",4,0.8888888888888888,5,9
CD005260,1,8,A programme of research that includes randomised controlled trials to examine key interventions is urgently required in this area.,delete,[],5,1.0,5,9
CD003991,0,0,Six studies met the inclusion criteria.,rephrase,['We found six studies.'],0,0.058823529411764705,1,17
CD003991,0,1,One trial compared vas occlusion with clips versus a conventional vasectomy technique.,rephrase,['One trial compared closing the vas with clips versus the usual cutting of the vas.'],1,0.11764705882352941,1,17
CD003991,0,2,No difference was found in failure to reach azoospermia (no sperm detected).,delete,[],2,0.17647058823529413,1,17
CD003991,0,3,Three trials examined vasectomy with vas irrigation.,merge,"['Three trials looked at flushing fluids through the vas: two compared vasectomy with water flushing versus vasectomy alone, and one compared using water versus euflavine (which kills sperm).']",2,0.23529411764705882,2,17
CD003991,0,4,"Two studies looked at irrigation with water versus no irrigation, while one examined irrigation with water versus the spermicide euflavine.",none,[],2,0.29411764705882354,2,17
CD003991,0,5,None found a difference between the groups for time to azoospermia.,rephrase,['None found a difference between the groups in time to low sperm count.'],3,0.35294117647058826,2,17
CD003991,0,6,"However, one trial reported that the median number of ejaculations to azoospermia was lower in the euflavine group compared to the water irrigation group.",rephrase,"['However, one trial found that the usual number of ejaculations before low sperm count was lower with euflavine than with water.']",4,0.4117647058823529,3,17
CD003991,0,7,One high-quality trial compared vasectomy with fascial interposition versus vasectomy without fascial interposition.,rephrase,['One trial that compared vasectomy with and without fascial interposition was a high-quality large study.'],5,0.47058823529411764,3,17
CD003991,0,8,The fascial interposition group was less likely to have vasectomy failure.,ignore,['The fascial interposition group was less likely to have vasectomy failure.'],6,0.5294117647058824,3,17
CD003991,0,9,"Fascial interposition had more surgical difficulties, but the groups were similar in side effects.",split,"['However, the surgery was more difficult.', 'Side effects were about the same in the two groups.']",7,0.5882352941176471,3,17
CD003991,0,10,"Lastly, one trial found that an intra-vas was less likely to produce azoospermia than was no-scalpel vasectomy.",rephrase,"['Lastly, one trial looked at a device placed into the vas versus vasectomy without a scalpel.']",9,0.6470588235294118,4,17
CD003991,0,11,"More men were satisfied with the intra-vas device, however.",rephrase,['The intra-vas device did not work as well for reaching a low sperm count but more men liked the method.'],10,0.7058823529411765,4,17
CD003991,1,12,"For vas occlusion with clips or vasectomy with vas irrigation, no conclusions can be made as those studies were of low quality and underpowered.",delete,[],11,0.7647058823529411,4,17
CD003991,1,13,Fascial interposition reduced vasectomy failure.,rephrase,"['Vasectomy with fascial interposition worked better than simply cutting and tying the vas, but the surgery was more difficult.']",11,0.8235294117647058,5,17
CD003991,1,14,An intra-vas device was less effective in reducing sperm count than was no-scalpel vasectomy.,delete,[],12,0.8823529411764706,5,17
CD003991,1,15,RCTs examining other vasectomy techniques were not available.,rephrase,"['Most of the studies that looked at vasectomy methods were small, not done well, or had poor reports.']",12,0.9411764705882353,5,17
CD003991,1,16,More and better quality research is needed to examine vasectomy techniques.,rephrase,['More and better research is needed on vasectomy methods.'],13,1.0,5,17
CD013290,0,0,We included 12 RCTs with a total of 1596 participants.,rephrase,['We found 12 studies with a total of 1596 participants.'],0,0.05555555555555555,1,18
CD013290,0,1,"Seven studies compared NSAIDs (ketorolac, diclofenac, flurbiprofen, parecoxib and celecoxib) to placebo.",ignore,"['Seven studies compared NSAIDs (ketorolac, diclofenac, flurbiprofen, parecoxib and celecoxib) to placebo.']",1,0.1111111111111111,1,18
CD013290,0,2,"Four studies compared NSAIDs (ketorolac, flurbiprofen, ibuprofen, and celecoxib) to other analgesics (morphine, hydrocodone, hydromorphone, fentanyl).",rephrase,"['Four studies compared NSAIDs (ketorolac, flurbiprofen, ibuprofen, and celecoxib) to other pain medications.']",2,0.16666666666666666,1,18
CD013290,0,3,One study compared NSAIDs (diclofenac) to no intervention.,rephrase,['One study compared NSAIDs (diclofenac) to no medication.'],3,0.2222222222222222,2,18
CD013290,1,4,"NSAIDs compared to placebo
Most outcomes are judged to have low-certainty evidence unless stated otherwise.",delete,[],4,0.2777777777777778,2,18
CD013290,1,5,"There may be little to no difference in the incidence of breast hematomas within 90 days of breast surgery (RR 0.33, 95% confidence interval (CI) 0.05 to 2.02; 2 studies, 230 participants; I2 = 0%).",rephrase,['the use of NSAIDs seems to make little difference to the incidence of breast hematoma (a collection of blood inside the armpit or breast surgical site) and bleeding from any location or increase in blood transfusions within 90 days of breast surgery.'],4,0.3333333333333333,2,18
CD013290,1,6,"NSAIDs may reduce pain intensity 24 (± 12) hours following surgery compared to placebo (SMD -0.26, 95% CI -0.49 to -0.03; 3 studies, 310 participants; I2 = 73%).",delete,[],5,0.3888888888888889,2,18
CD013290,1,7,"There may be little to no difference in the incidence rates or severities of postoperative nausea, vomiting, or both (RR 1.15, 95% CI 0.58 to 2.27; 4 studies, 939 participants; I2 = 81%), bleeding from any location within 90 days (RR 1.05, 95% CI 0.89 to 1.24; 2 studies, 251 participants; I2 = 8%), or need for blood transfusion compared to placebo groups, but we are very uncertain (RR 4.62, 95% CI 0.23 to 91.34; 1 study, 48 participants; very low-certainty evidence).",delete,[],5,0.4444444444444444,3,18
CD013290,1,8,"There may be no difference in other side effects (RR 1.12, 95% CI 0.44 to 2.86; 2 studies, 251 participants; I2 = 0%).",delete,[],5,0.5,3,18
CD013290,1,9,"NSAIDs may reduce opioid use within 24 hours of surgery compared to placebo (SMD -0.45, 95% CI -0.85 to -0.05; 4 studies, 304 participants; I2 = 63%).",rephrase,['NSAIDs may reduce pain within 24 hours after surgery and reduce the use of opioids within 24 hours after surgery.'],5,0.5555555555555556,3,18
CD013290,2,10,"NSAIDs compared to other analgesics
There is little to no difference in the incidence of breast hematomas within 90 days of breast surgery, but we are very uncertain (RR 0.33, 95% CI 0.01 to 7.99; 1 study, 100 participants; very low-certainty evidence).",rephrase,['the use of NSAIDs may make little difference to the incidence of breast hematoma or bleeding from any location or need for blood transfusion within 90 days of breast surgery.'],6,0.6111111111111112,4,18
CD013290,2,11,"NSAIDs may reduce pain intensity 24 (± 12) hours following surgery (SMD -0.68, 95% CI -0.97 to -0.39; 3 studies, 200 participants; I2 = 89%; low-certainty evidence) and probably reduce the incidence rates or severities of postoperative nausea, vomiting, or both compared to other analgesics (RR 0.18, 95% CI 0.06 to 0.57; 3 studies, 128 participants; I2 = 0%; moderate-certainty evidence).",rephrase,['NSAIDs may reduce pain within 24 hours and reduce the chance of nausea and vomiting after surgery.'],7,0.6666666666666666,4,18
CD013290,2,12,"There is little to no difference in the development of bleeding from any location within 90 days of breast surgery or in other side effects, but we are very uncertain (bleeding: RR 0.33, 95% CI 0.01 to 7.99; 1 study, 100 participants; other side effects: RR 0.11, 95% CI 0.01 to 1.80; 1 study, 48 participants; very low-certainty evidence).",rephrase,['There is little to no difference in the incidence of other side effects.'],8,0.7222222222222222,4,18
CD013290,2,13,"NSAIDs may reduce opioid use within 24 hours of surgery compared to other analgesics (SMD -6.87, 95% CI -10.93 to -2.81; 3 studies, 178 participants; I2 = 96%; low-certainty evidence).",rephrase,['NSAIDS may reduce opioid use within 24 hours of surgery compared to other pain medications.'],9,0.7777777777777778,4,18
CD013290,3,14,"NSAIDs compared to no intervention
There is little to no difference in pain intensity 24 (± 12) hours following surgery compared to no intervention, but we are very uncertain (SMD -0.54, 95% CI -1.09 to 0.00; 1 study, 60 participants; very low-certainty evidence).",rephrase,['the use of NSAIDs appears to make little to no difference in pain within 24 hours after surgery compared to no medication.'],10,0.8333333333333334,5,18
CD013290,4,15,"Low-certainty evidence suggests that NSAIDs may reduce postoperative pain, nausea and vomiting, and postoperative opioid use.",delete,[],11,0.8888888888888888,5,18
CD013290,4,16,"However, there was very little evidence to indicate whether NSAIDs affect the rate of breast hematoma or bleeding from any location within 90 days of breast surgery, the need for blood transfusion and incidence of other side effects compared to placebo or other analgesics.",rephrase,"['Many studies did not collect or report data on the need for blood transfusions, length of hospital stay, breast cancer recurrence, and non-prescribed NSAID pain medication use.']",11,0.9444444444444444,5,18
CD013290,4,17,High-quality large-scale RCTs are required before definitive conclusions can be made.,rephrase,['Good-quality large-scale studies are required before any definitive conclusions can be made.'],12,1.0,5,18
CD004807,0,0,We included 11 randomised controlled trials involving 2796 people.,rephrase,['We found 11 randomised controlled trials involving approximately 2796 people.'],0,0.047619047619047616,1,21
CD004807,0,1,"The quality of these studies was moderate to low, with most of the studies at unclear risk of bias in terms of random sequence generation and allocation concealment, and high risk of bias for blinded outcome assessment and selective outcome reporting.",rephrase,"['The quality of the evidence is moderate to low; it was unclear in many cases whether steps were taken to minimise bias, both in the way that participants were allocated to groups, and in how the outcomes were assessed and reported.']",1,0.09523809523809523,1,21
CD004807,1,2,"Five trials involving 581 people compared consumer-providers to professionals in similar roles within mental health services (case management roles (4 trials), facilitating group therapy (1 trial)).",ignore,"['Five of the 11 trials involving 581 people compared consumer-providers to professionals who occupied similar roles within mental health services (case management roles (4 trials), and facilitating group therapy (1 trial)).']",2,0.14285714285714285,1,21
CD004807,1,3,"There were no significant differences in client quality of life (mean difference (MD) -0.30, 95% confidence interval (CI) -0.80 to 0.20); depression (data not pooled), general mental health symptoms (standardised mean difference (SMD) -0.24, 95% CI -0.52 to 0.05); client satisfaction with treatment (SMD -0.22, 95% CI -0.69 to 0.25), client or professional ratings of client-manager relationship; use of mental health services, hospital admissions and length of stay; or attrition (risk ratio 0.80, 95% CI 0.58 to 1.09) between mental health teams involving consumer-providers or professional staff in similar roles.",rephrase,"['There were no significant differences between the two groups, in terms of client (care recipient) quality of life, mental health symptoms, satisfaction, use of mental health services, or on the numbers of people withdrawing from the study.']",3,0.19047619047619047,1,21
CD004807,2,4,There was a small reduction in crisis and emergency service use for clients receiving care involving consumer-providers (SMD -0.34 (95%CI -0.60 to -0.07).,delete,[],4,0.23809523809523808,2,21
CD004807,2,5,"Past or present consumers who provided mental health services did so differently than professionals; they spent more time face-to-face with clients, and less time in the office, on the telephone, with clients' friends and family, or at provider agencies.",split,"['People receiving care from past or present users of mental health services used crisis and emergency services slightly less than those receiving care from professional staff.', ""Past or present consumers who provided mental health services did so differently than professionals; they spent more time face-to-face with clients, and less time in the office, on the telephone, with clients' friends and family, or at provider agencies.""]",4,0.2857142857142857,2,21
CD004807,3,6,Six trials involving 2215 people compared mental health services with or without the addition of consumer-providers.,ignore,"['Six of the 11 trials, involving 2215 people, compared mental health services with or without the addition of consumer-providers.']",6,0.3333333333333333,2,21
CD004807,3,7,"There were no significant differences in psychosocial outcomes (quality of life, empowerment, function, social relations), client satisfaction with service provision (SMD 0.76, 95% CI -0.59 to 2.10) and with staff (SMD 0.18, 95% CI -0.43 to 0.79), attendance rates (SMD 0.52 (95% CI -0.07 to 1.11), hospital admissions and length of stay, or attrition (risk ratio 1.29, 95% CI 0.72 to 2.31) between groups with consumer-providers as an adjunct to professional-led care and those receiving usual care from health professionals alone.",rephrase,"['There were no significant differences in quality of life, empowerment, function and social relations, in client satisfaction, attendance rates, hospital use, or in the numbers of people withdrawing from the study, between groups with consumer-providers as an adjunct to professional care and those receiving usual care by health professionals alone.']",7,0.38095238095238093,2,21
CD004807,3,8,"One study found a small difference favouring the intervention group for both client and staff ratings of clients' needs having been met, although detection bias may have affected the latter.",delete,[],8,0.42857142857142855,3,21
CD004807,3,9,None of the six studies in this comparison reported client mental health outcomes.,rephrase,"[""None of these six studies reported on clients' mental health symptoms.""]",8,0.47619047619047616,3,21
CD004807,4,10,"No studies in either comparison group reported data on adverse outcomes for clients, or the financial costs of service provision.",rephrase,"['None of the studies reported on adverse outcomes (harms) for clients, or on the costs of providing the services.']",9,0.5238095238095238,3,21
CD004807,5,11,"Involving consumer-providers in mental health teams results in psychosocial, mental health symptom and service use outcomes for clients that were no better or worse than those achieved by professionals employed in similar roles, particularly for case management services.",rephrase,"['Overall, we concluded that employing past or present consumers of mental health services as providers of mental health services achieves psychosocial, mental health symptom and service use outcomes that are no better or worse than those achieved by professional staff in providing care.']",10,0.5714285714285714,3,21
CD004807,6,12,There is low quality evidence that involving consumer-providers in mental health teams results in a small reduction in clients' use of crisis or emergency services.,delete,[],11,0.6190476190476191,4,21
CD004807,6,13,"The nature of the consumer-providers' involvement differs compared to professionals, as do the resources required to support their involvement.",delete,[],11,0.6666666666666666,4,21
CD004807,6,14,The overall quality of the evidence is moderate to low.,delete,[],11,0.7142857142857143,4,21
CD004807,6,15,There is no evidence of harm associated with involving consumer-providers in mental health teams.,rephrase,['There is no evidence that the involvement of consumer-providers is harmful.'],11,0.7619047619047619,4,21
CD004807,7,16,"Future randomised controlled trials of consumer-providers in mental health services should minimise bias through the use of adequate randomisation and concealment of allocation, blinding of outcome assessment where possible, the comprehensive reporting of outcome data, and the avoidance of contamination between treatment groups.",delete,[],12,0.8095238095238095,5,21
CD004807,7,17,Researchers should adhere to SPIRIT and CONSORT reporting standards for clinical trials.,delete,[],12,0.8571428571428571,5,21
CD004807,8,18,"Future trials should further evaluate standardised measures of clients' mental health, adverse outcomes for clients, the potential benefits and harms to the consumer-providers themselves (including need to return to treatment), and the financial costs of the intervention.",rephrase,"['More high-quality and well-reported randomised trials are needed, particularly to evaluate mental health outcomes, adverse outcomes for clients, the potential benefits and harms to the consumer-providers themselves (including a need to return to treatment), and whether it is cost-effective to employ them.']",12,0.9047619047619048,5,21
CD004807,8,19,"They should utilise consistent, validated measurement tools and include a clear description of the consumer-provider role (eg specific tasks, responsibilities and expected deliverables of the role) and relevant training for the role so that it can be readily implemented.",merge,"['Future researchers should include a clear description of the consumer-provider role and relevant training for the role so that it can be readily implemented, and should investigate consumer-providers in settings outside the United States.']",13,0.9523809523809523,5,21
CD004807,8,20,"The weight of evidence being strongly based in the United States, future research should be located in diverse settings including in low- and middle-income countries.",none,[],13,1.0,5,21
CD012582,0,0,"In total, the search identified 2102 records, of which we reviewed 144 in full text.",delete,[],0,0.07692307692307693,1,13
CD012582,0,1,We included eight studies.,split,"['We included eight clinical studies.', 'We found five ongoing studies.']",0,0.15384615384615385,1,13
CD012582,0,2,Four interventions focused on patient–caregiver dyads and four were aimed specifically at the caregiver.,rephrase,['Four studies reported on interventions for patient–caregiver relationship and four studies were aimed specifically at improving caregiver well-being.'],2,0.23076923076923078,2,13
CD012582,0,3,Heterogeneity of populations and methodologies precluded meta-analysis.,delete,[],3,0.3076923076923077,2,13
CD012582,0,4,"Risk of bias varied, and all studies included only small numbers of neuro-oncology caregivers (13 to 56 participants).",rephrase,"['The interventions tested were diverse in nature (e.g. cognitive behavioural therapy (talking therapy); psychoeducation (providing education and information to people seeking or receiving mental health services); coping skills training; self-management; social network intervention); and delivery (e.g. face-to-face; web-based), and all studies were relatively small (included between 13 and 56 neuro-oncology caregivers).']",3,0.38461538461538464,2,13
CD012582,0,5,"There was some evidence for positive effects of caregiver support on psychological distress, mastery, and quality of life (low to very low certainty of evidence).",rephrase,"['We found some evidence for positive effects of caregiver support on psychological distress, feelings of mastery (i.e. the feeling of being in control of the caregiving situation), and quality of life.']",4,0.46153846153846156,3,13
CD012582,0,6,No studies reported significant effects on caregiver burden or quality of patient–caregiver relationship (low to very low certainty of evidence).,rephrase,['None of the studies reported effects on caregiver burden or quality of patient–caregiver relationship.'],5,0.5384615384615384,3,13
CD012582,0,7,None of the studies assessed caregiver physical functioning.,rephrase,['None of the studies measured caregiver physical well-being.'],6,0.6153846153846154,4,13
CD012582,0,8,"For secondary outcomes (patient emotional or physical well-being; health economic effects), we found very little to no evidence for the effectiveness of caregiver support.",delete,[],7,0.6923076923076923,4,13
CD012582,0,9,We identified five ongoing trials.,delete,[],7,0.7692307692307693,4,13
CD012582,1,10,"The eight small-scale studies included employed different methodologies across different populations, with low certainty of evidence overall.",rephrase,"['Overall, the certainty of the evidence was low to very low, which means the true effect of caregiver support may be substantially different.']",7,0.8461538461538461,5,13
CD012582,1,11,It is not currently possible to draw reliable conclusions regarding the effectiveness of supportive interventions aimed at improving neuro-oncology caregiver well-being.,rephrase,['Our findings suggest it is not currently possible to draw definitive conclusions about the effectiveness of supportive interventions to improve neuro-oncology caregiver well-being.'],8,0.9230769230769231,5,13
CD012582,1,12,"More high-quality research is needed on support for family caregivers of people diagnosed, and living, with a brain or spinal cord tumour.",ignore,"['More high-quality research is needed on support for family caregivers of patients diagnosed, and living, with a brain or spinal cord tumour.']",9,1.0,5,13
CD005030,0,0,"Seventeen studies, 9 cluster randomised studies, with 253 clusters, 8 individually randomised studies with 1230 participants, evaluating four types of intervention: motivational interviewing or brief intervention, education or skills training, family interventions and multi-component community interventions.",delete,[],0,0.1111111111111111,1,9
CD005030,0,1,"Many studies had methodological drawbacks, especially high levels of loss to follow-up.",rephrase,['Many of the studies lacked blinding and had high numbers of participants lost to follow up.'],0,0.2222222222222222,2,9
CD005030,0,2,There were too few studies for firm conclusions.,rephrase,['The studies were too few and each intervention too different to draw any firm conclusions on whether \nnon-school based interventions prevent or reduce drug use by young people.The interventions with suggested benefits need further evaluation before it \ncan be firmly established that they are effective.'],1,0.3333333333333333,2,9
CD005030,0,3,One study of motivational interviewing suggested that this intervention was beneficial on cannabis use.,rephrase,['One of two studies of motivational interviewing suggested that this intervention was beneficial on \nself-reported cannabis use.'],2,0.4444444444444444,3,9
CD005030,0,4,"Three family interventions (Focus on Families, Iowa Strengthening Families Program and Preparing for the Drug-Free Years), each evaluated in only one study, suggested that they may be beneficial in preventing cannabis use.",rephrase,"['Three family interventions (Focus on Families, Iowa Strengthening Families Program and Preparing for the Drug-Free Years) \nwere evaluated, in two separate studies, and may have been beneficial in preventing self-reported cannabis use.']",3,0.5555555555555556,3,9
CD005030,0,5,"The studies of multi component community interventions did not find any strong effects on drug use outcomes, and the two studies of education and skills training did not find any differences between the intervention and control groups.",split,"['Multicomponent community interventions did not have any strong effects on \ndrug use.', 'Education and skills training \nwas not effective in two studies.']",4,0.6666666666666666,4,9
CD005030,1,6,There is a lack of evidence of effectiveness of the included interventions.,delete,[],6,0.7777777777777778,4,9
CD005030,1,7,Motivational interviewing and some family interventions may have some benefit.,delete,[],6,0.8888888888888888,5,9
CD005030,1,8,"Cost-effectiveness has not yet been addressed in any studies, and further research is needed to determine whether any of these interventions can be recommended.",delete,[],6,1.0,5,9
CD002071,0,0,Twenty-two trials with a total of 3529 patients are included (14 in the original review and a further eight in this update).,rephrase,"['This review of 22 randomised clinical trials, with a combined total of 3529 patients, set out to determine if any drug was more effective than another in preventing occlusion or restenosis of the artery after the blood vessels have been surgically widened.']",0,0.07142857142857142,1,14
CD002071,0,1,"For the majority of comparisons, only one trial was available so results were rarely combined in meta-analyses.",rephrase,"['For the majority of comparisons, only one study was available.']",1,0.14285714285714285,1,14
CD002071,0,2,Individual trials were generally small and risk of bias was often unclear due to limitations in reporting.,delete,[],2,0.21428571428571427,2,14
CD002071,0,3,Three trials reported on drug versus placebo/control; results were consistently available for a maximum follow-up of only six months.,delete,[],2,0.2857142857142857,2,14
CD002071,0,4,"At six months post intervention, a statistically significant reduction in reocclusion was found for high-dose acetylsalicylic acid (ASA) combined with dipyridamole (DIP) (OR 0.40, 95% CI 0.19 to 0.84), but not for low-dose ASA combined with DIP (OR 0.69, 95% CI 0.44 to 1.10; P = 0.12) nor in major amputations for lipo-ecraprost (OR 0.89, 95% CI 0.44 to 1.80).",delete,[],2,0.35714285714285715,2,14
CD002071,0,5,The remaining trials compared different drugs; results were more consistently available for a longer period of 12 months.,delete,[],2,0.42857142857142855,3,14
CD002071,0,6,"At 12 months post intervention, no statistically significant difference in reocclusion/restenosis was detected for any of the following comparisons: high-dose ASA versus low-dose ASA (OR 0.98, 95% CI 0.64 to 1.48; P = 0.91), ASA/DIP versus vitamin K antagonists (VKA) (OR 0.65, 95% CI 0.40 to 1.06; P = 0.08), clopidogrel and aspirin versus low molecular weight heparin (LMWH) plus warfarin (OR 0.31, 95% CI 0.06 to 1.68; P = 0.18), suloctidil versus VKA: reocclusion (OR 0.59, 95% CI 0.20 to 1.76; P = 0.34), restenosis (OR 1.87, 95% CI 0.66 to 5.31; P = 0.24) and ticlopidine versus VKA (OR 0.71, 95% CI 0.37 to 1.36; P = 0.30).",delete,[],2,0.5,3,14
CD002071,0,7,"Treatment with cilostazol resulted in statistically significantly fewer reocclusions than ticlopidine (OR 0.32, 95% CI 0.13 to 0.76; P = 0.01).",delete,[],2,0.5714285714285714,3,14
CD002071,0,8,"Compared with aspirin alone, LMWH plus aspirin significantly decreased occlusion/restenosis (by up to 85%) in patients with critical limb ischaemia (OR 0.15, 95% CI 0.06 to 0.42; P = 0.0003) but not in patients with intermittent claudication (OR 1.73, 95% CI 0.97 to 3.08; P = 0.06) and batroxobin plus aspirin reduced restenosis in diabetic patients (OR 0.28, 95% CI 0.13 to 0.60).",rephrase,['Batroxobin plus aspirin compared with aspirin alone may be an effective treatment in diabetic patients.'],2,0.6428571428571429,4,14
CD002071,0,9,"Data on bleeding and other potential gastrointestinal side effects were not consistently reported, although there was some evidence that high-dose ASA increased gastrointestinal side effects compared with low-dose ASA, that clopidogrel and aspirin resulted in fewer major bleeding episodes compared with LMWH plus warfarin, and that abciximab resulted in more severe bleeding episodes.",delete,[],3,0.7142857142857143,4,14
CD002071,1,10,"There is limited evidence suggesting that restenosis/reocclusion at six months following peripheral endovascular treatment is reduced by use of antiplatelet drugs compared with placebo/control, but associated information on bleeding and gastrointestinal side effects is lacking.",rephrase,"['Evidence suggests that some drugs which reduce platelet aggregation, such as higher-dose aspirin, can reduce the rate of reocclusion six months after surgery, but evidence on associated side effects and for longer-term restenosis rates is scarce.']",3,0.7857142857142857,4,14
CD002071,1,11,There is also some evidence of variation in effect according to different drugs with cilostazol reducing reocclusion/restenosis at 12 months compared with ticlopidine and both LMWH and batroxobin combined with aspirin appearing beneficial compared with aspirin alone.,rephrase,"['There is also some evidence of variation in effect according to different drugs, with reocclusion/restenosis rates lower in people taking cilostazol compared with ticlopidine 12 months after surgery and, in patients with more severe disease, those taking low molecular weight heparin in addition to aspirin compared with aspirin alone.']",4,0.8571428571428571,5,14
CD002071,1,12,"However, available trials are generally small and of variable quality and side effects of drugs are not consistently addressed.",ignore,"['However, available trials are generally small and of variable quality and side effects of drugs are not consistently addressed.']",5,0.9285714285714286,5,14
CD002071,1,13,"Further good quality, large-scale RCTs, stratified by severity of disease, are required.",rephrase,"['Further good quality, large-scale randomised controlled trials, grouped by severity of disease, are required.']",6,1.0,5,14
CD003813,0,0,Our new search did not find any new studies for inclusion since the last version of the review in 2013.,rephrase,['There are no new studies to include in this updated review.'],0,0.08333333333333333,1,12
CD003813,1,1,"No randomised controlled trials (RCTs), controlled clinical trials (CCTs) or cohort studies were included in the previous versions of the review, but one case-control study met the inclusion criteria.",delete,[],1,0.16666666666666666,1,12
CD003813,1,2,The trial authors collected information on 48 people who had contracted bacterial endocarditis over a specific two-year period and had undergone a medical or dental procedure with an indication for prophylaxis within the past 180 days.,ignore,['The authors collected information on 48 people who had contracted bacterial endocarditis over a specific two-year period and had undergone a medical or dental procedure with an indication for prophylaxis within the past 180 days.'],1,0.25,2,12
CD003813,1,3,These people were matched to a similar group of people who had not contracted bacterial endocarditis.,split,"['Our original review included one study, based in the Netherlands, that compared the treatment of people at high risk of endocarditis who did or did not develop bacterial endocarditis.', 'These people were matched to a similar group of people who had not contracted bacterial endocarditis.']",2,0.3333333333333333,2,12
CD003813,1,4,All study participants had undergone an invasive medical or dental procedure.,ignore,['All study participants had undergone an invasive medical or dental procedure.'],4,0.4166666666666667,3,12
CD003813,1,5,The two groups were compared to establish whether those who had received preventive antibiotics (penicillin) were less likely to have developed endocarditis.,ignore,['The two groups were compared to establish whether those who had received preventive antibiotics were less likely to have developed endocarditis.'],5,0.5,3,12
CD003813,1,6,The authors found no significant effect of penicillin prophylaxis on the incidence of endocarditis.,delete,[],6,0.5833333333333334,3,12
CD003813,1,7,No data on other outcomes were reported.,delete,[],6,0.6666666666666666,4,12
CD003813,2,8,The level of certainty we have about the evidence is very low.,rephrase,['We are not confident about the evidence we found.'],6,0.75,4,12
CD003813,3,9,There remains no clear evidence about whether antibiotic prophylaxis is effective or ineffective against bacterial endocarditis in at-risk people who are about to undergo an invasive dental procedure.,rephrase,['It is unclear whether taking antibiotics as a preventive measure before undergoing invasive dental procedures is effective or ineffective against bacterial endocarditis in people at increased risk.'],7,0.8333333333333334,5,12
CD003813,3,10,We cannot determine whether the potential harms and costs of antibiotic administration outweigh any beneficial effect.,rephrase,['It is unclear whether the potential harms and costs of antibiotic administration outweigh any beneficial effects.'],8,0.9166666666666666,5,12
CD003813,3,11,"Ethically, practitioners should discuss the potential benefits and harms of antibiotic prophylaxis with their patients before a decision is made about administration.",rephrase,"['Ethically, practitioners should discuss the potential benefits and harms of preventive antibiotic treatment with their patients before a decision is made about whether to prescribe it.']",9,1.0,5,12
CD011646,0,0,We identified a total of 81 randomised clinical trials.,rephrase,['We identified 81 trials which were eligible for our review.'],0,0.037037037037037035,1,27
CD011646,0,1,"All the trials were at high risk of bias, and the overall quality of the evidence was low or very low for all outcomes.",delete,[],1,0.07407407407407407,1,27
CD011646,1,2,"Alcoholic hepatitis
Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis.",rephrase,['Fifty randomised clinical trials included 4484 participants with alcoholic hepatitis.'],1,0.1111111111111111,1,27
CD011646,1,3,The period of follow-up ranged from one to 12 months.,ignore,['The period of follow-up ranged from one to 12 months.'],2,0.14814814814814814,1,27
CD011646,1,4,"Because of concerns about transitivity assumption, we did not perform the network meta-analysis.",delete,[],3,0.18518518518518517,1,27
CD011646,1,5,"None of the active interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes mortality (at various time points), cirrhosis, decompensated cirrhosis, liver transplantation.",rephrase,"['None of the active interventions showed any improvement in any of the clinical outcomes reported in the trials, which includes deaths (at various time points), cirrhosis, liver failure or liver transplantation.']",3,0.2222222222222222,2,27
CD011646,1,6,None of the trials reported health-related quality of life or incidence of hepatocellular carcinoma.,rephrase,['None of the trials reported health-related quality of life or incidence of primary liver cancer.'],4,0.25925925925925924,2,27
CD011646,2,7,"Severe alcoholic hepatitis
Of the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis (Maddrey Discriminat Function > 32).",rephrase,"['Severe alcoholic hepatitis\nOf the trials on alcoholic hepatitis, 19 trials (2545 participants) included exclusively participants with severe alcoholic hepatitis.']",5,0.2962962962962963,2,27
CD011646,2,8,The period of follow-up ranged from one to 12 months.,ignore,['The period of follow-up ranged from one to 12 months.'],6,0.3333333333333333,2,27
CD011646,2,9,There was no alteration in the conclusions when only people with severe alcoholic hepatitis were included in the analysis.,ignore,['There was no alteration in the conclusions when only people with severe alcoholic hepatitis were included in the analysis.'],7,0.37037037037037035,2,27
CD011646,3,10,Source of funding: Eleven trials were funded by parties with vested interest in the results.,rephrase,['Eleven trials were funded by parties with vested interest in the results.'],8,0.4074074074074074,3,27
CD011646,3,11,Sixteen trials were funded by parties without vested interest in the results.,ignore,['Sixteen trials were funded by parties without vested interest in the results.'],9,0.4444444444444444,3,27
CD011646,3,12,The source of funding was not reported in 23 trials.,ignore,['The source of funding was not reported in 23 trials.'],10,0.48148148148148145,3,27
CD011646,4,13,"Other alcohol-related liver diseases
Thirty-one randomised clinical trials included 3695 participants with other alcohol-related liver diseases (with a wide spectrum of alcohol-related liver diseases).",rephrase,['Thirty-one randomised clinical trials included 3695 participants with other alcohol-related liver diseases (with a wide spectrum of alcohol-related liver diseases).'],11,0.5185185185185185,3,27
CD011646,4,14,The period of follow-up ranged from one to 48 months.,ignore,['The period of follow-up ranged from one to 48 months.'],12,0.5555555555555556,3,27
CD011646,4,15,"The mortality at maximal follow-up was lower in the propylthiouracil group versus the no intervention group (OR 0.45, 95% CI 0.26 to 0.78; 423 participants; 2 trials; low-quality evidence).",delete,[],13,0.5925925925925926,3,27
CD011646,4,16,"However, this result is based on two small trials at high risk of bias and further confirmation in larger trials of low risk of bias is necessary to recommend propylthiouracil routinely in people with other alcohol-related liver diseases.",rephrase,"['As a result, trials of low risk of bias of sufficient sample size are required before propylthiouracil can be recommended routinely.']",13,0.6296296296296297,4,27
CD011646,4,17,"The mortality at maximal follow-up was higher in the ursodeoxycholic acid group versus the no intervention group (OR 2.09, 95% CI 1.12 to 3.90; 226 participants; 1 trial; low-quality evidence).",delete,[],14,0.6666666666666666,4,27
CD011646,5,18,Source of funding: Twelve trials were funded by parties with vested interest in the results.,rephrase,['Twelve trials were funded by parties with vested interest in the results.'],14,0.7037037037037037,4,27
CD011646,5,19,Three trials were funded by parties without vested interest in the results.,ignore,['Three trials were funded by parties without vested interest in the results.'],15,0.7407407407407407,4,27
CD011646,5,20,The source of funding was not reported in 16 trials.,ignore,['The source of funding was not reported in 16 trials.'],16,0.7777777777777778,4,27
CD011646,6,21,"Because of very low-quality evidence, there is uncertainty in the effectiveness of any pharmacological intervention versus no intervention in people with alcoholic hepatitis or severe alcoholic hepatitis.",delete,[],17,0.8148148148148148,5,27
CD011646,6,22,"Based on low-quality evidence, propylthiouracil may decrease mortality in people with other alcohol-related liver diseases.",delete,[],17,0.8518518518518519,5,27
CD011646,6,23,"However, these results must be confirmed by adequately powered trials with low risk of bias before propylthiouracil can be considered effective.",delete,[],17,0.8888888888888888,5,27
CD011646,7,24,Future randomised clinical trials should be conducted with approximately 200 participants in each group and follow-up of one to two years in order to compare the benefits and harms of different treatments in people with alcoholic hepatitis.,merge,[],17,0.9259259259259259,5,27
CD011646,7,25,Randomised clinical trials should include health-related quality of life and report serious adverse events separately from adverse events.,merge,['Further high-quality randomised clinical trials are necessary.'],17,0.9629629629629629,5,27
CD011646,7,26,Future randomised clinical trials should have a low risk of bias and low risk of random errors.,none,[],17,1.0,5,27
CD008452,0,0,"With 8 studies added in this update, 17 met our inclusion criteria and had a total of 63,813 women.",rephrase,"['With 8 studies added in this update, we had 17 with a total of 63,813 women.']",0,0.045454545454545456,1,22
CD008452,0,1,"We focus here on 12 studies that provided high, moderate, or low quality evidence.",rephrase,"['We focus here on 12 studies with high, moderate, or low quality results.']",1,0.09090909090909091,1,22
CD008452,0,2,Most did not show a higher pregnancy risk among overweight or obese women.,split,"['Most did not show more pregnancies for overweight or obese women.', 'In one, overweight women had a higher pregnancy risk.', 'The other found a lower pregnancy rate for obese women versus nonobese women.', 'Obese women in the patch group had a higher pregnancy rate.']",2,0.13636363636363635,1,22
CD008452,0,3,"Of five COC studies, two found BMI to be associated with pregnancy but in different directions.",rephrase,['Two of five studies using birth control pills found differences between BMI groups.'],6,0.18181818181818182,1,22
CD008452,0,4,"With an OC containing norethindrone acetate and ethinyl estradiol (EE), pregnancy risk was higher for overweight women, i.e. with BMI ≥ 25 versus those with BMI < 25 (reported relative risk 2.49, 95% CI 1.01 to 6.13).",delete,[],7,0.22727272727272727,2,22
CD008452,0,5,"In contrast, a trial using an OC with levonorgestrel and EE reported a Pearl Index of 0 for obese women (BMI ≥ 30) versus 5.59 for nonobese women (BMI < 30).",delete,[],7,0.2727272727272727,2,22
CD008452,0,6,The same trial tested a transdermal patch containing levonorgestrel and EE.,delete,[],7,0.3181818181818182,2,22
CD008452,0,7,"Within the patch group, obese women in the ""treatment-compliant"" subgroup had a higher reported Pearl Index than nonobese women (4.63 versus 2.15).",delete,[],7,0.36363636363636365,2,22
CD008452,0,8,"Of five implant studies, two that examined the six-capsule levonorgestrel implant showed differences in pregnancy by weight.",split,"['Of five implant studies, two showed differences among weight groups.', 'They studied the older six-capsule implant.']",7,0.4090909090909091,3,22
CD008452,0,9,One study showed higher weight was associated with higher pregnancy rate in years 6 and 7 combined (reported P < 0.05).,rephrase,['One study showed a higher pregnancy rate in years 6 and 7 combined for women weighing 70 kg or more.'],9,0.45454545454545453,3,22
CD008452,0,10,"In the other, pregnancy rates differed in year 5 among the lower weight groups only (reported P < 0.01) and did not involve women weighing 70 kg or more.",rephrase,['The other reported pregnancy differences in year 5 among the lower weight groups only.'],10,0.5,3,22
CD008452,1,11,Analysis of data from other contraceptive methods indicated no association of pregnancy with overweight or obesity.,rephrase,['Results for other methods of birth control did not show overweight or obesity related to pregnancy rate.'],11,0.5454545454545454,3,22
CD008452,1,12,"These included depot medroxyprogesterone acetate (subcutaneous), levonorgestrel IUC, the two-rod levonorgestrel implant, and the etonogestrel implant.",rephrase,"['Those methods included an injectable, hormonal IUC, and the two-rod and single-rod implants.']",12,0.5909090909090909,3,22
CD008452,2,13,The evidence generally did not indicate an association between higher BMI or weight and effectiveness of hormonal contraceptives.,rephrase,['These studies generally did not show an association of BMI or weight with the effect of hormonal methods.'],13,0.6363636363636364,4,22
CD008452,2,14,"However, we found few studies for most contraceptive methods.",rephrase,['We found few studies for most methods.'],14,0.6818181818181818,4,22
CD008452,2,15,"Studies using BMI, rather than weight alone, can provide information about whether body composition is related to contraceptive effectiveness.",rephrase,['Studies using BMI rather than weight can show whether body fat is related to how well birth control prevents pregnancy.'],15,0.7272727272727273,4,22
CD008452,2,16,The contraceptive methods examined here are among the most effective when used according to the recommended regimen.,rephrase,['The methods studied here work very well when used according to directions.'],16,0.7727272727272727,4,22
CD008452,3,17,We considered the overall quality of evidence to be low for the objectives of this review.,merge,"['The overall study quality was low for this review, especially in the older reports.']",17,0.8181818181818182,5,22
CD008452,3,18,"More recent reports provided evidence of varying quality, while the quality was generally low for older studies.",none,[],17,0.8636363636363636,5,22
CD008452,3,19,For many trials the quality would be higher for their original purpose rather than the non-randomized comparisons here.,rephrase,"['However, many studies would have higher quality for their original purpose than for the comparisons here.']",18,0.9090909090909091,5,22
CD008452,3,20,Investigators should consider adjusting for potential confounding related to BMI or contraceptive effectiveness.,delete,[],19,0.9545454545454546,5,22
CD008452,3,21,"Newer studies included a greater proportion of overweight or obese women, which helps in examining effectiveness and side effects of hormonal contraceptives within those groups.",delete,[],19,1.0,5,22
CD005950,0,0,We included 25 studies involving 676 participants from nine countries.,split,"['We included 25 studies with 676 study participants.', 'The studies, which were reported from nine countries, measured one or more of the following outcomes: arm function for real-life tasks appropriate to the upper limb (e.g. drinking from a cup, manipulating a doorknob), the amount and quality of movement in the arm, and activities of daily living.']",0,0.08333333333333333,1,12
CD005950,0,1,"For the comparison of MP in addition to other treatment versus the other treatment, MP in combination with other treatment appears more effective in improving upper extremity activity than the other treatment without MP (standardized mean difference [SMD] 0.66, 95% confidence interval [CI] 0.39 to 0.94; I² = 39%; 15 studies; 397 participants); the GRADE certainty of evidence score was moderate based on risk of bias for the upper extremity activity outcome.",delete,[],2,0.16666666666666666,1,12
CD005950,0,2,"For upper extremity impairment, results were as follows: SMD 0.59, 95% CI 0.30 to 0.87; I² = 43%; 15 studies; 397 participants, with a GRADE score of moderate, based on risk of bias.",delete,[],2,0.25,2,12
CD005950,0,3,"For ADLs, results were as follows: SMD 0.08, 95% CI -0.24 to 0.39; I² = 0%; 4 studies; 157 participants; the GRADE score was low due to risk of bias and small sample size.",delete,[],2,0.3333333333333333,2,12
CD005950,0,4,"For the comparison of MP versus conventional treatment, the only outcome with available data to combine (3 studies; 50 participants) was upper extremity impairment (SMD 0.34, 95% CI -0.33 to 1.00; I² = 21%); GRADE for the impairment outcome in this comparison was low due to risk of bias and small sample size.",delete,[],2,0.4166666666666667,3,12
CD005950,0,5,"Subgroup analyses of time post stroke, dosage of MP, or comparison type for the MP in combination with other rehabilitation treatment versus the other treatment comparison showed no differences.",delete,[],2,0.5,3,12
CD005950,0,6,"The secondary outcome of health-related quality of life was reported in only one study, and no study noted the outcomes of economic costs and adverse events.",rephrase,"['We sought but did not find evidence related to health-related quality of life, economic costs, and adverse events.']",2,0.5833333333333334,3,12
CD005950,1,7,Moderate-certainty evidence shows that MP in addition to other treatment versus the other treatment appears to be beneficial in improving upper extremity activity.,rephrase,"['Our review of the available literature provided moderate-certainty evidence that mental practice, when added to other physical rehabilitation treatment, produced improved outcomes compared to use of the other rehabilitation treatment alone.']",3,0.6666666666666666,4,12
CD005950,1,8,Moderate-certainty evidence also shows that MP in addition to other treatment versus the other treatment appears to be beneficial in improving upper extremity impairment after stroke.,rephrase,"['For mental practice added to other physical rehabilitation treatment compared to use of the other rehabilitation treatment alone, the certainty of evidence was moderate for arm function and arm movement outcomes based on some challenges in study design.']",4,0.75,4,12
CD005950,1,9,Low-certainty evidence suggests that ADLs may not be improved with MP in addition to other treatment versus the other treatment.,rephrase,['The certainty of evidence was low for the activities of daily living outcome based on study design and the small number of participants included.'],5,0.8333333333333334,5,12
CD005950,1,10,Low-certainty evidence also suggests that MP versus conventional treatment may not improve upper extremity impairment.,rephrase,"['For the mental practice compared to conventional treatment comparison, the certainty of evidence for the arm movement outcome was determined to be low for the same reasons.']",6,0.9166666666666666,5,12
CD005950,1,11,"Further study is required to evaluate effects of MP on time post stroke, the volume of MP required to affect outcomes, and whether improvement is maintained over the long term.",delete,[],7,1.0,5,12
CD009496,0,0,"Only one eligible study, involving 21 participants, was included.",rephrase,"['Only one study, involving 21 participants, was included in this review.']",0,0.1,1,10
CD009496,0,1,The study compared platelet-rich therapy and allogenic bone graft with allogenic bone graft alone in patients undergoing corrective osteotomy for medial compartment osteoarthrosis of the knee.,rephrase,['The study compared PRT and bone graft versus bone graft alone (control) in patients with osteoarthritis of the knee who had surgery where a wedge of bone was cut (osteotomy) from their tibia (shin bone) in order to change the pattern of weight bearing on the knee.'],1,0.2,1,10
CD009496,0,2,The risk of bias associated with this study was substantial.,delete,[],2,0.3,2,10
CD009496,0,3,There was no significant difference in patient-reported or clinician-assessed functional outcome scores between groups at one year.,rephrase,['The study found no difference between the PRT and control groups in patient-reported or clinician-assessed functional outcomes at one year.'],2,0.4,2,10
CD009496,0,4,There was a statistically significant benefit from platelet-rich therapy in the proportion of bones that were united at one year (8/9 versus 3/9; RR 2.67; 95% CI 1.03 to 6.91).,delete,[],3,0.5,3,10
CD009496,0,5,"This benefit, however, was not maintained when assuming poor outcomes for participants who were lost to follow-up (8/11 versus 3/10; RR 2.42; 95% CI 0.88 to 6.68).",delete,[],3,0.6,3,10
CD009496,0,6,One adverse event was reported in a participant receiving platelet-rich therapy.,rephrase,"['One adverse event was reported in a participant receiving platelet-rich therapy\nFrom the limited evidence that is currently available, the review found that PRT had no effect on functional outcomes.']",3,0.7,4,10
CD009496,1,7,One other eligible study involving hip fracture patients is currently underway.,rephrase,"['One other study involving hip fracture patients is currently underway, and will provide further evidence concerning the use of PRT in the future.']",4,0.8,4,10
CD009496,2,8,"While a potential benefit of platelet-rich therapies to augment long bone healing in adults cannot be ruled out, the currently available evidence from a single trial is insufficient to support the routine use of this intervention in clinical practice.",delete,[],5,0.9,5,10
CD009496,2,9,Future trials should focus on reporting patient-reported functional outcomes from all trial participants for a minimum follow-up of one year.,delete,[],5,1.0,5,10
CD011319,0,0,Eleven trials that randomized 1838 participants met the study inclusion criteria.,rephrase,['Our review included 11 clinical trials that randomized 1838 participants (current until December 2015).'],0,0.058823529411764705,1,17
CD011319,0,1,"Seven of the trials included femoropopliteal arterial lesions, three included tibial arterial lesions, and one included both.",rephrase,['The trials included thigh and leg arteries above and below the knee.'],1,0.11764705882352941,1,17
CD011319,0,2,The trials were carried out in Europe and in the USA and all used the taxane drug paclitaxel in the DEB arm.,rephrase,"['The trials were carried out in Europe and the USA, and all used DEBs that contained paclitaxel.']",2,0.17647058823529413,1,17
CD011319,0,3,Nine of the 11 trials were industry-sponsored.,delete,[],3,0.23529411764705882,2,17
CD011319,0,4,"Four companies manufactured the DEB devices (Bard, Bavaria Medizin, Biotronik, and Medtronic).",ignore,"['Four companies manufactured the DEB devices: Bard, Bavaria Medizin, Biotronik, and Medtronic.']",3,0.29411764705882354,2,17
CD011319,0,5,The trials examined both anatomic and clinical endpoints.,delete,[],4,0.35294117647058826,2,17
CD011319,0,6,There was heterogeneity in the frequency of stent deployment and the type and duration of antiplatelet therapy between trials.,rephrase,"['All the trials had differences in the way in which they inserted the balloons, and in the type and duration of additional antiplatelet (anticlotting) therapy, leading to downgrading of the quality of the evidence.']",4,0.4117647058823529,3,17
CD011319,0,7,"Using GRADE assessment criteria, the quality of the evidence presented was moderate for the outcomes of target lesion revascularization and change in Rutherford category, and high for amputation, primary vessel patency, binary restenosis, death, and change in ankle-brachial index (ABI).",rephrase,"['The quality of the evidence presented was moderate for target lesion revascularization and change in Rutherford category (a way of classifying PAD), and high for amputation, primary vessel patency, binary restenosis, death, and change in ankle-brachial index (which is used to predict the severity of PAD).']",5,0.47058823529411764,3,17
CD011319,0,8,"Most participants were followed up for 12 months, but one trial reported outcomes at five years.",rephrase,['Most participants were followed for 12 or more months (called follow-up).'],6,0.5294117647058824,3,17
CD011319,1,9,"There were better outcomes for DEBs for up to two years in primary vessel patency (odds ratio (OR) 1.47, 95% confidence interval (CI) 0.22 to 9.57 at six months; OR 1.92, 95% CI 1.45 to 2.56 at 12 months; OR 3.51, 95% CI 2.26 to 5.46 at two years) and at six months and two years for late lumen loss (mean difference (MD) -0.64 mm, 95% CI -1.00 to -0.28 at six months; MD -0.80 mm, 95% CI -1.44 to -0.16 at two years).",rephrase,"['At six and 12 months of follow-up, DEBs were associated with improved primary vessel patency, which is an indicator of whether a vessel is still patent without any further interventions (blood flowing well), late lumen loss, which is the difference in millimeters between the angioplastied segment and how narrow it is on follow-up, target lesion revascularization, which is an indicator of whether a person received more than one treatment to the same artery during the period covered by the study, and binary restenosis, which occurs when a treated artery becomes narrowed again after being previously treated.']",7,0.5882352941176471,3,17
CD011319,1,10,"DEB were also superior to uncoated balloon angioplasty for up to five years in target lesion revascularization (OR 0.28, 95% CI 0.17 to 0.47 at six months; OR 0.40, 95% CI 0.31 to 0.51 at 12 months; OR 0.28, 95% CI 0.18 to 0.44 at two years; OR 0.21, 95% CI 0.09 to 0.51 at five years) and binary restenosis rate (OR 0.44, 95% CI 0.29 to 0.67 at six months; OR 0.38, 95% CI 0.15 to 0.98 at 12 months; OR 0.26, 95% CI 0.10 to 0.66 at two years; OR 0.12, 95% CI 0.05 to 0.30 at five years).",delete,[],8,0.6470588235294118,4,17
CD011319,1,11,"There was no significant difference between DEB and uncoated angioplasty in amputation, death, change in ABI, change in Rutherford category and quality of life (QoL) scores, or functional walking ability, although none of the trials were powered to detect a significant difference in these clinical endpoints.",delete,[],8,0.7058823529411765,4,17
CD011319,1,12,"We carried out two subgroup analyses to examine outcomes in femoropopliteal and tibial interventions as well as in people with CLI (4 or greater Rutherford class), and showed no advantage for DEBs in tibial vessels at six and 12 months compared with uncoated balloon angioplasty.",delete,[],8,0.7647058823529411,4,17
CD011319,1,13,There was also no advantage for DEBs in CLI compared with uncoated balloon angioplasty at 12 months.,split,"['When we specifically examined arteries below the knee and people who had very advanced PAD, we found no clinical or angiographic advantage for DEBs at 12 months of follow-up compared with uncoated balloon angioplasty.', 'In summary, DEBs have several anatomic advantages over uncoated balloons for the treatment of lower limb PAD for up to 12 months after undergoing the procedure.']",8,0.8235294117647058,5,17
CD011319,2,14,"Based on a meta-analysis of 11 trials with 1838 participants, there is evidence of an advantage for DEBs compared with uncoated balloon angioplasty in several anatomic endpoints such as primary vessel patency (high-quality evidence), binary restenosis rate (moderate-quality evidence), and target lesion revascularization (low-quality evidence) for up to 12 months.",delete,[],10,0.8823529411764706,5,17
CD011319,2,15,"Conversely, there is no evidence of an advantage for DEBs in clinical endpoints such as amputation, death, or change in ABI, or change in Rutherford category during 12 months' follow-up.",delete,[],10,0.9411764705882353,5,17
CD011319,2,16,Well-designed randomized trials with long-term follow-up are needed to compare DEBs with uncoated balloon angioplasties adequately for both anatomic and clinical study endpoints before the widespread use of this expensive technology can be justified.,delete,[],10,1.0,5,17
CD005086,0,0,Four studies with a total of 136 participants were included.,ignore,['Four studies with a total of 136 participants were included.'],0,0.08333333333333333,1,12
CD005086,0,1,"Two studies compared the use of plugs versus no plugs, one study compared two sizes of the same brand of plug, and one study compared two brands of plugs.",split,"['Two studies compared the use of plugs versus no plugs.', 'One study compared two sizes of the same brand of plug; due to the high dropout in this study and the incomplete data, no results concerning this comparison are available.', 'In one study a comparison of two different brands of plug was made.']",1,0.16666666666666666,1,12
CD005086,0,2,In all included studies there was considerable dropout (in total 48 (35%) dropped out before the end of the study) for varying reasons.,ignore,['In all included studies there was considerable dropout; in total 48 participants (35%) dropped out before the end of the study for varying reasons.'],4,0.25,2,12
CD005086,0,3,Data presented are thus subject to potential bias.,rephrase,"['Data presented are thus subject to potential bias, and only tentative conclusions are possible.']",5,0.3333333333333333,2,12
CD005086,0,4,"'Pseudo-continence' was, however, achieved by some of those who continued to use plugs, at least in the short-term.",rephrase,"['The involuntary loss of stool was effectively blocked (pseudo-continence) in six (38%) participants who continued to use the plugs, at least in the short-term.']",6,0.4166666666666667,3,12
CD005086,0,5,"In a comparison of two different types of plug, plug loss was less often reported and overall satisfaction was greater during use of polyurethane plugs than polyvinyl-alcohol plugs.",split,"['Loss of plug was reported by 7 patients (30%) with a polyurethane (PU) plug and by 15 patients (65%) with the polyvinyl-alcohol (PVA) plug.', ""Overall satisfaction, defined as patients' opinion that the plug was good to very good, was reported more often for the PU plug (n = 17) than for the PVA plug (n = 8).""]",7,0.5,3,12
CD005086,1,6,"The available data were limited and incomplete, and not all pre-specified outcomes could be evaluated.",delete,[],9,0.5833333333333334,3,12
CD005086,1,7,"Consequently, only tentative conclusions are possible.",delete,[],9,0.6666666666666666,4,12
CD005086,1,8,The available data suggest that anal plugs can be difficult to tolerate.,ignore,['The available data suggest that anal plugs can be difficult to tolerate.'],9,0.75,4,12
CD005086,1,9,"However, if they are tolerated they can be helpful in preventing incontinence.",ignore,"['However, if they are tolerated they can be helpful in preventing incontinence.']",10,0.8333333333333334,5,12
CD005086,1,10,Plugs could then be useful in a selected group of people either as a substitute for other forms of management or as an adjuvant treatment option.,ignore,['Plugs could then be useful in a selected group of people either as a substitute for other forms of management or as an adjuvant treatment option.'],11,0.9166666666666666,5,12
CD005086,1,11,Plugs come in different designs and sizes; the review showed that the selection of the type of plug can impact on its performance.,ignore,['Plugs come in different designs and sizes; the review showed that the selection of the type of plug can impact on its performance.'],12,1.0,5,12
CD013422,0,0,We identified eight RCTs reporting on 1239 participants.,rephrase,['We identified eight randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) reporting on 1239 participants.'],0,0.0625,1,16
CD013422,0,1,Five trials randomised participants to anticoagulation for up to three months versus no anticoagulation.,rephrase,['Five of these trials randomised participants to anticoagulation for up to three months compared with no anticoagulation.'],1,0.125,1,16
CD013422,0,2,Three trials compared anticoagulation treatment for different time periods.,ignore,['Three trials compared anticoagulation treatment for different time periods.'],2,0.1875,1,16
CD013422,1,3,"Anticoagulant compared to no intervention or placebo for distal DVT treatment
Anticoagulation with a vitamin K antagonist (VKA) reduced the risk of recurrent VTE during follow-up compared with participants receiving no anticoagulation (RR 0.34, 95% CI 0.15 to 0.77; 5 studies, 496 participants; I2 = 3%; high-certainty evidence), and reduced the risk of recurrence of DVT (RR 0.25, 95% CI 0.10 to 0.67; 5 studies, 496 participants; I2 = 0%; high-certainty evidence).",rephrase,"['Our review demonstrated that in participants with distal DVT compared with no anticoagulation or placebo (pretend treatment), anticoagulation reduced the risk of recurrence of VTE.']",3,0.25,2,16
CD013422,1,4,"There was no clear effect on risk of pulmonary embolism (PE) (RR 0.81, 95% CI 0.18 to 3.59; 4 studies, 480 participants; I2 = 0%; low-certainty evidence).",delete,[],4,0.3125,2,16
CD013422,1,5,"There was little to no difference in major bleeding with anticoagulation compared to placebo (RR 0.76, 95% CI 0.13 to 4.62; 4 studies, 480 participants; I2 = 26%; low-certainty evidence).",delete,[],4,0.375,2,16
CD013422,1,6,"There was an increase in clinically relevant non-major bleeding events in the group treated with anticoagulants (RR 3.34, 95% CI 1.07 to 10.46; 2 studies, 322 participants; I2 = 0%; high-certainty evidence).",delete,[],4,0.4375,3,16
CD013422,1,7,"There was one death, not related to PE or major bleeding, in the anticoagulation group.",delete,[],4,0.5,3,16
CD013422,2,8,"Anticoagulation for three months or more compared to anticoagulation for six weeks for distal DVT treatment
Three RCTs of 736 participants compared three or more months of anticoagulation with six weeks of anticoagulation.",delete,[],4,0.5625,3,16
CD013422,2,9,"Anticoagulation with a VKA for three months or more reduced the incidence of recurrent VTE to 5.8% compared with 13.9% in participants treated for six weeks (RR 0.42, 95% CI 0.26 to 0.68; 3 studies, 736 participants; I2 = 50%; high-certainty evidence).",rephrase,"['For the comparison anticoagulation for three months or more versus six weeks, the reliability of the evidence was high for recurrence of VTE and DVT; and low for PE, major bleeding and clinically relevant non-major bleeding, The reliability of the evidence was downgraded because of variation (or imprecision) of the results due to small numbers of events.']",4,0.625,4,16
CD013422,2,10,"The risk for recurrence of DVT was also reduced (RR 0.32, 95% CI 0.16 to 0.64; 2 studies, 389 participants; I2 = 48%; high-certainty evidence), but there was probably little or no difference in PE (RR 1.05, 95% CI 0.19 to 5.88; 2 studies, 389 participants; I2 = 0%; low-certainty evidence).",delete,[],5,0.6875,4,16
CD013422,2,11,"There was no clear difference in major bleeding events (RR 3.42, 95% CI 0.36 to 32.35; 2 studies, 389 participants; I2 = 0%; low-certainty evidence) or clinically relevant non-major bleeding events (RR 1.76, 95% CI 0.90 to 3.42; 2 studies, 389 participants; I2 = 1%; low-certainty evidence) between three months or more of treatment and six weeks of treatment.",delete,[],5,0.75,4,16
CD013422,2,12,There were no reports for overall mortality or PE and major bleeding-related deaths.,delete,[],5,0.8125,5,16
CD013422,3,13,Our review found a benefit for people with distal DVT treated with anticoagulation therapy using VKA with little or no difference in major bleeding events although there was an increase in clinically relevant non-major bleeding when compared to no intervention or placebo.,ignore,"['Our review found a benefit for people with distal DVT treated with anticoagulation therapy with little or no clear difference in major bleeding events, although there was an increase in clinically relevant non-major bleeding when compared with no treatment or placebo.']",5,0.875,5,16
CD013422,3,14,The small number of participants in this meta-analysis and strength of evidence prompts a call for more research regarding the treatment of distal DVT.,rephrase,['The small number of participants in this meta-analysis and strength of evidence suggests more research regarding the treatment of distal DVT is needed.'],6,0.9375,5,16
CD013422,3,15,"RCTs comparing different treatments and different treatment periods with placebo or compression therapy, are required.",rephrase,['Randomised controlled trials comparing different treatments and different treatment periods with placebo or compression therapy are required.'],7,1.0,5,16
CD008478,0,0,"Fifteen studies (2,223,592 participants - 25,008 treated and 2,198,584 untreated) that fulfilled the inclusion criteria for this review were identified from the literature search.",delete,[],0,0.07692307692307693,1,13
CD008478,0,1,The meta-analysis demonstrated that treatment for CIN did not adversely affect the chances of conception.,delete,[],0,0.15384615384615385,1,13
CD008478,0,2,"The overall pregnancy rate was higher for treated (43%) versus untreated women (38%; RR 1.29, 95% CI 1.02 to 1.64; 4 studies, 38,050 participants, very low quality), although the inter-study heterogeneity was considerable (P < 0.01).",rephrase,['We identified fifteen suitable studies.Fertility outcomesThe results suggest that local treatment of the cervix does not adversely affect the ability to conceive; in fact the overall pregnancy rate was higher for treated women when compared to untreated women (43% versus 38%).'],0,0.23076923076923078,2,13
CD008478,0,3,"The pregnancy rates in treated and untreated women with an intention to conceive (88% versus 95%, RR 0.93, 95% CI 0.80 to 1.08; 2 studies, 70 participants, very low quality) and the number of women requiring more than 12 months to conceive (14% versus 9%, RR 1.45, 95% CI 0.89 to 2.37; 3 studies, 1348 participants, very low quality) were no different.",rephrase,['There was no difference in the pregnancy rates in women that intended to conceive (88% treated versus 95% untreated) or in the number of women requiring more than 12 months to conceive (15% treated versus 9% untreated).'],1,0.3076923076923077,2,13
CD008478,0,4,"Although the total miscarriage rate (4.6% versus 2.8%, RR 1.04, 95% CI 0.90 to 1.21; 10 studies, 39,504 participants, low quality) and first trimester miscarriage rate (9.8% versus 8.4%, RR 1.16, 95% CI 0.80 to 1.69, 4 studies, 1103 participants, low quality) was similar for treated and untreated women, CIN treatment was associated with an increased risk of second trimester miscarriage, (1.6% versus 0.4%, RR 2.60, 95% CI 1.45 to 4.67; 8 studies, 2,182,268 participants, low quality).",delete,[],2,0.38461538461538464,2,13
CD008478,0,5,"The number of ectopic pregnancies (1.6% versus 0.8%, RR 1.89, 95% CI 1.50 to 2.39; 6 studies, 38,193 participants, low quality) and terminations (12.2% versus 7.4%, RR 1.71, 95% CI 1.31 to 2.22; 7 studies, 38,208 participants, low quality) were also higher in treated women.",rephrase,['The rates of ectopic pregnancies and terminations of pregnancy were higher for treated versus untreated women.'],2,0.46153846153846156,3,13
CD008478,1,6,The results should be interpreted with caution.,merge,['The results should be interpreted with caution as the included studies were small and of mixed design.'],3,0.5384615384615384,3,13
CD008478,1,7,The included studies were often small with heterogenous design.,none,[],3,0.6153846153846154,4,13
CD008478,1,8,Most of these studies were retrospective and of low or very low quality (GRADE assessment) and were therefore prone to bias.,rephrase,['Most of the studies were of low quality and retrospective (looking at information recorded previously).'],4,0.6923076923076923,4,13
CD008478,1,9,Subgroup analyses for the individual treatment methods and comparison groups and analysis to stratify for the cone length was not possible.,rephrase,['Investigation of the effect of different treatments techniques and of the size of the tissue removed (i.e. cone length) was not possible.'],5,0.7692307692307693,4,13
CD008478,2,10,"This meta-analysis suggests that treatment for CIN does not adversely affect fertility, although treatment was associated with an increased risk of miscarriage in the second trimester.",rephrase,"['The results suggest that treatment for CIN does not adversely affect the chances of a successful conception, although treatment is associated with an increased risk of miscarriage in the second trimester.']",6,0.8461538461538461,5,13
CD008478,2,11,These results should be interpreted with caution as the included studies were non-randomised and many were of low or very low quality and therefore at high risk of bias.,rephrase,['These conclusions should be interpreted with caution as the quality of the included studies was low or very low.'],7,0.9230769230769231,5,13
CD008478,2,12,Research should explore mechanisms that may explain the increase in mid-trimester miscarriage risk and stratify this impact of treatment by the length of the cone and the treatment method used.,rephrase,['Future research should investigate the impact related to the extent of the treatment and the treatment method used.'],8,1.0,5,13
CD010155,0,0,Two studies comprising 287 participants were included.,rephrase,['The review included two studies that lasted seven days with a total of 287 people.'],0,0.08333333333333333,1,12
CD010155,0,1,One study (with an overall unclear to high risk of bias) involved 253 participants and the quality of the evidence for most outcomes was very low.,rephrase,['One study involved 253 people (aged approximately 22 years) with sickle cell disease and compared tinzaparin with placebo and people were selected for one treatment or the other randomly.'],1,0.16666666666666666,1,12
CD010155,0,2,"This study, reported that pain severity at day two and day three was lower in the tinzaparin group than in the placebo group (P < 0.01, analysis of variance (ANOVA)) and additionally at day 4 (P < 0.05 (ANOVA)).",delete,[],2,0.25,2,12
CD010155,0,3,"Thus tinzaparin resulted in more rapid resolution of pain, as measured with a numerical pain scale.",rephrase,['Tinzaparin reduced the number of days spent in hospital and reduced the pain (and the intensity of the pain) more rapidly.'],2,0.3333333333333333,2,12
CD010155,0,4,The mean difference in duration of painful crises was statistically significant at -1.78 days in favour of the tinzaparin group (95% confidence interval -1.94 to -1.62).,delete,[],3,0.4166666666666667,3,12
CD010155,0,5,"Participants treated with tinzaparin had statistically significantly fewer hospitalisation days than participants in the group treated with placebo, with a mean difference of -4.98 days (95% confidence interval -5.48 to -4.48).",delete,[],3,0.5,3,12
CD010155,0,6,"Two minor bleeding events were reported as adverse events in the tinzaparin group, and none were reported in the placebo group.",rephrase,['Two minor bleedings were reported in the tinzaparin group versus none in the placebo group.'],3,0.5833333333333334,3,12
CD010155,0,7,The second study (unclear risk of bias) including 34 participants and was a conference abstract with limited data and only addressed one of the predefined outcomes of the review; i.e. pain intensity.,merge,[],4,0.6666666666666666,4,12
CD010155,0,8,"After one day pain intensity reduced more, as reported on a visual analogue scale, in the dalteparin group than in the placebo group, mean difference -1.30 (95% confidence interval -1.60 to -1.00), with the quality of evidence rated very low.",none,"['The data regarding the effectiveness of dalteparin were very limited and only addressed pain intensity, being more reduced by treatment with dalteparin than by placebo.']",4,0.75,4,12
CD010155,0,9,The most important reasons for downgrading the quality of evidence were serious risk of bias and imprecision (due to low sample size or low occurrence of events).,rephrase,"['The quality of the evidence for the majority of outcomes was very low, this had mainly to do with risk of bias of the studies (e.g. method of blinding unclear) or with small sample size of the studies.']",5,0.8333333333333334,5,12
CD010155,1,10,"Based on the results of two studies, evidence is incomplete to support or refute the effectiveness of low-molecular-weight heparins in people with sickle cell disease.",rephrase,['These data are not sufficient to support the conclusion that low-molecular-weight heparins are effective in the treatment of vaso-occlusive crises in people with sickle cell disease.'],6,0.9166666666666666,5,12
CD010155,1,11,"Vaso-occlusive crises are extremely debilitating for sufferers of sickle cell disease; therefore well-designed placebo-controlled studies with other types of low-molecular-weight heparins, and in participants with different genotypes of sickle cell disease, still need to be carried out to confirm or dismiss the results of this single study.",split,"['Additional studies with different types of low-molecular-weight heparin used in different forms of sickle cell disease, are necessary to confirm or dismiss the results of this single study.', 'Vaso-occlusive crises can be extremely debilitating and can have a significant impact on quality of life; therefore it is important to know whether low-molecular-weight heparins might serve as a useful treatment option with few side effects.']",7,1.0,5,12
CD011993,0,0,"We included nine RCTs (911 participants), including four different comparisons.",rephrase,['We included nine randomised controlled trials (RCTs) with a total of 910 participants in this review.'],0,0.043478260869565216,1,23
CD011993,0,1,"None of the studies evaluated our first primary outcome measure, disease-specific HRQL.",delete,[],1,0.08695652173913043,1,23
CD011993,1,2,"Fluticasone propionate versus beclomethasone dipropionate
We identified two small studies (56 participants with polyps) that evaluated disease severity  and looked at the primary adverse effect: epistaxis  , but no other outcomes.",rephrase,"['Different steroids: fluticasone propionate versus beclomethasone dipropionate\nTwo small studies (56 participants, unclear risk of bias) evaluated disease severity and looked at the primary adverse effect, epistaxis (nosebleed), but no other outcomes.']",1,0.13043478260869565,1,23
CD011993,1,3,We cannot report any numerical data but the study authors reported no difference between the two steroids.,merge,['No difference was found between the two steroids but we assessed the evidence to be of very low quality.'],2,0.17391304347826086,1,23
CD011993,1,4,The evidence was of very low quality.,none,[],2,0.21739130434782608,2,23
CD011993,2,5,"Fluticasone propionate versus mometasone furoate
We identified only one study (100 participants with polyps) that evaluated disease severity  (nasal symptoms scores), which reported no difference (no numerical data available).",rephrase,"['Different steroids: fluticasone propionate versus mometasone furoate\nOne study (100 participants, unclear risk of bias) found no difference in disease severity (nasal symptoms scores).']",3,0.2608695652173913,2,23
CD011993,2,6,The evidence was of very low quality.,rephrase,['We assessed this evidence to be of very low quality.'],4,0.30434782608695654,2,23
CD011993,3,7,"High-dose versus low-dose steroids
We included five studies (663 participants with nasal polyps), three using mometasone furoate (400 µg versus 200 µg in adults and older children, 200 µg versus 100 µg in younger children) and two using fluticasone propionate drops (800 µg versus 400 µg).",rephrase,"['High-dose versus low-dose steroids\nWe found five studies (663 participants, low or unclear risk of bias) that compared high-dose and low-dose steroids, three using mometasone furoate (400 µg versus 200 µg in adults and older children, 200 µg versus 100 µg in younger children), and two using fluticasone propionate drops (800 µg versus 400 µg).']",5,0.34782608695652173,2,23
CD011993,3,8,"We found low quality evidence relating to disease severity  and nasal polyps size, with results from the high-dose and low-dose groups being similar.",rephrase,['Effectiveness (disease severity and nasal polyps size) was similar between the high-dose and low-dose groups (low quality evidence).'],6,0.391304347826087,2,23
CD011993,3,9,"Although all studies reported more improvement in polyp score in the high-dose group, the significance of this is unclear due to the small size of the improvements.",rephrase,"['Although all studies reported more improvement in polyp score in the high-dose group, the significance of this is unclear because the improvements seen were small.']",7,0.43478260869565216,3,23
CD011993,4,10,"The primary adverse effect, epistaxis  , was more common when higher doses were used (risk ratio (RR) 2.06, 95% confidence interval (CI) 1.20 to 3.54, 637 participants, moderate quality evidence).",rephrase,"['The primary adverse effect, epistaxis, was more common when higher doses were used (moderate quality evidence).']",8,0.4782608695652174,3,23
CD011993,4,11,"Most of the studies that contributed data to this outcome used a broad definition of epistaxis, which ranged from frank bleeding to bloody nasal discharge to flecks of blood in the mucus.",delete,[],9,0.5217391304347826,3,23
CD011993,5,12,"Aqueous nasal spray versus aerosol spray
We identified only one poorly reported study (unclear number of participants for comparison of interest, 91 between three treatment arms), in which there were significant baseline differences between the participants in the two groups.",split,"['Different delivery methods: aqueous nasal spray versus aerosol spray\nWe identified only one poorly reported study with a high risk of bias.', 'There had also been significant differences between the participants in the two groups when they started the study.']",9,0.5652173913043478,3,23
CD011993,5,13,We were unable to draw meaningful conclusions from the data.,rephrase,['We were unable to draw any meaningful conclusions from this study.'],11,0.6086956521739131,4,23
CD011993,6,14,"We found insufficient evidence to suggest that one type of intranasal steroid is more effective than another in patients with chronic rhinosinusitis, nor that the effectiveness of a spray differs from an aerosol.",rephrase,"['We found no evidence that one type of intranasal steroid is more effective than another in patients with chronic rhinosinusitis, nor that higher doses are better than lower, nor that the effectiveness of a spray differs from an aerosol.']",12,0.6521739130434783,4,23
CD011993,6,15,We identified no studies that compared drops with spray.,rephrase,['We found no studies that compared nasal drops with spray.'],13,0.6956521739130435,4,23
CD011993,7,16,"It is unclear if higher doses result in better symptom improvements (low quality evidence), but there was moderate quality evidence of an increased risk of epistaxis as an adverse effect of treatment when higher doses were used.",rephrase,['We did find moderate quality evidence of an increased risk of epistaxis (nosebleed) as an adverse effect of treatment when higher doses were used.'],14,0.7391304347826086,4,23
CD011993,7,17,This included all levels of severity of epistaxis and it is likely that the proportion of events that required patients to discontinue usage is low due to the low numbers of withdrawals attributed to it.,delete,[],15,0.782608695652174,4,23
CD011993,7,18,If epistaxis is limited to streaks of blood in the mucus it may be tolerated by the patient and it may be safe to continue treatment.,delete,[],15,0.8260869565217391,5,23
CD011993,7,19,"However, it may be a factor that affects compliance.",delete,[],15,0.8695652173913043,5,23
CD011993,8,20,There is insufficient evidence to suggest that the different types of corticosteroid molecule or spray versus aerosol have different effects.,delete,[],15,0.9130434782608695,5,23
CD011993,8,21,Lower doses have similar effectiveness but fewer side effects.,delete,[],15,0.9565217391304348,5,23
CD011993,9,22,"Clearly more research in this area is needed, with specific attention given to trial design, disease-specific health-related quality of life outcomes and evaluation of longer-term outcomes and adverse effects.",split,"['More research in this area is clearly needed.', 'In the future studies should be well designed: they should measure chronic rhinosinusitis-specific health-related quality of life and adverse effects as outcomes, and look at what happens to patients taking intranasal steroids in the longer term.']",15,1.0,5,23
CD003353,0,0,"Four studies, with a total of 204 participants were included and analysed.",rephrase,"['The trials included a total of 204 adult participants; 108 participants were treated with metoclopramide, and 96 were given a placebo or no treatment.']",0,0.125,1,8
CD003353,0,1,The trials compared metoclopramide with placebo (two trials) or with no intervention (two trials).,delete,[],1,0.25,2,8
CD003353,0,2,Metoclopramide was investigated at doses of 10 mg (two trials) and 20 mg (two trials).,rephrase,"['They were all small, and examined two different doses of metoclopramide (10 mg and 20 mg), delivered in two different ways (intravenously, and injected into muscle).']",1,0.375,2,8
CD003353,0,3,"There was no statistically significant difference between metoclopramide versus placebo or no intervention administered to promote tube placement (RR 0.82, 95% CI 0.61 to 1.10).",delete,[],2,0.5,3,8
CD003353,0,4,"Metoclopramide at doses of 10 mg (RR 0.82, 95% CI 0.60 to 1.11) and 20 mg (RR 0.62, 95% CI 0.15 to 2.62) were equally ineffective in facilitating post-pyloric intubation when compared with placebo or no intervention.",delete,[],2,0.625,4,8
CD003353,1,5,"In this review, we found only four studies that fitted our inclusion criteria.",delete,[],2,0.75,4,8
CD003353,1,6,"These were small, underpowered studies, in which metoclopramide was given at doses of 10 mg and 20 mg. Our analysis showed that metoclopramide did not assist post-pyloric placement of naso-enteral feeding tubes.",rephrase,['Analysis of the four trials revealed that metoclopramide did not have a clear beneficial on the placement of post-pyloric naso-enteral feeding tubes.'],2,0.875,5,8
CD003353,2,7,"Ideally randomised clinical trials should be performed that have a significant sample size, administering metoclopramide against control, however, given the lack of efficacy revealed by this review it is unlikely that further studies will be performed.",rephrase,['It is unlikely that further studies will be performed to establish whether metoclopramide is helpful in placement of post-pyloric naso-enteral feeding tubes.'],3,1.0,5,8
CD010225,0,0,We included eight studies in the review and seven in the meta-analysis.,rephrase,['We included eight studies in our review and seven studies (involving 772 patients) in our meta-analysis.'],0,0.08333333333333333,1,12
CD010225,0,1,"Of those seven studies, only two were judged to be at low risk of bias.",delete,[],1,0.16666666666666666,1,12
CD010225,0,2,"Overall, no strong evidence exists that etomidate increases mortality in critically ill patients when compared to other bolus dose induction agents (odds ratio (OR) 1.17; 95% confidence interval (CI) 0.86 to 1.60, 6 studies, 772 participants, moderate quality evidence).",rephrase,"['No strong evidence exists to suggest that etomidate, when compared to other bolus dose induction agents, increases mortality in critically ill patients.']",1,0.25,2,12
CD010225,0,3,"Due to a large number of participants lost to follow-up, we performed a post hoc sensitivity analysis.",delete,[],2,0.3333333333333333,2,12
CD010225,0,4,This gave a similar result (OR 1.15; 95% CI 0.86 to 1.53).,delete,[],2,0.4166666666666667,3,12
CD010225,0,5,"There was evidence that the use of etomidate in critically ill patients was associated with a positive adrenocorticotropic hormone (ACTH) stimulation test, and this difference was more pronounced at between 4 to 6 hours (OR 19.98; 95% CI 3.95 to 101.11) than after 12 hours (OR 2.37; 95% CI 1.61 to 3.47) post-dosing.",delete,[],2,0.5,3,12
CD010225,0,6,"Etomidate's use in critically ill patients was associated with a small increase in SOFA score, indicating a higher risk of multisystem organ failure (mean difference (MD) 0.70; 95% CI 0.01 to 1.39, 2 studies, 591 participants, high quality evidence), but this difference was not clinically meaningful.",rephrase,['Using etomidate results in worse SOFA scores but this difference is small and not clinically meaningful.'],2,0.5833333333333334,3,12
CD010225,0,7,"Etomidate use did not have an effect on ICU LOS (MD 1.70 days; 95% CI -2.00 to 5.40, 4 studies, 621 participants, moderate quality evidence), hospital LOS (MD 2.41 days; 95% CI -7.08 to 11.91, 3 studies, 152 participants, moderate quality evidence), duration of mechanical ventilation (MD 2.14 days; 95% CI -1.67 to 5.95, 3 studies, 621 participants, moderate quality evidence), or duration of vasopressor use (MD 1.00 day; 95% CI -0.53 to 2.53, 1 study, 469 participants).",delete,[],3,0.6666666666666666,4,12
CD010225,1,8,"Although we have not found conclusive evidence that etomidate increases mortality or healthcare resource utilization in critically ill patients, it does seem to increase the risk of adrenal gland dysfunction and multi-organ system dysfunction by a small amount.",rephrase,['Etomidate does seem to impair adrenal gland functioning.'],3,0.75,4,12
CD010225,1,9,The clinical significance of this finding is unknown.,delete,[],4,0.8333333333333334,5,12
CD010225,1,10,"This evidence is judged to be of moderate quality, owing mainly to significant attrition bias in some of the smaller studies, and new research may influence the outcomes of our review.",rephrase,['Most of the evidence was moderate quality.'],4,0.9166666666666666,5,12
CD010225,1,11,"The applicability of these data may be limited by the fact that 42% of the patients in our review were intubated for ""being comatose"", a population less likely to benefit from the haemodynamic stability inherent in etomidate use, and less at risk from its potential negative downstream effects of adrenal suppression.",rephrase,['These people comprise 42% of those involved in the studies we looked at.'],5,1.0,5,12
CD008370,0,0,We identified 21 trials (19 trials of high risk of bias) involving 2348 people.,split,"['We included 21 randomised clinical trials in this review.', ""All trials had high risk of bias ('systematic error')."", 'A total of 2348 people were randomised either to somatostatin analogues or a control in the 21 trials.']",0,0.1,1,10
CD008370,0,1,There was no significant difference in the perioperative mortality (RR 0.80; 95% CI 0.56 to 1.16; n = 2210) or the number of people with drug-related adverse effects between the two groups (RR 2.09; 95% CI 0.83 to 5.24; n = 1199).,delete,[],3,0.2,1,10
CD008370,0,2,Quality of life was not reported in any of the trials.,rephrase,['Participant quality of life was not reported in any of the trials.'],3,0.3,2,10
CD008370,0,3,The overall number of participants with postoperative complications was significantly lower in the somatostatin analogue group (RR 0.70; 95% CI 0.61 to 0.80; n = 1903) but there was no significant difference in the re-operation rate (RR 1.26; 95% CI 0.58 to 2.70; n = 687) or hospital stay (MD -1.29 days; 95% CI -2.60 to 0.03; n = 1314) between the groups.,rephrase,"['The overall number of people with postoperative complications was lower by 30% in the somatostatin analogues group but there was no difference in postoperative mortality, re-operation rate or overall length of hospital stay between the groups.']",4,0.4,2,10
CD008370,0,4,The incidence of pancreatic fistula was lower in the somatostatin analogue group (RR 0.66; 95% CI 0.55 to 0.79; n = 2206).,delete,[],5,0.5,3,10
CD008370,0,5,The proportion of these fistulas that were clinically significant was not mentioned in most trials.,rephrase,['The proportion of these fistulas that resulted in change to the treatment given to the participants is not clear.'],5,0.6,3,10
CD008370,0,6,"On inclusion of trials that clearly distinguished clinically significant fistulas, there was no significant difference between the two groups (RR 0.69; 95% CI 0.38 to 1.28; n = 292).",rephrase,"['When we included trials that clearly distinguished fistulas that required change to the treatment given to the participants, there was no difference between the two groups.']",6,0.7,4,10
CD008370,1,7,Somatostatin analogues may reduce perioperative complications but do not reduce perioperative mortality.,rephrase,"['In conclusion, somatostatin analogues reduce the incidence of pancreatic fistula.']",7,0.8,4,10
CD008370,1,8,Further adequately powered trials with low risk of bias are necessary.,rephrase,['Further trials with sufficient participant numbers and a low risk of bias are necessary.'],8,0.9,5,10
CD008370,1,9,"Based on the current available evidence, somatostatin and its analogues are recommended for routine use in people undergoing pancreatic resection.",ignore,"['Based on the current available evidence, somatostatin and its analogues are recommended for routine use in people undergoing pancreatic resection.']",9,1.0,5,10
CD008758,0,0,Five trial reports were retrieved using the search strategies.,delete,[],0,0.05555555555555555,1,18
CD008758,0,1,Four trials were excluded.,delete,[],0,0.1111111111111111,1,18
CD008758,0,2,We did not identify any randomised controlled trials for inclusion but we included one quasi-randomised study (involving 210 women) that evaluated the effect of extra fluid for breastfeeding mothers on breastfeeding outcomes.,delete,[],0,0.16666666666666666,1,18
CD008758,0,3,The study was considered to be at a high risk of bias.,delete,[],0,0.2222222222222222,2,18
CD008758,0,4,Only one of this review's primary outcomes was reported (breast milk production (as defined by the trialist)) but data were not in a suitable format for analysis (no standard deviations or standard errors were reported).,delete,[],0,0.2777777777777778,2,18
CD008758,0,5,The trialist reported that advising women to drink extra fluids did not improve breast milk production.,delete,[],0,0.3333333333333333,2,18
CD008758,0,6,No data were reported for the review's other primary outcomes: satisfactory weight gain in the infant (as defined by the trialists) and duration of exclusive breastfeeding (months).,merge,"[""The trial was of low quality and did not report on two of this review's important outcomes (satisfactory weight gain in the infant or duration of exclusive breastfeeding).""]",0,0.3888888888888889,2,18
CD008758,0,7,"Similarly, no data were reported for any of this review's secondary outcomes: duration of any breastfeeding; mother's satisfaction with breastfeeding; hydration in mother; dehydration in the infant; or episodes of gastrointestinal illness.",none,[],0,0.4444444444444444,3,18
CD008758,1,8,This review only identified one small quasi-randomised controlled trial of low quality and high risk of bias.,rephrase,"['However, the review only identified one small quasi-randomised controlled trial (involving 210 women).']",1,0.5,3,18
CD008758,1,9,"The study provided limited data on only one of this review's primary outcomes, breast milk production, but the data were not reported in a format that permitted further analysis.",split,"['This review aimed to assess whether increasing fluid intake of breastfeeding mothers has a beneficial effect on breast milk production and infant growth.', ""The study did report on breast milk production (this review's other main outcome), but the data were not in a format that would permit further analysis in this review.""]",2,0.5555555555555556,3,18
CD008758,1,10,The trialist reported that extra fluids did not improve breast milk production.,merge,"['The trial reported that advising women to consume extra fluids did not result in increased breast milk production, as measured by test feeds (also known as test weighing).']",4,0.6111111111111112,4,18
CD008758,1,11,"However, this outcome was measured by using test feeds (also known as test weighing).",none,[],4,0.6666666666666666,4,18
CD008758,1,12,"In the 1950s, when the study was conducted, it was common for babies in developed countries to be weighed before and after a feed, known as test weighing or test feeding.",ignore,"['In the 1950s, when the study was conducted, it was common for babies in developed countries to be weighed before and after a feed, known as test weighing or test feeding.']",5,0.7222222222222222,4,18
CD008758,1,13,"However, this practice is not now routinely practiced for term infants due to concerns about lack of precision as a measure of breast milk production.",ignore,"['However, this practice is not now routinely practiced for term infants due to concerns about lack of precision as a measure of breast milk production.']",6,0.7777777777777778,4,18
CD008758,1,14,The included study did not report on this review's other primary outcomes (satisfactory weight gain in the infant or duration of exclusive breastfeeding) nor any of the review's secondary outcomes.,rephrase,"[""The included study did not report any of this review's secondary outcomes: duration of any breastfeeding; mother's satisfaction with breastfeeding; hydration in mother; dehydration in the infant; or episodes of gastrointestinal illness.""]",7,0.8333333333333334,5,18
CD008758,2,15,"The effect of additional fluids for breastfeeding mothers remains unknown, due to a lack of well-conducted trials.",ignore,"['The effect of additional fluids for breastfeeding mothers remains unknown, due to a lack of well-conducted trials.']",8,0.8888888888888888,5,18
CD008758,2,16,"However, because the physiological basis for any such improvement remains unclear, the conduct of further clinical trials may not be a priority.",ignore,"['However, because the physiological basis for any such improvement remains unclear, the conduct of further clinical trials may not be a priority.']",9,0.9444444444444444,5,18
CD008758,2,17,There is not enough evidence to support an increased fluid intake beyond what breastfeeding mothers are likely to require to meet their physiological needs.,ignore,['There is not enough evidence to support an increased fluid intake beyond what breastfeeding mothers are likely to require to meet their physiological needs.'],10,1.0,5,18
CD011015,0,0,We identified 13 studies (917 participants).,rephrase,"['In the current review, which looked for studies up to April 2015, we identified 13 studies involving 917 participants.']",0,0.0625,1,16
CD011015,0,1,"The evaluated treatment modalities consisted of a topical treatment (11 studies), an oral treatment (2 studies) and a parenteral treatment (2 studies).",rephrase,"['Eleven studies evaluated topical treatments (medication applied to the skin), two trials studied an oral treatment, and two studies assessed a parenteral treatment (via injection or infusion).']",1,0.125,1,16
CD011015,0,2,"Seven studies used a placebo or no intervention control group, whereas all others also or solely compared active treatment groups.",rephrase,"['Seven studies used a control group that received no treatment or a placebo, whereas all others also or solely compared two active treatment groups.']",2,0.1875,1,16
CD011015,0,3,No study evaluated the effects of ice or the application of cold or hot bandages.,ignore,['No study evaluated the effects of ice or the application of cold or hot bandages.'],3,0.25,2,16
CD011015,0,4,"Overall, the risk of bias in individual trials was moderate to high, although poor reporting hampered a full appreciation of the risk in most studies.",delete,[],4,0.3125,2,16
CD011015,0,5,"The overall quality of the evidence for each of the outcomes varied from low to moderate mainly due to risk of bias and imprecision, with only single trials contributing to most comparisons.",rephrase,"['The overall quality of the evidence for each of the outcomes varied from low to moderate, mainly because the studies had design flaws or were very small.']",4,0.375,2,16
CD011015,0,6,"Data on primary outcomes improvement of signs and symptoms and side effects attributed to the study treatment could not be statistically pooled because of the between-study differences in comparisons, outcomes and type of instruments to measure outcomes.",delete,[],5,0.4375,3,16
CD011015,1,7,"An array of topical treatments, such as heparinoid or diclofenac gels, improved pain compared to placebo or no intervention.",merge,"['Overall, topical treatments resulted in a higher and faster improvement of the clinical signs and symptoms compared to placebo or no intervention.']",5,0.5,3,16
CD011015,1,8,"Compared to placebo, oral non-steroidal anti-inflammatory drugs reduced signs and symptoms intensity.",none,[],5,0.5625,3,16
CD011015,1,9,"Safety issues were reported sparsely and were not available for some interventions, such as notoginseny creams, parenteral low-molecular-weight heparin or defibrotide.",rephrase,"['Reporting on safety data was limited, with no available information on some treatments (notoginseny creams, parenteral low-molecular-weight heparin or defibrotide).']",6,0.625,4,16
CD011015,1,10,"Although several trials reported on adverse events with topical heparinoid creams, Essaven gel or phlebolan versus control, the trials were underpowered to adequately measure any differences between treatment modalities.",rephrase,"['Although some studies reported on harmful side effects with topical heparinoid creams, Essaven gel or phlebolan, the trials were too small in size to adequately measure any differences between treatments.']",7,0.6875,4,16
CD011015,1,11,"Where reported, adverse events with topical treatments consisted mainly of local allergic reactions.",rephrase,['Reported side effects of topical treatments consisted mainly of local allergic reactions.'],8,0.75,4,16
CD011015,1,12,"Only one study of 15 participants assessed thrombus extension and symptomatic venous thromboembolism with either oral non-steroidal anti-inflammatory drugs or low-molecular-weight heparin, and it reported no cases of either.",split,"['Only one study with 15 participants assessed anything other than localised control of the condition.', 'That study reported on extension of the clot or symptomatic venous thromboembolism (when the blood clot breaks loose and travels in the blood stream), observing no cases when treated orally with non-steroidal anti-inflammatory drugs or with low-molecular-weight heparin.']",9,0.8125,5,16
CD011015,1,13,"No study reported on the development of suppurative phlebitis, catheter-related bloodstream infections or quality of life.",rephrase,"['None of the studies reported on the development of suppurative or septic phlebitis (when pus is formed inside the vein or around the vein wall or both), catheter-related bloodstream infections or quality of life.']",11,0.875,5,16
CD011015,2,14,The evidence about the treatment of acute infusion superficial thrombophlebitis is limited and of low quality.,rephrase,"['In short, the evidence about the treatment of acute infusion superficial thrombophlebitis is limited and of low quality, and we do not have enough information to recommend the use of any of the treatments studied.']",12,0.9375,5,16
CD011015,2,15,"Data appear too preliminary to assess the effectiveness and safety of topical treatments, systemic anticoagulation or oral non-steroidal anti-inflammatory drugs.",delete,[],13,1.0,5,16
CD011504,0,0,"We included 59 studies, including 214 to 169,485 participants, and 300 to 124, 644 households, mostly from Africa and Latin America, addressing the following six intervention types (three studies assessed two different types of interventions).",rephrase,"['We found 59 studies assessing different interventions in LMICs, including 214 to 169,485 participants and 300 to 124,644 households, mainly in Africa and Latin America.']",0,0.05263157894736842,1,19
CD011504,1,1,"Interventions that improved buying power:
Unconditional cash transfers (UCTs) (16 cRCTs, two RCTs, three PCSs): we found high-certainty evidence that UCTs improve food security and make little or no difference to cognitive function and development and low-certainty evidence that UCTs may increase dietary diversity and may reduce stunting.",rephrase,"['improve food security and make little or no difference to cognitive function (thoughts and understanding) and development (high-quality evidence), may increase dietary diversity (variety of the foods that people or households eat from different food groups) and reduce stunting (poor growth) (low-quality evidence).']",1,0.10526315789473684,1,19
CD011504,1,2,"The evidence was very uncertain about the effects of UCTs on the proportion of household expenditure on food, and on wasting.",rephrase,['It is very uncertain whether UCTs reduce the proportion of household expenditure on food and reduce wasting.'],2,0.15789473684210525,1,19
CD011504,1,3,"Regarding adverse outcomes, evidence from one trial indicates that UCTs reduce the proportion of infants who are overweight.",ignore,"['Regarding adverse outcomes, evidence from one trial indicates that UCTs reduce the proportion of infants who are overweight.']",3,0.21052631578947367,2,19
CD011504,2,4,"Conditional cash transfers (CCTs) (nine cRCTs, five PCSs): we found high-certainty evidence that CCTs result in little to no difference in the proportion of household expenditure on food and that they slightly improve cognitive function in children; moderate-certainty evidence that CCTs probably slightly improve dietary diversity and low-certainty evidence that they may make little to no difference to stunting or wasting.",rephrase,"['make little to no difference in the proportion of household expenditure on food and slightly improve cognitive function in children (high-quality evidence), probably slightly improve dietary diversity (moderate-quality evidence), and may make little to no difference to stunting or wasting (low bodyweight) (low-quality evidence).']",4,0.2631578947368421,2,19
CD011504,2,5,Evidence on adverse outcomes (two PCSs) shows that CCTs make no difference to the proportion of overweight children.,ignore,['Evidence on adverse outcomes (two studies) shows that CCTs make no difference to the proportion of overweight children.'],5,0.3157894736842105,2,19
CD011504,3,6,"Income generation interventions (six cRCTs, 11 PCSs): we found moderate-certainty evidence that income generation interventions probably make little or no difference to stunting or wasting; and low-certainty evidence that they may result in little to no difference to food security or that they may improve dietary diversity in children, but not for households.",rephrase,"['make little or no difference to stunting or wasting (moderate-quality evidence), may result in little to no difference to food security and may improve dietary diversity in children but not for households (low-quality evidence).']",6,0.3684210526315789,2,19
CD011504,4,7,"Interventions that addressed food prices:
Food vouchers (three cRCTs, one RCT): we found moderate-certainty evidence that food vouchers probably reduce stunting; and low-certainty evidence that that they may improve dietary diversity slightly, and may result in little to no difference in wasting.",rephrase,"['probably reduce stunting (moderate-quality evidence), may slightly improve dietary diversity and may result in little to no difference in wasting (low-quality evidence).']",7,0.42105263157894735,3,19
CD011504,5,8,"Food and nutrition subsidies (one cRCT, three PCSs): we found low-certainty evidence that food and nutrition subsidies may improve dietary diversity among school children.",rephrase,['may improve dietary diversity among school children (low-quality evidence).'],8,0.47368421052631576,3,19
CD011504,5,9,The evidence is very uncertain about the effects on household expenditure on healthy foods as a proportion of total expenditure on food (very low-certainty evidence).,ignore,['We are very uncertain about the effects on household expenditure on healthy foods as a proportion of total expenditure on food (very low-quality evidence).'],9,0.5263157894736842,3,19
CD011504,6,10,"Interventions that addressed the social environment:
Social support interventions (one cRCT, one PCS): we found moderate-certainty evidence that community grants probably make little or no difference to wasting; low-certainty evidence that they may make little or no difference to stunting.",rephrase,['community grants probably make little to no difference to wasting (moderate-quality evidence) and may make little or no difference to stunting (low-quality evidence).'],10,0.5789473684210527,3,19
CD011504,6,11,The evidence is very uncertain about the effects of village savings and loans on food security and dietary diversity.,rephrase,['We are very uncertain about the effects of village savings and loans on food security or dietary diversity (very low-quality evidence).'],11,0.631578947368421,4,19
CD011504,7,12,None of the included studies addressed the intervention category of infrastructure changes.,merge,['None of the included studies addressed the intervention category of infrastructure changes and none of the included studies reported on one of the primary outcomes: prevalence of undernourishment.'],12,0.6842105263157895,4,19
CD011504,7,13,"In addition, none of the studies reported on one of the primary outcomes of this review, namely prevalence of undernourishment.",none,[],12,0.7368421052631579,4,19
CD011504,8,14,The body of evidence indicates that UCTs can improve food security.,delete,[],13,0.7894736842105263,4,19
CD011504,8,15,"Income generation interventions do not seem to make a difference for food security, but the evidence is unclear for the other interventions.",rephrase,"['Seventeen studies looked at income generation interventions (for example, livestock management or self-help groups), four studies at food vouchers, four studies at providing food and nutrition subsidies, and two studies looked at social support interventions such as village savings and loans and community grant programmes.']",13,0.8421052631578947,5,19
CD011504,8,16,"CCTs, UCTs, interventions that help generate income, interventions that help minimise impact of food prices through food vouchers and subsidies can potentially improve dietary diversity.",delete,[],14,0.8947368421052632,5,19
CD011504,8,17,"UCTs and food vouchers may have a potential impact on reducing stunting, but CCTs, income generation interventions or social environment interventions do not seem to make a difference on wasting or stunting.",delete,[],14,0.9473684210526315,5,19
CD011504,8,18,"CCTs seem to positively impact cognitive function and development, but not UCTs, which may be due to school attendance, healthcare visits and other conditionalities associated with CCTs.",delete,[],14,1.0,5,19
CD006105,0,0,This updated review includes 13 RCTs involving a total of 1132 women with PCOS undergoing IVF/ICSI treatments.,rephrase,['We included 13 randomised controlled trials (a type of study in which participants are assigned to one of two or more treatment groups using a random method) involving a total of 1132 women assigned to receive either metformin (570) or placebo (dummy treatment)/no treatment (563).'],0,0.047619047619047616,1,21
CD006105,0,1,We stratified the analysis by type of ovarian stimulation protocol used (long gonadotrophin-releasing hormone agonist (GnRH-agonist) or short gonadotrophin-releasing hormone antagonist (GnRH-antagonist)) to determine whether the type of stimulation used influenced the outcomes.,merge,['We divided the analysis by type of ovarian stimulation protocol used during the IVF treatment (long GnRH-agonist or short GnRH-antagonist) to determine whether the type of stimulation used influenced the outcomes.'],1,0.09523809523809523,1,21
CD006105,0,2,We did not perform meta-analysis on the overall (both ovarian stimulation protocols combined) data for the outcomes of live birth and clinical pregnancy rates per woman because of substantial heterogeneity.,none,[],1,0.14285714285714285,1,21
CD006105,1,3,"In the long protocol GnRH-agonist subgroup, the pooled evidence showed that we are uncertain of the effect of metformin on live birth rate per woman when compared with placebo/no treatment (risk ratio (RR) 1.30, 95% confidence interval (CI) 0.94 to 1.79; 6 RCTs; 651 women; I2 = 47%; low-quality evidence).",rephrase,"['We are uncertain of the effect of metformin using long protocol GnRH-agonist on live birth rates compared with placebo or no treatment, but metformin may increase clinical pregnancy rate with this type of ovarian stimulation protocol.']",2,0.19047619047619047,1,21
CD006105,1,4,"This suggests that if the chance for live birth following placebo/no treatment is 28%, the chance following metformin would be between 27% and 51%.",split,"['We estimated that for a woman with a 28% chance of achieving a live birth (long protocol GnRH-agonist) following placebo or no treatment, the chance following metformin would be between 27% and 51%.', 'For a woman with a 28% chance of achieving a clinical pregnancy in long protocol GnRH-agonist without metformin, the chance using metformin would be between 30% and 45%.']",3,0.23809523809523808,2,21
CD006105,1,5,Only one study used short protocol GnRH-antagonist and reported live birth rate.,rephrase,"['For the short protocol GnRH-antagonist, metformin may reduce live birth rate, and we are uncertain of its effect on clinical pregnancy and OHSS rates compared with placebo/no treatment.']",5,0.2857142857142857,2,21
CD006105,1,6,"Metformin may reduce live birth rate compared with placebo/no treatment (RR 0.48, 95% CI 0.29 to 0.79; 1 RCT; 153 women; low-quality evidence).",rephrase,"['Overall, metformin may reduce the incidence of OHSS when compared with placebo/no treatment.']",6,0.3333333333333333,2,21
CD006105,1,7,"This suggests that if the chance for live birth following placebo/no treatment is 43%, the chance following metformin would be between 13% and 34% (short GnRH-antagonist protocol).",delete,[],7,0.38095238095238093,2,21
CD006105,1,8,"We found that metformin may reduce the incidence of OHSS (RR 0.46, 95% CI 0.29 to 0.72; 11 RCTs; 1091 women; I2 = 38%; low-quality evidence).",rephrase,['Metformin may reduce the incidence of OHSS.'],7,0.42857142857142855,3,21
CD006105,1,9,"This suggests that for a woman with a 20% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 14%.",ignore,"['For a woman with a 20% risk of OHSS without metformin, the corresponding risk using metformin would be between 6% and 14%.']",8,0.47619047619047616,3,21
CD006105,1,10,"Using long protocol GnRH-agonist stimulation, metformin may increase clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.32, 95% CI 1.08 to 1.63; 10 RCTs; 915 women; I2 = 13%; low-quality evidence).",delete,[],9,0.5238095238095238,3,21
CD006105,1,11,"Using short protocol GnRH-antagonist, we are uncertain of the effect of metformin on clinical pregnancy rate per woman compared with placebo/no treatment (RR 1.38, 95% CI 0.21 to 9.14; 2 RCTs; 177 women; I2 = 87%; very low-quality evidence).",delete,[],9,0.5714285714285714,3,21
CD006105,2,12,"We are uncertain of the effect of metformin on miscarriage rate per woman when compared with placebo/no treatment (RR 0.86, 95% CI 0.56 to 1.32; 8 RCTs; 821 women; I2 = 0%; low-quality evidence).",rephrase,['We are uncertain of the effect of metformin on miscarriage rates when compared with placebo/no treatment.'],9,0.6190476190476191,4,21
CD006105,2,13,"Metformin may result in an increase in side effects compared with placebo/no treatment (RR 3.35, 95% CI 2.34 to 4.79; 8 RCTs; 748 women; I2 = 0%; low-quality evidence).",delete,[],10,0.6666666666666666,4,21
CD006105,3,14,The overall quality of evidence ranged from very low to low.,split,"['The overall quality of evidence for the primary outcomes live birth rate and incidence of OHSS was low.', 'We assessed the evidence as low for the secondary outcomes clinical pregnancy rate (long protocol GnRH-agonist), miscarriage rate, and side effects, and very low for clinical pregnancy rate (short protocol GnRH-antagonist).']",10,0.7142857142857143,4,21
CD006105,3,15,"The main limitations were inconsistency, risk of bias, and imprecision.",rephrase,['The main limitations were risk of bias and imprecise results.'],12,0.7619047619047619,4,21
CD006105,4,16,This updated review on metformin versus placebo/no treatment before or during IVF/ICSI treatment in women with PCOS found no conclusive evidence that metformin improves live birth rates.,rephrase,"['This updated review on metformin versus placebo/no treatment before or during IVF/ICSI treatment in women with PCOS found no clear evidence that metformin improves live birth rates: the effect of metformin is uncertain using long protocol GnRH-agonist, but live birth rates may be reduced using short protocol GnRH-antagonist.']",13,0.8095238095238095,5,21
CD006105,4,17,"In a long GnRH-agonist protocol, we are uncertain whether metformin improves live birth rates, but metformin may increase the clinical pregnancy rate.",merge,"['Metformin may increase clinical pregnancy rates using long protocol GnRH-agonist, but we are uncertain of the effect using short protocol GnRH-antagonist.']",14,0.8571428571428571,5,21
CD006105,4,18,"In a short GnRH-antagonist protocol, metformin may reduce live birth rates, although we are uncertain about the effect of metformin on clinical pregnancy rate.",none,[],14,0.9047619047619048,5,21
CD006105,4,19,Metformin may reduce the incidence of OHSS but may result in a higher incidence of side effects.,ignore,"['Metformin may reduce the incidence of OHSS, but may result in a higher incidence of side effects.']",15,0.9523809523809523,5,21
CD006105,4,20,We are uncertain of the effect of metformin on miscarriage rate per woman.,ignore,['We are uncertain of the effect of metformin on miscarriage rate.'],16,1.0,5,21
CD002062,0,0,One non-blinded RCT comparing prednisone with no treatment in 35 eligible participants did not measure the primary outcome for this systematic review.,delete,[],0,0.058823529411764705,1,17
CD002062,0,1,The trial had a high risk of bias.,rephrase,"[""Those taking part and the trialists were aware of which treatment the participants received (i.e. they were not 'blinded'), which carries a risk of bias.""]",0,0.11764705882352941,1,17
CD002062,0,2,"Neuropathy Impairment Scale scores after 12 weeks improved in 12 of 19 participants randomised to prednisone, compared with five of 16 participants randomised to no treatment (risk ratio (RR) for improvement 2.02 (95% confidence interval (CI) 0.90 to 4.52; very low-quality evidence).",rephrase,"['After 12 weeks, in the trial of prednisone compared to no treatment, 12 of 19 participants on prednisone improved compared with five of 16 participants not on prednisone, based on measurement of disease severity by neurologists.']",1,0.17647058823529413,1,17
CD002062,0,3,"The trial did not report side effects in detail, but one prednisone-treated participant died.",delete,[],2,0.23529411764705882,2,17
CD002062,1,4,A double-blind RCT comparing daily standard-dose oral prednisolone with monthly high-dose oral dexamethasone in 40 participants reported none of the prespecified outcomes for this review.,rephrase,"['The second study compared two six-month corticosteroid treatment regimens: daily standard-dose prednisolone tablets, and high-dose dexamethasone tablets for four days each month.']",2,0.29411764705882354,2,17
CD002062,1,5,"The trial had a low risk of bias, but the quality of evidence was limited as it came from a single small study.",delete,[],3,0.35294117647058826,2,17
CD002062,1,6,"There was little or no difference in number of participants who achieved remission (RR 1.11; 95% CI 0.50 to 2.45 in favour of monthly dexamethasone; moderate-quality evidence), or change in disability or impairment after one year (low-quality evidence).",delete,[],3,0.4117647058823529,3,17
CD002062,1,7,Change of grip strength or Medical Research Council (MRC) scores demonstrated little or no difference between groups (moderate-quality to low-quality evidence).,delete,[],3,0.47058823529411764,3,17
CD002062,1,8,Eight of 16 people in the prednisolone group and seven of 24 people in the dexamethasone group deteriorated.,rephrase,"['In the RCT comparing two corticosteroid regimens, 10 of 24 people on monthly dexamethasone and six of 16 people on daily prednisolone were well and off treatment after a year, which indicates effects that are probably similar.']",3,0.5294117647058824,3,17
CD002062,1,9,"Side effects were similar with each regimen, except that sleeplessness was less common with monthly dexamethasone (low-quality evidence) as was moon facies (moon-shaped appearance of the face) (moderate-quality evidence).",rephrase,"['Monthly dexamethasone and daily prednisolone had similar side effects to one another, except that with high-dose monthly dexamethasone, sleeplessness may be less common and a moon-shaped facial appearance is probably less common.']",4,0.5882352941176471,3,17
CD002062,2,10,"Experience from large non-randomised studies suggests that corticosteroids are beneficial, but long-term use causes serious side effects.",rephrase,"['Corticosteroids are well known to cause side effects, especially when people take large doses for a long time.']",5,0.6470588235294118,4,17
CD002062,3,11,"We are very uncertain about the effects of oral prednisone compared with no treatment, because the quality of evidence from the only RCT that exists is very low.",rephrase,['The small numbers in the trial and its limitations meant that even with this difference we are very uncertain about the size of any effect of prednisone.'],6,0.7058823529411765,4,17
CD002062,3,12,"Nevertheless, corticosteroids are commonly used in practice, supported by very low-quality evidence from observational studies.",rephrase,"['Corticosteroids are commonly used for CIDP in practice, based on favourable reports from non-randomised studies.']",7,0.7647058823529411,4,17
CD002062,3,13,We also know from observational studies that corticosteroids carry the long-term risk of serious side effects.,delete,[],8,0.8235294117647058,5,17
CD002062,3,14,The efficacy of high-dose monthly oral dexamethasone is probably little different from that of daily standard-dose oral prednisolone.,rephrase,"['Monthly dexamethasone and daily prednisolone may be of similar benefit in CIDP, but monthly dexamethasone may have fewer side effects.']",8,0.8823529411764706,5,17
CD002062,3,15,"Most side effects occurred with similar frequencies in both groups, but with high-dose monthly oral dexamethasone moon facies is probably less common and sleeplessness may be less common than with oral prednisolone.",delete,[],9,0.9411764705882353,5,17
CD002062,3,16,We need further research to identify factors that predict response.,delete,[],9,1.0,5,17
CD003106,0,0,"We included six trials, with a total of 748 women in this review.",split,"['This review included six trials that randomly assigned women to a policy of interventionist management or expectant management when presenting with severe pre-eclampsia before 34 weeks of pregnancy.', 'A total of 748 women were included in these six trials.']",0,0.05555555555555555,1,18
CD003106,0,1,All trials included women in whom there was no overriding indication for immediate delivery in the fetal or maternal interest.,delete,[],2,0.1111111111111111,1,18
CD003106,0,2,Half of the trials were at low risk of bias for methods of randomisation and allocation concealment; and four trials were at low risk for selective reporting.,delete,[],2,0.16666666666666666,1,18
CD003106,0,3,"For most other domains, risk of bias was unclear.",delete,[],2,0.2222222222222222,2,18
CD003106,0,4,There were insufficient data for reliable conclusions about the comparative effects on most outcomes for the mother.,delete,[],2,0.2777777777777778,2,18
CD003106,0,5,Two studies reported on maternal deaths; neither study reported any deaths (two studies; 320 women; low-quality evidence).,rephrase,['There were no maternal deaths in the two studies that reported this outcome.'],2,0.3333333333333333,2,18
CD003106,0,6,"It was uncertain whether interventionist care reduced eclampsia (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.06 to 15.58; two studies; 359 women) or pulmonary oedema (RR 0.45, 95% CI 0.07 to 3.00; two studies; 415 women), because the quality of the evidence for these outcomes was very low.",rephrase,"[""The evidence was very low-quality for the outcome of fits or convulsions (eclampsia), or of fluid in the lungs (pulmonary oedema), and so it was uncertain whether interventionist care made any clear difference to the mothers' health.""]",3,0.3888888888888889,2,18
CD003106,0,7,"Evidence from two studies suggested little or no clear difference between the interventionist and expectant care groups for HELLP (haemolysis, elevated liver enzymes, and low platelets) syndrome (RR 1.09, 95% CI 0.62 to 1.91; two studies; 359 women; low-quality evidence).",rephrase,"['Evidence from two studies suggested little or no clear difference between the interventionist and expectant care groups for a severe form of pre-eclampsia, which affects the liver and blood clotting, called HELLP syndrome, which stands for haemolysis (breakdown of red blood cells), elevated liver enzymes (a sign of liver damage), and low platelets (platelets help the blood to clot).']",4,0.4444444444444444,3,18
CD003106,0,8,No study reported on stroke.,rephrase,['None of the studies reported on the incidence of stroke in the mother.'],5,0.5,3,18
CD003106,0,9,"With the addition of data from two studies for this update, there was now evidence to suggest that interventionist care probably made little or no difference to the incidence of caesarean section (average RR 1.01, 95% CI 0.91 to 1.12; six studies; 745 women; Heterogeneity: Tau² = 0.01; I² = 63%).",rephrase,"['With the addition of data from two studies for this update, there was now evidence to suggest that interventionist care probably made little or no difference to the caesarean section rate.']",6,0.5555555555555556,3,18
CD003106,1,10,"For the baby, there was insufficient evidence to draw reliable conclusions about the effects on perinatal deaths (RR 1.11, 95% CI 0.62 to 1.99; three studies; 343 women; low-quality evidence).",rephrase,['There was insufficient evidence for reliable conclusions about the effects on perinatal deaths.'],7,0.6111111111111112,4,18
CD003106,1,11,"Babies whose mothers had been allocated to the interventionist group had more intraventricular haemorrhage (RR 1.94, 95% CI 1.15 to 3.29; two studies; 537 women; moderate-quality evidence), more respiratory distress caused by hyaline membrane disease (RR 2.30, 95% CI 1.39 to 3.81; two studies; 133 women), required more ventilation (RR 1.50, 95% CI 1.11 to 2.02; two studies; 300 women), and were more likely to have a lower gestation at birth (mean difference (MD) -9.91 days, 95% CI -16.37 to -3.45 days; four studies; 425 women; Heterogeneity: Tau² = 31.74; I² = 76%).",merge,['Babies whose mothers had been allocated to the interventionist group were no more likely to be admitted to neonatal intensive care.'],8,0.6666666666666666,4,18
CD003106,1,12,"However, babies whose mothers had been allocated to the interventionist group were no more likely to be admitted to neonatal intensive care (average RR 1.19, 95% CI 0.89 to 1.60; three studies; 400 infants; Heterogeneity: Tau² = 0.05; I² = 84%).",merge,[],8,0.7222222222222222,4,18
CD003106,1,13,"Babies born to mothers in the interventionist groups were more likely to have a longer stay in the neonatal intensive care unit (MD 7.38 days, 95% CI -0.45 to 15.20 days; three studies; 400 women; Heterogeneity: Tau² = 40.93, I² = 85%) and were less likely to be small-for-gestational age (RR 0.38, 95% CI 0.24 to 0.61; three studies; 400 women).",none,[],8,0.7777777777777778,4,18
CD003106,1,14,There were no clear differences between the two strategies for any other outcomes.,delete,[],9,0.8333333333333334,5,18
CD003106,2,15,This review suggested that an expectant approach to the management of women with severe early onset pre-eclampsia may be associated with decreased morbidity for the baby.,delete,[],9,0.8888888888888888,5,18
CD003106,2,16,"However, this evidence was based on data from only six trials.",rephrase,['This evidence was based on data from only six trials.'],9,0.9444444444444444,5,18
CD003106,2,17,"Further large, high-quality trials are needed to confirm or refute these findings, and establish if this approach is safe for the mother.",rephrase,['Further large trials with long-term follow-up of the children are needed to confirm or refute whether expectant care is better than early delivery for women who suffer from severe pre-eclampsia before 34 weeks of pregnancy.'],10,1.0,5,18
CD004081,0,0,We included 19 studies involving 1940 participants in this updated review.,rephrase,['We included 19 randomized controlled trials (1940 participants) in this updated review.'],0,0.125,1,8
CD004081,0,1,"Of those 1940 participants, 952 received topical or systemic lidocaine therapy and 795 were allocated to the control groups.",delete,[],1,0.25,2,8
CD004081,0,2,"Topical and systemic lidocaine therapy appeared to reduce the risk of postoperative sore throat (16 studies, 1774 participants, risk ratio (RR) was 0.64 (95% confidence interval (CI) 0.48 to 0.85), the quality of the evidence was low), although when only high-quality trials were included (eight studies, 814 participants) the effect was no longer significant (RR 0.71, 95% CI 0.47 to 1.09).",rephrase,"['For lidocaine therapy versus control, the quality of the evidence for risk of sore throat was low (according to Grading of Recommendations Assessment, Development and Evaluation (GRADE)).']",1,0.375,2,8
CD004081,0,3,"Lidocaine given systemically in two studies (320 participants) did not reveal evidence of an effect (RR 0.44, 95% CI 0.19 to 1.05 ).",delete,[],2,0.5,3,8
CD004081,0,4,"The severity of sore throat as measured on a visual-analogue scale (VAS) was reduced by lidocaine therapy (six trials, 611 participants, (mean difference (MD) -10.80, 95% CI -14.63 to -6.98).",delete,[],2,0.625,4,8
CD004081,0,5,"The adverse effects of lidocaine were not reported in these studies, though toxicity is generally rare.",rephrase,"['Though the possible adverse effects of using lidocaine were not reported in the included studies, there are a few case reports about lidocaine toxicity, although this is very rare.']",2,0.75,4,8
CD004081,1,6,"In our revised systematic review, although the results of included studies show generally positive results, they should be interpreted carefully.",split,"['The summarized results of the included studies showed positive results.', 'However, the interpretation of the results should be judged carefully.']",3,0.875,5,8
CD004081,1,7,The effect size of lidocaine appeared to be affected by study quality; drug concentration; route of administration; management of cuff pressure during anaesthesia; the included population; and the type of outcome measured.,delete,[],5,1.0,5,8
CD012449,0,0,"We found 51 studies (52 papers), mostly from high-income countries and mostly describing women's perspectives.",ignore,"[""We found 51 studies, mostly from high-income countries and mostly describing women's perspectives.""]",0,0.03571428571428571,1,28
CD012449,0,1,We assessed our level of confidence in each finding using the GRADE-CERQual approach.,ignore,['We assessed our level of confidence in each finding using the GRADE-CERQual approach.'],1,0.07142857142857142,1,28
CD012449,0,2,We had high or moderate confidence in many of our findings.,ignore,['We had high or moderate confidence in many of our findings.'],2,0.10714285714285714,1,28
CD012449,0,3,"Where we only had low or very low confidence in a finding, we have indicated this.",ignore,"['Where we only had low or very low confidence in a finding, we have indicated this.']",3,0.14285714285714285,1,28
CD012449,1,4,Labour companions supported women in four different ways.,ignore,['Labour companions supported women in four different ways.'],4,0.17857142857142858,1,28
CD012449,1,5,"Companions gave informational support by providing information about childbirth, bridging communication gaps between health workers and women, and facilitating non-pharmacological pain relief.",ignore,"['Companions gave informational support by providing information about childbirth, bridging communication gaps between health workers and women, and facilitating non-pharmacological pain relief.']",5,0.21428571428571427,2,28
CD012449,1,6,"Companions were advocates, which means they spoke up in support of the woman.",ignore,"['Companions were advocates, which means they spoke up in support of the woman.']",6,0.25,2,28
CD012449,1,7,"Companions provided practical support, including encouraging women to move around, providing massage, and holding her hand.",ignore,"['Companions provided practical support, including encouraging women to move around, providing massage, and holding her hand.']",7,0.2857142857142857,2,28
CD012449,1,8,"Finally, companions gave emotional support, using praise and reassurance to help women feel in control and confident, and providing a continuous physical presence.",ignore,"['Finally, companions gave emotional support, using praise and reassurance to help women feel in control and confident, and providing a continuous physical presence.']",8,0.32142857142857145,2,28
CD012449,2,9,Women who wanted a companion present during labour and childbirth needed this person to be compassionate and trustworthy.,ignore,['Women who wanted a companion present during labour and childbirth needed this person to be compassionate and trustworthy.'],9,0.35714285714285715,2,28
CD012449,2,10,Companionship helped women to have a positive birth experience.,ignore,['Companionship helped women to have a positive birth experience.'],10,0.39285714285714285,2,28
CD012449,2,11,Women without a companion could perceive this as a negative birth experience.,ignore,['Women without a companion could perceive this as a negative birth experience.'],11,0.42857142857142855,3,28
CD012449,2,12,Women had mixed perspectives about wanting to have a male partner present (low confidence).,ignore,['Women had mixed perspectives about wanting to have a male partner present (low confidence).'],12,0.4642857142857143,3,28
CD012449,2,13,"Generally, men who were labour companions felt that their presence made a positive impact on both themselves (low confidence) and on the relationship with their partner and baby (low confidence), although some felt anxious witnessing labour pain (low confidence).",ignore,"['Generally, men who were labour companions felt that their presence made a positive impact on both themselves (low confidence) and on the relationship with their partner and baby (low confidence), although some felt anxious witnessing labour pain (low confidence).']",13,0.5,3,28
CD012449,2,14,Some male partners felt that they were not well integrated into the care team or decision-making.,ignore,['Some male partners felt that they were not well integrated into the care team or decision-making.'],14,0.5357142857142857,3,28
CD012449,3,15,Doulas often met with women before birth to build rapport and manage expectations.,ignore,['Doulas often met with women before birth to build rapport and manage expectations.'],15,0.5714285714285714,3,28
CD012449,3,16,Women could develop close bonds with their doulas (low confidence).,ignore,['Women could develop close bonds with their doulas (low confidence).'],16,0.6071428571428571,4,28
CD012449,3,17,Foreign-born women in high-income settings may appreciate support from community-based doulas to receive culturally-competent care (low confidence).,ignore,['Foreign-born women in high-income settings may appreciate support from community-based doulas to receive culturally-competent care (low confidence).'],17,0.6428571428571429,4,28
CD012449,4,18,"Factors affecting implementation included health workers and women not recognising the benefits of companionship, lack of space and privacy, and fearing increased risk of infection (low confidence).",ignore,"['Factors affecting implementation included health workers and women not recognising the benefits of companionship, lack of space and privacy, and fearing increased risk of infection (low confidence).']",18,0.6785714285714286,4,28
CD012449,4,19,Changing policies to allow companionship and addressing gaps between policy and practice were thought to be important (low confidence).,ignore,['Changing policies to allow companionship and addressing gaps between policy and practice were thought to be important (low confidence).'],19,0.7142857142857143,4,28
CD012449,4,20,"Some providers were resistant to or not well trained on how to use companions, and this could lead to conflict.",ignore,"['Some providers were resistant to or not well trained on how to use companions, and this could lead to conflict.']",20,0.75,4,28
CD012449,4,21,"Lay companions were often not integrated into antenatal care, which may cause frustration (low confidence).",ignore,"['Lay companions were often not integrated into antenatal care, which may cause frustration (low confidence).']",21,0.7857142857142857,4,28
CD012449,5,22,We compared our findings from this synthesis to the companionship programmes/approaches assessed in Bohren’s review of effectiveness.,ignore,['We compared our findings from this synthesis to the companionship programmes/approaches assessed in Bohren’s review of effectiveness.'],22,0.8214285714285714,5,28
CD012449,5,23,We found that most of these programmes did not appear to address these key features of labour companionship.,ignore,['We found that most of these programmes did not appear to address these key features of labour companionship.'],23,0.8571428571428571,5,28
CD012449,6,24,We have high or moderate confidence in the evidence contributing to several of these review findings.,delete,[],24,0.8928571428571429,5,28
CD012449,6,25,"Further research, especially in low- and middle-income settings and with different cadres of healthcare providers, could strengthen the evidence for low- or very low-confidence findings.",delete,[],24,0.9285714285714286,5,28
CD012449,6,26,"Ahead of implementation of labour companionship, researchers and programmers should consider factors that may affect implementation, including training content and timing for providers, women and companions; physical structure of the labour ward; specifying clear roles for companions and providers; integration of companions; and measuring the impact of companionship on women’s experiences of care.",delete,[],24,0.9642857142857143,5,28
CD012449,6,27,"Implementation research or studies conducted on labour companionship should include a qualitative component to evaluate the process and context of implementation, in order to better interpret results and share findings across contexts.",delete,[],24,1.0,5,28
CD005107,0,0,Seven heterogeneous English language RCTs with reasonable quality were included.,delete,[],0,0.1111111111111111,1,9
CD005107,1,1,Three small studies (168 people) separately showed statistically significant but clinically unimportant pain relief for LLLT versus sham therapy for sub-acute and chronic low-back pain at short-term and intermediate-term follow-up (up to six months).,rephrase,['Three studies (102 people) separately reported that LLLT with exercise was not better than exercise alone or exercise plus sham in short-term pain reduction.'],0,0.2222222222222222,2,9
CD005107,1,2,One study (56 people) showed that LLLT was more effective than sham at reducing disability in the short term.,ignore,['One study (56 people) showed that LLLT was more effective than sham at reducing disability in the short term.'],1,0.3333333333333333,2,9
CD005107,1,3,"Three studies (102 people) reported that LLLT plus exercise were not better than exercise, with or without sham in the short-term in reducing pain or disability.",rephrase,['Three studies (102 people) compared LLLT plus exercise with exercise plus sham or exercise alone and did not show significant reduction in disability.'],2,0.4444444444444444,3,9
CD005107,1,4,"Two studies (90 people) reported that LLLT was not more effective than exercise, with or without sham in reducing pain or disability in the short term.",rephrase,['Two studies (90 people) separately reported that LLLT was not more effective at reducing disability than exercise alone or exercise plus sham in the short-term.'],3,0.5555555555555556,3,9
CD005107,2,5,Two small trials (151 people) independently found that the relapse rate in the LLLT group was significantly lower than in the control group at the six-month follow-up.,delete,[],4,0.6666666666666666,4,9
CD005107,3,6,No side effects were reported.,delete,[],4,0.7777777777777778,4,9
CD005107,4,7,"Based on the heterogeneity of the populations, interventions and comparison groups, we conclude that there are insufficient data to draw firm conclusions on the clinical effect of LLLT for low-back pain.",rephrase,"['Based on these small trials, with different populations, LLLT doses and comparison groups, there are insufficient data to either support or refute the effectiveness of LLLT for the treatment of LBP.']",4,0.8888888888888888,5,9
CD005107,5,8,"There is a need for further methodologically rigorous RCTs to evaluate the effects of LLLT compared to other treatments, different lengths of treatment, wavelengths and dosages.",delete,[],5,1.0,5,9
CD002243,0,0,"We included 61 trials (12,192 participants), of which six included only children, two included children and adults, and the remaining trials included only adults.",rephrase,"['This review included 61 trials (12,192 participants).']",0,0.0625,1,16
CD002243,0,1,Nine studies are ongoing and will be considered in future versions of this review.,delete,[],1,0.125,1,16
CD002243,0,2,We judged 19 trials as being at low risk of bias.,delete,[],1,0.1875,1,16
CD002243,1,3,"Corticosteroids versus placebo or usual care
Compared to placebo or usual care, corticosteroids probably slightly reduce 28-day mortality (risk ratio (RR) 0.91, 95% confidence interval (CI) 0.84 to 0.99; 11,233 participants; 50 studies; moderate-certainty evidence).",rephrase,['• Corticosteroids versus placebo/usual care.'],1,0.25,2,16
CD002243,1,4,"Corticosteroids may result in little to no difference in long-term mortality (RR 0.97, 95% CI 0.91 to 1.03; 6236 participants; 7 studies; low-certainty evidence) and probably slightly reduce hospital mortality (RR 0.90, 95% CI 0.82 to 0.99; 8183 participants; 26 trials; moderate-certainty evidence).",rephrase,"['There may be little or no effect of corticosteroids on risk of dying over the long term (longer than three months), but these results are less certain.']",2,0.3125,2,16
CD002243,1,5,"Corticosteroids reduced length of intensive care unit (ICU) stay for all participants (mean difference (MD) -1.07 days, 95% CI -1.95 to -0.19; 7612 participants; 21 studies; high-certainty evidence) and resulted in a large reduction in length of hospital stay for all participants (MD -1.63 days, 95% CI -2.93 to -0.33; 8795 participants; 22 studies; high-certainty evidence).",rephrase,['Corticosteroids result in a large reduction in length of stay in the intensive care unit (ICU) and in hospital.'],3,0.375,2,16
CD002243,1,6,"Corticosteroids increase the risk of muscle weakness (RR 1.21, 95% CI 1.01 to 1.44; 6145 participants; 6 studies; high-certainty evidence).",rephrase,['Corticosteroids increase the risk of muscle weakness and hypernatraemia.'],4,0.4375,3,16
CD002243,1,7,"Corticosteroids probably do not increase the risk of superinfection (RR 1.06, 95% CI 0.95 to 1.19; 5356 participants; 25 studies; moderate-certainty evidence).",rephrase,['They probably do\xa0not increase the risk of superinfection.'],5,0.5,3,16
CD002243,1,8,Corticosteroids increase the risk of hypernatraemia (high-certainty evidence) and probably increase the risk of hyperglycaemia (moderate-certainty evidence).,rephrase,['They probably increase the risk of hyperglycaemia.'],6,0.5625,3,16
CD002243,1,9,"Moderate-certainty evidence shows that there is probably little or no difference in gastroduodenal bleeding, stroke, or cardiac events, and low-certainty evidence suggests that corticosteroids may result in little to no difference in neuropsychiatric events.",rephrase,"['There may be little or no effect of corticosteroids on risk of gastroduodenal bleeding, neuropsychiatric events, stroke, or cardiac events.']",7,0.625,4,16
CD002243,2,10,"Continuous infusion of corticosteroids versus intermittent bolus
We are uncertain about the effects of continuous infusion of corticosteroids compared with intermittent bolus administration.",rephrase,['We are uncertain about the effects of continuous infusion of corticosteroids compared with intermittent bolus administration.'],8,0.6875,4,16
CD002243,2,11,"Three studies reported data for this comparison, and the certainty of evidence for all outcomes was very low.",ignore,"['Three studies reported data for this comparison, and the certainty of evidence for all outcomes was very low.']",9,0.75,4,16
CD002243,3,12,Moderate-certainty evidence indicates that corticosteroids probably reduce 28-day and hospital mortality among patients with sepsis.,rephrase,"['• Corticosteroids versus placebo/usual care\nWe judged the certainty of evidence for 28-day mortality as moderate due to some inconsistency related to differences among study populations, types of corticosteroids and how they were given, and use of additional interventions.']",10,0.8125,5,16
CD002243,3,13,Corticosteroids result in large reductions in ICU and hospital length of stay (high-certainty evidence).,delete,[],11,0.875,5,16
CD002243,3,14,"There may be little or no difference in the risk of major complications; however, corticosteroids increase the risk of muscle weakness and hypernatraemia, and probably increase the risk of hyperglycaemia.",delete,[],11,0.9375,5,16
CD002243,3,15,The effects of continuous versus intermittent bolus administration of corticosteroids are uncertain.,rephrase,['• Continuous infusion versus intermittent boluses of corticosteroids\nWe judged the certainty of evidence for 28-day mortality as very low due to\xa0inconsistency and imprecision.'],11,1.0,5,16
CD004754,0,0,Five studies (316 adult patients) were included.,delete,[],0,0.125,1,8
CD004754,0,1,Four compared thiazides with standard treatment (periodic clinical follow-up and increased water intake) or specific dietary recommendations and one analysed the effect of thiazide plus a neutral potassium salt.,rephrase,['We identified four studies comparing thiazides (diuretics) with either standard treatment of clinical follow-up and increased water intake or specific dietary recommendations and one study comparing thiazides plus a potassium salt.'],0,0.25,2,8
CD004754,0,2,"There was a significant decrease in the number of new stone recurrences in those treated with thiazides (RR 1.61, 95% CI 1.33 to 1.96), although the follow-up periods varied.",rephrase,['There was a decrease in the number of new stones in the group receiving thiazides as well as an increase in the time taken for new stone formation.'],1,0.375,2,8
CD004754,0,3,"The stone formation rate also showed a statistically significant decrease in the patients treated with diuretics (MD -0.18, 95% CI -0.30 to -0.06).",delete,[],2,0.5,3,8
CD004754,0,4,Thiazides plus potassium salts significantly decreased calciuria and vitamin D levels.,rephrase,['The addition of potassium salts to thiazide treatment significantly reduced the amount of calcium excreted in the urine.'],2,0.625,4,8
CD004754,1,5,"There is some evidence that in patients with idiopathic hypercalciuria and recurrent stones, the addition of thiazides to a normal or modified diet for short to long periods (five months to three years) reduced the number of stone recurrences and decreased the stone formation rate.",delete,[],3,0.75,4,8
CD004754,1,6,Thiazides and neutral potassium phosphate decreased calciuria in symptomatic patients with idiopathic hypercalciuria.,delete,[],3,0.875,5,8
CD004754,1,7,There were no studies investigating the effect of pharmacological treatment on other clinical complications or asymptomatic idiopathic hypercalciuria.,rephrase,['No studies in children were identified and there were no studies investigating the use of drug treatment for those with hypercalciuria but were symptom free.'],3,1.0,5,8
CD009570,0,0,"We included 26 trials (2756 participants), all conducted in China.",split,"['We found 26 randomised controlled trials with 2756 participants.', 'All these trials were conducted in China with adult stroke patients of both sexes.']",0,0.1,1,10
CD009570,0,1,All participants were inpatients within the first few days after stroke onset (mean age 58 to 75 years and male proportion 45% to 80%).,rephrase,['All participants were in hospital and within the first few days after the onset of their stroke.'],2,0.2,1,10
CD009570,0,2,"Most trials delivered buflomedil intravenously, with a daily dose of 200 mg for 14 days.",ignore,"['Most trials delivered buflomedil intravenously, with a daily dose of 200 mg for 14 days.']",3,0.3,2,10
CD009570,0,3,The study quality was generally poor and many trials were poorly reported.,delete,[],4,0.4,2,10
CD009570,1,4,"Only one trial reported long-term death and disability, where stroke survivors in the buflomedil group had a lower risk of suffering 'death or disability' than those in the control group (200 participants, RR 0.71, 95% confidence interval (CI) 0.53 to 0.94).",delete,[],4,0.5,3,10
CD009570,1,5,"All 26 trials assessed outcomes by the end of treatment (eight trials with 1056 participants reported death, one trial with 85 participants reported disability, and 26 trials with 2756 participants reported neurological deficits), but there was no robust evidence for any of these short-term outcomes.",rephrase,"['Although all trials assessed outcomes immediately at the end of treatment, there was no robust evidence on the effects of buflomedil on any short-term outcomes.']",4,0.6,3,10
CD009570,1,6,"Seventeen trials (1899 participants) investigated the presence of adverse events during the treatment, of which six trials (853 participants) reported ""no significant adverse event in any participants"" and the other 11 trials (1046 participants) reported a total of 38 adverse events in the buflomedil group and two events in the control group.",delete,[],5,0.7,4,10
CD009570,1,7,"In general, for each of these outcomes the quality of evidence was low according to the GRADE principles.",rephrase,['The quality of evidence was generally low.'],5,0.8,4,10
CD009570,2,8,There is insufficient evidence on the efficacy or safety of buflomedil to support its use for the treatment of acute ischaemic stroke.,split,"['There was insufficient evidence to show whether buflomedil reduced the chance of dying or having less long-term disability in stroke survivors.', 'Also, there was insufficient evidence on the harms that the drug might cause.']",6,0.9,5,10
CD009570,2,9,"Given these uncertainties, the data support the rationale for an adequately powered RCT of buflomedil in people with acute ischaemic stroke.",delete,[],8,1.0,5,10
CD004962,0,0,We included seven trials (six randomised controlled trials and one quasi-randomised controlled trial) with 704 participants; three of these trials (234 participants) are new to this update.,split,"['We identified three new relevant studies in this update.', 'In total, this review now includes seven studies with 704 participants.']",0,0.037037037037037035,1,27
CD004962,0,1,"The mean age across the trials was 29 years (range 12 to 90 years), and 82% of the participants were male.",rephrase,['Most of the participants (82%) were male; the average age across the studies was 29 years (range 12 to 90 years).'],2,0.07407407407407407,1,27
CD004962,0,2,All trials compared immobilisation in external rotation (with or without an additional abduction component) versus internal rotation (the traditional method) following closed reduction.,rephrase,"['All of the studies investigated just one comparison: immobilisation in external rotation (when the arm is orientated outwards with the forearm away from the chest) versus immobilisation in internal rotation (the usual sling position, where the arm rests against the chest) following closed reduction.']",3,0.1111111111111111,1,27
CD004962,0,3,"No trial evaluated any other interventions or comparisons, such as rehabilitation.",delete,[],4,0.14814814814814814,1,27
CD004962,0,4,All trials provided data for a follow-up of one year or longer; the commonest length was two years or longer.,rephrase,['Participants were followed over different lengths of time; the most common duration was two years or longer.'],4,0.18518518518518517,1,27
CD004962,1,5,"All trials were at some risk of bias, commonly performance and detection biases given the lack of blinding.",delete,[],5,0.2222222222222222,2,27
CD004962,1,6,Two trials were at high risk of selection bias and some trials were affected by attrition bias for some outcomes.,delete,[],5,0.25925925925925924,2,27
CD004962,1,7,We rated the certainty of the evidence as very low for all outcomes.,delete,[],5,0.2962962962962963,2,27
CD004962,2,8,"We are uncertain whether immobilisation in external rotation makes a difference to the risk of re-dislocation after 12 months' or longer follow-up compared with immobilisation in internal rotation (55/245 versus 73/243; risk ratio (RR) 0.67, 95% confidence interval (CI) 0.38 to 1.19; 488 participants; 6 studies; I² = 61%; very low certainty evidence).",rephrase,['We are uncertain whether immobilisation in external rotation makes a difference to the risk of re-dislocation at one-year or more follow-up compared with immobilisation in internal rotation.'],5,0.3333333333333333,2,27
CD004962,2,9,"In a moderate-risk population with an illustrative risk of 312 per 1000 people experiencing a dislocation in the internal rotation group, this equates to 103 fewer (95% CI 194 fewer to 60 more) re-dislocations after immobilisation in external rotation.",delete,[],6,0.37037037037037035,2,27
CD004962,2,10,Thus this result covers the possibility of a benefit for each intervention.,delete,[],6,0.4074074074074074,3,27
CD004962,3,11,"Individually, the four studies (380 participants) reporting on validated patient-reported outcome measures for shoulder instability at a minimum of 12 months' follow-up found no evidence of a clinically important difference between the two interventions.",rephrase,['None of the four studies reporting on patient-reported outcome measures for shoulder instability at a minimum of one-year follow-up found evidence of any important difference between the two interventions.'],6,0.4444444444444444,3,27
CD004962,4,12,We are uncertain of the relative effects of the two methods of immobilisation on resumption of pre-injury activities or sports.,ignore,['We are uncertain of the relative effects of the two methods of immobilisation on resumption of pre-injury activities or sports.'],7,0.48148148148148145,3,27
CD004962,4,13,One study (169 participants) found no evidence of a difference between interventions in the return to pre-injury activity of the affected arm.,ignore,['One study found no evidence of a difference between interventions in the return to pre-injury activity of the affected arm.'],8,0.5185185185185185,3,27
CD004962,4,14,Two studies (135 participants) found greater return to sports in the external rotation group in a subgroup of participants who had sustained their injury during sports activities.,rephrase,['Two other studies found greater return to sports in the external rotation group in a small group of participants who had sustained their injury during sports activities.'],9,0.5555555555555556,3,27
CD004962,5,15,None of the trials reported on participant satisfaction or health-related quality of life.,ignore,['None of the trials reported on participant satisfaction or health-related quality of life.'],10,0.5925925925925926,3,27
CD004962,6,16,"We are uncertain whether there is a difference between the two interventions in the number of participants experiencing instability, defined as either re-dislocation or subluxation (RR 0.84, 95% CI 0.62 to 1.14; 395 participants, 3 studies; very low certainty evidence).",rephrase,"['We are uncertain whether there is a difference between the two interventions in the number of participants experiencing instability, defined as either re-dislocation or subluxation (a partial dislocation).']",11,0.6296296296296297,4,27
CD004962,7,17,Data on adverse events were collected only in an ad hoc way in the seven studies.,delete,[],12,0.6666666666666666,4,27
CD004962,7,18,"Reported ""transient and resolved adverse events"" were nine cases of shoulder stiffness or rigidity in the external rotation group and two cases of axillary rash in the internal rotation group.",rephrase,['There were reports of nine cases of short-term shoulder stiffness in the external rotation group and two cases of under-arm rash in the internal fixation group.'],12,0.7037037037037037,4,27
CD004962,7,19,"There were three ""important"" adverse events: hyperaesthesia and moderate hand pain; eighth cervical dermatome paraesthesia; and major movement restriction between 6 and 12 months.",rephrase,['There were three more serious adverse events: abnormal sensitivity and hand pain; abnormal sensation such as tingling in the little finger and along to the elbow; and major movement restriction.'],13,0.7407407407407407,4,27
CD004962,7,20,It was unclear to what extent these three events could be attributed to the treatment.,ignore,['It was unclear to what extent these three adverse events could be attributed to the treatment.'],14,0.7777777777777778,4,27
CD004962,8,21,The available evidence from randomised trials is limited to that comparing immobilisation in external versus internal rotation.,merge,[],15,0.8148148148148148,5,27
CD004962,8,22,"Overall, the evidence is insufficient to draw firm conclusions about whether immobilisation in external rotation confers any benefit over immobilisation in internal rotation.",none,"['Overall, the current evidence is insufficient to inform the choice of immobilisation in external versus internal rotation.']",15,0.8518518518518519,5,27
CD004962,9,23,"Considering that there are several unpublished and ongoing trials evaluating immobilisation in external versus internal rotation, the main priority for research on this question consists of the publication of completed trials and the completion and publication of ongoing trials.",delete,[],16,0.8888888888888888,5,27
CD004962,9,24,"Meanwhile, evaluation of other interventions, including rehabilitation, is warranted.",delete,[],16,0.9259259259259259,5,27
CD004962,9,25,"There is a need for sufficiently large, good-quality, well-reported randomised controlled trials with long-term follow-up.",delete,[],16,0.9629629629629629,5,27
CD004962,9,26,"Future research should aim to determine the optimal immobilisation duration, precise indications for immobilisation, optimal rehabilitation interventions, and the acceptability of these different interventions.",delete,[],16,1.0,5,27
CD010757,0,0,"The search identified 813 references on MEDLINE, 418 on EMBASE, 22 on CINAHL, 666 on PubMed, 291 on PsycINFO and 145 on CENTRAL.",delete,[],0,0.14285714285714285,1,7
CD010757,0,1,"When all references were imported into EndNote and duplications were removed, 1348 references remained.",delete,[],0,0.2857142857142857,2,7
CD010757,0,2,Initial screening of titles and abstracts of these references revealed that 42 references were potentially eligible for this review.,rephrase,"['We checked 1348 titles and abstracts of potentially relevant references, but we identified no randomised controlled trials (RCTs) that met our inclusion criteria.']",0,0.42857142857142855,3,7
CD010757,0,3,"After reading the full-text versions, we identified no relevant trials comparing hrHPV and cytology testing versus cytology testing alone for detecting residual or recurrent disease during follow-up to LLETZ treatment of adult women with CIN.",rephrase,"['We identified trials of interest, but they were deemed not relevant because of their focus on diagnostic outcomes and examination of how sensitive tests are, rather than on the effects of different follow-up strategies on long-term outcomes.']",1,0.5714285714285714,3,7
CD010757,1,4,"We found no evidence on the effects of hrHPV and cytology testing on residual or recurrent CIN2 or higher lesions, anxiety and psychosexual morbidity outcomes in women undergoing colposcopy and treatment for CIN.",rephrase,['Currently no evidence indicates whether hrHPV post-treatment testing is better or worse in terms of important long-term clinical outcomes.'],2,0.7142857142857143,4,7
CD010757,2,5,We found no evidence from RCTs to inform decisions about the best surveillance strategy for women following treatment for CIN.,ignore,['We found no evidence from RCTs to inform decisions about the best surveillance strategy following treatment for CIN.'],3,0.8571428571428571,5,7
CD010757,2,6,A prognostic systematic review is needed to investigate the risk of developing recurrent cervical intraepithelial neoplasia 2+ (CIN2+) in women with a positive hrHPV test after large loop excision of the transformation zone (LLETZ) treatment.,rephrase,['A prognostic systematic review is needed to investigate the risks and benefits of different follow-up strategies for women after LLETZ treatment.'],4,1.0,5,7
CD013373,0,0,"We included five trials (one RCT and four cluster-RCTs), with 16,257 health service users and more than 469 health service providers as trial participants.",rephrase,"['We found five studies that involved a total of 16,257 health service users and more than 469 health service providers.']",0,0.07142857142857142,1,14
CD013373,0,1,"For two trials, the aims of the partnerships were to directly improve the person-centredness of health services (via health service planning, and discharge co-ordination).",delete,[],1,0.14285714285714285,1,14
CD013373,0,2,"In the remaining trials, the aims were indirect (training first-year medical doctors on patient safety) or broader in focus (which could include person-centredness of health services that targeted the public/community, households or health service delivery to improve maternal and neonatal mortality).",delete,[],1,0.21428571428571427,2,14
CD013373,0,3,"Three trials were conducted in high income-countries, one was in a middle-income country and one was in a low-income country.",rephrase,['Three studies took place in high income-countries and one each in middle- and low-income countries.'],1,0.2857142857142857,2,14
CD013373,0,4,"Two studies evaluated working in partnership interventions, compared to usual practice without partnership (Comparison 1); and three studies evaluated working in partnership as part of a multi-component intervention, compared to the same intervention without partnership (Comparison 2).",rephrase,"['The studies compared:\n- working in partnership against usual practice without partnership working (2 studies); and\n- working in partnership as part of a wider strategy to promote person-centred health services, against the same wider strategy without partnership working (3 studies).']",2,0.35714285714285715,2,14
CD013373,0,5,No studies evaluated one form of working in partnership compared to another (Comparison 3).,rephrase,['No studies evaluated one form of working in partnership compared to another.'],3,0.42857142857142855,3,14
CD013373,1,6,"The effects of consumers and health providers working in partnership compared to usual practice without partnership are uncertain: only one of the two studies that assessed this comparison measured health service alteration outcomes, and data were not usable, as only intervention group data were reported.",delete,[],4,0.5,3,14
CD013373,1,7,"Additionally, none of the included studies evaluating this comparison measured the other primary or secondary outcomes we sought for the 'Summary of findings' table.",delete,[],4,0.5714285714285714,3,14
CD013373,2,8,We are also unsure about the effects of consumers and health providers working in partnership as part of a multi-component intervention compared to the same intervention without partnership.,delete,[],4,0.6428571428571429,4,14
CD013373,2,9,Very low-certainty evidence indicated there may be little or no difference on health service alterations or health service user health service performance ratings (two studies); or on health service user health service utilisation patterns and adverse events (one study each).,delete,[],4,0.7142857142857143,4,14
CD013373,2,10,"No studies evaluating this comparison reported the degree to which health service alterations reflect health service user priorities, or resource use.",rephrase,"['No studies investigated:\n- impacts on the extent to which changes to health services reflected service users’ priorities, or\n- the resources needed to make or act on decisions about health services.']",4,0.7857142857142857,4,14
CD013373,3,11,"Overall, our confidence in the findings about the effects of working in partnership interventions was very low due to indirectness, imprecision and publication bias, and serious concerns about risk of selection bias; performance bias, detection bias and reporting bias in most studies.",delete,[],5,0.8571428571428571,5,14
CD013373,4,12,"The effects of consumers and providers working in partnership as an intervention, or as part of a multi-component intervention, are uncertain, due to a lack of high-quality evidence and/or due to a lack of studies.",rephrase,"['There is not enough robust evidence to determine the effects of consumers and providers working in partnership to plan, deliver or evaluate health services.']",5,0.9285714285714286,5,14
CD013373,4,13,"Further well-designed RCTs with a clear focus on assessing outcomes directly related to partnerships for patient-centred health services are needed in this area, which may also benefit from mixed-methods and qualitative research to build the evidence base.",split,"['This review highlights the need for well-designed studies with a clear focus on evaluating the effects of partnerships for promoting person-centred care in health services.', 'This area of research may also benefit from studies that investigate why certain partnerships between consumers and healthcare providers may be more successful than others, and an accompanying qualitative evidence synthesis addressing this aspect is forthcoming.']",6,1.0,5,14
CD013107,0,0,We included eight randomised clinical trials with 555 randomised participants.,ignore,['We included eight randomised clinical trials with 555 participants.'],0,0.05,1,20
CD013107,0,1,All included trials compared acupuncture versus no intervention.,ignore,['All trials compared acupuncture versus no intervention.'],1,0.1,1,20
CD013107,0,2,These trials assessed heterogeneous acupuncture interventions.,rephrase,"['These trials assessed heterogeneous acupuncture interventions (i.e. manual needle acupuncture, acupoint herbal patching, acupoint injection, and moxibustion).']",2,0.15,1,20
CD013107,0,3,All trials used heterogeneous co-interventions applied equally in the compared groups.,ignore,['All trials used heterogeneous co-interventions applied equally in the compared groups.'],3,0.2,1,20
CD013107,0,4,"Seven trials included participants with chronic hepatitis B, and one trial included participants with chronic hepatitis B with comorbid tuberculosis.",split,"['Seven trials included participants with chronic hepatitis B.', 'One trial included chronic hepatitis B participants with tuberculosis and ascites.']",4,0.25,2,20
CD013107,0,5,"All trials were assessed at overall high risk of bias, and the certainty of evidence for all outcomes was very low due to high risk of bias for each outcome, imprecision of results (the confidence intervals were wide), and publication bias (small sample size of the trials, and all trials were conducted in China).",delete,[],6,0.3,2,20
CD013107,0,6,"Additionally, 79 trials lacked the necessary methodological information to ensure their inclusion in our review.",delete,[],6,0.35,2,20
CD013107,1,7,"None of the included trials aim to assess all-cause mortality, serious adverse events, health-related quality of life, hepatitis B-related mortality, and hepatitis B-related morbidity.",rephrase,"['None of the eight included trials reported data on clinically important outcomes such as all-cause mortality, serious adverse events, health-related quality of life, hepatitis B-related mortality, or hepatitis B-related morbidity.']",6,0.4,2,20
CD013107,1,8,"We are uncertain whether acupuncture, compared with no intervention, has an effect regarding adverse events considered not to be serious (RR 0.67, 95% CI 0.43 to 1.06; I² = 0%; 3 trials; 203 participants; very low-certainty evidence) or detectable hepatitis B e-antigen (HBeAg) (RR 0.64, 95% CI 0.11 to 3.68; I² = 98%; 2 trials; 158 participants; very low-certainty evidence).",rephrase,['We are uncertain whether acupuncture compared with no intervention has a beneficial or harmful effect regarding adverse events considered not to be serious.'],7,0.45,3,20
CD013107,1,9,"Acupuncture showed a reduction in detectable hepatitis B virus (HBV) DNA (a non-validated surrogate outcome; RR 0.45, 95% CI 0.27 to 0.74; 1 trial, 58 participants; very low-certainty evidence).",rephrase,['Acupuncture compared with no intervention seems to reduce the proportion of people with detectable hepatitis B virus (HBV) DNA (a non-validated surrogate outcome; only one trial).'],8,0.5,3,20
CD013107,1,10,We are uncertain whether acupuncture has an effect regarding the remaining separately reported adverse events considered not to be serious.,split,"['We are uncertain whether acupuncture compared with no intervention has an effect on the proportion of people with detectable HBeAg (a non-validated surrogate outcome; only two trials).', 'We are uncertain whether acupuncture compared with no intervention has an effect on the remaining separately reported adverse events considered not to be serious.']",9,0.55,3,20
CD013107,2,11,Three of the eight included trials received academic funding from government or hospital.,rephrase,['Three of the eight included randomised clinical trials received academic funding.'],11,0.6,3,20
CD013107,2,12,None of the remaining five trials reported information on funding.,ignore,['None of the remaining five trials reported information on support or funding.'],12,0.65,4,20
CD013107,3,13,The clinical effects of acupuncture for chronic hepatitis B remain unknown.,rephrase,"['Accordingly, we need more information from randomised clinical trials before benefits or harms of acupuncture for chronic hepatitis B can be determined.']",13,0.7,4,20
CD013107,3,14,"The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity.",delete,[],14,0.75,4,20
CD013107,3,15,The vast number of excluded trials lacked clear descriptions of their design and conduct.,delete,[],14,0.8,4,20
CD013107,3,16,Whether acupuncture influences adverse events considered not to be serious is uncertain.,delete,[],14,0.85,5,20
CD013107,3,17,"It remains unclear if acupuncture affects HBeAg, and if it is associated with reduction in detectable HBV DNA.",delete,[],14,0.9,5,20
CD013107,3,18,"Based on available data from only one or two small trials on adverse events considered not to be serious and on the surrogate outcomes HBeAg and HBV DNA, the certainty of evidence is very low.",split,"['The certainty of evidence on the use of acupuncture in people with chronic hepatitis B virus infection in terms of its beneficial or harmful effects on death, health-related quality of life, risk of dying due to HBV infection, and serious adverse events cannot be determined, as data on these outcomes were lacking.', 'The certainty of evidence on acupuncture, when compared with no intervention, in terms of adverse events considered not to be serious, the proportion of people with detectable HBV DNA, and the proportion of people with detectable HBeAg, is very low.', 'The very low certainty of the evidence is due to insufficient data ensuing from one, two, or very few trials with insufficient reporting.']",14,0.95,5,20
CD013107,3,19,"In view of the wide usage of acupuncture, any conclusion that one might try to draw in the future should be based on data on patient and clinically relevant outcomes, assessed in large, high-quality randomised sham-controlled trials with homogeneous groups of participants and transparent funding.",delete,[],17,1.0,5,20
CD011969,0,0,The review included six trials (n = 1758).,rephrase,['We found six trials with 1758 participants.'],0,0.09090909090909091,1,11
CD011969,0,1,"Trial participants were aged 48 to 57 years, except for one trial that had a mean age of 73 years.",rephrase,"['Participants were aged 48 to 57 years, except for one trial (average age of 73 years).']",1,0.18181818181818182,1,11
CD011969,0,2,All participants were from the outpatient setting and had either nonerosive reflux disease or milder grades of esophagitis (LA grade A or B).,rephrase,['The majority of participants had moderate heart burn and acid reflux with milder forms of esophagitis (inflammation of the food pipe that may lead to damage).'],2,0.2727272727272727,2,11
CD011969,0,3,Five trials investigated on-demand deprescribing and one trial examined abrupt discontinuation.,rephrase,"['Of these, five studies looked at on-demand deprescribing and one trial looked at abruptly stopping PPIs.']",3,0.36363636363636365,2,11
CD011969,0,4,"There was low quality evidence that on-demand use of PPI may increase risk of 'lack of symptom control' compared with continuous PPI use (risk ratio (RR) 1.71, 95% confidence interval (CI) 1.31 to 2.21), thereby favoring continuous PPI use (five trials, n = 1653).",delete,[],4,0.45454545454545453,3,11
CD011969,0,5,"There was a clinically significant reduction in 'drug burden', measured as PPI pill use per week with on-demand therapy (mean difference (MD) -3.79, 95% CI -4.73 to -2.84), favoring deprescribing based on moderate quality evidence (four trials, n = 1152).",delete,[],4,0.5454545454545454,3,11
CD011969,0,6,There was also low quality evidence that on-demand PPI use may be associated with reduced participant satisfaction compared with continuous PPI use.,delete,[],4,0.6363636363636364,4,11
CD011969,0,7,None of the included studies reported cost/resource use or positive drug withdrawal effects.,delete,[],4,0.7272727272727273,4,11
CD011969,1,8,"In people with mild GERD, on-demand deprescribing may lead to an increase in GI symptoms (e.g. dyspepsia, regurgitation) and probably a reduction in pill burden.",rephrase,['Deprescribing PPIs may lead to side effects such as inflammation of the esophagus.'],4,0.8181818181818182,5,11
CD011969,1,9,"There was a decline in participant satisfaction, although heterogeneity was high.",delete,[],5,0.9090909090909091,5,11
CD011969,1,10,"There were insufficient data to make a conclusion regarding long-term benefits and harms of PPI discontinuation, although two trials (one on-demand trial and one abrupt discontinuation trial) reported endoscopic findings in their intervention groups at study end.",rephrase,['Very few data were available to make a conclusion regarding long-term benefits and harms of PPI reduction or discontinuation.'],5,1.0,5,11
CD004219,0,0,We found six trials recruiting a total of 549 infants.,rephrase,['We found six small randomised controlled trials (enrolling 549 infants in total) that addressed this question.'],0,0.125,1,8
CD004219,0,1,"One trial showed that use of a percutaneous central venous catheter was associated with a smaller deficit between prescribed and actual nutrient intake during the trial period (mean difference (MD) -7.1%, 95% confidence interval (CI) -11.02 to -3.2).",merge,[],1,0.25,2,8
CD004219,0,2,"Infants in the percutaneous central venous catheter group needed significantly fewer catheters/cannulae (MD -4.3, 95% CI -5.24, -3.43).",none,['Analysis of data from three trials revealed that infants in the percutaneous central venous catheter group needed about four fewer catheters or cannulae during hospitalisation.'],1,0.375,2,8
CD004219,0,3,"Meta-analysis of data from all trials revealed no evidence of an effect on the incidence of invasive infection (typical risk ratio (RR) 0.95, 95% CI 0.72 to 1.25; typical risk difference (RD) -0.01, 95% CI -0.08 to 0.06).",rephrase,['Combined data from all trials showed no evidence of an effect on risk of bloodstream infection.'],2,0.5,3,8
CD004219,1,4,Data from one small trial suggest that use of percutaneous central venous catheters to deliver parenteral nutrition increases nutrient input.,delete,[],3,0.625,4,8
CD004219,1,5,The significance of this in relation to long-term growth and developmental outcomes is unclear.,delete,[],3,0.75,4,8
CD004219,1,6,Three trials suggest that use of percutaneous central venous catheters decreases the number of catheters/cannulae needed to deliver nutrition.,delete,[],3,0.875,5,8
CD004219,1,7,"No evidence suggests that percutaneous central venous catheter use increases risks of adverse events, particularly invasive infection, although none of the included trials was large enough to rule out an effect on uncommon severe adverse events such as pericardial effusion.",rephrase,"['Use of central venous catheters has been thought to increase the risk of bloodstream infection in newborn infants, but this review of randomised trials found no evidence that this was the case.']",3,1.0,5,8
CD000523,0,0,The updated search resulted in the identification of one ongoing trial comparing surgery versus conservative treatment.,delete,[],0,0.07142857142857142,1,14
CD000523,1,1,"Four trials, involving a total of 237 participants, were included.",rephrase,"['Four trials, involving a total of 237 participants, were included in the review.']",0,0.14285714285714285,1,14
CD000523,1,2,All four trials were methodologically flawed and potentially biased.,rephrase,['These trials had methodological weaknesses that could have resulted in serious bias.'],1,0.21428571428571427,2,14
CD000523,2,3,Three trials tested conservative treatment interventions.,delete,[],2,0.2857142857142857,2,14
CD000523,2,4,"One trial, which compared short arm (below elbow) pre-fabricated functional braces with long arm (elbow included) plaster casts, found there was no significant difference in the time it took for fracture union.",split,"[""One trial compared 'short arm' (splintage stopping below the elbow) pre-fabricated functional braces with 'long arm' (splintage includes the elbow) plaster casts."", 'It found no clear difference between the two groups in the time taken for the fracture to heal.']",2,0.35714285714285715,2,14
CD000523,2,5,Patient satisfaction and return to work during treatment were significantly better in the brace group.,rephrase,"['However, significantly more people in the brace group were satisfied with their treatment and significantly more returned to work during their treatment.']",4,0.42857142857142855,3,14
CD000523,2,6,"The other two trials, both quasi-randomised, had three treatment groups.",delete,[],5,0.5,3,14
CD000523,2,7,One trial compared Ace Wrap elastic bandage versus short arm plaster cast versus long arm plaster cast.,rephrase,"['One trial compared Ace Wrap elastic bandage, short arm plaster cast and long arm plaster cast.']",5,0.5714285714285714,3,14
CD000523,2,8,The large loss to follow-up in this trial makes any data analysis tentative.,rephrase,['The large loss to follow-up in this trial makes any findings tentative.'],6,0.6428571428571429,4,14
CD000523,2,9,"However, the need for replacement of the Ace wrap by other methods due to pain indicates the potential for a serious problem with this intervention.",ignore,"['However, the need for replacement of the Ace wrap by other methods due to pain does indicate the potential for a serious problem with this intervention.']",7,0.7142857142857143,4,14
CD000523,2,10,"The other trial, which compared immediate mobilisation versus short arm plaster cast versus long arm plaster cast for minimally displaced fractures, found no significant differences in outcome between these three interventions.",ignore,"['The third trial, which compared immediate mobilisation versus short arm plaster cast versus long arm plaster cast for minimally displaced fractures, found no clear differences in outcome between these three interventions.']",8,0.7857142857142857,4,14
CD000523,3,11,"The fourth trial, which compared two types of plates for surgical fixation, found no significant differences in functional or anatomical outcomes nor complications between the two groups.",rephrase,['The fourth trial found no significant differences in functional or anatomical outcomes nor complications between the two types of plates used for surgical fixation of the fracture.'],9,0.8571428571428571,5,14
CD000523,4,12,There is insufficient evidence from randomised trials to determine which method of treatment is the most appropriate for isolated fractures of the ulnar shaft in adults.,rephrase,"['Overall, there was not enough evidence from randomised controlled trials to show which methods of treatment are better for these injuries.']",10,0.9285714285714286,5,14
CD000523,4,13,Well designed and reported randomised trials of current forms of conservative treatment are recommended.,delete,[],11,1.0,5,14
CD005576,0,0,We have included 18 studies with 1087 participants of whom 545 received HS compared to 542 who received IS.,split,"['We included 18 trials that compared HS to IS in people undergoing surgery.', 'The trials included 1087 participants.', 'Five hundred and forty-five (545) participants received HS and 542 received IS during their operations.']",0,0.07142857142857142,1,14
CD005576,0,1,All participants were over 18 years of age and all trials excluded high-risk patients (ASA IV).,split,"['Study participants were over the age of 18.', 'All studies excluded people with serious health risks from participating.']",3,0.14285714285714285,1,14
CD005576,0,2,All trials assessed haematological parameters peri-operatively and up to three days post-operatively.,rephrase,['All studies monitored fluid levels during the operation and up to three days after.'],5,0.21428571428571427,2,14
CD005576,1,3,"There were three (< 1%) deaths reported in the IS group and four (< 1%) in the HS group, as assessed at 90 days in one study.",rephrase,"['There were seven deaths in total, three (less than 1%) from the IS group and four (less than 1%) from the HS group.']",6,0.2857142857142857,2,14
CD005576,1,4,There were no reports of serious adverse events.,rephrase,['The studies did not report the occurrence of serious adverse events.'],7,0.35714285714285715,2,14
CD005576,1,5,"Most participants were in a positive fluid balance postoperatively (4.4 L IS and 2.5 L HS), with the excess significantly less in HS participants (MD -1.92 L, 95% confidence interval (CI) -2.61 to -1.22 L; P < 0.00001).",merge,[],8,0.42857142857142855,3,14
CD005576,1,6,"IS participants received a mean volume of 2.4 L and HS participants received 1.49 L, significantly less fluid than IS-treated participants (MD -0.91 L, 95% CI -1.24 to -0.59 L; P < 0.00001).",none,['The IS group received a mean of 2.4 L and the HS group received 0.91 L less (1.49 L).'],8,0.5,3,14
CD005576,1,7,The maximum average serum sodium ranged between 138.5 and 159 in HS groups compared to between 136 and 143 meq/L in the IS groups.,rephrase,['The IS group had a median of 139 meq/L and the HS group was 7.73 meq/L higher.'],9,0.5714285714285714,3,14
CD005576,1,8,"The maximum serum sodium was significantly higher in HS participants (MD 7.73, 95% CI 5.84 to 9.62; P < 0.00001), although the level remained within normal limits (136 to 146 meq/L).",rephrase,['The normal acceptable range is 136 to 146 meq/L.'],10,0.6428571428571429,4,14
CD005576,2,9,A high degree of heterogeneity appeared to be related to considerable differences in the dose of HS between studies.,delete,[],11,0.7142857142857143,4,14
CD005576,2,10,The quality of the evidence for the outcomes reported ranged from high to very low.,rephrase,"['We assessed the quality of evidence for deaths to be very low, and future studies are likely to change the result reported here.']",11,0.7857142857142857,4,14
CD005576,2,11,"The risk of bias for many of the studies could not be determined for performance and detection bias, criteria that we assess as likely to impact the study outcomes.",delete,[],12,0.8571428571428571,5,14
CD005576,3,12,HS reduces the volume of intravenous fluid required to maintain people undergoing surgery but transiently increases serum sodium.,delete,[],12,0.9285714285714286,5,14
CD005576,3,13,"It is not known if HS affects survival and morbidity, but this should be examined in randomized controlled trials that are designed and powered to test these outcomes.",delete,[],12,1.0,5,14
CD008424,0,0,Only one trial (89 patients) fulfilled the inclusion criteria.,delete,[],0,0.0625,1,16
CD008424,0,1,This trial randomized 45 patients to curcumin and 44 patients to placebo.,rephrase,['This review includes one randomized trial with a total of 89 participants.'],0,0.125,1,16
CD008424,0,2,All patients received treatment with sulfasalazine or mesalamine.,rephrase,['All patients received treatment with sulfasalazine or mesalamine (drugs containing 5-aminosalicylic acid).'],1,0.1875,1,16
CD008424,0,3,The study was rated as low risk of bias.,delete,[],2,0.25,2,16
CD008424,0,4,Curcumin was administered orally in a dose of 2 g/day for six months.,delete,[],2,0.3125,2,16
CD008424,0,5,Fewer patients relapsed in the curcumin group than the placebo group at six months.,split,"['Fewer patients in the curcumin group relapsed at six months compared to patients who received placebo (e.g. fake drug).', 'Patients in the curcumin group had significantly lower disease activity index and endoscopic index scores at six months than patients in the placebo group.']",2,0.375,2,16
CD008424,0,6,"Four per cent of patients in the curcumin group relapsed at six months compared to 18% of patients in the placebo group (RR 0.24, 95% CI 0.05 to 1.09; P = 0.06).",delete,[],4,0.4375,3,16
CD008424,0,7,There was no statistically significant difference in relapse rates at 12 months.,rephrase,"['However, this result was not statistically significant.']",4,0.5,3,16
CD008424,0,8,"Twenty-two per cent of curcumin patients relapsed at 12 months compared to 32% of placebo patients (RR 0.70, 95% CI 0.35 to 1.40; P = 0.31).",delete,[],5,0.5625,3,16
CD008424,0,9,A total of nine adverse events were reported in seven patients.,rephrase,['A total of nine mild side effects were reported in seven patients.'],5,0.625,4,16
CD008424,0,10,"These adverse events included sensation of abdominal bulging, nausea, transient hypertension, and transient increase in the number of stools.",rephrase,"['These side effects included a sensation of abdominal bulging, nausea, a brief increase in blood pressure, and a brief increase in the number of stools.']",6,0.6875,4,16
CD008424,0,11,The authors did not report which treatment group the patients who experienced adverse events belonged to.,delete,[],7,0.75,4,16
CD008424,0,12,"The clinical activity index (CAI) at six months was significantly lower in the curcumin group compared to the placebo group (1.0 + 2.0 versus 2.2 + 2.3; MD -1.20, 95% CI -2.14 to -0.26).",delete,[],7,0.8125,5,16
CD008424,0,13,"The endoscopic index (EI) at six months was significantly lower in the curcumin group than in the placebo group (0.8 + 0.6 versus 1.6 + 1.6; MD -0.80, 95% CI -1.33 to -0.27).",delete,[],7,0.875,5,16
CD008424,1,14,Curcumin may be a safe and effective therapy for maintenance of remission in quiescent UC when given as adjunctive therapy along with mesalamine or sulfasalazine.,rephrase,['The results of this systematic review suggest that curcumin may be a safe and effective therapy for maintenance of remission in ulcerative colitis when given as additional therapy with mesalamine or sulfasalazine.'],7,0.9375,5,16
CD008424,1,15,"However, further research in the form of a large scale methodologically rigorous randomized controlled trial is needed to confirm any possible benefit of curcumin in quiescent UC.",rephrase,['Further research is needed to confirm any possible benefit of curcumin for maintenance therapy in ulcerative colitis.'],8,1.0,5,16
CD007018,0,0,Two studies of the 7880 identified from searching the electronic databases met the inclusion criteria.,delete,[],0,0.16666666666666666,1,6
CD007018,0,1,"Both studies were controlled before and after studies, of moderate to high risk of bias, that explored the effects of interventions to improve retention of minority groups in health professional training institutions.",delete,[],0,0.3333333333333333,2,6
CD007018,0,2,"These studies reported that an intervention comprising of a package of student support activities including social, academic, and career guidance and mentorship resulted in an increase in the number of minority students who enrolled and graduated from health training institutions.",rephrase,"['A comprehensive package comprising career guidance, mentoring, and academic, social and financial support may result in increased graduation rates among health professional students at risk of dropping out of study.']",0,0.5,3,6
CD007018,1,3,"The evidence to estimate the likely effects of interventions in pre-licensure education to increase health-worker supply is generally insufficient or unavailable, particularly in LMICs.",rephrase,['Evaluation of ongoing and planned interventions in pre-licensure education of health professionals is important.'],1,0.6666666666666666,4,6
CD007018,1,4,Promising innovations from a high-income country include providing financial support to health professional students or introducing mechanisms to identify and encourage potential students and offering support to 'at risk' students.,rephrase,"['Further research could focus on determining the magnitude of student drop-out rates in health professional training institutions, identifying the students at risk of dropping out, and determining the applicability of western-based innovations in low and middle-income countries.']",2,0.8333333333333334,5,6
CD007018,1,5,These and other promising interventions should be evaluated in LMIC.,delete,[],3,1.0,5,6
CD005255,0,0,We found nine eligible RCTs including 593 infants in total.,rephrase,"[""We found nine eligible randomised controlled trials (including a total of 593 infants) that examined whether feeding preterm infants in response to their own feeding and satiation cues (sometimes called 'demand' feeding) is better than feeding set volumes of milk at predefined intervals.""]",0,0.09090909090909091,1,11
CD005255,0,1,These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding.,ignore,['These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding.'],1,0.18181818181818182,1,11
CD005255,0,2,The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants.,merge,"['Although the trials were generally small and most had some methodological weaknesses, analysis suggests that responsive feeding results in slightly slower rates of weight gain and reduces the time taken for infants to transition from enteral tube to oral feeding.']",2,0.2727272727272727,2,11
CD005255,0,3,"Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD −1.36, 95% CI −2.44 to −0.29 g/kg/day), and provide some evidence that responsive feeding reduces the time taken for infants to transition from enteral tube to oral feeding (MD −5.53, 95% CI −6.80 to −4.25 days).",none,[],2,0.36363636363636365,2,11
CD005255,0,4,GRADE assessments indicated low quality of evidence.,delete,[],3,0.45454545454545453,3,11
CD005255,0,5,The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation.,rephrase,"['The quality of this evidence is low, and the importance of this finding is uncertain as the trials did not find a strong or consistent effect on the length of hospitalisation.']",3,0.5454545454545454,3,11
CD005255,0,6,"None of the included trials reported any parent, caregiver, or staff views.",ignore,"['None of the included trials reported any parent, caregiver, or staff views.']",4,0.6363636363636364,4,11
CD005255,1,7,"Overall, the data do not provide strong or consistent evidence that responsive feeding affects important outcomes for preterm infants or their families.",merge,['This Cochrane review does not provide strong or consistent evidence that responsive feeding improves outcomes for preterm infants or their families.'],5,0.7272727272727273,4,11
CD005255,1,8,Some (low quality) evidence exists that preterm infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals.,none,[],5,0.8181818181818182,5,11
CD005255,1,9,This finding should be interpreted cautiously because of methodological weaknesses in the included trials.,delete,[],6,0.9090909090909091,5,11
CD005255,1,10,A large RCT would be needed to confirm this finding and to determine if responsive feeding of preterm infants affects other important outcomes.,rephrase,"['Responsive feeding might help infants transition more quickly to oral feeding, but more randomised controlled trials would be needed to confirm this finding.']",6,1.0,5,11
CD006715,0,0,"We included 69 trials with 4860 participants: 2404 given epidural analgesia and 2456 receiving comparators (systemic analgesia, peripheral nerve block, intrapleural analgesia, or wound infiltration).",rephrase,['We included 69 studies with 4860 participants.'],0,0.05555555555555555,1,18
CD006715,0,1,The mean (or median) age of participants varied between 43.5 years and 74.6 years.,rephrase,['The average age of participants was between 43 and 75 years.'],1,0.1111111111111111,1,18
CD006715,0,2,Surgeries performed were coronary artery bypass grafting or valvular procedures and surgeries for congenital heart disease.,ignore,['Surgeries performed were coronary artery bypass grafting or valvular procedures and surgeries for congenital heart disease.'],2,0.16666666666666666,1,18
CD006715,0,3,"We judged that no trials were at low risk of bias for all domains, and that all trials were at unclear/high risk of bias for blinding of participants and personnel taking care of study participants.",delete,[],3,0.2222222222222222,2,18
CD006715,1,4,"Epidural analgesia versus systemic analgesia
Trials show there may be no difference in mortality at 0 to 30 days (risk difference (RD) 0.00, 95% confidence interval (CI) −0.01 to 0.01; 38 trials with 3418 participants; low-quality evidence), and there may be a reduction in myocardial infarction at 0 to 30 days (RD −0.01, 95% CI −0.02 to 0.00; 26 trials with 2713 participants; low-quality evidence).",rephrase,"['When researchers compared epidural analgesia versus systemic pain relief (e.g. by an analgesic given directly into a vein), they could not detect any difference in the number of deaths in the first 30 days after surgery (38 studies, 3418 participants).']",3,0.2777777777777778,2,18
CD006715,1,5,"Epidural analgesia may reduce the risk of 0 to 30 days respiratory depression (RD −0.03, 95% CI −0.05 to −0.01; 21 trials with 1736 participants; low-quality evidence).",rephrase,"['We found a small reduction in the risk of respiratory depression with epidural pain relief (21 studies, 1736 participants), but not in the risk of pneumonia (10 studies, 1107 participants) (low- or moderate-quality evidence).']",4,0.3333333333333333,2,18
CD006715,1,6,"There is probably little or no difference in risk of pneumonia at 0 to 30 days (RD −0.03, 95% CI −0.07 to 0.01; 10 trials with 1107 participants; moderate-quality evidence), and epidural analgesia probably reduces the risk of atrial fibrillation or atrial flutter at 0 to 2 weeks (RD −0.06, 95% CI −0.10 to −0.01; 18 trials with 2431 participants; moderate-quality evidence).",rephrase,"['Epidural analgesia reduced the risk of atrial fibrillation or atrial flutter early in recovery at zero to two weeks (18 studies, 2431 participants; moderate-quality evidence).']",5,0.3888888888888889,2,18
CD006715,1,7,"There may be no difference in cerebrovascular accidents at 0 to 30 days (RD −0.00, 95% CI −0.01 to 0.01; 18 trials with 2232 participants; very low-quality evidence), and none of the included trials reported any epidural haematoma events at 0 to 30 days (53 trials with 3982 participants; low-quality evidence).",rephrase,"['The number of cerebrovascular accidents was not clearly different (18 studies, 2232 participants), and no lasting neurological complications or epidural haematomas were reported (53 studies, 3982 participants; very low- or low-quality evidence).']",6,0.4444444444444444,3,18
CD006715,1,8,"Epidural analgesia probably reduces the duration of tracheal intubation by the equivalent of 2.4 hours (standardized mean difference (SMD) −0.78, 95% CI −1.01 to −0.55; 40 trials with 3353 participants; moderate-quality evidence).",rephrase,"['Although epidural analgesia may have reduced the duration of tracheal intubation, this was noted mainly in older studies, and clinical practices have changed since that time (40 trials, 3353 participants; moderate-quality evidence).']",7,0.5,3,18
CD006715,1,9,Epidural analgesia reduces pain at rest and on movement up to 72 hours after surgery.,delete,[],8,0.5555555555555556,3,18
CD006715,1,10,"At six to eight hours, researchers noted a reduction in pain, equivalent to a reduction of 1 point on a 0 to 10 pain scale (SMD −1.35, 95% CI −1.98 to −0.72; 10 trials with 502 participants; moderate-quality evidence).",delete,[],8,0.6111111111111112,4,18
CD006715,1,11,"Epidural analgesia may increase risk of hypotension (RD 0.21, 95% CI 0.09 to 0.33; 17 trials with 870 participants; low-quality evidence) but may make little or no difference in the need for infusion of inotropics or vasopressors (RD 0.00, 95% CI −0.06 to 0.07; 23 trials with 1821 participants; low-quality evidence).",delete,[],8,0.6666666666666666,4,18
CD006715,2,12,"Epidural analgesia versus other comparators
Fewer studies compared epidural analgesia versus peripheral nerve blocks (four studies), intrapleural analgesia (one study), and wound infiltration (one study).",rephrase,['We found only six studies that compared epidural pain relief versus application of local anaesthetic on the body surface to produce peripheral nerve blocks directly into the space around the lungs (intrapleural analgesia) and onto the surgical wound (wound infiltration).'],8,0.7222222222222222,4,18
CD006715,2,13,"Investigators provided no data for pulmonary complications, atrial fibrillation or flutter, or for any of the comparisons.",delete,[],9,0.7777777777777778,4,18
CD006715,2,14,"When reported, other outcomes for these comparisons (mortality, myocardial infarction, neurological complications, duration of tracheal intubation, pain, and haemodynamic support) were uncertain due to the small numbers of trials and participants.",delete,[],9,0.8333333333333334,5,18
CD006715,3,15,"Compared with systemic analgesia, epidural analgesia may reduce the risk of myocardial infarction, respiratory depression, and atrial fibrillation/atrial flutter, as well as the duration of tracheal intubation and pain, in adults undergoing cardiac surgery.",delete,[],9,0.8888888888888888,5,18
CD006715,3,16,"There may be little or no difference in mortality, pneumonia, and epidural haematoma, and effects on cerebrovascular accident are uncertain.",delete,[],9,0.9444444444444444,5,18
CD006715,3,17,"Evidence is insufficient to show the effects of epidural analgesia compared with peripheral nerve blocks, intrapleural analgesia, or wound infiltration.",delete,[],9,1.0,5,18
CD010914,0,0,This review included 15 studies (eight RCTs and seven quasi-RCTs).,delete,[],0,0.0625,1,16
CD010914,1,1,"Study characteristics
The trials included 649 participants of both sexes, ranging in age from five to 12 years.",rephrase,['We found 15 appropriate studies involving 649 children from five to 12 years of age with a diagnosis of DCD.'],0,0.125,1,16
CD010914,2,2,"The participants were from Australia, Canada, China, Sweden, Taiwan, and the UK.",ignore,"['The participants were from Australia, Canada, China, Sweden, Taiwan, and the UK.']",1,0.1875,1,16
CD010914,3,3,"Trials were conducted in hospital settings; at a university-based clinic, laboratory, or centre; in community centres; at home or school, or both at home and school.",ignore,"['Trials were conducted in hospital settings; at a university-based clinic, laboratory, or centre; in community centres; at home or school, or both at home and school.']",2,0.25,2,16
CD010914,4,4,"The durations of task-oriented interventions were mostly short term (less than six months), with the total number of sessions ranging from five to 50.",rephrase,['The duration of the intervention was often short (i.e. less than six months).'],3,0.3125,2,16
CD010914,4,5,"The length of each session ranged from 30 to 90 minutes, and the frequencies ranged from once to seven times per week.",delete,[],4,0.375,2,16
CD010914,5,6,We judged the risk of bias as moderate to high across the studies.,delete,[],4,0.4375,3,16
CD010914,5,7,Some elements were impossible to achieve (such as blinding of administering personnel or participants).,delete,[],4,0.5,3,16
CD010914,6,8,"Key results: primary outcomes
A meta-analysis of two RCTs and four quasi-RCTs found in favour of task-oriented interventions for improved motor performance compared to no intervention (mean difference (MD) -3.63, 95% confidence interval (CI) -5.88 to -1.39; P = 0.002; I2 = 43%; 6 trials, 169 children; very low-quality evidence).",delete,[],4,0.5625,3,16
CD010914,7,9,"A meta-analysis of two RCTs found no effect of task-oriented interventions for improved motor performance compared to no intervention (MD -2.34, 95% CI -7.50 to 2.83; P = 0.38; I2 = 42%; 2 trials, 51 children; low-quality evidence).",delete,[],4,0.625,4,16
CD010914,8,10,Two studies reported no adverse effects or events.,rephrase,['Two studies reported no side effects.'],4,0.6875,4,16
CD010914,8,11,"Through personal correspondence, the authors of nine studies indicated that no injuries had occurred.",ignore,"['Through email correspondence, the authors of nine studies indicated that no injuries had occurred.']",5,0.75,4,16
CD010914,9,12,"Key results: secondary outcomes
Due to the limited number of studies with complete and consistent data, we were unable to perform any meta-analyses on our secondary measures or any subgroup analysis on age, sex, severity of DCD, and intervention intensity.",split,"['We were unable to use the remaining nine included studies in a meta-analysis because of insufficient data, or because the interventions used in the control groups (without a task-oriented intervention) were too different to combine.', 'As a result, we were unable to perform any meta-analyses on many of our intended outcome measures or look at the effects of age, sex, severity of DCD, or how much intervention was received.']",6,0.8125,5,16
CD010914,10,13,We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.,delete,[],8,0.875,5,16
CD010914,10,14,"The conclusions drawn from previous reviews, which unanimously reported beneficial effects of intervention, are inconsistent with our conclusions.",delete,[],8,0.9375,5,16
CD010914,10,15,This review highlights the need for carefully designed and executed RCTs to investigate the effect of interventions for children with DCD.,rephrase,['Higher-quality research is needed to investigate and establish the effect of task-oriented intervention for children with DCD.'],8,1.0,5,16
CD001726,0,0,Two trials of moderate quality in children (n = 134) with no evidence of airflow restriction did not find any benefits from oral beta2-agonists.,rephrase,"['The trials were of short duration (three to seven days) and only two used inhaled beta2-agonists, which is now the usual way the drug is taken by adults and older children.']",0,0.1,1,10
CD001726,0,1,Five trials in adults (n = 418) had mixed results but overall summary statistics did not reveal any significant benefits from oral (three trials) nor from inhaled (two trials) beta2-agonists.,rephrase,['Two trials studied children aged one to 10 years (134 participants) and five were conducted in adults (418 participants).'],1,0.2,1,10
CD001726,0,2,"Three studies with low-quality evidence demonstrated no significant differences in daily cough scores, nor in the percentage of adults still coughing after seven days (control group 71%; risk ratio (RR) 0.86, 95% confidence interval (CI) 0.63 to 1.18; 220 participants).",rephrase,"['Daily cough scores, or the number of people still coughing after seven days, did not change in the adult trials either.']",2,0.3,2,10
CD001726,0,3,"In one trial, subgroups with evidence of airflow limitation had lower symptom scores if given beta2-agonists.",delete,[],3,0.4,2,10
CD001726,0,4,The trials that noted quicker resolution of cough with beta2-agonists were those with a higher proportion of people wheezing at baseline.,delete,[],3,0.5,3,10
CD001726,0,5,"Low-quality evidence suggests that adults given beta2-agonists were more likely to report tremor, shakiness or nervousness (RR 7.94, 95% CI 1.17 to 53.94; 211 participants; number needed to treat for an additional harmful outcome (NNTH) 2).",rephrase,"['More of the adults taking beta2-agonists had tremor, shakiness or nervousness.']",3,0.6,3,10
CD001726,1,6,There is no evidence to support the use of beta2-agonists in children with acute cough who do not have evidence of airflow restriction.,merge,[],4,0.7,4,10
CD001726,1,7,There is also little evidence that the routine use of beta2-agonists is helpful for adults with acute cough.,none,"['This may be because some participants also had wheezing or other signs of narrowed airways, in which case beta2-agonists may be helpful only for them.']",4,0.8,4,10
CD001726,1,8,"These agents may reduce symptoms, including cough, in people with evidence of airflow restriction.",delete,[],5,0.9,5,10
CD001726,1,9,"However, this potential benefit is not well supported by the available data and must be weighed against the adverse effects associated with their use.",delete,[],5,1.0,5,10
CD012091,0,0,"Four RCTs, 13 prospective cohort studies, and one unpublished ongoing cohort study met our inclusion criteria, and included a total of 2098 participants with TBM.",delete,[],0,0.045454545454545456,1,22
CD012091,0,1,"None of the included RCTs directly compared six months versus longer regimens, so we analysed all data as individual cohorts to obtain relapse rates in each set of cohorts.",split,"['None of the included studies directly compared people with TBM treated for six months with people with TBM treated for longer.', 'Two of the included studies analysed two groups of participants treated for six months and longer than six months.']",0,0.09090909090909091,1,22
CD012091,1,2,We included 20 cohorts reported in 18 studies.,rephrase,['Cochrane researchers examined the available evidence up to 31 March 2016 and they included 18 studies.'],2,0.13636363636363635,1,22
CD012091,1,3,"One of these was reported separately, leaving 19 cohorts in the main analysis.",delete,[],3,0.18181818181818182,1,22
CD012091,1,4,We included seven cohorts of participants treated for six months with a total of 458 participants.,delete,[],3,0.22727272727272727,2,22
CD012091,1,5,"Three studies were conducted in Thailand, two in South Africa, and one each in Ecuador and Papua New Guinea between the 1980s and 2009.",delete,[],3,0.2727272727272727,2,22
CD012091,1,6,"We included 12 cohorts of participants treated for longer than six months (ranging from eight to 16 months), with a total of 1423 participants.",rephrase,"['Therefore, the review authors included information from seven groups of people treated for six months (458 people), 12 groups of people treated for longer than 6 months (1423 people), and one ongoing study of 217 people which was analysed separately due to methodological concerns.']",3,0.3181818181818182,2,22
CD012091,1,7,"Four studies were conducted in India, three in Thailand and one each in China, South Africa, Romania, Turkey, and Vietnam, between the late 1970s and 2011.",delete,[],4,0.36363636363636365,2,22
CD012091,1,8,The unpublished ongoing cohort study is conducted in India and included 217 participants.,delete,[],4,0.4090909090909091,3,22
CD012091,2,9,"The proportion of participants classified as having stage III disease (severe) was higher in the cohorts treated for six months (33.2% versus 16.9%), but the proportion with known concurrent HIV was higher in the cohorts treated for longer (0/458 versus 122/1423).",delete,[],4,0.45454545454545453,3,22
CD012091,2,10,"Although there were variations in the treatment regimens, most cohorts received isoniazid, rifampicin, and pyrazinamide during the intensive phase.",rephrase,"['Although the treatment regimens in the included studies varied, most participants received standard first-line antituberculous drugs, and were followed up for more than a year after the end of treatment.']",4,0.5,3,22
CD012091,3,11,"Investigators achieved follow-up beyond 18 months after completing treatment in three out of the seven cohorts treated for six months, and five out of the 12 cohorts treated for eight to 16 months.",delete,[],5,0.5454545454545454,3,22
CD012091,3,12,"All studies had potential sources of bias in their estimation of the relapse rate, and comparisons between the cohorts could be confounded.",delete,[],5,0.5909090909090909,3,22
CD012091,4,13,"Relapse was an uncommon event across both groups of cohorts (3/369 (0.8%) with six months treatment versus 7/915 (0.8%) with longer), with only one death attributed to relapse in each group.",rephrase,"['Relapse was an uncommon event across both groups of studies, with only one death attributed to relapse in each group.']",5,0.6363636363636364,4,22
CD012091,5,14,"Overall, the proportion of participants who died was higher in the cohorts treated for longer than six months (447/1423 (31.4%) versus 58/458 (12.7%)).",delete,[],6,0.6818181818181818,4,22
CD012091,5,15,"However, most deaths occurred during the first six months in both treatment cohorts, which suggested that the difference in death rate was not directly related to duration of ATT but was due to confounding.",rephrase,"['Most deaths occurred during the first six months of treatment in both groups of studies, which showed that treatment duration did not have a direct impact on the risk of death in these studies.']",6,0.7272727272727273,4,22
CD012091,5,16,"Clinical cure was higher in the group of cohorts treated for six months (408/458 (89.1%) versus longer than six months (984/1336 (73.7%)), consistent with the observations for deaths.",rephrase,"['There was a higher death rate in participants treated for longer than six months, and this probably reflects the differences between the participants in the two groups of studies.']",7,0.7727272727272727,4,22
CD012091,6,17,"Few participants defaulted from treatment with six months treatment (4/370 (1.1%)) versus longer treatment (8/355 (2.3%)), and adherence was not well reported.",rephrase,"['Few participants defaulted from treatment, and adherence was not clearly documented.']",8,0.8181818181818182,5,22
CD012091,7,18,In all cohorts most deaths occurred in the first six months; and relapse was uncommon in all participants irrespective of the regimen.,rephrase,"['They found no evidence of high relapse rates in people treated for six months, and relapse was uncommon in all patients irrespective of regimen.']",9,0.8636363636363636,5,22
CD012091,7,19,Further inferences are probably inappropriate given this is observational data and confounding is likely.,rephrase,"['There may be differences between the participants treated for six months and longer than six months that could have led to bias (confounding factors), so further research would help determine if shorter regimens are safe.']",10,0.9090909090909091,5,22
CD012091,7,20,"These data are almost all from participants who are HIV-negative, and thus the inferences will not apply to the efficacy and safety of the six months regimens in HIV-positive people.",rephrase,"['Most of the data were in patients without HIV, and so these inferences do not apply to patients who are HIV-positive.']",11,0.9545454545454546,5,22
CD012091,7,21,"Well-designed RCTs, or large prospective cohort studies, comparing six months with longer treatment regimens with long follow-up periods established at initiation of ATT are needed to resolve the uncertainty regarding the safety and efficacy of six months regimens for TBM.",delete,[],12,1.0,5,22
CD011110,0,0,The overall quality of the evidence was low to very low.,rephrase,['The overall quality of the study evidence ranged from very low to low.'],0,0.06666666666666667,1,15
CD011110,0,1,"The main limitations were serious risk of bias related to blinding of participants and personnel, indirectness and imprecision.",rephrase,"['There were limitations to the studies, for example, a serious risk of bias related to participants and investigators knowing what treatment was given.']",1,0.13333333333333333,1,15
CD011110,0,2,"We identified 16 RCTs comparing a device versus no treatment (two studies; 90 women), hormonal treatment versus no treatment or placebo (two studies; 136 women), device combined with hormonal treatment versus no treatment (one study; 20 women), barrier gel versus no treatment (five studies; 464 women), device with graft versus device without graft (three studies; 190 women), one type of device versus another device (one study; 201 women), gel combined with hormonal treatment and antibiotics versus hormonal treatment with antibiotics (one study; 52 women) and device combined with gel versus device (one study; 120 women).",split,"['We found 16 studies.', 'Treatments included using a device versus no treatment (two studies; 90 women), hormonal treatment versus no treatment or placebo (two studies; 136 women), device combined with hormonal treatment versus no treatment (one study; 20 women), barrier gel versus no treatment (five studies; 464 women), device with the use of membranes of the afterbirth of newborn babies versus device without membranes (three studies; 190 women), one type of device versus another device (one study; 201 women), gel combined with hormonal treatment and antibiotics versus hormonal treatment with antibiotics (one study; 52 women) or device combined with gel versus device (one study; 120 women).']",2,0.2,1,15
CD011110,0,3,"The total number of participants was 1273, but data on 1133 women were available for analysis.",rephrase,"['From 1273 randomly assigned women, data on 1133 women were available for analysis.']",4,0.26666666666666666,2,15
CD011110,0,4,"Only two of 16 studies included 100% infertile women; in all other studies, the proportion was variable or unknown.",delete,[],5,0.3333333333333333,2,15
CD011110,1,5,"No study reported live birth, but some (five studies) reported outcomes that were used as surrogate outcomes for live birth (term delivery or ongoing pregnancy).",rephrase,"['As no study reported live births, we also included data on term delivery or ongoing pregnancy, which five studies reported.']",5,0.4,2,15
CD011110,2,6,Anti-adhesion therapy versus placebo or no treatment following operative hysteroscopy.,rephrase,['More research is needed before anti-adhesion treatment can be offered in everyday clinical practice after surgery of the womb in women having difficulty becoming pregnant.'],6,0.4666666666666667,3,15
CD011110,3,7,"There was insufficient evidence to determine whether there was a difference between the use of a device or hormonal treatment compared to no treatment or placebo with respect to term delivery or ongoing pregnancy rates (odds ratio (OR) 0.94, 95% confidence interval (CI) 0.42 to 2.12; 107 women; 2 studies; I² = 0%; very-low-quality evidence).",rephrase,"['It was unclear whether there was a difference between anti-adhesion treatment compared to no treatment (two studies; 107 women) or to other treatment (three studies; 180 women) for increasing the chance of a liveborn baby, a term delivery or an ongoing pregnancy.']",7,0.5333333333333333,3,15
CD011110,4,8,"There were fewer IUAs at second-look hysteroscopy using a device with or without hormonal treatment or hormonal treatment or barrier gels compared with no treatment or placebo (OR 0.35, 95% CI 0.21 to 0.60; 560 women; 8 studies; I² = 0%; low-quality evidence).",rephrase,['The use of some anti-adhesion therapies (device with or without hormonal treatment or hormonal treatment or gels) (eight studies; 560 women) may diminish the risk of scar tissue formation compared to no treatment.'],8,0.6,3,15
CD011110,4,9,The number needed to treat for an additional beneficial outcome (NNTB) was 9 (95% CI 5 to 17).,delete,[],9,0.6666666666666666,4,15
CD011110,5,10,"Comparisons of different anti-adhesion therapies following operative hysteroscopy
It was unclear whether there was a difference between the use of a device combined with graft versus device only for the outcome of ongoing pregnancy (OR 1.48, 95% CI 0.57 to 3.83; 180 women; 3 studies; I² = 0%; low-quality evidence).",delete,[],9,0.7333333333333333,4,15
CD011110,5,11,"There were fewer IUAs at second-look hysteroscopy using a device with or without graft/gel or gel combined with hormonal treatment and antibiotics compared with using a device only or hormonal treatment combined with antibiotics, but the findings of this meta-analysis were affected by evidence quality (OR 0.55, 95% CI 0.36 to 0.83; 451 women; 5 studies; I² = 0%; low-quality evidence).",delete,[],9,0.8,4,15
CD011110,6,12,"Implications for clinical practice
The quality of the evidence ranged from very low to low.",delete,[],9,0.8666666666666667,5,15
CD011110,6,13,The effectiveness of anti-adhesion treatment for improving key reproductive outcomes or for decreasing IUAs following operative hysteroscopy in subfertile women remains uncertain.,delete,[],9,0.9333333333333333,5,15
CD011110,7,14,"Implications for research
More research is needed to assess the comparative safety and (cost-)effectiveness of different anti-adhesion treatments compared to no treatment or other interventions for improving key reproductive outcomes in subfertile women.",delete,[],9,1.0,5,15
CD005937,0,0,We included 62 trials (6428 women).,rephrase,"['The review authors identified 62 controlled trials that randomised a total of 6428 mothers to receive the treatment under investigation, no treatment or another treatment.']",0,0.06666666666666667,1,15
CD005937,0,1,Twenty-two trials did not contribute data to the meta-analyses.,ignore,['Twenty-two trials did not contribute data to the meta-analyses.'],1,0.13333333333333333,1,15
CD005937,0,2,The trials were generally small and of limited quality.,rephrase,['The trials were generally of limited quality and most were conducted among healthy women who chose not to breastfeed for personal reasons at hospitals in industrialised countries before 1980.'],2,0.2,1,15
CD005937,0,3,"Three trials (107 women) indicated that bromocriptine significantly reduced the proportion of women lactating compared with no treatment at or within seven days postpartum (three trials, 107 women; risk ratio (RR) 0.36, 95% confidence interval (CI) 0.24 to 0.54).",rephrase,['Two trials (107 women) reported that taking bromocriptine was better than no treatment in suppressing lactation in the first week after giving birth.'],3,0.26666666666666666,2,15
CD005937,0,4,"Seven trials involving oestrogen preparations (diethylstilbestrol, quinestrol, chlorotrianisene, hexestrol) suggested that they significantly reduced the proportion of lactating women compared with no treatment at or within seven days postpartum (RR 0.40, 95% CI 0.29 to 0.56).",rephrase,"['The 11 trials using oestrogen preparations (diethylstilbestrol, quinestrol, chlorotrianisene, hexestrol) also showed suppression of lactation.']",4,0.3333333333333333,2,15
CD005937,0,5,We found no trials comparing non-pharmacologic methods with no treatment.,rephrase,['No trials compared non-drug approaches with no treatment and none of the included trials provided reliable data on women’s satisfaction with the treatment.'],5,0.4,2,15
CD005937,0,6,"Trials comparing bromocriptine with other pharmacologic agents such as methergoline, prostaglandins, pyridoxine, carbegoline, diethylstilbestrol and cyclofenil suggested similarity in their effectiveness.",rephrase,"['Other pharmacologic agents (clomiphene, tamoxifen, prostaglandins, pyridoxine, oxytocin, L-dopa and homeopathic preparation) were tested in single small trials.']",6,0.4666666666666667,3,15
CD005937,0,7,Side effects were poorly reported in the trials and no case of thromboembolism was recorded in the four trials that reported it as an outcome.,rephrase,"['Generally, side effects were poorly reported and no case of thromboembolism was recorded among trials that included it as an adverse treatment outcome.']",7,0.5333333333333333,3,15
CD005937,1,8,There is weak evidence that some pharmacologic treatments (most of which are currently unavailable to the public) are better than no treatment for suppressing lactation symptoms in the first postpartum week.,rephrase,['Most of the drugs tested are currently not available or registered for suppressing lactation.'],8,0.6,3,15
CD005937,1,9,No evidence currently exists to indicate whether non-pharmacologic approaches are more effective than no treatment.,delete,[],9,0.6666666666666666,4,15
CD005937,1,10,"Presently, there is insufficient evidence to address the side effects of methods employed for suppressing lactation.",delete,[],9,0.7333333333333333,4,15
CD005937,1,11,"When women desire treatment, bromocriptine may be considered where it is registered for lactation suppression in those without predisposition to its major side effects of public concerns.",delete,[],9,0.8,4,15
CD005937,1,12,Many trials did not contribute data that could be included in analyses.,delete,[],9,0.8666666666666667,5,15
CD005937,1,13,Large randomised trials are needed to compare the effectiveness of pharmacologic (especially bromocriptine) and non-pharmacologic methods with no treatment.,delete,[],9,0.9333333333333333,5,15
CD005937,1,14,Such trials should consider the acceptability of the intervention and lactation symptoms of concern to women and be large enough to detect clinically important differences in major side effects between comparison groups.,delete,[],9,1.0,5,15
CD012504,0,0,We excluded five studies that were not RCTs.,rephrase,['We excluded five trials because they were not randomised controlled trials.'],0,0.125,1,8
CD012504,0,1,There were no eligible trials for inclusion in this review.,rephrase,['We did not find any trials for inclusion in this review.'],1,0.25,2,8
CD012504,1,2,There is currently a lack of RCT evidence regarding the effectiveness of interventions for investigating and identifying the causes of stillbirth.,rephrase,['There is no evidence available to guide how best to investigate the causes of stillbirth.'],2,0.375,2,8
CD012504,1,3,"Seeking to determine the causes of stillbirth is an essential component of quality maternity care, but it remains unclear what impact these interventions have on the psychosocial outcomes of parents and families, the rates of diagnosis of the causes of stillbirth, and the care and management of subsequent pregnancies following stillbirth.",rephrase,"[""Seeking to determine the causes of a baby's death is an essential component of quality maternity care in any setting.""]",3,0.5,3,8
CD012504,1,4,"Due to the absence of trials, this review is unable to inform clinical practice regarding the investigation of stillbirths, and the specific investigations that would determine the causes.",delete,[],4,0.625,4,8
CD012504,2,5,"Future RCTs addressing this research question would be beneficial, but the settings in which the trials take place, and their design, need to be given careful consideration.",rephrase,"['Future trials on this topic would be helpful, but such trials would need to be designed in a way that ensures all parents in the trial still receive the minimum standard of care in their local setting.']",4,0.75,4,8
CD012504,2,6,"Trials need to be conducted with the utmost care and consideration for the needs, concerns, and values of parents and families.",ignore,"['Future trials would need to be conducted with the utmost care and consideration for the needs, concerns, and values of parents and families.']",5,0.875,5,8
CD012504,2,7,"Assessment of longer-term psychosocial variables, economic costs to health services, and effects on subsequent pregnancy care and outcomes should also be considered in any future trials.",ignore,"['Assessment of longer-term psychosocial variables, economic costs to health services, and effects on subsequent pregnancy care and outcomes should be considered in any future trials.']",6,1.0,5,8
CD009170,0,0,We located 10 RCTs involving 2961 participating surgeons performing an operation in which the use of blunt needles was compared to the use of sharp needles.,split,"['We reviewed the literature to evaluate the preventive effect of blunt needles compared to sharp needles on needle stick injuries among surgical staff.', 'We located 10 RCTs with 2961 operations in which blunt needles were compared to sharp needles.']",0,0.1,1,10
CD009170,0,1,"Four studies focused on abdominal closure, two on caesarean section, two on vaginal repair and two on hip replacement.",rephrase,"['Six studies focused on abdominal operations, two on vaginal repair and two on hip replacement.']",2,0.2,1,10
CD009170,0,2,"On average, a surgeon that used sharp needles sustained one glove perforation in three operations.",ignore,"['On average, a surgeon that used sharp needles sustained one glove perforation per three operations.']",3,0.3,2,10
CD009170,0,3,The use of blunt needles reduced the risk of glove perforations with a relative risk (RR) of 0.46 (95% confidence interval (CI) 0.38 to 0.54) compared to sharp needles.,rephrase,['The use of blunt needles reduced the risk of glove perforations by 54% (95% confidence interval 46% to 62%) compared to sharp needles.'],4,0.4,2,10
CD009170,0,4,The use of blunt needles will thus prevent one glove perforation in every six operations.,rephrase,['The use of blunt needles in six operations will thus prevent one glove perforation.'],5,0.5,3,10
CD009170,1,5,"In four studies, the use of blunt needles reduced the number of self-reported needle stick injuries with a RR of 0.31 (95% CI 0.14 to 0.68).",rephrase,['In four studies the use of blunt needles also reduced the number of self-reported needle stick injuries by 69% (95% confidence interval 14% to 68%).'],6,0.6,3,10
CD009170,1,6,"Because the force needed for the blunt needles is higher, their use was rated as more difficult but still acceptable in five out of six studies.",rephrase,"['Even though surgeons reported that the force needed for the blunt needles was higher, their use of the needles was still rated as acceptable in five out of six studies.']",7,0.7,4,10
CD009170,2,7,The quality of the evidence was rated as high.,delete,[],8,0.8,4,10
CD009170,3,8,There is high quality evidence that the use of blunt needles appreciably reduces the risk of exposure to blood and bodily fluids for surgeons and their assistants over a range of operations.,rephrase,['We concluded that there is high quality evidence that the use of blunt needles appreciably reduces the risk of contracting infectious diseases for surgeons and their assistants over a range of operations by reducing the number of needle stick injuries.'],8,0.9,5,10
CD009170,3,9,It is unlikely that future research will change this conclusion.,ignore,['It is unlikely that future research will change this conclusion.'],9,1.0,5,10
CD007689,0,0,We included eight RCTs with 1546 women.,rephrase,['We included eight studies with 1546 women in this review.'],0,0.041666666666666664,1,24
CD007689,0,1,Five RCTs were included in our previous review and three new RCTs were added in this update of the review.,delete,[],1,0.08333333333333333,1,24
CD007689,0,2,"They compared true acupuncture versus sham acupuncture (three RCTs), true acupuncture versus relaxation (one RCT), true acupuncture versus clomiphene (one RCT), low-frequency electroacupuncture versus physical exercise or no intervention (one RCT) and true acupuncture versus Diane-35 (two RCTs).",merge,"['The studies compared true acupuncture versus sham acupuncture, clomiphene (medicines to induce ovulation), relaxation and Diane-35 (combined oral contraceptive pill); and low-frequency electroacupuncture (where small electrical currents are passed through the acupuncture needles) versus physical exercise.']",1,0.125,1,24
CD007689,0,3,Studies that compared true acupuncture versus Diane-35 did not measure fertility outcomes as they were focused on symptom control.,none,[],1,0.16666666666666666,1,24
CD007689,1,4,Seven of the studies were at high risk of bias in at least one domain.,delete,[],2,0.20833333333333334,2,24
CD007689,2,5,"For true acupuncture versus sham acupuncture, we could not exclude clinically relevant differences in live birth (RR 0.97, 95% CI 0.76 to 1.24; 1 RCT, 926 women; low-quality evidence); multiple pregnancy rate (RR 0.89, 95% CI 0.33 to 2.45; 1 RCT, 926 women; low-quality evidence); ovulation rate (SMD 0.02, 95% CI –0.15 to 0.19, I2 = 0%; 2 RCTs, 1010 women; low-quality evidence); clinical pregnancy rate (RR 1.03, 95% CI 0.82 to 1.29; I2 = 0%; 3 RCTs, 1117 women; low-quality evidence) and miscarriage rate (RR 1.10, 95% CI 0.77 to 1.56; 1 RCT, 926 women; low-quality evidence).",delete,[],2,0.25,2,24
CD007689,3,6,"Number of intermenstrual days may have improved in participants receiving true acupuncture compared to sham acupuncture (MD –312.09 days, 95% CI –344.59 to –279.59; 1 RCT, 141 women; low-quality evidence).",delete,[],2,0.2916666666666667,2,24
CD007689,4,7,"True acupuncture probably worsens adverse events compared to sham acupuncture (RR 1.16, 95% CI 1.02 to 1.31; I2 = 0%; 3 RCTs, 1230 women; moderate-quality evidence).",delete,[],2,0.3333333333333333,2,24
CD007689,5,8,"No studies reported data on live birth rate and multiple pregnancy rate for the other comparisons: physical exercise or no intervention, relaxation and clomiphene.",delete,[],2,0.375,2,24
CD007689,5,9,Studies including Diane-35 did not measure fertility outcomes.,delete,[],2,0.4166666666666667,3,24
CD007689,6,10,"We were uncertain whether acupuncture improved ovulation rate (measured by ultrasound three months post treatment) compared to relaxation (MD 0.35, 95% CI 0.14 to 0.56; 1 RCT, 28 women; very low-quality evidence) or Diane-35 (RR 1.45, 95% CI 0.87 to 2.42; 1 RCT, 58 women; very low-quality evidence).",rephrase,"['Due to the very low quality of the evidence and imprecise results, we were uncertain of the effect of acupuncture on live birth rate, multiple pregnancy rate and ovulation rate compared to sham acupuncture.']",2,0.4583333333333333,3,24
CD007689,7,11,Overall evidence ranged from very low quality to moderate quality.,rephrase,"['The evidence ranged from very low to moderate quality, the main limitations were not reporting important clinical results and not enough data.']",3,0.5,3,24
CD007689,7,12,The main limitations were failure to report important clinical outcomes and very serious imprecision.,delete,[],4,0.5416666666666666,3,24
CD007689,8,13,"For true acupuncture versus sham acupuncture we cannot exclude clinically relevant differences in live birth rate, multiple pregnancy rate, ovulation rate, clinical pregnancy rate or miscarriage.",rephrase,"['For the same reasons, we were also uncertain of the effect of acupuncture on clinical pregnancy and miscarriage rate.']",4,0.5833333333333334,3,24
CD007689,8,14,Number of intermenstrual days may improve in participants receiving true acupuncture compared to sham acupuncture.,rephrase,['Acupuncture may have improved restoration of regular menstrual periods.'],5,0.625,4,24
CD007689,8,15,True acupuncture probably worsens adverse events compared to sham acupuncture.,rephrase,['Acupuncture probably worsened side effects when compared to sham acupuncture.'],6,0.6666666666666666,4,24
CD007689,9,16,"No studies reported data on live birth rate and multiple pregnancy rate for the other comparisons: physical exercise or no intervention, relaxation and clomiphene.",ignore,"['No studies reported data on live birth rate and multiple pregnancy rate for the other comparisons: physical exercise or no intervention, relaxation and clomiphene.']",7,0.7083333333333334,4,24
CD007689,9,17,Studies including Diane-35 did not measure fertility outcomes as the women in these trials did not seek fertility.,rephrase,['Studies including Diane-35 did not measure fertility outcomes as women were only interested in symptom control.'],8,0.75,4,24
CD007689,10,18,We are uncertain whether acupuncture improves ovulation rate (measured by ultrasound three months post treatment) compared to relaxation or Diane-35.,rephrase,"['We were uncertain whether acupuncture improved ovulation rate compared to relaxation or Diane-35 (measured by ultrasound, which uses high-frequency sound waves to create an image, three months after treatment).']",9,0.7916666666666666,4,24
CD007689,10,19,The other comparisons did not report on this outcome.,rephrase,['The other comparisons did not report on ovulation rate.'],10,0.8333333333333334,5,24
CD007689,11,20,"Adverse events were recorded in the acupuncture group for the comparisons physical exercise or no intervention, clomiphene and Diane-35.",ignore,"['Side effects were recorded in the acupuncture group for the comparisons physical exercise or no intervention, clomiphene and Diane-35.']",11,0.875,5,24
CD007689,11,21,"These included dizziness, nausea and subcutaneous haematoma.",rephrase,"['These included dizziness, nausea (feeling sick) and bruising.']",12,0.9166666666666666,5,24
CD007689,11,22,Evidence was very low quality with very wide CIs and very low event rates.,rephrase,['The overall evidence was low or very low quality.'],13,0.9583333333333334,5,24
CD007689,12,23,"There are only a limited number of RCTs in this area, limiting our ability to determine effectiveness of acupuncture for PCOS.",delete,[],14,1.0,5,24
CD010849,0,0,"No RCTs of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease are included.",delete,[],0,0.16666666666666666,1,6
CD010849,0,1,A trial identified earlier has published its results and has subsequently been listed as excluded in this review.,rephrase,"['In an earlier version of this review, we had already found the protocol for a trial that has now published its results, but we have excluded the trial in this version of the review because it did not look at the right topic after all.']",0,0.3333333333333333,2,6
CD010849,1,2,"As there are no RCTs of preconception genetic risk assessment for thalassaemia, sickle cell disease, cystic fibrosis, or Tay-Sachs disease included in either the earlier or current versions of this review, we recommend considering potential non-RCTs studies (for example prospective cohorts or before-and-after studies) for future reviews.",rephrase,['We recommend considering potential observational studies in future reviews as well as looking at ‘expanded carrier screening’ before pregnancy and not just screening for one condition.'],1,0.5,3,6
CD010849,1,3,"While RCTs are desirable to inform evidence-based practice and robust recommendations, the ethical, legal and social implications associated with using this trial design to evaluate the implementation of preconception genetic risk assessment involving carrier testing and reproductive autonomy must also be considered.",rephrase,"['Any future trials need to consider legal, ethical and cultural barriers to implementing genetic risk assessment before pregnancy.']",2,0.6666666666666666,4,6
CD010849,1,4,"In addition, rather than focusing on single gene-by-gene carrier testing for specific autosomal-recessive conditions as the intervention being evaluated, preconception expanded genetic screening should also be included in future searches as this has received much attention in recent years as a more pragmatic strategy.",delete,[],3,0.8333333333333334,5,6
CD010849,2,5,The research evidence for current international policy recommendations is limited to non-randomised studies.,delete,[],3,1.0,5,6
CD007560,0,0,Three trials (165 patients) fulfilled the inclusion criteria.,rephrase,['The researchers identified three studies that included a total of 165 patients.'],0,0.05263157894736842,1,19
CD007560,0,1,"One study compared oral methotrexate (12.5 mg/week) to placebo, another compared oral methotrexate (15 mg/week) to 6-mercaptopurine (6-MP, 1.5 mg/kg/day) or 5-aminosalicylic acid (5-ASA, 3 g/day) and the other compared methotrexate (15 mg/week) in combination sulfasalazine (3 g/day) to sulfasalazine.",rephrase,"['One study (67 patients) compared oral methotrexate (12.5 mg/week) to placebo (e.g. a sugar pill or fake medicine), one study (26 patients) compared oral methotrexate (15 mg/week) and sulfasalazine (3 g/day) to sulfasalazine alone, and one study (72 patients in total; of which, 34 had ulcerative colitis ) compared oral methotrexate (15 mg/week) to 6-mercaptopurine (1.5 mg/kg/day) or 5-aminosalicylic acid (3 g/day).']",1,0.10526315789473684,1,19
CD007560,0,2,The placebo-controlled study was rated as low risk of bias.,rephrase,['Two studies were judged to be of very low quality and the placebo-controlled study was judged to be of high quality.'],2,0.15789473684210525,1,19
CD007560,0,3,"The study comparing methotrexate to 6-MP and 5-ASA was rated as high risk of bias and the study assessing methotrexate and sulfasalazine was rated as unclear risk of bias for sequence generation, allocation concealment and blinding.",delete,[],3,0.21052631578947367,2,19
CD007560,0,4,The placebo-controlled study found no statistically significant differences in the proportion of patients who maintained remission.,merge,['There was no difference between the methotrexate and placebo treatment groups for the number of people who maintained remission at nine months.'],3,0.2631578947368421,2,19
CD007560,0,5,"At nine months, 36% (5/14) of methotrexate patients maintained remission compared to 54% (10/18) of placebo patients (RR 0.64, 95% CI 0.28 to 1.45).",none,[],3,0.3157894736842105,2,19
CD007560,0,6,A GRADE analysis indicated that the overall quality of the evidence for this outcome was low due to very sparse data (15 events).,delete,[],4,0.3684210526315789,2,19
CD007560,0,7,The study comparing combination therapy to sulfasalazine found no statistically significant difference in the proportion of patients who maintained remission.,rephrase,"['The other, small study showed no differences between methotrexate and the other treatments (6-mercaptopurine and 5-aminosalicylic acid) in the proportion of participants who were able to maintain remission.']",4,0.42105263157894735,3,19
CD007560,0,8,"At 12 months, 100% (14/14) of patients in the combination group maintained remission compared to 75% (9/12) of sulfasalazine patients (RR 1.32, 95% CI 0.94 to 0.86), A GRADE analysis indicated that the overall quality of the evidence for this outcome was very low due to unknown risk of bias and very sparse data (23 events).",delete,[],5,0.47368421052631576,3,19
CD007560,0,9,There were no statistically significant differences in maintenance of remission rates between methotrexate and 6-MP or between methotrexate and 5-ASA.,delete,[],5,0.5263157894736842,3,19
CD007560,0,10,"At 76 weeks, 14% (1/7) of methotrexate patients maintained remission compared to 64% (7/11) of 6-MP patients (RR 0.22, 95% CI 0.03 to 1.45) and 0% (0/2) of 5-ASA patients (RR 1.13, 95% CI 0.06 to 20.71).",delete,[],5,0.5789473684210527,3,19
CD007560,0,11,A GRADE analysis indicated that the overall quality of the evidence from this study was very low due to high risk of bias and very sparse data.,delete,[],5,0.631578947368421,4,19
CD007560,0,12,"Adverse events reported in these studies included transient leucopenia, migraine, nausea and dyspepsia, mild alopecia, mild increase in aspartate aminotransferase levels, peritoneal abscess, hypoalbuminemia, severe rash and atypical pneumonia",rephrase,"['The side effects reported in the studies included leucopenia (a decrease in the number of white blood cells), migraine, rash, nausea and dyspepsia (indigestion), mild alopecia (hair loss), mild increase in levels of an enzyme found in the liver (aspartate aminotransferase), a collection of pus in the abdominal tissue (peritoneal abscess), abnormally low levels of the protein albumin in the blood (hypoalbuminemia), and pneumonia.']",5,0.6842105263157895,4,19
CD007560,1,13,"The results for efficacy and safety outcomes between methotrexate and placebo, methotrexate and sulfasalazine, methotrexate and 6-mercaptopurine and methotrexate and 5-aminosalicylic acid were uncertain.",delete,[],6,0.7368421052631579,4,19
CD007560,1,14,Whether a higher dose or parenteral administration of methotrexate would be effective in quiescent ulcerative colitis is unknown.,rephrase,"['It is not known whether a higher dose of oral methotrexate, or giving methotrexate by a different route (e.g. by injection), would be effective for maintenance of remission in people with inactive ulcerative colitis.']",6,0.7894736842105263,4,19
CD007560,1,15,At present there is no evidence supporting the use of methotrexate for maintenance of remission in ulcerative colitis.,rephrase,"['At present, the results from medical trials do not support the use of low dose oral methotrexate (12.5 mg to 15 mg/week) for maintenance of remission in people with inactive ulcerative colitis.']",7,0.8421052631578947,5,19
CD007560,1,16,More studies are needed to determine the efficacy and safety of methotrexate maintenance therapy in patients with quiescent ulcerative colitis.,rephrase,['The results of such studies may resolve the uncertainty surrounding the use of methotrexate as maintenance therapy in people with inactive ulcerative colitis.'],8,0.8947368421052632,5,19
CD007560,1,17,Large scale methodologically rigorous randomized controlled trials are needed.,delete,[],9,0.9473684210526315,5,19
CD007560,1,18,These studies should investigate higher doses of methotrexate (e.g. 15 to 25 mg/week) and parenteral administration.,split,"['In future, researchers should consider organizing a study with a larger number of participants who receive a higher dose of methotrexate (15 to 25 mg/week).', 'Future studies should also investigate methotrexate given by injection.']",9,1.0,5,19
CD010075,0,0,Only one trial was identified for inclusion in this review.,rephrase,['We identified only one randomised controlled trial.'],0,0.1,1,10
CD010075,0,1,This trial was at a high risk of bias.,merge,"['This trial was at high risk of bias, i.e. there were flaws in the way it was conducted that could have given incorrect results.This trial included 857 people undergoing minor skin operations performed at a General Practitioner (GP) surgery.']",1,0.2,1,10
CD010075,0,2,This trial included 857 patients undergoing minor skin excision surgery in the primary care setting.,none,[],1,0.3,2,10
CD010075,0,3,The wounds were sutured after the excision.,delete,[],2,0.4,2,10
CD010075,0,4,Patients were randomised to early post-operative bathing (dressing to be removed after 12 hours and normal bathing resumed) (n = 415) or delayed post-operative bathing (dressing to be retained for at least 48 hours before removal and resumption of normal bathing) (n = 442).,rephrase,"['One group of 415 people was advised to remove the dressing 12 hours after surgery and then to bathe normally, while the other group of 442 people was advised to keep the dressing on for at least 48 hours and then to bathe normally.']",2,0.5,3,10
CD010075,0,5,The only outcome of interest reported in this trial was surgical site infection (SSI).,rephrase,['The only outcome of interest reported in this trial was wound infection.'],3,0.6,3,10
CD010075,0,6,There was no statistically significant difference in the proportion of patients who developed SSIs between the two groups (857 patients; RR 0.96; 95% CI 0.62 to 1.48).,merge,['The authors reported no statistically significant difference in the proportion of people who developed wound infection in the two groups (8.5% in the early bathing group and 8.8% in the delayed bathing group).'],4,0.7,4,10
CD010075,0,7,The proportions of patients who developed SSIs were 8.5% in the early bathing group and 8.8% in the delayed bathing group.,none,[],4,0.8,4,10
CD010075,1,8,"There is currently no conclusive evidence available from randomised trials regarding the benefits or harms of early versus delayed post-operative showering or bathing for the prevention of wound complications, as the confidence intervals around the point estimate are wide, and, therefore, a clinically significant increase or decrease in SSI by early post-operative bathing cannot be ruled out.",rephrase,"['There is currently no conclusive evidence available from randomised trials about the benefits, or harms, with regard to wound complications of early or delayed post-operative showering or bathing.']",5,0.9,5,10
CD010075,1,9,We recommend running further randomised controlled trials to compare early versus delayed post-operative showering or bathing.,ignore,['We recommend further randomised controlled trials to compare early versus delayed post-operative showering or bathing.'],6,1.0,5,10
CD013230,0,0,We included 24 trials involving 7099 participants.,rephrase,['We found 24 studies with 7099 participants.'],0,0.041666666666666664,1,24
CD013230,0,1,"Using the Cochrane 'Risk of bias' tool, we assessed no study as being at low risk of bias for all domains.",delete,[],1,0.08333333333333333,1,24
CD013230,0,2,"Many studies were poorly reported, so the risk of selection and detection biases were often unclear.",delete,[],1,0.125,1,24
CD013230,0,3,"Most studies reported important outcomes incompletely, and we judged them to be at high risk of reporting bias.",rephrase,['Outcomes important to patients and pre-specified by us as important outcomes for this review were often absent or incompletely reported.'],1,0.16666666666666666,1,24
CD013230,1,4,All but one study enrolled oral poisoning patients in an emergency department; the remaining study was conducted in a pre-hospital setting.,rephrase,['All but one study took place in hospitals; the remaining one was in a home setting.'],2,0.20833333333333334,2,24
CD013230,1,5,"Fourteen studies included multiple toxic syndromes or did not specify, while the other studies specifically investigated paracetamol (2 studies), carbamazepine (2 studies), tricyclic antidepressant (2 studies), yellow oleander (2 studies), benzodiazepine (1 study), or toxic berry intoxication (1 study).",split,"['Fourteen studies either did not specify the type of poison or studied different kinds.', 'The others investigated overdoses of specific medicines (paracetamol, carbamazepine, antidepressant, benzodiazepine) or poisonous plants (yellow oleander or poisonous berries).']",3,0.25,2,24
CD013230,1,6,"Twenty-one trials investigated the effects of activated charcoal (AC), administered as a single dose (SDAC) or in multiple doses (MDAC), alone or in combination with other first aid interventions (a cathartic) and/or hospital treatments.",rephrase,"['Twenty-one trials studied different treatments with activated charcoal: as a single dose or multiple doses, with or without other first aid treatments (a substance to speed up bowel transit), and with or without hospital treatments.']",5,0.2916666666666667,2,24
CD013230,1,7,Six studies investigated syrup of ipecac plus other first aid interventions (SDAC + cathartic) versus ipecac alone.,rephrase,"['Six studies compared syrup of ipecac, with or without other first aid treatments (single-dose activated charcoal plus bowel transit enhancing substance) versus no treatment.']",6,0.3333333333333333,2,24
CD013230,1,8,"The collected evidence was mostly of low to very low certainty, often downgraded for indirectness, risk of bias or imprecision due to low numbers of events.",rephrase,['Our certainty about the results of this review is mostly low to very low.'],7,0.375,2,24
CD013230,2,9,"First aid interventions that limit or delay the absorption of the poison in the body
We are uncertain about the effect of SDAC compared to no intervention on the incidence of adverse events in general (zero events in both treatment groups; 1 study, 451 participants) or vomiting specifically (Peto odds ratio (OR) 4.17, 95% confidence interval (CI) 0.30 to 57.26, 1 study, 25 participants), ICU admission (Peto OR 7.77, 95% CI 0.15 to 391.93, 1 study, 451 participants) and clinical deterioration (zero events in both treatment groups; 1 study, 451 participants) in participants with mixed types or paracetamol poisoning, as all evidence for these outcomes was of very low certainty.",rephrase,"[""We are uncertain about the treatment's side effects, admission to intensive care or worsening of the patient, and there was no information about effects on death, symptom duration, poison uptake or hospitalization.""]",8,0.4166666666666667,3,24
CD013230,2,10,"No studies assessed SDAC for mortality, duration of symptoms, drug absorption or hospitalization.",delete,[],9,0.4583333333333333,3,24
CD013230,3,11,"Only one study compared SDAC to syrup of ipecac in participants with mixed types of poisoning, providing very low-certainty evidence.",rephrase,['One study compared a single dose of activated charcoal to ipecac in mixed types of poisoning.'],9,0.5,3,24
CD013230,3,12,"Therefore we are uncertain about the effects on Glasgow Coma Scale scores (mean difference (MD) −0.15, 95% CI −0.43 to 0.13, 1 study, 34 participants) or incidence of adverse events (risk ratio (RR) 1.24, 95% CI 0.26 to 5.83, 1 study, 34 participants).",rephrase,"[""We are uncertain about the effect of activated charcoal compared to ipecac, on the patient's level of coma or the number of unwanted effects.""]",10,0.5416666666666666,3,24
CD013230,3,13,"No information was available concerning mortality, duration of symptoms, drug absorption, hospitalization or ICU admission.",rephrase,"['There was no information about effects on death, symptom duration, poison uptake, hospitalization or intensive care admission.']",11,0.5833333333333334,3,24
CD013230,4,14,"This review also considered the added value of SDAC or MDAC to hospital interventions, which mostly included gastric lavage.",delete,[],12,0.625,4,24
CD013230,4,15,No included studies investigated the use of body positioning in oral poisoning patients.,rephrase,['We found no studies that investigated the neutralization or dilution of the poison or the use of certain body positions.'],12,0.6666666666666666,4,24
CD013230,5,16,"First aid interventions that evacuate the poison from the gastrointestinal tract
We found one study comparing ipecac versus no intervention in toxic berry ingestion in a pre-hospital setting.",rephrase,['One study compared ipecac to no treatment in children who ate poisonous berries at home.'],13,0.7083333333333334,4,24
CD013230,5,17,"Low-certainty evidence suggests there may be an increase in the incidence of adverse events, but the study did not report incidence of mortality, incidence or duration of symptoms of poisoning, drug absorption, hospitalization or ICU admission (103 participants).",delete,[],14,0.75,4,24
CD013230,6,18,"In addition, we also considered the added value of syrup of ipecac to SDAC plus a cathartic and the added value of a cathartic to SDAC.",rephrase,"['Furthermore, we investigated the added value of ipecac to single-dose activated charcoal and the added value of adding bowel transit enhancing substances to AC.']",14,0.7916666666666666,4,24
CD013230,7,19,No studies used cathartics as an individual intervention.,delete,[],15,0.8333333333333334,5,24
CD013230,8,20,"First aid interventions that neutralize or dilute the poison
No included studies investigated the neutralization or dilution of the poison in oral poisoning patients.",delete,[],15,0.875,5,24
CD013230,9,21,The studies included in this review provided mostly low- or very low-certainty evidence about the use of first aid interventions for acute oral poisoning.,delete,[],15,0.9166666666666666,5,24
CD013230,9,22,"A key limitation was the fact that only one included study actually took place in a pre-hospital setting, which undermines our confidence in the applicability of these results to this setting.",rephrase,"['All but one study took place in a hospital setting, which means that the results cannot be directly applied to the lay setting.']",15,0.9583333333333334,5,24
CD013230,9,23,"Thus, the amount of evidence collected was insufficient to draw any conclusions.",rephrase,"['Based on the identified evidence, we cannot draw any conclusions about the effects of any of the investigated first aid treatments in a lay setting.']",16,1.0,5,24
CD008053,0,0,We included two trials (116 women) comparing planned home versus hospital management for PPROM.,split,"['We included two randomised controlled studies with 116 women in the review.', 'These studies compared planned home versus hospital management for women with preterm, prelabour rupture of the membranes (PPROM).']",0,0.07142857142857142,1,14
CD008053,0,1,"Overall, the number of included women in each trial was too small to allow adequate assessment of pre-specified outcomes.",rephrase,"['Overall, the number of women included in the two studies was too small to allow adequate assessment of outcomes.']",2,0.14285714285714285,1,14
CD008053,0,2,Investigators used strict inclusion criteria and in both studies relatively few of the women presenting with PPROM were eligible for inclusion.,rephrase,"['In both studies there were strict criteria for deciding whether women could be included; for example, women had to live within a certain distance of emergency facilities, and there had to be no signs that mothers and babies had infection or other problems.']",3,0.21428571428571427,2,14
CD008053,0,3,Women were monitored for 48 to 72 hours before randomisation.,delete,[],4,0.2857142857142857,2,14
CD008053,0,4,"Perinatal mortality was reported in one trial and there was insufficient evidence to determine whether it differed between the two groups (risk ratio (RR) 1.93, 95% confidence interval (CI) 0.19 to 20.05).",delete,[],4,0.35714285714285715,2,14
CD008053,0,5,"There was no evidence of differences between groups for serious neonatal morbidity, chorioamnionitis, gestational age at delivery, birthweight and admission to neonatal intensive care.",rephrase,"[""Results suggested that there were few differences in mothers' and babies' health for women cared for at home or in hospital including infant death, serious illness, or admission to intensive care baby units.""]",4,0.42857142857142855,3,14
CD008053,1,6,There was no information on serious maternal morbidity or mortality.,delete,[],5,0.5,3,14
CD008053,1,7,"There was some evidence that women managed in hospital were more likely to be delivered by caesarean section (RR (random-effects) 0.28, 95% CI 0.07 to 1.15).",rephrase,['There was some evidence that women managed in hospital were more likely to be delivered by caesarean section.'],5,0.5714285714285714,3,14
CD008053,1,8,"However, results should be interpreted cautiously as there is moderate heterogeneity for this outcome (I² = 35%).",delete,[],6,0.6428571428571429,4,14
CD008053,1,9,"Mothers randomised to care at home spent approximately 10 fewer days as inpatients (mean difference -9.60, 95% CI -14.59 to -4.61) and were more satisfied with their care.",rephrase,['Women cared for at home were likely to spend less time in hospital (spending approximately 10 fewer days as inpatients) and were more satisfied with their care.'],6,0.7142857142857143,4,14
CD008053,1,10,"Furthermore, home care was associated with reduced costs.",rephrase,"['In addition, home care was associated with reduced costs.']",7,0.7857142857142857,4,14
CD008053,2,11,The review included two relatively small studies that did not have sufficient statistical power to detect meaningful differences between groups.,delete,[],8,0.8571428571428571,5,14
CD008053,2,12,Future large and adequately powered randomised controlled trials are required to measure differences between groups for relevant pre-specified outcomes.,delete,[],8,0.9285714285714286,5,14
CD008053,2,13,Special attention should be given to the assessment of maternal satisfaction with care and cost analysis as they will have social and economic implications in both developed and developing countries.,delete,[],8,1.0,5,14
CD011188,0,0,"This update identified one new study, therefore the analysis included eight trials consisting of 1877 participants.",merge,"['We found eight studies involving 1877 participants, which compared the use of corticosteroids with no corticosteroids in children with Kawasaki disease.']",0,0.09090909090909091,1,11
CD011188,0,1,Seven trials investigated the use of corticosteroids in first-line treatment and one investigated second-line treatment.,none,[],0,0.18181818181818182,1,11
CD011188,0,2,The trials were all of good methodological quality.,delete,[],1,0.2727272727272727,2,11
CD011188,1,3,"On pooled analysis, corticosteroid treatment reduced the subsequent occurrence of coronary artery abnormalities (OR 0.32, 95% CI 0.14 to 0.75; 8 studies, 986 participants; moderate-certainty evidence), without resultant serious adverse events (0 events; 6 studies, 737 participants; moderate-certainty) and mortality (0 events; 8 studies, 1075 participants; moderate-certainty evidence).",delete,[],1,0.36363636363636365,2,11
CD011188,1,4,"In addition, corticosteroids reduced the duration of fever (MD −1.34 days, 95% CI −2.24 to -0.45; 3 studies, 290 participants; low-certainty evidence), time for laboratory parameters (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) to normalise (MD −2.80 days, 95% CI −4.38 to −1.22; 1 study, 178 participants; moderate-certainty evidence), and length of hospital stay (MD −1.01 days, 95% CI −1.72 to −0.30; 2 studies, 119 participants; moderate-certainty evidence).",delete,[],1,0.45454545454545453,3,11
CD011188,1,5,None of the included studies reported long-term (greater than one year after disease onset) coronary morbidity.,rephrase,"['None of the studies reported on long-term (more than one year after disease onset) heart problems (coronary morbidity), which can be associated with Kawasaki disease.']",1,0.5454545454545454,3,11
CD011188,2,6,"Moderate-certainty evidence shows that use of steroids in the acute phase of KD can be associated with reduced coronary artery abnormalities, reduced inflammatory markers and shorter duration of hospital stay when compared to no corticosteroids.",rephrase,"['Evidence was of moderate certainty for serious side effects and deaths, the risk of future heart problems, blood markers and length of hospital stay.']",2,0.6363636363636364,4,11
CD011188,2,7,There were no serious adverse events or deaths reported with or without corticosteroid use.,rephrase,['There were no serious side effects or deaths reported in the corticosteroid treatment groups or the no corticosteroid treatment groups.'],3,0.7272727272727273,4,11
CD011188,2,8,Low-certainty evidence shows use of corticosteroids can reduce duration of clinical symptoms (fever and rash).,rephrase,['Evidence was considered low certainty for the duration of clinical symptoms (fever and rash).'],4,0.8181818181818182,5,11
CD011188,2,9,None of the included studies reported on long-term (greater than one year after disease onset) coronary morbidity.,delete,[],5,0.9090909090909091,5,11
CD011188,2,10,Evidence presented in this systematic review agrees with current clinical guidelines on the use of corticosteroids in the first-line treatment in KD.,rephrase,['This Cochrane Review updates our previous evidence.'],5,1.0,5,11
CD004367,0,0,Five trials (1165 participants) were included in the review.,rephrase,['Five trials (1165 participants) met the inclusion criteria and are included in the review.'],0,0.14285714285714285,1,7
CD004367,0,1,"There was no statistically significant difference between olanzapine and placebo (either alone or in combination with lithium or valproate) in terms of number of participants who experienced relapse into mood episode (random effects RR 0.68, 95% CI 0.43 to 1.07, p = 0.09; 2 studies, n=460), however restricting the analysis to the trial that compared olanzapine monotherapy versus placebo, there was a statistically significant difference in favour of olanzapine (RR 0.58, 95% CI 0.49 to 0.69, p<0.00001).",delete,[],1,0.2857142857142857,2,7
CD004367,0,2,"No statistically significant difference was found between olanzapine and other mood stabilisers (lithium or valproate) in preventing symptomatic relapse for any mood episode, however, olanzapine was more effective than lithium in preventing symptomatic manic relapse (RR 0.59, 95% CI 0.39 to 0.89, p = 0.01; 1 study, n=361).",delete,[],1,0.42857142857142855,3,7
CD004367,0,3,Olanzapine either alone or as adjunctive treatment to mood stabilisers was associated with significantly greater weight gain than placebo.,rephrase,"['The olanzapine group had significantly fewer patients suffering from insomnia than the placebo group, but a significantly larger number of people suffering from weight gain.']",1,0.5714285714285714,3,7
CD004367,0,4,"By contrast, olanzapine was associated with a lower rate of manic worsening, but with a higher rate of weight increase and depression than lithium.",rephrase,"['When compared with lithium, olanzapine caused more weight gain and depressive symptoms but fewer insomnia and nausea symptoms and a lower rate of manic worsening.']",2,0.7142857142857143,4,7
CD004367,1,5,"Though based on a limited amount of information, there is evidence that olanzapine may prevent further mood episodes in patients who have responded to olanzapine during an index manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate.",rephrase,"['Based on a limited amount of information, olanzapine may prevent further mood episodes (especially manic relapse) in patients who responded to olanzapine during an index manic or mixed episode and who have not previously had a satisfactory response to lithium or valproate.']",3,0.8571428571428571,5,7
CD004367,1,6,"However, notwithstanding these positive results, the current evidence is stronger for lithium as first line maintenance treatment of bipolar disorder.",delete,[],4,1.0,5,7
CD009871,0,0,"Six studies met the inclusion criteria, with a total of 334 adult participants.",rephrase,"['We found six studies, with a total of 334 adult participants.']",0,0.08333333333333333,1,12
CD009871,0,1,We identified no studies that included children as participants.,rephrase,['We found no studies that included people younger than 18 years of age.'],1,0.16666666666666666,1,12
CD009871,0,2,All studies were affected by high risk of bias due to a lack of blinding of participants and personnel; five studies were affected by high risk of bias for lack of blinding of outcome assessors.,rephrase,"['All studies were at high risk of bias in some ways, and therefore it was not possible to draw conclusions in support of any intervention.']",2,0.25,2,12
CD009871,0,3,There was high or unclear risk of biases affecting some studies across all the Cochrane risk of bias measures.,delete,[],3,0.3333333333333333,2,12
CD009871,1,4,Three studies compared a psychological intervention (either cognitive behaviour therapy or mindfulness-based cognitive therapy) with a control intervention.,split,"['Three studies compared a psychological therapy (cognitive behaviour therapy or mindfulness-based cognitive therapy) with a no-treatment control intervention.', 'One study compared cognitive behavioural therapy with another psychological intervention (supportive psychotherapy), and did not find an effect in favour of either intervention.', 'One study compared a supervised exercise programme with exercise as usual, but did not find a effect in favour of either intervention.']",3,0.4166666666666667,3,12
CD009871,1,5,"Data regarding depression symptom outcome measures were combined in a meta-analysis, but did not find an effect in favour of treatment (SMD -0.14; 95% CI -0.47 to 0.19; Z = 0.83; P = 0.41).",delete,[],6,0.5,3,12
CD009871,1,6,"The other comparisons comprised of single studies of depression symptoms and compared; cognitive behaviour therapy versus supportive psychotherapy (SMD -0.09; 95% CI -0.65 to 0.48; Z = 0.30; P = 0.77); repetitive transcranial magnetic stimulation plus tricyclic antidepressant (rTMS + TCA) versus tricyclic antidepressant alone (SMD -0.84; 95% CI -1.36 to -0.32; Z = 3;19, P = 0.001); and a supervised exercise program versus exercise as usual (SMD -0.43; 95% CI -0.88 to 0.03; Z = 1.84; P = 0.07).",delete,[],6,0.5833333333333334,3,12
CD009871,1,7,"There was very-low quality evidence, small effect sizes and wide variability of results, suggesting that no comparisons showed a reliable effect for any intervention.",rephrase,"['Because the quality of the evidence was very low, it was not possible to draw the conclusion that the addition of rTMS improved outcomes.']",6,0.6666666666666666,4,12
CD009871,2,8,"Only one study mentioned minor, transient adverse events from repetitive transcranial magnetic stimulation.",rephrase,"['Only one study, of rTMS, reported any harmful effects and these were relatively minor and resolved quickly.']",7,0.75,4,12
CD009871,3,9,The review did not find compelling evidence in favour of any intervention.,delete,[],8,0.8333333333333334,5,12
CD009871,3,10,"Future studies should focus on participants with a diagnosed TBI and include only participants who have a diagnosis of depression, or who record scores above a clinical cutoff on a depression measure.",delete,[],8,0.9166666666666666,5,12
CD009871,3,11,There is a need for additional RCTs that include a comparison between an intervention and a control that replicates the effect of the attention given to participants during an active treatment.,delete,[],8,1.0,5,12
CD001964,0,0,Eight RCTs (enrolling 2515 patients) met the inclusion criteria.,rephrase,['We collected data from eight randomized controlled trials addressing this issue and enrolling a total of 2515 patients.'],0,0.16666666666666666,1,6
CD001964,0,1,"Three RCTs (all performed in Asian countries) compared D3 with D2 lymphadenectomy: data suggested no significant difference in OS between these two types of lymph node dissection (HR 0.99, 95% CI 0.81 to 1.21), with no significant difference in postoperative mortality (RR 1.67, 95% CI 0.41 to 6.73).",delete,[],1,0.3333333333333333,2,6
CD001964,0,2,Data for DFS were available only from one trial and for no trial were DSS data available.,delete,[],1,0.5,3,6
CD001964,0,3,"Five RCTs (n = 3 European; n = 2 Asian) compared D2 to D1 lymphadenectomy: OS (n = 5; HR 0.91, 95% CI 0.71 to 1.17) and DFS (n=3; HR 0.95, 95% CI 0.84 to 1.07) findings suggested no significant difference between these two types of lymph node dissection.",delete,[],1,0.6666666666666666,4,6
CD001964,0,4,"In contrast, D2 lymphadenectomy was associated with a significantly better DSS compared to D1 lymphadenectomy (HR 0.81, 95% CI 0.71 to 0.92), the quality of the body of evidence being moderate; however, D2 lymphadenectomy was also associated with a higher postoperative mortality rate (RR 2.02, 95% CI 1.34 to 3.04).",rephrase,"['However, D2 lymphadenectomy was also associated with a higher rate of postoperative mortality.']",1,0.8333333333333334,5,6
CD001964,1,5,"D2 lymphadenectomy can improve DSS in patients with resectable carcinoma of the stomach, although the increased incidence of postoperative mortality reduces its therapeutic benefit.",split,"['We found that D2 lymphadenectomy can reduce the number of deaths due to disease progression as compared to D1 lymphadenectomy.', 'In conclusion, our findings support the use of D2 lymphadenectomy in patients with resectable carcinoma of the stomach, although the increased incidence of postoperative mortality reduces its therapeutic effect.']",2,1.0,5,6
CD005508,0,0,"We included six RCTs that fulfilled the above criteria, with a total of 119 participants.",delete,[],0,0.1,1,10
CD005508,0,1,"The beta blockers studied were atenolol, propranolol, pindolol and metoprolol.",rephrase,"['The beta blockers studied were propranolol, pindolol, atenolol and metoprolol.']",0,0.2,1,10
CD005508,0,2,All trials were of poor quality with the drugs administered over a short time (10 days to two months).,rephrase,"['The drugs were administered over a short time (10 days to two months), and most of the outcome measures were reported in single studies.']",1,0.3,2,10
CD005508,0,3,None of the primary outcomes were reported by more than one study.,delete,[],2,0.4,2,10
CD005508,0,4,"Similarly, secondary outcome measures, with the exception of vascular resistance (as reported by three studies), were reported, each by only one study.",delete,[],2,0.5,3,10
CD005508,0,5,Pooling of such results was deemed inappropriate.,delete,[],2,0.6,3,10
CD005508,0,6,"None of the trials showed a statistically significant worsening effect of beta blockers on time to claudication, claudication distance and maximal walking distance as measured on a treadmill, nor on calf blood flow, calf vascular resistance and skin temperature, when compared with placebo.",ignore,"['None of the trials showed clear worsening effects of beta blockers on time to claudication, claudication distance and maximal walking distance as measured on a treadmill, nor on calf blood flow, calf vascular resistance and skin temperature, when compared with placebo.']",2,0.7,4,10
CD005508,0,7,No reports described adverse events associated with the beta blockers studied.,rephrase,['Trial investigators reported no adverse events or issues regarding taking the beta blockers studied.'],3,0.8,4,10
CD005508,1,8,"Currently, no evidence suggests that beta blockers adversely affect walking distance, calf blood flow, calf vascular resistance and skin temperature in people with intermittent claudication.",merge,"['Currently, no evidence from randomised controlled trials suggests that beta blockers adversely affect walking distance in people with intermittent claudication, and beta blockers should be used with caution, if clinically indicated.']",4,0.9,5,10
CD005508,1,9,"However, because of the lack of large published trials, beta blockers should be used with caution, if clinically indicated.",none,[],4,1.0,5,10
CD013488,0,0,No studies met the eligibility criteria and therefore we did not include any in this review.,delete,[],0,0.1111111111111111,1,9
CD013488,0,1,The excluded studies were either cross-over in design (but lacking a sufficient washout period between treatments) or did not assess the timing of PERT.,split,"['Four of these assessed the timing of PERT administration, but they had a cross-over design where participants had\xa0one intervention and then swapped to the second intervention.', 'Four studies\xa0did not look at the timing of PERT and one study evaluated a new educational program for PERT.']",0,0.2222222222222222,2,9
CD013488,0,2,One study which was terminated early is awaiting assessment pending further information.,rephrase,['One study was terminated early and we will assess this again at the first update of this review if we are able to obtain more information from the investigators.'],2,0.3333333333333333,2,9
CD013488,1,3,We were unable to determine whether one dosing schedule for PERT is better than another since we identified no eligible RCTs.,delete,[],3,0.4444444444444444,3,9
CD013488,1,4,"While the introduction of PERT to people with CF can improve their nutritional status, there are a limited number of studies which address this review question, and none met our eligibility criteria.",rephrase,['No studies met the eligibility criteria.'],3,0.5555555555555556,3,9
CD013488,1,5,"Since malnutrition and adverse gastrointestinal symptoms remain a common feature in CF, the assessment of the relative performance of dosing schedules may provide evidence to improve outcomes in people with CF who are pancreatic insufficient.",rephrase,['We did not find any studies where PERT was given to people with CF who were pancreatic insufficient at different timings relative to their meals.'],4,0.6666666666666666,4,9
CD013488,2,6,Further research is needed to fully evaluate the role of dosing schedules for PERT in fat absorption.,rephrase,['Further research is needed to work out the best time to take PERT in relation to a meal.'],5,0.7777777777777778,4,9
CD013488,2,7,Research should also establish reliable outcome measures and minimal clinically important differences.,delete,[],6,0.8888888888888888,5,9
CD013488,2,8,"While RCTs with a cross-over design may have advantages over a parallel group design, an adequate washout period between intervention periods is essential.",delete,[],6,1.0,5,9
CD012697,0,0,"We included one four-week study with 79 adults in acute schizophrenia, comparing MST plus standard care to ECT plus standard care in this review.",split,"['We found one short-term randomised controlled trial (RCT) with 79 adults that met the review requirements.', 'It compared MST plus standard care to ECT plus standard care.']",0,0.125,1,8
CD012697,0,1,We rated the overall risk of bias as high due to high risk of bias in the domains of selective reporting and other biases (early termination and baseline imbalance) and unclear risk of bias in the domain of blinding of participants and personnel.,delete,[],2,0.25,2,8
CD012697,1,2,"We found that MST and ECT may not differ in improving the global state (n = 79, risk ratio (RR) 1.12, 95% confidence interval (CI) 0.73 to 1.70), overall (n = 79, mean difference (MD) -0.20, 95% CI -8.08 to 7.68), the positive symptoms (n = 79, MD 1.40, 95% CI -1.97 to 4.77) and the negative symptoms (n = 79, MD -1.00, 95% CI -3.85 to 1.85) in people with schizophrenia.",rephrase,"['We found that MST and ECT may be comparable in improving the global state of people with schizophrenia, and in improving the overall, positive and negative symptoms of schizophrenia.']",2,0.375,2,8
CD012697,2,3,"We found  that MST compared to ECT may cause less delayed memory deficit and less cognitive deterioration (n = 79, number of people with a delayed memory deficit, RR 0.63, 95% CI 0.41 to 0.96; n = 79, mean change in global cognitive function, MD 5.80, 95% CI 0.80 to 10.80), but also may improve more cognitive function (n = 47, number of people with any cognitive improvement, RR 3.30, 95% CI 1.29 to 8.47).",rephrase,['MST may cause less delayed memory deficit and less cognitive deterioration and may improve cognitive function compared to ECT.'],3,0.5,3,8
CD012697,3,4,"We found that there may be no difference between the two groups in terms of leaving the study early due to any reason (n = 79, RR 2.51, 95% CI 0.73 to 8.59), due to adverse effects (n = 79, RR 3.35, 95% CI 0.39 to 28.64) or due to inefficacy (n = 79, RR 2.52, 95% CI 0.11 to 60.10).",rephrase,"['There may be no difference between the two groups in terms of leaving the study early due to any reason, adverse effects, or inefficacy.']",4,0.625,4,8
CD012697,4,5,"Since all findings were based on one study with high risk of bias and the confidence in the evidence was very low, we were not sure these comparable or favourable effects of MST over ECT were its true effects.",rephrase,['Our findings were based on very limited data.'],5,0.75,4,8
CD012697,5,6,"Due to the paucity of data, we cannot draw any conclusion on the efficacy and tolerability of MST for people with schizophrenia.",rephrase,['We cannot conclude whether MST is helpful or safe for people with schizophrenia based on limited data.'],6,0.875,5,8
CD012697,5,7,Well-designed RCTs are warranted to answer the question.,ignore,['Well-designed RCTs are warranted to answer the question.'],7,1.0,5,8
CD007102,0,0,We included seven RCTs (667 women) in this updated review.,rephrase,['This is an updated version of a review that was first published in 2009.'],0,0.09090909090909091,1,11
CD007102,0,1,"Most studies were at a low or moderate risk of bias and all compared methotrexate with actinomycin D. Three studies compared weekly intramuscular (IM) methotrexate with bi-weekly pulsed intravenous (IV) actinomycin D (393 women), one study compared five-day IM methotrexate with bi-weekly pulsed IV actinomycin D (75 women), one study compared eight-day IM methotrexate-folinic acid (MTX-FA) with five-day IV actinomycin D (49 women), and one study compared eight-day IM MTX-FA with bi-weekly pulsed IV actinomycin D. One study contributed no data.",rephrase,['We assessed these trials as being at low to moderate risk of bias.'],1,0.18181818181818182,1,11
CD007102,1,2,"Moderate-certainty evidence indicates that actinomycin D is probably more likely to lead to primary cure than methotrexate (risk ratio (RR) 0.65, 95% confidence interval (CI) 0.57 to 0.75; six trials, 577 participants; I2 = 26%), and first-line methotrexate treatment is probably more likely to fail than actinomycin D treatment (RR 3.55, 95% CI 1.81 to 6.95; six trials, 577 participants; I2 = 61%; moderate-certainty evidence)
Low-certainty evidence suggests that there may be little or no difference between methotrexate and actinomycin D treatment with respect to nausea (four studies, 466 women; RR 0.61, 95% CI 0.29 to 1.26) or any of the other individual side-effects reported, although data for all of these outcomes were insufficient and too inconsistent to be conclusive.",delete,[],2,0.2727272727272727,2,11
CD007102,1,3,"Low-certainty evidence suggests that there may be little or no difference in the risk of severe adverse events (SAEs) between the groups overall (five studies, 515 women; RR 0.35, 95% CI 0.08 to 1.66; I² = 60%); however, the direction of effect favours methotrexate and more evidence is needed.",merge,"['Low-certainty evidence suggests that severe adverse events may be more common with actinomycin D, particularly with the five-day regimen.']",2,0.36363636363636365,2,11
CD007102,1,4,"Furthermore, evidence from subgroup analyses suggests that actinomycin D may be associated with a greater risk of SAEs than methotrexate (low-certainty evidence).",none,[],2,0.45454545454545453,3,11
CD007102,1,5,We found no evidence on the effect of these treatments on future fertility.,rephrase,['More evidence is also needed on the effects of these treatments on future fertility.'],3,0.5454545454545454,3,11
CD007102,2,6,"Actinomycin D is probably more likely to achieve a primary cure in women with low-risk GTN, and less likely to result in treatment failure, than a methotrexate regimen.",rephrase,"['Overall, and for each treatment regimen compared, the review evidence shows that actinomycin D is probably more likely to achieve a cure in the first instance than methotrexate, and less likely to fail.']",4,0.6363636363636364,4,11
CD007102,2,7,There may be little or no difference between the pulsed actinomycin D regimen and the methotrexate regimen with regard to side-effects.,delete,[],5,0.7272727272727273,4,11
CD007102,2,8,"However, actinomycin D may be associated with a greater risk of severe adverse events (SAEs) than a methotrexate regimen.",delete,[],5,0.8181818181818182,5,11
CD007102,2,9,Higher-certainty evidence is still needed on treating low-risk GTN and the four ongoing trials are likely to make a significant contribution to this field.,rephrase,['Four RCTs comparing methotrexate and actinomycin D regimen are currently underway and these will make an important contribution to this field.'],5,0.9090909090909091,5,11
CD007102,2,10,"Given the variety of treatment regimens, findings from these trials could facilitate a network meta-analysis in the next version of this review to help women and clinicians determine the best treatment options for low-risk GTN.",delete,[],6,1.0,5,11
CD008472,0,0,We included 14 trials which randomised a total of 1295 participants (age range: 64.5 to 76 years; 84% male; study periods ranged from 2003 to 2019).,split,"['We found 14 studies including 1295 people from the UK, Ireland, Estonia, Spain, China, the USA, Singapore, and New Zealand.', 'The majority of the participants (84%) were men.']",0,0.14285714285714285,1,7
CD008472,0,1,"In general, the included studies were at low to unclear risk of bias for most risk of bias domains.",rephrase,"['We compared and summarised the results of the included studies and rated our confidence in the evidence, based on factors such as study methods and sizes.']",2,0.2857142857142857,2,7
CD008472,0,2,"The certainty of evidence of main outcomes was moderate due to imprecision of results, moderate heterogeneity, or possible publication bias.",rephrase,"['Our confidence in our findings is only moderate due to concerns about the following factors: firstly, the evidence was based on a few cases such as for death and limb loss, and some studies were small; secondly, the studies used different methods to detect outcomes such as kidney injury; and finally, for some results, such as heart attack, some of the studies conducted in the area have not made their results public yet, preventing an objective picture of all the available evidence (publication bias).']",3,0.42857142857142855,3,7
CD008472,1,3,"We found that RIPC made no clear difference in perioperative mortality compared with no RIPC (RR 1.41, 95% CI 0.59 to 3.40; I2 = 0%; 10 studies, 965 participants; moderate-certainty evidence).",delete,[],4,0.5714285714285714,3,7
CD008472,1,4,"Similarly, we found no clear difference between the two groups for myocardial infarction (RR 0.82, 95% CI 0.49 to 1.40; I2 = 7%; 11 studies, 1001 participants; moderate-certainty evidence), renal impairment (RR 1.07, 95% CI 0.62 to 1.86; I2 = 40%; 12 studies, 1054 participants; moderate-certainty evidence), stroke (RR 0.33, 95% CI 0.04 to 3.15; I2 = 0%; 4 studies, 392 participants; moderate-certainty evidence), limb loss (RR 0.74, 95% CI 0.05 to 10.61; I2 = 32%; 3 studies, 322 participants; low-certainty evidence), hospital stay (MD −0.94 day, 95% CI −1.95 to 0.07; I2 = 17%; 7 studies, 569 participants; moderate-certainty evidence), and operating time or total anaesthetic time (MD 5.76 minutes, 95% CI −3.25 to 14.76; I2 = 44%; 10 studies, 803 participants; moderate-certainty evidence).",delete,[],4,0.7142857142857143,4,7
CD008472,2,5,"Overall, compared with no RIPC, RIPC probably leads to little or no difference in perioperative mortality, myocardial infarction, renal impairment, stroke, hospital stay, and operating time, and may lead to little or no difference in limb loss in people undergoing elective major vascular and endovascular surgery.",rephrase,"['In people undergoing vascular surgery, compared to no RIPC:\n• RIPC probably leads to little or no difference in death (10 studies, 965 people), heart attack (11 studies, 1001 people), kidney injury (12 studies, 1054 people), and stroke (4 studies, 392 people), and may lead to little or no difference in limb loss (3 studies, 322 people); and\n• RIPC probably leads to little or no difference in hospital stay (7 studies, 569 people) and operating time (10 studies, 803 people).']",4,0.8571428571428571,5,7
CD008472,2,6,"Adequately powered and designed randomised studies are needed, focusing in particular on the clinical endpoints and patient-centred outcomes.",delete,[],5,1.0,5,7
CD010205,0,0,"Eight studies (with 85,629 infants) were included and five studies were meta-analysed, out of which four studies compared zinc with placebo, and one compared zinc plus riboflavin versus riboflavin.",rephrase,"['We included eight studies that covered zinc supplementation compared with placebo, zinc and riboflavin compared with riboflavin only, zinc, riboflavin and B complex vitamins compared with riboflavin and B complex vitamins.']",0,0.1111111111111111,1,9
CD010205,0,1,"Certain growth outcomes after six months of intervention (Weight for Age Z-scores (WAZ) (standardised mean difference) (SMD) 0.16, 95% CI 0.03 to 0.29; three studies, n = 955; fixed-effect; heterogeneity Chi² P = 0.96); I² = 0%); change in WAZ (SMD 0.16, 95% CI 0.07 to 0.25; one study, n = 386; fixed-effect); (Weight-for-Length Z-score (WLZ) (SMD 0.15, 95% CI 0.02 to 0.28; three studies, n = 955; fixed-effect; heterogeneity: Chi² P = 0.81); I² = 0%); (change in WLZ (SMD 0.17, 95% CI 0.06 to 0.28; one study, n = 386; fixed-effect)) were positively affected by zinc supplementation compared to placebo.",delete,[],1,0.2222222222222222,2,9
CD010205,0,2,A single study reported no difference in the incidence of diarrhoea and lower respiratory tract infection with zinc supplementation.,delete,[],1,0.3333333333333333,2,9
CD010205,0,3,Zinc had no effect on mortality in children younger than 12 months.,rephrase,['zinc had no effect on decreasing deaths or illnesses in children younger than 12 months.'],1,0.4444444444444444,3,9
CD010205,1,4,"When zinc plus riboflavin was compared to riboflavin only, significant improvement was observed in the incidence of wasting at 24 months (risk ratio (RR) 0.59, 95% CI 0.37 to 0.96; one study, n = 296; fixed-effect), but significant worsening of incidence of stunting was present at 21 months (RR 1.53, 95% CI 1.09 to 2.16; one study, n = 298; fixed-effect).",delete,[],2,0.5555555555555556,3,9
CD010205,2,5,There was a significant positive impact of zinc supplementation on WAZ and WLZ after six months of intervention in infants compared to placebo.,rephrase,['Moderate- to good-certainty evidence from three studies suggested an increase in weight-for-age Z-scores and weight-for-length Z-scores after zinc supplementation for six months compared to placebo only.'],2,0.6666666666666666,4,9
CD010205,2,6,"When a combined supplement of zinc and riboflavin was compared to riboflavin, there was a significant reduction in wasting at 24 months, but stunting at 21 months was negatively affected.",rephrase,"['Only one study could be analysed for zinc and riboflavin supplementation compared to riboflavin only, and the results suggested a decrease in wasting after 24 months of supplementation and an increase in stunting after 21 months.']",3,0.7777777777777778,4,9
CD010205,2,7,"Although included trials were of good-to-moderate quality, evidence that could be meta-analysed was based on a few studies which affected the overall quality of results.",delete,[],4,0.8888888888888888,5,9
CD010205,2,8,"Regardless, there is a need for strong trials conducted in infants younger than six months before a strong recommendation can be made supporting zinc supplementation in this age group.",rephrase,"['with this evidence, we cannot strongly recommend clinicians to prescribe zinc supplements to children under six months of age.']",4,1.0,5,9
CD008515,0,0,One study (34 patients) met our inclusion criteria although it was not yet a peer reviewed publication.,rephrase,['One unpublished trial met our inclusion criteria.'],0,0.1,1,10
CD008515,0,1,The study randomised patients with chronic frontal sinusitis who had failed a prolonged course of medical treatment into two groups: balloon dilatation of the frontal recess (plus conventional FESS of other involved sinuses) versus conventional FESS (Draf type 1/2a procedures on the frontal sinuses).,rephrase,['This randomised 34 patients with chronic frontal sinusitis into two groups: in one group balloon dilation was used to open up the drainage pathways of the frontal sinuses; in the other group conventional endoscopic sinus surgery was used to do the same.'],1,0.2,1,10
CD008515,0,2,At 12 months follow up there was no statistically significant difference in radiological resolution of frontal sinuses between the two groups.,delete,[],2,0.3,2,10
CD008515,0,3,The percentages of directly observed patent frontal recesses at 12 months were 75% in the balloon dilation group versus 63% in the FESS-only group.,delete,[],2,0.4,2,10
CD008515,0,4,The authors state that this was statistically significant but details of the analysis were not presented.,rephrase,"['However, it is not clear whether this was a statistically significant result.']",2,0.5,3,10
CD008515,0,5,Indeed the study as a whole suffers from a bias in the way its outcome measures were reported.,rephrase,['The study report appeared to be biased in the way it reported its outcome measures.'],3,0.6,3,10
CD008515,1,6,No major complications were reported.,delete,[],4,0.7,4,10
CD008515,1,7,"Three patients in the FESS-only group required further revision frontal sinus surgery compared to one in the balloon dilation group, although synechiae were more common in the latter.",delete,[],4,0.8,4,10
CD008515,2,8,At present there is no convincing evidence supporting the use of endoscopic balloon sinus ostial dilation compared to conventional surgical modalities in the management of CRS refractory to medical treatment.,merge,"['At present, therefore, we cannot recommend the use of balloon dilation of sinus ostia over conventional surgical treatment modalities in this setting.']",4,0.9,5,10
CD008515,2,9,"With the escalating use of balloon sinuplasty, there is an urgent need for more randomised controlled trials to determine its efficacy over conventional surgical treatment modalities.",none,[],4,1.0,5,10
CD008892,0,0,Thirty-seven studies met the inclusion criteria and included a total of 5080 participants (range 50 to 1732).,delete,[],0,0.047619047619047616,1,21
CD008892,0,1,"Enteric fever prevalence rates in the study populations ranged from 1% to 75% (median prevalence 24%, interquartile range (IQR) 11% to 46%).",delete,[],0,0.09523809523809523,1,21
CD008892,0,2,"The included studies evaluated 16 different RDTs, and 16 studies compared two or more different RDTs.",rephrase,['Two-thirds of the included studies did not evaluate the RDTs in the context of patients who are typically tested for the disease.'],0,0.14285714285714285,1,21
CD008892,0,3,"Only three studies used the Grade 1 reference standard, and only 11 studies recruited unselected febrile patients.",delete,[],1,0.19047619047619047,1,21
CD008892,0,4,"Most included studies were from Asia, with five studies from sub-Saharan Africa.",rephrase,['Most studies recruited participants from South Asia.'],1,0.23809523809523808,2,21
CD008892,0,5,All of the RDTs were designed to detect S.Typhi infection only.,rephrase,['All of the RDTs evaluated detected Salmonella Typhi (typhoid fever) only.'],2,0.2857142857142857,2,21
CD008892,1,6,"Most studies evaluated three RDTs and their variants: TUBEX in 14 studies; Typhidot (Typhidot, Typhidot-M, and TyphiRapid-Tr02) in 22 studies; and the Test-It Typhoid immunochromatographic lateral flow assay, and its earlier prototypes (dipstick, latex agglutination) developed by the Royal Tropical Institute, Amsterdam (KIT) in nine studies.",delete,[],3,0.3333333333333333,2,21
CD008892,1,7,Meta-analyses showed an average sensitivity of 78% (95% confidence interval (CI) 71% to 85%) and specificity of 87% (95% CI 82% to 91%) for TUBEX; and an average sensitivity of 69% (95% CI 59% to 78%) and specificity of 90% (95% CI 78% to 93%) for all Test-It Typhoid and prototype tests (KIT).,split,"['TUBEX showed an average sensitivity of 78% and specificity of 87%.', 'Test-It Typhoid and prototypes (KIT) showed an average sensitivity of 69% and specificity of 90%.']",3,0.38095238095238093,2,21
CD008892,1,8,"Across all forms of the Typhidot test, the average sensitivity was 84% (95% CI 73% to 91%) and specificity was 79% (95% CI 70% to 87%).",rephrase,"['Typhidot studies, grouped together to include Typhidot, Typhidot-M, and TyphiRapid-Tr02, showed an average sensitivity of 84% and specificity of 79%.']",5,0.42857142857142855,3,21
CD008892,1,9,"When we based the analysis on the 13 studies of the Typhidot test that either reported indeterminate test results or where the test format means there are no indeterminate results, the average sensitivity was 78% (95% CI 65% to 87%) and specificity was 77% (95% CI 66% to 86%).",merge,"['When Typhidot studies with clear reporting of indeterminate results are considered, the average sensitivity and specificity of Typhidot was 78% and 77% respectively.']",6,0.47619047619047616,3,21
CD008892,1,10,"We did not identify any difference in either sensitivity or specificity between TUBEX, Typhidot, and Test-it Typhoid tests when based on comparison to the 13 Typhidot studies where indeterminate results are either reported or not applicable.",none,[],6,0.5238095238095238,3,21
CD008892,1,11,"If TUBEX and Test-it Typhoid are compared to all Typhidot studies, the sensitivity of Typhidot was higher than Test-it Typhoid (15% (95% CI 2% to 28%), but other comparisons did not show a difference at the 95% level of CIs.",delete,[],7,0.5714285714285714,3,21
CD008892,2,12,"In a hypothetical cohort of 1000 patients presenting with fever where 30% (300 patients) have enteric fever, on average Typhidot tests reporting indeterminate results or where tests do not produce indeterminate results will miss the diagnosis in 66 patients with enteric fever, TUBEX will miss 66, and Test-It Typhoid and prototype (KIT) tests will miss 93.",rephrase,"['Based on these results, in 1000 patients with fever where 30% (300 patients) have enteric fever, we would expect Typhidot tests reporting indeterminate results or where tests do not produce indeterminate results to, on average, miss the diagnosis (give a false negative result) in 66 patients with enteric fever, TUBEX to miss 66, and Test-It Typhoid and prototypes (KIT) to miss 93.']",7,0.6190476190476191,4,21
CD008892,2,13,"In the 700 people without enteric fever, the number of people incorrectly diagnosed with enteric fever would be 161 with Typhidot tests, 91 with TUBEX, and 70 with Test-It Typhoid and prototype (KIT) tests.",rephrase,"['In the 700 people without enteric fever, the number of people incorrectly given a diagnosis of enteric fever (a false positive result) would be on average 161 with these Typhidot tests, 91 with TUBEX, and 70 with the Test-It Typhoid and prototypes (KIT).']",8,0.6666666666666666,4,21
CD008892,2,14,"The CIs around these estimates were wide, with no difference in false positive results shown between tests.",delete,[],9,0.7142857142857143,4,21
CD008892,3,15,The quality of the data for each study was evaluated using a standardized checklist called QUADAS-2.,rephrase,['The Cochrane researchers evaluated the quality of the data for each study using a standardized checklist called QUADAS-2.'],9,0.7619047619047619,4,21
CD008892,3,16,"Overall, the certainty of the evidence in the studies that evaluated enteric fever RDTs was low.",ignore,"['Overall, the certainty of the evidence in the studies that evaluated enteric fever RDTs was low.']",10,0.8095238095238095,5,21
CD008892,4,17,"In 37 studies that evaluated the diagnostic accuracy of RDTs for enteric fever, few studies were at a low risk of bias.",delete,[],11,0.8571428571428571,5,21
CD008892,4,18,The three main RDT tests and variants had moderate diagnostic accuracy.,delete,[],11,0.9047619047619048,5,21
CD008892,4,19,There was no evidence of a difference between the average sensitivity and specificity of the three main RDT tests.,delete,[],11,0.9523809523809523,5,21
CD008892,4,20,More robust evaluations of alternative RDTs for enteric fever are needed.,rephrase,['The RDTs evaluated are not sufficiently accurate to replace blood culture as a diagnostic test for enteric fever.'],11,1.0,5,21
CD010891,0,0,"One study, which was a randomised, double-blind, controlled, multicentre trial, fulfilled our inclusion criteria.",delete,[],0,0.043478260869565216,1,23
CD010891,0,1,"The trial included 1956 adult participants (74% men, with a mean age of 42 years) across 265 centres (medical centres, hospitals, outpatient clinics) in 19 countries around the world who were infected with HIV-type 1 and who had not received abacavir previously.",split,"['It included 1956 adult participants, of whom 74% were men, who tested positive for HIV-type 1 and were eligible to start highly active antiretroviral therapy including a medication called abacavir.', 'The participants were from 19 countries around the world in 265 healthcare centres (e.g. hospitals, clinics).']",0,0.08695652173913043,1,23
CD010891,0,2,"The participants, who had a clinical need for treatment with an antiretroviral-drug regimen containing abacavir, were randomly assigned to undergo prospective human leukocyte antigen (HLA) Class I, locus B, allele 57:01 (HLA-B*57:01) screening (prospective-screening group) before this treatment, or to undergo a standard-care approach of abacavir use without prospective HLA-B*57:01 screening (control group).",delete,[],2,0.13043478260869565,1,23
CD010891,0,3,"Participants who tested positive for HLA-B*57:01 were not given abacavir; instead, they received antiretroviral therapy that did not include abacavir.",split,"['HLA-B*57:01 is known to be key in developing severe skin reactions to the HIV antiretroviral drug, abacavir.', 'Participants who tested positive for the genotype were not given abacavir; instead, they were given a different antiretroviral therapy.']",2,0.17391304347826086,1,23
CD010891,0,4,The control group did have retrospective HLA-B*57:01 pharmacogenetic testing.,rephrase,['Control participants had HLA-B*5701 pharmacogenetic testing after they had received abacavir as standard of care.'],4,0.21739130434782608,2,23
CD010891,0,5,The trial duration was six months.,merge,[],5,0.2608695652173913,2,23
CD010891,0,6,Each participant was observed for six weeks.,none,['The study lasted six months and each participant was observed for six weeks.'],5,0.30434782608695654,2,23
CD010891,0,7,"Assessments were performed at the time of study entry, at baseline (day one of abacavir treatment), and at weeks one, two and six.",rephrase,"['Our one included study did not report data for all participants, and clinical assessment of hypersensitivity (HSS) was done at the time of study entry, at baseline (day one) and at weeks one, two and six, without using predefined criteria.']",6,0.34782608695652173,2,23
CD010891,0,8,"This study was funded by the manufacturer of abacavir, GlaxoSmithKline.",rephrase,"['GlaxoSmithKline, the company that manufactures abacavir, funded the study.']",7,0.391304347826087,2,23
CD010891,1,9,"The study did not assess any of our primary outcomes, and it measured none of our secondary outcomes in isolation.",rephrase,['The study did not measure the other outcomes of this review.'],8,0.43478260869565216,3,23
CD010891,1,10,"However, it did assess an outcome of (characteristically severe) hypersensitivity reaction which included (but was not limited to) our secondary outcomes of HSS and SJS/TEN.",rephrase,"['Based on these results, we would expect that out of 1000 people who did not have prospective pharmacogenetic screening (i.e. screening to assess how someone might respond to a particular drug), 78 would experience a hypersensitivity reaction including SJS/TEN (clinical assessment), compared with between 22 and 52 people who did have prospective pharmacogenetic screening to test for HLA-B*57:01.']",9,0.4782608695652174,3,23
CD010891,2,11,The study demonstrated that prospective HLA-B*57:01 screening probably reduces the incidence of hypersensitivity reaction to abacavir.,rephrase,"['Available data showed that prospective HLA-B*57:01 screening probably reduces the incidence of hypersensitivity reaction to abacavir (including, but not limited to, our secondary outcomes of hypersensitivity (HSS) syndrome and Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) (i.e. severe and blistering skin reactions caused by medications)).']",10,0.5217391304347826,3,23
CD010891,2,12,"The incidence of clinically diagnosed HSS reaction to abacavir was lower in the screening arm (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.28 to 0.67; 1650 participants; moderate-quality evidence), as was immunologically confirmed HSS reaction (RR 0.02, 95% 0.00 to 0.37; 1644 participants; moderate-quality evidence).",delete,[],11,0.5652173913043478,3,23
CD010891,2,13,A positive result from an epicutaneous patch test performed six to ten weeks after clinical diagnosis provided immunological confirmation.,rephrase,['A patch test on the skin provided immunological confirmation 6 to 10 weeks after clinical diagnosis.'],11,0.6086956521739131,4,23
CD010891,3,14,"Overall, the study demonstrates a low risk of bias across five out of seven domains.",delete,[],12,0.6521739130434783,4,23
CD010891,3,15,There was a high risk of detection bias because hypersensitivity reactions were diagnosed by the principal investigator at the recruitment site without the use of predefined clinical criteria.,rephrase,"['Some patients were withdrawn from the study and not included in the analyses, and the investigator that diagnosed HSS reactions did not use a predefined clinical criteria of hypersensitivity.']",12,0.6956521739130435,4,23
CD010891,3,16,"Although there was also high risk of attrition bias due to excluding participants with incomplete follow-up from analyses, the authors did undertake a series of sensitivity analyses based on the intention-to-treat population, which demonstrated consistent results with the primary analysis.",delete,[],13,0.7391304347826086,4,23
CD010891,3,17,We rated the study quality as moderate-quality using GRADE criteria.,rephrase,['The included study was rated as being of moderate quality.'],13,0.782608695652174,4,23
CD010891,4,18,Prospective screening for HLA-B*57:01 probably reduces severe hypersensitivity skin reactions to abacavir in patients positive for HIV-type 1.,delete,[],14,0.8260869565217391,5,23
CD010891,4,19,"However, these results are only based on one study, which was at high risk of attrition and detection bias.",delete,[],14,0.8695652173913043,5,23
CD010891,5,20,"Our primary outcomes (incidence of severe skin rashes with systemic symptoms, and long-term effects) were not assessed by the trial, and only one of the review’s secondary outcomes was measured (hypersensitivity reaction); thus, we found no evidence relating to hospitalisation, death, or long-term conditions resulting from drug injury.",delete,[],14,0.9130434782608695,5,23
CD010891,6,21,We found no eligible evidence on genetic testing for severe drug-induced skin rash in relation to different drugs and classes of drugs.,delete,[],14,0.9565217391304348,5,23
CD010891,6,22,"Further clinical trials based on other drugs, and in different patient populations, would be useful for advising policy changes for improving the prevention of adverse skin reactions to drug treatments.",delete,[],14,1.0,5,23
CD011296,0,0,"Of 720 records screened, we included eight trials that randomised 1048 participants with type 2 diabetes (387 SSI participants and 615 participants in comparator groups were available for final analysis).",rephrase,['We found eight randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups in a random manner) where 387 people on sliding scale insulin therapy and 615 on mainly basal-bolus insulin treatment with type 2 diabetes could be analysed.'],0,0.041666666666666664,1,24
CD011296,0,1,We included non-critically ill medical and surgical adults with the diagnosis of diabetes mellitus.,delete,[],1,0.08333333333333333,1,24
CD011296,0,2,The mean follow-up time was measured by the mean length of hospital stay and ranged between five and 24 days.,rephrase,['The average length of hospital stay was between five and 24 days.'],1,0.125,1,24
CD011296,0,3,The mean age of participants was 44.5 years to 71 years.,ignore,['The average age of participants was 44.5 years to 71 years.'],2,0.16666666666666666,1,24
CD011296,1,4,"Overall, we judged the risk of bias on the trial level as unclear for selection bias, high for outcome-related performance and detection bias with regard to hypoglycaemic episodes, other adverse events, and mean glucose levels, and low for all-cause mortality and length of hospital stay.",delete,[],3,0.20833333333333334,2,24
CD011296,1,5,Attrition bias was low for all outcome measures.,delete,[],3,0.25,2,24
CD011296,2,6,"Six trials compared SSI with a basal-bolus insulin scheme, three of which investigating 64% of all participants in this category also applying an SSI approach in the bolus comparator part.",merge,['Six studies compared sliding scale insulin with basal-bolus insulin; one study compared sliding scale insulin with basal insulin only; and the remaining study used continuous insulin infusion as the control group.'],3,0.2916666666666667,2,24
CD011296,2,7,"One trial had a basal insulin-only comparator arm, and the remaining trial used continuous insulin infusion as the comparator.",none,[],3,0.3333333333333333,2,24
CD011296,2,8,"For our main comparison of SSI versus basal-bolus insulin, the results were as follows.",rephrase,['The main comparison was between sliding scale insulin and basal-bolus insulin therapy with the following results.'],4,0.375,2,24
CD011296,2,9,Four trials reported mortality data.,delete,[],5,0.4166666666666667,3,24
CD011296,2,10,One out of 268 participants in the SSI group (0.3%) compared with two out of 334 participants in the basal-bolus group (0.6%) died (low-certainty evidence).,rephrase,"['Of the four studies reporting deaths, one out of 268 participants in the SSI group compared with two out of 334 participants in the basal-bolus group died.']",5,0.4583333333333333,3,24
CD011296,2,11,"Severe hypoglycaemic episodes, defined as blood glucose levels below 40 mg/dL (2.2 mmol/L), showed a risk ratio (RR) of 0.22, 95% confidence interval (CI) 0.05 to 1.00; P = 0.05; 5 trials; 667 participants; very low-certainty evidence.",rephrase,"['Severe hypoglycaemic episodes, defined as blood glucose levels below 40 mg/dL, occurred in 5 per 1000 people in the sliding scale insulin groups compared with 24 per 1000 people in the basal-bolus insulin groups.']",6,0.5,3,24
CD011296,2,12,The 95% prediction interval ranged between 0.02 and 2.57.,delete,[],7,0.5416666666666666,3,24
CD011296,2,13,All nine severe hypoglycaemic episodes were observed among the 369 participants on basal-bolus insulin (2.4%).,delete,[],7,0.5833333333333334,3,24
CD011296,2,14,"The mean length of hospital stay was 0.5 days longer for the SSI group, 95% CI -0.5 to 1.4; P = 0.32; 6 trials; 717 participants; very low-certainty evidence.",rephrase,"['The length of hospital stay in the sliding scale insulin groups compared with the basal-bolus insulin groups was 0.5 days longer, again with further analyses indicating that this information is uncertain.']",7,0.625,4,24
CD011296,2,15,The 95% prediction interval ranged between -1.7 days and 2.7 days.,delete,[],8,0.6666666666666666,4,24
CD011296,2,16,"Adverse events other than hypoglycaemic episodes, such as postoperative infections, showed a RR of 1.16, 95% CI 0.25 to 5.37; P = 0.85; 3 trials; 481 participants; very low-certainty evidence.",rephrase,"['The results for adverse events other than hypoglycaemic episodes, such as postoperative infections, did not indicate an advantage or disadvantage of either strategy.']",8,0.7083333333333334,4,24
CD011296,2,17,The mean blood glucose levels ranged across basal-bolus groups from 156 mg/dL (8.7 mmol/L) to 221 mg/dL (12.3 mmol/L).,merge,['The average blood glucose level during hospital stay in the sliding scale groups was 14.8 mg/dL higher compared with the basal-bolus groups.'],9,0.75,4,24
CD011296,2,18,The mean blood glucose level in the SSI groups was 14.8 mg/dL (0.8 mmol/L) higher (95% CI 7.8 (0.4) to 21.8 (1.2); P < 0.001; 6 trials; 717 participants; low-certainty evidence).,none,[],9,0.7916666666666666,4,24
CD011296,2,19,The 95% prediction interval ranged between -3.6 mg/dL (-0.2 mmol/L) and 33.2 mg/dL (1.8 mmol/L).,delete,[],10,0.8333333333333334,5,24
CD011296,2,20,No trial reported on diabetes-related mortality or socioeconomic effects.,rephrase,['No trial reported on deaths caused by diabetes as such or socioeconomic effects like costs of the interventions or absence from work.'],10,0.875,5,24
CD011296,3,21,We are uncertain which insulin strategy (SSI or basal-bolus insulin) is best for non-critically hospitalised adults with diabetes mellitus.,rephrase,['We are uncertain about these data because analyses showed neither a positive nor a negative effect comparing both insulin strategies.'],11,0.9166666666666666,5,24
CD011296,3,22,A basal-bolus insulin strategy in these patients might result in better short-term glycaemic control but could increase the risk for severe hypoglycaemic episodes.,delete,[],12,0.9583333333333334,5,24
CD011296,3,23,"The certainty of the body of evidence comparing SSI with basal-bolus insulin was low to very low and needs to be improved by adequately performed, well-powered RCTs in different hospital environments with well-educated medical staff using identical short-acting insulins in both intervention and comparator arms to compare the rigid SSI approach with flexible insulin application strategies.",delete,[],12,1.0,5,24
CD004177,0,0,"We identified four trials, with 116 participants, investigating the effectiveness of compression therapy for treatment of PTS.",rephrase,"['The review authors identified four trials, with 116 participants, investigating the effectiveness of compressing therapies for PTS (most recent search 2 July 2018).']",0,0.05,1,20
CD004177,0,1,"The methodology used by each trial was too heterogeneous to perform a meta-analysis, so we reported our findings narratively.",delete,[],1,0.1,1,20
CD004177,1,2,Two trials studied the effect of graduated elastic compression stockings (GECS) on improvement of PTS symptoms.,rephrase,['Two trials studied the effect of GECS.'],1,0.15,1,20
CD004177,1,3,"One study reported beneficial haemodynamic effects, while the other found no benefits on PTS severity compared to placebo (very low-certainty evidence).",rephrase,['One study showed an improvement of PTS symptoms and one showed no benefit.'],2,0.2,1,20
CD004177,1,4,There was very limited evidence available for adverse effects and quality of life (QoL).,delete,[],3,0.25,2,20
CD004177,1,5,The two studies did not report on compliance rates during the study period.,delete,[],3,0.3,2,20
CD004177,2,6,Two trials studied the effects of intermittent mechanical compression devices.,rephrase,['Two other trials studied the effect of an intermittent pneumatic compression device.'],3,0.35,2,20
CD004177,2,7,Both reported improvement in PTS severity (low-certainty evidence).,merge,['Both reported an improvement in PTS severity.'],4,0.4,2,20
CD004177,2,8,Improvement of the severity of PTS was defined by treatment 'success' or 'failure'.,none,[],4,0.45,3,20
CD004177,2,9,Only one study comparing compression devices evaluated adverse effects and QoL.,rephrase,['One study evaluated side effects and quality of life.'],5,0.5,3,20
CD004177,2,10,"Although 9% of the participants experienced adverse effects such as leg swelling, irritation, superficial bleeding, and skin itching (moderate-certainty evidence), QoL was improved (moderate-certainty evidence).",rephrase,"['Although 9% of the participants experienced side effects such as leg swelling, irritation, superficial bleeding, and skin itching, quality of life had positive outcomes.']",6,0.55,3,20
CD004177,2,11,Studies did not assess compliance using intermittent mechanical compression devices.,delete,[],7,0.6,3,20
CD004177,3,12,None of the studies evaluated patient satisfaction.,rephrase,['None of the studies assessed or reported on patient satisfaction or compliance rates.'],7,0.65,4,20
CD004177,4,13,There is very low-certainty evidence regarding the use of GECS for treatment of PTS as assessed by two small studies of short duration.,rephrase,['The evidence for use of GECS or intermittent pneumatic compression device compared to control for the treatment of PTS severity is of very-low and low-certainty reliability.'],8,0.7,4,20
CD004177,4,14,"One study reported beneficial haemodynamic effects, while one found no benefits on PTS severity compared to control/placebo stockings.",delete,[],9,0.75,4,20
CD004177,4,15,"There is very limited evidence for adverse effects, patient satisfaction, QoL, and compliance rates.",rephrase,"['Limited evidence was available for side effects, patient satisfaction, quality of life, and compliance.']",9,0.8,4,20
CD004177,4,16,There is low-certainty evidence favouring use of intermittent pneumatic compression devices compared to a control device for the treatment of severity owing to different measurements used by the studies reporting on this outcome and small studies of short duration.,rephrase,"['This is due to conflicting results, small studies of short duration, and differences in how the studies measured outcomes.']",10,0.85,5,20
CD004177,4,17,There is moderate-certainty evidence of improved QoL but possible increased adverse effects related to compression device use owing to small studies of short duration.,delete,[],11,0.9,5,20
CD004177,4,18,High-certainty evidence to support the use of compression therapy in prevention of PTS is lacking and any conclusions drawn from current evidence should be interpreted with care.,delete,[],11,0.95,5,20
CD004177,4,19,"Further research is needed to assess whether compression can result in long-term reduction and relief of the symptoms caused by PTS, or prevent deterioration and leg ulceration.",delete,[],11,1.0,5,20
CD007202,0,0,"We found three trials (involving 1915 babies) for inclusion in the review, but have included only two trials (involving 1302 healthy full-term breastfeeding infants) in the analysis.",split,"['We identified three studies, with a total of 1915 babies.', 'One study could not be included in the analysis and so findings are based on two studies involving 1302 infants.']",0,0.16666666666666666,1,6
CD007202,0,1,"Meta-analysis of the two combined studies showed that pacifier use in healthy breastfeeding infants had no significant effect on the proportion of infants exclusively breastfed at three months (risk ratio (RR) 1.01; 95% confidence interval (CI) 0.96 to 1.07, two studies, 1228 infants), and at four months of age (RR 1.01; 95% CI 0.94 to 1.09, one study, 970 infants, moderate-quality evidence), and also had no effect on the proportion of infants partially breastfed at three months (RR 1.00; 95% CI 0.98 to 1.02, two studies, 1228 infants), and at four months of age (RR 0.99; 95% CI 0.97 to 1.02, one study, 970 infants).",delete,[],2,0.3333333333333333,2,6
CD007202,0,2,"None of the included trials reported data on the other primary outcomes, i.e. duration of partial or exclusive breastfeeding, or secondary outcomes: breastfeeding difficulties (mastitis, cracked nipples, breast engorgement); infant's health (dental malocclusion, otitis media, oral candidiasis; sudden infant death syndrome (SIDS)); maternal satisfaction and level of confidence in parenting.",delete,[],2,0.5,3,6
CD007202,0,3,"One study reported that avoidance of pacifiers had no effect on cry/fuss behavior at ages four, six, or nine weeks and also reported no effect on the risk of weaning before age three months, however the data were incomplete and so could not be included for analysis.",delete,[],2,0.6666666666666666,4,6
CD007202,1,4,"Pacifier use in healthy term breastfeeding infants, started from birth or after lactation is established, did not significantly affect the prevalence or duration of exclusive and partial breastfeeding up to four months of age.",rephrase,"['In motivated mothers, there is moderate-quality evidence that pacifier use in healthy term breastfeeding infants before and after lactation is established does not reduce the duration of breastfeeding up to four months of age.']",2,0.8333333333333334,5,6
CD007202,1,5,Evidence to assess the short-term breastfeeding difficulties faced by mothers and long-term effect of pacifiers on infants' health is lacking.,rephrase,"['There was no information on the effect of pacifier use on any breastfeeding difficulties experienced by the mothers, maternal satisfaction, infant crying and fussing and infant problems such as otitis media and dental malocclusion.']",3,1.0,5,6
CD012527,0,0,We included 44 RCTs (high-income countries: 36).,delete,[],0,0.05263157894736842,1,19
CD012527,0,1,"Thirty-nine studies solely focused on healthcare professionals (6892 participants), including both healthcare staff delivering direct medical care and allied healthcare staff.",rephrase,"['Healthcare professionals were the focus of 39 studies, with a total of 6892 participants.']",0,0.10526315789473684,1,19
CD012527,0,2,"Four studies investigated mixed samples (1000 participants) with healthcare professionals and participants working outside of the healthcare sector, and one study evaluated training for emergency personnel in general population volunteers (82 participants).",split,"['Four studies included mixed samples (1000 participants) of healthcare professionals and non-healthcare participants.', 'One study of resilience training for emergency workers examined 82 volunteers.']",1,0.15789473684210525,1,19
CD012527,0,3,"The included studies were mainly conducted in a hospital setting and included physicians, nurses and different hospital personnel (37/44 studies).",delete,[],3,0.21052631578947367,2,19
CD012527,1,4,Participants mainly included women (68%) from young to middle adulthood (mean age range: 27 to 52.4 years).,rephrase,['The studies tested a range of resilience interventions in participants aged on average between 27 and 52.4 years.'],3,0.2631578947368421,2,19
CD012527,1,5,"Most studies investigated group interventions (30 studies) of high training intensity (18 studies; > 12 hours/sessions), that were delivered face-to-face (29 studies).",rephrase,"['Most interventions (30/44) were performed in groups, with high training intensity of more than 12 hours or sessions (18/44), and were delivered face-to-face (i.e. with direct contact and face-to-face meetings between the intervention provider and the participants; 29/44).']",4,0.3157894736842105,2,19
CD012527,1,6,"Of the included studies, 19 compared a resilience training based on combined theoretical foundation (e.g. mindfulness and cognitive-behavioural therapy) versus unspecific comparators (e.g. wait-list).",rephrase,"['Of the included studies, 19 compared a combined resilience intervention (e.g. mindfulness and cognitive-behavioural therapy) versus unspecific comparators (e.g. a wait-list control receiving the training after a waiting period).']",5,0.3684210526315789,2,19
CD012527,1,7,"The studies were funded by different sources (e.g. hospitals, universities), or a combination of different sources.",ignore,"['The included studies were funded by different sources (e.g. hospitals, universities), or a combination of different sources.']",6,0.42105263157894735,3,19
CD012527,1,8,"Fifteen studies did not specify the source of their funding, and one study received no funding support.",ignore,"['Fifteen studies did not specify the source of their funding, and one study received no funding support.']",7,0.47368421052631576,3,19
CD012527,2,9,"Risk of bias was high or unclear for most studies in performance, detection, and attrition bias domains.",delete,[],8,0.5263157894736842,3,19
CD012527,3,10,"At post-intervention, very-low certainty evidence indicated that, compared to controls, healthcare professionals receiving resilience training may report higher levels of resilience (standardised mean difference (SMD) 0.45, 95% confidence interval (CI) 0.25 to 0.65; 12 studies, 690 participants), lower levels of depression (SMD −0.29, 95% CI −0.50 to −0.09; 14 studies, 788 participants), and lower levels of stress or stress perception (SMD −0.61, 95% CI −1.07 to −0.15; 17 studies, 997 participants).",delete,[],8,0.5789473684210527,3,19
CD012527,3,11,"There was little or no evidence of any effect of resilience training on anxiety (SMD −0.06, 95% CI −0.35 to 0.23; 5 studies, 231 participants; very-low certainty evidence) or well-being or quality of life (SMD 0.14, 95% CI −0.01 to 0.30; 13 studies, 1494 participants; very-low certainty evidence).",delete,[],8,0.631578947368421,4,19
CD012527,3,12,Effect sizes were small except for resilience and stress reduction (moderate).,delete,[],8,0.6842105263157895,4,19
CD012527,3,13,"Data on adverse effects were available for three studies, with none reporting any adverse effects occurring during the study (very-low certainty evidence).",rephrase,"['Potential adverse events were only examined in three studies, showing no undesired effects.']",8,0.7368421052631579,4,19
CD012527,4,14,"For healthcare professionals, there is very-low certainty evidence that, compared to control, resilience training may result in higher levels of resilience, lower levels of depression, stress or stress perception, and higher levels of certain resilience factors at post-intervention.",delete,[],9,0.7894736842105263,4,19
CD012527,5,15,"The paucity of medium- or long-term data, heterogeneous interventions and restricted geographical distribution limit the generalisability of our results.",delete,[],9,0.8421052631578947,5,19
CD012527,5,16,Conclusions should therefore be drawn cautiously.,delete,[],9,0.8947368421052632,5,19
CD012527,5,17,"The findings suggest positive effects of resilience training for healthcare professionals, but the evidence is very uncertain.",split,"['For healthcare professionals, resilience training may improve resilience, and may reduce symptoms of depression and stress immediately after the end of treatment.', 'However, the evidence found in this review is limited and very uncertain.']",9,0.9473684210526315,5,19
CD012527,5,18,There is a clear need for high-quality replications and improved study designs.,rephrase,['More research is needed of high methodological quality and with improved study designs.'],11,1.0,5,19
CD006578,0,0,We included six trials with 560 patients.,rephrase,['A detailed and systematic review of the literature revealed that there were six randomised clinical trials including 560 patients.'],0,0.05,1,20
CD006578,0,1,One trial involving 129 patients did not state the number of patients randomised to the two groups.,ignore,['One trial involving 129 patients did not state the number of patients randomised to the two groups.'],1,0.1,1,20
CD006578,0,2,"In the remaining five trials 431 patients were randomised, 212 to the robot assistant group and 219 to the human assistant group.",rephrase,"['Of the remaining 431 patients in the remaining five trials, 212 patients underwent laparoscopic cholecystectomy with the help of robot assistant and 219 patients underwent the same procedure with the help of a human assistant.']",2,0.15,1,20
CD006578,0,3,All the trials were at high risk of bias.,rephrase,"['All the trials were at high risk of bias (that is, they were prone to systematic underestimation of harms or overestimation of the benefits of the robotic assistant group or the human assistant group because of the beliefs of the people conducting the trial) and errors due to play of chance.']",3,0.2,1,20
CD006578,0,4,Mortality and morbidity were reported in only one trial with 40 patients.,rephrase,['Mortality and surgical complications were reported in only one trial with 40 patients.'],4,0.25,2,20
CD006578,0,5,There was no mortality or morbidity in either group.,rephrase,['There were no mortality or surgical complications in either group in this trial.'],5,0.3,2,20
CD006578,0,6,Mortality and morbidity were not reported in the remaining trials.,ignore,['Mortality and morbidity were not reported in the remaining trials.'],6,0.35,2,20
CD006578,0,7,Quality of life or the proportion of patients who were discharged as day-patient laparoscopic cholecystectomy patients were not reported in any trial.,ignore,['Quality of life or the proportion of patients who were discharged as day-patient laparoscopic cholecystectomy patients were not reported in any trial.'],7,0.4,2,20
CD006578,0,8,There was no significant difference in the proportion of patients who required conversion to open cholecystectomy (2 trials; 4/63 (weighted proportion 6.4%) in the robot assistant group versus 5/70 (7.1%) in the human assistant group; RR 0.90; 95% CI 0.25 to 3.20).,merge,['There was no significant difference in the proportion of patients who underwent conversion to open cholecystectomy or in the operating time between the two groups.'],8,0.45,3,20
CD006578,0,9,There was no significant difference in the operating time between the two groups (4 trials; 324 patients; MD 5.00 minutes; 95% CI -0.55 to 10.54).,none,[],8,0.5,3,20
CD006578,0,10,"In one trial, about one sixth of the laparoscopic cholecystectomies in which a robot assistant was used required temporary use of a human assistant.",ignore,"['In one trial, about one sixth of the laparoscopic cholecystectomies in which a robot assistant was used required temporary use of a human assistant.']",9,0.55,3,20
CD006578,0,11,"In another trial, there was no requirement for human assistants.",ignore,"['In another trial, there was no requirement for human assistants.']",10,0.6,3,20
CD006578,0,12,One trial did not report this information.,ignore,['One trial did not report this information.'],11,0.65,4,20
CD006578,0,13,It appears that there was little or no requirement for human assistants in the other three trials.,ignore,['It appears that there was little or no requirement for human assistants in the other three trials.'],12,0.7,4,20
CD006578,0,14,There were no randomised trials comparing one type of robot versus another type of robot.,delete,[],13,0.75,4,20
CD006578,1,15,Robot assisted laparoscopic cholecystectomy does not seem to offer any significant advantages over human assisted laparoscopic cholecystectomy.,ignore,['Robot-assisted laparoscopic cholecystectomy does not seem to offer any significant advantages over human-assisted laparoscopic cholecystectomy.'],13,0.8,4,20
CD006578,1,16,"However, all trials had a high risk of systematic errors or bias (that is, risk of overestimation of benefit and underestimation of harm).",rephrase,"['However, our present evidence base is limited by trials that all have high risk of systematic errors (potential to underestimate harms or overestimate benefits of the robot assistant group or the human assistant group) and random errors (that is, play of chance).']",14,0.85,5,20
CD006578,1,17,"All trials were small, with few or no outcomes.",delete,[],15,0.9,5,20
CD006578,1,18,"Hence, the risk of random errors (that is, play of chance) is high.",delete,[],15,0.95,5,20
CD006578,1,19,Further randomised trials with low risk of bias or random errors are needed.,rephrase,"['Therefore, further well-designed randomised trials with low risk of systematic errors and low risk of random errors are needed.']",15,1.0,5,20
CD001951,0,0,We included 19 trials with 19 different randomised dose comparisons.,rephrase,['Nineteen trials were included that compared varying doses of haloperidol.'],0,0.125,1,8
CD001951,0,1,No studies reported data on relapse rates or quality of life and only one compared low dose (> 1.5 to 3 mg/day) haloperidol to higher dose ranges.,rephrase,"['Despite over 30 years of trials, data on the effects of differing doses of haloperidol are sparse and poorly reported.']",1,0.25,2,8
CD001951,0,2,"Using standard lower dose (> 3 to 7.5 mg/day) did not result in loss of efficacy (no clinically important improvement in global state, versus standard higher dose (> 7.5 to 15 mg/day, n = 48, 1 RCT, RR 1.09, 95% CI 0.7 to 1.8, very-low-quality evidence); versus high dose (> 15 to 35 mg/day, n = 81, 2 RCTs, RR 0.95, 95% CI 0.8 to 1.2, very-low-quality evidence).",delete,[],2,0.375,2,8
CD001951,0,3,"Doses of haloperidol in the range of > 3 to 7.5 mg/day had a lower rate of development of clinically significant extrapyramidal adverse effects than higher doses (clinically significant extrapyramidal adverse effects, versus standard higher dose, n = 64, 2 RCTs, RR 0.12, 95% CI 0.01 to 2.1, very-low-quality evidence); versus high dose, n = 144, 3 RCTs, RR 0.59, 95% CI 0.5 to 0.8, very-low-quality evidence; versus very high dose (> 35 mg/day, n = 86, 2 RCTs, RR 0.70, 95% CI 0.5 to 1.1, very-low-quality evidence).",delete,[],2,0.5,3,8
CD001951,0,4,"None of the other comparisons between dose ranges yielded statistically significant differences, but several, particularly with lower dose ranges, were underpowered to detect clinically meaningful differences.",delete,[],2,0.625,4,8
CD001951,1,5,"Noresults were conclusive and all were based on small, short studies of limited quality.",rephrase,"['Results are not conclusive and are based on small, short studies of limited quality.']",2,0.75,4,8
CD001951,1,6,"However, it would be understandable if clinicians were cautious in prescribing doses in excess of 7.5 mg/day of haloperidol to a person with uncomplicated acute schizophrenia, and if people with schizophrenia were equally reticent to take greater doses.",rephrase,['The authors of the review note that it would be understandable if psychiatrists were cautious about prescribing doses above 7.5 mg a day and if people with schizophrenia did not want to take higher dosages.'],3,0.875,5,8
CD001951,1,7,"Further research is needed regarding the efficacy and tolerability of the lower dose ranges, especially > 1.5 to 3 mg/day.",rephrase,['Further research is needed to assess the tolerability and effectiveness of lower doses.'],4,1.0,5,8
CD009802,0,0,Four studies randomising 163 people could be included in the review.,rephrase,"['Four randomised studies, with a total of 163 participants were included.']",0,0.1111111111111111,1,9
CD009802,0,1,"It is not clear if brief family intervention reduces the utilisation of health services by patients, as most results are equivocal at long term and only one study reported data for the primary outcomes of interest of hospital admission (n = 30, 1 RCT, RR 0.50, 95% CI 0.22 to 1.11, very low quality evidence).",rephrase,"['Results were limited, so it is not clear if brief family intervention reduces admission to hospital, decreases people using health services and reduces relapse for people with schizophrenia.']",1,0.2222222222222222,2,9
CD009802,0,2,"Data for relapse are also equivocal by medium term (n = 40, 1 RCT, RR 0.50, 95% CI 0.10 to 2.43, low quality evidence).",delete,[],2,0.3333333333333333,2,9
CD009802,0,3,"However, data for the family outcome of understanding of family member significantly favoured brief family intervention (n = 70, 1 RCT, MD 14.90, 95% CI 7.20 to 22.60, very low quality evidence).",delete,[],2,0.4444444444444444,3,9
CD009802,0,4,No study reported data for other outcomes of interest including days in hospital; adverse events; medication compliance; quality of life or satisfaction with care; or any economic outcomes.,delete,[],2,0.5555555555555556,3,9
CD009802,1,5,"The findings of this review are not outstanding due to the size and quality of studies providing data; the analysed outcomes were also minimal, with no meta-analysis possible.",delete,[],2,0.6666666666666666,4,9
CD009802,1,6,All outcomes in the 'Summary of findings' table were rated low or very low quality evidence.,rephrase,"['However, all main findings are not strong and based on low or very low quality evidence.']",2,0.7777777777777778,4,9
CD009802,1,7,"However, the importance of brief family intervention should not be dismissed outright, with the present state of demand and resources available.",rephrase,"['Despite this, the authors of the review suggest that brief family intervention should not be completely dismissed, as it is in a current state of demand and there are usually resources or local services available for people with mental health problems and their families to participate in as a part of recovery.']",3,0.8888888888888888,5,9
CD009802,1,8,"The designs of such brief interventions could be modified to be more effective with larger studies, which may then have enough power to inform clinical practice.",rephrase,"['The authors also suggest that brief family intervention could be improved to be more effective but this would depend on larger and better studies of brief family intervention being carried out, which would help guide good practice and lead to better outcomes for people with schizophrenia.']",4,1.0,5,9
CD004707,0,0,Three trials were included.,delete,[],0,0.08333333333333333,1,12
CD004707,0,1,"One trial compared voriconazole to liposomal amphotericin B as empirical treatment of fever of unknown origin (suspected fungal infection) in neutropenic cancer patients (849 patients, 58 deaths).",rephrase,['One trial compared voriconazole to liposomal amphotericin B in 849 men and women (58 deaths) with cancer and a poor immune system.'],0,0.16666666666666666,1,12
CD004707,0,2,"The second trial compared voriconazole to amphotericin B deoxycholate in the treatment of confirmed and presumed invasive Aspergillus infections (391 patients, 98 deaths).",rephrase,['The second trial compared voriconazole to amphotericin B deoxycholate in 391 men and women (98 deaths) with cancer and a poor immune system.'],1,0.25,2,12
CD004707,0,3,"The third trial compared fluconazole to voriconazole for prophylaxis of fungal infections in patients receiving allogeneic stem cell transplantation (600 patients, number of deaths not stated).",rephrase,['The third trial compared voriconazole to fluconazole in 600 men and women (the number of deaths was not stated) with cancer who had undergone a transplantation of their bone marrow after high-dose chemotherapy that suppresses their immune system.'],2,0.3333333333333333,2,12
CD004707,0,4,"In the first trial, voriconazole was significantly inferior to liposomal amphotericin B according to the trial authors' prespecified criteria.",rephrase,['This review found that voriconazole was inferior to liposomal amphotericin B for treatment of suspected fungal infections.'],3,0.4166666666666667,3,12
CD004707,0,5,More patients died in the voriconazole group and a claimed significant reduction in the number of breakthrough fungal infections disappeared when patients arbitrarily excluded from the analysis by the trial authors were included.,rephrase,['More patients treated with voriconazole died and a claimed benefit in terms of fewer new fungal infections disappeared when we included patients that had been excluded without good reason from the analyses presented in the published article.'],4,0.5,3,12
CD004707,0,6,"In the second trial, the deoxycholate preparation of amphotericin B was used without any indication of the use of premedication to counter side effects and replacement of electrolytes or use of salt water.",delete,[],5,0.5833333333333334,3,12
CD004707,0,7,This choice of comparator resulted in a marked difference in the duration of treatment on the trial drugs (77 days with voriconazole versus 10 days with amphotericin B) and precluded meaningful comparisons of the benefits and harms of the two drugs.,rephrase,['Voriconazole was given for 77 days on average whereas liposomal amphotericin B deoxycholate was given for 10 days on average.'],5,0.6666666666666666,4,12
CD004707,0,8,The third trial failed to find a difference in fungal free survival or invasive fungal infections at 180 days when voriconazole was compared to fluconazole.,delete,[],6,0.75,4,12
CD004707,1,9,Liposomal amphotericin B is significantly more effective than voriconazole for empirical therapy of fungal infections in neutropenic cancer patients and should be preferred.,delete,[],6,0.8333333333333334,5,12
CD004707,1,10,"For treatment of aspergillosis, there are no trials that have compared voriconazole with amphotericin B given under optimal conditions.",rephrase,"['We also found that voriconazole has not been compared with amphotericin B when given under optimal conditions for the treatment of invasive aspergillosis, and that voriconazole was no better than fluconazole in patients undergoing a bone marrow transplantation for preventing invasive fungal infections or for extending the time patients survive without a fungal infection.']",6,0.9166666666666666,5,12
CD004707,1,11,"For prophylactic fungal treatment in patients receiving allogeneic stem cell transplantation, there was no difference between voriconazole and fluconazole regarding fungal free survival or invasive fungal infections.",delete,[],7,1.0,5,12
CD012357,0,0,We included eight RCTs (with a total of 559 participants) in this review.,rephrase,"['We included eight studies (specifically, randomised controlled trials (RCTs)) with a total of 559 people aged between 17 and 76 years old.']",0,0.08333333333333333,1,12
CD012357,0,1,The studies recruited outpatients aged between 17 and 76 years who were referred to endoscopy centres in several different countries.,rephrase,['All studies recruited outpatients from endoscopy centres (centres that specialise in an examination done with a flexible tube with a camera that is inserted into stomach) in several countries.'],1,0.16666666666666666,1,12
CD012357,0,2,"The certainty of evidence was reduced for most outcomes due to the poor methodological quality of included studies; issues mainly related to the generation of allocation sequence, allocation concealment, and blinding (this last domain related specifically to adverse outcomes).",delete,[],2,0.25,2,12
CD012357,1,3,"We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence).",delete,[],2,0.3333333333333333,2,12
CD012357,1,4,"A post-hoc sensitivity analysis, in which we removed studies that tested antibiotic regimens no longer recommended in clinical practice, showed that the addition of NAC may improve eradication rates compared to control (27.2% versus 37.6%, RR 0.71, 95% CI 0.53 to 0.94; participants = 397; published studies = five).",delete,[],2,0.4166666666666667,3,12
CD012357,2,5,"We are uncertain whether NAC is associated with a higher risk of gastrointestinal adverse events compared to control (23.9% versus 18.9%, RR 1.25, 95% CI 0.85 to 1.85; participants = 336; studies = five; very low-certaintyevidence), or allergic adverse events (2% versus 0%, RR 2.98, 95% CI 0.32 to 27.74; participants = 336; studies = five; very low-certainty evidence).",delete,[],2,0.5,3,12
CD012357,2,6,There were no reports of toxic adverse events amongst included studies.,delete,[],2,0.5833333333333334,3,12
CD012357,3,7,We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates compared with the addition of placebo or no NAC.,ignore,['We are uncertain whether the addition of NAC to antibiotics improves H pylori cure rates compared with the addition of placebo or no NAC.'],2,0.6666666666666666,4,12
CD012357,3,8,"Due to the clinical, statistical and methodological heterogeneity found in included studies, and the uncertainty observed when analysing therapy subgroups, any possible beneficial effect of NAC should be regarded cautiously.",rephrase,"['Any possible beneficial effect of NAC should be regarded cautiously because the included studies were very different and of low certainty, with some flaws that could have compromised their results and consequently, the results of this review.']",3,0.75,4,12
CD012357,4,9,We are uncertain whether NAC is associated with a higher risk of gastrointestinal or allergic adverse events compared with placebo or no NAC.,ignore,['We are uncertain whether NAC is associated with a higher risk of gastrointestinal or allergic adverse events compared with placebo or no NAC.'],4,0.8333333333333334,5,12
CD012357,4,10,There were no reports of toxic adverse events amongst the included studies.,ignore,['There were no reports of toxic adverse events amongst the included studies.'],5,0.9166666666666666,5,12
CD012357,5,11,"Further large, well-designed, randomised clinical studies should be conducted, with good reporting standards and appropriate collection of efficacy and safety outcomes, especially for current recommended antibiotic regimens.",rephrase,"['Further large, well-designed randomised clinical studies, with good reporting standards and appropriate collection of effectiveness and safety outcomes should be done, especially for current recommended antibiotic combinations.']",6,1.0,5,12
CD004316,0,0,We found 33 trials that met our inclusion criteria.,rephrase,['We found 33 studies.'],0,0.05263157894736842,1,19
CD004316,0,1,The proportion of men who reportedly achieved azoospermia or had no detectable sperm varied widely.,rephrase,['The percent of men who achieved no sperm varied widely.'],1,0.10526315789473684,1,19
CD004316,0,2,A few important differences emerged.,rephrase,['We found a few major differences and list them here.'],2,0.15789473684210525,1,19
CD004316,0,3,1) Levonorgestrel implants (160 μg daily) combined with injectable testosterone enanthate (TE) were more effective than levonorgestrel 125 µg daily combined with testosterone patches.,rephrase,['1) Implants plus injected testosterone worked better than a pill plus testosterone patch.'],3,0.21052631578947367,2,19
CD004316,0,4,2) Levonorgestrel 500 μg daily improved the effectiveness of TE 100 mg injected weekly.,rephrase,['2) Adding a hormone pill improved the effect of testosterone injected weekly.'],4,0.2631578947368421,2,19
CD004316,0,5,3) Levonorgestrel 250 μg daily improved the effectiveness of testosterone undecanoate (TU) 1000 mg injection plus TU 500 mg injected at 6 and 12 weeks.,rephrase,['3) A hormone pill also improved the effect of a testosterone injection with more injections at 6 and 12 weeks.'],5,0.3157894736842105,2,19
CD004316,0,6,4) Desogestrel 150 μg was less effective than desogestrel 300 μg (with testosterone pellets).,rephrase,['4) A lower dose pill did not work as well as a higher dose when testosterone was put under the skin (implant).'],6,0.3684210526315789,2,19
CD004316,0,7,5) TU 500 mg was less likely to produce azoospermia than TU 1000 mg (with levonorgestrel implants).,rephrase,"['5) When used with implants, a lower dose of injected testosterone led to no sperm more often than a higher dose.']",7,0.42105263157894735,3,19
CD004316,0,8,6) Norethisterone enanthate 200 mg with TU 1000 mg led to more azoospermia when given every 8 weeks versus 12 weeks.,rephrase,['6) An injected hormone plus injected testosterone led to no sperm more often when given every 8 weeks versus 12 weeks.'],8,0.47368421052631576,3,19
CD004316,0,9,7) Four implants of 7-alpha-methyl-19-nortestosterone (MENT) were more effective than two MENT implants.,rephrase,['7) Four implants of a male hormone worked better than two implants.'],9,0.5263157894736842,3,19
CD004316,0,10,We did not conduct any meta-analysis due to intervention differences.,delete,[],10,0.5789473684210527,3,19
CD004316,1,11,Several trials showed promising efficacy in percentages with azoospermia.,rephrase,['Several trials showed good results for the percent with no sperm.'],10,0.631578947368421,4,19
CD004316,1,12,"Three examined desogestrel and testosterone preparations or etonogestrel and testosterone, and two examined levonorgestrel and testosterone.",rephrase,"['The other hormones were desogestrel, etonogestrel, and levonorgestrel.']",11,0.6842105263157895,4,19
CD004316,2,13,No male hormonal contraceptive is ready for clinical use.,rephrase,['No hormonal birth control for men is ready for general use.'],12,0.7368421052631579,4,19
CD004316,2,14,Most trials were small exploratory studies.,rephrase,['Most trials were small pilot studies trying out different hormone treatments.'],13,0.7894736842105263,4,19
CD004316,2,15,Their power to detect important differences was limited and their results imprecise.,delete,[],14,0.8421052631578947,5,19
CD004316,2,16,"In addition, assessment of azoospermia can vary by sensitivity of the method used.",delete,[],14,0.8947368421052632,5,19
CD004316,2,17,Future trials need more attention to the methodological requirements for RCTs.,delete,[],14,0.9473684210526315,5,19
CD004316,2,18,More trials with adequate power would also be helpful.,delete,[],14,1.0,5,19
CD013496,0,0,"Our search yielded 39,165 records after the removal of duplicates.",delete,[],0,0.05555555555555555,1,18
CD013496,0,1,"From this, 26 studies met our criteria, and 18 were included in the pooled analysis.",rephrase,['We found 26 relevant studies; we then used the results from 18 of the studies to compare the different diets.'],0,0.1111111111111111,1,18
CD013496,0,2,The 18 studies included 1125 participants and observed outcomes ranging from four weeks to six months.,rephrase,['The 18 studies included 1125 adults (aged over 18 years).'],1,0.16666666666666666,1,18
CD013496,0,3,"Of quantitatively analysed data, seven studies compared IF with ab libitum feeding, eight studies compared IF with CER, and three studies compared IF with both ad libitum feeding and CER.",delete,[],2,0.2222222222222222,2,18
CD013496,0,4,Outcomes were reported at short term (≤ 3 months) and medium term (> 3 months to 12 months) follow-up.,rephrase,"['Results were reported after three months (short-term), and between three and 12 months (medium-term).']",2,0.2777777777777778,2,18
CD013496,1,5,"None of the included studies reported on all-cause mortality, cardiovascular mortality, stroke, myocardial infarction or heart failure.",rephrase,"[""We didn't find any data on mortality, cardiovascular mortality or risk of stroke, heart attack or heart failure.""]",3,0.3333333333333333,2,18
CD013496,2,6,"Body weight was reduced with IF compared to ad libitum feeding in the short term (MD -2.88 kg, 95% CI -3.96 to -1.80; 224 participants; 7 studies; low-certainty evidence).",rephrase,['We found that people may lose more weight by intermittent fasting than by usual eating over three months (evidence from 7 studies in 224 people); but not when compared against energy restriction diets for three months (10 studies; 719 people) or longer (3 to 12 months; 4 studies; 279 people).'],4,0.3888888888888889,2,18
CD013496,2,7,"We are uncertain of the effect of IF when compared to CER in the short term (MD -0.88 kg, 95% CI -1.76 to 0.00; 719 participants; 10 studies; very low-certainty evidence) and there may be no effect in the medium term (MD -0.56 kg, 95% CI -1.68 to 0.56; 279 participants; 4 studies; low-certainty evidence).",delete,[],5,0.4444444444444444,3,18
CD013496,3,8,"We are uncertain about the effect of IF on glucose when compared to ad libitum feeding in the short term (MD -0.03 mmol/L, 95% CI -0.26 to 0.19; 95 participants; 3 studies; very-low-certainty of evidence) and when compared to CER  in the short term: MD -0.02 mmol/L, 95% CI -0.16 to 0.12; 582 participants; 9 studies; very low-certainty; medium term: MD 0.01, 95% CI -0.10 to 0.11; 279 participants; 4 studies; low-certainty evidence).",delete,[],5,0.5,3,18
CD013496,4,9,The changes in body weight and glucose were not deemed to be clinically significant.,split,"['The weight losses and changes in blood sugars reported in the studies were small.', 'These changes were not deemed to be clinically significant.']",5,0.5555555555555556,3,18
CD013496,5,10,"Four studies reported data on side effects, with some participants complaining of mild headaches.",rephrase,['Only four studies reported unwanted effects of intermittent fasting: some people taking part reported mild headaches.'],7,0.6111111111111112,4,18
CD013496,5,11,One study reported on the quality of life using the RAND SF-36 score.,rephrase,"[""Only one study reported on people's well-being, showing a small increase in scores for physical well-being.""]",8,0.6666666666666666,4,18
CD013496,5,12,There was a modest increase in the physical component summary score.,delete,[],9,0.7222222222222222,4,18
CD013496,6,13,"We are uncertain about the effects of intermittent fasting on clinical events such as mortality, myocardial infarction and heart failure due to lack of data for these outcomes.",rephrase,['We did not find enough good certainty evidence to know whether intermittent fasting could prevent CVD.'],9,0.7777777777777778,4,18
CD013496,6,14,The individual meta-analyses show that intermittent fasting may be effective in reducing weight when compared to ad libitum feeding and may be as effective as continuous energy restriction.,rephrase,"[""We found that intermittent fasting may help people to lose more weight than 'eating as usual' (not dieting) but was similar to energy restriction diets.""]",10,0.8333333333333334,5,18
CD013496,6,15,"Despite this, these changes appear to be clinically insignificant at short-term follow-up.",delete,[],11,0.8888888888888888,5,18
CD013496,6,16,The quality of the available evidence is low to very low which means that many areas of uncertainty remain.,delete,[],11,0.9444444444444444,5,18
CD013496,6,17,Further research is needed to understand which patient groups would and would not benefit from intermittent fasting (e.g. patients with diabetes or eating disorders) as well as the effect on longer-term outcomes such as all-cause mortality and myocardial infarction.,rephrase,"['We need further research to test the benefits and potential harms of intermittent fasting, and to test if it might affect how many people die or develop CVD.']",11,1.0,5,18
CD006659,0,0,No trials were included in the review.,rephrase,"['Unfortunately, we did not find any good quality trials to include in the review.']",0,0.14285714285714285,1,7
CD006659,1,1,There are no published or ongoing randomised controlled clinical trials relevant to this review question.,delete,[],1,0.2857142857142857,2,7
CD006659,1,2,"Therefore, in the absence of any high level evidence, clinicians should base their decisions on clinical experience and in conjunction with preferences of the individual where appropriate.",rephrase,"['Therefore, we recommend that clinicians base their decision to prescribe carnitine on clinical experience together with individual preferences.']",1,0.42857142857142855,3,7
CD006659,1,3,This does not mean that carnitine is ineffective or should not be used in any inborn error of metabolism.,merge,"['This does not mean that carnitine is ineffective or should not be used in treating inborn errors of metabolism; however, individuals receiving carnitine should be carefully observed and monitored.']",2,0.5714285714285714,3,7
CD006659,1,4,"However, given the lack of evidence both on the effectiveness and safety of carnitine and on the necessary dose and frequency to be prescribed, the current prescribing practice should continue to be observed and monitored with care until further evidence is available.",none,[],2,0.7142857142857143,4,7
CD006659,1,5,"Methodologically sound trials, reported according to the Consolidated Standards of Reporting Trials (CONSORT) statement, are required.",delete,[],3,0.8571428571428571,5,7
CD006659,1,6,"It should be considered whether placebo-controlled trials in potentially lethal diseases, e.g. carnitine transporter disorder or glutaric aciduria type I, are ethical.",ignore,"['It should be carefully considered whether placebo-controlled trials in potentially lethal diseases, e.g. carnitine transporter disorder or glutaric aciduria type I, are ethical.']",3,1.0,5,7
CD006556,0,0,All four included studies were in Chinese; two of which were unpublished.,rephrase,['All four included studies were in Chinese and two of these studies were unpublished.'],0,0.2,1,5
CD006556,0,1,Effect sizes were not clinically relevant and there was low quality evidence for all outcomes due to study limitations and sparse data (single studies).,delete,[],1,0.4,2,5
CD006556,0,2,"Two trials (680 participants) found that Compound Qishe Tablets relieved pain better in the short-term than either placebo or Jingfukang; one trial (60 participants) found than an oral herbal formula of Huangqi ((Radix Astragali)18 g, Dangshen (Radix Codonopsis) 9 g, Sanqi (Radix Notoginseng) 9 g, Chuanxiong (Rhizoma Chuanxiong)12 g, Lujiao (Cornu Cervi Pantotrichum) 12 g, and Zhimu (Rhizoma Anemarrhenae)12 g) relieved pain better than Mobicox or Methycobal and one trial (360 participants) showed that a topical herbal medicine, Compound Extractum Nucis Vomicae, relieved pain better than Diclofenac Diethylamine Emulgel.",delete,[],1,0.6,3,5
CD006556,1,3,"There is low quality evidence that an oral herbal medication, Compound Qishe Tablet, reduced pain more than placebo or Jingfukang and a topical herbal medicine, Compound Extractum Nucis Vomicae, reduced pain more than Diclofenac Diethylamine Emulgel.",rephrase,['Oral herbal medications may reduce neck pain more than placebo and Jingfukang.'],1,0.8,4,5
CD006556,1,4,Further research is very likely to change both the effect size and our confidence in the results.,ignore,['Further research is very likely to change both the effect size and our confidence in the results.'],2,1.0,5,5
CD006832,0,0,We identified five trials that met our inclusion criteria.,rephrase,['We identified and analysed five trials that were suitable for inclusion in our review.'],0,0.04,1,25
CD006832,0,1,Two trials compared intensive insulin therapy (IIT) to conventional insulin therapy (CIT).,rephrase,"['Two trials, with a total of 825 adults staying in ICU for one week or more, studied the effect of IIT\xa0versus conventional insulin therapy (CIT) on the incidence of CIP/CIM.']",1,0.08,1,25
CD006832,0,2,"IIT significantly reduced CIP/CIM in the screened (n = 825; risk ratio (RR) 0.65, 95% confidence interval (CI) 0.55 to 0.77) and total (n = 2748; RR 0.70, 95% CI 0.60 to 0.82) population randomised.",delete,[],2,0.12,1,25
CD006832,0,3,"IIT reduced duration of mechanical ventilation, ICU stay and 180-day mortality, but not 30-day mortality compared with CIT.",delete,[],2,0.16,1,25
CD006832,0,4,Hypoglycaemia increased with IIT but did not cause early deaths.,delete,[],2,0.2,1,25
CD006832,1,5,One trial compared corticosteroids with placebo (n = 180).,rephrase,['The third trial compared corticosteroid therapy with a placebo in 180 people with acute respiratory distress syndrome (ARDS).'],2,0.24,2,25
CD006832,1,6,"The trial found no effect of treatment on CIP/CIM (RR 1.27, 95% CI 0.77 to 2.08), 180-day mortality, new infections, glycaemia at day seven, or episodes of pneumonia, but did show a reduction of new shock events.",rephrase,"['High quality evidence showed no effect on 180-day mortality, new serious infections, blood glucose levels on day seven or episodes of suspected or probable pneumonia.']",3,0.28,2,25
CD006832,2,7,"In the fourth trial, early physical therapy reduced CIP/CIM in 82/104 evaluable participants in ICU (RR 0.62.",split,"['The fourth trial was of on early rehabilitation in 104 participants in a medical ICU.', 'There was moderate quality evidence of a reduction in CIP/CIM in the 82 participants who could be evaluated in the ICU.']",4,0.32,2,25
CD006832,2,8,95% CI 0.39 to 0.96).,delete,[],6,0.36,2,25
CD006832,2,9,"Statistical significance was lost when we performed a full intention-to-treat analysis (RR 0.81, 95% CI 0.60 to 1.08).",rephrase,['This effect was not significant when imputation to intention-to-treat analysis was performed.'],6,0.4,2,25
CD006832,2,10,Duration of mechanical ventilation but not ICU stay was significantly shorter in the intervention group.,rephrase,['Early rehabilitation reduced the duration of mechanical ventilation but did not affect ICU stay or deaths.'],7,0.44,3,25
CD006832,2,11,Hospital mortality was not affected but 30- and 180-day mortality results were not available.,delete,[],8,0.48,3,25
CD006832,2,12,No adverse effects were noticed.,rephrase,['The trial reported no serious adverse events.'],8,0.52,3,25
CD006832,3,13,"The last trial found a reduced incidence of CIP/CIM in 52 evaluable participants out of a total of 140 who were randomised to electrical muscle stimulation (EMS) versus no stimulation (RR 0.32, 95% CI 0.10 to 1.01).",delete,[],9,0.56,3,25
CD006832,3,14,These data were prone to bias due to imbalances between treatment groups in this subgroup of participants.,delete,[],9,0.6,3,25
CD006832,3,15,"After we imputed missing data and performed an intention-to-treat analysis, there was still no significant effect (RR 0.94, 95% CI 0.78 to 1.15).",rephrase,['Results were even less significant when imputation to intention-to-treat analysis was performed.'],9,0.64,4,25
CD006832,3,16,"The investigators found no effect on duration of mechanical ventilation and noted no difference in ICU mortality, but did not report 30- and 180-day mortality.",split,"['There was no effect on duration of mechanical ventilation or deaths.', 'The study found no effect of EMS on duration of mechanical ventilation or deaths.']",10,0.68,4,25
CD006832,4,17,We updated the searches in December 2013 and identified nine potentially eligible studies that will be assessed for inclusion in the next update of the review.,rephrase,['We re-ran the search for studies in December 2013 and identified nine additional potentially eligible studies that we will assess in the next update of the review.'],12,0.72,4,25
CD006832,5,18,"There is moderate quality evidence from two large trials that intensive insulin therapy reduces CIP/CIM, and high quality evidence that it reduces duration of mechanical ventilation, ICU stay and 180-day mortality, at the expense of hypoglycaemia.",split,"['Combining the results of both trials showed moderate quality evidence that IIT reduces CIP/CIM.', 'There was high quality evidence that it reduced time spent on a ventilator, ICU stay and 180-day mortality but not 30-day mortality.']",13,0.76,4,25
CD006832,5,19,Consequences and prevention of hypoglycaemia need further study.,delete,[],15,0.8,4,25
CD006832,5,20,"There is moderate quality evidence which suggests no effect of corticosteroids on CIP/CIM and high quality evidence that steroids do not affect secondary outcomes, except for fewer new shock episodes.",delete,[],15,0.84,5,25
CD006832,5,21,Moderate quality evidence suggests a potential benefit of early rehabilitation on CIP/CIM which is accompanied by a shorter duration of mechanical ventilation but without an effect on ICU stay.,delete,[],15,0.88,5,25
CD006832,5,22,"Very low quality evidence suggests no effect of EMS, although data are prone to bias.",rephrase,['It supplied very low quality evidence that EMS was without effect in preventing CIP/CIM.'],15,0.92,5,25
CD006832,5,23,Strict diagnostic criteria for CIP/CIM are urgently needed for research purposes.,delete,[],16,0.96,5,25
CD006832,5,24,Large RCTs need to be conducted to further explore the role of early rehabilitation and EMS and to develop new preventive strategies.,delete,[],16,1.0,5,25
CD009059,0,0,"We included 77 randomised clinical trials, which included 6753 participants with fatty liver disease.",rephrase,"['We included 77 randomised clinical trials in this review, which tested 75 herbal medicines.']",0,0.0625,1,16
CD009059,0,1,The risks of bias (overestimation of benefits and underestimation of harms) was high in all trials.,rephrase,"['All trials had high risk of systematic errors (ie, bias or risk of overestimation of benefits and overestimation of harms) as well as high risks of random errors (ie, play of chance) due to the small number of people in the trials.']",1,0.125,1,16
CD009059,0,2,The mean sample size was 88 participants (ranging from 40 to 200 participants) per trial.,delete,[],2,0.1875,1,16
CD009059,0,3,Seventy-five different herbal medicine products were tested.,delete,[],2,0.25,2,16
CD009059,0,4,"Herbal medicines tested in the randomised trials included single-herb products (Gynostemma pentaphyllum, Panax notoginseng, andPrunus armeniaca), proprietary herbal medicines commercially available, and combination formulas prescribed by practitioners.",rephrase,"['Herbal medicines tested in the randomised clinical trials included single-herb products (Gynostemma pentaphyllum,Panax notoginseng, andPrunus armeniaca), commercially available branded herbal medicines, and combination formulas prescribed by practitioners.']",2,0.3125,2,16
CD009059,0,5,"The most commonly used herbs wereCrataegus pinnatifida,Salvia miltiorrhiza,Alisma orientalis,Bupleurum chinense,Cassia obtusifolia, Astragalus membranaceous, and Rheum palmatum.",rephrase,"['Herbs most commonly included as an ingredient in different products wereCrataegus pinnatifida,Salvia miltiorrhiza,Alisma orientalis,Bupleurum chinense,Cassia obtusifolia,Astragalus membranaceous, andRheum palmatum.']",3,0.375,2,16
CD009059,0,6,"None of the trials reported death, hepatic-related morbidity, quality of life, or costs.",rephrase,"['We could not reach any conclusions about the use of herbal medicines for people with fatty liver disease as none of the trials reported results on death, liver-related illnesses, quality of life, or costs.']",4,0.4375,3,16
CD009059,0,7,"A large number of trials reported positive effects on putative surrogate outcomes such as serum aspartate aminotransferase, alanine aminotransferase, glutamyltransferase, alkaline phosphatases, ultrasound, and computed tomography scan.",rephrase,"['A number of trials showed positive effects of herbal medicines compared with control interventions on enzyme activity (enzymes are proteins that cause chemical reactions in the body; eg, serum aspartate aminotransferase, alanine aminotransferase, glutamyltransferase, alkaline phosphatases), ultrasound scan findings, and computed tomography scan findings.']",5,0.5,3,16
CD009059,0,8,Twenty-seven trials reported adverse effects and found no significant difference between herbal medicines versus control.,rephrase,['No serious adverse effects were reported for herbal medicines.'],6,0.5625,3,16
CD009059,0,9,"However, the risk of bias of the included trials was high.",rephrase,"['However, the methodology of the trials had high risk of systematic errors (bias).']",7,0.625,4,16
CD009059,1,10,"The outcomes were ultrasound findings in 22 trials, liver computed tomography findings in eight trials, aspartate aminotransferase levels in 64 trials, alanine aminotransferase activity in 77 trials, and glutamyltransferase activities in 44 trials.",delete,[],8,0.6875,4,16
CD009059,1,11,"Six herbal medicines showed statistically significant beneficial effects on ultrasound, four on liver computed tomography, 42 on aspartate aminotransferase activity, 49 on alanine aminotransferase activity, three on alkaline phosphatases activity, and 32 on glutamyltransferase activity compared with control interventions.",delete,[],8,0.75,4,16
CD009059,2,12,"Some herbal medicines seemed to have positive effects on aspartate aminotransferase, alanine aminotransferase, ultrasound, and computed tomography.",delete,[],8,0.8125,5,16
CD009059,2,13,We found no significant difference on adverse effects between herbal medicine and control groups.,delete,[],8,0.875,5,16
CD009059,2,14,The findings are not conclusive due to the high risk of bias of the included trials and the limited number of trials testing individual herbal medicines.,rephrase,"['Therefore, the findings are inconclusive, and rigorously conducted randomised clinical trials are required to establish the benefits and harms of herbal medicines for fatty liver disease.']",8,0.9375,5,16
CD009059,2,15,"Accordingly, there is also high risk of random errors.",delete,[],9,1.0,5,16
CD003142,0,0,In total 437 eligible women were randomised to receive high dose chemotherapy with autograft and 413 were randomised to receive conventional treatment.,rephrase,['This review identified six randomised trials including 437 women receiving high dose chemotherapy with autograft and 413 women receiving conventional chemotherapy treatment.'],0,0.125,1,8
CD003142,0,1,"There were fifteen treatment-related deaths among the high dose group and two in the control (conventional dose) group (RR 4.08, 95% CI 1.40 to 11.93).",rephrase,"['In the group receiving the high dose chemotherapy, there were 15 treatment-related deaths as opposed to two in the conventional chemotherapy arm.']",1,0.25,2,8
CD003142,0,2,There was no statistically significant difference in overall survival between the high dose and control groups at three years or five years.,rephrase,"['Although the high-dose treatment did not increase overall survival at 5 years compared with conventional treatment, women on the high-dose treatment survived significantly longer before experiencing recurrence of cancer.']",2,0.375,2,8
CD003142,0,3,"At five years of follow up, there was a statistically significant difference in event-free survival, favouring the high dose group (RR 2.84, 95% CI 1.07 to 7.50).",merge,[],3,0.5,3,8
CD003142,0,4,Toxicity was more severe in the high dose group.,none,['Treatment side-effects were worse in the high-dose group.'],3,0.625,4,8
CD003142,0,5,Only one of the trials has followed up all women for five years.,delete,[],4,0.75,4,8
CD003142,1,6,Although there is evidence that high dose chemotherapy and autograft significantly improves event-free survival compared to conventional chemotherapy in women with metastatic breast cancer there is no significant evidence of benefit in overall survival.,delete,[],4,0.875,5,8
CD003142,1,7,High dose chemotherapy with bone marrow or stem cell transplantation should not be given to women with metastatic breast cancer outside of clinical trials.,rephrase,"['On the basis of this review, the authors conclude that high dose chemotherapy with bone marrow or stem cell transplantation should not be given to women with metastatic breast cancer outside of clinical trials.']",4,1.0,5,8
CD001970,0,0,We included 14 trials in which a total of 1551 infants participated.,rephrase,['We found 14 trials with 1551 infants participating.'],0,0.125,1,8
CD001970,0,1,"Potential sources of bias were lack of clarity on methods to generate random sequences and conceal allocation in half of the trials, and lack of masking of caregivers or investigators in all of the trials.",delete,[],1,0.25,2,8
CD001970,0,2,Trials typically defined delayed introduction of progressive enteral feeds as later than four to seven days after birth and early introduction as four days or fewer after birth.,delete,[],1,0.375,2,8
CD001970,0,3,Infants in six trials (accounting for about half of all of the participants) had intrauterine growth restriction or circulatory redistribution demonstrated by absent or reversed end-diastolic flow velocities in the fetal aorta or umbilical artery.,delete,[],1,0.5,3,8
CD001970,1,4,"Meta-analyses showed that delayed introduction of progressive enteral feeds may not reduce the risk of necrotising enterocolitis (RR 0.81, 95% confidence interval (CI) 0.58 to 1.14; RD -0.02, 95% CI -0.04 to 0.01; 13 trials, 1507 infants; low-certainty evidence due risk of bias and imprecision) nor all-cause mortality before hospital discharge (RR 0.97, 95% CI 0.70 to 1.36; RD -0.00, 95% CI -0.03 to 0.03; 12 trials, 1399 infants; low-certainty evidence due risk of bias and imprecision).",rephrase,['Combined analysis of these trials showed that delayed introduction of progressive enteral feeds may not reduce the risk of necrotising enterocolitis or death.'],1,0.625,4,8
CD001970,1,5,"Delayed introduction of progressive enteral feeds may slightly reduce the risk of feed intolerance (RR 0.81, 95% CI 0.68 to 0.97; RD -0.09, 95% CI -0.17 to -0.02; number needed to treat for an additional beneficial outcome = 11, 95% CI 6 to 50; 6 trials, 581 infants; low-certainty evidence due to risk of bias and imprecision) and probably increases the risk of invasive infection (RR 1.44, 95% CI 1.15 to 1.80; RD 0.10, 95% CI 0.04 to 0.15; number needed to treat for a harmful outcome = 10, 95% CI 7 to 25; 7 trials, 872 infants; moderate-certainty evidence due to risk of bias).",rephrase,"['Delayed feeding may slightly reduce the risk of feed intolerance, but probably increases the risk of serious infection occurring.']",2,0.75,4,8
CD001970,2,6,Delaying the introduction of progressive enteral feeds beyond four days after birth (compared with earlier introduction) may not reduce the risk of necrotising enterocolitis or death in very preterm or VLBW infants.,rephrase,"['This review provides low-certainty evidence that delaying the introduction of enteral feeds may not reduce the risk of necrotising enterocolitis or death for very preterm or VLBW infants, including infants whose growth in the womb was compromised.']",3,0.875,5,8
CD001970,2,7,"Delayed introduction may slightly reduce feed intolerance, and probably increases the risk of invasive infection.",delete,[],4,1.0,5,8
CD008099,0,0,"Thirty-five studies were included (1223 participants received codeine 60 mg, 27 codeine 90 mg, and 1252 placebo).",delete,[],0,0.1111111111111111,1,9
CD008099,0,1,"Combining all types of surgery (33 studies, 2411 participants), codeine 60 mg had an NNT of at least 50% pain relief over 4 to 6 hours of 12 (8.4 to 18) compared with placebo.",split,"['This review assessed evidence from 2411 adults with moderate to severe postoperative pain in studies comparing single doses of codeine 60 mg with placebo.', 'In all types of surgery combined, 12 participants would need to be treated with codeine 60 mg for one to experience this amount of pain relief who would not have done so with placebo.']",0,0.2222222222222222,2,9
CD008099,0,2,At least 50% pain relief was achieved by 26% on codeine 60 mg and 17% on placebo.,rephrase,['The number of individuals achieving a clinically useful amount of pain relief (at least 50%) with codeine compared to placebo was low.'],2,0.3333333333333333,2,9
CD008099,1,3,"Following dental surgery the NNT was 21 (12 to 96) (15 studies, 1146 participants), and following other types of surgery the NNT was 6.8 (4.6 to 13) (18 studies, 1265 participants).",delete,[],3,0.4444444444444444,3,9
CD008099,1,4,"The NNT to prevent use of rescue medication within 4 to 6 hours was 11 (6.3 to 50) (11 studies, 765 participants, mostly non-dental); the mean time to its use was 2.7 hours with codeine and 2.0 hours with placebo.",rephrase,"['The need for use of additional analgesia within 4 to 6 hours was 38% with codeine compared with 46% with placebo, and the mean time to the use of additional analgesia was only slightly longer with codeine (2.7 hours) than with placebo (2 hours).']",3,0.5555555555555556,3,9
CD008099,1,5,More participants experienced adverse events with codeine 60 mg than placebo; the difference was not significant and none were serious.,merge,"['More individuals experienced adverse events with codeine than with placebo, but the difference was not significant and none were serious or led to withdrawal.']",4,0.6666666666666666,4,9
CD008099,1,6,Two adverse event withdrawals occurred with placebo.,none,[],4,0.7777777777777778,4,9
CD008099,2,7,"Single dose codeine 60 mg provides good analgesia to few individuals, and does not compare favourably with commonly used alternatives such as paracetamol, NSAIDs and their combinations with codeine, especially after dental surgery; the large difference between dental and other surgery was unexpected.",rephrase,"['Other commonly used analgesics, alone and in combination with codeine 60 mg, provide better pain relief.']",5,0.8888888888888888,5,9
CD008099,2,8,Higher doses were not evaluated.,rephrase,['Higher doses of codeine were not investigated in these studies.'],6,1.0,5,9
MR000036,0,0,Eleven studies met our eligibility criteria and all were at medium or high risk of bias.,rephrase,['We found 11 studies that assessed recruitment strategies used with healthcare staff in search of the literature in January 2015.'],0,0.1,1,10
MR000036,0,1,Only five studies gave the total number of participants (totalling 7372 participants).,rephrase,['Five included the total number of participants (7372).'],1,0.2,1,10
MR000036,0,2,"Three studies used a randomised design, with the others using pre-post comparisons.",delete,[],2,0.3,2,10
MR000036,0,3,Several different strategies were investigated.,rephrase,['There were three main strategies:\n1.'],2,0.4,2,10
MR000036,0,4,"Four studies examined the impact of additional visits or information for the study site, with no increases in recruitment demonstrated.",split,"['Five studies examined the alert system to identify participants who might be suitable for a study.', 'The four studies that evaluated the provision of additional information, visits or education to the sites recruiting participants found that none of the tested strategies led to improved recruitment.']",3,0.5,3,10
MR000036,0,5,"Increased recruitment rates were reported in two studies that used a dedicated clinical recruiter, and five studies that introduced an automated alert system for identifying eligible participants.",delete,[],5,0.6,3,10
MR000036,0,6,"The studies were embedded into trials evaluating care in oncology mainly but also in emergency departments, diabetes and lower back pain.",delete,[],5,0.7,4,10
MR000036,1,7,There is no strong evidence for any single strategy to help healthcare professionals to recruit participants in research studies.,rephrase,['More research is still needed to evaluate the role of a designated person to recruit to research studies.'],5,0.8,4,10
MR000036,1,8,Additional visits or information did not appear to increase recruitment by healthcare professionals.,delete,[],6,0.9,5,10
MR000036,1,9,"The most promising strategies appear to be those with a dedicated resource (e.g. a clinical recruiter or automated alert system) for identifying suitable participants that reduced the demand on healthcare professionals, but these were assessed in studies at high risk of bias.",split,"['The most promising strategy appears to be the employment of someone such as a clinical trials officer or research nurse with the specific task of recruiting participants to research studies.', 'The two studies using this strategy showed improvement in recruitment rates but both were at high risk of bias.']",6,1.0,5,10
CD009151,0,0,Studies: Twenty-three studies involving 2212 women aged 17 to 67 years met the inclusion criteria.,rephrase,['We identified 23 studies involving 2212 participants between 17 and 67 years old with a diagnosis of RVVC confirmed by a positive test.'],0,0.05263157894736842,1,19
CD009151,0,1,Most studies excluded pregnant women and women with diabetes or immunosuppression.,delete,[],1,0.10526315789473684,1,19
CD009151,0,2,The predominant species found on culture at study entry was Candida albicans.,delete,[],1,0.15789473684210525,1,19
CD009151,0,3,"Overall, the included studies were small (<100 participants).",delete,[],1,0.21052631578947367,2,19
CD009151,0,4,Six studies compared antifungal treatment with placebo (607 participants); four studies compared oral versus topical antifungals (543 participants); one study compared different oral antifungals (45 participants); two studies compared different dosing regimens for antifungals (100 participants); one study compared two different dosing regimens of the same topical agent (23 participants); one study compared short versus longer treatment duration (26 participants); two studies assessed the effect of partner treatment (98 participants); one study compared a complementary treatment (Lactobacillus vaginal tablets and probiotic oral tablets) with placebo (34 participants); three studies compared complementary medicine with antifungals (354 participants); two studies compared 'dermasilk' briefs with cotton briefs (130 participants); one study examined Lactobacillus vaccination versus heliotherapy versus ciclopyroxolamine (90 participants); one study compared CAM treatments to an antifungal treatment combined with CAM treatments (68 participants).,rephrase,['Six studies (607 participants) compared antifungal medication with placebo or no treatment.'],1,0.2631578947368421,2,19
CD009151,0,5,We did not find any studies comparing different topical antifungals.,rephrase,"['The studies compared a range of antifungal medicines (taken by mouth or inserted into the vagina), and some complementary or alternative treatments (such as Lactobacillus vaccines or probiotics and special underwear).']",2,0.3157894736842105,2,19
CD009151,0,6,"Nine studies reported industry funding, three were funded by an independent source and eleven did not report their funding source.",ignore,"['Nine studies reported industry funding, three were funded by an independent source and nine studies did not report their funding source.']",3,0.3684210526315789,2,19
CD009151,1,7,"Risk of bias: Overall, the risk of bias was high or unclear due to insufficient blinding of allocation and participants and poor reporting.",rephrase,"['Our confidence in the evidence was low to very low due to serious concerns about risk of bias, unclear reporting and the limited number of studies that could be combined.']",4,0.42105263157894735,3,19
CD009151,2,8,"Primary outcomes: Meta-analyses comparing drug treatments (oral and topical) with placebo or no treatment showed there may be a clinically relevant reduction in clinical recurrence at 6 months (RR 0.36, 95% CI 0.21 to 0.63; number needed to treat for an additional beneficial outcome (NNTB) = 2; participants = 607; studies = 6; I² = 82%; low-certainty evidence) and 12 months (RR 0.80, 95% CI 0.72 to 0.89; NNTB = 6; participants = 585; studies = 6; I² = 21%; low-certainty evidence).",rephrase,['Based on low certainty evidence antifungal treatments may give a clinically relevant reduction in clinical recurrence at 6 and 12 months.'],5,0.47368421052631576,3,19
CD009151,2,9,No study reported on the number of clinical recurrences per participant per year.,split,"['The studies reported the effects on recurrence of thrush after 6 and 12 months.', 'Only one study reported the number of clinical recurrences at 12 months.']",6,0.5263157894736842,3,19
CD009151,3,10,"We are very uncertain whether oral drug treatment compared to topical treatment increases the risk of clinical recurrence at 6 months (RR 1.66, 95% CI 0.83 to 3.31; participants = 206; studies = 3; I² = 0%; very low-certainty evidence) and reduces the risk of clinical recurrence at 12 months (RR 0.95, 95% CI 0.71 to 1.27; participants = 206; studies = 3; I² = 10%; very low-certainty evidence).",rephrase,['We are uncertain if oral treatments are better than topical treatments (very low certainty evidence for no difference).'],8,0.5789473684210527,3,19
CD009151,3,11,No study reported on the number of clinical recurrences per participant per year.,delete,[],9,0.631578947368421,4,19
CD009151,4,12,Adverse events were scarce across both treatment and control groups in both comparisons.,delete,[],9,0.6842105263157895,4,19
CD009151,4,13,"The reporting of adverse events varied amongst studies, was generally of very low quality and could not be pooled.",rephrase,"['Studies reported on adverse effects differently, making comparisons difficult.']",9,0.7368421052631579,4,19
CD009151,4,14,Overall the adverse event rate was low for both placebo and treatment arms and ranged from less than 5% to no side effects or complications.,delete,[],10,0.7894736842105263,4,19
CD009151,5,15,"In women with RVVC, treatment with oral or topical antifungals may reduce symptomatic clinical recurrences when compared to placebo or no treatment.",delete,[],10,0.8421052631578947,5,19
CD009151,5,16,"We were unable to find clear differences between different treatment options (e.g. oral versus topical treatment, different doses and durations).",delete,[],10,0.8947368421052632,5,19
CD009151,5,17,These findings are not applicable to pregnant or immunocompromised women and women with diabetes as the studies did not include or report on them.,delete,[],10,0.9473684210526315,5,19
CD009151,5,18,"More research is needed to determine the optimal medication, dose and frequency.",ignore,"['More research is needed to determine the optimal medication, dose and frequency.']",10,1.0,5,19
CD006169,0,0,Eleven studies met our inclusion criteria.,delete,[],0,0.05263157894736842,1,19
CD006169,0,1,"Two studies did not report any outcome data relevant to the review, so the results of the review are based on nine trials that contributed data.",delete,[],0,0.10526315789473684,1,19
CD006169,0,2,"Primary outcomes were perinatal mortality, serious maternal or infant outcomes, adverse drug reactions, birth before 48 hours of trial entry, birth before 34 weeks' gestation and preterm neonates delivered without a full course of antenatal steroids completed 24 hours before birth.",delete,[],0,0.15789473684210525,1,19
CD006169,0,3,The quality of evidence in included trials was mixed; only three of the trials were placebo controlled.,delete,[],0,0.21052631578947367,2,19
CD006169,1,4,"The included trials examined seven different comparisons: intravenous (IV) ritodrine plus oral or IV magnesium (sulphate or gluconate) versus IV ritodrine alone (three trials, 231 women); IV ritodrine plus indomethacin suppositories versus IV ritodrine alone (one trial, 208 women); IV ritodrine plus vaginal progesterone versus IV ritodrine alone (one trial, 83 women); IV hexoprenaline sulphate plus IV magnesium hydrochloride versus IV hexoprenaline sulphate alone (one trial, 24 women); IV fenoterol plus oral naproxen versus IV fenoterol alone (one trial, 72 women); oral pentoxifylline plus IV magnesium sulphate plus IV fenoterol versus IV magnesium sulphate plus IV fenoterol (one trial, 125 women); and, IV terbutaline plus oral metoprolol versus IV terbutaline alone (one trial, 17 women).",delete,[],0,0.2631578947368421,2,19
CD006169,1,5,"Few studies with small numbers of women were available for each comparison, hence very little data were pooled in meta-analysis.",delete,[],0,0.3157894736842105,2,19
CD006169,1,6,"In all trials, not many of the primary outcomes were reported.",rephrase,"['The trials reported on adverse side effects, with inconsistency between the trials as to which treatment gave fewer severe side effects.']",0,0.3684210526315789,2,19
CD006169,2,7,Three trials examined intravenous (IV) ritodrine plus IV or oral magnesium (sulphate or gluconate) compared with IV ritodrine alone.,rephrase,['Three trials examined the betamimetic drug ritodrine plus magnesium compared with ritodrine alone.'],1,0.42105263157894735,3,19
CD006169,2,8,"One study, with 41 women, reported more adverse drug reactions in the group receiving the combined tocolytics (risk ratio (RR) 7.79, 95% confidence interval (CI) 1.11 to 54.80).",delete,[],2,0.47368421052631576,3,19
CD006169,2,9,"Two trials reported discontinuation of therapy due to severe side effects (results were not combined due to high statistical heterogeneity, I² = 83%); one trial reported increased severe side effects in the group receiving IV ritodrine alone (RR 7.79, 95% CI 1.11 to 54.80, 41 women); in the other trial there was no clear difference between groups (RR 0.23, 95% CI 0.03 to 1.97, 107 women).",delete,[],2,0.5263157894736842,3,19
CD006169,2,10,Other primary outcomes were not reported.,rephrase,['Other outcomes were either not reported or not clearly different between treatment groups.'],2,0.5789473684210527,3,19
CD006169,3,11,One trial assessed IV ritodrine plus indomethacin suppositories versus IV ritodrine alone.,rephrase,['One trial looked at ritodrine plus indomethacin versus ritodrine alone.'],3,0.631578947368421,4,19
CD006169,3,12,There were no significant differences between groups for perinatal mortality or serious neonatal morbidity.,rephrase,['There were no clear differences between groups for serious newborn ill health.'],4,0.6842105263157895,4,19
CD006169,3,13,Results for other primary outcomes were not reported.,rephrase,['Results for other outcomes were not clearly different.'],5,0.7368421052631579,4,19
CD006169,4,14,"There were no significant differences between groups receiving IV ritodrine plus vaginal progesterone compared with IV ritodrine alone for most outcomes reported, although the latency period (time from recruitment to delivery) was increased in the group receiving the combination of tocolytics.",rephrase,"['There were no clear differences between groups receiving ritodrine plus progesterone compared with ritodrine alone for most outcomes reported, although the time between giving the drugs and the birth was increased in the group receiving the combination of tocolytics.']",6,0.7894736842105263,4,19
CD006169,5,15,"For other combinations of tocolytic agents, primary outcomes were rarely reported and for secondary outcomes results did not demonstrate differences between groups.",rephrase,"['For other combinations of tocolytic agents, results did not demonstrate differences between groups.']",7,0.8421052631578947,5,19
CD006169,6,16,"It is unclear whether a combination of tocolytic drugs for preterm labour is more advantageous for women and/or newborns due to a lack of large, well-designed trials including the outcomes of interest.",rephrase,"['Due to insufficient evidence, it is unclear if combination tocolytic regimens are more or less effective than using a single tocolytic drug, or if they have more adverse effects.']",8,0.8947368421052632,5,19
CD006169,6,17,"There are no trials of combination regimens using widely used tocolytic agents, such as calcium channel blockers (nifedipine) and/or oxytocin receptor antagonists (atosiban).",ignore,"['There were no trials of combination regimens using widely used tocolytic agents, such as calcium channel blockers (nifedipine) and oxytocin receptor antagonists (atosiban).']",9,0.9473684210526315,5,19
CD006169,6,18,Further trials are needed before specific conclusions on use of combination tocolytic therapy for preterm labour can be made.,delete,[],10,1.0,5,19
CD009058,0,0,"We found no randomised clinical trials comparing cryotherapy versus no intervention or versus systemic treatments; however, we identified one randomised clinical trial comparing cryotherapy with conventional surgery.",delete,[],0,0.041666666666666664,1,24
CD009058,0,1,The trial was conducted in Ukraine.,rephrase,"[""We included only one trial conducted in Ukraine, and participants' primary cancer was colorectal (bowel) cancer in 66% of instances, but there were also people with stomach, breast, skin, and other tumours.""]",0,0.08333333333333333,1,24
CD009058,0,2,"The trial included 123 participants with solitary, or multiple unilobar or bilobar liver metastases; 63 participants received cryotherapy and 60 received conventional surgery.",rephrase,"['In this trial, 123 participants were allocated at random to receive either cryotherapy (63 people) or conventional surgery (affected parts of the liver were removed; 60 people).']",1,0.125,1,24
CD009058,0,3,There were 36 women and 87 men.,delete,[],2,0.16666666666666666,1,24
CD009058,0,4,"The primary sites for the metastases were colon and rectum (66.6%), stomach (7.3%), breast (6.5%), skin (4.9%), ovaries (4.1%), uterus (3.3%), kidney (3.3%), intestines (1.6%), pancreas (1.6%), and unknown (0.8%).",delete,[],2,0.20833333333333334,2,24
CD009058,0,5,"The trial was not reported sufficiently enough to assess the risk of bias of the randomisation process, allocation concealment, or presence of blinding.",delete,[],2,0.25,2,24
CD009058,0,6,It was also not possible to assess incomplete outcome data and selective outcome reporting bias.,delete,[],2,0.2916666666666667,2,24
CD009058,0,7,The certainty of evidence was low because of risk of bias and imprecision.,rephrase,['The trial was at high risk of bias.'],2,0.3333333333333333,2,24
CD009058,1,8,The participants were followed for up to 10 years (minimum five months).,ignore,['The participants were followed for up to 10 years (minimum five months).'],3,0.375,2,24
CD009058,1,9,The trial reported that the mortality at 10 years was 81% (51/63) in the cryotherapy group and 92% (55/60) in the conventional surgery group.,ignore,['The trial reported that the mortality at 10 years was 81% (51/63) in the cryotherapy group and 92% (55/60) in the conventional surgery group.'],4,0.4166666666666667,3,24
CD009058,1,10,"The calculated by us relative risk (RR) with 95% Confidence Interval (CI) was: RR 0.88, 95% CI 0.77 to 1.02.",delete,[],5,0.4583333333333333,3,24
CD009058,1,11,We judged the evidence as low-certainty evidence.,ignore,['We judged the evidence as low-certainty evidence.'],5,0.5,3,24
CD009058,1,12,"Regarding adverse events and complications, separately and in total, our calculation showed no evidence of a difference in recurrence of the malignancy in the liver: 86% (54/63) of the participants in the cryotherapy group and 95% (57/60) of the participants in the conventional surgery group developed a new malignancy (RR 0.90, 95% CI 0.80 to 1.01; low-certainty evidence).",rephrase,['We found no evidence of a difference in proportion of participants with recurrence of the malignancy in the liver: 86% (54/63) of the participants in the cryotherapy group and 95% (57/60) of the participants in the conventional surgery group developed a new malignancy (low-certainty evidence).'],6,0.5416666666666666,3,24
CD009058,1,13,"The frequency of reported complications was similar between the cryotherapy group and the conventional surgery group, except for postoperative pain.",split,"['The frequency of reported complications was similar between the cryotherapy group and the conventional surgery group, except for postoperative pain.', 'The frequency of unwanted effects (adverse events or complications) was mostly similar in both groups, but pain intensity and frequency seemed to differ between the groups.']",7,0.5833333333333334,3,24
CD009058,1,14,Both insignificant and pronounced pain were reported to be more common in the cryotherapy group while intense pain was reported to be more common in the conventional surgery group.,ignore,['Both insignificant and pronounced pain were reported to be more common in the cryotherapy group while intense pain was reported to be more common in the conventional surgery group.'],9,0.625,4,24
CD009058,1,15,"However, the authors did not report whether there was any evidence of a difference.",rephrase,"['However, it was not reported whether there was any evidence of a difference.']",10,0.6666666666666666,4,24
CD009058,1,16,There were no intervention-related mortality or bile leakages.,ignore,['There were no intervention-related mortality or bile leakages.'],11,0.7083333333333334,4,24
CD009058,2,17,"We identified no evidence for health-related quality of life, cancer mortality, or time to progression of liver metastases.",rephrase,"['The trial did not provide data on quality of life; cancer mortality, and time to progression of liver metastases.']",12,0.75,4,24
CD009058,2,18,"The study reported tumour response in terms of the carcinoembryonic antigen level in 69% of participants, and reported results in the form of a graph for 30% of participants.",delete,[],13,0.7916666666666666,4,24
CD009058,2,19,"The carcinoembryonic antigen level was lower in the cryotherapy group, and decreased to normal values faster in comparison with the control group (P < 0.05).",delete,[],13,0.8333333333333334,5,24
CD009058,3,20,Funding: the trial did not provide information on funding.,delete,[],13,0.875,5,24
CD009058,4,21,The evidence for the effectiveness of cryotherapy versus conventional surgery in people with liver metastases is of low certainty.,ignore,['The evidence for the effectiveness of cryotherapy versus conventional surgery in people with liver metastases is of low certainty.'],13,0.9166666666666666,5,24
CD009058,4,22,We are uncertain about our estimate and cannot determine whether cryotherapy compared with conventional surgery is beneficial or harmful.,ignore,['We are uncertain about our estimate and cannot determine whether cryotherapy compared with conventional surgery is beneficial or harmful.'],14,0.9583333333333334,5,24
CD009058,4,23,"We found no evidence for the benefits or harms of cryotherapy compared with no intervention, or versus systemic treatments.",ignore,"['We found no evidence for the benefits or harms of cryotherapy compared with no intervention, or versus systemic treatments.']",15,1.0,5,24
CD012665,0,0,"We included four cross-over RCTs with a total of 209 participants, ranging in age from 23 to 85 and with a preponderance of men.",rephrase,"['We included four studies with a total of 209 patients, ranging in age from 23 to 85 and with more men than women.']",0,0.05263157894736842,1,19
CD012665,0,1,All the studies allowed the use of hearing aids for a total period of at least eight weeks before questions on preference were asked.,rephrase,['All the studies allowed the use of hearing aids for a total period of at least eight weeks before questions were asked about their preference for one or two aids.'],1,0.10526315789473684,1,19
CD012665,0,2,All studies recruited patients with bilateral hearing loss but there was considerable variation in the types and degree of sensorineural hearing loss that the participants were experiencing.,rephrase,['In all the studies the patients had bilateral hearing loss but there was considerable variation in what type of hearing loss they suffered from and how bad their hearing was.'],2,0.15789473684210525,1,19
CD012665,1,3,Three of the studies were published before the mid-1990s whereas the fourth study was published in 2011.,ignore,['Three of the studies were published before the mid-1990s and the fourth study was published in 2011.'],3,0.21052631578947367,2,19
CD012665,1,4,"Therefore, only the most recent study used hearing aids incorporating technology comparable to that currently readily available in high-income settings.",rephrase,"[""Therefore, only the most recent study used 'modern' hearing aids similar to those that are widely available in high-income countries.""]",4,0.2631578947368421,2,19
CD012665,1,5,"Of the four studies, two were conducted in the UK in National Health Service (NHS – public sector) patients: one recruited patients from primary care with hearing loss detected by a screening programme whereas the other recruited patients who had been referred by their primary care practitioner to an otolaryngology department for hearing aids.",split,"['Of the four studies, two were conducted in the UK in National Health Service (NHS – public sector) patients.', 'One of these looked at patients from primary care whose hearing loss had been picked up by a screening programme.', 'The other looked at patients whose primary care practitioner thought they might benefit from hearing aids so had referred them to the local ENT department to get them.']",5,0.3157894736842105,2,19
CD012665,1,6,The other two studies were conducted in the United States: one study recruited only military personnel or veterans with noise-induced hearing loss whereas about half of the participants in the other study were veterans.,split,"['The other two studies were conducted in the United States: one study recruited only people on active military duty, or who had served in the military and had hearing loss due to being exposed to loud noises.', 'About half of the people in the other study were ex-military.']",8,0.3684210526315789,2,19
CD012665,2,7,Only one primary outcome (patient preference) was reported in all studies.,rephrase,['Only one of the outcomes we thought was most important - patient preference - was reported in all studies.'],10,0.42105263157894735,3,19
CD012665,2,8,"The percentage of patients who preferred bilateral hearing aids varied between studies: this was 54% (51 out of 94 participants), 39% (22 out of 56), 55% (16 out of 29) and 77% (23 out of 30), respectively.",ignore,"['The percentage of patients who preferred two hearing aids to one varied between studies: this was 54% (51 out of 94), 39% (22 out of 56), 55% (16 out of 29) and 77% (23 out of 30), respectively.']",11,0.47368421052631576,3,19
CD012665,2,9,We have not combined the data from these four studies.,rephrase,['We did not combine the numbers from these four studies because it would not have been right to do so.'],12,0.5263157894736842,3,19
CD012665,2,10,The evidence for this outcome is of very low quality.,rephrase,['We graded the quality of evidence for this outcome as very low on a scale that goes high – medium – low – very low.'],13,0.5789473684210527,3,19
CD012665,3,11,The other outcomes of interest were not reported in the included studies.,rephrase,['There was no information in the four studies on the other outcomes we were interested in.'],14,0.631578947368421,4,19
CD012665,4,12,This review identified only four studies comparing the use of one hearing aid with two.,ignore,['This review identified only four studies comparing the use of one hearing aid with two.'],15,0.6842105263157895,4,19
CD012665,4,13,The studies were small and included participants of widely varying ages.,rephrase,['The studies were small and included people of widely varying ages.'],16,0.7368421052631579,4,19
CD012665,4,14,There was also considerable variation in the types and degree of sensorineural hearing loss that the participants were experiencing.,rephrase,['There was also considerable variation in the types of their deafness and in how deaf they were.'],17,0.7894736842105263,4,19
CD012665,5,15,"For the most part, the types of hearing aid evaluated would now be regarded, in high-income settings, as 'old technology', with only one study looking at 'modern' digital aids.",ignore,"[""For the most part, the types of hearing aid evaluated would now be regarded, in high-income countries, as 'old technology', with only one study looking at 'modern' digital aids.""]",18,0.8421052631578947,5,19
CD012665,5,16,"However, the relevance of this is uncertain, as this review did not evaluate the differences in outcomes between the different types of technology.",rephrase,"[""This review did not look at the differences between other 'old' and 'new' types of hearing aid.""]",19,0.8947368421052632,5,19
CD012665,6,17,We were unable to pool data from the four studies and the very low quality of the evidence leads us to conclude that we do not know if people with hearing loss have a preference for one aid or two.,split,"['We could not combine the numbers from the four studies.', 'Overall, this fact and the very low quality of the evidence leads us to conclude that we do not know if patients have a preference for one aid or two.']",20,0.9473684210526315,5,19
CD012665,6,18,"Similarly, we do not know if hearing-specific health-related quality of life, or any of our other outcomes, are better with bilateral or unilateral aids.",rephrase,"[""Similarly, we do not know if a patient's quality of life is better with one or two aids.""]",22,1.0,5,19
CD009551,0,0,"We included 29 primary studies (18 from the original review and 11 from this update), corresponding to 34 data sets, published between 2000 and 2018 in the meta-analyses, with a mean prevalence of proven or probable IA of 16.3 (median prevalence 11.1% , range 2.5% to 57.1%).",delete,[],0,0.08333333333333333,1,12
CD009551,0,1,Most patients had received chemotherapy for haematological malignancy or had undergone hematopoietic stem cell transplantation.,delete,[],0,0.16666666666666666,1,12
CD009551,0,2,Several PCR techniques were used among the included studies.,rephrase,['Several PCR techniques were used in the studies.'],0,0.25,2,12
CD009551,0,3,The sensitivity and specificity of PCR for the diagnosis of IA varied according to the interpretative criteria used to define a test as positive.,merge,"['Pooling the data from the studies showed that sensitivity and specificity of PCR for the diagnosis of IA varied (from 59% to 79.2% and from 79% to 95.2%, respectively) depending on the interpretative criteria used to define a test as positive.']",1,0.3333333333333333,2,12
CD009551,0,4,"The summary estimates of sensitivity and specificity were 79.2% (95% confidence interval (CI) 71.0 to 85.5) and 79.6% (95% CI 69.9 to 86.6) for a single positive test result, and 59.6% (95% CI 40.7 to 76.0) and 95.1% (95% CI 87.0 to 98.2) for two consecutive positive test results.",none,[],1,0.4166666666666667,3,12
CD009551,1,5,PCR shows moderate diagnostic accuracy when used as screening tests for IA in high-risk patient groups.,ignore,"['Overall, PCR shows moderate diagnostic accuracy when used as a screening test for IA in high-risk patient groups.']",2,0.5,3,12
CD009551,1,6,Importantly the sensitivity of the test confers a high negative predictive value (NPV) such that a negative test allows the diagnosis to be excluded.,split,"['Importantly, when the rate of sensitivity is low, the sensitivity of the tests means that a negative result allows the diagnosis to be excluded with confidence except when the patient is receiving certain antifungal drugs.', 'With the low prevalence of the disease, a high negative predictive value such that a negative test allows the diagnosis to be excluded.']",3,0.5833333333333334,3,12
CD009551,1,7,Consecutive positives show good specificity in diagnosis of IA and could be used to trigger radiological and other investigations or for pre-emptive therapy in the absence of specific radiological signs when the clinical suspicion of infection is high.,delete,[],5,0.6666666666666666,4,12
CD009551,1,8,"When a single PCR positive test is used as the diagnostic criterion for IA in a population of 100 people with a disease prevalence of 16.3% (overall mean prevalence), three people with IA would be missed (sensitivity 79.2%, 20.8% false negatives), and 17 people would be unnecessarily treated or referred for further tests (specificity of 79.6%, 21.4% false positives).",rephrase,"['When used as a diagnostic criterion for IA in a population of 100 people with a disease prevalence of 16.3% (overall mean prevalence), a single PCR positive test would have missed three people with the disease, and falsely classified 17 people as having the disease, who would be treated unnecessarily or referred for further tests.']",5,0.75,4,12
CD009551,1,9,"If we use the two positive test requirement in a population with the same disease prevalence, it would mean that nine IA people would be missed (sensitivity 59.6%, 40.4% false negatives) and four people would be unnecessarily treated or referred for further tests (specificity of 95.1%, 4.9% false positives).",rephrase,['A requirement of two positive tests as a diagnostic criterion in a population with the same disease prevalence would miss nine people with the disease and falsely classify four people as having the disease.'],6,0.8333333333333334,5,12
CD009551,1,10,"Like galactomannan, PCR has good NPV for excluding disease, but the low prevalence of disease limits the ability to rule in a diagnosis.",delete,[],7,0.9166666666666666,5,12
CD009551,1,11,"As these biomarkers detect different markers of disease, combining them is likely to prove more useful.",delete,[],7,1.0,5,12
CD001081,0,0,We included three trials involving 6343 participants.,rephrase,"['This review identified three randomised controlled trials (6343 participants randomised), which compared carotid surgery with no carotid surgery (i.e. best medical therapy plus surgery versus best medical therapy alone) in participants with carotid stenosis and recent transient ischaemic attacks (TIA), or minor ischaemic strokes in the territory of that artery.']",0,0.125,1,8
CD001081,0,1,The trials differed in the methods of measuring carotid stenosis and in the definition of stroke.,rephrase,"['The results of the three trials were initially conflicting, because they differed in how they measured carotid stenosis and how they defined the outcomes.']",1,0.25,2,8
CD001081,0,2,"Using the primary electronic data files, we pooled and analysed individual patient data on 6092 participants (35,000 patient-years of follow-up), after reassessing the carotid angiograms and outcomes from all three trials, and redefining outcome events where necessary, to achieve comparability.",delete,[],2,0.375,2,8
CD001081,1,3,"Surgery increased the five-year risk of any stroke or operative death in participants with less than 30% stenosis (risk ratio (RR) 1.25, 95% confidence interval (CI) 0.99 to 1.56; 2 studies, 1746 participants; high-quality evidence).",delete,[],2,0.5,3,8
CD001081,1,4,"Surgery decreased the five-year risk of any stroke or operative death in participants with 30% to 49% stenosis (RR 0.97, 95% CI 0.79 to 1.19; 2 studies, 1429 participants; high-quality evidence), was of benefit in participants with 50% to 69% stenosis (RR 0.77, 95% CI 0.63 to 0.94; 3 studies, 1549 participants; moderate-quality evidence), and was highly beneficial in participants with 70% to 99% stenosis without near-occlusion (RR 0.53, 95% CI 0.42 to 0.67; 3 studies, 1095 participants; moderate-quality evidence).",delete,[],2,0.625,4,8
CD001081,1,5,"However, surgery decreased the five-year risk of any stroke or operative death in participants with near-occlusions (RR 0.95, 95% CI 0.59 to 1.53; 2 studies, 271 participants; moderate-quality evidence).",rephrase,['The evidence was of moderate or high quality for all the results.'],2,0.75,4,8
CD001081,2,6,Carotid endarterectomy reduced the risk of recurrent stroke for people with significant stenosis.,ignore,['Carotid endarterectomy reduced the risk of further stroke for people with significant stenosis.'],3,0.875,5,8
CD001081,2,7,Endarterectomy might be of some benefit for participants with 50% to 69% symptomatic stenosis (moderate-quality evidence) and highly beneficial for those with 70% to 99% stenosis (moderate-quality evidence).,rephrase,['Endarterectomy might be of some benefit for participants with 50% to 69% stenosis.'],4,1.0,5,8
CD010961,0,0,"We included seven trials involving 2524 participants, all aged over 12 years.",rephrase,"['The studies involved 2524 people, who were all aged 12 years and over.']",0,0.07692307692307693,1,13
CD010961,0,1,"The trials were double-blind, randomised, placebo-controlled trials with treatment duration of 12 to 19 weeks.",rephrase,['The people in the studies received their treatment for 12 to 19 weeks.'],1,0.15384615384615385,1,13
CD010961,0,2,"We assessed four trials at overall low risk of bias, and three trials at overall unclear risk of bias, due to risk of detection, reporting, and other biases.",rephrase,['We judged that most studies were at low risk of bias.'],2,0.23076923076923078,2,13
CD010961,1,3,"Compared with placebo, participants receiving perampanel were more likely to achieve a 50% or greater reduction in seizure frequency (RR 1.67, 95% CI 1.43 to 1.95; 7 trials, 2524 participants; high-certainty evidence).",rephrase,['People who received perampanel were more likely to have a 50% or more reduction in the number of seizures that they normally experience.'],3,0.3076923076923077,2,13
CD010961,1,4,"Compared to placebo, perampanel increased seizure freedom (RR 2.50, 95% CI 1.38 to 4.54; 5 trials, 2323 participants; low-certainty evidence) and treatment withdrawal (RR 1.30, 95% CI 1.03 to 1.63; 7 trials, 2524 participants; low-certainty evidence).",delete,[],4,0.38461538461538464,2,13
CD010961,1,5,"Participants treated with perampanel were more likely to withdraw from treatment due to adverse effects compared to those receiving placebo (RR 2.36, 95% CI 1.59 to 3.51; 7 trials, 2524 participants; low-certainty evidence).",rephrase,"['There was low-certainty evidence that more people became free of all seizures, withdrew from treatment, and experienced problems with co-ordination, balance, and speech (known as ataxia) or dizziness, meaning that the findings for these measures may be inaccurate.']",4,0.46153846153846156,3,13
CD010961,1,6,"A higher proportion of participants receiving perampanel reported one or more adverse effects when compared to participants who received placebo (RR 1.17, 95% CI 1.10 to 1.24; 7 trials, 2524 participants; high-certainty evidence).",merge,[],5,0.5384615384615384,3,13
CD010961,1,7,"Compared with placebo, participants receiving perampanel were more likely to experience ataxia (RR 14.32, 99% CI 1.09 to 188.31; 2 trials, 1098 participants; low-certainty evidence), dizziness (RR 2.87, 99% CI 1.45 to 5.70; 7 trials, 2524 participants; low-certainty evidence), and somnolence (RR 1.76, 99% CI 1.02 to 3.04; 7 trials, 2524 participants).",none,['People taking perampanel were more likely to experience side effects than those taking placebo.'],5,0.6153846153846154,4,13
CD010961,2,8,"Subgroup analysis indicated that a larger proportion of participants who received perampanel at a dose of 4 mg/day (RR 1.38, 95% CI 1.05 to 1.83; 2 trials, 710 participants), 8 mg/day (RR 1.83, 95% CI 1.51 to 2.22; 4 trials, 1227 participants), or 12 mg/day (RR 2.38, 95% CI 1.86 to 3.04; 3 trials, 869 participants) achieved a 50% or greater reduction in seizure frequency compared to placebo; however, treatment with perampanel 12 mg/day also increased treatment withdrawal (RR 1.77, 95% CI 1.31 to 2.40; 3 trials, 869 participants).",delete,[],6,0.6923076923076923,4,13
CD010961,3,9,Add-on perampanel is effective at reducing seizure frequency and may be effective at maintaining seizure freedom for people with drug-resistant focal epilepsy.,rephrase,['We wanted to know whether perampanel was effective and tolerable when used as an add-on therapy for people with drug-resistant focal epilepsy.'],6,0.7692307692307693,4,13
CD010961,3,10,"Although perampanel was well-tolerated, there was a higher proportion of treatment withdrawals with perampanel compared with placebo.",delete,[],7,0.8461538461538461,5,13
CD010961,3,11,"Subgroup analysis suggested that 8 mg/day and 12 mg/day are the most efficacious perampanel doses; however, the use of 12 mg/day would likely increase the number of treatment withdrawals.",rephrase,"['The results indicated that perampanel 8 mg per day or 12 mg per day were most effective at controlling seizures; however, perampanel 12 mg per day also led to more people withdrawing from treatment.']",7,0.9230769230769231,5,13
CD010961,4,12,"Future research should focus on investigating the efficacy and tolerability of perampanel with longer-term follow-up, as well as exploring an optimal dose.",delete,[],8,1.0,5,13
CD004468,0,0,"Three studies each with the number of participants ranging from 60 to 80, and a total of 216 participants, were included in this review.",delete,[],0,0.1111111111111111,1,9
CD004468,0,1,The interventions used in the included studies were different from one another.,delete,[],0,0.2222222222222222,2,9
CD004468,0,2,One study compared TCHP with nitrates and was of good methodological quality whereas the remaining two trials compared one preparation with another preparation and one was of poor methodological quality.,delete,[],0,0.3333333333333333,2,9
CD004468,0,3,"As such, we were unable to perform a summary meta-analysis.",delete,[],0,0.4444444444444444,3,9
CD004468,0,4,"Only one trial with small patient numbers showed positive results favouring TCHP treatment compared with nitrates, in improved angina symptoms.",rephrase,['Only one small trial was able to detect benefits of using TCHP compared with nitrates in improving angina symptoms.'],0,0.5555555555555556,3,9
CD004468,0,5,Two of the trials stated that adverse reactions occurred but detailed data could not be obtained.,rephrase,['The remaining two trials were inconclusive.'],1,0.6666666666666666,4,9
CD004468,1,6,"There is currently insufficient evidence for effectively treating stable angina pectoris with any of the examined TCHP in this review, due to the small number of included studies and participants.",rephrase,['The authors of this review undertook a systematic review of the potential benefits and safety of TCHP in patients with stable angina.'],2,0.7777777777777778,4,9
CD004468,1,7,"Therefore, TCHP should be used with caution.",rephrase,"['Due to the very small number of included studies and participants in the studies, TCHP should be used with caution.']",3,0.8888888888888888,5,9
CD004468,1,8,High quality randomised trials with similar interventions are required to strengthen the evidence for the effectiveness and safety of Chinese medicinal herbs in angina pectoris.,rephrase,['We recommend that larger-scale high quality randomised controlled trials of TCHP are required to strengthen the evidence for the efficacy and safety of certain TCHP in treating angina.'],4,1.0,5,9
CD009128,0,0,Three RCTs met our inclusion criteria: these investigated a total of 140 participants and ranged from six weeks to five months in duration.,delete,[],0,0.1,1,10
CD009128,0,1,All three studies were performed by the same trialist.,delete,[],0,0.2,1,10
CD009128,0,2,"Overall, the risk of bias of these trials was unclear or high.",delete,[],0,0.3,2,10
CD009128,0,3,All RCTs compared the effect of sweet potato preparations with placebo on glycaemic control in type 2 diabetes mellitus.,delete,[],0,0.4,2,10
CD009128,0,4,There was a statistically significant improvement in glycosylated haemoglobin A1c (HbA1c) at three to five months with 4 g/day sweet potato preparation compared to placebo (mean difference -0.3% (95% confidence interval -0.6 to -0.04); P = 0.02; 122 participants; 2 trials).,rephrase,['Two studies with 122 participants showed improved long-term metabolic control of blood sugar levels as measured by glycosylated haemoglobin A1c (HbA1c) which was moderately lowered by 0.3% in participants who were given 4 g sweet potato tablets a day for three to five months.'],0,0.5,3,10
CD009128,0,5,No serious adverse effects were reported.,rephrase,"['Adverse effects were mostly mild, and included abdominal distension and pain.']",1,0.6,3,10
CD009128,0,6,"Diabetic complications and morbidity, death from any cause, health-related quality of life, well-being, functional outcomes and costs were not investigated.",rephrase,"['No study investigated diabetic complications, death from any cause, health-related quality of life, well-being, functional outcomes or costs.']",2,0.7,4,10
CD009128,1,7,There is insufficient evidence about the use of sweet potato for type 2 diabetes mellitus.,split,"['We decided to investigate whether there is enough evidence from medical trials to show whether sweet potato works as a treatment for diabetes.', 'This review of randomised controlled trials found only three studies (with a total of 140 participants) that evaluated the effects of sweet potato for type 2 diabetes mellitus compared with a fake medicine (placebo).']",3,0.8,4,10
CD009128,1,8,"In addition to improvement in trial methodology, issues of standardization and quality control of preparations - including other varieties of sweet potato - need to be addressed.",merge,[],5,0.9,5,10
CD009128,1,9,Further observational trials and RCTs evaluating the effects of sweet potato are needed to guide any recommendations in clinical practice.,none,['More trials are needed to assess the quality of the various sweet potato preparations as well as to evaluate further the use of different varieties of sweet potato in the diet of diabetic people.'],5,1.0,5,10
CD012184,0,0,We included eight RCTs comprising a total of 662 distinct febrile neutropenia episodes.,split,"['We included eight studies involving people with neutropenia and fever and comparing short antibiotic therapy to long antibiotic therapy until normalisation of neutrophils.', 'A total of 662 episodes of fever in people with neutropenia were randomly assigned to a treatment group (314 to short antibiotic treatment and 348 to long antibiotic treatment).']",0,0.0625,1,16
CD012184,0,1,"The studies included adults and children, and had variable design and criteria for discontinuation of antibiotics in both study arms.",delete,[],2,0.125,1,16
CD012184,0,2,All included studies but two were performed before the year 2000.,delete,[],2,0.1875,1,16
CD012184,0,3,All studies included people with cancer with fever of unknown origin and excluded people with microbiological documented infections.,split,"['All trials excluded people who had bacteria growing in any culture before the time of randomisation.', 'All studies except two excluded people with infection in a specific organ.']",2,0.25,2,16
CD012184,1,4,"We found no significant difference between the short-antibiotic therapy arm and the long-antibiotic therapy arm for all-cause mortality (RR 1.38, 95% CI 0.73 to 2.62; RD 0.02, 95% CI -0.02 to 0.05; low-certainty evidence).",rephrase,"['We found no differences in the rate of fungal infections and development of antibiotic resistance, with few studies reporting the latter outcome.']",4,0.3125,2,16
CD012184,1,5,We downgraded the certainty of the evidence to low due to imprecision and high risk of selection bias.,rephrase,['We assessed the certainty of the evidence for the primary outcome of all-cause mortality as low and for the outcomes of clinical failure and bacteraemia occurring after randomisation as very low.'],5,0.375,2,16
CD012184,1,6,"The number of fever days was significantly lower for people in the short-antibiotic treatment arm compared to the long-antibiotic treatment arm (mean difference -0.64, 95% CI -0.96 to -0.32; I² = 30%).",rephrase,['The number of days with fever was lower for people treated with short antibiotic courses compared to those treated with long antibiotic courses.'],6,0.4375,3,16
CD012184,1,7,"In all studies, total antibiotic days were fewer in the intervention arm by three to seven days compared to the long antibiotic therapy.",rephrase,['In all trials the number of antibiotic treatment days was fewer in the short-antibiotic therapy arm by three to seven days compared to the long-antibiotic therapy arm.'],7,0.5,3,16
CD012184,1,8,"We found no significant differences in the rates of clinical failure (RR 1.23, 95% CI 0.85 to 1.77; very low-certainty evidence).",delete,[],8,0.5625,3,16
CD012184,1,9,"We downgraded the certainty of the evidence for clinical failure due to variable and inconsistent definitions of clinical failure across studies, possible selection bias, and wide confidence intervals.",delete,[],8,0.625,4,16
CD012184,1,10,"There was no significant difference in the incidence of bacteraemia occurring after randomisation (RR 1.56, 95% CI 0.91 to 2.66; very low-certainty evidence), while the incidence of any documented infections was significantly higher in the short-antibiotic therapy arm (RR 1.67, 95% CI 1.08 to 2.57).",rephrase,['There was no difference in mortality between the short- and long-antibiotic therapy arm.'],8,0.6875,4,16
CD012184,1,11,"There was no significant difference in the incidence of invasive fungal infections (RR 0.86, 95% CI 0.32 to 2.31) and development of antibiotic resistance (RR 1.49, 95% CI 0.62 to 3.61).",rephrase,['There was no difference in the number of people with severe infections presenting as bacteria in blood.'],9,0.75,4,16
CD012184,1,12,The data on hospital stay were too sparse to permit any meaningful conclusions.,rephrase,['Data on hospital length of stay were insufficient to permit any meaningful conclusions.'],10,0.8125,5,16
CD012184,2,13,We could make no strong conclusions on the safety of antibiotic discontinuation before neutropenia resolution among people with cancer with febrile neutropenia based on the existing evidence and its low certainty.,delete,[],11,0.875,5,16
CD012184,2,14,Results of microbiological outcomes favouring long antibiotic therapy may be misleading due to lower culture positivity rates under antibiotic therapy and not true differences in infection rates.,delete,[],11,0.9375,5,16
CD012184,2,15,"Well-designed, adequately powered RCTs are required that address this issue in the era of rising antibiotic resistance.",delete,[],11,1.0,5,16
CD011320,0,0,We included nine RCTs (N = 2955 infertile couples).,rephrase,"['We included nine studies (randomised controlled trials, that is studies in which participants are assigned to one of two or more treatment groups using a random method) of 2955 infertile couples undergoing IVF or ICSI.']",0,0.05,1,20
CD011320,0,1,The quality of the evidence ranged from very low to low.,ignore,['The quality of the evidence ranged from very low to low.'],1,0.1,1,20
CD011320,0,2,"The main limitations were high risk of bias in the included studies, imprecision, indirectness, and inconsistency.",ignore,"['The main limitations were high risk of bias in the included studies, imprecision, indirectness, and inconsistency.']",2,0.15,1,20
CD011320,0,3,There were no data on cumulative live birth or ongoing pregnancy rate or cumulative clinical pregnancy rate.,delete,[],3,0.2,1,20
CD011320,1,4,"TLS with conventional morphological assessment of still TLS images versus conventional incubation and assessment
It is unclear whether there is any difference between interventions in rates of live birth or ongoing pregnancy (odds ratio (OR) 0.91, 95% confidence interval (CI) 0.67 to 1.23, 3 RCTs, N = 826, I2 = 33%, low-quality evidence) or in miscarriage rates (OR 1.90, 95% CI 0.99 to 3.61, 3 RCTs, N = 826, I2 = 0%, low-quality evidence).",rephrase,['TLS with conventional assessment of still TLS images versus conventional incubation and assessment\nAll the evidence for this comparison was low-quality.'],3,0.25,2,20
CD011320,1,5,"The evidence suggests that if the rate of live birth or ongoing pregnancy associated with conventional incubation and assessment is 35%, the rate with the use of TLS with conventional morphological assessment of still TLS images would be between 27% and 40%, and if the miscarriage rate with conventional incubation is 4%, the rate associated with conventional morphological assessment of still TLS images would be between 4% and 14%.",ignore,"['The evidence suggests that if the rate of livebirth or ongoing pregnancy associated with conventional incubation and assessment is 35%, the rate with use of TLS with conventional morphological assessment of still TLS images would be between 27% and 40%, and if the miscarriage rate with conventional incubation is 4%, the rate associated with conventional morphological assessment of still TLS images would be between 4% and 14%.']",4,0.3,2,20
CD011320,1,6,"It is unclear whether there is a difference between the interventions in rates of stillbirth (OR 1.00, 95% CI 0.13 to 7.49, 1 RCT, N = 76, low-quality evidence) or clinical pregnancy (OR 1.06, 95% CI 0.79 to 1.41, 4 RCTs, N = 875, I2 = 0%, low-quality evidence).",split,"['It is unclear whether there is any difference between the interventions in rates of livebirth or ongoing pregnancy or miscarriage.', 'It is unclear whether there is a difference between interventions in rates of stillbirth or clinical pregnancy.']",5,0.35,2,20
CD011320,2,7,"TLS utilising embryo selection software versus TLS with conventional morphological assessment of still TLS images
All findings for this comparison were very uncertain due to the very low-quality of the evidence.",ignore,['TLS utilising embryo selection software versus TLS with conventional assessment of still TLS images\nAll findings for this comparison were very uncertain due to very low-quality evidence.'],7,0.4,2,20
CD011320,2,8,"No data were available on live birth, but one RCT reported ongoing pregnancy.",ignore,"['No data were available on livebirth, but one study reported ongoing pregnancy.']",8,0.45,3,20
CD011320,2,9,"It is unclear whether there is any difference between the interventions in rates of ongoing pregnancy (OR 0.61, 95% CI 0.32 to 1.20, 1 RCT, N = 163); miscarriage (OR 1.39, 95% CI 0.64 to 3.01, 2 RCTs, N = 463, I2 = 0%); or clinical pregnancy (OR 0.97, 95% CI 0.67 to 1.42, 2 RCTs, N = 463, I2 = 0%).",rephrase,"['It is unclear whether there is any difference between interventions in rates of ongoing pregnancy, miscarriage, or clinical pregnancy.']",9,0.5,3,20
CD011320,2,10,"The evidence suggests that if the rate of ongoing pregnancy associated with TLS with conventional morphological assessment of still TLS images is 47%, the rate associated with TLS utilising embryo selection software would be between 22% and 52%, and if the miscarriage rate associated with conventional morphological assessment of still TLS images is 5%, the rate associated with TLS utilising embryo selection software would be between 4% and 15%.",ignore,"['The evidence suggests that if the rate of ongoing pregnancy associated with TLS with conventional morphological assessment of still TLS images is 47%, the rate associated with TLS utilising embryo selection software would be between 22% and 52%, and if the miscarriage rate associated with conventional morphological assessment of still TLS images is 5%, the rate associated with TLS utilising embryo selection software would be between 4% and 15%.']",10,0.55,3,20
CD011320,2,11,No studies reported stillbirth.,ignore,['No studies reported stillbirth.'],11,0.6,3,20
CD011320,3,12,"TLS utilising embryo selection software versus conventional incubation and assessment
The findings for this comparison were also very uncertain due to the very low quality of the evidence.",ignore,['TLS utilising embryo selection software versus conventional incubation and assessment\nAll findings for this comparison were very uncertain due to the very low-quality of the evidence.'],12,0.65,4,20
CD011320,3,13,"It is unclear whether there is any difference between the interventions in rates of live birth (OR 1.12, 95% CI 0.92 to 1.36, 3 RCTs, N = 1617, I2 = 84%).",delete,[],13,0.7,4,20
CD011320,3,14,"There was very low-quality evidence that TLS might reduce miscarriage rates (OR 0.63, 95% CI 0.45 to 0.89, 3 RCTs, N = 1617, I2 = 0%).",delete,[],13,0.75,4,20
CD011320,3,15,"It is unclear whether there is any difference between the interventions in rates of clinical pregnancy (OR 0.95, 95% CI 0.78 to 1.16, 3 RCTs, N = 1617, I2 = 89%).",rephrase,['It is unclear whether there is any difference between interventions with respect to rates of livebirth or clinical pregnancy.'],13,0.8,4,20
CD011320,3,16,"The evidence suggests that if the rate of live birth associated with conventional incubation and assessment is 48%, the rate with TLS utilising embryo selection software would be between 46% and 55%, and if the miscarriage rate with conventional incubation and assessment is 11%, the rate associated with TLS would be between 5% and 10%.",split,"['The evidence suggests lower rates of miscarriage in the TLS group for the outcome of miscarriage.', 'The evidence suggests that if the livebirth rate associated with conventional incubation is 48%, the rate with the use of TLS would be between 46% and 55%, and if the miscarriage rate with conventional incubation is 11%, the rate associated with TLS would be between 5% and 10%.']",14,0.85,5,20
CD011320,3,17,No stillbirths occurred in the only study reporting this outcome.,delete,[],16,0.9,5,20
CD011320,4,18,"There is insufficient good-quality evidence of differences in live birth or ongoing pregnancy, miscarriage and stillbirth, or clinical pregnancy to choose between TLS, with or without embryo selection software, and conventional incubation.",rephrase,['There is no good evidence showing that TLS is more or less effective than conventional methods of embryo incubation.'],16,0.95,5,20
CD011320,4,19,"As the evidence is of low or very low-quality, our findings should be interpreted with caution.",delete,[],17,1.0,5,20
CD006639,0,0,No new trials were identified for inclusion in this update.,delete,[],0,0.1111111111111111,1,9
CD006639,0,1,"We identified 12 trials for inclusion, 10 of which contributed outcomes data.",rephrase,"['We found 10 eligible studies, all conducted amongst young children.']",0,0.2222222222222222,2,9
CD006639,0,2,There were a total of 6820 participants.,rephrase,['The total number of participants was 6820.'],1,0.3333333333333333,2,9
CD006639,0,3,"In trials of healthy children living in low-income communities, two trials did not demonstrate a significant difference between the zinc-supplemented and placebo groups in the numbers of participants experiencing an episode of definite otitis media during follow-up (3191 participants); another trial showed a significantly lower incidence rate of otitis media in the zinc group (rate ratio 0.69, 95% confidence interval (CI) 0.61 to 0.79, n = 1621).",delete,[],2,0.4444444444444444,3,9
CD006639,0,4,"A small trial of 39 infants undergoing treatment for severe malnutrition suggested a benefit of zinc for the mean number of episodes of otitis media (mean difference (MD) -1.12 episodes, 95% CI -2.21 to -0.03).",delete,[],2,0.5555555555555556,3,9
CD006639,0,5,Zinc supplements did not seem to cause any serious adverse events but a small minority of children were reported to have vomited shortly after ingestion of the supplements.,rephrase,['The only adverse effect was vomiting.'],2,0.6666666666666666,4,9
CD006639,0,6,"The trial evidence included is generally of good quality, with a low risk of bias.",ignore,"['The trial evidence included is generally of good quality, with a low risk of bias.']",3,0.7777777777777778,4,9
CD006639,1,7,Evidence on whether zinc supplementation can reduce the incidence of otitis media in healthy children under the age of five years living in low- and middle-income countries is mixed.,rephrase,['The results of the trials provided no convincing evidence that zinc supplements reduce the occurrence of middle ear infections in healthy children.'],4,0.8888888888888888,5,9
CD006639,1,8,"There is some evidence of benefit in children being treated for marasmus (severe malnutrition), but this is based on one small trial and should therefore be treated with caution.",delete,[],5,1.0,5,9
CD011337,0,0,We included two small trials (involving a total of 99 pregnant women) that compared guided imagery with quiet rest.,split,"['Both trials compared guided imagery with quiet rest.', 'There were no trials comparing guided imagery with no intervention, or other with another non-pharmacological method for hypertension.']",0,0.058823529411764705,1,17
CD011337,0,1,The trials were conducted in Canada and the USA.,rephrase,['We searched for evidence (October 2018) and found two trials (involving 99 women) conducted in Canada and the USA.'],2,0.11764705882352941,1,17
CD011337,0,2,"We assessed both trials as at high risk of performance bias, and low risk of attrition bias; one trial was at low risk for selection, detection, and reporting bias, while the other was at unclear risk for the same domains.",delete,[],3,0.17647058823529413,1,17
CD011337,1,3,"We could not perform a meta-analysis because the two included studies reported different outcomes, and the frequency of the intervention was slightly different between the two studies.",rephrase,['The two included studies reported different outcomes and the Intervention frequency was slightly different between the two studies.'],3,0.23529411764705882,2,17
CD011337,1,4,"One study performed guided imagery for 15 minutes at least twice daily for four weeks, or until the baby was born (whichever came first).",ignore,['One study performed guided imagery for 15 minutes at least twice daily for four weeks or until the baby was born (whichever came first).'],4,0.29411764705882354,2,17
CD011337,1,5,"In the other study, the intervention included guided imagery, self-monitoring of blood pressure, and thermal biofeedback-assisted relaxation training for four total hours; the participants were instructed to practice the procedures twice daily and complete at least three relief relaxation breaks each day.",rephrase,"['The other study involved guided imagery, self-monitoring of blood pressure, and thermal biofeedback-assisted relaxation training for a total of four hours; the women were instructed to practice the procedures twice daily and complete at least three relaxation breaks each day.']",5,0.35294117647058826,2,17
CD011337,1,6,"The control groups were similar - one was quiet rest, and the other was quiet rest as bed rest.",rephrase,['The control groups between the two studies were similar - one used quiet rest and the other used quiet rest as bed rest.'],6,0.4117647058823529,3,17
CD011337,2,7,"None of our primary outcomes were reported in the included trials: severe hypertension (either systolic blood pressure of 160 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher); severe pre-eclampsia, or perinatal death (stillbirths plus deaths in the first week of life).",rephrase,"['Neither trial reported data for our main outcomes of interest: severe hypertension, severe pre-eclampsia, or death of the baby during birth or within the first week of life.']",7,0.47058823529411764,3,17
CD011337,2,8,Only one of the secondary outcomes was measured.,rephrase,['The trials provided data for only one of our secondary outcomes of interest.'],8,0.5294117647058824,3,17
CD011337,3,9,"Low-certainty evidence from one trial (69 women) suggests that guided imagery may make little or no difference in the use of antihypertensive drugs (risk ratio 1.27, 95% confidence interval 0.72 to 2.22).",rephrase,"['Low-certainty evidence from the one trial (69 women) suggests that, compared with quiet rest, guided imagery may make little or no difference in the use of antihypertensive drugs.']",9,0.5882352941176471,3,17
CD011337,4,10,There is insufficient evidence to inform practice about the use of guided imagery for hypertension in pregnancy.,ignore,['There is insufficient evidence to inform practice about using guided imagery for hypertension in pregnancy.'],10,0.6470588235294118,4,17
CD011337,5,11,"The available evidence for this review topic is sparse, and the effect of guided imagery for treating hypertension during pregnancy (compared with quiet rest) remains unclear.",ignore,['The available evidence for this review is sparse and the effect of guided imagery for treating hypertension during pregnancy (compared with quiet rest) remains unclear.'],11,0.7058823529411765,4,17
CD011337,5,12,"There was low-certainty evidence that guided imagery made little or no difference to the use of antihypertensive drugs, downgraded because of imprecision.",delete,[],12,0.7647058823529411,4,17
CD011337,6,13,The two included trials did not report on any of the primary outcomes of this review.,rephrase,['The included trials did not report on any of the main outcomes in this review and only provided low-certainty evidence on the uncertain effect on the use of antihypertensive drugs.'],12,0.8235294117647058,5,17
CD011337,6,14,"We did not identify any trials comparing guided imagery with no intervention, or with another non-pharmacological method for hypertension.",split,"['We included two small trials comparing guided imagery with quiet rest.', 'We did not identify any trials comparing guided imagery with no intervention, or another non-pharmacological treatment for hypertension.']",13,0.8823529411764706,5,17
CD011337,7,15,Large and well-designed RCTs are needed to identify the effects of guided imagery on hypertension during pregnancy and on other relevant outcomes associated with short-term and long-term maternal and neonatal health.,rephrase,['Large and well-designed studies are needed to identify the effects of guided imagery on hypertension during pregnancy and on other relevant outcomes associated with the short-term and long-term health of mothers and their babies.'],15,0.9411764705882353,5,17
CD011337,7,16,Trials could also consider utilisation and costs of health service.,rephrase,['The trials should also consider the use and costs of health services.'],16,1.0,5,17
CD007912,0,0,We considered that seven of the 10 included RCTs had a low risk of bias.,delete,[],0,0.0625,1,16
CD007912,0,1,"However, the results may be vulnerable to performance and detection bias as none of the RCTs were able to blind participants to treatment allocation and, while most RCTs reported blinded outcome assessment, pain, physical function and quality of life were participant self reported.",delete,[],0,0.125,1,16
CD007912,0,2,One of the 10 RCTs was only reported as a conference abstract and did not provide sufficient data for the evaluation of bias risk.,delete,[],0,0.1875,1,16
CD007912,1,3,"High-quality evidence from nine trials (549 participants) indicated that exercise reduced pain (standardised mean difference (SMD) -0.38, 95% confidence interval (CI) -0.55 to -0.20) and improved physical function (SMD -0.38, 95% CI -0.54 to -0.05) immediately after treatment.",rephrase,['Low-quality evidence indicated that exercise may not improve quality of life.'],0,0.25,2,16
CD007912,1,4,Pain and physical function were estimated to be 29 points on a 0- to 100-point scale (0 was no pain or loss of physical function) in the control group; exercise reduced pain by an equivalent of 8 points (95% CI 4 to 11 points; number needed to treat for an additional beneficial outcome (NNTB) 6) and improved physical function by an equivalent of 7 points (95% CI 1 to 12 points; NNTB 6).,rephrase,['Pain on a scale of 0 to 100 points (lower scores mean reduced pain):\n- People who completed an exercise programme rated their pain to be 8 points lower (4 to 11 points lower) at end of treatment (8% absolute improvement) compared with people who did not exercise.'],1,0.3125,2,16
CD007912,1,5,"Only three small studies (183 participants) evaluated quality of life, with overall low quality evidence, with no benefit of exercise demonstrated (SMD -0.07, 95% CI -0.23 to 0.36).",delete,[],2,0.375,2,16
CD007912,1,6,Quality of life was estimated to be 50 points on a norm-based mean (standard deviation (SD)) score of 50 (10) in the general population in the control group; exercise improved quality of life by 0 points.,rephrase,['- People who did not exercise rated their quality of life as 50 points on a population norm-based scale.'],2,0.4375,3,16
CD007912,1,7,"Moderate-quality evidence from seven trials (715 participants) indicated an increased likelihood of withdrawal from the exercise allocation (event rate 6%) compared with the control group (event rate 3%), but this difference was not significant (risk difference 1%; 95% CI -1% to 4%).",rephrase,['Moderate-quality evidence showed that exercise probably does not increase study drop-outs.'],3,0.5,3,16
CD007912,1,8,"Of the five studies reporting adverse events, each study reported only one or two events and all were related to increased pain attributed to the exercise programme.",delete,[],4,0.5625,3,16
CD007912,2,9,"The reduction in pain was sustained at least three to six months after ceasing monitored treatment (five RCTs, 391 participants): pain (SMD -0.38, 95% CI -0.58 to -0.18).",delete,[],4,0.625,4,16
CD007912,2,10,"Pain was estimated to be 29 points on a 0- to 100-point scale (0 was no pain) in the control group, the improvement in pain translated to a sustained reduction in pain intensity of 8 points (95% CI 4 to 12 points) compared with the control group (0 to 100 scale).",rephrase,['- People who did not exercise rated their pain as 29 points.'],4,0.6875,4,16
CD007912,2,11,"The improvement in physical function was also sustained (five RCTs, 367 participants): physical function (SMD -0.37, 95% CI -0.57 to -0.16).",delete,[],5,0.75,4,16
CD007912,2,12,"Physical function was estimated to be 24 points on a 0- to 100-point scale (0 was no loss of physical function) in the control group, the improvement translated to a mean of 7 points (95% CI 4 to 13) compared with the control group.",rephrase,['Physical function on a scale of 0 to 100 points (lower score means better physical function):\n- People who completed an exercise programme rated their physical function to be 7 points lower (1 to 12 points lower) at end of treatment (7% absolute improvement) compared with people who did not exercise.'],5,0.8125,5,16
CD007912,3,13,Only five of the 10 RCTs exclusively recruited people with symptomatic hip OA (419 participants).,rephrase,"['After searching for all relevant studies up to February 2013, we included five new studies since the last version of the review, giving 10 studies (549 participants) with mostly mild-to-moderate symptomatic hip OA, alone or with knee OA.']",6,0.875,5,16
CD007912,3,14,There was no significant difference in pain or physical function outcomes compared with five studies recruiting participants with hip or knee OA (130 participants).,delete,[],7,0.9375,5,16
CD007912,4,15,Pooling the results of these 10 RCTs demonstrated that land-based therapeutic exercise programmes can reduce pain and improve physical function among people with symptomatic hip OA.,rephrase,"['This review showed that there is high-quality evidence that in people with hip OA, exercise reduced pain slightly and improved physical function slightly.']",7,1.0,5,16
CD011194,0,0,"We identified 25 RCTs from 27 papers (with 8453 participants) studying the effect of PPIs versus placebo, H2RAs or prokinetics for improvement of global symptoms of dyspepsia and quality of life in people with FD.",rephrase,['We included 25 studies (with 8453 participants).'],0,0.08333333333333333,1,12
CD011194,0,1,"Low-dose PPIs had similar efficacy as standard-dose PPIs, therefore we combined these subgroups for the analysis.",rephrase,"['Low-dose and standard-dose PPIs were similarly effective on the relief of indigestion, so we combined the results of the two doses of PPI.']",1,0.16666666666666666,1,12
CD011194,0,2,"PPI was more effective than placebo at relieving overall dyspepsia symptoms in people with FD (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.82 to 0.94; participants = 6172; studies = 18; number needed to treat for an additional beneficial outcome (NNTB) 11; moderate quality evidence).",rephrase,"['PPI was more effective than placebo, with 31% of the PPI group reporting no or minimal symptoms compared with 26% of the placebo group.']",2,0.25,2,12
CD011194,0,3,"PPIs may have little or no effect compared with H2RAs (RR 0.88, 95% CI 0.74 to 1.04; participants = 740; studies = 2; low quality evidence), and may be slightly more effective than prokinetics (RR 0.89, 95% CI 0.81 to 0.99; participants = 1033; studies = 5; NNTB 16; low quality evidence) at relieving overall dyspepsia symptoms in people with FD.",rephrase,"['The effect of PPI was probably slightly more effective than H2RAs; however, the two studies involved in the analysis were so different that it may have influenced the results.']",3,0.3333333333333333,2,12
CD011194,0,4,"PPIs plus prokinetics have probably little or no effect compared with PPIs alone at relieving overall dyspepsia symptoms (RR 0.85, 95% CI 0.68 to 1.08; participants = 407; studies = 2; moderate quality evidence).",delete,[],4,0.4166666666666667,3,12
CD011194,1,5,"There was no difference when subgrouped by Helicobacter pylori status, country of origin, or presence of reflux or Rome III subtypes.",delete,[],4,0.5,3,12
CD011194,1,6,There were no differences in the number of adverse events observed between PPIs and any of the other treatments.,rephrase,"['There was no difference in the number of reported side effects when comparing PPIs, H2RAs and prokinetics.']",4,0.5833333333333334,3,12
CD011194,1,7,"There were fewer adverse events in the combination of PPI plus prokinetics compared to prokinetics alone (RR 0.60, 95% CI 0.39 to 0.93; participants = 407; studies = 2; moderate quality evidence).",delete,[],5,0.6666666666666666,4,12
CD011194,2,8,"There is evidence that PPIs are effective for the treatment of FD, independent of the dose and duration of treatment compared with placebo.",delete,[],5,0.75,4,12
CD011194,2,9,"PPIs may be slightly more effective than prokinetics for the treatment of FD; however, the evidence is scarce.",delete,[],5,0.8333333333333334,5,12
CD011194,2,10,The trials evaluating PPIs versus prokinetics are difficult to interpret as they are at risk of bias.,split,"['The studies evaluating the effect of PPIs compared to placebo or PPIs combined with prokinetics versus prokinetics were in general of good quality.', 'However, the studies that compared PPIs versus H2RAs and prokinetics had serious quality issues.']",5,0.9166666666666666,5,12
CD011194,2,11,"Although the effect of these drugs seems to be small, the drugs are well tolerated.",delete,[],7,1.0,5,12
CD013170,0,0,"The review included 11 studies involving 287 adults and children, aged three to 73 years.",rephrase,['We found 11 studies with 287 people and several cough augmentation techniques.'],0,0.125,1,8
CD013170,0,1,Inadequately reported cross-over studies and the limited additional information provided by authors severely restricted the number of analyses that could be performed.,delete,[],1,0.25,2,8
CD013170,1,2,"Studies compared manually assisted cough, mechanical insufflation, manual and mechanical breathstacking, mechanical insufflation-exsufflation, glossopharyngeal breathing, and combination techniques to unassisted cough and alternative or sham interventions.",delete,[],1,0.375,2,8
CD013170,1,3,None of the included studies reported on the primary outcomes of this review (number and duration of unscheduled hospital admissions) or listed 'adverse events' as primary or secondary outcome measures.,split,"['None of the studies reported on the outcomes we thought were the most important for making decisions about the effectiveness and safety of cough augmentation techniques.', 'For example, the studies did not report on the number or duration of unscheduled hospital admissions for chest infections, survival, functional ability, or quality of life.']",1,0.5,3,8
CD013170,2,4,"The evidence suggests that a range of cough augmentation techniques may increase peak cough flow compared to unassisted cough (199 participants, 8 RCTs), but the evidence is very uncertain.",merge,"['Some studies suggested that cough augmentation techniques may be better than an unassisted cough, but the results are very uncertain.']",3,0.625,4,8
CD013170,2,5,"There may be little to no difference in peak cough flow outcomes between alternative cough augmentation techniques (216 participants, 9 RCTs).",none,[],3,0.75,4,8
CD013170,3,6,"There was insufficient evidence to determine the effect of interventions on measures of gaseous exchange, pulmonary function, quality of life, general function, or participant preference and satisfaction.",delete,[],4,0.875,5,8
CD013170,4,7,We are very uncertain about the safety and efficacy of cough augmentation techniques in adults and children with chronic neuromuscular disorders and further studies are needed.,split,"['The findings of this review provided insufficient information to make decisions about when and how to use cough augmentation techniques in people with chronic neuromuscular disorders.', 'There is currently very low certainty evidence for or against the safety and effectiveness of cough augmentation techniques in people with chronic neuromuscular diseases and more studies are needed.']",4,1.0,5,8
CD005274,0,0,"We found 8 RCTs with 11,164 participants but one study did not provide enough data.",rephrase,"['We included eight studies with 11,164 participants but one study did not provide enough data to be useful.']",0,0.08333333333333333,1,12
CD005274,0,1,Studies compared VCT to no VCT and education to no intervention and to alternative education.,delete,[],1,0.16666666666666666,1,12
CD005274,1,2,VCT uptake increased to 51% when provided at the workplace compared to a voucher for VCT (RR=14.0 (95% CI 11.8 to16.7)).,rephrase,['One study from Africa found a strong increase in uptake of Voluntary Counseling and Testing (VCT) to 51% when delivered on-site which was 14 times more compared to a voucher for off-site testing.'],1,0.25,2,12
CD005274,1,3,"After VCT, self-reported STD decreased (RR = 0.10 (95% CI 0.01 to 0.73)) but HIV incidence (RR=1.4 (95% CI 0.7 to 2.7)) and unprotected sex (RR=0.71 (0.48 to 1.06)) did not decrease significantly.",rephrase,"['In another study among HongKong truck drivers, VCTdecreased self-reported sexually transmitted diseases (STD) but VCT did not decrease unprotected sex significantly.']",2,0.3333333333333333,2,12
CD005274,1,4,.,delete,[],3,0.4166666666666667,3,12
CD005274,2,5,"Education reduced STDs (RR = 0.68 (95%CI 0.48 to 0.96)), unprotected sex (Standardised Mean Difference (SMD)= -0.17 (95% CI -0.29 to -0.05), sex with a commercial sex worker (RR = 0.88 (95% CI 0.81 to 0.96) but not multiple sexual partners (Mean Difference (MD) = -0.22 (95% CI -0.52 to 0.08) nor use of alcohol before sex (MD = -0.01 (95% CI of -0.11 to 0.08).",rephrase,"['Education was studied among soldiers in Nigeria, Angola and the US, truck drivers in India and factory workers in Thailand.. Education that was modelled after a motivational theory reduced STDs with 32%, decreased unprotected sex with a small amount, reduced sex with a commercial sex worker with 12% but did not decrease the number of partners or the habit of using alcohol before sex.']",3,0.5,3,12
CD005274,3,6,Workplace interventions to prevent HIV are feasible.,rephrase,['We concluded that workplace interventions for preventing HIV are feasible and that it is possible to study them in a randomised controlled trial.'],4,0.5833333333333334,3,12
CD005274,3,7,There is moderate quality evidence that VCT offered at the work site increases the uptake of testing.,delete,[],5,0.6666666666666666,4,12
CD005274,3,8,"Even though this did no lower HIV-incidence, there was a decrease in self-reported sexual transmitted diseases and a decrease in risky sexual behaviour.",delete,[],5,0.75,4,12
CD005274,3,9,"There is low quality evidence that educational interventions decrease sexually transmitted diseases, unprotected sex and sex with commercial sex workers but not sex with multiple partners and the use of alcohol before sex.",delete,[],5,0.8333333333333334,5,12
CD005274,4,10,More and better randomised trials are needed directed at high risk groups such as truck drivers or workers in areas with a very high HIV prevalence such as Southern Africa.,rephrase,['More randomised trials are needed in high risk groups or in areas with high HIV prevalence to find more effective interventions.'],5,0.9166666666666666,5,12
CD005274,4,11,Risky sexual behaviour should be measured in a standardised way.,delete,[],6,1.0,5,12
CD014785,0,0,We included six studies reported in eight publications.,rephrase,['We included six studies.'],0,0.08333333333333333,1,12
CD014785,0,1,We grouped the findings according to intervention.,rephrase,"['We grouped the findings according to the type of intervention, which varied across studies.']",1,0.16666666666666666,1,12
CD014785,1,2,"Community-based growth monitoring and promotion (without supplementary feeding) versus standard care
We are unsure if GMP compared to standard care improves infant and child feeding practices, as measured at 24 months by the proportion of infants who have fluids other than breast milk introduced early (49.7% versus 70.5%; 1 study; 4296 observations; very low-certainty evidence).",rephrase,"['When looking at infant and child feeding practices at 24 months, we are unsure if GMP has any impact on the percentage of infants who had fluids other than breast milk introduced early (this was the case for 49.7% of infants in the GMP group and 70.5% of infants in the control group in one study).']",2,0.25,2,12
CD014785,1,3,"We are unsure if GMP improves health service usage, as measured at 24 months by the proportion of children who receive vitamin A (72.5% versus 62.9%; 1 study; 4296 observations; very low-certainty evidence) and the proportion of children who receive deworming (29.2% versus 14.6%; 1 study; 4296 observations; very low-certainty evidence).",rephrase,"['When looking at health service usage at 24 months, we are unsure if GMP has any impact on the percentage of children who receive vitamin A (72.5% of the GMP group and 62.9% of the control group in one study), or on the percentage of children who receive deworming (29.2% of the GMP group and 14.6% of the control group in one study).']",3,0.3333333333333333,2,12
CD014785,1,4,"No studies reported selected anthropometric indicators (weight-for-age z-score or height-for-age z-score) at 12 or 24 months, infant and child feeding practices at 12 months, or health service usage at 12 months.",rephrase,"['No studies reported child growth at 12 or 24 months, infant and child feeding practices at 12 months, or health service usage at 12 months.']",4,0.4166666666666667,3,12
CD014785,2,5,"Community-based growth monitoring and promotion (with supplementary feeding) versus standard care
Two studies (with 569 participants) reported the mean weight-for-age z-score at 12 months, providing very low-certainty evidence: in one study, there was little or no difference between GMP and standard care (mean difference (MD) −0.07, 95% confidence interval (CI) −0.19 to 0.06); in the other study, mean weight-for-age z-score worsened in both groups, but we were unable to calculate a relative effect.",delete,[],5,0.5,3,12
CD014785,2,6,"GMP versus standard care may make little to no difference to the mean height-for-age z-score at 12 months (MD −0.15, 95% CI −0.34 to 0.04; 1 study, 337 participants; low-certainty evidence).",rephrase,"['When looking at infant and child growth at 12 months, we are unsure if GMP makes any difference to average weight-for-age (one study), and GMP may make little or no difference to the average height-for-age (one study).']",5,0.5833333333333334,3,12
CD014785,2,7,"Two studies (with 564 participants) reported a range of outcome measures related to infant and child feeding practices at 12 months, showing little or no difference between the groups (very low-certainty evidence).",rephrase,"['Two studies reported a range of outcome measures related to infant and child feeding practices at 12 months, and we are unsure if GMP had any impact.']",6,0.6666666666666666,4,12
CD014785,2,8,"No studies reported health service usage at 12 or 24 months, feeding practices at 24 months, or selected anthropometric indicators at 24 months.",rephrase,"['No studies reported health service usage at 12 or 24 months, feeding practices at 24 months, or infant and child growth at 24 months.']",7,0.75,4,12
CD014785,3,9,"There is limited uncertain evidence on the effectiveness of GMP for identifying and addressing faltering growth, improving infant and child feeding practices, and promoting contact with and use of health services in children aged under five years in LMICs.",merge,['There is limited and uncertain evidence on the effectiveness of GMP.'],8,0.8333333333333334,5,12
CD014785,3,10,Future studies should explore the reasons for the apparent limited impact of GMP on key child health indicators.,none,[],8,0.9166666666666666,5,12
CD014785,3,11,Reporting of GMP interventions and important outcomes must be transparent and consistent.,delete,[],9,1.0,5,12
CD004704,0,0,Eleven campaigns met the inclusion criteria for this review.,delete,[],0,0.07692307692307693,1,13
CD004704,0,1,"Studies differed in design, settings, duration, content and intensity of intervention, length of follow-up, methods of evaluation and also in definitions and measures of smoking behaviour used.",rephrase,"['Studies differed in setting, duration, content of the intervention, length of observation, measures of smoking behaviour and the way of showing results.']",0,0.15384615384615385,1,13
CD004704,0,2,"Among seven campaigns reporting smoking prevalence, significant decreases were observed in the California and Massachusetts statewide tobacco control campaigns compared with the rest of the USA.",merge,"['Two campaigns reported definite decreases in smoking prevalence, and some positive effects were observed in another three.']",1,0.23076923076923078,2,13
CD004704,0,3,Some positive effects on prevalence in the whole population or in the subgroups were observed in three of the remaining seven studies.,none,[],1,0.3076923076923077,2,13
CD004704,0,4,Three large-scale campaigns of the seven presenting results for tobacco consumption found statistically significant decreases.,rephrase,['Three large-scale campaigns reported lower tobacco consumption.'],2,0.38461538461538464,2,13
CD004704,0,5,"Among the eight studies presenting abstinence or quit rates, four showed some positive effect, although in one of them the effect was measured for quitting and cutting down combined.",rephrase,['Three studies showed some positive effect in abstinence or quit rates.'],3,0.46153846153846156,3,13
CD004704,0,6,"Among the three that did not show significant decreases, one demonstrated a significant intervention effect on smokers and ex-smokers combined.",rephrase,['One study did not show significant decreases but did demonstrate an effect of the intervention on smokers and ex-smokers combined.'],4,0.5384615384615384,3,13
CD004704,1,7,"There is evidence that comprehensive tobacco control programmes which include mass media campaigns can be effective in changing smoking behaviour in adults, but the evidence comes from a heterogeneous group of studies of variable methodological quality.",rephrase,"['Tobacco control programmes that include mass media campaigns may change smoking behaviour in adults, but the evidence comes from studies of variable quality and scale and often occur in an environment where there are other influences on smoking, making it hard to isolate the effects of the media campaign itself.']",5,0.6153846153846154,4,13
CD004704,1,8,One state-wide tobacco control programme (Massachusetts) showed positive results up to eight years after the campaign.,delete,[],6,0.6923076923076923,4,13
CD004704,1,9,Another (California) showed positive results during the period of adequate funding and implementation and in final evaluation since the beginning of the programme.,delete,[],6,0.7692307692307693,4,13
CD004704,1,10,Six of nine studies carried out in communities or regions showed some positive effects on smoking behaviour and at least one significant change in smoking prevalence (Sydney).,delete,[],6,0.8461538461538461,5,13
CD004704,1,11,"The intensity and duration of mass media campaigns may influence effectiveness, but length of follow-up and concurrent secular trends and events can make this difficult to quantify.",delete,[],6,0.9230769230769231,5,13
CD004704,1,12,"No consistent relationship was observed between campaign effectiveness and age, education, ethnicity or gender.",rephrase,"['No consistent patterns by age, education, ethnicity or gender were found.']",6,1.0,5,13
CD003352,0,0,"Twenty four studies, including 2147 participants, met the inclusion criteria.",rephrase,"['We included 24 studies with 2147 participants, who were all addicted to cocaine.']",0,0.1111111111111111,1,9
CD003352,0,1,"Comparing any dopamine agonist versus placebo, we found no differences for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence).",merge,[],1,0.2222222222222222,2,9
CD003352,0,2,This was also observed when single dopamine agonists were compared against placebo.,none,['All compared dopamine agonist versus placebo.'],1,0.3333333333333333,2,9
CD003352,0,3,"Comparing amantadine versus antidepressants, we found low quality of evidence that antidepressants performed better for abstinence (RR 0.25, 95% CI 0.12 to 0.53) based on two studies with 44 participants.",rephrase,['Four studies compared amantidine versus antidepressants.'],2,0.4444444444444444,3,9
CD003352,0,4,"No differences were found for dropout or adverse events, for both moderate quality of evidence.",rephrase,"['No differences were found between the drugs and placebo for any of the outcomes considered: dropout (moderate quality of evidence), abstinence (low quality of evidence), severity of dependence (low quality of evidence), adverse events (moderate quality of evidence).']",3,0.5555555555555556,3,9
CD003352,1,5,The major flaws of the included studies concerned selection bias because most studies did not report information about sequence generation (80%) and allocation concealment methods (86%): half of the included studies were judged at unclear risk of performance bias and 62.5% at unclear risk of detection bias for what concerns subjective outcomes.,delete,[],4,0.6666666666666666,4,9
CD003352,2,6,Current evidence from RCTs does not support the use of dopamine agonists for treating cocaine misuse.,rephrase,['There is no current evidence supporting the clinical use of dopamine agonist medications in the treatment of cocaine misuse.'],4,0.7777777777777778,4,9
CD003352,2,7,This absence of evidence may leave to clinicians the alternative of balancing the possible benefits against the potential adverse effects of the treatment.,delete,[],5,0.8888888888888888,5,9
CD003352,2,8,"Even the potential benefit of combining a dopamine agonist with a more potent psychosocial intervention, which was suggested by the previous Cochrane Review (Soares 2003), is not supported by the results of this Cochrane Review update.",delete,[],5,1.0,5,9
CD008533,0,0,We identified two trials (of high risk of bias) involving 152 patients randomised to gastrojejunostomy (80 patients) and no gastrojejunostomy (72 patients).,rephrase,['We identified two trials (of high risk of bias or systematic error) involving 152 patients randomised to gastrojejunostomy (80) and no gastrojejunostomy (72).'],0,0.14285714285714285,1,7
CD008533,0,1,"In both trials, patients were found to be unresectable during exploratory laparotomy.",rephrase,"['In both studies, patients were found to be unresectable during operations aimed at surgical removal i.e. the stomach was opened to remove the cancer but the cancer could not be removed.']",1,0.2857142857142857,2,7
CD008533,0,2,Most of the patients also underwent biliary-enteric drainage.,delete,[],2,0.42857142857142855,3,7
CD008533,0,3,"There was no evidence of difference in the overall survival (HR 1.02; 95% CI 0.84 to 1.25), peri-operative mortality or morbidity, quality of life, or hospital stay (MD 0.97 days; 95%CI -0.18 to 2.12) between the two groups.",rephrase,"['There was no evidence of any difference in the overall survival, surgical complications, quality of life, or hospital stay between the two groups.']",2,0.5714285714285714,3,7
CD008533,0,4,The proportion of patients who developed long-term gastric outlet obstruction was significantly lower in the prophylactic gastrojejunostomy group (2/80; 2.5%) compared with no gastrojejunostomy group (20/72; 27.8%) (RR 0.10; 95%CI 0.03 to 0.37).,rephrase,['The proportion of patients who developed long-term stomach outflow obstruction was significantly lower in the prophylactic gastrojejunostomy group (2.5%) compared with no gastrojejunostomy group (27.8%).'],3,0.7142857142857143,4,7
CD008533,0,5,The operating time was significantly longer in the gastrojejunostomy group compared with no gastrojejunostomy group (MD 45.00 minutes; 95%CI 21.39 to 68.61).,rephrase,['The operating time was significantly longer in the gastrojejunostomy group compared with no gastrojejunostomy group by about 45 minutes.'],4,0.8571428571428571,5,7
CD008533,1,6,Routine prophylactic gastrojejunostomy is indicated in patients with unresectable periampullary cancer undergoing exploratory laparotomy (with or without hepaticojejunostomy).,split,"['Routine prophylactic gastrojejunostomy is indicated in patients with unresectable periampullary cancer undergoing open operation of the stomach.', 'There is no information available currently about the necessity for prophylactic gastrojejunostomy in patients with periampullary cancer diagnosed to be unresectable by investigations such as scans.', 'Further trials of low risk of bias are necessary to assess the role of prophylactic gastrojejunostomy in patients with unresectable periampullary cancer.']",5,1.0,5,7
CD002964,0,0,"We included eight studies with 513 participants, providing a total of 47 comparisons of outcome between intervention and control conditions.",rephrase,"['The findings are based on eight studies measuring a variety of outcomes, using a range of standardised measures.']",0,0.14285714285714285,1,7
CD002964,0,1,"Nineteen comparisons were statistically significant, all favouring the intervention group.",delete,[],1,0.2857142857142857,2,7
CD002964,0,2,We conducted nine meta-analyses using data from four studies in total (each meta-analysis included data from two studies).,rephrase,['It was possible to combine results (meta-analysis) for nine comparisons.'],1,0.42857142857142855,3,7
CD002964,0,3,"Four meta-analyses showed statistically significant findings favouring the intervention group for the following outcomes: parent responsiveness to the child post-intervention (SMD -0.91, 95% CI -1.52 to -0.30, P = 0.04); infant responsiveness to mother at follow-up (SMD -0.65, 95% CI -1.25 to -0.06, P = 0.03); and an overall measure of parent-child interactions post-intervention (SMD -0.71, 95% CI -1.31 to -0.11, P = 0.02), and at follow-up (SMD -0.90, 95% CI -1.51 to -0.30, P = 0.004).",split,"['Results from four of these meta-analyses suggest that parenting programmes may be effective in improving parent responsiveness to the child, and parent-child interaction, both post-intervention and at follow-up.', 'Infant responsiveness to the mother also showed improvement at follow-up.']",2,0.5714285714285714,3,7
CD002964,0,4,The results of the remaining five meta-analyses were inconclusive.,rephrase,['The results of the other five meta-analyses we carried out were inconclusive.'],4,0.7142857142857143,4,7
CD002964,1,5,"Variation in the measures used, the included populations and interventions, and the risk of bias within the included studies limit the conclusions that can be reached.",delete,[],5,0.8571428571428571,5,7
CD002964,1,6,"The findings provide some evidence to suggest that parenting programmes may be effective in improving a number of aspects of parent-child interaction both in the short- and long-term, but further research is now needed.",rephrase,"['Further rigorous research is needed that provides both short- and long-term follow-up of the children of teenage parents, and that assesses the benefits of parenting programmes for young fathers as well as young mothers.']",5,1.0,5,7
CD006522,0,0,"Nine small trials involving 510 adults with potentially or evidently unstable fractures, were grouped into five comparisons.",ignore,"['Nine small randomised trials involving 510 adults with potentially or evidently unstable fractures, were grouped into five comparisons.']",0,0.06666666666666667,1,15
CD006522,0,1,"The interventional, clinical and methodological heterogeneity of trials precluded data pooling.",rephrase,['The trials were too different to justify pooling of results.'],1,0.13333333333333333,1,15
CD006522,0,2,Only one trial had secure allocation concealment.,rephrase,['Only one trial used a best-practice method for preventing selection bias.'],2,0.2,1,15
CD006522,1,3,Two trials comparing a bridging (of the wrist) external fixator versus pins and plaster external fixation found no significant differences in function or deformity.,ignore,['Two trials comparing a bridging (of the wrist) external fixator versus pins and plaster external fixation found no statistically significant differences in function or deformity.'],3,0.26666666666666666,2,15
CD006522,1,4,One trial found tendencies for more serious complications but less subsequent discomfort and deformity in the fixator group.,ignore,['One trial found tendencies for more serious complications but less subsequent discomfort and deformity in the fixator group.'],4,0.3333333333333333,2,15
CD006522,2,5,Three trials compared non-bridging versus bridging fixation.,rephrase,"['Three trials compared non-bridging versus bridging fixation, using external fixators.']",5,0.4,2,15
CD006522,2,6,"Of the two trials testing uni-planar non-bridging fixation, one found no significant differences in functional or clinical outcomes; the other found non-bridging fixation significantly improved grip strength, wrist flexion and anatomical outcome.",ignore,"['Two trials tested similar non-bridging fixators: one found no significant differences in functional or clinical outcomes, whereas the other found non-bridging fixation significantly improved grip strength, wrist flexion and anatomical outcome.']",6,0.4666666666666667,3,15
CD006522,2,7,The third trial found no significant findings in favour of multi-planar non-bridging fixation of complex intra-articular fractures.,ignore,['The third trial found no significant findings in favour of multi-planar non-bridging fixation of complex fractures.'],7,0.5333333333333333,3,15
CD006522,3,8,One trial using a bridging external fixator found that deploying an extra external fixator pin to fix the 'floating' distal fragment gave superior functional and anatomical results.,rephrase,['One trial using a bridging external fixator found that fixing the distal fracture fragment with an extra external fixator pin gave superior functional and anatomical results.'],8,0.6,3,15
CD006522,4,9,One trial found no evidence of differences in clinical outcomes for hydroxyapatite coated pins compared with standard uncoated pins.,ignore,['One trial found no evidence of differences in clinical outcomes for hydroxyapatite coated pins compared with standard uncoated pins.'],9,0.6666666666666666,4,15
CD006522,5,10,Two trials compared dynamic versus static external fixation.,ignore,['Two trials compared dynamic versus static external fixation.'],10,0.7333333333333333,4,15
CD006522,5,11,One trial found no significant effects from early dynamism of an external fixator.,ignore,"[""One trial found no significant effects from the early 'dynamism' of an external fixator.""]",11,0.8,4,15
CD006522,5,12,The poor quality of the other trial undermines its findings of poorer functional and anatomical outcomes for dynamic fixation.,rephrase,['The poor quality of the other trial undermines its findings of poorer results for dynamic fixation.'],12,0.8666666666666667,5,15
CD006522,6,13,There is insufficient robust evidence to determine the relative effects of different methods of external fixation.,rephrase,['The review concluded that there is insufficient robust evidence to determine the relative effects of the different methods of external fixation.'],13,0.9333333333333333,5,15
CD006522,6,14,Adequately powered studies could provide better evidence.,delete,[],14,1.0,5,15
CD013733,0,0,"We included two studies in our review, with 628 participants aged five to 41 years.",rephrase,['The larger study involved 608 people aged 16 years and older.'],0,0.05555555555555555,1,18
CD013733,0,1,There was one study each for two different comparisons.,delete,[],1,0.1111111111111111,1,18
CD013733,1,2,"Nebuliser target inhalation mode versus standard inhalation mode
The included parallel study was carried out over 10 weeks after a run-in period of four to six weeks.",delete,[],1,0.16666666666666666,1,18
CD013733,1,3,The study compared the effects of a digitally enhanced inhalation mode (target inhalation mode) for nebulised antibiotics compared to standard mode in children attending a regional CF clinic in the United Kingdom.,rephrase,['One small study compared two breathing modes of a digital\xa0nebuliser in 20 children aged 5 to 16 years (the nebuliser delivered an antibiotic as an inhaled mist).'],1,0.2222222222222222,2,18
CD013733,1,4,"The study's primary outcome was the time taken to complete the inhaled treatment, but investigators also reported on adherence to therapy.",delete,[],2,0.2777777777777778,2,18
CD013733,1,5,"The results showed that there may be an improvement in adherence with the target inhalation mode when this intervention is used (mean difference (MD) 24.0%, 95% confidence interval (CI) 2.95 to 45.05; low-certainty evidence).",delete,[],2,0.3333333333333333,2,18
CD013733,1,6,"The target inhalation mode may make little or no difference to forced expiratory volume in one second (FEV1) % predicted (MD 1.00 % predicted, 95% CI -9.37 to 11.37; low-certainty evidence).",delete,[],2,0.3888888888888889,2,18
CD013733,1,7,"The study did not report on treatment burden, quality of life (QoL) or pulmonary exacerbations.",delete,[],2,0.4444444444444444,3,18
CD013733,2,8,"eNebuliser with digital support versus eNebuliser without support
One large multicentre RCT monitored adherence via data-tracking nebulisers.",delete,[],2,0.5,3,18
CD013733,2,9,"The intervention group also receiving access to an online web-based platform, CFHealthHub, which offered tailored, flexible support from the study interventionist as well as access to their adherence data, educational and problem-solving information throughout the 12-month trial period.",rephrase,"['CFHealthHub gave participants access to their adherence data and individual support from study investigators, who collected data for 12 months.']",2,0.5555555555555556,3,18
CD013733,2,10,We graded all evidence as moderate certainty.,rephrase,"['We summarised the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes.']",3,0.6111111111111112,4,18
CD013733,2,11,"Compared to usual care, the digital intervention probably improves adherence to inhaled therapy (MD 18%, 95% CI 12.90 to 23.10); probably leads to slightly reduced treatment burden (MD 5.1, 95% CI 1.79 to 8.41); and may lead to slightly improved FEV1 % predicted (MD 3.70, 95% CI -0.23 to 7.63).",delete,[],4,0.6666666666666666,4,18
CD013733,2,12,There is probably little or no difference in the incidence of pulmonary exacerbations or QoL between the two groups.,rephrase,"['However, it probably makes little or no difference to quality of life or the number of flare-ups of disease.']",4,0.7222222222222222,4,18
CD013733,3,13,Digital monitoring plus tailored support via an online platform probably improves adherence to inhaled therapies and reduces treatment burden (but without a corresponding change in QoL) in the medium term (low- and moderate-certainty evidence).,rephrase,"[""The combination of nebuliser plus online support also probably lowers the 'burden of treatment'.""]",5,0.7777777777777778,4,18
CD013733,3,14,"In a shorter time frame, technological enhancement of inhaling antibiotics may improve adherence to treatment (low-certainty evidence).",rephrase,['Current evidence for how digital technology can improve adherence to inhaled treatments is limited.'],6,0.8333333333333334,5,18
CD013733,3,15,"There may be little or no effect on lung function with either intervention, and online monitoring probably makes no difference to pulmonary exacerbations.",rephrase,"['However, this may make little difference to lung function.']",7,0.8888888888888888,5,18
CD013733,4,16,Future research should assess the effect of digital technology on adherence in both children and adults.,merge,['Future research should assess how technology can improve adherence to inhaled treatments in children and adults and consider how this affects the total treatment plan (adhering to inhaled treatments may decrease time spent on other treatments).'],8,0.9444444444444444,5,18
CD013733,4,17,"Consideration of adherence to the total treatment regimen is also important, as an improvement in adherence to inhaled therapies could come at the cost of adherence to other parts of the treatment regimen.",none,[],8,1.0,5,18
CD006811,0,0,We included one RCT with 41 participants.,rephrase,['We found only one small study with 41 people who had recently been admitted to the intensive care unit after a traumatic head injury.'],0,0.06666666666666667,1,15
CD006811,0,1,"This study recruited adult participants admitted to two intensive care units in Australia, and evaluated a pharmacological intervention.",delete,[],1,0.13333333333333333,1,15
CD006811,0,2,Researchers gave participants 1 g paracetamol or a placebo intravenously at four-hourly intervals for 72 hours.,rephrase,"['This study assessed the effects of paracetamol, given intravenously (through a needle or tube inserted into a vein) for 72 hours, compared to an intravenous salt solution that was disguised to look like the paracetamol solution.']",1,0.2,1,15
CD006811,1,3,"We could not be certain whether intravenous paracetamol influenced mortality at 28 days (risk ratio 2.86, 95% confidence interval 0.32 to 25.24).",rephrase,['We were not sure whether paracetamol affected the number of people who died within 28 days of injury.'],2,0.26666666666666666,2,15
CD006811,1,4,"We judged the evidence for this outcome to be very low certainty, meaning we have very little confidence in this effect estimate, and the true result may be substantially different to this effect.",split,"['We judged the evidence for death to be very low certainty.', 'This means we are not very confident about the key results in this review.']",3,0.3333333333333333,2,15
CD006811,1,5,"We downgraded the certainty for imprecision (because the evidence was from a single study with very few participants), and study limitations (because we noted a high risk of selective reporting bias).",delete,[],5,0.4,2,15
CD006811,1,6,This study was otherwise at low risk of bias.,rephrase,"['Although the study that provided the data generally appeared to use good methods, we judged it to have a high risk of bias because the study authors did not record in advance that they planned to report on the number of people who died, even though they had shared their study plans before they started the study.']",5,0.4666666666666667,3,15
CD006811,2,7,"The included study did not report the primary outcome for this review, which was the number of people with a poor outcome at the end of follow-up (defined as death or dependency, as measured on a scale such as the Glasgow Outcome Score), or any of our secondary outcomes, which included the number of people with further intracranial haemorrhage, extracranial haemorrhage, abnormal intracranial pressure, or pneumonia or other serious infections.",rephrase,"['This study did not report information on the outcomes of interest to us, which included: whether people had a poor outcome (defined as death or dependency); additional serious bleeding inside the brain; bleeding of the head outside the brain; increased pressure within the skull (intracranial pressure); pneumonia or other serious infections.']",6,0.5333333333333333,3,15
CD006811,3,8,The only other completed trial that we found was of a physical intervention that compared advanced fever control (using a surface cooling device) versus conventional fever control in 12 participants.,rephrase,['We found a short report about one very small study of a physical cooling treatment.'],7,0.6,3,15
CD006811,3,9,"The trial was published as an abstract only, with insufficient details to allow inclusion, so we have added this to the 'studies awaiting classification' section, pending further information from the study authors or publication of the full study report.",delete,[],8,0.6666666666666666,4,15
CD006811,4,10,"We identified four ongoing studies that will contribute evidence to future updates of the review if they measure relevant outcomes and, in studies with a mixed population, report data separately for participants with TBI.",rephrase,"['We also found four ongoing studies, which may provide more evidence for the review once they have completed.']",8,0.7333333333333333,4,15
CD006811,5,11,One small study contributed very low-certainty evidence for mortality to this review.,delete,[],9,0.8,4,15
CD006811,5,12,The uncertainty is largely driven by limited research into reduction of body temperature to 35 °C to 37.5 °C in people with TBI.,rephrase,"['We are uncertain of the effects of medicines and other physical cooling treatments to reduce body temperature to 35 °C to 37.5 °C, when given to people in hospital after a traumatic head injury.']",9,0.8666666666666667,5,15
CD006811,5,13,"Further research that evaluates pharmacological or physical interventions, or both, may increase certainty in this field.",delete,[],10,0.9333333333333333,5,15
CD006811,5,14,"We propose that future updates of the review, and ongoing and future research in this field, incorporate outcomes that are important to the people receiving the interventions, including side effects of any pharmacological agent (e.g. nausea or vomiting), and discomfort caused by physical therapies.",rephrase,"['In future updates, we will assess the side effects of treatments, such as nausea and vomiting, or discomfort, and we hope that ongoing and future studies will also look at these important outcomes.']",10,1.0,5,15
CD009878,0,0,"Among 22 eligible trials, 17 pairs of groups comparisons were derived from 10 trials (3394 children with mild to moderate asthma), measured growth and contributed data to the meta-analysis.",split,"['We found 22 eligible trials, but only 10 of them measured growth or other measures of interest.', 'Overall, 3394 children included in the review combined 17 group comparisons (i.e. 17 pairs of groups of children with mild to moderate asthma using a particular dose and type of steroid in 10 trials).']",0,0.08333333333333333,1,12
CD009878,0,1,"Trials used ICS (beclomethasone, budesonide, ciclesonide, fluticasone or mometasone) as monotherapy or as combination therapy with a long-acting beta2-agonist and generally compared low (50 to 100 μg) versus low to medium (200 μg) doses of hydrofluoroalkane (HFA)-beclomethasone equivalent over 12 to 52 weeks.",rephrase,"['Trials used different ICS molecules (beclomethasone, budesonide, ciclesonide, fluticasone or mometasone) either on their own or in combination with a long-acting beta2-agonist (a drug used to open up the airways) and generally compared low doses of corticosteroids (50 to 100 μg) with low to medium (200 μg) doses of corticosteroids (converted in μg HFA-beclomethasone equivalent) over 12 to 52 weeks.']",2,0.16666666666666666,1,12
CD009878,0,2,"In the four comparisons reporting linear growth over 12 months, a significant group difference was observed, clearly indicating lower growth velocity in the higher ICS dose group of 5.74 cm/y compared with 5.94 cm/y on lower-dose ICS (N = 728 school-aged children; mean difference (MD)0.20 cm/y, 95% confidence interval (CI) 0.02 to 0.39; high-quality evidence): No statistically significant heterogeneity was noted between trials contributing data.",rephrase,['We found a small but statistically significant group difference in growth over 12 months between these different doses clearly favouring the lower dose of ICS.'],3,0.25,2,12
CD009878,0,3,"The ICS molecules (ciclesonide, fluticasone, mometasone) used in these four comparisons did not significantly influence the magnitude of effect (X2 = 2.19 (2 df), P value 0.33).",rephrase,"['The type of corticosteroid among newer molecules (ciclesonide, fluticasone, mometasone) did not seem to influence the impact on growth over one year.']",4,0.3333333333333333,2,12
CD009878,0,4,"Subgroup analyses on age, baseline severity of airway obstruction, ICS dose and concomitant use of non-steroidal antiasthmatic drugs were not performed because of similarity across trials or inadequate reporting.",delete,[],5,0.4166666666666667,3,12
CD009878,0,5,"A statistically significant group difference was noted in unadjusted change in height from zero to three months (nine comparisons; N = 944 children; MD 0.15, 95% CI -0.28 to -0.02; moderate-quality evidence) in favour of a higher ICS dose.",delete,[],5,0.5,3,12
CD009878,0,6,"No statistically significant group differences in change in height were observed at other time points, nor were such differences in weight, body mass index and skeletal maturation reported with low quality of evidence due to imprecision.",delete,[],5,0.5833333333333334,3,12
CD009878,1,7,"In prepubescent school-aged children with mild to moderate persistent asthma, a small but statistically significant group difference in growth velocity was observed between low doses of ICS and low to medium doses of HFA-beclomethasone equivalent, favouring the use of low-dose ICS.",rephrase,['We report an ICS dose–dependent reduction in growth velocity in prepubescent school-aged children with mild to moderate persistent asthma.'],5,0.6666666666666666,4,12
CD009878,1,8,"No apparent difference in the magnitude of effect was associated with three molecules reporting one-year growth velocity, namely, mometasone, ciclesonide and fluticasone.",rephrase,"['The choice of ICS molecule (mometasone, ciclesonide or fluticasone) was not found to affect the level of growth velocity response over a year.']",6,0.75,4,12
CD009878,1,9,"In view of prevailing parents’ and physicians’ concerns about the growth suppressive effect of ICS, lack of or incomplete reporting of growth velocity in more than 86% (19/22) of eligible paediatric trials, including those using beclomethasone and budesonide, is a matter of concern.",rephrase,"[""In view of parents' and clinicians' concerns, lack of or incomplete reporting of growth is a matter of concern given the importance of the topic.""]",7,0.8333333333333334,5,12
CD009878,1,10,All future paediatric trials comparing different doses of ICS with or without placebo should systematically document growth.,rephrase,['We recommend that growth be systematically reported in all trials involving children taking ICS for three months or longer.'],8,0.9166666666666666,5,12
CD009878,1,11,Findings support use of the minimal effective ICS dose in children with asthma.,rephrase,"['Until further data comparing low versus high ICS dose and trials of longer duration are available, we recommend that the minimal effective ICS dose be used in all children with asthma.']",9,1.0,5,12
CD011548,0,0,Five studies including 523 participants reported the diagnostic accuracy of ultrasound.,rephrase,['We identified five studies including 523 participants that reported the diagnostic test accuracy of ultrasound.'],0,0.05263157894736842,1,19
CD011548,0,1,"One studies (262 participants) compared the accuracy of ultrasound, serum bilirubin and serum alkaline phosphatase in the same participants.",rephrase,"['One of these studies, involving 262 participants, also reported the diagnostic test accuracy of serum bilirubin and serum alkaline phosphatase.']",1,0.10526315789473684,1,19
CD011548,0,2,All the studies included people with symptoms.,ignore,['All the studies included people with symptoms.'],2,0.15789473684210525,1,19
CD011548,0,3,One study included only participants without previous cholecystectomy but this information was not available from the remaining studies.,split,"['One study included only participants who had not undergone previous cholecystectomy (removal of gallbladder).', 'This information was not available from the remaining studies.']",3,0.21052631578947367,2,19
CD011548,0,4,All the studies were of poor methodological quality.,rephrase,"['All the studies were of low methodological quality, which may undermine the validity of our findings.']",5,0.2631578947368421,2,19
CD011548,0,5,"The sensitivities for ultrasound ranged from 0.32 to 1.00, and the specificities ranged from 0.77 to 0.97.",delete,[],6,0.3157894736842105,2,19
CD011548,0,6,The summary sensitivity was 0.73 (95% CI 0.44 to 0.90) and the specificity was 0.91 (95% CI 0.84 to 0.95).,delete,[],6,0.3684210526315789,2,19
CD011548,0,7,"At the median pre-test probability of common bile duct stones of 0.408, the post-test probability (95% CI) associated with positive ultrasound tests was 0.85 (95% CI 0.75 to 0.91), and negative ultrasound tests was 0.17 (95% CI 0.08 to 0.33).",delete,[],6,0.42105263157894735,3,19
CD011548,1,8,The single study of liver function tests reported diagnostic accuracy at two cut-offs for bilirubin (greater than 22.23 μmol/L and greater than twice the normal limit) and two cut-offs for alkaline phosphatase (greater than 125 IU/L and greater than twice the normal limit).,rephrase,['Evidence from one study suggested that using a level of serum alkaline phosphatase higher than 125 units to distinguish between people who have and people who do not have common bile duct stones gave better diagnostic accuracy than using a level twice the normal limit (which usually ranges between 0 and 40).'],6,0.47368421052631576,3,19
CD011548,1,9,This study also assessed ultrasound and reported higher sensitivities for bilirubin and alkaline phosphatase at both cut-offs but the specificities of the markers were higher at only the greater than twice the normal limit cut-off.,rephrase,['The study also showed better accuracy for serum alkaline phosphatase compared to serum bilirubin.'],7,0.5263157894736842,3,19
CD011548,1,10,"The sensitivity for ultrasound was 0.32 (95% CI 0.15 to 0.54), bilirubin (cut-off greater than 22.23 μmol/L) was 0.84 (95% CI 0.64 to 0.95), and alkaline phosphatase (cut-off greater than 125 IU/L) was 0.92 (95% CI 0.74 to 0.99).",rephrase,"['The sensitivity of serum alkaline phosphatase at the 125 units cut-off was 92%, which means that 92 out of 100 people with common bile duct stones would be detected but 8 out of 100 people will be missed.']",8,0.5789473684210527,3,19
CD011548,1,11,"The specificity for ultrasound was 0.95 (95% CI 0.91 to 0.97), bilirubin (cut-off greater than 22.23 μmol/L) was 0.91 (95% CI 0.86 to 0.94), and alkaline phosphatase (cut-off greater than 125 IU/L) was 0.79 (95% CI 0.74 to 0.84).",rephrase,"['Based on an average specificity of 91% for ultrasound, we would expect that on average 91 out of 100 people without common bile duct stones would be identified as not having common bile duct stones; 9 out of 100 would be false positives and not receive appropriate treatment.']",9,0.631578947368421,4,19
CD011548,1,12,"No study reported the diagnostic accuracy of a combination of bilirubin and alkaline phosphatase, or combinations with ultrasound.",delete,[],10,0.6842105263157895,4,19
CD011548,2,13,Many people may have common bile duct stones in spite of having a negative ultrasound or liver function test.,rephrase,['The average number of people with common bile duct stones detected using ultrasound may vary between 44 and 90 out of 100 people.'],10,0.7368421052631579,4,19
CD011548,2,14,Such people may have to be re-tested with other modalities if the clinical suspicion of common bile duct stones is very high because of their symptoms.,delete,[],11,0.7894736842105263,4,19
CD011548,2,15,False-positive results are also possible and further non-invasive testing is recommended to confirm common bile duct stones to avoid the risks of invasive testing.,delete,[],11,0.8421052631578947,5,19
CD011548,3,16,It should be noted that these results were based on few studies of poor methodological quality and the results for ultrasound varied considerably between studies.,delete,[],11,0.8947368421052632,5,19
CD011548,3,17,"Therefore, the results should be interpreted with caution.",delete,[],11,0.9473684210526315,5,19
CD011548,3,18,Further studies of high methodological quality are necessary to determine the diagnostic accuracy of ultrasound and liver function tests.,delete,[],11,1.0,5,19
CD010052,0,0,"We included 16 randomized controlled trials of dihydropyridine calcium channel blockers in this systematic review, with 2768 randomized participants.",merge,"['We found 16 trials involving 2768 participants that studied five drugs given once a day (amlodipine, lercanidipine, mandipine, nifedipine, and felodipine) and one drug given twice a day (nicardipine).']",0,0.1,1,10
CD010052,0,1,"Drugs studied included amlodipine, lercanidipine, mandipine, nifedipine, and felodipine (all administered once daily) and nicardipine (administered twice daily).",none,[],0,0.2,1,10
CD010052,0,2,We analyzed and presented data by hour post dose.,delete,[],1,0.3,2,10
CD010052,0,3,The blood pressure-lowering effect was stable over time; there were no clinically important differences in blood pressure-lowering effect of calcium channel blockers between each hour for either systolic blood pressure (estimated mean hourly differences ranged between 9.45 mmHg and 13.2 mmHg) or diastolic blood pressure (estimated mean hourly differences ranged between 5.85 mmHg and 8.5 mmHg).,rephrase,['The average hourly differences in blood pressure were between 9.45 mmHg and 13.2 mmHg for systolic blood pressure and between 5.85 mmHg and 8.5 mmHg for diastolic blood pressure.'],1,0.4,2,10
CD010052,0,4,"However, there was a moderate risk of bias for this finding.",delete,[],2,0.5,3,10
CD010052,0,5,Once-daily dihydropyridine calcium channel blockers appeared to lower blood pressure by a relatively constant amount throughout the 24-hour dosing interval.,rephrase,['The amount of blood pressure lowering by dihydropyridine calcium channel blockers stayed relatively the same at every hour throughout a 24-hour day.'],2,0.6,3,10
CD010052,1,6,Six dihydropyridine calcium channel blockers studied in this review lowered blood pressure by a relatively similar amount each hour over the course of 24 hours.,split,"['This review explores whether the blood pressure lowering effect of dihydropyridine calcium channel blockers in adults (aged 18 years or over) with high blood pressure (systolic blood pressure (the upper blood pressure reading) of at least 140 mmHg or diastolic blood pressure (the lower blood pressure reading) of at least 90 mmHg, or both of these) is consistent or variable over a 24-hour period.', 'We performed a review of studies that compared the 24-hour blood pressure lowering effects of six of these drugs versus a control treatment for at least three weeks.']",3,0.7,4,10
CD010052,1,7,The benefits and harms of this pattern of blood pressure lowering are unknown.,rephrase,"['At the present time, the benefits and harms of this pattern of blood pressure lowering are unknown.']",5,0.8,4,10
CD010052,1,8,Further trials are needed with accurate recording of time of drug intake and with reporting of standard deviation of blood pressure at each hour.,delete,[],6,0.9,5,10
CD010052,1,9,We did not attempt to assess adverse effects in this review due to the lack of reporting and the short duration of follow-up.,delete,[],6,1.0,5,10
CD009917,0,0,We identified two studies with a total of 100 participants for inclusion in the review.,rephrase,['We found two studies that met our inclusion criteria.'],0,0.07142857142857142,1,14
CD009917,0,1,We found the overall risk of bias to be unclear in a number of domains.,delete,[],1,0.14285714285714285,1,14
CD009917,0,2,Neither study reported the time taken to the ﬁrst INR in range.,split,"['In this review, our primary outcomes were to assess if the addition of low-dose vitamin K to warfarin had an effect on the time taken to the ﬁrst INR in range; the mean within the therapeutic range; or any adverse events, such as thromboembolic events, haemorrhage, or mortality.', 'Neither study reported the time taken to the ﬁrst INR in range.']",1,0.21428571428571427,2,14
CD009917,0,3,Only one study (70 participants) reported the mean time in therapeutic range as a percentage.,merge,[],3,0.2857142857142857,2,14
CD009917,0,4,"This study found that in the group of participants deemed to have poor INR control, the addition of 150 micrograms (mcg) oral vitamin K significantly improved anticoagulation control in those with unexplained instability of response to warfarin.",none,"['This study reported the mean time in therapeutic range as a percentage and found that in the group of participants deemed to have poor INR control, the addition of 150 mcg oral vitamin K significantly improved their anticoagulation control.']",3,0.35714285714285715,2,14
CD009917,0,5,The second study (30 participants) reported the effect of 175 mcg oral vitamin K versus placebo on participants with high variability in their INR levels.,rephrase,['A second six-month study gave a small dose of vitamin K (150 mcg daily) or placebo to participants taking warfarin with existing poor INR control.'],4,0.42857142857142855,3,14
CD009917,0,6,The study concluded that vitamin K supplementation did not significantly improve the stability of anticoagulation for participants on chronic anticoagulation therapy.,rephrase,"['Nonetheless, it was suggested that the addition of vitamin K had no benefit.']",5,0.5,3,14
CD009917,0,7,"However, the study was only available in abstract form, and communication with the lead author confirmed that there were no further publications.",rephrase,"['One study was only available in an abbreviated format, so we were unable to interpret the results fully.']",6,0.5714285714285714,3,14
CD009917,0,8,"Therefore, we interpreted this conclusion with caution.",delete,[],7,0.6428571428571429,4,14
CD009917,0,9,"Neither study reported any thromboembolic events, haemorrhage, or death from the addition of vitamin K supplementation.",rephrase,"['Neither study reported any adverse events, such as thromboembolism, haemorrhage, or death.']",7,0.7142857142857143,4,14
CD009917,1,10,Two included studies in this review compared whether the addition of a low dose (150 to 175 mcg) of vitamin K given to participants with a high-variability response to warfarin improved their INR control.,delete,[],8,0.7857142857142857,4,14
CD009917,1,11,"One study demonstrated a significant improvement, while another smaller study (published in abstract only) suggested no overall benefit.",delete,[],8,0.8571428571428571,5,14
CD009917,1,12,"Currently, there are insufficient data to suggest an overall benefit.",delete,[],8,0.9285714285714286,5,14
CD009917,1,13,"Larger, higher quality trials are needed to examine if low-dose vitamin K improves INR control in those starting or already taking warfarin.",rephrase,"['We conclude that further larger, higher quality studies are needed to conclude whether adding vitamin K to warfarin for patients starting or already on warfarin improves their anticoagulation control.']",8,1.0,5,14
CD008678,0,0,We included five randomised studies with total of 1049 women evaluating five different technique modifications during either amniocentesis (three studies) or CVS (two studies).,rephrase,['We compare the safety and accuracy of various modifications and included five randomised studies with 1049 women.'],0,0.14285714285714285,1,7
CD008678,1,1,"For amniocentesis three interventions were evaluated - intramuscular progesterone, hexoprenaline and selecting high or low puncture sites for late 'blind' procedure - each intervention in a single small study.",rephrase,"['For amniocentesis, studies evaluated drugs that relax the uterus (tocolytics), progesterone prophylaxis, or compared the difference in safety for different puncture sites.']",1,0.2857142857142857,2,7
CD008678,1,2,There was no conclusive evidence of benefit for any of them.,delete,[],2,0.42857142857142855,3,7
CD008678,1,3,The same applies for terbutaline tocolysis and use of continuous vacuum aspiration during CVS.,rephrase,"['For CVS, one study included tocolysis prior to procedure and the other evaluated the role of continuous vacuum for aspiration of the placental tissue.']",2,0.5714285714285714,3,7
CD008678,2,4,"Overall, the quality of evidence summarised in this review is not of sufficient quality to change current clinical practice.",rephrase,"['Overall, we found no evidence of sufficient quality to change current clinical practice.']",3,0.7142857142857143,4,7
CD008678,2,5,"In the absence of clear evidence, the operators should continue to use methods and technique modifications with which they are most familiar with.",delete,[],4,0.8571428571428571,5,7
CD008678,3,6,Any randomised trials of technique modifications that are performed to high standard with adequate safety outcomes and power to detect important clinical differences would be clearly welcome.,rephrase,['Studies of high quality with adequate safety outcomes and power to detect important clinical differences would be clearly welcome.'],4,1.0,5,7
CD000974,0,0,"Sixteen trials, involving over one million adults, children and infants, fulfilled the inclusion criteria.",rephrase,"['Sixteen trials, involving over one million adults, children, and infants, were included.']",0,0.1,1,10
CD000974,0,1,Twenty-four comparisons reported on vaccine efficacy (cholera cases and/or deaths) and 11 comparisons considered adverse effects (nine reported on both).,delete,[],1,0.2,1,10
CD000974,0,2,"Compared to placebo, vaccinees had a reduced risk of death from cholera (RR 0.49, 95% CI 0.25 to 0.93; 837,442 participants) and a reduced risk of contracting cholera at 12 months (RR 0.52, 95% CI 0.42 to 0.65, random-effects model; 1,512,573 participants).",rephrase,['Injected cholera vaccines reduced the risk of death from cholera and the risk of contracting cholera at 12 months.'],1,0.3,2,10
CD000974,0,3,"This translates to an efficacy of 48%, 95% confidence interval 35% to 58%.",delete,[],2,0.4,2,10
CD000974,0,4,"Significant protection lasted for two years, even after only a single dose, and for three years with an annual booster.",merge,['Significant protection lasted for two years.'],2,0.5,3,10
CD000974,0,5,"Children over five years and adults were protected for up to three years, while children under five years were protected for up to a year.",none,[],2,0.6,3,10
CD000974,0,6,"Injected cholera vaccines were associated with more systemic and local adverse effects compared to placebo, but these were not severe or life-threatening.",rephrase,"['Injected cholera vaccines had more systemic and local adverse effects than placebo, but these adverse effects were relatively well tolerated and were not severe or life-threatening.']",3,0.7,4,10
CD000974,1,7,Injected cholera vaccines appear to be safe and relatively more effective than usually realized.,split,"['The authors conclude that injected cholera vaccines appear to be relatively safe and more effective than usually realized.', 'This review provides a solid background of evidence for the effects of cholera injected vaccines, against which to compare the effects of oral vaccines.']",4,0.8,4,10
CD000974,1,8,"Protection against cholera persists for up to two years following a single dose of vaccine, and for three years with an annual booster.",delete,[],6,0.9,5,10
CD000974,1,9,"However, they have been superseded by oral vaccines.",delete,[],6,1.0,5,10
CD011126,0,0,"Thirteen studies (1053 women) reported the accuracy of 3D SIS for focal uterine abnormalities; 11 of these (846 women) were suitable for meta-analysis, and eight reported accuracy according to the type of focal abnormality.",rephrase,"['Review authors searched for studies published from inception until March 2016 and found 13 studies (in total 1053 women), eight of which directly compared 3D SIS versus 2D SIS.']",0,0.07692307692307693,1,13
CD011126,0,1,The design of the included studies seems applicable.,delete,[],1,0.15384615384615385,1,13
CD011126,0,2,"The main problem involving the quality of included studies is insufficient reporting of study methods, resulting in unclear risk of bias for several of the quality domains assessed.",ignore,"['The main problem involving the quality of included studies is insufficient reporting of study methods, resulting in unclear risk of bias for several of the quality domains assessed.']",1,0.23076923076923078,2,13
CD011126,0,3,"Therefore, we considered the overall quality of the evidence as low.",rephrase,"['Therefore, review authors considered the overall quality of the evidence as low.']",2,0.3076923076923077,2,13
CD011126,0,4,The summary estimate (11 studies reporting absence or presence of abnormality at 3D SIS) for sensitivity was 94.5% (95% confidence interval (CI) 90.6% to 96.9%) and for specificity 99.4% (95% CI 96.2% to 99.9%).,delete,[],3,0.38461538461538464,2,13
CD011126,0,5,Meta-analysis of the eight studies (N = 716) directly comparing 2D SIS versus 3D SIS showed summary sensitivity of 96.9% (95% CI 91.9% to 98.8%) and summary specificity of 99.5% (95% CI 96.1% to 100%) for 3D SIS.,delete,[],3,0.46153846153846156,3,13
CD011126,0,6,"For 2D SIS, summary sensitivity was 90.9% (95% CI 81.2% to 95.8%) and summary specificity was 96.3% (95% CI 86.1% to 99.1%).",delete,[],3,0.5384615384615384,3,13
CD011126,0,7,The difference in accuracy between 2D SIS and 3D SIS was non-significant (P values of 0.07 for sensitivity and 0.10 for specificity).,delete,[],3,0.6153846153846154,4,13
CD011126,1,8,Low-quality evidence suggests that 3D SIS may be very accurate in detecting intracavitary abnormalities.,rephrase,['Low-quality evidence suggests that 3D SIS may be very accurate in detecting polyps and fibroids.'],3,0.6923076923076923,4,13
CD011126,1,9,Meta-analysis revealed no statistically significant differences between 2D SIS and 3D SIS.,rephrase,['Our analysis revealed no clear differences between 2D SIS and 3D SIS.'],4,0.7692307692307693,4,13
CD011126,1,10,"Summary sensitivity and summary specificity are higher for 3D SIS, but margins of improvement are limited because 2D SIS is already very accurate.",rephrase,['Summary results are higher for 3D SIS but margins of improvement are limited because 2D SIS is already very accurate.'],5,0.8461538461538461,5,13
CD011126,1,11,"When the technology and appropriate expertise are available, 3D SIS offers an alternative to 2D SIS.",rephrase,['3D SIS is an alternative to 2D SIS for which the technology and appropriate expertise are available.'],6,0.9230769230769231,5,13
CD011126,1,12,Both 2D SIS and 3D SIS should be considered alternatives to diagnostic hysteroscopy when intracavitary pathology is suspected in subfertile women and in those with abnormal uterine bleeding.,ignore,['Both 2D SIS and 3D SIS should be considered alternatives to diagnostic hysteroscopy when intracavitary pathology is suspected in subfertile women and in those with abnormal uterine bleeding.'],7,1.0,5,13
CD005978,0,0,We did not identify any new studies for inclusion in this update.,delete,[],0,0.2,1,5
CD005978,0,1,We included six studies that involved 5193 participants.,split,"['We included six studies that investigated zinc supplements to prevent pneumonia.', 'The studies were conducted in Bangladesh, India, Peru and South Africa and involved 5193 children aged from two to 59 months.']",0,0.4,2,5
CD005978,1,2,"Analysis showed that zinc supplementation reduced the incidence of pneumonia by 13% (fixed-effect risk ratio (RR) 0.87; 95% confidence interval (CI) 0.81 to 0.94, six studies, low-quality evidence) and prevalence of pneumonia by 41% (random-effects RR 0.59; 95% CI 0.35 to 0.99, one study, n = 609, low-quality evidence).",delete,[],2,0.6,3,5
CD005978,1,3,"On subgroup analysis, we found that zinc reduced the incidence of pneumonia defined by specific clinical criteria by 21% (i.e. confirmation by chest examination or chest radiograph) (fixed-effect RR 0.79; 95% CI 0.71 to 0.88, four studies, n = 3261), but had no effect on lower specificity pneumonia case definition (i.e. age-specific fast breathing with or without lower chest indrawing) (fixed-effect RR 0.95; 95% CI 0.86 to 1.06, four studies, n = 1932).",rephrase,"['On subgroup analysis, we found that a more stringent diagnosis (radiological examination) increased the reduction in pneumonia incidence.']",2,0.8,4,5
CD005978,2,4,Zinc supplementation in children is associated with a reduction in the incidence and prevalence of pneumonia.,rephrase,['Zinc supplementation was significantly associated with reducing the incidence and prevalence of pneumonia among children aged from two to 59 months.'],3,1.0,5,5
CD013514,0,0,This review included 12 studies (with a total of  1915 participants).,rephrase,['We found 12 studies (with a total of 1915 people who participated).'],0,0.043478260869565216,1,23
CD013514,0,1,Eleven studies compared the effects of Ginkgo biloba with placebo and one study compared the effects of Ginkgo biloba with hearing aids to hearing aids alone.,split,"['Eleven studies compared the effects of Ginkgo biloba with placebo.', 'One study compared the effects of Ginkgo biloba combined with hearing aids to hearing aids alone.']",1,0.08695652173913043,1,23
CD013514,0,2,All included studies were parallel-group RCTs.,delete,[],3,0.13043478260869565,1,23
CD013514,0,3,"In general, risk of bias was high or unclear due to selection bias and poor reporting of allocation concealment and blinding of participants, personnel and outcome assessments.",delete,[],3,0.17391304347826086,1,23
CD013514,0,4,"Due to heterogeneity in the outcomes measured and measurement methods used, only limited data pooling was possible.",delete,[],3,0.21739130434782608,2,23
CD013514,1,5,"Ginkgo biloba versus placebo
When we pooled data from two studies for the primary outcome tinnitus symptom severity, we found that Ginkgo biloba may have little to no effect (Tinnitus Handicap Inventory scores) at three to six months compared to placebo, but the evidence is very uncertain (mean difference (MD) -1.35 (scale 0 to 100), 95% confidence interval (CI) -8.26 to 5.55; 2 studies; 85 participants) (very low-certainty).",split,"['When we combined the results of two studies that measured tinnitus severity in the same way we found that Ginkgo biloba may have little to no effect compared to placebo, but the evidence is very uncertain.', 'We looked at four studies that recorded any serious harmful effects, all of which reported none, so Ginkgo probably does not result in any difference in risk compared to placebo.']",3,0.2608695652173913,2,23
CD013514,1,6,"Ginkgo biloba may result in little to no difference in the risk of bleeding or seizures, with no serious adverse effects reported in either group (4 studies; 1154 participants; low-certainty).",delete,[],5,0.30434782608695654,2,23
CD013514,2,7,"For the secondary outcomes, one study found that there may be little to no difference between the effects of Ginkgo biloba and placebo on tinnitus loudness measured with audiometric loudness matching at 12 weeks, but the evidence is very uncertain (MD -4.00 (scale -10 to 140 dB), 95% CI -13.33 to 5.33; 1 study; 73 participants) (very low-certainty).",rephrase,"['There may not be any difference between Ginkgo biloba and placebo in the effect on tinnitus loudness, but this is very uncertain.']",5,0.34782608695652173,2,23
CD013514,2,8,"One study found that there may be little to no difference between the effects of Ginkgo biloba and placebo on health-related quality of life measured with the Glasgow Health Status Inventory at three months (MD -0.58 (scale 0 to 100), 95% CI -4.67 to 3.51; 1 study; 60 participants) (low-certainty).",rephrase,"['We also found that there may not be any difference in other outcomes (health-related quality of life and minor unwanted effects such as gastrointestinal upset, headache and allergic reaction).']",6,0.391304347826087,2,23
CD013514,2,9,"Ginkgo biloba may not increase the frequency of other adverse effects (gastrointestinal upset, headache, allergic reaction) at three months compared to placebo (risk ratio 0.91, 95% CI 0.52 to 1.60; 4 studies; 1175 participants) (low-certainty).",rephrase,['There is no evidence to suggest that Ginkgo biloba has an effect on tinnitus when compared to placebo.'],7,0.43478260869565216,3,23
CD013514,2,10,"None of the studies reported the other secondary outcomes of tinnitus intrusiveness or changes in depressive symptoms or depression, anxiety symptoms or generalised anxiety.",rephrase,"['For tinnitus loudness we are not confident in the evidence because the study that measured this was very small, some people dropped out and only this one study reported this important outcome.']",8,0.4782608695652174,3,23
CD013514,3,11,"Gingko biloba with concurrent intervention versus concurrent intervention only
One study compared Ginkgo biloba with hearing aids to hearing aids only.",rephrase,['We looked at the study that compared Ginkgo biloba combined with hearing aids to hearing aids alone.'],9,0.5217391304347826,3,23
CD013514,3,12,It assessed the mean difference in the change in Tinnitus Handicap Inventory scores and tinnitus loudness using a 10-point visual analogue scale (VAS) at three months.,rephrase,['It assessed the difference in the change in tinnitus severity and loudness using a scale at three months.'],10,0.5652173913043478,3,23
CD013514,3,13,"The study did not report adverse effects, tinnitus intrusiveness, changes in depressive symptoms or depression, anxiety symptoms or generalised anxiety, or health-related quality of life.",rephrase,['The study did not report any of the other outcomes we were interested in.'],11,0.6086956521739131,4,23
CD013514,3,14,"This was a single, very small study (22 participants) and for all outcomes the certainty of the evidence was very low.",rephrase,"['This was a single, very small study (22 people) and the evidence was very uncertain.']",12,0.6521739130434783,4,23
CD013514,3,15,We were unable to draw meaningful conclusions from the numerical results.,rephrase,['We were unable to draw meaningful conclusions from the findings of this study.'],13,0.6956521739130435,4,23
CD013514,4,16,There is uncertainty about the benefits and harms of Ginkgo biloba for the treatment of tinnitus when compared to placebo.,rephrase,['We are not confident in the evidence for the effect on tinnitus severity of Ginkgo biloba compared to placebo.'],14,0.7391304347826086,4,23
CD013514,4,17,We were unable to draw meaningful conclusions regarding the benefits and harms of Ginkgo biloba when used with concurrent intervention (hearing aids).,rephrase,['We are not confident in the evidence for the effects of Ginkgo in combination with hearing aids because the number of participants in the study was very small.'],15,0.782608695652174,4,23
CD013514,4,18,"The certainty of the evidence for the reported outcomes, assessed using GRADE, ranged from low to very low.",delete,[],16,0.8260869565217391,5,23
CD013514,4,19,Future research into the effectiveness of Ginkgo biloba in patients with tinnitus should use rigorous methodology.,delete,[],16,0.8695652173913043,5,23
CD013514,4,20,"Randomisation and blinding should be of the highest quality, given the subjective nature of tinnitus and the strong likelihood of a placebo response.",delete,[],16,0.9130434782608695,5,23
CD013514,4,21,The CONSORT statement should be used in the design and reporting of future studies.,delete,[],16,0.9565217391304348,5,23
CD013514,4,22,"We also recommend the use of validated, patient-centred outcome measures for research in the field of tinnitus.",delete,[],16,1.0,5,23
CD006123,0,0,Two new studies incorporating 96 participants were identified in this update and were added to the six previously included studies.,delete,[],0,0.07142857142857142,1,14
CD006123,0,1,A total of eight studies incorporating 399 participants are included in the updated review.,rephrase,"['We included eight studies, involving 399 adults with traumatic brain injuries, in this review.']",0,0.14285714285714285,1,14
CD006123,0,2,The participants were primarily men aged in their mid-thirties who had sustained a severe TBI.,rephrase,['Most study participants were men in their mid-thirties who had severe brain injuries.'],1,0.21428571428571427,2,14
CD006123,0,3,No studies included children.,rephrase,['We found no studies that included children.'],2,0.2857142857142857,2,14
CD006123,0,4,"The studies were clinically diverse with regard to the interventions, time postinjury and the outcome measures used.",delete,[],3,0.35714285714285715,2,14
CD006123,0,5,"At the end of intervention, the mean difference in peak power output was 35.47 watts (W) in favour of fitness training (MD 35.47 W, 95% CI 2.53 to 68.41 W; 3 studies, 67 participants; low-quality evidence).",delete,[],3,0.42857142857142855,3,14
CD006123,0,6,"The CIs include both a possible clinically important effect and a possible negligible effect, and there was moderate heterogeneity among the studies.",delete,[],3,0.5,3,14
CD006123,1,7,"Five of the secondary outcomes had sufficient data at the end of intervention to enable meta-analysis: body composition (SMD 0.29 standard deviations (favouring control), 95% CI -0.22 to 0.79; 2 studies, 61 participants; low-quality evidence), strength (SMD -0.02 (favouring control), 95% CI -0.86 to 0.83; 2 studies, 23 participants; very low-quality evidence), fatigue (SMD -0.32 (favouring fitness training), 95% CI -0.90 to 0.26; 3 studies, 130 participants; very low-quality evidence), depression (SMD -0.43 (favouring fitness training), 95% CI -0.92 to 0.06; 4 studies, 220 participants; very low-quality evidence), and neuromotor function (MD 0.01 m (favouring fitness training), 95% CI -0.25 to 0.27; 2 studies, 109 participants; moderate-quality evidence).",delete,[],3,0.5714285714285714,3,14
CD006123,1,8,It was uncertain whether fitness training was more or less effective at improving these secondary outcomes compared to the control interventions.,rephrase,['It was unclear whether fitness training was better or worse than the non-exercise interventions or no intervention at improving these outcomes.'],3,0.6428571428571429,4,14
CD006123,1,9,"Quality of life was assessed in three trials, but we did not pool the data because of substantial heterogeneity.",delete,[],4,0.7142857142857143,4,14
CD006123,1,10,Five of the eight included studies had no dropouts from their intervention group and no adverse events were reported in any study.,delete,[],4,0.7857142857142857,4,14
CD006123,2,11,There is low-quality evidence that fitness training is effective at improving cardiorespiratory deconditioning after TBI; there is insufficient evidence to draw any definitive conclusions about the other outcomes.,rephrase,['There is not enough evidence to understand the effect of fitness training on other important outcomes.'],4,0.8571428571428571,5,14
CD006123,2,12,"Whilst the intervention appears to be accepted by people with TBI, and there is no evidence of harm, more adequately powered and well-designed studies are required to determine a more precise estimate of the effect on cardiorespiratory fitness, as well as the effects across a range of important outcome measures and in people with different characteristics (e.g. children).",rephrase,"['Whilst fitness training appears to be well attended by people with traumatic brain injury, particularly when supervised, and there is no evidence of harm, further well-designed studies are required before we can draw any definite conclusions.']",5,0.9285714285714286,5,14
CD006123,2,13,"In the absence of high quality evidence, clinicians may be guided by pre-exercise screening checklists to ensure the person with traumatic brain injury is safe to exercise, and set training parameters using guidelines established by the American College of Sports Medicine for people who have suffered a brain injury.",ignore,"['In the absence of high quality evidence, health professionals may be guided by pre-exercise screening checklists to ensure the person with traumatic brain injury is safe to exercise, and to set training parameters using guidelines established by the American College of Sports Medicine for people who have suffered a brain injury.']",6,1.0,5,14
CD000380,0,0,Twenty trials were included.,ignore,['Twenty trials were included.'],0,0.09090909090909091,1,11
CD000380,0,1,These involved a total of 2562 mostly young active adult males.,ignore,['These involved a total of 2562 mostly young active adult males.'],1,0.18181818181818182,1,11
CD000380,0,2,All trials had methodological weaknesses.,rephrase,['All trials had methodological flaws that could have affected their results.'],2,0.2727272727272727,2,11
CD000380,0,3,"Specifically, concealment of allocation was confirmed in only one trial.",delete,[],3,0.36363636363636365,2,11
CD000380,0,4,Data for pooling individual outcomes were only available for a maximum of 12 trials and under 60% of participants.,rephrase,['Data for pooling individual outcomes were only available for a maximum of 12 trials.'],3,0.45454545454545453,3,11
CD000380,1,5,"The findings of statistically significant differences in favour of the surgical treatment group for the four primary outcomes (non-return to pre-injury level of sports; ankle sprain recurrence; long-term pain; subjective or functional instability) when using the fixed-effect model were not robust when using the random-effects model, nor on the removal of one low quality (quasi-randomised) trial that had more extreme results.",rephrase,"['When this trial was excluded, the findings of better results for surgery in terms of return to sports, re-injury, persistent pain and ankle instability as judged by the patient were no longer statistically significant.']",4,0.5454545454545454,3,11
CD000380,1,6,A corresponding drop in the I² statistics showed the remaining trials to be more homogeneous.,delete,[],5,0.6363636363636364,4,11
CD000380,2,7,The functional implications of the statistically significantly higher incidence of objective instability in conservatively treated trial participants are uncertain.,delete,[],5,0.7272727272727273,4,11
CD000380,2,8,"There was some limited evidence for longer recovery times, and higher incidences of ankle stiffness, impaired ankle mobility and complications in the surgical treatment group.",ignore,"['Conversely, there was some limited evidence for longer recovery times, and higher incidences of ankle stiffness, impaired ankle mobility and complications in the surgical treatment group.']",5,0.8181818181818182,5,11
CD000380,3,9,There is insufficient evidence available from randomised controlled trials to determine the relative effectiveness of surgical and conservative treatment for acute injuries of the lateral ligament complex of the ankle.,merge,['We concluded that there was not enough evidence from randomised controlled trials to say whether surgery gives a better result than conservative treatment for acute ankle sprain in adults.'],6,0.9090909090909091,5,11
CD000380,3,10,High quality randomised controlled trials of primary surgical repair versus the best available conservative treatment for well-defined injuries are required.,none,[],6,1.0,5,11
CD003689,0,0,"We included 19 RCTs (21 interventions), with 1771 participants in the review.",rephrase,['We included 19 trials (12 pharmacological and seven psychological) involving 1771 participants.'],0,0.1,1,10
CD003689,0,1,Data were available for 12 pharmacological trials (14 interventions) and seven psychological trials.,rephrase,"['Outcome information was available for nine pharmacological and two psychological trials, which suggested that these treatments might reduce the risk of developing depression.']",1,0.2,1,10
CD003689,0,2,"There were no trials of non-invasive brain stimulation compared with sham stimulation or usual care, a combination of pharmacological intervention and one of various forms of psychological therapy with placebo and psychological therapy, or a combination of non-invasive brain stimulation and a pharmacological intervention with a pharmacological intervention and sham stimulation or usual care to prevent depression after stroke.",rephrase,['We included trials which reported on the use of pharmacological and psychological interventions to prevent depression after stroke.'],2,0.3,2,10
CD003689,0,3,"Treatment effects were observed on the primary outcome of meeting the study criteria for depression at the end of treatment: there is very low-certainty evidence from eight trials (nine interventions) that pharmacological interventions decrease the number of people meeting the study criteria for depression (RR 0.50, 95% CI 0.37 to 0.68; 734 participants) compared to placebo.",delete,[],3,0.4,2,10
CD003689,0,4,"There is very low-certainty evidence from two trials that psychological interventions reduce the proportion of people meeting the study criteria for depression (RR 0.68, 95% CI 0.49 to 0.94, 607 participants) compared to usual care and/or attention control.",delete,[],3,0.5,3,10
CD003689,1,5,"Eight trials (nine interventions) found no difference in death and other adverse events between pharmacological intervention and placebo groups (RR 1.25, 95% CI 0.32 to 4.91; 496 participants) based on very low-certainty evidence.",merge,['A smaller number of studies (eight pharmacological and five psychological studies) found no increase in death or adverse events.'],3,0.6,3,10
CD003689,1,6,"Five trials found no difference in psychological intervention and usual care and/or attention control groups for death and other adverse events (RR 1.18, 95% CI 0.73 to 1.91; 975 participants) based on very low-certainty evidence.",none,[],3,0.7,4,10
CD003689,2,7,The available evidence suggests that pharmacological interventions and psychological therapy may prevent depression and improve mood after stroke.,delete,[],4,0.8,4,10
CD003689,2,8,"However, there is very low certainty in these conclusions because of the very low-certainty evidence.",rephrase,['We rated the certainty of evidence as very low due to limitations in study design.'],4,0.9,5,10
CD003689,2,9,More trials are required before reliable recommendations can be made about the routine use of such treatments after stroke.,rephrase,['More well-designed clinical trials are needed that test practical interventions for preventing depression across all stroke survivors.'],5,1.0,5,10
CD008085,0,0,Six trials involving 849 patients satisfied the inclusion criteria.,rephrase,['This systematic review included six trials with 849 patients.'],0,0.08333333333333333,1,12
CD008085,0,1,"Pharmacological interventions included aprotinin, desmopressin, recombinant factor VIIa, antithrombin III, and tranexamic acid.",rephrase,"['The trials included comparison of medicines (such as aprotinin, desmopressin, recombinant factor VIIa, antithrombin III, and tranexamic acid) with controls (no medicines).']",1,0.16666666666666666,1,12
CD008085,0,2,One or two trials could be included under most comparisons.,delete,[],2,0.25,2,12
CD008085,0,3,All trials had a high risk of bias.,rephrase,"[""All trials had high risk of bias ('systematic error') as well of play of chance ('random error').""]",2,0.3333333333333333,2,12
CD008085,0,4,"There was no significant difference in the peri-operative mortality, survival at maximal follow-up, liver failure, or other peri-operative morbidity.",rephrase,['There was no difference in the death or complications due to surgery or long-term survival in any of the comparisons.'],3,0.4166666666666667,3,12
CD008085,0,5,The risk ratio of requiring allogeneic blood transfusion was significantly lower in the aprotinin and tranexamic acid groups than the respective control groups.,rephrase,['Fewer patients required transfusion of blood donated by others when aprotinin or tranexamic acid were compared to controls not receiving the interventions.'],4,0.5,3,12
CD008085,0,6,Other interventions did not show significant decreases of allogeneic transfusion requirements.,split,"['This systematic review was aimed at determining whether any medical treatment decreased blood loss and decreased allogeneic blood transfusion requirements in patients undergoing liver resections.', 'The other comparisons did not decrease the transfusion requirements.']",5,0.5833333333333334,3,12
CD008085,1,7,None of the interventions seem to decrease peri-operative morbidity or offer any long-term survival benefit.,delete,[],7,0.6666666666666666,4,12
CD008085,1,8,Aprotinin and tranexamic acid show promise in the reduction of blood transfusion requirements in liver resection surgery.,ignore,['Aprotinin and tranexamic acid show promise in the reduction of blood transfusion requirements in liver resections.'],7,0.75,4,12
CD008085,1,9,"However, there is a high risk of type I (erroneously concluding that an intervention is beneficial when it is actually not beneficial) and type II errors (erroneously concluding that an intervention is not beneficial when it is actually beneficial) because of the few trials included, the small sample size in each trial, and the high risk of bias.",ignore,"['However, there is a high risk of type I errors (erroneously concluding that an intervention is beneficial when it is actually not beneficial) and type II errors (erroneously concluding that an intervention is not beneficial when it is actually beneficial) because of the few trials included and the small sample size in each trial as well as the inherent risk of bias (systematic errors).']",8,0.8333333333333334,5,12
CD008085,1,10,Further randomised clinical trials with low risk of bias and random errors assessing clinically important outcomes such as peri-operative mortality are necessary to assess any pharmacological interventions aimed at decreasing blood loss and blood transfusion requirements in liver resections.,rephrase,['Further randomised clinical trials with low risk of bias (systematic errors) and low risk of play of chance (random errors) which assess clinically important outcomes (such as death and complications due to operation) are necessary to assess any pharmacological interventions aimed at decreasing blood transfusion and blood transfusion requirements in liver resections.'],9,0.9166666666666666,5,12
CD008085,1,11,Trials need to be designed to assess the effect of a combination of different interventions in liver resections.,ignore,['Trials need to be designed to assess the effect of a combination of different interventions in liver resections.'],10,1.0,5,12
CD012009,0,0,A total of five studies including 868 participants met the inclusion criteria for this review.,rephrase,['We identified five studies reporting information on 868 people who underwent pancreatic resections for cancer and non-cancerous growths.'],0,0.125,1,8
CD012009,0,1,The five studies included in this review reported the value of drain fluid amylase at different thresholds and different postoperative days.,rephrase,['We performed a thorough literature search for studies reporting the accuracy of drain fluid amylase in identifying pancreatic leaks.'],1,0.25,2,8
CD012009,0,2,The sensitivities and specificities were variable; the sensitivities ranged between 0.72 and 1.00 while the specificities ranged between 0.73 and 0.99 for different thresholds on different postoperative days.,delete,[],2,0.375,2,8
CD012009,0,3,"At the median prevalence (pre-test probability) of 15.9%, the post-test probabilities for pancreatic leak ranged between 35.9% and 95.4% for a positive drain fluid amylase test and ranged between 0% and 5.5% for a negative drain fluid amylase test.",delete,[],2,0.5,3,8
CD012009,1,4,"None of the studies used the reference standard of confirmation by surgery or by a combination of surgery and clinical follow-up, but used the International Study Group on Pancreatic Fistula (ISGPF) grade B and C as the reference standard.",delete,[],2,0.625,4,8
CD012009,1,5,The overall methodological quality was unclear or high in all the studies.,rephrase,"['All of the studies were of unclear or low methodological quality, which may result in arriving at false conclusions.']",2,0.75,4,8
CD012009,2,6,"Because of the paucity of data and methodological deficiencies in the studies, we are uncertain whether drain fluid amylase should be used as a method for testing for pancreatic leak in an unselected population after pancreatic resection; and we judge that the optimal cut-off of drain fluid amylase for making the diagnosis of pancreatic leak is also not clear.",rephrase,['We are uncertain whether drain fluid amylase is useful in identifying pancreatic leaks because of the following reasons.'],3,0.875,5,8
CD012009,2,7,"Further well-designed diagnostic test accuracy studies with pre-specified index test threshold of drain fluid amylase (at three times more on postoperative day 5 or another suitable pre-specified threshold), appropriate follow-up (for at least six to eight weeks to ensure that there are no pancreatic leaks), and clearly defined reference standards (of surgical, clinical, and radiological confirmation of pancreatic leak) are important to reliably determine the diagnostic accuracy of drain fluid amylase in the diagnosis of pancreatic leak.",delete,[],4,1.0,5,8
CD002842,0,0,We included no new trials in this update.,delete,[],0,0.1,1,10
CD002842,0,1,The results are unchanged from the previous review and are based on the data of six RCTs with 223 participants.,rephrase,['The six studies involved 223 participants who demonstrated attentional problems or reported having such problems following stroke.'],0,0.2,1,10
CD002842,0,2,All six RCTs compared cognitive rehabilitation with a usual care control.,rephrase,['We identified six studies that compared cognitive rehabilitation with a control group who received their usual care (but not cognitive rehabilitation) for people with attention problems following stroke.'],1,0.3,2,10
CD002842,1,3,"Meta-analyses demonstrated no convincing effect of cognitive rehabilitation on subjective measures of attention either immediately after treatment (standardised mean difference (SMD) 0.53, 95% confidence interval (CI) –0.03 to 1.08; P = 0.06; 2 studies, 53 participants; very low-quality evidence) or at follow-up (SMD 0.16, 95% CI –0.23 to 0.56; P = 0.41; 2 studies, 99 participants; very low-quality evidence).",delete,[],2,0.4,2,10
CD002842,2,4,"People receiving cognitive rehabilitation (when compared with control) showed that measures of divided attention recorded immediately after treatment may improve (SMD 0.67, 95% CI 0.35 to 0.98; P < 0.0001; 4 studies, 165 participants; low-quality evidence), but it is uncertain that these effects persisted (SMD 0.36, 95% CI –0.04 to 0.76; P = 0.08; 2 studies, 99 participants; very low-quality evidence).",rephrase,['The group that received cognitive rehabilitation performed better than the control group on tasks that required people to divide attention.'],2,0.5,3,10
CD002842,2,5,"There was no evidence for immediate or persistent effects of cognitive rehabilitation on alertness, selective attention, and sustained attention.",rephrase,['We found no evidence that cognitive rehabilitation improved general (global) measures of attention.'],3,0.6,3,10
CD002842,3,6,"There was no convincing evidence for immediate or long-term effects of cognitive rehabilitation for attentional problems on functional abilities, mood, and quality of life after stroke.",rephrase,"['There was no evidence to suggest that cognitive rehabilitation was beneficial for other types of attention problems, or daily life activities, mood, or quality of life.']",4,0.7,4,10
CD002842,4,7,The effectiveness of cognitive rehabilitation for attention deficits following stroke remains unconfirmed.,rephrase,"['The very low to moderate methodological quality of the studies identified, and the lack of studies means that we cannot draw firm conclusions about the effect of cognitive rehabilitation for attention following stroke.']",5,0.8,4,10
CD002842,4,8,"The results suggest there may be an immediate effect after treatment on attentional abilities, but future studies need to assess what helps this effect persist and generalise to attentional skills in daily life.",delete,[],6,0.9,5,10
CD002842,4,9,Trials also need to have higher methodological quality and better reporting.,delete,[],6,1.0,5,10
CD004753,0,0,We identified no new trials for the 2016 update.,rephrase,['We searched for new evidence in October 2016 and identified no new randomised controlled trials.'],0,0.09090909090909091,1,11
CD004753,0,1,"This review includes two trials, but we included only one trial, with 24 women, in the analyses.",rephrase,"['This review is also limited in that it includes only one study with data suitable for analysis, and this study involved only 20 women.']",1,0.18181818181818182,1,11
CD004753,1,2,The overall risk of bias was unclear owing to lack of methodological detail.,delete,[],2,0.2727272727272727,2,11
CD004753,1,3,"Using the GRADE method, we judged the quality of the evidence to be very low.",rephrase,"['Available evidence is of very low quality, mainly owing to poor reporting of methods, lack of precision in findings for overall pain relief, unintended side effects of treatment and the need for extra pain relief.']",2,0.36363636363636365,2,11
CD004753,1,4,We downgraded evidence for risk of bias and for imprecision (wide confidence intervals and evidence based on a single small trial).,rephrase,['Evidence was of very low quality owing to risk of bias and imprecision (findings were based on a single small trial).'],3,0.45454545454545453,3,11
CD004753,2,5,"Comparison of NSAIDs (naproxen) versus placebo revealed no evidence of a positive effect on pain relief (odds ratio (OR) 3.27, 95% confidence interval (CI) 0.61 to 17.69; one trial, 24 women; very low-quality evidence) in women with endometriosis.",delete,[],4,0.5454545454545454,3,11
CD004753,2,6,"Evidence indicating whether women taking NSAIDs (naproxen) were less likely to require additional analgesia (OR 0.12, 95% CI 0.01 to 1.29; one trial, 24 women; very low-quality evidence) or to experience side effects (OR 0.46, 95% CI 0.09 to 2.47; one trial, 24 women; very low-quality evidence) when compared with placebo was inconclusive.",delete,[],4,0.6363636363636364,4,11
CD004753,3,7,"Studies provided no data on quality of life, effects on daily activities, absence from work or school, need for more invasive treatment or participant satisfaction with treatment.",rephrase,"['The included trial did not report on quality of life, effects on daily activities, absence from work or school or participant satisfaction with treatment.']",4,0.7272727272727273,4,11
CD004753,4,8,"Owing to lack of high-quality evidence and lack of reporting of outcomes of interest for this review, we can make no judgement as to whether NSAIDs (naproxen) are effective in managing pain caused by endometriosis.",merge,[],5,0.8181818181818182,5,11
CD004753,4,9,There is no evidence that one NSAID is more effective than another.,none,"['Available evidence does not allow us to conclude whether NSAIDs are effective for managing pain caused by endometriosis, or whether any individual NSAID is more effective than another.']",5,0.9090909090909091,5,11
CD004753,4,10,"As shown in other Cochrane reviews, women taking NSAIDs must be aware that these drugs may cause unintended effects.",rephrase,"['As has been shown in other Cochrane reviews, women who use NSAIDs must be aware that NSAIDs may cause adverse effects such as nausea, vomiting, headache and drowsiness.']",6,1.0,5,11
CD004213,0,0,"In this updated analysis, we included nine trials (N = 1070 infants) comparing prophylactic ibuprofen (IV or oral) with placebo/no intervention or indomethacin.",delete,[],0,0.05555555555555555,1,18
CD004213,0,1,"Ibuprofen (IV or oral) probably decreases the risk of PDA on day 3 or 4 (typical RR 0.39, 95% CI 0.31 to 0.48; typical RD -0.26, 95% CI -0.31 to -0.21; NNTB 4, 95% CI 3 to 5; 9 trials; N = 1029) (moderate-quality evidence).",delete,[],0,0.1111111111111111,1,18
CD004213,0,2,"In the control group, the spontaneous closure rate was 58% by day 3 to 4 of age.",delete,[],0,0.16666666666666666,1,18
CD004213,0,3,"In addition, ibuprofen probably decreases the need for rescue treatment with cyclo-oxygenase inhibitors (typical RR 0.17, 95% CI 0.11 to 0.26; typical RD -0.27, 95% CI -0.32 to -0.22; NNTB 4; 95% CI 3 to 5),and the need for surgical ductal ligation (typical RR 0.46, 95% CI 0.22 to 0.96; typical RD -0.03, 95% CI -0.05 to -0.00; NNTB 33, 95% CI 20 to infinity; 7 trials; N = 925) (moderate-quality evidence).",delete,[],0,0.2222222222222222,2,18
CD004213,0,4,"There was a possible decrease in the risk of grade 3 or 4 intraventricular haemorrhage (IVH) in infants receiving prophylactic ibuprofen (typical RR 0.67, 95% CI 0.45 to 1.00; I² = 34%; typical RD -0.04, 95% CI -0.08 to- 0.00; I² = 60%; 7 trials; N = 925) (moderate-quality evidence).",delete,[],0,0.2777777777777778,2,18
CD004213,0,5,"High quality evidence showed increased risk for oliguria (typical RR 1.45, 95% CI 1.04 to 2.02; typical RD 0.06, 95% CI 0.01 to 0.11; NNTH 17, 95% CI 9 to 100; 4 trials; N = 747).",delete,[],0,0.3333333333333333,2,18
CD004213,0,6,"Low quality results from four studies (N = 202) showed that administering oral ibuprofen may decrease the risk of PDA (typical RR 0.47, 95% CI 0.30 to 0.74) and may increase risk of gastrointestinal bleeding (NNTH 7, 95% CI 4 to 25).",delete,[],0,0.3888888888888889,2,18
CD004213,0,7,"No evidence of a difference was identified for mortality, any intraventricular haemorrhage (IVH), or chronic lung disease.",delete,[],0,0.4444444444444444,3,18
CD004213,1,8,"This review shows that prophylactic use of ibuprofen, compared to placebo or no intervention, probably decreases the incidence of patent ductus arteriosus, the need for rescue treatment with cyclo-oxygenase inhibitors, and for surgical ductal closure.",rephrase,"['Prophylactic use of ibuprofen reduces the incidence of patent ductus arteriosus (PDA), the need for rescue treatment with other medications, or the need for surgical closure.']",0,0.5,3,18
CD004213,1,9,"Adverse effects associated with ibuprofen (IV or oral) included increased risks for oliguria, increase in serum creatinine levels, and increased risk of gastrointestinal haemorrhage.",rephrase,['Adverse effects in the ibuprofen group compared to the placebo or no interventions group included significantly increased risk of kidney complications.'],1,0.5555555555555556,3,18
CD004213,1,10,"There was a reduced risk for intraventricular haemorrhage (grade III - IV) but no evidence of a difference in mortality, chronic lung disease, necrotising enterocolitis, or time to reach full feeds.",rephrase,"[""Risk of intraventricular haemorrhage, or bleeding into the brain (grade II to IV), of borderline significance was reduced, but researchers reported no statistically significant differences in mortality, chronic lung disease at 28 days' or 36 weeks' postmenstrual age, necrotising enterocolitis, or time to reach full feeds.""]",2,0.6111111111111112,4,18
CD004213,1,11,"In the control group, the patent ductus arteriosus had closed spontaneously by day 3 or 4 in 58% of neonates.",rephrase,"['In the control group, the PDA had closed spontaneously by day 3 or 4 in 58% of neonates.']",3,0.6666666666666666,4,18
CD004213,1,12,Prophylactic treatment exposes a large proportion of infants unnecessarily to a drug that has important side effects without conferring any important short-term benefits.,rephrase,['Preventative treatment therefore exposes a large proportion of infants unnecessarily to a drug that has important side effects without conferring any important short-term benefit for outcomes.'],4,0.7222222222222222,4,18
CD004213,1,13,Current evidence does not support the use of ibuprofen for prevention of patent ductus arteriosus.,rephrase,['Current evidence does not support the use of ibuprofen for prevention of PDA.'],5,0.7777777777777778,4,18
CD004213,1,14,"Until long-term follow-up results of the trials included in this review have been published, no further trials of prophylactic ibuprofen are recommended.",rephrase,['No long-term follow-up studies have been published.'],6,0.8333333333333334,5,18
CD004213,2,15,"A new approach to patent ductus arteriosus management is an early targeted treatment based on echocardiographic criteria within the first 72 hours of life, that have a high sensitivity for diagnosing a patent ductus arteriosus that is unlikely to close spontaneously.",rephrase,"['A new approach for management of PDA is an early targeted treatment based on echocardiographic (ECG), or image of the heart, criteria within the first 72 hours of life; this has high sensitivity for diagnosing a PDA that is unlikely to close spontaneously.']",7,0.8888888888888888,5,18
CD004213,2,16,Such trials are currently ongoing in many parts of the world.,ignore,['Such trials are currently ongoing in many parts of the world.'],8,0.9444444444444444,5,18
CD004213,2,17,"Results of such trials will be included in updates of our ""Ibuprofen for treatment of PDA"" review.",rephrase,['This updated review of trials found that ibuprofen can prevent PDA but does not confer any other short-term or long-term benefits.'],9,1.0,5,18
CD010209,0,0,We included three studies involving 275 women (data reported for 271) with PPROM at up to 34 weeks' gestation.,rephrase,"[""The review included three randomised controlled studies that involved a total of 275 women (data reported for 271) with PPROM at up to 34 weeks' gestation.""]",0,0.07142857142857142,1,14
CD010209,0,1,All three studies were conducted in the United States.,rephrase,['All three studies were from the USA.'],1,0.14285714285714285,1,14
CD010209,0,2,Each study investigated different methods of fetal assessment.,rephrase,"['They each investigated different methods of fetal assessment, so no meta-analysis could be conducted.']",2,0.21428571428571427,2,14
CD010209,0,3,"One study compared weekly endovaginal ultrasound scans with no assessment (n = 93), one compared amniocentesis with no assessment (n = 47), and one compared daily nonstress testing with daily modified biophysical profiling (n = 135).",delete,[],3,0.2857142857142857,2,14
CD010209,0,4,"We were unable to perform a meta-analysis, but were able to report data from individual studies.",delete,[],3,0.35714285714285715,2,14
CD010209,1,5,"There was no convincing evidence of increased risk of neonatal death in the group receiving endovaginal ultrasound scans compared with the group receiving no assessment (risk ratio (RR) 7.30, 95% confidence interval (CI) 0.39 to 137.54; one study, 92 women), or in the group receiving amniocentesis compared with the group receiving no amniocentesis (RR 1.00, 95% CI 0.07 to 15.00; one study, 44 women).",delete,[],3,0.42857142857142855,3,14
CD010209,1,6,"For both these interventions, we inferred that there were no fetal deaths in the intervention or control groups.",delete,[],3,0.5,3,14
CD010209,1,7,The study comparing daily nonstress testing with daily modified biophysical profiling did not report fetal or neonatal death.,rephrase,"[""One study compared weekly endovaginal ultrasound scans where the probe is placed inside the vagina versus no assessment, one compared an amniotic fluid test to measure levels of fetal lung surfactant with no assessment, and one compared a daily 'nonstress test' (recording the fetal heartbeat) with daily modified biophysical profiling (recording the fetal heartbeat as well as estimating the volume of amniotic fluid surrounding the baby).""]",3,0.5714285714285714,3,14
CD010209,1,8,Primary outcomes of maternal death and serious maternal morbidity were not reported in any study.,delete,[],4,0.6428571428571429,4,14
CD010209,1,9,"Overall, there were few statistically significant differences in outcomes between the comparisons.",rephrase,"['In each study, there were few statistically significant differences between groups in outcomes for the mother, fetus or neonate.']",4,0.7142857142857143,4,14
CD010209,2,10,"The overall quality of evidence is poor, because participant blinding was not possible for any study.",rephrase,"['The overall quality of the evidence was poor, because participants knew which group they were in.']",5,0.7857142857142857,4,14
CD010209,3,11,There is insufficient evidence on the benefits and harms of fetal assessment methods for improving neonatal and maternal outcomes in women with PPROM to draw firm conclusions.,rephrase,['More studies are needed to assess the benefits and harms of fetal assessment methods for improving neonatal and maternal outcomes in women with PPROM before firm conclusions can be drawn.'],6,0.8571428571428571,5,14
CD010209,3,12,The overall quality of evidence that does exist is poor.,delete,[],7,0.9285714285714286,5,14
CD010209,4,13,Further high-quality randomised controlled trials are required to guide clinical practice.,delete,[],7,1.0,5,14
CD009029,0,0,"Twenty-four RCTs, including 53,247 participants, met the inclusion criteria.",rephrase,"['We included 24 randomized controlled trials and 53,247 participants in this review.']",0,0.07142857142857142,1,14
CD009029,0,1,Four studies assessed the protective efficacy of oral cholera vaccines when used to prevent diarrhoea due to ETEC and seven studies assessed the protective efficacy of ETEC-specific vaccines.,rephrase,['Four studies assessed the use of oral cholera vaccines to prevent diarrhoea caused by ETEC and eight trials assessed the use of ETEC-specific vaccines to prevent diarrhoea.'],1,0.14285714285714285,1,14
CD009029,0,2,"Of these 11 studies, seven studies presented efficacy data from field trials and four studies presented efficacy data from artificial challenge studies.",rephrase,['Seven studies presented data from field trials and four studies presented data from studies where people were artificially infected with ETEC bacteria.'],2,0.21428571428571427,2,14
CD009029,0,3,An additional 13 trials contributed safety and immunological data only.,rephrase,"['Also, 13 trials gave safety and immunological data only.']",3,0.2857142857142857,2,14
CD009029,1,4,"Cholera vaccines
The currently available, oral cholera killed whole cell vaccine (Dukoral®) was evaluated for protection of people against 'travellers' diarrhoea' in a single RCT in people arriving in Mexico from the USA.",rephrase,['There is currently insufficient evidence to support the use of the oral cholera vaccine Dukoral® to protect travellers against ETEC diarrhoea.'],4,0.35714285714285715,2,14
CD009029,1,5,"We did not identify any statistically significant effects on ETEC diarrhoea or all-cause diarrhoea (one trial, 502 participants, low quality evidence).",rephrase,"['Based on a single trial in people travelling from the USA to Mexico, the oral cholera vaccine Dukoral® may have little or no effect in preventing ETEC diarrhoea (one trial, 502 participants, low quality evidence).']",5,0.42857142857142855,3,14
CD009029,2,6,"Two earlier trials, one undertaken in an endemic population in Bangladesh and one undertaken in people travelling from Finland to Morocco, evaluated a precursor of this vaccine containing purified cholera toxin B subunit rather than the recombinant subunit in Dukoral®.",rephrase,"['Two earlier trials, one undertaken in an endemic population in Bangladesh and one undertaken in people travelling from Finland to Morocco, evaluated a precursor of the oral cholera vaccine Dukoral®.']",6,0.5,3,14
CD009029,2,7,"Short term protective efficacy against ETEC diarrhoea was demonstrated, lasting for around three months (RR 0.43, 95% CI 0.26 to 0.71; two trials, 50,227 participants).",ignore,"['Short term protection against ETEC diarrhoea was demonstrated, lasting for around three months (RR 0.43, 95% CI 0.26 to 0.71; two trials, 50,227 participants).']",7,0.5714285714285714,3,14
CD009029,2,8,This vaccine is no longer available.,rephrase,"['However, this vaccine is no longer available.']",8,0.6428571428571429,4,14
CD009029,3,9,"ETEC vaccines
An ETEC-specific, killed whole cell vaccine, which also contains the recombinant cholera toxin B-subunit, was evaluated in people travelling from the USA to Mexico or Guatemala, and from Austria to Latin America, Africa, or Asia.",ignore,"['An ETEC-specific, killed whole cell vaccine, which also contains the recombinant cholera toxin\xa0B-subunit, was evaluated in people travelling from the USA to Mexico or Guatemala, and from Austria to Latin America, Africa, or Asia.']",9,0.7142857142857143,4,14
CD009029,3,10,"We did not identify any statistically significant differences in ETEC-specific diarrhoea or all-cause diarrhoea (two trials, 799 participants), and the vaccine was associated with increased vomiting (RR 2.0, 95% CI 1.16 to 3.45; nine trials, 1528 participants).",ignore,"['There were no statistically significant differences in ETEC-specific diarrhoea or all-cause diarrhoea (two trials, 799 participants) found and the vaccine was associated with increased vomiting (RR 2.0, 95% CI 1.16 to 3.45; nine trials, 1528 participants).']",10,0.7857142857142857,4,14
CD009029,3,11,The other ETEC-specific vaccines in development have not yet demonstrated clinically important benefits.,ignore,['The other ETEC-specific vaccines in development have not yet demonstrated clinically important benefits.'],11,0.8571428571428571,5,14
CD009029,4,12,There is currently insufficient evidence from RCTs to support the use of the oral cholera vaccine Dukoral® for protecting travellers against ETEC diarrhoea.,delete,[],12,0.9285714285714286,5,14
CD009029,4,13,Further research is needed to develop safe and effective vaccines to provide both short and long-term protection against ETEC diarrhoea.,ignore,['Further research is needed to develop safe and effective vaccines to provide both short and long-term protection against ETEC diarrhoea.'],12,1.0,5,14
CD001006,0,0,"We identified eight eligible studies reporting information about mass media smoking campaigns, one of which is new for this update.",split,"['We found eight studies out of 1326 publications, covering 52,746 participants.', 'One of these studies is new to this updated version of the review.']",0,0.08333333333333333,1,12
CD001006,0,1,Seven of the studies used a controlled trial design and one an interrupted time-series analysis.,delete,[],2,0.16666666666666666,1,12
CD001006,0,2,"Risks of bias were high across all included studies and there was considerable heterogeneity in study design, intervention and population being assessed.Three studies (n = 17,385), one of which compared a mass media intervention to no intervention and two of which evaluated mass media interventions as adjuncts to school-based interventions, found that the mass media interventions reduced the smoking behaviour of young people.",delete,[],2,0.25,2,12
CD001006,0,3,"The remaining five studies (n = 72,740) did not detect a significant effect on smoking behaviour.",rephrase,['The remaining five studies did not detect an effect.'],2,0.3333333333333333,2,12
CD001006,0,4,"These included three studies comparing a mass media intervention to no intervention, one study evaluating a mass media intervention as an adjunct to a school-based intervention, and one interrupted time-series study of a social media intervention.",delete,[],3,0.4166666666666667,3,12
CD001006,0,5,"The three campaigns which found a significant effect described their theoretical basis, used formative research in designing the campaign messages, and used message broadcast of reasonable intensity over extensive periods of time.",delete,[],3,0.5,3,12
CD001006,0,6,"However, some of the campaigns which did not detect an effect also exhibited these characteristics.",delete,[],3,0.5833333333333334,3,12
CD001006,0,7,Effective campaigns tended to last longer (minimum 3 years) and were more intense (more contact time) for both school-based lessons (minimum eight lessons per grade) and media spots (minimum four weeks' duration across multiple media channels with between 167 and 350 TV and radio spots).,rephrase,"[""Although there was some overlap in characteristics between both effective and ineffective programmes, effective campaigns tended to last longer (minimum 3 years) and were more intense (more contact time) for both school-based lessons (minimum eight lessons per grade) and media spots (minimum four weeks' duration across multiple media channels with between 167 and 350 TV and radio spots).""]",3,0.6666666666666666,4,12
CD001006,0,8,"Implementation of combined school-based components (e.g. school posters) and the use of repetitive media messages delivered by multiple channels (e.g. newspapers, radio, television) appeared to contribute to successful campaigns.",ignore,"['Implementation of combined school-based components (e.g. school posters) and the use of repetitive media messages delivered by multiple channels (e.g. newspapers, radio, television) appeared to contribute to successful campaigns.']",4,0.75,4,12
CD001006,1,9,"Certainty about the effects of mass media campaigns on smoking behaviour in youth is very low, due to inconsistency between studies in both design and results, and due to methodological issues amongst the included studies.",delete,[],5,0.8333333333333334,5,12
CD001006,1,10,It would therefore be unwise to offer firm conclusions based on the evidence in this review.,ignore,['It would therefore be unwise to offer firm conclusions based on the evidence in this review.'],5,0.9166666666666666,5,12
CD001006,1,11,Methodologically rigorous studies investigating the effect of social media and novel forms of technology as part of tobacco prevention campaigns for youth are needed.,rephrase,['More high-quality studies are needed.'],6,1.0,5,12
CD007373,0,0,We included 33 trials with 5710 participants total; 29 were published from 2010 to 2015.,rephrase,['We found 33 studies with a total of 5710 women.'],0,0.037037037037037035,1,27
CD007373,0,1,"Studies examined lidocaine, misoprostol, NSAIDs, and other interventions.",rephrase,"['Methods tested were nonsteroidal anti-inflammatory drugs (NSAIDs), lidocaine, misoprostol, and other treatments.']",1,0.07407407407407407,1,27
CD007373,0,2,Here we synthesize results from trials with sufficient outcome data and moderate- or high-quality evidence.,delete,[],2,0.1111111111111111,1,27
CD007373,1,3,"For lidocaine, meta-analysis showed topical 2% gel had no effect on pain at tenaculum placement (two trials) or on pain during IUC insertion (three trials).",rephrase,['Lidocaine 2% gel had no effect on pain during IUC insertion (three trials) or pain with tenaculum (type of forceps) placement (two trials).'],2,0.14814814814814814,1,27
CD007373,1,4,Other formulations were effective compared with placebo in individual trials.,delete,[],3,0.18518518518518517,1,27
CD007373,1,5,"Mean score for IUC-insertion pain was lower with lidocaine and prilocaine cream (MD -1.96, 95% CI -3.00 to -0.92).",split,"['Pain score for IUC insertion was lower with a lidocaine and prilocaine cream and with 10% lidocaine spray.', 'With 4% lidocaine gel, pain scores were lower shortly after IUC insertion.']",3,0.2222222222222222,2,27
CD007373,1,6,"Among nulliparous women, topical 4% formulation showed lower scores for IUC-insertion pain assessed within 10 minutes (MD -15.90, 95% CI -22.77 to -9.03) and at 30 minutes later (MD -11.10, 95% CI -19.05 to -3.15).",delete,[],5,0.25925925925925924,2,27
CD007373,1,7,"Among parous women, IUC-insertion pain was lower with 10% spray (median 1.00 versus 3.00).",delete,[],5,0.2962962962962963,2,27
CD007373,1,8,"Compared with no intervention, pain at tenaculum placement was lower with 1% paracervical block (median 12 versus 28).",rephrase,"['With 1% lidocaine injection, pain score at tenaculum placement was lower compared with no intervention.']",5,0.3333333333333333,2,27
CD007373,2,9,"For misoprostol, meta-analysis showed a higher mean score for IUC insertion compared with placebo (SMD 0.27, 95% CI 0.07 to 0.46; four studies).",delete,[],6,0.37037037037037035,2,27
CD007373,2,10,"In meta-analysis, cramping was more likely with misoprostol (OR 2.64, 95% CI 1.46 to 4.76; four studies).",rephrase,"['In analysis of four trials, cramping was more likely with misoprostol versus placebo.']",6,0.4074074074074074,3,27
CD007373,2,11,A trial with nulliparous women found a higher score for IUC-insertion pain with misoprostol (median 46 versus 34).,rephrase,"[""With four misoprostol trials, the pain score with IUC insertion was higher for misoprostol versus placebo ('dummy' treatment).""]",7,0.4444444444444444,3,27
CD007373,2,12,"Pain before leaving the clinic was higher for misoprostol in two trials with nulliparous women (MD 7.60, 95% CI 6.48 to 8.72; medians 35.5 versus 20.5).",delete,[],8,0.48148148148148145,3,27
CD007373,2,13,"In one trial with nulliparous women, moderate or severe pain at IUC insertion was less likely with misoprostol (OR 0.30, 95% CI 0.16 to 0.55).",delete,[],8,0.5185185185185185,3,27
CD007373,2,14,"In the same trial, the misoprostol group was more likely to rate the experience favorably.",rephrase,"['Also, the misoprostol group rated the insertion more favorably.']",8,0.5555555555555556,3,27
CD007373,2,15,"Within two trials of misoprostol plus diclofenac, shivering, headache, or abdominal pain were more likely with misoprostol.",rephrase,"['Within two other trials, the misoprostol group was more likely to have shivering, headache, or abdominal pain.']",9,0.5925925925925926,3,27
CD007373,2,16,Participants had no vaginal delivery.,delete,[],10,0.6296296296296297,4,27
CD007373,2,17,One trial showed the misoprostol group less likely to choose or recommend the treatment.,split,"['Two other trials showed higher pain scores with misoprostol versus placebo either at IUC insertion or after.', 'However, another study showed the misoprostol group had less serious IUC-insertion pain.', 'In one study, the misoprostol group was less likely to choose the treatment again or recommend it.']",10,0.6666666666666666,4,27
CD007373,3,18,"Among multiparous women, mean score for IUC-insertion pain was lower for tramadol 50 mg versus naproxen 550 mg (MD -0.63, 95% CI -0.94 to -0.32) and for naproxen versus placebo (MD -1.94, 95% CI -2.35 to -1.53).",split,"['Pain score during IUC insertion was lower for the opioid tramadol versus naproxen.', 'In the same trial, pain was lower for naproxen versus placebo.']",13,0.7037037037037037,4,27
CD007373,3,19,The naproxen group was less likely than the placebo group to report the insertion experience as unpleasant and not want the medication in the future.,rephrase,['The naproxen group was less likely than the placebo group to rate the experience as unpleasant and not want the treatment in the future.'],15,0.7407407407407407,4,27
CD007373,3,20,"An older trial showed repeated doses of naproxen 300 mg led to lower pain scores at one hour (MD -1.04, 95% CI -1.67 to -0.41) and two hours (MD -0.98, 95% CI -1.64 to -0.32) after insertion.",rephrase,"['In another trial, women with several naproxen doses had lower pain scores after IUC insertion than the placebo group.']",16,0.7777777777777778,4,27
CD007373,3,21,Most women were nulliparous and also had lidocaine paracervical block.,delete,[],17,0.8148148148148148,5,27
CD007373,4,22,Nearly all trials used modern IUC.,delete,[],17,0.8518518518518519,5,27
CD007373,4,23,"Most effectiveness evidence was of moderate quality, having come from single trials.",rephrase,"['Overall, the effectiveness results were of moderate quality, having come from single studies.']",17,0.8888888888888888,5,27
CD007373,4,24,"Lidocaine 2% gel, misoprostol, and most NSAIDs did not help reduce pain.",delete,[],18,0.9259259259259259,5,27
CD007373,4,25,"Some lidocaine formulations, tramadol, and naproxen had some effect on reducing IUC insertion-related pain in specific groups.",rephrase,"['Trials of lidocaine, tramadol and naproxen showed some effect on reducing pain from IUC insertion.']",18,0.9629629629629629,5,27
CD007373,4,26,The ineffective interventions do not need further research.,delete,[],19,1.0,5,27
CD006524,0,0,"We included six RCTs, with a total of 449 patients.",rephrase,"['In our review we found six studies, with a total of 449 patients, in which one of two interventions were applied.']",0,0.125,1,8
CD006524,0,1,"In four studies (267 patients) the CL intervention resulted in reduced medical costs (in two studies the outcomes could be pooled: MD -352.55 US Dollars (95% CI -522.32 to -182.78)) and improved physical functioning (three studies, MD 5.71 (95% CI 4.11 to 7.31)).",split,"['One intervention (four studies, 267 patients) was a CL following a consultation between the patient and the psychiatrist; the other (two studies, 182 patients) was a CL following a joint consultation between patient, psychiatrist and primary care physician.', 'The first intervention resulted in reduced medical costs (three studies) and improved physical functioning (three studies).']",1,0.25,2,8
CD006524,0,2,"In two studies (182 patients) the intervention was a joint consultation with a psychiatrist in presence of the physician, and resulted in reduced severity of somatization symptoms, reduced medical consumption and improved social functioning.",rephrase,"['We found evidence for a slight reduction in the severity of the MUPS, reduced medical consumption and improved social functioning following the second intervention, although in only one of two studies assessed.']",3,0.375,2,8
CD006524,1,3,There is limited evidence that a CL is effective in terms of medical costs and improvement of physical functioning for patients with MUPS in primary care.,rephrase,['Our final conclusion is that CLs may be helpful for physicians who treat patients with MUPS (based on the provider-related outcomes).'],4,0.5,3,8
CD006524,1,4,"The results are even less pronounced in patients with clinically less severe, but more meaningful, forms of MUPS and the results vary for other patient-related outcomes.",rephrase,"['There are serious limitations in generalizability of the results to modern healthcare: most trials reported doctor-related outcomes with patient-related outcomes varying in results; the intervention appears to be far more effective for the most serious but rare disorders, and less so in the more common forms of MUPS; five of the six studies were performed in the United States and four studies before 1995.']",5,0.625,4,8
CD006524,1,5,"All studies, except one, were performed in the United States and therefore the results can not be generalized directly to countries with other healthcare systems.",delete,[],6,0.75,4,8
CD006524,1,6,Furthermore all studies were small and of only moderate quality.,rephrase,['Furthermore the studied populations were small and five of the six studies were of moderate quality.'],6,0.875,5,8
CD006524,1,7,"There is very limited evidence that a joint consultation with the patient by a psychiatrist in the presence of the physician, together with the provision of a CL, reduces severity of somatization symptoms and medical consumption.",delete,[],7,1.0,5,8
CD006880,0,0,We included seven trials randomising 556 patients.,rephrase,"['In this systematic review of seven randomised clinical trials including 556 patients, various methods of parenchymal transection techniques were compared.']",0,0.07692307692307693,1,13
CD006880,0,1,The comparisons include CUSA (cavitron ultrasound surgical aspirator) versus clamp-crush (two trials); radiofrequency dissecting sealer (RFDS) versus clamp-crush (two trials); sharp dissection versus clamp-crush technique (one trial); and hydrojet versus CUSA (one trial).,delete,[],1,0.15384615384615385,1,13
CD006880,0,2,"One trial compared CUSA, RFDS, hydrojet, and clamp-crush technique.",delete,[],1,0.23076923076923078,2,13
CD006880,0,3,The infective complications and transection blood loss were greater in the RFDS than clamp-crush.,rephrase,['The infective complications and transection blood loss were greater in the radio frequency dissecting sealer (RFDS ) than clamp-crush technique.'],1,0.3076923076923077,2,13
CD006880,0,4,"There was no difference in the blood transfusion requirements, intensive therapy unit (ITU) stay, or hospital stay in this comparison.",rephrase,['Intensive therapy unit stay and hospital stay were similar.'],2,0.38461538461538464,2,13
CD006880,0,5,"There was no significant differences in the mortality, morbidity, markers of liver parenchymal injury or liver dysfunction, ITU, or hospital stay in the other comparisons.",split,"['There were no significant differences in the mortality or in the morbidity between the other techniques of parenchymal transection.', 'There was also no difference in the markers of liver parenchymal injury or liver dysfunction between the different methods used.']",3,0.46153846153846156,3,13
CD006880,0,6,The blood transfusion requirements were lower in the clamp-crush technique than CUSA and hydrojet.,rephrase,['The blood transfusion requirements were lower in the clamp-crush technique than CUSA (cavitron ultrasonic surgical aspirator) and hydrojet.'],5,0.5384615384615384,3,13
CD006880,0,7,There was no difference in the transfusion requirements of clamp-crush technique and sharp dissection.,ignore,['There was no difference in the transfusion requirements of clamp-crush technique and sharp dissection.'],6,0.6153846153846154,4,13
CD006880,0,8,"Clamp-crush technique is quicker than CUSA, hydrojet, and RFDS.",ignore,"['Clamp-crush technique is quicker than CUSA, hydrojet, and RFDS.']",7,0.6923076923076923,4,13
CD006880,0,9,The transection speed of sharp dissection and clamp-crush technique was not compared.,ignore,['The transection speed of sharp dissection and clamp-crush technique was not compared.'],8,0.7692307692307693,4,13
CD006880,0,10,There was no clinically or statistically significant difference in the operating time between sharp dissection and clamp-crush techniques.,ignore,['There was no clinically or statistically significant difference in the operating time between sharp dissection and clamp-crush techniques.'],9,0.8461538461538461,5,13
CD006880,0,11,Clamp-crush technique is two to six times cheaper than the other methods depending upon the number of surgeries performed each year.,ignore,['Clamp-crush technique is two to six times cheaper than the other methods depending upon the number of surgeries performed each year.'],10,0.9230769230769231,5,13
CD006880,1,12,"Clamp-crush technique is advocated as the method of choice in liver parenchymal transection because it avoids special equipment, whereas the newer methods do not seem to offer any benefit in decreasing the morbidity or transfusion requirement.",ignore,['Clamp-crush technique is advocated as the method of choice in liver parenchymal transection because it avoids the need for special equipment and the newer methods do not seem to offer any benefit in decreasing the morbidity or transfusion requirement.'],11,1.0,5,13
CD011169,0,0,"We included only one RCT, which included 93 women, comparing the SERM raloxifene with placebo in biopsy-proven endometriosis.",merge,"[""This study compared the SERM 'raloxifene' versus placebo in 93 women\xa0who had undergone\xa0complete surgical excision of all endometriosis lesions.""]",0,0.05555555555555555,1,18
CD011169,0,1,All women first underwent complete surgical excision of all lesions.,none,[],0,0.1111111111111111,1,18
CD011169,0,2,"Evidence was of very low quality: the main limitation was imprecision - with very sparse data from only one small study, which included only women after surgical treatment.",rephrase,['The main limitations were inclusion of only one study with a small number of participants and lack of both primary and secondary outcome data.'],1,0.16666666666666666,1,18
CD011169,1,3,"Relief of pelvic pain
The included study did not specifically measure the primary outcome of pain relief.",rephrase,['The included study did not report the primary outcome of pain relief.'],2,0.2222222222222222,2,18
CD011169,1,4,Study authors reported that time to return of pelvic pain (defined as two months of pain equal to or more severe than pain at study entry) was more rapid in the raloxifene group (P = 0.03).,rephrase,"['However, study authors reported that women in the raloxifene group were likely to experience return of pain sooner than women in the placebo group.']",3,0.2777777777777778,2,18
CD011169,2,5,"Adverse events
The included study reported adverse events such as pelvic pain, ovarian cyst, headache, migraine, and depression.",rephrase,"['Adverse events such as pelvic pain, ovarian cyst,\xa0headache, migraine, and depression did not differ between study groups.']",4,0.3333333333333333,2,18
CD011169,2,6,"We are uncertain whether raloxifene improves the incidence of pelvic pain (RR 1.25, 95% CI 0.63 to 2.45), ovarian cysts (RR 1.57, 95% CI 0.55 to 4.43), headache (RR 1.09, 95% CI 0.49 to 2.43), migraine (RR 0.73, 95% CI 0.28 to 1.95), depression (RR 1.96, 95% CI 0.63 to 6.06), or other adverse events (RR 0.08, 95% CI 0.00 to 1.30) (all: 1 study, n = 93; very low-quality evidence).",rephrase,"['We are uncertain whether raloxifene improves adverse outcomes when compared with placebo (1 study, 93 women; very low-quality evidence).']",5,0.3888888888888889,2,18
CD011169,3,7,"Quality of life
The study described a statistically significant difference in mental health quality of life (QoL) by 12 months, in favour of placebo treatment (mean difference 11.1, 95% CI 0.01 to 21.19).",split,"['The included study reported that quality of life measurements did not differ between raloxifene and placebo groups, except in the domain of mental health.', 'By 12 months, mental health quality of life scores favoured placebo treatment (mean difference 11.1, 95% confidence interval (CI) 0.01 to 21.19).']",6,0.4444444444444444,3,18
CD011169,3,8,Other QoL data did not differ between groups but were not reported in detail.,delete,[],8,0.5,3,18
CD011169,4,9,"Recurrence rate, fertility, and economic outcomes
We are uncertain whether raloxifene improves the recurrence rate of endometriosis, proven by biopsy, when compared to placebo (RR 1.20, 95% CI 0.66 to 2.21; 1 study, n = 93; very low-quality evidence).",rephrase,"['We are uncertain whether\xa0raloxifene improves the recurrence rate of endometriosis,\xa0as proven by biopsy, when compared to placebo (1 study, 93 women; very low-quality evidence).']",8,0.5555555555555556,3,18
CD011169,4,10,"This suggests that if 28% of women taking placebo have biopsy-proven recurrence of endometriosis, between 19% and 62% of those taking raloxifene will do so.",ignore,"['This\xa0suggests that if 28% of women taking placebo have biopsy-proven recurrence of endometriosis pelvic pain, between 19% and 62% of those taking raloxifene will do so.']",9,0.6111111111111112,4,18
CD011169,4,11,"These outcomes are prone to bias, as not all women had an actual second laparoscopy.",rephrase,"['These outcomes are limited, as not all women had an actual second laparoscopy to take biopsy samples.']",10,0.6666666666666666,4,18
CD011169,4,12,"Recurrence based on symptoms (non-menstrual pain, dysmenorrhoea, or dyspareunia) was described; in these cases, symptoms improved after use of raloxifene as well as after use of placebo.",delete,[],11,0.7222222222222222,4,18
CD011169,5,13,The included study did not report data on economic outcomes.,rephrase,['There were no usable data on fertility nor on economic outcomes.'],11,0.7777777777777778,4,18
CD011169,5,14,"No comparative data were available on pregnancy, as the study included only women who agreed to postpone pregnancy until after the study endpoint; the few pregnancies that did occur were uneventful but were regarded as an adverse event.",delete,[],12,0.8333333333333334,5,18
CD011169,6,15,"Based on a single, small RCT and incomplete data, we are uncertain of the effects of SERMs on pain relief in surgically treated patients with endometriosis.",rephrase,"['Based on the single study included in this review, reviewers found no evidence of a beneficial effect of SERMs\xa0as treatment for pain relief in\xa0surgically treated endometriosis.']",12,0.8888888888888888,5,18
CD011169,6,16,The included study was stopped prematurely because of higher pain scores among women who took SERMs when compared to scores among those receiving placebo.,rephrase,"['On the contrary, the study was prematurely stopped because women who used SERMs experienced a return of pain sooner than women who used placebo.']",13,0.9444444444444444,5,18
CD011169,6,17,Further research is needed to fully evaluate the role of SERMs in endometriosis.,delete,[],14,1.0,5,18
CD009756,0,0,Two RCTs from Kenya were included in the review.,rephrase,['Two randomised controlled trials from Kenya were included in the review.'],0,0.0625,1,16
CD009756,0,1,One trial compared short weekly text messages against standard care.,ignore,['One trial compared short weekly text messages against standard care.'],1,0.125,1,16
CD009756,0,2,"The other trial compared short daily, long daily, short weekly and long weekly messages against standard care.",ignore,"['The other trial compared short daily, long daily, short weekly and long weekly messages against standard care.']",2,0.1875,1,16
CD009756,0,3,Both trials were with adult patients.,delete,[],3,0.25,2,16
CD009756,1,4,"In the trial comparing only short weekly messages to standard care, text messaging was associated with a lower risk of non-adherence at 12 months (RR 0.77, 95% CI 0.63 to 0.93) and with the non-occurrence of virologic failure at 12 months (RR 0.83, 95% CI 0.69 to 0.99).",rephrase,"['In the trial comparing only short weekly messages to standard care, text messaging was associated with lower risk of non-adherence at 12 months, and with the non-occurrence of virologic failure at 12 months.']",3,0.3125,2,16
CD009756,2,5,"In the trial that compared different intervals and lengths for text-messaging to standard care, long weekly text-messaging was not significantly associated with a lower risk of non-adherence compared to standard care (RR 0.79, 95% CI 0.60 to 1.04).",ignore,"['In the trial that compared different intervals and lengths for text-messaging to standard care, long weekly text-messaging was not significantly associated with a lower risk of non-adherence compared to standard care.']",4,0.375,2,16
CD009756,2,6,"Patients receiving weekly text-messages of any length were at lower risk of non-adherence at 48 weeks than were patients receiving daily messages of any length (RR 0.79, 95% CI 0.64 to 0.99).",rephrase,['Patients receiving weekly text-messages of any length were at lower risk of non-adherence at 48 weeks than were patients receiving daily messages of any length.'],5,0.4375,3,16
CD009756,2,7,"There were no significant differences between weekly text-messaging of any length (RR 1.01, 95% CI 0.75 to 1.37) and between short or long messaging at either interval (RR 0.99, 95% CI 0.78 to 1.27).",rephrase,['There were no significant differences between weekly text-messaging of any length and between short or long messaging at either interval.'],6,0.5,3,16
CD009756,2,8,"Compared to standard care, any daily text-messaging, whether short or long, did not reduce the risk for non-adherence (RR 0.99, 95% CI 0.82 to 1.20).",rephrase,"['Compared to standard care, any daily text-messaging, whether short or long, did not reduce the risk for non-adherence.']",7,0.5625,3,16
CD009756,3,9,"In meta-analysis of both trials, any weekly text-messaging (i.e. whether short or long messages) was associated with a lower risk of non-adherence at 48-52 weeks (RR 0.78, 95% CI 0.68 to 0.89).",rephrase,"['Combining the data from both trials, weekly mobile phone text-messaging was associated with greater ART adherence at 48-52 weeks.']",8,0.625,4,16
CD009756,3,10,"The effect of short weekly text-messaging was also significant (RR 0.77, 95% CI 0.67 to 0.89).",rephrase,['The effect of short weekly text-messaging was also significant.'],9,0.6875,4,16
CD009756,4,11,"There is high-quality evidence from the two RCTs that mobile phone text-messaging at weekly intervals is efficacious in enhancing adherence to ART, compared to standard care.",delete,[],10,0.75,4,16
CD009756,4,12,There is high quality evidence from one trial that weekly mobile phone text-messaging is efficacious in improving HIV viral load suppression.,delete,[],10,0.8125,5,16
CD009756,4,13,Policy-makers should consider funding programs proposing to provide weekly mobile phone text-messaging as a means for promoting adherence to antiretroviral therapy.,delete,[],10,0.875,5,16
CD009756,4,14,Clinics and hospitals should consider implementing such programs.,delete,[],10,0.9375,5,16
CD009756,4,15,"There is a need for large RCTs of this intervention in adolescent populations, as well as in high-income countries.",split,"['Because the two included trials were with adult patients only, there is a need for trials of this intervention with adolescents.', 'Also, as the two trials were conducted in Kenya, a low-income country, there is a need for trials of this intervention in high-income countries.']",10,1.0,5,16
CD010915,0,0,We identified four studies that met the inclusion criteria: three randomized controlled trials and a pilot study for one of the included trials.,split,"['We only found four studies to include.', 'Three were randomized trials and the fourth was a pilot study for one of the included trials.']",0,0.07142857142857142,1,14
CD010915,0,1,"The interventions differed markedly: computer-delivered, individually tailored sessions; phone counseling added to clinic counseling; and case management plus a peer-leadership program.",rephrase,['They included computer-delivered sessions tailored for each person; phone counseling added to clinic counseling; and case management plus a peer-leadership program.'],2,0.14285714285714285,1,14
CD010915,0,2,"The latter study, which addressed multiple risks, showed an effect on contraceptive use.",delete,[],3,0.21428571428571427,2,14
CD010915,0,3,"Compared to the control group, the intervention group was more likely to report consistent dual-method use, i.e., oral contraceptives and condoms.",rephrase,"['In the latter study, more women in the intervention group reported regular use of dual methods, namely birth control pills plus condoms, than the control group.']",3,0.2857142857142857,2,14
CD010915,0,4,The reported relative risk was 1.58 at 12 months (95% CI 1.03 to 2.43) and 1.36 at 24 months (95% CI 1.01 to 1.85).,delete,[],4,0.35714285714285715,2,14
CD010915,0,5,The related pilot study showed more reporting of consistent dual-method use for the intervention group compared to the control group (reported P value = 0.06); the investigators used a higher alpha (P < 0.10) for this pilot study.,rephrase,['The pilot study reported a trend toward more regular dual-method use for the intervention group compared to the control group.'],4,0.42857142857142855,3,14
CD010915,0,6,The other two trials did not show any significant difference between the study groups in reported dual-method use or in test results for pregnancy or STIs at 12 or 24 months.,rephrase,['The other two trials did not show any major difference between the study groups in reported use of dual methods or in test results for pregnancy or STIs.'],5,0.5,3,14
CD010915,1,7,We found few behavioral interventions for improving dual-method contraceptive use and little evidence of effectiveness.,merge,"['We found few programs to improve use of dual methods, and only one showed an effect.']",6,0.5714285714285714,3,14
CD010915,1,8,A multifaceted program showed some effect but only had self-reported outcomes.,none,[],6,0.6428571428571429,4,14
CD010915,1,9,"Two trials were more applicable to clinical settings and had objective outcomes measures, but neither showed any effect.",delete,[],7,0.7142857142857143,4,14
CD010915,1,10,The included studies had adequate information on intervention fidelity and sufficient follow-up periods for change to occur.,rephrase,['The studies had adequate follow-up periods of 12 to 24 months.'],7,0.7857142857142857,4,14
CD010915,1,11,"However, the overall quality of evidence was considered low.",rephrase,"['However, the overall quality of results was low, mainly due to study design and losing many women to follow up.']",8,0.8571428571428571,5,14
CD010915,1,12,"Two trials had design limitations and two had high losses to follow up, as often occurs in contraceptive trials.",delete,[],9,0.9285714285714286,5,14
CD010915,1,13,Good quality studies are still needed of carefully designed and implemented programs or services.,delete,[],9,1.0,5,14
CD005983,0,0,We included two eligible studies with a total of 287 participants; both had good methodological quality.,rephrase,['The review authors identified two good quality controlled trials that randomized 287 children aged one day to 16 years to either a heparin-bonded catheter or a standard catheter.'],0,0.1,1,10
CD005983,0,1,There was no difference in the duration of catheter patency between heparin-bonded and non-heparin bonded catheters (median duration seven days versus six days) reported in one study.,split,"['The median duration of time that the catheter could be used to give fluids (its patency) was not clearly different with the two types of catheter.', 'This was seven days in the heparin-bonded catheter group and six days in the standard catheter group.']",1,0.2,1,10
CD005983,0,2,"There was no difference in the risk of catheter-related thrombosis (two studies, RR 0.34, 95% CI 0.01 to 7.68; I2 = 80%; RD -0.06, 95% CI -0.17 to 0.06).",rephrase,['There was a no difference between the two groups for risk of catheter-related thrombosis over the time the catheter was in.'],3,0.3,2,10
CD005983,0,3,"Data from one study revealed a statistically significant reduction in the risk of catheter occlusion (RR 0.06, 95% CI 0.00 to 1.07; RD -0.08, 95% CI -0.13 to -0.02; NNT 13, 95% CI 8 to 50), catheter-related blood stream infections (RR 0.06, 95% CI 0.01 to 0.41; RD -0.17, 95% CI -0.25 to -0.10; NNT 6, 95% CI 4 to 10) and catheter colonization (RR 0.21, 95% CI 0.06 to 0.71; RD -0.11, 95% CI -0.19 to -0.04; NNT 9, 95% CI 5 to 25) in the heparin-bonded catheter group.",rephrase,"['There was a trend towards a reduction in the risk of catheter occlusion in the first week after catheter placement, reported in one study only.']",4,0.4,2,10
CD005983,0,4,The second study did not report on these outcomes.,delete,[],5,0.5,3,10
CD005983,0,5,"There was no significant difference in risk of thrombocytopenia after catheter placement (RR 0.73, 95% CI 0.38 to 1.39; RD -0.02, 95% CI -0.10 to 0.07).",rephrase,['There was no significant difference in risk of thrombocytopenia after catheter placement.'],5,0.6,3,10
CD005983,1,6,Two eligible studies on the use of heparin-bonded catheters versus placebo in children were identified.,delete,[],6,0.7,4,10
CD005983,1,7,Meta-analysis of the two studies revealed no reduction in catheter-related thrombosis with heparin-bonded catheters.,delete,[],6,0.8,4,10
CD005983,1,8,One study reported a reduction in catheter-related blood stream infection and colonization following the use of heparin-bonded catheters.,merge,"['The risks of catheter-related blood stream infections and bacterial colonization of the catheter were significantly reduced using the heparin-bonded catheter, with a longer time to develop infection (delayed in the heparin-bonded catheter group); however, it was reported in one study only and the strength of evidence was low.']",6,0.9,5,10
CD005983,1,9,The strength of evidence is low and further well-designed multicenter randomized controlled trials are warranted.,none,[],6,1.0,5,10
CD007286,0,0,"We included 10 RCTs (N = 1815), which were published between 1983 and 2015.",rephrase,"['Ten trials met our inclusion criteria, and included 1815 people.']",0,0.07142857142857142,1,14
CD007286,0,1,Three trials compared a single AED (phenytoin) with placebo or no treatment.,rephrase,['Three trials compared phenytoin (an AED) with a placebo (sham) or no treatment.'],1,0.14285714285714285,1,14
CD007286,0,2,"One, three-armed trial compared two AEDs (phenytoin, carbamazepine) with no treatment.",rephrase,['One trial compared the AEDs phenytoin or carbamazepine with no treatment.'],2,0.21428571428571427,2,14
CD007286,0,3,"A second three-armed trial compared phenytoin, phenobarbital with no treatment.",merge,['One trial compared the AEDs phenytoin or phenobarbital with no treatment.'],3,0.2857142857142857,2,14
CD007286,0,4,"Of these five trials comparing AEDs with placebo or no treatment, two trials reported a statistically significant advantage for AED treatment compared to controls for early seizure occurrence; all other comparisons showed no clear or statistically significant differences between AEDs and control treatment.",none,[],3,0.35714285714285715,2,14
CD007286,0,5,"None of the trials that were head-to-head comparisons of AEDs (phenytoin versus sodium valproate, phenytoin versus phenobarbital, levetiracetam versus phenytoin, zonisamide versus phenobarbital) reported any statistically significant differences between treatments for either early or late seizure occurrence.",rephrase,['Five other trials were head-to-head trials (where one drug is directly compared against another drug) of AEDs (phenytoin versus valproate; zonisamide versus phenobarbital and levetiracetam versus phenytoin).'],4,0.42857142857142855,3,14
CD007286,1,6,Only five trials reported incidences of death.,delete,[],5,0.5,3,14
CD007286,1,7,"One trial reported statistically significantly fewer deaths in the carbamazepine and no-treatment groups compared with the phenytoin group after 24 months of treatment, but not after six months of treatment.",delete,[],5,0.5714285714285714,3,14
CD007286,1,8,"Incidences of adverse effects of treatment were poorly reported; however, three trials did show that significantly more adverse events occurred on phenytoin compared to valproate, placebo, or no treatment.",delete,[],5,0.6428571428571429,4,14
CD007286,1,9,No trials reported any results relating to functional outcomes such as disability.,delete,[],5,0.7142857142857143,4,14
CD007286,2,10,We considered the evidence to be of low certainty for all reported outcomes due to methodological issues and variability of comparisons made in the trials.,rephrase,"['Taking all the trials together, we considered that the certainty of the evidence was low due to potential problems with the designs of the trials.']",5,0.7857142857142857,4,14
CD007286,3,11,"There is limited, low-certainly evidence to suggest that AED treatment administered prophylactically is either effective or not effective in the prevention of postcraniotomy (early or late) seizures.",rephrase,"['We did not find any consistent evidence to suggest that preventative AED treatments are effective in reducing the number of seizures that occurred postsurgery, deaths or adverse effects.']",6,0.8571428571428571,5,14
CD007286,3,12,The current evidence base is limited due to the different methodologies employed in the trials and inconsistencies in the reporting of outcomes including deaths and adverse events.,delete,[],7,0.9285714285714286,5,14
CD007286,3,13,"Further evidence from good-quality, contemporary trials is required in order to assess the clinical effectiveness of prophylactic AED treatment compared to placebo or no treatment, or other AEDs in preventing postcraniotomy seizures in this select group of patients.",rephrase,['Further good-quality studies are needed to validate the findings mentioned above.'],7,1.0,5,14
CD010690,0,0,We included nine studies enrolling 220 dialysis participants.,rephrase,"['Of the nine studies, one was sponsored by a pharmaceutical company and funding sources were reported for only two other studies.']",0,0.043478260869565216,1,23
CD010690,0,1,Seven studies were deemed to have moderate to high risk of bias.,rephrase,['The quality of the studies was deemed to be moderate.'],1,0.08695652173913043,1,23
CD010690,0,2,All studies were small in size and had a short follow-up period (two to six months).,rephrase,"['The included studies were heterogeneous, small in size and had short follow-up periods.']",2,0.13043478260869565,1,23
CD010690,0,3,Studies evaluated the effects of six different interventions against placebo or standard treatment.,delete,[],3,0.17391304347826086,1,23
CD010690,0,4,"The interventions studied included aerobic resistance exercise, gabapentin, ropinirole, levodopa, iron dextran, and vitamins C and E (individually and in combination).",ignore,"['The interventions studied included exercise, gabapentin, ropinirole, levodopa, iron dextran, and vitamins C and E (individually and in combination).']",3,0.21739130434782608,2,23
CD010690,1,5,"Aerobic resistance exercise showed a significant reduction in severity of RLS compared to no exercise (2 studies, 48 participants: MD -7.56, 95% CI -14.20 to -0.93; I2 = 65%), and when compared to exercise with no resistance (1 study, 24 participants: MD -11.10, 95% CI -17.11 to -5.09), however there was no significant reduction when compared to ropinirole (1 study, 22 participants): MD -0.55, 95% CI -6.41 to 5.31).",rephrase,['Intradialytic aerobic exercise reduced the severity of RLS however the safety of this intervention is unclear.'],4,0.2608695652173913,2,23
CD010690,1,6,There were no significant differences between aerobic resistance exercise and either no exercise or ropinirole in the physical or mental component summary scores (using the SF-36 form).,rephrase,['This improvement in mental health component was not significant when compared to no exercise or ropinirole.'],5,0.30434782608695654,2,23
CD010690,1,7,Improvement in sleep quality varied.,rephrase,['Resistance exercise did not improve sleep quality but improved the mental health component on a quality of life questionnaire.'],6,0.34782608695652173,2,23
CD010690,1,8,"There was no significant difference in subjective sleep quality between exercise and no exercise; however one study reported a significant improvement with ropinirole compared to resistance exercise (MD 3.71, 95% CI 0.89 to 6.53).",delete,[],7,0.391304347826087,2,23
CD010690,1,9,"Using the Epworth Sleepiness Scale there were no significant differences between resistance exercise and no exercise, ropinirole, or exercise with no resistance.",delete,[],7,0.43478260869565216,3,23
CD010690,1,10,Two studies reported there were no adverse events and one study did not mention if there were any adverse events.,delete,[],7,0.4782608695652174,3,23
CD010690,1,11,"In one study, one patient in each group dropped out but the reason for dropout was not reported.",delete,[],7,0.5217391304347826,3,23
CD010690,1,12,Two studies reported no adverse events and one study did not report adverse events.,delete,[],7,0.5652173913043478,3,23
CD010690,2,13,"Gabapentin was associated with reduced RLS severity when compared to placebo or levodopa, and there was a significant improvement in sleep quality, latency and disturbance reported in one study when compared to levodopa.",delete,[],7,0.6086956521739131,4,23
CD010690,2,14,"Three patients dropped out due to lethargy (2 patients), and drowsiness, syncope and fatigue (1 patient).",delete,[],7,0.6521739130434783,4,23
CD010690,3,15,"Because of a short duration of action, rebound and augmentation were noted with levodopa treatment even though it conferred some benefit in reducing the symptoms of RLS.",delete,[],7,0.6956521739130435,4,23
CD010690,3,16,"Reported adverse events were severe vomiting, agitation after caffeine intake, headaches, dry mouth, and gastrointestinal symptoms.",rephrase,"['Gabapentin and levodopa improved the symptoms of RLS; however there were several adverse events reported included lethargy, drowsiness and fatigue for gabapentin, and vomiting, agitation, headaches, dry mouth, and gastrointestinal symptoms for levodopa.']",7,0.7391304347826086,4,23
CD010690,4,17,"One study (25 participants) reported iron dextran reduced the severity of RLS at weeks one and two, but not at week four.",rephrase,['Iron dextran infusion reduced the symptoms of RLS but was only significant up to two weeks after treatment.'],8,0.782608695652174,4,23
CD010690,4,18,"Vitamins C, E and C plus E (1 study, 60 participants) helped the symptoms of RLS with minimal side effects (nausea and dyspepsia) but more evidence is needed before any conclusions can be drawn.",rephrase,"['Vitamin C, E and their combination also reduced RLS symptoms with minimal side effects.']",9,0.8260869565217391,5,23
CD010690,5,19,"Given the small size of the studies and short follow-up, it can only be concluded that pharmacological interventions and intra-dialytic exercise programs have uncertain effects on RLS in haemodialysis patients.",split,"['The small number of studies, small sample sizes and short duration of follow up make it difficult to draw any firm conclusions.', 'The effects of aerobic exercise and other pharmacological agents on RLS are uncertain in haemodialysis patients.']",10,0.8695652173913043,5,23
CD010690,5,20,"There have been no studies performed in non-dialysis CKD, peritoneal dialysis patients, or kidney transplant recipients.",delete,[],12,0.9130434782608695,5,23
CD010690,5,21,Further studies are warranted before any conclusions can be drawn.,delete,[],12,0.9565217391304348,5,23
CD010690,5,22,Aerobic resistance exercise and ropinirole may be suitable interventions for further evaluation.,ignore,['Aerobic exercise and ropinirole may be suitable interventions for further evaluation.'],12,1.0,5,23
CD007743,0,0,One study (186 infants up to two years old) comparing five monthly doses of palivizumab (N = 92) to placebo (N = 94) over one respiratory syncytial virus season was identified and met our inclusion criteria.,rephrase,['We found one study with 186 participants (infants with cystic fibrosis up to two years of age) which was run across 40 centres in the USA.'],0,0.08333333333333333,1,12
CD007743,0,1,We judged there to be a low risk of bias with respect to the concealment of the randomization schedule (although it was not clear how this was generated) and to blinding of participants and study personnel.,rephrase,['We also thought that participants and study personnel were sufficiently blinded to the treatment to avoid bias and that any missing data were unlikely to bias the study results.'],1,0.16666666666666666,1,12
CD007743,0,2,There is also a low risk of bias with regards to incomplete outcome data.,delete,[],2,0.25,2,12
CD007743,0,3,"However, we judged there to be a high risk of bias from selective reporting (summary statements presented but no data) and the fact that this industry-supported study has not been published as a full report in a peer-reviewed journal.",rephrase,"['However, we did have concerns about bias from selective reporting (summary statements were presented but without any data) and the fact that this industry-supported study has not been published as a full report in a peer-reviewed journal.']",2,0.3333333333333333,2,12
CD007743,1,4,"At six months follow-up, one participant in each group was hospitalised due to respiratory syncytial virus; there were no deaths in either group.",delete,[],3,0.4166666666666667,3,12
CD007743,1,5,"In the palivizumab and placebo groups, 86 and 90 children experienced any adverse event, while five and four children had related adverse events respectively.",delete,[],3,0.5,3,12
CD007743,1,6,Nineteeen children receiving palivizumab and 16 receiving placebo suffered serious adverse events; one participant receiving palivizumab discontinued due to this.,delete,[],3,0.5833333333333334,3,12
CD007743,1,7,"At 12 months follow-up, there were no significant differences between groups in number of Pseudomonas bacterial colonisations or change in weight-to-height ratio.",rephrase,"['Over the longer term (12 months), weight gain and the number of infections with Pseudomonas aeruginosa (a common bacterial infection in cystic fibrosis) were similar between groups.']",3,0.6666666666666666,4,12
CD007743,2,8,We identified one randomised controlled trial comparing five monthly doses of palivizumab to placebo in infants up to two years old with cystic fibrosis.,delete,[],4,0.75,4,12
CD007743,2,9,"While the overall incidence of adverse events was similar in both groups, it is not possible to draw firm conclusions on the safety and tolerability of respiratory syncytial virus prophylaxis with palivizumab in infants with cystic fibrosis.",rephrase,"['Overall, the number of adverse events in the palivizumab group was similar to that in the placebo group.']",4,0.8333333333333334,5,12
CD007743,2,10,"Six months after treatment, the authors reported no clinically meaningful differences in outcomes.",delete,[],5,0.9166666666666666,5,12
CD007743,2,11,Additional randomised studies are needed to establish the safety and efficacy of palivizumab in children with cystic fibrosis.,rephrase,['More research is needed on the use of the palivizumab vaccination in children with cystic fibrosis.'],5,1.0,5,12
CD006342,0,0,"We included two studies in this review, both of which were double-blind, randomised controlled trials comparing perioperative beta-adrenergic blockade (metoprolol) with placebo, on cardiovascular outcomes in people undergoing major non-cardiac vascular surgery.",split,"['We identified two studies that evaluated beta-blockers giving during surgery (perioperatively) in people undergoing major non-cardiac vascular surgery, with follow-up data on cardiovascular outcomes.', 'Both studies were double-blind (neither participants nor surgeon were aware of the treatment), randomised controlled trials evaluating the beta-blocker, metoprolol.']",0,0.1111111111111111,1,9
CD006342,0,1,We included 599 participants receiving beta-adrenergic blockers (301 participants) or placebo (298 participants).,rephrase,['A total of 599 participants were randomised to receive beta-blockers (301 participants) or placebo (298 participants).'],2,0.2222222222222222,2,9
CD006342,0,2,The overall quality of studies was good.,rephrase,['Study quality was good for both trials.'],3,0.3333333333333333,2,9
CD006342,0,3,"However, one study did not report random sequence generation or allocation concealment techniques, indicating possible selection bias, and the other study did not report outcome assessor blinding and was possibly underpowered.",rephrase,"['One trial did not adequately describe their randomisation techniques and the other trial did not report whether the outcome assessors were blinded to the treatment group, and was possibly underpowered.']",4,0.4444444444444444,3,9
CD006342,0,4,"It should be noted that several of the outcomes were only reported in a single study and neither of the studies reported on vascular patency/graft occlusion, which reduces the quality of evidence to moderate.",rephrase,"['With only two studies included, several of the outcomes only had data from a single study, and neither of the studies reported on blockage or obstruction of blood vessels (vascular patency/graft occlusion), reducing the quality of evidence to moderate.']",5,0.5555555555555556,3,9
CD006342,0,5,"There was no evidence that perioperative beta-adrenergic blockade reduced all-cause mortality (OR 0.62, 95% CI 0.03 to 15.02), cardiovascular mortality (OR 0.34, 95% CI 0.01 to 8.32), non-fatal myocardial infarction (OR 0.83, 95% CI 0.46 to 1.49; P value = 0.53), arrhythmia (OR 0.70, 95% CI 0.26 to 1.88), heart failure (OR 1.71, 95% CI 0.40 to 7.23), stroke (OR 2.67, 95% CI 0.11 to 67.08), composite cardiovascular events (OR 0.87, 95% CI 0.55 to 1.39; P value = 0.57) or re-hospitalisation at 30 days (OR 0.86, 95% CI 0.48 to 1.52).",delete,[],6,0.6666666666666666,4,9
CD006342,0,6,"However, there was strong evidence that beta-adrenergic blockers increased the odds of intra-operative bradycardia (OR 4.97, 95% CI 3.22 to 7.65; P value < 0.00001) and intra-operative hypotension (OR 1.84, 95% CI 1.31 to 2.59; P value = 0.0005).",delete,[],6,0.7777777777777778,4,9
CD006342,1,7,This meta-analysis currently offers no clear evidence that perioperative beta-adrenergic blockade reduces postoperative cardiac morbidity and mortality in people undergoing major non-cardiac vascular surgery.,rephrase,"['The results of the analysis offered no clear evidence that perioperative beta-blockers reduced death from any cause (all-cause mortality), cardiovascular death, non-fatal heart attack, irregular heartbeat (arrhythmia), heart failure, stroke, combined cardiovascular events or re-hospitalisation at 30 days.']",6,0.8888888888888888,5,9
CD006342,1,8,"There is evidence that intra-operative bradycardia and hypotension are more likely in people taking perioperative beta-adrenergic blockers, which should be weighed with any benefit.",split,"['There was evidence to support that beta-blockers increased the risk of intra-operative low heart rate (bradycardia) and low blood pressure (hypotension).', 'These complications should be weighed with any benefit when considering the use of beta-blockers in this population.']",7,1.0,5,9
CD006597,0,0,"One randomised controlled trial of 100 IBD patients receiving a specialist nurse delivered counselling package (n = 50) or routine outpatient clinic follow-up (n = 50), with assessments at entry and six and 12 months, was included in this review.",rephrase,['This review included one low quality trial of a specialist nurse counselling intervention compared with routine outpatient clinic follow up.'],0,0.125,1,8
CD006597,0,1,This study was of low methodological quality.,delete,[],1,0.25,2,8
CD006597,0,2,"Disease remission, patient compliance, clinical improvement, utilisation of nurse-led services, patient satisfaction, hospital admission, outpatient attendance, progression to surgery, length of hospital stay and cost effectiveness data were not reported.",rephrase,['No data were reported on remission outcomes.'],1,0.375,2,8
CD006597,0,3,Pooled mean mental health scores at 6 months were higher in patients who received nurse-led counselling compared to patients who received routine follow-up.,delete,[],2,0.5,3,8
CD006597,0,4,"However, this difference was not statistically significant (WMD 3.67; 95% CI -0.44 to 7.77; P = 0.08).",delete,[],2,0.625,4,8
CD006597,0,5,Other pooled assessments of physical and psychological well-being showed no statistically significant differences.,delete,[],2,0.75,4,8
CD006597,1,6,Although specialist nurse counselling interventions might provide benefit for IBD patients the one included study was of low quality and the results of this study should be interpreted with caution.,split,"['Counselling by a specialist nurse might improve mental health related quality of life for some IBD patients in the short term.', 'However, the poor quality of the one included study does not allow for any definitive conclusions regarding the impact of the nurse-led counselling program.']",2,0.875,5,8
CD006597,1,7,Higher quality trials of gastroenterology and IBD specialist nursing interventions are needed to assess the impact of specialist nursing interventions on the care and management of patients with inflammatory bowel disease.,rephrase,['Better designed studies are needed to assess the impact of specialist nursing interventions on the care and management of patients with inflammatory bowel disease.'],4,1.0,5,8
CD006589,0,0,"Thirty-five trials (31,955 children) met the inclusion criteria.",rephrase,"['Cochrane researchers searched the available evidence up to 30 August 2015 and included 35 trials (31,955 children).']",0,0.1,1,10
CD006589,0,1,"Overall, iron does not cause an excess of clinical malaria (risk ratio (RR) 0.93, 95% confidence intervals (CI) 0.87 to 1.00; 14 trials, 7168 children, high quality evidence).",rephrase,"['Iron did not increase the risk of malaria, indicated by fever and the presence of parasites in the blood (high quality evidence).']",1,0.2,1,10
CD006589,0,2,Iron probably does not cause an excess of clinical malaria in both populations where anaemia is common and those in which anaemia is uncommon.,delete,[],2,0.3,2,10
CD006589,0,3,"In areas where there are prevention and management services for malaria, iron (with or without folic acid) may reduce clinical malaria (RR 0.91, 95% CI 0.84 to 0.97; seven trials, 5586 participants, low quality evidence), while in areas where such services are unavailable, iron (with or without folic acid) may increase the incidence of malaria, although the lower CIs indicate no difference (RR 1.16, 95% CI 1.02 to 1.31; nine trials, 19,086 participants, low quality evidence).",split,"['In areas where health services are sufficient to help prevent and treat malaria, giving iron supplements (with or without folic acid) may reduce clinical malaria.', 'In areas where these services are not available, iron supplementation (with or without folic acid) may increase the number of children with clinical malaria (low quality evidence).']",2,0.4,2,10
CD006589,0,4,"Iron supplementation does not cause an excess of severe malaria (RR 0.90, 95% CI 0.81 to 0.98; 6 trials, 3421 children, high quality evidence).",split,"['Among children treated with iron, there was no increased risk of severe malaria (high quality evidence).', 'Although it is hypothesized that iron supplementation might harm children who do not have anaemia living in malarial areas, there is probably no increased risk for malaria in these children (moderate quality evidence).']",4,0.5,3,10
CD006589,0,5,"We did not observe any differences for deaths (control event rate 1%, low quality evidence).",delete,[],6,0.6,3,10
CD006589,0,6,"Iron and antimalarial treatment reduced clinical malaria (RR 0.54, 95% CI 0.43 to 0.67; three trials, 728 children, high quality evidence).",delete,[],6,0.7,4,10
CD006589,0,7,"Overall, iron resulted in fewer anaemic children at follow up, and the end average change in haemoglobin from base line was higher with iron.",ignore,"['Overall, iron resulted in fewer anaemic children at follow up, and the end average change in haemoglobin from base line was higher with iron.']",6,0.8,4,10
CD006589,1,8,Iron treatment does not increase the risk of clinical malaria when regular malaria prevention or management services are provided.,split,"['Our conclusions are that iron supplementation does not adversely affect children living in malaria-endemic areas.', 'Based on our review, routine iron supplementation should not be withheld from children living in countries where malaria is prevalent and malaria management services are available.']",7,0.9,5,10
CD006589,1,9,"Where resources are limited, iron can be administered without screening for anaemia or for iron deficiency, as long as malaria prevention or management services are provided efficiently.",delete,[],9,1.0,5,10
CD013297,0,0,We included one study in the review.,rephrase,['We found only one study that met our criteria.'],0,0.06666666666666667,1,15
CD013297,0,1,This was a RCT including 53 eyes of 53 participants with mild symptomatic epiretinal membrane and BCVA of 65 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letters.,rephrase,['This study took place in Denmark and included 53 people who had epiretinal membranes causing mild impairment of sight.'],1,0.13333333333333333,1,15
CD013297,0,2,Participants were randomly allocated to immediate surgery or to watchful waiting with deferred surgery if indicated by evidence of disease progression.,rephrase,['Participants were randomly assigned to one of two groups.'],2,0.2,1,15
CD013297,0,3,The study was limited by imprecision owing to the small number of participants and was at some risk of bias owing to inconsistencies in the time points for outcome assessment and in the management of lens opacity.,delete,[],3,0.26666666666666666,2,15
CD013297,1,4,"At 12 months, the visual acuity in the immediate surgery group was higher by a mean of 2.1 (95% confidence interval (CI) -2.0 to 6.2 ETDRS letters; 53 participants; low-certainty evidence) than the watchful waiting/deferred surgery group.",delete,[],3,0.3333333333333333,2,15
CD013297,2,5,"The evidence of the effect of immediate surgery on gains of 0.3 logMAR or more of visual acuity is very uncertain (risk ratio (RR) 0.55, 95% CI 0.06 to 4.93; 53 participants; very low-certainty evidence).",delete,[],3,0.4,2,15
CD013297,3,6,"At 12 months, no participant in either group sustained a loss of 0.3 logMAR or more of visual acuity (53 participants; low-certainty evidence).",delete,[],3,0.4666666666666667,3,15
CD013297,4,7,The included study did not measure quality of life.,rephrase,['The study did not investigate the impact of surgery on participants’ quality of life.'],3,0.5333333333333333,3,15
CD013297,5,8,"At 12 months, no serious adverse event was identified in any participant.",delete,[],4,0.6,3,15
CD013297,5,9,One participant developed chronic minimal cystoid macular oedema following immediate surgery (53 participants; low-certainty evidence).,delete,[],4,0.6666666666666666,4,15
CD013297,6,10,We found no RCT that directly investigated the effect of surgery compared to no intervention.,rephrase,"['First, we searched the medical literature for studies:\n- in which epiretinal membrane was not caused by a pre-existing condition or surgery;\n- that compared the effects of surgery against no surgery or a placebo (sham) procedure; and\n- where people were randomly assigned to one of two groups: a group that underwent surgery for epiretinal membrane, and a group that did not have surgery for epiretinal membrane.']",4,0.7333333333333333,4,15
CD013297,6,11,"For severe disabling epiretinal membrane, the lack of a RCT comparing surgery to no intervention may reflect evidence from non-randomised studies in favour of surgery; a RCT may be considered unnecessary and ethically unacceptable because a superior effect of surgery is widely accepted.",split,"['For epiretinal membrane causing severe disabling impairment of sight, we found no carefully-controlled study that measured the effect of surgery.', 'A carefully controlled trial comparing surgery to no treatment is considered unecessary and ethically inappropriate.']",5,0.8,4,15
CD013297,6,12,"For mild symptomatic epiretinal membrane, however, the value of surgery is uncertain.",rephrase,"['For epiretinal membrane causing mild impairment of sight, however, the effect of surgery is uncertain.']",7,0.8666666666666667,5,15
CD013297,6,13,Low-certainty evidence from this review suggests that watchful waiting or deferred surgery may offer outcomes as favourable as immediate surgery.,rephrase,['There is some evidence that the outcome of watchful waiting may be as good as the effect of immediate surgery.'],8,0.9333333333333333,5,15
CD013297,6,14,"However, this finding needs to be confirmed in further RCTs with appropriate statistical power, masking of treatment allocation, consistent management of cataract, and measurement of outcomes including patient-reported quality of life over a more extended time frame.",delete,[],9,1.0,5,15
CD014763,0,0,Nine RCTs involving 757 participants were eligible for inclusion.,rephrase,['We found nine studies that involved 757 people undergoing reversal of stoma.'],0,0.09090909090909091,1,11
CD014763,0,1,"Eight studies recruited only adults (aged 18 years and older), and one study included people aged 12 years and older.",delete,[],1,0.18181818181818182,1,11
CD014763,0,2,The participants underwent elective reversal of either ileostomy (82%) or colostomy (18%).,delete,[],1,0.2727272727272727,2,11
CD014763,0,3,We considered all studies at high risk of performance and detection bias (lack of blinding) and four studies at unclear risk of selection bias related to random sequence generation.,delete,[],1,0.36363636363636365,2,11
CD014763,1,4,"PSSC compared with LSC likely reduces the risk of SSI (OR 0.17, 95% CI 0.09 to 0.29; I2 = 0%; 9 studies, 757 participants; moderate-certainty evidence).",rephrase,['PSSC probably reduces the risk of wound infection compared with LSC.'],1,0.45454545454545453,3,11
CD014763,1,5,The anticipated absolute risk of SSI is 52 per 1000 people who have PSSC and 243 per 1000 people who have LSC.,rephrase,"['For every 1000 people who have PSSC, 52 will develop a wound infection, compared with 243 of every 1000 people who have LSC.']",2,0.5454545454545454,3,11
CD014763,2,6,"The likelihood of being very satisfied or satisfied with stoma closure may be higher amongst people who have PSSC compared with people who have LSC (100% vs 89%; OR 20.11, 95% CI 1.09 to 369.88; 2 studies, 122 participants; low-certainty evidence).",delete,[],3,0.6363636363636364,4,11
CD014763,3,7,"The results of the analysis suggest that PSSC compared with LSC may have little or no effect on the risk of incisional hernia (OR 0.51, 95% CI 0.07 to 3.70; I2 = 49%; 4 studies, 297 participants; very low-certainty evidence) and operative time (MD −2.67 minutes, 95% CI −8.56 to 3.22; I2 = 65%; 6 studies, 460 participants; very low-certainty evidence).",delete,[],3,0.7272727272727273,4,11
CD014763,4,8,PSSC compared with LSC likely reduces the risk of SSI in people undergoing reversal of stoma.,rephrase,['We searched for studies that compared PSSC with LSC in people undergoing reversal of stoma.'],3,0.8181818181818182,5,11
CD014763,4,9,People who have PSSC may be more satisfied with the result compared with people who have LSC.,split,"['People who have PSSC may be more satisfied with the result compared with people who have LSC.', 'In the studies included in this review, all participants in the PSSC group said they were satisfied or very satisfied with the stoma closure, compared with 89% of participants in the LSC group.']",4,0.9090909090909091,5,11
CD014763,4,10,"There may be little or no difference between the skin closure techniques in terms of incisional hernia and operative time, though the evidence for these two outcomes is very uncertain.",rephrase,"['There may be little or no difference between the two techniques in the risk of incisional hernia or in operative time, but the results are very uncertain.']",6,1.0,5,11
CD005436,0,0,"Thirty-three trials that included 10,841 children met our inclusion criteria.",rephrase,"['Thirty-three trials that included 10,841 children met the inclusion criteria of this review.']",0,0.09090909090909091,1,11
CD005436,0,1,Most included trials were conducted in Asian countries that were at high risk of zinc deficiency.,delete,[],1,0.18181818181818182,1,11
CD005436,1,2,"Acute diarrhoea
There is currently not enough evidence from well-conducted RCTs to be able to say whether zinc supplementation during acute diarrhoea reduces death or number of children hospitalized (very low certainty evidence).",rephrase,"[""Among children with acute diarrhoea, we don't know if treating children with zinc has an effect on death or number of children hospitalized (very low certainty evidence).""]",1,0.2727272727272727,2,11
CD005436,2,3,"In children older than six months of age, zinc supplementation may shorten the average duration of diarrhoea by around half a day (MD −11.46 hours, 95% CI −19.72 to −3.19; 2581 children, 9 trials, low certainty evidence), and probably reduces the number of children whose diarrhoea persists until day seven (RR 0.73, 95% CI 0.61 to 0.88; 3865 children, 6 trials, moderate certainty evidence).",rephrase,"['In children older than six months, zinc supplementation may shorten the average duration of diarrhoea by around half a day (low certainty evidence), and probably reduces the number of children whose diarrhoea persists until day seven (moderate certainty evidence).']",2,0.36363636363636365,2,11
CD005436,2,4,"In children with signs of malnutrition the effect appears greater, reducing the duration of diarrhoea by around a day (MD −26.39 hours, 95% CI −36.54 to −16.23; 419 children, 5 trials, high certainty evidence).",rephrase,"['In children with signs of malnutrition the effect appears greater, reducing the duration of diarrhoea by around a day (high certainty evidence).']",3,0.45454545454545453,3,11
CD005436,3,5,"Conversely, in children younger than six months of age, the available evidence suggests zinc supplementation may have no effect on the mean duration of diarrhoea (MD 5.23 hours, 95% CI −4.00 to 14.45; 1334 children, 2 trials, low certainty evidence), or the number of children who still have diarrhoea on day seven (RR 1.24, 95% CI 0.99 to 1.54; 1074 children, 1 trial, low certainty evidence).",rephrase,"['Conversely, in children younger than six months, the available evidence suggests zinc supplementation may have no effect on the mean duration of diarrhoea (low certainty evidence), or the number of children who still have diarrhoea on day seven (low certainty evidence).']",4,0.5454545454545454,3,11
CD005436,4,6,None of the included trials reported serious adverse events.,rephrase,['No other adverse effects were reported.'],5,0.6363636363636364,4,11
CD005436,4,7,"However, zinc supplementation increased the risk of vomiting in both age groups (children greater than six months of age: RR 1.57, 95% CI 1.32 to 1.86; 2605 children, 6 trials, moderate certainty evidence; children less than six months of age: RR 1.54, 95% CI 1.05 to 2.24; 1334 children, 2 trials, moderate certainty evidence).",rephrase,['Zinc supplementation increased the risk of vomiting in both age groups (moderate certainty evidence).'],6,0.7272727272727273,4,11
CD005436,5,8,"Persistent diarrhoea
In children with persistent diarrhoea, zinc supplementation probably shortens the average duration of diarrhoea by around 16 hours (MD −15.84 hours, 95% CI −25.43 to −6.24; 529 children, 5 trials, moderate certainty evidence).",rephrase,"['Among children with persistent diarrhoea, zinc supplementation probably shortens the average duration of diarrhoea by around 16 hours (moderate certainty) but it probably increases the risk of vomiting (moderate certainty evidence).']",7,0.8181818181818182,5,11
CD005436,6,9,"In areas where the prevalence of zinc deficiency or the prevalence of malnutrition is high, zinc may be of benefit in children aged six months or more.",ignore,"['In areas where the prevalence of zinc deficiency or the prevalence of malnutrition is high, zinc may be of benefit in children aged six months or more.']",8,0.9090909090909091,5,11
CD005436,6,10,"The current evidence does not support the use of zinc supplementation in children less six months of age, in well-nourished children, and in settings where children are at low risk of zinc deficiency.",ignore,"['The current evidence does not support the use of zinc supplementation in children less six months of age, in well-nourished children, and in settings where children are at low risk of zinc deficiency.']",9,1.0,5,11
CD013204,0,0,We included three randomised clinical trials.,rephrase,"['We found three randomised clinical trials with 241 participants, of which 199 participants stayed until the end of the trial.']",0,0.041666666666666664,1,24
CD013204,0,1,"The trials randomised 241 adults with liver transplantation, of which 199 participants completed the trials.",rephrase,['All trials included adults who had received liver transplantation.'],1,0.08333333333333333,1,24
CD013204,0,2,"The trials were conducted in the USA, Spain, and Turkey.",ignore,"['The trials were conducted in the USA, Spain, and Turkey.']",2,0.125,1,24
CD013204,0,3,They compared exercise versus usual care.,rephrase,['All trials compared exercise-based interventions against usual care.'],3,0.16666666666666666,1,24
CD013204,0,4,The duration of the interventions ranged from two to 10 months.,rephrase,"['The durations of the exercise were two, six, and 10 months in the different trials.']",4,0.20833333333333334,2,24
CD013204,0,5,One trial reported that 69% of participants who received the exercise intervention were adherent to the exercise prescription.,delete,[],5,0.25,2,24
CD013204,0,6,"A second trial reported a 94% adherence to the exercise programme, with participants attending 45/48 sessions.",delete,[],5,0.2916666666666667,2,24
CD013204,0,7,The remaining trial reported a 96.8% adherence to the exercise intervention during the hospitalisation period.,delete,[],5,0.3333333333333333,2,24
CD013204,1,8,Two trials received funding; one from the National Center for Research Resources (US) and the other from Instituto de Salud Carlos III (Spain).,ignore,['Two trials received funding; one from the National Center for Research Resources and the other from Instituto de Salud Carlos III.'],5,0.375,2,24
CD013204,1,9,The remaining trial did not receive funding.,rephrase,['The other trial did not receive funding.'],6,0.4166666666666667,3,24
CD013204,2,10,"All trials were at an overall high risk of bias, derived from high risk of selective reporting bias and attrition bias in two trials.",delete,[],7,0.4583333333333333,3,24
CD013204,2,11,"The results on all-cause mortality showed a higher risk of death in the exercise group versus the control group, but these results are very uncertain (risk ratio (RR) 3.14, 95% confidence interval (CI) 0.74 to 13.37; 2 trials, 165 participants; I² = 0%; very low-certainty evidence).",delete,[],7,0.5,3,24
CD013204,2,12,The trials did not report data on serious adverse events excluding mortality or non-serious adverse events.,rephrase,['The trials did not report data on serious or non-serious side effects.'],7,0.5416666666666666,3,24
CD013204,2,13,"However, all trials reported that there were no adverse effects associated with exercise.",rephrase,"['However, all trials reported that there were no side effects associated with participants who performed exercise.']",8,0.5833333333333334,3,24
CD013204,2,14,"We are very uncertain on whether exercise compared with usual care has a beneficial or harmful effect on health-related quality of life assessed using the 36-item Short Form Physical Functioning subscale at the end of the intervention (mean difference (MD) 10.56, 95% CI −0.12 to 21.24; 2 trials, 169 participants; I² = 71%; very low-certainty evidence).",split,"['We are very uncertain whether exercise compared with usual care has a beneficial or harmful effect on death from any cause.', 'We are very uncertain whether exercise compared with usual care has a beneficial or harmful effect on health-related quality of life at the end of the intervention.']",9,0.625,4,24
CD013204,2,15,"None of the trials reported data on composite of cardiovascular mortality and cardiovascular disease, and cardiovascular disease post-transplantation.",rephrase,['None of the trials reported data on other cardiovascular measures.'],11,0.6666666666666666,4,24
CD013204,2,16,"We are very uncertain if there are differences in aerobic capacity in terms of VO2peak at the end of the intervention between groups (MD 0.80, 95% CI −0.80 to 2.39; 3 trials, 199 participants; I² = 0%; very low-certainty evidence).",rephrase,['We are very uncertain whether there is a difference in effect between exercise versus usual care on aerobic capacity (which indicates the level of cardiovascular (blood vessels and heart) fitness) at the end of the intervention.'],12,0.7083333333333334,4,24
CD013204,2,17,"We are very uncertain if there are differences in muscle strength at end of the intervention between groups (MD 9.91, 95% CI −3.68 to 23.50; 3 trials, 199 participants; I² = 44%; very low-certainty evidence).",rephrase,['We are very uncertain whether exercise has an effect regarding muscle strength in people after liver transplantation.'],13,0.75,4,24
CD013204,2,18,One trial measured perceived fatigue using the Checklist Individual Strength (CIST).,merge,['One trial reported a higher perception of fatigue in the exercise group.'],14,0.7916666666666666,4,24
CD013204,2,19,"Participants in the exercise group showed a clinically important lower degree of fatigue perception than participants in the control group, with a mean reduction of 40 points in the CIST (95% CI 15.62 to 64.38; 1 trial, 30 participants).",none,[],14,0.8333333333333334,5,24
CD013204,3,20,We identified three ongoing studies.,delete,[],15,0.875,5,24
CD013204,4,21,"Based on very low-certainty evidence in our systematic review, we are very uncertain of the role of exercise training (aerobic, resistance-based exercises, or both) in affecting mortality, health-related quality of life, and physical function (i.e. aerobic capacity and muscle strength) in liver transplant recipients.",rephrase,"['We are not confident in the evidence of the effect of exercise training that included aerobic, resistance-based exercises, or a combination of both on physical function (that is, aerobic capacity and muscle strength) in liver transplant recipients due to its high uncertainty.']",15,0.9166666666666666,5,24
CD013204,4,22,"There were few data on the composite of cardiovascular mortality and cardiovascular disease, cardiovascular disease post-transplantation, and adverse event outcomes.",delete,[],16,0.9583333333333334,5,24
CD013204,4,23,"We lack larger trials with blinded outcome assessment, designed according to the SPIRIT statement and reported according to the CONSORT statement.",rephrase,"['We need larger trials with blinded outcome assessment (process of concealing treatment group identity from outcome assessors), designed according to guidance of clinical trial protocols and recommendations for reporting randomised trials.']",16,1.0,5,24
CD005590,0,0,"Thirteen trials performed between the years 1974 and 2008 were included, involving 1412 patients.",merge,[],0,0.1,1,10
CD005590,0,1,"Four trials included 520 children with acute lymphoblastic leukemia and the remaining trials included adults with acute leukemia, solid organ transplantation or autologous bone marrow transplantation.",none,['The patients included in the 13 trials we identified were adults with acute leukemia or solid organ transplantation and children with acute leukemia.'],0,0.2,1,10
CD005590,0,2,"Compared to no treatment or treatment with fluoroquinolones (inactive against Pneumocystis), there was an 85% reduction in the occurrence of PCP in patients receiving prophylaxis with trimethoprim/sulfamethoxazole, RR of 0.15 (95% CI 0.04 to 0.62; 10 trials, 1000 patients).",rephrase,"['This review of randomised controlled trials (RCTs) found that prophylaxis with trimethoprim/sulfamethoxazole, an antibiotic effective against PCP, significantly reduced the occurrence of PCP by 85%.']",1,0.3,2,10
CD005590,0,3,The evidence was graded as moderate due to possible risk of bias.,delete,[],2,0.4,2,10
CD005590,0,4,"PCP-related mortality was also significantly reduced, RR of 0.17 (95% CI 0.03 to 0.94; nine trials, 886 patients) (low quality of evidence due to possible risk of bias and imprecision), but in trials comparing PCP prophylaxis against placebo or no treatment there was no significant effect on all-cause mortality (low quality of evidence due to imprecision).",rephrase,['We found no evidence for a reduction in all cause mortality.'],2,0.5,3,10
CD005590,0,5,Occurrence of leukopenia or neutropenia and their duration were not reported consistently.,delete,[],3,0.6,3,10
CD005590,0,6,"No significant differences in overall adverse events or events requiring discontinuation were seen comparing trimethoprim/sulfamethoxazole to no treatment or placebo (four trials, 470 patients, moderate quality evidence).",delete,[],3,0.7,4,10
CD005590,0,7,"No differences between once daily versus thrice weekly trimethoprim/sulfamethoxazole were seen (two trials, 207 patients).",rephrase,['Trimethoprim/sulfamethoxazole may be administered thrice weekly as effectively as once daily.'],3,0.8,4,10
CD005590,1,8,"Given an event rate of 6.2% in the control groups of the included trials, prophylaxis for PCP using trimethoprim/sulfamethoxazole is highly effective among non-HIV immunocompromised patients, with a number needed to treat to prevent PCP of 19 patients (95% CI 17 to 42).",rephrase,"['Based on our results, the number of people that need to be treated with trimethoprim/sulfamethoxazole for a prolonged period of time (ranging between several weeks to three years in the included trials) in order to prevent one episode of PCP infection was 19; when PCP infection occurs at a rate of about 6% without prophylaxis.']",4,0.9,5,10
CD005590,1,9,Prophylaxis should be considered for patients with a similar baseline risk of PCP.,rephrase,"['Given the low rate of adverse events, prophylaxis should be considered for patients at similar risk of PCP.']",5,1.0,5,10
CD008593,0,0,"Five studies were included in this review with a total of 1,726 patients.",rephrase,"['We identified five randomised controlled trials with a total of 1,726 patients comparing the combination of IRI and fluoropyrimidine with IRI alone.']",0,0.1111111111111111,1,9
CD008593,0,1,"The top-up search resulted in an additional ongoing trial, the results of which have not been incorporated in this review.",rephrase,"['The search in January 2016 resulted in an additional ongoing trial, the results of which have not been incorporated in this review.']",1,0.2222222222222222,2,9
CD008593,0,2,"Among five included studies, no reduction in all-cause mortality was observed in the combination arm, with a summary hazard ratio (HR) of 0.91 (95% CI: 0.81-1.02).",delete,[],2,0.3333333333333333,2,9
CD008593,0,3,"Longer progression-free survival was observed in those treated with the combination chemotherapy (HR: 0.68, 95% CI: 0.53-0.87), however, this result may have been driven by findings from the single first-line treatment setting study.",delete,[],2,0.4444444444444444,3,9
CD008593,1,4,"The quality of evidence for overall survival was low and for progression-free survival was moderate, mainly due to study limitation from the lack of information on randomisation methods and allocation concealment.",rephrase,['There was moderate quality evidence from these studies suggesting longer progression-free survival from adding fluoropyrimidines to IRI.'],2,0.5555555555555556,3,9
CD008593,2,5,"There were higher risks of toxicity outcomes grade 3 or 4 diarrhoea and grade 1 or 2 alopecia, and a lower risk of grade 3 or 4 neutropenia in controls compared to the invervention group.",delete,[],3,0.6666666666666666,4,9
CD008593,2,6,Evidence for toxicity has been assessed to be low to moderate quality.,delete,[],3,0.7777777777777778,4,9
CD008593,3,7,"There was no overall survival benefit of the irinotecan and fluoropyrimidine treatment over irinotecan alone, thus both regimens remain reasonable options in treating patients with advanced or metastatic CRC.",split,"['There is no evidence to suggest any superiority of the combination of IRI and fluoropyrimidine over IRI alone, but our results on overall survival are limited by the number of studies available to date.', 'Based on current evidence, both the combination regimens and IRI alone seem equally effective for treating advanced or metastatic patients.']",3,0.8888888888888888,5,9
CD008593,3,8,"Given the low and moderate quality of the evidence, future studies with sufficient numbers of patients in each treatment arms are needed to clarify the benefit observed in progression-free survival with combination irinotecan and fluoropyrimidines.",rephrase,['Longer progression-free survival was seen from adding fluoropyrimidines to IRI.'],5,1.0,5,9
CD011639,0,0,"We included a total of 26 trials (3842 participants) in the review, and 23 trials (3693 participants) were included in one or more outcomes in the review.",split,"['We identified 26 randomised clinical trials with a total of 3842 participants.', 'Of these, 23 randomised clinical trials (3693 participants) provided information for one or more outcomes.']",0,0.05263157894736842,1,19
CD011639,0,1,The vast majority of the participants underwent primary liver transplantation.,delete,[],2,0.10526315789473684,1,19
CD011639,0,2,"All of the trials were at high risk of bias, and all of the evidence was of low or very low quality.",rephrase,"['The overall quality of the evidence was low or very low, and all of the trials were at high risk of bias, which means it is possible that the conclusions made could overestimate the benefits or underestimate the harms of a given intervention because of the way the trials were conducted.']",2,0.15789473684210525,1,19
CD011639,0,3,"In addition, because of sparse data involving trials at high risk of bias, it is not possible to entirely rely on the results of the network meta-analysis.",rephrase,"['In addition, because of insufficient information, the results of network meta-analysis are not entirely reliable.']",3,0.21052631578947367,2,19
CD011639,0,4,The trials included mainly participants undergoing primary liver transplantation of varied aetiologies.,rephrase,"['The trials mainly included participants undergoing liver transplantation for the first time, for various reasons.']",4,0.2631578947368421,2,19
CD011639,0,5,The follow-up in the trials ranged from 3 to 144 months.,delete,[],5,0.3157894736842105,2,19
CD011639,0,6,The most common maintenance immunosuppression used as a control was tacrolimus.,delete,[],5,0.3684210526315789,2,19
CD011639,0,7,There was no evidence of difference in mortality (21 trials; 3492 participants) or graft loss (15 trials; 2961 participants) at maximal follow-up between the different maintenance immunosuppressive regimens based on the network meta-analysis.,rephrase,['We found no evidence of difference in the risk of death or graft loss between the different immunosuppressive regimens based on the network meta-analysis.'],5,0.42105263157894735,3,19
CD011639,0,8,"In the direct comparison, based on a single trial including 222 participants, tacrolimus plus sirolimus had increased mortality (HR 2.76, 95% CrI 1.30 to 6.69) and graft loss (HR 2.34, 95% CrI 1.28 to 4.61) at maximal follow-up compared with tacrolimus.",rephrase,"['In the direct comparison, based on a single trial including 222 participants, the risk of death and graft loss was higher with tacrolimus plus sirolimus than with tacrolimus alone.']",6,0.47368421052631576,3,19
CD011639,0,9,"There was no evidence of differences in the proportion of people with serious adverse events (1 trial; 719 participants), proportion of people with any adverse events (2 trials; 940 participants), renal impairment (8 trials; 2233 participants), chronic kidney disease (1 trial; 100 participants), graft rejections (any) (16 trials; 2726 participants), and graft rejections requiring treatment (5 trials; 1025 participants) between the different immunosuppressive regimens.",rephrase,"['There was no evidence of differences between the various immunosuppressive regimens in percentage of people who developed serious adverse events, percentage of people who developed any adverse events, risk of poor kidney function requiring dialysis or kidney transplantation (kidney dysfunction), prolonged kidney disease, graft rejections requiring treatment, and any graft rejections.']",7,0.5263157894736842,3,19
CD011639,0,10,"The network meta-analysis showed that the number of adverse events was lower with cyclosporine A than with many other immunosuppressive regimens (12 trials; 1748 participants), and the risk of retransplantation (13 trials; 1994 participants) was higher with cyclosporine A than with tacrolimus (HR 3.08, 95% CrI 1.13 to 9.90).",split,"['The number of adverse events was lower with cyclosporine A than with many other immunosuppressive regimens.', 'The risk of retransplantation was higher with cyclosporine A than with tacrolimus.']",8,0.5789473684210527,3,19
CD011639,0,11,"None of the trials reported number of serious adverse events, health-related quality of life, or costs.",ignore,"['None of the trials reported number of serious adverse events, health-related quality of life, or costs.']",10,0.631578947368421,4,19
CD011639,1,12,Funding: 14 trials were funded by pharmaceutical companies who would benefit from the results of the trial; two trials were funded by parties who had no vested interest in the results of the trial; and 10 trials did not report the source of funding.,delete,[],11,0.6842105263157895,4,19
CD011639,2,13,"Based on low-quality evidence from a single small trial from direct comparison, tacrolimus plus sirolimus increases mortality and graft loss at maximal follow-up compared with tacrolimus.",delete,[],11,0.7368421052631579,4,19
CD011639,2,14,"Based on very low-quality evidence from network meta-analysis, we found no evidence of difference between different immunosuppressive regimens.",delete,[],11,0.7894736842105263,4,19
CD011639,2,15,We found very low-quality evidence from network meta-analysis and low-quality evidence from direct comparison that cyclosporine A causes more retransplantation compared with tacrolimus.,delete,[],11,0.8421052631578947,5,19
CD011639,2,16,"Future randomised clinical trials should be adequately powered; performed in people who are generally seen in the clinic rather than in highly selected participants; employ blinding; avoid postrandomisation dropouts or planned cross-overs; and use clinically important outcomes such as mortality, graft loss, renal impairment, chronic kidney disease, and retransplantation.",rephrase,"['Future trials should be performed in people who are generally seen in the clinic rather than in highly selected participants and report clinically important outcomes such as death, graft loss, kidney dysfunction, long-term kidney disease, and retransplantation.']",11,0.8947368421052632,5,19
CD011639,2,17,Such trials should use tacrolimus as one of the control groups.,ignore,['Such trials should use tacrolimus as one of the control groups.'],12,0.9473684210526315,5,19
CD011639,2,18,"Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random errors.",ignore,"['Moreover, such trials ought to be designed in such a way as to ensure low risk of bias and low risks of random errors.']",13,1.0,5,19
CD012544,0,0,Three randomised controlled trials met the inclusion criteria for our systematic review - the studies randomised a total of 524 women.,rephrase,['We searched for evidence on the 29th of January 2019 and identified three small randomised controlled trials (involving a total of 524 women) for inclusion in our review.'],0,0.07142857142857142,1,14
CD012544,1,1,We assessed the three included studies as being at a low to moderate risk of bias; the nature of the intervention made it difficult to achieve blinding of participants and personnel and none of the trial reports contained information about methods of allocation concealment (and were therefore assessed as being at an unclear risk of selection bias).,delete,[],1,0.14285714285714285,1,14
CD012544,2,2,"In all studies, the intervention was the use of fetal biometry on ultrasound to identify fetuses displaying signs of fetal macrosomia, and the use of this information to indicate the use of medical anti-hyperglycaemic treatments.",delete,[],1,0.21428571428571427,2,14
CD012544,2,3,Those pregnancies were subject to more stringent blood glucose targets than those without signs of fetal macrosomia.,delete,[],1,0.2857142857142857,2,14
CD012544,3,4,"Maternal outcomes
The use of fetal biometry in addition to maternal blood glucose concentration (compared with maternal blood glucose concentration alone) may make little or no difference to the incidence of caesarean delivery (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.59 to 1.10; 2 trials, 428 women; low-certainty evidence).",rephrase,"[""Compared with monitoring the mothers' blood glucose levels alone, the addition of ultrasound may make little or no difference to the risk of having a caesarean birth (2 trials, 428 women, low-certainty evidence).""]",1,0.35714285714285715,2,14
CD012544,3,5,"We are unclear about the results for hypertensive disorders of pregnancy (RR 0.80, 95% CI 0.34 to 1.89; 2 trials, 325 women) due to very low-certainty evidence.",rephrase,"['Very low-certainty evidence means that we are unclear about the results relating to the risks of the mother having blood pressure disorders during pregnancy (2 trials, 325 women).']",2,0.42857142857142855,3,14
CD012544,3,6,The included trials did not report on development of type 2 diabetes in the mother or maternal hypoglycaemia.,rephrase,"['The included trials did not report on the important maternal outcomes of low blood glucose, or development of type 2 diabetes.']",3,0.5,3,14
CD012544,4,7,"Fetal and neonatal outcomes
The use of fetal biometry may make little or no difference to the incidence of neonatal hypoglycaemia (RR 0.90, 95% CI 0.57 to 1.42; 3 trials, 524 women; low-certainty evidence).",rephrase,"[""Using ultrasound in addition to monitoring the mother's blood glucose levels may make little or no difference to the risk of the newborn baby having low blood glucose levels (3 trials, 524 women, low-certainty evidence).""]",4,0.5714285714285714,3,14
CD012544,4,8,"Very low-certainty evidence means that we are unclear about the results for large-for-gestational age (RR 0.81, 95% CI 0.38 to 1.74; 3 trials, 524 women); shoulder dystocia (RR 0.33, 95% CI 0.01 to 7.98; 1 trial, 96 women); a composite measure of perinatal morbidity or mortality (RR 1.00, 95% CI 0.21 to 4.71; 1 study, 96 women); or perinatal mortality (RR 0.33, 95% CI 0.01 to 7.98; 1 trial, 96 women).",rephrase,"[""Very low-certainty evidence means that we are unclear about results relating to the risks of: having a baby that is large for gestational age (3 trials, 524 women); the baby's shoulders becoming entrapped in the birth canal (1 trial, 96 women); death or illness in the newborn baby (1 trial, 96 women); or the baby dying during pregnancy or birth (1 trial, 96 women).""]",5,0.6428571428571429,4,14
CD012544,5,9,This review is based on evidence from three trials involving 524 women.,rephrase,['This review was based on limited evidence from three trials (involving 524 women).'],6,0.7142857142857143,4,14
CD012544,5,10,"The trials did not report some important outcomes of interest to this review, and the majority of our secondary outcomes were also unreported.",ignore,"['The trials did not report some important outcomes of interest to this review, and the majority of our secondary outcomes were also unreported.']",7,0.7857142857142857,4,14
CD012544,5,11,"The available evidence ranged from low- to very low-certainty, with downgrading decisions based on limitations in study design, imprecision and inconsistency.",rephrase,['The certainty of the available evidence ranged from low to very low.'],8,0.8571428571428571,5,14
CD012544,6,12,"There is insufficient evidence to evaluate the use of fetal biometry (in addition to maternal blood glucose concentration values) to assist in guiding the medical management of GDM, on either maternal or perinatal health outcomes, or the associated costs.",rephrase,"['There was insufficient evidence to evaluate the use of ultrasound (in addition to maternal blood glucose concentration values) to assist in guiding the medical management of GDM, and the effect on important short- and long-term outcomes for the mother or her baby, or the associated costs.']",9,0.9285714285714286,5,14
CD012544,7,13,"More research is required, ideally larger randomised studies which report the maternal and infant short- and long-term outcomes listed in this review, as well as those outcomes relating to financial and resource implications.",split,"['Large, randomised trials are needed.', 'Such trials could consider important short- and long-term outcomes (as listed in this review) for the mother, her baby, and resource use.']",10,1.0,5,14
CD011558,0,0,"We included 31 studies that explored the views and experiences of different types of SBAs, including doctors, midwives, nurses, auxiliary nurses and their managers.",split,"['We included 31 studies conducted in Africa, Asia, and Latin America.', 'Participants were skilled birth attendants including doctors, midwives, nurses, auxiliary nurses and their managers.']",0,0.041666666666666664,1,24
CD011558,0,1,"The included studies took place in Africa, Asia, and Latin America.",delete,[],2,0.08333333333333333,1,24
CD011558,1,2,Our synthesis pointed to a number of factors affecting SBAs’ provision of quality care.,rephrase,['Our synthesis pointed to several factors that affected skilled birth attendants’ provision of quality care.'],2,0.125,1,24
CD011558,1,3,The following factors were based on evidence assessed as of moderate to high confidence.,ignore,['The following factors are based on evidence assessed as of moderate to high confidence.'],3,0.16666666666666666,1,24
CD011558,1,4,Skilled birth attendants reported that they were not always given sufficient training during their education or after they had begun clinical work.,rephrase,['Skilled birth attendants reported that they sometimes had insufficient training during their education or after they had begun work.'],4,0.20833333333333334,2,24
CD011558,1,5,"Also, inadequate staffing of facilities could increase the workloads of skilled birth attendants, make it difficult to provide supervision and result in mothers being offered poorer care.",rephrase,"['Where facilities lacked staff, skilled birth attendants’ workloads could increase, it could become difficult to provide supervision, and mothers could receive poorer care.']",5,0.25,2,24
CD011558,1,6,"In addition, SBAs did not always believe that their salaries and benefits reflected their tasks and responsibilities and the personal risks they undertook.",ignore,"['In addition, skilled birth attendants did not always believe that their salaries and benefits reflected their tasks and responsibilities and the personal risks they undertook.']",6,0.2916666666666667,2,24
CD011558,1,7,"Together with poor living and working conditions, these issues were seen to increase stress and to negatively affect family life.",rephrase,"[""Together with poor living and working conditions, these issues could lead to stress and affect skilled birth attendants' family life.""]",7,0.3333333333333333,2,24
CD011558,1,8,"Some SBAs also felt that managers lacked capacity and skills, and felt unsupported when their workplace concerns were not addressed.",rephrase,"['Some skilled birth attendants felt that managers lacked capacity and skills, and they felt unsupported when their workplace concerns were not addressed.']",8,0.375,2,24
CD011558,2,9,Possible causes of staff shortages in facilities included problems with hiring and assigning health workers to facilities where they were needed; lack of funding; poor management and bureaucratic systems; and low salaries.,rephrase,['Possible causes of staff shortages included problems with hiring and assigning health workers to health facilities; lack of funding; poor management and bureaucratic systems; and low salaries.'],9,0.4166666666666667,3,24
CD011558,2,10,"Skilled birth attendants and their managers suggested factors that could help recruit, keep, and motivate health workers, and improve the quality of care; these included good-quality housing, allowances for extra work, paid vacations, continuing education, appropriate assessments of their work, and rewards.",ignore,"['Skilled birth attendants and their managers suggested factors that could help recruit, keep, and motivate health workers, and improve the quality of their work; these included good-quality housing, allowances for extra work, paid vacations, continued education, proper assessments of their work, and rewards.']",10,0.4583333333333333,3,24
CD011558,3,11,"Skilled birth attendants’ ability to provide quality care was also limited by a lack of equipment, supplies, and drugs; blood and the infrastructure to manage blood transfusions; electricity and water supplies; and adequate space and amenities on maternity wards.",ignore,"['Skilled birth attendants’ ability to provide quality care was also limited by a lack of equipment, drugs, and supplies; blood and the infrastructure to manage blood transfusions; electricity and water supplies; and adequate space and amenities on maternity wards.']",11,0.5,3,24
CD011558,3,12,"These factors were seen to reduce SBAs’ morale, increase their workload and infection risk, and make them less efficient in their work.",rephrase,"['These factors were seen to reduce skilled birth attendants’ morale, increase their workload and infection risk, and make them less efficient in their work.']",12,0.5416666666666666,3,24
CD011558,3,13,A lack of transport sometimes made it difficult for SBAs to refer women on to higher levels of care.,rephrase,['A lack of transport sometimes made it difficult for skilled birth attendants to refer women to higher levels of care.'],13,0.5833333333333334,3,24
CD011558,3,14,"In addition, women’s negative perceptions of the health system could make them reluctant to accept referral.",ignore,"['In addition, women’s negative perceptions of the health system could make them reluctant to accept referral.']",14,0.625,4,24
CD011558,4,15,"We identified some other factors that also may have affected the quality of care, which were based on findings assessed as of low or very low confidence.",ignore,"['We identified some other factors that also may have affected the quality of care, which were based on findings assessed as of low or very low confidence.']",15,0.6666666666666666,4,24
CD011558,4,16,Poor teamwork and lack of trust and collaboration between health workers appeared to negatively influence care.,ignore,['Poor teamwork and lack of trust and collaboration between health workers appeared to negatively influence care.'],16,0.7083333333333334,4,24
CD011558,4,17,"In contrast, good collaboration and teamwork appeared to increase skilled birth attendants’ motivation, their decision-making abilities, and the quality of care.",ignore,"['In contrast, good collaboration and teamwork appeared to increase skilled birth attendants’ motivation, their decision-making abilities, and the quality of care.']",17,0.75,4,24
CD011558,4,18,Skilled birth attendants’ workloads and staff shortages influenced their interactions with mothers.,ignore,['Skilled birth attendants’ workloads and staff shortages influenced their interactions with mothers.'],18,0.7916666666666666,4,24
CD011558,4,19,"In addition, poor communication undermined trust between skilled birth attendants and mothers.",ignore,"['In addition, poor communication undermined trust between skilled birth attendants and mothers.']",19,0.8333333333333334,5,24
CD011558,5,20,Many factors influence the care that SBAs are able to provide to mothers during childbirth.,delete,[],20,0.875,5,24
CD011558,5,21,"These include access to training and supervision; staff numbers and workloads; salaries and living conditions; and access to well-equipped, well-organised healthcare facilities with water, electricity, and transport.",delete,[],20,0.9166666666666666,5,24
CD011558,5,22,"Other factors that may play a role include the existence of teamwork and of trust, collaboration, and communication between health workers and with mothers.",delete,[],20,0.9583333333333334,5,24
CD011558,5,23,Skilled birth attendants reported many problems tied to all of these factors.,delete,[],20,1.0,5,24
CD006987,0,0,We included four randomised trials (257 participants).,split,"['We searched for randomised controlled trials (RCTs) which compared treatment of sudden hearing loss with antiviral drugs (either alone or in combination with another treatment) with placebo or no antiviral drug, in patients of any age.', 'We found four RCTs (257 patients).']",0,0.06666666666666667,1,15
CD006987,0,1,The overall risk of bias in the included studies was low.,rephrase,['The overall risk of bias in the studies was low.'],2,0.13333333333333333,1,15
CD006987,0,2,Two trials compared the addition of intravenous acyclovir to a steroid (prednisolone).,rephrase,['All four trials compared steroid treatment (either alone or plus a placebo drug) with steroid plus antiviral treatment.'],3,0.2,1,15
CD006987,0,3,"One included 43 participants, the other 70 patients.",delete,[],4,0.26666666666666666,2,15
CD006987,0,4,Neither demonstrated any hearing improvement with ISSHL.,delete,[],4,0.3333333333333333,2,15
CD006987,0,5,Another (84 patients) did not show any statistically significant difference between groups with the addition of valacyclovir to prednisolone (compared to steroid plus placebo) with respect to change in pure-tone audiogram.,merge,[],4,0.4,2,15
CD006987,0,6,"Comparing the addition of intravenous acyclovir to hydrocortisone with hydrocortisone alone, the final trial did not show any statistically significant difference between groups (60 patients).",none,['None of the trials found a statistically significant difference between groups.'],4,0.4666666666666667,3,15
CD006987,0,7,No trial documented any serious adverse effects related to the use of antiviral treatment.,ignore,['No trial documented any serious adverse effects related to using antiviral treatments.'],5,0.5333333333333333,3,15
CD006987,0,8,One study reported slight to moderate nausea equally in the acyclovir and placebo groups (one patient in each).,rephrase,"['One study reported slight to moderate nausea equally in the acyclovir and placebo groups (one patient in each), both attributable to the steroid treatment.']",6,0.6,3,15
CD006987,0,9,"Another reported insomnia, nervousness and weight gain with valacyclovir (number not specified).",ignore,"['Another reported insomnia, nervousness and weight gain with valacyclovir (number not specified).']",7,0.6666666666666666,4,15
CD006987,0,10,"Even though no meta-analysis was possible, evidence from the four RCTs has demonstrated no statistically significant advantage in the use of antivirals in the treatment of ISSHL.",delete,[],8,0.7333333333333333,4,15
CD006987,1,11,There is currently no evidence to support the use of antiviral drugs in the treatment of ISSHL.,split,"['The effectiveness of antiviral drugs in the treatment of sudden hearing loss of unknown origin is questionable.', 'Certainly, this review of the clinical trials did not identify any substantial evidence to support their use.']",8,0.8,4,15
CD006987,1,12,"The four trials included in this review were, however, small and with a low risk of bias.",delete,[],10,0.8666666666666667,5,15
CD006987,1,13,"Further randomised controlled trials with larger patient populations, using standardised inclusion criteria, antiviral regimes and outcome measures, are needed in order for adequate meta-analysis to be performed to reach definitive conclusions.",rephrase,"['Further research is required with larger patient numbers and standardised inclusion criteria, antiviral regimes and outcome measures.']",10,0.9333333333333333,5,15
CD006987,1,14,"A uniform definition of ISSHL should also be established, together with what constitutes adequate recovery.",delete,[],11,1.0,5,15
CD009452,0,0,Three RCTs (involving 386 women) were included in the review.,rephrase,['Three studies with 386 participants were included in the review.'],0,0.058823529411764705,1,17
CD009452,0,1,Peri-implantation low molecular weight heparin (LMWH) during IVF/ICSI was given at or after egg collection or at embryo transfer in these studies.,rephrase,['In all cases a daily injection of low molecular weight heparin was given to women from the time of egg collection or embryo transfer during assisted reproduction.'],1,0.11764705882352941,1,17
CD009452,0,2,The characteristics of the participants differed across studies.,rephrase,['Their characteristics differed across studies.'],2,0.17647058823529413,1,17
CD009452,0,3,"One included women having their first IVF cycle, with no blood clotting disorder; another included women with at least one blood clotting disorder and the third included women who had undergone at least two previous unsuccessful ART cycles.",split,"['One study included women having their first IVF cycle, with no blood clotting disorder.', 'Another study included women with at least one blood clotting disorder.', 'The third study included women with at least two previous unsuccessful assisted reproduction treatment cycles.']",3,0.23529411764705882,2,17
CD009452,1,4,Our findings differed according to choice of statistical model.,delete,[],6,0.29411764705882354,2,17
CD009452,1,5,"When we used a fixed effect analysis, the evidence suggested that peri-implantation heparin was associated with an improvement in live birth rate compared with placebo or no heparin (odds ratio (OR) 1.77, 95% confidence interval (CI) 1.07 to 2.90, three studies, 386 women, I2 = 51%, very low quality evidence) and also an improvement in the clinical pregnancy rate (OR 1.61, 95% CI 1.03 to 2.53, three studies, 386 women, I2 = 29%, low quality evidence).",delete,[],6,0.35294117647058826,2,17
CD009452,1,6,"However when a random effects model was used there was no longer a difference between the groups for either live birth (OR 1.85, 95% CI 0.80 to 4.24) or clinical pregnancy (OR 1.66, 95% CI 0.94 to 2.90).",delete,[],6,0.4117647058823529,3,17
CD009452,1,7,Moreover there was high heterogeneity (I2 = 51%) for the analysis of live birth.,delete,[],6,0.47058823529411764,3,17
CD009452,2,8,Adverse events were poorly reported in all the included studies.,delete,[],6,0.5294117647058824,3,17
CD009452,2,9,"Events such as bleeding, and thrombocytopenia were reported in women receiving heparin and affected 5-7% of women in the heparin group in one study.",delete,[],6,0.5882352941176471,3,17
CD009452,2,10,However no studies reported data suitable for analysis and so no firm conclusions could be drawn regarding adverse effects.,delete,[],6,0.6470588235294118,4,17
CD009452,3,11,"The main limitations in the evidence were inconsistency, imprecision and inadequate reporting of adverse events.",rephrase,"['Quality of Evidence\nThe evidence was of low or very low quality, mainly due to imprecision, inconsistency and inadequate reporting of advere events.']",6,0.7058823529411765,4,17
CD009452,4,12,"It is unclear whether peri-implantation heparin in assisted reproduction treatment (ART) cycles improves live birth and clinical pregnancy rates in subfertile women, as the evidence was sensitive to choice of statistical model and no benefit was apparent when a random effects model was used.",rephrase,['Key Results\nIt is unclear whether peri-implantation heparin in assisted reproduction treatment (ART) cycles improves live birth and clinical pregnancy rates in subfertile women.'],7,0.7647058823529411,4,17
CD009452,4,13,Side effects have been reported with use of heparin and no firm conclusions can be drawn regarding its safety.,rephrase,"['Heparin had side effects such as bruising and bleeding, but no conclusions could be drawn regarding its safety because none of the studies reported comparative data on adverse effects.']",8,0.8235294117647058,5,17
CD009452,4,14,"Our results do not justify the use of heparin in this context, except in well-conducted research trials.",rephrase,['The evidence does not justify the use of heparin except in well-designed clinical research trials.'],9,0.8823529411764706,5,17
CD009452,5,15,"These findings need to be further investigated with well-designed, adequately powered, double-blind, randomised, placebo-controlled, multicentre trials.",rephrase,['Further well-designed randomised controlled trials with larger sample sizes are needed to clarify the possible role of heparin in assisted reproduction.'],10,0.9411764705882353,5,17
CD009452,5,16,Further investigations could also focus on the effects of the local (uterine) and non-systemic application of heparin during ART.,delete,[],11,1.0,5,17
CD003493,0,0,Sixteen trials were included in the review and fourteen contained data in a suitable form for quantitative analysis.,ignore,['Sixteen trials were included in the review and fourteen contained data in a suitable form for quantitative analysis.'],0,0.2,1,5
CD003493,0,1,Most comparisons did not show differences between rTMS and other interventions.,ignore,['Most comparisons did not show differences between repetitive (rTMS) and other interventions.'],1,0.4,2,5
CD003493,0,2,"No difference was seen between rTMS and sham TMS using the Beck Depression Inventory or the Hamilton Depression Rating Scale, except for one time period (after two weeks of treatment) for left dorsolateral prefrontal cortex and high frequency; and also for right dorsolateral prefrontal cortex and low frequency, both in favour of rTMS and both using the Hamilton scale.",ignore,"['No difference was seen between rTMS and sham TMS using the Beck Depression Inventory or the Hamilton Depression Rating Scale, except for one time period (after two weeks of treatment) for left dorsolateral prefrontal cortex and high frequency; and also for right dorsolateral prefrontal cortex and low frequency, both in favour of rTMS and both using the Hamilton scale.']",2,0.6,3,5
CD003493,0,3,"Comparison of rTMS (left dorsolateral prefrontal cortex and high frequency) with electroconvulsive therapy showed no difference except for psychotic patients after two weeks treatment, using the Hamilton scale, which indicated that electroconvulsive therapy was more effective than rTMS.",ignore,"['Comparison of rTMS (left dorsolateral prefrontal cortex and high frequency) with electroconvulsive therapy showed no difference except for psychotic patients after two weeks treatment, using the Hamilton scale, which indicated that electroconvulsive therapy was more effective than rTMS.']",3,0.8,4,5
CD003493,1,4,"The information in this review suggests that there is no strong evidence for benefit from using transcranial magnetic stimulation to treat depression, although the small sample sizes do not exclude the possibility of benefit.",delete,[],4,1.0,5,5
CD013240,0,0,"We included eight parallel-design RCTs, involving a total of 640 participants.",delete,[],0,0.09090909090909091,1,11
CD013240,0,1,"We did not assess any of the studies as being at low risk of bias across all domains, with the main limitation being lack of blinding.",rephrase,"['The main limitations in the evidence were lack of blinding (the process where the women participating in the trial, as well as the research staff, are not aware of the intervention used), inconsistency (differences between different studies) and imprecision (random error and small size of each study).']",0,0.18181818181818182,1,11
CD013240,0,2,"Using GRADE methodology, the quality of the evidence ranged from very low to low quality.",rephrase,['The evidence was of very low quality.'],1,0.2727272727272727,2,11
CD013240,1,3,"Long-term GnRH agonist therapy versus no pretreatment
We are uncertain whether long-term GnRH agonist therapy affects the live birth rate (RR 0.48, 95% CI 0.26 to 0.87; 1 RCT, n = 147; I2 not calculable; very low-quality evidence) or the overall complication rate (Peto OR 1.23, 95% CI 0.37; to 4.14; 3 RCTs, n = 318; I2 = 73%; very low-quality evidence) compared to standard IVF/ICSI.",split,"['Compared to no pretreatment, we are uncertain whether long-term GnRH agonist therapy prior to IVF/ICSI in women with endometriosis affects the live birth rate.', 'The evidence suggests that if the chance of live birth rate is assumed to be 36% with no pretreatment, the chance following long-term GnRH agonist therapy would be between 9% and 31%.']",2,0.36363636363636365,2,11
CD013240,1,4,"Further, we are uncertain whether this intervention affects the clinical pregnancy rate (RR 1.13, 95% CI 0.91 to 1.41; 6 RCTs, n = 552, I2 = 66%; very low-quality evidence), multiple pregnancy rate (Peto OR 0.14, 95% CI 0.03 to 0.56; 2 RCTs, n = 208, I2 = 0%; very low-quality evidence), miscarriage rate (Peto OR 0.45, 95% CI 0.10 to 2.00; 2 RCTs, n = 208; I2 = 0%; very low-quality evidence), mean number of oocytes (MD 0.72, 95% CI 0.06 to 1.38; 4 RCTs, n = 385; I2 = 81%; very low-quality evidence) or mean number of embryos (MD -0.76, 95% CI -1.33 to -0.19; 2 RCTs, n = 267; I2 = 0%; very low-quality evidence).",rephrase,"['We are also uncertain whether this intervention affects complication rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, mean number of oocytes and mean number of embryos.']",4,0.45454545454545453,3,11
CD013240,2,5,"Long-term GnRH agonist therapy versus long-term continuous COC
No studies reported on this comparison.",rephrase,['No studies compared long-term GnRH agonist therapy to long-term continuous COC therapy or surgery to remove endometriomas.'],5,0.5454545454545454,3,11
CD013240,3,6,"Long-term GnRH agonist therapy versus surgical therapy of endometrioma
No studies reported on this comparison.",delete,[],6,0.6363636363636364,4,11
CD013240,4,7,This review raises important questions regarding the merit of long-term GnRH agonist therapy compared to no pretreatment prior to standard IVF/ICSI in women with endometriosis.,rephrase,['We found eight randomised controlled trials comparing long-term GnRH agonist therapy with no pretreatment including a total of 640 women with endometriosis prior to IVF/ICSI.'],6,0.7272727272727273,4,11
CD013240,4,8,"Contrary to previous findings, we are uncertain as to whether long-term GnRH agonist therapy impacts on the live birth rate or indeed the complication rate compared to standard IVF/ICSI.",delete,[],7,0.8181818181818182,5,11
CD013240,4,9,"Further, we are uncertain whether this intervention impacts on the clinical pregnancy rate, multiple pregnancy rate, miscarriage rate, mean number of oocytes and mean number of embryos.",delete,[],7,0.9090909090909091,5,11
CD013240,4,10,"In light of the paucity and very low quality of existing data, particularly for the primary outcomes examined, further high-quality trials are required to definitively determine the impact of long-term GnRH agonist therapy on IVF/ICSI outcomes, not only compared to no pretreatment, but also compared to other proposed alternatives to endometriosis management.",delete,[],7,1.0,5,11
CD006049,0,0,We identified two double-blind RCTs of gabapentin treatment in ALS for inclusion in this review.,merge,[],0,0.0625,1,16
CD006049,0,1,We found no eligible RCTs of baclofen or other GABA modulators.,none,['We found no trials of baclofen or other GABA modulators in ALS that met our selection criteria.'],0,0.125,1,16
CD006049,0,2,"The selected studies were phase II and phase III trials, which lasted six and nine months, respectively.",delete,[],1,0.1875,1,16
CD006049,0,3,"They were highly comparable because both were comparisons of oral gabapentin and placebo, performed by the same investigators.",rephrase,['A systematic search of the medical literature found two randomized trials of gabapentin compared with placebo (inactive treatment).'],1,0.25,2,16
CD006049,0,4,The trials enrolled 355 participants with ALS: 80 in the gabapentin group and 72 in the placebo group in the first (phase II) trial and 101 in the gabapentin group and 102 in the placebo group in the second (phase III) trial.,rephrase,['The trials involved a total of 355 people with ALS.'],2,0.3125,2,16
CD006049,0,5,"Neither trial was long enough to report survival at one year, which was our primary outcome.",rephrase,['Neither of the trials were long enough to for us to report survival at one year.'],3,0.375,2,16
CD006049,0,6,"We found little or no difference in estimated one-year survival between the treated group and the placebo group (78% versus 77%, P = 0.63 by log-rank test; high-quality evidence).",merge,"['Combined results from the two studies (based on 274 participants) provided high-quality evidence of little or no difference in estimated one-year survival, the rate of decline in respiratory function, or rate of decline in arm strength in people treated with gabapentin compared to those treated with placebo.']",4,0.4375,3,16
CD006049,0,7,"We also found little or no difference in the rate of decline of MVIC expressed as arm megascore, or rate of FVC decline (high-quality evidence).",none,[],4,0.5,3,16
CD006049,0,8,One trial investigated monthly decline in the ALSFRS and quality of life measured using the 12-Item Short Form Survey (SF-12) and found little or no difference between groups (moderate-quality evidence).,split,"['One trial (128 participants) measured quality of life and monthly decline in function (measured by the ALS Functional Rating Scale).', 'There was little or no difference in the ALS Functional Rating Scale (ALSFRS) or quality of life between the gabapentin group and the placebo group.']",5,0.5625,3,16
CD006049,0,9,The trials reported similar adverse events.,delete,[],7,0.625,4,16
CD006049,0,10,"Complaints that were clearly elevated in those taking gabapentin, based on analyses of the combined data, were light-headedness, drowsiness, and limb swelling (high-quality evidence).",rephrase,"['People who received gabapentin had more light-headedness, drowsiness, and limb swelling than those taking placebo when we combined data from both trials (353 participants).']",7,0.6875,4,16
CD006049,0,11,"Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but when we combined the data for fatigue from both trials, there was no clear difference between the groups.",ignore,"['Fatigue and falls occurred more frequently with gabapentin than with placebo in one trial, but when we combined the data for fatigue from both trials, there was no clear difference between the groups.']",8,0.75,4,16
CD006049,0,12,We assessed the overall risk of bias in the included trials as low.,delete,[],9,0.8125,5,16
CD006049,1,13,"According to high-quality evidence, gabapentin is not effective in treating ALS.",rephrase,"['In conclusion, high-quality evidence indicates that gabapentin does not extend survival or slow the rate of decline of muscle strength or respiratory function.']",9,0.875,5,16
CD006049,1,14,"It does not extend survival, slow the rate of decline of muscle strength, respiratory function and, based on moderate-quality evidence, probably does not improve quality of life or slow monthly decline in the ALSFRS.",rephrase,['Moderate-quality evidence shows no effect on quality of life or decline in ALSFRS.'],10,0.9375,5,16
CD006049,1,15,Other GABA modulators have not been studied in randomized trials.,ignore,['Other GABA modulators have not been studied in randomized trials.'],11,1.0,5,16
CD009584,0,0,"Eight randomised controlled trials, enrolling 10,037 children, met our inclusion criteria.",rephrase,"['We found eight relevant randomised controlled trials, enrolling 10,037 children under five years of age.']",0,0.045454545454545456,1,22
CD009584,0,1,Seven of the trials were conducted in Africa.,rephrase,['All but one study was conducted in Africa.'],1,0.09090909090909091,1,22
CD009584,0,2,"In general, the included studies were at a low risk of bias.",rephrase,"['The risk of bias in the studies was generally low, though two studies had a high dropout rate.']",2,0.13636363636363635,1,22
CD009584,0,3,"There may have been a risk of performance bias as trial participants were aware which intervention group they were in, but we did not consider this likely to have biased the outcome measurement.",rephrase,['The participants were aware which intervention group they were in and this may have influenced their behaviour but we thought it unlikely it would have influenced the results since the outcomes measured were objective ones.'],3,0.18181818181818182,1,22
CD009584,0,4,We were unable to assess the risk of reporting bias in half of the trials and two trials were at high risk of attrition bias.,rephrase,"['For four of the studies, we were unable to assess if the study authors reported all the outcomes they intended to measure.']",4,0.22727272727272727,2,22
CD009584,1,5,"Any specially formulated food versus standard care - the provision of food increased the recovery rate by 29% (RR 1.29, 95% CI 1.20 to 1.38; 2152 children, two trials; moderate quality evidence), decreased the number dropping out by 70% (RR 0.30, 95% CI 0.22 to 0.39; 1974 children, one trial; moderate quality evidence), and improved weight-for-height (MD 0.20 z-score, 95% CI 0.03 to 0.37; 1546 children, two trials; moderate quality evidence).",rephrase,"['When any type of specially formulated food was compared to standard care (medical care and counselling without foods), the children treated with foods had a higher chance of recovering from moderate malnutrition (two studies), greater improvement in nutritional status (two studies), and a lower number of dropouts (one study).']",5,0.2727272727272727,2,22
CD009584,1,6,"The reduction in mortality did not reach statistical significance (RR 0.44; 95% CI 0.14 to 1.36; 1974 children, one trial; low quality evidence).",rephrase,['A reduction in mortality was not shown.'],6,0.3181818181818182,2,22
CD009584,2,7,"Lipid-based nutrient supplements versus any blended foods (dry food mixtures, without high lipid content), at full doses - there was no significant difference in mortality (RR 0.93, 95% CI 0.54 to 1.62; 6367 children, five trials; moderate quality evidence), progression to severe malnutrition (RR 0.88, 95% CI 0.72 to 1.07; 4537 children, three trials; high quality evidence), or the number of dropouts from the nutritional programme (RR 1.14, 95% CI 0.62 to 2.11; 5107 children, four trials; moderate quality evidence).",rephrase,"['When lipid-based nutrient supplements (which are food with high energy density and high lipid content) at full dose were compared to blended foods at full dose (which are dry food mixtures without high lipid content), there was no difference between these two types of foods in terms of number of deaths (five studies), children progressing to severe acute malnutrition (three studies), and children dropping out (four studies).']",7,0.36363636363636365,2,22
CD009584,2,8,"However, lipid-based nutrient supplements significantly increased the number of children recovered (RR 1.10, 95% CI 1.04 to 1.16; 6367 children, five trials; moderate quality evidence), and decreased the number of non-recovering children (RR 0.53, 95% CI 0.40 to 0.69; 4537 children, three trials; high quality evidence).",rephrase,"['However, lipid-based nutrient supplements increased the number recovered by 10% (five studies), decreased the number of children non-recovering (three studies), and slightly improved the nutritional status among the recovered.']",8,0.4090909090909091,3,22
CD009584,2,9,"LNS also improved weight gain, weight-for-height, and mid-upper arm circumference, although for these outcomes, the improvement was modest (moderate quality evidence).",delete,[],9,0.45454545454545453,3,22
CD009584,2,10,"One trial observed more children with vomiting in the lipid-based nutrient supplements group compared to those receiving blended food (RR 1.43, 95% CI 1.11 to 1.85; 2712 children, one trial; low quality evidence).",rephrase,"['One study observed more children vomiting when given lipid-based nutrient supplements compared to blended foods, but this was not reported by the other studies.']",9,0.5,3,22
CD009584,3,11,Foods at complementary doses - no firm conclusion could be drawn on the comparisons between LNS at complementary dose and blended foods at complementary or full dose (low quality evidence).,rephrase,"['Few studies evaluated foods at complementary dosage (i.e. foods given in low quantity, just to complement the diet and not to fully substitute it), and no conclusion could be drawn from these studies.']",10,0.5454545454545454,3,22
CD009584,4,12,"Lipid-based nutrient supplements versus specific types of blended foods - a recently developed enriched blended food (CSB++) resulted in similar outcomes to LNS (4758 children, three trials; moderate to high quality evidence).",rephrase,"['When specific foods were compared to each other, a type of corn-soy blended food called CSB++ compared to lipid-based nutrient supplements resulted in similar outcomes, while results of another blended food (CSB pre-mix) versus lipid-based nutrient supplements were unclear.']",11,0.5909090909090909,3,22
CD009584,5,13,"Different types of blended foods - in one trial, CSB++ did not show any significant benefit over locally made blended food, for example, Misola, in number who recovered, number who died, or weight gain (moderate to high quality evidence).",rephrase,"['In one study, CSB++ did not show any significant benefit over locally-made blended foods, for example, Misola.']",12,0.6363636363636364,4,22
CD009584,6,14,"Improved adequacy of home diet - no study evaluated the impact of improving adequacy of local diet, such as local foods prepared at home according to a given recipe or of home processing of local foods (soaking, germination, malting, fermentation) in order to increase their nutritional content.",ignore,"['No study evaluated the impact of improving adequacy of local diet, such as local foods prepared at home according to a given recipe or of home processing of local foods (soaking, germination, malting, fermentation) in order to increase their nutritional content.']",13,0.6818181818181818,4,22
CD009584,7,15,"In conclusion, there is moderate to high quality evidence that both lipid-based nutrient supplements and blended foods are effective in treating children with MAM.",rephrase,"['In conclusion, there is moderate to high quality evidence that both lipid-based nutrient supplements and blended foods are effective in treating children with moderate acute malnutrition.']",14,0.7272727272727273,4,22
CD009584,7,16,"Although lipid-based nutrient supplements (LNS) led to a clinically significant benefit in the number of children recovered in comparison with blended foods, LNS did not reduce mortality, the risk of default or progression to SAM.",ignore,"['Although lipid-based nutrient supplements (LNS) led to a clinically significant benefit in the number of children recovered in comparison with blended foods, LNS did not reduce mortality, the risk of default or progression to SAM.']",15,0.7727272727272727,4,22
CD009584,7,17,It also induced more vomiting.,ignore,['It also induced more vomiting.'],16,0.8181818181818182,5,22
CD009584,7,18,Blended foods such as CSB++ may be equally effective and cheaper than LNS.,ignore,['Blended foods such as CSB++ may be equally effective and cheaper than LNS.'],17,0.8636363636363636,5,22
CD009584,7,19,"Most of the research so far has focused on industrialised foods, and on short-term outcomes of MAM.",delete,[],18,0.9090909090909091,5,22
CD009584,7,20,"There are no studies evaluating interventions to improve the quality of the home diet, an approach that should be evaluated in settings where food is available, and nutritional education and habits are the main determinants of malnutrition.",ignore,"['There are no studies evaluating special recipes to improve the adequacy of the usual home diet, an approach that should be evaluated in settings where food is available, and nutritional education and habits are the main determinants of malnutrition.']",18,0.9545454545454546,5,22
CD009584,7,21,"There are no studies from Asia, where moderate acute malnutrition is most prevalent.",ignore,"['There are no studies from Asia, where moderate acute malnutrition is most prevalent.']",19,1.0,5,22
CD012002,0,0,"Three studies met the inclusion criteria, enrolling 451 participants.",rephrase,"['In August 2016, we found three relevant studies with 451 participants.']",0,0.07692307692307693,1,13
CD012002,0,1,The trial size varied from 51 to 280 participants.,ignore,['The trial size varied from 51 to 280 participants.'],1,0.15384615384615385,1,13
CD012002,0,2,"Two studies compared dexamethasone to placebo, and the third study compared a number of additional interventions in various combinations, including metoclopramide, chlorpromazine, tropisetron, and dexamethasone.",split,"['Two studies compared dexamethasone to placebo.', 'The third study compared a number of additional medicines in various combinations, including metoclopramide, chlorpromazine, tropisetron, and dexamethasone.']",2,0.23076923076923078,2,13
CD012002,0,3,The duration of the studies ranged from seven to 14 days.,ignore,['The duration of the included studies ranged from seven to 14 days.'],4,0.3076923076923077,2,13
CD012002,0,4,We included two studies (127 participants) with data at eight days in the meta-analysis for nausea intensity; no data were available that incorporated the same outcome measures for the third study.,delete,[],5,0.38461538461538464,2,13
CD012002,0,5,"Corticosteroid therapy with dexamethasone resulted in less nausea (measured on a scale of 0 to 10, with a lower score indicating less nausea) compared to placebo at eight days (MD 0.48 lower nausea, 95% CI 1.53 lower to 0.57 higher; very low-quality evidence), although this result was not statistically significant (P = 0.37).",delete,[],5,0.46153846153846156,3,13
CD012002,0,6,"Frequency of adverse events was not significantly different between groups, and the interventions were well tolerated.",delete,[],5,0.5384615384615384,3,13
CD012002,0,7,"Factors limiting statistical analysis included the lack of standardised measurements of nausea, and the use of different agents, dosages, and comparisons.",delete,[],5,0.6153846153846154,4,13
CD012002,0,8,Subgroup analysis according to type of cancer was not possible due to insufficient data.,delete,[],5,0.6923076923076923,4,13
CD012002,0,9,"The quality of this evidence was downgraded by three levels, from high to very low due to imprecision, likely selection bias, attrition bias, and the small number of participants in the included studies.",rephrase,"['We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high.']",5,0.7692307692307693,4,13
CD012002,1,10,"There are few studies assessing the effects of corticosteroids on nausea and vomiting not related to chemotherapy, radiotherapy, or surgery in adult cancer patients.",delete,[],6,0.8461538461538461,5,13
CD012002,1,11,This review found very low-quality evidence which neither supported nor refuted corticosteroid use in this setting.,split,"['Very low quality evidence means that we are very uncertain about the results.', 'High quality evidence means that we are very confident in the results.', 'We made the following conclusions from the available evidence:\n1) we found very low-quality evidence of the effects of steroids on nausea and vomiting in cancer patients;\n2) there was no evidence about how steroids work in different types of cancer; and\n3) there were few reported side effects, and the drugs were generally well tolerated.']",6,0.9230769230769231,5,13
CD012002,1,12,Further high quality studies are needed to determine if corticosteroids are efficacious in this setting.,rephrase,['More high quality studies are needed to determine if steroids are effective anti-nausea agents.'],9,1.0,5,13
CD008788,0,0,We included four RCTs involving 438 patients (220 patients in the drain group and 218 in the no-drain group).,rephrase,['This review included four RCTs involving 438 patients that investigated the benefits and harms of routine abdominal drainage post-gastrectomy for gastric cancer.'],0,0.16666666666666666,1,6
CD008788,0,1,"There was no evidence of a difference between the two groups in mortality (RR 1.73, 95% CI 0.38 to 7.84); re-operations (RR 2.49, 95% CI 0.71 to 8.74); post-operative complications (pneumonia: RR 1.18, 95% CI 0.55 to 2.54; wound infection: RR 1.23, 95% CI 0.47 to 3.23; intra-abdominal abscess: RR 1.27, 95% CI 0.29 to 5.51; anastomotic leak: RR 0.93, 95% CI 0.06 to 14.47); or initiation of soft diet (MD 0.15 days, 95% CI -0.07 to 0.37).",rephrase,"['There was no evidence of a difference between the two groups in deaths, post-operative complications, and initiation of a soft diet.']",1,0.3333333333333333,2,6
CD008788,0,2,"However, the addition of a drain prolonged the operation time (MD 9.07 min, 95% CI 2.56 to 15.57) and post-operative hospital stay (MD 0.69 day, 95% CI 0.18 to 1.21) and led to drain-related complications.",rephrase,"['The results showed that drains increased harms by prolonging operation time and post-operative hospital stay, and led to drain-related complications without providing any additional benefit for patients with gastric cancer undergoing gastrectomy.']",2,0.5,3,6
CD008788,0,3,"Additionally, we should note that 30-day mortality and re-operations are very rare events and, as a result, very large numbers of patients would be required to make any sensible conclusions about whether the two groups were similar.",delete,[],3,0.6666666666666666,4,6
CD008788,0,4,"The overall quality of the evidence according to the GRADE approach was 'very low' for mortality and re-operations, and 'low' for post-operative complications, operation time, and post-operative length of stay.",ignore,"[""The overall quality of the evidence according to the GRADE approach was 'very low' for deaths and re-operations, and 'low' for post-operative complications, operation time, and post-operative length of stay.""]",3,0.8333333333333334,5,6
CD008788,1,5,We found no convincing evidence to support routine drain use after gastrectomy for gastric cancer.,rephrase,['There was no convincing evidence to support the routine use of drains after gastrectomy for gastric cancer.'],4,1.0,5,6
CD008363,0,0,We found two studies involving 4993 participants.,rephrase,['The review of randomised controlled trials of routine Doppler ultrasound of the uterus or placenta identified two studies involving 4993 women.'],0,0.1,1,10
CD008363,0,1,The methodological quality of the trials was good.,delete,[],1,0.2,1,10
CD008363,0,2,"Both studies included women at low risk for hypertensive disorders, with Doppler ultrasound of the uterine arteries performed in the second trimester of pregnancy.",rephrase,['All the women were in the second trimester of pregnancy and at low risk for hypertensive disorders.'],1,0.3,2,10
CD008363,0,3,"In both studies, pathological finding of uterine arteries was followed by low-dose aspirin administration.",delete,[],2,0.4,2,10
CD008363,1,4,We identified no difference in short-term maternal and fetal clinical outcomes.,rephrase,['We identified no improvements for the baby or the mother.'],2,0.5,3,10
CD008363,2,5,We identified no randomised studies assessing the utero-placental vessels in the first trimester or in women at high risk for hypertensive disorders.,delete,[],3,0.6,3,10
CD008363,3,6,Present evidence failed to show any benefit to either the baby or the mother when utero-placental Doppler ultrasound was used in the second trimester of pregnancy in women at low risk for hypertensive disorders.,delete,[],3,0.7,4,10
CD008363,3,7,"Nevertheless, this evidence cannot be considered conclusive with only two studies included.",delete,[],3,0.8,4,10
CD008363,3,8,"There were no randomised studies in the first trimester, or in women at high risk.",rephrase,['We did not find any studies in the first trimester of pregnancy or in women at risk of high blood pressure disorders.'],3,0.9,5,10
CD008363,3,9,More research is needed to investigate whether the use of utero-placental Doppler ultrasound may improve pregnancy outcome.,split,"[""We set out to assess the value of using Doppler ultrasound of the mother's uterus or placenta (utero-placental Doppler ultrasound) as a screening tool."", 'However, more data would be needed to show whether maternal Doppler is effective, or not, for improving outcomes.', 'More research is needed on this important aspect of care.']",4,1.0,5,10
CD003045,0,0,"Combining the results of five randomised clinical trials randomising 499 patients with alcoholic hepatitis and/or cirrhosis demonstrated no significant effects of anabolic-androgenic steroids on mortality (relative risk (RR) 1.01, 95% confidence interval (CI) 0.79 to 1.29), liver-related mortality (RR 0.83, 95% CI 0.60 to 1.15), complications of liver disease (RR 1.25, 95% CI 0.74 to 2.10), and liver histology.",delete,[],0,0.25,2,4
CD003045,0,1,"Anabolic-androgenic steroids did not significantly affect a number of other outcome measures, including sexual function and liver biochemistry.",delete,[],0,0.5,3,4
CD003045,0,2,"Anabolic-androgenic steroids were not associated with a significantly increased risk of non-serious adverse events (RR 1.14, 95% CI 0.50 to 2.59) or with serious adverse events (RR 4.54, 95% CI 0.57 to 36.30).",rephrase,"['Anabolic-androgenic steroid intervention is not associated with a significant increase in non-serious adverse events, but with the seldom occurrence of serious adverse events.']",0,0.75,4,4
CD003045,1,3,"This systematic review could not demonstrate any significant beneficial effects of anabolic-androgenic steroids on any clinically important outcomes (mortality, liver-related mortality, liver complications, and histology) of patients with alcoholic liver disease.",split,"['Several trials have addressed the effects of anabolic-androgenic steroids for alcoholic liver disease.', 'This systematic review could not demonstrate any significant effects of anabolic-androgenic steroids on mortality, liver-related mortality, liver complications, and histology of patients with alcoholic liver disease.', 'Accordingly, there is no evidence supporting the use of anabolic-androgenic steroids for alcoholic liver disease, but further randomised clinical trials may be needed to settle the question.']",1,1.0,5,4
CD008720,0,0,"We included four studies, with a total of 522 women, in the review.",rephrase,"['This review included four randomised controlled trials, with a total of 522 women.']",0,0.06666666666666667,1,15
CD008720,0,1,"One of these studies did not report outcomes per woman randomised, and so was not included in formal analysis.",rephrase,['Only one study reported the main outcome of live birth per woman randomised; two studies reported clinical pregnancy.'],1,0.13333333333333333,1,15
CD008720,0,2,"Three studies investigated 10,000 units hCG priming compared to no priming.",rephrase,"['One study investigated the use of 20,000 units hCG priming compared to 10,000 units.']",2,0.2,1,15
CD008720,0,3,"One study investigated 20,000 units hCG compared to 10,000 units hCG priming.",rephrase,"['The remaining studies investigated 10,000 units hCG priming compared to no priming.']",3,0.26666666666666666,2,15
CD008720,0,4,"Three studies only included women with PCOS (N = 122), while this was an exclusion criteria in the fourth study (N = 400).",delete,[],4,0.3333333333333333,2,15
CD008720,1,5,We rated all four studies as having an unclear risk of bias in more than one of the seven domains assessed.,delete,[],4,0.4,2,15
CD008720,1,6,"The quality of the evidence was low, the main limitations being lack of blinding and imprecision.",rephrase,"['The quality of the evidence was low, the main limitations being imprecision (random error) and lack of blinding (the process in which participant and assessor are prevented from knowing which intervention has been received).']",4,0.4666666666666667,3,15
CD008720,2,7,"When 10,000 units hCG priming was compared to no priming, we found no evidence of a difference in the live birth rates per woman randomised (OR 0.65, 95% confidence intervals (CI) 0.24 to 1.74; one RCT; N = 82; low quality evidence); miscarriage rate (OR 0.60, 95% CI 0.21 to 1.72; two RCTs; N = 282; I² statistic = 21%; low quality evidence), or clinical pregnancy rate (OR 0.52, 95% CI 0.26 to 1.03; two RCTs, N = 282, I² statistic = 0%, low quality evidence).",split,"['We found no certain evidence of a difference between 10,000 units hCG priming and no priming.', 'Two studies reported miscarriage rate per woman randomised, and found no evidence of a difference between 10,000 units hCG priming and no priming.']",5,0.5333333333333333,3,15
CD008720,2,8,"Though inconclusive, our findings suggested that hCG may be associated with a reduction in clinical pregnancy rates; 22% of women who received no priming achieved pregnancy, while between 7% and 23% of women who received hCG priming did so.",rephrase,"['However, there was some low quality evidence to suggest that hCG may be associated with a reduction in pregnancy rates; 22% of women who received no priming achieved pregnancy, while between 7% and 23% of women who received hCG priming did so.']",7,0.6,3,15
CD008720,3,9,"The study comparing 20,000 units hCG with 10,000 units hCG did not report sufficient data to enable us to calculate odds ratios.",delete,[],8,0.6666666666666666,4,15
CD008720,4,10,No studies reported on adverse events (other than miscarriage) or drug reactions.,ignore,['No studies reported on adverse events (other than miscarriage) or drug reactions.'],8,0.7333333333333333,4,15
CD008720,5,11,"This review found no conclusive evidence that hCG priming had an effect on live birth, pregnancy, or miscarriage rates in IVM.",rephrase,"['Overall, there was insufficient evidence to draw any definite conclusions on the use of hCG priming in IVM.']",9,0.8,4,15
CD008720,5,12,"There was low quality evidence that suggested that hCG priming may reduce clinical pregnancy rates, however, these findings were limited by the small number of data included.",delete,[],10,0.8666666666666667,5,15
CD008720,5,13,"As no data were available on adverse events (other than miscarriage) or on drug reactions, we could not adequately assess the safety of hCG priming.",delete,[],10,0.9333333333333333,5,15
CD008720,5,14,"We need further evidence from well-designed RCTs before we can come to definitive conclusions about the role of hCG priming, and the optimal dose and timing.",delete,[],10,1.0,5,15
CD008808,0,0,"We included 30 trials, with a total of 1569 participants, in this review.",merge,"['We found 30 trials, with a total of 1569 participants, and the interventions included changes to ventilator type and settings, earplugs and eye masks, relaxation therapy, sleep-inducing music, massage, foot baths, aromatherapy, valerian acupressure, sound masking, and changing the visiting times of family members.']",0,0.06666666666666667,1,15
CD008808,0,1,"We included trials of ventilator mode or type, earplugs or eye masks or both, massage, relaxation interventions, foot baths, music interventions, nursing interventions, valerian acupressure, aromatherapy, and sound masking.",none,[],0,0.13333333333333333,1,15
CD008808,0,2,"Outcomes included objective sleep outcomes, subjective sleep quality and quantity, risk of delirium, participant satisfaction, length of ICU stay, and adverse events.",rephrase,"['We assessed the effects of these interventions on sleep outcomes (e.g., quality and amount of sleep), length of stay in the ICU, the occurrence of delirium, other adverse events, and death.']",1,0.2,1,15
CD008808,0,3,"Clinical heterogeneity (e.g., participant population, outcomes measured) and research design limited quantitative synthesis, and only a small number of studies were available for most interventions.",delete,[],2,0.26666666666666666,2,15
CD008808,0,4,The quality of the evidence for an effect of non-pharmacological interventions on any of the outcomes examined was generally low or very low.,rephrase,"['Overall, the quality of the evidence for an effect of the interventions on any of the outcomes was low or very low.']",2,0.3333333333333333,2,15
CD008808,0,5,"Only three trials, all of earplugs or eye masks or both, provided data suitable for two separate meta-analyses.",delete,[],3,0.4,2,15
CD008808,0,6,"These meta-analyses, each of two studies, showed a lower incidence of delirium during ICU stay (risk ratio 0.55, 95% confidence interval (CI) 0.38 to 0.80, P value = 0.002, two studies, 177 participants) and a positive effect of earplugs or eye masks or both on total sleep time (mean difference 2.19 hours, 95% CI 0.41 to 3.96, P value = 0.02, two studies, 116 participants); we rated the quality of the evidence for both of these results as low.",delete,[],3,0.4666666666666667,3,15
CD008808,1,7,"There was also some low quality evidence that music (350 participants; four studies) may improve subjective sleep quality and quantity, but we could not pool the data.",rephrase,"['There was also some low quality evidence from four studies that music may improve subjective sleep quality and quantity, but we could not pool the data.']",3,0.5333333333333333,3,15
CD008808,1,8,"Similarly, there was some evidence that relaxation techniques, foot massage, acupressure, nursing or social intervention, and sound masking can provide small improvements in various subjective measures of sleep quality and quantity, but the quality of the evidence was low.",rephrase,"['Similarly, a low number of studies found that relaxation techniques, foot massage, acupressure, nursing or social intervention, and sound masking can provide small improvements in participant-reported or nurse-assessed sleep quality and quantity, but the quality of the evidence was low.']",4,0.6,3,15
CD008808,1,9,"The effects of non-pharmacological interventions on objective sleep outcomes were inconsistent across 16 studies (we rated the quality of the evidence as very low): the majority of studies relating to the use of earplugs and eye masks found no benefit; results from six trials of ventilator modes suggested that certain ventilator settings might offer benefits over others, although the results of the individual trials did not always agree with each other.",rephrase,"['The effects of the interventions on objective sleep outcomes (e.g., sleep measured by a machine) varied: the majority of studies that looked at the use of earplugs and eye masks found no benefit, and although the results from six trials of ventilator modes suggested that certain ventilator settings might offer benefits over others, the results of the individual trials did not always agree with each other.']",5,0.6666666666666666,4,15
CD008808,1,10,Only one study measured length of stay in the ICU and found no significant effect of earplugs plus eye masks.,ignore,['Only one study measured length of stay in the ICU and found no significant effect of earplugs plus eye masks.'],6,0.7333333333333333,4,15
CD008808,1,11,"No studies examined the effect of any non-pharmacological intervention on mortality, risk of post-traumatic stress disorder, or cost-effectiveness; the included studies did not clearly report adverse effects, although there was very low quality evidence that ventilator mode influenced the incidence of central apnoeas and patient-ventilator asynchronies.",split,"['None of the included studies looked at economic outcomes, risk of post-traumatic stress disorder, or deaths.', 'The trials did not clearly report adverse effects, although there was very low quality evidence that ventilator mode might influence certain adverse effects that can happen when people are on a ventilator.']",7,0.8,4,15
CD008808,2,12,The quality of existing evidence relating to the use of non-pharmacological interventions for promoting sleep in adults in the ICU was low or very low.,delete,[],9,0.8666666666666667,5,15
CD008808,2,13,"We found some evidence that the use of earplugs or eye masks or both may have beneficial effects on sleep and the incidence of delirium in this population, although the quality of the evidence was low.",rephrase,['We were able to combine the results from three trials of earplugs and eye masks and found that their use increased the number of hours slept and prevented delirium in adults in the ICU.'],9,0.9333333333333333,5,15
CD008808,2,14,Further high-quality research is needed to strengthen the evidence base.,rephrase,"['In summary, further well-designed and conducted research is needed to strengthen the evidence for the use of these interventions for improving sleep in critically ill adults.']",10,1.0,5,15
CD012047,0,0,We included seven randomised controlled trials involving 493 participants.,rephrase,"['We included seven studies, recruiting 493 patients.']",0,0.05263157894736842,1,19
CD012047,0,1,In all studies the participants were adults undergoing septoplasty.,rephrase,['The participants were adults having septoplasty in all of the included studies and the percentage of females ranged from 20.7% to 58.3%.'],1,0.10526315789473684,1,19
CD012047,0,2,These studies were heterogeneous and the quality of the body of evidence ranged from low to very low.,delete,[],2,0.15789473684210525,1,19
CD012047,0,3,Few of the studies provided reliable data for the primary outcome in this review.,delete,[],2,0.21052631578947367,2,19
CD012047,1,4,"Local anaesthetic injection versus no treatment/placebo
Two studies (142 participants) compared local anaesthetic injection versus placebo but these studies did not report postoperative pain at 12, 24 or 48 hours.",rephrase,"['Two studies, recruiting 142 participants, assessed local anaesthetic injection.']",2,0.2631578947368421,2,19
CD012047,1,5,"It is unclear whether local anaesthetic injection changed the risk of vomiting (odds ratio (OR) 3.10, 95% confidence interval (CI) 0.12 to 79.23; 60 participants; one study) (low-quality evidence).",rephrase,['It is unclear whether local injection increased postoperative vomiting.'],3,0.3157894736842105,2,19
CD012047,1,6,"Neither study reported the requirement for additional analgesia, duration of hospitalisation or uncontrollable postoperative bleeding.",rephrase,['Neither study reported uncontrollable postoperative bleeding.'],4,0.3684210526315789,2,19
CD012047,2,7,"Local anaesthetic application via nasal packing versus no packing/packing with placebo
Four studies (301 participants) used nasal packing postoperatively and compared the addition of local anaesthetic to the pack versus packing with a placebo added.",rephrase,['Local anaesthetic application via nasal packing compared to no packing/packing with placebo\nFour studies that used nasal packing after the operation assessed the addition of a local anaesthetic to the pack compared to packing with a placebo added.'],5,0.42105263157894735,3,19
CD012047,2,8,"Compared with packing with placebo, the addition of local anaesthetic to nasal packing reduced the pain score on a VAS (ranging from 0 to 100) at 12 hours (mean difference (MD) -16.95, 95% CI -22.27 to -11.62; 151 participants; two studies; I2 = 49%) (low-quality evidence) and at 24 hours postoperatively (MD -7.53, 95% CI -9.76 to -5.29; 268 participants; four studies; I2 = 83%) (very low-quality evidence).",rephrase,['Local anaesthetic added to nasal packing reduced pain by 17.0 points on a 100-point scale at 12 hours postoperatively and by 7.5 points at 24 hours postoperatively.'],6,0.47368421052631576,3,19
CD012047,2,9,These studies did not report postoperative pain at 48 hours.,split,"['Four of these studies reported pain at 12 or 24 hours (or both) postoperatively.', 'These studies did not report on pain at 48 hours postoperatively.']",7,0.5263157894736842,3,19
CD012047,2,10,"The addition of local anaesthetic to nasal packing decreased the requirement for additional analgesia (OR 0.15, 95% CI 0.07 to 0.34; 151 participants; two studies; I2 = 15%) (moderate-quality evidence).",rephrase,['Local anaesthetic application by nasal packing decreased the need for additional analgesia (painkillers) postoperatively.'],9,0.5789473684210527,3,19
CD012047,2,11,"No studies reported duration of hospitalisation, postoperative vomiting or uncontrollable postoperative bleeding.",rephrase,['No studies reported postoperative vomiting or uncontrollable postoperative bleeding.'],10,0.631578947368421,4,19
CD012047,3,12,No studies compared the addition of local anaesthetic to nasal packing versus no packing.,rephrase,['No studies evaluated local anaesthetic application via nasal packing compared to no packing.'],11,0.6842105263157895,4,19
CD012047,4,13,"Sphenopalatine ganglion block versus no treatment/placebo
One study (50 participants) compared sphenopalatine ganglion block versus no treatment but this study did not report postoperative pain, requirement for additional analgesia, duration of hospitalisation, vomiting or uncontrollable postoperative bleeding.",rephrase,"['Regional nerve block compared to no treatment/placebo\nOne study compared a regional nerve block with no treatment, but this study did not report postoperative pain or any of our other outcomes.']",12,0.7368421052631579,4,19
CD012047,5,14,"The addition of local anaesthesia to nasal packs (if these are being used) following septal surgery may reduce postoperative pain within the first 12 hours, compared to nasal packing with a placebo added.",ignore,['The addition of local anaesthesia to nasal packs (if these are being used) following septal surgery may reduce postoperative pain within the first 12 hours postoperatively compared to nasal packing with a placebo added.'],13,0.7894736842105263,4,19
CD012047,5,15,The effect is uncertain at 24 hours because the quality of the evidence is very low.,split,"['We graded the quality of evidence for the use of local anaesthetic injection as low, which means that further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.', 'We downgraded the quality of the evidence because of the small number of patients and events.']",14,0.8421052631578947,5,19
CD012047,5,16,"Evidence was lacking for other outcomes, including adverse effects.",delete,[],16,0.8947368421052632,5,19
CD012047,5,17,There is a lack of evidence about the effects of local anaesthesia added to nasal packing compared to no nasal packing.,split,"['However, our review revealed a lack of evidence on which to base comparisons of the various types of local anaesthesia.', 'This review should prompt further research comparing local anaesthesia by injection, as an addition to nasal packing and as a regional nerve block following septal surgery.']",16,0.9473684210526315,5,19
CD012047,5,18,There is also a lack of evidence about the effects of local anaesthesia given by injection and the effects of sphenopalatine ganglion block.,delete,[],18,1.0,5,19
CD001159,0,0,We included 49 trials (3061 participants; 1553 randomized to PNBs and 1508 to no nerve block (or sham block)).,delete,[],0,0.045454545454545456,1,22
CD001159,0,1,"For this update, we added 18 new trials.",delete,[],0,0.09090909090909091,1,22
CD001159,0,2,Trials were published from 1981 to 2020.,rephrase,['Studies were conducted in\xa0various countries\xa0and published between 1980\xa0and 2020.'],0,0.13636363636363635,1,22
CD001159,0,3,Trialists followed participants for periods ranging from 5 minutes to 12 months.,delete,[],1,0.18181818181818182,1,22
CD001159,0,4,The average age of participants ranged from 59 to 89 years.,rephrase,['We included 49 studies with 3061 participants (average age 59 to 89 years); 1553 participants received PNBs and 1508 received no nerve block.'],1,0.22727272727272727,2,22
CD001159,0,5,People with dementia were often excluded from the included trials.,delete,[],2,0.2727272727272727,2,22
CD001159,0,6,Additional analgesia was available for all participants.,rephrase,"['Additional pain relief, including opioids, was available for all participants when required.']",2,0.3181818181818182,2,22
CD001159,1,7,"Results of 11 trials with 503 participants show that PNBs reduced pain on movement within 30 minutes of block placement (standardized mean difference (SMD) -1.05, 95% confidence interval (CI) -1.25 to -0.86; equivalent to -2.5 on a scale from 0 to 10; high-certainty evidence).",rephrase,"['PNBs reduced pain on movement by 2.5 on a scale of 1 to 10, compared with no nerve block\xa0(11 studies, 503 participants).']",3,0.36363636363636365,2,22
CD001159,1,8,Effect size was proportionate to the concentration of local anaesthetic used (P = 0.0003).,delete,[],4,0.4090909090909091,3,22
CD001159,1,9,"Based on 13 trials with 1072 participants, PNBs reduce the risk of acute confusional state (risk ratio (RR) 0.67, 95% CI 0.50 to 0.90; number needed to treat for an additional beneficial outcome (NNTB) 12, 95% CI 7 to 47; high-certainty evidence).",rephrase,"['PNBs reduced the risk of confusion; for every 12 people with a hip fracture, one person less will become confused with PNBs (13 studies, 1072 participants).']",4,0.45454545454545453,3,22
CD001159,1,10,"For myocardial infarction, there were no events in one trial with 31 participants (RR not estimable; low-certainty evidence).",rephrase,"['We did not find a\xa0difference in risk of myocardial infarction (1 study, 31 participants).']",5,0.5,3,22
CD001159,1,11,"From three trials with 131 participants, PNBs probably reduce the risk for chest infection (RR 0.41, 95% CI 0.19 to 0.89; NNTB 7, 95% CI 5 to 72; moderate-certainty evidence).",rephrase,"['PNBs probably reduce the risk of chest infection (3 studies, 131 participants) and time to first mobilization after surgery by 11 hours (3 studies, 208 participants).']",6,0.5454545454545454,3,22
CD001159,1,12,"Based on 11 trials with 617 participants, the effects of PNBs on mortality within six months are uncertain due to very serious imprecision (RR 0.87, 95% CI 0.47 to 1.60; low-certainty evidence).",rephrase,"['We did not find a difference in deaths from any cause within six months\xa0(11 studies, 617 participants).']",7,0.5909090909090909,3,22
CD001159,1,13,"From three trials with 208 participants, PNBs likely reduce time to first mobilization (mean difference (MD) -10.80 hours, 95% CI -12.83 to -8.77 hours; moderate-certainty evidence).",delete,[],8,0.6363636363636364,4,22
CD001159,1,14,"One trial with 75 participants indicated there may be a small reduction in the cost of analgesic drugs with a single-injection PNB (MD -4.40 euros, 95% CI -4.84 to -3.96 euros; low-certainty evidence).",rephrase,"['Costs of drugs used for pain management were slightly lower when a single-injection PNB was compared to no PNB (1 study, 75 participants).']",8,0.6818181818181818,4,22
CD001159,2,15,"We identified 29 ongoing trials, of which 15 were first posted or at least were last updated after 1 January 2018.",delete,[],9,0.7272727272727273,4,22
CD001159,3,16,"PNBs reduce pain on movement within 30 minutes after block placement, risk of acute confusional state, and probably also reduce the risk of chest infection and time to first mobilization.",rephrase,"['We wanted to know whether using PNBs compared to no nerve block (no block at all or a placebo nerve block), in people with hip fracture could reduce:\n• pain on movement;\n• confusion, myocardial infarction, and chest infection;\n• death from any cause within six months;\n• length of time until people were mobile after surgery; and\n• costs of drugs used to manage\xa0pain.']",9,0.7727272727272727,4,22
CD001159,3,17,There may be a small reduction in the cost of analgesic drugs for single-injection PNB.,delete,[],10,0.8181818181818182,5,22
CD001159,3,18,"We did not find a difference for myocardial infarction and mortality, but the numbers of participants included for these two outcomes were insufficient.",rephrase,"['However, we are less confident about the evidence for myocardial infarction, death, time to first mobilization, and costs of drugs used for pain management, mainly because this evidence came from small studies with few participants.']",10,0.8636363636363636,5,22
CD001159,3,19,"Although randomized clinical trials may not be the best way to establish risks associated with an intervention, our review confirms low risks of permanent injury associated with PNBs, as found by others.",delete,[],11,0.9090909090909091,5,22
CD001159,4,20,"Some trials are ongoing, but it is unclear whether any further RCTs should be registered, given the benefits found.",delete,[],11,0.9545454545454546,5,22
CD001159,4,21,Good-quality non-randomized trials with appropriate sample size may help to clarify the potential effects of PNBs on myocardial infarction and mortality.,rephrase,['Larger studies are required to clarify the effects of PNBs on myocardial infarction and death.'],11,1.0,5,22
CD000490,0,0,"We included 15 studies, involving over 2000 women.",rephrase,"['We found 15 randomised controlled studies involving over 2000 pregnant women with urinary infections, but no symptoms.']",0,0.09090909090909091,1,11
CD000490,0,1,"Antibiotic treatment compared with placebo or no treatment may reduce the incidence of pyelonephritis (average risk ratio (RR) 0.24, 95% confidence interval (CI) 0.13 to 0.41; 12 studies, 2017 women; low-certainty evidence).",rephrase,"['Antibiotics may be effective in reducing the incidence of kidney infection in the mother (12 studies, 2017 women) and clearing the infection from the urine (four studies, 596 women).']",1,0.18181818181818182,1,11
CD000490,0,2,"Antibiotic treatment may be associated with a reduction in the incidence of preterm birth (RR 0.34, 95% CI 0.13 to 0.88; 3 studies, 327 women; low-certainty evidence), and low birthweight babies (average RR 0.64, 95% CI 0.45 to 0.93; 6 studies, 1437 babies; low-certainty evidence).",rephrase,"['They may also reduce the incidence of preterm births (three studies, 327 women) and low birthweight babies (six studies, 1437 babies).']",2,0.2727272727272727,2,11
CD000490,0,3,"There may be a reduction in persistent bacteriuria at the time of delivery (average RR 0.30, 95% CI 0.18 to 0.53; 4 studies; 596 women), but the results were inconclusive for serious adverse neonatal outcomes (average RR 0.64, 95% CI 0.23 to 1.79, 3 studies; 549 babies).",delete,[],3,0.36363636363636365,2,11
CD000490,0,4,"There were very limited data on which to estimate the effect of antibiotics on other infant outcomes, and maternal adverse effects were rarely described.",delete,[],3,0.45454545454545453,3,11
CD000490,1,5,"Overall, we judged only one trial at low risk of bias across all domains; the other 14 studies were assessed as high or unclear risk of bias.",delete,[],3,0.5454545454545454,3,11
CD000490,1,6,"Many studies lacked an adequate description of methods, and we could only judge the risk of bias as unclear, but in most studies, we assessed at least one domain at high risk of bias.",delete,[],3,0.6363636363636364,4,11
CD000490,1,7,"We assessed the quality of the evidence for the three primary outcomes with GRADE software, and found low-certainty evidence for pyelonephritis, preterm birth, and birthweight less than 2500 g.",rephrase,"['We assessed the three main outcomes with the GRADE approach, and found low-certainty evidence that antibiotic treatment may prevent pyelonephritis, preterm birth, and birthweight less than 2500 g.']",3,0.7272727272727273,4,11
CD000490,2,8,"Antibiotic treatment may be effective in reducing the risk of pyelonephritis in pregnancy, but our confidence in the effect estimate is limited given the low certainty of the evidence.",rephrase,['Antibiotic treatment may reduce the risk of kidney infections in pregnant women who have a urine infection but show no symptoms of infection.'],4,0.8181818181818182,5,11
CD000490,2,9,"There may be a reduction in preterm birth and low birthweight with antibiotic treatment, consistent with theories about the role of infection in adverse pregnancy outcomes, but again, the confidence in the effect is limited given the low certainty of the evidence.",split,"['Antibiotics may also reduce the chance a baby will be born too early or have a low birthweight.', 'However, because of the low certainty of the evidence, it is difficult to draw conclusions; more research is needed.']",5,0.9090909090909091,5,11
CD000490,3,10,"Research implications identified in this review include the need for an up-to-date cost-effectiveness evaluation of diagnostic algorithms, and more evidence to learn whether there is a low-risk group of women who are unlikely to benefit from treatment of asymptomatic bacteriuria.",delete,[],7,1.0,5,11
CD010622,0,0,We included six RCTs.,rephrase,['We found six studies that included a total of 321 participants.'],0,0.08333333333333333,1,12
CD010622,0,1,"A total of 197 participants were allocated to rhTSh-aided radioiodine therapy, and 124 participants were allocated to radioiodine.",delete,[],1,0.16666666666666666,1,12
CD010622,0,2,A single dose of radioiodine was administered 24 hours after the intramuscular injection of a single dose of rhTSH.,ignore,['A single dose of radioiodine was administered 24 hours after the intramuscular injection of a single dose of rhTSH.'],1,0.25,2,12
CD010622,0,3,The duration of follow-up ranged between 12 and 36 months.,rephrase,['Participants were followed up for 12 to 36 months.'],2,0.3333333333333333,2,12
CD010622,1,4,"Low-certainty evidence from one study, with 85 participants, showed uncertain effects for QoL for either intervention.",rephrase,['One study with 85 participants showed there was not a clear beneficial or harmful effect on health-related quality of life for either intervention.'],3,0.4166666666666667,3,12
CD010622,1,5,"RhTSH-aided radioiodine increased hypothyroidism compared with radioiodine alone (64/197 participants (32.5%) in the rhTSH-aided radioiodine group versus 15/124 participants (12.1%) in the radioiodine alone group; RR 2.53, 95% CI 1.52 to 4.20; 6 studies, 321 participants; moderate-certainty evidence in favour of radioiodine alone).",delete,[],4,0.5,3,12
CD010622,1,6,"A total of 118/197 participants (59.9%) in the rhTSH-aided radioiodine group compared with 60/124 participants (48.4%) in the radioiodine alone group experienced adverse events (random-effects RR 1.24, 95% CI 0.94 to 1.63; 6 studies, 321 participants; fixed-effect RR 1.23, 95% CI 1.02 to 1.49 in favour of radioiodine only; low-certainty evidence).",delete,[],4,0.5833333333333334,3,12
CD010622,2,7,"RhTSH-aided radioiodine reduced thyroid volume with a MD of 11.9% (95% CI 4.4 to 19.4; 6 studies, 268 participants; moderate-certainty evidence).",rephrase,"['On the other hand, rhTSH-aided radioiodine reduced thyroid volume by, on average, 12% more than radioiodine treatment alone.']",4,0.6666666666666666,4,12
CD010622,2,8,One study with 28 participants reported one death in the radioiodine alone group (very-low certainty evidence).,rephrase,"['One study, with 28 participants, reported one death in the radioiodine alone group.']",5,0.75,4,12
CD010622,2,9,No study reported on costs.,ignore,['No study reported on costs.'],6,0.8333333333333334,5,12
CD010622,3,10,"RhTSH-aided radioiodine treatment for non-toxic multinodular goitre, compared to radioiodine alone, probably increased the risk of hypothyroidism but probably led to a greater reduction in thyroid volume.",delete,[],7,0.9166666666666666,5,12
CD010622,3,11,Data on QoL and costs were sparse or missing.,delete,[],7,1.0,5,12
CD006180,0,0,One study was identified that compared protein containing synthetic surfactants (PCSS) to protein free synthetic surfactants.,delete,[],0,0.16666666666666666,1,6
CD006180,0,1,"Infants who received protein containing synthetic surfactant compared to protein free synthetic surfactant did not demonstrate significantly different risks of prespecified primary outcomes: mortality at 36 weeks postmenstrual age (PMA) [RR 0.89 (95% CI 0.71, 1.11)], chronic lung disease at 36 weeks PMA [RR 0.89 (95% CI 0.78, 1.03)], or the combined outcome of mortality or chronic lung disease at 36 weeks PMA [RR 0.88 (95% CI 0.77, 1.01)].",delete,[],0,0.3333333333333333,2,6
CD006180,0,2,"Among the secondary outcomes, a decrease in the incidence of respiratory distress syndrome at 24 hours of age was demonstrated in the group that received PCSS [RR 0.83 (95% CI 0.72, 0.95).",delete,[],0,0.5,3,6
CD006180,1,3,"In the one trial comparing protein containing synthetic surfactants compared to protein free synthetic surfactant for the prevention of RDS, no statistically different clinical differences in death and chronic lung disease were noted.",rephrase,['A recent trial of protein containing synthetic surfactant compared to protein free synthetic surfactant suggests that these protein containing synthetic surfactants help prevent respiratory distress syndrome and may or may not lead to a decrease in lung injury (chronic lung disease).'],0,0.6666666666666666,4,6
CD006180,1,4,Clinical outcomes between the two groups were generally similar although the group receiving protein containing synthetic surfactants did have decreased incidence of respiratory distress syndrome.,rephrase,['Other clinical outcomes were similar.'],1,0.8333333333333334,5,6
CD006180,1,5,Further well designed studies comparing protein containing synthetic surfactant to the more widely used animal derived surfactant extracts are indicated.,rephrase,['Further studies will help refine recommendations concerning use of protein containing synthetic surfactants.'],2,1.0,5,6
CD011940,0,0,"We included in the meta-analysis 37 studies that included adults undergoing a large variety of surgical procedures (i.e. abdominal surgery, cardiac surgery, neurosurgery, and orthopaedic surgery).",rephrase,['All studies included adults undergoing surgery.'],0,0.07142857142857142,1,14
CD011940,0,1,"We excluded one previously included study, as this study was recently retracted.",rephrase,['One previously included study was recently retracted and subsequently excluded from this review.'],1,0.14285714285714285,1,14
CD011940,0,2,Age range of participants was 18 to 80 years.,delete,[],2,0.21428571428571427,2,14
CD011940,0,3,"There is probably little or no difference in the risk of postoperative (wound or systemic) infection with dexamethasone compared with no treatment, placebo, or active control (ramosetron, ondansetron, or tropisetron) (Peto OR 1.01, 95% confidence interval (CI) 0.80 to 1.27; 4603 participants, 26 studies; I² = 32%; moderate-quality evidence).",delete,[],2,0.2857142857142857,2,14
CD011940,0,4,"The effects of dexamethasone on delayed wound healing are unclear because the wide confidence interval includes both meaningful benefit and harm (Peto OR 0.99, 95% CI 0.28 to 3.43; 1072 participants, eight studies; I² = 0%; low-quality evidence).",delete,[],2,0.35714285714285715,2,14
CD011940,0,5,"Dexamethasone may produce a mild increase in glucose levels among participants without diabetes during the first 12 hours after surgery (MD 13 mg/dL, 95% CI 6 to 21; 10 studies; 595 participants; I² = 50%; low-quality evidence).",delete,[],2,0.42857142857142855,3,14
CD011940,0,6,"We identified two studies reporting on glycaemic response after dexamethasone in participants with diabetes within 24 hours after surgery (MD 32 mg/dL, 95% CI 15 to 49; 74 participants; I² = 0%; very low-quality evidence).",delete,[],2,0.5,3,14
CD011940,1,7,A single dose of dexamethasone probably does not increase the risk for postoperative infection.,rephrase,['dexamethasone probably does not increase the risk of infection after surgery.'],2,0.5714285714285714,3,14
CD011940,1,8,It is uncertain whether dexamethasone has an effect on delayed wound healing in the general surgical population owing to imprecision in trial results.,rephrase,['Not enough information is available to determine whether dexamethasone has an effect on the time it takes for surgical wounds to heal.'],3,0.6428571428571429,4,14
CD011940,1,9,"Participants with increased risk for delayed wound healing (e.g. participants with diabetes, those taking immunosuppressive drugs) were not included in the randomized studies reporting on delayed wound healing included in this meta-analysis; therefore our findings should be extrapolated to the clinical setting with caution.",rephrase,"['However, included studies did not focus on patients with high risk for delayed wound healing, for example, patients with diabetes or those taking steroids; thus more studies are needed on this topic.']",4,0.7142857142857143,4,14
CD011940,1,10,"Furthermore, one has to keep in mind that dexamethasone induces a mild increase in glucose.",rephrase,"['Additionally, one has to keep in mind that taking dexamethasone leads to a mild increase in blood sugar.']",5,0.7857142857142857,4,14
CD011940,1,11,"For patients with diabetes, very limited evidence suggests a more pronounced increase in glucose.",rephrase,"['For patients with diabetes, very limited evidence suggests a greater increase in blood sugar.']",6,0.8571428571428571,5,14
CD011940,1,12,Whether this influences wound healing in a clinically relevant way remains to be established.,rephrase,['Whether or not the small increase in blood sugar has any effect on healing of surgical wounds has yet to be established.'],7,0.9285714285714286,5,14
CD011940,1,13,"Once assessed, the two studies awaiting classification and three that are ongoing may alter the conclusions of this review.",rephrase,"['The two studies awaiting classification and three ongoing trials may alter the conclusions of this review, once assessed.']",8,1.0,5,14
CD005162,0,0,We included nine RCTs with a total of 534 participants with cirrhosis and ascites.,rephrase,['The review includes nine randomised clinical trials (RCTs) and a total of 534 participants.'],0,0.0625,1,16
CD005162,0,1,One RCT had a low risk of bias for mortality and a high risk of bias for the remaining outcomes.,delete,[],1,0.125,1,16
CD005162,0,2,All included trials had a high risk of bias for non-mortality outcomes.,delete,[],1,0.1875,1,16
CD005162,0,3,"In total, 473 participants had type 1 hepatorenal syndrome.",rephrase,['Seven trials included only participants with type 1 hepatorenal syndrome.'],1,0.25,2,16
CD005162,0,4,Seven RCTs specifically evaluated terlipressin and albumin.,delete,[],2,0.3125,2,16
CD005162,0,5,"Terlipressin was associated with a beneficial effect on mortality when including all RCTs (RR 0.85, 95% CI 0.73 to 0.98; 534 participants; number needed to treat for an additional beneficial outcome (NNTB) 10.3 people; low-quality evidence).",merge,['Terlipressin was also associated with a beneficial effect on renal function.'],2,0.375,2,16
CD005162,0,6,Trial Sequential Analysis including all RCTs also found a beneficial effect of terlipressin.,none,[],2,0.4375,3,16
CD005162,0,7,"Additional analyses showed a beneficial effect of terlipressin and albumin on reversal of hepatorenal syndrome (RR 0.63, 95% CI 0.48 to 0.82; 510 participants; 8 RCTs; NNTB 4 people; low-quality evidence).",delete,[],3,0.5,3,16
CD005162,0,8,"Terlipressin increased the risk of serious cardiovascular adverse events (RR 7.26, 95% CI 1.70 to 31.05; 234 participants; 4 RCTs), but it had no effect on the risk of serious adverse events when analysed as a composite outcome (RR 0.91, 95% CI 0.68 to 1.21; 534 participants; 9 RCTs; number needed to treat for an additional harmful outcome 24.5 people; low-quality evidence).",rephrase,['Terlipressin increased the risk of serious circulation and heart problems (so-called cardiovascular events).'],3,0.5625,3,16
CD005162,0,9,"Non-serious adverse events were mainly gastrointestinal, including diarrhoea (RR 5.76, 95% CI 2.19 to 15.15; 240 participants; low-quality evidence) and abdominal pain (RR 1.54, 95% CI 0.97 to 2.43; 294 participants; low-quality evidence).",rephrase,['Other adverse events included diarrhoea and abdominal pain.'],4,0.625,4,16
CD005162,1,10,"We identified one ongoing trial on terlipressin versus placebo in participants with cirrhosis, ascites, and hepatorenal syndrome type 1.",delete,[],5,0.6875,4,16
CD005162,2,11,Three RCTs reported funding from a pharmaceutical company.,ignore,['Three RCTs reported funding from a pharmaceutical company.'],5,0.75,4,16
CD005162,2,12,The remaining trials did not report funding or did not receive funding from pharmaceutical companies.,ignore,['The remaining trials did not report funding or did not receive funding from pharmaceutical companies.'],6,0.8125,5,16
CD005162,3,13,"This review suggests that terlipressin may be associated with beneficial effects on mortality and renal function in people with cirrhosis and type 1 hepatorenal syndrome, but it is also associated with serious adverse effects.",rephrase,['No beneficial or harmful effects of terlipressin were found when analysing participants with type 2 hepatorenal syndrome (possibly due to the small number of participants).'],7,0.875,5,16
CD005162,3,14,"We downgraded the strength of the evidence due to methodological issues including bias control, clinical heterogeneity, and imprecision.",merge,['We considered the evidence to be of low quality.'],8,0.9375,5,16
CD005162,3,15,"Consequently, additional evidence is needed.",none,[],8,1.0,5,16
CD009946,0,0,"We included 10 trials involving 878 participants, among which 28 participants in two trials did not provide complete data due to loss to follow-up.",rephrase,['We identified 10 studies involving 878 participants.'],0,0.09090909090909091,1,11
CD009946,0,1,We judged all trials to be at high risk of bias.,delete,[],1,0.18181818181818182,1,11
CD009946,1,2,"Semi-recumbent position (30º to 60º) versus supine position (0° to 10°)
A semi-recumbent position (30º to 60º) significantly reduced the risk of clinically suspected VAP compared to a 0º to 10º supine position (eight trials, 759 participants, 14.3% versus 40.2%, RR 0.36; 95% CI 0.25 to 0.50; risk difference (RD) 25.7%; 95% CI 20.1% to 30.1%; GRADE: moderate quality evidence).",split,"['Moderate quality evidence from eight studies involving 759 participants demonstrated that a semi-recumbent (30º to 60º) position reduced clinically suspected VAP by 25.7% when compared to a 0° to 10° supine position.', 'Based on this result, we would expect that out of 1000 critically ill adult patients who are nursed in the semi-recumbent position (30º to 60º) for more than 48 hours, 145 patients would experience clinically suspected VAP compared to 402 patients nursed in the 0° to 10° supine position.']",1,0.2727272727272727,2,11
CD009946,2,3,"There was no significant difference between the two positions in the following outcomes: microbiologically confirmed VAP (three trials, 419 participants, 12.6% versus 31.6%, RR 0.44; 95% CI 0.11 to 1.77; GRADE: very low quality evidence), ICU mortality (two trials, 307 participants, 29.8% versus 34.3%, RR 0.87; 95% CI 0.59 to 1.27; GRADE: low quality evidence), hospital mortality (three trials, 346 participants, 23.8% versus 27.6%, RR 0.84; 95% CI 0.59 to 1.20; GRADE: low quality evidence), length of ICU stay (three trials, 346 participants, MD -1.64 days; 95% CI -4.41 to 1.14 days; GRADE moderate quality evidence), length of hospital stay (two trials, 260 participants, MD -9.47 days; 95% CI -34.21 to 15.27 days; GRADE: very low quality evidence), duration of ventilation (four trials, 458 participants, MD -3.35 days; 95% CI -7.80 to 1.09 days), antibiotic use (three trials, 284 participants, 84.8% versus 84.2%, RR 1.00; 95% CI 0.97 to 1.03) and pressure ulcers (one trial, 221 participants, 28% versus 30%, RR 0.91; 95% CI 0.60 to 1.38; GRADE: low quality evidence).",rephrase,"['There was no significant difference between the two positions in reducing microbiologically confirmed VAP (very low quality evidence), mortality (low quality evidence), length of ICU stay (moderate quality evidence), hospital stay (very low quality evidence), duration of ventilation or use of antibiotics.']",3,0.36363636363636365,2,11
CD009946,2,4,No other adverse events were reported.,delete,[],4,0.45454545454545453,3,11
CD009946,3,5,"Semi-recumbent position (45°) versus 25° to 30°
We found no statistically significant differences in the following prespecified outcomes: clinically suspected VAP (two trials, 91 participants, RR 0.74; 95% CI 0.35 to 1.56; GRADE: very low quality evidence), microbiologically confirmed VAP (one trial, 30 participants, RR 0.61; 95% CI 0.20 to 1.84: GRADE: very low quality evidence), ICU mortality (one trial, 30 participants, RR 0.57; 95% CI 0.15 to 2.13; GRADE: very low quality evidence), hospital mortality (two trials, 91 participants, RR 1.00; 95% CI 0.38 to 2.65; GRADE: very low quality evidence), length of ICU stay (one trial, 30 participants, MD 1.6 days; 95% CI -0.88 to 4.08 days; GRADE: very low quality evidence) and antibiotic use (two trials, 91 participants, RR 1.11; 95% CI 0.84 to 1.47).",split,"['Only two studies with 91 participants compared different degrees of bed head angle (45° versus 25° to 30° semi-recumbent position).', 'Very low quality evidence showed no statistically significant differences in the effects of VAP (clinically suspected and microbiologically confirmed), mortality (ICU and hospital), length of ICU stay or use of antibiotics.']",4,0.5454545454545454,3,11
CD009946,3,6,No adverse events were reported.,split,"['Only one study reported the adverse event of pressure ulcers and did not find a difference between the 45° semi-recumbent and 10° supine positions.', 'No other adverse events, such as thromboembolism, or side effects on heart rate or blood pressure were reported.']",6,0.6363636363636364,4,11
CD009946,4,7,A semi-recumbent position (≧ 30º) may reduce clinically suspected VAP compared to a 0° to 10° supine position.,delete,[],8,0.7272727272727273,4,11
CD009946,4,8,"However, the evidence is seriously limited with a high risk of bias.",delete,[],8,0.8181818181818182,5,11
CD009946,4,9,No adequate evidence is available to draw any definitive conclusion on other outcomes and the comparison of alternative semi-recumbent positions.,split,"['The balance of the benefit and harm of semi-recumbent positioning still remains uncertain due to the limited numbers of studies and the low quality of the existing evidence.', 'More high quality evidence is required on the effects of the semi-recumbent versus supine position and the optimal body positions.']",8,0.9090909090909091,5,11
CD009946,4,10,"Adverse events, particularly venous thromboembolism, were under-reported.",delete,[],10,1.0,5,11
CD002928,0,0,"Our update search identified 465 citations, which we assessed for eligibility.",delete,[],0,0.05555555555555555,1,18
CD002928,0,1,"Three new studies met the criteria for inclusion, giving a total of 14 included studies (n = 3370).",rephrase,"['We searched for studies published up to April 2018, and found three new studies that we could include, giving a total of 14 studies with 3370 participants.']",0,0.1111111111111111,1,18
CD002928,0,2,The definition of partner varied among the studies.,rephrase,"['The smoking status of partners providing support varied, but most were non-smokers.']",1,0.16666666666666666,1,18
CD002928,0,3,We compared partner support versus control interventions at six- to nine-month follow-up and at 12 or more months follow-up.,delete,[],2,0.2222222222222222,2,18
CD002928,0,4,"We also examined outcomes among three subgroups: interventions targeting relatives, friends or coworkers; interventions targeting spouses or cohabiting partners; and interventions targeting fellow cessation programme participants.",rephrase,['We also split the studies in each analysis based on the type of partner giving support (relatives/friends/co-workers versus spouses/cohabiting partners versus fellow cessation-programme participants).'],2,0.2777777777777778,2,18
CD002928,0,5,"All studies gave self-reported smoking cessation rates, with limited biochemical verification of abstinence.",delete,[],3,0.3333333333333333,2,18
CD002928,0,6,"The pooled risk ratio (RR) for abstinence was 0.97 (95% confidence interval (CI) 0.83 to 1.14; 12 studies; 2818 participants) at six to nine months, and 1.04 (95% CI 0.88 to 1.22; 7 studies; 2573 participants) at 12 months or more post-treatment.",rephrase,"['We combined 12 studies (2818 participants) to measure successful quitting at six to nine months follow-up, and seven studies (2573 participants) to measure quitting at 12-month follow-up.']",3,0.3888888888888889,2,18
CD002928,0,7,"Of the 11 studies that measured partner support at follow-up, only two reported a significant increase in partner support in the intervention groups.",rephrase,['Only one study reported that partner support improved more in the group given the partner-support intervention than in the group where no partner-support intervention was provided.'],4,0.4444444444444444,3,18
CD002928,0,8,"One of these studies reported a significant increase in partner support in the intervention group, but smokers' reports of partner support received did not differ significantly.",rephrase,['Another study reported that partner support improved more in a more intensive partner-support intervention than a less intensive partner-support intervention.'],5,0.5,3,18
CD002928,0,9,"We judged one of the included studies to be at high risk of selection bias, but a sensitivity analysis suggests that this did not have an impact on the results.",delete,[],6,0.5555555555555556,3,18
CD002928,0,10,"There were also potential issues with detection bias due to a lack of validation of abstinence in five of the 14 studies; however, this is not apparent in the statistically homogeneous results across studies.",delete,[],6,0.6111111111111112,4,18
CD002928,0,11,Using the GRADE system we rated the overall quality of the evidence for the two primary outcomes as low.,merge,['We rated the overall quality of the evidence as low.'],6,0.6666666666666666,4,18
CD002928,0,12,"We downgraded due to the risk of bias, as we judged studies with a high weighting in analyses to be at a high risk of detection bias.",none,[],6,0.7222222222222222,4,18
CD002928,0,13,"In addition, a study in both analyses was insufficiently randomised.",delete,[],7,0.7777777777777778,4,18
CD002928,0,14,"We also downgraded the quality of the evidence for indirectness, as very few studies provided any evidence that the interventions tested actually increased the amount of partner support received by participants in the relevant intervention group.",rephrase,"['Also, very few studies found that the intervention actually increased the level of partner support that participants received.']",7,0.8333333333333334,5,18
CD002928,1,15,Interventions that aim to enhance partner support appear to have no impact on increasing long-term abstinence from smoking.,rephrase,['This review therefore cannot tell us whether receiving more support from a partner can help a person to give up smoking.'],8,0.8888888888888888,5,18
CD002928,1,16,"However, most interventions that assessed partner support showed no evidence that the interventions actually achieved their aim and increased support from partners for smoking cessation.",delete,[],9,0.9444444444444444,5,18
CD002928,1,17,"Future research should therefore focus on developing behavioural interventions that actually increase partner support, and test this in small-scale studies, before large trials assessing the impact on smoking cessation can be justified.",delete,[],9,1.0,5,18
CD012893,0,0,Four studies involving 1485 participants with moderate to severe CD met the inclusion criteria and were used in the meta-analyses.,rephrase,['Four studies involving 1485 patients compared certolizumab pegol with placebo (a dummy drug).'],0,0.07692307692307693,1,13
CD012893,0,1,All studies included active CD patients with CDAI ranging from 220 to 450.,rephrase,['All studies included patients with active Crohn’s disease.'],1,0.15384615384615385,1,13
CD012893,0,2,Most patients were adults over 18 years of age.,rephrase,"['Most patients were adults over 18 years of age, except for six patients aged 16 or 17 years old.']",2,0.23076923076923078,2,13
CD012893,0,3,One study was identified as high risk of bias due to a non-identical placebo while the other studies were judged to be at low risk of bias.,delete,[],3,0.3076923076923077,2,13
CD012893,1,4,"CZP (100 mg to 400 mg every 2 to 4 weeks) was shown to be superior to placebo for achieving clinical remission at week 8 (RR 1.36, 95% CI 1.11 to 1.66; moderate certainty evidence).",rephrase,"['In a combined analysis of the four studies, patients with active Crohn’s disease who received certolizumab pegol at a dose ranging from 100 mg to 400 mg every 2 to 4 weeks, responded to the treatment and achieved remission at 8 weeks more often than patients taking placebo.']",3,0.38461538461538464,2,13
CD012893,1,5,"The raw numbers of participants achieving clinical remission at week 8 were 26.9% (225/835) and 19.8% (129/650) in the CZP and the placebo groups, respectively.",delete,[],4,0.46153846153846156,3,13
CD012893,2,6,"CZP was shown to be superior to placebo for achieving clinical response at week 8 (RR 1.29, 95% CI 1.09 to 1.53; moderate certainty evidence).",delete,[],4,0.5384615384615384,3,13
CD012893,2,7,"In raw numbers, clinical response at week 8 was achieved in 40.2% (336/835) and 30.9% (201/650) of participants in the CZP and the placebo groups, respectively.",delete,[],4,0.6153846153846154,4,13
CD012893,3,8,"In raw numbers, serious adverse events were observed in 8.7% (73/835) and 6.2% (40/650) of participants in the CZP and the placebo groups, respectively (RR 1.35, 95% CI 0.93 to 1.97; moderate certainty evidence).",delete,[],4,0.6923076923076923,4,13
CD012893,3,9,"Serious adverse events included worsening Crohn's disease, infections, and malignancy.",rephrase,"[""Serious side effects included worsening Crohn's disease, infections, and malignancy (i.e. cancer).""]",4,0.7692307692307693,4,13
CD012893,4,10,Moderate certainty evidence suggests that CZP is effective for induction of clinical remission and clinical response in participants with active CD patients.,rephrase,"[""Moderate certainty evidence suggests that certolizumab pegol is effective for induction of clinical remission and clinical response in people with active Crohn's disease.""]",5,0.8461538461538461,5,13
CD012893,4,11,It is uncertain whether the risk of serious adverse events differs between CZP and placebo as the 95% CI includes the possibility of a small decrease or doubling of events.,rephrase,['It is uncertain whether the risk of serious side effects differs between certolizumab pegol and placebo.'],6,0.9230769230769231,5,13
CD012893,4,12,Future studies are needed to evaluate the long-term efficacy and safety of CZP in CD patients.,rephrase,"[""Future studies are needed to evaluate the long-term benefits and harms of certolizumab pegol in people with Crohn's disease.""]",7,1.0,5,13
CD001920,0,0,"We included a total of 96 studies (10,401 participants) in this review.",split,"['We identified 96 studies, up to December 2012, for inclusion in the review.', 'These studies, involving 10,401 stroke survivors, investigated physical rehabilitation approaches aimed at promoting recovery of function or mobility in adult participants with a clinical diagnosis of stroke compared with no treatment, usual care or attention control or in comparisons of different physical rehabilitation approaches.']",0,0.0625,1,16
CD001920,0,1,More than half of the studies (50/96) were carried out in China.,ignore,['More than half of the studies (50/96) were carried out in China.'],2,0.125,1,16
CD001920,0,2,"Generally the studies were heterogeneous, and many were poorly reported.",delete,[],3,0.1875,1,16
CD001920,1,3,"Physical rehabilitation was found to have a beneficial effect, as compared with no treatment, on functional recovery after stroke (27 studies, 3423 participants; standardised mean difference (SMD) 0.78, 95% confidence interval (CI) 0.58 to 0.97, for Independence in ADL scales), and this effect was noted to persist beyond the length of the intervention period (nine studies, 540 participants; SMD 0.58, 95% CI 0.11 to 1.04).",rephrase,['We were able to combine the results from 27 studies (3243 stroke survivors) that compared physical rehabilitation versus no treatment.'],3,0.25,2,16
CD001920,1,4,"Subgroup analysis revealed a significant difference based on dose of intervention (P value < 0.0001, for independence in ADL), indicating that a dose of 30 to 60 minutes per day delivered five to seven days per week is effective.",delete,[],4,0.3125,2,16
CD001920,1,5,This evidence principally arises from studies carried out in China.,rephrase,['Twenty-five of these 27 studies were carried out in China.'],4,0.375,2,16
CD001920,1,6,"Subgroup analyses also suggest significant benefit associated with a shorter time since stroke (P value 0.003, for independence in ADL).",delete,[],5,0.4375,3,16
CD001920,2,7,"We found physical rehabilitation to be more effective than usual care or attention control in improving motor function (12 studies, 887 participants; SMD 0.37, 95% CI 0.20 to 0.55), balance (five studies, 246 participants; SMD 0.31, 95% CI 0.05 to 0.56) and gait velocity (14 studies, 1126 participants; SMD 0.46, 95% CI 0.32 to 0.60).",rephrase,"['When we looked at studies that compared additional physical rehabilitation versus usual care or a control intervention, we found evidence to show that the additional physical treatment improved motor function (12 studies, 887 stroke survivors), standing balance (five studies, 246 stroke survivors) and walking speed (14 studies, 1126 stroke survivors).']",5,0.5,3,16
CD001920,2,8,"Subgroup analysis demonstrated a significant difference based on dose of intervention (P value 0.02 for motor function), indicating that a dose of 30 to 60 minutes delivered five to seven days a week provides significant benefit.",rephrase,"['Very limited evidence suggests that, for comparisons of physical rehabilitation versus no treatment and versus usual care, treatment that appeared to be effective was given between 30 and 60 minutes per day, five to seven days per week, but further research is needed to confirm this.']",6,0.5625,3,16
CD001920,2,9,"Subgroup analyses also suggest significant benefit associated with a shorter time since stroke (P value 0.05, for independence in ADL).",rephrase,"['We also found evidence of greater benefit associated with a shorter time since stroke, but again further research is needed to confirm this.']",7,0.625,4,16
CD001920,3,10,"No one physical rehabilitation approach was more (or less) effective than any other approach in improving independence in ADL (eight studies, 491 participants; test for subgroup differences: P value 0.71) or motor function (nine studies, 546 participants; test for subgroup differences: P value 0.41).",rephrase,['We found evidence showing that no one physical rehabilitation approach was more effective than any other approach.'],8,0.6875,4,16
CD001920,3,11,"These findings are supported by subgroup analyses carried out for comparisons of intervention versus no treatment or usual care, which identified no significant effects of different treatment components or categories of interventions.",delete,[],9,0.75,4,16
CD001920,4,12,"Physical rehabilitation, comprising a selection of components from different approaches, is effective for recovery of function and mobility after stroke.",delete,[],9,0.8125,5,16
CD001920,4,13,Evidence related to dose of physical therapy is limited by substantial heterogeneity and does not support robust conclusions.,delete,[],9,0.875,5,16
CD001920,4,14,No one approach to physical rehabilitation is any more (or less) effective in promoting recovery of function and mobility after stroke.,rephrase,"['This review brings together evidence confirming that physical rehabilitation (often delivered by a physiotherapist, physical therapist or rehabilitation therapist) can improve function, balance and walking after stroke.']",9,0.9375,5,16
CD001920,4,15,"Therefore, evidence indicates that physical rehabilitation should not be limited to compartmentalised, named approaches, but rather should comprise clearly defined, well-described, evidenced-based physical treatments, regardless of historical or philosophical origin.",delete,[],10,1.0,5,16
CD007818,0,0,"We included 10 pharmacological (modafinil, intravenous immunoglobulin (IVIg), pyridostigmine, lamotrigine, amantadine, prednisone) and three non-pharmacological (muscle strengthening, rehabilitation in a warm climate (that is temperature ± 25°C, dry and sunny) and a cold climate (that is temperature ± 0°C, rainy or snowy), static magnetic fields) studies with a total of 675 participants with PPS in this review.",rephrase,"['Ten studies evaluated the effects of drugs (modafinil, intravenous immunoglobulin (IVIg), pyridostigmine, lamotrigine, amantadine, prednisone), and three studies evaluated other treatments (muscle strengthening, rehabilitation in a warm climate (that is temperature ± 25°C, dry and sunny) and a cold climate (that is temperature ± 0°C, rainy or snowy), static magnetic fields).']",0,0.1111111111111111,1,9
CD007818,0,1,"None of the included studies were completely free from any risk of bias, the most prevalent risk of bias being lack of blinding.",delete,[],1,0.2222222222222222,2,9
CD007818,1,2,"There was moderate- and low-quality evidence that IVIg has no beneficial effect on activity limitations in the short term and long term, respectively, and inconsistency in the evidence for effectiveness on muscle strength.",split,"['There was moderate- and low-quality evidence that IVIg has no beneficial effect on activity limitations in the short term and long term, respectively.', 'Evidence for effectiveness on muscle strength was inconsistent, as results differed across studies.']",1,0.3333333333333333,2,9
CD007818,1,3,IVIg caused minor adverse events in a substantial proportion of the participants.,ignore,['IVIg caused minor side effects in a substantial proportion of the participants.'],3,0.4444444444444444,3,9
CD007818,1,4,"Results of one trial provided very low-quality evidence that lamotrigine might be effective in reducing pain and fatigue, resulting in fewer activity limitations without generating adverse events.",split,"['Results of one trial provided very low-quality evidence that lamotrigine might be effective in reducing pain and fatigue, resulting in fewer activity limitations, and in this study it was well-tolerated.', 'We based these conclusions on results of only one small trial with important limitations in study design.']",4,0.5555555555555556,3,9
CD007818,1,5,"Data from two single trials suggested that muscle strengthening of thumb muscles (very low-quality evidence) and static magnetic fields (moderate-quality evidence) are safe and beneficial for improving muscle strength and pain, respectively, with unknown effects on activity limitations.",rephrase,['There was very low-quality evidence that muscle strengthening of thumb muscles is safe and beneficial for improving muscle strength.'],6,0.6666666666666666,4,9
CD007818,1,6,"Finally, there was evidence varying from very low quality to high quality that modafinil, pyridostigmine, amantadine, prednisone and rehabilitation in a warm or cold climate are not beneficial in PPS.",ignore,"['Finally, there was evidence varying from very low quality to high quality that modafinil, pyridostigmine, amantadine, prednisone and rehabilitation in a warm or cold climate are not beneficial in PPS.']",7,0.7777777777777778,4,9
CD007818,2,7,"Due to insufficient good-quality data and lack of randomised studies, it was impossible to draw definite conclusions about the effectiveness of interventions for PPS.",delete,[],8,0.8888888888888888,5,9
CD007818,2,8,"Results indicated that IVIg, lamotrigine, muscle strengthening exercises and static magnetic fields may be beneficial but need further investigation to clarify whether any real and meaningful effect exists.",delete,[],8,1.0,5,9
CD002891,0,0,"Combined data from two eating disorder prevention programs based on a media literacy and advocacy approach indicate a reduction in the internalisation or acceptance of societal ideals relating to appearance at a 3- to 6-month follow-up (Kusel 1999; Neumark* 2000) [SMD -0.28, -0.51 to -0.05, 95% CI].",delete,[],0,0.16666666666666666,1,6
CD002891,0,1,There is insufficient evidence to support the effect of five programs designed to address eating attitudes and behaviours and other adolescent issues in the general community or those classified as being at high risk for eating disorder (Buddeberg* 1998; Dalle Grave 2001; Killen 1993; Santonastaso 1999; Zanetti 1999) and insufficient evidence to support the effect of two programs designed to improve self-esteem (O'Dea 2000; Wade 2003).,delete,[],0,0.3333333333333333,2,6
CD002891,0,2,Data from two didactic eating disorder awareness programs could not be pooled for analysis.,delete,[],0,0.5,3,6
CD002891,0,3,There is not sufficient evidence to suggest that harm resulted from any of the prevention programs included in the review.,split,"['There is currently limited evidence in the published literature to suggest that any particular type of program is effective in preventing eating disorders and there has been concern that some interventions have the potential to cause harm.', 'There is not sufficient evidence to suggest that harm was caused by any of the 12 randomised controlled trials included in the review at short-term follow-up.']",0,0.6666666666666666,4,6
CD002891,1,4,"The one significant pooled effect in the current review does not allow for any firm conclusions to be made about the impact of prevention programs for eating disorders in children and adolescents, although none of the pooled comparisons indicated evidence of harm.",split,"['Several eating disorder prevention programs have been developed and trialled with children and adolescents.', 'The aim of this systematic review is to determine whether these interventions are effective in the prevention of eating disorders in children and adolescents.']",2,0.8333333333333334,5,6
CD002891,1,5,The meta-analysis is in the process of being revised to account for the impact of cluster randomised trials.,ignore,['The meta-analysis is in the process of being revised to account for the impact of cluster randomised trials.'],4,1.0,5,6
CD007208,0,0,We included four studies (365 women).,rephrase,['We included four studies involving 365 women.'],0,0.14285714285714285,1,7
CD007208,0,1,"Three RCTs (346 participants) reported the effect of high versus low feedback during ultrasound on state anxiety scores (mean difference (MD) 0.92, 95% confidence interval (CI) -0.58 to 2.43; participants = 346; three studies, low quality evidence).",rephrase,"[""High or low feedback of prenatal ultrasound to reduce women's state of anxiety is not supported by evidence from the three randomised controlled trials, involving 346 pregnant women, that looked at this outcome (low-quality evidence).""]",1,0.2857142857142857,2,7
CD007208,0,2,Two trials (148 participants) reported women's views of the level of feedback.,rephrase,"[""Two trials with a total of 148 women reported on the women's views on the level of feedback.""]",2,0.42857142857142855,3,7
CD007208,0,3,They do not show that women in the high feedback groups are more likely to choose very positive adjectives to describe their feelings after the scan (risk ratio (RR) 3.30; 95% CI 0.73 to 14.85).,rephrase,['The women in the high feedback groups were not clearly more likely to choose very positive adjectives to describe their feelings after the scan.'],3,0.5714285714285714,3,7
CD007208,0,4,"Women who had a high feedback during ultrasound were more likely to stop smoking during pregnancy (RR 2.93, 95% CI 1.25 to 6.86; participants = 129; one study; low quality evidence) and to avoid alcohol during pregnancy (RR 2.96, 95% CI 1.15 to 7.60; participants = 129; one study; low quality evidence).",rephrase,['One trial with 129 participants reported that women who had high feedback during ultrasound were more likely to stop smoking and avoid alcohol during pregnancy.'],4,0.7142857142857143,4,7
CD007208,0,5,"Downgrading of evidence was based on the unclear risk of bias of included studies, wide CI crossing the line of no effect or presence of heterogeneity.",delete,[],5,0.8571428571428571,5,7
CD007208,1,6,There is insufficient evidence to support either high or low feedback during a prenatal ultrasound to reduce maternal anxiety and promote health behaviour.,delete,[],5,1.0,5,7
CD004112,0,0,Two randomized controlled trials evaluated the no-scalpel technique and differed in their findings.,delete,[],0,0.125,1,8
CD004112,0,1,"The larger trial demonstrated less perioperative bleeding (OR 0.49; 95% CI 0.27 to 0.89) and pain during surgery (OR 0.75; 95% CI 0.61 to 0.93), scrotal pain (OR 0.63; 95% 0.50 to 0.80), and incisional infection (OR 0.21; 95% CI 0.06 to 0.78) during follow up than the standard incisional group.",merge,"['The larger trial showed the no-scalpel method led to less bleeding, infection, and pain during and after the procedure.']",0,0.25,2,8
CD004112,0,2,Both studies found less hematoma with the no-scalpel technique (OR 0.23; 95% CI 0.15 to 0.36).,none,[],0,0.375,2,8
CD004112,0,3,Operations using the no-scalpel approach were faster and had a quicker resumption of sexual activity.,rephrase,['The no-scalpel approach required less time for the operation and had a faster return to sexual activity.'],1,0.5,3,8
CD004112,0,4,"The smaller study did not find these differences; however, the study could have failed to detect differences due to a small sample size as well as a high loss to follow up.",rephrase,['The smaller study did not show these differences.'],2,0.625,4,8
CD004112,0,5,Neither trial found differences in vasectomy effectiveness between the two approaches to the vas.,rephrase,['We found two trials that looked at the no-scalpel approach to the vas.'],3,0.75,4,8
CD004112,1,6,"The no-scalpel approach to the vas resulted in less bleeding, hematoma, infection, and pain as well as a shorter operation time than the traditional incision technique.",delete,[],4,0.875,5,8
CD004112,1,7,No difference in effectiveness was found between the two approaches.,delete,[],4,1.0,5,8
CD010807,0,0,"We included 70 studies in the review; 66 studies with 17,067 participants were included in the quantitative analysis.",rephrase,"['We included 70 studies and were able to include information from 66 of those studies (17,067 participants) in the numerical analysis.']",0,0.06666666666666667,1,15
CD010807,0,1,An additional 18 studies are awaiting classification and 12 are ongoing.,ignore,['An additional 18 studies are awaiting classification and 12 are ongoing.'],1,0.13333333333333333,1,15
CD010807,0,2,"Fifteen of the 18 studies awaiting classification mainly correspond to congress summaries published before 2010, in which the available information does not allow the complete evaluation of all their risks of bias and characteristics.",delete,[],2,0.2,1,15
CD010807,0,3,"Our main outcome was prevention of PDPH, but we also assessed the onset of severe PDPH, headache in general and adverse events.",rephrase,['We searched the medical literature for studies carried out in any setting comparing needles of different characteristics (i.e. different tip designs and sizes) for the prevention of PDPH.'],2,0.26666666666666666,2,15
CD010807,0,4,The quality of evidence was moderate for most of the outcomes mainly due to risk of bias issues.,delete,[],3,0.3333333333333333,2,15
CD010807,0,5,"For the analysis, we undertook three main comparisons: 1) traumatic needles versus atraumatic needles; 2) larger gauge traumatic needles versus smaller gauge traumatic needles; and 3) larger gauge atraumatic needles versus smaller gauge atraumatic needles.",delete,[],3,0.4,2,15
CD010807,0,6,"For each main comparison, if data were available, we performed a subgroup analysis evaluating lumbar puncture indication, age and posture.",delete,[],3,0.4666666666666667,3,15
CD010807,1,7,"For the first comparison, the use of traumatic needles showed a higher risk of onset of PDPH compared to atraumatic needles (36 studies, 9378 participants, risk ratio (RR) 2.14, 95% confidence interval (CI) 1.72 to 2.67, I2 = 9%).",rephrase,['We found that the use of needles with a traumatic tip resulted in a higher risk of PDPH when compared to needles with atraumatic tips.'],3,0.5333333333333333,3,15
CD010807,2,8,"In the second comparison of traumatic needles, studies comparing various sizes of large and small gauges showed no significant difference in effects in terms of risk of PDPH, with the exception of one study comparing 26 and 27 gauge needles (one study, 658 participants, RR 6.47, 95% CI 2.55 to 16.43).",delete,[],4,0.6,3,15
CD010807,3,9,"In the third comparison of atraumatic needles, studies comparing various sizes of large and small gauges showed no significant difference in effects in terms of risk of PDPH.",rephrase,"['When we compared the different studies comparing various sizes of large and small traumatic gauges, we did not find any difference in effects in terms of the risk of PDPH.']",4,0.6666666666666666,4,15
CD010807,4,10,"We observed no significant difference in the risk of paraesthesia, backache, severe PDPH and any headache between traumatic and atraumatic needles.",split,"['Finally, when we compared atraumatic needles with a higher gauge to those with a smaller gauge, we observed no significant differences in terms of the development of PDPH in any of the scenarios analysed.', 'We also found no significant differences in the use of traumatic versus atraumatic needles in the development of adverse effects such as paraesthesia, backache and severe PDPH.']",5,0.7333333333333333,4,15
CD010807,4,11,"Sensitivity analyses of PDPH results between traumatic and atraumatic needles omitting high risk of bias studies showed similar results regarding the benefit of atraumatic needles in the prevention of PDPH (three studies, RR 2.78, 95% CI 1.26 to 6.15; I2 = 51%).",delete,[],7,0.8,4,15
CD010807,5,12,There is moderate-quality evidence that atraumatic needles reduce the risk of post-dural puncture headache (PDPH) without increasing adverse events such as paraesthesia or backache.,delete,[],7,0.8666666666666667,5,15
CD010807,5,13,"The studies did not report very clearly on aspects related to randomization, such as random sequence generation and allocation concealment, making it difficult to interpret the risk of bias in the included studies.",split,"['The studies did not report clearly on aspects of their design related to randomization.', 'This made it difficult for us to interpret the risk of bias in the included studies.']",7,0.9333333333333333,5,15
CD010807,5,14,The moderate quality of the evidence for traumatic versus atraumatic needles suggests that further research is likely to have an important impact on our confidence in the estimate of effect.,rephrase,['We therefore considered the quality of the evidence for most of the outcomes assessed in this review to be moderate.'],9,1.0,5,15
CD011787,0,0,"We included 38 studies, mostly from high-income countries, many of which explored mothers' perceptions of vaccine communication.",split,"['We included 38 studies in our review.', ""Most of the studies were from high-income countries and explored mothers' perceptions of vaccine communication.""]",0,0.06666666666666667,1,15
CD011787,0,1,"Some focused on the MMR (measles, mumps, rubella) vaccine.",delete,[],2,0.13333333333333333,1,15
CD011787,1,2,"In general, parents wanted more information than they were getting (high confidence in the evidence).",rephrase,"['In general, parents wanted more information than they were getting (high confidence).']",2,0.2,1,15
CD011787,1,3,Lack of information led to worry and regret about vaccination decisions among some parents (moderate confidence).,rephrase,"['For some parents, a lack of information led to worry and regret about their vaccination decision (moderate confidence).']",3,0.26666666666666666,2,15
CD011787,2,4,"Parents wanted balanced information about vaccination benefits and harms (high confidence), presented clearly and simply (moderate confidence) and tailored to their situation (low confidence in the evidence).",rephrase,"['Parents wanted balanced information about both the benefits and risks of vaccination (high confidence), presented in a clear and simple manner (moderate confidence) and tailored to their situation (low confidence).']",4,0.3333333333333333,2,15
CD011787,2,5,"Parents wanted vaccination information to be available at a wider variety of locations, including outside health services (low confidence) and in good time before each vaccination appointment (moderate confidence).",split,"['Parents wanted vaccination information to be available outside of the health services (low confidence).', 'They wanted this information in good time before each vaccination appointment and not while their child was being vaccinated (moderate confidence).']",5,0.4,2,15
CD011787,3,6,Parents viewed health workers as an important source of information and had specific expectations of their interactions with them (high confidence).,ignore,['Parents viewed health workers as an important source of information and had specific expectations of their interactions with them (high confidence).'],7,0.4666666666666667,3,15
CD011787,3,7,Poor communication and negative relationships with health workers sometimes impacted on vaccination decisions (moderate confidence).,ignore,['Poor communication and negative relationships with health workers sometimes impacted on vaccination decisions (moderate confidence).'],8,0.5333333333333333,3,15
CD011787,4,8,Parents generally found it difficult to know which vaccination information source to trust and challenging to find information they felt was unbiased and balanced (high confidence).,rephrase,['Parents generally found it difficult to know which vaccination information source to trust and found it difficult to find information that they felt was unbiased and balanced (high confidence).'],9,0.6,3,15
CD011787,5,9,"The amount of information parents wanted and the sources they felt could be trusted appeared to be linked to acceptance of vaccination, with parents who were more hesitant wanting more information (low to moderate confidence).",ignore,"['The amount of information parents wanted and the sources they felt they could trust seem to be linked to their acceptance of vaccination, with parents who were more hesitant wanting more information (low to moderate confidence).']",10,0.6666666666666666,4,15
CD011787,6,10,"Our synthesis and comparison of the qualitative evidence shows that most of the trial interventions addressed at least one or two key aspects of communication, including the provision of information prior to the vaccination appointment and tailoring information to parents' needs.",delete,[],11,0.7333333333333333,4,15
CD011787,6,11,None of the interventions appeared to respond to negative media stories or address parental perceptions of health worker motives.,delete,[],11,0.8,4,15
CD011787,7,12,We have high or moderate confidence in the evidence contributing to several review findings.,delete,[],11,0.8666666666666667,5,15
CD011787,7,13,"Further research, especially in rural and low- to middle-income country settings, could strengthen evidence for the findings where we had low or very low confidence.",delete,[],11,0.9333333333333333,5,15
CD011787,7,14,"Planners should consider the timing for making vaccination information available to parents, the settings where information is available, the provision of impartial and clear information tailored to parental needs, and parents' perceptions of health workers and the information provided.",delete,[],11,1.0,5,15
CD010339,0,0,We identified five studies including 318 participants (180 participants with and 138 participants without common bile duct stones) that reported the diagnostic accuracy of ERCP and five studies including 654 participants (125 participants with and 529 participants without common bile duct stones) that reported the diagnostic accuracy of IOC.,rephrase,['We identified five studies including 318 participants that reported the diagnostic test accuracy of ERCP and five studies including 654 participants that reported the diagnostic test accuracy of IOC.'],0,0.058823529411764705,1,17
CD010339,0,1,"Most studies included people with symptoms (participants with jaundice or pancreatitis) suspected of having common bile duct stones based on blood tests, ultrasound, or both, prior to the performance of ERCP or IOC.",rephrase,"['Most studies included people with symptoms (participants with jaundice or pancreatitis) who were suspected of having CBD stones based on blood tests, ultrasound (use of sound waves higher than audible range to differentiate tissues based on how they reflect the sound waves), or both, prior to the having ERCP or IOC.']",1,0.11764705882352941,1,17
CD010339,0,2,Most studies included participants who had not previously undergone removal of the gallbladder (cholecystectomy).,rephrase,['Most studies included participants who had not previously undergone cholecystectomy.'],2,0.17647058823529413,1,17
CD010339,0,3,None of the included studies was of high methodological quality as evaluated by the QUADAS-2 tool (quality assessment tool for diagnostic accuracy studies).,rephrase,['Further studies of high methodological quality are necessary.'],3,0.23529411764705882,2,17
CD010339,0,4,The sensitivities of ERCP ranged between 0.67 and 0.94 and the specificities ranged between 0.92 and 1.00.,delete,[],4,0.29411764705882354,2,17
CD010339,0,5,"For ERCP, the summary sensitivity was 0.83 (95% confidence interval (CI) 0.72 to 0.90) and specificity was 0.99 (95% CI 0.94 to 1.00).",rephrase,"['Given an average sensitivity of 83% for ERCP, we would expect that on average 83 out of 100 people (this may vary between 72 and 90 out of 100 people) with CBD stones would be detected while the remaining 17 people would be missed and would not receive appropriate treatment.']",4,0.35294117647058826,2,17
CD010339,0,6,The sensitivities of IOC ranged between 0.75 and 1.00 and the specificities ranged between 0.96 and 1.00.,delete,[],5,0.4117647058823529,3,17
CD010339,0,7,"For IOC, the summary sensitivity was 0.99 (95% CI 0.83 to 1.00) and specificity was 0.99 (95% CI 0.95 to 1.00).",rephrase,"['For IOC, an average sensitivity of 99% means that on average 99 out of 100 people (this may vary between 83 and 100 out of 100 people) with CBD stones would be detected while only one person would be missed and would not receive appropriate treatment.']",5,0.47058823529411764,3,17
CD010339,0,8,"For ERCP, at the median pre-test probability of common bile duct stones of 0.35 estimated from the included studies (i.e., 35% of people suspected of having common bile duct stones were confirmed to have gallstones by the reference standard), the post-test probabilities associated with positive test results was 0.97 (95% CI 0.88 to 0.99) and negative test results was 0.09 (95% CI 0.05 to 0.14).",delete,[],6,0.5294117647058824,3,17
CD010339,0,9,"For IOC, at the median pre-test probability of common bile duct stones of 0.35, the post-test probabilities associated with positive test results was 0.98 (95% CI 0.85 to 1.00) and negative test results was 0.01 (95% CI 0.00 to 0.10).",delete,[],6,0.5882352941176471,3,17
CD010339,0,10,There was weak evidence of a difference in sensitivity (P value = 0.05) with IOC showing higher sensitivity than ERCP.,delete,[],6,0.6470588235294118,4,17
CD010339,0,11,There was no evidence of a difference in specificity (P value = 0.7) with both tests having similar specificity.,delete,[],6,0.7058823529411765,4,17
CD010339,1,12,"Although the sensitivity of IOC appeared to be better than that of ERCP, this finding may be unreliable because none of the studies compared both tests in the same study populations and most of the studies were methodologically flawed.",delete,[],6,0.7647058823529411,4,17
CD010339,1,13,It appears that both tests were fairly accurate in guiding further invasive treatment as most people diagnosed with common bile duct stones by these tests had common bile duct stones.,rephrase,['It appears that both tests are fairly accurate in guiding further invasive treatment as most people diagnosed with CBD stones by these tests have CBD stones.'],6,0.8235294117647058,5,17
CD010339,1,14,Some people may have common bile duct stones in spite of having a negative ERCP or IOC result.,rephrase,"['However, some people may have CBD stones in spite of having a negative ERCP or IOC test result.']",7,0.8823529411764706,5,17
CD010339,1,15,Such people may have to be re-tested if the clinical suspicion of common bile duct stones is very high because of their symptoms or persistently abnormal liver function tests.,rephrase,['Such people may have to be re-tested if the clinical suspicion of CBD stones is very high because of their symptoms.'],8,0.9411764705882353,5,17
CD010339,1,16,"However, the results should be interpreted with caution given the limited quantity and quality of the evidence.",delete,[],9,1.0,5,17
CD012003,0,0,We found 10 trials (23 reports) of education and support for breastfeeding that included women with twins or higher order multiples.,rephrase,['We searched for randomised controlled trials on 30 June 2016 and 1 July 2016 and found 10 studies (23 reports) to include in our review.'],0,0.06666666666666667,1,15
CD012003,0,1,"The quality of evidence was mixed, and the risk of bias was mostly high or unclear.",delete,[],1,0.13333333333333333,1,15
CD012003,0,2,"It is difficult to blind women or staff to group allocation for this intervention, so in all studies there was high risk of performance and high or unclear risk of detection bias.",delete,[],1,0.2,1,15
CD012003,0,3,"Trials recruited 5787 women (this included 512 women interviewed as part of a cluster randomised trial); of these, data were available from two studies for 42 women with twins or higher order multiples.",rephrase,['Trials recruited 5787 women (this included 512 women interviewed as part of a cluster randomised trial).'],1,0.26666666666666666,2,15
CD012003,0,4,"None of the interventions were specifically designed for women with more than one infant, and the outcomes for multiples were not reported separately for each infant.",delete,[],2,0.3333333333333333,2,15
CD012003,0,5,"Due to the scarcity of evidence and the format in which data were reported, a narrative description of the data is presented, no analyses are presented in this review, and we were unable to GRADE the evidence.",delete,[],2,0.4,2,15
CD012003,1,6,"The two trials with data for women with multiple births compared home nurse visits versus usual care (15 women), and telephone peer counselling versus usual care (27 women).",split,"['The authors of two of the studies sent us their findings for women with multiple births (42 women in total).', 'The trials compared home nurse visits versus usual care (15 women), and telephone peer counselling versus usual care (27 women).']",2,0.4666666666666667,3,15
CD012003,1,7,"The number of women who initiated breastfeeding was reported (all 15 women in one study, 25 out of 27 women in one study).",rephrase,['All 15 women in one study and 25 out of 27 women in the other had started breastfeeding.'],4,0.5333333333333333,3,15
CD012003,1,8,"Stopping any breastfeeding before four to six weeks postpartum, stopping exclusive breastfeeding before four to six weeks postpartum, stopping any breastfeeding before six months postpartum andstopping exclusive breastfeeding before six months postpartum were not explicitly reported, and there were insufficient data to draw any meaningful conclusions from survival data.",delete,[],5,0.6,3,15
CD012003,2,9,"Stopping breast milk expression before four to six weeks postpartum, andstopping breast milk expression before six months postpartum were not reported.",rephrase,['There was no information on breast milk expression.'],5,0.6666666666666666,4,15
CD012003,2,10,"Measures ofmaternal satisfaction were reported in one study of 15 women, but there were insufficient data to draw any conclusions; no other secondary outcomes were reported for women with multiple births in either study.",rephrase,"['Other outcome measures were reported, including a measure of maternal satisfaction in one study of 15 women, but there were not sufficient numbers to allow us to draw any conclusions.']",6,0.7333333333333333,4,15
CD012003,2,11,No adverse events were reported.,ignore,['No adverse events were reported.'],7,0.8,4,15
CD012003,3,12,"We found no evidence from randomised controlled trials about the effectiveness of breastfeeding education and support for women with twins or higher order multiples, or the most effective way to provide education and support .",rephrase,['We could not draw conclusions from the evidence available from randomised controlled trials about whether education and support helps mothers of multiples to breastfeed.'],8,0.8666666666666667,5,15
CD012003,3,13,"There was no evidence about the best way to deliver the intervention, the timing of care, or the best person to deliver the care.",delete,[],9,0.9333333333333333,5,15
CD012003,3,14,"There is a need for well-designed, adequately powered studies of interventions designed for women with twins or higher order multiples to find out what types of education and support are effective in helping these mothers to breastfeed their babies.",rephrase,['More research is needed to find out what types of education and support could help mothers of multiples to breastfeed their babies.'],9,1.0,5,15
CD006176,0,0,We included nine studies involving 1118 women.,delete,[],0,0.125,1,8
CD006176,1,1,We identified four comparisons.,delete,[],0,0.25,2,8
CD006176,1,2,"One comparison included six studies (which randomised 394 women) comparing umbilical vein injection of normal saline plus oxytocin versus that of normal saline, as well as three other comparisons, each of which includes one study.",rephrase,['This review included nine randomised controlled trials involving 1118 women and assessed six of these studies (involving 394 women) comparing umbilical vein injection of normal saline with or without oxytocin.'],0,0.375,2,8
CD006176,1,3,"Comparing intraumbilical injection of normal saline plus oxytocin with intraumbilical injection of saline only, there was no evidence of difference in any of the relevant outcomes reported namely the number of women who required blood transfusion, the incidence of manual removal of placenta, blood loss, and length of the third stage of labour.",delete,[],1,0.5,3,8
CD006176,1,4,Subgroup analyses by both total amount of solution administered and dose of oxytocin showed no evidence of difference.,delete,[],1,0.625,4,8
CD006176,1,5,"Other comparisons included only one study for each, and there was no relevant information available.",rephrase,['Other comparisons did not provide the required information.'],1,0.75,4,8
CD006176,2,6,Routine use of oxytocin or any other uterotonics with normal saline via umbilical vein injection is not recommended until new evidence is available.,rephrase,"['With umbilical vein injection of saline solution plus oxytocin versus umbilical vein injection of saline solution there was no evidence of a difference in the amount of blood lost, duration of the third stage of labour or need for manual removal of a retained placenta.']",2,0.875,5,8
CD006176,2,7,Further research should be conducted to show effectiveness of oxytocin with normal saline via umbilical vein injection.,rephrase,"['routine use of umbilical injection after childbirth to deliver any infusion, though the combined results of the small number of relevant studies showed no evidence of effect and further research is needed to make a conclusion.']",3,1.0,5,8
CD010647,0,0,We found no studies that compared multiple-micronutrient supplementation (with three or more micronutrients) versus supplementation with two or fewer micronutrients.,rephrase,['This review looked at the use of multiple-micronutrient supplements for breastfeeding women for improving outcomes for the mother and her baby.'],0,0.05,1,20
CD010647,1,1,Two small studies (involving a total of 52 women) were included.,rephrase,['We searched for studies on 30 September 2015 and identified two small studies (involving 52 women) for inclusion in this review.'],1,0.1,1,20
CD010647,1,2,One study compared multiple micronutrients with placebo and the other study compared multiple micronutrients with a group who received no supplementation.,rephrase,['Previous studies have assessed supplementation of individual micronutrients.'],2,0.15,1,20
CD010647,1,3,The studies were carried out in Brazil (36 adolescent mothers) and the USA (16 women) and included women with a low socioeconomic status.,rephrase,['The studies were carried out in Brazil and the USA and included women who had a low socioeconomic status.'],3,0.2,1,20
CD010647,1,4,A lack of information in the study reports meant that risk of bias could not be adequately assessed (unclear risk of bias for many domains).,rephrase,['The studies were poorly reported and this lack of information made it difficult to determine whether the studies were at risk of bias.'],4,0.25,2,20
CD010647,1,5,There were no quantitative data for any of this review's outcomes so meta-analysis was not possible.,rephrase,"['Similarly, there were no data for any of the other outcomes that we were interested in.']",5,0.3,2,20
CD010647,2,6,"Neither of the studies reported on the primary outcomes of interest in this review: maternal morbidity (febrile illness, respiratory tract infection, diarrhoea), adverse effects of micronutrients within three days of receiving the supplement, infant mortality (defined as a child dying before completing the first year of age).",rephrase,"[""Neither of the studies provided data for any of this review's important outcomes: maternal illness (fever, respiratory infection, diarrhoea), adverse effects of micronutrients within three days of taking them, infant death (defined as a child dying before reaching one year of age).""]",6,0.35,2,20
CD010647,3,7,One study reported qualitatively on maternal anaemia (a secondary outcome of this review) - the study found that multiple-micronutrient supplementation was effective for recuperating from anaemia but there were no data for inclusion in our analyses.,delete,[],7,0.4,2,20
CD010647,3,8,Maternal satisfaction was not reported in the included studies.,delete,[],7,0.45,3,20
CD010647,3,9,"Similarly, none of this review's infant secondary outcomes were reported in the included studies: clinical micronutrient deficiency; morbidity episodes (febrile illness, respiratory tract infection, diarrhoea, other), adverse effects of micronutrients within three days of receiving the supplement.",rephrase,"['For the baby, these outcomes were micronutrient deficiency; illness episodes (fever, respiratory infection, diarrhoea, other), adverse effects of micronutrients within three days of the woman receiving the supplement.']",7,0.5,3,20
CD010647,4,10,We found no evidence to quantitatively assess the effectiveness of multiple-micronutrient supplementation in improving health outcomes in mother and baby.,rephrase,"['However, one of the included studies reported that multiple-micronutrient supplementation was effective for lactating women recuperating from anaemia.']",8,0.55,3,20
CD010647,4,11,"The results of this review are limited by the small numbers of studies available, small sample sizes and the studies not reporting on the outcomes of interest in this review.",delete,[],9,0.6,3,20
CD010647,4,12,"There is no evidence to evaluate potential adverse effects of multiple-micronutrient supplements, particularly excess dosages.",delete,[],9,0.65,4,20
CD010647,5,13,There is a need for high-quality studies to assess the effectiveness and safety of multiple-micronutrient supplementation for breastfeeding women for improving outcomes for the mother and her baby.,ignore,['There is a need for high-quality studies to assess the effectiveness and safety of multiple-micronutrient supplementation for breastfeeding women for improving outcomes for the mother and her baby.'],9,0.7,4,20
CD010647,5,14,"Further research should focus on whether multiple-micronutrient supplementation during lactation compared with none, a placebo or supplementation with fewer than two micronutrients is beneficial to maternal and infant health outcomes.",rephrase,"['Further research should focus on whether multiple-micronutrient supplementation during lactation (compared with no supplementation, a placebo or supplementation with fewer than two micronutrients) is beneficial to the mother and her baby and any associated adverse effects of the intervention.']",10,0.75,4,20
CD010647,5,15,"Future studies should collect data on outcomes beyond micronutrient concentrations, for example: maternal and infant morbidity, adverse effects, maternal satisfaction, the risks of excess supplementation, and potential adverse interactions between the micronutrients and the other outcomes.",rephrase,['Futher studies should report on important outcomes such as those listed in this review and consider the risks of excess supplementation.'],11,0.8,4,20
CD010647,5,16,This would help to bridge the gap between research on intermediary outcomes and health outcomes in order to develop sound policy in this field.,delete,[],12,0.85,5,20
CD010647,5,17,Future studies could more precisely assess a variety of multiple-micronutrient combinations and different dosages and look at how these affect maternal and infant health outcomes.,rephrase,['Future studies could more precisely assess a variety of multiple-micronutrient combinations and different dosages and look at how these effect outcomes for the mother and her baby.'],12,0.9,5,20
CD010647,5,18,Larger studies with longer follow-up would improve the quality of studies and provide stronger evidence.,ignore,['Larger studies with longer-term follow-up would improve the quality of studies and provide stronger evidence.'],13,0.95,5,20
CD010647,5,19,"In most of the included studies, bias could not be adequately assessed due to lack of information, therefore attention should be given to adequate methods of randomisation and allocation concealment, adequate methods of blinding of the participants, providers and the outcome assessors to improve the methodological quality of studies in this field.",delete,[],14,1.0,5,20
CD009849,0,0,We included 14 studies (7 case-control and 7 cohort studies).,rephrase,['We found 14 studies.'],0,0.045454545454545456,1,22
CD009849,0,1,"These examined oral contraceptives (OCs), depot medroxyprogesterone acetate (DMPA), and the hormonal intrauterine device (IUD).",delete,[],1,0.09090909090909091,1,22
CD009849,0,2,This section focuses on the sensitivity analysis with six studies that provided moderate or high quality evidence.,delete,[],1,0.13636363636363635,1,22
CD009849,1,3,All six studies examined oral contraceptive use.,rephrase,['Six of them had good quality results and looked at use of birth control pills.'],1,0.18181818181818182,1,22
CD009849,1,4,We noted few associations with fracture risk.,rephrase,['We did not find an overall difference in fracture risk for users and nonusers of birth control pills.'],2,0.22727272727272727,2,22
CD009849,1,5,"One cohort study reported OC ever-users had increased risk for all fractures (RR 1.20, 95% CI 1.08 to 1.34).",rephrase,['One study found pill users were more likely to have fractures overall.'],3,0.2727272727272727,2,22
CD009849,1,6,"However, a case-control study with later data from a subset reported no association except for those with 10 years or more since use (OR 1.55, 95% CI 1.03 to 2.33).",delete,[],4,0.3181818181818182,2,22
CD009849,1,7,"Another case-control study reported increased risk only for those who had 10 or more prescriptions (OR 1.09, 95% CI 1.03 to 1.16).",rephrase,['Still another study showed more risk when the woman had 10 or more prescriptions.'],4,0.36363636363636365,2,22
CD009849,1,8,A cohort study of postmenopausal women found no increased fracture risk for OC use after excluding women with prior fracture.,rephrase,"['When a study of postmenopausal women removed the women with prior fracture, pill users did not have higher fracture risk.']",5,0.4090909090909091,3,22
CD009849,1,9,Two other studies found little evidence of association between OC use and fracture risk.,rephrase,['Two more studies saw more fractures in pill users but only for certain subgroups.'],6,0.45454545454545453,3,22
CD009849,1,10,"A cohort study noted increased risk for subgroups, such as those with longer use or specific intervals since use.",delete,[],7,0.5,3,22
CD009849,1,11,A case-control study reported increased risk for any fracture only among young women with less than average use.,delete,[],7,0.5454545454545454,3,22
CD009849,2,12,Two case-control studies also examined progestin-only contraceptives.,rephrase,['Two studies looked at birth control methods that contain only the hormone progestin.'],7,0.5909090909090909,3,22
CD009849,2,13,"One reported increased fracture risk for DMPA ever-use (OR 1.44, 95% CI 1.01 to 2.06), more than four years of use (OR 2.16, 95% CI 1.32 to 3.53), and women over 50 years old.",delete,[],8,0.6363636363636364,4,22
CD009849,2,14,"The other reported increased risk for any past use, including one or two prescriptions (OR 1.17, 95% CI 1.07 to 1.29) and for current use of 3 to 9 prescriptions (OR 1.36, 95% CI 1.15 to 1.60) or 10 or more (OR 1.54, 95% CI 1.33 to 1.78).",delete,[],8,0.6818181818181818,4,22
CD009849,2,15,"For the levonorgestrel-releasing IUD, one study reported reduced fracture risk for ever-use (OR 0.75, 95% CI 0.64 to 0.87) and for longer use.",delete,[],8,0.7272727272727273,4,22
CD009849,3,16,Observational studies do not indicate an overall association between oral contraceptive use and fracture risk.,rephrase,['These studies did not show that birth control pills are generally related to more fractures.'],8,0.7727272727272727,4,22
CD009849,3,17,Some reported increased risk for specific user subgroups.,rephrase,['Some studies reported greater risk for subgroups.'],9,0.8181818181818182,5,22
CD009849,3,18,DMPA users may have an increased fracture risk.,rephrase,['Users of ‘depo’ may have more fracture risk.'],10,0.8636363636363636,5,22
CD009849,3,19,One study indicated hormonal IUD use may be associated with decreased risk.,rephrase,['Another study showed that women who had used the hormonal intrauterine device (IUD) were less likely to have a fracture.'],11,0.9090909090909091,5,22
CD009849,3,20,Observational studies need adjusted analysis because the comparison groups usually differ.,rephrase,['Observational studies need to examine differences between study groups.'],12,0.9545454545454546,5,22
CD009849,3,21,Investigators should be clear about the variables examined in multivariate analysis.,rephrase,['Investigators should be clear about the factors studied in the analysis.'],13,1.0,5,22
CD014799,0,0,We identified 25 studies including a total of 3079 participants.,rephrase,['We found 25 studies including a total of 3079 men.'],0,0.045454545454545456,1,22
CD014799,0,1,"Twenty-three studies assessed men who had previously undergone radical prostatectomy or radical retropubic prostatectomy, while only one study assessed men who had undergone transurethral resection of the prostate.",split,"['Twenty-three of these recruited men who had previously undergone a form of radical prostate surgery, where the entire prostate is removed.', 'Only one study recruited men who had previously undergone transurethral resection of the prostate, a procedure where parts of the prostate are removed through the penis.']",1,0.09090909090909091,1,22
CD014799,0,2,One study did not report on previous surgery.,rephrase,['Ten studies did not report where they had obtained funding for their study.'],3,0.13636363636363635,1,22
CD014799,0,3,Most studies were at high risk of bias for at least one domain.,delete,[],4,0.18181818181818182,1,22
CD014799,0,4,The certainty of evidence assessed using GRADE was mixed.,delete,[],4,0.22727272727272727,2,22
CD014799,1,5,"PFMT plus biofeedback versus no treatment, sham treatment or verbal/written instructions
Four studies reported on this comparison.",rephrase,"['Four studies reported on PFMT plus biofeedback versus no treatment, sham treatment and/or verbal or written instructions to perform the intervention.']",4,0.2727272727272727,2,22
CD014799,1,6,PFMT plus biofeedback may result in greater subjective cure of incontinence from 6 to 12 months (1 study; n = 102; low-certainty evidence).,rephrase,['PFMT plus biofeedback may result in more men reporting cure of incontinence from 6 to 12 months.'],5,0.3181818181818182,2,22
CD014799,1,7,"However, men undertaking PFMT and biofeedback may be less likely to be objectively cured at from 6 to 12 months (2 studies; n = 269; low-certainty evidence).",rephrase,"[""However, men undertaking PFMT and biofeedback may be less likely to be cured according to clinicians' measures at from 6 to 12 months.""]",6,0.36363636363636365,2,22
CD014799,1,8,It is uncertain whether undertaking PFMT and biofeedback has an effect on surface or skin-related adverse events (1 study; n = 205; very low-certainty evidence) or muscle-related adverse events (1 study; n = 205; very low-certainty evidence).,rephrase,['It is uncertain whether undertaking PFMT and biofeedback has an effect on surface- or skin-related adverse events (e.g. skin reactions or bruising) or muscle-related side-effects (e.g. soreness or discomfort).'],7,0.4090909090909091,3,22
CD014799,1,9,"Condition-specific quality of life, participant adherence to the intervention and general quality of life were not reported by any study for this comparison.",ignore,"['Condition-specific quality of life, participant adherence to the intervention and general quality of life were not reported by any study for this comparison.']",8,0.45454545454545453,3,22
CD014799,2,10,"Combinations of conservative treatments versus no treatment, sham treatment or verbal/written instructions
Eleven studies assessed this comparison.",rephrase,"['Eleven studies assessed combinations of conservative treatments versus no treatment, sham treatment and/or verbal or written instructions to perform the intervention.']",9,0.5,3,22
CD014799,2,11,"Combinations of conservative treatments may lead to little difference in the number of men being subjectively cured or improved of incontinence between 6 and 12 months (RR 0.97, 95% CI 0.79 to 1.19; 2 studies; n = 788; low-certainty evidence; in absolute terms: no treatment or sham arm: 307 per 1000 and intervention arm: 297 per 1000).",rephrase,['Combinations of treatments may lead to little difference in the number of men reporting cure or improvement of incontinence between 6 and 12 months.'],10,0.5454545454545454,3,22
CD014799,2,12,"Combinations of conservative treatments probably lead to little difference in condition-specific quality of life (MD -0.28, 95% CI -0.86 to 0.29; 2 studies; n = 788; moderate-certainty evidence) and probably little difference in general quality of life between 6 and 12 months (MD -0.01, 95% CI -0.04 to 0.02; 2 studies; n = 742; moderate-certainty evidence).",rephrase,['Combinations of treatments probably lead to little difference in condition-specific quality of life and probably little difference in general quality of life between 6 and 12 months.'],11,0.5909090909090909,3,22
CD014799,2,13,"There is little difference between combinations of conservative treatments and control in terms of objective cure or improvement of incontinence between 6 and 12 months (MD 0.18, 95% CI -0.24 to 0.60; 2 studies; n = 565; high-certainty evidence).",rephrase,"[""There is little difference between combinations of treatments and control in terms of cure or improvement of incontinence using clinicians' measures between 6 and 12 months.""]",12,0.6363636363636364,4,22
CD014799,2,14,"However, it is uncertain whether participant adherence to the intervention between 6 and 12 months is increased for those undertaking combinations of conservative treatments (RR 2.08, 95% CI 0.78 to 5.56; 2 studies; n = 763; very low-certainty evidence; in absolute terms: no intervention or sham arm: 172 per 1000 and intervention arm: 358 per 1000).",rephrase,"['However, it is uncertain whether participant adherence to the intervention between 6 and 12 months is increased for those undertaking combinations of treatments.']",13,0.6818181818181818,4,22
CD014799,2,15,"There is probably no difference between combinations and control in terms of the number of men experiencing surface or skin-related adverse events (2 studies; n = 853; moderate-certainty evidence), but it is uncertain whether combinations of treatments lead to more men experiencing muscle-related adverse events (RR 2.92, 95% CI 0.31 to 27.41; 2 studies; n = 136; very low-certainty evidence; in absolute terms: 0 per 1000 for both arms).",rephrase,['There is probably no difference between combinations and control in terms of the number of men experiencing surface- or skin-related side-effects but it is uncertain whether combinations of treatments lead to more men experiencing muscle-related side effects.'],14,0.7272727272727273,4,22
CD014799,3,16,"Electrical or magnetic stimulation versus no treatment, sham treatment or verbal/written instructions
We did not identify any studies for this comparison that reported on our key outcomes of interest.",rephrase,"['We did not identify any studies assessing electrical or magnetic stimulation versus no intervention, sham or verbal or written instructions that reported on our key outcomes of interest.']",15,0.7727272727272727,4,22
CD014799,4,17,"Despite a total of 25 trials, the value of conservative interventions for urinary incontinence following prostate surgery alone, or in combination, remains uncertain.",rephrase,['We searched for studies investigating the effects of non-surgical and non-pharmacological treatments on urinary incontinence in men who have undergone prostate surgery.'],16,0.8181818181818182,5,22
CD014799,4,18,Existing trials are typically small with methodological flaws.,delete,[],17,0.8636363636363636,5,22
CD014799,4,19,These issues are compounded by a lack of standardisation of the PFMT technique and marked variations in protocol concerning combinations of conservative treatments.,delete,[],17,0.9090909090909091,5,22
CD014799,4,20,Adverse events following conservative treatment are often poorly documented and incompletely described.,delete,[],17,0.9545454545454546,5,22
CD014799,4,21,"Hence, there is a need for large, high-quality, adequately powered, randomised control trials with robust methodology to address this subject.",delete,[],17,1.0,5,22
CD007578,0,0,"Results of the Cochrane review
No studies meeting the study design criteria were identified for inclusion in this Cochrane review.",delete,[],0,0.16666666666666666,1,6
CD007578,1,1,"Results of thematic synthesis
In total, 49 studies and pieces of literature meeting the same population, intervention and outcome criteria as the Cochrane review, but identified from the broader literature providing evidence on policy implementation and consumer experiences, were included and formed the basis of a thematic synthesis, and which is presented in appendices to this Cochrane review.",rephrase,['This research formed the basis of a thematic synthesis.'],0,0.3333333333333333,2,6
CD007578,1,2,"The thematic synthesis indicates that ideally communication may be considered as a longitudinal multicomponent programme, ensuring that notification and support are coordinated; that communication is tailored and responsive to need; and that activities to support individual risk communication, such as widespread education and monitoring of access to health care for those at risk, are in place.",rephrase,"['It indicates that communication may be best considered as a longitudinal multicomponent programme occurring over time, ensuring that notification is coordinated and considers impact; that support is in place and is offered over time; that communication is flexible, tailored and responsive to need; and that supporting activities, such as widespread education of the healthcare workforce, the public and the media, and monitoring of access to health care for those at risk, are in place.']",1,0.5,3,6
CD007578,1,3,"The thematic synthesis also indicates that poor communication practices may have negative impacts or cause harm, such as discrimination in accessing health care.",ignore,"['The thematic synthesis also indicates that poor communication practices may have negative impacts or cause harm, such as discrimination in accessing health care.']",2,0.6666666666666666,4,6
CD007578,2,4,"There is insufficient rigorous evidence to determine the effects of interventions to notify people at CJD or vCJD risk and to support them subsequently, or to identify the best approach to communication in these situations.",split,"['That CJD and vCJD are very rare diseases creates challenges for researchers aiming to conduct rigorous quantitative studies in this area.', 'Although we searched widely to identify all relevant research evaluating the effects of interventions to communicate with (notify and support) people at risk, we did not identify any studies that met the criteria for inclusion in this Cochrane review.']",3,0.8333333333333334,5,6
CD007578,2,5,The thematic synthesis can be used to inform policy and practice decisions for communicating with people at risk in the absence of rigorous evaluative studies.,rephrase,['In the absence of rigorous evaluative studies the results of this thematic synthesis can be used to inform policy and practice decisions for communicating with people at risk.'],5,1.0,5,6
CD009332,0,0,"Seven trials, involving 7817 women, met the inclusion criteria for this review.",rephrase,['We searched for evidence from randomised controlled trials on 19 December 2019 and identified seven studies (involving 7817 women).'],0,0.05,1,20
CD009332,0,1,The trials compared intravenous versus intramuscular administration of oxytocin just after the birth of the anterior shoulder or soon after the birth of the baby.,rephrase,['The studies compared oxytocin injected into a vein with injection into muscle during or immediately after the vaginal birth of the baby.'],1,0.1,1,20
CD009332,0,2,"All trials were conducted in hospital settings, mainly in middle- and high-income countries, and included women with term pregnancies, undergoing a vaginal birth.",rephrase,['All studies were conducted in hospitals and mostly recruited women giving birth vaginally to one baby at term.'],2,0.15,1,20
CD009332,0,3,"Overall, the included studies were at moderate or low risk of bias, with two trials providing clear information on allocation concealment and blinding.",rephrase,"['Overall, the included studies were at moderate or low risk of bias, and the certainty of the generated evidence was generally moderate to high.']",3,0.2,1,20
CD009332,1,4,"High-certainty evidence suggests that intravenous administration of oxytocin in the third stage of labour compared with intramuscular administration carries a lower risk for postpartum haemorrhage (PPH) ≥ 500 mL (average risk ratio (RR) 0.78, 95% confidence interval (CI) 0.66 to 0.92; six trials; 7731 women) and blood transfusion (average RR 0.44, 95% CI 0.26 to 0.77; four trials; 6684 women).",rephrase,['There was high-certainty evidence for both of these outcomes.'],4,0.25,2,20
CD009332,1,5,"Intravenous administration of oxytocin probably reduces the risk of PPH ≥ 1000 mL, although the 95% CI crosses the line of no-effect (average RR 0.65, 95% CI 0.39 to 1.08; four trials; 6681 women; moderate-certainty evidence).",split,"['We found that women receiving oxytocin through a vein were at lower risk for blood loss of 500 mL or more (six trials; 7731 women) and blood transfusion (four trials; 6684 women) compared with women receiving oxytocin into muscle.', 'The administration of oxytocin through a vein probably reduced the risk for severe blood loss of 1000 mL or more, compared with oxytocin into muscle (four trials; 6681 women; moderate-certainty evidence).']",5,0.3,2,20
CD009332,1,6,"In all studies but one, there was a reduction in the risk of PPH ≥ 1000 mL with intravenous oxytocin.",rephrase,"['In all but two studies, both women and hospital staff were aware of how the oxytocin was given.']",7,0.35,2,20
CD009332,1,7,"The study that found a large increase with intravenous administration was small (256 women), and contributed only 3% of total events.",delete,[],8,0.4,2,20
CD009332,1,8,"Once this small study was removed from the meta-analysis, heterogeneity was eliminated and the treatment effect favoured intravenous oxytocin (average RR 0.61, 95% CI 0.42 to 0.88; three trials; 6425 women; high-certainty evidence).",delete,[],8,0.45,3,20
CD009332,1,9,"Additionally, a sensitivity analysis, exploring the effect of risk of bias by restricting analysis to those studies rated as 'low risk of bias' for random sequence generation and allocation concealment, found that the prophylactic administration of intravenous oxytocin reduces the risk for PPH ≥ 1000 mL, compared with intramuscular oxytocin (average RR 0.64, 95% CI 0.43 to 0.94; two trials; 1512 women).",delete,[],8,0.5,3,20
CD009332,1,10,"There may be little to no difference between the two routes of oxytocin administration in terms of additional uterotonic use (average RR 0.78, 95% CI 0.49 to 1.25; six trials; 7327 women; low-certainty evidence).",rephrase,"['Although the two ways of giving oxytocin may have been similar in terms of women requiring additional medications to contract the uterus, we have little confidence in these results (six trials; 7327 women; low-certainty evidence).']",8,0.55,3,20
CD009332,1,11,"Although intravenous compared with intramuscular administration of oxytocin probably results in a lower risk for serious maternal morbidity (e.g. hysterectomy, organ failure, coma, intensive care unit admissions), the size of the effect is uncertain as the confidence interval is wide, including a substantial reduction, but also touches the line of no-effect (average RR 0.47, 95% CI 0.22 to 1.00; four trials; 7028 women; moderate-certainty evidence).",delete,[],9,0.6,3,20
CD009332,1,12,"Most events occurred in one study from Ireland reporting high dependency unit admissions, whereas in the remaining three studies there was only one case of uvular oedema.",delete,[],9,0.65,4,20
CD009332,1,13,There were no maternal deaths reported in any of the included studies (very low-certainty evidence).,rephrase,['No mother died in any of the included studies.'],9,0.7,4,20
CD009332,2,14,"There is probably little or no difference in the risk of hypotension between intravenous and intramuscular administration of oxytocin (RR 1.01, 95% CI 0.88 to 1.15; four trials; 6468 women; moderate-certainty evidence).",split,"['Both routes of oxytocin appear safe with probably same number of women experiencing side effects, including low blood pressure (four trials; 6468 women; moderate-certainty evidence).', 'Probably fewer women receiving oxytocin through a vein experienced serious complications related to excessive bleeding, such as admission to intensive care, loss of consciousness, or organ failure (four trials; 7028 women; moderate-certainty evidence).']",10,0.75,4,20
CD009332,3,15,Subgroup analyses based on the mode of administration of intravenous oxytocin (bolus injection or infusion) versus intramuscular oxytocin did not show any evidence of substantial differences on the primary outcomes.,delete,[],12,0.8,4,20
CD009332,3,16,"Similarly, additional subgroup analyses based on whether oxytocin was used alone or as part of active management of the third stage of labour (AMTSL) did not show any evidence of substantial differences between the two routes of administration.",delete,[],12,0.85,5,20
CD009332,4,17,Intravenous administration of oxytocin is more effective than its intramuscular administration in preventing PPH during vaginal birth.,rephrase,['Oxytocin is more effective when given through a vein than oxytocin injected into muscle for preventing excessive bleeding soon after vaginal birth.'],12,0.9,5,20
CD009332,4,18,Intravenous oxytocin administration presents no evidence of additional safety concerns and has a comparable side effects profile with its intramuscular administration.,rephrase,['Giving oxytocin into a vein did not cause additional safety concerns and had similar side effects compared with oxytocin injected into muscle.'],13,0.95,5,20
CD009332,4,19,"Future studies should consider the acceptability, feasibility and resource use for the intervention, especially in low-resource settings.",rephrase,['Future studies need to consider the acceptability of the two different ways of giving oxytocin to women and healthcare providers as important study outcomes.'],14,1.0,5,20
CD005640,0,0,"We included six trials randomising 359 participants, 178 to T-tube drainage and 181 to primary closure.",rephrase,['We identified a total of six trials including 359 participants of whom 178 had primary closure and 181 patients had T-tube drainage after open exploration of the common bile duct.'],0,0.08333333333333333,1,12
CD005640,0,1,All trials were at high risk of bias.,rephrase,['All six trials were at high risk of bias (risk of overestimating the benefits and underestimating the harms of the intervention or the control).'],1,0.16666666666666666,1,12
CD005640,0,2,There was no significant difference in mortality between the two groups (4/178 (weighted percentage 1.2%) in the T-tube group versus 1/181 (0.6%) in the primary closure group; RR 2.25; 95% CI 0.55 to 9.25; six trials).,rephrase,['There was no significant difference in mortality (12 deaths per 1000 participants in the T-tube drainage group versus 6 deaths per 1000 participants in the primary closure group) or in the serious complication rate after surgery between the two groups (approximately 145 complications per 1000 participants in the T-tube drainage group versus 66 complications per 1000 participants in the primary closure group).'],2,0.25,2,12
CD005640,0,3,"There was no significant difference in the serious morbidity rate between the two groups (24/136 (weighted serious morbidity rate, 145 events per 1000 patients) in the T-tube group versus 9/136 (weighted serious morbidity rate, 66 events per 1000 patients) in the primary closure group; RaR 2.19; 95% CI 0.98 to 4.91; four trials).",rephrase,"['Although the number of deaths and complication rates in the primary closure group appeared to be less than half those in the T-tube group, there is a possibility that this was not a true observation but rather a difference that occurred by chance (similar to there being one chance in eight of flipping a coin and having it come up heads or tails three times in a row).']",3,0.3333333333333333,2,12
CD005640,0,4,Quality of life and return to work were not reported in any of the trials.,rephrase,['None of the trials reported quality of life or the time taken for patients to return to work.'],4,0.4166666666666667,3,12
CD005640,0,5,The operating time was significantly longer in the T-tube drainage group compared with the primary closure group (MD 28.90 minutes; 95% CI 17.18 to 40.62 minutes; one trial).,rephrase,['The average operating time was significantly longer in the T-tube drainage group than in the primary closure group (by about 30 minutes).'],5,0.5,3,12
CD005640,0,6,The hospital stay was significantly longer in the T-tube drainage group compared with the primary closure group (MD 4.72 days; 95% CI 0.83 days to 8.60 days; five trials).,rephrase,['The average hospital stay was significantly longer in the T-tube group than in the primary closure group (by about five days).'],6,0.5833333333333334,3,12
CD005640,1,7,T-tube drainage appeared to result in significantly longer operating time and hospital stay compared with primary closure without any apparent evidence of benefit on clinically important outcomes after open common bile duct exploration.,delete,[],7,0.6666666666666666,4,12
CD005640,1,8,"Based on the currently available evidence, there is no justification for the routine use of T-tube drainage after open common bile duct exploration in patients with common bile duct stones.",delete,[],7,0.75,4,12
CD005640,1,9,T-tube drainage should not be used outside well designed randomised clinical trials.,rephrase,['Use of a T-tube appears to increase the cost without providing any benefit to the patients.'],7,0.8333333333333334,5,12
CD005640,1,10,More randomised trials comparing the effects of T-tube drainage versus primary closure after open common bile duct exploration may be needed.,split,"['Further randomised trials with low risk of bias (low chance of arriving at the wrong conclusions because of prejudice by healthcare providers, researchers, or patients) and low risk of random errors (arriving at wrong conclusions because of chance) are necessary to confirm whether the use of T-tubes is justified anymore.', 'Until the results from such trials are available, we discourage the routine use of T-tube after open common bile duct exploration.']",8,0.9166666666666666,5,12
CD005640,1,11,"Such trials should be conducted with low risk of bias and assessing the long-term beneficial and harmful effects of T-tube drainage, including long-term complications such as bile stricture and recurrence of common bile duct stones.",delete,[],10,1.0,5,12
CD011112,0,0,"We included six studies (reported as seven papers) involving 326 participants whose ages ranged from 39 to 83 years, with a gender bias towards men (73% to 95% across studies), reflecting the characteristics of patients with HNC.",rephrase,"['We included six studies with 326 participants who undertook therapeutic exercises before, during and/or after HNC treatment.']",0,0.08333333333333333,1,12
CD011112,0,1,The risk of bias in the studies was generally high.,delete,[],1,0.16666666666666666,1,12
CD011112,1,2,We did not pool data from studies because of significant differences in the interventions and outcomes evaluated.,rephrase,"[""We could not combine the results of the studies because of the variation in participants' cancers, their treatments, the outcomes measured and the tools used to assess them, as well as the differing time points for testing.""]",1,0.25,2,12
CD011112,1,3,We found a lack of standardisation and consistency in the outcomes measured and the endpoints at which they were evaluated.,delete,[],2,0.3333333333333333,2,12
CD011112,2,4,"We found no evidence that therapeutic exercises were better than TAU, or any other treatment, in improving the safety and efficiency of oral swallowing (our primary outcome) or in improving any of the secondary outcomes.",delete,[],2,0.4166666666666667,3,12
CD011112,3,5,"Using the GRADE system, we classified the overall quality of the evidence for each outcome as very low, due to the limited number of trials and their low quality.",delete,[],2,0.5,3,12
CD011112,3,6,There were no adverse events reported that were directly attributable to the intervention (swallowing exercises).,rephrase,['There were no reported adverse events directly attributable to the intervention (swallowing exercises).'],2,0.5833333333333334,3,12
CD011112,4,7,"We found no evidence that undertaking therapeutic exercises before, during and/or immediately after HNC treatment leads to improvement in oral swallowing.",split,"['We found no evidence that therapeutic exercises were better than TAU, or any other treatment, in improving the safety and efficiency of oral swallowing (our primary outcome) or in improving any of the secondary outcomes.', 'However, there is insufficient evidence to draw any clear conclusion about the effects of undertaking therapeutic exercises before during and/or immediately after HNC treatment on preventing or reducing dysphagia.']",3,0.6666666666666666,4,12
CD011112,4,8,"This absence of evidence may be due to the small participant numbers in trials, resulting in insufficient power to detect any difference.",rephrase,"['Studies had small participant numbers, used complex interventions and varied in the choice of outcomes measured, making it difficult to draw reliable conclusions.']",5,0.75,4,12
CD011112,4,9,"Data from the identified trials could not be combined due to differences in the choice of primary outcomes and in the measurement tools used to assess them, and the differing baseline and endpoints across studies.",delete,[],6,0.8333333333333334,5,12
CD011112,5,10,Designing and implementing studies with stronger methodological rigour is essential.,rephrase,"['We need better designed, rigorous studies with larger participant numbers and agreed endpoints and outcome measurements in order to draw clear(er) conclusions.']",6,0.9166666666666666,5,12
CD011112,5,11,"There needs to be agreement about the key primary outcomes, the choice of validated assessment tools to measure them and the time points at which those measurements are made.",delete,[],7,1.0,5,12
CD008388,0,0,"Twenty studies (732 randomised participants, with data for 547 participants with stroke) met the inclusion criteria for this review.",rephrase,['We included 20 studies (involving 547 stroke participants) that investigated the effect of treatments for visual field defects.'],0,0.05263157894736842,1,19
CD008388,0,1,"However, only 10 of these studies compared the effect of an intervention with a placebo, control, or no treatment group, and eight had data which could be included in meta-analyses.",rephrase,"['However, only 10 of these studies compared the effect of a particular treatment with no treatment.']",1,0.10526315789473684,1,19
CD008388,0,2,Only two of these eight studies presented data relating to our primary outcome of functional abilities in activities of daily living.,rephrase,"[""Only two studies presented data relating to how treatment can improve stroke survivors' abilities in activities of daily living, and there was a lack of consistency across studies that limited our ability to draw clear conclusions.""]",2,0.15789473684210525,1,19
CD008388,0,3,One study reported evidence relating to adverse events.,delete,[],3,0.21052631578947367,2,19
CD008388,1,4,"Three studies (88 participants) compared a restitutive intervention with a control, but data were only available for one study (19 participants).",rephrase,"[""Three of these studies investigated a type of eye movement training designed to improve the lost visual field (a 'restitutive' intervention).""]",3,0.2631578947368421,2,19
CD008388,1,5,"There was very low-quality evidence that visual restitution therapy had no effect on visual field outcomes, and a statistically significant effect on quality of life, but limitations with these data mean that there is insufficient evidence to draw any conclusions about the effectiveness of restitutive interventions as compared to control.",rephrase,['There was insufficient evidence to draw any conclusions about the effectiveness of restitutive interventions as compared to control.'],4,0.3157894736842105,2,19
CD008388,2,6,Four studies (193 participants) compared the effect of scanning (compensatory) training with a control or placebo intervention.,rephrase,"[""Four of the included studies investigated the effect of scanning training, which involves training people to 'scan' across the space in front of them and into the 'lost' visual field, in order to better cope with their lost vision (a 'compensatory' intervention).""]",5,0.3684210526315789,2,19
CD008388,2,7,"There was low-quality evidence that scanning training was more beneficial than control or placebo on quality of life, measured using the Visual Function Questionnaire (VFQ-25) (two studies, 96 participants, mean difference (MD) 9.36, 95% confidence interval (CI) 3.10 to 15.62).",merge,[],6,0.42105263157894735,3,19
CD008388,2,8,"However, there was low or very-low quality evidence of no effect on measures of visual field, extended activities of daily living, reading, and scanning ability.",merge,[],6,0.47368421052631576,3,19
CD008388,2,9,"There was low-quality evidence of no significant increase in adverse events in people doing scanning training, as compared to no treatment.",none,"['There was low or very low-quality evidence that scanning training may help improve quality of life, but may have no effect on other outcomes (including adverse events).']",6,0.5263157894736842,3,19
CD008388,3,10,Three studies (166 participants) compared a substitutive intervention (a type of prism) with a control.,rephrase,"[""Three of the included studies investigated the effect of wearing a special prism on a pair of glasses, which increases the amount a person can see on their affected side (a 'substitutive' intervention).""]",7,0.5789473684210527,3,19
CD008388,3,11,"There was low or very-low quality evidence that prisms did not have an effect on measures of activities of daily living, extended activities of daily living, reading, falls, or quality of life, and very low-quality evidence that they may have an effect on scanning ability (one study, 39 participants, MD 9.80, 95% CI 1.91 to 17.69).",delete,[],8,0.631578947368421,4,19
CD008388,3,12,"There was low-quality evidence of an increased odds of an adverse event (primarily headache) in people wearing prisms, as compared to no treatment.",rephrase,"['There was low or very-low quality evidence that prisms may have an effect on ability to scan (look) for objects, but may cause a range of minor adverse events (particularly headache) and may have no effect on other outcomes.']",8,0.6842105263157895,4,19
CD008388,4,13,One study (39 participants) compared the effect of assessment by an orthoptist to standard care (no assessment) and found very low-quality evidence that there was no effect on measures of activities of daily living.,rephrase,"['One of the studies investigated the effect of specialised assessment by an orthoptist (a hospital-based vision specialist), compared to standard care.']",9,0.7368421052631579,4,19
CD008388,5,14,"Due to the quality and quantity of evidence, we remain uncertain about the benefits of assessment interventions.",rephrase,['Limitations with the evidence meant that we could not draw any conclusions about the benefits of assessment interventions.'],10,0.7894736842105263,4,19
CD008388,6,15,There is a lack of evidence relating to the effect of interventions on our primary outcome of functional ability in activities of daily living.,delete,[],11,0.8421052631578947,5,19
CD008388,6,16,"There is limited low-quality evidence that compensatory scanning training may be more beneficial than placebo or control at improving quality of life, but not other outcomes.",delete,[],11,0.8947368421052632,5,19
CD008388,6,17,"There is insufficient evidence to reach any generalised conclusions about the effect of restitutive interventions or substitutive interventions (prisms) as compared to placebo, control, or no treatment.",delete,[],11,0.9473684210526315,5,19
CD008388,6,18,There is low-quality evidence that prisms may cause minor adverse events.,delete,[],11,1.0,5,19
CD012214,0,0,We included three RCTs in which a total of 77 women took part.,rephrase,['We included three randomised controlled trials in which a total of 77 women took part.'],0,0.08333333333333333,1,12
CD012214,0,1,"We rated the quality of the evidence as very low for all outcomes owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision.",ignore,"['We rated the quality of evidence as very low for all outcomes owing to very serious risk of bias (associated with poor reporting, attrition, and limitations in study design) and imprecision.']",1,0.16666666666666666,1,12
CD012214,1,2,We performed a meta-analysis of two trials with 59 participants.,delete,[],2,0.25,2,12
CD012214,1,3,"When metformin was compared with megestrol acetate in women with endometrial hyperplasia, we found insufficient evidence to determine whether there were differences between groups for the following outcomes: regression of endometrial hyperplasia histology towards normal histology (odds ratio (OR) 3.34, 95% confidence interval (CI) 0.97 to 11.57, two RCTs, n = 59, very low-quality evidence), hysterectomy rates (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 59, very low-quality evidence), and rates of abnormal uterine bleeding (OR 0.91, 95% CI 0.05 to 15.52, two RCTs, n = 44 , very low-quality evidence).",rephrase,['Comparisons of metformin versus megestrol acetate have provided insufficient evidence to show differences in effectiveness for curing endometrial hyperplasia.'],2,0.3333333333333333,2,12
CD012214,1,4,We found no data for recurrence of endometrial hyperplasia or health-related quality of life.,delete,[],3,0.4166666666666667,3,12
CD012214,1,5,"Both studies (n = 59) provided data on progression of endometrial hyperplasia to endometrial cancer as well as one (n = 16) reporting some adverse effects in the metformin arm, notably nausea, thrombosis, lactic acidosis, abnormal liver and renal function among others.",rephrase,"['Although both studies provided data on progression of endometrial hyperplasia to endometrial cancer, there were no events in either arm, and study authors reported no data on adverse effects.']",3,0.5,3,12
CD012214,2,6,Another trial including 16 participants compared metformin plus megestrol acetate versus megestrol acetate alone in women with endometrial hyperplasia.,rephrase,"['Two studies compared metformin versus megestrol acetate (a form of progesterone), and one study compared metformin plus megestrol acetate versus megestrol acetate alone.']",4,0.5833333333333334,3,12
CD012214,2,7,"We found insufficient evidence to determine whether there were differences between groups for the following outcomes: regression of endometrial hyperplasia histology towards normal histology (OR 9.00, 95% CI 0.94 to 86.52, one RCT, n = 16, very low-quality evidence), recurrence of endometrial hyperplasia among women who achieve regression (OR not estimable, no events recorded, one RCT, n = 8, very low-quality evidence), progression of endometrial hyperplasia to endometrial cancer (OR not estimable, no events recorded, one RCT, n = 13, very low-quality evidence), or hysterectomy rates (OR 0.29, 95% CI 0.01 to 8.37, one RCT, n = 16, very low-quality evidence).",delete,[],5,0.6666666666666666,4,12
CD012214,2,8,Investigators provided no data on abnormal uterine bleeding or health-related quality of life.,delete,[],5,0.75,4,12
CD012214,2,9,"In terms of adverse effects, three of eight participants (37.5%) in the metformin plus megestrol acetate study arm reported nausea.",rephrase,['Three of eight patients in the metformin plus megestrol acetate study arm reported nausea.'],5,0.8333333333333334,5,12
CD012214,3,10,"At present, evidence is insufficient to support or refute the use of metformin alone or in combination with standard therapy - specifically, megestrol acetate - versus megestrol acetate alone, for treatment of endometrial hyperplasia.",delete,[],6,0.9166666666666666,5,12
CD012214,3,11,Robustly designed and adequately powered randomised controlled trials yielding long-term outcome data are needed to address this clinical question.,delete,[],6,1.0,5,12
CD000501,0,0,Eleven trials met the inclusion criteria.,merge,[],0,0.1111111111111111,1,9
CD000501,0,1,Ten trials (1460 infants) compared vitamin A supplementation with a control and one (120 infants) compared different regimens of vitamin A supplementation.,none,"['Eleven trials were included in this review, ten comparing vitamin A with a control (placebo or no supplementation) and one comparing different vitamin A regimens.']",0,0.2222222222222222,2,9
CD000501,0,2,"Compared to the control group, vitamin A appeared to have a small benefit in reducing the risk of death or oxygen requirement at one month of age (typical RR 0.93, 95% CI 0.88 to 0.99; typical RD −0.05, 95% CI −0.10 to −0.01; NNTB 20, 95% CI 10 to 100; 6 studies, 1165 infants) and the risk of chronic lung disease (oxygen requirement) at 36 weeks' postmenstrual age (typical RR 0.87, 95% CI 0.77 to 0.99; typical RD −0.07, 95% CI −0.13 to −0.01; NNTB 11, 95% CI 6 to 100; 5 studies, 986 infants) (moderate-quality evidence).",rephrase,"[""Compared to the control group, supplementing very low birth weight infants with vitamin A appears to have a small benefit in reducing the risk of death or oxygen requirement at one month of age and the risk of chronic lung disease (oxygen requirement) at 36 weeks' postmenstrual age (moderate-quality evidence).""]",1,0.3333333333333333,2,9
CD000501,0,3,"There was a marginal reduction of the combined outcome of death or chronic lung disease (typical RR 0.92, 95% CI 0.84 to 1.01; typical RD −0.05, 95% CI −0.11 to 0.01; 4 studies, 1089 infants).",split,"['There was a marginal reduction of the combined outcome of death or chronic lung disease (moderate-quality evidence).', 'Although there is a statistical reduction in chronic lung disease, these findings are consistent with either a meaningful impact on chronic lung disease or a negligible impact.']",2,0.4444444444444444,3,9
CD000501,0,4,"Neurodevelopmental assessment of 88% of the surviving infants in the largest trial showed no difference between the groups at 18 to 22 months of age, corrected for prematurity (low-quality evidence).",rephrase,['The one trial that investigated neurodevelopmental status at 18 to 22 months of age correcting for prematurity found no evidence of benefit or harm associated with vitamin A supplementation compared to control (low-quality evidence).'],4,0.5555555555555556,3,9
CD000501,0,5,There is no evidence to support different vitamin A dosing regimens.,delete,[],5,0.6666666666666666,4,9
CD000501,0,6,"No adverse effects of vitamin A supplementation were reported, but it was noted that intramuscular injections of vitamin A were painful.",ignore,"['No adverse effects of vitamin A supplementation were reported, but it was noted that intramuscular injections of vitamin A were painful.']",5,0.7777777777777778,4,9
CD000501,1,7,Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in the outcome balanced against the lack of other proven benefits and the acceptability of the treatment.,ignore,['Whether clinicians decide to utilise repeat intramuscular doses of vitamin A to prevent chronic lung disease may depend upon the local incidence of this outcome and the value attached to achieving a modest reduction in the outcome balanced against the lack of other proven benefits and the acceptability of the treatment.'],6,0.8888888888888888,5,9
CD000501,1,8,Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.,ignore,['Information on long-term neurodevelopmental status suggests no evidence of either benefit or harm from the intervention.'],7,1.0,5,9
CD006117,0,0,"A total of 59 studies, mostly of low quality, were included in the review, involving multiple treatment comparisons between sertraline and other antidepressant agents.",delete,[],0,0.14285714285714285,1,7
CD006117,0,1,"Evidence favouring sertraline over some other antidepressants for the acute phase treatment of major depression was found, either in terms of efficacy (fluoxetine) or acceptability/tolerability (amitriptyline, imipramine, paroxetine and mirtazapine).",rephrase,"['In the present review we assessed the evidence for the efficacy, acceptability and tolerability of sertraline in comparison with all other antidepressants in the acute-phase treatment of major depression.']",0,0.2857142857142857,2,7
CD006117,0,2,"However, some differences favouring newer antidepressants in terms of efficacy (mirtazapine) and acceptability (bupropion) were also found.",delete,[],1,0.42857142857142855,3,7
CD006117,0,3,"In terms of individual side effects, sertraline was generally associated with a higher rate of participants experiencing diarrhoea.",delete,[],1,0.5714285714285714,3,7
CD006117,1,4,"This systematic review and meta-analysis highlighted a trend in favour of sertraline over other antidepressive agents both in terms of efficacy and acceptability, using 95% confidence intervals and a conservative approach, with a random effects analysis.",rephrase,"['The review showed evidence of differences in efficacy, acceptability and tolerability between sertraline and other antidepressants, with meta-analyses highlighting a trend in favour of sertraline over other antidepressants, both in terms of efficacy and acceptability, in a homogeneous sample of clinical trials, using conservative statistical methods.']",1,0.7142857142857143,4,7
CD006117,1,5,"However, the included studies did not report on all the outcomes that were pre-specified in the protocol of this review.",ignore,['The included studies did not report on all the outcomes that were pre-specified in the protocol of this review.'],2,0.8571428571428571,5,7
CD006117,1,6,Outcomes of clear relevance to patients and clinicians were not reported in any of the included studies.,rephrase,"[""Outcomes of clear relevance to patients and clinicians, in particular, patients and their carers' attitudes to treatment, their ability to return to work and resume normal social functioning, were not reported in the included studies.""]",3,1.0,5,7
CD007028,0,0,"We included 21 trials, involving 1746 participants, in this update; six trials were new.",rephrase,"['We searched for trials up to June 2014 and included 21 randomised controlled trials, involving 1746 participants, of mailuoning for people with acute ischaemic stroke.']",0,0.1,1,10
CD007028,0,1,The included trials did not report the numbers of dead and dependent participants at the end of at least three months' follow-up.,delete,[],1,0.2,1,10
CD007028,0,2,"Of the 12 trials that reported adverse events, five events occurred in two trials.",delete,[],1,0.3,2,10
CD007028,0,3,There was no significant difference between the treatment group and the control group.,rephrase,"['When we analysed these trials together, there was no significant difference for adverse events between the mailuoning-treatment group and the control group; mailuoning improved neurological impairment and cognitive function significantly.']",1,0.4,2,10
CD007028,0,4,"We assessed 20 trials to be of a poor quality: When analysing these trials together, mailuoning was associated with a significant increase in the number of participants with an improved neurological deficit (risk ratio (RR) 0.31, 95% confidence interval (CI) 0.23 to 0.42) and showed a significant improvement of neurological deficit with the European Stroke Scale (ESS) (mean difference (MD) (fixed) 8.29, 95% CI 3.44 to 13.15).",rephrase,['We assessed 20 trials to be of a low quality.'],2,0.5,3,10
CD007028,0,5,"One placebo-controlled trial, assessed to be of a better methodological quality, failed to show a significant improvement of neurological deficit at the end of three months' follow-up (MD (fixed) 2.49, 95% CI -1.45 to 6.43) or in quality of life.",merge,[],3,0.6,3,10
CD007028,0,6,"One trial, which reported cognitive function using the Montreal Cognitive Assessment as a continuous scale, showed a significant improvement of cognitive function (MD (fixed) 2.68, 95% CI 1.82 to 3.54).",merge,[],3,0.7,4,10
CD007028,0,7,"Two trials assessed activities of daily life: One trial showed a significant improvement, but the other did not.",none,"['One trial, assessed to be of a higher quality, failed to show any significant improvement made by mailuoning on neurological deficit, activities of daily life, or quality of life.']",3,0.8,4,10
CD007028,1,8,This review did not provide sufficient evidence to support the routine use of mailuoning for the treatment of people with acute ischaemic stroke.,rephrase,['There was no convincing evidence from trials with sufficient methodological quality to support the routine use of mailuoning to promote recovery after stroke.'],4,0.9,5,10
CD007028,1,9,High-quality large-scale randomised controlled trials are needed to confirm the efficacy of mailuoning.,rephrase,['High-quality large-scale randomised controlled trials are needed to confirm its effect.'],5,1.0,5,10
CD009829,0,0,We found four eligible RCTs (115 participants).,rephrase,['We found four small studies including a total of 115 young men exhibiting harmful sexual behaviour.'],0,0.04,1,25
CD009829,0,1,Participants in two studies were adolescent males aged 12 to 18 years old.,rephrase,"['In two studies, participants were aged 12 to 18 years old.']",1,0.08,1,25
CD009829,0,2,"In two studies participants were males simply described as ""adolescents.""",rephrase,"['In the other two studies the male participants were simply described as ""adolescents"".']",2,0.12,1,25
CD009829,1,3,Three studies took place in the USA and one in South Africa.,rephrase,['Three studies were conducted in the USA and one in South Africa.'],3,0.16,1,25
CD009829,1,4,The four studies were of short duration: one lasted two months; two lasted three months; and one lasted six months.,split,"['Studies were short.', 'One lasted two months; two lasted three months; one lasted six months.']",4,0.2,1,25
CD009829,1,5,No information was available on funding sources.,rephrase,['We do not know who funded these studies.'],6,0.24,2,25
CD009829,2,6,Two studies compared group-based CBT respectively to no treatment (18 participants) or treatment as usual (21 participants).,rephrase,['Two studies (39 participants) compared CBT to no treatment or treatment as usual.'],7,0.28,2,25
CD009829,2,7,The third compared CBT with sexual education (16 participants).,rephrase,['Another study (16 participants) compared CBT with sexual education.'],8,0.32,2,25
CD009829,2,8,The fourth compared CBT (19 participants) with mode-deactivation therapy (21 participants) and social skills training (20 participants).,rephrase,"['One study compared CBT (19 participants) with mode deactivation therapy (explicit, systematic, goal-oriented approach to address problematic emotions, behaviours and thoughts) (21 participants) and social skills training (social skills development and role playing) (20 participants).']",9,0.36,2,25
CD009829,2,9,"Three interventions delivered treatment in a residential setting by someone working there, and one in a community setting by licensed therapist undertaking a PhD.",split,"['In three studies, CBT was delivered in a residential setting by someone working there.', 'In the fourth, it was provided in community by a licensed therapist studying for a PhD.']",10,0.4,2,25
CD009829,3,10,"CBT compared with no treatment or treatment as usual
Primary outcomes
No study in this comparison reported the impact of CBT on any measure of primary outcomes (recidivism, and adverse events such as self-harm or suicidal behaviour).",delete,[],12,0.44,3,25
CD009829,4,11,"Secondary outcomes
There was little to no difference between CBT and treatment as usual on cognitive distortions in general (mean difference (MD) 1.56, 95% confidence interval (CI) -11.54 to 14.66, 1 study, 18 participants; very low-certainty evidence), assessed with Abel and Becker Cognition Scale (higher scores indicate more problematic distortions); and specific cognitive distortions about rape (MD 8.75, 95% CI 2.83 to 14.67, 1 study, 21 participants; very low-certainty evidence), measured with the Bumby Cardsort Rape Scale (higher scores indicate more justifications, minimisations, rationalisations and excuses for HSB).",delete,[],12,0.48,3,25
CD009829,5,12,"One study (18 participants) reported very low-certainty evidence that CBT may result in greater improvements in victim empathy (MD 5.56, 95% CI 0.94 to 10.18), measured with the Attitudes Towards Women Scale, compared with no treatment.",rephrase,"['One study (18 participants) showed CBT meant the young men understood how their behaviour had effected their victims, compared to the no-treatment group (very low-certainty evidence).']",12,0.52,3,25
CD009829,5,13,"One additional study also measured this, but provided no usable data.",rephrase,"['One study (21 participants) measured this, but reported no usable data.']",13,0.56,3,25
CD009829,6,14,"CBT compared with alternative interventions
Primary outcomes
One study (59 participants) found little to no difference between CBT and alternative treatments on post-treatment sexual aggression scores (MD 0.09, 95% CI -0.18 to 0.37, very low-certainty evidence), assessed using Daily Behaviour Reports and Behaviour Incidence Report Forms.",rephrase,['One study (59 participants) found little to no difference in how CBT improved psychological well-being compared with other treatments (very low-certainty evidence).'],14,0.6,3,25
CD009829,6,15,No study in this comparison reported the impact of CBT on any measure of our remaining primary outcomes.,rephrase,['No studies looked at the impact of CBT on girls with harmful sexual behaviour.'],15,0.64,4,25
CD009829,7,16,"Secondary outcomes
One study (16 participants) provided very low-certainty evidence that, compared to sexual education, mean cognitive distortions pertaining to justification or taking responsibility for actions (MD 3.27, 95% CI −4.77 to −1.77) and apprehension confidence (MD 2.47 95% CI −3.85 to −1.09) may be lower in the CBT group.",rephrase,['One study (18 participants) reported no significant difference between CBT and receiving no treatment on general cognitive distortions about sexual behaviour (very low-certainty evidence).'],16,0.68,4,25
CD009829,7,17,"The same study indicated that mean cognitive distortions pertaining to social-sexual desirability may be lower in the CBT group, and there may be little to no difference between the groups for cognitive distortions pertaining to inappropriate sexual fantasies measured with the Multiphasic Sex Inventory.",delete,[],17,0.72,4,25
CD009829,8,18,It is uncertain whether CBT reduces HSB in male adolescents compared to other treatments.,rephrase,['We cannot tell whether CBT reduces harmful sexual behaviour in male adolescents.'],17,0.76,4,25
CD009829,8,19,All studies had insufficient detail in what they reported to allow for full assessment of risk of bias.,delete,[],18,0.8,4,25
CD009829,8,20,'Risk of bias' judgements were predominantly rated as unclear or high.,rephrase,['Available reports did not provide enough information or were rated at high risk of bias in some sections.'],18,0.84,5,25
CD009829,8,21,"Sample sizes were very small, and the imprecision of results was significant.",rephrase,['The four studies had very small sample sizes.'],19,0.88,5,25
CD009829,8,22,"There is very low-certainty evidence that group-based CBT may improve victim empathy when compared to no treatment, and may improve cognitive distortions when compared to sexual education, but not treatment as usual.",ignore,"['Overall, there is very low-certainty evidence that group-based CBT may improve victim empathy compared to no treatment, and may improve cognitive distortions compared to sexual education, but not treatment as usual.']",20,0.92,5,25
CD009829,8,23,Further research is likely to change the estimate.,rephrase,['The very low-certainty of this evidence means that the results are likely to change when further studies are carried out.'],21,0.96,5,25
CD009829,8,24,"More robust evaluations of both individual and group-based CBT are required, particularly outside North America, and which look at the effects of CBT on diverse participants.",split,"['More, better quality randomised controlled trials of individual and group-based CBT are needed, particularly outside North America.', 'Evaluations need to also include more diverse participants.']",22,1.0,5,25
CD007371,0,0,No new trials were identified in the search for this review update.,delete,[],0,0.058823529411764705,1,17
CD007371,0,1,In total five trials involving 365 participants were included in this review.,rephrase,['This review on the effects of Padma 28 includes five trials with a total of 365 participants (current until September 2015).'],0,0.11764705882352941,1,17
CD007371,0,2,All trials compared Padma 28 with placebo for at least 16 weeks of follow-up.,delete,[],1,0.17647058823529413,1,17
CD007371,0,3,"Pain-free and maximum walking distances both increased significantly in the groups treated with Padma 28, with no significant change in the placebo group.",split,"['The review showed that Padma 28 has some beneficial effects in improving maximum and pain-free walking distance.', 'The groups treated with placebo did not show an improved maximum and pain-free walking distance.']",1,0.23529411764705882,2,17
CD007371,0,4,"In general, the studies presented results comparing the treatment arms before and after treatment but made no comparisons between the Padma 28 and placebo groups.",rephrase,['Unfortunately the studies reported insufficient data to allow the comparison of the change in walking distances in the Padma 28 group with the change in walking distances in the placebo group.'],3,0.29411764705882354,2,17
CD007371,0,5,"Pooled data of maximum walking distance after treatment with Padma 28 and placebo from two studies (193 participants) indicated a higher maximum walking distance (mean difference (MD) 95.97 m, 95% confidence interval (CI) 79.07 m to 112.88 m, P < 0.00001, very low quality evidence) in the Padma 28 group compared with placebo.",rephrase,['Combining the data of maximum walking distance after treatment in two studies showed that there was a longer maximum walking distance in the Padma 28 group compared with the placebo group after 16 weeks of treatment.'],4,0.35294117647058826,2,17
CD007371,0,6,The clinical importance of these observed changes in walking distance is unclear as no quality of life data were reported.,delete,[],5,0.4117647058823529,3,17
CD007371,0,7,"There was no effect on ankle brachial index (ABI): change in ABI values between baseline and six months follow up MD -0.01, 95% CI -0.07 to 0.05, 1 study, 56 participants, P = 0.72, very low quality evidence).",rephrase,['No change in ankle brachial pressure was observed.'],5,0.47058823529411764,3,17
CD007371,0,8,"Mild side effects, especially gastrointestinal discomfort, tiredness and skin eruption, were reported but this outcome was not different between the Padma 28 and placebo groups (odds ratio 1.09, 95% CI 0.42 to 2.83, four studies, 231 participants, P = 0.86, very low quality evidence).",rephrase,"['Mild side effects such as gastrointestinal discomfort, tiredness and skin eruption were also noted but these were not different between the Padma 28 and placebo groups.']",6,0.5294117647058824,3,17
CD007371,1,9,"Some evidence exists from individual trials to suggest that Padma 28 may be effective in increasing walking distances, at least in the short term (four months), in people with IC.",delete,[],7,0.5882352941176471,3,17
CD007371,1,10,Side effects do not appear to be a problem.,delete,[],7,0.6470588235294118,4,17
CD007371,1,11,"However, the longer term effects of treatment are unknown and the clinical significance of the improvements in walking distance are questionable.",delete,[],7,0.7058823529411765,4,17
CD007371,1,12,"Moreover, the quality of the evidence is limited by the small sample size of the available trials, limited reporting of statistical analyses that compared treatment groups, and relatively high withdrawal rates that were linked to the outcome.",rephrase,"['Quality of the evidence\nOverall, the quality of the studies was low, with evidence of publication bias, small number of trials, limited reporting of the analyses that compared treatment groups and bias due to a high percentage of withdrawals in the placebo groups because of lack of improvement or deterioration of the overall condition.']",7,0.7647058823529411,4,17
CD007371,1,13,"That is, patients were withdrawn if they failed to improve walking distance.",delete,[],8,0.8235294117647058,5,17
CD007371,1,14,There was also evidence of publication bias.,delete,[],8,0.8823529411764706,5,17
CD007371,1,15,We therefore feel there is currently insufficient evidence to draw conclusions regards the effectiveness of Padma 28 in the routine management of IC.,ignore,['We therefore feel there is currently insufficient evidence to draw conclusions about the effectiveness of Padma 28 in the routine management of IC.'],8,0.9411764705882353,5,17
CD007371,1,16,Further well-designed research would be required to determine the true effects of this herbal preparation.,ignore,['Further well-designed research would be required to determine the true effects of this herbal preparation.'],9,1.0,5,17
CD011226,0,0,We included eleven studies (523 participants) in this review.,rephrase,['We found 11 studies involving a total of 539 participants.'],0,0.125,1,8
CD011226,0,1,Ten studies had two arms and one had three arms that were all relevant to this review.,delete,[],1,0.25,2,8
CD011226,0,2,Three studies compared a hydrogel dressing with a basic wound contact dressing; three studies compared a hydrogel dressing with a hydrocolloid dressing; three studies compared a hydrogel dressing with another hydrogel dressing; one study compared a hydrogel dressing with a foam dressing; one study compared a hydrogel dressing with a dextranomer paste dressing and one study compared a hydrogel dressing with a topical treatment (collagenase).,delete,[],1,0.375,2,8
CD011226,0,3,Limited data were available for analyses in this review: we conducted no meta-analyses.,delete,[],1,0.5,3,8
CD011226,0,4,Where data were available there was no evidence of a difference between hydrogel and alternative treatments in terms of complete wound healing or adverse events.,rephrase,['From the results of these studies we could not tell whether hydrogel wound dressings heal pressure ulcers more quickly or slowly than other types of dressing or topical treatments.'],1,0.625,4,8
CD011226,0,5,"One small study reported that using hydrogel dressings was, on average, less costly than hydrocolloid dressings, but this estimate was imprecise and its methodology was not clear.",delete,[],2,0.75,4,8
CD011226,0,6,"All included studies were small, had short follow-up times and were at unclear risk of bias.",rephrase,"['Generally, the studies we found were small and the results inconclusive.']",2,0.875,5,8
CD011226,1,7,"It is not clear if hydrogel dressings are more or less effective than other treatments in healing pressure ulcers or if different hydrogels have different effects, Most trials in this field are very small and poorly reported so that risk of bias is unclear.",rephrase,['More research of better quality is needed before it can be determined whether hydrogel dressings are better or worse at healing pressure ulcers than other types of dressings or topical treatments.'],3,1.0,5,8
CD007220,0,0,One study was included.,rephrase,"['Despite the evidence accumulated from biological and epidemiological (observational) studies and non-randomised clinical trials, only one randomised, controlled trial could be included in this review.']",0,0.14285714285714285,1,7
CD007220,0,1,"It involved 44 adults aged 60 to 80 years and compared a glucose drink with a saccharin drink, given on only a single occasion.",rephrase,['This study had 44 participants.'],1,0.2857142857142857,2,7
CD007220,0,2,"Those receiving the glucose drink were significantly faster in completing the switching condition of the modified Stroop test (F 1, 41 = 10.47; P < 0.01) compared to those receiving the saccharin drink.",rephrase,['Participants who were given a single glucose drink showed possible momentary enhancement of cognitive performance compared to those given a saccharin drink.'],2,0.42857142857142855,3,7
CD007220,0,3,"Participants in the glucose group also showed a significantly smaller dual-task cost in a computerised test of divided attention compared to the placebo group (F 1, 38 = 8.49; P < 0.01, ƞ2 = 0.18).",delete,[],3,0.5714285714285714,3,7
CD007220,0,4,"As a glucose drink was administered only once, safety, global function, behaviour disturbance, and activities of daily living were not investigated in the study.",delete,[],3,0.7142857142857143,4,7
CD007220,1,5,"With only one RCT included, there is insufficient evidence to base any recommendations about the use of any form of carbohydrate for enhancing cognitive performance in older adults with normal cognition or mild cognitive impairment.",merge,[],3,0.8571428571428571,5,7
CD007220,1,6,More studies of many different carbohydrates are needed to tease out complex nutritional issues and to further evaluate memory improvement.,none,"['We need more studies on different types of carbohydrates, particularly those from fruit, vegetable and whole grain sources, for older adults with normal cognition and mild cognitive impairment to understand the role of this nutrient type in the prevention or reduction of cognitive decline.']",3,1.0,5,7
CD009516,0,0,We included 10 studies (12 trial reports) from which 5041 women contributed data for the primary outcome.,rephrase,['The review includes 10 studies (with data from 5041 women).'],0,0.09090909090909091,1,11
CD009516,0,1,The overall risk of bias was low.,rephrase,['The studies were at a low risk of bias.'],1,0.18181818181818182,1,11
CD009516,1,2,"When comparing prophylactic intravenous (IV) antibiotic administration in women undergoing cesarean delivery, there was a reduction in composite maternal infectious morbidity (risk ratio (RR) 0.57, 95% confidence interval (CI) 0.45 to 0.72, high quality evidence), which was specifically due to the reduction in endometritis (RR 0.54, 95% CI 0.36 to 0.79, high quality evidence) and wound infection (RR 0.59, 95% CI 0.44 to 0.81, high quality evidence) in those that received antibiotics preoperatively as compared to those who received antibiotics after neonatal cord clamping.",delete,[],2,0.2727272727272727,2,11
CD009516,1,3,"There were no clear differences in neonatal sepsis (RR 0.76, 95% CI 0.51 to 1.13, moderate quality evidence).",delete,[],2,0.36363636363636365,2,11
CD009516,2,4,"There were no clear differences for other maternal outcomes such as urinary tract infection (UTI), cystitis and pyelonephritis (moderate quality evidence), respiratory infection (low quality evidence), or any neonatal outcomes.",rephrase,"['Other maternal infections such as urinary or lung infections were no different between the two groups of women, nor were adverse effects in newborns.']",2,0.45454545454545453,3,11
CD009516,2,5,Maternal side effects were not reported in the included studies.,rephrase,['Maternal side effects were not consistently reported.'],3,0.5454545454545454,3,11
CD009516,3,6,"The quality of the evidence using GRADE was high for composite morbidity, endomyometritis, wound infection and neonatal intensive care unit admission, moderate for UTI/cystitis/pyelonephritis and neonatal sepsis, and low for maternal respiratory infection.",delete,[],4,0.6363636363636364,4,11
CD009516,4,7,"Based on high quality evidence from studies whose overall risk of bias is low, intravenous prophylactic antibiotics for cesarean administered preoperatively significantly decreases the incidence of composite maternal postpartum infectious morbidity as compared with administration after cord clamp.",rephrase,"['High quality evidence shows that preoperative intravenous antibiotic administration decreases postpartum infections and is, therefore, beneficial for the mother.']",4,0.7272727272727273,4,11
CD009516,4,8,There were no clear differences in adverse neonatal outcomes reported.,delete,[],5,0.8181818181818182,5,11
CD009516,4,9,Women undergoing cesarean delivery should receive antibiotic prophylaxis preoperatively to reduce maternal infectious morbidities.,rephrase,['This review of randomized controlled studies looked at the different timing options for administration of prophylactic antibiotics to prevent infectious complications in women undergoing cesarean delivery.'],5,0.9090909090909091,5,11
CD009516,4,10,Further research may be needed to elucidate short- and long-term adverse effects for neonates.,rephrase,['Further research may be needed to determine adverse effects on the babies.'],6,1.0,5,11
CD011317,0,0,"Ten trials involving 10,479 participants were included.",delete,[],0,0.09090909090909091,1,11
CD011317,0,1,"There was inconclusive evidence of an effect on the proportion of participants with index case management (defined as individuals tested, diagnosed and treated for CT or NG, or both) in the group with home-based (45/778, 5.8%) compared with clinic-based (51/788, 6.5%) specimen collection (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.60 to 1.29; 3 trials, I² = 0%, 1566 participants, moderate quality).",delete,[],0,0.18181818181818182,1,11
CD011317,0,2,Harms of home-based specimen collection were not evaluated in any trial.,rephrase,['The potential harms of testing with home-collected specimens were not evaluated in any trial.'],0,0.2727272727272727,2,11
CD011317,0,3,All 10 trials compared the proportions of individuals tested.,split,"['We found 10 relevant trials in total.', 'Three trials (including 1566 people) provided data to assess the proportion of people who completed testing, diagnosis and treatment.', 'All trials gave information about the percentages of people who took self-collected specimens for detection of chlamydia and gonorrhoea infections at home and those who took the test at a clinic.']",1,0.36363636363636365,2,11
CD011317,0,4,The results for the proportion of participants completing testing had high heterogeneity (I² = 100%) and were not pooled.,delete,[],4,0.45454545454545453,3,11
CD011317,0,5,"We could not combine data from individual studies looking at the number of participants tested because the proportions varied widely across the studies, ranging from 30% to 96% in home group and 6% to 97% in clinic group (low-quality evidence).",rephrase,['We could not combine data from individual studies looking at the number of participants tested because the proportions varied widely.'],4,0.5454545454545454,3,11
CD011317,0,6,"The number of participants with positive test was lower in the home-based specimen collection group (240/2074, 11.6%) compared with the clinic-based group (179/967, 18.5%) (RR 0.72, 95% CI 0.61 to 0.86; 9 trials, I² = 0%, 3041 participants, moderate quality).",delete,[],5,0.6363636363636364,4,11
CD011317,1,7,Home-based specimen collection could result in similar levels of index case management for CT or NG infection when compared with clinic-based specimen collection.,rephrase,['Home-based specimen collection could result in similar levels of index case management forChlamydia trachomatisorNeisseria gonorrhoeaeinfection when compared with clinic-based specimen collection.'],5,0.7272727272727273,4,11
CD011317,1,8,"Increases in the proportion of individuals tested as a result of home-based, compared with clinic-based, specimen collection are offset by a lower proportion of positive results.",rephrase,"['There was no evidence of a difference between home-based and clinic-based specimen collection in the proportion of people who completed testing, diagnosis and treatment.']",6,0.8181818181818182,5,11
CD011317,1,9,The harms of home-based specimen collection compared with clinic-based specimen collection have not been evaluated.,ignore,['The safety of home-based specimen collection compared with clinic-based specimen collection have not been evaluated.'],7,0.9090909090909091,5,11
CD011317,1,10,"Future RCTs to assess the effectiveness of home-based specimen collection should be designed to measure biological outcomes of STI case management, such as proportion of participants with negative tests for the relevant STI at follow-up.",delete,[],8,1.0,5,11
CD004215,0,0,Three studies met the criteria.,merge,['Three studies were found that met our criteria.'],0,0.1111111111111111,1,9
CD004215,0,1,"Four other studies were excluded, as they did not compare double versus single wall incubators.",none,[],0,0.2222222222222222,2,9
CD004215,0,2,"Double wall incubators have the advantage of decreasing heat loss, decreasing heat production and decreasing radiant heat loss when compared to single wall incubators.",rephrase,['The double wall incubators had advantages as far as decreasing heat loss and decreasing heat production.'],1,0.3333333333333333,2,9
CD004215,0,3,There is also the advantage of reduced oxygen consumption.,delete,[],2,0.4444444444444444,3,9
CD004215,0,4,A minimal increase in conductive heat loss was noted when compared to single wall incubators.,delete,[],2,0.5555555555555556,3,9
CD004215,0,5,All of these effects are small and do not support the proposition that double wall incubators have a beneficial effect on long-term outcomes including mortality or the duration of hospitalization.,rephrase,"['However, these effects were small and did not provide any evidence of any long-term improvement regarding duration of hospitalization or survival.']",2,0.6666666666666666,4,9
CD004215,1,6,"Although it appears that caring for extremely small infants in double wall incubators may theoretically result in shorter hospitalization and may have metabolic advantages, this review was unable to find any data in the literature to support or refute this hypothesis.",rephrase,"['Although it appears that caring for extremely small infants in double wall incubators may result in certain metabolic advantages, this review was unable to find any data in the literature to support or refute this theory.']",3,0.7777777777777778,4,9
CD004215,1,7,The studies do not provide any evidence that the small decrease in heat loss improves clinical outcome.,delete,[],4,0.8888888888888888,5,9
CD004215,1,8,"Therefore, the available data is insufficient to directly guide clinical practice.",rephrase,['Available data is insufficient to directly guide clinical practice.'],4,1.0,5,9
CD011405,0,0,"We identified one RCT, which investigated the effects of HDC with AHCT versus conventional chemotherapy with whole lung irradiation (WLI) in people with Ewing sarcoma metastasised to the lungs only at diagnosis.",rephrase,"['We identified one study (267 participants, who were included over a 15-year period, from 144 international centres) that compared high dose chemotherapy plus autologous haematopoietic cell transplantation with conventional chemotherapy and whole lung irradiation in children, adolescents, and young adults with Ewing sarcoma with pulmonary metastases at diagnosis.']",0,0.09090909090909091,1,11
CD011405,0,1,Only a selection of the participants were eligible for our review (N = 267: HDC with AHCT group N = 134; control group N = 133).,delete,[],1,0.18181818181818182,1,11
CD011405,1,2,"There may be no difference in event-free survival between the two treatment groups (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.59 to 1.17; low-certainty evidence).",rephrase,"['In young people with pulmonary metastatic Ewing sarcoma at diagnosis, low-certainty evidence from one study found no clear difference between treatment groups in event-free survival.']",1,0.2727272727272727,2,11
CD011405,1,3,We downgraded one level each because of study limitations and imprecision.,delete,[],2,0.36363636363636365,2,11
CD011405,1,4,"Overall survival and toxicity were not reported separately for the participants eligible for this review, while quality-adjusted survival and progression-free survival were not reported at all.",rephrase,"['There were no data available for overall survival, quality-adjusted survival, adverse effects, or progression-free survival.']",2,0.45454545454545453,3,11
CD011405,1,5,"We did not identify any studies that addressed children, adolescents, and young adults with Ewing sarcoma with metastases to other locations.",rephrase,"['We did not find any studies that addressed children, adolescents, and young adults with Ewing sarcoma that had metastasised to locations besides the lungs at diagnosis.']",3,0.5454545454545454,3,11
CD011405,2,6,"In people with Ewing sarcoma with primary metastases to locations other than the lungs, there is currently no evidence from RCTs or CCTs to determine the efficacy of HDC with AHCT compared to conventional chemotherapy.",delete,[],4,0.6363636363636364,4,11
CD011405,3,7,"Based on low-certainty evidence from one study (267 participants), there may be no difference in event-free survival between children, adolescents, and young adults with primary pulmonary metastatic Ewing sarcoma who receive HDC with AHCT and those who receive conventional chemotherapy with WLI.",rephrase,['The certainty of the evidence was low.'],4,0.7272727272727273,4,11
CD011405,4,8,Further high-quality research is needed.,rephrase,['We need high-quality research before definite conclusions can be made.'],5,0.8181818181818182,5,11
CD011405,4,9,"Results are anticipated for the EuroEwing 2008R3 study, in which the effects of HDC with treosulfan and melphalan followed by AHCT on survival, in people with Ewing sarcoma with metastatic disease to bone, other sites, or both were explored.",delete,[],6,0.9090909090909091,5,11
CD011405,4,10,"Achieving high-quality studies in a selection of people with rare sarcoma requires long-term, multi-centre, international participant inclusion.",delete,[],6,1.0,5,11
CD008674,0,0,We included only one RCT that involved 64 women.,rephrase,"['Only one eligible randomised controlled trial (RCT) was found, which involved 64 women.']",0,0.125,1,8
CD008674,0,1,We judged this study as being at high risk of bias.,delete,[],1,0.25,2,8
CD008674,0,2,"Post-operative morbidity and mortality were not addressed, and secondary outcomes of patient cosmetic evaluations and psychosocial well-being post-reconstruction were inadequately reported.",rephrase,"['This review sought to compare the effects of the timing of reconstruction on morbidity and mortality, patient satisfaction and psychosocial well-being.']",1,0.375,2,8
CD008674,0,3,"Based on limited data there was some, albeit unreliable, evidence that immediate reconstruction compared with delayed or no reconstruction, reduced psychiatric morbidity reported three months post-operatively.",delete,[],2,0.5,3,8
CD008674,1,4,"The current level of evidence for the effectiveness of immediate versus delayed reconstruction following surgery for breast cancer was based on a single RCT with methodological flaws and a high risk of bias, which does not allow confident decision-making about choice between these surgical options.",rephrase,['Methodological flaws and a high risk of bias also diminished the quality of evidence found in the RCT.'],2,0.625,4,8
CD008674,1,5,"Until high quality evidence is available, clinicians may wish to consider the recommendations of relevant guidelines and protocols.",delete,[],3,0.75,4,8
CD008674,1,6,"Although the limitations and ethical constraints of conducting RCTs in this field are recognised, adequately powered controlled trials with a focus on clinical and psychological outcomes are still required.",delete,[],3,0.875,5,8
CD008674,1,7,"Given the paucity of RCTs in this subject, in future versions of this review we will look at study designs other than RCTs specifically good quality cohort and case-control studies.",rephrase,"['Since we have only identified one RCT in this area, an updated version of this review will evaluate other study designs specifically good quality cohort and case-control studies.']",3,1.0,5,8
CD001516,0,0,"Three double-blind, parallel group, randomised, controlled trials have been conducted on 263 patients.",rephrase,"[""Three trials have compared ropinirole with an inactive placebo in 263 patients in the later stages of Parkinson's disease.""]",0,0.06666666666666667,1,15
CD001516,0,1,"The two phase II studies were relatively small, were conducted over the short term (12 weeks), and used relatively low doses of ropinirole (mean administered doses 3.3 and 3.5 mg/d) in a twice daily regime.",rephrase,"['Two studies were relatively small, were conducted over the short term (12 weeks), and used relatively low doses of ropinirole (maximum allowed 8 and 10 mg/d) in a twice daily administration regime.']",1,0.13333333333333333,1,15
CD001516,0,2,"In view of this clinical heterogeneity and some statistical heterogeneity, the results of these trials have not been included in a meta-analysis.",rephrase,"['For these reasons, the results of these trials have not been included in a statistical overview.']",2,0.2,1,15
CD001516,0,3,The conclusions of this review are based on the evidence from a single phase III study which was medium term (26 weeks) and used ropinirole doses in line with the current UK licensed maximum in a thrice daily regime.,split,"['The other study was medium term (26 weeks) and used ropinirole doses in line with the current UK licensed maximum (24 mg/d) in a three times a day regime.', 'The conclusions of this review are based on this single trial and thus should be viewed with some caution.']",3,0.26666666666666666,2,15
CD001516,1,4,"In view of difficulties in assessing changes in off time in Leiberman 98, caused by the initial imbalance between the arms of the trial, it is unsafe to draw any firm conclusion about the effect of ropinirole on off time.",delete,[],5,0.3333333333333333,2,15
CD001516,1,5,"However, as an adverse event, dyskinesia was significantly increased in those who received ropinirole (Leiberman 98; odds ratio 2.90; 1.36, 6.19 95% CI; Table 8).",rephrase,"['However, dyskinesia was increased in those who received ropinirole (2.9 times more common with ropinirole than placebo).']",5,0.4,2,15
CD001516,1,6,Measurements of motor impairments and disability were poor in this study with incomplete information available.,rephrase,['were poor in these studies with incomplete information available.'],6,0.4666666666666667,3,15
CD001516,1,7,"Levodopa dose could be reduced in Leiberman 98 with a significantly larger reduction on ropinirole than on placebo (weighted mean difference 180 mg/d; 106, 253 95% CI; Table 2).",rephrase,['Levodopa dose reduction was greater with ropinirole than placebo by 180 mg/d.'],7,0.5333333333333333,3,15
CD001516,1,8,No significant differences in the frequency of adverse event reports were noted between ropinirole and placebo apart from the increase in dyskinesia with ropinirole.,rephrase,['No clear difference in the time patients spent in the immobile off state was found between ropinirole and placebo.'],8,0.6,3,15
CD001516,1,9,There was a trend towards fewer withdrawals from ropinirole in Leiberman 98 but this did not reach statistical significance.,delete,[],9,0.6666666666666666,4,15
CD001516,2,10,Ropinirole therapy can reduce levodopa dose but at the expense of increased dyskinetic adverse events.,rephrase,['Ropinirole reduces levodopa dose but at the expense of increased dyskinetic side effects.'],9,0.7333333333333333,4,15
CD001516,2,11,No clear effect on off time reduction was found but this may have been due to the under-powering of the single evaluable trial.,rephrase,['No clear effect on off time reduction was found in this single trial.'],10,0.8,4,15
CD001516,2,12,Inadequate data on motor impairments and disability was collected to assess these outcomes.,delete,[],11,0.8666666666666667,5,15
CD001516,2,13,"These conclusions apply to short and medium term treatment, up to 26 weeks.",ignore,"['These conclusions apply to short and medium term treatment, up to 26 weeks.']",11,0.9333333333333333,5,15
CD001516,2,14,"Further longer term trials are required, with measurements of effectiveness, and also studies to compare the newer with the older dopamine agonists.",rephrase,"['Further longer term trials are required, with measurements of quality of life and costs, and also studies to compare the newer with the older dopamine agonists.']",12,1.0,5,15
CD004714,0,0,"We included 35 studies, which randomised 3249 participants to periodontal treatment or control.",rephrase,['The trials randomised 3249\xa0participants in total.'],0,0.07142857142857142,1,14
CD004714,0,1,All studies used a parallel-RCT design and followed up participants for between 3 and 12 months.,rephrase,['The studies followed up participants for between 3 and 12 months.'],1,0.14285714285714285,1,14
CD004714,0,2,"The studies focused on people with type 2 diabetes, other than one study that included participants with type 1 or type 2 diabetes.",merge,"['Almost all participants had type 2 diabetes, with a mix of good, fair, and poor diabetic control.']",2,0.21428571428571427,2,14
CD004714,0,3,"Most studies were mixed in terms of whether metabolic control of participants at baseline was good, fair, or poor.",none,[],2,0.2857142857142857,2,14
CD004714,0,4,Most studies were carried out in secondary care.,rephrase,['Most of the studies were carried out in hospitals.'],3,0.35714285714285715,2,14
CD004714,1,5,"We assessed two studies as being at low risk of bias, 14 studies at high risk of bias, and the risk of bias in 19 studies was unclear.",delete,[],4,0.42857142857142855,3,14
CD004714,1,6,We undertook a sensitivity analysis for our primary outcome based on studies at low risk of bias and this supported the main findings.,delete,[],4,0.5,3,14
CD004714,2,7,Moderate-certainty evidence from 30 studies (2443 analysed participants) showed an absolute reduction in HbA1c of 0.43% (4.7 mmol/mol) 3 to 4 months after treatment of periodontitis (95% confidence interval (CI) -0.59% to -0.28%; -6.4 mmol/mol to -3.0 mmol/mol).,rephrase,['Evidence from 30 trials (results from 2443 participants) showed that periodontitis treatment reduces blood sugar levels (measured by HbA1c) in diabetic patients on average by 0.43 percentage points (e.g. from 7.43% to 7%; 4.7 mmol/mol) 3 to 4 months after receiving the treatment compared with no active treatment or usual care.'],4,0.5714285714285714,3,14
CD004714,2,8,"Similarly, after 6 months, we found an absolute reduction in HbA1c of 0.30% (3.3 mmol/mol) (95% CI -0.52% to -0.08%; -5.7 mmol/mol to -0.9 mmol/mol; 12 studies, 1457 participants), and after 12 months, an absolute reduction of 0.50% (5.4 mmol/mol) (95% CI -0.55% to -0.45%; -6.0 mmol/mol to -4.9 mmol/mol; 1 study, 264 participants).",rephrase,"['A difference of 0.30% (3.3 mmol/mol) was seen after 6 months (12 studies), and 0.50% (5.4 mmol/mol) at 12 months (one study).']",5,0.6428571428571429,4,14
CD004714,3,9,"Studies that measured adverse effects generally reported that no or only mild harms occurred, and any serious adverse events were similar in intervention and control arms.",delete,[],6,0.7142857142857143,4,14
CD004714,3,10,"However, adverse effects of periodontal treatments were not evaluated in most studies.",rephrase,['There were not enough studies measuring side effects to be able to evaluate the risk of harm from gum disease treatments.'],6,0.7857142857142857,4,14
CD004714,4,11,"Our 2022 update of this review has doubled the number of included studies and participants, which has led to a change in our conclusions about the primary outcome of glycaemic control and in our level of certainty in this conclusion.",delete,[],7,0.8571428571428571,5,14
CD004714,4,12,We now have moderate-certainty evidence that periodontal treatment using subgingival instrumentation improves glycaemic control in people with both periodontitis and diabetes by a clinically significant amount when compared to no treatment or usual care.,rephrase,"['In summary, currently there is moderate-certainty evidence to support gum disease treatment (known as subgingival instrumentation) for controlling blood sugar levels in people with periodontitis (gum disease) and diabetes up to 12 months after the start of the periodontal treatment.']",7,0.9285714285714286,5,14
CD004714,4,13,Further trials evaluating periodontal treatment versus no treatment/usual care are unlikely to change the overall conclusion reached in this review.,delete,[],8,1.0,5,14
CD009535,0,0,"We identified a single cross-over RCT (enrolling 9 participants) that compared home haemodialysis (long hours: 6 to 8 hours, 3 times/week) with in-centre haemodialysis (short hours: 3.5 to 4.5 hours, 3 times/weeks) for 8 weeks in prevalent home haemodialysis patients.",delete,[],0,0.16666666666666666,1,6
CD009535,0,1,Outcome data were limited and not available for the end of the first phase of treatment in this cross-over study which was at risk of bias due to differences in dialysate composition between the two treatment comparisons.,delete,[],0,0.3333333333333333,2,6
CD009535,1,2,"Overall, home haemodialysis reduced 24 hour ambulatory blood pressure and improved uraemic symptoms, but increased treatment-related burden of disease and interference in social activities.",rephrase,"['Home haemodialysis may improve blood pressure and physical symptoms, but may increase the burden of care for families and patients.']",0,0.5,3,6
CD009535,1,3,"Insufficient data were available for mortality, hospitalisation or dialysis vascular access complications or treatment durability.",delete,[],1,0.6666666666666666,4,6
CD009535,2,4,"Insufficient randomised data were available to determine the effects of home haemodialysis on survival, hospitalisation, and quality of life compared with in-centre haemodialysis.",split,"['We found that only one study that involved nine patients had compared home haemodialysis with in-centre haemodialysis.', 'There was insufficient information to understand the effects of home haemodialysis on survival or need for hospital admission in this study.']",1,0.8333333333333334,5,6
CD009535,2,5,"Given the consistently observed benefits of home haemodialysis on quality of life and survival in uncontrolled studies, and the low prevalence of home haemodialysis globally, randomised studies evaluating home haemodialysis would help inform clinical practice and policy.",rephrase,"['Given the potential benefits of home haemodialysis in non-randomised studies, larger randomised trials of home haemodialysis could help inform clinical care and policy.']",3,1.0,5,6
CD009376,0,0,"We included four trials involving 307 participants aged 31 to 85 years, who had been previously treated for moderate to severe chronic periodontitis.",split,"['We found four relevant studies known as randomised controlled trials (RCTs), with 307 participants aged 31 to 85 years.', 'All participants had previously been treated for moderate to severe chronic periodontitis and enrolled in a SPT programme for at least three months.']",0,0.05263157894736842,1,19
CD009376,0,1,Three studies compared adjuncts to mechanical debridement in SPT versus debridement only.,rephrase,"['The studies compared: additional use of an antibiotic (doxycycline in one study, minocycline in another) to professional cleaning (debridement); additional use of photodynamic therapy to debridement only, and SPT provided by a specialist versus a general dentist.']",2,0.10526315789473684,1,19
CD009376,0,2,The adjuncts were local antibiotics in two studies (one at high risk of bias and one at low risk) and photodynamic therapy in one study (at unclear risk of bias).,delete,[],3,0.15789473684210525,1,19
CD009376,0,3,One study at high risk of bias compared provision of SPT by a specialist versus general practitioner.,delete,[],3,0.21052631578947367,2,19
CD009376,0,4,"We did not identify any RCTs evaluating the effects of SPT versus monitoring only, or of providing SPT at different time intervals, or that compared the effects of mechanical debridement using different approaches or technologies.",rephrase,"['We did not identify any RCTs comparing the effects of providing SPT versus monitoring only, the effects of SPT provided at different time intervals or the effects of mechanical debridement using different approaches or technologies.']",3,0.2631578947368421,2,19
CD009376,1,5,"No included trials measured our primary outcome 'tooth loss'; however, studies evaluated signs of inflammation and potential periodontal disease progression, including bleeding on probing (BoP), clinical attachment level (CAL) and probing pocket depth (PPD).",split,"['None of the studies reported tooth loss.', 'However, studies evaluated signs of inflammation and potential periodontal disease progression, including bleeding on probing, clinical attachment level and probing pocket depth.']",4,0.3157894736842105,2,19
CD009376,2,6,There was no evidence of a difference between SPT delivered by a specialist versus a general practitioner for BoP or PPD at 12 months (very low-quality evidence).,delete,[],6,0.3684210526315789,2,19
CD009376,2,7,This study did not measure CAL or adverse events.,delete,[],6,0.42105263157894735,3,19
CD009376,3,8,"Due to heterogeneous outcome reporting, it was not possible to combine data from the two studies comparing mechanical debridement with or without the use of adjunctive local antibiotics.",delete,[],6,0.47368421052631576,3,19
CD009376,3,9,Both studies found no evidence of a difference between groups at 12 months (low to very low-quality evidence).,delete,[],6,0.5263157894736842,3,19
CD009376,3,10,There were no adverse events in either study.,delete,[],6,0.5789473684210527,3,19
CD009376,4,11,The use of adjunctive photodynamic therapy did not demonstrate evidence of benefit compared to mechanical debridement only (very low-quality evidence).,rephrase,['Low- to very low-quality evidence suggests that adjunctive treatments may not provide any additional benefit for SPT compared with mechanical debridement alone.'],6,0.631578947368421,4,19
CD009376,4,12,Adverse events were not measured.,delete,[],7,0.6842105263157895,4,19
CD009376,5,13,The quality of the evidence is low to very low for these comparisons.,rephrase,"[""We judged the evidence to be of low or very low quality, therefore we cannot be confident in any conclusions drawn from the studies' results.""]",7,0.7368421052631579,4,19
CD009376,5,14,"Future research is likely to change the findings, therefore the results should be interpreted with caution.",delete,[],8,0.7894736842105263,4,19
CD009376,6,15,"Overall, there is insufficient evidence to determine the superiority of different protocols or adjunctive strategies to improve tooth maintenance during SPT.",rephrase,"['Overall, there is not enough evidence available to recommend a certain approach or additional treatment in SPT to maintain teeth, promote gum health and prevent relapse.']",8,0.8421052631578947,5,19
CD009376,6,16,No trials evaluated SPT versus monitoring only.,rephrase,"['We found insufficient evidence about the best approaches to SPT, and no RCTs evaluated SPT versus monitoring only.']",9,0.8947368421052632,5,19
CD009376,6,17,"The evidence available for the comparisons evaluated is of low to very low quality, and hampered by dissimilarities in outcome reporting.",rephrase,"['The evidence we found was low to very low quality, and studies used different methods to report their results, making comparison difficult.']",10,0.9473684210526315,5,19
CD009376,6,18,More trials using uniform definitions and outcomes are required to address the objectives of this review.,rephrase,['More studies are needed that report their findings in a uniform manner.'],11,1.0,5,19
CD008878,0,0,We included four trials involving 388 women that were judged to be at an unclear to high risk of bias overall.,rephrase,"['This review found that there is not enough evidence from the four included randomised controlled trials, involving 388 women and their babies, to determine the most effective and safe analgesic agent or technique for women who are undergoing a forceps delivery.']",0,0.09090909090909091,1,11
CD008878,0,1,"A variety of different agents for providing analgesia were assessed in the trials, and a number of different methods to measure pain relief were used, and thus results could not be combined in meta-analysis.",rephrase,['A number of different methods were used to measure pain relief and the results could not be combined.'],1,0.18181818181818182,1,11
CD008878,0,2,"Three trials compared diazepam with an alternative agent (ketamine; vinydan-ether; ""other"" anaesthesic agent) for the provision of general anaesthesia, and one trial compared spinal analgesia to pudendal nerve block (in both groups lignocaine was administered).",rephrase,"['Three of the four trials compared diazepam with alternative agents (ketamine, vinydan-ether, or ""other"" anaesthesic agent) to provide general anaesthesia during forceps delivery.']",2,0.2727272727272727,2,11
CD008878,1,3,"With regard to the primary outcomes, women receiving diazepam for forceps delivery in one small trial were more likely to judge their pain relief as effective compared with women receiving vinydan-ether (risk ratio (RR) 1.13; 95% confidence interval (CI) 1.02 to 1.25; 101 women).",rephrase,['Women who received diazepam were more likely to judge their pain relief as effective compared with women who received vinydan-ether in one small trial.'],3,0.36363636363636365,2,11
CD008878,1,4,"In a further small trial, no significant difference was seen in the number of women judging their pain relief as effective when diazepam was compared with ketamine (RR 1.42; 95% CI 0.98 to 2.07; 26 women).",rephrase,"['In another small trial, however, no difference in pain relief was shown when diazepam was compared with ketamine.']",4,0.45454545454545453,3,11
CD008878,1,5,"In the trial that compared spinal analgesia to pudendal nerve block, women receiving spinal analgesia were significantly more likely to regard their analgesia as adequate (RR 3.36; 95% CI 2.46 to 4.60; 183 women) and were less likely to report severe pain during forceps delivery (RR 0.02; 95% CI 0.00 to 0.27; 183 women).",rephrase,"['In the trial that compared spinal analgesia with pudendal nerve block, women receiving spinal analgesia were more likely to report their pain relief as adequate and were less likely to report severe pain.']",5,0.5454545454545454,3,11
CD008878,1,6,"No trials reported on the review's other two primary outcomes of serious maternal adverse effects or complications, and neonatal mortality or serious morbidity.",rephrase,['None of the four trials reported on serious complications or death for the mother or baby.'],6,0.6363636363636364,4,11
CD008878,2,7,"In terms of secondary outcomes, women receiving diazepam compared with vinydan-ether, were significantly less likely to experience vomiting (RR 0.04; 95% CI 0.00 to 0.62; 101 women).",delete,[],7,0.7272727272727273,4,11
CD008878,2,8,No significant differences were seen for the few neonatal outcomes that were reported across any of the comparisons (including Agpar score of less than seven at five minutes and acidosis as defined by cord blood arterial pH less than 7.2).,delete,[],7,0.8181818181818182,5,11
CD008878,3,9,There is insufficient evidence to support any particular analgesic agent or method as most effective in providing pain relief for forceps delivery.,delete,[],7,0.9090909090909091,5,11
CD008878,3,10,Neonatal outcomes have largely not been evaluated.,delete,[],7,1.0,5,11
CD010766,0,0,We excluded nine studies because they were non-randomised trials or were withdrawn before enrolment.,delete,[],0,0.1,1,10
CD010766,0,1,"We included one study, which was conducted in two phases.",rephrase,['The trial that we found was conducted in two phases.'],0,0.2,1,10
CD010766,0,2,"During the first phase of the study, 77 children with ASD were randomly assigned to receive seven days of glutathione lotion or placebo lotion, followed by three days of oral dimercaptosuccinic acid (DMSA).",rephrase,"['During the first phase, 77 children with ASD were assigned randomly to receive seven days of glutathione lotion or placebo lotion, followed by three days of oral DMSA.']",1,0.3,2,10
CD010766,0,3,"Forty-nine children who were found to be high excreters of heavy metals during phase one continued on to phase two to receive three days of oral DMSA or placebo followed by 11 days off, with the cycle repeated up to six times.",ignore,"['Forty-nine children who excreted high levels of heavy metals during phase one continued on to phase two to receive three days of oral DMSA or placebo followed by 11 days off, with the cycle repeated up to six times.']",2,0.4,2,10
CD010766,0,4,The second phase thus assessed the effectiveness of multiple doses of oral DMSA compared with placebo in children who were high excreters of heavy metals and who received a three-day course of oral DMSA.,delete,[],3,0.5,3,10
CD010766,0,5,"Overall, no evidence suggests that multiple rounds of oral DMSA had an effect on ASD symptoms.",rephrase,['Results from the included study show that multiple rounds of oral DMSA did not have an effect on any of the ASD symptoms measured in children found to be high excreters who had already received three doses of a pharmaceutical chelating agent.'],3,0.6,3,10
CD010766,1,6,"This review included data from only one study, which had methodological limitations.",rephrase,"['The quality of the evidence is poor, with only one study, which had methodological shortcomings, included in this review.']",4,0.7,4,10
CD010766,1,7,"As such, no clinical trial evidence was found to suggest that pharmaceutical chelation is an effective intervention for ASD.",rephrase,['Currently no clinical trial evidence suggests that pharmaceutical chelation is an effective intervention for ASD.'],5,0.8,4,10
CD010766,1,8,"Given prior reports of serious adverse events, such as hypocalcaemia, renal impairment and reported death, the risks of using chelation for ASD currently outweigh proven benefits.",rephrase,"['Given prior reports of serious adverse events, such as changes to calcium levels in blood, kidney impairment and reported death, risks of using pharmaceutical chelating agents for ASD currently outweigh proven benefits.']",6,0.9,5,10
CD010766,1,9,"Before further trials are conducted, evidence that supports a causal link between heavy metals and autism and methods that ensure the safety of participants are needed.",rephrase,"['However, before further trials are conducted, more evidence is needed to show that heavy metals cause or worsen the severity of autism, and the safety of pharmaceutical chelating agents for participants must be established.']",7,1.0,5,10
CD010618,0,0,"We included 22 studies (21 RCTs, 1 quasi-RCT) of 2404 participants.",rephrase,['Results\nWe found 22 studies of 2404 participants who were caring for children with a wide range of conditions.'],0,0.0625,1,16
CD010618,0,1,Sixteen studies compared peer support to usual care; three studies compared peer support to an alternative intervention and to usual care but only data from the usual care arm contributed to results; and three studies compared peer support to an alternative intervention only.,rephrase,['All studies were RCTs or quasi-RCTs and compared peer support to usual care (comparison 1) or to another intervention (comparison 2).'],1,0.125,1,16
CD010618,1,2,"We judged risk of bias as moderate to high across all studies, particularly for selection, performance, and detection bias.",delete,[],2,0.1875,1,16
CD010618,2,3,"Included studies contributed data to seven effect estimates compared to usual care: psychological distress (standardised mean difference (SMD) -0.10, 95% confidence interval (CI) -0.32 to 0.11; 8 studies, 864 participants), confidence and self-efficacy (SMD 0.04, 95% CI -0.14 to 0.21; 8 studies, 542 participants), perception of coping (SMD -0.08, 95% CI -0.38 to 0.21; 3 studies, 293 participants), quality of life and life satisfaction (SMD 0.03, 95% CI -0.32 to 0.38; 2 studies, 143 participants), family functioning (SMD 0.15, 95% CI -0.09 to 0.38; 4 studies, 272 participants), perceived social support (SMD 0.31, 95% CI -0.15 to 0.77; 4 studies, 191 participants), and confidence and skill in navigating medical services (SMD 0.05, 95% CI -0.17 to 0.28; 4 studies, 304 participants).",delete,[],2,0.25,2,16
CD010618,2,4,"In comparisons to alternative interventions, one pooled effect estimate was possible: psychological distress (SMD 0.2, 95% CI -0.38 to 0.79; 2 studies, 95 participants).",delete,[],2,0.3125,2,16
CD010618,2,5,No studies reported on adverse outcomes.,delete,[],2,0.375,2,16
CD010618,3,6,"All narratively synthesised data for psychological distress (compared to usual care - 2 studies), family functioning (compared to usual care - 1 study; compared to an alternative intervention - 1 study), perceived social support (compared to usual care - 2 studies), and self-efficacy (compared to alternative interventions - 1 study) were equivocal.",delete,[],2,0.4375,3,16
CD010618,3,7,"Comparisons with usual care showed no difference between intervention and control groups (perceived social support), some effect over time for both groups but more effect for intervention (distress), or mixed effects for intervention (family function).",delete,[],2,0.5,3,16
CD010618,3,8,Comparisons with alternative interventions showed no difference between the intervention of interest and the alternative.,delete,[],2,0.5625,3,16
CD010618,3,9,"This may indicate similar effects to the intervention of interest or lack of effect of both, and we are  uncertain which option is likely.",delete,[],2,0.625,4,16
CD010618,4,10,"We found no clear evidence of effects of peer support interventions on any parent outcome, for any comparator; however, the certainty of evidence for each outcome was low to very low, and true effects may differ substantially from those reported here.",rephrase,"['Although we found studies that evaluated effects of peer support on all outcomes in comparison 1, and several outcomes in comparison 2, we did not see any benefit from peer support compared to usual care or compared to another intervention.']",2,0.6875,4,16
CD010618,5,11,"We found no evidence of adverse events such as mood contagion,  negative group interactions, or worsened psychological health.",rephrase,"[""We found no studies that reported on adverse effects (such as stress from hearing others' stories or conflicts with group members).""]",3,0.75,4,16
CD010618,6,12,Qualitative data suggest that parents and carers value peer support interventions and appreciate emotional support.,rephrase,"['Feedback from parents and carers suggests that they value emotional support, validation of their experiences, and access to knowledge that they find in peer support groups.']",4,0.8125,5,16
CD010618,7,13,"Parents and carers of children with complex needs perceive peer support interventions as valuable, but this review found no evidence of either benefit or harm.",rephrase,['This means that further research is likely to change these findings while making clearer the possible benefits or harms of peer support interventions.'],5,0.875,5,16
CD010618,7,14,"Currently, there is uncertainty about the effects of peer support interventions for parents and carers of children with complex needs.",rephrase,"['Conclusion\nAt the moment, we are uncertain about whether peer support helps or harms parents and carers of children with complex needs.']",6,0.9375,5,16
CD010618,7,15,"However, given the overall low to very low certainty of available evidence, our estimates showing no effects of interventions may very well change with further research of higher quality.",rephrase,"['The overall quality of evidence for each outcome was low to very low, and because of this, our certainty about these findings is low.']",7,1.0,5,16
CD010181,0,0,We identified 13 eligible cohort studies including 2837 participants with a hearing test after treatment with a platinum analogue for different types of childhood cancers.,rephrase,['We found 13 studies including 2837 participants with a hearing test after platinum-based therapy for different types of childhood cancers.'],0,0.04,1,25
CD010181,0,1,"All studies had methodological limitations, with regard to both internal (risk of bias) and external validity.",delete,[],1,0.08,1,25
CD010181,0,2,"Participants were treated with cisplatin, carboplatin or both, in varying doses.",ignore,"['Participants were treated with cisplatin, carboplatin or both, in varying doses.']",1,0.12,1,25
CD010181,0,3,The reported prevalence of hearing loss varied considerably between 0% and 90.1%; none of the studies provided data on tinnitus.,rephrase,"['The reported frequency of hearing loss varied between 0% and 90.1%; none of the studies provided data on tinnitus (that is, ringing in the ears).']",2,0.16,1,25
CD010181,0,4,"Three studies reported a prevalence of 0%, but none of these studies provided a definition for hearing loss and there might be substantial or even complete overlap in included participants between these three studies.",ignore,"['Three studies reported a frequency of 0%, but none of these studies provided a definition for hearing loss and there might be substantial or even complete overlap in included participants between these three studies.']",3,0.2,1,25
CD010181,0,5,"When only studies that did provide a definition for hearing loss were included, the prevalence of hearing loss still varied widely between 1.7% and 90.1%.",ignore,"['When only studies that did provide a definition for hearing loss were included, the frequency of hearing loss still varied between 1.7% and 90.1%.']",4,0.24,2,25
CD010181,0,6,"All studies were very heterogeneous with regard to, for example, definitions of hearing loss, used diagnostic tests, participant characteristics, (prior) anti-tumour treatment, other ototoxic drugs and length of follow-up.",rephrase,"['All studies were very different with regard to definitions of hearing loss, used diagnostic tests, participant characteristics, (prior) anti-cancer treatment, other ototoxic drugs and length of follow-up.']",5,0.28,2,25
CD010181,0,7,"Therefore, pooling of results was not possible.",delete,[],6,0.32,2,25
CD010181,1,8,Only two studies included a control group of people who had not received platinum treatment.,rephrase,['Only two studies included people who had not received platinum treatment (called control group).'],6,0.36,2,25
CD010181,1,9,"In one study, the prevalence of hearing loss was 67.1% (95% confidence interval (CI) 59.3% to 74.1%) in platinum-treated participants, while in the control participants it was 7.4% (95% CI 6.2% to 8.8%).",rephrase,"['In one study, the frequency of hearing loss was 67.1% in people treated with platinum, while in the control group it was 7.4%.']",7,0.4,2,25
CD010181,1,10,"However, hearing loss was detected by screening in survivors treated with platinum analogues and by clinical presentation in control participants.",delete,[],8,0.44,3,25
CD010181,1,11,It is uncertain what the effect of this difference in follow-up/diagnostic testing was.,delete,[],8,0.48,3,25
CD010181,1,12,"In the other study, the prevalence of hearing loss was 20.1% (95% CI 17.4% to 23.2%) in platinum-treated participants and 0.4% (95% CI 0.12% to 1.6%) in control participants.",rephrase,"['In the other study, the frequency of hearing loss was 20.1% in people treated with platinum and 0.44% in the control group.']",8,0.52,3,25
CD010181,1,13,"As neither study was a randomized controlled trial or controlled clinical trial, the calculation of a risk ratio was not feasible as it is very likely that both groups differed more than only the platinum treatment.",delete,[],9,0.56,3,25
CD010181,2,14,Only two studies evaluated possible risk factors using multivariable analysis.,rephrase,['Only two studies evaluated possible risk factors.'],9,0.6,3,25
CD010181,2,15,"One study identified a significantly higher risk of hearing loss in people treated with cisplatin 400 mg/m2 plus carboplatin 1700 mg/m2 as compared to treatment with cisplatin 400 mg/m2 or less, irrespective of the definition of hearing loss.",ignore,"['One study found a higher risk of hearing loss in people treated with cisplatin 400 mg/m2 plus carboplatin 1700 mg/m2 compared to treatment with cisplatin 400 mg/m2 or less, irrespective of the definition of hearing loss.']",10,0.64,4,25
CD010181,2,16,"They also identified a significantly higher risk of hearing loss in people treated with non-anthracycline aminoglycosides antibiotics (using a surrogate marker) as compared to people not treated with them, for three out of four definitions of hearing loss.",rephrase,"['They also found a higher risk of hearing loss in people treated with non-anthracycline aminoglycosides antibiotics (that is, a certain type of antibiotics) as compared to people not treated with these antibiotics, for three out of four definitions of hearing loss.']",11,0.68,4,25
CD010181,2,17,"The other study reported that age at treatment (odds ratio less than 1 for each single-unit increase) and single maximum cisplatin dose (odds ratio greater than 1 for each single-unit increase) were significant predictors for hearing loss, while gender was not.",rephrase,"['The other study reported that age at treatment (lower risk in older children) and single maximum cisplatin dose (higher risk with an increasing dose) were significant predictors for hearing loss, while gender was not.']",12,0.72,4,25
CD010181,3,18,"This systematic review shows that children treated with platinum analogues are at risk for developing hearing loss, but the exact prevalence and risk factors remain unclear.",delete,[],13,0.76,4,25
CD010181,3,19,There were no data available for tinnitus.,delete,[],13,0.8,4,25
CD010181,3,20,Based on the currently available evidence we can only advise that children treated with platinum analogues are screened for ototoxicity in order to make it possible to diagnose hearing loss early and to take appropriate measures.,ignore,"['Based on the currently available evidence, we can only advise that children treated with platinum analogues are screened for ototoxicity in order to make it possible to diagnose hearing loss early and to take appropriate measures.']",13,0.84,5,25
CD010181,3,21,"However, we are unable to give recommendations for specific follow-up protocols including frequency of testing.",rephrase,"['However, we are unable to give recommendations for specific follow-up methods including how often hearing is tested.']",14,0.88,5,25
CD010181,3,22,"Counselling regarding the prevention of noise pollution can be considered, such as the use of noise-limiting equipment, avoiding careers with excess noise and ototoxic medication.",ignore,"['Counselling regarding the prevention of noise pollution can be considered, like the use of noise-limiting equipment, avoiding careers with excess noise and ototoxic medicines.']",15,0.92,5,25
CD010181,3,23,"Before definitive conclusions on the prevalence and associated risk factors of platinum-induced ototoxicity can be made, more high-quality research is needed.",rephrase,"['Before definitive conclusions on how often hearing loss happens (called prevalence) and associated risk factors of platinum-induced ototoxicity can be made, more high-quality research is needed.']",16,0.96,5,25
CD010181,3,24,Accurate and transparent reporting of findings will make it possible for readers to appraise the results of these studies critically.,delete,[],17,1.0,5,25
CD010183,0,0,"We located 23 studies: two RCTs with 1414 workplaces, two CBAs with 9903 workplaces, one ITS with six outcome measurements, 12 panel studies and six qualitative studies with 310 participants.",rephrase,['We found 23 studies.'],0,0.045454545454545456,1,22
CD010183,0,1,"Studies evaluated the effects of inspections in general and the effects of their consequences, such as penalties.",delete,[],1,0.09090909090909091,1,22
CD010183,0,2,"Studies on the effects of prosecution, warnings or closure were not available or were of such quality that we could not include their results.",delete,[],1,0.13636363636363635,1,22
CD010183,0,3,"The effect was measured on injury rates, on exposure to physical workload and on compliance with regulation, with a follow-up varying from one to four years.",delete,[],1,0.18181818181818182,1,22
CD010183,0,4,All studies had serious limitations and therefore the quality of the evidence was low to very low.,delete,[],1,0.22727272727272727,2,22
CD010183,0,5,The injury rates in the control groups varied across studies from 1 to 23 injuries per 100 person-years and compliance rates varied from 40% to 75% being compliant.,delete,[],1,0.2727272727272727,2,22
CD010183,1,6,The effects of inspections were inconsistent in seven studies: injury rates decreased or stayed at a similar level compared to no intervention at short and medium-term follow-up.,rephrase,['Another five similar but lower quality studies had inconsistent results at short and medium-term follow-up.'],1,0.3181818181818182,2,22
CD010183,1,7,In studies that found a decrease the effect was small with a 10% decrease of the injury rate.,delete,[],2,0.36363636363636365,2,22
CD010183,1,8,"At long-term follow-up, in one study there was a significant decrease of 23% (95% confidence interval 8% to 23%) in injury rates and in another study a substantial decrease in accident rates, both compared to no intervention.",delete,[],2,0.4090909090909091,3,22
CD010183,2,9,"First inspections, follow-up inspections, complaint and accident inspections resulted in higher compliance rates compared to the average effect of any other type of inspections.",rephrase,['Specific inspections resulted in higher compliance rates.'],2,0.45454545454545453,3,22
CD010183,3,10,"In small firms, inspections with citations or with more penalties could result in fewer injuries or more compliance in the short term but not in the medium term.",rephrase,['Inspections with penalties could result in fewer injuries and more compliance in the short term in small firms.'],3,0.5,3,22
CD010183,4,11,Longer inspections and more frequent inspections probably do not result in more compliance.,ignore,['Longer inspections and more frequent inspections probably do not result in more compliance.'],4,0.5454545454545454,3,22
CD010183,5,12,"In two studies, there was no adverse effect of inspections on firm survival, employment or sales.",rephrase,['Two studies did not find a harmful effect of inspections on firm lifetime or employment.'],5,0.5909090909090909,3,22
CD010183,6,13,Qualitative studies show that there is support for enforcement among workers.,ignore,['Qualitative studies showed that there is support for enforcement among workers.'],6,0.6363636363636364,4,22
CD010183,6,14,"However, workers doubt if the inspections are effective because inspections are rare and violations can be temporarily fixed to mislead inspectors.",ignore,"['However, workers doubt if inspections are effective because they are rare and violations can be temporarily fixed to mislead the inspectors.']",7,0.6818181818181818,4,22
CD010183,7,15,There is evidence that inspections decrease injuries in the long term but not in the short term.,rephrase,['We concluded that inspections decrease injuries in the long term but probably not in the short term.'],8,0.7272727272727273,4,22
CD010183,7,16,The magnitude of the effect is uncertain.,rephrase,"['In addition, the magnitude of the effect is uncertain because it varies from a 3 to 23 per cent decrease in injury rates.']",9,0.7727272727272727,4,22
CD010183,7,17,There are no studies that used chemical or physical exposures as outcome.,delete,[],10,0.8181818181818182,5,22
CD010183,7,18,"Specific, focused inspections could have larger effects than inspections in general.",delete,[],10,0.8636363636363636,5,22
CD010183,7,19,The effect of fines and penalties is uncertain.,delete,[],10,0.9090909090909091,5,22
CD010183,7,20,The quality of the evidence is low to very low and therefore these conclusions are tentative and can be easily changed by better future studies.,split,"['The evidence is of low to very low quality because the results across studies are inconsistent and studies are observational and do not take into account other factors that could affect the results.', 'Because the quality of the evidence is low, future studies can easily change our conclusions.']",10,0.9545454545454546,5,22
CD010183,7,21,"There is an urgent need for better designed evaluations, such as pragmatic randomised trials, to establish the effects of existing and novel enforcement methods, especially on exposure and disorders.",rephrase,"['There is an urgent need for large-scale randomised trials to evaluate different types of inspection methods on exposure, disorders and injuries.']",12,1.0,5,22
CD009263,0,0,Eleven studies met the inclusion criteria.,delete,[],0,0.045454545454545456,1,22
CD009263,0,1,Ten studies reported data on patient level: the scan was positive or negative.,delete,[],0,0.09090909090909091,1,22
CD009263,0,2,One study reported on all single lesions (lesion level).,delete,[],0,0.13636363636363635,1,22
CD009263,0,3,"The sensitivity of ¹²³I-MIBG (SPECT-CT) scintigraphy (objective 1.1), determined in 608 of 621 eligible patients included in the 11 studies, varied from 67% to 100%.",delete,[],0,0.18181818181818182,1,22
CD009263,0,4,"One study, that reported on a lesion level, provided data to calculate the specificity: 68% in 115 lesions in 22 patients.",delete,[],0,0.22727272727272727,2,22
CD009263,0,5,The sensitivity of ¹²³I-MIBG scintigraphy for detecting metastases separately from the primary tumour in patients with all neuroblastoma stages ranged from 79% to 100% in three studies and the specificity ranged from 33% to 89% for two of these studies.,delete,[],0,0.2727272727272727,2,22
CD009263,1,6,One study reported on the diagnostic accuracy of 18F-FDG-PET(-CT) imaging (add-on test) in patients with negative ¹²³I-MIBG scintigraphy (objective 1.2).,delete,[],0,0.3181818181818182,2,22
CD009263,1,7,Two of the 24 eligible patients with proven neuroblastoma had a negative ¹²³I-MIBG scan and a positive 18F-FDG-PET(-CT) scan.,rephrase,['We identified 11 eligible studies including 621 children that fulfilled our inclusion criteria: children < 18 years old with a neuroblastoma and ¹²³I-MIBG or 18F-FDG-PET imaging or both.'],0,0.36363636363636365,2,22
CD009263,2,8,The sensitivity of 18F-FDG-PET(-CT) imaging as a single diagnostic test (objective 2.1) and compared to ¹²³I-MIBG (SPECT-CT) (objective 2.2) was only reported in one study.,rephrase,"['We searched scientific databases for clinical studies comparing ¹²³I-MIBG or 18F-FDG-PET imaging, or both, with microscopic examination of tissue suspected of neuroblastoma (histopathology).']",1,0.4090909090909091,3,22
CD009263,2,9,The sensitivity of 18F-FDG-PET(-CT) imaging was 100% versus 92% of ¹²³I-MIBG (SPECT-CT) scintigraphy.,rephrase,['This means that ¹²³I-MIBG imaging and 18F-FDG-PET imaging incorrectly identified neuroblastoma lesions in patients which might result in wrongly classifying a patient with metastatic disease.'],2,0.45454545454545453,3,22
CD009263,2,10,We could not calculate the specificity for both modalities.,rephrase,"[""Only one included study provided data on specificity (the ability of a test to correctly classify an individual as 'disease-free') and therefore we could not perform all of the planned analyses.""]",3,0.5,3,22
CD009263,3,11,The reported sensitivities of ¹²³-I MIBG scintigraphy for the detection of neuroblastoma and its metastases ranged from 67 to 100% in patients with histologically proven neuroblastoma.,split,"[""When compared to histopathological results the sensitivity (the ability of a test to correctly classify an individual person as 'diseased') of ¹²³I-MIBG imaging varied from 67% to 100% in patients with histologically proven neuroblastoma."", 'This means that in 100 children with proven neuroblastoma ¹²³I-MIBG imaging will correctly identify 67 to 100 of the neuroblastoma cases.', 'This means that of 100 disease-free lesions in patients with proven neuroblastoma ¹²³I-MIBG imaging will correctly identify 68 lesions.']",4,0.5454545454545454,3,22
CD009263,4,12,Only one study in this review reported on false positive findings.,rephrase,['Only one included study reported on false positive findings.'],7,0.5909090909090909,3,22
CD009263,4,13,It is important to keep in mind that false positive findings can occur.,merge,"['It is important to keep in mind that false positive findings can occur, although more research is needed before definitive conclusions can be made.']",8,0.6363636363636364,4,22
CD009263,4,14,"For example, physiological uptake should be ruled out, by using SPECT-CT scans, although more research is needed before definitive conclusions can be made.",none,[],8,0.6818181818181818,4,22
CD009263,5,15,"As described both in the literature and in this review, in about 10% of the patients with histologically proven neuroblastoma the tumour does not accumulate ¹²³I-MIBG (false negative results).",rephrase,"['So, in about 10% of the cases the neuroblastoma is not visible on ¹²³I-MIBG imaging (false negative results).']",9,0.7272727272727273,4,22
CD009263,5,16,"For these patients, it is advisable to perform an additional test for staging and assess response to therapy.",merge,"['For these cases, it is advisable to perform an additional test like 18F-FDG-PET imaging, but to be certain of its clinical value, more evidence is needed.']",10,0.7727272727272727,4,22
CD009263,5,17,"Additional tests might for example be 18F-FDG-PET(-CT), but to be certain of its clinical value, more evidence is needed.",none,[],10,0.8181818181818182,5,22
CD009263,6,18,"The diagnostic accuracy of 18F-FDG-PET(-CT) imaging in case of a negative ¹²³I-MIBG scintigraphy could not be calculated, because only very limited data were available.",rephrase,"['We could not determine the diagnostic accuracy of 18F-FDG-PET imaging, in case the neuroblastoma was incorrectly not identified with ¹²³I-MIBG, due to limited data.']",11,0.8636363636363636,5,22
CD009263,6,19,"Also the detection of the diagnostic accuracy of index test 18F-FDG-PET(-CT) imaging for detecting a neuroblastoma tumour and its metastases, and to compare this to comparator test ¹²³I-MIBG (SPECT-CT) scintigraphy, could not be calculated because of the limited available data at time of this search.",rephrase,"['Also, we could not calculate the diagnostic accuracy of 18F-FDG-PET imaging for detecting a neuroblastoma and compare this to ¹²³I-MIBG imaging because of the limited available data.']",12,0.9090909090909091,5,22
CD009263,7,20,"At the start of this project, we did not expect to find only very limited data on specificity.",delete,[],13,0.9545454545454546,5,22
CD009263,7,21,"We now consider it would have been more appropriate to use the term ""the sensitivity to assess the presence of neuroblastoma"" instead of ""diagnostic accuracy"" for the objectives.",delete,[],13,1.0,5,22
CD010167,0,0,"The updated search retrieved 535 records; we included 13 parallel-designed RCTs comparing IMSI and ICSI (four studies were added since the previous version), comprising 2775 couples (IMSI = 1256; ICSI = 1519).",rephrase,"['We found 13 randomised controlled trials (four more than in the previous version), evaluating 2775 couples, that compared regular ICSI with IMSI for assisted reproduction.']",0,0.09090909090909091,1,11
CD010167,1,1,"We are uncertain if IMSI improves live birth rates (risk ratio (RR) 1.11, 95% confidence interval (CI) 0.89 to 1.39; 5 studies, 929 couples; I² = 1%), miscarriage rates per couple (RR 1.07, 95% CI 0.78 to 1.48; 10 studies, 2297 couples; I² = 0%, very-low quality evidence), and miscarriage rate per pregnancy (RR 0.90, 95% CI 0.68 to 1.20; 10 studies, 783 couples; I² = 0%, very-low quality evidence).",delete,[],1,0.18181818181818182,1,11
CD010167,1,2,"We are uncertain if IMSI improves clinical pregnancy rates (RR 1.23, 95% CI 1.11 to 1.37; 13 studies, 2775 couples; I² = 47%, very-low quality evidence).",rephrase,"['The clinical pregnancy rate with IMSI was between 35% and 44%, compared with 32% with ICSI.']",1,0.2727272727272727,2,11
CD010167,1,3,None of the included studies reported congenital abnormalities.,rephrase,['There was no evidence concerning congenital abnormalities.'],2,0.36363636363636365,2,11
CD010167,1,4,We judged the evidence for all outcomes to be of very low-quality.,rephrase,['We conclude that the current evidence is very limited for suggesting using IMSI instead of ICSI in clinical practice.'],3,0.45454545454545453,3,11
CD010167,1,5,"We downgraded the quality of the evidence due to limitations of the included studies (risk of bias), inconsistency of results, and a strong indication of publication bias.",rephrase,"['We downgraded the quality of the evidence because of limitations in the included studies (risk of bias), inconsistency of the observed effect across studies, and high risk of publication bias.']",4,0.5454545454545454,3,11
CD010167,2,6,The current evidence from randomised controlled trials does not support or refute the clinical use of intracytoplasmic sperm injection (intracytoplasmic morphologically selected sperm injection (IMSI).,delete,[],5,0.6363636363636364,4,11
CD010167,2,7,We are very uncertain of the chances of having a live birth and of the risk of having a miscarriage.,delete,[],5,0.7272727272727273,4,11
CD010167,2,8,"We found very low-quality evidence that IMSI may increase chances of a clinical pregnancy, which means that we are still very uncertain about any real difference.",rephrase,"['Based on the very low-quality evidence that we found, we are uncertain of the benefit of IMSI over ICSI.']",5,0.8181818181818182,5,11
CD010167,3,9,We did not find any trials reporting on the risk of congenital abnormalities.,delete,[],6,0.9090909090909091,5,11
CD010167,3,10,Well-designed and sufficiently powered trials are still required.,delete,[],6,1.0,5,11
CD005433,0,0,We included 33 trials enrolling 2973 children with acute diarrhoea.,rephrase,['We looked for research up to 13 May 2013 and included 33 trials in our analyses.'],0,0.1111111111111111,1,9
CD005433,0,1,"Twenty-nine trials were exclusively conducted on inpatients, all from high- or middle-income countries.",rephrase,['Twenty-two trials compared outcomes for children given a lactose-free feed with those for children given a lactose-containing feed and 11 trials compared outcomes for children fed a diluted milk feed with those for children given an undiluted milk feed.'],1,0.2222222222222222,2,9
CD005433,0,2,"Fifteen trials included children aged below 12 months, and 22 excluded children who were being breast-fed.",rephrase,"['The majority of trials excluded breast fed infants, and none were conducted in low-income countries where diarrhoea can cause death, so the review is relevant to infants and young children who are receiving formula or are weaned in high- and middle-income countries.']",2,0.3333333333333333,2,9
CD005433,1,3,"Compared to lactose-containing milk, milk products, or foodstuffs, lactose-free products may reduce the duration of diarrhoea by an average of about 18 hours (MD -17.77, 95% CI -25.32 to -10.21, 16 trials, 1467 participants, low quality evidence).",rephrase,['We found evidence that feeds that do not contain lactose may reduce the duration of diarrhoea by an average of about 18 hours (low quality evidence).'],3,0.4444444444444444,3,9
CD005433,1,4,"Lactose-free products probably also reduce treatment failure (defined variously as continued or worsening diarrhoea or vomiting, the need for additional rehydration therapy, or continuing weight loss) by around a half (RR 0.52, 95% CI 0.39 to 0.68, 18 trials, 1470 participants, moderate quality evidence).",rephrase,['Lactose-free feeds probably lower the risk of children having prolonged or worsening diarrhoea (moderate quality evidence).'],4,0.5555555555555556,3,9
CD005433,2,5,"Diluted lactose-containing milk has not been shown to reduce the duration of diarrhoea compared to undiluted milk or milk products (five trials, 417 participants, low quality evidence), but may reduce the risk of treatment failure (RR 0.65, 95% CI 0.45 to 0.94, nine trials, 687 participants, low quality evidence).",delete,[],5,0.6666666666666666,4,9
CD005433,3,6,"In young children with acute diarrhoea who are not predominantly breast-fed, change to a lactose-free diet may result in earlier resolution of acute diarrhoea and reduce treatment failure.",delete,[],5,0.7777777777777778,4,9
CD005433,3,7,Diluting lactose-containing formulas may also have some benefits but further trials are required to have confidence in this finding.,delete,[],5,0.8888888888888888,5,9
CD005433,3,8,"There are no trials from low-income countries, where mortality for diarrhoea is high, and malnutrition is more common.",delete,[],5,1.0,5,9
CD003721,0,0,"In this review update, we included five new trials, bringing the total number of included studies to eight.",delete,[],0,0.14285714285714285,1,7
CD003721,0,1,"The included trials (pertaining to 10 papers), provided data on 1973 participants and assessed the impact of cancer genetic risk assessment on outcomes including perceived risk of inherited cancer, and psychological distress.",delete,[],0,0.2857142857142857,2,7
CD003721,0,2,"This review suggests that cancer genetic risk-assessment services help to reduce distress, improve the accuracy of the perceived risk of breast cancer, and increase knowledge about breast cancer and genetics.",rephrase,"[""Although limited, the findings of this review suggest that cancer genetic risk-assessment services can help to reduce distress, improve the accuracy of the individual's perceived risk of breast cancer, and increase knowledge about breast cancer and genetics.""]",0,0.42857142857142855,3,7
CD003721,0,3,The health professional delivering the risk assessment does not appear to have a significant impact on these outcomes.,rephrase,"['From this review, it does not appear that the health professional delivering the risk assessment has a significant impact on these outcomes.']",1,0.5714285714285714,3,7
CD003721,1,4,This review found favourable outcomes for patients after risk assessment for familial breast cancer.,rephrase,['This review included eight trials (10 papers) which covered the process of risk assessment for familial breast cancer.'],2,0.7142857142857143,4,7
CD003721,1,5,"However, there were too few papers to make any significant conclusions about how best to deliver cancer genetic risk-assessment services.",merge,"['Due to the limited number of trials, this review found insufficient evidence to make any firm conclusions about the best way to deliver risk-assessment services for individuals concerned about a family history of breast cancer.']",3,0.8571428571428571,5,7
CD003721,1,6,"Further research is needed assessing the best means of delivering cancer risk assessment, by different health professionals, in different ways and in alternative locations.",none,[],3,1.0,5,7
CD011341,0,0,We included two randomised controlled trials that involved a total of 147 adult outpatients with acute sinusitis confirmed by radiology or nasal endoscopy who were assigned to Cyclamen europaeum nasal spray or placebo study arms for up to 15 days.,split,"['We included two studies involving 147 adults with acute sinusitis.', 'Participants were randomly allocated to receive Cyclamen europaeum delivered as an intranasal spray or a non-active substance for up to 15 days.']",0,0.14285714285714285,1,7
CD011341,0,1,"The risk of selection and detection bias was unclear, as allocation concealment and blinding of outcome assessors were not reported in either study.",delete,[],2,0.2857142857142857,2,7
CD011341,0,2,"Attrition was high (60%) in one study, although dropouts were balanced between study arms.",rephrase,"['One study had a high dropout rate (60%), but dropouts were described and balanced between study arms.']",2,0.42857142857142855,3,7
CD011341,1,3,Neither study reported our two primary outcomes: proportion of participants whose symptoms resolved or improved at 14 days and 30 days.,rephrase,['Neither study reported whether the outcomes assessors knew which treatments the participants received.'],3,0.5714285714285714,3,7
CD011341,1,4,"No serious adverse events or complications related to treatment were reported; however, more mild adverse events such as nasal and throat irritation, mild epistaxis, and sneezing occurred in Cyclamen europaeum group participants (50%) compared to placebo group participants (24%) (risk ratio 2.11, 95% confidence interval 1.35 to 3.29); moderate-quality evidence.",delete,[],4,0.7142857142857143,4,7
CD011341,2,5,The effectiveness of Cyclamen europaeum for people with acute sinusitis is unknown.,rephrase,['We found no evidence as to whether Cyclamen europaeum is effective or not.'],4,0.8571428571428571,5,7
CD011341,2,6,"Although no serious side effects were observed, 50% of participants who received Cyclamen europaeum reported adverse events compared with 24% of those who received placebo.",split,"['People who received Cyclamen europaeum rather than a non-active substance reported more side effects like nasal irritation, sneezing, and mild nasal bleeding.', 'No major side effects occurred.']",5,1.0,5,7
CD013497,0,0,"We included five studies, the data for three of which (1532 participants) were meta-analysed.",rephrase,"['We obtained data from three randomised controlled trials (a type of study in which participants are randomly assigned to one of two or more treatment groups) of 1532 infertile women undergoing IVF or intracytoplasmic sperm injection (ICSI), a specialised form of IVF whereby the sperm is injected into the egg.']",0,0.1,1,10
CD013497,0,1,"We are uncertain whether GM-CSF-supplemented culture media makes any difference to the live-birth rate when compared to using conventional culture media not supplemented with GM-CSF (odds ratio (OR) 1.19, 95% confidence interval (CI) 0.93 to 1.52, 2 RCTs, N = 1432, I2 = 69%, low-quality evidence).",rephrase,['Low-quality evidence reveals that we are uncertain whether GM-CSF-containing culture media makes any difference to the live-birth rate when compared to using culture media not containing GM-CSF.'],1,0.2,1,10
CD013497,0,2,"The evidence suggests that if the rate of live birth associated with conventional culture media not supplemented with GM-CSF was 22%, the rate with the use of GM-CSF-supplemented culture media would be between 21% and 30%.",rephrase,"['This suggests that if the rate of live birth associated with culture media not containing GM-CSF is 22%, the rate with the use of GM-CSF-containing culture media would be between 21% and 30%.']",2,0.3,2,10
CD013497,1,3,"We are uncertain whether GM-CSF-supplemented culture media makes any difference to the miscarriage rate when compared to using conventional culture media not supplemented with GM-CSF (OR 0.75, 95% CI 0.41 to 1.36, 2 RCTs, N = 1432, I2 = 0%, low-quality evidence).",rephrase,['Low-quality evidence also reveals that we are uncertain whether GM-CSF-containing culture media makes any difference to miscarriage when compared to using culture media not containing GM-CSF.'],3,0.4,2,10
CD013497,1,4,"This evidence suggests that if the miscarriage rate associated with conventional culture media not supplemented with GM-CSF was 4%, the rate with the use of GM-CSF-supplemented culture media would be between 2% and 5%.",rephrase,"['This suggests that if the miscarriage rate associated with culture media not containing GM-CSF is 4%, the rate with the use of GM-CSF-containing culture media would be between 2% and 5%.']",4,0.5,3,10
CD013497,2,5,"Furthermore, we are uncertain whether GM-CSF-supplemented culture media makes any difference to the following outcomes: clinical pregnancy (OR 1.16, 95% CI 0.93 to 1.45, 3 RCTs, N = 1532 women, I2 = 67%, low-quality evidence); multiple gestation (OR 1.24, 95% CI 0.73 to 2.10, 2 RCTs, N = 1432, I2 = 35%, very low-quality evidence); preterm birth (OR 1.20, 95% CI 0.70 to 2.04, 2 RCTs, N = 1432, I2 = 76%, very low-quality evidence); birth defects (OR 1.33, 95% CI 0.59 to 3.01, I2 = 0%, 2 RCTs, N = 1432, low-quality evidence); and aneuploidy (OR 0.34, 95% CI 0.03 to 3.26, I2 = 0%, 2 RCTs, N = 1432, low-quality evidence).",rephrase,"['Low-quality evidence for pregnancy, birth defects, and genetic problems with the baby, and very low-quality evidence for twin or triplet pregnancies, and premature birth, reveals that we are uncertain whether GM-CSF-containing culture media makes any difference to these outcomes when compared to culture media not containing GM-CSF.']",5,0.6,3,10
CD013497,2,6,"We were unable to undertake analysis of stillbirth, as there were no events in either arm of the two studies that assessed this outcome.",rephrase,"['Two studies looked at stillbirth, but as no stillbirths occurred in either study, we were unable to analyse this outcome.']",6,0.7,4,10
CD013497,3,7,"Due to the very low to low quality of the evidence, we cannot be certain whether GM-CSF is any more or less effective than culture media not supplemented with GM-CSF for clinical outcomes that reflect effectiveness and safety.",rephrase,"['Due to the very low to low quality of the evidence, we cannot be certain whether GM-CSF is any more or less effective or harmful than culture media not supplemented with GM-CSF.']",7,0.8,4,10
CD013497,3,8,It is important that independent information on the available evidence is made accessible to those considering using GM-CSF-supplemented culture media.,ignore,['It is important that independent information on the available evidence is made accessible to those considering using GM-CSF-supplemented culture media.'],8,0.9,5,10
CD013497,3,9,"The claims from marketing information that GM-CSF has a positive effect on pregnancy rates are not supported by the available evidence presented here; further well-designed, properly powered RCTs are needed to lend certainty to the evidence.",delete,[],9,1.0,5,10
CD008716,0,0,"We included 21 trials with 1420 participants, of these, 14 were new trials.",merge,[],0,0.05,1,20
CD008716,0,1,"Fourteen trials compared a probiotic with placebo or no treatment, and seven trials compared a probiotic with lactulose.",none,"['Of the 21 included trials including 1420 participants, 14 trials compared a probiotic with placebo or no treatment and seven trials compared a probiotic with lactulose.']",0,0.1,1,20
CD008716,0,2,"The trials used a variety of probiotics; the most commonly used group of probiotic was VSL#3, a proprietary name for a group of eight probiotics.",delete,[],1,0.15,1,20
CD008716,0,3,Duration of administration ranged from 10 days to 180 days.,rephrase,['The treatment duration of the trials ranged from 10 days to 180 days.'],1,0.2,1,20
CD008716,0,4,"Eight trials declared their funding source, of which six were independently funded and two were industry funded.",ignore,"['Eight trials declared their funding source, of which six were independently funded and two were industry funded.']",2,0.25,2,20
CD008716,0,5,The remaining 13 trials did not disclose their funding source.,ignore,['The remaining 13 trials did not disclose their funding source.'],3,0.3,2,20
CD008716,0,6,We classified 19 of the 21 trials at high risk of bias.,delete,[],4,0.35,2,20
CD008716,1,7,"We found no effect on all-cause mortality when probiotics were compared with placebo or no treatment (7 trials; 404 participants; RR 0.58, 95% CI 0.23 to 1.44; low-quality evidence).",delete,[],4,0.4,2,20
CD008716,1,8,"No-recovery (as measured by incomplete resolution of symptoms) was lower for participants treated with probiotic (10 trials; 574 participants; RR 0.67, 95% CI 0.56 to 0.79; moderate-quality evidence).",delete,[],4,0.45,3,20
CD008716,1,9,"Adverse events were lower for participants treated with probiotic than with no intervention when considering the development of overt hepatic encephalopathy (10 trials; 585 participants; RR 0.29, 95% CI 0.16 to 0.51; low-quality evidence), but effects on hospitalisation and change of/or withdrawal from treatment were uncertain (hospitalisation: 3 trials, 163 participants; RR 0.67, 95% CI 0.11 to 4.00; very low-quality evidence; change of/or withdrawal from treatment: 9 trials, 551 participants; RR 0.70, 95% CI 0.46 to 1.07; very low-quality evidence).",delete,[],4,0.5,3,20
CD008716,1,10,Probiotics may slightly improve quality of life compared with no intervention (3 trials; 115 participants; results not meta-analysed; low-quality evidence).,split,"['Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but may lead to little or no difference in mortality.', 'Probiotics may slightly improve quality of life when compared with no intervention; however, this conclusion is based on three trials with low-quality evidence.']",4,0.55,3,20
CD008716,1,11,"Plasma ammonia concentration was lower for participants treated with probiotic (10 trials; 705 participants; MD -8.29 μmol/L, 95% CI -13.17 to -3.41; low-quality evidence).",delete,[],6,0.6,3,20
CD008716,1,12,There were no reports of septicaemia attributable to probiotic in any trial.,delete,[],6,0.65,4,20
CD008716,2,13,"When probiotics were compared with lactulose, the effects on all-cause mortality were uncertain (2 trials; 200 participants; RR 5.00, 95% CI 0.25 to 102.00; very low-quality evidence); lack of recovery (7 trials; 430 participants; RR 1.01, 95% CI 0.85 to 1.21; very low-quality evidence); adverse events considering the development of overt hepatic encephalopathy (6 trials; 420 participants; RR 1.17, 95% CI 0.63 to 2.17; very low-quality evidence); hospitalisation (1 trial; 80 participants; RR 0.33, 95% CI 0.04 to 3.07; very low-quality evidence); intolerance leading to discontinuation (3 trials; 220 participants; RR 0.35, 95% CI 0.08 to 1.43; very low-quality evidence); change of/or withdrawal from treatment (7 trials; 490 participants; RR 1.27, 95% CI 0.88 to 1.82; very low-quality evidence); quality of life (results not meta-analysed; 1 trial; 69 participants); and plasma ammonia concentration overall (6 trials; 325 participants; MD -2.93 μmol/L, 95% CI -9.36 to 3.50; very low-quality evidence).",delete,[],6,0.7,4,20
CD008716,2,14,There were no reports of septicaemia attributable to probiotic in any trial.,ignore,['There were no reports of septicaemia attributable to probiotic in any trial.'],6,0.75,4,20
CD008716,3,15,The majority of included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’).,ignore,['Many of the included trials suffered from a high risk of systematic error (‘bias’) and a high risk of random error (‘play of chance’).'],7,0.8,4,20
CD008716,3,16,"Accordingly, we consider the evidence to be of low quality.",ignore,"['Accordingly, we consider the evidence to be of low quality.']",8,0.85,5,20
CD008716,3,17,"Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality.",ignore,"['Compared with placebo or no intervention, probiotics probably improve recovery and may lead to improvements in the development of overt hepatic encephalopathy, quality of life, and plasma ammonia concentrations, but probiotics may lead to little or no difference in mortality.']",9,0.9,5,20
CD008716,3,18,Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence is very low.,ignore,['Whether probiotics are better than lactulose for hepatic encephalopathy is uncertain because the quality of the available evidence was very low.'],10,0.95,5,20
CD008716,3,19,High-quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics.,ignore,['High-quality randomised clinical trials with standardised outcome collection and data reporting are needed to further clarify the true efficacy of probiotics.'],11,1.0,5,20
CD008039,0,0,No new studies were found for this update.,delete,[],0,0.07692307692307693,1,13
CD008039,0,1,"Nine included studies (4373 participants, 5223 attacks) compared ibuprofen with placebo or other active comparators; none combined ibuprofen with a self-administered antiemetic.",rephrase,"['There is no information for ibuprofen combined with a self-administered antiemetic, and little information comparing ibuprofen with other medications.']",0,0.15384615384615385,1,13
CD008039,0,2,All studies treated attacks with single doses of medication.,delete,[],1,0.23076923076923078,2,13
CD008039,0,3,"For ibuprofen 400 mg versus placebo, NNTs for 2-hour pain-free (26% versus 12% with placebo), 2-hour headache relief (57% versus 25%) and 24-hour sustained headache relief (45% versus 19%) were 7.2, 3.2 and 4.0, respectively.",rephrase,"['There were no significant differences between ibuprofen 400 mg and rofecoxib 25 mg (now withdrawn) for 2-hour headache relief, 24-hour sustained headache relief, or use of rescue medication.']",1,0.3076923076923077,2,13
CD008039,0,4,"For ibuprofen 200 mg versus placebo, NNTs for 2-hour pain-free (20% versus 10%) and 2-hour headache relief (52% versus 37%) were 9.7 and 6.3, respectively.",delete,[],2,0.38461538461538464,2,13
CD008039,0,5,The higher dose was significantly better than the lower dose for 2-hour headache relief.,delete,[],2,0.46153846153846156,3,13
CD008039,0,6,"Soluble formulations of ibuprofen 400 mg were better than standard tablets for 1-hour, but not 2-hour headache relief.",delete,[],2,0.5384615384615384,3,13
CD008039,1,7,"Similar numbers of participants experienced adverse events, which were mostly mild and transient, with ibuprofen and placebo.",rephrase,"['Of those who experience effective headache relief at two hours, more have that relief sustained over 24 hours with ibuprofen than with placebo.']",2,0.6153846153846154,4,13
CD008039,2,8,Ibuprofen 400 mg did not differ from rofecoxib 25 mg for 2-hour headache relief or 24-hour headache relief.,rephrase,['A single oral dose of ibuprofen 200 mg or 400 mg is effective in relieving pain in migraine headaches.'],3,0.6923076923076923,4,13
CD008039,3,9,We found no new studies since the last version of this review.,rephrase,"['This is an updated version of the original Cochrane review published in Issue 10, 2010 (Rabbie 2010); no new studies were found.']",4,0.7692307692307693,4,13
CD008039,3,10,"Ibuprofen is an effective treatment for acute migraine headaches, providing pain relief in about half of sufferers, but complete relief from pain and associated symptoms for only a minority.",delete,[],5,0.8461538461538461,5,13
CD008039,3,11,"NNTs for all efficacy outcomes were better with 400 mg than 200 mg in comparisons with placebo, and soluble formulations provided more rapid relief.",split,"['A 200-mg dose is slightly less effective, while soluble formulations give more rapid responses.', 'A single 400-mg dose of ibuprofen has efficacy similar to that shown for a single dose of 1000 mg aspirin in a separate Cochrane review (Kirthi 2013).']",5,0.9230769230769231,5,13
CD008039,3,12,"Adverse events were mostly mild and transient, occurring at the same rate as with placebo.",rephrase,"['Adverse events are mostly mild and transient, occurring in the same proportion of participants treated with ibuprofen and placebo.']",7,1.0,5,13
CD001836,0,0,Two trials met the inclusion criteria.,delete,[],0,0.07692307692307693,1,13
CD001836,0,1,"One compared 2% ketanserin ointment in polyethylene glycol (PEG) with PEG alone, used twice a day by 40 participants with arterial leg ulcers, for eight weeks or until healing, whichever was sooner.",rephrase,"['One study randomised participants to either 2% ketanserin ointment in polyethylene glycol (PEG) or PEG alone, administered twice a day over eight weeks.']",0,0.15384615384615385,1,13
CD001836,0,2,"One compared topical application of blood-derived concentrated growth factor (CGF) with standard dressing (polyurethane film or foam); both applied weekly for six weeks by 61 participants with non-healing ulcers (venous, diabetic arterial, neuropathic, traumatic, or vasculitic).",delete,[],1,0.23076923076923078,2,13
CD001836,0,3,"Both trials were small, reported results inadequately, and were of low methodological quality.",delete,[],1,0.3076923076923077,2,13
CD001836,0,4,Short follow-up times (six and eight weeks) meant it would be difficult to capture sufficient healing events to allow us to make comparisons between treatments.,rephrase,['The follow-up periods (six and eight weeks) were too short to measure healing.'],1,0.38461538461538464,2,13
CD001836,1,5,One trial demonstrated accelerated wound healing in the ketanserin group compared with the control group.,rephrase,"['This study reported increased wound healing in the ketanserin group, when compared with the control group.']",2,0.46153846153846156,3,13
CD001836,1,6,"In the trial that compared CGF with standard dressings, the number of participants with diabetic arterial ulcers were only reported in the CGF group (9/31), and the number of participants with diabetic arterial ulcers and their data were not reported separately for the standard dressing group.",delete,[],3,0.5384615384615384,3,13
CD001836,1,7,"In the CGF group, 66.6% (6/9) of diabetic arterial ulcers showed more than a 50% decrease in ulcer size compared to 6.7% (2/30) of non-healing ulcers treated with standard dressing.",rephrase,"['This study reported that 66.6% of CGF-treated diabetic arterial ulcers showed more than a 50% decrease in ulcer size, compared to 6.7% of non-healing ulcers treated with standard dressing.']",3,0.6153846153846154,4,13
CD001836,1,8,"We assessed this as very-low certainty evidence due to the small number of studies and arterial ulcer participants, inadequate reporting of methodology and data, and short follow-up period.",rephrase,"[""We downgraded the overall certainty of the available evidence to 'very low' and 'low', because the studies reported their methods poorly, there were only two studies and few participants with arterial disease, and because the studies were short and reported few results.""]",4,0.6923076923076923,4,13
CD001836,2,9,"Only one trial reported side effects (complications), stating that no participant experienced these during follow-up (six weeks, low-certainty evidence).",rephrase,"['Only one study mentioned side effects, and reported that no participant experienced side effects during follow-up (six weeks).']",5,0.7692307692307693,4,13
CD001836,2,10,It should also be noted that ketanserin is not licensed in all countries for use in humans.,rephrase,['It should be noted that ketanserin is not licensed for use in humans in all countries.'],6,0.8461538461538461,5,13
CD001836,2,11,"Neither study reported time to ulcer healing, patient satisfaction or quality of life.",rephrase,"['Neither of the two studies reported time to ulcer healing, patient satisfaction or quality of life measures.']",7,0.9230769230769231,5,13
CD001836,3,12,There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers.,ignore,['There is insufficient evidence to determine whether the choice of topical agent or dressing affects the healing of arterial leg ulcers.'],8,1.0,5,13
CD008944,0,0,"Apart from the remaining 37 studies included from the original review, the search resulted in the inclusion of 24 new studies.",delete,[],0,0.030303030303030304,1,33
CD008944,0,1,"In total, we included 61 studies; 46 for prevalence, six for both prevalence and risk factors, and nine not meeting the inclusion criteria, but assessing risk factors.",rephrase,"['We included 61 studies; 46 on prevalence, six for both prevalence and risk factors, and nine studies that did not meet all the requirements for this review, but evaluated risk factors (non-eligible studies).']",0,0.06060606060606061,1,33
CD008944,0,2,"The 52 studies evaluating the prevalence of renal dysfunction included 13,327 participants of interest, of whom at least 4499 underwent renal function testing.",rephrase,"['The 52 studies that evaluated prevalence of adverse kidney effects included 13,327 participants, of whom 4499 underwent kidney function tests.']",1,0.09090909090909091,1,33
CD008944,0,3,The prevalence of adverse renal effects ranged from 0% to 84%.,rephrase,['The percentage of CCS with kidney problems ranged from 0% to 84%.'],2,0.12121212121212122,1,33
CD008944,0,4,"This variation may be due to diversity of included malignancies, received treatments, reported outcome measures, follow-up duration and the methodological quality of available evidence.",delete,[],3,0.15151515151515152,1,33
CD008944,1,5,"Seven out of 52 studies, including 244 participants, reported the prevalence of chronic kidney disease, which ranged from 2.4% to 32%.",rephrase,['The prevalence of chronic kidney disease ranged from 2.4% to 32% in 244 participants (7/52 studies).'],3,0.18181818181818182,1,33
CD008944,2,6,"Of these 52 studies, 36 studied a decreased (estimated) GFR, including at least 432 CCS, and found it was present in 0% to 73.7% of participants.",rephrase,['An abnormal GFR was found to be present in 0% to 73.7% of participants.'],4,0.21212121212121213,2,33
CD008944,2,7,One eligible study reported an increased risk of glomerular dysfunction after concomitant treatment with aminoglycosides and vancomycin in CCS receiving total body irradiation (TBI).,rephrase,['One eligible study found an increased risk of abnormal GFR in participants who had been treated with total body irradiation (TBI) and received certain types of antibiotics (aminoglycosides and vancomycin).'],5,0.24242424242424243,2,33
CD008944,2,8,"Four non-eligible studies assessing a total cohort of CCS, found nephrectomy and (high-dose (HD)) ifosfamide as risk factors for decreased GFR.",rephrase,['Four non-eligible studies reported an increased risk of abnormal GFR for participants treated with surgery of the kidney and ifosfamide.'],6,0.2727272727272727,2,33
CD008944,2,9,The majority also reported cisplatin as a risk factor.,rephrase,['Some studies also reported that cisplatin and long follow-up duration were risk factors.'],7,0.30303030303030304,2,33
CD008944,2,10,"In addition, two non-eligible studies showed an association of a longer follow-up period with glomerular dysfunction.",delete,[],8,0.3333333333333333,2,33
CD008944,3,11,"Twenty-two out of 52 studies, including 851 participants, studied proteinuria, which was present in 3.5% to 84% of participants.",rephrase,"['Twenty-two out of 52 studies, including 851 participants, assessed an abnormal amount of proteins in the urine, which they found in 3.5% to 84% of participants.']",8,0.36363636363636365,2,33
CD008944,3,12,"Risk factors, analysed by three non-eligible studies, included HD cisplatin, (HD) ifosfamide, TBI, and a combination of nephrectomy and abdominal radiotherapy.",rephrase,"['Risk factors, evaluated by three non-eligible studies, included cisplatin, ifosfamide, TBI, and a combination of surgery and radiation involving the kidney.']",9,0.3939393939393939,2,33
CD008944,3,13,"However, studies were contradictory and incomparable.",rephrase,"['However, studies were contradictory.']",10,0.42424242424242425,3,33
CD008944,4,14,"Eleven out of 52 studies assessed hypophosphataemia or tubular phosphate reabsorption (TPR), or both.",rephrase,"['Eleven out of 52 studies looked at a low level of phosphate in the blood (hypophosphataemia), or problems with the reabsorption of phosphate by the kidneys in 246 participants.']",11,0.45454545454545453,3,33
CD008944,4,15,"Prevalence ranged between 0% and 36.8% for hypophosphataemia in 287 participants, and from 0% to 62.5% for impaired TPR in 246 participants.",rephrase,['Prevalence of hypophosphataemia ranged between 0% and 36.8% in 287 participants.'],12,0.48484848484848486,3,33
CD008944,4,16,"One non-eligible study investigated risk factors for hypophosphataemia, but could not find any association.",rephrase,"['One non-eligible study investigated risk factors, but could not find any association with hypophosphataemia.']",13,0.5151515151515151,3,33
CD008944,5,17,"Four out of 52 studies, including 128 CCS, assessed the prevalence of hypomagnesaemia, which ranged between 13.2% and 28.6%.",split,"['Four out of 52 studies, including 128 CCS, evaluated a low level of magnesium in the blood (hypomagnesaemia).', 'Prevalence ranged between 13.2% and 28.6%.']",14,0.5454545454545454,3,33
CD008944,5,18,Both non-eligible studies investigating risk factors identified cisplatin as a risk factor.,rephrase,['Two non-eligible studies identified cisplatin as risk factor for hypomagnesaemia.'],16,0.5757575757575758,3,33
CD008944,5,19,"Carboplatin, nephrectomy and follow-up time were other reported risk factors.",rephrase,"['Other reported risk factors were carboplatin, surgery of the kidney, and follow-up time.']",17,0.6060606060606061,4,33
CD008944,6,20,The prevalence of hypertension ranged from 0% to 50% in 2464 participants (30/52 studies).,rephrase,['The prevalence of high blood pressure ranged from 0% to 50% in 2464 participants (30/52 studies).'],18,0.6363636363636364,4,33
CD008944,6,21,Risk factors reported by one eligible study were older age at screening and abdominal radiotherapy.,rephrase,['Risk factors reported by one eligible study were older age at screening and radiation involving the kidney.'],19,0.6666666666666666,4,33
CD008944,6,22,A non-eligible study also found long follow-up time as risk factor.,merge,[],20,0.696969696969697,4,33
CD008944,6,23,Three non-eligible studies showed that a higher body mass index increased the risk of hypertension.,none,['A high body mass index was reported as a risk factor by three non-eligible studies.'],20,0.7272727272727273,4,33
CD008944,6,24,"Treatment-related risk factors were abdominal radiotherapy and TBI, but studies were inconsistent.",delete,[],21,0.7575757575757576,4,33
CD008944,7,25,"Because of the profound heterogeneity of the studies, it was not possible to perform meta-analyses.",delete,[],21,0.7878787878787878,4,33
CD008944,7,26,Risk of bias was present in all studies.,delete,[],21,0.8181818181818182,5,33
CD008944,8,27,"The prevalence of adverse renal effects after treatment with cisplatin, carboplatin, ifosfamide, radiation therapy involving the kidney region, nephrectomy, or any combination of these, ranged from 0% to 84% depending on the study population, received treatment combination, reported outcome measure, follow-up duration and methodological quality.",delete,[],21,0.8484848484848485,5,33
CD008944,8,28,"With currently available evidence, it was not possible to draw solid conclusions regarding the prevalence of, and treatment-related risk factors for, specific adverse renal effects.",rephrase,"['More, and especially higher-quality research is needed to gain better insight into kidney adverse effects and related risk factors.']",21,0.8787878787878788,5,33
CD008944,8,29,"Future studies should focus on adequate study designs and reporting, including large prospective cohort studies with adequate control groups when possible.",delete,[],22,0.9090909090909091,5,33
CD008944,8,30,"In addition, these studies should deploy multivariable risk factor analyses to correct for possible confounding.",delete,[],22,0.9393939393939394,5,33
CD008944,8,31,"Next to research concerning known nephrotoxic therapies, exploring nephrotoxicity after new therapeutic agents is advised for future studies.",delete,[],22,0.9696969696969697,5,33
CD008944,8,32,"Until more evidence becomes available, CCS should preferably be enrolled into long-term follow-up programmes to monitor their renal function and blood pressure.",delete,[],22,1.0,5,33
CD009753,0,0,"We identified six eligible trials including 16,135 individuals.",rephrase,"['We identified six eligible primary prevention trials including 16,135 individuals without established cardiovascular disease that compared fibrate therapy with placebo or usual care.']",0,0.07692307692307693,1,13
CD009753,0,1,The mean age of trial populations varied across trials; between 47.3 and 62.3 years.,merge,['The mean age of the trial populations varied between 47.3 and 62.3 years; the majority of included individuals had diabetes mellitus type 2.'],1,0.15384615384615385,1,13
CD009753,0,2,Four trials included individuals with diabetes mellitus type 2 only.,none,[],1,0.23076923076923078,2,13
CD009753,0,3,The mean treatment duration and follow-up of participants across trials was 4.8 years.,ignore,['The mean treatment duration and follow-up of participants across trials was 4.8 years.'],2,0.3076923076923077,2,13
CD009753,0,4,"We judged the risks of selection and performance bias to be low; risks of detection bias, attrition bias, and reporting bias were unclear.",delete,[],3,0.38461538461538464,2,13
CD009753,0,5,Reporting of adverse effects by included trials was very limited; that is why we used discontinuation of therapy due to adverse effects as a proxy for adverse effects.,rephrase,['The reporting of adverse effects by identified trials was very limited.'],3,0.46153846153846156,3,13
CD009753,0,6,"Patients treated with fibrates had a reduced risk for the combined primary outcome of CVD death, non-fatal myocardial infarction, or non-fatal stroke compared to patients on placebo (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.74 to 0.96; participants = 16,135; studies = 6; moderate-quality of evidence).",merge,"['Moderate-quality evidence suggests a risk reduction of 16% with fibrate therapy for the combined outcome of death due to cardiovascular disease, heart attack, or stroke.']",4,0.5384615384615384,3,13
CD009753,0,7,"For secondary outcomes we found RRs for fibrate therapy compared with placebo of 0.79 for combined coronary heart disease death or non-fatal myocardial infarction (95% CI 0.68 to 0.92; participants = 16,135; studies = 6; moderate-quality of evidence); 1.01 for overall mortality (95% CI 0.81 to 1.26; participants = 8471; studies = 5; low-quality of evidence); 1.01 for non-CVD mortality (95% CI 0.76 to 1.35; participants = 8471; studies = 5; low-quality of evidence); and 1.38 for discontinuation of therapy due to adverse effects (95% CI 0.71 to 2.68; participants = 4805; studies = 3; I2 = 74%; very low-quality of evidence).",none,[],4,0.6153846153846154,4,13
CD009753,0,8,Data on quality of life were not available from any trial.,rephrase,['Data on quality of life were not available from any included study.'],5,0.6923076923076923,4,13
CD009753,0,9,Trials that evaluated fibrates in the background of statins (2 studies) showed no benefits in preventing cardiovascular events.,ignore,['Trials that evaluated fibrates in the background of statin treatment showed no benefits in preventing cardiovascular events.'],6,0.7692307692307693,4,13
CD009753,1,10,"Moderate-quality evidence suggests that fibrates lower the risk for cardiovascular and coronary events in primary prevention, but the absolute treatment effects in the primary prevention setting are modest (absolute risk reductions < 1%).",merge,[],7,0.8461538461538461,5,13
CD009753,1,11,There is low-quality evidence that fibrates have no effect on overall or non-CVD mortality.,none,"['Moderate-quality evidence also suggests a risk reduction for fatal and non-fatal heart attacks with fibrates, but there is low-quality evidence for no risk reduction for overall mortality or death from non-CVD with fibrates.']",7,0.9230769230769231,5,13
CD009753,1,12,Very low-quality evidence suggests that fibrates are not associated with increased risk for adverse effects.,rephrase,['Very-low quality evidence suggests that there is no increased risk for adverse effects with fibrate treatment.'],8,1.0,5,13
CD000437,0,0,We included only one trial in the review.,delete,[],0,0.1,1,10
CD000437,0,1,Keszler 1991 randomly assigned 166 preterm infants; reported data on 144 infants; and permitted cross-over to the alternate treatment if initial treatment failed.,rephrase,['One study randomly assigned 166 preterm infants and reported data on 144 infants.'],0,0.2,1,10
CD000437,0,2,"Investigators found no statistically significant differences in overall mortality (including survival after cross-over) between the two groups (RR 1.07, 95% confidence interval (CI) 0.67 to 1.72).",rephrase,['Investigators found no statistically significant differences in overall mortality (including survival after cross-over) between the two groups.'],1,0.3,2,10
CD000437,0,3,"In a secondary analysis of infants up to the time of cross-over, rescue treatment with HFJV was associated with lower mortality (RR 0.66, 95% CI 0.45 to 0.97).",rephrase,"['In a secondary analysis, researchers showed that rescue treatment with HFJV, up to the time of cross-over, was associated with lower mortality.']",2,0.4,2,10
CD000437,0,4,"Researchers reported no significant differences in the incidence of CLD among survivors at 28 days of age, nor in the incidence of intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.",rephrase,"['Researchers reported no differences in the incidence of chronic lung disease among survivors at 28 days of age, and they found no differences in intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.']",3,0.5,3,10
CD000437,1,5,"Study authors reported no significant differences in overall mortality between rescue high-frequency jet ventilation and conventional ventilation and presented highly imprecise results for important adverse effects such as intraventricular haemorrhage, new air leaks, airway obstruction and necrotising tracheobronchitis.",delete,[],4,0.6,3,10
CD000437,2,6,The overall quality of evidence is affected by limitations in trial design and by imprecision due to the small number of infants in the included study.,delete,[],4,0.7,4,10
CD000437,2,7,Existing evidence does not support the use of high-frequency jet ventilation as rescue therapy in preterm infants.,rephrase,['Existing evidence does not support the use of rescue high-frequency jet ventilation compared with conventional mechanical ventilation for treatment of preterm infants with severe pulmonary problems.'],4,0.8,4,10
CD000437,3,8,Studies that target populations at greatest risk and that have sufficient power to assess important outcomes are needed.,rephrase,['Additional research is needed.'],5,0.9,5,10
CD000437,3,9,These trials should incorporate long-term pulmonary and neurodevelopmental outcomes.,delete,[],6,1.0,5,10
CD011608,0,0,We included 51 RCTs with 2793 participants; of these 45 RCTs (2491 participants: peripheral nerve block = 1288; comparators = 1203) were included in meta-analyses.,rephrase,['We included 51 studies (2793 participants) in the review and analysed results from 45 studies (2491 participants).'],0,0.07692307692307693,1,13
CD011608,0,1,There are 11 ongoing studies and three awaiting classification.,ignore,['There are 11 ongoing studies and three awaiting classification.'],1,0.15384615384615385,1,13
CD011608,1,2,"Compared to systemic analgesia alone, peripheral nerve blocks reduced: pain at rest on arrival in the postoperative care unit (SMD -1.12, 95% CI -1.67 to -0.56; 9 trials, 429 participants; equivalent to 3.2 on 0 to 10 scale; moderate-quality evidence); risk of acute confusional status: risk ratio (RR) 0.10 95% CI 0.02 to 0.54; 1 trial, 225 participants; number needed to treat for additional benefit (NNTB) 12, 95% CI 11 to 22; very low-quality evidence); pruritus (RR 0.16, 95% CI 0.04 to 0.70; 2 trials, 259 participants for continuous peripheral nerve blocks; NNTB 4 (95% CI 4 to 8); very low-quality evidence); hospital length of stay (SMD -0.75, 95% CI -1.02 to -0.48; very low-quality evidence; 2 trials, 249 participants; equivalent to 0.75 day).",rephrase,"['Compared to systemic analgesia, we found that peripheral nerve blocks reduce pain, reduce the risk of becoming confused (e.g. not knowing the date, time, or location) (for every 12 people treated one fewer will become confused), reduce itching (for every 4 people treated one fewer will develop itch), hospital length of stay (equivalent to 0.75 day) and increase patient satisfaction for pain treatment (equivalent to 2.4 points more on a 0 to 10 scale).']",2,0.23076923076923078,2,13
CD011608,1,3,"Participant satisfaction increased (SMD 0.67, 95% CI 0.45 to 0.89; low-quality evidence; 5 trials, 363 participants; equivalent to 2.4 on 0 to 10 scale).",delete,[],3,0.3076923076923077,2,13
CD011608,1,4,We did not find a difference for the number of participants walking on postoperative day one (very low-quality evidence).,rephrase,['We did not find a difference in time to first walk after surgery.'],3,0.38461538461538464,2,13
CD011608,1,5,Two nerve block-related complications were reported: one local haematoma and one delayed persistent paresis.,rephrase,['Two people had complications: one local haematoma and one delayed persistent muscle weakness.'],4,0.46153846153846156,3,13
CD011608,2,6,"Compared to neuraxial blocks, peripheral nerve blocks reduced the risk of pruritus (RR 0.33, 95% CI 0.19 to 0.58; 6 trials, 299 participants; moderate-quality evidence; NNTB 6 (95% CI 5 to 9).",delete,[],5,0.5384615384615384,3,13
CD011608,2,7,We did not find a difference for pain at rest on arrival in the postoperative care unit (moderate-quality evidence); number of nerve block-related complications (low-quality evidence); acute confusional status (very low-quality evidence); hospital length of stay (low quality-evidence); time to first walk (low-quality evidence); or participant satisfaction (high-quality evidence).,delete,[],5,0.6153846153846154,4,13
CD011608,3,8,We found that peripheral nerve blocks provide better pain control compared to systemic analgesia with no major differences between peripheral nerve blocks and neuraxial blocks.,delete,[],5,0.6923076923076923,4,13
CD011608,3,9,We also found that peripheral nerve blocks may be associated with reduced risk of postoperative acute confusional state and a modest reduction in hospital length of stay that could be meaningful in terms of cost reduction considering the increasing numbers of procedures performed annually.,delete,[],5,0.7692307692307693,4,13
CD011608,4,10,"Compared to systemic analgesia alone, there is moderate-quality evidence that peripheral nerve blocks reduce postoperative pain, low-quality evidence that patient satisfaction is increased and very low-quality evidence for reductions in acute confusional status, pruritus and hospital length of stay .",rephrase,['The quality of evidence for peripheral nerve blocks compared with systemic pain relievers was rated as moderate to very low.'],5,0.8461538461538461,5,13
CD011608,5,11,We found moderate-quality evidence that peripheral nerve blocks reduce pruritus compared with neuraxial blocks.,rephrase,"['The quality of evidence for peripheral nerve blocks compared to neuraxial blocks was rated as high for patient satisfaction, moderate for reducing itch, similar pain relief, low for similar block-related complications, hospital length of stay and time to first walk.']",6,0.9230769230769231,5,13
CD011608,6,12,"The 11 ongoing studies, once completed, and the three studies awaiting classification may alter the conclusions of the review once assessed",delete,[],7,1.0,5,13
CD006061,0,0,One randomised controlled trial and eleven prospective cohort studies were identified.,split,"['In this review the effect of whole grain foods and cereal fibre (as a marker of whole-grain food intake) on the prevention of type 2 diabetes mellitus (T2DM) was assessed using all available prospective cohort studies and randomised controlled trials.', 'In addition eleven prospective cohort studies were found.']",0,0.09090909090909091,1,11
CD006061,0,1,"The randomised controlled trial, which was of low methodological quality, reported the change in insulin sensitivity in 12 obese hyperinsulinemic participants after six-week long interventions.",rephrase,['Only one randomised controlled trial was found which was of low methodological quality.'],2,0.18181818181818182,1,11
CD006061,0,2,Intake of whole grain foods resulted in a slight improvement of insulin sensitivity and no adverse effects.,split,"['This study investigated in 12 overweight persons during six weeks the effect of the consumption of refined grain foods versus that of whole grain foods on insulin sensitivity (risk factor for the development of T2DM).', 'Intake of whole grain foods resulted in a slight improvement of insulin sensitivity, increased bowel movements and no adverse effects.']",3,0.2727272727272727,2,11
CD006061,0,3,"Patient satisfaction, health related quality of life, total mortality and morbidity was not reported.",rephrase,"['No information was given about patient satisfaction, health related quality of life, total mortality and morbidity.']",5,0.36363636363636365,2,11
CD006061,1,4,"Four of the eleven cohort studies measured cereal fibre intake, three studies whole grain intake and two studies both.",delete,[],6,0.45454545454545453,3,11
CD006061,1,5,Two studies measured the change in whole grain food intake and one of them also change in cereal fibre intake.,delete,[],6,0.5454545454545454,3,11
CD006061,1,6,The incidence of T2DM was assessed in nine studies and changes in weight gain in two studies.,delete,[],6,0.6363636363636364,4,11
CD006061,1,7,The prospective studies consistently showed a reduced risk for high intake of whole grain foods (27% to 30%) or cereal fibre (28% to 37%) on the development of T2DM.,rephrase,['They consistently showed that a high intake of whole grain foods or cereal fibre is associated with a lower risk of the development of T2DM.'],6,0.7272727272727273,4,11
CD006061,2,8,The evidence from only prospective cohort trials is considered to be too weak to be able to draw a definite conclusion about the preventive effect of whole grain foods on the development of T2DM.,rephrase,"['However, evidence for a protective effect coming from prospective cohort studies only has to be considered as weak as with this design no cause and effect relationship can be established.']",7,0.8181818181818182,5,11
CD006061,2,9,Properly designed long-term randomised controlled trials are needed.,rephrase,['Well-designed randomised controlled trials are needed to be able to draw definite conclusions about the preventive effects of whole grain consumption on development of T2DM.'],8,0.9090909090909091,5,11
CD006061,2,10,"To facilitate this, further mechanistic research should focus on finding a set of relevant intermediate endpoints for T2DM and on identifying genetic subgroups of the population at risk that are most susceptible to dietary intervention.",delete,[],9,1.0,5,11
CD011247,0,0,"Three studies (one cluster-RCT and two CBAs) comprising a total of 13,885 participants (9640 children and 4245 adults) as well as 1200 households in two LMICs (Nicaragua and Niger) met the inclusion criteria.",rephrase,"['We included three studies on a total of 13,885 participants (9640 children and 4245 adults) and 1200 households in Nicaragua and Niger.']",0,0.07142857142857142,1,14
CD011247,0,1,"They examined five UCTs between USD 145 and USD 250 (or more, depending on household characteristics) that were provided by governmental, non-governmental or research organisations during experiments or pilot programmes in response to droughts.",rephrase,"['They examined five programmes by governmental, non-governmental or research organisations that gave recipients cash handouts worth USD 145 to USD 250 (or more, depending on household characteristics) as part of a disaster response (in these cases, to droughts).']",1,0.14285714285714285,1,14
CD011247,0,2,"Two studies examined the effectiveness of UCTs, and one study examined the relative effectiveness of in-hand UCTs compared with in-kind transfers and UCTs paid via mobile phone.",delete,[],2,0.21428571428571427,2,14
CD011247,0,3,"Due to the methodologic limitations of the retrieved records, which carried a high risk of bias and very serious indirectness, we considered the body of evidence to be of very low overall quality and thus very uncertain across all outcomes.",rephrase,"['The studies had some serious methodological limitations, so we considered the evidence to be of very low quality and very uncertain.']",2,0.2857142857142857,2,14
CD011247,1,4,"Depending on the specific health services use and health outcomes examined, the included studies either reported no evidence that UCTs had impacted the outcome, or they reported that UCTs improved the outcome.",delete,[],3,0.35714285714285715,2,14
CD011247,1,5,No single outcome was reported by more than one study.,delete,[],3,0.42857142857142855,3,14
CD011247,1,6,"There was a very small increase in the proportion of children who received vitamin or iron supplements (mean difference (MD) 0.10 standard deviations (SDs), 95% confidence interval (CI) 0.06 to 0.14) and on the child's home environment, as well as clinically meaningful, very large reductions in the chance of child death (hazard ratio (HR) 0.26, 95% CI 0.10 to 0.66) and the incidence of severe acute malnutrition (HR 0.44, 95% CI 0.24 to 0.80).",rephrase,"[""UCTs appeared to contribute to a very small increase in the proportion of children who received vitamin or iron supplements and a beneficial effect on children's home environment.""]",3,0.5,3,14
CD011247,1,7,"There was also a moderate reduction in the number of days children spent sick in bed (MD − 0.36 SDs, 95% CI − 0.62 to − 0.10).",rephrase,"[""They may have resulted in a very large reduction in the chance of dying, a moderate reduction in the number of days spent sick in bed, and a large reduction in children's risk of acute malnutrition.""]",4,0.5714285714285714,3,14
CD011247,1,8,"There was no evidence for any effect on the proportion of children receiving deworming drugs, height for age among children, adults' level of depression, or the quality of parenting behaviour.",rephrase,"[""UCTs had no clear effect on the proportion of children who received deworming drugs, children's height for age, adults' level of depression, or the quality of parenting behaviour.""]",5,0.6428571428571429,4,14
CD011247,1,9,No adverse effects were identified.,merge,[],6,0.7142857142857143,4,14
CD011247,1,10,"The included comparisons did not examine several important outcomes, including food security and equity impacts.",none,"['No adverse effects were identified.The included studies did not examine several important outcomes, including food security and equity impacts.']",6,0.7857142857142857,4,14
CD011247,2,11,"With regard to the relative effectiveness of UCTs compared with a food transfer providing a relatively high total caloric value, there was no evidence that a UCT had any effect on the chance of child death (HR 2.27, 95% CI 0.69 to 7.44) or severe acute malnutrition (HR 1.15, 95% CI 0.67 to 1.99).",rephrase,"['Compared with grants of food, there was no evidence that a UCT influenced the chance of child death or severe acute malnutrition.']",7,0.8571428571428571,5,14
CD011247,2,12,"A UCT paid in-hand led to a clinically meaningful, moderate increase in the household dietary diversity score, compared with the same UCT paid via mobile phone (difference-in-differences estimator 0.43 scores, 95% CI 0.06 to 0.80), but there was no evidence for an effect on social determinants of health, health service expenditure, or local markets and infrastructure.",rephrase,"['Compared with the same UCT paid via mobile phone, a UCT paid in-hand led to a moderate increase in household dietary diversity, but there was no evidence for any effect on social determinants of health, health service expenditure, or local markets and infrastructure.']",8,0.9285714285714286,5,14
CD011247,3,13,Additional high-quality evidence (especially RCTs of humanitarian disaster contexts other than droughts) is required to reach clear conclusions regarding the effectiveness and relative effectiveness of UCTs for improving health services use and health outcomes in humanitarian disasters in LMICs.,rephrase,['Additional research is required to reach clear conclusions regarding the effectiveness and relative effectiveness of UCTs in improving health services use and health outcomes in humanitarian disasters in LMICs.'],9,1.0,5,14
CD014989,0,0,We included nine RCTs with a total of 513 participants included in the final analysis.,rephrase,"['We found nine trials with a total of 526 participants, of which 13 participants were not included in the final analysis because they were either lost to follow-up or did not follow the trial instructions.']",0,0.1,1,10
CD014989,0,1,Three studies included patients younger than 60 years of age; two trials accepted patients up to 80 years of age; and one trial only included patients 60 years or older.,rephrase,"['Two trials recruited patients up to 80 years of age, and one trial only included patients above 60 years old.']",1,0.2,1,10
CD014989,0,2,"The majority of included trials (six) mandated a time from stroke ictus to treatment of < 48 hours, whilst in two of them this was < 96 hours.",rephrase,['Six trials treated patients within 48 hours of when their stroke was first noted.'],2,0.3,2,10
CD014989,1,3,"Surgical decompression was associated with a reduction in death (odds ratio (OR) 0.18, 95% confidence interval (CI) 0.12 to 0.27, 9 trials, 513 participants, P < 0.001; high-certainty evidence); death or severe disability (mRS > 4, OR 0.22, 95% CI 0.15 to 0.32, 9 trials, 513 participants, P < 0.001; high-certainty evidence); and death or moderate disability (mRS > 3, OR 0.34, 95% CI 0.22 to 0.52, 9 trials, 513 participants, P < 0.001; moderate-certainty evidence).",delete,[],3,0.4,2,10
CD014989,1,4,Subgroup analysis did not reveal any significant effect on treatment outcomes when analysing age (< 60 years versus ≥ 60 years); time from stroke ictus to intervention (< 48 hours versus ≥ 48 hours); or dysphasia.,delete,[],3,0.5,3,10
CD014989,1,5,"There was a significant subgroup effect of time at follow-up (6 versus 12 months, P = 0.02) on death as well as death or severe disability (mRS > 4); however, the validity of this finding was affected by fewer participant numbers in the six-month follow-up subgroup.",delete,[],3,0.6,3,10
CD014989,1,6,"There was no consistent reporting of per-participant adverse event rates in any of the included studies, which prevented further analysis.",rephrase,"['The harms of surgery, or any intervention including medical management, were not reported in a consistent manner across the included trials, therefore we could draw no meaningful conclusions on potential harms.']",3,0.7,4,10
CD014989,2,7,"Surgical decompression improves outcomes in the management of malignant oedema after acute ischaemic stroke, including a considerable reduction in death or severe disability (mRS > 4) and a reduction in death or moderate disability (mRS > 3).",rephrase,['Surgical decompression improved outcomes in people with large strokes when compared to medical treatment alone.'],4,0.8,4,10
CD014989,2,8,"Whilst there is evidence that this positive treatment effect is present in patients > 60 years old, it is important to take into account that these patients have a poorer prospect of functional survival independent of this treatment effect.",delete,[],5,0.9,5,10
CD014989,2,9,"In interpreting these results it must also be considered that the data demonstrating benefit are drawn from a unique patient subset with profound neurological deficit, reduced level of consciousness, and no pre-morbid disability or severe comorbidity.",delete,[],5,1.0,5,10
CD008203,0,0,"For this update we included one RCT with 17,802 participants that assessed rosuvastatin compared with placebo for the prevention of VTE.",split,"['Our review included one published randomised controlled trial, involving 17,802 participants, which reported outcomes of VTE.', 'This trial investigated rosuvastatin compared with placebo for the primary prevention of VTE.']",0,0.14285714285714285,1,7
CD008203,0,1,"The quality of the evidence was moderate because of imprecision, as the required sample size for the outcomes of this review was not achieved.",ignore,"['Quality of the evidence\nThe quality of the evidence was moderate because of imprecision, as the required sample size for the outcomes of this review was not achieved.']",2,0.2857142857142857,2,7
CD008203,0,2,"Analysis showed that when compared with placebo rosuvastatin reduced the incidence of VTE (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.37 to 0.86) and deep vein thrombosis (DVT) (OR 0.45, 95% CI 0.25 to 0.79), the risk of any (fatal and non-fatal) myocardial infarction (MI) (OR 0.45, 95% CI 0.30 to 0.69), and any (fatal and non-fatal) stroke (OR 0.51, 95% CI 0.34 to 0.78).",rephrase,"['Analysis showed that, compared with placebo, rosuvastatin reduced the incidence of VTE and DVT, the risk of any (fatal and non-fatal) myocardial infarction, and any (fatal and non-fatal) stroke.']",3,0.42857142857142855,3,7
CD008203,0,3,"There was no difference in the incidence of pulmonary embolism (PE) (OR 0.77, 95% CI 0.41 to 1.46), fatal MI (OR 1.50, 95% CI 0.53 to 4.22), fatal stroke (OR 0.30, 95% CI 0.08 to 1.09) or death after VTE (OR 0.50, 95% CI 0.20 to 1.24).",rephrase,"['There were no differences between rosuvastatin and placebo in the incidence of pulmonary embolism, fatal myocardial infarction, fatal stroke, and death after VTE.']",4,0.5714285714285714,3,7
CD008203,0,4,"The incidence of any serious adverse events was no different between the rosuvastatin and placebo groups (OR 1.07, 95% CI 0.95 to 1.20).",rephrase,['The incidence of any serious adverse events was not different between rosuvastatin and placebo.'],5,0.7142857142857143,4,7
CD008203,1,5,"Available evidence showed that rosuvastatin was associated with a reduced incidence of VTE, but the evidence was limited to a single RCT and any firm conclusions and suggestions could be not drawn.",rephrase,['No firm conclusions or suggestions could be made from these findings.'],6,0.8571428571428571,5,7
CD008203,1,6,Randomised controlled trials of statins (including rosuvastatin) are needed to evaluate their efficacy in the prevention of VTE.,ignore,['More randomised controlled trials of statins (including rosuvastatin) are needed to evaluate the efficacy of statins in the prevention of VTE.'],7,1.0,5,7
CD011679,0,0,"We included three randomised, placebo-controlled trials investigating Souvenaid in 1097 community-dwelling participants with Alzheimer's disease.",split,"['We found three RCTs with a total of 1097 participants to include in the review.', 'Two of the trials investigated Souvenaid in people with dementia over a treatment period of 24 weeks.']",0,0.058823529411764705,1,17
CD011679,0,1,"One study each included participants with prodromal AD, mild AD dementia and mild-to-moderate AD dementia.",rephrase,['One of these included 527 participants with mild-to-moderate dementia due to AD and the other included 259 participants with mild dementia due to AD.'],2,0.11764705882352941,1,17
CD011679,0,2,We rated the risks of bias of all trials as low.,delete,[],3,0.17647058823529413,1,17
CD011679,0,3,One study (in prodromal AD) was funded by European grants.,rephrase,['The third study (in prodromal AD) was funded by European grants.'],3,0.23529411764705882,2,17
CD011679,0,4,The other two studies were funded by the manufacturer of Souvenaid.,rephrase,['Two studies were funded by the manufacturer of Souvenaid.'],4,0.29411764705882354,2,17
CD011679,1,5,"One trial investigated the incidence of dementia in people with prodromal AD at baseline, and found little to no difference between the Souvenaid group and the placebo group after 24 months (RR 1.09, 95% CI 0.82 to 1.43; 1 trial, 311 participants; moderate quality of evidence).",rephrase,['The third trial investigated the use of Souvenaid for two years in 311 people with prodromal AD.'],5,0.35294117647058826,2,17
CD011679,2,6,"In prodromal AD, and in mild and mild-to-moderate Alzheimer's disease dementia, Souvenaid probably results in little or no difference in global or specific cognitive functions (moderate quality of evidence).",rephrase,['Souvenaid probably had little or no effect on measures of memory or other thinking skills in people with prodromal AD (after two years of treatment) or with mild or mild-to-moderate dementia due to AD (after 24 weeks of treatment).'],6,0.4117647058823529,3,17
CD011679,2,7,"Everyday function, or the ability to perform activities of daily living, were measured in mild and mild-to-moderate AD dementia.",merge,['It also probably had little or no effect on the ability of people with mild or mild-to-moderate dementia due to AD to manage everyday activities (again after 24 weeks).'],7,0.47058823529411764,3,17
CD011679,2,8,Neither study found evidence of a difference between the groups after 24 weeks of treatment (moderate quality of evidence).,none,[],7,0.5294117647058824,3,17
CD011679,2,9,Two studies investigated combined cognitive-functional outcomes with the Clinical Dementia Rating Sum of Boxes and observed conflicting results.,rephrase,['Two studies used an outcome scale which combined memory and thinking skills with practical skills (described as a combined cognitive-functional outcome).'],8,0.5882352941176471,3,17
CD011679,2,10,"Souvenaid probably results in slight improvement, which is below estimates of meaningful change, in participants with prodromal Alzheimer's disease after 24 months (moderate quality of evidence), but probably has little to no effect in mild-to-moderate Alzheimer's disease dementia after 24 weeks (moderate quality of evidence).",delete,[],9,0.6470588235294118,4,17
CD011679,3,11,"Adverse effects observed were low in all trials, and the available data were insufficient to determine any connection with Souvenaid.",delete,[],9,0.7058823529411765,4,17
CD011679,4,12,Two years of treatment with Souvenaid probably does not reduce the risk of progression to dementia in people with prodromal AD.,rephrase,['There was probably a small benefit of Souvenaid on this outcome among people with prodromal AD who took Souvenaid for two years.'],9,0.7647058823529411,4,17
CD011679,4,13,There is no convincing evidence that Souvenaid affects other outcomes important to people with AD in the prodromal stage or mild-to-moderate stages of dementia.,rephrase,"['However, there was probably little or no effect of Souvenaid on this outcome among people with mild-to-moderate AD dementia who took it for 24 weeks.']",10,0.8235294117647058,5,17
CD011679,4,14,Conflicting evidence on combined cognitive-functional outcomes in prodromal AD and mild AD dementia warrants further investigation.,delete,[],11,0.8823529411764706,5,17
CD011679,4,15,"Adverse effects of Souvenaid seem to be uncommon, but the evidence synthesised in this review does not permit us to make a definitive statement on the long-term tolerability of Souvenaid.",delete,[],11,0.9411764705882353,5,17
CD011679,4,16,The effects of Souvenaid in more severe AD dementia or in people with AD at risk of nutritional deficiencies remain unclear.,delete,[],11,1.0,5,17
CD006830,0,0,We identified two studies with a total of 79 participants.,split,"['We searched extensively through scientific publications and found two trials, with a total of 79 participants.', 'A total of 35 of the 79 participants in the two trials were given cyclobenzaprine.']",0,0.1,1,10
CD006830,0,1,"One study, with 41 participants, compared cyclobenzaprine with clonazepam and with placebo.",split,"['These tested cyclobenzaprine against another drug called clonazepam, and fake medication (placebo), or against injections of a local anesthetic called lidocaine.', 'Cyclobenzaprine was slightly better than clonazepam and placebo at reducing jaw pain, but was no better at improving sleep quality.']",2,0.2,1,10
CD006830,0,2,"Participants taking cyclobenzaprine had some improvement of pain intensity compared to those on clonazepam, mean difference (MD) -0.25 (95% CI, -0.41 to -0.09; P value 0.002) and placebo, MD -0.25 (95% CI, 0.41 to -0.09; P value 0.002).",delete,[],4,0.3,2,10
CD006830,0,3,"The other study, with 38 participants, compared cyclobenzaprine with lidocaine infiltration.",rephrase,"['The results from the other trial were not scientifically reliable because of the small number of participants involved, but lidocaine injections seemed to reduce pain slightly better than cyclobenzaprine pills.']",4,0.4,2,10
CD006830,0,4,"Thirty days after treatment there were statistically non-significant differences between comparison groups, favoring lidocaine infiltration, for the mean for global pain, MD 0.90 (95% CI -0.35 to 2.15, P value 0.16), and for the mean for pain at digital compression, MD 0.60 (95% CI -0.55 to 1.75, P value 0.30).",delete,[],5,0.5,3,10
CD006830,0,5,There were no life-threatening adverse events associated with the medications.,rephrase,['There were no life-threatening adverse events associated with any of the medications studied.'],5,0.6,3,10
CD006830,1,6,There was insufficient evidence to support the use of cyclobenzaprine in the treatment of MP.,split,"['Despite this result, it is likely that, because it is uncomfortable to receive any form of injection, people who suffer from MP will prefer to be treated with cyclobenzaprine pills.', 'Further studies are needed to show whether cyclobenzaprine really works for treating MP, but at the moment doctors cannot say whether it is really useful.']",6,0.7,4,10
CD006830,1,7,"We identified only two small studies in which a total of 35 participants were given cyclobenzaprine, and it was not possible to estimate risks for benefits or harms.",delete,[],8,0.8,4,10
CD006830,1,8,Further high quality RCTs of cyclobenzaprine for treating MP need to be conducted before firm conclusions on its effectiveness and safety can be made.,delete,[],8,0.9,5,10
CD006830,1,9,"Experts in this area should elect cut-off points for participants to identify whether a patient has achieved a clinically relevant reduction of pain (primary outcome), so that their results can be combined easily into future versions of this review.",delete,[],8,1.0,5,10
CD010191,0,0,We included three trials involving 538 participants.,rephrase,"['Overall, we found three trials with 538 participants which could be included in this review.']",0,0.08333333333333333,1,12
CD010191,0,1,"We found low quality of evidence indicating uncertainty whether pre-hopsital thrombolysis reduces all-cause mortality in individuals with STEMI compared to in-hospital thrombolysis (risk ratio 0.73, 95% confidence interval 0.37 to 1.41).",rephrase,['We found low-quality evidence indicating uncertainty whether the numbers of people dying were different when therapy was given before hospital compared to in hospital (3 trials).'],1,0.16666666666666666,1,12
CD010191,0,2,"We found high-quality evidence (two trials, 438 participants) that pre-hospital thrombolysis reduced the time to receipt of thrombolytic treatment compared with in-hospital thrombolysis.",merge,"['We found high-quality evidence that giving therapy before hospital reduced the time taken for an individual to receive thrombolytic therapy by more than 30 minutes (two studies) and generally low-quality evidence that side effects, such as allergic reactions and bleeding, were similar whether therapy was given pre-hospital or in hospital.']",2,0.25,2,12
CD010191,0,3,"For adverse events, we found moderate-quality evidence that the occurrence of bleeding events was similar between participants receiving in-hospital or pre-hospital thrombolysis (two trials, 438 participants), and low-quality evidence that the occurrence of ventricular fibrillation (two trials, 178 participants), stroke (one trial, 78 participants) and allergic reactions (one trial, 100 participants) was also similar between participants receiving in-hospital or pre-hospital thrombolysis.",none,[],2,0.3333333333333333,2,12
CD010191,0,4,We considered the included studies to have an overall unclear/high risk of bias.,rephrase,['The main limitations of the evidence were the unclear/high risk of bias in the studies and the low numbers of people recruited.'],3,0.4166666666666667,3,12
CD010191,1,5,"Pre-hospital thrombolysis reduces time to treatment, based on studies conducted in higher income countries.",rephrase,['We conclude that clot-busting therapy given before arriving at a hospital reduces the time taken for an individual to receive thrombolytic treatment.'],4,0.5,3,12
CD010191,1,6,"In settings where it can be safely and correctly administered by trained staff, pre-hospital thrombolysis may be an appropriate intervention.",rephrase,"['The limitations of the evidence we have found should be considered carefully, especially in settings where thrombolysis can be safely and correctly administered by trained staff.']",5,0.5833333333333334,3,12
CD010191,1,7,"Pre-hospital thrombolysis has the potential to reduce the burden of STEMI in lower- and middle-income countries, especially in individuals who have limited access to in-hospital thrombolysis or percutaneous coronary interventions.",delete,[],6,0.6666666666666666,4,12
CD010191,1,8,We found no randomised controlled trials evaluating the efficacy of pre-hospital thrombolysis for STEMI in lower- and middle-income countries.,rephrase,"['We found that there were no trials evaluating pre-hospital thrombolytic therapy in poorer countries, and therefore further research in such settings will provide more information to advise on whether giving this therapy for heart attacks is safe and effective.']",6,0.75,4,12
CD010191,1,9,Large high-quality multicentre randomised controlled trials implemented in resource-constrained countries will provide additional evidence for the efficacy and safety of this intervention.,delete,[],7,0.8333333333333334,5,12
CD010191,1,10,Local policy makers should consider their local health infrastructure and population distribution needs.,delete,[],7,0.9166666666666666,5,12
CD010191,1,11,These considerations should be taken into account when developing clinical guidelines for pre-hospital thrombolysis.,delete,[],7,1.0,5,12
CD006435,0,0,Only one study (156 children aged between seven weeks and 24 months with signs and symptoms of bronchiolitis) met the eligibility criteria for inclusion.,rephrase,['We found only one study (156 children) that met our criteria for analysis.'],0,0.125,1,8
CD006435,0,1,"Participants were randomised into three groups: nebulised salbutamol, nebulised saline and mist in a tent.",rephrase,['The study compared nebulised salbutamol and mist in a tent (humidified air).'],1,0.25,2,8
CD006435,0,2,The results showed a significant decrease in respiratory distress symptom (RDS) score in the nebulised salbutamol group but no significant decrease in the RDS score in the mist in a tent or nebulised saline groups.,rephrase,['The results showed that nebulised salbutamol was effective in relieving respiratory distress in acute bronchiolitis in young children while mist therapy was not effective.'],2,0.375,2,8
CD006435,0,3,The study did not report on adverse effects of the interventions.,ignore,['The study did not report on adverse effects for either intervention.'],3,0.5,3,8
CD006435,1,4,Steam inhalation (or cool mist therapy) is commonly used to treat acute bronchiolitis in resource-constrained settings.,delete,[],4,0.625,4,8
CD006435,1,5,One study was eligible for inclusion and found that nebulised salbutamol was an effective intervention for young children with bronchiolitis but mist in a tent did not lead to a significant decrease in RDS score.,delete,[],4,0.75,4,8
CD006435,1,6,Since only one study was analysed it would be misleading to conclude that mist therapy is ineffective in children with bronchiolitis.,delete,[],4,0.875,5,8
CD006435,1,7,We conclude that there is insufficient evidence to inform practice regarding using steam inhalation or mist therapy for acute bronchiolitis in children up to three years old.,split,"['There is currently not enough evidence to state that steam inhalation or mist is useful in young children with bronchiolitis.', 'More well-designed trials of the effectiveness of humidified oxygen, mist therapy or steam inhalation compared with other treatments for acute bronchiolitis are needed.']",4,1.0,5,8
CD009986,0,0,"We included three small studies with a cross-over design, involving a total of 20 participants (11 adults and 9 children), in this review.",split,"['We found three small studies, with a total of 20 people (11 adults and 9 children).', 'The studies had a cross-over design (participants received the study interventions in a random order, and served as their own control) and looked at the effect of different head positions.']",0,0.08333333333333333,1,12
CD009986,0,1,"Our primary outcome was mortality, and there was one death by the time of follow-up 28 days after hospital admission.",rephrase,"['At the time of follow-up 28 days following hospital admission, one child had died.']",2,0.16666666666666666,1,12
CD009986,0,2,"The trials did not measure the clinical secondary outcomes of quality of life, GCS, and disability.",rephrase,"['None of the studies assessed quality of life, Glasgow Coma Scale (a measurement of how conscious someone is), or disability.']",3,0.25,2,12
CD009986,0,3,"The included studies provided information only for the secondary outcomes intracranial pressure (ICP), cerebral perfusion pressure (CPP), and adverse effects.",rephrase,['Researchers measured the pressure inside the skull (intracranial pressure (ICP)) and the pressure gradient causing blood flow to the brain (cerebral perfusion pressure (CPP)).'],4,0.3333333333333333,2,12
CD009986,1,4,We were unable to pool the results as the data were either presented in different formats or no numerical data were provided.,delete,[],5,0.4166666666666667,3,12
CD009986,1,5,We included narrative interpretations of the available data.,delete,[],5,0.5,3,12
CD009986,2,6,The overall risk of bias of the studies was unclear due to poor reporting of the methods.,rephrase,"['The body of evidence for this research question is very low due to variability in physiological response in the study participants, unclear risk of bias in the study methods, and the small number of people enrolled in each study.']",5,0.5833333333333334,3,12
CD009986,2,7,There was marked inconsistency across studies for the outcome of ICP and small sample sizes or wide confidence intervals for all outcomes.,delete,[],6,0.6666666666666666,4,12
CD009986,2,8,We therefore rated the quality of the evidence as very low for all outcomes and have not included the results of individual studies here.,rephrase,"['The studies gave varied results and our certainty in the results is very low, so we do not consider the body of evidence to be reliable.']",6,0.75,4,12
CD009986,2,9,We do not have enough evidence to draw conclusions about the effect of HBE during intensive care management of people with TBI.,delete,[],7,0.8333333333333334,5,12
CD009986,3,10,"The lack of consistency among studies, scarcity of data and the absence of evidence to show a correlation between physiological measurements such as ICP, CCP and clinical outcomes, mean that we are uncertain about the effects of HBE during intensive care management in people with severe TBI.",rephrase,['We are uncertain about the effects of different backrest positions in people with serious brain injury.'],7,0.9166666666666666,5,12
CD009986,4,11,Well-designed and larger trials that measure long-term clinical outcomes are needed to understand how and when different backrest positions can affect the management of severe TBI.,split,"['Well-designed and larger trials are needed.', 'Trials also need to measure the right patient outcomes over a longer period of time in order to understand how and when different backrest positions can affect people with brain injury.']",8,1.0,5,12
CD012331,0,0,Five studies including a total of 1146 participants met the inclusion criteria for this review.,rephrase,['We found five studies including 1146 adolescents with asthma.'],0,0.0625,1,16
CD012331,0,1,"As ever with systematic reviews of complex interventions, studies varied by design (cluster and individually randomised), duration (2.5 to 9 months), setting (school, day camp, primary care) and intervention content.",rephrase,"['Studies varied by design, duration (2.5 to 9 months), setting (school, day camp, primary care) and the way that peer support or lay-led sessions were given.']",1,0.125,1,16
CD012331,0,2,"Most risk of bias concerns were related to blinding and incomplete reporting, which limited the meta-analyses that could be performed.",delete,[],2,0.1875,1,16
CD012331,0,3,Studies generally controlled well for selection and attrition biases.,delete,[],2,0.25,2,16
CD012331,1,4,All participants were between 11 and 17 years of age.,delete,[],2,0.3125,2,16
CD012331,1,5,"Asthma diagnosis and severity varied, as did smoking prevalence.",rephrase,"['Asthma severity varied, as did the number who smoked.']",2,0.375,2,16
CD012331,1,6,Three studies used the Triple A programme; one of these studies tested the addition of a smoke-free pledge; another delivered peer support group sessions and mp3 messaging to encourage adherence; and the third compared a peer-led asthma day camp with an equivalent camp led by healthcare practitioners.,rephrase,"['Three studies used a programme called Triple A (Adolescent Asthma Action), by which older adolescents are trained to deliver sessions to younger students; one of these studies tested the addition of a pledge to stop smoking; another delivered peer support group sessions including messages played through an mp3 player to encourage adherence; and the third compared an asthma day camp led by peers against one led by nurses and doctors.']",3,0.4375,3,16
CD012331,2,7,"We had low confidence in all findings owing to risk of bias, inconsistency and imprecision.",rephrase,"['For these reasons, we have low confidence in all study findings.']",4,0.5,3,16
CD012331,2,8,"Results from an analysis of asthma-related quality of life based on the prespecified random-effects model were imprecise and showed no differences (MD 0.40, 95% confidence interval (CI) -0.02 to 0.81); a sensitivity analysis based on a fixed-effect model and a responder analysis suggested small benefit may be derived for this outcome.",delete,[],5,0.5625,3,16
CD012331,2,9,"Most other results were summarised narratively and did not show an important benefit of the intervention; studies provided no analysable data on asthma exacerbations or unscheduled visits (data were skewed), and one study measuring adherence reported a drop in both groups.",split,"['Most other outcomes did not show an important benefit of the intervention.', ""These studies provided very little information about asthma attacks or unscheduled visits during the trial, and we couldn't be sure whether the intervention was beneficial in terms of asthma control.""]",5,0.625,4,16
CD012331,2,10,Effects on asthma control favoured the intervention but findings were not statistically significant.,delete,[],7,0.6875,4,16
CD012331,2,11,"Results from two studies with high levels of baseline smoking showed some promise for self-efficacy to stop smoking, but overall nicotine dependence and smoking-related knowledge were not significantly better in the intervention group.",rephrase,"['Results from two studies in which a lot of the adolescents smoked showed some promise that adolescents had the confidence to stop, but overall nicotine dependence and smoking-related knowledge were not much better than in controls.']",7,0.75,4,16
CD012331,2,12,Investigators did not report adverse events.,rephrase,['Studies provided no reports of adverse events.'],8,0.8125,5,16
CD012331,3,13,"Although weak evidence suggests that lay-led and peer support interventions could lead to a small improvement in asthma-related quality of life for adolescents, benefits for asthma control, exacerbations and medication adherence remain unproven.",delete,[],9,0.875,5,16
CD012331,3,14,Current evidence is insufficient to reveal whether routine use of lay-led or peer support programmes is beneficial for adolescents receiving asthma care.,delete,[],9,0.9375,5,16
CD012331,4,15,"Ongoing and future research may help to identify target populations for lay-led and peer support interventions, along with attributes that constitute a successful programme.",delete,[],9,1.0,5,16
CD001134,0,0,"Twenty-eight trials, involving almost 17,000 women, contributed data to the review.",rephrase,"['This review includes data from 28 randomised controlled trials involving almost 17,000 women.']",0,0.1111111111111111,1,9
CD001134,0,1,"Overall, women who received a psychosocial or psychological intervention were significantly less likely to develop postpartum depression compared with those receiving standard care (average RR 0.78, 95% confidence interval (CI) 0.66 to 0.93; 20 trials, 14,727 women).",delete,[],1,0.2222222222222222,2,9
CD001134,0,2,"Several promising interventions include: (1) the provision of intensive, individualised postpartum home visits provided by public health nurses or midwives (RR 0.56, 95% CI 0.43 to 0.73; two trials, 1262 women); (2) lay (peer)-based telephone support (RR 0.54, 95% CI 0.38 to 0.77; one trial, 612 women); and (3) interpersonal psychotherapy (standardised mean difference -0.27, 95% CI -0.52 to -0.01; five trials, 366 women).",delete,[],1,0.3333333333333333,2,9
CD001134,0,3,Professional- and lay-based interventions were both effective in reducing the risk to develop depressive symptomatology.,rephrase,['Interventions provided by various health professionals and lay individuals were similarly beneficial.'],1,0.4444444444444444,3,9
CD001134,0,4,"Individually-based interventions reduced depressive symptomatology at final assessment (RR 0.75, 95% CI 0.61 to 0.92; 14 trials, 12,914 women) as did multiple-contact interventions (RR 0.78, 95% CI 0.66 to 0.93; 16 trials, 11,850 women).",rephrase,['Interventions that were individually-based were beneficial as were those that involved multiple contacts.'],2,0.5555555555555556,3,9
CD001134,0,5,"Interventions that were initiated in the postpartum period also significantly reduced the risk to develop depressive symptomatology (RR 0.73, 95% CI 0.59 to 0.90; 12 trials, 12,786 women).",merge,[],3,0.6666666666666666,4,9
CD001134,0,6,"Identifying mothers 'at-risk' assisted the prevention of postpartum depression (RR 0.66, 95% CI 0.50 to 0.88; eight trials, 1853 women).",none,"[""There is also evidence that interventions initiated postnatally assisted in preventing postpartum depression as were those specifically targeting 'at-risk' mothers.""]",3,0.7777777777777778,4,9
CD001134,1,7,"Overall, psychosocial and psychological interventions significantly reduce the number of women who develop postpartum depression.",split,"['The purpose of this review was to examine the effect of psychosocial and psychological interventions to reduce the risk of postpartum depression compared with usual care.', 'A clear beneficial effect in the prevention of postpartum depression was found from a range of psychosocial and psychological interventions.']",4,0.8888888888888888,5,9
CD001134,1,8,"Promising interventions include the provision of intensive, professionally-based postpartum home visits, telephone-based peer support, and interpersonal psychotherapy.",rephrase,"['Promising interventions included professionally-based postpartum home visits, lay- or peer-based postpartum telephone support, and interpersonal psychotherapy.']",6,1.0,5,9
CD006028,0,0,"Nineteen studies (11 prevention, 8 treatment; 1,861 participants) were included.",rephrase,"['We identified 19 studies (11 prevention and 8 treatment) using low or high dose ANP, enrolling 1,861 patients.']",0,0.07692307692307693,1,13
CD006028,0,1,There was no difference in mortality between ANP and control in either the low or high dose prevention studies.,rephrase,['There was no difference in the number of deaths between ANP and control for studies preventing or treating AKI.'],1,0.15384615384615385,1,13
CD006028,0,2,"Low (but not high) dose ANP was associated with a reduced need for RRT in the prevention studies (RR 0.32, 95% CI 0.14 to 0.71).",rephrase,['The need for dialysis was significantly lower in both the low dose ANP treatment and prevention studies as well as for patients undergoing major surgery.'],2,0.23076923076923078,2,13
CD006028,0,3,Length of hospital and ICU stay were significantly shorter in the low dose ANP group.,rephrase,['The length of time spend in hospital and ICU was shorter for patients receiving low dose ANP.'],3,0.3076923076923077,2,13
CD006028,0,4,"For established AKI, there was no difference in mortality with either low or high dose ANP.",delete,[],4,0.38461538461538464,2,13
CD006028,0,5,"Low (but not high) dose ANP was associated with a reduction in the need for RRT (RR 0.54, 95% CI 0.30 to 0.98).",merge,[],4,0.46153846153846156,3,13
CD006028,0,6,"High dose ANP was associated with more adverse events (hypotension, arrhythmias).",none,['High dose ANP was associated with more hypotension and cardiac arrhythmias in patients with established AKI.'],4,0.5384615384615384,3,13
CD006028,0,7,"After major surgery there was a significant reduction in RRT requirement with ANP in the prevention studies (RR 0.56, 95% CI 0.32 to 0.99), but not in the treatment studies.",delete,[],5,0.6153846153846154,4,13
CD006028,0,8,There was no difference in mortality between ANP and control in either the prevention or treatment studies.,delete,[],5,0.6923076923076923,4,13
CD006028,0,9,"There was a reduced need for RRT with low dose ANP in patients undergoing cardiovascular surgery (RR 0.35, 95% CI 0.18 to 0.70).",delete,[],5,0.7692307692307693,4,13
CD006028,0,10,ANP was not associated with outcome improvement in either radiocontrast nephropathy or oliguric AKI.,delete,[],5,0.8461538461538461,5,13
CD006028,1,11,ANP may be associated with improved outcomes when used in low doses for preventing AKI and in managing postsurgery AKI and should be further explored in these two settings.,rephrase,['ANP may be associated with improved outcomes when used in low doses for preventing AKI and in managing postsurgery AKI.'],5,0.9230769230769231,5,13
CD006028,1,12,"There were no significant adverse events in the prevention studies, however in the high dose ANP treatment studies there were significant increases hypotension and arrhythmias.",ignore,"['There were no significant adverse events in the prevention studies, however in the high dose ANP treatment studies there were significant increases in hypotension and arrhythmias.']",6,1.0,5,13
CD013837,0,0,We included five RCTs (865 participants).,rephrase,['We included five trials randomising 865 participants.'],0,0.09090909090909091,1,11
CD013837,0,1,All trials were at high risk of bias.,rephrase,['The five trials had high risk of bias (i.e. the trials were conducted in a way that may have skewed results to the positive side).'],1,0.18181818181818182,1,11
CD013837,0,2,The certainty of the evidence according to GRADE was very low.,delete,[],2,0.2727272727272727,2,11
CD013837,0,3,The included trials assessed five different comparisons of antibiotics.,rephrase,['The included trials compared five different antibiotic regimens.'],2,0.36363636363636365,2,11
CD013837,1,4,We did not conduct any meta-analyses due to lack of relevant data.,delete,[],3,0.45454545454545453,3,11
CD013837,2,5,Of the five included trials one trial compared ampicillin plus gentamicin with benzylpenicillin plus gentamicin; one trial compared piperacillin plus tazobactam with amikacin; one trial compared ticarcillin plus clavulanic acid with piperacillin plus gentamicin; one trial compared piperacillin with ampicillin plus amikacin; and one trial compared ceftazidime with benzylpenicillin plus gentamicin.,ignore,['We included five trials:\xa0one trial compared ampicillin plus gentamicin with benzylpenicillin plus gentamicin; one trial compared piperacillin plus tazobactam with amikacin; one trial compared ticarcillin plus clavulanic acid with piperacillin plus gentamicin; one trial compared piperacillin with ampicillin plus amikacin; and one trial compared ceftazidime with benzylpenicillin plus gentamicin.'],3,0.5454545454545454,3,11
CD013837,3,6,"None of the five comparisons found any evidence of a difference when assessing all-cause mortality, serious adverse events, circulatory support, nephrotoxicity, neurological developmental impairment, or necrotising enterocolitis; however, none of the trials were near an information size that could contribute significantly to the evidence of the comparative benefits and risks of any particular antibiotic regimen.",rephrase,"[""None of the five comparisons showed any difference when assessing death from all causes, serious adverse events (i.e. major complications), respiratory support, circulatory support, nephrotoxicity (toxicity in the kidneys), neurological developmental impairment (disabilities in the functioning of the brain that affect a child's behaviour, memory, or ability to learn), necrotising enterocolitis (tissues in the gut become inflamed and start to die), or ototoxicity (toxic to the ear).""]",4,0.6363636363636364,4,11
CD013837,4,7,None of the trials assessed respiratory support or ototoxicity.,delete,[],5,0.7272727272727273,4,11
CD013837,5,8,The benefits and harms of different antibiotic regimens remain unclear due to the lack of well-powered trials and the high risk of systematic errors.,delete,[],5,0.8181818181818182,5,11
CD013837,6,9,Current evidence is insufficient to support any antibiotic regimen being superior to another.,rephrase,['Current evidence cannot confirm or reject one antibiotic regimen being superior to another.'],5,0.9090909090909091,5,11
CD013837,6,10,Large RCTs assessing different antibiotic regimens in early-onset neonatal sepsis with low risk of bias are warranted.,delete,[],6,1.0,5,11
CD012607,0,0,We included 10 studies in the review.,rephrase,['We included studies where chance determined what treatment people in the study would get.'],0,0.05263157894736842,1,19
CD012607,0,1,"Participant age varied among studies, ranging from 20 to 60 years.",delete,[],1,0.10526315789473684,1,19
CD012607,0,2,Detailed information on stone characteristics was rarely presented.,delete,[],1,0.15789473684210525,1,19
CD012607,1,3,"Tubeless PNL versus standard PNL
We are very uncertain whether there is a difference in severe adverse events (SAEs) between tubeless PNL and standard PNL (risk ratio (RR) 1.53, 95% confidence interval (CI) 0.14 to 16.46; I2 = 42%; 2 studies, 46 participants; very low-certainty evidence).",rephrase,['Tubeless PNL versus standard PNL: We are very uncertain how severe adverse events compare between the two approaches.'],1,0.21052631578947367,2,19
CD012607,1,4,"Tubeless PNL may have little to no effect on pain on postoperative day one (mean difference (MD) 0.56 lower, 95% CI 1.34 lower to 0.21 higher; I2 = 84%; 4 studies, 186 participants; low-certainty evidence), and probably results in little to no difference in operating room time (MD 0.40 longer (in minutes), 95% CI 4.82 shorter to 5.62 longer; I2 = 0%; 3 studies, 81 participants; moderate-certainty evidence).",rephrase,"['Pain on day one after surgery may be no different, and operating room time is probably not different between treatment groups.']",2,0.2631578947368421,2,19
CD012607,1,5,"Tubeless PNL may reduce length of hospital stay (MD 0.90 shorter, 95% CI 1.45 shorter to 0.35 shorter; I2 = 84%; 6 studies, 238 participants; low-certainty evidence).",rephrase,['Tubeless PNL may reduce length of hospital stay.'],3,0.3157894736842105,2,19
CD012607,1,6,"We are very uncertain of the effect of tubeless PNL on blood transfusions (RR 0.64, 95% CI 0.16 to 2.52; I2 = 0%; 4 studies, 161 participants; very low-certainty evidence), sepsis or fever (RR 0.50, 95% CI 0.05 to 4.75; I2 = not applicable; 2 studies, 82 participants; very low-certainty evidence), or readmissions (RR 1.00, 95% CI 0.07 to 14.21; I2 = not applicable, 1 study, 24 participants; very low-certainty evidence).",rephrase,"['We are very uncertain how blood transfusions, sepsis/fever, or readmissions compare between the two approaches.']",4,0.3684210526315789,2,19
CD012607,2,7,"Totally tubeless versus standard PNL
Totally tubeless PNL may result in lower SAE rates (RR 0.49, 95% CI 0.19 to 1.25; I2 = 0%; 2 studies, 174 participants; low-certainty evidence) and pain on postoperative day one (MD 3.60 lower, 95% CI 4.24 lower to 2.96 lower; I2 = Not applicable; 1 study, 50 participants; low-certainty evidence).",rephrase,['Totally tubeless PNL versus standard PNL: Totally tubeless PNL may reduce severe adverse events compared to standard PNL.'],5,0.42105263157894735,3,19
CD012607,2,8,"Totally tubeless PNL may result in little to no difference in operating room time (MD 6.23 shorter (in minutes), 95% CI 14.29 shorter to 1.84 longer; I2 = 72%; 2 studies, 174 participants; moderate-certainty evidence) and sepsis or fever (RR 0.33, 95% CI 0.01 to 7.97; I2 = not applicable; 1 study, 90 participants; low-certainty evidence).",rephrase,['Totally tubeless PNL may result in little to no difference in sepsis/fever.'],6,0.47368421052631576,3,19
CD012607,2,9,"Totally tubeless PNL likely shortens the length of hospital stay (MD 1.55 shorter, 95% CI 1.82 shorter to 1.29 shorter; I2 = 0%; 4 studies, 274 participants; moderate-certainty evidence).",rephrase,['Totally tubeless PNL probably reduces length of stay.'],7,0.5263157894736842,3,19
CD012607,2,10,"We are very uncertain of the effect of totally tubeless PNL on blood transfusions (RR 0.62, 95% CI 0.26 to 1.48; I2 = 0%; 4 studies, 274 participants; very low-certainty evidence) or readmissions (RR not estimable, 95% CI not estimable; I2 = not applicable; 1 study, 50 participants; very low-certainty evidence).",rephrase,['We are very uncertain how blood transfusions and readmissions compare.'],8,0.5789473684210527,3,19
CD012607,3,11,We found no studies comparing tubeless mini versus standard mini-PNL or totally tubeless mini versus standard mini-PNL.,rephrase,['Totally tubeless mini-PNL versus standard mini-PNL: We did not find any studies for this comparison.'],9,0.631578947368421,4,19
CD012607,4,12,"When comparing tubeless to standard PNL with regard to the predefined primary outcomes of this review, there may be little difference in early postoperative pain, while we are very uncertain of the effect on SAEs.",delete,[],10,0.6842105263157895,4,19
CD012607,4,13,People treated with tubeless PNL may benefit from a reduced length of stay compared to standard PNL.,delete,[],10,0.7368421052631579,4,19
CD012607,4,14,"When comparing totally tubeless to standard PNL, early postoperative pain and severe adverse events may be reduced with totally tubeless PNL.",delete,[],10,0.7894736842105263,4,19
CD012607,4,15,The certainty of evidence by outcome was mostly very low (range: moderate to very low) for the comparison of tubeless to standard PNL and low (range: moderate to very low) for the comparison of totally tubeless to standard PNL.,merge,"['The certainty of evidence by outcome ranged from moderate to very low, mainly because of study limitations and imprecision due to small studies with few events.']",10,0.8421052631578947,5,19
CD012607,4,16,"The most common reasons for downgrading the certainty of the evidence were study limitations, inconsistency, and imprecision.",none,[],10,0.8947368421052632,5,19
CD012607,4,17,We did not find randomized trial evidence for other comparisons.,delete,[],11,0.9473684210526315,5,19
CD012607,4,18,"Overall, further and higher-quality studies are needed to inform clinical practice.",delete,[],11,1.0,5,19
CD005641,0,0,We included three trials randomising 295 participants: 147 to T-tube drainage versus 148 to primary closure.,rephrase,"['We identified a total of three trials including 295 participants, of whom 148 were randomly chosen to receive primary closure and the remaining patients had T-tube drainage after laparoscopic exploration of common bile duct.']",0,0.08333333333333333,1,12
CD005641,0,1,All trials had a high risk of bias.,rephrase,['All three trials were at high risk of bias (risk of underestimating or overestimating the benefits and harms of the intervention).'],1,0.16666666666666666,1,12
CD005641,0,2,No one died during the follow-up period.,delete,[],2,0.25,2,12
CD005641,0,3,"There was no significant difference in the proportion of patients with serious morbidity (17/147 (weighted percentage 11.3%) in the T-tube drainage versus 9/148 (6.1%) in the primary closure group; RR 1.86; 95% CI 0.87 to 3.96; three trials), and no significant difference was found in the serious morbidity rates (weighted serious morbidity rate = 97 events per 1000 patients) in participants randomised to T-tube drainage versus serious morbidity rate = 61 events per 1000 patients in the primary closure group; RR 1.59; 95% CI 0.66 to 3.83; three trials).",rephrase,['There was no significant difference in the serious complication rate (approximately 97 complications per 1000 patients in the T-tube group versus 61 complications per 1000 participants in the primary closure group) or in the proportion of participants who developed serious complications (11.3% in the T-tube group versus 6.2% in the primary closure group).'],2,0.3333333333333333,2,12
CD005641,0,4,Quality of life was not reported in any of the trials.,rephrase,['None of the trials reported the quality of life of the participants.'],3,0.4166666666666667,3,12
CD005641,0,5,The operating time was significantly longer in the T-tube drainage group compared with the primary closure group (MD 21.22 minutes; 95% CI 12.44 minutes to 30.00 minutes; three trials).,rephrase,['The average operating time was significantly longer in the T-tube group than in the primary closure group (by about 20 minutes).'],4,0.5,3,12
CD005641,0,6,The hospital stay was significantly longer in the T-tube drainage group compared with the primary closure group (MD 3.26 days; 95% CI 2.49 days to 4.04 days; three trials).,rephrase,['The average hospital stay was significantly longer in the T-tube group than in the primary closure group (by about three days).'],5,0.5833333333333334,3,12
CD005641,0,7,"According to one trial, the participants randomised to T-tube drainage returned to work approximately eight days later than the participants randomised to the primary closure group (P < 0.005).",rephrase,['Participants returned to work significantly later in the T-tube group than primary closure group (by about eight days).'],6,0.6666666666666666,4,12
CD005641,1,8,T-tube drainage appears to result in significantly longer operating time and hospital stay as compared with primary closure without any evidence of benefit after laparoscopic common bile duct exploration.,rephrase,['Use of T-tube appears to increase the cost without providing any benefit to the patients.'],7,0.75,4,12
CD005641,1,9,"Based on currently available evidence, there is no justification for the routine use of T-tube drainage after laparoscopic common bile duct exploration in patients with common bile duct stones.",delete,[],8,0.8333333333333334,5,12
CD005641,1,10,More randomised trials comparing the effects of T-tube drainage versus primary closure after laparoscopic common bile duct exploration may be needed.,split,"['Further randomised trials with low risk of bias (low chance of arriving at wrong conclusions because of prejudice by healthcare providers, researchers, or patients) with longer follow-up period are necessary.', 'Until the results from such trials are available, we discourage the routine use of T-tube after laparoscopic common bile duct exploration.']",8,0.9166666666666666,5,12
CD005641,1,11,"Such trials should be conducted with low risk of bias, assessing the long-term beneficial and harmful effects including long-term complications such as bile stricture and recurrence of common bile duct stones.",delete,[],10,1.0,5,12
CD007425,0,0,No randomised controlled trials or controlled clinical trials were identified for the original review or this update.,rephrase,"['This review did not find any high quality randomised controlled trials that examined the effectiveness of such multidisciplinary care, either when originally published in 2009 or for the update in 2011.']",0,0.1111111111111111,1,9
CD007425,0,1,We summarised the results of five observational studies (including one with two reports) in the Discussion section of this review.,delete,[],1,0.2222222222222222,2,9
CD007425,1,2,"In the absence of randomised controlled trials or controlled clinical trials, the 'best' evidence to date is based on three ‘low’ and two ‘very low quality’ observational studies.",delete,[],1,0.3333333333333333,2,9
CD007425,1,3,"These suggest 'very low quality evidence' for an advantage for mental health domains (only) of quality of life without increasing healthcare costs, and 'low level quality' evidence for reduced hospitalisation for MDC in low-intensity outpatient settings; and 'very low quality' evidence for improved disability in high-intensity settings.",rephrase,"['The evidence from low quality studies suggests that such care may improve some aspects of quality of life, reduce the frequency of hospitalisation and hospital length of stay and improve disability in persons with ALS or MND.']",1,0.4444444444444444,3,9
CD007425,1,4,The evidence for survival is conflicting.,rephrase,['The evidence for multidisciplinary care on survival is conflicting.'],2,0.5555555555555556,3,9
CD007425,1,5,These conclusions are tentative and the gap in current research should not be interpreted as proof that MDC is ineffective.,rephrase,['The gap in current research should not be interpreted as proof that multidisciplinary care is ineffective.'],3,0.6666666666666666,4,9
CD007425,1,6,"Further research is needed into appropriate study designs; outcome measurement; caregiver needs; and the evaluation of optimal settings, type, intensity or frequency and cost-effectiveness of MDC in the MND population.",rephrase,"['Further research into types of appropriate studies, caregiver needs and various aspects of multidisciplinary care in the MND population is needed.']",4,0.7777777777777778,4,9
CD007425,1,7,Future research should focus on observational designs to assess care and outcomes in 'real-life' settings.,delete,[],5,0.8888888888888888,5,9
CD007425,1,8,"The interface between neurology, rehabilitation and palliative care should be explored to provide long-term support for MND.",delete,[],5,1.0,5,9
CD009060,0,0,We included 12 trials with 798 participants undergoing elective laparoscopic cholecystectomy randomised to different methods of intraperitoneal local anaesthetic instillation.,rephrase,['We identified 12 randomised clinical trials involving 798 people undergoing planned laparoscopic cholecystectomy.'],0,0.09090909090909091,1,11
CD009060,0,1,All the trials were at high risk of bias.,rephrase,"['Most of the trials were of high risk of bias, that is, there is possibility of arriving at wrong conclusions overestimating benefits or underestimating harms of one method or the other because of the way that the study was conducted.']",1,0.18181818181818182,1,11
CD009060,0,2,Most trials included only people with low anaesthetic risk.,delete,[],2,0.2727272727272727,2,11
CD009060,0,3,The comparisons included in the trials that met the eligibility criteria were the following; comparison of one local anaesthetic agent with another local anaesthetic agent (three trials); comparison of timing of delivery (six trials); comparison of different methods of delivery of the anaesthetic agent (two trials); comparison of location of the instillation of the anaesthetic agent (one trial); three trials reported mortality and morbidity.,delete,[],2,0.36363636363636365,2,11
CD009060,1,4,There were no mortalities or serious adverse events in either group in the following comparisons: bupivacaine (0/100 (0%)) versus lignocaine (0/106 (0%)) (one trial; 206 participants); just after creation of pneumoperitoneum (0/55 (0%)) versus end of surgery (0/55 (0%)) (two trials; 110 participants); just after creation of pneumoperitoneum (0/15 (0%)) versus after the end of surgery (0/15 (0%)) (one trial; 30 participants); end of surgery (0/15 (0%)) versus after the end of surgery (0/15 (0%)) (one trial; 30 participants).,rephrase,['There were no deaths or serious complications in either group in the comparisons that reported these.'],2,0.45454545454545453,3,11
CD009060,2,5,"None of the trials reported quality of life, the time taken to return to normal activity, or the time taken to return to work.",ignore,"['None of the trials reported quality of life, the time taken to return to normal activity, or the time taken to return to work.']",3,0.5454545454545454,3,11
CD009060,2,6,The differences in the proportion of people who were discharged as day-surgery and the length of hospital stay were imprecise in all the comparisons included that reported these outcomes (very low quality evidence).,rephrase,['The differences in hospital stay between the methods being compared was imprecise in all the comparisons that reported hospital stay.'],4,0.6363636363636364,4,11
CD009060,2,7,There were some differences in the pain scores on the visual analogue scale (1 to 10 cm) but these were neither consistent nor robust to fixed-effect versus random-effects meta-analysis or sensitivity analysis.,rephrase,"['Although there were some differences in the pain scores on the visual analogue scale (a chart that rates the amount of pain on a scale of 1 to 10 cm), these differences were neither consistent nor robust to different methods of statistical analysis.']",5,0.7272727272727273,4,11
CD009060,3,8,The currently available evidence is inadequate to determine the effects of one method of local anaesthetic intraperitoneal instillation compared with any other method of local anaesthetic intraperitoneal instillation in low anaesthetic risk individuals undergoing elective laparoscopic cholecystectomy.,ignore,['The evidence currently available is inadequate to determine the effects of one method of local anaesthetic intraperitoneal instillation compared with any other method of local anaesthetic intraperitoneal instillation in low anaesthetic risk individuals undergoing elective laparoscopic cholecystectomy.'],6,0.8181818181818182,5,11
CD009060,3,9,Further randomised clinical trials of low risk of systematic and random errors are necessary.,rephrase,['Further trials are necessary.'],7,0.9090909090909091,5,11
CD009060,3,10,Such trials should include important clinical outcomes such as quality of life and time to return to work in their assessment.,rephrase,"['Such trials should include outcomes such as quality of life, the time taken to return to normal activity, and the time taken to return to work, which are important for the person undergoing the procedure and the people who provide funds for the treatment.']",8,1.0,5,11
CD006260,0,0,Five studies were included.,ignore,['Five studies were included.'],0,0.07692307692307693,1,13
CD006260,0,1,No new eligible studies have been found since the review was initially conducted.,delete,[],1,0.15384615384615385,1,13
CD006260,0,2,Method discontinuation was similar between groups in all trials.,rephrase,"['In this review, the numbers of women who stopped using their birth control method early were similar between groups in all trials.']",1,0.23076923076923078,2,13
CD006260,0,3,Bleeding patterns and side effects were similar in trials that compared immediate with conventional start.,rephrase,['We included trials that compared quick start to the usual start of birth control.'],2,0.3076923076923077,2,13
CD006260,0,4,"In a study of depot medroxyprogesterone acetate (DMPA), immediate start of DMPA showed fewer pregnancies than a 'bridge' method before DMPA (OR 0.36; 95% CI 0.16 to 0.84).",delete,[],3,0.38461538461538464,2,13
CD006260,0,5,"Further, more women in the immediate-DMPA group were very satisfied versus those with a 'bridge' method (OR 1.99; 95% CI 1.05 to 3.77).",rephrase,"['In the depo trial, more women with quick start of depo were very satisfied.']",3,0.46153846153846156,3,13
CD006260,0,6,A trial of two immediate-start methods showed the vaginal ring group had less prolonged bleeding (OR 0.42; 95% CI 0.20 to 0.89) and less frequent bleeding (OR 0.23; 95% CI 0.05 to 1.03) than COC users.,rephrase,['A trial of two quick-start methods showed women with the vaginal ring had less long-term bleeding and less frequent bleeding than those with pills.'],4,0.5384615384615384,3,13
CD006260,0,7,The ring group also reported fewer side effects.,rephrase,"['For six side effects, including changes in breasts, mood, and nausea, quick start of the ring showed fewer problems than quick start of pills.']",5,0.6153846153846154,4,13
CD006260,0,8,"Also, more immediate ring users were very satisfied than immediate COC users (OR 2.88; 95% CI 1.59 to 5.22).",delete,[],6,0.6923076923076923,4,13
CD006260,1,9,We found limited evidence that immediate start of hormonal contraception reduces unintended pregnancies or increases method continuation.,rephrase,['We found little evidence that quick start leads to fewer pregnancies or fewer women stopping early.'],6,0.7692307692307693,4,13
CD006260,1,10,"However, the pregnancy rate was lower with immediate start of DMPA versus another method.",delete,[],7,0.8461538461538461,5,13
CD006260,1,11,"Some differences were associated with contraceptive type rather than initiation method, i.e., immediate ring versus immediate COC.",rephrase,['Other differences were between types of birth control rather than start times.'],7,0.9230769230769231,5,13
CD006260,1,12,More studies are needed of immediate versus conventional start of the same hormonal contraceptive.,rephrase,['More studies are needed comparing quick start versus usual start of the same hormonal birth control method.'],8,1.0,5,13
CD001496,0,0,The systematic search yielded a total of 3354 citations; 23 studies (n = 2872 participants) were suitable for inclusion.,split,"['We found 23 studies for inclusion in this review.', 'These studies focused mostly on adults, with a total of 2872 participants involved.']",0,0.0625,1,16
CD001496,0,1,"Included studies reported data from participants in 25 different countries across Europe, North and South America, Asia, Australia, and the Middle East.",delete,[],2,0.125,1,16
CD001496,0,2,Participants included in this review had moderate to severe asthma and a diagnosis of GORD and were predominantly adults presenting to a clinic for treatment.,delete,[],2,0.1875,1,16
CD001496,0,3,"Only two studies assessed effects of intervention on children, and two assessed the impact of surgical intervention.",rephrase,"['Only two studies assessed the effects of treating GORD in children, and two investigated the benefits of using surgery for GORD to improve asthma control.']",2,0.25,2,16
CD001496,0,4,The remainder were concerned with medical intervention using a variety of dosing protocols.,delete,[],3,0.3125,2,16
CD001496,1,5,"There was an uncertain reduction in the number of participants experiencing one or more moderate/severe asthma exacerbations with medical treatment for GORD (odds ratio 0.53, 95% confidence interval (CI) 0.17 to 1.63; 1168 participants, 2 studies; low-certainty evidence).",delete,[],3,0.375,2,16
CD001496,1,6,"None of the included studies reported data related to the other primary outcomes for this review: hospital admissions, emergency department visits, and unscheduled doctor visits.",rephrase,['We did not find any data in the included studies related to hospital admissions nor to emergency room or unscheduled doctor visits.'],3,0.4375,3,16
CD001496,2,7,"Medical treatment for GORD probably improved forced expiratory volume in one second (FEV₁) by a small amount (mean difference (MD) 0.10 L, 95% CI 0.05 to 0.15; 1333 participants, 7 studies; moderate-certainty evidence) as well as use of rescue medications (MD -0.71 puffs per day, 95% CI -1.20 to -0.22; 239 participants, 2 studies; moderate-certainty evidence).",delete,[],4,0.5,3,16
CD001496,2,8,"However, the benefit of GORD treatment for morning peak expiratory flow rate was uncertain (MD 6.02 L/min, 95% CI 0.56 to 11.47; 1262 participants, 5 studies).",delete,[],4,0.5625,3,16
CD001496,2,9,It is important to note that these mean improvements did not reach clinical importance.,rephrase,['It is important to note that these benefits may be too small to make an impact on the daily life of someone with asthma.'],4,0.625,4,16
CD001496,2,10,"The benefit of GORD treatment for outcomes synthesised narratively including benefits of treatment for asthma symptoms, quality of life, and treatment preference was likewise uncertain.",rephrase,"['Based on available evidence, this review is not able to show if there was clear benefit of treatment for asthma symptoms for quality of life, or how many flare-ups are experienced by a person with asthma.']",5,0.6875,4,16
CD001496,2,11,"Data related to adverse events with intervention were generally underreported by the included studies, and those that were available indicated similar rates regardless of allocation to treatment or placebo.",delete,[],6,0.75,4,16
CD001496,3,12,Effects of GORD treatment on the primary outcomes of number of people experiencing one or more exacerbations and hospital utilisation remain uncertain.,rephrase,"['However, the impact of treatment for GORD on events such as asthma flare-ups, symptoms, or the need to go to the hospital or consult a doctor is uncertain.']",6,0.8125,5,16
CD001496,3,13,Medical treatment for GORD in people with asthma may provide small benefit for a number of secondary outcomes related to asthma management.,merge,[],7,0.875,5,16
CD001496,3,14,"This review determined with moderate certainty that with treatment, lung function measures improved slightly, and use of rescue medications for asthma control was reduced.",none,"['Moderate-certainty evidence (as some of the included studies were poorly described) shows that with medical treatment for GORD, people with asthma may experience a small improvement in their lung function and may be able to reduce their need to use rescue medications.']",7,0.9375,5,16
CD001496,3,15,"Further, evidence is insufficient to assess results in children, or to compare surgery versus medical therapy.",rephrase,"['Additionally, there was not enough evidence, with only two studies reporting on each, to assess surgical treatment or the effectiveness of GORD treatment in children.']",8,1.0,5,16
CD013365,0,0,We identified 13 eligible uncontrolled studies evaluating a single or multiple arms of CAR T-cell therapies.,rephrase,['We identified many ongoing studies and some of them compare CAR T-cells with standard care.'],0,0.03125,1,32
CD013365,0,1,"We also identified 38 ongoing studies, including three RCTs.",rephrase,['We also found 38 ongoing studies.'],1,0.0625,1,32
CD013365,0,2,Ten studies are awaiting classification due to completion with no retrievable results data or insufficient data to justify inclusion.,delete,[],2,0.09375,1,32
CD013365,0,3,"The mean number of participants enrolled, treated with CAR T-cell therapy and evaluated in the included studies were 79 (range 12 to 344; data unavailable for two studies), 61 (range 12 to 294; data unavailable for one study) and 52 (range 11 to 256), respectively.",delete,[],2,0.125,1,32
CD013365,1,4,Most studies included people with r/r DLBCL among people with other haematological B-cell malignancies.,delete,[],2,0.15625,1,32
CD013365,1,5,"Participants had received at least a median of three prior treatment lines (data unavailable for four studies), 5% to 50% had undergone ASCT (data unavailable for five studies) and, except for two studies, 3% to 18% had undergone allogenic stem-cell transplantation (data unavailable for eight studies).",delete,[],2,0.1875,1,32
CD013365,2,6,"The overall risk of bias was high for all studies, in particular, due to incomplete follow-up and the absence of blinding.",delete,[],2,0.21875,2,32
CD013365,2,7,None of the included studies had a control group so that no adequate comparative effect measures could be calculated.,rephrase,['None of the studies had a control group.'],2,0.25,2,32
CD013365,2,8,"The duration of follow-up varied substantially between studies, in particular, for harms.",delete,[],3,0.28125,2,32
CD013365,2,9,Our certainty in the evidence is very low for all outcomes.,delete,[],3,0.3125,2,32
CD013365,3,10,Overall survival was reported by eight studies (567 participants).,rephrase,['Eight studies with 567 participants evaluated overall survival.'],3,0.34375,2,32
CD013365,3,11,"Four studies reported survival rates at 12 months which ranged between 48% and 59%, and one study reported an overall survival rate of 50.5% at 24 months.",delete,[],4,0.375,2,32
CD013365,3,12,The evidence is very uncertain about the effect of CAR T-cell therapy on overall survival.,rephrase,['The evidence is very uncertain about the effect of CAR T-cells on survival.'],4,0.40625,3,32
CD013365,4,13,Two studies including 294 participants at baseline and 59 participants at the longest follow-up (12 months or 18 months) described improvements of quality of life measured with the EuroQol 5-Dimension 5-Level visual analogue scale (EQ-5D-5L VAS) or Function Assessment of Cancer Therapy-Lymphoma (FACT-Lym).,rephrase,['Two studies (294 participants at study start; 59 participants at study end) reported that quality of life improved over time.'],5,0.4375,3,32
CD013365,4,14,The evidence is very uncertain about the effect of CAR T-cell therapy on quality of life.,ignore,['The evidence is very uncertain about the effect of CAR T-cells on quality of life.'],6,0.46875,3,32
CD013365,5,15,None of the studies reported treatment-related mortality.,rephrase,['Deaths related to the therapy were not reported.'],7,0.5,3,32
CD013365,6,16,"Five studies (550 participants) reported the occurrence of adverse events among participants, ranging between 99% and 100% for any grade adverse events and 68% to 98% for adverse events grade ≥ 3.",split,"['Five studies (550 participants) reported on adverse events.', 'Almost all participants (99% to 100%) experienced some kind of adverse event (including mild events).']",8,0.53125,3,32
CD013365,6,17,"In three studies (253 participants), 56% to 68% of participants experienced serious adverse events, while in one study (28 participants), no serious adverse events occurred.",rephrase,"['In three studies (253 participants), 56% to 68% of participants experienced serious adverse events, while in one study (28 participants), participants had no serious adverse events.']",10,0.5625,3,32
CD013365,6,18,CAR T-cell therapy may increase the risk of adverse events and serious adverse events but the evidence is very uncertain about the exact risk.,rephrase,['CAR T-cells may increase the risk of serious adverse events but the evidence about the exact risk is very uncertain.'],11,0.59375,3,32
CD013365,7,19,The occurrence of cytokine release syndrome (CRS) was reported in 11 studies (675 participants) under use of various grading criteria.,rephrase,"[""Eleven studies (675 participants) reported on the frequency of 'cytokine release syndrome' (CRS), an overreaction of the immune system that is typically seen in CAR T-cell therapy.""]",12,0.625,4,32
CD013365,7,20,Five studies reported between 42% and 100% of participants experiencing CRS according to criteria described in Lee 2014.,rephrase,"['In five studies using the same scale, between 42% and 100% of participants had CRS.']",13,0.65625,4,32
CD013365,7,21,CAR T-cell therapy may increase the risk of CRS but the evidence is very uncertain about the exact risk.,rephrase,['CAR T-cells may increase the risk of CRS but the evidence about the exact risk is very uncertain.'],14,0.6875,4,32
CD013365,8,22,"Nine studies (575 participants) reported results on progression-free survival, disease-free survival or relapse-free survival.",rephrase,['Nine studies (575 participants) reported when DLBCL relapsed (returned) or progressed (got worse).'],15,0.71875,4,32
CD013365,8,23,Twelve-month progression-free survival rates were reported by four studies and ranged between 44% and 75%.,rephrase,"['Four studies reported that, at 12 months, DLBCL did not progress in 44% to 75% of participants.']",16,0.75,4,32
CD013365,8,24,"In one study, relapse-free survival remained at a rate of 64% at both 12 and 18 months.",rephrase,"['In one study, 64% of participants did not relapse at both 12, and 18 months.']",17,0.78125,4,32
CD013365,8,25,The evidence is very uncertain about the effect of CAR T-cell therapy on progression-free survival.,rephrase,['The evidence is very uncertain about the effect of CAR T-cells on DLBCL relapse or progress.'],18,0.8125,5,32
CD013365,9,26,Thirteen studies (620 participants) provided data on complete response rates.,rephrase,['Thirteen studies (620 participants) reported how many participants had a complete response (all signs of cancer disappeared).'],19,0.84375,5,32
CD013365,9,27,"At six months, three studies reported complete response rates between 40% and 45%.",rephrase,"['In three studies, between 40% and 45% of participants experienced a complete response at six months.']",20,0.875,5,32
CD013365,9,28,The evidence is very uncertain about the effect of CAR T-cell therapy on complete response rates.,rephrase,['The evidence is very uncertain about the effect of CAR T-cells on complete response.'],21,0.90625,5,32
CD013365,10,29,"The available evidence on the benefits and harms of CAR T-cell therapy for people with r/r DLBCL is limited, mainly because of the absence of comparative clinical trials.",rephrase,"['This is mainly because, today, there are no direct comparisons of CAR T-cells with other treatments.']",22,0.9375,5,32
CD013365,10,30,The results we present should be regarded in light of this limitation and conclusions should be drawn very carefully.,delete,[],23,0.96875,5,32
CD013365,10,31,"Due to the uncertainty in the current evidence, a large number of ongoing investigations and a risk of substantial and potentially life-threatening complications requiring supplementary treatment, it is critical to continue evaluating the evidence on this new therapy.",delete,[],23,1.0,5,32
CD009098,0,0,We included four new studies (1343 participants) in this review update.,merge,[],0,0.0625,1,16
CD009098,0,1,"In total, we included 10 studies (3851 participants).",none,['We included 10 studies with 3851 participants (6 from the previous review and 4 from our updated search of the literature).'],0,0.125,1,16
CD009098,0,2,"We found evidence of risk of bias in six studies, and the remaining studies fulfilled all criteria for low risk of bias.",delete,[],1,0.1875,1,16
CD009098,0,3,"In eight studies (3703 participants), a comparison was made between high and low levels of PEEP, with the same tidal volume in both groups.",rephrase,"['In eight studies (3703 participants), a comparison was made between high and low levels of PEEP, with the same amount of air delivered to the lungs and breathed out (exhaled) with each breath (tidal volume) in each group.']",1,0.25,2,16
CD009098,0,4,"In the remaining two studies (148 participants), the tidal volume was different between high- and low-level groups.",rephrase,['The other two studies used different tidal volumes for the two groups and could not be included in all of the review results.'],2,0.3125,2,16
CD009098,1,5,"In the main analysis, we assessed mortality occurring before hospital discharge only in studies that compared high versus low PEEP, with the same tidal volume in both groups.",rephrase,['We noted the following findings.'],3,0.375,2,16
CD009098,1,6,"Evidence suggests that high PEEP may result in little to no difference in mortality compared to low PEEP (risk ratio (RR) 0.97, 95% confidence interval (CI) 0.90 to 1.04; I² = 15%; 7 studies, 3640 participants; moderate-certainty evidence).",rephrase,"['• Higher levels of PEEP (compared to lower levels) may make little to no difference in the number of patients who die before hospital discharge (7 studies, 3642 participants; moderate-certainty evidence).']",4,0.4375,3,16
CD009098,2,7,"In addition, high PEEP may result in little to no difference in barotrauma (RR 1.00, 95% CI 0.64 to 1.57; I² = 63%; 9 studies, 3791 participants; low-certainty evidence).",rephrase,"['• Higher levels of PEEP were not associated with barotrauma (9 studies, 3790 participants; low-certainty evidence).']",5,0.5,3,16
CD009098,2,8,"High PEEP may improve oxygenation in patients up to the first and third days of mechanical ventilation (first day: mean difference (MD) 51.03, 95% CI 35.86 to 66.20; I² = 85%; 6 studies, 2594 participants; low-certainty evidence; third day: MD 50.32, 95% CI 34.92 to 65.72; I² = 83%; 6 studies, 2309 participants; low-certainty evidence) and probably improves oxygenation up to the seventh day (MD 28.52, 95% CI 20.82 to 36.21; I² = 0%; 5 studies, 1611 participants; moderate-certainty evidence).",rephrase,"['• Blood oxygenation was improved with higher PEEP on the first, third (6 studies, over 2300 participants, both low-certainty evidence), and seventh days (5 studies, 1611 participants; moderate-certainty evidence) of studies.']",6,0.5625,3,16
CD009098,2,9,"Evidence suggests that high PEEP results in little to no difference in the number of ventilator-free days (MD 0.45, 95% CI -2.02 to 2.92; I² = 81%; 3 studies, 1654 participants; low-certainty evidence).",rephrase,"['• High PEEP levels did not increase the number of ventilator-free days over a 28-day time period (3 studies, 1654 participants; low-certainty evidence).']",7,0.625,4,16
CD009098,2,10,Available data were insufficient to pool the evidence for length of stay in the intensive care unit.,rephrase,"['Finally, available data were insufficient to evaluate the impact of PEEP on length of stay in the intensive care unit, which is required with mechanical ventilation.']",8,0.6875,4,16
CD009098,3,11,Moderate-certainty evidence shows that high levels compared to low levels of PEEP do not reduce mortality before hospital discharge.,merge,[],9,0.75,4,16
CD009098,3,12,Low-certainty evidence suggests that high levels of PEEP result in little to no difference in the risk of barotrauma.,merge,[],9,0.8125,5,16
CD009098,3,13,"Low-certainty evidence also suggests that high levels of PEEP improve oxygenation up to the first and third days of mechanical ventilation, and moderate-certainty evidence indicates that high levels of PEEP improve oxygenation up to the seventh day of mechanical ventilation.",none,"['The highest level of certainty of evidence was moderate, and some outcomes were supported by low-certainty evidence.']",9,0.875,5,16
CD009098,3,14,"As in our previous review, we found clinical heterogeneity - mainly within participant characteristics and methods of titrating PEEP - that does not allow us to draw definitive conclusions regarding the use of high levels of PEEP in patients with ALI and ARDS.",merge,['Patients in the different studies varied in severity of ALI or ARDS and in other clinical factors (causing heterogeneity).'],10,0.9375,5,16
CD009098,3,15,Further studies should aim to determine the appropriate method of using high levels of PEEP and the advantages and disadvantages associated with high levels of PEEP in different ARDS and ALI patient populations.,none,[],10,1.0,5,16
CD009241,0,0,"We included two studies, involving 319 women.",rephrase,"['Data were collected from two randomised studies (involving 319 women) which compared women with epidurals who were given either oxytocin, or a placebo.']",0,0.16666666666666666,1,6
CD009241,0,1,"There was no statistically significant difference between the two groups in either of the primary outcomes of caesarean section (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.42 to 2.12) or instrumental delivery (RR 0.88, 95% CI 0.72 to 1.08).",merge,[],1,0.3333333333333333,2,6
CD009241,0,2,"Similarly, there were no statistically significant differences between the two groups in any of the secondary outcomes for which data were available.",none,"['The rates of operative deliveries were not clearly different between the two groups There were also no significant differences between the other outcomes analysed, such as the Apgar scores of the newborn babies, admissions to the neonatal nursery, rates of post birth haemorrhage or rates of over stimulation of the uterus.']",1,0.5,3,6
CD009241,0,3,"This included Apgar score less than seven at five minutes (RR 3.06, 0.13 to 73.33), admission to neonatal intensive care unit (RR 1.07, 95% CI 0.29 to 3.93), uterine hyperstimulation (RR 1.32, 95% CI 0.97 to 1.80) and postpartum haemorrhage (RR 0.96, 95% CI 0.58, 1.59).",delete,[],2,0.6666666666666666,4,6
CD009241,1,4,"There was no statistically significant difference identified between women in spontaneous labour with epidural analgesia who were augmented with oxytocin, compared with those who received placebo.",rephrase,"['Overall, there was no significant difference between the rates of operative deliveries in women with epidurals who were given oxytocin compared with those who received the placebo.']",2,0.8333333333333334,5,6
CD009241,1,5,"However, due to the limited number of women included in the studies, further research in the form of randomised controlled trials are required.",delete,[],3,1.0,5,6
CD008482,0,0,"Three trials (total 70 participants, aged 8 to 46 years) assessed as having a moderate risk of bias were included.",rephrase,['We included three trials (total of 70 participants aged between 8 and 46 years) in the review.'],0,0.08333333333333333,1,12
CD008482,0,1,"One trial compared vitamin K to placebo, a second to no supplementation and the third compared two doses of vitamin K. No trial in either comparison reported our primary outcomes of coagulation and quality of life or the secondary outcomes of nutritional parameters and adverse events.",rephrase,['No trial in either comparison reported our primary outcomes of blood clotting and quality of life or the secondary measures of nutrition and adverse events.'],1,0.16666666666666666,1,12
CD008482,1,2,"Vitamin K versus control
Two trials compared vitamin K to control, but data were not available for analysis.",merge,['Two trials compared vitamin K to a control.'],2,0.25,2,12
CD008482,1,3,One 12-month trial (n = 38) compared 10 mg vitamin K daily or placebo in a parallel design and one trial (n = 18) was of cross-over design with no washout period and compared 5 mg vitamin K/week for four-weeks to no supplementation for four-weeks.,none,[],2,0.3333333333333333,2,12
CD008482,1,4,Only the 12-month trial reported on the primary outcome of bone formation; we are very uncertain whether vitamin K supplementation has any effect on bone mineral density at the femoral hip or lumbar spine (very low-quality evidence).,rephrase,['Vitamin K versus control\nOnly the 12-month trial reported on the primary outcome of bone formation; we are very uncertain whether vitamin K supplementation has any effect on bone mineral density measured at the hip or lower back (very low-quality evidence).'],3,0.4166666666666667,3,12
CD008482,1,5,Both trials reported an increase in serum vitamin K levels and a decrease in undercarboxylated osteocalcin levels.,rephrase,['Both trials reported an increase in vitamin K levels in the blood and a decrease in undercarboxylated osteocalcin levels (this is an indicator of the risk of hip fracture).'],4,0.5,3,12
CD008482,1,6,"The cross-over trial also reported that levels of proteins induced by vitamin K absence (PIVKA) showed a decrease and a return to normal following supplementation, but due to the very low-quality evidence we are not certain that this is due to the intervention.",rephrase,"['The four-week trial also reported that levels of proteins induced by vitamin K absence (PIVKA) dropped and returned to normal levels, but due to the very low-quality evidence we are not certain that this is due to supplementation.']",5,0.5833333333333334,3,12
CD008482,2,7,"High-dose versus low-dose vitamin K
One parallel trial (n = 14) compared 1 mg vitamin K/day to 5 mg vitamin K/day for four weeks.",rephrase,['High-dose versus low-dose vitamin K\nThe trial reported that while vitamin K levels improved there did not seem to be any difference between the high-dose and low-dose groups.'],6,0.6666666666666666,4,12
CD008482,2,8,The trial did report that there did not appear to be any difference in serum undercarboxylated osteocalcin or vitamin K levels (very low-quality evidence).,rephrase,['There also did not seem to be any difference in undercarboxylated osteocalcin levels (very low-quality evidence).'],7,0.75,4,12
CD008482,2,9,"While the trial reported that serum vitamin K levels improved with supplementation, there was no difference between the high-dose and low-dose groups.",delete,[],8,0.8333333333333334,5,12
CD008482,3,10,There is very low-quality evidence of any effect of vitamin K in people with cystic fibrosis.,delete,[],8,0.9166666666666666,5,12
CD008482,3,11,"While there is no evidence of harm, until better evidence is available the ongoing recommendations by national CF guidelines should be followed.",delete,[],8,1.0,5,12
CD001863,0,0,"Twelve trials met our eligibility criteria, included the three added in this update.",merge,[],0,0.05,1,20
CD001863,0,1,The studies included a total of 4145 women.,none,['We found 12 trials with 4145 women.'],0,0.1,1,20
CD001863,0,2,"Eight trials were conducted in the USA; the others were from Australia, Nepal, Pakistan, and Syria.",rephrase,"['Eight studies were from the USA and the others were from Australia, Nepal, Pakistan, and Syria.']",1,0.15,1,20
CD001863,0,3,Four studies provided one session before hospital discharge; three had structured counseling of varying intensity and one involved informal counseling.,rephrase,['Four trials provided one counseling session before hospital discharge.'],2,0.2,1,20
CD001863,0,4,"Of eight interventions with than one contact, five focused on adolescents.",rephrase,"['Of eight studies with more than one contact, five focused on teens.']",3,0.25,2,20
CD001863,0,5,"Three of the five involved home visiting, one provided multiple clinic services, and one had in-person contact and phone follow-up.",rephrase,"['Three of the five had home visiting, one used clinic services, and one had personal and phone contacts.']",4,0.3,2,20
CD001863,0,6,"Of the remaining three for women of varying ages, two involved home visits and one provided phone follow-up.",rephrase,"['Of three studies with women and teens, two had home visits and one used phone contact.']",5,0.35,2,20
CD001863,1,7,Our sensitivity analysis included six trials with evidence of moderate or high quality.,rephrase,['Six trials had results of moderate quality.'],6,0.4,2,20
CD001863,1,8,"In a study with adolescents, the group with home-based mentoring had fewer second births within two years compared to the control group (OR 0.41, 95% CI 0.17 to 1.00).",rephrase,"['In a study with adolescents, the group with home-based mentoring had fewer second births within two years compared to the control group.']",7,0.45,3,20
CD001863,1,9,The other five interventions had no effect.,delete,[],8,0.5,3,20
CD001863,1,10,"Of trials with lower quality evidence, two showed some effectiveness.",ignore,"['Of trials with lower quality evidence, two showed some effect.']",8,0.55,3,20
CD001863,1,11,"In Nepal, women with an educational session immediately postpartum were more likely to use contraception at six months than those with a later or no session (OR 1.62, 95% CI 1.06 to 2.50).",rephrase,"['In Nepal, more of the women with some counseling right after delivery may use birth control at six months than those with a session later or none.']",9,0.6,3,20
CD001863,1,12,"In an Australian study, teenagers in a structured home-visiting program were more likely to have effective contraception use at six months than those with standard home visits (OR 3.24; 95% CI 1.35 to 7.79).",rephrase,"['In Australia, more teens in a special home-visiting program used birth control correctly at six months than those with standard home visits.']",10,0.65,4,20
CD001863,2,13,We focused our results summary on trials with moderate or high quality evidence.,merge,['We found moderate to low quality results overall.'],11,0.7,4,20
CD001863,2,14,"Overall, the overall quality of evidence in this review was moderate to low and the evidence of effectiveness was mostly low quality.",none,[],11,0.75,4,20
CD001863,2,15,The interventions could be improved by strengthening the program design and implementation.,rephrase,['Better program design and carrying out could make them stronger.'],12,0.8,4,20
CD001863,2,16,"Some studies did not report program training for providers, adherence to the intervention protocol, or measurement of participants' knowledge and skills.",delete,[],13,0.85,5,20
CD001863,2,17,"Many trials did not have an objective outcome measure, i.e., pregnancy test or structured questionnaire for contraceptive use.",delete,[],13,0.9,5,20
CD001863,2,18,Valid and reliable outcome measures are needed to obtain meaningful results.,delete,[],13,0.95,5,20
CD001863,2,19,"Still, given the associated costs and logistics, some programs would not be feasible in many settings.",rephrase,"['Even still, some programs might cost too much for some settings.']",13,1.0,5,20
CD009398,0,0,"Two small studies involving 116 children, mainly boys between 10 and 18 years of age, met the inclusion criteria.",rephrase,['We found two small studies involving 116 children that met our inclusion criteria.'],0,0.06666666666666667,1,15
CD009398,0,1,"One study was conducted in a school setting, the other at a specialised clinic.",rephrase,"['Most of these studies involved boys between 10 and 18 years of age - one was conducted in a school setting, and the other at a specialised clinic.']",1,0.13333333333333333,1,15
CD009398,0,2,Both studies used three months of a combination of omega-3 and omega-6 supplements as the intervention compared with placebo.,rephrase,['Both studies gave children a combination of omega-3 and omega-6 capsules as the intervention for three months.'],2,0.2,1,15
CD009398,0,3,"Although both studies had generally low risk of bias, we judged the risk of reporting bias as unclear in one study, and as high in the other study.",delete,[],3,0.26666666666666666,2,15
CD009398,0,4,"In addition, one of the studies was funded by industry and reported active company involvement in the study.",rephrase,['One of the studies was funded by the company that supplied the omega-3 and omega-6 supplements.'],3,0.3333333333333333,2,15
CD009398,1,5,"None of the studies reported data on the primary outcomes of reading, writing, spelling and mathematics scores, as assessed by standardised tests.",rephrase,"['None of the included studies reported effects of PUFAs on reading, writing, spelling or mathematical abilities of children.']",4,0.4,2,15
CD009398,2,6,"Evidence of low quality indicates that supplementation of PUFAs did not increase the risk of gastrointestinal disturbances (risk ratio 1.43, 95% confidence interval 0.25 to 8.15; two studies, 116 children).",rephrase,['Evidence of low quality (because studies included few participants and showed evidence of bias) suggests that using PUFAs did not increase the risk of minor disturbances to the digestive system.'],5,0.4666666666666667,3,15
CD009398,2,7,Investigators reported no other adverse effects.,rephrase,['Included studies reported no other types of adverse effects.'],6,0.5333333333333333,3,15
CD009398,3,8,Both studies reported attention deficit hyperactivity disorder (ADHD)-related behaviour outcomes.,rephrase,['Both studies reported on ADHD-related behaviour.'],7,0.6,3,15
CD009398,3,9,"We were unable to combine the results in a meta-analysis because one study reported findings as a continuous outcome, and the other as a dichotomous outcome.",rephrase,"['However, the format of available data did not allow us to readily combine them or to reach any conclusions.']",8,0.6666666666666666,4,15
CD009398,3,10,No other secondary outcomes were reported.,rephrase,['Included studies reported no other secondary outcomes.'],9,0.7333333333333333,4,15
CD009398,4,11,"We excluded one study because it used a cointervention (carnosine), and five other studies because they did not provide a robust diagnosis of a specific learning disorder.",rephrase,['Review authors excluded five studies because it was not confirmed that a specific learning disorder was diagnosed in these children.'],10,0.8,4,15
CD009398,4,12,We identified one ongoing study and found three studies awaiting classification.,delete,[],11,0.8666666666666667,5,15
CD009398,5,13,Evidence is insufficient to permit any conclusions about the effect of PUFAs on the learning abilities of children with specific learning disorders.,rephrase,['Evidence is not sufficient to support or refute the use of PUFAs in children with specific learning disorders.'],11,0.9333333333333333,5,15
CD009398,5,14,Well-designed RCTs with clearly defined populations of children with specific learning disorders who have been diagnosed by standardised diagnostic criteria are needed.,delete,[],12,1.0,5,15
CD006094,0,0,Twenty eight studies met our inclusion criteria.,ignore,['Twenty eight studies met our inclusion criteria.'],0,0.09090909090909091,1,11
CD006094,0,1,"The majority of the studies were for the management of osteoporosis or low back pain, and most evaluated interventions aimed at health professionals.",rephrase,"['The majority of studies evaluated interventions designed to change health professional behaviour, for example, the distribution of educational materials, reminders to health professionals and patient education.']",1,0.18181818181818182,1,11
CD006094,0,2,"To improve the use of imaging in the management of osteoporosis, the effect of any type of intervention compared to no-intervention controls was modest (absolute improvement in bone mineral density test ordering +10%, IQR 0.0 to +27.7).",merge,[],2,0.2727272727272727,2,11
CD006094,0,3,"Patient mediated, reminder, and organisational interventions appeared to have most potential for improving imaging use in osteoporosis.",none,"['For improving the use of imaging in osteoporosis, most interventions aimed at health professionals demonstrated benefit, and patient mediated, reminder, and organisational interventions appeared to have most potential for benefit.']",2,0.36363636363636365,2,11
CD006094,0,4,"For low back pain studies, the most common intervention evaluated was distribution of educational materials and this showed varying effects.",ignore,"['For low back pain studies, the most common intervention evaluated was distribution of educational materials and this showed varying effects.']",3,0.45454545454545453,3,11
CD006094,0,5,Other interventions in low back pain studies also showed variable effects.,ignore,['Other interventions in low back pain studies showed variable effects.'],4,0.5454545454545454,3,11
CD006094,0,6,"For other musculoskeletal conditions, distribution of educational materials, educational meetings and audit and feedback were not shown to be effective for changing imaging ordering behaviour.",ignore,"['For other musculoskeletal conditions, distribution of educational materials, educational meetings and audit and feedback were not shown to be effective for changing imaging ordering behaviour.']",5,0.6363636363636364,4,11
CD006094,0,7,"Across all conditions, increasing the number of intervention components did not increase effect.",rephrase,"['Across all conditions, increasing the number of intervention components did not result in a larger effect of interventions.']",6,0.7272727272727273,4,11
CD006094,1,8,"For improving the use of imaging in osteoporosis, most professional interventions demonstrated benefit, and patient mediated, reminder, and organisational interventions appeared to have most potential for benefit.",delete,[],7,0.8181818181818182,5,11
CD006094,1,9,For low back pain studies interventions showed varying effects.,delete,[],7,0.9090909090909091,5,11
CD006094,1,10,"For other musculoskeletal conditions, no firm conclusions can be drawn.",delete,[],7,1.0,5,11
CD003877,0,0,We included 50 studies with a total of 3704 participants.,rephrase,['A total of 50 randomised controlled trials were included with a total of 3704 participants.'],0,0.09090909090909091,1,11
CD003877,0,1,"Forty studies (81%) were at high risk of bias, nine (18%) were at unclear risk of bias, with just one assessed as at low risk of bias.",delete,[],1,0.18181818181818182,1,11
CD003877,0,2,There were 34 different sedatives used with or without inhalational nitrous oxide.,rephrase,"['Within these studies 34 different sedatives were used, often with inhalational nitrous oxide as well.']",1,0.2727272727272727,2,11
CD003877,0,3,"Dosages, mode of administration and time of administration varied widely.",rephrase,['Dosages and delivery of these drugs varied widely.'],2,0.36363636363636365,2,11
CD003877,0,4,"Studies were grouped into placebo-controlled, dosage and head-to-head comparisons.",rephrase,"['We grouped studies into those where drugs were compared to a placebo, where drugs were compared to other drugs or where different dosages of drugs were compared.']",3,0.45454545454545453,3,11
CD003877,0,5,Meta-analysis of the available data for the primary outcome (behaviour) was possible for studies investigating oral midazolam versus placebo only.,rephrase,['Because all the studies were so different we could only carry out a meta-analysis for studies comparing oral midazolam to a placebo.'],4,0.5454545454545454,3,11
CD003877,0,6,"There is moderate-certainty evidence from six small clinically heterogeneous studies at high or unclear risk of bias, that the use of oral midazolam in doses between 0.25 mg/kg to 1 mg/kg is associated with more co-operative behaviour compared to placebo; standardized mean difference (SMD) favoured midazolam (SMD 1.96, 95% confidence interval (CI) 1.59 to 2.33, P < 0.0001, I2 = 90%; 6 studies; 202 participants).",delete,[],5,0.6363636363636364,4,11
CD003877,0,7,It was not possible to draw conclusions regarding the secondary outcomes due to inconsistent or inadequate reporting or both.,delete,[],5,0.7272727272727273,4,11
CD003877,1,8,There is some moderate-certainty evidence that oral midazolam is an effective sedative agent for children undergoing dental treatment.,rephrase,['There is some moderate-certainty evidence that midazolam administered in a drink of juice is effective.'],5,0.8181818181818182,5,11
CD003877,1,9,There is a need for further well-designed and well-reported clinical trials to evaluate other potential sedation agents.,delete,[],6,0.9090909090909091,5,11
CD003877,1,10,Further recommendations for future research are described and it is suggested that future trials evaluate experimental regimens in comparison with oral midazolam or inhaled nitrous oxide.,delete,[],6,1.0,5,11
CD006567,0,0,"We included four RCTs (n = 1392 women) which administered the following interventions: bed rest (two trials), fibrin sealant (one trial), and mechanical closure of the cervix (one trial).",delete,[],0,0.07142857142857142,1,14
CD006567,0,1,"Our primary outcome, live birth rate, was not reported in any of the included trials; nor were the data available from the corresponding authors.",rephrase,"['Our primary measure of success, live birth rate, was not reported in any of the included trials.']",0,0.14285714285714285,1,14
CD006567,0,2,"For the ongoing pregnancy rate, two trials comparing more bed rest with less bed rest showed no evidence of a difference between groups (odds ratio (OR) 0.88; 95% confidence interval (CI) 0.60 to 1.31, 542 women, I2 = 0%, low quality evidence).",delete,[],1,0.21428571428571427,2,14
CD006567,0,3,"Secondary outcomes were sporadically reported with the exception of the clinical pregnancy rate, which was reported in all of the included trials.",delete,[],1,0.2857142857142857,2,14
CD006567,0,4,"There was no evidence of a difference in clinical pregnancy rate between more bed rest and less bed rest (OR 0.88; 95% CI 0.60 to 1.31, 542 women, I2 = 0%, low quality evidence) or between fibrin sealant and usual care (OR 0.98; 95% CI 0.54 to 1.78, 211 women, very low quality evidence).",delete,[],1,0.35714285714285715,2,14
CD006567,0,5,"However, mechanical closure of the cervix was associated with a higher clinical pregnancy rate than usual care (OR 1.92; 95% CI 1.40 to 2.63, very low quality evidence).",delete,[],1,0.42857142857142855,3,14
CD006567,0,6,The quality of the evidence was rated as low or very low for all outcomes.,rephrase,['The quality of the evidence was low or very low for all comparisons.'],1,0.5,3,14
CD006567,0,7,"The main limitations were failure to report live births, imprecision and risk of bias.",ignore,"['The main limitations were failure to report live births, imprecision and risk of bias.']",2,0.5714285714285714,3,14
CD006567,0,8,"Overall, the risk of bias of the included trials was high.",merge,[],3,0.6428571428571429,4,14
CD006567,0,9,"The use of a proper method of randomisation and allocation concealment was fairly well reported, while only one trial clearly reported blinding.",none,"['Study risk of bias was variable, with the reporting of a proper method of randomisation and allocation concealment demonstrated in most trials while only one trial clearly blinded both the patients and the clinicians to the intervention received.']",3,0.7142857142857143,4,14
CD006567,0,10,There was no evidence that any of the interventions had an effect on adverse event rates but data were too few to reach any conclusions.,ignore,"['There was no evidence that any of the interventions had an effect on adverse event rates, but data were too few to reach any conclusions.']",4,0.7857142857142857,4,14
CD006567,1,11,"There is insufficient evidence to support any specific length of time for women to remain recumbent, if at all, following embryo transfer, nor is there sufficient evidence to recommend the use of fibrin sealants added to the embryo transfer fluid.",rephrase,"['There was insufficient evidence to support a specific length of time for women to remain recumbent, if at all, following ET, nor was there sufficient evidence to recommend the use of fibrin sealants.']",5,0.8571428571428571,5,14
CD006567,1,12,There is very limited evidence to support the use of mechanical pressure to close the cervical canal following embryo transfer.,rephrase,['There was very limited evidence to support the use of mechanical pressure to close the cervical canal.'],6,0.9285714285714286,5,14
CD006567,1,13,Further well-designed and powered studies are required to determine the true effectiveness and safety of these interventions.,ignore,['Further large well-designed studies are required to determine the true effectiveness and safety of these interventions.'],7,1.0,5,14
CD006836,0,0,Ten heterogenous trials involving 874 adults with generally unstable fractures were grouped into six comparisons.,ignore,['Ten very different trials involving 874 adults with generally unstable fractures were grouped into six comparisons.'],0,0.07692307692307693,1,13
CD006836,0,1,No trial had proven allocation concealment.,rephrase,['No trial used a best-practice method for preventing selection bias.'],1,0.15384615384615385,1,13
CD006836,1,2,Four trials (239 participants) found implantation of bone scaffolding (autogenous bone graft (one trial); Norian SRS - a bone substitute (two trials); methylmethacrylate cement (one trial)) improved anatomical outcomes compared with plaster cast alone; and two found it improved function.,ignore,['Four trials (239 participants) found implantation of bone scaffolding (autogenous - from the patient - bone graft (one trial); Norian SRS - a bone substitute (two trials); methylmethacrylate cement (one trial)) improved anatomical outcomes compared with plaster cast alone; and two found it improved function.'],2,0.23076923076923078,2,13
CD006836,1,3,Reported complications of bone scaffolding were transient discomfort resulting from extraosseous deposits of Norian SRS; with surgical removal of one intra-articular deposit.,split,"['Reported complications of bone scaffolding were transient discomfort resulting from deposits of Norian SRS outside the bone.', 'One deposit required surgical removal.']",3,0.3076923076923077,2,13
CD006836,2,4,One trial (323 participants) comparing bone substitute (Norian SRS) versus plaster cast or external fixation found no difference in functional or anatomical outcomes at one year.,ignore,['One trial (323 participants) comparing Norian SRS versus plaster cast or external fixation found no difference in functional or anatomical outcomes at one year.'],5,0.38461538461538464,2,13
CD006836,2,5,Statistically significant complications in the respective groups were extraosseous Norian SRS deposits and pin track infection.,rephrase,['External deposits of bone cement and pin track infection were the only significant differences between the two groups.'],6,0.46153846153846156,3,13
CD006836,3,6,One trial (48 participants with external fixation) found that autogenous bone graft did not significantly change outcome.,rephrase,['One trial (48 participants) found that autogenous (from the patient) bone graft in the context of external fixation did not significantly change outcome.'],7,0.5384615384615384,3,13
CD006836,3,7,There was one serious donor-site complication.,ignore,['There was one serious donor-site complication.'],8,0.6153846153846154,4,13
CD006836,4,8,One trial (21 participants) found some indication of worse outcomes for hydroxyapatite bone cement compared with Kapandji's intrafocal pinning.,rephrase,['One trial (21 participants) found some indication of worse outcomes with bone cement compared with percutaneous (through the skin) pinning.'],9,0.6923076923076923,4,13
CD006836,5,9,Three trials (180 participants) found bone scaffolding (autogenous bone graft (one trial); Norian SRS (one trial); methylmethacrylate cement (one trial)) gave no significant difference in functional outcomes but some indication of better anatomical outcomes compared with external fixation.,ignore,['Three trials (180 participants) found bone scaffolding (autogenous bone graft (one trial); Norian SRS (one trial); methylmethacrylate cement (one trial)) gave no significant difference in functional outcomes but some indication of better anatomical outcomes compared with external fixation.'],10,0.7692307692307693,4,13
CD006836,5,10,Most reported complications were associated with external fixation; extraosseous deposits of Norian SRS occurred in one trial.,rephrase,['Most reported complications were associated with external fixation; deposits of Norian SRS outside the bone occurred in one trial.'],11,0.8461538461538461,5,13
CD006836,6,11,One trial (93 participants with dorsal plate fixation) found autografts slightly improved wrist function compared with allogenic bone material but with an excess of donor site complications.,rephrase,['One trial (93 participants treated with plate fixation) comparing allogenic bone material (from other people) versus autogenic bone-graft found slightly improved wrist function for the autograft group but an excess of complications relating to graft harvesting.'],12,0.9230769230769231,5,13
CD006836,7,12,Bone scaffolding may improve anatomical outcome compared with plaster cast alone but there is insufficient evidence to conclude on functional outcome and safety; or for other comparisons.,rephrase,"['The review concluded that while bone scaffolding may improve anatomical outcome compared with plaster cast immobilisation alone, there is insufficient evidence to conclude on function and safety; or on outcome for other comparisons.']",13,1.0,5,13
CD008596,0,0,"Four studies of a relatively small size, involving 144 participants, were included in this review.",rephrase,"['This review evaluated the efficacy and safety of a similar category, the H2-antihistamines, and included 4 low-quality studies, which examined 144 participants.']",0,0.1111111111111111,1,9
CD008596,0,1,"A combination of ranitidine with diphenhydramine was more effective at improving the resolution of urticaria than diphenhydramine administered alone (risk ratio (RR) 1.59, 95% confidence interval (CI) 1.07 to 2.36).",rephrase,"['No firm conclusions could be drawn, but the combination of ranitidine with diphenhydramine appeared to be slightly more effective in reducing the symptoms of urticaria than diphenhydramine alone.']",1,0.2222222222222222,2,9
CD008596,0,2,"Although there was a similar improvement in itching, weal size, and intensity, cimetidine provided no statistically significant greater overall improvement in symptoms of urticaria when compared to diphenhydramine.",rephrase,"['In one study, cimetidine appeared to be as effective as diphenhydramine.']",2,0.3333333333333333,2,9
CD008596,0,3,"However, a combination of these medications was more effective than diphenhydramine alone (RR 2.02, 95% CI 1.03 to 3.94).",rephrase,"['However, the combination of both drugs was more effective than diphenhydramine alone.']",3,0.4444444444444444,3,9
CD008596,0,4,"Adverse events were reported with several of the interventions, i.e. ranitidine and diphenhydramine, causing drowsiness and sedation, but there was no significant difference in the level of sedation from baseline with either famotidine or diphenhydramine.",rephrase,"['Drowsiness and sedation were reported with diphenhydramine, but there was no significant difference in the level of sedation with either famotidine or diphenhydramine.']",4,0.5555555555555556,3,9
CD008596,1,5,"The very limited evidence provided by this review was based on a few old studies of a relatively small size, which we categorised as having high to unclear risk of bias.",delete,[],5,0.6666666666666666,4,9
CD008596,1,6,"Thus, at present, the review does not allow confident decision-making about the use of H2-receptor antagonists for urticaria.",delete,[],5,0.7777777777777778,4,9
CD008596,1,7,"Although some of these studies have reported a measure of relief of symptoms of urticaria and rather minimal clinical improvement in some of the participants, the evidence was weak and unreliable.",delete,[],5,0.8888888888888888,5,9
CD008596,1,8,We have emphasised the lack of precision and limitations in the reported data where appropriate in this review.,delete,[],5,1.0,5,9
CD012439,0,0,"We included six trials, four of which took place in the USA.",delete,[],0,0.045454545454545456,1,22
CD012439,0,1,Four trials employed randomised controlled trial (RCT) designs.,delete,[],0,0.09090909090909091,1,22
CD012439,0,2,"Trials were conducted in workplaces from the manufacturing, industrial and services-based sectors.",rephrase,"['Most took place in the USA, and workplaces were in the manufacturing, industrial and services-based sectors.']",0,0.13636363636363635,1,22
CD012439,0,3,The sample sizes of workplaces ranged from 12 to 114.,rephrase,['The number of workplaces examined in the studies ranged from 12 to 114.'],1,0.18181818181818182,1,22
CD012439,0,4,Workplace policies and practices targeted included: healthy catering policies; point-of-purchase nutrition labelling; environmental supports for healthy eating and physical activity; tobacco control policies; weight management programmes; and adherence to guidelines for staff health promotion.,rephrase,['Implementation strategies in the six studies targeted different workplace policies and practices: healthy catering; point-of-purchase nutrition labelling; environmental prompts and supports for healthy eating and physical activity; tobacco control policies; sponsorship of employee weight management programmes; and adherence to national guidelines for staff health promotion.'],2,0.22727272727272727,2,22
CD012439,0,5,"All implementation interventions utilised multiple implementation strategies, the most common of which were educational meetings, tailored interventions and local consensus processes.",rephrase,"['All studies used multiple strategies to improve the implementation of these policies and practices, including: educational meetings, interventions tailored to the specific needs of the workplace, and workplace consensus processes to implement a policy or practice.']",3,0.2727272727272727,2,22
CD012439,0,6,"Four trials compared an implementation strategy intervention with a no intervention control, one trial compared different implementation interventions, and one three-arm trial compared two implementation strategies with each other and a control.",rephrase,"['Four studies compared implementation strategies versus no intervention, one study compared different implementation strategies, and one study compared two implementation strategies with each other and a control.']",4,0.3181818181818182,2,22
CD012439,0,7,"Four trials reported a single implementation outcome, whilst the other two reported multiple outcomes.",delete,[],5,0.36363636363636365,2,22
CD012439,0,8,"Investigators assessed outcomes using surveys, audits and environmental observations.",rephrase,"['Researchers used surveys, audits and observations in workplaces to evaluate the effect of the strategies on the implementation of workplace policies and practices.']",5,0.4090909090909091,3,22
CD012439,0,9,We judged most trials to be at high risk of performance and detection bias and at unclear risk of reporting and attrition bias.,delete,[],6,0.45454545454545453,3,22
CD012439,1,10,"Of the five trials comparing implementation strategies with a no intervention control, pooled analysis was possible for three RCTs reporting continuous score-based measures of implementation outcomes.",delete,[],6,0.5,3,22
CD012439,1,11,"The meta-analysis found no difference in standardised effects (standardised mean difference (SMD) −0.01, 95% CI −0.32 to 0.30; 164 participants; 3 studies; low certainty evidence), suggesting no benefit of implementation support in improving policy or practice implementation, relative to control.",delete,[],6,0.5454545454545454,3,22
CD012439,1,12,Findings for other continuous or dichotomous implementation outcomes reported across these five trials were mixed.,delete,[],6,0.5909090909090909,3,22
CD012439,1,13,"For the two non-randomised trials examining comparative effectiveness, both reported improvements in implementation, favouring the more intensive implementation group (very low certainty evidence).",rephrase,"['In the two trials comparing different implementation strategies, both reported improvements in implementation, favouring the more intensive implementation support group.']",6,0.6363636363636364,4,22
CD012439,1,14,"Three trials examined the impact of implementation strategies on employee health behaviours, reporting mixed effects for diet and weight status (very low certainty evidence) and no effect for physical activity (very low certainty evidence) or tobacco use (low certainty evidence).",merge,"['Findings for effects on employee health behaviours were inconsistent and based on very low to low certainty evidence, so it is unclear whether the implementation strategies improved these outcomes.']",7,0.6818181818181818,4,22
CD012439,1,15,One trial reported an increase in absolute workplace costs for health promotion in the implementation group (low certainty evidence).,none,[],7,0.7272727272727273,4,22
CD012439,1,16,None of the included trials assessed adverse consequences.,rephrase,"['One of the included studies reported on cost, and none on the unintended adverse consequences of implementation strategies.']",8,0.7727272727272727,4,22
CD012439,1,17,"Limitations of the review included the small number of trials identified and the lack of consistent terminology applied in the implementation science field, which may have resulted in us overlooking potentially relevant trials in the search.",delete,[],9,0.8181818181818182,5,22
CD012439,2,18,Available evidence regarding the effectiveness of implementation strategies for improving implementation of health-promoting policies and practices in the workplace setting is sparse and inconsistent.,rephrase,['We looked for studies that compared strategies to support the implementation of health-promoting policies and practices in workplaces versus either no implementation strategy or different implementation strategies.'],9,0.8636363636363636,5,22
CD012439,2,19,Low certainty evidence suggests that such strategies may make little or no difference on measures of implementation fidelity or different employee health behaviour outcomes.,rephrase,"['We rated the certainty of the evidence as low for the effect of implementation strategies on policy and practice implementation, based on four randomised studies (where groups are randomly assigned to different study groups), and very low based on two non-randomised studies.']",10,0.9090909090909091,5,22
CD012439,2,20,It is also unclear if such strategies are cost-effective or have potential unintended adverse consequences.,delete,[],11,0.9545454545454546,5,22
CD012439,2,21,"The limited number of trials identified suggests implementation research in the workplace setting is in its infancy, warranting further research to guide evidence translation in this setting.",rephrase,['Further research is needed.'],11,1.0,5,22
CD008325,0,0,"The search update identified 273 new references, of which none fulfilled our inclusion criteria.",delete,[],0,0.1,1,10
CD008325,0,1,"We included four studies (643 participants) in this updated review, which were all included in the previous (2004) update.",rephrase,"['We included four studies in this review, which we included in the previous version of this review, which means that we did not identify any new relevant studies for inclusion in this update.']",0,0.2,1,10
CD008325,0,2,The quality of the evidence was very low for all outcomes.,rephrase,"['The quality of the evidence was very low for all the outcomes according to the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.']",1,0.3,2,10
CD008325,0,3,"As data were too clinically heterogeneous to be pooled, we described individual trial results.",rephrase,['The treatment comparisons were too dissimilar to be pooled and half of the studies were at high risk of bias.'],2,0.4,2,10
CD008325,0,4,"The results indicate that there is very low quality evidence that back schools are no more effective than a placebo (or sham or attention control) or another treatment (physical therapies, myofascial therapy, joint manipulations, advice) on pain, disability, work status and adverse events at short-term, intermediate-term and long-term follow-up.",rephrase,['One study compared back school with a placebo (sham treatment) and found no difference between groups for pain at short-term follow-up.'],3,0.5,3,10
CD008325,0,5,There is very low quality evidence that shows a statistically significant difference between back schools and a placebo (or sham or attention control) for return to work at short-term follow-up in favour of back school.,rephrase,"['Concerning work status, people in the back school group had a significantly shorter duration of sick-leave than people in the placebo group at short-term follow-up.']",4,0.6,3,10
CD008325,0,6,Very low quality evidence suggests that back school added to a back care programme is more effective than a back care programme alone for disability at short-term follow-up.,rephrase,['Only one study showed that back school added to a back care programme was more effective than back school alone for disability at short-term follow-up.'],5,0.7,4,10
CD008325,0,7,"Very low quality evidence also indicates that there is no difference in terms of adverse events between back school and myofascial therapy, joint manipulation and combined myofascial therapy and joint manipulation.",delete,[],6,0.8,4,10
CD008325,1,8,It is uncertain if back schools are effective for acute and subacute non-specific LBP as there is only very low quality evidence available.,merge,"['However, back schools do not seem to be a treatment widely used nowadays for people with acute and subacute non-specific low-back pain and are not endorsed by guidelines.']",6,0.9,5,10
CD008325,1,9,"While large well-conducted studies will likely provide more conclusive findings, back schools are not widely used interventions for acute and subacute LBP and further research into this area may not be a priority.",none,[],6,1.0,5,10
CD006429,0,0,"Compared with the previous review, which was published in 2011, we included 14 additional studies (493 participants), excluded one study and included data for meta-analysis of HRQOL.",rephrase,"['Compared with the previous review, which was published in 2011, we have added 14 studies (493 participants) to this review.']",0,0.09090909090909091,1,11
CD006429,0,1,"In total, we included in this review 44 studies including 1195 participants, and we included 33 of these (901 participants)in the meta-analysis.",rephrase,['We included a total of 44 studies (1195 participants) in this review.'],1,0.18181818181818182,1,11
CD006429,1,2,"We found that breathlessness during exercise or daily activities was reduced by oxygen compared with air (32 studies; 865 participants; SMD -0.31, 95% CI -0.43 to -0.20; I2 = 29%; low-quality evidence).",rephrase,['We found that oxygen can modestly reduce breathlessness.'],2,0.2727272727272727,2,11
CD006429,1,3,This translates to a decrease in breathlessness of about 0.7 points on a 0 to 10 numerical rating scale.,delete,[],3,0.36363636363636365,2,11
CD006429,1,4,"In contrast, we found no effect of short-burst oxygen given before exercise (four studies; 90 participants; SMD -0.03, 95% CI -0.28 to 0.22; I2 = 0%; low-quality evidence).",delete,[],3,0.45454545454545453,3,11
CD006429,1,5,"Oxygen reduced breathlessness measured during exercise tests (30 studies; 591 participants; SMD -0.34, 95% CI -0.46 to -0.22; I2 = 29%; moderate-quality evidence), whereas evidence of an effect on breathlessness measured in daily life was limited (two studies; 274 participants; SMD -0.13, 95% CI, -0.37 to 0.11; I2 = 0%; low-quality evidence).",delete,[],3,0.5454545454545454,3,11
CD006429,2,6,"Oxygen did not clearly affect HRQOL (five studies; 267 participants; SMD 0.12, 95% CI -0.04 to 0.28; I2 = 0%; low-quality evidence).",delete,[],3,0.6363636363636364,4,11
CD006429,2,7,Patient preference and adverse events could not be analysed owing to insufficient data.,delete,[],3,0.7272727272727273,4,11
CD006429,3,8,We are moderately confident that oxygen can relieve breathlessness when given during exercise to mildly hypoxaemic and non-hypoxaemic people with chronic obstructive pulmonary disease who would not otherwise qualify for home oxygen therapy.,rephrase,['We are moderately confident that oxygen can relieve breathlessness when given during exercise to people with COPD with mildly or moderately decreased blood oxygen levels.'],3,0.8181818181818182,5,11
CD006429,3,9,"Most evidence pertains to acute effects during exercise tests, and no evidence indicates that oxygen decreases breathlessness in the daily life setting.",rephrase,"['However, most studies reported acute effects during an exercise test, and no evidence suggests that oxygen decreases breathlessness during daily life.']",4,0.9090909090909091,5,11
CD006429,3,10,Findings show that oxygen does not affect health-related quality of life.,ignore,['Findings indicate that oxygen does not affect health-related quality of life.'],5,1.0,5,11
CD010237,0,0,Sixteen studies involving 1063 participants were identified.,rephrase,['Study characteristics: We included sixteen randomised controlled trials (1063 participants) comparing Tong-xin-luo capsules plus conventional treatment with placebo plus/or conventional treatment (literature search date: though June 2014).'],0,0.125,1,8
CD010237,0,1,"The risk of bias for fifteen studies was high and along with imprecision and possible publication bias, this lowered our confidence in the results.",rephrase,"['Quality of evidence: Because of high risk of bias for fifteen studies, imprecision and possible publication bias, the quality of evidence was low or very low for all study outcomes.']",1,0.25,2,8
CD010237,0,2,"There was low quality evidence that Tong-xi-luo reduced the rates of angiographic restenosis (RR 0.16, 95% CI 0.07 to 0.34), myocardial infarction (RR 0.32, 95% CI 0.16 to 0.66), heart failure (RR 0.26, 95% CI 0.11 to 0.62), and use of revascularisation (RR 0.26, 95% CI 0.15 to 0.45).",delete,[],2,0.375,2,8
CD010237,0,3,"There was very low quality evidence for the effect of Tong-xin-luo on all-cause mortality (RR 0.38, 95% CI 0.06 to 2.56), angina (RR 0.24, 95% CI 0.17 to 0.34) and death due to any cardiovascular event (RR 0.31, 95% CI 0.08 to 1.12).",delete,[],2,0.5,3,8
CD010237,0,4,"Adverse events were seldom reported, and included gastrointestinal reactions and nausea.",rephrase,['Adverse events were seldom reported.'],2,0.625,4,8
CD010237,1,5,The addition of Tong-xin-luo to conventional Western medicine may possibly prevent restenosis and recurrence of cardiovascular events in patients with CHD after PCI.,rephrase,"['Key results: We found that Tong-xin-luo may possibly reduce the risk of narrowing of a blood vessel detected by angiography, cardiovascular events (including myocardial infarction, angina and heart failure) and use of repeat procedure.']",3,0.75,4,8
CD010237,1,6,"However, the data are limited by publication bias and high risk of bias for included studies.",delete,[],4,0.875,5,8
CD010237,1,7,Further high-quality trials are required to evaluate the potential effects of this intervention.,delete,[],4,1.0,5,8
CD007707,0,0,The search resulted in 2693 articles that we screened on title and abstract for eligibility.Thirteen studies were selected for full text assessment.,delete,[],0,0.09090909090909091,1,11
CD007707,0,1,We included three randomised trials involving 1150 women.,rephrase,['This review found three studies that were of high quality with a total of 1150 women randomly allocated to induction in the morning or the evening.'],0,0.18181818181818182,1,11
CD007707,0,2,"Two trials compared the administration of prostaglandins in the morning versus the evening in women with an unfavourable cervix, and one trial compared induction of labour in the morning versus the evening in women with a favourable cervix and/or ruptured membranes with intravenous oxytocin.",split,"['One trial used intravenous oxytocin in women who had a dilated cervix or rupture of membranes and two trials used prostaglandins to induce labour.', 'Prostaglandins are hormones used when the cervix is not ripe, intravenous oxytocin is mostly needed afterwards to really get labour started.']",1,0.2727272727272727,2,11
CD007707,0,3,"Because of the different mechanism, we have reported results for these two comparisons separately.",rephrase,"['Therefore, these two different methods, prostaglandins and intravenous oxytocin, rely on a different mechanism and were assessed separately.']",3,0.36363636363636365,2,11
CD007707,1,4,In the two trials comparing prostaglandins in the morning versus the evening there were few clinically significant differences between study groups for maternal or neonatal outcomes.,delete,[],4,0.45454545454545453,3,11
CD007707,1,5,One study reported a statistically significant preference by women to start induction of labour with prostaglandins in the morning.,split,"['This review found no differences in effect between starting induction in morning or evening on outcomes for mother or child.', 'One study reported that women had a preference to start induction of labour with prostaglandins in the morning, and more women in the evening admission group did not like the interruptions to sleep that were associated with the induction protocol.']",4,0.5454545454545454,3,11
CD007707,2,6,"In the trial examining induction of labour with intravenous oxytocin, the number of neonatal admissions was statistically significantly increased in the group of women that started induction in the morning.",delete,[],6,0.6363636363636364,4,11
CD007707,2,7,"This finding was unexpected, and while the trial authors offered some possible explanations for this, it is important that any future trials examine neonatal outcomes.",delete,[],6,0.7272727272727273,4,11
CD007707,3,8,"Taking into account women's preferences that favoured administration of prostaglandins in the morning, we conclude that caregivers should preferably consider administering prostaglandins in the morning.",rephrase,"['However, given the preference of most women, administration of prostaglandins should preferably be done in the morning.']",6,0.8181818181818182,5,11
CD007707,4,9,There is no strong evidence that induction of labour with intravenous oxytocin in the evening is more or less effective than induction in the morning.,rephrase,"['This review, with only three studies with two different comparisons, concludes that induction of labour in the evening is as effective and safe as induction in the morning.']",7,0.9090909090909091,5,11
CD007707,4,10,Consideration may be given to start induction of labour with oxytocin in the evening when indicated.,delete,[],8,1.0,5,11
CD012278,0,0,"We identified one eligible study that examined the effect of computerised cognitive training (CCT) in 6742 participants over 50 years of age, with training and follow-up duration of six months.",delete,[],0,0.125,1,8
CD012278,0,1,We considered the study to be at high risk of attrition bias and the overall quality of the evidence to be low.,rephrase,"['We thought this put the results at high risk of bias; therefore we considered the quality of evidence provided by this study to be low, meaning that further research might well lead to different results.']",0,0.25,2,8
CD012278,1,2,Researchers provided no data on our primary outcome.,delete,[],1,0.375,2,8
CD012278,1,3,"Results indicate that there may be a small advantage for the CCT group for executive function (mean difference (MD) -1.57, 95% confidence interval (CI) -1.85 to -1.29; participants = 3994; low-quality evidence) and a very small advantage for the control group for working memory (MD 0.09, 95% CI 0.03 to 0.15; participants = 5831; low-quality evidence).",delete,[],1,0.5,3,8
CD012278,1,4,"The intervention may have had little or no effect on episodic memory (MD -0.03, 95% CI -0.10 to 0.04; participants = 3090; low-quality evidence).",delete,[],1,0.625,4,8
CD012278,2,5,We found low-quality evidence from only one study.,rephrase,"['We found that a lot of shorter studies had been conducted, but only one study met our criteria for this review.']",1,0.75,4,8
CD012278,2,6,We are unable to determine whether computerised cognitive training is effective in maintaining global cognitive function among healthy adults in midlife.,rephrase,['We were not able to tell whether taking part in computerised cognitive training in midlife has any lasting effects on cognitive function.'],2,0.875,5,8
CD012278,2,7,"We strongly recommend that high-quality studies be undertaken to investigate the effectiveness and acceptability of cognitive training in midlife, using interventions that last long enough that they may have enduring effects on cognitive and brain reserve, and with investigators following up long enough to assess effects on clinically important outcomes in later life.",rephrase,['We think this is an important question that should be investigated further in trials that test cognitive training over three months or longer.'],3,1.0,5,8
CD011532,0,0,We included 10 randomised clinical trials with 474 participants.,rephrase,['We included 10 clinical trials with 474 participants.'],0,0.0625,1,16
CD011532,0,1,"The trials compared terlipressin versus noradrenaline (seven trials), octreotide (one trial), midodrine and octreotide (one trial), or dopamine (one trial).",split,"['Seven trials compared terlipressin and albumin versus noradrenaline and albumin.', 'The remaining three trials compared terlipressin and albumin versus midodrine and octreotide, or octreotide alone, or dopamine.']",1,0.125,1,16
CD011532,0,2,All participants in both groups received albumin as cointervention.,delete,[],3,0.1875,1,16
CD011532,0,3,We classified two trials at low risk of bias and eight trials at high risk of bias in the assessment of mortality and all trials at high risk of bias for remaining outcomes.,delete,[],3,0.25,2,16
CD011532,0,4,"In five trials, investigators specifically stated that they did not receive funding from for-profit organisations.",rephrase,"['In five trials, investigators specifically stated that they did not receive funding from organisations that could profit from the trial results.']",3,0.3125,2,16
CD011532,0,5,We had no information about the funding source from the remaining five trials.,ignore,['We did not have information about the funding source from the remaining five trials.'],4,0.375,2,16
CD011532,1,6,"Terlipressin was not superior or inferior compared with other vasoactive drugs in regard to mortality when including the two trials with a low risk of bias (RR 0.92, 95% CI 0.63 to 1.36; 94 participants, very low quality evidence) or when including all 10 trials (RR 0.96, 95% CI 0.88 to 1.06; 474 participants; I² = 0%; very low quality evidence).",delete,[],5,0.4375,3,16
CD011532,1,7,"One meta-analysis including nine trials suggested a beneficial effect of terlipressin on hepatorenal syndrome (RR 0.79, 95% CI 0.63 to 0.99; 394 participants; I² = 26%; very low quality evidence).",rephrase,['Our analyses suggested that treatment with terlipressin may have a beneficial effect on hepatorenal syndrome by reducing the number of participants with persistent hepatorenal syndrome.'],5,0.5,3,16
CD011532,1,8,"Due to the high mortality of hepatorenal syndrome, the registration of other serious adverse events is uncertain, but comparing terlipressin and other vasoactive drugs we found no significant difference (RR 0.96, 95% CI 0.88 to 1.06; 474 participants; I² = 0%; very low quality evidence).",rephrase,['Our analyses found uncertain evidence to support or refute terlipressin versus other vasoactive drugs in the treatment of hepatorenal syndrome when evaluating mortality or serious side effects.'],6,0.5625,3,16
CD011532,1,9,"Several trials did not report systematically of adverse events, but terlipressin seemed to increase the risks of diarrhoea or abdominal pain, or both (RR 3.50, 95% CI 1.19 to 10.27; 221 participants; 5 trials, I² = 0%).",delete,[],7,0.625,4,16
CD011532,1,10,"However, Trial Sequential Analyses found insufficient evidence to support or refute any differences between interventions for all outcomes.",delete,[],7,0.6875,4,16
CD011532,1,11,"Considering reversal of hepatorenal syndrome, subgroup analyses on the type of other vasoactive drugs found that terlipressin was superior compared with midodrine and octreotide (RR 0.47, 95% CI 0.30 to 0.72) or octreotide alone (RR 0.56, 95% CI 0.33 to 0.96), but each subgroup only included one small trial.",delete,[],7,0.75,4,16
CD011532,1,12,None of the remaining subgroup or sensitivity analyses found differences between terlipressin and other vasoactive drugs.,rephrase,"['Accordingly, we found that important differences between terlipressin and other vasoactive drugs may be overlooked.']",7,0.8125,5,16
CD011532,1,13,"We downgraded the evidence to very low quality because of the high risk of bias, imprecision, and the results of the Trial Sequential Analyses.",rephrase,['We found that the evidence was of very low quality due to the high risk of bias and the small number of participants.'],8,0.875,5,16
CD011532,2,14,This review found insufficient evidence to support or refute beneficial or harmful effects of terlipressin and albumin versus other vasoactive drugs and albumin.,delete,[],9,0.9375,5,16
CD011532,2,15,Additional research is needed to evaluate if clinically meaningful differences exist between interventions.,rephrase,['We need additional large trials of a high quality to evaluate if terlipressin is more beneficial or safer than other vasoactive drugs.'],9,1.0,5,16
CD004665,0,0,Three studies involving 1257 women met our inclusion criteria.,rephrase,['This review included three studies involving 1257 birthing women.'],0,0.1111111111111111,1,9
CD004665,0,1,"Cord drainage reduced the length of the third stage of labour (mean difference (MD) -2.85 minutes, 95% confidence interval (CI) -4.04 to -1.66; three trials, 1257 women (heterogeneity: T² = 0.87; Chi²P=17.19, I² = 88%)) and reduced the average amount of blood loss (MD -77.00 ml, 95% CI -113.73 to -40.27; one trial, 200 women).",rephrase,['The findings showed that placental cord drainage in the management of third stage of labour reduced the length of third stage of labour by a mean of about three minutes and reduced blood loss by average of 77 ml.'],1,0.2222222222222222,2,9
CD004665,1,2,"No incidence of retained placenta at 30 minutes after birth was observed in the included studies, therefore, it was not possible to compare this outcome.",rephrase,"['Other desired outcomes were either not reported or were not reported in an appropriate way for statistical analysis (e.g. placenta not delivered within 30 minutes after birth, maternal haemoglobin changes).']",2,0.3333333333333333,2,9
CD004665,1,3,The differences between the cord drainage and the control group were not statistically significant for postpartum haemorrhage or manual removal of the placenta.,rephrase,['There was no clear difference in the manual removal of placenta or the risk of postpartum haemorrhage or incidence of blood transfusion.'],3,0.4444444444444444,3,9
CD004665,1,4,None of the included studies reported fetomaternal transfusion outcomes and there were no data relating to maternal pain or discomfort during the third stage of labour.,rephrase,['The trials did not report on maternal pain or discomfort during the third stage of labour.'],4,0.5555555555555556,3,9
CD004665,2,5,There was a small reduction in the length of the third stage of labour and also in the amount of blood loss when cord drainage was applied compared with no cord drainage.,delete,[],5,0.6666666666666666,4,9
CD004665,2,6,"The clinical importance of such observed statistically significant reductions, is open to debate.",delete,[],5,0.7777777777777778,4,9
CD004665,2,7,"There is no clear difference in the need for manual removal of placenta, blood transfusion or the risk of postpartum haemorrhage.",delete,[],5,0.8888888888888888,5,9
CD004665,2,8,"Due to small trials with medium risk of bias, the results should be interpreted with caution.",delete,[],5,1.0,5,9
CD009387,0,0,"A total of four studies were included that involved 823 participants, 412 in the exercise group and 411 in the control group.",rephrase,"['We included four studies, with 823 participants in total, comparing exercise for increased-risk individuals against control or no treatment.']",0,0.1111111111111111,1,9
CD009387,0,1,Follow-up of participants ranged from 16 weeks to 6 months.,rephrase,['Follow-up of patients ranged from 16 weeks to six months.'],1,0.2222222222222222,2,9
CD009387,0,2,"Overall, the included studies had a high risk of selection, detection, and attrition bias.",delete,[],2,0.3333333333333333,2,9
CD009387,0,3,"Meta-analysis was not possible because the interventions (setting, type and intensity of exercise) and outcome measurements were not comparable, and the risk of bias in the identified studies was high.",delete,[],2,0.4444444444444444,3,9
CD009387,0,4,No study assessed cardiovascular or all‑cause mortality or cardiovascular events as individual outcomes.,ignore,"['No study assessed cardiovascular or all-cause mortality, or cardiovascular events as individual outcomes.']",2,0.5555555555555556,3,9
CD009387,0,5,"One or more of the studies reported on total cardiovascular risk, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, blood pressure, body mass index, exercise capacity, and health-related quality of life but the available evidence was not sufficient to determine the effectiveness of exercise.",rephrase,"['One or more of the studies reported on total cardiovascular risk, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, blood pressure, body mass index, exercise capacity, and health-related quality of life, but the results did not provide conclusive evidence of the effects of exercise in this population.']",3,0.6666666666666666,4,9
CD009387,0,6,Adverse events and smoking cessation were not assessed in the included studies.,rephrase,['The included studies did not assess smoking cessation or any adverse effects of the exercise intervention.'],4,0.7777777777777778,4,9
CD009387,1,7,"Evidence to date is entirely limited to small studies with regard to sample size, short-term follow-up, and high risk of methodological bias, which makes it difficult to derive any conclusions on the efficacy or safety of aerobic or resistance exercise on groups with increased cardiovascular risk or in individuals with two or more coexisting risk factors.",rephrase,"['We conclude that the evidence to date is entirely limited to small studies in terms of sample size, short-term follow-up, and high-risk of methodological bias, which makes it difficult to derive any conclusions on the efficacy or safety of the exercise carried out in the included trials on total cardiovascular risk, mortality, or cardiovascular events.']",5,0.8888888888888888,5,9
CD009387,1,8,Further randomized clinical trials assessing controlled exercise programmes on total cardiovascular risk in individuals are warranted.,rephrase,['It is necessary to conduct high-quality clinical trials that evaluate the effect of exercise on people with increased cardiovascular risk.'],6,1.0,5,9
CD013570,0,0,We included two studies (162 participants) in this review.,rephrase,['We found two studies with 162 participants.'],0,0.07142857142857142,1,14
CD013570,0,1,"One study with three arms and 101 participants (15 months' duration) was conducted in a children's hospital, and compared hydrogel dressings in the form of Sorbact with Algisite, an alginate dressing and Cuticerin, a smooth acetate gauze impregnated with water-repellent ointment.",rephrase,['- One study with 101 participants was conducted at a children’s burns unit and compared a hydrogel dressing (gauze mesh coated with hydrogel) with an alginate (algae- or seaweed-based) dressing or Cuticerin (a smooth acetate gauze impregnated with water-repellent ointment).'],1,0.14285714285714285,1,14
CD013570,0,2,Another study with two arms and 61 participants (19 months' duration) was conducted in three surgery departments and compared an octenidine-containing hydrogel dressing with an identical non-antimicrobial hydrogel dressing.,rephrase,"['- The second study, with 61 participants, took place in three surgery departments and compared a hydrogel dressing that contained an antiseptic (octenidine - to reduce the chance of infection) with a dressing with no octenidine.']",2,0.21428571428571427,2,14
CD013570,0,3,"We identified no studies that compared hydrogel dressings with another therapy such as a topical agent (a topical agent is a cream, an ointment or a solution that is applied directly to the wound), or no dressing, or a combination of hydrogel dressings and another therapy versus another therapy alone.",rephrase,['We did not find any studies that compared hydrogel dressings with treatments directly applied to the wound (like creams or ointments).'],3,0.2857142857142857,2,14
CD013570,0,4,Both studies were at high risk of attrition bias and the second study was also at unclear risk of selection bias.,delete,[],4,0.35714285714285715,2,14
CD013570,1,5,"Amorphous hydrogel dressings versus other types of dressings
Amorphous hydrogel dressings may increase time to wound healing when compared with alginate (mean difference (MD) 1.67 days, 95% confidence interval (CI) 0.56 to 2.78; 1 study, 69 participants; low-certainty evidence) or Cuticerin dressings (MD 1.67 days, 95% CI 0.55 to 2.79; 1 study, 68 participants; low-certainty evidence).",rephrase,"['Hydrogel dressings may increase time to wound healing by about 1.7 days compared with alginate (1 study, 69 participants) or Cuticerin dressings (1 study 68 participants).']",4,0.42857142857142855,3,14
CD013570,1,6,"The effect of amorphous hydrogel dressings compared with other types of dressings is uncertain for pain at the donor site and wound complications, including scarring and itching (very low-certainty evidence).",rephrase,"['We are not sure about the results for hydrogel dressings compared with other dressings for pain at the donor site and wound complications, including scarring and itching.']",5,0.5,3,14
CD013570,1,7,No adverse events were reported in any of the groups.,delete,[],6,0.5714285714285714,3,14
CD013570,1,8,The study did not report health-related quality of life or wound infection.,rephrase,['The study did not report health-related quality of life or wound infection and did not report any unwanted effects of the dressings.'],6,0.6428571428571429,4,14
CD013570,2,9,"Octenidine-based hydrogel dressing versus octenidine-free hydrogel dressing
The effect of octenidine-based hydrogel dressings versus octenidine-free hydrogel dressings is uncertain for time to wound healing (MD 0.40, 95% CI 0.28 to 0.52; 1 study, 41 participants) and wound infection, as the certainty of the evidence is very low.",rephrase,"['We are unsure of the effect of octenidine-based hydrogel dressings versus octenidine-free hydrogel dressings for time to wound healing, wound infection and unwanted effects.']",7,0.7142857142857143,4,14
CD013570,2,10,"The certainty of the evidence is also very low for adverse events, with two participants in the intervention group and one participant in the comparison group reporting adverse events (risk ratio (RR) 0.58, 95% CI 0.06 to 5.89; 1 study, 41 participants).",delete,[],8,0.7857142857142857,4,14
CD013570,2,11,"The study did not report donor site pain, health-related quality of life, or wound complications.",ignore,"['The study did not report donor site pain, health-related quality of life, or wound complications.']",8,0.8571428571428571,5,14
CD013570,3,12,There is insufficient evidence to determine the effect of hydrogel dressings on donor site wounds of split thickness skin grafts compared with other types of dressings.,rephrase,['We searched for studies that compared hydrogel dressings with other treatments for healing donor site wounds after partial skin grafts.'],9,0.9285714285714286,5,14
CD013570,3,13,"There is a need for adequately powered and well-designed RCTs, with adequate sample sizes, types of populations and subgroups, types of interventions, and outcomes, that compare hydrogel dressings with other treatment options in the treatment of donor site wounds of split-thickness skin grafts.",delete,[],10,1.0,5,14
CD006933,0,0,We included seven trials including 521 patients for this review.,ignore,['We included seven trials involving 521 patients for this review.'],0,0.07142857142857142,1,14
CD006933,0,1,The sample size in the trials varied from 12 to 180 patients.,rephrase,['The number of patients included in the trials varied from 12 to 180.'],1,0.14285714285714285,1,14
CD006933,0,2,All the trials were of high risks of systematic errors and of random errors.,delete,[],2,0.21428571428571427,2,14
CD006933,0,3,Four trials included patients who underwent liver resection only.,delete,[],2,0.2857142857142857,2,14
CD006933,0,4,"In the remaining three trials, patients underwent combined liver resection with extrahepatic biliary resection resulting in a biliary enteric anastomosis.",delete,[],2,0.35714285714285715,2,14
CD006933,0,5,Four trials included only major liver resection.,delete,[],2,0.42857142857142855,3,14
CD006933,0,6,The remaining three trials included a mixture of major and minor liver resections.,delete,[],2,0.5,3,14
CD006933,0,7,It appears that the proportion of cirrhotic patients in the trials was very low.,delete,[],2,0.5714285714285714,3,14
CD006933,0,8,"The comparisons performed included whether antibiotics are necessary routinely during the peri-operative period of liver resection, the duration of antibiotics, the use of prebiotics and probiotics in the perioperative period, use of recombinant bactericidal-permeability increasing protein 21 (rBPI21), and the use of topical povidone iodine gel at the time of wound closure.",rephrase,"['The comparisons performed included whether antibiotics are necessary routinely during the peri-operative period of liver resection, the duration of antibiotics, and the use of other agents to improve the general body resistance to infection.']",2,0.6428571428571429,4,14
CD006933,0,9,Only one or two trials were included under each comparison.,merge,[],3,0.7142857142857143,4,14
CD006933,0,10,There was no significant differences in mortality or severe morbidity in any of the comparisons.,none,['There was no difference in the risk of death or in the major complication rates between the compared groups in any of the comparisons.'],3,0.7857142857142857,4,14
CD006933,0,11,Quality of life was not reported in any of the trials.,ignore,['Quality of life was not reported in any of the trials.'],4,0.8571428571428571,5,14
CD006933,1,12,There is currently no evidence to support or refute the use of any treatment to reduce infectious complications after liver resections.,rephrase,['We are unable to advocate or refute any method of decreasing infectious complications after liver resection.'],5,0.9285714285714286,5,14
CD006933,1,13,Further well designed trials with low risk of systematic error and low risk of random errors are necessary.,ignore,['Further well designed trials with low risk of systematic error and low risk of random errors are necessary.'],6,1.0,5,14
CD004982,0,0,"We identified three additional trials (613 participants), therefore this update considered 33 studies involving 7296 people with ST of the legs.",rephrase,['This update included 33 randomised controlled trials (clinical trials where people are randomly put into one of two or more treatment groups) involving 7296 participants.'],0,0.0625,1,16
CD004982,0,1,"Treatment included fondaparinux; rivaroxaban; low molecular weight heparin (LMWH); unfractionated heparin (UFH); non-steroidal anti-inflammatory drugs (NSAIDs); compression stockings; and topical, intramuscular, or intravenous treatment to surgical interventions such as thrombectomy or ligation.",rephrase,"['Treatments included rivaroxaban (a medicine called a direct oral inhibitor of activated factor X), injections of medicines under the skin to prevent blood clotting (e.g. fondaparinux, low molecular weight heparin, or unfractionated heparin), elastic compression stockings, oral non-steroidal anti-inflammatory drugs (NSAIDs; a pain killer medicine), topical treatment (medicine applied to the skin), and surgery.']",1,0.125,1,16
CD004982,0,2,Only a minority of trials compared treatment with placebo rather than an alternative treatment and many studies were small and of poor quality.,delete,[],2,0.1875,1,16
CD004982,0,3,"Pooling of the data was possible for few outcomes, and none were part of a placebo-controlled trial.",delete,[],2,0.25,2,16
CD004982,0,4,"In one large, placebo-controlled RCT of 3002 participants, subcutaneous fondaparinux was associated with a significant reduction in symptomatic VTE (risk ratio (RR) 0.15, 95% confidence interval (CI) 0.04 to 0.50; moderate-quality evidence), ST extension (RR 0.08, 95% CI 0.03 to 0.22; moderate-quality evidence), and ST recurrence (RR 0.21, 95% CI 0.08 to 0.54; moderate-quality evidence) relative to placebo.",rephrase,"['One large study, accounting for half of the participants included in the review, showed that treatment with fondaparinux for 45 days was associated with a significant reduction in symptomatic VTE (where symptoms indicate there is a VTE), ST extension (where the clot moves further up the leg), and recurrence of ST (where clots return) compared to placebo.']",2,0.3125,2,16
CD004982,0,5,"Major bleeding was infrequent in both groups with very wide CIs around risk estimate (RR 0.99, 95% CI 0.06 to 15.86; moderate-quality evidence).",rephrase,['Major bleeding was infrequent in both groups.'],3,0.375,2,16
CD004982,0,6,"In one RCT on 472 high-risk participants with ST, fondaparinux was associated with a non-significant reduction of symptomatic VTE compared to rivaroxaban 10 mg (RR 0.33, 95% CI 0.03 to 3.18; low-quality evidence).",rephrase,"['In one study in people with ST at high risk of recurrent thromboembolic events, fondaparinux was associated with a non-significant reduction of symptomatic VTE compared to rivaroxaban.']",4,0.4375,3,16
CD004982,0,7,There were no major bleeding events in either group (low-quality evidence).,rephrase,['There were no major bleeding events in either group.'],5,0.5,3,16
CD004982,0,8,"In another placebo-controlled trial, both prophylactic and therapeutic doses of LMWH (prophylactic: RR 0.44, 95% CI 0.26 to 0.74; therapeutic: RR 0.46, 95% CI 0.27 to 0.77) and NSAIDs (RR 0.46, 95% CI 0.27 to 0.78) reduced the extension (low-quality evidence) and recurrence of ST (low-quality evidence) in comparison to placebo, with no significant effects on symptomatic VTE (low-quality evidence) or major bleeding (low-quality evidence).",rephrase,['The quality of evidence was low to moderate for comparisons in two placebo-controlled trials.'],6,0.5625,3,16
CD004982,0,9,"Overall, topical treatments improved local symptoms compared with placebo, but no data were provided on the effects on VTE and ST extension.",rephrase,['Topical treatments relieved local symptoms but the trials did not report on progression to VTE.'],7,0.625,4,16
CD004982,0,10,Surgical treatment combined with elastic stockings was associated with a lower VTE rate and ST progression compared with elastic stockings alone.,rephrase,['Surgical treatment and wearing elastic stockings were associated with a lower rate of VTE and progression of the ST compared with elastic stockings alone.'],8,0.6875,4,16
CD004982,0,11,"However, the majority of studies that compared different oral treatments, topical treatments, or surgery did not report VTE, ST progression, adverse events, or treatment adverse effects.",delete,[],9,0.75,4,16
CD004982,1,12,Prophylactic dose fondaparinux given for 45 days appears to be a valid therapeutic option for ST of the legs for most people.,rephrase,"['In conclusion, fondaparinux appears to be an adequate treatment for most people with ST.']",9,0.8125,5,16
CD004982,1,13,The evidence on topical treatment or surgery is too limited and does not inform clinical practice about the effects of these treatments in terms of VTE.,delete,[],10,0.875,5,16
CD004982,1,14,"Further research is needed to assess the role of rivaroxaban and other direct oral factor-X or thrombin inhibitors, LMWH, and NSAIDs; the optimal doses and duration of treatment in people at various risk of recurrence; and whether a combination therapy may be more effective than single treatment.",split,"['The optimal dose and duration of treatment need to be established in people at high risk as well as people at low risk for recurrent thrombotic events.', 'Further research is needed to assess the role of rivaroxaban and other such medicines, or thrombin, low molecular weight heparin or NSAIDs and to demonstrate the effectiveness, if any, of topical treatment, or surgery in terms of VTE.']",10,0.9375,5,16
CD004982,1,15,Adequately designed and conducted studies are required to clarify the role of topical and surgical treatments.,delete,[],12,1.0,5,16
CD006965,0,0,Two studies met the inclusion criteria but only one contributed data for the prespecified outcomes.,rephrase,['Two studies met the inclusion criteria but only one contributed data to the outcomes of interest.'],0,0.125,1,8
CD006965,0,1,"Caffeinated instant coffee (568 women) was compared with decaffeinated instant coffee (629 women) and it was found that reducing the caffeine intake of regular coffee drinkers (3+ cups/day) during the second and third trimester by an average of 182 mg/day did not affect birthweight (g) (mean difference (MD) 20.00, 95% confidence interval (CI) -48.68 to 88.68; one study, 1197 participants; low quality evidence), preterm birth (risk ratio (RR) 0.81, 95% CI 0.48 to 1.37; one study, 1153 participants; low quality evidence) or small-for-gestational age (RR 0.97, 95% 0.57 to 1.64; one study, 1150 participants).",rephrase,['Women less than 20 weeks pregnant were randomly assigned to drinking caffeinated instant coffee (568 women after exclusions) or decaffeinated instant coffee (629 women).'],1,0.25,2,8
CD006965,0,2,Risk of bias was moderate in both studies.,delete,[],2,0.375,2,8
CD006965,1,3,Two outcomes were assessed and assigned a quality rating using the GRADE methods.,ignore,['Two outcomes were assessed and assigned a quality rating using the GRADE methods.'],2,0.5,3,8
CD006965,1,4,"Evidence for these two outcomes (birthweight and preterm birth) was assessed as of low quality, with downgrading decisions due to the relatively small sample sizes and the wide confidence interval of the one included trial that contributed data.",ignore,"['Evidence for these two outcomes, namely birthweight and frequency of preterm birth, was assessed as of low quality, with downgrading decisions due in part to the relatively small sample sizes and the wide confidence interval of the one included trial that contributed data.']",3,0.625,4,8
CD006965,1,5,Neither of the studies reported on any of the other primary outcomes (low birthweight; first trimester fetal loss; perinatal mortality; fetal hypoxia; fetal tachycardia) or on any of the reviews neonatal or maternal outcomes.,delete,[],4,0.75,4,8
CD006965,2,6,There is insufficient evidence to confirm or refute the effectiveness of caffeine avoidance on birthweight or other pregnancy outcomes.,ignore,['There is insufficient evidence to confirm or refute the effectiveness of caffeine avoidance on birthweight or other pregnancy outcomes.'],4,0.875,5,8
CD006965,2,7,"There is a need to conduct high-quality, double-blinded RCTs to determine whether caffeine has any effect on pregnancy outcome.",delete,[],5,1.0,5,8
CD000491,0,0,"We included 13 studies, involving 1622 women.",rephrase,"['The review of 13 studies, involving over 1622 women, found that a seven-day regimen is more effective than a one-day course, especially for the outcome of low birthweight (high quality evidence), but this result is based on just one study.']",0,0.08333333333333333,1,12
CD000491,0,1,All were comparisons of single-dose treatment with short-course (four- to seven-day) treatments.,delete,[],1,0.16666666666666666,1,12
CD000491,0,2,"The risk of bias of trials included in this review was largely unclear, and most trials were at high risk of performance bias.",rephrase,"['In general, the risk of bias of trials included in this review was largely unclear.']",1,0.25,2,12
CD000491,0,3,The quality of the evidence was assessed using the GRADE approach.,ignore,['The overall quality of the evidence was assessed using the GRADE approach.'],2,0.3333333333333333,2,12
CD000491,0,4,"When the any antibiotic agent was used, the 'no cure' rate for asymptomatic bacteriuria in pregnant women was slightly lower for the short-course treatment over the single-dose treatment, although there was evidence of statistical heterogeneity (average risk ratio (RR) 1.28, 95% confidence interval (CI) 0.87 to 1.88; women = 1502, studies = 13; I² = 56%; very low quality evidence).",delete,[],3,0.4166666666666667,3,12
CD000491,0,5,"Data from only good quality trials also showed better cure rates with short (four- to seven-day) regimens of the same microbial agent (average RR 1.72, 95% CI 1.27 to 2.33; women = 803, studies = two; I² = 0%; high quality evidence).",delete,[],3,0.5,3,12
CD000491,0,6,"There was no clear difference in the recurrence of asymptomatic bacteriuria rate between treatment and control groups, whether the same or different microbial agents were used (RR 1.13, 95% CI 0.77 to 1.66; 445 women studies = eight; I² = 0%; very low quality evidence).",merge,"['There were no clear differences between a single dose and a four- to seven-day short course of antibiotics for other review outcomes, including kidney infection (very low quality evidence) and preterm birth (moderate quality evidence).']",3,0.5833333333333334,3,12
CD000491,0,7,"Differences were detected for low birthweight babies, favoring a short course (four- to seven-day treatment) of the same microbial agent, although the data come from a single trial (RR 1.65, 95% CI 1.06 to 2.57; 714 women; high quality evidence), but no differences were observed for preterm delivery (RR 1.17, 95% CI 0.77 to 1.78; women = 804; studies = three; I² = 23%; moderate quality) or pyelonephritis (RR 3.09, 95% CI 0.54 to 17.55; women = 102; studies = two; I² = 0%; very low quality evidence).",none,[],3,0.6666666666666666,4,12
CD000491,0,8,"Finally, single-dose treatment of any microbial agent was associated with a decrease in reports of 'any side effects' (RR 0.70, 95% CI 0.56 to 0.88; 1460 women, studies = 12; I² = 9%; low quality evidence).",rephrase,['Women with a single-dose regimen reported fewer side effects (low quality evidence).'],4,0.75,4,12
CD000491,0,9,"Evidence was downgraded for risk of bias concerns in trials contributing data and for imprecise effect estimates (wide confidence intervals crossing the line of no effect, and in some cases, small studies with few events).",delete,[],5,0.8333333333333334,5,12
CD000491,1,10,"A single-dose regimen of antibiotics may be less effective than a short-course (four- to seven-day) regimen, but more evidence is needed from large trials measuring important outcomes, such as cure rate.",rephrase,['More trials are needed to confirm which length of treatment is best for women and babies.'],5,0.9166666666666666,5,12
CD000491,1,11,Women with asymptomatic bacteriuria in pregnancy should be treated by the standard regimen of antibiotics until more data become available testing seven-day treatment compared with shorter courses of three- or five-day regimens.,delete,[],6,1.0,5,12
CD005467,0,0,"One hundred and eight randomised trials involving 10,655 participants were included.",delete,[],0,0.07142857142857142,1,14
CD005467,0,1,"Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus western medicine were compared with western medicine (47 trials).",ignore,"['Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus conventional medicine were compared with conventional medicine (47 trials).']",0,0.14285714285714285,1,14
CD005467,0,2,The risk of bias across all studies was unclear for most domains primarily due to inadequate reporting of study design.,delete,[],1,0.21428571428571427,2,14
CD005467,0,3,"Although we rated the risk of selective reporting for all studies as unclear, only a few studies contributed numerical data to the key outcomes.",delete,[],1,0.2857142857142857,2,14
CD005467,1,4,"Seven trials reported fracture incidence, but they were small in sample size, suffered from various biases and tested different Chinese herbal medicines.",split,"['We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture.', 'Seven trials evaluated the incidence of fractures.']",1,0.35714285714285715,2,14
CD005467,1,5,"These trials compared Kanggusong capsules versus placebo, Kanggusong granule versus Caltrate or ipriflavone plus Caltrate, Yigu capsule plus calcium versus placebo plus calcium, Xianlinggubao capsule plus Caltrate versus placebo plus Caltrate, Bushen Zhuanggu granules plus Caltrate versus placebo granules plus Caltrate, Kanggusong soup plus Caltrate versus Caltrate, Zhuangguqiangjin tablets and Shujinbogu tablets plus calcitonin ampoule versus calcitonin ampoule.",delete,[],3,0.42857142857142855,3,14
CD005467,1,6,The results were inconsistent.,delete,[],3,0.5,3,14
CD005467,2,7,"One trial showed that Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol had a better effect on quality of life score (scale 0 to 100, higher is better) than calcium carbonate tablets and alfacalcidol (mean difference (MD) 5.30; 95% confidence interval (CI) 3.67 to 6.93).",rephrase,['People who took Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol rated their quality of life to be 56.05 on a scale of 0 to 100.'],3,0.5714285714285714,3,14
CD005467,3,8,"Compared with placebo in three separate trials, Chinese herbal medicines (Migu decoction, Bushen Yigu soft extract, Kanggusong capsules) showed a statistically significant increase in bone mineral density (BMD) (e.g. Kanggusong capsules, MD 0.06 g/cm3; 95% CI 0.02 to 0.10).",rephrase,"['Compared to placebo (fake treatment), three studies showed that bone mineral density increased slightly with Chinese herbal medicines.']",4,0.6428571428571429,4,14
CD005467,3,9,"Compared with no intervention in five trials, only two showed that Chinese herbal medicines had a statistically significant effect on increase in BMD (e.g. Shigu yin, MD 0.08 g/cm3; 95% CI 0.03 to 0.13).",delete,[],5,0.7142857142857143,4,14
CD005467,3,10,"Compared with conventional medicine in 61 trials, 23 showed that Chinese herbal medicines had a statistically significant effect on increase in BMD.",merge,"['When Chinese herbal medicines plus conventional medication was compared with just conventional medicine, some studies showed an increase in bone mineral density while others did not.']",5,0.7857142857142857,4,14
CD005467,3,11,"In 48 trials evaluating Chinese herbal medicines plus western medication against western medication, 26 showed better effects of the combination therapy on increase in BMD.",none,[],5,0.8571428571428571,5,14
CD005467,4,12,"No trial reported death or serious adverse events of Chinese herbal medicines, while some trials reported minor adverse effects such as nausea, diarrhoea, etc.",rephrase,['- No trial reported death or serious side effects.'],6,0.9285714285714286,5,14
CD005467,5,13,Current findings suggest that the beneficial effect of Chinese herbal medicines in improving BMD is still uncertain and more rigorous studies are warranted.,rephrase,['- We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture.'],7,1.0,5,14
CD006821,0,0,We identified five RCTs that randomised 544 children (three studies) and 205 adults (exclusively from two studies).,rephrase,"['We identified five studies, with a total of 749 participants enrolled and 565 participants providing data, which addressed the research question and met the inclusion criteria.']",0,0.07692307692307693,1,13
CD006821,0,1,"They all compared saline irrigation to routine care or other nose sprays, rather than placebo.",rephrase,['They all compared saline irrigation with routine care or other nose sprays.'],1,0.15384615384615385,1,13
CD006821,0,2,"We included two new trials in this update, which did not contribute data of sufficient size or quality to materially change the original findings.",rephrase,['The two additional studies included since the original systematic review have not contributed data of sufficient size or quality to materially change the original findings.'],2,0.23076923076923078,2,13
CD006821,0,3,"Most trials were small and we judged them to be of low quality, contributing to an unclear risk of bias.",rephrase,['Most studies were small and had significant shortcomings in the design or implementation of the research.'],3,0.3076923076923077,2,13
CD006821,0,4,Most outcome measures differed greatly between included studies and therefore could not be pooled.,rephrase,['This resulted in very few common outcome measures that could be combined across these five studies.'],4,0.38461538461538464,2,13
CD006821,0,5,Most results showed no difference between nasal saline treatment and control.,delete,[],5,0.46153846153846156,3,13
CD006821,0,6,"However, one larger trial, conducted with children, did show a significant reduction in nasal secretion score (mean difference (MD) -0.31, 95% confidence interval (CI) -0.48 to -0.14) and nasal breathing (obstruction) score (MD -0.33, 95% CI -0.47 to -0.19) in the saline group.",rephrase,"['Only the largest study, which studied 401 children aged 6 to 10 years, found significant reductions in a number of symptoms, including nasal secretions, sore throat, nasal breathing score and nasal obstruction, as well as reduced use of additional nasal decongestant medications.']",5,0.5384615384615384,3,13
CD006821,0,7,"However, a MD of -0.33 on a four-point symptom scale may have minimal clinical significance.",delete,[],6,0.6153846153846154,4,13
CD006821,0,8,The trial also showed a significant reduction in the use of decongestant medication by the saline group.,delete,[],6,0.6923076923076923,4,13
CD006821,0,9,Minor nasal discomfort and/or irritation was the only side effect reported by a minority of participants.,delete,[],6,0.7692307692307693,4,13
CD006821,1,10,Nasal saline irrigation possibly has benefits for relieving the symptoms of acute URTIs.,rephrase,"['Further studies, preferably larger in size and using common outcome measures, are needed to establish the potential for the role of nasal saline irrigation in reducing the severity and duration of acute URTI symptoms, secondary infections and possibly antibiotic usage.']",6,0.8461538461538461,5,13
CD006821,1,11,"However, the included trials were generally too small and had a high risk of bias, reducing confidence in the evidence supporting this.",delete,[],7,0.9230769230769231,5,13
CD006821,1,12,Future trials should involve larger numbers of participants and report standardised and clinically meaningful outcome measures.,delete,[],7,1.0,5,13
CD005353,0,0,"We found three trials which met our inclusion criteria, covering 1567 smokers (cessation: STRATUS-EU and STRATUS-US), and 1661 quitters (relapse prevention: STRATUS-WW).",rephrase,"['We found two randomized controlled trials (RCTs) of rimonabant for smoking cessation, covering 1567 smokers, and one RCT of rimonabant for relapse prevention covering 1661 quitters.']",0,0.058823529411764705,1,17
CD005353,0,1,"At one year, the pooled risk ratio (RR) for quitting with rimonabant 20 mg was 1.50 (95% confidence interval (CI) 1.10 to 2.05).",rephrase,"['The available information shows that rimonabant at the 20 mg dose increased by 1½-fold the chances of not smoking at one year, compared with placebo.']",1,0.11764705882352941,1,17
CD005353,0,2,No significant benefit was demonstrated for rimonabant at 5 mg dosage.,rephrase,['Rimonabant 5 mg did no better than placebo at any time point.'],2,0.17647058823529413,1,17
CD005353,0,3,Adverse events included nausea and upper respiratory tract infections.,rephrase,"['Main side effects for rimonabant included nausea and upper respiratory tract infections, and serious harms were reported to be low.']",3,0.23529411764705882,2,17
CD005353,1,4,"In the relapse prevention trial, smokers who had quit on the 20 mg regimen were more likely to remain abstinent on either active regimen than on placebo; the RR for the 20 mg maintenance group was 1.29 (95% CI 1.06 to 1.57), and for the 5 mg maintenance group 1.30 (95% CI 1.06 to 1.59).",rephrase,"['In the relapse prevention trial, smokers who quit successfully with rimonabant 20 mg were 1½ times more likely to remain abstinent on active treatment (5 mg or 20 mg for 42 weeks) than on placebo.']",4,0.29411764705882354,2,17
CD005353,1,5,There appeared to be no significant benefit of maintenance treatment for the 5 mg quitters.,rephrase,"['For those who quit successfully on 5 mg, neither active nor placebo treatment appeared to benefit them in avoiding relapse.']",5,0.35294117647058826,2,17
CD005353,2,6,"One trial of taranabant was not included in our meta-analyses, as it followed participants only until end of treatment; at eight weeks it found no benefit for treatment over placebo, with an OR of 1.2 (90% CI 0.6 to 2.5).",rephrase,"['One trial of taranabant (317 smokers) did not find a benefit for treatment over placebo, and the taranabant group suffered more side effects than the placebo group.']",6,0.4117647058823529,3,17
CD005353,3,7,"For rimonabant, weight gain was reported to be significantly lower among the 20 mg quitters than in the 5 mg or placebo quitters.",rephrase,"['Although the evidence on weight change is sparse in these trials, weight gain was reported to be significantly lower among the rimonabant 20 mg quitters than in the 5 mg or placebo quitters.']",7,0.47058823529411764,3,17
CD005353,3,8,"During treatment, overweight or obese smokers tended to lose weight, while normal weight smokers did not.",ignore,"['During treatment, overweight or obese smokers tended to lose weight on 20 mg, while normal weight smokers did not.']",8,0.5294117647058824,3,17
CD005353,3,9,"For taranabant, weight gain was significantly lower for 2-8 mg versus placebo at the end of eight weeks of treatment.",delete,[],9,0.5882352941176471,3,17
CD005353,4,10,"In 2008, post-marketing surveillance led the European Medicines Agency (EMEA) to require Sanofi Aventis to withdraw rimonabant, because of links to mental disorders.",delete,[],9,0.6470588235294118,4,17
CD005353,4,11,The development of taranabant was also suspended by Merck & Co because of unacceptable adverse events.,delete,[],9,0.7058823529411765,4,17
CD005353,5,12,"From the trial reports available, rimonabant 20 mg may increase the chances of quitting approximately 1½-fold.",delete,[],9,0.7647058823529411,4,17
CD005353,5,13,The evidence for rimonabant in maintaining abstinence is inconclusive.,delete,[],9,0.8235294117647058,5,17
CD005353,6,14,Rimonabant 20 mg may moderate weight gain in the long term.,delete,[],9,0.8823529411764706,5,17
CD005353,6,15,"Taranabant 2-8 mg may moderate weight gain, at least in the short term.",rephrase,['Taranabant also limited weight gain during cessation attempts.'],9,0.9411764705882353,5,17
CD005353,7,16,"In 2008, development of both rimonabant and taranabant was discontinued by the manufacturers.",rephrase,"['In 2008 both rimonabant and taranabant were withdrawn by the manufacturers, because of links to mental disorders and unacceptable side effects.']",10,1.0,5,17
CD012202,0,0,"We included 11 randomised trials, involving 638 women.",split,"['We searched for evidence from randomised controlled trials in August 2016.', 'We identified 11 trials that involved 638 pregnant women.']",0,0.0625,1,16
CD012202,0,1,The overall risk of bias was judged to be unclear due to lack of methodological detail in the included studies.,rephrase,['We judged the overall risk of bias in the trials as unclear because of a lack of information about how the trials were conducted.'],2,0.125,1,16
CD012202,1,2,"For the mother, there was no clear evidence of a difference between women in the exercise group and those in the control group for the risk of pre-eclampsia as the measure of hypertensive disorders of pregnancy (risk ratio (RR) 0.31, 95% confidence interval (CI) 0.01 to 7.09; two RCTs, 48 women; low-quality evidence), birth by caesarean section (RR 0.86, 95% CI 0.63 to 1.16; five RCTs, 316 women; I2 = 0%; moderate-quality evidence), the risk of induction of labour (RR 1.38, 95% CI 0.71 to 2.68; one RCT, 40 women; low-quality evidence) or maternal body mass index at follow-up (postnatal weight retention or return to pre-pregnancy weight) (mean difference (MD) 0.11 kg/m2, 95% CI -1.04 to 1.26; three RCTs, 254 women; I2 = 0%; high-quality evidence).",delete,[],3,0.1875,1,16
CD012202,1,3,"Development of type 2 diabetes, perineal trauma/tearing and postnatal depression were not reported as outcomes in the included studies.",rephrase,"['None of the included trials reported on perineal trauma, postnatal depression or development of type 2 diabetes.']",3,0.25,2,16
CD012202,2,4,"For the infant/child/adult, a single small (n = 19) trial reported no perinatal mortality (stillbirth and neonatal mortality) events in either the exercise intervention or control group (low-quality evidence).",rephrase,"['For the babies, no deaths occurred around the time of birth in (one trial, 19 babies, low-quality evidence) and there was no evidence of any difference in the risk of ill-health (two trials, 169 babies, moderate-quality evidence) or low blood sugar levels (one trial, 34 babies, low-quality evidence).']",4,0.3125,2,16
CD012202,2,5,"There was no clear evidence of a difference between groups for a mortality and morbidity composite (variously defined by trials, e.g. perinatal or infant death, shoulder dystocia, bone fracture or nerve palsy) (RR 0.56, 95% CI 0.12 to 2.61; two RCTs, 169 infants; I2 = 0%; moderate-quality evidence) or neonatal hypoglycaemia (RR 2.00, 95% CI 0.20 to 20.04; one RCT, 34 infants; low-quality evidence).",delete,[],5,0.375,2,16
CD012202,2,6,"None of the included trials pre-specified large-for-gestational age, adiposity (neonatal/infant, childhood or adulthood), diabetes (childhood or adulthood) or neurosensory disability (neonatal/infant) as trial outcomes.",rephrase,['None of the trials reported on the number of large-for-gestational-age babies or babies that went on to develop diabetes in childhood or adulthood or neurosensory disability that became apparent during childhood.'],5,0.4375,3,16
CD012202,3,7,"Other maternal outcomes of interest: exercise interventions were associated with both reduced fasting blood glucose concentrations (average standardised mean difference (SMD) -0.59, 95% CI -1.07 to -0.11; four RCTs, 363 women; I2 = 73%; T2 = 0.19) and a reduced postprandial blood glucose concentration compared with control interventions (average SMD -0.85, 95% CI -1.15 to -0.55; three RCTs, 344 women; I2 = 34%; T2 = 0.03).",delete,[],6,0.5,3,16
CD012202,4,8,Short- and long-term outcomes of interest for this review were poorly reported.,delete,[],6,0.5625,3,16
CD012202,4,9,Current evidence is confounded by the large variety of exercise interventions.,merge,[],6,0.625,4,16
CD012202,4,10,There was insufficient high-quality evidence to be able to determine any differences between exercise and control groups for our outcomes of interest.,none,['The present evidence is insufficient to advise for or against women enrolling in exercise programmes.'],6,0.6875,4,16
CD012202,4,11,"For the woman, both fasting and postprandial blood glucose concentrations were reduced compared with the control groups.",delete,[],7,0.75,4,16
CD012202,4,12,There are currently insufficient data for us to determine if there are also benefits for the infant.,delete,[],7,0.8125,5,16
CD012202,4,13,"The quality of the evidence in this review ranged from high to low quality and the main reason for downgrading was for risk of bias and imprecision (wide CIs, low event rates and small sample size).",rephrase,"['The main reasons for downgrading the quality were for risk of bias in the trials and imprecise effect sizes, low event rates and small numbers of participants.']",7,0.875,5,16
CD012202,4,14,"Development of type 2 diabetes, perineal trauma/tearing, postnatal depression, large-for-gestational age, adiposity (neonate/infant, childhood or adulthood), diabetes (childhood or adulthood) or neurosensory disability (neonate/infant) were not reported as outcomes in the included studies.",delete,[],8,0.9375,5,16
CD012202,5,15,Further research is required comparing different types of exercise interventions with control groups or with another exercise intervention that reports on both the short- and long-term outcomes (for both the mother and infant/child) as listed in this review.,rephrase,['Further research is needed comparing one exercise intervention with another (or with a control) and reporting on both the short- and long-term outcomes (for both the mother and infant/child/adult) as listed in this review.'],8,1.0,5,16
CD011058,0,0,"We included nine trials about CME, of which six trials with 333 patient-caregiver couples were included in the meta-analysis.",rephrase,['We included 333 patient-caregiver couples in the review.'],0,0.0625,1,16
CD011058,0,1,"The small number of studies, participants, and a variety of outcome measures rendered summarising and combining of data in meta-analysis difficult.",delete,[],1,0.125,1,16
CD011058,0,2,"In addition, in some studies, CME was the only intervention (CME-core), whereas in other studies, caregivers provided another, existing intervention, such as constraint-induced movement therapy.",rephrase,"['In addition, we found trials in which the caregiver was the provider of another, already existing intervention.']",1,0.1875,1,16
CD011058,0,3,"For trials in the latter category, it was difficult to separate the effects of CME from the effects of the other intervention.",rephrase,"['In the latter category, it was difficult to separate the effect of caregiver-mediated exercises from the effect of the other intervention.']",2,0.25,2,16
CD011058,1,4,"We found no significant effect of CME on basic ADL when pooling all trial data post intervention (4 studies; standardised mean difference (SMD) 0.21, 95% confidence interval (CI) -0.02 to 0.44; P = 0.07; moderate-quality evidence) or at follow-up (2 studies; mean difference (MD) 2.69, 95% CI -8.18 to 13.55; P = 0.63; low-quality evidence).",delete,[],3,0.3125,2,16
CD011058,1,5,"In addition, we found no significant effects of CME on extended ADL at post intervention (two studies; SMD 0.07, 95% CI -0.21 to 0.35; P = 0.64; low-quality evidence) or at follow-up (2 studies; SMD 0.11, 95% CI -0.17 to 0.39; P = 0.45; low-quality evidence).",rephrase,"[""We found evidence that caregiver-mediated exercises could have a positive effect on patients' standing balance (low-quality evidence) and quality of life (very low-quality evidence) directly after the intervention.""]",3,0.375,2,16
CD011058,2,6,"Caregiver burden did not increase at the end of the intervention (2 studies; SMD -0.04, 95% CI -0.45 to 0.37; P = 0.86; moderate-quality evidence) or at follow-up (1 study; MD 0.60, 95% CI -0.71 to 1.91; P = 0.37; very low-quality evidence).",delete,[],4,0.4375,3,16
CD011058,3,7,"At the end of intervention, CME significantly improved the secondary outcomes of standing balance (3 studies; SMD 0.53, 95% CI 0.19 to 0.87; P = 0.002; low-quality evidence) and quality of life (1 study; physical functioning: MD 12.40, 95% CI 1.67 to 23.13; P = 0.02; mobility: MD 18.20, 95% CI 7.54 to 28.86; P = 0.0008; general recovery: MD 15.10, 95% CI 8.44 to 21.76; P < 0.00001; very low-quality evidence).",delete,[],4,0.5,3,16
CD011058,3,8,"At follow-up, we found a significant effect in favour of CME for Six-Minute Walking Test distance (1 study; MD 109.50 m, 95% CI 17.12 to 201.88; P = 0.02; very low-quality evidence).",rephrase,"['In the long term, we found very low-quality evidence for a positive effect on walking distance.']",4,0.5625,3,16
CD011058,3,9,"We also found a significant effect in favour of the control group at the end of intervention, regarding performance time on the Wolf Motor Function test (2 studies; MD -1.72, 95% CI -2.23 to -1.21; P < 0.00001; low-quality evidence).",rephrase,"['For speed of use of the arm and hand, we found low-quality evidence in favour of the control group.']",5,0.625,4,16
CD011058,3,10,"We found no significant effects for the other secondary outcomes (i.e. patient: motor impairment, upper limb function, mood, fatigue, length of stay and adverse events; caregiver: mood and quality of life).",split,"['We found no significant side effects or beneficial effects on caregiver strain; we judged the quality of this evidence as moderate (after intervention) to very low (long term).', 'Furthermore, we found no significant effects for basic activities of daily living, such as dressing and bathing, after intervention (moderate-quality evidence) or follow-up (low-quality evidence).', 'In addition, we found no significant effects for extended activities of daily living, such as cooking and gardening, after intervention or at follow-up (both low-quality evidence).']",6,0.6875,4,16
CD011058,4,11,"In contrast to the primary analysis, sensitivity analysis of CME-core showed a significant effect of CME on basic ADL post intervention (2 studies; MD 9.45, 95% CI 2.11 to 16.78; P = 0.01; moderate-quality evidence).",rephrase,"['In the CME-core analysis, we found moderate-quality evidence for a positive effect of caregiver-mediated exercises for basic activities of daily living.']",9,0.75,4,16
CD011058,5,12,"The methodological quality of the included trials and variability in interventions (e.g. content, timing, and duration), affected the validity and generalisability of these observed results.",delete,[],10,0.8125,5,16
CD011058,6,13,There is very low- to moderate-quality evidence that CME may be a valuable intervention to augment the pallet of therapeutic options for stroke rehabilitation.,merge,[],10,0.875,5,16
CD011058,6,14,"Included studies were small, heterogeneous, and some trials had an unclear or high risk of bias.",none,['The number of included trials was small and the level of evidence was of very low to moderate quality.'],10,0.9375,5,16
CD011058,6,15,Future high-quality research should determine whether CME interventions are (cost-)effective.,delete,[],11,1.0,5,16
CD001304,0,0,"We included four studies in this review (251 participants), and found few significant differences between treatment and comparison groups for the outcomes of interest.",rephrase,['The review included four studies with 251 people with phenylketonuria.'],0,0.1111111111111111,1,9
CD001304,0,1,"Blood phenylalanine levels were significantly lower in participants with phenylketonuria following a low-phenylalanine diet compared to those on a less restricted diet, mean difference (MD) at three months -698.67 (95% confidence interval (CI) -869.44 to -527.89).",ignore,"['Blood phenylalanine levels were significantly lower in participants with phenylketonuria following a low-phenylalanine diet compared to those on a less restricted diet, mean difference (MD) at three months -698.67 (95% confidence interval (CI) -869.44 to -527.89).']",1,0.2222222222222222,2,9
CD001304,0,2,"Intelligence quotient was significantly higher in participants who continued the diet than in those who stopped the diet, MD after 12 months 5.00 (95% CI 0.40 to 9.60).",ignore,"['Intelligence quotient was significantly higher in participants who continued the diet than in those who stopped the diet, MD after 12 months 5.00 (95% CI 0.40 to 9.60).']",2,0.3333333333333333,2,9
CD001304,0,3,"However, these results came from a single study.",ignore,"['However, these results came from a single study.']",3,0.4444444444444444,3,9
CD001304,1,4,The results of non-randomised studies have concluded that a low-phenylalanine diet is effective in reducing blood phenylalanine levels and improving intelligence quotient and neuropsychological outcomes.,delete,[],4,0.5555555555555556,3,9
CD001304,1,5,We were unable to find any randomised controlled studies that have assessed the effect of a low-phenylalanine diet versus no diet from diagnosis.,rephrase,"['One study looked at the effects of stopping a low-phenylalanine diet at four years of age, a second study looked at the effect of returning to low-phenylalanine diets in children who had previously relaxed their diet, a third study looked at the effect of increasing phenylalanine intake in children who had continued on a low-phenylalanine diet since diagnosis and the fourth (a large, multicentre study) investigated the use of a strict low-phenylalanine diet compared to a moderately strict low-phenylalanine diet in newly diagnosed children.']",4,0.6666666666666666,4,9
CD001304,1,6,"In view of evidence from non-randomised studies, such a study would be unethical and it is recommended that low-phenylalanine diet should be commenced at the time of diagnosis.",delete,[],5,0.7777777777777778,4,9
CD001304,1,7,"There is uncertainty about the precise level of phenylalanine restriction and when, if ever, the diet should be relaxed.",delete,[],5,0.8888888888888888,5,9
CD001304,1,8,"This should be addressed by randomised controlled studies; however, no new studies are expected in this area so we do not plan to update this review.",rephrase,"['More research is needed to show if it is safe to relax this diet later on; however, no new studies are expected in this area so we do not plan to update the review.']",5,1.0,5,9
CD005511,0,0,We included 20 RCTs.,rephrase,['We identified 20 studies that randomised participants to groups receiving different forms of retreatment of periapical lesions.'],0,0.0625,1,16
CD005511,0,1,Two trials at high risk of bias assessed surgery versus a non-surgical approach: root-end resection with root-end filling versus root canal retreatment.,delete,[],1,0.125,1,16
CD005511,0,2,"The other 18 trials evaluated different surgical protocols: cone beam computed tomography (CBCT) versus periapical radiography for preoperative assessment (one study at high risk of bias); antibiotic prophylaxis versus placebo (one study at unclear risk); different magnification devices (loupes, surgical microscope, endoscope) (two studies at high risk); types of incision (papilla base incision, sulcular incision) (one study at high risk and one at unclear risk); ultrasonic devices versus handpiece burs (one study at high risk); types of root-end filling material (glass ionomer cement, amalgam, intermediate restorative material (IRM), mineral trioxide aggregate (MTA), gutta-percha (GP), super-ethoxy benzoic acid (EBA)) (five studies at high risk of bias, one at unclear risk and one at low risk); grafting versus no grafting (three studies at high risk and one at unclear risk); and low energy level laser therapy versus placebo (irradiation without laser activation) versus control (no use of the laser device) (one study at high risk).",rephrase,"[""These studies evaluated nine different comparisons: surgical versus non-surgical treatment (two studies, one monitoring participants for up to 10 years); two diagnostic radiographic techniques (one study); the occurrence of postoperative infection with or without antibiotics (one study); use of different devices for enhancing the surgeon's view during the most critical steps of the surgical procedure (one study); the aesthetic appearance of the gum next to the treated tooth and pain after operation when two different types of gingival incision were used (two studies); use of minimally invasive ultrasonic devices or traditional rotating burs to manage the tip of the root (one study); use of different materials for filling the root-end (seven studies); filling of the periapical lesion with a grafting material (four studies); and exposure of the surgical site to a low energy level laser to reduce pain (one study).""]",1,0.1875,1,16
CD005511,1,3,"There was no clear evidence of superiority of the surgical or non-surgical approach for healing at one-year follow-up (RR 1.15, 95% CI 0.97 to 1.35; two RCTs, 126 participants) or at four- or 10-year follow-up (one RCT, 82 to 95 participants), although the evidence is very low quality.",rephrase,['There is no evidence that a surgical approach leads to better results compared with non-surgical retreatment at one year (or at four or 10 years) after intervention.'],2,0.25,2,16
CD005511,1,4,"More participants in the surgically treated group reported pain in the first week after treatment (RR 3.34, 95% CI 2.05 to 5.43; one RCT, 87 participants; low quality evidence).",rephrase,"['However, people treated surgically reported more pain and swelling during the first week after treatment.']",3,0.3125,2,16
CD005511,2,5,"In terms of surgical protocols, there was some inconclusive evidence that ultrasonic devices for root-end preparation may improve healing one year after retreatment, when compared with the traditional bur (RR 1.14, 95% CI 1.00 to 1.30; one RCT, 290 participants; low quality evidence).",rephrase,"['Healing at one-year follow-up seemed to be improved by use of ultrasonic devices, instead of the traditional bur, for root-end preparation.']",4,0.375,2,16
CD005511,3,6,"There was evidence of better healing when root-ends were filled with MTA than when they were treated by smoothing of orthograde GP root filling, after one-year follow-up (RR 1.60, 95% CI 1.14 to 2.24; one RCT, 46 participants; low quality evidence).",rephrase,['There was some evidence of better healing at one-year follow-up when root-ends were filled with mineral trioxide aggregate compared with their being treated by smoothing of orthograde gutta percha root filling.'],5,0.4375,3,16
CD005511,4,7,"There was no evidence that using CBCT rather than radiography for preoperative evaluation was advantageous for healing (RR 1.02, 95% CI 0.70 to 1.47; one RCT, 39 participants; very low quality evidence), nor that any magnification device affected healing more than any other (loupes versus endoscope at one year: RR 1.05, 95% CI 0.92 to 1.20; microscope versus endoscope at two years: RR 1.01, 95% CI 0.89 to 1.15; one RCT, 70 participants, low quality evidence).",delete,[],6,0.5,3,16
CD005511,5,8,"There was no evidence that antibiotic prophylaxis reduced incidence of postoperative infection (RR 0.49, 95% CI 0.09 to 2.64; one RCT, 250 participants; low quality evidence).",rephrase,"['There was no evidence that use of antibiotics reduces the occurrence of postoperative infection (although when the procedure is done well, infection is an extremely rare event).']",6,0.5625,3,16
CD005511,6,9,"There was some evidence that using a papilla base incision (PBI) may be beneficial for preservation of the interdental papilla compared with complete papilla mobilisation (one RCT (split-mouth), 12 participants/24 sites; very low quality evidence).",delete,[],7,0.625,4,16
CD005511,6,10,"There was no evidence of less pain in the PBI group at day 1 post surgery (one RCT, 38 participants; very low quality evidence).",delete,[],7,0.6875,4,16
CD005511,7,11,"There was evidence that adjunctive use of a gel of plasma rich in growth factors reduced postoperative pain compared with no grafting (measured on visual analogue scale: one day postoperative MD -51.60 mm, 95% CI -63.43 to -39.77; one RCT, 36 participants; low quality evidence).",delete,[],7,0.75,4,16
CD005511,8,12,There was no evidence that use of low energy level laser therapy (LLLT) prevented postoperative pain (very low quality evidence).,rephrase,"['It is difficult to draw conclusions, as the evidence currently available is of low to very low quality.']",7,0.8125,5,16
CD005511,9,13,Available evidence does not provide clinicians with reliable guidelines for treating periapical lesions.,delete,[],8,0.875,5,16
CD005511,9,14,"Further research is necessary to understand the effects of surgical versus non-surgical approaches, and to determine which surgical procedures provide the best results for periapical lesion healing and postoperative quality of life.",rephrase,"['More randomised controlled trials conducted to high standards are needed to find out the effects of the surgical versus non-surgical approach and, when surgery is used, which materials, devices or operative protocols are best for improving lesion healing and reducing patient discomfort.']",8,0.9375,5,16
CD005511,9,15,"Future studies should use standardised techniques and success criteria, precisely defined outcomes and the participant as the unit of analysis.",delete,[],9,1.0,5,16
CD007491,0,0,We included 20 randomised controlled trials with a total of 3100 participants; four trials recruited participants with chronic obstructive pulmonary disease; two trials recruited participants recovering from a stroke; seven trials recruited participants with an acute medical condition who were mainly older; and the remaining trials recruited participants with a mix of conditions.,split,"['We found 20 studies, of which four were identified for this update, with a total of 3100 patients with a range of acute conditions.', 'Four studies recruited participants with chronic obstructive (lung) disease; two studies recruited participants recovering from a stroke; seven studies recruited participants with a (sudden or short-term) medical condition who were mainly older; and the remaining studies recruited participants with a mix of conditions.']",0,0.1,1,10
CD007491,0,1,"We assessed the majority of the included studies as at low risk of selection, detection, and attrition bias, and unclear for selective reporting and performance bias.",rephrase,"['We compared and summarised the results of the studies, and rated our confidence in the evidence based on factors such as study methods and sizes.']",2,0.2,1,10
CD007491,1,2,"For an older population, admission avoidance hospital at home probably makes little or no difference on mortality at six months' follow-up (risk ratio (RR) 0.88, 95% confidence interval (CI) 0.68 to 1.13; P = 0.30; I2 = 0%; 5 trials, 1502 participants; moderate-certainty evidence); little or no difference on the likelihood of being readmitted to hospital after discharge from hospital at home or inpatient care within 3 to 12 months' follow-up (RR 1.14, 95% CI 0.97 to 1.34; P = 0.11; I2 = 41%; 8 trials, 1757 participants; moderate-certainty evidence); and probably reduces the likelihood of living in residential care at six months' follow-up (RR 0.53, 95% CI 0.41 to 0.69; P < 0.001; I2 = 67%; 4 trials, 1271 participants; moderate-certainty evidence).",rephrase,"[""When compared to in-hospital care, admission avoidance hospital at home services for a select group of patients probably make little or no difference to risk of death or to the likelihood of being taken to hospital in the next 3 to 12 months, and probably increase the chances of living at home at six months' follow-up.""]",3,0.3,2,10
CD007491,2,3,Hospital at home probably results in little to no difference in patient's self-reported health status (2006 patients; moderate-certainty evidence).,rephrase,"[""Hospital at home probably results in little to no difference in patients' health status.""]",4,0.4,2,10
CD007491,2,4,Satisfaction with health care received may be improved with admission avoidance hospital at home (1812 participants; low-certainty evidence); few studies reported the effect on caregivers.,rephrase,"['Patients who receive care at home may have increased satisfaction compared to those in hospital; however, the effects of this type of care on the caregivers who support them are unclear.']",5,0.5,3,10
CD007491,2,5,"Hospital at home reduced the initial average hospital length of stay (2036 participants; low-certainty evidence), which ranged from 4.1 to 18.5 days in the hospital group and 1.2 to 5.1 days in the hospital at home group.",delete,[],6,0.6,3,10
CD007491,2,6,Hospital at home length of stay ranged from an average of 3 to 20.7 days (hospital at home group only).,rephrase,"['Hospital at home decreases the amount of time patients spend in hospital, while length of stay in hospital at home tended to be longer than a typical hospital stay.']",6,0.7,4,10
CD007491,2,7,"Admission avoidance hospital at home probably reduces costs to the health service compared with hospital admission (2148 participants; moderate-certainty evidence), though by a range of different amounts and using different methods to cost resource use, and there is some evidence that it decreases overall societal costs to six months' follow-up.",rephrase,"['Admission avoidance hospital at home probably decreases treatment costs, though by a range of different amounts.']",7,0.8,4,10
CD007491,3,8,"Admission avoidance hospital at home, with the option of transfer to hospital, may provide an effective alternative to inpatient care for a select group of older people who have been referred for hospital admission.",delete,[],8,0.9,5,10
CD007491,3,9,The intervention probably makes little or no difference to patient health outcomes; may improve satisfaction; probably reduces the likelihood of relocating to residential care; and probably decreases costs.,rephrase,['We wanted to find out if hospital at home makes a difference to patient health outcomes and to living independently at home.'],8,1.0,5,10
CD001206,0,0,"We included 66 RCTs in the review (> 24 weeks; 11,597 participants; age range 18 to 70 years) and 63 in the meta-analysis.",delete,[],0,0.07142857142857142,1,14
CD001206,0,1,"For the primary outcome of treatment response, we found very low-quality evidence of treatment response for selective serotonin reuptake inhibitors (SSRIs) compared with placebo (number of studies (k) = 24, risk ratio (RR) 1.65; 95% confidence interval (CI) 1.48 to 1.85, N = 4984).",rephrase,"['There was evidence of benefit that selective serotonin reuptake inhibitors (SSRIs) were more effective than placebo, although the evidence was of very low quality.']",0,0.14285714285714285,1,14
CD001206,0,2,"On this outcome there was also evidence of benefit for monoamine oxidase inhibitors (MAOIs) (k = 4, RR 2.36; 95% CI 1.48 to 3.75, N = 235), reversible inhibitors of monoamine oxidase A (RIMAs) (k = 8, RR 1.83; 95% CI 1.32 to 2.55, N = 1270), and the benzodiazepines (k = 2, RR 4.03; 95% CI 2.45 to 6.65, N = 132), although the evidence was low quality.",rephrase,"['There was also evidence of benefit for monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A (RIMAs), and benzodiazepines, even though the evidence was low in quality.']",1,0.21428571428571427,2,14
CD001206,0,3,"We also found clinical response for the anticonvulsants with gamma-amino butyric acid (GABA) analogues (k = 3, RR 1.60; 95% CI 1.16 to 2.20, N = 532; moderate-quality evidence).",rephrase,['The anticonvulsants gabapentin and pregabalin also showed moderate-quality evidence of a clinical response.'],2,0.2857142857142857,2,14
CD001206,0,4,The SSRIs were the only medication proving effective in reducing relapse based on moderate-quality evidence.,split,"['The SSRIs were the only medication proving effective in reducing relapse based on moderate-quality evidence.', 'There was low-quality evidence that more people taking SSRIs and SNRIs dropped out due to side effects than those taking placebo, but absolute withdrawal rates were low.']",3,0.35714285714285715,2,14
CD001206,0,5,"We assessed the SSRIs and the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine on the basis of treatment withdrawal; this was higher for medication than placebo (SSRIs: k = 24, RR 2.59; 95% CI 1.97 to 3.39, N = 5131, low-quality evidence; venlafaxine: k = 4, RR 3.23; 95% CI 2.15 to 4.86, N = 1213, moderate-quality evidence), but there were low absolute rates of withdrawal for both these medications classes compared to placebo.",delete,[],5,0.42857142857142855,3,14
CD001206,0,6,We did not find evidence of a benefit for the rest of the medications compared to placebo.,rephrase,['We did not observe this effect for the remaining medication classes.'],5,0.5,3,14
CD001206,1,7,"For the secondary outcome of SAnD symptom severity, there was benefit for the SSRIs, the SNRI venlafaxine, MAOIs, RIMAs, benzodiazepines, the antipsychotic olanzapine, and the noradrenergic and specific serotonergic antidepressant (NaSSA) atomoxetine in the reduction of SAnD symptoms, but most of the evidence was of very low quality.",rephrase,"['For the outcome of SAnD symptom severity, there was evidence of benefit for SSRIs, the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine, MAOIs, RIMAs, benzodiazepines, the antipsychotic olanzapine, and the noradrenergic and specific serotonergic antidepressant (NaSSA) atomoxetine, but most of the evidence was of very low quality.']",6,0.5714285714285714,3,14
CD001206,1,8,Treatment with SSRIs and RIMAs was also associated with a reduction in depression symptoms.,rephrase,"['SSRIs and RIMAs reduced depression symptoms, and SSRIs reduced functional disability across all domains.']",7,0.6428571428571429,4,14
CD001206,1,9,The SSRIs were the only medication class that demonstrated evidence of reduction in disability across a number of domains.,delete,[],8,0.7142857142857143,4,14
CD001206,2,10,"We observed a response to long-term treatment with medication for the SSRIs (low-quality evidence), for the MAOIs (very low-quality evidence) and for the RIMAs (moderate-quality evidence).",rephrase,"['We also observed response to long-term treatment with SSRIs (based on low-quality evidence), MAOIs (based on very low-quality evidence), and RIMAs (based on moderate-quality evidence).']",8,0.7857142857142857,4,14
CD001206,3,11,"We found evidence of treatment efficacy for the SSRIs, but it is based on very low- to moderate-quality evidence.",rephrase,['Most evidence for treatment efficacy is related to SSRIs.'],9,0.8571428571428571,5,14
CD001206,3,12,"Tolerability of SSRIs was lower than placebo, but absolute withdrawal rates were low.",delete,[],10,0.9285714285714286,5,14
CD001206,4,13,"While a small number of trials did report treatment efficacy for benzodiazepines, anticonvulsants, MAOIs, and RIMAs, readers should consider this finding in the context of potential for abuse or unfavourable side effects.",delete,[],10,1.0,5,14
CD008562,0,0,In this Cochrane Review update we did not include any new RCT compared with the first review version.,delete,[],0,0.05,1,20
CD008562,0,1,"Accordingly, four RCTs (388 participants) met the inclusion criteria.",delete,[],0,0.1,1,20
CD008562,0,2,"These trials evaluated the human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate.",rephrase,"['We included four trials that had a limited number of patients (388) and assessed four different interventions: human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate with heparin or placebo.']",0,0.15,1,20
CD008562,0,3,Included trials reported data on mortality and bleeding.,delete,[],1,0.2,1,20
CD008562,0,4,"The studies were conducted in Japan, Italy and the Netherlands.",rephrase,"['The studies were published between 1989 and 2007, and were conducted in Japan, Italy and the Netherlands.']",1,0.25,2,20
CD008562,0,5,We classified the included trials as: 1) including patients with or without leukemia which did not report data for the leukemia subgroup (366 participants); and 2) only including patients with leukemia (22 participants).,rephrase,['Two small trials which included patients with leukemia only (22 participants) reported bleeding data.'],2,0.3,2,20
CD008562,0,6,"Overall, the risk of bias of the included trials was high, since the trial authors did not provide a detailed description about trial design and execution.",rephrase,['All trials have a high risk of bias.'],3,0.35,2,20
CD008562,1,7,"According to the GRADE recommendations, we judged the overall quality of the body of evidence for all prefixed outcomes as 'very low', due to methodological limitations and very small sample size.",delete,[],4,0.4,2,20
CD008562,2,8,"One trial, including 10 participants with leukemia and comparing dermatan sulphate with heparin, reported no deaths during trial treatment.",rephrase,['There were no deaths reported in a trial comparing dermatan sulphate with heparin.'],4,0.45,3,20
CD008562,3,9,"In terms of bleeding data, we were unable to pool results from two studies that were only conducted with leukemia patients due to the inconsistency in the measurement and reporting of this outcome.",rephrase,['These results were not compiled due to inconsistency in the measurement and reporting of that outcome.'],5,0.5,3,20
CD008562,3,10,"One trial, including 12 participants with leukemia, found very low quality evidence that tranexamic acid can reduce the cumulative hemorrhagic score in participants compared with those assigned to placebo (P = 0.0015, very low quality evidence).",rephrase,['One trial found very low quality evidence that tranexamic acid compared with placebo reduces bleeding in leukemia patients.'],6,0.55,3,20
CD008562,3,11,"On the contrary, there is no evidence that dermatan sulphate compared with placebo reduces new events of hemorrhagic diathesis (1/5 (20%) versus 2/5 (40%); RR 0.50; 95% CI 0.06 to 3.91; P = 0.51, very low quality evidence).",rephrase,"['On the contrary, there is no evidence that dermatan sulphate compared with placebo reduces new events of hemorrhagic diathesis in patients with leukemia.']",7,0.6,3,20
CD008562,4,12,No thromboembolic complications were reported in either trial that included patients with leukemia only (very low quality evidence).,rephrase,['No thromboembolic complications were reported in both the trials.'],8,0.65,4,20
CD008562,4,13,The safety profile was inconclusive.,rephrase,['Saftey profile is inconclusive.'],9,0.7,4,20
CD008562,5,14,"The included trials did not assess overall mortality, resolution of respiratory failure, renal failure or shock.",rephrase,"['These trials did not report overall mortality, resolution of respiratory failure, renal failure and shock.']",10,0.75,4,20
CD008562,6,15,"Due to a lack of new RCTs, our conclusions in this Cochrane Review update are the same as the previous review version.",delete,[],11,0.8,4,20
CD008562,6,16,We included four RCTs which reported mortality and bleeding data.,delete,[],11,0.85,5,20
CD008562,6,17,"It is not possible to determine whether human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate are effective or harmful for patients presenting with DIC related to acute or chronic leukemia.",rephrase,"['Well conducted larger studies will provide more information about the effect of human activated protein C, recombinant human soluble thrombomodulin, tranexamic acid and dermatan sulphate for treating DIC in patients with acute or chronic leukemia.']",11,0.9,5,20
CD008562,6,18,The quality of the evidence was low to very low.,delete,[],12,0.95,5,20
CD008562,6,19,"Therefore, prescription of these interventions for treating DIC in patients with acute and chronic leukemia can neither be supported nor rejected, unless new evidence from a large high-quality trial alters this conclusion.",delete,[],12,1.0,5,20
CD014067,0,0,We included six trials in which a total of 925 infants participated.,rephrase,['We found six trials with a total of 925 infant participants.'],0,0.09090909090909091,1,11
CD014067,0,1,Most trials were small (median sample size 200).,rephrase,"['Trials were mostly small, and most had design flaws that might have biased their findings.']",1,0.18181818181818182,1,11
CD014067,0,2,Lack of clarity on methods used to conceal allocation and mask caregivers or investigators were potential sources of bias in four of the trials.,delete,[],2,0.2727272727272727,2,11
CD014067,0,3,The studied synbiotics preparations contained lactobacilli or bifidobacteria (or both) combined with fructo- or galacto-oligosaccharides (or both).,delete,[],2,0.36363636363636365,2,11
CD014067,1,4,"Meta-analyses suggested that synbiotics may reduce the risk of NEC (RR 0.18, 95% CI 0.09 to 0.40; RD 70 fewer per 1000, 95% CI 100 fewer to 40 fewer; number needed to treat for an additional beneficial outcome (NNTB) 14, 95% CI 10 to 25; six trials (907 infants); low certainty evidence); and all-cause mortality prior to hospital discharge (RR 0.53, 95% CI 0.33 to 0.85; RD 50 fewer per 1000, 95% CI 120 fewer to 100 fewer; NNTB 20, 95% CI 8 to 100; six trials (925 infants); low-certainty evidence).",rephrase,['Combined analyses showed that giving synbiotics to very preterm or very low birth weight infants may reduce the risk of necrotising enterocolitis and death.'],2,0.45454545454545453,3,11
CD014067,1,5,"Synbiotics may have little or no effect on late-onset invasive infection, but the evidence is very uncertain (RR 0.84, 95% CI 0.58 to 1.21; RD 20 fewer per 1000, 95% CI 70 fewer to 30 more; five trials (707 infants); very low-certainty evidence).",rephrase,"['Synbiotics may have little or no effect in reducing the risk of serious infection, but the evidence is very uncertain.']",3,0.5454545454545454,3,11
CD014067,1,6,None of the trials assessed neurodevelopmental outcomes.,rephrase,['None of the studies that we identified assessed the effect of synbiotics on disability or developmental outcomes.'],4,0.6363636363636364,4,11
CD014067,1,7,"In the absence of high levels of heterogeneity, we did not undertake any subgroup analysis (including the type of feeding).",delete,[],5,0.7272727272727273,4,11
CD014067,2,8,The available trial data provide only low-certainty evidence about the effects of synbiotics on the risk of NEC and associated morbidity and mortality for very preterm or very low birth weight infants.,split,"['There is low-certainty evidence that synbiotics prevent necrotising enterocolitis and death from any cause.', 'There is very low-certainty evidence that synbiotics may have little or no effect in preventing serious infection.']",5,0.8181818181818182,5,11
CD014067,2,9,Our confidence in the effect estimates is limited; the true effects may be substantially different from these estimates.,delete,[],7,0.9090909090909091,5,11
CD014067,2,10,"Large, high-quality trials would be needed to provide evidence of sufficient validity and applicability to inform policy and practice.",delete,[],7,1.0,5,11
CD011942,0,0,Most of the 43 included sample studies were from low- or middle-income countries.,split,"['We sampled 43 of the 53 included studies in this review.', 'Most were from low- or middle-income countries, and included both lay health workers and health professionals.']",0,0.03125,1,32
CD011942,0,1,"In many of the studies, the mobile devices had decision support software loaded onto them, which showed the steps the health workers had to follow when they provided health care.",rephrase,['Many of the mobile devices had software that helped health workers follow the correct steps when providing services.'],2,0.0625,1,32
CD011942,0,2,"Other uses included in-person and/or text message communication, and recording clients' health information.",rephrase,"[""Health workers also used mobile phones to communicate with clients, and to record clients' health information.""]",3,0.09375,1,32
CD011942,0,3,"Almost half of the studies looked at health workers' use of mobile devices for mother, child, and newborn health.",rephrase,"['Many used mobile phones or tablets when delivering health care to mothers, children or newborns.']",4,0.125,1,32
CD011942,1,4,We have moderate or high confidence in the following findings.,ignore,['We have moderate or high confidence in the following findings.'],5,0.15625,1,32
CD011942,2,5,"mHealth changed how health workers worked with each other : health workers appreciated being more connected to colleagues, and thought that this improved co-ordination and quality of care.",rephrase,"['health workers appreciated being more connected to colleagues, and thought that this improved co-ordination and quality of care.']",6,0.1875,1,32
CD011942,2,6,"However, some described problems when senior colleagues did not respond or responded in anger.",ignore,"['However, some described problems when senior colleagues did not respond or responded in anger.']",7,0.21875,2,32
CD011942,2,7,Some preferred face-to-face connection with colleagues.,ignore,['Some preferred face-to-face connection with colleagues.'],8,0.25,2,32
CD011942,2,8,"Some believed that mHealth improved their reporting, while others compared it to ""big brother watching"".",ignore,"['Some believed that mHealth improved their reporting, while others compared it to ""big brother watching"".']",9,0.28125,2,32
CD011942,3,9,"mHealth changed how health workers delivered care : health workers appreciated how mHealth let them take on new tasks, work flexibly, and reach clients in difficult-to-reach areas.",rephrase,"['health workers appreciated how mHealth let them take on new tasks, work flexibly, and reach clients in difficult-to-reach areas.']",10,0.3125,2,32
CD011942,3,10,"They appreciated mHealth when it improved feedback, speed and workflow, but not when it was slow or time consuming.",ignore,"['They appreciated mHealth when it improved feedback, speed and workflow, but not when it was slow or time consuming.']",11,0.34375,2,32
CD011942,3,11,Some health workers found decision support software useful; others thought it threatened their clinical skills.,ignore,['Some health workers found decision support software useful; others thought it threatened their clinical skills.'],12,0.375,2,32
CD011942,3,12,"Most health workers saw mHealth as better than paper, but some preferred paper.",merge,"['Most health workers saw mHealth as better than paper, but others saw mHealth as creating more work.']",13,0.40625,3,32
CD011942,3,13,Some health workers saw mHealth as creating more work.,none,[],13,0.4375,3,32
CD011942,4,14,"mHealth led to new forms of engagement and relationships with clients and communities : health workers felt that communicating with clients by mobile phone improved care and their relationships with clients, but felt that some clients needed face-to-face contact.",rephrase,"['health workers felt that communicating with clients by mobile phone improved care and their relationships with clients, but felt that some clients needed face-to-face contact.']",14,0.46875,3,32
CD011942,4,15,Health workers were aware of the importance of protecting confidential client information when using mobile devices.,ignore,['Health workers were aware of the importance of protecting confidential client information when using mobile devices.'],15,0.5,3,32
CD011942,4,16,"Some health workers did not mind being contacted by clients outside working hours, while others wanted boundaries.",ignore,"['Some health workers did not mind being contacted by clients outside working hours, while others wanted boundaries.']",16,0.53125,3,32
CD011942,4,17,Health workers described how some community members trusted health workers that used mHealth while others were sceptical.,ignore,['Health workers described how some community members trusted health workers that used mHealth while others were sceptical.'],17,0.5625,3,32
CD011942,4,18,Health workers pointed to problems when clients needed to own their own phones.,ignore,['Health workers pointed to problems when clients needed to own their own phones.'],18,0.59375,3,32
CD011942,5,19,"Health workers' use and perceptions of mHealth could be influenced by factors tied to costs, the health worker, the technology, the health system and society, poor network access, and poor access to electricity : some health workers did not mind covering extra costs.",rephrase,['some health workers did not mind covering extra costs.'],19,0.625,4,32
CD011942,5,20,Others complained that phone credit was not delivered on time.,ignore,['Others complained that phone credit was not delivered on time.'],20,0.65625,4,32
CD011942,5,21,Health workers who were accustomed to using mobile phones were sometimes more positive towards mHealth.,ignore,['Health workers who were accustomed to using mobile phones were sometimes more positive towards mHealth.'],21,0.6875,4,32
CD011942,5,22,"Others with less experience, were sometimes embarrassed about making mistakes in front of clients or worried about job security.",ignore,"['Others with less experience, were sometimes embarrassed about making mistakes in front of clients or worried about job security.']",22,0.71875,4,32
CD011942,5,23,"Health workers wanted training, technical support, user-friendly devices, and systems that were integrated into existing electronic health systems.",ignore,"['Health workers wanted training, technical support, user-friendly devices, and systems that were integrated into existing electronic health systems.']",23,0.75,4,32
CD011942,5,24,"The main challenges health workers experienced were poor network connections, access to electricity, and the cost of recharging phones.",ignore,"['The main challenges health workers experienced were poor network connections, access to electricity, and the cost of recharging phones.']",24,0.78125,4,32
CD011942,5,25,Other problems included damaged phones.,ignore,['Other problems included damaged phones.'],25,0.8125,5,32
CD011942,5,26,"Factors outside the health system also influenced how health workers experienced mHealth, including language, gender, and poverty issues.",ignore,"['Factors outside the health system also influenced how health workers experienced mHealth, including language, gender, and poverty issues.']",26,0.84375,5,32
CD011942,5,27,Health workers felt that their commitment to clients helped them cope with these challenges.,ignore,['Health workers felt that their commitment to clients helped them cope with these challenges.'],27,0.875,5,32
CD011942,6,28,Our findings propose a nuanced view about mHealth programmes.,delete,[],28,0.90625,5,32
CD011942,6,29,The complexities of healthcare delivery and human interactions defy simplistic conclusions on how health workers will perceive and experience their use of mHealth.,delete,[],28,0.9375,5,32
CD011942,6,30,"Perceptions reflect the interplay between the technology, contexts, and human attributes.",delete,[],28,0.96875,5,32
CD011942,6,31,"Detailed descriptions of the programme, implementation processes and contexts, alongside effectiveness studies, will help to unravel this interplay to formulate hypotheses regarding the effectiveness of mHealth.",delete,[],28,1.0,5,32
CD005440,0,0,We identified seven trials that met the inclusion criteria.,merge,[],0,0.038461538461538464,1,26
CD005440,0,1,"Out of these, six trials provided data for the meta-analyses.",none,['Six trials providing information on the review question were identified.'],0,0.07692307692307693,1,26
CD005440,0,2,A total of 488 participants with acute cholecystitis and fit to undergo laparoscopic cholecystectomy were randomised to early laparoscopic cholecystectomy (ELC) (244 people) and delayed laparoscopic cholecystectomy (DLC) (244 people) in the six trials.,split,"['A total of 488 people with acute cholecystitis were included.', 'Laparoscopic cholecystectomy was performed early (within seven days of people presenting to the doctor with symptoms) in 244 people while it was performed after at least six weeks in the remaining 244 people.']",1,0.11538461538461539,1,26
CD005440,0,3,Blinding was not performed in any of the trials and so all the trials were at high risk of bias.,merge,['All the trials were at high risk of bias (and might have overestimated the benefits or underestimated the harms of either early laparoscopic cholecystectomy or delayed laparoscopic cholecystectomy).'],3,0.15384615384615385,1,26
CD005440,0,4,"Other than blinding, three of the six trials were at low risk of bias in the other domains such as sequence generation, allocation concealment, incomplete outcome data, and selective outcome reporting.",none,[],3,0.19230769230769232,1,26
CD005440,0,5,The proportion of females ranged between 43.3% and 80% in the trials that provided this information.,ignore,['The proportion of females ranged between 43.3% and 80% in the trials that provided this information.'],4,0.23076923076923078,2,26
CD005440,0,6,The average age of participants ranged between 40 years and 60 years.,ignore,['The average age of participants ranged between 40 years and 60 years.'],5,0.2692307692307692,2,26
CD005440,0,7,There was no mortality in any of the participants in five trials that reported mortality.,delete,[],6,0.3076923076923077,2,26
CD005440,0,8,There was no significant difference in the proportion of people who developed bile duct injury in the two groups (ELC 1/219 (adjusted proportion 0.4%) versus DLC 2/219 (0.9%); Peto OR 0.49; 95% CI 0.05 to 4.72 (5 trials)).,merge,"['There was no significant difference in the proportion of people who developed bile duct injury, surgical complications, or who required conversion from key-hole to open operation between the two groups.']",6,0.34615384615384615,2,26
CD005440,0,9,There was no significant difference between the two groups (ELC 14/219 (adjusted proportion 6.5%) versus DLC 11/219 (5.0%); RR 1.29; 95% CI 0.61 to 2.72 (5 trials)) in terms of other serious complications.,none,[],6,0.38461538461538464,2,26
CD005440,0,10,None of the trials reported quality of life from the time of randomisation.,ignore,['None of the trials reported quality of life from the time of randomisation.'],7,0.4230769230769231,3,26
CD005440,0,11,There was no significant difference between the two groups in the proportion of people who required conversion to open cholecystectomy (ELC 49/244 (adjusted proportion 19.7%) versus DLC 54/244 (22.1%); RR 0.89; 95% CI 0.63 to 1.25 (6 trials)).,delete,[],8,0.46153846153846156,3,26
CD005440,0,12,The total hospital stay was shorter in the early group than the delayed group by four days (MD -4.12 days; 95% CI -5.22 to -3.03 (4 trials; 373 people)).,rephrase,['The total hospital stay was shorter in the early group than the delayed group by four days.'],8,0.5,3,26
CD005440,0,13,There was no significant difference in the operating time between the two groups (MD -1.22 minutes; 95% CI -3.07 to 0.64 (6 trials; 488 people)).,rephrase,['There was no significant difference in the operating time between the two groups.'],9,0.5384615384615384,3,26
CD005440,0,14,Only one trial reported return to work.,rephrase,['Only one trial reported the time taken for employed people to return to work.'],10,0.5769230769230769,3,26
CD005440,0,15,The people belonging to the ELC group returned to work earlier than the DLC group (MD -11.00 days; 95% CI -19.61 to -2.39 (1 trial; 36 people)).,rephrase,"['The people belonging to the early laparoscopic cholecystectomy group returned to work 11 days, on average, earlier than the delayed laparoscopic cholecystectomy group.']",11,0.6153846153846154,4,26
CD005440,0,16,Four trials did not report any gallstone-related morbidity during the waiting period.,rephrase,['Four trials did not report any gallstone-related complications during the waiting period.'],12,0.6538461538461539,4,26
CD005440,0,17,One trial reported five gallstone-related morbidities (cholangitis: two; biliary colic not requiring urgent operation: one; acute cholecystitis not requiring urgent operation: two).,rephrase,"['One trial reported five gallstone-related complications, including two people with cholangitis.']",13,0.6923076923076923,4,26
CD005440,0,18,There were no reports of pancreatitis during the waiting time.,ignore,['There were no reports of pancreatitis during the waiting time.'],14,0.7307692307692307,4,26
CD005440,0,19,Gallstone-related morbidity was not reported in the remaining trials.,ignore,['Gallstone-related morbidity was not reported in the remaining trial.'],15,0.7692307692307693,4,26
CD005440,0,20,Forty (18.3%) of the people belonging to the delayed group had either non-resolution of symptoms or recurrence of symptoms before their planned operation and had to undergo emergency laparoscopic cholecystectomy in five trials.,ignore,['Approximately one-sixth of people belonging to the delayed group had either non-resolution of symptoms or recurrence of symptoms before their planned operation and had to undergo emergency laparoscopic cholecystectomy in five trials.'],16,0.8076923076923077,5,26
CD005440,0,21,The proportion with conversion to open cholecystectomy was 45% (18/40) in this group of people.,delete,[],17,0.8461538461538461,5,26
CD005440,1,22,We found no significant difference between early and late laparoscopic cholecystectomy on our primary outcomes.,delete,[],17,0.8846153846153846,5,26
CD005440,1,23,"However, trials with high risk of bias indicate that early laparoscopic cholecystectomy during acute cholecystitis seems safe and may shorten the total hospital stay.",rephrase,"['Based on information from a varied number of participants as well as trials at high risk of bias, early laparoscopic cholecystectomy during acute cholecystitis appears safe and shortens the total hospital stay.']",17,0.9230769230769231,5,26
CD005440,1,24,"The majority of the important outcomes occurred rarely, and hence the confidence intervals are wide.",rephrase,['The majority of the important outcomes occurred rarely and hence one cannot rule out that future trials may show that one treatment or another may be better in terms of complications.'],18,0.9615384615384616,5,26
CD005440,1,25,"It is unlikely that future randomised clinical trials will be powered to measure differences in bile duct injury and other serious complications since this might involve performing a trial of more than 50,000 people, but several smaller randomised trials may answer the questions through meta-analyses.",split,"['However, the trial size required to show such differences involves a clinical trial on more than 50,000 people and so it is unlikely that such large trials will be performed.', 'Several smaller randomised trials may answer the questions through meta-analyses.']",19,1.0,5,26
CD010441,0,0,The search strategy identified six potentially eligible studies.,delete,[],0,0.07142857142857142,1,14
CD010441,0,1,Two studies were excluded.,delete,[],0,0.14285714285714285,1,14
CD010441,0,2,We included four randomised controlled trials that randomised a total of 599 women (data were available for 595 women).,delete,[],0,0.21428571428571427,2,14
CD010441,1,3,Two trials (283 women) compared the effects of perineal HAase injection during the second stage of labour with placebo injection and were at low risk of bias.,rephrase,['Two trials involving 283 women compared the effects of perineal HAase injection with placebo injection during second stage of labour and were at low risk of bias.'],0,0.2857142857142857,2,14
CD010441,1,4,Three trials (one three-armed trial was analysed twice) (373 women) compared the effects of perineal HAase injection during second stage of labour with no intervention and two out of the three trials were at high risk of bias.,rephrase,['Three trials (one three-armed trial was analysed twice) with 373 women compared the effects of perineal HAase injection during second stage of labour with no intervention.'],1,0.35714285714285715,2,14
CD010441,1,5,"Data from four trials involving 599 women suggested that perineal HAase injection during second stage of labour had a lower incidence of perineal trauma (average risk ratio (RR) 0.69, 95% confidence interval (CI) 0.50 to 0.95,Tau² = 0.08, I² = 82% compared with women in the control group, but there was no clear evidence of a reduction in the incidence of episiotomy (average RR 0.74, 95% CI 0.43 to 1.29, Tau² = 0.17, I² = 66%), first and second degree perineal lacerations (average RR 0.54, 95% CI 0.38 to 1.33, Tau² = 0.30 , I² = 85%) and third and fourth degree perineal lacerations (RR 0.12, 95% CI 0.01 to 2.13).",delete,[],2,0.42857142857142855,3,14
CD010441,1,6,"Data from two trials involving 283 women indicated that there was no clear evidence of a reduction in the incidence of perineal trauma (RR 0.90, 95% CI 0.77 to 1.06, Tau²=1.07, I² = 7%), episiotomy (RR 0.77, 95% CI 0.32 to 1.89, Tau² = 0.27, I² = 54%), first and second degree perineal lacerations (RR 1.08, 95% CI 0.83 to 1.40, Tau² = 1.11, I² = 10%) and third and fourth degree perineal lacerations (RR 0.12, 95% CI 0.01 to 2.13) with perineal HAase injection.",delete,[],2,0.5,3,14
CD010441,1,7,"Data from three trials involving 373 women suggested that perineal HAase injection during second stage of labour had a lower incidence of perineal trauma (RR 0.61, 95% CI 0.42 to 0.88, Tau² = 0.08, I² = 78%) compared with no intervention, but had no clear effect on in the incidence of episiotomy (RR 0.79, 95% CI 0.44 to 1.42, Tau² = 0.16, I² = 70%) and first and second degree perineal lacerations (RR 0.58, 95% CI 0.31 to 1.10, Tau² = 0.18, I² = 59%).",delete,[],2,0.5714285714285714,3,14
CD010441,1,8,No side effects were reported in the included trials.,ignore,['No side effects were reported in the included trials.'],2,0.6428571428571429,4,14
CD010441,2,9,No included trials reported on perineal pain and other pre-specified secondary outcomes: perineal trauma requiring suturing; blood loss; dyspareunia; urinary incontinence; faecal incontinence; assisted delivery rate; women's satisfaction; Apgar score less than seven at five minutes and need for admission to special care baby unit.,rephrase,['Other measures such as perineal pain and other pre-specified secondary outcomes were not measured by the included trials.'],3,0.7142857142857143,4,14
CD010441,3,10,"Perineal HAase injection during second stage of labour had a lower incidence of perineal trauma compared with control or no intervention, but there was no clear evidence of benefit compared with placebo injection.",rephrase,"['There was no clear evidence that HAase injection lowered the incidence of perineal trauma, episiotomy, first and second degree and more severe (third and fourth degree) perineal tears when compared with placebo injection.']",4,0.7857142857142857,4,14
CD010441,3,11,"The difference in incidence of perineal trauma may probably be due to bias and confounding in the non-placebo controlled comparison, this result should be interpreted cautiously.",ignore,"['The difference in the incidence of perineal trauma may be due to bias and confounding in the non-placebo controlled comparison, this result should be interpreted cautiously.']",5,0.8571428571428571,5,14
CD010441,3,12,"The potential use of perineal HAase injection as a method to reduce perineal trauma were yet to be determined as there was no appropriate established dose for HAase, no evidence of follow up, and the number of high-quality trials and outcomes reported were too limited to draw conclusions on its effectiveness and safety.",ignore,"['The potential use of this intervention as a method to reduce perineal trauma are yet to be determined as there was no appropriate established dose for HAase, no evidence of follow-up and side effects, and the number of high-quality trials and outcomes reported was too limited to draw conclusions on its effectiveness and safety.']",6,0.9285714285714286,5,14
CD010441,3,13,Further rigorous randomised controlled trials are required to evaluate the role of perineal HAase injection in vaginal deliveries.,ignore,['Further rigorous randomised controlled trials are required to evaluate the role of perineal HAase injection in vaginal deliveries.'],7,1.0,5,14
CD012137,0,0,"One randomised controlled trial (RCT) and two quasi-RCTs contributed data on 1779 women who had uncomplicated vaginal births, comparing different antibiotic regimens with placebo or no treatment.",delete,[],0,0.05555555555555555,1,18
CD012137,0,1,The included trials took place in the 1960s (one trial) and 1990s (two trials).,merge,"['The trials took place in the 1960s (one trial) and 1990s (two trials), and were carried out in France, the USA and Brazil.']",0,0.1111111111111111,1,18
CD012137,0,2,"The trials were conducted in France, the USA and Brazil.",none,[],0,0.16666666666666666,1,18
CD012137,0,3,"Antibiotics administered included: oral sulphamethoxypyridazine or chloramphenicol for three to five days, and intravenous amoxicillin and clavulanic acid in a single dose one hour after birth.",delete,[],1,0.2222222222222222,2,18
CD012137,0,4,"We rated most of the domains for risk of bias as high risk, with the exception of reporting bias and other potential bias.",delete,[],1,0.2777777777777778,2,18
CD012137,1,5,"The quality of evidence ranged from low to very low, based on the GRADE quality assessment, given very serious design limitations of the included studies, few events and wide confidence intervals (CIs) of effect estimates.",rephrase,['The quality of the evidence ranged from low to very low.'],1,0.3333333333333333,2,18
CD012137,2,6,"We found a decrease in the risk of endometritis (RR 0.28, 95% CI 0.09 to 0.83, two trials, 1364 women,very low quality).",delete,[],2,0.3888888888888889,2,18
CD012137,2,7,"However, one trial reported zero events for this outcome and we rate the evidence as very low quality.",delete,[],2,0.4444444444444444,3,18
CD012137,2,8,"There was little or no difference between groups for the risk of urinary tract infection (RR 0.25, 95% CI 0.05 to 1.19, two trials, 1706 women,low quality), wound infection after episiotomy (reported as wound dehiscence in the included trials) (RR 0.78, 95% CI 0.31 to 1.96, two trials, 1364 women, very low quality) and length of maternal hospital stay in days (MD -0.15, 95% CI -0.31 to 0.01, one trial, 1291 women, very low quality).",delete,[],2,0.5,3,18
CD012137,2,9,"Cost of care in US dollar equivalent was 2½ times higher in the control group compared to the group receiving antibiotics prophylaxis (USD 3600: USD 9000, one trial, 1291 women).",rephrase,['The cost of care was higher in the group that did not receive antibiotic prophylaxis.'],2,0.5555555555555556,3,18
CD012137,2,10,"There were few or no differences between treated and control groups for adverse effects of antibiotics (skin rash) reported in one woman in each of the two trials (RR 3.03, 95% CI 0.32 to 28.95, two trials, 1706 women, very low quality).",rephrase,"['There were no differences between the groups for skin rash due to antibiotics, reported in one woman in each of the two trials (1706 women).']",3,0.6111111111111112,4,18
CD012137,2,11,"The incidence of severe maternal infectious morbidity, antimicrobial resistance or women's satisfaction with care were not addressed by any of the included studies.",rephrase,"[""The incidence of severe maternal infections and illness, antimicrobial resistance or women's satisfaction with care were not addressed.""]",4,0.6666666666666666,4,18
CD012137,3,12,Routine administration of antibiotics may reduce the risk of endometritis after uncomplicated vaginal birth.,merge,[],5,0.7222222222222222,4,18
CD012137,3,13,"The small number and nature of the trials limit the interpretation of the evidence for application in practice, particularly in settings where women may be at higher risk of developing endometritis.",none,['The small number of trials limits the interpretation of the evidence for routine use of antibiotics after normal vaginal births.'],5,0.7777777777777778,4,18
CD012137,3,14,"The use of antibiotics did not reduce the incidence of urinary tract infections, wound infection or the length of maternal hospital stay.",rephrase,"['The use of antibiotics did not reduce the incidence of urinary tract infections (2 trials, 1706 women), wound infections after episiotomy (2 trials, 1364 women) or length of maternal hospital stay (1 trial, 1291 women).']",6,0.8333333333333334,5,18
CD012137,3,15,Antibiotics are not a substitute for infection prevention and control measures around the time of childbirth and the postpartum period.,delete,[],7,0.8888888888888888,5,18
CD012137,3,16,"The decision to routinely administer prophylactic antibiotics after normal vaginal births needs to be balanced by patient features, childbirth setting and provider experience, including considerations of the contribution of indiscriminate use of antibiotics to raising antimicrobial resistance.",rephrase,"[""There needs to be a balance between women's needs, childbirth setting and provider experience (for example, with frequent vaginal examinations or interventions) and the public health threat of antibiotics resistance.""]",7,0.9444444444444444,5,18
CD012137,3,17,Well-designed and high-powered randomised controlled trials would help to evaluate the added value of routine antibiotic administration as a measure to prevent maternal infections after normal vaginal delivery.,rephrase,['Further research from well-designed randomised controlled trials would help to evaluate the added value of routinely giving women antibiotics after normal vaginal birth to prevent maternal infections.'],8,1.0,5,18
CD009438,0,0,We included one RCT with 178 participants and one CBA with 860 participants.,rephrase,['We also found one CBA with 860 participants.'],0,0.0625,1,16
CD009438,0,1,"The RCT allocated university students, with a mean age of 18 years, who had not yet acquired a driving licence, to one of four interventions that provided educational information about negative aspects of car use, or to a fifth group in which no information was given.",rephrase,"['This study gave 178 university students (average age 18 years) who did not hold a driving licence, different types of information to educate them about the negative aspects of car use.']",1,0.125,1,16
CD009438,0,2,"Types of educational information about car use related to cost, risk, or stress, or all three types of educational information combined.",rephrase,"['Students received information about cost, risk, or stress related to car use, or a combination of all three, while a fifth group of students received no information.']",2,0.1875,1,16
CD009438,1,3,"In the CBA, 860 school students, aged 17 to 18 years taking a driving theory course, had an additional interactive lesson about active transport (walking or cycling), and some were invited to join a relevant Facebook group with posts targeting awareness and habit.",split,"['In this study, 17- to 18-year-old school students taking a driving theory course received an additional lesson about active transport, such as walking or cycling.', 'Some were also invited to join a relevant Facebook group.']",3,0.25,2,16
CD009438,2,4,We did not conduct meta-analyses because we had insufficient studies.,delete,[],5,0.3125,2,16
CD009438,3,5,"We could not be certain whether educational interventions versus no information affected people's decision to obtain a driving licence 18 months after receiving the intervention (risk ratio 0.62, 95% confidence interval 0.45 to 0.85; very low-certainty evidence).",delete,[],5,0.375,2,16
CD009438,3,6,"We noted that fewer participants who were given information obtained a driving licence (42.6%) compared to those who did not receive information (69%), but we had very little confidence in the effect estimate; the study had high or unclear risks of bias and the evidence was from one small study and was therefore imprecise.",rephrase,['The RCT reported that fewer students obtained a driving licence 18 months after they were given negative car-related information than students given no information.'],5,0.4375,3,16
CD009438,4,7,"We could not be certain whether interventions about active transport, given during a driving theory course, could influence behavioural predictors of car use.",rephrase,"['Similarly, we could not be certain whether these programmes would be effective in real-world settings.']",6,0.5,3,16
CD009438,4,8,"Study authors noted:
- an increased intention to use active transport after obtaining a driving licence between postintervention and an eight-week follow-up in students who were given an active transport lesson and a Facebook invitation compared to those given only the active transport lesson; and
- a decrease in intention between pre- and postintervention in those given an active transport lesson and Facebook invitation compared to those given the active transport lesson only.",rephrase,"['The CBA reported a decreased intention to use active transport immediately after the lesson in students invited to the Facebook group only, but eight weeks later this was the only group where intention to use active transport had increased.']",7,0.5625,3,16
CD009438,5,9,"There were high risks of bias in this CBA study design, a large amount of missing data (very few participants accepted the Facebook invitation), and data came from a single study only, so we judged the evidence to be of very low certainty.",rephrase,"['CBA study designs have higher risks of bias because participants are not randomised to groups, and, in this CBA, the characteristics of students varied between groups.']",8,0.625,4,16
CD009438,6,10,"These studies did not measure our primary outcome (driving frequency), or other secondary outcomes (driving distance, driving hours, use of alternative modes of transport, or car crashes).",rephrase,"['The studies did not report frequency of driving, driving distance, driving hours, use of alternative modes of transport, or car crashes.']",9,0.6875,4,16
CD009438,7,11,"We found only two small studies, and could not determine whether mobility management interventions were effective to prevent, reduce, or delay car driving in teenagers.",rephrase,"['We found only two small studies investigating different types of mobility management, so could not compare their findings with other similar experiments to see if they produced the same results.']",10,0.75,4,16
CD009438,7,12,The lack of evidence in this review raises two points.,delete,[],11,0.8125,5,16
CD009438,7,13,"First, more foundational research is needed to discover how and why young people make decisions surrounding their personal transport, in order to find out what might encourage them to delay licensing and driving.",delete,[],11,0.875,5,16
CD009438,7,14,"Second, we need longitudinal studies with a robust study design – such as RCTs – and with large sample sizes that incorporate different socioeconomic groups in order to evaluate the feasibility and effectiveness of relevant interventions.",delete,[],11,0.9375,5,16
CD009438,7,15,"Ideally, evaluations will include an assessment of how attitudes and beliefs evolve in teenagers during these transition years, and the potential effect of these on the design of a mobility management intervention for this age group.",delete,[],11,1.0,5,16
CD007892,0,0,"We included 21 trials, reporting results for 7038 women evaluating the effects of vaginal cleansing (17 using povidone-iodine, 3 chlorhexidine, 1 benzalkonium chloride) on post-cesarean infectious morbidity.",split,"['In this update, we have included 21 randomized controlled studies, involving a total of 7038 women undergoing cesarean section.', 'We did not include trials that did not give antibiotics before or during the surgery, or where women received vaginal preparation during labor.', 'Seventeen studies used povidone-iodine for vaginal cleansing, three chlorhexidine, and one benzalkonium chloride.']",0,0.045454545454545456,1,22
CD007892,0,1,"Trials used vaginal preparations administered by sponge sticks, douches, or soaked gauze wipes.",delete,[],3,0.09090909090909091,1,22
CD007892,0,2,The control groups were typically no vaginal preparation (17 trials) or the use of a saline vaginal preparation (4 trials).,rephrase,['The control group had no vaginal preparation in 18 studies and in three studies participants used a saline vaginal preparation.'],3,0.13636363636363635,1,22
CD007892,0,3,One trial did not report on any outcomes of interest.,delete,[],4,0.18181818181818182,1,22
CD007892,0,4,"Trials were performed in 10 different countries (Saudi Arabia, Pakistan, Iran, Thailand, Turkey, USA, Egypt, UK, Kenya and India).",rephrase,"['The studies took place in 10 countries (Saudi Arabia, Pakistan, Iran, Thailand, Turkey, USA, Egypt, UK, Kenya and India).']",4,0.22727272727272727,2,22
CD007892,0,5,"The overall risk of bias was low for areas of attrition, reporting, and other bias.",delete,[],5,0.2727272727272727,2,22
CD007892,0,6,"About half of the trials had low risk of selection bias, with most of the remainder rated as unclear.",delete,[],5,0.3181818181818182,2,22
CD007892,0,7,"Due to lack of blinding, we rated performance bias as high risk in nearly one-third of the trials, low risk in one-third, and unclear in one-third.",delete,[],5,0.36363636363636365,2,22
CD007892,1,8,"Vaginal preparation with antiseptic solution immediately before cesarean delivery probably reduces the incidence of post-cesarean endometritis from 7.1% in control groups to 3.1% in vaginal cleansing groups (average risk ratio (aRR) 0.41, 95% confidence interval (CI) 0.29 to 0.58; 20 trials, 6918 women; moderate-certainty evidence).",rephrase,"['(20 trials, 6918 women; moderate-certainty evidence).']",5,0.4090909090909091,3,22
CD007892,1,9,This reduction in endometritis was seen for both iodine-based solutions and chlorhexidine-based solutions.,rephrase,['This reduction was seen for both iodine-based solutions and chlorhexidine-based solutions.'],6,0.45454545454545453,3,22
CD007892,1,10,"Risks of postoperative fever and postoperative wound infection are also probably reduced by vaginal antiseptic preparation (fever: aRR 0.64, 0.50 to 0.82; 16 trials, 6163 women; and wound infection: RR 0.62, 95% CI 0.50 to 0.77; 18 trials, 6385 women; both moderate-certainty evidence).",rephrase,"['The risk of postoperative fever (16 trials, 6163 women) and postoperative wound infection (18 trials, 6385 women) are also probably reduced by vaginal cleansing; both moderate-certainty evidence).']",7,0.5,3,22
CD007892,1,11,"Two trials found that there may be a lower risk of a composite outcome of wound complication or endometritis in women receiving preoperative vaginal preparation (RR 0.46, 95% CI 0.26 to 0.82; 2 trials, 499 women; low-certainty evidence).",rephrase,"['The risk of having wound complication or infection of the uterus may be lower in women receiving preoperative vaginal cleansing with antiseptic solution (2 trials, 499 women).']",8,0.5454545454545454,3,22
CD007892,1,12,No adverse effects were reported with either the povidone-iodine or chlorhexidine vaginal cleansing.,rephrase,"['None of the studies reported any adverse events, such as an allergic reaction to the cleansing solution or irritation.']",9,0.5909090909090909,3,22
CD007892,2,13,Subgroup analysis suggested a greater effect with vaginal preparations for those women in labour versus those not in labour for four out of five outcomes examined (post-cesarean endometritis; postoperative fever; postoperative wound infection; composite wound complication or endometritis).,merge,['Further analysis suggested a greater effect for those women in labour versus those not in labour for four out of five outcomes examined (post-cesarean infection of the uterus; postoperative fever; postoperative wound infection; wound complication or infection of the uterus) but this apparent difference needs to be investigated further in future trials.'],10,0.6363636363636364,4,22
CD007892,2,14,This apparent difference needs to be investigated further in future trials.,none,[],10,0.6818181818181818,4,22
CD007892,2,15,We did not observe any subgroup differences between women with ruptured membranes and women with intact membranes.,rephrase,['We did not observe any differences between groups of women with ruptured membranes and women with intact membranes.'],11,0.7272727272727273,4,22
CD007892,3,16,"Vaginal preparation with povidone-iodine or chlorhexidine solution compared to saline or not cleansing immediately before cesarean delivery probably reduces the risk of post-cesarean endometritis, postoperative fever, and postoperative wound infection.",rephrase,"['Cleansing the vagina with povidone-iodine or chlorhexidine solution (compared to saline or not cleansing) immediately before cesarean delivery probably reduces the risk of infection of the uterus, fever, and infection of the surgical wound.']",12,0.7727272727272727,4,22
CD007892,3,17,Subgroup analysis found that these benefits were typically present whether iodine-based or chlorhexidine-based solutions were used and when women were in labor before the cesarean.,ignore,['Further analysis found that these benefits were typically present whether iodine-based or chlorhexidine-based solutions were used and when women were in labor before the cesarean.'],13,0.8181818181818182,5,22
CD007892,3,18,The suggested benefit in women in labor needs further investigation in future trials.,delete,[],14,0.8636363636363636,5,22
CD007892,4,19,"There was moderate-certainty evidence using GRADE for all reported outcomes, with downgrading decisions based on limitations in study design or imprecision.",delete,[],14,0.9090909090909091,5,22
CD007892,5,20,"As a simple intervention, providers may consider implementing preoperative vaginal cleansing with povidone-iodine or chlorhexidine before performing cesarean deliveries.",delete,[],14,0.9545454545454546,5,22
CD007892,5,21,Future research on this intervention being incorporated into bundles of care plans for women receiving cesarean delivery will be needed.,delete,[],14,1.0,5,22
CD012197,0,0,We included 21 studies involving a total of 6384 participants in the quantitative analyses.,rephrase,['We found 21 RCTs involving more than 6300 people with Alzheimer’s disease.'],0,0.05555555555555555,1,18
CD012197,0,1,Risk of bias is very low to moderate.,delete,[],1,0.1111111111111111,1,18
CD012197,0,2,All studies reported appropriate methods of randomization and blinding.,delete,[],1,0.16666666666666666,1,18
CD012197,0,3,Most studies reported appropriate methods of allocation concealment.,delete,[],1,0.2222222222222222,2,18
CD012197,0,4,"Four studies, three with methylphenidate and one with modafinil, had a primary aim of improving apathy.",rephrase,"['Four trials of two different medicines (methylphenidate and modafinil) had been done specifically to study apathy, so all the people taking part were known to be significantly apathetic before the trial started.']",1,0.2777777777777778,2,18
CD012197,0,5,"In these studies, all participants had clinically significant apathy at baseline.",delete,[],2,0.3333333333333333,2,18
CD012197,0,6,Methylphenidate may improve apathy compared to placebo.,rephrase,"['From the three trials with methylphenidate, we found that it may improve apathy, although this depended on how the apathy was measured.']",2,0.3888888888888889,2,18
CD012197,0,7,"This finding was present when apathy was assessed using the apathy evaluation scale (AES), which was used by all three studies investigating methylphenidate: MD -4.99, 95% CI -9.55 to -0.43, n = 145, 3 studies, low quality of evidence, but not when assessed with the neuropsychiatric inventory (NPI)-apathy subscale, which was used by two of the three studies investigating methylphenidate: MD -0.08, 95% CI -3.85 to 3.69, n = 85, 2 studies, low quality of evidence.",delete,[],3,0.4444444444444444,3,18
CD012197,0,8,"As well as having potential benefits for apathy, methylphenidate probably also slightly improves cognition (MD 1.98, 95% CI 1.06 to 2.91, n = 145, 3 studies, moderate quality of evidence), and probably improves instrumental activities of daily living (MD 2.30, 95% CI 0.74 to 3.86, P = 0.004, n = 60, 1 study, moderate quality of evidence), compared to placebo.",rephrase,"['The people taking methylphenidate also did slightly better than those taking placebo on scales measuring cognition (thinking, remembering, etc.)']",3,0.5,3,18
CD012197,0,9,"There may be no difference between methylphenidate and placebo in the risk of developing an adverse event: RR 1.28, 95% CI 0.67 to 2.42, n = 145, 3 studies, low quality of evidence.",delete,[],4,0.5555555555555556,3,18
CD012197,0,10,"There was insufficient evidence from one very small study of modafinil to determine the effect of modafinil on apathy assessed with the FrSBe-apathy subscale: MD 0.27, 95% CI -3.51 to 4.05, n = 22, 1 study, low quality of evidence.",rephrase,['There was only one very small trial with modafinil and there was no evidence that it was effective for apathy.'],4,0.6111111111111112,4,18
CD012197,0,11,"In all other included studies, apathy was a secondary outcome and participants were not selected on the basis of clinically significant apathy at baseline.",delete,[],5,0.6666666666666666,4,18
CD012197,0,12,We considered the evidence on apathy from these studies to be indirect and associated with publication bias.,split,"['We therefore thought they were only indirectly relevant to our review question.', 'It is also highly likely that other trials of the same drugs have measured apathy but have not published the results, so we were concerned about possible publication bias (that the studies we found could have been a biased subset).']",5,0.7222222222222222,4,18
CD012197,0,13,"There was low or very low quality of evidence on cholinesterase inhibitors (ChEIs) (six studies), ChEI discontinuation (one study), antipsychotics (two studies), antipsychotic discontinuation (one study), antidepressants (two studies), mibampator (one study), valproate (three studies) and semagacestat (one study).",split,"['The quality of this evidence was low or moderate, so we cannot be certain that other similar studies would not have different results.', 'We therefore thought the quality of evidence for all these other medicines was low or very low, meaning that we can have limited or little confidence in the results.']",7,0.7777777777777778,4,18
CD012197,1,14,"Methylphenidate may demonstrate a benefit for apathy and may have slight benefits for cognition and functional performance in people with AD, but this finding is associated with low-quality evidence.",rephrase,"[""Current evidence suggests that methylphenidate may be useful for treating apathy in Alzheimer's disease.""]",9,0.8333333333333334,5,18
CD012197,1,15,"Our meta-analysis is limited by the small number of studies within each drug class, risk of bias, publication bias, imprecision and inconsistency between studies.",delete,[],10,0.8888888888888888,5,18
CD012197,1,16,"Additional studies should be encouraged targeting people with AD with clinically significant apathy which investigate apathy as a primary outcome measure, and which have a longer duration and a larger sample size.",rephrase,"['However, more trials should be done specifically targeting apathy in order to improve the overall quality of the evidence.']",10,0.9444444444444444,5,18
CD012197,1,17,"This could increase the quality of evidence for methylphenidate, and may confirm whether or not it is an effective pharmacotherapy for apathy in AD.",delete,[],11,1.0,5,18
CD011640,0,0,We identified 77 trials including 6287 participants that met the inclusion criteria of this review.,rephrase,['We included 77 randomised clinical trials that involved a total of 6287 participants.'],0,0.041666666666666664,1,24
CD011640,0,1,Forty-one trials (3829 participants) provided information for one or more outcomes.,rephrase,"['Of these, 41 trials (3829 participants) provided information for one or more outcomes for this review.']",1,0.08333333333333333,1,24
CD011640,0,2,Only one trial was at low risk of bias in all domains.,delete,[],2,0.125,1,24
CD011640,0,3,All other trials were at high risk of bias in one or more domains.,merge,[],2,0.16666666666666666,1,24
CD011640,0,4,"Overall, all the evidence was very low quality.",none,"['Evidence quality was very low overall, and there was a high risk of bias.']",2,0.20833333333333334,2,24
CD011640,0,5,Thirty-five trials included only participants with non-alcohol related steatohepatitis (NASH) (based on biopsy confirmation).,delete,[],3,0.25,2,24
CD011640,0,6,Five trials included only participants with diabetes mellitus; 14 trials included only participants without diabetes mellitus.,rephrase,['Thirty-five trials only included participants with NASH; five included only people with diabetes mellitus; and 14 included only people who did not have diabetes mellitus.'],3,0.2916666666666667,2,24
CD011640,0,7,The follow-up in the trials ranged from one month to 24 months.,rephrase,['The average follow-up period in the trials ranged from one month to two years in the trials that reported this information.'],4,0.3333333333333333,2,24
CD011640,1,8,"We present here only the comparisons of active intervention versus no intervention in which two or more trials reported at least one of the following outcomes: mortality at maximal follow-up, serious adverse events, and health-related quality of life, the outcomes that determine whether a treatment should be used.",delete,[],5,0.375,2,24
CD011640,2,9,"Antioxidants versus no intervention
There was no mortality in either group (87 participants; 1 trial; very low quality evidence).",rephrase,"['There were no deaths in either group (87 participants, 1 trial).']",5,0.4166666666666667,3,24
CD011640,2,10,None of the participants developed serious adverse events in the trial which reported the proportion of people with serious adverse events (87 participants; 1 trial; very low quality evidence).,rephrase,"['None of the participants developed serious adverse events in the trial which reported the percentage of people with serious adverse events (87 participants, 1 trial).']",6,0.4583333333333333,3,24
CD011640,2,11,"There was no evidence of difference in the number of serious adverse events between antioxidants and no intervention (rate ratio 0.89, 95% CI 0.36 to 2.19; 254 participants; 2 trials; very low quality evidence).",rephrase,"['There was no evidence of difference in the number of serious adverse events between antioxidants and no intervention (254 participants, 2 trials).']",7,0.5,3,24
CD011640,2,12,None of the trials reported health-related quality of life.,delete,[],8,0.5416666666666666,3,24
CD011640,3,13,"Bile acids versus no intervention
There was no evidence of difference in mortality at maximal follow-up (OR 5.11, 95% CI 0.24 to 107.34; 659 participants; 4 trials; very low quality evidence), proportion of people with serious adverse events (OR 1.56, 95% CI 0.84 to 2.88; 404 participants; 3 trials; very low quality evidence), or the number of serious adverse events (rate ratio 1.01, 95% CI 0.66 to 1.54; 404 participants; 3 trials; very low quality evidence) between bile acids and no intervention.",rephrase,"['There was no evidence of difference in deaths at maximal follow-up (659 participants, 4 trials), percentage of people with serious adverse events (404 participants, 3 trials), or the number of serious adverse events (404 participants, 3 trials) between bile acids and no intervention.']",8,0.5833333333333334,3,24
CD011640,3,14,None of the trials reported health-related quality of life.,ignore,['None of the trials reported health-related quality of life.'],9,0.625,4,24
CD011640,4,15,"Thiazolidinediones versus no intervention
There was no mortality in either group (74 participants; 1 trial; very low quality evidence).",rephrase,"['There were no deaths in either group (74 participants, 1 trial).']",10,0.6666666666666666,4,24
CD011640,4,16,None of the participants developed serious adverse events in the two trials which reported the proportion of people with serious adverse events (194 participants; 2 trials; very low quality evidence).,rephrase,"['None of the participants developed serious adverse events in the two trials which reported the percentage of people with serious adverse events (194 participants, 2 trials).']",11,0.7083333333333334,4,24
CD011640,4,17,"There was no evidence of difference in the number of serious adverse events between thiazolidinediones and no intervention (rate ratio 0.25, 95% CI 0.06 to 1.05; 357 participants; 3 trials; very low quality evidence).",rephrase,"['There was no evidence of difference in the number of serious adverse events between thiazolidinediones and no intervention (357 participants, 3 trials).']",12,0.75,4,24
CD011640,4,18,None of the trials reported health-related quality of life.,ignore,['None of the trials reported health-related quality of life.'],13,0.7916666666666666,4,24
CD011640,5,19,"Source of funding
Twenty-six trials were partially- or fully-funded by pharmaceutical companies that would benefit, based on the results of the trial.",delete,[],14,0.8333333333333334,5,24
CD011640,5,20,Twelve trials did not receive any additional funding or were funded by parties with no vested interest in the results.,merge,['Twelve trials did not receive any additional funding or were funded by sources with no vested interest in the results; 26 were funded by drug companies that could potentially benefit from trial results; and the funding source was not available from 39 trials.'],14,0.875,5,24
CD011640,5,21,The source of funding was not provided in 39 trials.,none,[],14,0.9166666666666666,5,24
CD011640,6,22,"Due to the very low quality evidence, we are very uncertain about the effectiveness of pharmacological treatments for people with NAFLD including those with steatohepatitis.",delete,[],15,0.9583333333333334,5,24
CD011640,6,23,Further well-designed randomised clinical trials with sufficiently large sample sizes are necessary.,delete,[],15,1.0,5,24
CD012514,0,0,Two randomised trials assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy in a total of 118 adults with a mean age of 62.8 years.,split,"['In October 2017, we identified two relevant studies comparing oral plus inhaled dual therapy versus oral therapy alone.', 'They included a total of 118 adults with an average age of 62.8 years.']",0,0.07692307692307693,1,13
CD012514,0,1,"One multi-centre trial compared inhaled tobramycin plus oral ciprofloxacin versus ciprofloxacin alone, and one single-centre trial compared nebulised gentamicin plus systemic antibiotics versus a systemic antibiotic alone.",rephrase,"['One study compared inhaled tobramycin plus oral ciprofloxacin with oral ciprofloxacin, and the second study compared inhaled gentamicin plus a systemic (affecting the whole body, rather than just the lungs) antibiotic with a systemic antibiotic alone.']",2,0.15384615384615385,1,13
CD012514,0,2,Published papers did not report study funding sources.,ignore,['Published papers did not report study funding sources'],3,0.23076923076923078,2,13
CD012514,1,3,"Effect estimates from one small study with 53 adults showed no evidence of treatment benefit with oral plus inhaled dual therapy for the following primary outcomes at the end of the study: successful management of exacerbation - cure at day 42 (odds ratio (OR) 0.66, 95% confidence interval (CI) 0.22 to 2.01; 53 participants; one study; very low-quality evidence); number of participants with Pseudomonas aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24; 53 participants; one study; very low-quality evidence); and serious adverse events (OR 0.48, 95% CI 0.08 to 2.87; 53 participants; one study; very low-quality evidence).",rephrase,"['Results from one small trial of 53 adults show no evidence of treatment benefit with oral plus inhaled dual therapy in terms of successful treatment of exacerbations, the occurrence of serious unwanted events, amount of phlegm, lung function, or resistance to antibiotic treatment.']",4,0.3076923076923077,2,13
CD012514,1,4,"Similarly, researchers provided no evidence of treatment benefit for the following secondary outcomes: clinical response rates - relapse at day 42 (OR 0.57, 95% CI 0.12 to 2.69; 53 participants; one study; very low-quality evidence); microbiological response rate at day 21 - eradicated (OR 2.40, 95% CI 0.67 to 8.65; 53 participants; one study; very low-quality evidence); and adverse events - incidence of wheeze (OR 5.75, 95% CI 1.55 to 21.33).",delete,[],5,0.38461538461538464,2,13
CD012514,1,5,"Data show no evidence of benefit in terms of sputum volume, lung function, or antibiotic resistance.",delete,[],5,0.46153846153846156,3,13
CD012514,1,6,"Outcomes from a second small study with 65 adults, available only as an abstract, were not included in the quantitative data synthesis.",delete,[],5,0.5384615384615384,3,13
CD012514,1,7,The included studies did not report our other primary outcomes: duration; frequency; and time to next exacerbation; nor our secondary outcomes: systemic markers of infection; exercise capacity; and quality of life.,rephrase,"['Information on exacerbations, exercise ability, and quality of life was not reported.']",5,0.6153846153846154,4,13
CD012514,1,8,We did not identify any trials that included children.,rephrase,"['We did not identify any trials that compared other types of dual antibiotic therapy, and we found none that included children.']",6,0.6923076923076923,4,13
CD012514,2,9,"A small number of studies in adults have generated high-quality evidence that is insufficient to inform robust conclusions, and studies in children have provided no evidence.",delete,[],7,0.7692307692307693,4,13
CD012514,2,10,We identified only one dual-therapy combination of oral and inhaled antibiotics.,delete,[],7,0.8461538461538461,5,13
CD012514,2,11,"Results from this single trial of 53 adults that we were able to include in the quantitative synthesis showed no evidence of treatment benefit with oral plus inhaled dual therapy in terms of successful treatment of exacerbations, serious adverse events, sputum volume, lung function, and antibiotic resistance.",delete,[],7,0.9230769230769231,5,13
CD012514,2,12,"Further high-quality research is required to determine the efficacy and safety of other combinations of dual antibiotics for both adults and children with bronchiectasis, particularly in terms of antibiotic resistance.",rephrase,"['Therefore uncertainty remains concerning the use of dual antibiotics, and further high-quality studies are needed to examine the role of dual antibiotics in the treatment of adults and children with bronchiectasis.']",7,1.0,5,13
CD008825,0,0,Our search strategy identified six reports for potential inclusion.,delete,[],0,0.07692307692307693,1,13
CD008825,0,1,"Of those, we included one trial (four reports) involving 158 women, which was at low risk of bias.",rephrase,['We included one randomised controlled trial involving 158 women who were from 19 to 27 weeks pregnant with a baby with severe spina bifida and evidence of hindbrain herniation.'],0,0.15384615384615385,1,13
CD008825,1,2,The one included trial examined the effect of prenatal repair versus postnatal repair.,rephrase,['This review aimed to compare the effects of in utero repair versus repair as a newborn.'],1,0.23076923076923078,2,13
CD008825,1,3,"For the primary infant outcome of neonatal mortality, there was no clear evidence of a difference identified for prenatal versus postnatal repair (one study, 158 infants, risk ratio (RR) 0.51, 95% confidence interval (CI) 0.05 to 5.54), however event rates were uncommon and so the analysis is likely to be underpowered to detect differences.",split,"['For neonatal mortality, there was no clear difference identified for prenatal versus postnatal repair.', 'However, the numbers of neonates who died were low and so the review was likely underpowered to detect any difference.']",2,0.3076923076923077,2,13
CD008825,2,4,"Prenatal repair was associated with an earlier gestational age at birth (one study, 158 infants, mean difference (MD) -3.20 weeks, 95% CI -3.93 to -2.47) and a corresponding increase in both the risk of preterm birth before 37 weeks (one study, 158 infants, RR 5.30, 95% CI 3.11 to 9.04) and preterm birth before 34 weeks (one study, 158 infants, RR 9.23, 95% CI 3.45 to 24.71).",merge,[],4,0.38461538461538464,2,13
CD008825,2,5,Prenatal repair was associated with a reduction in shunt dependent hydrocephalus and moderate to severe hindbrain herniation.,none,['Prenatal repair was associated with reduced need for shunt placement and a reduction in the risk of moderate to severe hindbrain herniation after birth.'],4,0.46153846153846156,3,13
CD008825,2,6,"For women, prenatal repair was associated with increased preterm ruptured membranes (one study, 158 women, RR 6.15, 95% CI 2.75 to 13.78), although there was no clear evidence of difference in the risk of chorioamnionitis or blood transfusion, although again, event rates were uncommon.",rephrase,['Prenatal repair was associated with an increased risk of the women experiencing preterm ruptured membranes and subsequent preterm birth (both before 34 and 37 weeks).'],5,0.5384615384615384,3,13
CD008825,3,7,A number of this review's secondary infant and maternal outcomes were not reported.,delete,[],6,0.6153846153846154,4,13
CD008825,3,8,For the infant: days of hospital admission; survival to discharge; stillbirth; need for further surgery (e.g. skin grafting); neurogenic bladder dysfunction; childhood/infant quality of life.,delete,[],6,0.6923076923076923,4,13
CD008825,3,9,For the mother: admission to intensive care; women's emotional wellbeing and satisfaction with care.,delete,[],6,0.7692307692307693,4,13
CD008825,4,10,This review is based one small well-conducted study.,delete,[],6,0.8461538461538461,5,13
CD008825,4,11,There is insufficient evidence to recommend drawing firm conclusions on the benefits or harms of prenatal repair as an intervention for fetuses with spina bifida.,rephrase,['There is currently insufficient evidence to recommend in utero repair for unborn babies with spina bifida.'],6,0.9230769230769231,5,13
CD008825,4,12,Current evidence is limited by the small number of pregnancies that have been included in the single conducted randomised trial to date.,rephrase,['The included trial was of high quality (low risk of bias) but included a small number of pregnancies.'],7,1.0,5,13
CD010284,0,0,"We only found studies (47 studies, 3581 participants) for 18 of the 29 eligible TCHMs as defined by our inclusion criteria.",rephrase,['We included 47 trials with 3581 participants of 18 TCHMs in this review.'],0,0.09090909090909091,1,11
CD010284,0,1,"All were superiority trials conducted in China between 1997 and 2013, with most employing a two-arm parallel design with sample sizes ranging from 26 to 240 and a median treatment duration of 12 weeks (range: 2 to 24 weeks).",rephrase,['All were conducted in mainland China between 1997 and 2013 with participant numbers ranging from 26 to 240 and an average study duration of 12 weeks.'],1,0.18181818181818182,1,11
CD010284,1,2,"We found that reporting and trial methodology were generally poor; in particular, there was a lack of information on randomisation, an absence of blinding of participants and outcome assessors and incomplete reporting of adverse events (AEs).",delete,[],2,0.2727272727272727,2,11
CD010284,1,3,None of the 30 trials published from 2007 onwards adopted the CONSORT recommendations for reporting RCTs of herbal interventions.,delete,[],2,0.36363636363636365,2,11
CD010284,2,4,We found seven TCHMs which each had potentially large benefits in studies estimating the TCHM versus 'no treatment' effect and in studies estimating the TCHM versus the WM effect.,rephrase,"['Despite these reservations, we found seven TCHMs which each had potentially large benefits in studies comparing TCHMs to no treatment or Western Medicine.']",2,0.45454545454545453,3,11
CD010284,2,5,Two TCHMs (NaoXinTong and TongXinLuo) were common to both groups.,delete,[],3,0.5454545454545454,3,11
CD010284,2,6,"Three of these TCHMs – Nao XinTong, NaoMaiTai and TongXinLuo – had the strongest evidence to justify further research.",ignore,"['Three of these – Nao XinTong, NaoMaiTai and TongXinLuo – had the strongest evidence to justify further research.']",3,0.6363636363636364,4,11
CD010284,2,7,"Two TCHMs (NaoMaiTai and TongXinLuo) had a 5% or more increased risk of AEs compared to the 'no Treatment' control, but the quality of this evidence was poor.",rephrase,"['We found that the risk of harmful effects was at least 5% higher than the risk for participants in the control group for NaoMaiTai and TongXinLuo, but the quality of this evidence was poor.']",4,0.7272727272727273,4,11
CD010284,3,8,We found moderate- to very low-quality evidence of benefit and harm of TCHMs for VaD.,rephrase,"['For these and other reasons, we rated the overall quality of the evidence as variable, ranging from moderate to very low.']",5,0.8181818181818182,5,11
CD010284,3,9,Methodological inadequacies need to be addressed by better conducted and reported trials.,delete,[],6,0.9090909090909091,5,11
CD010284,3,10,"We identified NaoMaiTai, NaoXinTong and TongXinLuo as warranting special research priority.",delete,[],6,1.0,5,11
CD014676,0,0,Four RCTs were eligible.,delete,[],0,0.125,1,8
CD014676,0,1,The current meta-analysis included two trials with 651 participants comparing thrombo-aspiration with stent-retrieval thrombectomy.,split,"['We combined data from two randomized controlled trials (a type of study where participants are randomly assigned to one of two or more treatment groups) with a total of 651 participants who had AIS due to large vessel occlusion confirmed by imaging, such as computed tomographic angiography (CTA) and digital subtraction angiography (DSA).', 'These trials took place in multiple centers and compared thrombo-aspiration with stent-retrieval thrombectomy.']",0,0.25,2,8
CD014676,0,2,We judged the quality of evidence to be high in both trials according to Cochrane's risk of bias tool RoB 2.,rephrase,"['The quality of evidence in the review was high, although the doctors and participants knew which treatment was being given, which could have led to bias.']",2,0.375,2,8
CD014676,1,3,"There were no significant differences between thrombo-aspiration and stent-retrieval thrombectomy in rate of mRS of 0 to 2 at three months (risk ratio [RR] 0.97, 95% confidence interval [CI] 0.82 to 1.13; P = 0.68; 633 participants; 2 RCTs); rate of mTICI of 2b to 3 postprocedure (RR 1.01, 95% CI 0.95 to 1.07; P = 0.77; 650 participants; 2 RCTs); all-cause mortality within three months (RR 1.01, 95% CI 0.74 to 1.37; P = 0.95; 633 participants; 2 RCTs); rate of intracranial hemorrhage on imaging at 24 hours (RR 1.03, 95% CI 0.86 to 1.24; P = 0.73; 645 participants; 2 RCTs); rate of symptomatic intracranial hemorrhage at 24 hours (RR 0.90, 95% CI 0.49 to 1.68; P = 0.75; 645 participants; 2 RCTs); and rate of procedure-related adverse events within three months (RR 0.98, 95% CI 0.68 to 1.41; P = 0.90; 651 participants; 2 RCTs).",delete,[],3,0.5,3,8
CD014676,2,4,Another two included studies reported no differences for the comparisons of combined therapy versus stent-retrieval thrombectomy or thrombo-aspiration.,rephrase,['Another two studies compared the combined technique with thrombo-aspiration and stent-retriever thrombectomy alone.'],3,0.625,4,8
CD014676,2,5,One RCT is ongoing.,delete,[],4,0.75,4,8
CD014676,3,6,This review did not establish any difference in safety and effectiveness between the thrombo-aspiration approach and stent-retrieval thrombectomy for treating people with AIS.,rephrase,['There was no clear difference in safety and effectiveness of the two approaches (thrombo-aspiration and stent-retrieval thrombectomy) in the management of AIS patients.'],4,0.875,5,8
CD014676,3,7,"Furthermore, the combined group did not show any obvious advantage over either intervention applied alone.",delete,[],5,1.0,5,8
CD008092,0,0,"Fifteen RCTs were included, giving a total of 473 participants with ELP (study sizes ranged between 8-94).",rephrase,"['This review looked at the effectiveness of treatments for ELP and included 15 studies, with 473 participants with ELP.']",0,0.05263157894736842,1,19
CD008092,0,1,All studies involved oral sites only.,rephrase,"['All involved oral, but not genital, disease.']",1,0.10526315789473684,1,19
CD008092,0,2,Six studies included participants with non-erosive lichen planus but only the erosive subgroup was included for intended subgroup analysis.,delete,[],2,0.15789473684210525,1,19
CD008092,0,3,"We were unable to pool data from any of the nine studies with only ELP participants or any of the six studies with the ELP subgroup, due to small numbers and the heterogeneity of the interventions, design methods, and outcome variables between studies.",delete,[],2,0.21052631578947367,2,19
CD008092,1,4,"One study involving 50 participants found that 0.025% clobetasol propionate administered as liquid microspheres significantly reduced pain compared to ointment (Mean difference (MD) -18.30, 95% confidence interval (CI) -28.57 to -8.03), but outcome data was only available in 45 participants (high risk of performance bias for blinding of participants, low/unclear risk of bias overall).",rephrase,['One small study found that 0.025% clobetasol propionate (a very potent topical steroid) administered as a spray significantly reduced pain when compared to ointment.'],2,0.2631578947368421,2,19
CD008092,1,5,"However, in another study, a significant difference in pain was seen in the small subgroup of 11 ELP participants, favouring ciclosporin solution over 0.1% triamcinolone acetonide in orabase (MD -1.40, 95% CI -1.86 to -0.94) (high risk of performance and detection bias due to likely lack of blinding, low/unclear risk of bias overall).",rephrase,"['In another study, a significant difference in pain was seen in the small subgroup of 11 ELP participants, favouring ciclosporin solution over 0.1% triamcinolone acetonide in orabase (a potent topical steroid).']",3,0.3157894736842105,2,19
CD008092,1,6,"Aloe vera gel was 6 times more likely to result in at least a 50% improvement in pain symptoms compared to placebo in a study involving 45 ELP participants (Risk ratio (RR) 6.16, 95% CI 2.35 to 16.13) (low risk of bias overall).",rephrase,"['In a study involving 45 ELP participants, aloe vera gel was 6 times more likely to result in at least a 50% improvement in pain symptoms compared to placebo.']",4,0.3684210526315789,2,19
CD008092,1,7,No significant difference was seen in Physician Global Assessment in these three studies.,delete,[],5,0.42105263157894735,3,19
CD008092,2,8,"In a small single study involving 20 ELP participants, 1% pimecrolimus cream was 7 times more likely to result in a strong improvement as rated by the Physician Global Assessment when compared to vehicle cream (RR 7.00, 95% CI 1.04 to 46.95) (low risk of bias overall).",delete,[],5,0.47368421052631576,3,19
CD008092,2,9,"In a study involving a small subgroup of 8 ELP participants, a significant difference was seen for an improvement in the severity of the disease as rated by the Physician Global Assessment, in favour of the ciclosporin group when compared to the vehicle (MD -1.40, 95% CI -1.86 to -0.94) (unclear risk of selection bias for allocation concealment, overall risk of bias low).",rephrase,"['In a study involving a small subgroup of 8 ELP participants, a significant difference was seen for an improvement in the severity of the disease in favour of the ciclosporin group when compared to the vehicle.']",5,0.5263157894736842,3,19
CD008092,3,10,No statistically significant benefits were shown for topical tacrolimus or fluticasone spray in two separate studies of 29 and 44 participants respectively.,delete,[],6,0.5789473684210527,3,19
CD008092,4,11,"There is no overwhelming evidence for the efficacy of a single treatment, including topical steroids, which are the widely accepted first-line therapy for ELP.",rephrase,"['Overall, there was no overwhelming evidence for the effectiveness of any single treatment, including topical steroids, which are the widely accepted first-line therapy for ELP.']",6,0.631578947368421,4,19
CD008092,4,12,"Several side-effects were reported, but none were serious.",ignore,"['Several side-effects were reported, but none were serious.']",7,0.6842105263157895,4,19
CD008092,4,13,"With topical corticosteroids, the main side-effects were oral candidiasis and dyspepsia.",rephrase,"['With topical corticosteroids, the main side-effects were oral candida (yeast) infection and pain or discomfort in the upper abdomen.']",8,0.7368421052631579,4,19
CD008092,5,14,"This review suggests that there is only weak evidence for the effectiveness of any of the treatments for oral ELP, whilst no evidence was found for genital ELP.",rephrase,['We found only weak evidence for the effectiveness of any of the treatments for oral ELP.'],9,0.7894736842105263,4,19
CD008092,5,15,More RCTs on a larger scale are needed in the oral and genital ELP populations.,delete,[],10,0.8421052631578947,5,19
CD008092,5,16,We suggest that future studies should have standardised outcome variables that are clinically important to affected individuals.,delete,[],10,0.8947368421052632,5,19
CD008092,5,17,We recommend the measurement of a clinical severity score and a participant-rated symptom score using agreed and validated severity scoring tools.,delete,[],10,0.9473684210526315,5,19
CD008092,5,18,We also recommend the development of a validated combined severity scoring tool for both oral and genital populations.,delete,[],10,1.0,5,19
CD007559,0,0,"We included eight trials (556 participants), evaluating hypnotherapy (one trial), imagery (five trials), autogenic training (one trial) and yoga (one trial).",rephrase,['We included eight randomized controlled studies with 556 women in this review.'],0,0.125,1,8
CD007559,0,1,"Due to the small number of studies per intervention and to the diversity of outcome measurements, we performed no meta-analysis, and have reported results individually for each study.",delete,[],1,0.25,2,8
CD007559,0,2,"Compared with usual care, in one study (133 women), imagery may have a positive effect on anxiety during labor decreasing anxiety at the early and middle stages of labor (MD -1.46; 95% CI -2.43 to -0.49; one study, 133 women) and (MD -1.24; 95% CI -2.18 to -0.30).",rephrase,"['Compared with usual care, imagery may have a positive effect on anxiety during labor.']",1,0.375,2,8
CD007559,0,3,Another study showed that imagery had a positive effect on anxiety and depression in the immediate postpartum period.,ignore,['Another study showed that imagery had a positive effect on anxiety and depression in the immediate postpartum period.'],2,0.5,3,8
CD007559,0,4,Autogenic training might be effective for decreasing women's anxiety before delivering.,ignore,"[""Autogenic training might be effective for decreasing women's anxiety before delivering.""]",3,0.625,4,8
CD007559,1,5,Mind-body interventions might benefit women’s anxiety during pregnancy.,split,"['Their effectiveness for treatment or prevention of women’s anxiety during pregnancy needs to be confirmed in clinical trials, as anxiety during the different stages of pregnancy can affect women’s health and have consequences for the\xa0child.', 'The studies used different mind-body interventions, sometimes as part of a complex intervention,\xa0that they compared with usual care or other potentially active interventions using diverse outcome measures.']",4,0.75,4,8
CD007559,1,6,"Based on individual studies, there is some but no strong evidence for the effectiveness of mind-body interventions for the management of anxiety during pregnancy.",rephrase,"['Based on these studies, there is some not strong evidence for the effectiveness of mind-body interventions in the management of anxiety during pregnancy, labor, or in the first four weeks after giving birth.']",6,0.875,5,8
CD007559,1,7,The main limitations of the studies were the lack of blinding and insufficient details on the methods used for randomization.,delete,[],7,1.0,5,8
CD008130,0,0,We included one trial reporting outcome at follow-up times ranging between two and 47 months for 81 participants with Mason type 1 and 2 radial head fractures.,rephrase,['We included one trial reporting results at times ranging from two to 47 months for 81 people who had had an elbow fracture that involved the head of the radius.'],0,0.125,1,8
CD008130,0,1,This poorly-reported trial was at particular high risk of detection and reporting biases.,delete,[],1,0.25,2,8
CD008130,0,2,The trial found no significant differences between early and delayed mobilisation in the numbers of participants with pain or limitations in their range of elbow motion.,ignore,['The trial found no important differences between early and delayed mobilisation in the numbers of participants with pain or limitations in their range of elbow motion.'],1,0.375,2,8
CD008130,0,3,All participants were reported as being able to use their arms for full activities of daily living and none had changed their occupation or lifestyle.,ignore,['All participants were reported as being able to use their arms for full activities of daily living and none had changed their occupation or lifestyle.'],2,0.5,3,8
CD008130,0,4,There was no mention of fracture complications.,ignore,['There was no mention of fracture complications.'],3,0.625,4,8
CD008130,1,5,"There is a lack of robust evidence to inform on the timing of mobilisation, and specifically on the use of early mobilisation, after non-surgical or surgical treatment for adults with elbow fractures.",rephrase,['We concluded that there was a lack of reliable evidence to answer the question of whether early mobilisation improved function without increasing complications in adults with elbow fractures.'],4,0.75,4,8
CD008130,2,6,"There is a need for high quality, well-reported, adequately powered, randomised controlled trials that compare early versus delayed mobilisation in people with commonly-occurring elbow fractures, treated with or without surgery.",rephrase,['We searched for randomised controlled trials that compared early movement with delayed movement of the elbow after elbow fracture.'],5,0.875,5,8
CD008130,2,7,"Trials should use validated upper limb function scales, and assessment should be both short-term (to monitor recovery and early complications) and long-term (at least one year).",delete,[],6,1.0,5,8
CD010269,0,0,"Seven studies, covering 1624 participants, met the inclusion criteria.",delete,[],0,0.058823529411764705,1,17
CD010269,0,1,"All included studies investigated adults and compared dexmedetomidine with traditional sedatives, including propofol, midazolam and lorazepam.",rephrase,"['The alternative sedatives included propofol, midazolam and lorazepam.']",0,0.11764705882352941,1,17
CD010269,0,2,"Compared with traditional sedatives, dexmedetomidine reduced the geometric mean duration of mechanical ventilation by 22% (95% CI 10% to 33%; four studies, 1120 participants, low quality evidence), and consequently the length of stay in the intensive care unit (ICU) by 14% (95% CI 1% to 24%; five studies, 1223 participants, very low quality evidence).",delete,[],1,0.17647058823529413,1,17
CD010269,0,3,"There was no evidence that dexmedetomidine decreased the risk of delirium (RR 0.85; 95% CI 0.63 to 1.14; seven studies, 1624 participants, very low quality evidence) as results were consistent with both no effect and appreciable benefit.",rephrase,"['We included seven randomized controlled trials, with a total of 1624 participants, comparing dexmedetomidine versus traditional sedatives.']",1,0.23529411764705882,2,17
CD010269,0,4,"Only one study assessed the risk of coma, but lacked methodological reliability (RR 0.69; 95% CI 0.55 to 0.86, very low quality evidence).",delete,[],2,0.29411764705882354,2,17
CD010269,0,5,"Of all the adverse events included, the most commonly reported one was bradycardia, and we observed a doubled (111%) increase in the incidence of bradycardia (RR 2.11; 95% CI 1.39 to 3.20; six studies, 1587 participants, very low quality evidence).",delete,[],2,0.35294117647058826,2,17
CD010269,0,6,"Our meta-analysis provided no evidence that dexmedetomidine had any impact on mortality (RR 0.99; 95% CI 0.79 to 1.24; six studies, 1584 participants, very low quality evidence).",delete,[],2,0.4117647058823529,3,17
CD010269,0,7,"We observed high levels of heterogeneity in risk of delirium (I² = 70%), but due to the limited number of studies we were unable to determine the source of heterogeneity through subgroup analyses or meta-regression.",delete,[],2,0.47058823529411764,3,17
CD010269,0,8,We judged six of the seven studies to be at high risk of bias.,rephrase,"['Of the seven studies, six were funded by the drug manufacturer, and one did not state any conflict of interest.']",2,0.5294117647058824,3,17
CD010269,1,9,"In this review, we found no eligible studies for children or for clonidine.",rephrase,['We found no eligible studies in children or for clonidine.'],3,0.5882352941176471,3,17
CD010269,1,10,"Compared with traditional sedatives, long-term sedation using dexmedetomidine in critically ill adults reduced the duration of mechanical ventilation and ICU length of stay.",split,"['Compared with traditional sedatives, dexmedetomidine reduced the breathing support time by approximately one-fifth, and the length of stay time in ICU by one-seventh.', 'Dexmedetomidine was at least as effective as traditional sedatives for producing sedation and maintaining a light sedation level.']",4,0.6470588235294118,4,17
CD010269,1,11,There was no evidence for a beneficial effect on risk of delirium and the heterogeneity was high.,rephrase,"['There was no clear evidence in support of dexmedetomidine reducing the risk of delirium (a kind of acute confusion state), as results were consistent with both no effect and appreciable benefit.']",6,0.7058823529411765,4,17
CD010269,1,12,The evidence for risk of coma was inadequate.,rephrase,['We had insufficient information to draw conclusions about reducing the risk of coma.'],7,0.7647058823529411,4,17
CD010269,1,13,The most common adverse event was bradycardia.,delete,[],8,0.8235294117647058,5,17
CD010269,1,14,No evidence indicated that dexmedetomidine changed mortality.,rephrase,['Our review provides no evidence that dexmedetomidine changed the overall death rate.'],8,0.8823529411764706,5,17
CD010269,1,15,"The general quality of evidence ranged from very low to low, due to high risks of bias, serious inconsistency and imprecision, and strongly suspected publication bias.",rephrase,"['The general quality of evidence ranged from very low to low, as most of the studies were at high risk of bias, serious inconsistency and imprecision, or strongly suspected publication bias.']",9,0.9411764705882353,5,17
CD010269,1,16,Future studies could pay more attention to children and to using clonidine.,delete,[],10,1.0,5,17
CD008727,0,0,We identified 10 studies (total of 298 children; we identified two studies for this update) including two randomised controlled trials (RCTs) that assessed adrenal function.,rephrase,['This systematic review included eight cohort studies and two randomised studies with a total number of 298 patients.'],0,0.047619047619047616,1,21
CD008727,0,1,"None of the included studies assessed the HPA axis at the level of the hypothalamus, the pituitary, or both.",split,"['All studies assessed adrenal function in paediatric patients treated with glucocorticoids for ALL.', 'None of these studies assessed the HPA axis at the level of the hypothalamus, the pituitary, or both.']",1,0.09523809523809523,1,21
CD008727,0,2,"Owing to substantial differences between studies, we could not pool results.",rephrase,['We could not combine the results of different studies because of heterogeneity.'],3,0.14285714285714285,1,21
CD008727,0,3,All studies had risk of bias issues.,rephrase,['All of the included studies had some risk of bias issues.'],4,0.19047619047619047,1,21
CD008727,0,4,Included studies demonstrated that adrenal insufficiency occurs in nearly all children during the first days after cessation of glucocorticoid treatment for childhood ALL.,rephrase,['Adrenal insufficiency occurred in nearly all children during the first days after completion of glucocorticoid therapy.'],5,0.23809523809523808,2,21
CD008727,0,5,"Most children recovered within a few weeks, but a small number of children had ongoing adrenal insufficiency lasting up to 34 weeks.",ignore,"['Most children recovered within a few weeks, but a small number had ongoing adrenal insufficiency lasting up to 34 weeks.']",6,0.2857142857142857,2,21
CD008727,1,6,Included studies evaluated several risk factors for (prolonged) adrenal insufficiency.,merge,[],7,0.3333333333333333,2,21
CD008727,1,7,"First, three studies including two RCTs investigated the difference between prednisone and dexamethasone in terms of occurrence and duration of adrenal insufficiency.",none,['Three studies looked into differences in duration of adrenal insufficiency between children who received prednisone and those who were given dexamethasone (two types of glucocorticoids).'],7,0.38095238095238093,2,21
CD008727,1,8,The RCTs found no differences between prednisone and dexamethasone arms.,rephrase,['Two of these three studies found no differences.'],8,0.42857142857142855,3,21
CD008727,1,9,"In the other (observational) study, children who received prednisone recovered earlier than children who received dexamethasone.",rephrase,"['In the other study, children who received prednisone recovered earlier than those who received dexamethasone.']",9,0.47619047619047616,3,21
CD008727,1,10,"Second, treatment with fluconazole appeared to prolong the duration of adrenal insufficiency, which was evaluated in two studies.",rephrase,"['Also, treatment with a certain antifungal drug (fluconazole) seemed to prolong the duration of adrenal insufficiency.']",10,0.5238095238095238,3,21
CD008727,1,11,One of these studies reported that the effect was present only when children received fluconazole at a dose higher than 10 mg/kg/d.,delete,[],11,0.5714285714285714,3,21
CD008727,1,12,"Finally, two studies evaluated the presence of infection, stress episodes, or both, as a risk factor for adrenal insufficiency.",split,"['Two studies investigated this.', 'Finally, two studies evaluated the presence of infection/stress as a risk factor for adrenal insufficiency.']",11,0.6190476190476191,4,21
CD008727,1,13,"In one of these studies (an RCT), trial authors found no relationship between the presence of infection/stress and adrenal insufficiency.",rephrase,['One study found no relationship.'],13,0.6666666666666666,4,21
CD008727,1,14,The other study found that increased infection was associated with prolonged duration of adrenal insufficiency.,ignore,['The other study reported that increased infection was associated with a longer duration of adrenal insufficiency.'],14,0.7142857142857143,4,21
CD008727,2,15,"We concluded that adrenal insufficiency commonly occurs in the first days after cessation of glucocorticoid therapy for childhood ALL, but the exact duration is unclear.",delete,[],15,0.7619047619047619,4,21
CD008727,2,16,"No data were available on the levels of the hypothalamus and the pituitary; therefore, we could draw no conclusions regarding these outcomes.",delete,[],15,0.8095238095238095,5,21
CD008727,2,17,Clinicians may consider prescribing glucocorticoid replacement therapy during periods of serious stress in the first weeks after cessation of glucocorticoid therapy for childhood ALL to reduce the risk of life-threatening complications.,delete,[],15,0.8571428571428571,5,21
CD008727,2,18,"However, additional high-quality research is needed to inform evidence-based guidelines for glucocorticoid replacement therapy.",rephrase,['More high-quality research is needed to define the exact occurrence and duration of HPA axis suppression.'],15,0.9047619047619048,5,21
CD008727,3,19,"Special attention should be paid to patients receiving fluconazole therapy, and perhaps similar antifungal drugs, as these treatments may prolong the duration of adrenal insufficiency, especially when administered at a dose higher than 10 mg/kg/d.",delete,[],16,0.9523809523809523,5,21
CD008727,4,20,"Finally, it would be relevant to investigate further the relationship between present infection/stress and adrenal insufficiency in a larger, separate study specially designed for this purpose.",delete,[],16,1.0,5,21
CD006580,0,0,"In this review update, an additional three studies and 220 participants were added.",merge,[],0,0.08333333333333333,1,12
CD006580,0,1,"A total of seven RCTs (two in adults, four in children, one in both children and adults) with 837 participants (aged from one to 63 years) with asthma from ethnic minority groups were eligible for inclusion in this review.",none,"['Seven studies with 837 participants, aged from one to 63 years old were included in this review update.']",0,0.16666666666666666,1,12
CD006580,0,2,The methodological quality of studies ranged from very low to low.,merge,['This review was limited by few studies and the quality of evidence was very low to low.'],1,0.25,2,12
CD006580,0,3,"For our primary outcome (asthma exacerbations during follow-up), the quality of evidence was low for all outcomes.",none,[],1,0.3333333333333333,2,12
CD006580,0,4,"In adults, use of a culture-specific programme, compared to generic programmes or usual care did not significantly reduce the number of participants from two studies with 294 participants for: exacerbations with one or more exacerbations during follow-up (odds ratio (OR) 0.80, 95% confidence interval (CI) 0.50 to 1.26), hospitalisations over 12 months (OR 0.83, 95% CI 0.31 to 2.22) and exacerbations requiring oral corticosteroids (OR 0.97, 95% CI 0.55 to 1.73).",merge,"['In adults, we found that culture-specific programmes did not improve any of our primary outcomes, but were better in improving quality of life (although the mean difference was less that the minimum important difference for the score) (secondary outcome).']",2,0.4166666666666667,3,12
CD006580,0,5,"However, use of a culture-specific programme, improved asthma quality of life scores in 280 adults from two studies (mean difference (MD) 0.26, 95% CI 0.17 to 0.36) (although the MD was less then the minimal important difference for the score).",none,[],2,0.5,3,12
CD006580,0,6,"In children, use of a culture-specific programme was superior to generic programmes or usual care in reducing severe asthma exacerbations requiring hospitalisation in two studies with 305 children (rate ratio 0.48, 95% CI 0.24 to 0.95), asthma control in one study with 62 children and QoL in three studies with 213 children, but not for the number of exacerbations during follow-up (OR 1.55, 95% CI 0.66 to 3.66) or the number of exacerbations (MD 0.18, 95% CI -0.25 to 0.62) among 100 children from two studies.",rephrase,"['In children however, when data were combined from studies, culture-specific programmes reduced severe exacerbations requiring hospitalisation (primary outcome), while single studies showed improved asthma control, asthma knowledge and adherence outcomes for our secondary outcomes.']",3,0.5833333333333334,3,12
CD006580,1,7,The available evidence showed that culture-specific education programmes for adults and children from minority groups are likely effective in improving asthma-related outcomes.,split,"['The available evidence showed that culture-specific education programmes for adults and children from minority groups are likely effective in improving asthma-related outcomes.', 'Although more robust evidence is required, asthma education programmes should be as culturally specific as possible in the context of chronic disease management and the complexity of health outcomes and culture, In the absence of any economic data, cost-effectiveness studies are also required']",4,0.6666666666666666,4,12
CD006580,1,8,This review was limited by few studies and evidence of very low to low quality.,rephrase,['The quality of the evidence was very low to low for all outcomes.'],6,0.75,4,12
CD006580,1,9,Not all asthma-related outcomes improved with culture-specific programs for both adults and children.,delete,[],7,0.8333333333333334,5,12
CD006580,1,10,"Nevertheless, while modified culture-specific education programs are usually more time intensive, the findings of this review suggest using culture-specific asthma education programmes for children and adults from minority groups.",delete,[],7,0.9166666666666666,5,12
CD006580,1,11,"However, more robust RCTs are needed to further strengthen the quality of evidence and determine the cost-effectiveness of culture-specific programs.",delete,[],7,1.0,5,12
CD013779,0,0,We included 16 studies that reported implementation of an intervention aimed at supporting the resilience or mental health of frontline workers during disease outbreaks (severe acute respiratory syndrome (SARS): 2; Ebola: 9; Middle East respiratory syndrome (MERS): 1; COVID-19: 4).,rephrase,['We searched medical databases for any kind of study that investigated interventions designed to support resilience and mental well-being in healthcare professionals working at the front line during infectious disease outbreaks.'],0,0.0625,1,16
CD013779,0,1,"Interventions studied included workplace interventions, such as training, structure and communication (6 studies); psychological support interventions, such as counselling and psychology services (8 studies); and multifaceted interventions (2 studies).",rephrase,"['The studies mainly looked at workplace interventions that involved either psychological support (for example, counselling or seeing a psychologist) or work-based interventions (for example, giving training, or changing routines).']",1,0.125,1,16
CD013779,1,2,"Objective 1: a mixed-methods study that incorporated a cluster-randomised trial, investigating the effect of a work-based intervention, provided very low-certainty evidence about the effect of training frontline healthcare workers to deliver psychological first aid on a measure of burnout.",rephrase,['Objective 1: one study investigated how well an intervention worked.'],2,0.1875,1,16
CD013779,2,3,Objective 2: we included all 16 studies in our qualitative evidence synthesis; we classified seven as qualitative and nine as descriptive studies.,rephrase,['Objective 2: all 16 studies provided some evidence about barriers and facilitators to implement interventions.'],3,0.25,2,16
CD013779,2,4,We identified 17 key findings from multiple barriers and facilitators reported in studies.,rephrase,['We found 17 main findings from these studies.'],4,0.3125,2,16
CD013779,2,5,We did not have high confidence in any of the findings; we had moderate confidence in six findings and low to very low confidence in 11 findings.,ignore,['We do not have high confidence in any of the findings; we had moderate confidence in six findings and low to very low confidence in 11 findings.'],5,0.375,2,16
CD013779,2,6,"We are moderately confident that the following two factors were barriers to intervention implementation: frontline workers, or the organisations in which they worked, not being fully aware of what they needed to support their mental well-being; and a lack of equipment, staff time or skills needed for an intervention.",ignore,"['We are moderately confident that the following two factors were barriers to implementation of an intervention: frontline workers, or the organisations in which they worked, not being fully aware of what they needed to support their mental well-being; and a lack of equipment, staff time or skills needed for an intervention.']",6,0.4375,3,16
CD013779,2,7,"We are moderately confident that the following three factors were facilitators of intervention implementation: interventions that could be adapted for local needs; having effective communication, both formally and socially; and having positive, safe and supportive learning environments for frontline workers.",rephrase,"['We are moderately confident that the following three factors were facilitators to implementation of an intervention: interventions that could be adapted for a local area; having effective communication, both formally within an organisation and informal or social networks; and having positive, safe and supportive learning environments for frontline healthcare professionals.']",7,0.5,3,16
CD013779,2,8,"We are moderately confident that the knowledge or beliefs, or both, that people have about an intervention can act as either barriers or facilitators to implementation of the intervention.",rephrase,['We are moderately confident that the knowledge and beliefs that frontline healthcare professionals have about an intervention can either help or hinder implementation of the intervention.'],8,0.5625,3,16
CD013779,3,9,There is a lack of both quantitative and qualitative evidence from studies carried out during or after disease epidemics and pandemics that can inform the selection of interventions that are beneficial to the resilience and mental health of frontline workers.,rephrase,['We did not find any evidence that tells us about how well different strategies work at supporting the resilience and mental well-being of frontline workers.'],9,0.625,4,16
CD013779,3,10,"Alternative sources of evidence (e.g. from other healthcare crises, and general evidence about interventions that support mental well-being) could therefore be used to inform decision making.",delete,[],10,0.6875,4,16
CD013779,3,11,"When selecting interventions aimed at supporting frontline workers' mental health, organisational, social, personal, and psychological factors may all be important.",delete,[],10,0.75,4,16
CD013779,3,12,Research to determine the effectiveness of interventions is a high priority.,rephrase,['Properly planned research studies to find out the best ways to support the resilience and mental well-being of health and social care workers are urgently required.'],10,0.8125,5,16
CD013779,3,13,The COVID-19 pandemic provides unique opportunities for robust evaluation of interventions.,delete,[],11,0.875,5,16
CD013779,3,14,"Future studies must be developed with appropriately rigorous planning, including development, peer review and transparent reporting of research protocols, following guidance and standards for best practice, and with appropriate length of follow-up.",delete,[],11,0.9375,5,16
CD013779,3,15,Factors that may act as barriers and facilitators to implementation of interventions should be considered during the planning of future research and when selecting interventions to deliver within local settings.,delete,[],11,1.0,5,16
CD012668,0,0,We included two studies (involving a total of 49 women).,split,"['We found two studies involving a total of 49 women.', 'We also identified an ongoing study involving 50 women that aims to compare yoga with stretching; we will include this study when the results are reported.']",0,0.05,1,20
CD012668,0,1,"Each study compared yoga to a different comparator, therefore we were unable to combine the data in a meta-analysis.",delete,[],2,0.1,1,20
CD012668,0,2,A third study that has been completed but not yet fully reported is awaiting assessment.,delete,[],2,0.15,1,20
CD012668,1,3,One included study was a six-week study comparing yoga to a waiting list in 19 women with either urgency urinary incontinence or stress urinary incontinence.,split,"['One was a six-week study comparing yoga to a waiting list (delayed treatment) in women with either stress or urgency urinary incontinence.', 'The other was an eight-week study comparing yoga to mindfulness-based stress reduction (MBSR) in women with urgency urinary incontinence.']",2,0.2,1,20
CD012668,1,4,"We judged the certainty of the evidence for all reported outcomes as very low due to performance bias, detection bias, and imprecision.",delete,[],4,0.25,2,20
CD012668,1,5,The number of women reporting cure was not reported.,rephrase,"['The trial comparing yoga to a waiting list did not report the number of women reporting cure but did report on symptoms, condition-specific quality of life and adverse effects.']",4,0.3,2,20
CD012668,1,6,"We are uncertain whether yoga results in satisfaction with cure or improvement of incontinence (risk ratio (RR) 6.33, 95% confidence interval (CI) 1.44 to 27.88; an increase of 592 from 111 per 1000, 95% CI 160 to 1000).",rephrase,"['While this comparison generally favoured the yoga intervention, we are uncertain whether yoga improves urinary incontinence due to the very low certainty of the evidence.']",5,0.35,2,20
CD012668,1,7,"We are uncertain whether there is a difference between yoga and waiting list in condition-specific quality of life as measured on the Incontinence Impact Questionnaire Short Form (mean difference (MD) 1.74, 95% CI -33.02 to 36.50); the number of micturitions (MD -0.77, 95% CI -2.13 to 0.59); the number of incontinence episodes (MD -1.57, 95% CI -2.83 to -0.31); or the bothersomeness of incontinence as measured on the Urogenital Distress Inventory 6 (MD -0.90, 95% CI -1.46 to -0.34).",merge,[],6,0.4,2,20
CD012668,1,8,"There was no evidence of a difference in the number of women who experienced at least one adverse event (risk difference 0%, 95% CI -38% to 38%; no difference from 222 per 1000, 95% CI 380 fewer to 380 more).",none,"['There was no difference between groups in the number of women reporting an adverse event and no serious adverse events were reported, but we are uncertain whether yoga increases harms as the certainty of the evidence is very low.']",6,0.45,3,20
CD012668,2,9,The second included study was an eight-week study in 30 women with urgency urinary incontinence that compared mindfulness-based stress reduction (MBSR) to an active control intervention of yoga classes.,delete,[],7,0.5,3,20
CD012668,2,10,"The study was unblinded, and there was high attrition from both study arms for all outcome assessments.",delete,[],7,0.55,3,20
CD012668,2,11,"We judged the certainty of the evidence for all reported outcomes as very low due to performance bias, attrition bias, imprecision and indirectness.",delete,[],7,0.6,3,20
CD012668,2,12,The number of women reporting cure was not reported.,rephrase,['The trial comparing yoga to MBSR reported on symptoms and condition-specific quality of life but did not report the number of women reporting cure.'],7,0.65,4,20
CD012668,2,13,"We are uncertain whether women in the yoga group were less likely to report improvement in incontinence at eight weeks compared to women in the MBSR group (RR 0.09, 95% CI 0.01 to 1.43; a decrease of 419 from 461 per 1000, 95% CI 5 to 660).",merge,[],8,0.7,4,20
CD012668,2,14,"We are uncertain about the effect of MBSR compared to yoga on reports of cure or improvement in incontinence, improvement in condition-specific quality of life measured on the Overactive Bladder Health-Related Quality of Life Scale, reduction in incontinence episodes or reduction in bothersomeness of incontinence as measured on the Overactive Bladder Symptom and Quality of Life-Short Form at eight weeks.",none,"['While this comparison generally favoured the MBSR intervention, we are uncertain whether yoga improves urinary incontinence due to the very low certainty of the evidence.']",8,0.75,4,20
CD012668,2,15,The study did not report on adverse effects.,rephrase,['There was no information on adverse events.'],9,0.8,4,20
CD012668,3,16,"We identified few trials on yoga for incontinence, and the existing trials were small and at high risk of bias.",split,"['Although we identified some evidence on yoga treatment for treating urinary incontinence in women, the included studies were very small and there were issues with the way they were conducted, which limits our confidence in the results.', 'The trial comparing yoga to MBSR did not intend to test yoga as a treatment for incontinence.']",10,0.85,5,20
CD012668,3,17,"In addition, we did not find any studies of economic outcomes related to yoga for urinary incontinence.",rephrase,['We did not find any information on the value for money of yoga for urinary incontinence.'],12,0.9,5,20
CD012668,3,18,"Due to the lack of evidence to answer the review question, we are uncertain whether yoga is useful for women with urinary incontinence.",rephrase,['There is currently insufficient good-quality evidence to judge whether yoga is useful for women with urinary incontinence.'],13,0.95,5,20
CD012668,3,19,"Additional, well-conducted trials with larger sample sizes are needed.",delete,[],14,1.0,5,20
CD008652,0,0,"In this review update, we screened 722 records, selected 26 full-text reports for evaluation.",rephrase,"['In this update, we examined 722 records, and selected 26 for further evaluation.']",0,0.1111111111111111,1,9
CD008652,0,1,We identified no ongoing studies and did not add any new studies.,rephrase,['We did not find any additional studies to add to the three studies (211 participants) that were already included in the review.'],1,0.2222222222222222,2,9
CD008652,0,2,"We included three randomised controlled trials (RCTs), enrolling 211 people with hypertension or prehypertension, plus hyperuricaemia.",delete,[],2,0.3333333333333333,2,9
CD008652,1,3,"Low-certainty evidence from three RCTs found inconclusive results between those who received UA-lowering drugs and placebo, in 24-hour ambulatory systolic (MD -6.2 mmHg, 95% CI -12.8 to 0.5) or diastolic BP (-3.9 mmHg, 95% CI -9.2 to 1.4).",rephrase,['The results for side effects were inconclusive between the drug therapy and placebo groups.'],2,0.4444444444444444,3,9
CD008652,2,4,"Low-certainty evidence from two RCTs found that UA-lowering drugs reduced clinic-measured systolic BP (-8.43 mmHg, 95% CI -15.24 to -1.62) but results for clinic-measured diastolic BP were inconclusive (-6.45 mmHg, 95% CI -13.60 to 0.70).",rephrase,['We reduced the certainty of the evidence because the studies presented limited data and inconsistent results for this outcome.'],3,0.5555555555555556,3,9
CD008652,3,5,High-certainty evidence from three RCTs found that serum UA levels were reduced by 3.1 mg/dL (95% CI 2.4 to 3.8) in the participants that received UA-lowering drugs.,rephrase,['High-certainty evidence found that uric acid-lowering drug therapy decreases uric acid.'],4,0.6666666666666666,4,9
CD008652,4,6,"Low-certainty evidence from three RCTs found inconclusive results regarding the occurrence of adverse events between those who received UA-lowering drugs and placebo (RR 1.86, 95% CI 0.43 to 8.10).",rephrase,['Low-certainty evidence failed to establish whether drug therapy increased the occurrence of side effects.'],5,0.7777777777777778,4,9
CD008652,5,7,"In this updated Cochrane Review, the current RCT data are insufficient to know whether UA-lowering therapy lowers BP.",delete,[],6,0.8888888888888888,5,9
CD008652,5,8,More studies are needed.,rephrase,['More research on this question is needed.'],6,1.0,5,9
CD006681,0,0,"We included eight RCTs that fulfilled our criteria, with a total of 3680 participants.",split,"['We included eight studies in this review (current until April 2017).', 'The studies included a total of 3680 participants.']",0,0.07692307692307693,1,13
CD006681,0,1,"The quality of evidence, according GRADE, varied by outcome and ranged from low to moderate.",delete,[],2,0.15384615384615385,1,13
CD006681,0,2,"We found an incidence of DVT ranging from 4.3% to 40% in patients who had a leg injury that had been immobilized in a plaster cast or a brace for at least one week, and who received no prophylaxis, or placebo.",rephrase,['New cases of DVT ranged from 4.3% to 40% in the control groups and ranged from 0% to 37% in the LMWH groups.'],2,0.23076923076923078,2,13
CD006681,0,3,"This number was significantly lower in patients who received daily subcutaneous injections of LMWH during immobilization, with event rates ranging from 0% to 37% (odds ratio (OR) 0.45, 95% confidence interval (CI) 0.33 to 0.61; with minimal evidence of heterogeneity: I² = 26%, P = 0.23; seven studies; 1676 participants, moderate-quality evidence).",delete,[],3,0.3076923076923077,2,13
CD006681,0,4,"Comparable results were seen in the following groups of participants: patients with below-knee casts, conservatively treated patients (non-operated patients), operated patients, patients with fractures, patients with soft-tissue injuries, and patients with distal or proximal thrombosis.",rephrase,"['Further analysis also showed a reduction in the occurrence of DVT when the use of LMWH was compared to no treatment or placebo in the following groups of participants: patients with below-knee casts, conservatively treated patients (patients not operated), operated patients, patients with fractures, patients with soft-tissue injuries, patients with above-knee thrombosis, and patients with below-knee thrombosis.']",3,0.38461538461538464,2,13
CD006681,0,5,"No clear differences were found between the LMWH and control groups for pulmonary embolism (OR 0.50, 95% CI 0.17 to 1.47; with no evidence of heterogeneity: I² = 0%, P = 0.56; five studies, 2517 participants; low-quality evidence).",rephrase,['No clear differences were found between the LMWH and control groups for pulmonary embolism.'],4,0.46153846153846156,3,13
CD006681,0,6,"The studies also showed less symptomatic VTE in the LMWH groups compared with the control groups (OR 0.40, 95% CI 0.21 to 0.76; with minimal evidence of heterogeneity: I² = 16%, P = 0.31; six studies; 2924 participants; low-quality evidence).",rephrase,['The studies showed less symptomatic venous thromboembolism in the LMWH groups compared with the control groups.'],5,0.5384615384615384,3,13
CD006681,0,7,"One death was reported in the included studies, but no deaths due to pulmonary embolism were reported.",split,"['No cases of death due to pulmonary embolism were reported.', 'One study reported one death in the control group.']",6,0.6153846153846154,4,13
CD006681,0,8,"Complications of major adverse events were rare, with minor bleeding the main adverse events reported.",rephrase,"['The main adverse events reported were cases of minor bleeding such as nose bleeds, blood in urine and dark stool.']",8,0.6923076923076923,4,13
CD006681,1,9,"Moderate-quality evidence showed that the use of LMWH in outpatients reduced DVT when immobilization of the lower limb was required, when compared with no prophylaxis or placebo.",rephrase,"['The use of LMWH in adult patients reduced DVT when immobilization of the lower limb was required, compared with no prevention or placebo.']",9,0.7692307692307693,4,13
CD006681,1,10,The quality of the evidence was reduced to moderate because of risk of selection and attrition bias in the included studies.,rephrase,"['The quality of the evidence was downgraded to moderate due to risks of bias in some trials, such as lack of blinding of participants, or unclear reasons for excluding participants from the analyses.']",10,0.8461538461538461,5,13
CD006681,1,11,"Low-quality evidence showed no clear differences in PE between the LMWH and control groups, but less symptomatic VTE in the LMWH groups.",rephrase,"['Low-quality evidence showed no clear differences in pulmonary embolism between LMWH and the control groups, but fewer symptomatic venous thromboemboli in the LMWH groups.']",11,0.9230769230769231,5,13
CD006681,1,12,The quality of the evidence was downgraded due to risk of bias and imprecision.,rephrase,['The quality of evidence was downgraded due to methodological issues and imprecision of the results.'],12,1.0,5,13
CD004559,0,0,We included 18 studies involving 2521 participants.,rephrase,['Eighteen studies involving 2521 participants were included in the review.'],0,0.08333333333333333,1,12
CD004559,0,1,The methodological quality of 17 included studies was poor.,delete,[],1,0.16666666666666666,1,12
CD004559,0,2,"Included RCTs separately compared medicinal herbs with different antiviral drugs, precluding any pooling of results.",delete,[],1,0.25,2,12
CD004559,0,3,"Only three indicated that compared with antiviral drugs, Chinese medicinal herbs may be effective in preventing influenza and alleviating influenza symptoms.",rephrase,['This updated review assessed the therapeutic effects and safety of Chinese medicinal herbs as an alternative and adjunctive therapy to other commonly used drugs for influenza.'],1,0.3333333333333333,2,12
CD004559,0,4,'Ganmao' capsules were found to be more effective than amantadine in decreasing influenza symptoms and speeding recovery in one study (in which adverse reactions were mentioned in the amantadine group although no data were reported).,ignore,"[""'Ganmao' capsules were found to be more effective than amantadine in decreasing influenza symptoms and aiding recovery in one study (in which adverse reactions were mentioned in the amantadine group although no data were reported).""]",2,0.4166666666666667,3,12
CD004559,0,5,"There were no significant differences between 'E Shu You' and ribavirin in treating influenza, nor in the occurrence of adverse reactions.",ignore,"[""There were no significant differences between 'E Shu You' and ribavirin in treating influenza, nor in the occurrence of adverse reactions.""]",3,0.5,3,12
CD004559,0,6,Ten studies reported mild adverse reactions.,delete,[],4,0.5833333333333334,3,12
CD004559,1,7,Most Chinese medical herbs in the included studies showed similar effects to antiviral drugs in preventing or treating influenza.,split,"['The remaining 17 Chinese herbal trials showed a similar effect to antiviral drugs in preventing or treating influenza.', 'However, since these included studies were of poor quality, the evidence does not support or reject the use of any Chinese herbal preparations for influenza.']",4,0.6666666666666666,4,12
CD004559,1,8,Few were shown to be superior to antiviral drugs.,delete,[],6,0.75,4,12
CD004559,1,9,No obvious adverse events were reported in the included studies.,delete,[],6,0.8333333333333334,5,12
CD004559,1,10,"However, current evidence remains weak due to methodological limitations of the trials.",delete,[],6,0.9166666666666666,5,12
CD004559,1,11,More high-quality RCTs with larger numbers of participants and clear reporting are needed.,rephrase,['High-quality trials are required.'],6,1.0,5,12
CD008508,0,0,Thirteen trials were included.,delete,[],0,0.08333333333333333,1,12
CD008508,0,1,None measured an injury outcome.,delete,[],0,0.16666666666666666,1,12
CD008508,0,2,"Two trials measured error, and the remaining trials used neuropsychological tests to assess cognitive performance.",rephrase,"['They found 13 trials - none of the trials looked at the effect on injury, two trials measured error, while the remaining trials used neuropsychological tests to assess cognitive performance.']",0,0.25,2,12
CD008508,0,3,The trials assessing the impact on errors found that caffeine significantly reduced the number of errors compared to placebo.,merge,"['The results of the trials suggest that compared to no intervention, caffeine can reduce the number of errors and improve cognitive performance in shift workers.']",1,0.3333333333333333,2,12
CD008508,0,4,"The pooled effect estimates on performance by cognitive domain suggest that, when compared to placebo, caffeine improved concept formation and reasoning (SMD -0.41; 95% CI -1.04 to 0.23), memory (SMD -1.08; 95% CI -2.07 to -0.09), orientation and attention (SMD -0.55; 95% CI -0.83 to -0.27) and perception (SMD -0.77; 95% CI -1.73 to 0.20); although there was no beneficial effect on verbal functioning and language skills (SMD 0.18; 95% CI -0.50 to 0.87).",none,[],1,0.4166666666666667,3,12
CD008508,0,5,One trial comparing the effects of caffeine with a nap found that there were significantly less errors made in the caffeine group.,merge,[],2,0.5,3,12
CD008508,0,6,"Other trials comparing caffeine with other active interventions (for example nap, bright light, modafinil) found no significant differences.",none,"['No difference in effect was found by the trials comparing caffeine with other interventions (such as nap, bright light and modafinil).']",2,0.5833333333333334,3,12
CD008508,0,7,There is a high risk of bias for the adequacy of allocation concealment and presence of selective outcome reporting amongst the trials.,delete,[],3,0.6666666666666666,4,12
CD008508,1,8,"Caffeine may be an effective intervention for improving performance in shift workers however, there are no trials from which we can assess its effect on injuries.",rephrase,"['The authors of the systematic review conclude that caffeine may be an effective intervention for improving performance in shift workers however, there are no trials from which they could assess its effect on injuries.']",3,0.75,4,12
CD008508,1,9,"The results largely originate from studies involving young participants under simulated conditions, and the extent to which the findings are generalisable to older workers and real world shift work is unclear.",delete,[],4,0.8333333333333334,5,12
CD008508,1,10,"Based on the current evidence, there is no reason for healthy individuals who already use caffeine within recommended levels to improve their alertness to stop doing so.",rephrase,"['Based on the current evidence, the review authors judge that there is no reason for healthy shift workers who already use caffeine within recommended levels to improve their alertness, to stop doing so.']",4,0.9166666666666666,5,12
CD008508,1,11,The assessment of the relative effects of caffeine to other potential countermeasures should be a focus of future research.,rephrase,['They go on to suggest that it would be useful for further trials to be undertaken to assess the effects of caffeine against other potential countermeasures.'],5,1.0,5,12
CD009195,0,0,We included in the review seven trials with 542 participants.,rephrase,['We identified seven trials with a combined total of 542 participants comparing percutaneous transluminal angioplasty (PTA) alone versus PTA with stent placement (current until June 2018).'],0,0.07142857142857142,1,14
CD009195,0,1,"One trial randomised limbs to undergo PTA alone or PTA with stent placement, and the remaining studies randomised participants.",ignore,"['One trial randomised limbs to PTA alone or PTA with stent placement, and the remaining studies randomised participants.']",1,0.14285714285714285,1,14
CD009195,0,2,"Five trials with 476 participants show that the technical success rate was greater in the stent group than in the angioplasty group (odds ratio (OR) 3.00, 95% confidence interval (CI) 1.14 to 7.93; 476 lesions; 5 studies; I² = 23%).",rephrase,['Full analysis of five trials shows that the technical success rate of re-opening the narrowed artery was higher in the stent group than in the PTA group.'],2,0.21428571428571427,2,14
CD009195,0,3,"Meta-analysis of three eligible trials with 456 participants did not show a clear difference in short-term (within six months) patency between infrapopliteal arterial lesions treated with PTA and those treated with PTA and stenting (OR 0.88, 95% CI 0.37 to 2.11; 456 lesions; 3 studies; I² = 77%).",delete,[],3,0.2857142857142857,2,14
CD009195,0,4,"Results also did not show clear differences between treatment groups in procedure complication rate (OR 0.87, 95% CI 0.01 to 53.60; 360 participants; 5 studies; I² = 85%), rate of major amputations at 12 months (OR 1.34, 95% CI 0.56 to 3.22; 306 participants; 4 studies; I² = 0%), and rate of mortality at 12 months (OR 0.71, 95% CI 0.43 to 1.17; 497 participants; 6 studies; I² = 0%).",rephrase,"['The complication rate of the procedure, the number of major amputations at 12 months, and the number of deaths at 12 months also did not differ greatly between treatment groups.']",3,0.35714285714285715,2,14
CD009195,0,5,Heterogeneity between studies was high for the outcomes procedure complications and primary patency.,delete,[],4,0.42857142857142855,3,14
CD009195,0,6,The overall methodological quality of the trials included in this review was moderate due to selection and performance bias.,rephrase,['The overall certainty of evidence provided by the trials included in this review was moderate.'],4,0.5,3,14
CD009195,0,7,Studies used different regimens for pretreatment and post-treatment antiplatelet/anticoagulant medication.,delete,[],5,0.5714285714285714,3,14
CD009195,0,8,We downgraded the certainty of the overall evidence for all outcomes by one level to moderate due to inconsistency of results across studies and large confidence intervals (small numbers of trials and participants).,rephrase,"['Overall, we downgraded the certainty of evidence for all outcomes by one level to moderate due to inconsistency of results across studies and the small numbers of studies and participants.']",5,0.6428571428571429,4,14
CD009195,1,9,Trials show that the immediate technical success rate of restoring luminal patency is higher in the stent group but reveal no clear differences in short-term patency at six months between infrapopliteal arterial lesions treated with PTA with stenting versus those treated with PTA without stenting.,rephrase,['PTA with stent placement is better than PTA alone for restoring vessel patency immediately; however we found no clear difference in short-term patency at six months between the two groups.'],6,0.7142857142857143,4,14
CD009195,1,10,"We ascertained no clear differences between groups in periprocedural complications, major amputation, and mortality.",rephrase,"['Trials show no clear differences between groups in complications at or around the time of the procedure, major amputation, and death.']",7,0.7857142857142857,4,14
CD009195,1,11,"However, use of different regimens for pretreatment and post-treatment antiplatelet/anticoagulant medication and the duration of its use within and between trials may have influenced the outcomes.",delete,[],8,0.8571428571428571,5,14
CD009195,1,12,Limited currently available data suggest that high-quality evidence is insufficient to show that PTA with stent insertion is superior to use of standard PTA alone without stenting for treatment of infrapopliteal arterial lesions.,rephrase,['Currently available data suggest that high-certainty evidence is insufficient to show that PTA with stent placement is superior to PTA alone for treatment of infrapopliteal arterial lesions.'],8,0.9285714285714286,5,14
CD009195,1,13,Further studies should standardise the use of antiplatelets/anticoagulants before and after the intervention to improve the comparability of the two treatments.,ignore,['Further studies should standardise the use of blood-thinning drugs (antiplatelets/anticoagulants) before and after both interventions to improve the comparability of the two treatments.'],9,1.0,5,14
CD001876,0,0,"Six trials with 590 participants met the inclusion criteria, which were conducted in Asia (three trials), Africa (two trials), and Europe (one trial).",rephrase,"['We examined the available evidence up to 13 April 2016 and included six trials with 590 people, which evaluated prednisolone given with antituberculous treatment (ATT).']",0,0.07692307692307693,1,13
CD001876,0,1,"Two trials were in HIV-negative people, one trial was in HIV-positive people, and three trials did not report HIV status.",rephrase,"['All the included trials were in adults; one trial included only HIV-positive people, two included only HIV-negative people, and three did not report the HIV status of the participants.']",1,0.15384615384615385,1,13
CD001876,1,2,Corticosteroids may reduce the time to resolution of pleural effusion.,rephrase,['Corticosteroids may reduce the time to resolution of the symptoms of TB pleurisy and the time to resolution of the pleural effusion on chest X-ray (low certainty evidence).'],2,0.23076923076923078,2,13
CD001876,1,3,"Risk of residual pleural effusion on chest X-ray was reduced by 45% at eight weeks (RR 0.54, 95% CI 0.37 to 0.78; 237 participants, 2 trials, low certainty evidence), and 65% at 24 weeks (RR 0.35, 95% CI 0.18 to 0.66; 237 participants, 2 trials, low certainty evidence).",delete,[],3,0.3076923076923077,2,13
CD001876,2,4,"Compared with control, corticosteroids may reduce the risk of having pleural changes (such as pleural thickening or pleural adhesions), on chest X-ray at the end of follow-up by almost one third (RR 0.72, 95% CI 0.57 to 0.92; 393 participants, 5 trials,low certainty evidence), which translates to an absolute risk reduction of 16%.",rephrase,['Corticosteroids may also reduce the risk of having signs of pleural scarring on chest X-ray (pleural thickening and pleural adhesions) after the disease has resolved (low certainty evidence).'],3,0.38461538461538464,2,13
CD001876,3,5,"One trial reported deaths in people that were HIV-positive, with no obvious difference between the groups; the trial authors' analysis suggests that the deaths observed in this trial were related to HIV disease rather than pleural TB (RR 0.91, 95% CI 0.64 to 1.31; 197 participants, 1 trial).",delete,[],4,0.46153846153846156,3,13
CD001876,4,6,"We found limited data on long-term functional respiratory impairment on 187 people in two trials, which reported that average percentage predicted forced vital capacity was similar in the group receiving prednisolone and in the control group (very low certainty evidence).",rephrase,['There was not enough information about lung function to be sure whether or not corticosteroids reduce the risk of lung function impairment after TB pleurisy (very low certainty evidence).'],4,0.5384615384615384,3,13
CD001876,5,7,"The risk of adverse events that led to discontinuation of the trial drug was higher in people with pleural TB receiving corticosteroids (RR 2.78, 95% CI 1.11 to 6.94; 587 participants, 6 trials, low certainty evidence).",rephrase,['Corticosteroids may increase the risk of adverse events leading to discontinuation of the trial drug (low certainty evidence).'],5,0.6153846153846154,4,13
CD001876,5,8,"The trial in HIV-positive people reported on six different HIV-related infections, with no obvious differences.",merge,[],6,0.6923076923076923,4,13
CD001876,5,9,"However, cases of Kaposi's sarcoma were only seen in the corticosteroid group (with 6/99 cases in the steroid group compared to 0/98 in the control group) (very low certainty evidence).",none,"[""From one trial in people living with HIV, there was no detectable increase in HIV-related conditions with corticosteroids, although cases of Kaposi's sarcoma were only seen in the corticosteroid group and numbers of participants and events were too small to rule out an effect of corticosteroids (very low certainty evidence).""]",6,0.7692307692307693,4,13
CD001876,6,10,Long-term respiratory function is potentially the most important outcome for assessing the effects of adjunctive treatments for people with pleural TB.,delete,[],7,0.8461538461538461,5,13
CD001876,6,11,"However, the information on the impact of pleural TB on long-term respiratory function is unknown and could be eclipsed by other risk factors, such as concurrent pulmonary TB, smoking, and HIV.",delete,[],7,0.9230769230769231,5,13
CD001876,6,12,This probably needs to be quantified to help decide whether further trials of corticosteroids for pleural TB would be worthwhile.,rephrase,"['As the risk of disability and long-term illness after TB pleurisy is unclear, research looking at the association between TB pleurisy and lung function impairment would be useful to inform future research into corticosteroids for TB pleurisy.']",7,1.0,5,13
CD013018,0,0,"Two trials, involving a total of 50 participants with CF and postural abnormalities, were included in this review.",rephrase,['We included two trials in this review with 50 participants aged between 17 and 58 years and diagnosed with cystic fibrosis and postural abnormalities.'],0,0.07692307692307693,1,13
CD013018,0,1,One was in people with stable disease (lasting three months) and one in hospital inpatients experiencing an exacerbation (20 days).,rephrase,['One trial was in hospital inpatients and lasted 20 days and the second was in outpatients and lasted three months.'],1,0.15384615384615385,1,13
CD013018,0,2,"Both trials compared manual therapy comprising mobilizations to the rib cage and thoracic spine, treatment of specific muscle dysfunction or tight muscle groups; and postural awareness and education versus medical usual care.",rephrase,"['The trials compared manual therapy (all physical therapies that promote relaxation of the muscles, as well as mobilization of the spine, such as massage, spinal mobilization) with usual care (the normal treatment they used to receive).']",2,0.23076923076923078,2,13
CD013018,0,3,The age of participants ranged from 17 years to 58 years.,delete,[],3,0.3076923076923077,2,13
CD013018,0,4,Both trials were conducted in the UK.,rephrase,['Most of the outcomes were reported in both trials.'],3,0.38461538461538464,2,13
CD013018,1,5,"The following outcomes were measured: change in quality of life, change in pain, change in trunk deformity and change in pulmonary function.",rephrase,"['We think the fact that people knew which treatment they were receiving can affect the results for the change in quality of life, change in pain and change in lung function outcomes, but this may not affect the other outcomes.']",4,0.46153846153846156,3,13
CD013018,1,6,Manual therapy may make little or no difference to the change in trunk deformity compared to usual care (low-quality evidence).,rephrase,['Low-quality evidence means that our confidence in the effect of manual therapy is limited and the true effect may be very different.'],5,0.5384615384615384,3,13
CD013018,1,7,No results could be analysed for quality of life (very low-quality evidence) and pain outcomes (very low-quality evidence) because of the high heterogeneity between trials.,rephrase,['We could not combine results for quality of life or pain scores because they were too different.'],6,0.6153846153846154,4,13
CD013018,1,8,It is uncertain whether the intervention improves lung function: forced vital capacity (very low-quality evidence); forced expiratory volume in one second (very low-quality evidence); or Tiffeneau’s index (ratio of forced expiratory volume at one second (FEV1) and forced vital capacity (FVC)).,delete,[],7,0.6923076923076923,4,13
CD013018,1,9,"Only one trial (15 participants) measured functional capacity, and the change in walked distance seemed to favour intervention over usual care, but with the possibility of no effect due to wide confidence intervals.",rephrase,"['Only one trial (15 participants) measured the change in walked distance which seemed to favour manual therapy over usual care, but this was not clear because there were a large range of results.']",7,0.7692307692307693,4,13
CD013018,1,10,The same trial also reported that six participants in the intervention group had positive comments about the intervention and no adverse events were mentioned.,delete,[],8,0.8461538461538461,5,13
CD013018,2,11,"Due to methodological limitations in the included trials, and in addition to the very low to low quality of the current evidence, there is limited evidence about the benefits of physical therapies on postural abnormalities in people with CF.",delete,[],8,0.9230769230769231,5,13
CD013018,2,12,"Therefore, further well-conducted trials with robust methodologies are required considering a prior inclusion criterion to identify the participants who have postural abnormalities.",delete,[],8,1.0,5,13
CD010513,0,0,We included five trials (one of which was quasi-randomised) that reported results for 368 people who had PFPS.,rephrase,['We searched electronic databases and other sources up to June 2015 and found five relevant studies that reported the results for 368 adults with PFPS.'],0,0.037037037037037035,1,27
CD010513,0,1,Participants were recruited from health clinics in three trials and were military recruits undergoing training in the other two trials.,rephrase,['Participants were recruited from health clinics in three studies and were military trainees in the other two studies.'],1,0.07407407407407407,1,27
CD010513,0,2,"Although no trials recruited participants who were categorised as elite or professional athletes, military training does comprise intensive exercise regimens.",delete,[],2,0.1111111111111111,1,27
CD010513,0,3,"All five trials were at high risk of bias, including performance bias reflecting the logistical problems in these trials of blinding of participants and care providers.",rephrase,"['All five studies were small and at high risk of bias, which means that their findings may not be reliable.']",2,0.14814814814814814,1,27
CD010513,0,4,"As assessed using the GRADE approach, the available evidence for all reported outcomes is 'very low' quality.",delete,[],3,0.18518518518518517,1,27
CD010513,0,5,This means that we are very uncertain about the results.,delete,[],3,0.2222222222222222,2,27
CD010513,1,6,The trials covered three different types of comparison: knee orthosis and exercises versus exercises alone; one type of orthosis versus another; and knee orthosis versus exercises.,ignore,['The studies covered three different types of comparison: knee orthosis and exercises versus exercises alone; one type of orthosis versus another; and knee orthosis versus exercises.'],3,0.25925925925925924,2,27
CD010513,1,7,"No trials assessed the mode of knee orthosis use, such as whether the orthosis was worn all day or only during physical activity.",ignore,"['No study assessed the mode of knee orthosis use, such as whether the orthosis was worn all day or only during physical activity.']",4,0.2962962962962963,2,27
CD010513,1,8,Two trials had two groups; two trials had three groups; and one trial had four groups.,delete,[],5,0.3333333333333333,2,27
CD010513,2,9,"All five trials compared a knee orthosis (knee sleeve, knee brace, or patellar strap) versus a 'no treatment' control group, with all participants receiving exercises, either through a military training programme or a home-based exercise programme.",rephrase,"['All five trials compared a knee orthosis (either sleeve, brace or strap) plus exercise versus exercise alone.']",5,0.37037037037037035,2,27
CD010513,2,10,"There is very low quality evidence of no clinically important differences between the two groups in short-term (2 to 12 weeks follow-up) knee pain based on the visual analogue scale (0 to 10 points; higher scores mean worse pain): MD -0.46 favouring knee orthoses, 95% CI -1.16 to 0.24; P = 0.19; 234 participants, 3 trials).",delete,[],6,0.4074074074074074,3,27
CD010513,2,11,"A similar lack of clinically important difference was found for knee function (183 participants, 2 trials).",delete,[],6,0.4444444444444444,3,27
CD010513,2,12,"None of the trials reported on quality of life measures, resource use or participant satisfaction.",delete,[],6,0.48148148148148145,3,27
CD010513,2,13,"Although two trials reported on the impact on sporting or occupational participation, one trial (35 participants) did not provide data split by treatment group on the resumption of sport activity and the other reported only on abandonment of military training due to knee pain (both cases were allocated a knee orthosis).",delete,[],6,0.5185185185185185,3,27
CD010513,2,14,"One trial (59 participants, 84 affected knees) recording only adverse events in the two knee orthoses (both were knee sleeves) groups, reported 16 knees (36% of 44 knees) had discomfort or skin abrasion.",delete,[],6,0.5555555555555556,3,27
CD010513,3,15,"Three trials provided very low quality evidence on single comparisons of different types of knee orthoses: a knee brace versus a knee sleeve (63 participants), a patella strap with a knee sleeve (31 participants), and a knee sleeve with a patellar ring versus a knee sleeve only (44 knees).",ignore,"['Three studies provided very low quality evidence on single comparisons of different types of knee orthoses: a knee brace versus a knee sleeve (63 participants), a patella strap with a knee sleeve (31 participants), and a knee sleeve with a patellar ring versus a knee sleeve only (44 knees).']",6,0.5925925925925926,3,27
CD010513,3,16,None of three trials found an important difference between the two types of knee orthosis in pain.,ignore,['None of three studies found an important difference between the two types of knee orthosis in knee pain.'],7,0.6296296296296297,4,27
CD010513,3,17,One trial found no clinically important difference in function between a knee brace and a knee sleeve.,rephrase,['One study found no important difference in function between a knee brace and a knee sleeve.'],8,0.6666666666666666,4,27
CD010513,3,18,"None of the three trials reported on quality of life, resource use or participant satisfaction.",ignore,"['None of the three studies reported on quality of life, resource use or participant satisfaction.']",9,0.7037037037037037,4,27
CD010513,3,19,One trial comparing a patella strap with a knee sleeve reported that both participants quitting military training due to knee pain were allocated a knee sleeve.,ignore,['One study comparing a patella strap with a knee sleeve reported that both participants quitting military training due to knee pain were allocated a knee sleeve.'],10,0.7407407407407407,4,27
CD010513,3,20,One poorly reported trial found three times as many knees with adverse effects (discomfort or skin abrasion) in those given knee sleeves with a patella ring than those given knee sleeves only.,ignore,['One poorly reported study found three times as many knees with discomfort or skin abrasion in those given knee sleeves with a patella ring than those given knee sleeves only.'],11,0.7777777777777778,4,27
CD010513,4,21,One trial compared a knee orthosis (knee brace) with exercise (66 participants).,rephrase,['One study (66 participants) compared a knee orthosis (knee brace) with exercise.'],12,0.8148148148148148,5,27
CD010513,4,22,It found very low quality evidence of no clinically important difference between the two intervention groups in pain or knee function.,ignore,['It provided very low quality evidence of no clinically important difference between the two intervention groups in pain or knee function.'],13,0.8518518518518519,5,27
CD010513,4,23,"The trial did not report on quality of life, impact on sporting or occupational participation, resource use, participant satisfaction or complications.",rephrase,['It did not report on other outcomes including complications.'],14,0.8888888888888888,5,27
CD010513,5,24,"Overall, this review has found a lack of evidence to inform on the use of knee orthoses for treating PFPS.",ignore,"['Overall, we found a lack of evidence to inform on the use of knee orthoses for treating PFPS.']",15,0.9259259259259259,5,27
CD010513,5,25,"There is, however, very low quality evidence from clinically heterogeneous trials using different types of knee orthoses (knee brace, sleeve and strap) that using a knee orthosis did not reduce knee pain or improve knee function in the short term (under three months) in adults who were also undergoing an exercise programme for treating PFPS.",rephrase,"['Our review found very low quality evidence from trials testing different knee orthoses (knee brace, sleeve and strap) that using a knee orthosis may not reduce knee pain or improve knee function in the short term (under three months) in adults who were also undergoing an exercise programme for treating PFPS.']",16,0.9629629629629629,5,27
CD010513,5,26,This points to the need for good-quality clinically-relevant research to inform on the use of commonly-available knee orthoses for treating PFPS.,ignore,['These findings point to the need for good-quality clinically-relevant research to inform on the use of commonly-available knee orthoses for treating PFPS.'],17,1.0,5,27
CD004655,0,0,Three RCTs met our inclusion criteria.,delete,[],0,0.05263157894736842,1,19
CD004655,0,1,The trials randomised 153 participants (74 participants to oral vitamin B12 and 79 participants to IM vitamin B12).,rephrase,['The studies randomised 153 participants (74 participants to oral vitamin B12 and 79 participants to intramuscular vitamin B12).'],0,0.10526315789473684,1,19
CD004655,0,2,Treatment duration and follow-up ranged between three and four months.,ignore,['Treatment duration and follow-up ranged between three and four months.'],1,0.15789473684210525,1,19
CD004655,0,3,The mean age of participants ranged from 38.6 to 72 years.,ignore,['The mean age of participants ranged from 39 to 72 years.'],2,0.21052631578947367,2,19
CD004655,0,4,The treatment frequency and daily dose of vitamin B12 in the oral and IM groups varied among trials.,delete,[],3,0.2631578947368421,2,19
CD004655,0,5,Only one trial had low or unclear risk of bias across all domains and outcome measures.,delete,[],3,0.3157894736842105,2,19
CD004655,0,6,Two trials reported data for serum vitamin B12 levels.,delete,[],3,0.3684210526315789,2,19
CD004655,0,7,The overall quality of evidence for this outcome was low due to serious imprecision (low number of trials and participants).,rephrase,"['The overall quality of the evidence was low or very low, mainly due to the small number of included studies and the low numbers of participants in these studies.']",3,0.42105263157894735,3,19
CD004655,0,8,"In two trials employing 1000 μg/day oral vitamin B12, there was no clinically relevant difference in vitamin B12 levels when compared with IM vitamin B12.",rephrase,['Two studies used 1000 μg/day oral vitamin B12 and showed no relevant difference to intramuscularly applied vitamin B12 with regard to vitamin B12 blood levels.'],4,0.47368421052631576,3,19
CD004655,0,9,One trial used 2000 μg/day vitamin B12 and demonstrated a mean difference of 680 pg/mL (95% confidence interval 392.7 to 967.3) in favour of oral vitamin B12.,rephrase,['One trial used 2000 μg/day vitamin B12 and showed higher vitamin B12 blood levels in favour of oral vitamin B12.'],5,0.5263157894736842,3,19
CD004655,0,10,"Two trials reported data on adverse events (very low-quality evidence due to risk of performance bias, detection bias, and serious imprecision).",rephrase,['Two studies reported side effects.'],6,0.5789473684210527,3,19
CD004655,0,11,One trial stated that no treatment-related adverse events were seen in both the oral and IM vitamin B12 groups.,rephrase,['One study stated that no treatment-related side effects were seen in both the oral and intramuscular vitamin B12 groups.'],7,0.631578947368421,4,19
CD004655,0,12,One trial reported that 2 of 30 participants (6.7%) in the oral vitamin B12 group left the trial early due to adverse events.,rephrase,['One study reported that 2 of 30 participants in the oral vitamin B12 group left the trial early due to side effects.'],8,0.6842105263157895,4,19
CD004655,0,13,Orally taken vitamin B12 showed lower treatment-associated costs than IM vitamin B12 in one trial (low-quality evidence due to serious imprecision).,rephrase,['Orally taken vitamin B12 showed lower treatment-associated costs than intramuscular vitamin B12 in one trial.'],9,0.7368421052631579,4,19
CD004655,0,14,"No trial reported on clinical signs and symptoms of vitamin B12 deficiency, health-related quality of life, or acceptability of the treatment scheme.",rephrase,"['No study reported on clinical signs and symptoms of vitamin B12 deficiency (e.g. fatigue, depression, neurological complications), health-related quality of life, or acceptability of the treatment scheme.']",10,0.7894736842105263,4,19
CD004655,1,15,"Low quality evidence shows oral and IM vitamin B12 having similar effects in terms of normalising serum vitamin B12 levels, but oral treatment costs less.",delete,[],11,0.8421052631578947,5,19
CD004655,1,16,We found very low-quality evidence that oral vitamin B12 appears as safe as IM vitamin B12.,delete,[],11,0.8947368421052632,5,19
CD004655,1,17,"Further trials should conduct better randomisation and blinding procedures, recruit more participants, and provide adequate reporting.",delete,[],11,0.9473684210526315,5,19
CD004655,1,18,"Future trials should also measure important outcomes such as the clinical signs and symptoms of vitamin B12 deficiency, health related-quality of life, socioeconomic effects, and report adverse events adequately, preferably in a primary care setting.",delete,[],11,1.0,5,19
CD008123,0,0,A single RCT met the inclusion criteria.,delete,[],0,0.08333333333333333,1,12
CD008123,0,1,Our 2018 search update identified no additional trials.,rephrase,"['The evidence is up-to-date to January 2018, when we updated the searches and found no new trials.']",0,0.16666666666666666,1,12
CD008123,0,2,The included trial evaluated BIG-IV for the treatment of infant botulism and included 59 treatment participants and 63 control participants.,delete,[],1,0.25,2,12
CD008123,0,3,The control group received a control immune globulin that did not have an effect on botulinum toxin.,delete,[],1,0.3333333333333333,2,12
CD008123,0,4,Participants were followed during the length of their hospitalization to measure the outcomes of interest.,rephrase,['Each study participant was followed up for the duration of their hospitalization.'],1,0.4166666666666667,3,12
CD008123,0,5,"There was some violation of intention-to-treat principles, and possibly some between-treatment group imbalances among participants admitted to the intensive care unit and mechanically ventilated, but otherwise the risk of bias was low.",delete,[],2,0.5,3,12
CD008123,0,6,"There were no deaths in either group, making any treatment effect on mortality inestimable.",rephrase,['There were no deaths in either group in the trial.'],2,0.5833333333333334,3,12
CD008123,0,7,"There was a benefit in the treatment group on mean duration of hospitalization (BIG-IV: 2.60 weeks, 95% confidence interval (CI) 1.95 to 3.25; control: 5.70 weeks, 95% CI 4.40 to 7.00; mean difference (MD) -3.10 weeks, 95% CI -4.52 to -1.68; moderate-certainty evidence); mechanical ventilation (BIG-IV: 1.80 weeks, 95% CI 1.20 to 2.40; control: 4.40 weeks, 95% CI 3.00 to 5.80; MD -2.60 weeks, 95% CI -4.06 to -1.14; low-certainty evidence); and tube or parenteral feeding (BIG-IV: 3.60 weeks, 95% CI 1.70 to 5.50; control: 10.00 weeks, 95% CI 6.85 to 13.15; MD -6.40 weeks, 95% CI -10.00 to -2.80; moderate-certainty evidence), but not on proportion of participants with adverse events or complications (BIG-IV: 63.08%; control: 68.75%; risk ratio 0.92, 95% CI 0.72 to 1.18; absolute risk reduction 0.06, 95% CI 0.22 to -0.11; moderate-certainty evidence).",delete,[],3,0.6666666666666666,4,12
CD008123,1,8,We found low- and moderate-certainty evidence supporting the use of BIG-IV in infant intestinal botulism.,rephrase,['The evidence was mostly of moderate certainty (low certainty for time spent on a ventilator).'],3,0.75,4,12
CD008123,1,9,A single RCT demonstrated that BIG-IV probably decreases the duration of hospitalization; may decrease the duration of mechanical ventilation; and probably decreases the duration of tube or parenteral feeding.,rephrase,['The review shows that BIG-IV probably shortens hospitalization; may shorten time spent on a ventilator; and probably reduces the duration of tube feeding compared to placebo.'],4,0.8333333333333334,5,12
CD008123,1,10,Adverse events were probably no more frequent with immune globulin than with placebo.,delete,[],5,0.9166666666666666,5,12
CD008123,1,11,Our search did not reveal any evidence examining the use of other medical treatments including serum trivalent botulism antitoxin.,rephrase,"['Our searches of the medical literature revealed one relevant study, which was in infant botulism.']",5,1.0,5,12
CD010873,0,0,One study from Australia including 46 children aged 8 to 18 years was eligible for inclusion.,rephrase,"['The participants of the included study were 46 children aged 8 to 18 years recruited from the clinic of a tertiary hospital in Melbourne, Australia who were diagnosed with long-term constipation either based on their symptoms and/or X-ray studies.']",0,0.05263157894736842,1,19
CD010873,0,1,"There were multiple reports identified, including one unpublished report, that focused on different outcomes of the same study.",rephrase,['We included a single study with 11 reports that focused on results for different outcomes.'],1,0.10526315789473684,1,19
CD010873,0,2,"The study had unclear risk of selection bias, high risks of performance, detection and attrition biases, and low risks of reporting biases.",delete,[],2,0.15789473684210525,1,19
CD010873,1,3,"We are very uncertain about the effects of TES on bowel movements, colonic transit, soiling symptoms and quality of life due to high risk of bias, indirectness and imprecision.",delete,[],2,0.21052631578947367,2,19
CD010873,1,4,For our outcomes of interest the 95% CI of most analysis results include potential benefit and no effect.,delete,[],2,0.2631578947368421,2,19
CD010873,1,5,There is insufficient evidence to determine the effect of TES on bowel movements and colonic transit.,delete,[],2,0.3157894736842105,2,19
CD010873,1,6,"The study reported that 16/21 children in the TES group and 15/21 in the sham group had > 3 complete spontaneous bowel movements (CSBM) per week (RR 1.07, 95% CI 0.74 to 1.53; very low-quality evidence).",delete,[],2,0.3684210526315789,2,19
CD010873,1,7,"Ten out of 14 children in the TES group had improved colonic transit compared to 1/7 in the sham group (RR 5.00, 95% CI 0.79 to 31.63; very low-quality evidence).",delete,[],2,0.42105263157894735,3,19
CD010873,1,8,"Mean colonic transit rate, measured as the position of the geometric centre of the radioactive substance ingested along the intestinal tract, was higher in children who received TES compared to sham (MD 1.05, 95% CI 0.36 to 1.74; one study, 30 participants; very low-quality evidence).",rephrase,"['The only difference noted was in mean bowel transit rate, namely, distance travelled by the radioactive substance along the bowel, in which children who received TES had their radioactive substance slightly further down their bowel compared to children who received a sham stimulation.']",2,0.47368421052631576,3,19
CD010873,1,9,The radiological assessment of colonic transit outcomes means that these results might not translate to important improvement in clinical symptoms or increased bowel movements.,delete,[],3,0.5263157894736842,3,19
CD010873,1,10,There is insufficient evidence to determine the effect of TES on symptoms and quality of life (QoL) outcomes.,rephrase,['The very low quality evidence for all of the results means that we are uncertain about the effects of TES when compared with sham stimulation.'],3,0.5789473684210527,3,19
CD010873,1,11,"Nine out of 13 children in the TES group had improved soiling-related symptoms compared to 4/12 sham participants (RR 2.08, 95% CI 0.86 to 5.00; very low-quality evidence).",rephrase,"['Overall, there were no differences between children who received TES and sham stimulation in the number of children with improved complete spontaneous bowel movements, improved bowel movements (as assessed by X-Ray with special contrast), improved symptoms related to soiling and quality of life.']",4,0.631578947368421,4,19
CD010873,1,12,"Four out of 8 TES participants reported an improvement in QoL compared to 1/8 sham participants (RR 4.00, 95% CI 0.56 to 28.40; very low-quality evidence).",delete,[],5,0.6842105263157895,4,19
CD010873,1,13,"The effects of TES on self-perceived (MD 5.00, 95% CI -1.21 to 11.21; one study, 33 participants; very low-quality evidence) or parent-perceived QoL (MD -0.20, 95% CI -7.57 to 7.17, one study, 33 participants; very low-quality evidence) are uncertain.",delete,[],5,0.7368421052631579,4,19
CD010873,1,14,No adverse effects were reported in the included study.,rephrase,['No side effects were reported in the study.'],5,0.7894736842105263,4,19
CD010873,2,15,The results for the outcomes assessed in this review are uncertain.,ignore,['The results for the outcomes assessed in this review are uncertain.'],6,0.8421052631578947,5,19
CD010873,2,16,Thus no firm conclusions regarding the efficacy and safety of TES in children with chronic constipation can be drawn.,rephrase,['Thus no firm conclusions regarding the effectiveness and side effects of TES in children with chronic constipation can be drawn.'],7,0.8947368421052632,5,19
CD010873,2,17,Further randomized controlled trials assessing TES for the management of childhood constipation should be conducted.,rephrase,['Further studies assessing TES for the management of constipation are needed.'],8,0.9473684210526315,5,19
CD010873,2,18,"Future trials should include clear documentation of methodologies, especially measures to evaluate the effectiveness of blinding, and incorporate patient-important outcomes such as the number of patients with improved CSBM, improved clinical symptoms and quality of life.",rephrase,"['We suggest that future research should provide clear documentation on specific methods in the conduct of the trials, and include outcomes that are important for patients, such as spontaneous or complete bowel movements or improvement in constipation-related symptoms along with assessments of quality of life.']",9,1.0,5,19
CD009194,0,0,We included three small RCTs enrolling 79 participants.,rephrase,['Three small randomised controlled trials (RCTs) enrolling 79 participants were included in the review.'],0,0.08333333333333333,1,12
CD009194,0,1,Two trials did not use a placebo in the control arms and the third trial used air placebo.,delete,[],1,0.16666666666666666,1,12
CD009194,0,2,Two included studies reported no mortality.,ignore,['Two included studies reported no mortality.'],1,0.25,2,12
CD009194,0,3,We judged all three of the included studies to be at low risk or unclear risk across all risk of bias categories; we did not judge any of the studies to be at high risk of bias in any category.,delete,[],2,0.3333333333333333,2,12
CD009194,0,4,"Our pooled analysis of the three trials revealed that duration of mechanical ventilation was not significantly different between the groups (mean difference (MD) -63.04, 95% confidence interval (CI) -130.43 to 4.35 hours) but duration of intensive care unit (ICU) stay was less in the surfactant group compared to the control group: MD -3.31, 95% CI -6.38 to -0.25 days.",delete,[],2,0.4166666666666667,3,12
CD009194,0,5,"After excluding one trial which produced significant heterogeneity, the duration of mechanical ventilation and duration of ICU stay were significantly lower in the surfactant group compared to the control group: MD -28.99, 95% CI -40.10 to -17.87 hours; and MD -1.81, 95% CI -2.42 to -1.19 days, respectively.",delete,[],2,0.5,3,12
CD009194,0,6,Use of surfactant had favourable effects on oxygenation and CO2 elimination.,delete,[],2,0.5833333333333334,3,12
CD009194,0,7,No adverse effects and no complications were observed in any of the three included studies.,rephrase,['No complications were observed in any of the three included studies.'],2,0.6666666666666666,4,12
CD009194,0,8,"The level of evidence for duration of mechanical ventilation, duration of intensive care unit stay, oxygenation parameters, and carbon dioxide parameters was of moderate quality.",ignore,"['The level of evidence for duration of mechanical ventilation, duration of intensive care unit stay, oxygenation parameters, and carbon dioxide parameters was of moderate quality.']",3,0.75,4,12
CD009194,1,9,"Use of surfactant had favourable effects on duration of mechanical ventilation, duration of ICU stay, oxygenation, and CO2 elimination.",split,"['Use of surfactant for mechanically ventilated infants and children with bronchiolitis did not decrease the duration of mechanical ventilation.', 'However, the intervention decreased duration of stay in the intensive care unit and had favourable effects on oxygenation and carbon dioxide removal.']",4,0.8333333333333334,5,12
CD009194,1,10,"However, the studies are few and small (n = 79) so available evidence is insufficient to establish the effectiveness of surfactant therapy for bronchiolitis in critically ill infants who require mechanical ventilation.",merge,[],6,0.9166666666666666,5,12
CD009194,1,11,There is a need for larger trials with adequate power and a cost-effectiveness analysis to evaluate the effectiveness of exogenous surfactant therapy for infants with bronchiolitis who require intensive care management.,none,['There is a need for larger trials to establish any benefits of surfactant for bronchiolitis in critically ill infants and children.'],6,1.0,5,12
CD007747,0,0,"Fifteen studies (8 parallel, 7 crossover; 352 patients) were included.",merge,[],0,0.1,1,10
CD007747,0,1,Only one study enrolled women.,none,['We identified 15 studies enrolling 352 patients with only one study enrolling both men and women.'],0,0.2,1,10
CD007747,0,2,"Studies evaluated the effects of phosphodiesterase-5 inhibitors (PDE5i), zinc, vitamin E, vitamin D or bromocriptine compared to placebo.",ignore,"['Studies evaluated the effects of phosphodiesterase-5 inhibitors (PDE5i), zinc, vitamin E, vitamin D or bromocriptine compared to placebo.']",1,0.3,2,10
CD007747,0,3,"PDE5i significantly increased the overall International Index of Erectile Function-5 (IIEF-5) score (2 studies, 101 patients, MD 10.65, 95% CI 5.34 to 15.96), all its individual domains and the complete 15-item IIEF tool (1 study, 41 patients, MD 2.64, 95% CI 1.32 to 3.96).",rephrase,"['In two studies (101 patients) PDE5i significantly increased the individual domains and the overall International Index of Erectile Function-5 (IIEF-5) score and the complete 15-item IIEF tool (1 study, 41 patients).']",2,0.4,2,10
CD007747,0,4,"End of treatment testosterone levels were not significantly increased by addition of zinc to dialysate (2 studies, 22 patients, MD 0.21 ng/mL, 95% CI -2.14 to 2.55) but oral zinc improved end of treatment testosterone levels (1 study, 20 patients, SMD 1.62, 95% CI 0.58 to 2.66).",rephrase,"['End of treatment testosterone levels were not significantly increased by addition of zinc to dialysate (2 studies, 22 patients) but oral zinc improved end of treatment testosterone levels (1 study, 20 patients).']",3,0.5,3,10
CD007747,0,5,There was no difference in plasma luteinizing and follicle-stimulating hormone levels at the end of the study period with zinc therapy.,ignore,['There was no difference in plasma luteinizing and follicle-stimulating hormone levels at the end of the study period with zinc therapy.'],4,0.6,3,10
CD007747,0,6,"Only sparse data were available for vitamin E, bromocriptine and dihydroxycholecalciferol in CKD patients and there were no studies of intracavernous injections, transurethral injections, mechanical devices or psychosexual therapies in people with CKD.",ignore,"['Little data were available for vitamin E, bromocriptine and dihydroxycholecalciferol in CKD patients and there were no studies of intracavernous injections, transurethral injections, mechanical devices or behavioural therapy in people with CKD.']",5,0.7,4,10
CD007747,1,7,PDE5i and zinc are promising interventions for treating sexual dysfunction in men with CKD.,merge,['PDE5i and zinc are promising interventions for treating sexual dysfunction in men with CKD however\xa0evidence supporting their routine use in CKD patients is limited.'],6,0.8,4,10
CD007747,1,8,Evidence supporting their routine use in CKD patients is limited.,none,[],6,0.9,5,10
CD007747,1,9,"There is an unmet need for studying interventions for both male and female sexual dysfunction in CKD, considering the significant disease burden.",ignore,"['There is an unmet need for studying interventions for both male and female sexual dysfunction in CKD, considering the significant disease burden.']",7,1.0,5,10
CD013384,0,0,"Quantitative studies
We included seven studies (1197 participants) in the quantitative analyses, with interventions including telemonitoring, pulmonary rehabilitation, treatment optimisation, water-based exercise training and case management.",rephrase,"[""We found seven \xa0eligible randomised controlled trials (RCTs) including 1197 people, and one qualitative study which was part of one of the randomised trials and provided information about people's opinions and experiences of using telehealth equipment.""]",0,0.043478260869565216,1,23
CD013384,0,1,Interventions were either compared with usual care or with an active comparator (such as land-based exercise training).,delete,[],1,0.08695652173913043,1,23
CD013384,0,2,Duration of trials ranged from 4 to 52 weeks.,delete,[],1,0.13043478260869565,1,23
CD013384,0,3,Mean age of participants ranged from 64 to 72 years and COPD severity ranged from mild to very severe.,rephrase,"['People included in the trials were aged between 64 and 72 years, and their COPD severity ranged from mild to very severe.']",1,0.17391304347826086,1,23
CD013384,0,4,"Trials included either people with COPD and a specific comorbidity (including cardiovascular disease, metabolic syndrome, lung cancer, head or neck cancer, and musculoskeletal conditions), or with one or more comorbidities of any type.",rephrase,"['The trials either included people with COPD and a specific comorbidity such as cardiovascular disease or lung cancer, or they included people with COPD and one or more other conditions of any sort.']",2,0.21739130434782608,2,23
CD013384,1,5,"Overall, we judged the evidence presented to be of moderate to very low certainty (GRADE), mainly due to the methodological quality of included trials and imprecision of effect estimates.",delete,[],3,0.2608695652173913,2,23
CD013384,2,6,"Intervention versus usual care
Quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) total score may improve with tailored pulmonary rehabilitation compared to usual care at 52 weeks (mean difference (MD) −10.85, 95% confidence interval (CI) −12.66 to −9.04; 1 study, 70 participants; low-certainty evidence).",rephrase,"[""The available evidence indicated the following:\n- Quality of life as measured by the St George's Respiratory Questionnaire (SGRQ) total score may improve with tailored pulmonary rehabilitation compared to usual care (note that there is a strong evidence base for pulmonary rehabilitation in people with COPD).""]",3,0.30434782608695654,2,23
CD013384,2,7,"Tailored pulmonary rehabilitation is likely to improve COPD assessment test (CAT) scores compared with usual care at 52 weeks (MD −8.02, 95% CI −9.44 to −6.60; 1 study, 70 participants, moderate-certainty evidence) and with a multicomponent telehealth intervention at 52 weeks (MD −6.90, 95% CI −9.56 to −4.24; moderate-certainty evidence).",rephrase,['- Pulmonary rehabilitation is likely to improve quality of life as measured by the COPD assessment test (CAT) scores compared with usual care at 52 weeks and with a multicomponent telehealth intervention.'],4,0.34782608695652173,2,23
CD013384,2,8,Evidence is uncertain about effects of pharmacotherapy optimisation or telemonitoring interventions on CAT improvement compared with usual care.,ignore,['- Evidence is uncertain about the effects of pharmacotherapy optimisation or telemonitoring interventions on CAT improvement compared with usual care.'],5,0.391304347826087,2,23
CD013384,3,9,"There may be little to no difference in the number of people experiencing exacerbations, or mean exacerbations with case management compared with usual care (OR 1.09, 95% CI 0.75 to 1.57; 1 study, 470 participants; very low-certainty evidence).",rephrase,"['- There may be little to no difference in the number of people experiencing exacerbations, or mean exacerbations with case management compared with usual care.']",6,0.43478260869565216,3,23
CD013384,4,10,"For secondary outcomes, six-minute walk distance (6MWD) may improve with pulmonary rehabilitation, water-based exercise or multicomponent interventions at 38 to 52 weeks (low-certainty evidence).",rephrase,"['- For secondary outcomes, the distance walked by participants in six minutes may improve with pulmonary rehabilitation, water-based exercise or multicomponent interventions.']",7,0.4782608695652174,3,23
CD013384,4,11,"A multicomponent intervention may result in fewer people being admitted to hospital at 17 weeks, although there may be little to no difference in a telemonitoring intervention.",ignore,"['A multicomponent intervention may result in fewer people being admitted to hospital, although there may be little to no difference in a telemonitoring intervention.']",8,0.5217391304347826,3,23
CD013384,4,12,There may be little to no difference between intervention and usual care for mortality.,rephrase,['- There may be little to no difference between intervention and usual care for deaths across several studies.'],9,0.5652173913043478,3,23
CD013384,5,13,"Intervention versus active comparator
We included one study comparing water-based and land-based exercise (30 participants).",rephrase,['- One study compared water-based exercise with land-based exercise.'],10,0.6086956521739131,4,23
CD013384,5,14,We found no evidence for quality of life or exacerbations.,ignore,['We found no evidence for quality of life or exacerbations.'],11,0.6521739130434783,4,23
CD013384,6,15,"There may be little to no difference between water- and land-based exercise for 6MWD (MD 5 metres, 95% CI −22 to 32; 38 participants; very low-certainty evidence).",rephrase,['There may be little to no difference between water- and land-based exercise on the distance walked by participants in six minutes.'],12,0.6956521739130435,4,23
CD013384,7,16,"Qualitative studies
One nested qualitative study (21 participants) explored perceptions and experiences of people with COPD and long-term conditions, and of researchers and health professionals who were involved in an RCT of telemonitoring equipment.",rephrase,"['- One qualitative study explored perceptions and experiences of people with COPD and long-term conditions, and of researchers and health professionals who were involved in an RCT of telemonitoring equipment.']",13,0.7391304347826086,4,23
CD013384,8,17,"Several themes were identified, including health status, beliefs and concerns, reliability of equipment, self-efficacy, perceived ease of use, factors affecting usefulness and perceived usefulness, attitudes and intention, self-management and changes in healthcare use.",ignore,"['Several themes were identified, including health status, beliefs and concerns, reliability of equipment, self-efficacy, perceived ease of use, factors affecting usefulness and perceived usefulness, attitudes and intention, self-management and changes in healthcare use.']",14,0.782608695652174,4,23
CD013384,8,18,We judged the qualitative evidence presented as of very low certainty overall.,delete,[],15,0.8260869565217391,5,23
CD013384,9,19,"Owing to a paucity of eligible trials, as well as diversity in the intervention type, comorbidities and the outcome measures reported, we were unable to provide a robust synthesis of data.",delete,[],15,0.8695652173913043,5,23
CD013384,9,20,"Pulmonary rehabilitation or multicomponent interventions may improve quality of life and functional status (6MWD), but the evidence is too limited to draw a robust conclusion.",delete,[],15,0.9130434782608695,5,23
CD013384,9,21,The key take-home message from this review is the lack of data from RCTs on treatments for people living with COPD and comorbidities.,delete,[],15,0.9565217391304348,5,23
CD013384,10,22,"Given the variation in number and type of comorbidity(s) an individual may have, and severity of COPD, larger studies reporting individual patient data are required to determine these effects.",delete,[],15,1.0,5,23
CD010996,0,0,"We identified one new study for this update, bringing the total number of included studies to four (255 participants).",rephrase,['We included four studies with a total of 255 participants in the review.'],0,0.07692307692307693,1,13
CD010996,0,1,"The four trials directly compared the use of normal saline and heparin; the studies all used different protocols for the intervention and control arms, however, and all used different concentrations of heparin.",rephrase,"['The four trials were all undertaken in large teaching (tertiary) hospitals, and directly compared the use of saline and heparin.']",1,0.15384615384615385,1,13
CD010996,0,2,Different frequencies of flushes were also reported between studies.,rephrase,"['The studies were, however, very different in the way they compared saline and heparin, with different concentrations of heparin and different frequencies of flushes reported.']",2,0.23076923076923078,2,13
CD010996,0,3,"In addition, not all studies reported on all outcomes.",rephrase,"['There was high risk of bias for blinding, there were differences between the studies methods and interventions, inconsistent results between the studies, and not all studies reported all outcomes of interest.']",3,0.3076923076923077,2,13
CD010996,0,4,The certainty of the evidence ranged from moderate to very low because there was no blinding; heterogeneity and inconsistency between studies was high; and the CIs were wide.,rephrase,['The overall certainty of the evidence ranged from moderate to very low.'],4,0.38461538461538464,2,13
CD010996,0,5,CVC occlusion was assessed in all four trials.,delete,[],5,0.46153846153846156,3,13
CD010996,0,6,We were able to pool the results of two trials for the outcomes of CVC occlusion and CVC-associated blood stream infection.,rephrase,['We were able to combine the results of two studies: the analysis showed imprecise results for the blocking of catheters and blood stream infections for normal saline versus heparin.'],5,0.5384615384615384,3,13
CD010996,0,7,"The estimated RR for CVC occlusion per 1000 catheter days between the normal saline and heparin groups was 0.75 (95% CI 0.10 to 5.51; 2 studies, 229 participants; very low certainty evidence).",delete,[],6,0.6153846153846154,4,13
CD010996,0,8,"The estimated RR for CVC-associated blood stream infection was 1.48 (95% CI 0.24 to 9.37; 2 studies, 231 participants; low-certainty evidence).",delete,[],6,0.6923076923076923,4,13
CD010996,0,9,"The duration of catheter placement was reported to be similar for the two study arms in one study (203 participants; moderate-certainty evidence), and not reported in the remaining studies.",rephrase,['One study reported the duration of catheter placement to be similar between the two study arms.'],6,0.7692307692307693,4,13
CD010996,1,10,The review found that there was not enough evidence to determine the effects of intermittent flushing with normal saline versus heparin to prevent occlusion in long-term central venous catheters in infants and children.,rephrase,"['We found there was not enough evidence to determine which solution, saline or heparin, is more effective for reducing complications.']",7,0.8461538461538461,5,13
CD010996,1,11,"It remains unclear whether heparin is necessary to prevent occlusion, CVC-associated blood stream infection or effects duration of catheter placement.",delete,[],8,0.9230769230769231,5,13
CD010996,1,12,Lack of agreement between institutions around the world regarding the appropriate care and maintenance of these devices remains.,delete,[],8,1.0,5,13
CD007748,0,0,We included one randomised trial (involving 98 women) that evaluated the effectiveness of one type of COX inhibitor (rofecoxib) for preventing preterm birth.,rephrase,"['We included one small randomised trial (involving 98 women) that involved the drug rofecoxib, which is one type of COX inhibitor.']",0,0.1,1,10
CD007748,0,1,The included study did not report any data for one of our primary outcomes: preterm labour.,rephrase,['The included study did not report any information about prevention of labour before full-term pregnancy.'],1,0.2,1,10
CD007748,0,2,Rofecoxib use was associated with an increased risk for preterm birth and preterm premature rupture of membranes (PPROM).,delete,[],2,0.3,2,10
CD007748,0,3,Rofecoxib was associated with a higher risk of oligohydramnios and low fetal urine production but the effects were reversible after stopping treatment.,delete,[],2,0.4,2,10
CD007748,0,4,There were no differences in the number of women who discontinued treatment before 32 weeks of gestation.,delete,[],2,0.5,3,10
CD007748,0,5,There was no difference in neonatal morbidities and admission to neonatal intensive care unit.,delete,[],2,0.6,3,10
CD007748,0,6,There were no maternal adverse effects or perinatal mortalities in either group.,delete,[],2,0.7,4,10
CD007748,1,7,There was very little evidence about using COX inhibitors for preventing preterm labour.,rephrase,"['However, use of this COX inhibitor was associated with an increased risk of the baby being born before full term.']",2,0.8,4,10
CD007748,1,8,There are inadequate data to make any recommendation about using COX inhibitor in practice to prevent preterm labour.,rephrase,['We found insufficient data to make any recommendation about using COX inhibitors for preventing preterm labour.'],3,0.9,5,10
CD007748,1,9,Future research should include follow-up of the babies to examine the short-term and long-term effects of COX inhibitors.,rephrase,['Future research should include the follow-up of babies to examine the short- and longer-term effects associated with using COX inhibitors during pregnancy.'],4,1.0,5,10
CD011644,0,0,We identified 10 randomised clinical trials with 488 randomised participants that met our inclusion criteria.,rephrase,['We identified 10 randomised clinical trials which were eligible for our review.'],0,0.041666666666666664,1,24
CD011644,0,1,All the trials were at high risk of bias in one or more domains.,merge,"['All the trials were at high risk of bias, and the overall quality of the evidence was very low.']",1,0.08333333333333333,1,24
CD011644,0,2,"Overall, the evidence for all the outcomes was very low quality evidence.",none,[],1,0.125,1,24
CD011644,0,3,Nine trials (467 participants) provided information for one or more outcomes.,rephrase,['Nine randomised clinical trials (467 participants) provided information for one or more measures (outcomes).'],2,0.16666666666666666,1,24
CD011644,0,4,Three trials (99 participants) compared interferon-alpha versus no intervention.,delete,[],3,0.20833333333333334,2,24
CD011644,0,5,Three trials (90 participants) compared interferon-beta versus no intervention.,delete,[],3,0.25,2,24
CD011644,0,6,"One trial (21 participants) compared pegylated interferon-alpha versus no intervention, but it did not provide any data for analysis.",delete,[],3,0.2916666666666667,2,24
CD011644,0,7,One trial (41 participants) compared MTH-68/B vaccine versus no intervention.,rephrase,"['The main interventions compared included different forms of interferon (protein secreted in response to viral infection), namely, interferon-alpha alone, interferon-beta alone, pegylated interferon-alpha alone, pegylated interferon-alpha plus ribavirin (another antiviral drug), a vaccine called MTH-68/B made from a different virus, versus no intervention.']",3,0.3333333333333333,2,24
CD011644,0,8,Two trials (237 participants) compared pegylated interferon-alpha versus pegylated interferon-alpha plus ribavirin.,delete,[],4,0.375,2,24
CD011644,0,9,None of the trials compared direct-acting antivirals versus placebo or other interventions.,rephrase,['None of the trials compared direct-acting antivirals (the latest option for treating HCV infection) versus placebo or other interventions.'],4,0.4166666666666667,3,24
CD011644,0,10,The mean or median follow-up period in the trials ranged from six to 36 months.,rephrase,['The average follow-up period in the trials ranged from six months to three years.'],5,0.4583333333333333,3,24
CD011644,1,11,There was no short-term mortality (less than one year) in any group in any trial except for one trial where one participant died in the pegylated interferon-alpha plus ribavirin group (1/95: 1.1%).,rephrase,['No deaths occurred less than one year after treatment in any group in any trial except for one trial where one participant died in the pegylated interferon-alpha plus ribavirin group (1/95: 1.1%).'],6,0.5,3,24
CD011644,1,12,"In the trials that reported follow-up beyond one year, there were no further deaths.",rephrase,"['In the trials in which participants were followed up beyond one year, there were no further deaths.']",7,0.5416666666666666,3,24
CD011644,1,13,"The number of serious adverse events was higher with pegylated interferon-alpha plus ribavirin than with pegylated interferon-alpha (rate ratio 2.74, 95% CI 1.40 to 5.33; participants = 237; trials = 2; I2 = 0%).",rephrase,['The number of serious complications was higher with pegylated interferon-alpha plus ribavirin than with pegylated interferon-alpha.'],8,0.5833333333333334,3,24
CD011644,1,14,"The proportion of people with any adverse events was higher with interferon-alpha and interferon-beta compared with no intervention (OR 203.00, 95% CI 9.01 to 4574.81; participants = 33; trials = 1 and OR 27.88, 95% CI 1.48 to 526.12; participants = 40; trials = 1).",rephrase,['The percentage of people with any complications was higher with interferon-alpha and interferon-beta than with no intervention.'],9,0.625,4,24
CD011644,1,15,"None of the trials reported health-related quality of life, liver transplantation, decompensated liver disease, cirrhosis, or hepatocellular carcinoma.",rephrase,"['None of the trials reported health-related quality of life, liver transplantation, liver failure, severe liver damage, or liver cancer.']",10,0.6666666666666666,4,24
CD011644,1,16,"The proportion of people with chronic HCV infection as indicated by the lack of sustained virological response was lower in the interferon-alpha group versus no intervention (OR 0.27, 95% CI 0.09 to 0.76; participants = 99; trials = 3; I2 = 0%).",rephrase,['The percentage of people in whom the virus remained in the blood six months after the end of treatment was lower in the interferon-alpha than in the no intervention groups.'],11,0.7083333333333334,4,24
CD011644,1,17,The differences between the groups were imprecise or not estimable (because neither group had any events) for all the remaining comparisons.,rephrase,['There was no evidence of differences between the groups for all the remaining comparisons.'],12,0.75,4,24
CD011644,2,18,"Four of the 10 trials (40%) received financial or other assistance from pharmaceutical companies who would benefit from the findings of the research; the source of funding was not available in five trials (50%), and one trial (10%) was funded by a hospital.",delete,[],13,0.7916666666666666,4,24
CD011644,3,19,Very low quality evidence suggests that interferon-alpha may decrease the incidence of chronic HCV infection as measured by sustained virological response.,delete,[],13,0.8333333333333334,5,24
CD011644,3,20,"However, the clinical impact such as improvement in health-related quality of life, reduction in cirrhosis, decompensated liver disease, and liver transplantation has not been reported.",delete,[],13,0.875,5,24
CD011644,3,21,"It is also not clear whether this finding is applicable in the current clinical setting dominated by the use of pegylated interferons and direct-acting antivirals, although we found no evidence to support that pegylated interferons or ribavirin or both are effective in people with acute HCV infection.",delete,[],13,0.9166666666666666,5,24
CD011644,3,22,We could find no randomised trials comparing direct-acting antivirals with placebo or other interventions for acute HCV infection.,delete,[],13,0.9583333333333334,5,24
CD011644,3,23,"There is significant uncertainty in the benefits and harms of the interventions, and high-quality randomised clinical trials are required.",rephrase,['There is significant uncertainty about the size and direction of the results and high quality randomised clinical trials are required.'],13,1.0,5,24
CD015219,0,0,We included 25 trials that randomized 5750 adults (most under 60 years of age).,rephrase,['We found 25 relevant studies involving 5750 people.'],0,0.07142857142857142,1,14
CD015219,0,1,"The trials were conducted in Bahrain, Brazil, China, India, Iran, Kuwait, Malaysia, Mexico, Russia, Saudi Arabia, Thailand, the UK, and the USA.",rephrase,"['The studies were conducted in 13 different countries: Bahrain, Brazil, China, India, Iran, Kuwait, Malaysia, Mexico, Russia, Saudi Arabia, Thailand, the UK, and the USA.']",1,0.14285714285714285,1,14
CD015219,0,2,Most participants were hospitalized with mild to moderate disease (89%).,rephrase,['Most people were under 60 years old and had mild to moderate COVID-19 symptoms.'],2,0.21428571428571427,2,14
CD015219,0,3,"Twenty-two of the 25 trials investigated the role of favipiravir compared to placebo or standard of care, whilst lopinavir/ritonavir was the comparator in two trials, and umifenovir in one trial.",delete,[],3,0.2857142857142857,2,14
CD015219,0,4,"Most trials (24 of 25) initiated favipiravir at 1600 mg or 1800 mg twice daily for the first day, followed by 600 mg to 800 mg twice a day.",delete,[],3,0.35714285714285715,2,14
CD015219,0,5,The duration of treatment varied from five to 14 days.,delete,[],3,0.42857142857142855,3,14
CD015219,1,6,"We do not know whether favipiravir reduces all-cause mortality at 28 to 30 days, or in-hospital (risk ratio (RR) 0.84, 95% confidence interval (CI) 0.49 to 1.46; 11 trials, 3459 participants; very low-certainty evidence).",split,"['• We do not know if favipiravir reduces the number of people who die from COVID-19 when compared to dummy treatment, standard of care, or other antiviral medicines.', 'The evidence supporting this is not very strong (derived from 11 studies involving 3459 people).']",3,0.5,3,14
CD015219,1,7,"We do not know if favipiravir reduces the progression to invasive mechanical ventilation (RR 0.86, 95% CI 0.68 to 1.09; 8 trials, 1383 participants; very low-certainty evidence).",rephrase,['• It is also very unclear if favipiravir reduces the need for people to be put on ventilators compared to a dummy treatment or any other antiviral treatments (derived from 8 studies involving 1383 people).'],5,0.5714285714285714,3,14
CD015219,1,8,"Favipiravir may make little to no difference in the need for admission to hospital (if ambulatory) (RR 1.04, 95% CI 0.44 to 2.46; 4 trials, 670 participants; low-certainty evidence).",rephrase,"['• In people with mild symptoms, using favipiravir may not reduce the likelihood of needing hospitalization, but more research is needed to be sure (derived from 4 studies involving 670 people).']",6,0.6428571428571429,4,14
CD015219,1,9,"We do not know if favipiravir reduces the time to clinical improvement (defined as time to a 2-point reduction in patients’ admission status on the WHO’s ordinal scale) (hazard ratio (HR) 1.13, 95% CI 0.69 to 1.83; 4 trials, 721 participants; very low-certainty evidence).",rephrase,"['• Favipiravir has an unclear effect on the time it takes for people to improve, as defined by a reduction in their illness severity (derived from 4 studies involving 721 people).']",7,0.7142857142857143,4,14
CD015219,1,10,"Favipiravir may make little to no difference to the progression to oxygen therapy (RR 1.20, 95% CI 0.83 to 1.75; 2 trials, 543 participants; low-certainty evidence).",rephrase,"['• Favipiravir seems to make very little difference in reducing the need for treatment with oxygen, compared to a dummy treatment or other antiviral treatment (derived from 2 studies involving 543 people).']",8,0.7857142857142857,4,14
CD015219,1,11,"Favipiravir may lead to an overall increased incidence of adverse events (RR 1.27, 95% CI 1.05 to 1.54; 18 trials, 4699 participants; low-certainty evidence), but may result in little to no difference inserious adverse eventsattributable to the drug (RR 1.04, 95% CI 0.76 to 1.42; 12 trials, 3317 participants; low-certainty evidence).",rephrase,"[""• Favipiravir might lead to mild side effects (derived from 18 studies involving 4699 people) but doesn't seem to cause major or severe side effects (derived from 12 studies involving 3317 people).""]",9,0.8571428571428571,5,14
CD015219,2,12,"The low- to very low-certainty evidence means that we do not know whether favipiravir is efficacious in people with COVID-19 illness, irrespective of severity or admission status.",rephrase,['Our confidence in the evidence for using favipiravir is limited because people in the studies had different disease severities and the studies were of varying sizes and had inconsistent results.'],10,0.9285714285714286,5,14
CD015219,2,13,Treatment with favipiravir may result in an overall increase in the incidence of adverse events but may not result in serious adverse events.,delete,[],11,1.0,5,14
CD007629,0,0,We included four trials with 271 patients undergoing open liver resections.,rephrase,['Four randomised clinical trials including 271 patients undergoing open liver resections fulfilled the inclusion criteria of this review.'],0,0.09090909090909091,1,11
CD007629,0,1,The patients were randomised to ischaemic preconditioning (n = 135) and no ischaemic preconditioning (n = 136) prior to continuous vascular occlusion (portal triad clamping in three trials and hepatic vascular exclusion in one trial).,rephrase,['The patients were randomised to ischaemic preconditioning (n = 135) and no ischaemic preconditioning (n = 136) prior to continuous vascular occlusion.'],1,0.18181818181818182,1,11
CD007629,0,2,All the trials excluded cirrhotic patients.,ignore,['All the trials excluded cirrhotic patients.'],2,0.2727272727272727,2,11
CD007629,0,3,We assessed all the four trials as having high risk of bias.,rephrase,['We assessed all the four trials as having high risk of bias (high risk of systematic error).'],3,0.36363636363636365,2,11
CD007629,0,4,"There was no difference in mortality, liver failure, other peri-operative morbidity, hospital stay, intensive therapy unit stay, and operating time between the two groups.",ignore,"['There was no difference in mortality, liver failure, post-operative complications, hospital stay, intensive therapy unit stay, and operating time between the two groups.']",4,0.45454545454545453,3,11
CD007629,0,5,The proportion of patients requiring blood transfusion was lower in the ischaemic preconditioning group.,ignore,['The proportion of patients requiring blood transfusion was lower in the ischaemic preconditioning group.'],5,0.5454545454545454,3,11
CD007629,0,6,There was also a trend towards a lower amount of red cell transfusion favouring ischaemic preconditioning group.,delete,[],6,0.6363636363636364,4,11
CD007629,0,7,"There was no difference in the haemodynamic changes, blood loss, bilirubin, or prothrombin activity between the two groups.",rephrase,['There was no difference in blood loss or enzyme markers of liver function between the two groups.'],6,0.7272727272727273,4,11
CD007629,0,8,The enzyme markers of liver injury were lower in the ischaemic preconditioning group on the first post-operative day.,split,"['The enzyme markers of liver injury were lower in the ischaemic preconditioning group on the first post-operative day.', 'Further studies are necessary to understand the mechanism of ischaemic preconditioning.']",7,0.8181818181818182,5,11
CD007629,1,9,"Currently, there is no evidence to suggest a protective effect of ischaemic preconditioning in non-cirrhotic patients undergoing liver resection under continuous vascular occlusion.",ignore,"['Currently, there is no evidence to suggest a protective effect of ischaemic preconditioning in non-cirrhotic patients undergoing liver resection under continuous vascular occlusion.']",9,0.9090909090909091,5,11
CD007629,1,10,Ischaemic preconditioning reduces the blood transfusion requirements in patients undergoing liver resection.,ignore,['Ischaemic preconditioning reduces the blood transfusion requirements in patients undergoing liver resection.'],10,1.0,5,11
CD009361,0,0,Six RCTs ranging from 8 to 26 weeks investigating 1450 participants met the inclusion criteria.,split,"['A total of 1450 patients took part in six studies investigating colesevelam.', 'These studies lasted 8 to 26 weeks.']",0,0.07142857142857142,1,14
CD009361,0,1,"Overall, the risk of bias of these trials was unclear or high.",delete,[],2,0.14285714285714285,1,14
CD009361,0,2,All RCTs compared the effects of colesevelam with or without other antidiabetic drug treatments with placebo only (one study) or combined with antidiabetic drug treatments.,rephrase,"['Only one small study compared colesevelam directly to placebo, the other five studies investigated a combination of colesevelam with other antidiabetic agents versus a combination of placebo with other antidiabetic agents.']",2,0.21428571428571427,2,14
CD009361,0,3,"Colesevelam with add-on antidiabetic agents demonstrated a statistically significant reduction in fasting blood glucose with a mean difference (MD) of -15 mg/dL (95% confidence interval (CI) -22 to - 8), P < 0.0001; 1075 participants, 4 trials, no trial with low risk of bias in all domains.",delete,[],3,0.2857142857142857,2,14
CD009361,0,4,"There was also a reduction in glycosylated haemoglobin A1c (HbA1c) in favour of colesevelam (MD -0.5% (95% CI -0.6 to -0.4), P < 0.00001; 1315 participants, 5 trials, no trial with low risk of bias in all domains.",delete,[],3,0.35714285714285715,2,14
CD009361,0,5,"However, the single trial comparing colesevelam to placebo only (33 participants) did not reveal a statistically significant difference between the two arms - in fact, in both arms HbA1c increased.",delete,[],3,0.42857142857142855,3,14
CD009361,0,6,"Colesevelam with add-on antidiabetic agents demonstrated a statistical significant reduction in low-density lipoprotein (LDL)-cholesterol with a MD of -13 mg/dL (95% CI -17 to - 9), P < 0.00001; 886 participants, 4 trials, no trial with low risk of bias in all domains.",delete,[],3,0.5,3,14
CD009361,0,7,Non-severe hypoglycaemic episodes were infrequently observed.,merge,[],3,0.5714285714285714,3,14
CD009361,0,8,No other serious adverse effects were reported.,none,"['The same is true for adverse effects: three studies reported on just a few non-severe hypoglycaemic episodes, no other serious side effects were observed.']",3,0.6428571428571429,4,14
CD009361,0,9,"There was no documentation of complications of the disease, morbidity, mortality, health-related quality of life and costs.",rephrase,"['No study investigated mortality; complications of type 2 diabetes such as eye disease, kidney disease, heart attack and stroke; health-related quality of life; functional outcomes and costs of treatment.']",4,0.7142857142857143,4,14
CD009361,1,10,Colesevelam added on to antidiabetic agents showed significant effects on glycaemic control.,rephrase,['When added to other antidiabetic agents colesevelam showed improvements in the control of blood glucose and blood lipids.'],5,0.7857142857142857,4,14
CD009361,1,11,"However, there is a limited number of studies with the different colesevelam/antidiabetic agent combinations.",rephrase,"['However, it is difficult to disentangle the effects of colesevelam from the other antidiabetic agents used because only one study compared colesevelam to placebo.']",6,0.8571428571428571,5,14
CD009361,1,12,"More information on the benefit-risk ratio of colesevelam treatment is necessary to assess the long-term effects, particularly in the management of cardiovascular risks as well as the reduction in micro- and macrovascular complications of type 2 diabetes mellitus.",merge,[],7,0.9285714285714286,5,14
CD009361,1,13,"Furthermore, long-term data on health-related quality of life and all-cause mortality also need to be investigated.",none,"['Therefore, long-term data on the efficacy and safety of colesevelam are necessary.']",7,1.0,5,14
CD012023,0,0,We included five RCTs involving 825 participants.,delete,[],0,0.06666666666666667,1,15
CD012023,0,1,"The studies were carried out in the USA and Europe, and were published between 1987 and 2017.",delete,[],0,0.13333333333333333,1,15
CD012023,0,2,Risk of bias across the studies varied.,delete,[],0,0.2,1,15
CD012023,0,3,"Most had low risk for selection, reporting and attrition bias, and a high risk for performance and detection bias because blinding was inadequate or absent.",delete,[],0,0.26666666666666666,2,15
CD012023,1,4,All participants had mild to moderate hearing loss.,rephrase,"['We found five clinical studies involving 825 adults with mild to moderate hearing loss who were randomly given either hearing aids, no hearing aids or placebo hearing aids.']",0,0.3333333333333333,2,15
CD012023,1,5,The average age across all five studies was between 69 and 83 years.,rephrase,['Studies involved older adults with the average age within studies between 69 and 83 years.'],1,0.4,2,15
CD012023,1,6,The duration of the studies ranged between six weeks and six months.,ignore,['The duration of the studies was between six weeks and six months.'],2,0.4666666666666667,3,15
CD012023,2,7,"There was a large beneficial effect of hearing aids on hearing-specific health-related quality of life associated with participation in daily life as measured using the Hearing Handicap Inventory for the Elderly (HHIE, scale range 1 to 100) compared to the unaided/placebo condition (mean difference (MD) -26.47, 95% confidence interval (CI) -42.16 to -10.77; 722 participants; three studies) (moderate-quality evidence).",rephrase,['We found evidence in three studies that hearing aids have a large beneficial effect in improving the ability of adults with mild to moderate hearing loss to take part in everyday situations.'],3,0.5333333333333333,3,15
CD012023,3,8,"There was a small beneficial effect of hearing aids on general health-related quality of life (standardised mean difference (SMD) -0.38, 95% CI -0.55 to -0.21; 568 participants; two studies) (moderate-quality evidence).",rephrase,"['Hearing aids have a small beneficial effect in improving general health-related quality of life, such as physical, social, emotional and mental well-being, and have a large effect in improving the ability to listen to other people.']",4,0.6,3,15
CD012023,3,9,"There was a large beneficial effect of hearing aids on listening ability (SMD -1.88, 95% CI -3.24 to -0.52; 534 participants; two studies) (moderate-quality evidence).",delete,[],5,0.6666666666666666,4,15
CD012023,4,10,Adverse effects were measured in only one study (48 participants) and none were reported (very low-quality evidence).,delete,[],5,0.7333333333333333,4,15
CD012023,5,11,"The available evidence concurs that hearing aids are effective at improving hearing-specific health-related quality of life, general health-related quality of life and listening ability in adults with mild to moderate hearing loss.",rephrase,"['We judged the evidence that hearing aids improve the ability to take part in everyday situations, improve general health-related quality of life and improve listening ability to be of moderate quality.']",5,0.8,4,15
CD012023,5,12,The evidence is compatible with the widespread provision of hearing aids as the first-line clinical management in those who seek help for hearing difficulties.,rephrase,"['If an adult with mild to moderate hearing loss seeks help for their hearing difficulties, hearing aids are an effective clinical option.']",6,0.8666666666666667,5,15
CD012023,5,13,Greater consistency is needed in the choice of outcome measures used to assess benefits from hearing aids.,merge,"['It is important that future studies measure benefits consistently and report benefits separately for different age groups, genders, levels of hearing loss and types of hearing aids.']",7,0.9333333333333333,5,15
CD012023,5,14,"Further placebo-controlled studies would increase our confidence in the estimates of these effects and ascertain whether they vary according to age, gender, degree of hearing loss and type of hearing aid.",none,[],7,1.0,5,15
CD012431,0,0,We included five trials (2891 children and adult participants in total; 2545 participants after adjusting for clustering).,rephrase,['We identified five randomised controlled trials with a total of 2545\xa0participants with sore throat in primary care settings.'],0,0.1,1,10
CD012431,0,1,"Management in the intervention group was as follows: in three trials rapid tests were used in combination with a clinical scoring system; in one trial, some physicians were asked to use rapid tests alone, while others were asked to use rapid tests in combination with a clinical scoring system; in one trial, rapid tests were used alone.",delete,[],1,0.2,1,10
CD012431,1,2,"Based on data from five trials (2545 participants), a large reduction in prescribed antibiotics was found in the rapid test group (481/1197) versus management based on clinical grounds (865/1348), for a summary risk difference (RD) of −25%, 95% confidence interval (CI) −31% to −18%; I2 = 62%; moderate-certainty evidence.",rephrase,['Participants in the rapid test group were less likely to be prescribed antibiotics than participants managed based on clinical grounds (481/1197 versus 865/1348).'],1,0.3,2,10
CD012431,1,3,Estimates of effect on antibiotic prescription rates were stable in various sensitivity analyses.,delete,[],2,0.4,2,10
CD012431,2,4,"Based on data from two trials (900 people) originating from the same overarching study, the evidence suggests that rapid tests may not reduce dispensed antibiotic treatments: rapid test group (156/445) versus management based on clinical grounds (197/455); summary RD −7%, 95% CI −17% to 2%; I2 = 53%; low-certainty evidence.",delete,[],2,0.5,3,10
CD012431,3,5,"Four trials (2075 participants) reported data on the number of participants with a complication attributed to the index infection; the summary odds ratio (OR) was 0.85, 95% CI 0.03 to 26.65; P = 0.93; I2 = 62%; very low-certainty evidence, which means that people in the rapid testing group were less likely to develop complications of the index infection, but the evidence is very uncertain.",rephrase,"['Four trials reported data on the number of participants with a complication attributed to the initial infection\xa0(e.g., tonsil abscess): complications were rare (0 to 3 per trial), and there may be little or no difference between people managed on clinical grounds alone and those managed with rapid testing\xa0but the evidence is very uncertain.']",2,0.6,3,10
CD012431,4,6,"Two trials (1161 participants) reported on the number of participants in need of re-consultation by the end of follow-up; the summary OR was 1.12, 95% CI 0.57 to 2.21; P = 0.74; I2 = 59%; low-certainty evidence, which means that participants in the rapid testing group were more likely to be in need of re-consultation by the end of the study follow-up, but the evidence is uncertain.",delete,[],3,0.7,4,10
CD012431,5,7,Lack of data impeded assessment of other secondary outcomes (including safety outcomes) and of sources of heterogeneity.,delete,[],3,0.8,4,10
CD012431,6,8,"Rapid testing to guide antibiotic treatment for sore throat in primary care probably reduces antibiotic prescription rates by 25% (absolute risk difference), but may have little or no impact on antibiotic dispensing.",rephrase,"['Compared with usual decision-making based on clinical examination alone, implementing rapid tests can reduce antibiotic prescription rates, but may have little or no impact on antibiotic dispensing.']",3,0.9,5,10
CD012431,6,9,"More studies are needed to assess the efficacy and safety of rapid test-guided antibiotic prescribing, notably to evaluate patient-centred outcomes and variability across subgroups (e.g. adults versus children).",rephrase,"['More studies are needed to assess other outcomes that are important to patients, including safety.']",4,1.0,5,10
CD007519,0,0,The search identified 102 potentially eligible studies.,delete,[],0,0.09090909090909091,1,11
CD007519,0,1,"Judged from the information in the title and abstract six of these concerning the percutaneous block, involving 358 participants, fulfilled the inclusion criteria and were included in the review.",rephrase,['Six studies (358 participants) comparing CPB with standard therapy (painkillers) met our inclusion criteria.'],0,0.18181818181818182,1,11
CD007519,0,2,All were RCTs in which the participants were followed for at least four weeks.,delete,[],1,0.2727272727272727,2,11
CD007519,0,3,We excluded studies published only as abstracts.,delete,[],1,0.36363636363636365,2,11
CD007519,0,4,"We identified one RCT comparing EUS-guided or computed tomography (CT) -guided CPB but its aim was to assess efficacy in controlling chronic abdominal pain associated with chronic pancreatitis rather than pancreatic cancer, so it was excluded.",rephrase,['We searched for studies comparing CPB with standard analgesic therapy in patients with inoperable pancreatic cancer.'],1,0.45454545454545453,3,11
CD007519,1,5,"For pain (VAS) at four weeks the mean difference was -0.42 in favour of CPB (95% confidence interval (CI) -0.70 to - 0.13, P = 0.004, fixed-effect model).",rephrase,['At four weeks pain scores were significantly lower in the CPB group.'],2,0.5454545454545454,3,11
CD007519,1,6,"At eight weeks the mean difference was -0.44 (95% CI -0.89 to - 0.01, random-effects model).",delete,[],3,0.6363636363636364,4,11
CD007519,1,7,At eight weeks there was significant heterogeneity (I2 = 89%).,delete,[],3,0.7272727272727273,4,11
CD007519,2,8,Opioid consumption was significantly lower in the CPB group than the control group (P < 0.00001).,split,"['Opioid consumption was also significantly lower than in the control group.', 'The main adverse effects were diarrhoea or constipation (this symptom was significantly more likely in the control group, where opioid consumption was higher).']",3,0.8181818181818182,5,11
CD007519,3,9,"Although statistical evidence is minimal for the superiority of pain relief over analgesic therapy, the fact that CPB causes fewer adverse effects than opioids is important for patients.",ignore,"['We conclude that, although statistical evidence is minimal for the superiority of pain relief over analgesic therapy, the fact that CPB causes fewer adverse effects than opioids is important for patients.']",5,0.9090909090909091,5,11
CD007519,3,10,Further studies and RCTs are recommended to demonstrate the potential efficacy of a less invasive technique under EUS guidance.,rephrase,"['Although the data on EUS-guided CPB and pain control are promising, we await rigorously designed RCTs that may validate these findings.']",6,1.0,5,11
CD007987,0,0,"As of July 2017, we identified four trials with 192 participants that met the review inclusion criteria.",delete,[],0,0.043478260869565216,1,23
CD007987,0,1,"Participating parents were mostly mothers (seven fathers were included in two studies), and children's ages ranged from one month to six years and five months.",rephrase,['All but seven of the participating parents were mothers.'],0,0.08695652173913043,1,23
CD007987,1,2,"One study was conducted in Australia, one in Canada, one in the Netherlands, and one in the USA.",rephrase,"['The four RCTs were conducted in Australia, Canada, the Netherlands and USA, and involved 192 parents.']",1,0.13043478260869565,1,23
CD007987,1,3,Each studied a different intervention and considered different outcomes.,ignore,['Each studied a different intervention and considered different outcomes.'],2,0.17391304347826086,1,23
CD007987,1,4,"Three interventions were delivered at home, and one in a community venue (e.g. a church).",ignore,"['Three interventions were delivered at home, and one in a community venue (e.g. a church).']",3,0.21739130434782608,2,23
CD007987,1,5,Interventions varied in duration from seven weeks to 12 months.,ignore,['Interventions varied in duration from seven weeks to 12 months.'],4,0.2608695652173913,2,23
CD007987,1,6,"They included a range of practical childcare skills, home safety and developing parents' ability to respond sensitively to their children.",ignore,"[""They included a range of practical childcare skills, home safety and developing parents' ability to respond sensitively to their children.""]",5,0.30434782608695654,2,23
CD007987,1,7,Parents in the comparison groups included in the review received treatment as usual and most of these received the index intervention after the study was complete.,rephrase,['Parents in the control groups all received treatment as usual.'],6,0.34782608695652173,2,23
CD007987,2,8,"One study was funded by the Ontario Mental Health Foundation and the Ontario Ministry of Community and Social Services Research Grants Program; one by the Alabama Development Disabilities Council; one by the Best Practice Parenting Education Initiative of the Commonwealth Department of Family and Community Services and the New South Wales Aging and Disability Department; and one by ZonMw, The Netherlands Organisation for Health Research and Development.",split,"['One study was funded by the Ontario Mental Health Foundation and the Ontario Ministry of Community and Social Services Research Grants Program.', 'Another was funded by the Alabama Development Disabilities Council.', 'A third was funded by the Best Practice Parenting Education Initiative of the Commonwealth Department of Family and Community Services and the New South Wales Aging and Disability Department.', 'The fourth study was funded by ZonMw, The Netherlands Organisation for Health Research and Development.']",7,0.391304347826087,2,23
CD007987,3,9,It was not possible for us to conduct a meta-analysis.,delete,[],11,0.43478260869565216,3,23
CD007987,3,10,The GRADE quality assessment varied from very low to moderate across the studies.,delete,[],11,0.4782608695652174,3,23
CD007987,4,11,"Primary outcomes
No study reported on the 'attainment of specific parenting skill targets'.",delete,[],11,0.5217391304347826,3,23
CD007987,5,12,"'Safe home practices' and 'understanding of child health': one study (30 parents, very low-quality evidence) reported some improvements in parents' knowledge of life-threatening emergencies, ability to recognise dangers, and identify precautions, in favour of the intervention group.",split,"['Compared to those parents without parent training, the studies reported some improvements in parents in the intervention group.', 'One study reported improvement in safe home practices, recognition of child illness and safe use of medicines, in favour of the intervention group.']",11,0.5652173913043478,3,23
CD007987,5,13,"It also found limited, very low-quality evidence that parent training improved parents' ability to understand child health, implement precautions, use medicines safely, recognise child illness and symptoms, and seek medical advice (i.e. visit the doctor).",delete,[],13,0.6086956521739131,4,23
CD007987,5,14,"Another study (22 mothers, very low-quality evidence) reported improved attainment of skills related to childcare and safety, in favour of the intervention group.",rephrase,"['Another study reported improvements in childcare and safety, also in favour of the intervention group; and a third study found that parents who had attended parent training reported less child-related parenting stress compared to the control group.']",13,0.6521739130434783,4,23
CD007987,6,15,"Secondary outcomes
'Parent-child interaction': one study (40 mothers, very low-quality evidence) reported improved maternal-child interaction following parent training at 12 months follow-up.",delete,[],14,0.6956521739130435,4,23
CD007987,6,16,"Another study (83 mothers, 2 fathers, moderate-quality evidence) reported that inclusion in the intervention group led to a steeper decline in parenting stress related to the child compared to the control group.",delete,[],14,0.7391304347826086,4,23
CD007987,7,17,"'Parents' retention of child': one study (22 participants; very low-quality evidence) reported that before joining the programme nine of 11 (82%) families with a previous child had had the child removed from their care by child protection authorities due to maternal maltreatment, compared with only four of 22 (19%) families after participating in the programme (only one of these four mothers had also had a previous child removed).",delete,[],14,0.782608695652174,4,23
CD007987,8,18,No study reported data on: 'return to independent care of child' or 'lifting of child-related court order'.,rephrase,['No study reported that interventions caused harm.'],14,0.8260869565217391,5,23
CD007987,9,19,"There is some very low-quality evidence that some parents, mainly mothers, with intellectual disabilities are able to provide adequate parenting if they are given appropriate training and support to learn the parenting skills they need.",split,"['There is some low-quality evidence that parent training interventions for parents with intellectual disabilities may support their parenting.', 'However, given the low quality of the evidence, the results should be interpreted with caution.', 'Better-quality research is needed to evaluate the effectiveness of parent training interventions for parents with intellectual disabilities.']",15,0.8695652173913043,5,23
CD007987,9,20,"However, there are few studies exploring how interventions might work, for whom and in what circumstances.",delete,[],18,0.9130434782608695,5,23
CD007987,9,21,"In particular, there have been few studies that include fathers with intellectual disabilities, or that explore the views of parents themselves.",delete,[],18,0.9565217391304348,5,23
CD007987,10,22,"There is a need for larger RCTs of parenting interventions, with longer follow-up, before conclusions can be drawn about the effectiveness of parent training for this group of parents.",delete,[],18,1.0,5,23
CD012602,0,0,"Our network meta-analysis included 78 randomised trials involving 17,795 women from 37 countries.",rephrase,"['We searched for evidence in February\xa02021\xa0and identified 78\xa0studies involving 17,795 women.']",0,0.05555555555555555,1,18
CD012602,0,1,Most trials (71/78) were conducted in hospital settings and included women with missed or incomplete miscarriage.,rephrase,['Women were diagnosed with missed (also called silent miscarriage where no pregnancy tissue has been expelled and there is no bleeding or pain) or incomplete miscarriage (already started to bleed or have pain and perhaps expelled some pregnancy tissue).'],1,0.1111111111111111,1,18
CD012602,0,2,"Across 158 trial arms, the following methods were used: 51 trial arms (33%) used misoprostol; 50 (32%) used suction aspiration; 26 (16%) used expectant management or placebo; 17 (11%) used dilatation and curettage; 11 (6%) used mifepristone plus misoprostol; and three (2%) used suction aspiration plus cervical preparation.",delete,[],2,0.16666666666666666,1,18
CD012602,0,3,"Of these 78 studies, 71 (90%) contributed data in a usable form for meta-analysis.",delete,[],2,0.2222222222222222,2,18
CD012602,1,4,"Complete miscarriage
Based on the relative effects from the network meta-analysis of 59 trials (12,591 women), we found that five methods may be more effective than expectant management or placebo for achieving a complete miscarriage:
· suction aspiration after cervical preparation (risk ratio (RR) 2.12, 95% confidence interval (CI) 1.41 to 3.20, low-certainty evidence),
· dilatation and curettage (RR 1.49, 95% CI 1.26 to 1.75, low-certainty evidence),
· suction aspiration (RR 1.44, 95% CI 1.29 to 1.62, low-certainty evidence),
· mifepristone plus misoprostol (RR 1.42, 95% CI 1.22 to 1.66, moderate-certainty evidence),
· misoprostol (RR 1.30, 95% CI 1.16 to 1.46, low-certainty evidence).",rephrase,['The analysis suggested that all three surgical methods and both medical methods may be more effective than expectant management or placebo for completing the process of miscarriage.'],2,0.2777777777777778,2,18
CD012602,2,5,The highest ranked surgical method was suction aspiration after cervical preparation.,rephrase,"['Suction aspiration plus cervical preparation was the best method of miscarriage management followed by dilatation and curettage, and suction aspiration alone.']",3,0.3333333333333333,2,18
CD012602,2,6,The highest ranked non-surgical treatment was mifepristone plus misoprostol.,rephrase,"['The two medical methods of mifepristone combined with misoprostol, and misoprostol alone were ranked fourth and fifth best methods, respectively.']",4,0.3888888888888889,2,18
CD012602,2,7,"All surgical methods were ranked higher than medical methods, which in turn ranked above expectant management or placebo.",delete,[],5,0.4444444444444444,3,18
CD012602,3,8,"Composite outcome of death and serious complications
Based on the relative effects from the network meta-analysis of 35 trials (8161 women), we found that four methods with available data were compatible with a wide range of treatment effects compared with expectant management or placebo:
· dilatation and curettage (RR 0.43, 95% CI 0.17 to 1.06, low-certainty evidence),
· suction aspiration (RR 0.55, 95% CI 0.23 to 1.32, low-certainty evidence),
· misoprostol (RR 0.50, 95% CI 0.22 to 1.15, low-certainty evidence),
· mifepristone plus misoprostol (RR 0.76, 95% CI 0.31 to 1.84, low-certainty evidence).",rephrase,"['From the available data, we cannot learn much for the outcome of death or serious complications.']",5,0.5,3,18
CD012602,4,9,"Importantly, no deaths were reported in these studies, thus this composite outcome was entirely composed of serious complications, including blood transfusions, uterine perforations, hysterectomies, and intensive care unit admissions.",rephrase,['No deaths were reported in the studies that contributed towards this outcome.'],6,0.5555555555555556,3,18
CD012602,4,10,Expectant management and placebo ranked the lowest when compared with alternative treatment interventions.,delete,[],7,0.6111111111111112,4,18
CD012602,5,11,"Subgroup analyses by type of miscarriage (missed or incomplete) agreed with the overall analysis in that surgical methods were the most effective treatment, followed by medical methods and then expectant management or placebo, but there are possible subgroup differences in the effectiveness of the available methods.",rephrase,"['These analyses for incomplete and missed miscarriages agreed with the overall analysis in that surgical methods were better for providing a definitive treatment for a miscarriage than medical methods, which in turn were better than expectant management or placebo.']",7,0.6666666666666666,4,18
CD012602,6,12,"Based on relative effects from the network meta-analysis, all surgical and medical methods for managing a miscarriage may be more effective than expectant management or placebo.",split,"['For both groups of women, all three surgical methods and both medical methods were found to be more effective than expectant management or placebo for providing a definitive treatment for a miscarriage.', 'However, the benefits for women with missed miscarriages undergoing any management method other than expectant management or placebo were far greater compared to women with incomplete miscarriages.', 'This is probably because expectant management or placebo is more effective in women in whom the process of miscarriage has already started compared with women in whom the process is yet to start.']",8,0.7222222222222222,4,18
CD012602,6,13,"Surgical methods were ranked highest for managing a miscarriage, followed by medical methods, which in turn ranked above expectant management or placebo.",rephrase,"['All methods were generally more effective for managing a miscarriage compared with expectant management or placebo, but surgical methods were more effective than medical methods.']",11,0.7777777777777778,4,18
CD012602,6,14,"Expectant management or placebo had the highest chance of serious complications, including the need for unplanned or emergency surgery.",rephrase,['Expectant management or placebo has the lowest chance of successfully treating a miscarriage and has the highest chance of serious complications and the need for unplanned or emergency surgery.'],12,0.8333333333333334,5,18
CD012602,6,15,A subgroup analysis showed that surgical and medical methods may be more beneficial in women with missed miscarriage compared to women with incomplete miscarriage.,rephrase,['We also looked separately at women suffering from an incomplete miscarriage compared to those suffering from a missed miscarriage.'],13,0.8888888888888888,5,18
CD012602,6,16,"Since type of miscarriage (missed and incomplete) appears to be a source of inconsistency and heterogeneity within these data, we acknowledge that the main network meta-analysis may be unreliable.",delete,[],14,0.9444444444444444,5,18
CD012602,6,17,"However, we plan to explore this further in future updates and consider the primary analysis as separate networks for missed and incomplete miscarriage.",delete,[],14,1.0,5,18
CD005170,0,0,22 short-term (<= 16 weeks) RCTs were included in the analysis (2519 participants).,rephrase,['This systematic review of randomised controlled trials (RCTs) of pharmacotherapy of anxiety disorders in children and adolescents identified 22 short-term (<= 16 weeks) randomised controlled trials which were eligible for inclusion (2519 participants).'],0,0.09090909090909091,1,11
CD005170,0,1,The majority of the trials assessed the efficacy of the SSRIs (N = 15).,delete,[],1,0.18181818181818182,1,11
CD005170,1,2,"Medication and placebo response occurred in 58.1% and 31.5% of patients, respectively (Number of studies (N) = 14, Number needed to treat (NNT) = 4).",rephrase,['Treatment response was significantly greater after treatment with medication (58.1%) than with placebo (31.5%) in 14 trials.'],1,0.2727272727272727,2,11
CD005170,1,3,"Medication was more effective than placebo in reducing overall symptom severity in OCD in a post-hoc comparison (N = 7, Weighted Mean Difference (WMD) = -4.45, 95%CI = -5.94, -2.97, n = 765).",rephrase,['Medication was more effective than placebo in reducing overall symptom severity across all of the anxiety disorders (number of studies (N) = 9).'],2,0.36363636363636365,2,11
CD005170,1,4,"Medication was less well tolerated than placebo overall, though the absolute proportion of participants who withdrew due to drug-related adverse events was low (4.9%).",rephrase,"['Medication was less well tolerated than placebo, as indicated by the significant proportion of children and adolescents who dropped out due to adverse effects during the short term trials.']",3,0.45454545454545453,3,11
CD005170,2,5,"Medication treatments can be effective in paediatric anxiety disorders, acting to reduce core symptoms, and should be considered as part of the treatment of these disorders.",rephrase,"['In conclusion, medication should be considered as part of the treatment of paediatric anxiety disorders over the short-term.']",4,0.5454545454545454,3,11
CD005170,2,6,The greatest number of trials showing efficacy to date have assessed the SSRIs in treating paediatric OCD.,split,"['The greatest number of trials were for obsessive compulsive disorder (OCD), for which treatment efficacy in reducing symptom severity was also observed .', 'The greatest number of trials showing efficacy to date have used the selective serotonin reuptake inhibitors (SSRIs).']",5,0.6363636363636364,4,11
CD005170,3,7,There is no clear evidence to show that any particular class of medication is more effective or better tolerated than any other.,rephrase,"['No controlled evidence could be found for the effectiveness of benzodiazepines, despite their continued prescription for paediatric anxiety disorders.']",7,0.7272727272727273,4,11
CD005170,3,8,"As quantitative data was only available for the SSRIs and venlafaxine the routine use of benzodiazepines cannot be recommended, especially given concerns of dependency and treatment -related emergent adverse events associated with this class of drugs.",delete,[],8,0.8181818181818182,5,11
CD005170,4,9,Future RCTs could help identify potential clinical moderators of treatment efficacy.,delete,[],8,0.9090909090909091,5,11
CD005170,4,10,"Studies of the long-term efficacy of medication treatment, optimal dosage, as well as direct comparisons of pharmacotherapy and psychotherapy are also warranted.",rephrase,"['Additional research into the optimal dose and duration of medication treatment, as well as the effects of age on the efficacy and tolerability of medication is warranted.']",8,1.0,5,11
CD003139,0,0,We included 14 RCTs of 5600 women randomised to receive high-dose chemotherapy and autograft (bone marrow transplant or stem cell rescue) versus chemotherapy without autograft for women with early poor prognosis breast cancer.,rephrase,['We included 14 randomised controlled trials (5600 women) which compared high-dose chemotherapy versus conventional chemotherapy in women with early breast cancer and with a high risk of recurrence.'],0,0.1111111111111111,1,9
CD003139,0,1,The studies were at low risk of bias in most areas.,delete,[],1,0.2222222222222222,2,9
CD003139,1,2,"There is high-quality evidence that high-dose chemotherapy does not increase the likelihood of overall survival at any stage of follow-up (at three years: RR 1.02, 95% CI 0.95 to 1.10, 3 RCTs, 795 women, I² = 56%; at five years: RR 1.00, 95% CI 0.96 to 1.04, 9 RCTs, 3948 women, I² = 0%; at six years: RR 0.94, 95% CI 0.81 to 1.08, 1 RCT, 511 women; at eight years: RR1.17, 95% CI 0.95 to 1.43, 1 RCT, 344 women; at 12 years: RR 1.18, 95% CI 0.99 to 1.42, 1 RCT, 382 women).",rephrase,['Using high-dose chemotherapy has little or no effect on increasing survival.'],1,0.3333333333333333,2,9
CD003139,2,3,"There is high-quality evidence that high-dose chemotherapy improves the likelihood of event-free survival at three years (RR 1.19, 95% CI 1.06 to 1.34, 3 RCTs, 795 women, I² = 56%) but this effect was no longer apparent at longer duration of follow-up (at five years: RR 1.04, 95% CI 0.99 to 1.09, 9 RCTs, 3948 women, I² = 14%; at six years RR 1.04, 95% CI 0.87 to 1.24, 1 RCT, 511 women; at eight years: RR 1.27, 95% CI 0.99 to 1.64, 1 RCT, 344 women; at 12 years: RR 1.18, 95% CI 0.95 to 1.45, 1 RCT, 382 women).",rephrase,"['Although rates of event-free survival were higher in the high-dose arm over three-year follow-up, this effect was not apparent at longer follow-up.']",2,0.4444444444444444,3,9
CD003139,3,4,"Treatment-related deaths were much more frequent in the high-dose arm (RR 7.97, 95% CI 3.99 to 15.92, 14 RCTs, 5600 women, I² = 12%, high-quality evidence) and non-fatal morbidity was also more common and more severe in the high-dose group.",split,"['Treatment-related deaths were much more common in the high-dose group.', 'Side-effects were also more common and more severe in the high-dose group.']",3,0.5555555555555556,3,9
CD003139,3,5,"There was little or no difference between the groups in the incidence of second cancers at four to nine years' median follow-up (RR 1.25, 95% CI 0.90 to 1.73, 7 RCTs, 3423 women, I² = 0%, high-quality evidence).",delete,[],5,0.6666666666666666,4,9
CD003139,3,6,"Women in the high-dose group reported significantly worse quality-of-life scores immediately after treatment, but there were few statistically significant differences between the groups by one year.",delete,[],5,0.7777777777777778,4,9
CD003139,4,7,"The primary studies were at low risk of bias in most areas, and the evidence was assessed using GRADE methods and rated as high quality for all comparisons.",delete,[],5,0.8888888888888888,5,9
CD003139,5,8,There is high-quality evidence of increased treatment-related mortality and little or no increase in survival by using high-dose chemotherapy with autograft for women with early poor prognosis breast cancer.,rephrase,['The evidence was of high quality.'],5,1.0,5,9
CD002835,0,0,"Effect of PEP on HIV seroconversion 
No randomized controlled trials were identified.",rephrase,['No randomized controlled trials were identified.'],0,0.05555555555555555,1,18
CD002835,0,1,Only one case-control study was included.,rephrase,['Only one case-control study provides evidence for using zidovudine monotherapy.'],1,0.1111111111111111,1,18
CD002835,0,2,"HIV transmission was significantly associated with deep injury (OR 15, 95% CI 6.0 to 41), visible blood on the device (OR 6.2, 95% CI 2.2 to 21), procedures involving a needle placed in the source patient's blood vessel (OR 4.3, 95% CI 1.7 to 12), and terminal illness in the source patient (OR 5.6, 95% CI 2.0 to 16).",rephrase,"[""The study found that, in the occupational setting, HIV transmission was significantly associated with deep injury, visible blood on the sharp instrument, procedures involving a needle placed in the source patient's blood vessel, and terminal illness in the source patient.""]",2,0.16666666666666666,1,18
CD002835,0,3,"After controlling for these risk factors, no differences were detected in the rates at which cases and controls were offered post-exposure prophylaxis with zidovudine.",delete,[],3,0.2222222222222222,2,18
CD002835,0,4,"However, cases had significantly lower odds of having taken zidovudine after exposure compared to controls (OR 0.19, 95%CI 0.06 to 0.52).",rephrase,"['After taking these into account, it was found that those who became infected with HIV had significantly lower odds of having taken zidovudine after exposure, compared to those who did not seroconvert.']",3,0.2777777777777778,2,18
CD002835,0,5,No studies were found that evaluated the effect of two or more antiretroviral drugs for occupational PEP.,rephrase,['This review evaluated the effects of antiretroviral post-exposure prophylaxis (PEP) for preventing HIV infection following occupational exposure.'],4,0.3333333333333333,2,18
CD002835,1,6,"Adherence to and complications with PEP 
Eight reports from observational comparative studies confirmed findings that adverse events were higher with a three-drug regimen, especially one containing indinavir.",merge,"['Eight reports from other studies confirmed the findings that adverse events were higher with a three-drug regimen; however, discontinuation rates were not significantly different.']",5,0.3888888888888889,2,18
CD002835,1,7,"However, discontinuation rates were not significantly different.",none,[],5,0.4444444444444444,3,18
CD002835,2,8,The use of occupational PEP is based on limited direct evidence of effect.,delete,[],6,0.5,3,18
CD002835,2,9,"However, it is highly unlikely that a definitive placebo-controlled trial will ever be conducted, and, therefore, on the basis of results from a single case-control study, a four-week regimen of PEP should be initiated as soon as possible after exposure, depending on the risk of seroconversion.",rephrase,"['A four-week regimen of post-exposure prophylaxis should be initiated as soon as possible after exposure, depending on the risk of seroconversion.']",6,0.5555555555555556,3,18
CD002835,2,10,There is no direct evidence to support the use of multi-drug antiretroviral regimens following occupational exposure to HIV.,ignore,['There is no direct evidence to support the use of multi-drug antiretroviral regimens following occupational exposure to HIV.'],7,0.6111111111111112,4,18
CD002835,2,11,"However, due to the success of combination therapies in treating HIV-infected individuals, a combination of antiretroviral drugs should be used for PEP.",ignore,"['However, due to the success of combination therapies in treating HIV-infected individuals, a combination of drugs should be used for PEP.']",8,0.6666666666666666,4,18
CD002835,2,12,Healthcare workers should be counseled about expected adverse events and the strategies for managing these.,ignore,['Healthcare workers should be counseled about expected adverse events and given strategies for managing these events.'],9,0.7222222222222222,4,18
CD002835,2,13,They should also be advised that PEP is not 100% effective in preventing HIV seroconversion.,ignore,['They should also be advised that PEP is not 100% effective in preventing HIV seroconversion.'],10,0.7777777777777778,4,18
CD002835,2,14,A randomized controlled clinical trial is neither ethical nor practical.,delete,[],11,0.8333333333333334,5,18
CD002835,2,15,"Due to the low risk of HIV seroconversion, a very large sample size would be required to have enough power to show an effect.",delete,[],11,0.8888888888888888,5,18
CD002835,2,16,"More rigorous evaluation of adverse events, especially in the developing world, are required.",delete,[],11,0.9444444444444444,5,18
CD002835,2,17,"Seeing that current practice is partly based on results from individual primary animal studies, we recommend a formal systematic review of all relevant animal studies.",delete,[],11,1.0,5,18
CD003124,0,0,We included six trials involving 497 participants to study efficacy.,rephrase,"['Six trials involving 497 participants were included to study efficacy, and compared acetylcysteine or carbocysteine to placebo.']",0,0.1,1,10
CD003124,0,1,"They showed some benefit (e.g. reduction of cough at day seven) from mucolytic agents, although differences were of little clinical relevance.",delete,[],1,0.2,1,10
CD003124,0,2,No conclusion was drawn about the subgroup of infants younger than two years because data were unavailable.,delete,[],1,0.3,2,10
CD003124,0,3,"Thirty-four studies, including the previous six trials involving 2064 children, were eligible to study safety.",rephrase,['Thirty-four trials (including the previous six) were eligible to study safety and involved 2064 paediatric patients.'],1,0.4,2,10
CD003124,0,4,Overall safety was good but very few data were available to evaluate safety in infants younger than two years.,delete,[],2,0.5,3,10
CD003124,0,5,"However, 59 cases of paradoxically increased bronchorrhoea observed in infants were reported to the French pharmacovigilance system.",delete,[],2,0.6,3,10
CD003124,1,6,The results have to be interpreted with caution because they are based on a limited number of participants included in studies whose methodological quality is questionable.,rephrase,"['However, the number of participants included was limited and the methodological quality was questionable.']",2,0.7,4,10
CD003124,1,7,Acetylcysteine and carbocysteine seem to have a limited efficacy and appear to be safe in children older than two years.,rephrase,['The results of this review suggest actual but limited efficacy of acetylcysteine and carbocysteine (e.g. reduction of cough at day seven) and good overall safety (except for rare mild gastrointestinal side effects) among children older than two years of age.'],3,0.8,4,10
CD003124,1,8,"These results should take into consideration the fact that acetylcysteine and carbocysteine are prescribed for self limiting diseases (for example, acute cough, bronchitis).",ignore,"['These results should also take into consideration the fact that acetylcysteine and carbocysteine are prescribed for self limiting diseases (for example, acute cough, bronchitis).']",4,0.9,5,10
CD003124,1,9,"Given strong concerns about safety, these drugs should only be used for acute upper and lower RTIs in the context of a RCT with regards to children younger than two years.",rephrase,"['In children younger than two years, and given strong concerns about safety (increased instead of decreased bronchial secretions), these drugs should only be used for acute upper and lower respiratory tract infections in the context of a randomised controlled trial.']",5,1.0,5,10
CD008896,0,0,"Nine studies representing 7960 women met our inclusion criteria, including seven randomised controlled trials and two controlled before and after studies that reported IUD uptake postintervention.",merge,[],0,0.1111111111111111,1,9
CD008896,0,1,We evaluated the quality of evidence as moderate to low.,none,['We found nine studies of moderate to low quality.'],0,0.2222222222222222,2,9
CD008896,0,2,Three studies on contraceptive counselling and referrals by community workers showed an increase in uptake of the IUD among intervention groups (Peto OR 2.00; 95% CI 1.40 to 2.85).,rephrase,['Three studies on contraceptive counselling and referrals by community workers showed an increase in use of the copper IUD.'],1,0.3333333333333333,2,9
CD008896,0,3,Two studies on antenatal contraceptive counselling also favoured the intervention groups (Peto OR 2.33; 95% CI 1.39 to 3.91).,merge,"['Two studies on antenatal contraceptive counselling and one study on postnatal couple counselling, with provision of an information leaflet before being discharged from the maternity ward, also showed an increase in use of the copper IUD.']",2,0.4444444444444444,3,9
CD008896,0,4,One study on postnatal couple contraceptive counselling also showed an increase in IUD uptake compared to control (Peto OR 5.73; 95% CI 3.59 to 9.15).,none,[],2,0.5555555555555556,3,9
CD008896,0,5,The results of one study evaluating postnatal home visits and two studies on enhanced postabortion contraceptive counselling did not reach statistical significance.,rephrase,['A study on postnatal home visits and two studies on enhanced postabortion contraceptive counselling did not show an increase in use of the copper IUD.'],3,0.6666666666666666,4,9
CD008896,1,6,Community-based interventions and antenatal contraceptive counselling improved uptake of copper IUD contraception.,rephrase,['More high-quality research is needed to look at the longer-term effectiveness of interventions to improve use of the copper IUD.'],4,0.7777777777777778,4,9
CD008896,1,7,"Since the copper IUD is one of the most effective reversible contraceptive methods, primary care and family planning and practitioners could consider adopting these interventions.",delete,[],5,0.8888888888888888,5,9
CD008896,1,8,"Although our review suggests these interventions are clinically effective, a cost-benefit analysis may be required to evaluate applicability.",delete,[],5,1.0,5,9
CD011457,0,0,Six studies (484 participants) met our inclusion criteria.,rephrase,['Six randomised controlled trials (484 patients) met our inclusion criteria.'],0,0.08333333333333333,1,12
CD011457,0,1,"Five studies compared high volume PD with daily haemodialysis, extended daily haemodialysis, or continuous renal replacement therapy.",rephrase,"['Five studies compared high volume PD with daily haemodialysis, extended daily haemodialysis, or continuous renal replacement therapy, and one study compared different intensities of PD on AKI patients.']",1,0.16666666666666666,1,12
CD011457,0,2,One study focused on the intensity of PD.,delete,[],2,0.25,2,12
CD011457,0,3,The overall risk of bias was low to unclear.,delete,[],2,0.3333333333333333,2,12
CD011457,0,4,"Compared to extracorporeal therapy, PD probably made little or no difference to all-cause mortality (4 studies, 383 participants: RR 1.12, 95% CI 0.81 to 1.55; I2 = 69%; moderate certainty evidence), or kidney function recovery (3 studies, 333 participants: RR 0.95, 95% CI 0.68 to 1.35; I2 = 0%; moderate certainty evidence).",rephrase,"['Compared to extracorporeal therapy, PD probably made little or no difference to death due to any cause or recovery of kidney function.']",2,0.4166666666666667,3,12
CD011457,0,5,"PD probably slightly reduces the amount of fluid removal compared to extracorporeal therapy (3 studies, 313 participants: MD -0.59 L/d, 95% CI -1.19 to 0.01; I2 = 89%; low certainty evidence), and probably made little or no difference to infectious complications (2 studies, 263 participants: RR 1.03, 95% CI 0.60 to 1.78; I2 = 0%; low certainty evidence).",rephrase,"['PD probably slightly reduces the amount of fluid removal compared to extracorporeal therapy, and probably made little or no difference to infectious complications.']",3,0.5,3,12
CD011457,0,6,"It is uncertain whether PD compared to extracorporeal therapy has any effects on weekly delivered Kt/V (2 studies, 263 participants: MD -2.47, 95% CI -5.17 to 0.22; I2 = 99%; very low certainty evidence), correction of acidosis (2 studies, 89 participants: RR 1.32, 95% CI 0.13 to 13.60; I2 = 96%; very low certainty evidence), or duration of dialysis (2 studies, 170 participants: MD -1.01 hours, 95% CI -91.49 to 89.47; I2 = 98%; very low certainty evidence).",rephrase,"['It is uncertain whether PD compared to extracorporeal therapy has any effects on weekly delivered Kt/V, correction of acidosis, or duration of dialysis.']",4,0.5833333333333334,3,12
CD011457,0,7,Heterogeneity was high and this may be due to the different extracorporeal therapies used.,delete,[],5,0.6666666666666666,4,12
CD011457,1,8,"One study (61 participants) reported little or no difference to all-cause mortality, kidney function recovery, or infection between low and high and intensity PD.",rephrase,"['One study (61 participants) reported little or no difference to death due to any cause, kidney function recovery, or infection between low and high and intensity PD.']",5,0.75,4,12
CD011457,1,9,Weekly delivered Kt/V and fluid removal was lower with low compared to high intensity PD.,ignore,['Weekly delivered Kt/V and fluid removal was lower with low compared to high intensity PD.'],6,0.8333333333333334,5,12
CD011457,2,10,"Based on moderate (mortality, recovery of kidney function), low (infectious complications), or very low certainty evidence (correction of acidosis) there is probably little or no difference between PD and extracorporeal therapy for treating AKI.",rephrase,"['There is currently not enough evidence to determine whether there are significant differences in death due to any cause or recovery of kidney function between patients treated with PD, extracorporeal therapies, or intensity of PD.']",7,0.9166666666666666,5,12
CD011457,2,11,Fluid removal (low certainty) and weekly delivered Kt/V (very low certainty) may be higher with extracorporeal therapy.,delete,[],8,1.0,5,12
CD008131,0,0,"We included seven studies, which involved 723 participants.",delete,[],0,0.125,1,8
CD008131,0,1,We assessed four of the seven studies as being at high risk of bias and three had an unclear risk of bias; the quality of the evidence was difficult to assess as there was often insufficient detail reported to enable any conclusions to be drawn about the methodological rigour of the studies.,rephrase,['The quality of the evidence in the studies was difficult to assess due to poor reporting.'],0,0.25,2,8
CD008131,0,2,Four trials involving 285 participants measured cognitive development and we synthesised these data in a meta-analysis.,delete,[],1,0.375,2,8
CD008131,0,3,"Compared to the control group, there was no statistically significant impact of the intervention on cognitive development (standardised mean difference (SMD) 0.30; 95% confidence interval -0.18 to 0.78).",delete,[],1,0.5,3,8
CD008131,0,4,Only three studies reported socioemotional outcomes and there was insufficient data to combine into a meta-analysis.,rephrase,['Socioemotional development was measured in three studies but we could not combine this data to help reach a conclusion about effectiveness.'],1,0.625,4,8
CD008131,0,5,No study reported on adverse effects.,rephrase,['None of the studies measured adverse effects.'],2,0.75,4,8
CD008131,1,6,This review does not provide evidence of the effectiveness of home-based interventions that are specifically targeted at improving developmental outcomes for preschool children from socially disadvantaged families.,rephrase,"['The purpose of this review was to look at whether home-based parenting programmes, which aim to improve child development by showing parents how to provide a better quality home environment for their child, are effective in doing so.']",3,0.875,5,8
CD008131,1,7,Future studies should endeavour to better document and report their methodological processes.,delete,[],4,1.0,5,8
CD012499,0,0,"We included three studies, involving 105 participants.",rephrase,"['We found three small studies, enrolling 105 participants, that met our requirements for the review.']",0,0.047619047619047616,1,21
CD012499,0,1,"All were cross-over studies, one involving 19 participants with diverse neuropathic pain syndromes, the other two involving 86 participants with postherpetic neuralgia.",delete,[],1,0.09523809523809523,1,21
CD012499,0,2,Study phases ranged from 20 days to approximately eight weeks.,rephrase,"['The lengths of the studies varied, from 20 days to around eight weeks for each phase.']",1,0.14285714285714285,1,21
CD012499,0,3,"All administered methadone orally, in doses ranging from 10 mg to 80 mg daily.",rephrase,"['The studies were similar in that all administered low doses of methadone, which may or may not reflect the doses typically prescribed in clinical practice.']",2,0.19047619047619047,1,21
CD012499,0,4,"Comparators were primarily placebo, but one study also included morphine and tricyclic antidepressants.",delete,[],3,0.23809523809523808,2,21
CD012499,1,5,"The included studies had several limitations related to risk of bias, particularly incomplete reporting, selective outcome reporting, and small sample sizes.",delete,[],3,0.2857142857142857,2,21
CD012499,2,6,There were very limited data for our primary outcomes of participants with at least 30% or at least 50% pain relief.,delete,[],3,0.3333333333333333,2,21
CD012499,2,7,Two studies reported that 11/29 participants receiving methadone achieved 30% pain relief versus 7/29 participants receiving placebo.,split,"['Two studies looked at how many participants got at least 30% pain relief.', 'Eleven of 29 participants receiving methadone achieved 30% pain relief versus seven of 29 receiving placebo.']",3,0.38095238095238093,2,21
CD012499,2,8,Only one study presented data in a manner that allowed us to calculate the number of participants with at least 50% pain relief.,delete,[],5,0.42857142857142855,3,21
CD012499,2,9,"None of the 19 participants achieved a 50% reduction in pain intensity, either when receiving methadone or when receiving placebo.",split,"['In one study, none of the 19 participants achieved a 50% reduction in pain intensity, either when receiving methadone or when receiving placebo (a sugar pill).', 'These reductions in pain intensity have been shown to be important to patients.']",5,0.47619047619047616,3,21
CD012499,2,10,No study provided data for our other primary outcomes of Patient Global Impression of Change scale (PGIC) much or very much improved (equivalent to at least 30% pain relief) and PGIC very much improved (equivalent to at least 50% pain relief).,delete,[],7,0.5238095238095238,3,21
CD012499,3,11,"For secondary efficacy outcomes, one study reported maximum and mean pain intensity and pain relief, and reported statistically significant improvements versus placebo for all outcomes with 20 mg daily doses of methadone, but not with 10 mg daily doses.",merge,"['In addition, one study found improvements in average and maximum pain intensity and pain relief when comparing methadone with placebo.']",7,0.5714285714285714,3,21
CD012499,3,12,The second study reported differences in pain reduction between methadone (n = 26) and morphine (n = 38) and found morphine to be statistically superior.,merge,[],7,0.6190476190476191,4,21
CD012499,3,13,The third study reported the number of responders (variously defined) for several pain and functional outcomes and found methadone to be statistically superior to placebo for the outcomes of categorical pain intensity and evoked pain.,none,[],7,0.6666666666666666,4,21
CD012499,3,14,"In the two studies that reported data, 0/29 participants withdrew due to lack of efficacy, whereas 4/29 participants withdrew due to adverse events while taking methadone versus 3/29 while taking placebo.",rephrase,"['In the two studies that reported dropouts from the study, none of 29 participants dropped out because they thought methadone or the placebo was not helping their pain; whereas four of 29 dropped out because of side effects while taking methadone and three of 29 while taking placebo.']",8,0.7142857142857143,4,21
CD012499,4,15,"One study reported incidences for several individual adverse events, but found a statistically significant increased incidence for methadone over placebo for only one event, dizziness.",rephrase,"['One study reported how many participants had specific side effects, and found increased dizziness with methadone compared to placebo.']",9,0.7619047619047619,4,21
CD012499,4,16,The other studies did not report data in a manner that enabled us to analyze adverse events.,delete,[],10,0.8095238095238095,5,21
CD012499,4,17,There were no serious adverse events or deaths reported.,rephrase,['There were no serious side effects or deaths reported.'],10,0.8571428571428571,5,21
CD012499,5,18,"We assessed the quality of the evidence as very low for all efficacy and safety outcomes using GRADE, primarily because of the heterogeneity of study designs and populations, short durations, cross-over methodology, and few participants and events.",rephrase,"['We rated the quality of the evidence as very low because there were only three small studies with different designs, and with few participants and events.']",11,0.9047619047619048,5,21
CD012499,6,19,"The three studies provide very limited, very low quality evidence of the efficacy and safety of methadone for chronic neuropathic pain, and there were too few data for pooled analysis of efficacy or harm, or to have confidence in the results of the individual studies.",rephrase,['Very low quality evidence means that we are very uncertain about the results.'],12,0.9523809523809523,5,21
CD012499,6,20,"No conclusions can be made regarding differences in efficacy or safety between methadone and placebo, other opioids, or other treatments.",rephrase,['There was so little information from these studies that we concluded there was no convincing evidence to support or reject a meaningful benefit for methadone versus placebo or any other treatment.'],13,1.0,5,21
CD008973,0,0,"In this update, we identified two new studies with 111 participants, bringing the total number of included studies to 14 (1459 randomized participants).",rephrase,"['We found 14 randomized trials, including 1459 boys.']",0,0.05,1,20
CD008973,0,1,"We found that types of corticosteroids investigated, participant age, degree of phimosis, type of phimosis, and treatment duration varied considerably among studies.",rephrase,['We searched for studies that looked at topical corticosteroids compared with placebo or no treatment in boys (aged birth to 18 years) with phimosis.'],1,0.1,1,20
CD008973,1,2,"Compared with placebo or no treatment, topical corticosteroids may increase the complete resolution of phimosis after four to eight weeks of treatment (RR 2.73, 95% CI 1.79 to 4.16; I² = 72%; 10 trials, 834 participants; low-certainty evidence).",rephrase,['We found that topical corticosteroids compared to placebo or no treatment may increase the frequency of complete and partial retraction of the foreskin after four to eight weeks of treatment.'],2,0.15,1,20
CD008973,1,3,"Based on 252 complete resolutions per 1000 boys in the control group, this corresponds to 436 more complete resolutions per 1000 boys (95% CI 199 more to 796 more).",delete,[],3,0.2,1,20
CD008973,1,4,We downgraded the certainty of the evidence by one level for serious study limitations and by one level for serious inconsistency.,rephrase,"['We compared and summarized the results of the studies and rated our confidence in the evidence, based on factors such as study methods and sizes.']",3,0.25,2,20
CD008973,2,5,"Topical corticosteroids may also increase the partial resolution of phimosis at four to eight weeks of treatment compared with placebo or no treatment (RR 1.68, 95% CI 1.17 to 2.40; I² = 44%; 7 trials, 745 participants; low-certainty evidence).",rephrase,['Topical corticosteroids may also increase the probability of complete retraction of the foreskin measured six months after treatment.'],4,0.3,2,20
CD008973,2,6,"Based on 297 partial resolutions per 1000 boys in the control group, this corresponds to 202 more partial resolutions per 1000 boys (95% CI 50 more to 416 more).",delete,[],5,0.35,2,20
CD008973,2,7,We downgraded the certainty of the evidence by one level for serious study limitations and by one level for serious inconsistency.,delete,[],5,0.4,2,20
CD008973,3,8,"We are uncertain of the effect of topical corticosteroids compared to placebo on change in retractability score (standardized mean difference [SMD] −1.48, 95% CI −2.93 to −0.03; I²91%; 2 trials, 177 participants; very low-certainty evidence).",rephrase,['We are uncertain of the effect of corticosteroids on retractability of the foreskin compared to placebo.'],5,0.45,3,20
CD008973,3,9,"We downgraded the certainty of the evidence by one level for serious study limitations, one level for serious heterogeneity, and one level for serious imprecision.",delete,[],6,0.5,3,20
CD008973,4,10,"Compared with placebo, topical corticosteroids may increase the long-term complete resolution of phimosis six or more months after treatment (RR 4.09, 95% CI 2.80 to 5.97; I² = 0%; 2 trials, 280 participants; low-certainty evidence).",delete,[],6,0.55,3,20
CD008973,4,11,"Based on 171 long-term complete resolutions per 1000 boys in the control group, this corresponds to 528 more complete resolutions per 1000 boys (95% CI 308 more to 850 more).",delete,[],6,0.6,3,20
CD008973,4,12,We downgraded the certainty of the evidence by one level for serious study limitations and by one level for serious imprecision.,delete,[],6,0.65,4,20
CD008973,5,13,"There may be little or no difference in the risk of adverse effects between topical corticosteroids and placebo or no treatment (RR 0.28, 95% CI 0.03 to 2.62; I² = 22%; 11 trials, 1091 participants; low-certainty evidence).",rephrase,['There may be little or no difference between corticosteroids and placebo or no treatment in the occurrence of unwanted effects.'],6,0.7,4,20
CD008973,5,14,Only two of 11 studies that recorded adverse effects reported any adverse effects; one event occurred in the corticosteroid group and six in the control group.,rephrase,['Only two studies reported unwanted effects at the site of treatment (out of 11 studies that measured unwanted effects).'],7,0.75,4,20
CD008973,5,15,We downgraded the certainty of the evidence by one level for serious study limitations and by one level for serious imprecision.,rephrase,"['We have little or very little confidence in the evidence because most publications provided an inadequate description of the study methods; because there were important differences between the boys included in the studies (age, how severe the phimosis was) and between the treatments used (type of corticosteroids, duration of treatment); and because some of the results were very imprecise.']",8,0.8,4,20
CD008973,6,16,"Topical corticosteroids, compared to placebo or no treatment, may increase complete and partial resolution of phimosis when assessed after four to eight weeks of treatment, and may increase long-term complete resolution of phimosis assessed six or more months after treatment.",rephrase,['We wanted to find out if corticosteroid creams or ointments (topical corticosteroids) were better than dummy treatment (placebo) or no treatment for improving the following outcomes.'],9,0.85,5,20
CD008973,6,17,"Topical corticosteroids may have few or no adverse effects, and we are uncertain about their effect on retractability scores.",delete,[],10,0.9,5,20
CD008973,6,18,"The body of evidence is limited by poor reporting of methods in the studies, important clinical heterogeneity, and serious imprecision in the results.",delete,[],10,0.95,5,20
CD008973,6,19,"Future, higher-quality trials with long-term follow-up would likely improve our understanding of the effects of topical corticoids on phimosis in boys.",delete,[],10,1.0,5,20
CD006422,0,0,"We included five studies, involving 756 participants.",delete,[],0,0.09090909090909091,1,11
CD006422,0,1,"Three studies assessed the effect of brief psychological therapies, one assessed the impact of a self-help booklet, and one the effect of collaborative care.",delete,[],0,0.18181818181818182,1,11
CD006422,0,2,"The disparate nature of the trials covering different patient populations, interventions and outcomes meant that it was not possible to pool data meaningfully across studies.",delete,[],0,0.2727272727272727,2,11
CD006422,0,3,There was no evidence of a protective effect of brief psychological therapy or educational booklets on preventing disability.,rephrase,"['In particular, self-help booklets and interpersonal therapies had no effect on preventing disability.']",0,0.36363636363636365,2,11
CD006422,0,4,"There was evidence from one trial of a reduction in both post-traumatic stress disorder (PTSD) and depressive symptoms one month after injury in those who received a collaborative care intervention combined with a brief psycho-educational intervention, however this was not retained at follow up.",rephrase,['There was some evidence that a more complex intervention involving collaborative care reduced symptoms of depression and PTSD in the short but not the medium term.'],1,0.45454545454545453,3,11
CD006422,0,5,Overall mental health status was the only disability outcome affected by any intervention.,delete,[],2,0.5454545454545454,3,11
CD006422,0,6,In three trials the psychosocial intervention had a detrimental effect on the mental health status of patients.,rephrase,['There was evidence from three trials that psychosocial interventions had a detrimental effect on mental health.'],2,0.6363636363636364,4,11
CD006422,1,7,This review provides no convincing evidence of the effectiveness of psychosocial interventions for the prevention of disability following traumatic physical injury.,split,"['This review identified five randomised controlled trials, involving 756 participants, which evaluated psychosocial interventions for the prevention of disability following traumatic injury.', 'No convincing evidence was found supporting the efficacy of these interventions.']",3,0.7272727272727273,4,11
CD006422,1,8,"Taken together, our findings cannot be considered as supporting the provision of psychosocial interventions to prevent aspects of disability arising from physical injury.",ignore,"['Taken together, our findings cannot be taken as supporting the provision of psychosocial interventions to prevent aspects of disability arising from physical injury.']",5,0.8181818181818182,5,11
CD006422,1,9,"However, these conclusions are based on a small number of disparate trials with small to moderate sample sizes and are therefore necessarily cautious.",rephrase,"['However, the strength of these conclusions is limited by the small size and varied nature of many of the trials, which means that their results cannot be pooled.']",6,0.9090909090909091,5,11
CD006422,1,10,"More research, using larger sample sizes, and similar interventions and patient populations to enable pooling of results, is needed before these findings can be confirmed.",delete,[],7,1.0,5,11
CD008883,0,0,One study (recruiting 48 women with idiopathic hyperprolactinemia) met our inclusion criteria; 46 women (42 pregnancies - 4/46 women did not conceive during the study period) were included in the analysis.,rephrase,['We searched for evidence on 30 June 2016 and identified one trial with a small number of women - 48 women were recruited but 46 women (42 pregnancies - 4/46 women did not conceive during the study period) are included in the analysis).'],0,0.047619047619047616,1,21
CD008883,0,1,"The study compared the use of a dopamine agonist (bromocriptine, 2.5 mg to 5.0 mg/day until the end of the ninth week of gestation) versus a no-treatment control.",rephrase,"['In the study, one group of women received a dopamine agonist, bromocriptine (2.5 to 5.0 mg/day until the end of the ninth week of gestation), and the other group of women did not receive any treatment (control group).']",1,0.09523809523809523,1,21
CD008883,0,2,The study was judged as being at a high risk of bias.,rephrase,['The trial took place in Japan and was judged to have a high risk of bias.'],2,0.14285714285714285,1,21
CD008883,0,3,It was not possible to carry out meta-analysis due to insufficient data.,delete,[],3,0.19047619047619047,1,21
CD008883,1,4,The study reported both of this review's primary outcomes of miscarriage and live birth.,delete,[],3,0.23809523809523808,2,21
CD008883,1,5,"Results from this single study suggest that, compared to no treatment, oral bromocriptine was effective in preventing future miscarriage (risk ratio (RR) 0.28, 95% confidence interval (CI) 0.09 to 0.87, 46 participants (low-quality evidence)) in women with idiopathic hyperprolactinemia.",rephrase,['Evidence from this study showed that the dopamine agonist bromocriptine was effective in preventing future miscarriage (low-quality evidence).'],3,0.2857142857142857,2,21
CD008883,1,6,"There was no clear difference with regard to the other primary outcome of live births (RR 1.50, 95% CI 0.93 to 2.42, 46 participants (very low-quality evidence)).",rephrase,"['However, live birth and conception rates remained similar between women who received bromocriptine and the women who did not receive treatment (very low-quality evidence).']",4,0.3333333333333333,2,21
CD008883,2,7,"There was no difference with regard to this review's secondary outcome of conception (RR 0.92, 95% CI 0.77 to 1.09, 46 participants (very low-quality evidence)) between the group of women who received dopamine (21 out of 24 women conceived) and women in the no-treatment group (21 out of 22 women conceived).",delete,[],5,0.38095238095238093,2,21
CD008883,2,8,The included study only reported the serum prolactin levels in pregnant women and therefore the data could not be analyzed in this review.,rephrase,['The study only reported on serum prolactin levels in the women who were pregnant.'],5,0.42857142857142855,3,21
CD008883,2,9,"No other secondary outcomes relevant to this review were reported; adverse effects for women (nausea, vomiting, headache, vertigo, fatigue, hypotension, arrhythmia, and psychotic symptoms) and infants (birth defects, low birthweight, and developmental disabilities) were not reported.",rephrase,"['The study did not report on any adverse effects that dopamine agonists might possibly have for the women (e.g. nausea, vomiting, headache, vertigo, fatigue, hypotension, arrhythmia, and psychotic symptoms) or her baby (e.g. birth defects, low birthweight, and developmental disabilities).']",6,0.47619047619047616,3,21
CD008883,3,10,"We downgraded the quality of the evidence for risk of bias in the one trial contributing outcome data (no description of allocation concealment, lack of blinding and possible reporting bias) and for imprecision (all effect estimates were based on small sample size, miscarriage was based on few events, and the 95% CIs of live birth and conception cross the line of no effect).",rephrase,"['We rated the evidence for the review outcomes of miscarriage as low quality and live birth and conception as very low quality due to questions we had about the study design, the small number of women in the study, and because only one randomized controlled study was identified.']",7,0.5238095238095238,3,21
CD008883,4,11,"Currently, there is insufficient evidence (from a single randomized trial with a small sample size, and judged to be at high risk of bias) to evaluate the effectiveness of dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and a history of recurrent miscarriage.",rephrase,"['Currently, there is not enough evidence (from one small trial) to evaluate the effectiveness and safety of dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.']",8,0.5714285714285714,3,21
CD008883,4,12,We assessed outcomes using GRADE methodology.,delete,[],9,0.6190476190476191,4,21
CD008883,4,13,"Miscarriage was assessed as low quality due to risk of bias concerns in the one trial contributing data (no description of allocation concealment, lack of blinding and possible reporting bias) and to imprecision (effect estimates were based on small sample size and few events).",delete,[],9,0.6666666666666666,4,21
CD008883,4,14,"Live births and conception were assessed as of very low quality due to the same risk of bias concerns in study design and to imprecision (with a wide 95% CI consistent with either benefit or harm), and a small sample size.",delete,[],9,0.7142857142857143,4,21
CD008883,4,15,There were no data relating to adverse effects of the intervention for either the mother or her baby.,delete,[],9,0.7619047619047619,4,21
CD008883,5,16,Futher high-quality research in this area is warranted.,merge,"['There is a need for further, high-quality research in this area.']",9,0.8095238095238095,5,21
CD008883,5,17,"There is a need for well-designed, larger RCTs to confirm and extend the findings of the trial reviewed here.",none,[],9,0.8571428571428571,5,21
CD008883,5,18,Many questions remain unanswered.,delete,[],10,0.9047619047619048,5,21
CD008883,5,19,"Some important considerations for future research include, the need for well-designed RCTs with large sample sizes, and for those studies to consider important outcomes (including adverse effects for both the mother and her baby).",merge,[],10,0.9523809523809523,5,21
CD008883,5,20,"Future studies should examine the effectiveness and safety of various dopamine agonists including bromocriptine, cabergoline and quinagolide.",none,"['Further studies should examine various dopamine agonists (including bromocriptine, cabergoline and quinagolide) and consider important outcomes (including adverse effects for both the mother and her baby).']",10,1.0,5,21
CD001519,0,0,"Cabergoline has been compared with bromocriptine in five randomised, double-blind, parallel group studies including 1071 patients.",rephrase,['Cabergoline has been compared with the older agonist bromocriptine in five studies including 1071 patients.'],0,0.08333333333333333,1,12
CD001519,0,1,"Only one of the phase II studies was medium term (36 weeks), the others all being short term (12 -15 weeks).",ignore,"['Only one of the smaller studies was medium term (36 weeks), the others all being short term (12 -15 weeks).']",1,0.16666666666666666,1,12
CD001519,0,2,"The non-significant difference in off time reduction produced by cabergoline compared with bromocriptine was 0.29 hours/day in favour of the former (weighted mean difference; 95% CI -0.10, 0.68; p = 0.15).",delete,[],2,0.25,2,12
CD001519,0,3,"Dyskinesia reported as an adverse event was significantly increased with cabergoline compared with bromocriptine (Peto odds ratio 1.57; 95% CI 1.05, 2.35; p = 0.03).",rephrase,['Dyskinesia reported as a side effect was significantly increased with cabergoline compared with bromocriptine.'],2,0.3333333333333333,2,12
CD001519,0,4,Motor impairment and disability were measured in four of the studies using the UPDRS rating scale but the small differences in UPDRS ADL (part II) and motor (part III) scores were not statistically significant in any study.,rephrase,['Physical impairment and disability were measured in four of the studies but no statistically significant advantage for cabergoline was found.'],3,0.4166666666666667,3,12
CD001519,0,5,"Similarly, no significant difference in Schwab and England score was seen.",delete,[],4,0.5,3,12
CD001519,0,6,The number of patients rated as much or very much improved on a clinician's global impression scale was similar with both agonists.,split,"['The time patients spent in the immobile off state was reduced with both agonists but slightly more by cabergoline compared with bromocriptine.', ""The number of patients rated as much or very much improved on a clinician's global impression scale was similar with both agonists.""]",4,0.5833333333333334,3,12
CD001519,0,7,Levodopa dose reduction was no different between cabergoline and bromocriptine.,ignore,['Levodopa dose reduction was no different between cabergoline and bromocriptine.'],6,0.6666666666666666,4,12
CD001519,0,8,"There was more confusion with cabergoline (Peto odds ratio 2.02; 95% CI 1.09, 3.76; p = 0.03).",rephrase,['There was significantly more confusion with cabergoline.'],7,0.75,4,12
CD001519,0,9,"Otherwise, dopaminergic adverse events were comparable with these agonists and no significant difference in all cause withdrawal rate was found.",rephrase,"['Otherwise, dopaminergic side effects were comparable with these agonists and no significant difference in the withdrawal rate from the trials was found.']",8,0.8333333333333334,5,12
CD001519,1,10,"Cabergoline produces similar benefits to bromocriptine in off time reduction, motor impairment and disability ratings, and levodopa dose reduction over the first three months of therapy.",ignore,"['Cabergoline produces similar benefits to bromocriptine in off time reduction, physical impairment and disability ratings, and levodopa dose reduction over the first three months of therapy.']",9,0.9166666666666666,5,12
CD001519,1,11,Dyskinesia and confusion were increased with cabergoline but otherwise the frequency of adverse events and withdrawals from treatment were similar with the two agonists.,rephrase,['The frequency of side effects and withdrawals from treatment were similar with the two agonists apart from increased dyskinesia and confusion with cabergoline.'],10,1.0,5,12
CD003674,0,0,Twelve trials involving 844 participants were included.,rephrase,['Twelve trials including 794 participants acute Achilles tendon rupture were included.'],0,0.1,1,10
CD003674,0,1,One trial tested two comparisons.,delete,[],1,0.2,1,10
CD003674,1,2,"Quality assessment revealed a poor level of methodological rigour in many studies, particularly with regard to concealment of allocation and the lack of assessor blinding.",delete,[],1,0.3,2,10
CD003674,2,3,"Open surgical treatment compared with non-surgical treatment (6 trials, 536 participants) was associated with a statistically significant lower risk of rerupture (risk ratio (RR) 0.41, 95% confidence interval (CI) 0.21 to 0.77), but a higher risk of other complications including infection (RR 4.89, 95% CI 1.09 to 21.91), adhesions and disturbed skin sensibility (numbness).",rephrase,"['Open surgical treatment compared with non-surgical treatment (6 studies, 502 participants) was associated with a lower risk of rerupture, but a higher risk of other complications such as infection, adhesions and disturbed skin sensibility (numbness and tingling).']",1,0.4,2,10
CD003674,2,4,"Functional status including sporting activity was variably and often incompletely reported, including frequent use of non standardised outcome measures, and the results were inconclusive.",rephrase,['There were insufficient and inconclusive data on function and sporting activities.'],2,0.5,3,10
CD003674,3,5,"Open surgical repair compared with percutaneous repair (4 trials, 174 participants) was associated with a higher risk of infection (RR 9.32, 95% CI 1.77 to 49.16).",rephrase,"['Percutaneous repair (involving stab incisions through which the repair suture is passed through without direct exposure of the tendon) compared with open repair (4 studies, 174 participants) was associated with a lower risk of infection.']",3,0.6,3,10
CD003674,3,6,These figures should be interpreted with caution because of the small numbers involved.,ignore,['These figures should be interpreted with caution because of the small numbers involved.'],4,0.7,4,10
CD003674,3,7,"Similarly, no definitive conclusions could be made regarding different tendon repair techniques (3 trials, 147 participants).",ignore,"['Similarly, no definitive conclusions could be made regarding different tendon repair techniques (3 studies, 141 participants).']",5,0.8,4,10
CD003674,4,8,"Open surgical treatment of acute Achilles tendon ruptures significantly reduces the risk of rerupture compared with non-surgical treatment, but produces significantly higher risks of other complications, including wound infection.",delete,[],6,0.9,5,10
CD003674,4,9,The latter may be reduced by performing surgery percutaneously.,delete,[],6,1.0,5,10
CD010347,0,0,We included in the review 37 studies representing 6128 adult and adolescent participants (most with mild to moderate asthma).,split,"['We found 37 studies (representing 6128 adults and adolescents).', 'The people in these trials had mild to moderate asthma.']",0,0.05263157894736842,1,19
CD010347,0,1,"Investigators in these studies used three leukotriene receptor antagonists (LTRAs): montelukast (n = 24), zafirlukast (n = 11) and pranlukast (n = 2); studies lasted from four weeks to five years.",rephrase,"['Most (24) studies used the LTRA called montelukast, 11 studies used zafirlukast and only two studies used pranlukast.']",2,0.10526315789473684,1,19
CD010347,1,2,"Anti-leukotrienes and ICS versus same dose of ICS
Of 16 eligible studies, 10 studies, representing 2364 adults and adolescents, contributed data.",rephrase,['• Anti-leukotrienes and ICS versus same dose of ICS: Ten studies (representing 2364 adults and adolescents) contributed data for analysis.'],3,0.15789473684210525,1,19
CD010347,1,3,"Anti-leukotriene agents given as adjunct therapy to ICS reduced by half the number of participants with exacerbations requiring oral corticosteroids (risk ratio (RR) 0.50, 95% confidence interval (CI) 0.29 to 0.86; 815 participants; four studies; moderate quality); this is equivalent to a number needed to treat for additional beneficial outcome (NNTB) over six to 16 weeks of 22 (95% CI 16 to 75).",split,"['Anti-leukotrienes given with ICS reduced by half the number of patients with exacerbations requiring oral steroids (from 9% to 5% over three months), but we are unsure about effects of this treatment on quality of life or serious side effects.', 'Anti-leukotrienes given with ICS improved lung function and asthma control measures.']",4,0.21052631578947367,2,19
CD010347,1,4,"Only one trial including 368 participants reported mortality and serious adverse events, but events were too infrequent for researchers to draw a conclusion.",delete,[],6,0.2631578947368421,2,19
CD010347,1,5,"Four trials reported all adverse events, and the pooled result suggested little difference between groups (RR 1.06, 95% CI 0.92 to 1.22; 1024 participants; three studies; moderate quality).",delete,[],6,0.3157894736842105,2,19
CD010347,1,6,"Investigators noted between-group differences favouring the addition of anti-leukotrienes for morning peak expiratory flow rate (PEFR), forced expiratory volume in one second (FEV1), asthma symptoms and night-time awakenings, but not for reduction in β2-agonist use or evening PEFR.",delete,[],6,0.3684210526315789,2,19
CD010347,2,7,"Anti-leukotrienes and ICS versus higher dose of ICS
Of 15 eligible studies, eight studies, representing 2008 adults and adolescents, contributed data.",rephrase,['• Anti-leukotrienes and ICS versus higher dose of ICS: Eight studies (representing 2008 adults and adolescents) contributed data for analysis.'],6,0.42105263157894735,3,19
CD010347,2,8,"Results showed no statistically significant difference in the number of participants with exacerbations requiring oral corticosteroids (RR 0.90, 95% CI 0.58 to 1.39; 1779 participants; four studies; moderate quality) nor in all adverse events between groups (RR 0.96, 95% CI 0.89 to 1.03; 1899 participants; six studies; low quality).",rephrase,['Results showed no reduction in the number of patients with exacerbations requiring oral steroids and no difference in quality of life nor in side effects.'],7,0.47368421052631576,3,19
CD010347,2,9,Three trials reported no deaths among 834 participants.,delete,[],8,0.5263157894736842,3,19
CD010347,2,10,Results showed no statistically significant differences in lung function tests including morning PEFR and FEV1 nor in asthma control measures including use of rescue β2-agonists or asthma symptom scores.,rephrase,['Data showed no improvement in lung function nor in asthma control measures.'],8,0.5789473684210527,3,19
CD010347,3,11,"Anti-leukotrienes and ICS versus tapering dose of ICS
Seven studies, representing 1150 adults and adolescents, evaluated the combination of anti-leukotrienes and tapering-dose of ICS compared with tapering-dose of ICS alone and contributed data.",rephrase,['• Anti-leukotrienes and gradual reduction of ICS dose versus gradual reduction of ICS dose alone: Seven studies (representing 1150 adults and adolescents) evaluated anti-leukotrienes given with a gradually reduced dose of ICS compared with a gradually reduced dose of ICS without use of anti-leukotriene agents.'],9,0.631578947368421,4,19
CD010347,3,12,"Investigators observed no statistically significant difference in % change from baseline ICS dose (mean difference (MD) -3.05, 95% CI -8.13 to 2.03; 930 participants; four studies; moderate quality), number of participants with exacerbations requiring oral corticosteroids (RR 0.46, 95% CI 0.20 to 1.04; 542 participants; five studies; low quality) or all adverse events (RR 0.95, 95% CI 0.83 to 1.08; 1100 participants; six studies; moderate quality).",delete,[],10,0.6842105263157895,4,19
CD010347,3,13,"Serious adverse events occurred more frequently among those taking anti-leukotrienes plus tapering ICS than in those taking tapering doses of ICS alone (RR 2.44, 95% CI 1.52 to 3.92; 621 participants; two studies; moderate quality), but deaths were too infrequent for researchers to draw any conclusions about mortality.",delete,[],10,0.7368421052631579,4,19
CD010347,3,14,Data showed no improvement in lung function nor in asthma control measures.,rephrase,['More people receiving anti-leukotriene and ICS compared with ICS alone experienced increased serious side effects and showed no improvement in lung function nor in asthma control measures.'],10,0.7894736842105263,4,19
CD010347,4,15,"For adolescents and adults with persistent asthma, with suboptimal asthma control with daily use of ICS, the addition of anti-leukotrienes is beneficial for reducing moderate and severe asthma exacerbations and for improving lung function and asthma control compared with the same dose of ICS.",split,"['For adolescents and adults with asthma not controlled with daily low-dose ICS, adding anti-leukotriene agents to ICS reduced by half the number of patients with asthma exacerbations requiring an oral corticosteroid.', 'Anti-leukotrienes and ICS also improved lung function and asthma control.']",11,0.8421052631578947,5,19
CD010347,4,16,"We cannot be certain that the addition of anti-leukotrienes is superior, inferior or equivalent to a higher dose of ICS.",split,"['However, we are not sure whether the combination of anti-leukotrienes and ICS is superior to higher-dose ICS.', 'In general, addition of anti-leukotrienes to ICS therapy was not associated with increased side effects, if the dose of ICS was maintained.']",13,0.8947368421052632,5,19
CD010347,4,17,"Scarce available evidence does not support anti-leukotrienes as an ICS sparing agent, and use of LTRAs was not associated with increased risk of withdrawals or adverse effects, with the exception of an increase in serious adverse events when the ICS dose was tapered.",rephrase,['Limited available evidence does not support use of anti-leukotrienes as a way to decrease ICS dose.'],15,0.9473684210526315,5,19
CD010347,4,18,Information was insufficient for assessment of mortality.,delete,[],16,1.0,5,19
CD013440,0,0,"We identified 9748 references from the searches, with 8337 remaining after duplicates were removed.",delete,[],0,0.08333333333333333,1,12
CD013440,0,1,"After full-text review, we included one trial.",delete,[],0,0.16666666666666666,1,12
CD013440,0,2,"There were no studies of early specialist palliative care interventions or of early, co-ordinated generalist palliative care approaches.",rephrase,['We could not find any trials examining the impact of specialist palliative care teams on outcomes for patients or their carers.'],0,0.25,2,12
CD013440,1,3,"The included randomised trial addressed a single symptom area, focusing on early cognitive rehabilitation, administered within two weeks of surgery in a mixed brain tumour population, of whom approximately half had a high-grade glioma.",split,"['We included one trial which focused on a single symptom area – that of cognition – in a patient group of whom about half had a high-grade tumour.', 'The trial randomised patients between a group receiving a structured cognitive rehabilitation intervention and a group receiving usual rehabilitation care of medications and physiotherapy.']",1,0.3333333333333333,2,12
CD013440,1,4,"The intervention was administered individually as therapist-led computerised exercises over 16 one-hour sessions, four times/week for four weeks.",rephrase,"['Cognitive rehabilitation consisted of supervised computer-based exercises, lasting 45 minutes at a time, four times a week, over a four-week period.']",3,0.4166666666666667,3,12
CD013440,1,5,"Sessions addressed several cognitive domains including time orientation, spatial orientation, visual attention, logical reasoning, memory, and executive function.",delete,[],4,0.5,3,12
CD013440,2,6,"There were no between-group differences in outcome for tests of logical-executive function, but differences were observed in the domains of visual attention and verbal memory.",rephrase,['There was no important difference between the two groups apart from some improvement in visual attention and verbal memory in those who received the cognitive rehabilitation intervention.'],4,0.5833333333333334,3,12
CD013440,2,7,Risk of bias was assessed and stated as high for performance bias and attrition bias but for selective reporting it was unclear whether all outcomes were reported.,delete,[],5,0.6666666666666666,4,12
CD013440,2,8,"We considered the certainty of the evidence, as assessed by GRADE, to be very low.",rephrase,"['However, we assessed the certainty of the evidence as being very low, and we could find no evidence in this or other studies on any other aspect of palliative care.']",5,0.75,4,12
CD013440,3,9,"Currently there is a lack of research focusing on the introduction of early palliative interventions specifically for people with primary brain tumours, either as co-ordinated specialist palliative care approaches or interventions focusing on a specific aspect of palliation.",split,"['Not enough research has been undertaken on early palliative care interventions which support people with primary brain tumours, and their caregivers.', 'Research is needed which examines co-ordinated approaches to overall palliative care provision, and interventions which focus on specific aspects of palliation in this population.']",6,0.8333333333333334,5,12
CD013440,3,10,Future research should address the methodological shortcomings described in early palliative intervention studies in other cancers and chronic conditions.,delete,[],8,0.9166666666666666,5,12
CD013440,3,11,"In particular, the specific population under investigation, the timing and the setting of the intervention should be clearly described and the standardised palliative care-specific components of the intervention should be defined in detail.",delete,[],8,1.0,5,12
CD001929,0,0,In total we included 25 trials (3096 participants) in this review update.,rephrase,['In total we included 25 RCTs and 3096 participants in this review update.'],0,0.06666666666666667,1,15
CD001929,0,1,The majority was funded by not-for-profit organizations.,rephrase,"['Seven studies did not report the sources of funding, Sixteen studies were funded by not-for-profit organizations.']",1,0.13333333333333333,1,15
CD001929,0,2,"One trial included participants with acute LBP, and the remaining trials included people with sub-acute or chronic LBP (CLBP).",rephrase,"['Only one trial included patients with acute LBP (pain duration less than four weeks), while all the others included patients with sub-acute (four to 12 weeks) or chronic LBP (12 weeks or longer).']",2,0.2,1,15
CD001929,0,3,"In three trials massage was done with a mechanical device, and the remaining trials used only the hands.",rephrase,"['In three studies, massage was applied using a mechanical device (such as a metal bar to increase the compression to the skin or a vibrating instrument), and in the remaining trials it was done using the hands.']",3,0.26666666666666666,2,15
CD001929,0,4,"The most common type of bias in these studies was performance and measurement bias because it is difficult to blind participants, massage therapists and the measuring outcomes.",delete,[],4,0.3333333333333333,2,15
CD001929,0,5,"We judged the quality of the evidence to be ""low"" to ""very low"", and the main reasons for downgrading the evidence were risk of bias and imprecision.",rephrase,"['The quality of the evidence for all comparisons was graded ""low "" or ""very low"" which means that we have very little confidence in these results.']",4,0.4,2,15
CD001929,0,6,There was no suggestion of publication bias.,delete,[],5,0.4666666666666667,3,15
CD001929,0,7,"For acute LBP, massage was found to be better than inactive controls for pain ((SMD -1.24, 95% CI -1.85 to -0.64; participants = 51; studies = 1)) in the short-term, but not for function ((SMD -0.50, 95% CI -1.06 to 0.06; participants = 51; studies = 1)).",rephrase,"['Massage was better than inactive controls for pain and function in the short-term, but not in the long-term follow-up.']",5,0.5333333333333333,3,15
CD001929,0,8,"For sub-acute and chronic LBP, massage was better than inactive controls for pain ((SMD -0.75, 95% CI -0.90 to -0.60; participants = 761; studies = 7)) and function (SMD -0.72, 95% CI -1.05 to -0.39; 725 participants; 6 studies; ) in the short-term, but not in the long-term; however, when compared to active controls, massage was better for pain, both in the short ((SMD -0.37, 95% CI -0.62 to -0.13; participants = 964; studies = 12)) and long-term follow-up ((SMD -0.40, 95% CI -0.80 to -0.01; participants = 757; studies = 5)), but no differences were found for function (both in the short and long-term).",rephrase,"['Massage was better than active controls for pain both in the short and long-term follow-ups, but we found no differences for function, either in the short or long-term follow-ups.']",6,0.6,3,15
CD001929,0,9,There were no reports of serious adverse events in any of these trials.,ignore,['There were no reports of serious adverse events in any of these trials.'],7,0.6666666666666666,4,15
CD001929,0,10,Increased pain intensity was the most common adverse event reported in 1.5% to 25% of the participants.,rephrase,['The most common adverse events were increased pain intensity in 1.5% to 25% of the participants.'],8,0.7333333333333333,4,15
CD001929,1,11,We have very little confidence that massage is an effective treatment for LBP.,delete,[],9,0.8,4,15
CD001929,1,12,"Acute, sub-acute and chronic LBP had improvements in pain outcomes with massage only in the short-term follow-up.",delete,[],9,0.8666666666666667,5,15
CD001929,1,13,"Functional improvement was observed in participants with sub-acute and chronic LBP when compared with inactive controls, but only for the short-term follow-up.",delete,[],9,0.9333333333333333,5,15
CD001929,1,14,There were only minor adverse effects with massage.,delete,[],9,1.0,5,15
CD007095,0,0,We identified five clinical trials that involved 3405 children for inclusion.,rephrase,"['We identified five clinical trials that involved 3405 children, mostly from the same research group.']",0,0.1,1,10
CD007095,0,1,"For this 2016 update, we identified one new trial for inclusion.",delete,[],1,0.2,1,10
CD007095,0,2,"This trial was systematically reviewed but due to several sources of heterogeneity, was not included in the meta-analysis.",delete,[],1,0.3,2,10
CD007095,0,3,The remaining four trials were of adequate methodological quality.,delete,[],1,0.4,2,10
CD007095,0,4,"In three RCTs that involved a total of 1826 healthy Finnish children attending daycare, there is moderate quality evidence that xylitol (in any form) can reduce the risk of AOM from 30% to around 22% compared with the control group (RR 0.75, 95% CI 0.65 to 0.88).",delete,[],1,0.5,3,10
CD007095,0,5,"Among the reasons for dropouts, there were no significant differences in abdominal discomfort and rash between the xylitol and the control groups.",rephrase,"['There is no difference in side effects (namely, abdominal discomfort and rash).']",1,0.6,3,10
CD007095,0,6,"Xylitol was not effective in reducing AOM among healthy children during a respiratory infection (RR 1.13, 95% CI 0.83 to 1.53; moderate quality evidence) or among otitis-prone healthy children (RR 0.90, 95% CI 0.67 to 1.21; low-quality evidence).",rephrase,['The quality of evidence was moderate for healthy children and children with respiratory infections but low for otitis-prone children.'],2,0.7,4,10
CD007095,1,7,There is moderate quality evidence showing that the prophylactic administration of xylitol among healthy children attending daycare centres can reduce the occurrence of AOM.,rephrase,"['Xylitol, administered in chewing gum, lozenges or syrup, can reduce the occurrence of AOM among healthy children with no acute upper respiratory infection from 30% to 22%.']",3,0.8,4,10
CD007095,1,8,"There is inconclusive evidence with regard to the efficacy of xylitol in preventing AOM among children with respiratory infection, or among otitis-prone children.",rephrase,['The preventive effect among healthy children with respiratory infection or among otitis-prone children is inconclusive.'],4,0.9,5,10
CD007095,1,9,"The meta-analysis was limited because data came from a small number of studies, and most were from the same research group.",delete,[],5,1.0,5,10
CD006263,0,0,"Eleven studies with a total of 404 participants (337 pemphigus vulgaris, 27 pemphigus foliaceus and 40 not specified ) were identified.",delete,[],0,0.08333333333333333,1,12
CD006263,0,1,"The quality of included studies was not high, the majority of studies did not report allocation concealment, and power was limited by very small sample sizes.",delete,[],0,0.16666666666666666,1,12
CD006263,0,2,"Interventions assessed included prednisolone dose regimen, pulsed dexamethasone, azathioprine, cyclophosphamide, cyclosporine, dapsone, mycophenolate, plasma exchange, topical epidermal growth factor and traditional Chinese medicine.",rephrase,"['Ten different active treatments were studied, including prednisolone, pulsed oral dexamethasone, azathioprine, cyclophosphamide, cyclosporine, dapsone, mycophenolate, plasma exchange, topical epidermal growth factor and traditional Chinese medicine.']",0,0.25,2,12
CD006263,0,3,"Ten studies included participants with newly diagnosed or newly active recurrent disease, and one trial included participants in maintenance phase.",delete,[],1,0.3333333333333333,2,12
CD006263,1,4,"There was sufficient data for 4 meta-analyses, each pooling results of two studies only.",delete,[],1,0.4166666666666667,3,12
CD006263,1,5,"For the majority of interventions, results were inconclusive.",delete,[],1,0.5,3,12
CD006263,1,6,"We found some interventions to be superior for certain outcomes, although we were unable to conclude which treatments are superior overall.",split,"['We found no difference in withdrawal due to adverse events in any study, although differing adverse event profiles were observed for each intervention.', 'We were not able to conclude which treatments are superior overall.']",1,0.5833333333333334,3,12
CD006263,1,7,"Mycophenolate was more effective in achieving disease control than azathioprine (1 study; n=40; RR 0.72; 95% CI 0.52 to 0.99, NNT 3.7).",rephrase,"['We found that mycophenolate mofetil appears to be more effective than azathioprine in controlling disease, although no difference was seen in remission.']",3,0.6666666666666666,4,12
CD006263,1,8,There was evidence of a steroid-sparing benefit of azathioprine (1 study; n=57; MWD -3919 mg prednisolone; 95% CI -6712 to -1126) and cyclophosphamide (1 study; n=54; MWD -3355 mg prednisolone; 95% CI -6144 to -566) compared to glucocorticoids alone.,rephrase,['We found that taking azathioprine and cyclophosphamide decreased the amount of glucocorticoids required.'],4,0.75,4,12
CD006263,1,9,Topical epidermal growth factor decreased time to control (1 study; n=20; HR 2.35; 95% CI 1.62 to 3.41).,rephrase,['Topical epidermal growth factor decreased time required for lesions to heal by 6 days (median).'],5,0.8333333333333334,5,12
CD006263,2,10,There is inadequate information available at present to ascertain the optimal therapy for pemphigus vulgaris or pemphigus foliaceus.,split,"['Multiple treatments are available for pemphigus vulgaris and pemphigus foliaceus and there is a variation in dosage plan and combination of drugs used, which makes choice of treatment schedule complex.', 'This review found insufficient information to conclude which is the most effective and safest treatment regimen.']",6,0.9166666666666666,5,12
CD006263,2,11,"Further research is required, especially to assess the optimal glucocorticoid dose, the role of adjuvant immunosuppressive medications, and long-term adverse events to improve harm:benefit analyses.",rephrase,"['Further studies are required to determine the optimal treatment regimen, especially to assess the optimal glucocorticoid dose, the role of adjuvant immunosuppressive medications, and long-term adverse events to improve harm:benefit analyses.']",8,1.0,5,12
CD000934,0,0,"We included seven trials (more than 60,000 women): four in high-income countries with individual randomisation; three in low- and middle-income countries with cluster randomisation (clinics as the unit of randomisation).",rephrase,"['We included seven randomised controlled trials involving more than 60,000 women.']",0,0.05555555555555555,1,18
CD000934,0,1,"Most of the data included in the review came from the three large, well-designed cluster-randomised trials that took place in Argentina, Cuba, Saudi Arabia, Thailand and Zimbabwe.",delete,[],1,0.1111111111111111,1,18
CD000934,0,2,All results have been adjusted for the cluster design effect.,delete,[],1,0.16666666666666666,1,18
CD000934,0,3,All of the trials were at some risk of bias as blinding of women and staff was not feasible with this type of intervention.,delete,[],1,0.2222222222222222,2,18
CD000934,0,4,"For primary outcomes, evidence was graded as being of moderate or low quality, with downgrading decisions due to risks of bias and imprecision of effects.",rephrase,['We assessed studies for risk of bias and graded the quality of the evidence.'],1,0.2777777777777778,2,18
CD000934,1,5,"The number of visits for standard care varied, with fewer visits in low- and middle- income country trials.",rephrase,['The trials were carried out in both high-income (four trials) and low- and middle-income countries (three trials).'],2,0.3333333333333333,2,18
CD000934,1,6,"In studies in high-income countries, women in the reduced visits groups, on average, attended between 8.2 and 12 times.",rephrase,['In high-income countries the number of visits was reduced to around eight.'],3,0.3888888888888889,2,18
CD000934,1,7,"In low- and middle- income country trials, many women in the reduced visits group attended on fewer than five occasions, although in these trials the content as well as the number of visits was changed, so as to be more 'goal-oriented'.",rephrase,"['In lower-income countries many women in the reduced visits group attended for care on fewer than five occasions, although the content of visits was altered so as to focus on specific goals.']",4,0.4444444444444444,3,18
CD000934,2,8,"Perinatal mortality was increased for those randomised to reduced visits rather than standard care, and this difference was borderline for statistical significance (risk ratio (RR) 1.14; 95% confidence interval (CI) 1.00 to 1.31; five trials, 56,431 babies; moderate-quality evidence).",split,"['In this review there was no strong evidence of differences between groups receiving a reduced number of antenatal visits compared with standard care on the number of preterm births or low birthweight babies (moderate-quality evidence).', 'However, there was some evidence from these trials that in low- and middle-income countries perinatal mortality may be increased with reduced visits (low-quality evidence) although there may have been fewer admissions to neonatal intensive care but the evidence for this latter outcome was not strong.']",5,0.5,3,18
CD000934,2,9,"In the subgroup analysis, for high-income countries the number of deaths was small (32/5108), and there was no clear difference between the groups (RR 0.90; 95% CI 0.45 to 1.80, two trials); for low- and middle-income countries perinatal mortality was significantly higher in the reduced visits group (RR 1.15; 95% CI 1.01 to 1.32, three trials).",delete,[],7,0.5555555555555556,3,18
CD000934,3,10,"There was no clear difference between groups for our other primary outcomes: maternal death (RR 1.13, 95%CI 0.50 to 2.57, three cluster-randomised trials, 51,504 women, low-quality evidence); hypertensive disorders of pregnancy (various definitions including pre-eclampsia) (RR 0.95, 95% CI 0.80 to 1.12, six studies, 54,108 women, low-quality evidence); preterm birth (RR 1.02, 95% CI 0.94 to 1.11; seven studies, 53,661 women, moderate-quality evidence); and small-for-gestational age (RR 0.99, 95% CI 0.91 to 1.09, four studies 43,045 babies, moderate-quality evidence).",delete,[],7,0.6111111111111112,4,18
CD000934,4,11,"Reduced visits were associated with a reduction in admission to neonatal intensive care that was borderline for significance (RR 0.89; 95% CI 0.79 to 1.02, five studies, 43,048 babies, moderate quality evidence).",delete,[],7,0.6666666666666666,4,18
CD000934,4,12,There were no clear differences between the groups for the other secondary clinical outcomes.,rephrase,['There was no clear difference between groups for our other primary outcomes including maternal death and hypertensive disorders of pregnancy (including pre-eclampsia).'],7,0.7222222222222222,4,18
CD000934,5,13,Women in all settings were less satisfied with the reduced visits schedule and perceived the gap between visits as too long.,rephrase,['There was evidence that women in all settings were less satisfied with the reduced schedule of visits; for some women the gap between visits was perceived as too long.'],8,0.7777777777777778,4,18
CD000934,5,14,Reduced visits may be associated with lower costs.,ignore,['Reduced visits may be associated with lower costs.'],9,0.8333333333333334,5,18
CD000934,6,15,"In settings with limited resources where the number of visits is already low, reduced visits programmes of antenatal care are associated with an increase in perinatal mortality compared to standard care, although admission to neonatal intensive care may be reduced.",delete,[],10,0.8888888888888888,5,18
CD000934,6,16,Women prefer the standard visits schedule.,delete,[],10,0.9444444444444444,5,18
CD000934,6,17,"Where the standard number of visits is low, visits should not be reduced without close monitoring of fetal and neonatal outcome.",delete,[],10,1.0,5,18
CD005079,0,0,We included two trials that compared surgical with non-surgical treatment for patients with thoracolumbar burst fractures without neurological deficit.,split,"['We included data from two trials, which included 87 participants.', 'The trials compared surgical with non-surgical treatment for these fractures in the thoracolumbar region of the spine.']",0,0.09090909090909091,1,11
CD005079,0,1,These recruited a total of 87 participants and reported outcomes for 79 participants at follow-up of two years or more.,delete,[],2,0.18181818181818182,1,11
CD005079,0,2,"Both trials were judged at unclear risk of selection bias and at high risk of performance and detection biases, resulting from lack of blinding.",delete,[],2,0.2727272727272727,2,11
CD005079,1,3,"The two trials reported contrasting results for pain and function-related outcomes at final follow-up, and numbers returning to work.",rephrase,['They reported contrasting results for patient pain and function at a minimum of two years after treatment.'],2,0.36363636363636365,2,11
CD005079,1,4,"One trial found less pain (mean difference (MD) -15.09 mm, 95% CI -27.81 to -2.37; 100 mm visual analogue scale), and better function based on the Roland and Morris disability questionnaire results (MD -5.87, 95% CI -10.10 to -1.64; 24 points = maximum disability) in the surgical group.",rephrase,['One study found patients had less pain and better function after surgery compared with patients who did not have surgery.'],3,0.45454545454545453,3,11
CD005079,1,5,"Based on the same outcome measures, the other trial found the surgical group had more pain (MD 13.60 mm, 95% CI -0.31 to 27.51) and worse function (MD 4.31, 95% CI 0.54 to 8.08).",merge,['The other trial found the opposite.'],4,0.5454545454545454,3,11
CD005079,1,6,Neither trial reported a statistically significant difference in return to work.,none,[],4,0.6363636363636364,4,11
CD005079,1,7,"There were greater numbers of participants with complications in the surgical group of both trials (21/41 versus 6/38; RR 2.85, 95% CI 0.83 to 9.75; 2 trials), and only participants of this group had subsequent surgery, involving implant removal either for complications or as a matter of course.",rephrase,['Both trials found there were more early complications in the surgical group and only participants of this group had subsequent additional surgery.'],5,0.7272727272727273,4,11
CD005079,1,8,One trial reported that surgery was over four times more costly than non-surgical treatment.,ignore,['One trial reported that surgery was over four times more costly than non-surgical treatment.'],6,0.8181818181818182,5,11
CD005079,2,9,The contradictory evidence provided by two small and potentially biased randomised controlled trials is insufficient to conclude whether surgical or non-surgical treatment yields superior pain and functional outcomes for people with thoracolumbar burst fractures without neurological deficit.,rephrase,['Our review concluded that the weak evidence from these two trials was insufficient to say whether surgery or non-surgical treatment was better for these fractures.'],7,0.9090909090909091,5,11
CD005079,2,10,"It is likely, however, that surgery is associated with more early complications and the need for subsequent surgery, as well as greater initial healthcare costs.",rephrase,"['However, surgery is likely to be associated with more early complications and the need for subsequent surgery, as well as greater initial healthcare costs.']",8,1.0,5,11
CD000996,0,0,"The review included seven studies, involving 380 adults.",rephrase,['The participants included in the seven studies were 380 adults who had bronchiectasis diagnosed by symptoms or from a detailed lung scan (computed tomography (CT)).'],0,0.08333333333333333,1,12
CD000996,0,1,"Of the 380 randomised participants, 348 completed the studies.",delete,[],1,0.16666666666666666,1,12
CD000996,1,2,"Due to differences in outcomes reported among the seven studies, we could only perform limited meta-analysis for both the short-term ICS use (6 months or less) and the longer-term ICS use (> 6 months).",delete,[],1,0.25,2,12
CD000996,2,3,"During stable state in the short-term group (ICS for 6 months or less), based on the two studies from which data could be included, there were no significant differences from baseline values in the forced expiratory volume in the first second (FEV1) at the end of the study (mean difference (MD) -0.09, 95% confidence interval (CI) -0.26 to 0.09) and forced vital capacity (FVC) (MD 0.01 L, 95% CI -0.16 to 0.17) in adults on ICS (compared to no ICS).",delete,[],1,0.3333333333333333,2,12
CD000996,2,4,"Similarly, we did not find any significant difference in the average exacerbation frequency (MD 0.09, 95% CI -0.61 to 0.79) or health-related quality of life (HRQoL) total scores in adults on ICS when compared with no ICS, though data available were limited.",delete,[],1,0.4166666666666667,3,12
CD000996,2,5,"Based on a single non-placebo controlled study from which we could not extract clinical data, there was marginal, though statistically significant improvement in sputum volume and dyspnoea scores on ICS.",delete,[],1,0.5,3,12
CD000996,3,6,"The single study on long-term outcomes (over 6 months) that examined lung function and other clinical outcomes, showed no significant effect of ICS on any of the outcomes.",rephrase,['The single study on long-term use of ICS (i.e. for over 6 months) showed no meaningful benefit of ICS for any of the outcomes.'],1,0.5833333333333334,3,12
CD000996,3,7,We could not draw any conclusion on adverse effects due to limited available data.,rephrase,"['Importantly, we do not know if ICS are linked to more unwanted side effects, because the studies did not provide much information about this.']",2,0.6666666666666666,4,12
CD000996,4,8,"Despite the authors of all seven studies stating they were double-blind, we judged one study (in the short duration ICS) as having a high risk of bias based on blinding, attrition and reporting of outcomes.",merge,[],3,0.75,4,12
CD000996,4,9,"The GRADE quality of evidence was low for all outcomes (due to non-placebo controlled trial, indirectness and imprecision with small numbers of participants and studies).",none,"['Overall, we judged the quality of evidence to be low.']",3,0.8333333333333334,5,12
CD000996,5,10,This updated review indicates that there is insufficient evidence to support the routine use of ICS in adults with stable state bronchiectasis.,rephrase,['The review found that there is not enough evidence for the routine use of ICS in adults with stable bronchiectasis.'],4,0.9166666666666666,5,12
CD000996,5,11,"Further, we cannot draw any conclusion for the use of ICS in adults during an acute exacerbation or in children (for any state), as there were no studies.",rephrase,"['We can make no conclusions about the use of ICS for flare-ups of bronchiectasis, or about their use in children, because we did not find any studies.']",5,1.0,5,12
CD007647,0,0,"We included in this review 33 original trials (reported in 62 separate articles), which were conducted across Africa and Central and South America, with most reported from Asia, specifically India, Pakistan, and Bangladesh.",rephrase,"['A total of 33 experimental studies were conducted across Africa and Central and South America, with most reported from Asia, specifically India, Pakistan, and Bangladesh.']",0,0.1111111111111111,1,9
CD007647,0,1,"Of the 33 community educational interventions provided, 16 included family members in educational counselling, most frequently the mother-in-law or the expectant father.",rephrase,"['Of the 33 community educational interventions, 16 required involvement of family members, most frequently the mother-in-law or the expectant father.']",1,0.2222222222222222,2,9
CD007647,0,2,"Most studies (n = 14) required one-to-one counselling between a healthcare worker and a mother, and 12 interventions involved group counselling for mothers and occasionally family members; the remaining seven incorporated components of both counselling methods.",rephrase,"['Most studies (n = 14) involved one-to-one counselling between a range of community healthcare workers and mothers, and 12 involved group counselling consisting predominantly of mothers, with family members included occasionally; the remaining seven had components of both one-to-one and group counselling.']",2,0.3333333333333333,2,9
CD007647,1,3,"Our analyses show that community health educational interventions had a significant impact on reducing overall neonatal mortality (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.78 to 0.96; random-effects model; 26 studies; n = 553,111; I² = 88%; very low-quality evidence), early neonatal mortality (RR 0.74, 95% CI 0.66 to 0.84; random-effects model; 15 studies that included 3 subsets from 3 studies; n = 321,588; I² = 86%; very low-quality evidence), late neonatal mortality (RR 0.54, 95% CI 0.40 to 0.74; random-effects model; 11 studies; n = 186,643; I² = 88%; very low-quality evidence), and perinatal mortality (RR 0.83, 95% CI 0.75 to 0.91; random-effects model; 15 studies; n = 262,613; I² = 81%; very low-quality evidence).",split,"['This review found that community health educational interventions significantly reduced newborn death, early newborn mortality, and late newborn mortality, as well as perinatal mortality.', 'Educational interventions delivered during antenatal care were more effective for reducing early neonatal deaths, and those delivered during both antenatal and postnatal (after birth) periods were effective for reducing late neonatal deaths and perinatal deaths.']",3,0.4444444444444444,3,9
CD007647,1,4,"Moreover, community health educational interventions increased utilisation of any antenatal care (RR 1.16, 95% CI 1.11 to 1.22; random-effects model; 18 studies; n = 307,528; I² = 96%) and initiation of breastfeeding (RR 1.56, 95% CI 1.37 to 1.77; random-effects model; 19 studies; n = 126,375; I² = 99%).",rephrase,"['These interventions also positively impacted utilisation of any before birth (antenatal), care during pregnancy, and initiation of breastfeeding within an hour after birth.']",5,0.5555555555555556,3,9
CD007647,1,5,"In contrast, community health educational interventions were found to have a non-significant impact on use of modern contraceptives (RR 1.10, 95% CI 0.86 to 1.41; random-effects model; 3 studies; n = 22,237; I² = 80%); presence of skilled birth attendance at birth (RR 1.09, 95% CI 0.94 to 1.25; random-effects model; 10 studies; n = 117,870; I² = 97%); utilisation of clean delivery kits (RR 4.44, 95% CI 0.71 to 27.76; random-effects model; 2 studies; n = 17,087; I² = 98%); and care-seeking (RR 1.11, 95% CI 0.97 to 1.27; random-effects model; 7 studies; n = 46,154; I² = 93%).",delete,[],6,0.6666666666666666,4,9
CD007647,2,6,"Cost-effectiveness analysis conducted in seven studies demonstrated that the cost-effectiveness for intervention packages ranged between USD 910 and USD 11,975 for newborn lives saved and newborn deaths averted.",delete,[],6,0.7777777777777778,4,9
CD007647,2,7,"For averted disability-adjusted life-year, costs ranged from USD 79 to USD 146, depending on the intervention strategy; for cost per year of lost lives averted, the most effective strategy was peer counsellors, and the cost was USD 33.",delete,[],6,0.8888888888888888,5,9
CD007647,3,8,"This review offers encouraging evidence on the value of integrating packages of interventions with educational components delivered by a range of community workers in group settings in LMICs, with groups consisting of mothers, and additional education for family members, for improved neonatal survival, especially early and late neonatal survival.",rephrase,['The review shows that educational interventions delivered to both mothers and other family members in a group setting had a greater impact on these outcomes.'],6,1.0,5,9
CD010326,0,0,We identified one trial comparing early versus delayed laparoscopic cholecystectomy for people with mild acute pancreatitis.,delete,[],0,0.06666666666666667,1,15
CD010326,0,1,"Fifty participants with mild acute gallstone pancreatitis were randomised either to early laparoscopic cholecystectomy (within 48 hours of admission irrespective of whether the abdominal symptoms were resolved or the laboratory values had returned to normal) (n = 25), or to delayed laparoscopic cholecystectomy (surgery after resolution of abdominal pain and after the laboratory values had returned to normal) (n = 25).",delete,[],0,0.13333333333333333,1,15
CD010326,0,2,This trial is at high risk of bias.,rephrase,"['The one trial identified is at high risk of bias, i.e. there was potential to arrive at wrong conclusions because of the way that the study was designed and conducted.']",0,0.2,1,15
CD010326,0,3,There was no short-term mortality in either group.,delete,[],1,0.26666666666666666,2,15
CD010326,0,4,There was no significant difference between the groups in the proportion of participants who developed serious adverse events (RR 0.33; 95% CI 0.01 to 7.81).,rephrase,['There was no significant difference between the two groups in the proportion of participants who developed complications.'],1,0.3333333333333333,2,15
CD010326,0,5,Health-related quality of life was not reported in this trial.,ignore,['Health-related quality of life was not reported in this trial.'],2,0.4,2,15
CD010326,0,6,There were no conversions to open cholecystectomy in either group.,ignore,['There were no conversions to open cholecystectomy in either group.'],3,0.4666666666666667,3,15
CD010326,0,7,The total hospital stay was significantly shorter in the early laparoscopic cholecystectomy group than in the delayed laparoscopic cholecystectomy group (MD -2.30 days; 95% CI -4.40 to -0.20).,rephrase,['The total hospital stay was shorter by approximately two days in the early laparoscopic cholecystectomy group than in the delayed laparoscopic cholecystectomy group.'],4,0.5333333333333333,3,15
CD010326,0,8,This trial reported neither the number of work-days lost nor the costs.,rephrase,['The trial did not report the number of work-days lost or the costs.'],5,0.6,3,15
CD010326,0,9,We did not identify any trials comparing early versus delayed laparoscopic cholecystectomy after severe acute pancreatitis.,split,"['We identified one trial comparing early versus delayed laparoscopic cholecystectomy for people with mild acute pancreatitis.', 'We did not identify any trials comparing early versus delayed laparoscopic cholecystectomy after severe acute pancreatitis.']",6,0.6666666666666666,4,15
CD010326,1,10,There is no evidence of increased risk of complications after early laparoscopic cholecystectomy.,rephrase,"['Based on the observations in the one trial included in this review, there appears to be no evidence of increased risk of complications after early laparoscopic cholecystectomy.']",8,0.7333333333333333,4,15
CD010326,1,11,Early laparoscopic cholecystectomy may shorten the total hospital stay in people with mild acute pancreatitis.,ignore,['Early laparoscopic cholecystectomy may shorten the total hospital stay in people with mild acute pancreatitis.'],9,0.8,4,15
CD010326,1,12,"If appropriate facilities and expertise are available, early laparoscopic cholecystectomy appears preferable to delayed laparoscopic cholecystectomy in those with mild acute pancreatitis.",ignore,"['If appropriate facilities and expertise are available, early laparoscopic cholecystectomy appears preferable to delayed laparoscopic cholecystectomy in people with mild acute pancreatitis.']",10,0.8666666666666667,5,15
CD010326,1,13,There is currently no evidence to support or refute early laparoscopic cholecystectomy for people with severe acute pancreatitis.,ignore,['There is currently no evidence to support or refute early laparoscopic cholecystectomy for people with severe acute pancreatitis.'],11,0.9333333333333333,5,15
CD010326,1,14,Further randomised controlled trials at low risk of bias are necessary in people with mild acute pancreatitis and severe acute pancreatitis.,rephrase,['Further well-designed randomised controlled trials are necessary in people with mild acute pancreatitis and severe acute pancreatitis.'],12,1.0,5,15
CD006899,0,0,"The search identified one new RCT, making a total of 10 included RCTs (442 participants, 42% women).",rephrase,"['We included 10 randomised clinical trials, with a total of 442 participants (mean age 61 years and 42% women).']",0,0.07692307692307693,1,13
CD006899,0,1,The median number of participants per RCT was 29 (range 10 to 117).,delete,[],1,0.15384615384615385,1,13
CD006899,0,2,"Four RCTs recruited people with a range of chronic wounds; three RCTs recruited people with venous leg ulcers, and three RCTs considered foot ulcers in people with diabetes.",rephrase,['Four included studies recruited people with a range of chronic wounds; three studies enrolled people with venous leg ulcers; and the other three studies included people with diabetes who had foot ulcers.'],1,0.23076923076923078,2,13
CD006899,0,3,The median length of treatment was 12 weeks (range 8 to 40 weeks).,rephrase,['The median length of treatment was 12 weeks.'],2,0.3076923076923077,2,13
CD006899,1,4,"It is unclear whether autologous PRP improves the healing of chronic wounds generally compared with standard treatment (with or without placebo) (risk ratio (RR) 1.19, 95% confidence interval (CI) 0.95 to 1.50; I2 = 27%, low quality evidence, 8 RCTs, 391 participants).",rephrase,['The results were non-conclusive as to whether autologous PRP improves the healing of chronic wounds generally compared with standard treatment.'],3,0.38461538461538464,2,13
CD006899,1,5,"Autologous PRP may increase the healing of foot ulcers in people with diabetes compared with standard care (with or without placebo) (RR 1.22, 95% CI 1.01 to 1.49; I2 = 0%, low quality evidence, 2 RCTs, 189 participants).",merge,"['Autologous PRP may increase the healing of foot ulcers in people with diabetes compared with standard care, but it is unclear if autologous PRP has an effect on other types of chronic wound.']",4,0.46153846153846156,3,13
CD006899,1,6,"It is unclear if autologous PRP affects the healing of venous leg ulcers (RR 1.02, 95% CI 0.81 to 1.27; I2 = 0% ).",none,[],4,0.5384615384615384,3,13
CD006899,1,7,"It is unclear if there is a difference in the risk of adverse events in people treated with PRP or standard care (RR 1.05, 95% CI 0.29 to 3.88; I2 = 0%, low quality evidence from 3 trials, 102 participants).",rephrase,"['Three studies reported wound complications such as infection or dermatitis, but results showed no difference in the risk of adverse events in people treated with PRP or standard care.']",5,0.6153846153846154,4,13
CD006899,2,8,"PRP may improve the healing of foot ulcers associated with diabetes, but this conclusion is based on low quality evidence from two small RCTs.",rephrase,"['These findings are based on low quality evidence due to the small number of studies and patients included, and their poor methodological quality.']",6,0.6923076923076923,4,13
CD006899,2,9,It is unclear whether PRP influences the healing of other chronic wounds.,delete,[],7,0.7692307692307693,4,13
CD006899,2,10,The overall quality of evidence of autologous PRP for treating chronic wounds is low.,delete,[],7,0.8461538461538461,5,13
CD006899,2,11,"There are very few RCTs evaluating PRP, they are underpowered to detect treatment effects, if they exist, and are generally at high or unclear risk of bias.",delete,[],7,0.9230769230769231,5,13
CD006899,2,12,Well designed and adequately powered clinical trials are needed.,delete,[],7,1.0,5,13
CD007796,0,0,Forty-nine randomised trials involving 3639 participants were included.,rephrase,['This systematic review identified a total of 49 trials that included 3639 participants with DPN.'],0,0.07692307692307693,1,13
CD007796,0,1,All trials were conducted and published in China.,rephrase,['All the identified clinical trials were performed and published in China.'],1,0.15384615384615385,1,13
CD007796,0,2,"Thirty-eight different herbal medicines were tested in these trials, including four single herbs (extracts from a single herb), eight traditional Chinese patent medicines, and 26 self concocted Chinese herbal compound prescriptions.",rephrase,"['We evaluated the effects of various herbal formulations (including single herbs, Chinese proprietary medicines and mixtures of different herbs) for treating people with DPN.']",2,0.23076923076923078,2,13
CD007796,0,3,The trials reported on global symptom improvement (including improvement in numbness or pain) and changes in nerve conduction velocity.,ignore,['The trials reported on global symptom improvement (including improvement in numbness or pain) and changes in nerve conduction velocity.'],3,0.3076923076923077,2,13
CD007796,0,4,The positive results described from the 49 studies of low quality are of questionable significance.,ignore,['The positive results described from the 49 studies of low quality are of questionable significance.'],4,0.38461538461538464,2,13
CD007796,0,5,There was inadequate reporting on adverse events in the included trials.,ignore,['There was inadequate reporting on adverse events in the included trials.'],5,0.46153846153846156,3,13
CD007796,0,6,Eighteen trials found no adverse events.,delete,[],6,0.5384615384615384,3,13
CD007796,0,7,"Two trials reported adverse events: adverse events occurred in the control group in one trial, and in the other it was unclear in which group the adverse events occurred.",rephrase,['Only two trials reported adverse events but an adverse event occurred in the control group in one trial and it was unclear in which group they occurred in the other trial.'],6,0.6153846153846154,4,13
CD007796,0,8,29 trials did not mention whether they monitored adverse events.,rephrase,['Most of the trials did not mention whether they monitored for adverse effects.'],7,0.6923076923076923,4,13
CD007796,0,9,"Conclusions cannot be drawn from this review about the safety of herbal medicines, due to inadequate reporting.",rephrase,['Conclusions about the safety of herbal medicines cannot therefore be drawn from this review due to inadequate reporting.'],8,0.7692307692307693,4,13
CD007796,0,10,Most of the trials were of very low methodological quality and therefore the interpretation of any positive findings for the efficacy of the included Chinese herbal medicines for treating diabetic peripheral neuropathy should be made with caution.,rephrase,['Most of the trials were of very low methodological quality and the interpretation of any positive findings for the efficacy of the included Chinese herbal medicines for treating DPN should be made with caution.'],9,0.8461538461538461,5,13
CD007796,1,11,"Based on this systematic review, there is no evidence to support the objective effectiveness and safety of Chinese herbal medicines for diabetic peripheral neuropathy.",rephrase,"['Based on this systematic review, there is no evidence to support the objective effectiveness and safety of Chinese herbal medicines for DPN.']",10,0.9230769230769231,5,13
CD007796,1,12,"No well-designed, randomised, placebo controlled trial with objective outcome measures has been conducted.",ignore,"['No well-designed, randomised placebo controlled trial with objective outcome measures has been conducted.']",11,1.0,5,13
CD004362,0,0,Fifteen trials involving 2022 people were included.,rephrase,['Fifteen trials met the inclusion criteria and are included in the review.'],0,0.1,1,10
CD004362,0,1,"Compared to placebo, haloperidol was more effective at reducing manic symptoms, both as monotherapy (Weighted Mean Difference (WMD) -5.85, 95% Confidence Interval (CI) -7.69 to -4.00) and as adjunctive treatment to lithium or valproate (WMD -5.20, 95% CI -9.26 to -1.14).",delete,[],1,0.2,1,10
CD004362,0,2,"There was a statistically significant difference, with haloperidol being less effective than aripiprazole (Relative Risk (RR) 1.45, 95% CI 1.22 to 1.73).",delete,[],1,0.3,2,10
CD004362,0,3,"No significant differences between haloperidol and risperidone, olanzapine, carbamazepine or valproate were found.",rephrase,"['Haloperidol caused more EPS than valproate but no difference was found between haloperidol and lithium, carbamazepine, sultopride and risperidone in terms of side effects profile.']",1,0.4,2,10
CD004362,0,4,"Compared with placebo, a statistically significant difference in favour of haloperidol in failure to complete treatment (RR 0.74, 95% Cl 0.57 to 0.96) was reported.",delete,[],2,0.5,3,10
CD004362,0,5,"Haloperidol was associated with less weight gain than olanzapine (RR: 0.28, 95% CI 0.12 to 0.67), but with a higher incidence of tremor (RR: 3.01, 95% CI 1.55 to 5.84) and other movement disorders.",rephrase,['Haloperidol caused more extrapyramidal symptoms (EPS) than placebo and more movement disorders and EPS but less weight gain than olanzapine.'],2,0.6,3,10
CD004362,1,6,There is some evidence that haloperidol is an effective treatment for acute mania.,rephrase,"['There was some evidence that haloperidol was more efficacious than placebo in terms of reduction of manic and psychotic symptom scores, when used both as monotherapy and as add-on treatment to lithium or valproate.']",3,0.7,4,10
CD004362,1,7,"From the limited data available, there was no difference in overall efficacy of treatment between haloperidol and olanzapine or risperidone.",rephrase,"['There is no evidence of difference in efficacy between haloperidol and risperidone, olanzapine, valproate, carbamazepine, sultopride and zuclopentixol.']",4,0.8,4,10
CD004362,1,8,Some evidence suggests that haloperidol could be less effective than aripiprazole.,rephrase,['There was a statistically significant difference with haloperidol being probably less effective than aripiprazole.'],5,0.9,5,10
CD004362,1,9,"Referring to tolerability, when considering the poor evidence comparing drugs, clinicians and patients should consider different side effect profiles as an important issue to inform their choice.",delete,[],6,1.0,5,10
CD013134,0,0,We included five studies in the review and identified two ongoing studies.,rephrase,['We included five studies and two ongoing studies.'],0,0.058823529411764705,1,17
CD013134,0,1,The five included studies involved a total of 2655 participants; two studies were RCTs and three were quasi-RCTs.,merge,[],1,0.11764705882352941,1,17
CD013134,0,2,The included studies were conducted in one high-income country (USA) and three lower-middle-income countries (Bangladesh and Pakistan).,none,['The five included studies involved a total of 2655 participants and were conducted in one high-income country (USA) and two lower-middle-income countries (Bangladesh and Pakistan).'],1,0.17647058823529413,1,17
CD013134,0,3,"Three studies were conducted in hospital inpatient settings, one in school, and one in a military training centre.",ignore,"['Three studies were conducted in hospital settings, one in schools, and one at a military training centre.']",2,0.23529411764705882,2,17
CD013134,0,4,"Three studies included children under five years of age, one study included school-aged children, and one study included adult participants.",rephrase,"['Three studies included children under five years of age, one school-aged children, and one adult participants.']",3,0.29411764705882354,2,17
CD013134,0,5,Two studies assessed the effect of vitamin C supplementation for pneumonia prevention; and three studies assessed the effect of vitamin C supplementation as an adjunct to pneumonia treatment.,ignore,['Two studies assessed the effect of vitamin C supplementation for pneumonia prevention; and three studies assessed the effect of vitamin C supplementation in pneumonia treatment.'],4,0.35294117647058826,2,17
CD013134,0,6,"For pneumonia prevention, the included studies provided supplementation in doses of 1 g daily for 14 weeks, 2 g daily for 8 weeks, and 2 g daily for 14 weeks.",delete,[],5,0.4117647058823529,3,17
CD013134,0,7,"For pneumonia treatment, the included studies provided vitamin C supplementation in doses of 125 mg daily and 200 mg daily until the symptoms resolved or discharge, as an adjunct to the pneumonia treatment.",rephrase,"['The doses of vitamin C supplementation used were 125 mg, 200 mg, 1 g and 2 g.']",5,0.47058823529411764,3,17
CD013134,0,8,"Overall, the included studies were judged to be at either high or unclear risk of bias for random sequence generation, allocation concealment, and blinding; and the evidence certainty was very low.",split,"['We judged the included studies to be at overall high or unclear risk of bias.', 'The evidence certainty was very low due to study limitations, variations amongst the studies, small sample sizes and uncertainty of estimates.']",6,0.5294117647058824,3,17
CD013134,1,9,Two studies assessed the effect of vitamin C supplementation for pneumonia prevention; we judged the certainty of the evidence as very low.,rephrase,"['We assessed the rate of pneumonia (incidence), how common pneumonia is (prevalence), numbers of deaths from pneumonia (mortality), and unintended and harmful outcomes (adverse effects) associated with vitamin C for preventing pneumonia.']",8,0.5882352941176471,3,17
CD013134,1,10,We are uncertain about the effect of vitamin C supplementation on pneumonia incidence and adverse events (urticaria).,rephrase,"['Only one study (674 participants) reported incidence, and one study reported one adverse effect (hives) associated with vitamin C for preventing pneumonia.']",9,0.6470588235294118,4,17
CD013134,1,11,None of the included studies reported other primary outcomes (pneumonia prevalence and mortality) or any of the secondary outcomes.,rephrase,['No study reported on prevalence or mortality.'],10,0.7058823529411765,4,17
CD013134,2,12,Three studies assessed the effect of vitamin C supplementation as an adjunct to pneumonia treatment; we judged the certainty of the evidence as very low.,merge,"['We also assessed how long people were ill (duration of illness), how many people were cured, mortality, and adverse effects associated with the use of vitamin C as a treatment for pneumonia.']",11,0.7647058823529411,4,17
CD013134,2,13,We are uncertain of the effect of vitamin C supplementation on duration of illness and hospitalisation.,none,[],11,0.8235294117647058,5,17
CD013134,2,14,None of the included studies reported other primary or secondary outcomes.,delete,[],12,0.8823529411764706,5,17
CD013134,3,15,"Due to the small number of included studies and very low certainty of the existing evidence, we are uncertain of the effect of vitamin C supplementation for the prevention and treatment of pneumonia.",delete,[],12,0.9411764705882353,5,17
CD013134,3,16,Further good-quality studies are required to assess the role of vitamin C supplementation in the prevention and treatment of pneumonia.,delete,[],12,1.0,5,17
CD008413,0,0,Seventeen trials were included.,ignore,['Seventeen trials were included.'],0,0.07142857142857142,1,14
CD008413,0,1,"These involved 1433 people, mostly young physically active adults.",rephrase,"['These involved 1433 patients, who were mostly young physically active adults.']",1,0.14285714285714285,1,14
CD008413,0,2,"All included trials had methodological weaknesses and were at risk of bias, notably selection bias from inadequate or lack of allocation concealment.",rephrase,['All included trials had methodological weaknesses that are likely to undermine the reliability of their results.'],2,0.21428571428571427,2,14
CD008413,0,3,Data for pooling individual outcomes were available for a maximum of nine trials and 54% of participants.,rephrase,['Data for pooling individual outcomes were available for a maximum of nine trials.'],3,0.2857142857142857,2,14
CD008413,1,4,"There were no statistically or clinically significant differences between double-bundle and single-bundle reconstruction in the subjective functional knee scores (subjective IKDC score, Tegner activity score, Lysholm score) in the intermediate (six months up to two years since surgery) or long term (two to five years from surgery).",delete,[],4,0.35714285714285715,2,14
CD008413,1,5,"For example, the long term results for the Lysholm score (0 to 100: best score) were: mean difference (MD) 0.12, 95% confidence interval (CI) -1.50 to 1.75; 5 trials, 263 participants).",delete,[],4,0.42857142857142855,3,14
CD008413,1,6,The only trial reporting on long term knee pain found no statistically significant differences between the two groups.,merge,[],4,0.5,3,14
CD008413,1,7,"There were no significant differences between the two groups in adverse effects and complications (e.g. infection reported by nine trials (7/285 versus 7/393; risk ratio (RR) 1.14, 95% CI 0.46 to 2.81); graft failure reported by six trials (1/169 versus 4/185; RR 0.45; 95% CI 0.07 to 2.90).",none,"['There was not enough evidence of differences between two groups in terms of functional knee scores, adverse effects and complications (infection, hardware problem such as pain from fixation device, graft failure), range of motion (flexion and extension deficit).']",4,0.5714285714285714,3,14
CD008413,2,8,"Limited data from five trials found a better return to pre-injury level of activity after double-bundle reconstruction (147/162 versus 208/255; RR 1.15, 95% CI 1.07 to 1.25).",merge,[],5,0.6428571428571429,4,14
CD008413,2,9,"At long term follow-up, there were statistically significant differences in favour of double-bundle reconstruction for IKDC knee examination (normal or nearly normal categories: 325/344 versus 386/429; RR 1.05, 95% CI 1.01 to 1.08; 9 trials), knee stability measured with KT-1000 arthrometer (MD -0.74 mm, 95% CI -1.10 to -0.37; 5 trials, 363 participants) and rotational knee stability tested by the pivot-shift test (normal or nearly normal categories: 293/298 versus 382/415; RR 1.06, 95% CI 1.02 to 1.09; 9 trials).",none,"['At long term follow-up, some clinician-assessed measures of knee stability and repeated rupture rate or occurrence of new meniscal injuries were better after double-bundle reconstruction.']",5,0.7142857142857143,4,14
CD008413,2,10,"There were also statistically significant differences in favour of double-bundle reconstruction for newly occurring meniscal injury (9/240 versus 24/358; RR 0.46, 95% CI 0.23 to 0.92; 6 trials) and traumatic ACL rupture (1/120 versus 8/149; RR 0.17, 95% CI 0.03 to 0.96; 3 trials).",delete,[],6,0.7857142857142857,4,14
CD008413,2,11,There were no statistically significant differences found between the two groups in range of motion (flexion and extension) deficits.,delete,[],6,0.8571428571428571,5,14
CD008413,3,12,"There is insufficient evidence to determine the relative effectiveness of double-bundle and single-bundle reconstruction for anterior cruciate ligament rupture in adults, although there is limited evidence that double-bundle ACL reconstruction has some superior results in objective measurements of knee stability and protection against repeat ACL rupture or a new meniscal injury.",split,"['We concluded that there was not enough evidence to say whether double-bundle reconstruction gives better results than single-bundle reconstruction for anterior cruciate ligament rupture in adults.', 'However, there is limited evidence that double-bundle ACL reconstruction has some superior results for knee stability and protection against repeat ACL rupture or newly occurring meniscal injury.']",6,0.9285714285714286,5,14
CD008413,3,13,"High quality, large and appropriately reported randomised controlled trials of double-bundle versus single-bundle reconstruction for anterior cruciate ligament rupture in adults appear justified.",delete,[],8,1.0,5,14
CD003167,0,0,"We included 26 trials, which randomised 4979 participants, in this review.",rephrase,"['The review authors identified a total of 26 controlled trials that randomised 4979 people with OHT or open angle glaucoma to receive topical medication or a placebo, another topical medication or no treatment for at least a year.']",0,0.1,1,10
CD003167,0,1,"Meta-analysis of 10 trials clearly demonstrated reduction of onset of VF defects in treated OHT (OR 0.62, 95% CI 0.47 to 0.81).",rephrase,['Meta-analysis of 10 trials testing different topical medications against placebo or untreated controls showed reduced incidence of glaucomatous visual field defects with treatment for people with OHT.'],1,0.2,1,10
CD003167,0,2,No single drug showed a significant VF protection compared to placebo or untreated controls.,rephrase,['No single drug showed significant visual field protection in OHT with the evidence available.'],2,0.3,2,10
CD003167,0,3,"We did identify some border line evidence for a positive influence of treatment on VF prognosis (OR 0.67, 95% CI 0.45 to 1.00) for the beta-blockers .",delete,[],3,0.4,2,10
CD003167,1,4,The results of this review support the current practice of IOP lowering treatment of OHT.,merge,['The results of this review support the current practice of topical medication to lower IOP and clearly demonstrate a visual field protective effect.'],3,0.5,3,10
CD003167,1,5,A visual field protective effect has been clearly demonstrated for medical IOP lowering treatment.,none,[],3,0.6,3,10
CD003167,1,6,Positive but weak evidence for a beneficial effect of the class of beta-blockers has been shown.,rephrase,"['The class of beta-blockers (including timolol) had positive but weak evidence for a beneficial effect in protecting against visual field defects (OR 0.7, range 0.5 to 1.0).']",4,0.7,4,10
CD003167,2,7,Direct comparisons of prostaglandins or brimonidine to placebo are not available and the comparison of dorzolamide to placebo failed to demonstrate a protective effect.,delete,[],5,0.8,4,10
CD003167,2,8,"However, absence of data or failure to prove effectiveness should not be interpreted as proof of absence of any effect.",delete,[],5,0.9,5,10
CD003167,2,9,"The decision to treat a patient or not, as well as the decision regarding the drug with which to start treatment, should remain individualised, taking in to account the amount of damage, the level of IOP, age and other patient characteristics.",delete,[],5,1.0,5,10
CD010816,0,0,"We screened a total of 3667 records, identifying 16 relevant RCTs involving 5626 patients and included 12 trials in the meta-analyses.",rephrase,['We found 16 studies involving 5626 myeloma patients.'],0,0.0625,1,16
CD010816,0,1,All trials were randomised and open-label studies.,delete,[],1,0.125,1,16
CD010816,0,2,Two trials were published in abstract form and therefore we were unable to assess potential risk of bias in full.,delete,[],1,0.1875,1,16
CD010816,1,3,"There is moderate-quality evidence that bortezomib prolongs OS (four studies, 1586 patients; Peto OR 0.77, 95% CI 0.65 to 0.92) and PFS (five studies, 1855 patients; Peto OR 0.65, 95% CI 0.57 to 0.74) from analysing trials of bortezomib versus no bortezomib with the same background therapy in each arm.",delete,[],1,0.25,2,16
CD010816,2,4,"There is high-quality evidence that bortezomib prolongs OS (five studies, 2532 patients; Peto OR 0.76, 95% CI 0.67 to 0.88) but low-quality evidence for PFS (four studies, 2489 patients; Peto OR 0.67, 95% CI 0.61 to 0.75) from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s).",delete,[],1,0.3125,2,16
CD010816,3,5,"Four trials (N = 716) examined different doses, methods of administrations and treatment schedules and were reviewed qualitatively only.",delete,[],1,0.375,2,16
CD010816,4,6,"We identified four trials in the meta-analysis that measured time to progression (TTP) and were able to extract and analyse PFS data for three of the studies, while in the case of one study, we included TTP data as PFS data were not available.",delete,[],1,0.4375,3,16
CD010816,4,7,We therefore did not analyse TTP separately in this review.,delete,[],1,0.5,3,16
CD010816,5,8,"Patients treated with bortezomib have increased risk of thrombocytopenia, neutropenia, gastro-intestinal toxicities, peripheral neuropathy, infection and fatigue with the quality of evidence highly variable.",rephrase,['the quality of evidence for adverse events was highly variable (low to high).'],1,0.5625,3,16
CD010816,5,9,There is high-quality evidence for increased risk of cardiac disorders from analysing trials of bortezomib versus no bortezomib with different background therapy in each arm or versus other agents.,rephrase,"['For assessment of treatment-related death, there was no evidence of a difference, with low-quality evidence in one comparison (bortezomib compared to no bortezomib with the same background therapy) and very low-quality evidence in comparison two (bortezomib compared to no bortezomib with different background therapy or compared to other drugs).']",2,0.625,4,16
CD010816,5,10,The risk of TRD in either comparison group analysed is uncertain due to the low quality of the evidence.,rephrase,['Risk of death from bortezomib treatment was uncertain in either group analysed.'],3,0.6875,4,16
CD010816,6,11,Only four trials analysed HRQoL and the data could not be meta-analysed.,rephrase,['Only four studies assessed quality of life and could not be analysed together.'],4,0.75,4,16
CD010816,7,12,"Subgroup analyses by disease setting revealed improvements in all outcomes, whereas for therapy setting, an improved benefit for bortezomib was observed in all outcomes and subgroups except for OS following consolidation therapy.",delete,[],5,0.8125,5,16
CD010816,8,13,"This meta-analysis found that myeloma patients receiving bortezomib benefited in terms of OS, PFS and response rate compared to those who did not receive bortezomib.",rephrase,"['Patients receiving bortezomib had better response rates, longer time without progression and appeared to live longer compared to those not receiving bortezomib, however patients receiving bortezomib experienced more side effects.']",5,0.875,5,16
CD010816,8,14,This benefit was observed in trials of bortezomib versus no bortezomib with the same background therapy and in trials of bortezomib versus no bortezomib with different background therapy in each arm or compared to other agent(s).,rephrase,"['We included studies of bortezomib compared to no bortezomib, with either the same or different background therapy or compared to other drugs.']",6,0.9375,5,16
CD010816,8,15,"Further evaluation of newer proteasome inhibitors is required to ascertain whether these agents offer an improved risk-benefit profile, while more studies of HRQoL are also required.",rephrase,"['Other proteasome inhibitor drugs have also been developed, therefore further research should focus on whether these newer drugs provide additional benefits and fewer side effects than bortezomib.']",7,1.0,5,16
CD007312,0,0,Eleven studies involving 496 participants met some of the inclusion criteria stated in the protocol.,delete,[],0,0.043478260869565216,1,23
CD007312,0,1,"One hundred and eighty patients in five studies had peripheral interventions, 229 patients in five studies had percutaneous interventions applied to the Gasserian ganglion, and 87 patients in one study underwent two modalities of stereotactic radiosurgery (Gamma Knife) treatment.",delete,[],0,0.08695652173913043,1,23
CD007312,0,2,No studies addressing microvascular decompression (which is the only non-ablative procedure) met the inclusion criteria.,rephrase,['None of the three studies evaluated the non-destructive procedure of microvascular decompression and this is a major drawback in the literature.'],0,0.13043478260869565,1,23
CD007312,0,3,All but two of the identified studies had a high to medium risk of bias because of either missing data or methodological inconsistency.,delete,[],1,0.17391304347826086,1,23
CD007312,0,4,It was not possible to undertake meta-analysis because of differences in the intervention modalities and variable outcome measures.,delete,[],1,0.21739130434782608,2,23
CD007312,0,5,Three studies had sufficient outcome data for analysis.,rephrase,"['We found 11 studies, which included 496 patients, but only three had sufficient outcome data to report.']",1,0.2608695652173913,2,23
CD007312,0,6,"One trial, which involved 40 participants, compared two techniques of radiofrequency thermocoagulation (RFT) of the Gasserian ganglion at six months.",rephrase,"['One study compared two different techniques of radiofrequency thermocoagulation, in 40 participants six months after the procedure.']",2,0.30434782608695654,2,23
CD007312,0,7,Pulsed RFT resulted in return of pain in all participants by three months.,rephrase,['If the radiofrequency was given as pulsed treatment (which causes the tip of the needle to heat up intermittently and not continuously) the original pain in all participants returned by three months.'],3,0.34782608695652173,2,23
CD007312,0,8,When this group were converted to conventional (continuous) treatment these participants achieved pain control comparable to the group that had received conventional treatment from the outset.,rephrase,"['The continuous radiofrequency treatment then had to be applied, and these participants then achieved pain control comparable to those who had received continuous radiofrequency throughout.']",4,0.391304347826087,2,23
CD007312,0,9,Sensory changes were common in the continuous treatment group.,rephrase,['Changes in sensation ranging from mild to severe numbness were common in the conventional (continuous) radiofrequency treatment group.'],5,0.43478260869565216,3,23
CD007312,0,10,"In another trial, of 87 participants, investigators compared radiation treatment to the trigeminal nerve at one or two isocentres in the posterior fossa.",rephrase,"['A second trial, in 87 participants, looked at using one or two isocentres (specific points in the nerve) to deliver radiation to the trigeminal nerve just as it leaves the brainstem inside the skull.']",6,0.4782608695652174,3,23
CD007312,0,11,There were insufficient data to determine if one technique was superior to another.,rephrase,['There were insufficient data given to judge the effectiveness of one procedure better than the other.'],7,0.5217391304347826,3,23
CD007312,0,12,Two isocentres increased the incidence of sensory loss.,rephrase,['Use of two isocentres increased the occurrence of sensory loss as a complication.'],8,0.5652173913043478,3,23
CD007312,0,13,Increased age and prior surgery were predictors for poorer pain relief.,ignore,['Increased age and prior surgery were predictors for poorer pain relief.'],9,0.6086956521739131,4,23
CD007312,0,14,"Relapses were nonsignificantly reduced with two isocentres (risk ratio (RR) 0.72, 95% confidence intervaI (CI) 0.30 to 1.71).",delete,[],10,0.6521739130434783,4,23
CD007312,0,15,A third study compared two techniques for RFT in 54 participants for 10 to 54 months.,rephrase,['A third study compared two techniques for performing radiofrequency thermocoagulation of the Gasserian ganglion in 54 participants.'],10,0.6956521739130435,4,23
CD007312,0,16,"Both techniques produced pain relief (not significantly in favour of neuronavigation (RR 0.70, 95% CI 0.46 to 1.04) but relief was more sustained and side effects fewer if a neuronavigation system was used.",rephrase,['Both techniques provided pain relief (which did not differ significantly between the two arms) but it was more sustained if a neuronavigation system was used and this system also decreased side effects.'],11,0.7391304347826086,4,23
CD007312,0,17,The remaining eight studies did not report outcomes as predetermined in our protocol.,delete,[],12,0.782608695652174,4,23
CD007312,1,18,There is very low quality evidence for the efficacy of most neurosurgical procedures for trigeminal neuralgia because of the poor quality of the trials.,delete,[],12,0.8260869565217391,5,23
CD007312,1,19,"All procedures produced variable pain relief, but many resulted in sensory side effects.",split,"['All the reviewed procedures resulted in pain relief and some participants were then able to stop taking medications.', 'However, many procedures tended to result in sensory side effects.']",12,0.8695652173913043,5,23
CD007312,1,20,There were no studies of microvascular decompression which observational data suggests gives the longest pain relief.,delete,[],14,0.9130434782608695,5,23
CD007312,1,21,There is little evidence to help comparative decision making about the best surgical procedure.,rephrase,['There is little evidence from these trials to guide the person with trigeminal neuralgia as to the most effective surgical procedure.'],14,0.9565217391304348,5,23
CD007312,1,22,Well designed studies are urgently needed.,rephrase,['There is now an urgent need to evaluate the surgical interventions used in trigeminal neuralgia and to design robust studies; either randomised controlled trials or long-term prospective independently assessed cohort studies.'],15,1.0,5,23
CD009679,0,0,"We included six trials in the review, with a total of 429 adult participants, the majority of whom were male (63%).",rephrase,['We found six small studies (involving 429 adults) of different fixation methods and bone fillers in September 2014.'],0,0.038461538461538464,1,26
CD009679,0,1,Three trials evaluated different types of fixation and three analysed different types of bone graft substitutes.,delete,[],1,0.07692307692307693,1,26
CD009679,0,2,All six trials were small and at substantial risk of bias.,ignore,['All six trials were small and at substantial risk of bias.'],1,0.11538461538461539,1,26
CD009679,0,3,"We judged the quality of most of the available evidence to be very low, meaning that we are very uncertain about these results.",rephrase,"['We judged the quality of most of the available evidence to be very low, meaning that we are very uncertain about these results\nThree studies evaluated different methods of fixation.']",2,0.15384615384615385,1,26
CD009679,1,4,One trial compared the use of a circular fixator combined with insertion of percutaneous screws (hybrid fixation) versus standard open reduction and internal fixation (ORIF) in people with open or closed Schatzker types V or VI tibial plateau fractures.,delete,[],3,0.19230769230769232,1,26
CD009679,1,5,"Results (66 participants) for quality of life scores using the 36-item Short Form Health Survey (SF-36)), Hospital for Special Surgery (HSS) scores and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function scores tended to favour hybrid fixation, but a benefit of ORIF could not be ruled out.",rephrase,"['However, the possibility of a better result from ORIF could not be ruled out.']",3,0.23076923076923078,2,26
CD009679,1,6,"Participants in the hybrid fixation group had a lower risk for an unplanned reoperation (351 per 1000 people compared with 450 in the ORIF group; 95% CI 197 fewer to 144 more) and were more likely to have returned to their pre-injury activity level (303 per 1000 people, compared with 121 in the ORIF group; 95% CI 15 fewer to 748 more).",delete,[],4,0.2692307692307692,2,26
CD009679,1,7,"Results of the two groups were comparable for the WOMAC pain subscale and stiffness scores, but mean knee range of motion values were higher in the hybrid group.",delete,[],4,0.3076923076923077,2,26
CD009679,2,8,Another trial compared the use of a minimally invasive plate (LISS system) versus double-plating ORIF in 84 people who had open or closed bicondylar tibial plateau fractures.,rephrase,"['Another study compared a minimally invasive, single-plate technique with a traditional open technique using two plates.']",4,0.34615384615384615,2,26
CD009679,2,9,Nearly twice as many participants (22 versus 12) in the ORIF group had a bone graft.,delete,[],5,0.38461538461538464,2,26
CD009679,2,10,"Quality of life, pain, knee range of motion and return to pre-injury activity were not reported.",delete,[],5,0.4230769230769231,3,26
CD009679,2,11,"The trial provided no evidence of differences in HSS knee scores, complications or reoperation entailing implant removal or revision fixation.",rephrase,"['This study found very little difference between the two groups in knee function, complications or reoperations.']",5,0.46153846153846156,3,26
CD009679,2,12,A quasi-randomised trial comparing arthroscopically-assisted percutaneous reduction and internal fixation versus standard ORIF reported results at 14 months in 58 people with closed Schatzker types II or III tibial plateau fracture.,rephrase,['The third study compared arthroscopic surgery (which uses a tiny camera to visualise the joint) and internal fixation versus ORIF.'],6,0.5,3,26
CD009679,2,13,"Quality of life, pain and return to pre-injury activity were not reported.",delete,[],7,0.5384615384615384,3,26
CD009679,2,14,There was very low quality evidence of higher HSS knee scores and higher knee range of motion values in the arthroscopically assisted group.,delete,[],7,0.5769230769230769,3,26
CD009679,2,15,No reoperations were reported.,rephrase,['There were no reoperations.'],7,0.6153846153846154,4,26
CD009679,3,16,Three trials compared different types of bone substitute versus autologous bone graft (autograft) for managing bone defects.,rephrase,"['Three studies compared different bone substitutes versus bone grafts for managing bone defects, but reported on only a few outcomes.']",8,0.6538461538461539,4,26
CD009679,3,17,"Quality of life, pain and return to pre-injury activity were not reported.",delete,[],9,0.6923076923076923,4,26
CD009679,3,18,"Only one trial (25 participants) reported on lower limb function, finding good or excellent results in both groups for walking, climbing stairs, squatting and jumping at 12 months.",rephrase,"['One study found similar results in the two groups in the numbers of participants with good walking, stair climbing, squatting and jumping ability at one year.']",9,0.7307692307692307,4,26
CD009679,3,19,The incidences of individual complications were similar between groups in all three trials.,rephrase,['All three studies found similar numbers of specific complications in the two groups.'],10,0.7692307692307693,4,26
CD009679,3,20,"One trial found no cases of inflammatory response in the 20 participants receiving bone substitute, and two found no complications associated with the donor site in the autograft group (58 participants).",delete,[],11,0.8076923076923077,5,26
CD009679,3,21,"However, all 38 participants in the autologous iliac bone graft group of one trial reported prolonged pain from the harvest site.",rephrase,['One study found that all participants in the bone graft group had prolonged pain from the harvest site of the bone graft.'],11,0.8461538461538461,5,26
CD009679,3,22,"Two trials reported similar range of motion results in the two groups, whereas the third trial favoured the bone substitute group.",rephrase,"['Two studies reported similar range of motion results in the two groups, whereas the third study found better results in the bone substitute group at one year.']",12,0.8846153846153846,5,26
CD009679,4,23,"Currently, there is insufficient evidence to ascertain the best method of fixation or the best method of addressing bone defects during surgery.",rephrase,"['Currently, there is insufficient evidence to ascertain the best surgical methods of fixation and bone defect treatment for tibial plateau fractures in adults.']",13,0.9230769230769231,5,26
CD009679,4,24,"However, the evidence does not contradict approaches aiming to limit soft-tissue dissection and damage or to avoid autograft donor site complications through using bone substitutes.",delete,[],14,0.9615384615384616,5,26
CD009679,4,25,"Further well-designed, larger randomised trials are warranted.",delete,[],14,1.0,5,26
CD004250,0,0,Twenty-seven trials (2485 analyzed /3005 randomized participants) met our inclusion criteria.,rephrase,"['We found 27 trials (with a total of 2485 participants) examining whether exercise can help reduce neck pain and disability; improve function, global perceived effect, patient satisfaction and/or quality of life.']",0,0.07692307692307693,1,13
CD004250,1,1,"For acute neck pain only, no evidence was found.",split,"['Twenty-four of 27 trials evaluating neck pain reported on the duration of the disorder: 1 acute; 1 acute to chronic; 1 subacute; 4 subacute/chronic; and 16 chronic.', 'One study reported on neck disorder with acute radiculopathy; two trials investigated subacute to chronic cervicogenic headache.']",1,0.15384615384615385,1,13
CD004250,2,2,"For chronic neck pain, moderate quality evidence supports 1) cervico-scapulothoracic and upper extremity strength training to improve pain of a moderate to large amount immediately post treatment [pooled SMD (SMDp) -0.71 (95% CI: -1.33 to -0.10)] and at short-term follow-up; 2) scapulothoracic and upper extremity endurance training for slight beneficial effect on pain at immediate post treatment and short-term follow-up; 3) combined cervical, shoulder and scapulothoracic strengthening and stretching exercises varied from a small to large magnitude of beneficial effect on pain at immediate post treatment [SMDp -0.33 (95% CI: -0.55 to -0.10)] and up to long-term follow-up and a medium magnitude of effect improving function at both immediate post treatment and at short-term follow-up [SMDp -0.45 (95%CI: -0.72 to -0.18)]; 4) cervico-scapulothoracic strengthening/stabilization exercises to improve pain and function at intermediate term [SMDp -14.90 (95% CI:-22.40 to -7.39)]; 5) Mindfulness exercises (Qigong) minimally improved function but not global perceived effect at short term.",delete,[],3,0.23076923076923078,2,13
CD004250,2,3,Low evidence suggests 1) breathing exercises; 2) general fitness training; 3) stretching alone; and 4) feedback exercises combined with pattern synchronization may not change pain or function at immediate post treatment to short-term follow-up.,delete,[],3,0.3076923076923077,2,13
CD004250,2,4,Very low evidence suggests neuromuscular eye-neck co-ordination/proprioceptive exercises may improve pain and function at short-term follow-up.,delete,[],3,0.38461538461538464,2,13
CD004250,3,5,"For chronic cervicogenic headache, moderate quality evidence supports static-dynamic cervico-scapulothoracic strengthening/endurance exercises including pressure biofeedback immediate post treatment and probably improves pain, function and global perceived effect at long-term follow-up.",delete,[],3,0.46153846153846156,3,13
CD004250,3,6,Low grade evidence supports sustained natural apophyseal glides (SNAG) exercises.,delete,[],3,0.5384615384615384,3,13
CD004250,4,7,"For acute radiculopathy, low quality evidence suggests a small benefit for pain reduction at immediate post treatment with cervical stretch/strengthening/stabilization exercises.",delete,[],3,0.6153846153846154,4,13
CD004250,5,8,"No high quality evidence was found, indicating that there is still uncertainty about the effectiveness of exercise for neck pain.",ignore,"['No high quality evidence was found, indicating that there is still uncertainty about the effectiveness of exercise for neck pain.']",3,0.6923076923076923,4,13
CD004250,5,9,"Using specific strengthening exercises as a part of routine practice for chronic neck pain, cervicogenic headache and radiculopathy may be beneficial.",split,"['There appears to be a role for strengthening exercises in the treatment of chronic neck pain, cervicogenic headache and cervical radiculopathy if these exercises are focused on the neck, shoulder and shoulder blade region.', 'There is some evidence to suggest the beneficial effects of specific exercises (e.g. sustained natural apophyseal glides) with cervicogenic headaches and mindfulness exercises (e.g. Qigong) for chronic mechanical neck pain.']",4,0.7692307692307693,4,13
CD004250,5,10,Research showed the use of strengthening and endurance exercises for the cervico-scapulothoracic and shoulder may be beneficial in reducing pain and improving function.,rephrase,"['Furthermore, the use of strengthening exercises, combined with endurance or stretching exercises has also been shown to be beneficial.']",6,0.8461538461538461,5,13
CD004250,5,11,"However, when only stretching exercises were used no beneficial effects may be expected.",rephrase,"['There appears to be minimal effect on neck pain and function when only stretching or endurance type exercises are used for the neck, shoulder and shoulder blade region.']",7,0.9230769230769231,5,13
CD004250,5,12,Future research should explore optimal dosage.,rephrase,"['Future research is likely to have an important impact on the effect estimate.There were a number of challenges with this review; for example, the number of participants in most trials was small, more than half of the included studies were either of low or very low quality and there was limited evidence on optimum dosage requirements.']",8,1.0,5,13
CD007546,0,0,"We identified six new studies and included 11 studies with 19,003 participants in this review update.",rephrase,['We included eleven studies.'],0,0.03333333333333333,1,30
CD007546,0,1,All studies were conducted in long-term residential care facilities.,rephrase,['All of them were conducted in long-term care facilities (residential and nursing homes).'],1,0.06666666666666667,1,30
CD007546,0,2,Ten studies were RCTs and one study a CCT.,delete,[],2,0.1,1,30
CD007546,0,3,All studies included people with dementia.,delete,[],2,0.13333333333333333,1,30
CD007546,0,4,The mean age of the participants was approximately 85 years.,rephrase,['The average age of the people in the studies was about 85 years.'],2,0.16666666666666666,1,30
CD007546,1,5,Four studies investigated organisational interventions aiming to implement a least-restraint policy; six studies investigated simple educational interventions; and one study tested an intervention that provided staff with information about residents' fall risk.,rephrase,"['Four studies tested organisational interventions, which aimed to change policy and practice so that nursing staff would use PR less often or not at all.']",3,0.2,1,30
CD007546,1,6,"The control groups received usual care only in most studies although, in two studies, additional information materials about physical restraint reduction were provided.",rephrase,"['In most studies, the intervention being tested was compared with treatment-as-usual although, in two studies, managers of nursing homes in the control group also received some additional information about PR.']",4,0.23333333333333334,2,30
CD007546,2,7,We judged the risk of selection bias to be high or unclear in eight studies.,delete,[],5,0.26666666666666666,2,30
CD007546,2,8,Risk of reporting bias was high in one study and unclear in eight studies.,delete,[],5,0.3,2,30
CD007546,3,9,"The organisational interventions intended to promote a least-restraint policy included a variety of components, such as education of staff, training of 'champions' of low-restraint practice, and components which aimed to facilitate a change in institutional policies and culture of care.",rephrase,['Interventions for preventing and reducing the use of PR typically include education and training for nursing staff and may also include changes to policies and the way care is organised.'],5,0.3333333333333333,2,30
CD007546,3,10,"We found moderate-certainty evidence that organisational interventions aimed at implementation of a least-restraint policy probably lead to a reduction in the number of residents with at least one use of PR (RR 0.86, 95% CI 0.78 to 0.94; 3849 participants, 4 studies) and a large reduction in the number of residents with at least one use of a belt for restraint (RR 0.54, 95% CI 0.40 to 0.73; 2711 participants, 3 studies).",rephrase,['We found that organisational interventions probably lead to a reduction in the number of people restrained and a large reduction in the number of people restrained with a belt.'],6,0.36666666666666664,2,30
CD007546,3,11,No adverse events occurred in the one study which reported this outcome.,rephrase,['One study reported whether the residents came to any harm during the study period and it reported no harmful events.'],7,0.4,2,30
CD007546,3,12,There was evidence from one study that organisational interventions probably reduce the duration of physical restraint use.,delete,[],8,0.43333333333333335,3,30
CD007546,3,13,We found that the interventions may have little or no effect on the number of falls or fall-related injuries (low-certainty evidence) and probably have little or no effect on the number of prescribed psychotropic medications (moderate-certainty evidence).,rephrase,"['We did not find any evidence that the interventions made a difference to the number of people with at least one fall or at least one fall-related injury, or the number of people prescribed medication to modify behaviour.']",8,0.4666666666666667,3,30
CD007546,3,14,One study found that organisational interventions result in little or no difference in quality of life (high-certainty evidence) and another study found that they may make little or no difference to agitation (low-certainty evidence).,delete,[],9,0.5,3,30
CD007546,4,15,The simple educational interventions were intended to increase knowledge and change staff attitudes towards PR.,rephrase,"['For simple educational interventions, the quality of the studies and how well they were reported varied, and this affected our confidence in the results.']",9,0.5333333333333333,3,30
CD007546,4,16,"As well as providing education, some interventions included further components to support change, such as ward-based guidance.",delete,[],10,0.5666666666666667,3,30
CD007546,4,17,"We found pronounced between-group baseline imbalances in PR prevalence in some of the studies, which might have occurred because of the small number of clusters in the intervention and control groups.",delete,[],10,0.6,3,30
CD007546,4,18,"One study did not assess bedrails, which is the most commonly used method of restraint in nursing homes.",delete,[],10,0.6333333333333333,4,30
CD007546,4,19,"Regarding the number of residents with at least one restraint, the results were inconsistent.",rephrase,"['The results of the studies were inconsistent, so we could not draw any conclusion about the effect of this type of intervention on the use of PR.']",10,0.6666666666666666,4,30
CD007546,4,20,We found very-low certainty evidence and we are uncertain about the effects of simple educational interventions on the number of residents with PR.,delete,[],11,0.7,4,30
CD007546,4,21,None of the studies assessed or reported any serious adverse events.,rephrase,['None of these studies reported harmful events.'],11,0.7333333333333333,4,30
CD007546,4,22,"We found moderate-certainty evidence that simple educational interventions probably result in little or no difference in restraint intensity and may have little or no effect on falls, fall-related injuries, or agitation (low-certainty evidence each).",merge,"['Again, we did not find any evidence that the interventions made a difference to the number of people with at least one fall or at least one fall-related injury, and we could not be sure of the effect on prescription of medication.']",12,0.7666666666666667,4,30
CD007546,4,23,Based on very low-certainty evidence we are uncertain about the effects of simple educational interventions on the number of participants with a prescription of at least one psychotropic medication.,none,[],12,0.8,4,30
CD007546,5,24,One study investigated an intervention that provided information about residents' fall risk to the nursing staff.,split,"['Six studies tested less complex interventions that offered education directly to nursing staff.', 'One study provided nursing staff with specific assessments of the fall risk of individual residents.']",13,0.8333333333333334,5,30
CD007546,5,25,We found low-certainty evidence that providing information about residents' fall risk may result in little or no difference in the mean number of PR or the number of falls.,delete,[],15,0.8666666666666667,5,30
CD007546,5,26,The study did not assess overall adverse events.,delete,[],15,0.9,5,30
CD007546,6,27,Organisational interventions aimed to implement a least-restraint policy probably reduce the number of residents with at least one PR and probably largely reduce the number of residents with at least one belt.,rephrase,['Organisational interventions aimed at reducing use of PR through changing policy and practice in care homes are probably effective at reducing the number of people restrained overall and especially with belts.'],15,0.9333333333333333,5,30
CD007546,6,28,"We are uncertain whether simple educational interventions reduce the use of physical restraints, and interventions providing information about residents' fall risk may result in little to no difference in the use of physical restraints.",rephrase,"[""We are uncertain whether simple educational interventions reduce the use of PR, and interventions providing information about residents' fall risk may have little or no effect on the use of PR.""]",16,0.9666666666666667,5,30
CD007546,6,29,These results apply to long-term care institutions; we found no studies from community settings.,rephrase,"[""All the evidence came from studies in institutions and it may not apply to care in people's own homes.""]",17,1.0,5,30
CD009163,0,0,Twenty-five trials (3663 children) were eligible for inclusion.,rephrase,['In total 25 studies (3663 children) were eligible for inclusion.'],0,0.058823529411764705,1,17
CD009163,0,1,"Two trials did not report on any of the outcomes of interest, leaving 23 trials (3258 children) covering a range of antibiotics, participants, outcome measures and time points for evaluation.",rephrase,"['Two studies did not report on any of the outcomes of interest, leaving 23 studies (3258 children).']",1,0.11764705882352941,1,17
CD009163,0,2,"Overall, we assessed most studies as being at low to moderate risk of bias.",ignore,"['Overall, we assessed most studies as being at low to moderate risk of bias.']",2,0.17647058823529413,1,17
CD009163,1,3,"We found moderate quality evidence (six trials including 484 children) that children treated with oral antibiotics are more likely to have complete resolution at two to three months post-randomisation (primary outcome) than those allocated to the control treatment (risk ratio (RR) 2.00, 95% confidence interval (CI) 1.58 to 2.53; number needed to treat to benefit (NNTB) 5).",split,"['We found moderate quality evidence (six trials including 484 children) that children treated with oral antibiotics are more likely to have glue ear resolved two to three months after the treatment was started than those allocated to control treatment.', 'The number of children needed to treat for one beneficial outcome (NNTB) was five.']",3,0.23529411764705882,2,17
CD009163,1,4,"However, there is evidence (albeit of low quality; five trials, 742 children) indicating that children treated with oral antibiotics are more likely to experience diarrhoea, vomiting or skin rash (primary outcome) than those allocated to control treatment (RR 2.15, 95% CI 1.29 to 3.60; number needed to treat to harm (NNTH) 20).",split,"['However, there is evidence (albeit of low quality; five trials, 742 children) indicating that children treated with oral antibiotics are more likely to experience diarrhoea, vomiting or skin rash than those allocated to control treatment.', 'The number of children needed to treat for one harmful outcome (NNTH) was 20.']",5,0.29411764705882354,2,17
CD009163,2,5,"In respect of the secondary outcome of complete resolution at any time point, we found low to moderate quality evidence from five meta-analyses, including between two and 14 trials, of a beneficial effect of antibiotics, with a NNTB ranging from 3 to 7.",rephrase,"['In respect of the secondary outcome of having glue ear resolved at any time point, we found low to moderate quality evidence from five of our analyses where we combined data from studies (meta-analyses), which included between two and 14 studies, of a beneficial effect of antibiotics, with a NNTB ranging from three to seven.']",7,0.35294117647058826,2,17
CD009163,2,6,Time periods ranged from 10 to 14 days to six months.,ignore,['Time periods ranged from 10 to 14 days to six months.'],8,0.4117647058823529,3,17
CD009163,3,7,"In terms of other secondary outcomes, only two trials (849 children) reported on hearing levels at two to four weeks and found conflicting results.",ignore,"['In terms of other secondary outcomes, only two trials (849 children) reported on hearing levels at two to four weeks and found conflicting results.']",9,0.47058823529411764,3,17
CD009163,3,8,"None of the trials reported data on speech, language and cognitive development or quality of life.",ignore,"['None of the trials reported data on speech, language and cognitive development or quality of life.']",10,0.5294117647058824,3,17
CD009163,3,9,"Low quality evidence did not show that oral antibiotics were associated with a decrease in the rate of ventilation tube insertion (two trials, 121 children) or in tympanic membrane sequelae (one trial, 103 children), while low quality evidence indicated that children treated with antibiotics were less likely to have acute otitis media episodes within four to eight weeks (five trials, 1086 children; NNTB 18) and within six months post-randomisation (two trials, 199 children; NNTB 5).",split,"['Low quality evidence did not show that oral antibiotics were associated with fewer ventilation tube (grommet) insertions (two trials, 121 children) or in adverse consequences for the tympanic membrane (ear drum) (one trial, 103 children).', 'Low quality evidence indicated that children treated with oral antibiotics were less likely to have acute otitis media (ear infection) episodes within four to eight weeks (five trials, 1086 children; NNTB 18) and within six months after treatment was started (two trials, 199 children; NNTB 5).']",11,0.5882352941176471,3,17
CD009163,3,10,"It should, however, be noted that the beneficial effect of oral antibiotics on acute otitis media episodes within four to eight weeks was no longer significant when we excluded studies with high risk of bias.",rephrase,['It should however be noted that the beneficial effect of oral antibiotics on ear infection episodes within four to eight weeks was no longer significant when studies with high risk of bias were excluded.'],13,0.6470588235294118,4,17
CD009163,4,11,This review presents evidence of both benefits and harms associated with the use of oral antibiotics to treat children up to 16 years with OME.,rephrase,['Moderate quality evidence is available that children with glue ear do benefit from oral antibiotics in terms of resolving glue ear at various time points and reducing acute otitis media episodes during follow-up compared with control treatment.'],14,0.7058823529411765,4,17
CD009163,4,12,"Although evidence indicates that oral antibiotics are associated with an increased chance of complete resolution of OME at various time points, we also found evidence that these children are more likely to experience diarrhoea, vomiting or skin rash.",rephrase,"['Low quality evidence is available that children treated with oral antibiotics are more likely to experience diarrhoea, vomiting and skin rash than those receiving the control treatment.']",15,0.7647058823529411,4,17
CD009163,4,13,The impact of antibiotics on short-term hearing is uncertain and low quality evidence did not show that oral antibiotics were associated with fewer ventilation tube insertions.,split,"['Currently only two trials have assessed the impact of oral antibiotics on hearing and these showed conflicting results (low quality evidence).', 'Low quality evidence did not show that oral antibiotics were associated with fewer ventilation tube insertions or in adverse consequences for the tympanic membrane.']",16,0.8235294117647058,5,17
CD009163,4,14,"Furthermore, we found no data on the impact of antibiotics on other important outcomes such as speech, language and cognitive development or quality of life.",delete,[],18,0.8823529411764706,5,17
CD009163,5,15,"Even in situations where clear and relevant benefits of oral antibiotics have been demonstrated, these must always be carefully balanced against adverse effects and the emergence of bacterial resistance.",delete,[],18,0.9411764705882353,5,17
CD009163,5,16,This has specifically been linked to the widespread use of antibiotics for common conditions such as otitis media.,delete,[],18,1.0,5,17
CD002193,0,0,We included a total of nine RCTs (981 participants) in this review.,delete,[],0,0.08333333333333333,1,12
CD002193,0,1,Five studies were conducted in Europe and four in North America.,ignore,['Five studies were conducted in Europe and four in North America.'],0,0.16666666666666666,1,12
CD002193,0,2,Sample sizes ranged from 33 to 351.,ignore,['Sample sizes ranged from 33 to 351.'],1,0.25,2,12
CD002193,0,3,The mean age across trials ranged between 32.0 and 43.7 years.,ignore,['The mean age across trials ranged between 32.0 and 43.7 years.'],2,0.3333333333333333,2,12
CD002193,1,4,"All included studies were judged as having high risk of performance bias and high risk of detection bias due to lack of blinding, and four of the nine studies suffered from at least one additional source of possible bias.",delete,[],3,0.4166666666666667,3,12
CD002193,2,5,"In MBR compared to usual care for subacute LBP, individuals receiving MBR had less pain (four studies with 336 participants; SMD -0.46, 95% CI -0.70 to -0.21, moderate-quality of evidence due to risk of bias) and less disability (three studies with 240 participants; SMD -0.44, 95% CI -0.87 to -0.01, low-quality of evidence due to risk of bias and inconsistency), as well as increased likelihood of return-to-work (three studies with 170 participants; OR 3.19, 95% CI 1.46 to 6.98, very low-quality of evidence due to serious risk of bias and imprecision) and fewer sick leave days (two studies with 210 participants; SMD -0.38 95% CI -0.66 to -0.10, low-quality of evidence due to risk of bias and imprecision) at 12-month follow-up.",delete,[],3,0.5,3,12
CD002193,2,6,"The effect sizes for pain and disability were low in terms of clinical meaningfulness, whereas effects for work-related outcomes were in the moderate range.",delete,[],3,0.5833333333333334,3,12
CD002193,3,7,"However, when comparing MBR to other treatments (i.e. brief intervention with features from a light mobilization program and a graded activity program, functional restoration, brief clinical intervention including education and advice on exercise, and psychological counselling), we found no differences between the groups in terms of pain (two studies with 336 participants; SMD -0.14, 95% CI -0.36 to 0.07, low-quality evidence due to imprecision and risk of bias), functional disability (two studies with 345 participants; SMD -0.03, 95% CI -0.24 to 0.18, low-quality evidence due to imprecision and risk of bias), and time away from work (two studies with 158 participants; SMD -0.25 95% CI -0.98 to 0.47, very low-quality evidence due to serious imprecision, inconsistency and risk of bias).",rephrase,"['However, when comparing multidisciplinary treatments to other treatments (e.g. brief clinical intervention including education and advice on exercise), we found that multidisciplinary treatments may be no better than other treatments.']",3,0.6666666666666666,4,12
CD002193,3,8,Return-to-work was not reported in any of the studies.,delete,[],4,0.75,4,12
CD002193,4,9,"Although we looked for adverse events in both comparisons, none of the included studies reported this outcome.",rephrase,"['Although we examined adverse events as a secondary outcome, none of the included studies reported this outcome.']",4,0.8333333333333334,5,12
CD002193,5,10,"On average, people with subacute LBP who receive MBR will do better than if they receive usual care, but it is not clear whether they do better than people who receive some other type of treatment.",delete,[],5,0.9166666666666666,5,12
CD002193,5,11,"However, the available research provides mainly low to very low-quality evidence, thus additional high-quality trials are needed before we can describe the value of MBP for clinical practice.",rephrase,"['In sum, there is a need for additional, large, high-quality randomised controlled trials before we can make definitive recommendations for clinical practice.']",5,1.0,5,12
CD005646,0,0,Three trials that examined cotrimoxazole prophylaxis and involving 268 adults were included.,rephrase,['Three trials examining the use of cotrimoxazole in preventing opportunistic infections were included in the review.'],0,0.16666666666666666,1,6
CD005646,0,1,"Meta-analysis of these studies found a beneficial effect of using a desensitization protocol over a rechallenge protocol at six months of follow-up for preventing discontinuation of cotrimoxazole (number needed to treat (NNT) 7.14, 95% confidence interval (CI) 4.0-33.0), and for lower incidence of overall hypersensitivity (NNT 4.55, 95% CI 3.03-9.09).",rephrase,"['It is important to note that reintroduction of cotrimoxazole was usually successful using either desensitization or rechallenge, with 44.4% to 79.4% of patients still on cotrimoxazole after six months in the three studies.']",1,0.3333333333333333,2,6
CD005646,0,2,No severe hypersensitivity reactions occurred for either protocol in the three studies.,rephrase,"['Furthermore, in the studies reviewed, no strategy resulted in severe hypersensitivity reactions.']",2,0.5,3,6
CD005646,1,3,"In the small trials included in this review, when compared to cotrimoxazole rechallenge for prophylaxis of opportunistic infections, cotrimoxazole desensitization resulted in fewer treatment discontinuations and overall adverse reactions in HIV-infected patients with a previous history of mild or moderate hypersensitivity to cotrimoxazole.",rephrase,"['When compared to rechallenge, desensitization appeared to result in fewer treatment stoppages and side effects in HIV-infected adult patients who had a previous mild or moderate reaction to cotrimoxazole.']",3,0.6666666666666666,4,6
CD005646,1,4,Paediatric data and trials in resource-poor settings are urgently required.,rephrase,['Severe limitations of this review included the absence of data in paediatric populations and the minimal data from resource-poor populations.'],4,0.8333333333333334,5,6
CD005646,1,5,"Further randomised controlled trials are also needed for the treatment of opportunistic infections, treating-through, adjunctive medications, and different desensitization-dosing schedules.",delete,[],5,1.0,5,6
CD013635,0,0,We included 127 studies in the review and sampled 41 of these studies for our analysis.,ignore,['We included 127 studies in the review and sampled 41 of these studies for our analysis.'],0,0.058823529411764705,1,17
CD013635,0,1,Thirty-two further studies were found after the updated search on 5 July 2022 and are awaiting classification.,ignore,['Thirty-two further studies were found after the updated search on 5 July 2022 and are awaiting classification.'],1,0.11764705882352941,1,17
CD013635,0,2,"The sampled studies were from 24 different countries: 17 studies were from the African region, seven were from the region of the Americas, seven were from the European region, six were from the South-East Asian region, three from the Western Pacific region and one study was multiregional, covering both the African and the Eastern Mediterranean regions.",rephrase,"['The sampled studies were from 24 different countries, across all World Health Organization regions.']",2,0.17647058823529413,1,17
CD013635,0,3,"These studies primarily explored the views and experiences of cash transfer recipients with different health conditions, such as infectious diseases, disabilities and long-term illnesses, sexual and reproductive health, and maternal and child health.",ignore,"['These studies primarily explored the views and experiences of cash transfer recipients with different health conditions, such as infectious diseases, disabilities and long-term illnesses, sexual and reproductive health, and maternal and child health.']",3,0.23529411764705882,2,17
CD013635,0,4,Our GRADE-CERQual assessment indicated we had mainly moderate- and high-confidence findings.,rephrase,['We had mainly moderate-to-high confidence in our findings.'],4,0.29411764705882354,2,17
CD013635,0,5,"We found that recipients perceived the cash transfers as necessary and helpful for immediate needs and, in some cases, helpful for longer-term benefits.",rephrase,['We found that people receiving the cash transfers saw them as necessary.'],5,0.35294117647058826,2,17
CD013635,0,6,"However, across conditional and unconditional programmes, recipients often felt that the amount given was too little in relation to their total needs.",rephrase,"['However, people often felt that the amount given was too little to meet their needs.']",6,0.4117647058823529,3,17
CD013635,0,7,"They also felt that the cash alone was not enough to change their behaviour and, to change behaviour, additional types of support would be required.",rephrase,"['They also felt that the cash alone was not enough to change their behaviour and that they also needed other types of support, such as social or psychological support or training and opportunities for employment.']",7,0.47058823529411764,3,17
CD013635,0,8,"The cash transfer was reported to have important effects on empowerment, autonomy and agency, but also in some settings, recipients experienced pressure from family or programme staff on cash usage.",rephrase,"['In some settings, people experienced pressure from family or programme staff on how to use cash.']",8,0.5294117647058824,3,17
CD013635,0,9,The cash transfer was reported to improve social cohesion and reduce intrahousehold tension.,delete,[],9,0.5882352941176471,3,17
CD013635,0,10,"However, in settings where some received the cash and others did not, the lack of an equal approach caused tension, suspicion and conflict.",rephrase,"['However, in communities where some received the cash and others did not, this could also cause tension, suspicion and conflict.']",9,0.6470588235294118,4,17
CD013635,0,11,"Recipients also reported stigma in terms of cash transfer programme assessment processes and eligibility, as well as inappropriate eligibility processes.",rephrase,['Some people also described being stigmatised for receiving cash transfers.'],10,0.7058823529411765,4,17
CD013635,0,12,"Across settings, recipients experienced barriers in accessing the cash transfer programme, and some refused or were hesitant to receive the cash.",rephrase,"['While people often experienced barriers to accessing cash, some refused or were hesitant to receive the cash.']",11,0.7647058823529411,4,17
CD013635,0,13,Some recipients found cash transfer programmes more acceptable when they agreed with the programme's goals and processes.,ignore,['Some recipients found cash transfer programmes more acceptable when they agreed with programme goals and processes.'],12,0.8235294117647058,5,17
CD013635,1,14,"Our findings highlight the impact of the sociocultural context on the functioning and interaction between the individual, family and cash transfer programmes.",delete,[],13,0.8823529411764706,5,17
CD013635,1,15,"Even where the goals of a cash transfer programme are explicitly health-related, the outcomes may be far broader than health alone and may include, for example, reduced stigma, empowerment and increased agency of the individual.",delete,[],13,0.9411764705882353,5,17
CD013635,1,16,"When measuring programme outcomes, therefore, these broader impacts could be considered for understanding the health and well-being benefits of cash transfers.",delete,[],13,1.0,5,17
CD011627,0,0,We included 13 trials with 1316 participants in a qualitative synthesis.,rephrase,"['We found thirteen, mostly small, trials, involving 1316 participants.']",0,0.047619047619047616,1,21
CD011627,0,1,"Participants were incontinent for urine, stool, or both, and were residents in a nursing home or were hospitalised.",rephrase,"['All participants were incontinent for urine, stool, or both and lived in nursing homes or were hospitalised.']",1,0.09523809523809523,1,21
CD011627,1,2,Eleven trials had a small sample size and short follow-up periods.,rephrase,['Eleven trials had small numbers of participants and were of short duration.'],2,0.14285714285714285,1,21
CD011627,1,3,.The overall risk of bias in the included studies was high.,rephrase,['The overall risk of bias was high.'],3,0.19047619047619047,1,21
CD011627,1,4,"The data were not suitable for meta-analysis due to heterogeneity in participant population, skin care products, skin care procedures, outcomes, and measurement tools.",delete,[],4,0.23809523809523808,2,21
CD011627,2,5,"Nine trials compared different topical skin care products, including a combination of products.",merge,[],4,0.2857142857142857,2,21
CD011627,2,6,Two trials tested a structured skin care procedure.,merge,"['The trials tested skin care products, procedures, and frequencies of using a skin care product.']",4,0.3333333333333333,2,21
CD011627,2,7,One trial compared topical skin care products alongside frequencies of application.,none,[],4,0.38095238095238093,2,21
CD011627,2,8,One trial compared frequencies of application of topical skin care products.,rephrase,"['We included randomised controlled trials which compared skin care products, procedures, methods for using skin care products and frequencies of using a skin care product.']",5,0.42857142857142855,3,21
CD011627,3,9,"We found evidence in two trials, being of low and moderate quality, that soap and water performed poorly in the prevention and treatment of IAD (primary outcomes of this review).",split,"['Two trials showed that soap and water performed poorly in the prevention and treatment of IAD.', 'We found no evidence that one skin care product performed better than another.']",6,0.47619047619047616,3,21
CD011627,3,10,"The first trial indicated that the use of a skin cleanser might be more effective than the use of soap and water (risk ratio (RR) 0.39, 95% confidence interval (CI) 0.17 to 0.87; low quality evidence).",merge,[],8,0.5238095238095238,3,21
CD011627,3,11,"The second trial indicated that a structured skin care procedure, being a washcloth with cleansing, moisturising, and protecting properties, might be more effective than soap and water (RR 0.31, 95% CI 0.12 to 0.79; moderate quality evidence).",none,"['A skin cleanser or a washcloth with cleansing, moisturising and protecting properties may be more effective than soap and water.']",8,0.5714285714285714,3,21
CD011627,3,12,"Findings from the other trials, all being of low to very low quality, suggest that applying a leave-on product (moisturiser, skin protectant, or a combination) might be more effective than not applying a leave-on product.",rephrase,['The findings from the other trials suggest that using a skin care product is more effective than withholding a skin care product.'],9,0.6190476190476191,4,21
CD011627,3,13,No trial reported on the third primary outcome 'number of participants not satisfied with treatment' or on adverse effects.,rephrase,['The trials did not report on adverse effects.'],10,0.6666666666666666,4,21
CD011627,4,14,"Little evidence, of very low to moderate quality, exists on the effects of interventions for preventing and treating IAD in adults.",rephrase,['Very limited evidence exists on the effects of interventions for preventing and treating IAD in adults.'],11,0.7142857142857143,4,21
CD011627,4,15,Soap and water performed poorly in the prevention and treatment of IAD.,delete,[],12,0.7619047619047619,4,21
CD011627,4,16,"Application of leave-on products (moisturisers, skin protectants, or a combination) and avoiding soap seems to be more effective than withholding these products.",delete,[],12,0.8095238095238095,5,21
CD011627,4,17,"The performance of leave-on products depends on the combination of ingredients, the overall formulation and the usage (e.g. amount applied).",delete,[],12,0.8571428571428571,5,21
CD011627,4,18,"High quality confirmatory trials using standardised, and comparable prevention and treatment regimens in different settings/regions are required.",delete,[],12,0.9047619047619048,5,21
CD011627,4,19,"Furthermore, to increase the comparability of trial results, we recommend the development of a core outcome set, including validated measurement tools.",rephrase,"['Furthermore, we recommend the development of a list of outcomes which are important for patients and will guide researchers in their study.']",12,0.9523809523809523,5,21
CD011627,4,20,The evidence in this review is current up to 28 September 2016.,rephrase,['The review authors searched for studies that had been published up to 28 September 2016.'],13,1.0,5,21
CD012454,0,0,We included four studies with 149 randomized participants.,rephrase,['We included four randomized controlled studies (clinical studies where people are randomly put into one of two or more treatment groups) with 149 participants in the review.'],0,0.05263157894736842,1,19
CD012454,0,1,We identified two studies awaiting classification for which we were unable to assess eligibility and one ongoing study.,rephrase,['Two studies are awaiting classification (because we could not assess their eligibility) and one study is ongoing.'],1,0.10526315789473684,1,19
CD012454,1,2,Participants differed in severity of illness as assessed by APACHE II scores in three studies and further differences existed between comparisons and methods.,delete,[],2,0.15789473684210525,1,19
CD012454,1,3,"One study compared propofol versus no agent, one study compared different doses of propofol and two studies compared propofol versus a benzodiazepine (flunitrazepam, one study; midazolam, one study).",rephrase,['Two studies compared propofol with benzodiazepines (a tranquilizing medicine; flunitrazepam in one study and midazolam in one study).'],2,0.21052631578947367,2,19
CD012454,1,4,All studies reported randomization and allocation concealment inadequately.,delete,[],3,0.2631578947368421,2,19
CD012454,1,5,We judged all studies to have high risk of performance bias from personnel who were unblinded.,delete,[],3,0.3157894736842105,2,19
CD012454,1,6,We noted that some study authors had blinded study outcome assessors and participants for relevant outcomes.,delete,[],3,0.3684210526315789,2,19
CD012454,2,7,It was not appropriate to combine data owing to high levels of methodological heterogeneity.,rephrase,['We did not combine the results from the studies because of differences in comparison (called control) treatments and study design.'],3,0.42105263157894735,3,19
CD012454,3,8,"One study comparing propofol with no agent (13 participants) measured quantity and quality of sleep using polysomnography; study authors reported no evidence of a difference in duration of sleep or sleep efficiency, and reported disruption to usual REM (rapid eye movement sleep) with propofol.",split,"['One study compared propofol with no agent.', 'This study used polysomnography (which records brain waves, oxygen level in blood, heart rate, breathing, and eye and leg movements) to measure sleep quality and quantity.']",4,0.47368421052631576,3,19
CD012454,4,9,"One study comparing different doses of propofol (30 participants) measured quantity and quality of sleep by personnel using the Ramsay Sedation Scale; study authors reported that more participants who were given a higher dose of propofol had a successful diurnal rhythm, and achieved a greater sedation rhythmicity.",rephrase,"['One study compared a higher dose of propofol at night described as additional night sedation, with a constant day-time and night-time dose.']",6,0.5263157894736842,3,19
CD012454,5,10,"Two studies comparing propofol with a different agent (106 participants) measured quantity and quality of sleep using the Pittsburgh Sleep Diary and the Hospital Anxiety and Depression Scale; one study reported fewer awakenings of reduced duration with propofol, and similar total sleep time between groups, and one study reported no evidence of a difference in sleep quality.",split,"['It reported no improvement in duration of sleep with propofol but participants woke up less often and for shorter lengths of time and described their sleep quality as being improved with propofol.', 'These studies used the Pittsburgh Sleep Diary and the Hospital Anxiety and Depression Scale to measure quantity and quality of sleep.', 'The study with flunitrazepam reported fewer awakenings of reduced duration with propofol but similar total sleep time in each group and the study with midazolam reported no difference in sleep quality.']",7,0.5789473684210527,3,19
CD012454,5,11,"One study comparing propofol with another agent (66 participants) measured quantity and quality of sleep with the Bispectral Index and reported longer time in deep sleep, with fewer arousals.",rephrase,"['The study with flunitrazepam also measured sleep with Bispectral Index (used by anaesthetists to assess depth of anaesthesia) and reported longer time in deep sleep, with fewer awakenings.']",10,0.631578947368421,4,19
CD012454,5,12,"One study comparing propofol with another agent (40 participants) reported higher levels of anxiety and depression in both groups, and no evidence of a difference when participants were given propofol.",rephrase,"['The study with midazolam reported higher levels of anxiety and depression in both groups, and no difference when participants were given propofol.']",11,0.6842105263157895,4,19
CD012454,6,13,No studies reported adverse events.,rephrase,['No study reported on side effects.'],12,0.7368421052631579,4,19
CD012454,7,14,We used the GRADE approach to downgrade the certainty of the evidence for each outcome to very low.,merge,['We judged the evidence to be very low quality.'],13,0.7894736842105263,4,19
CD012454,7,15,"We identified sparse data with few participants, and methodological differences in study designs and comparative agents introduced inconsistency, and we noted that measurement tools were imprecise or not valid for purpose.",none,[],13,0.8421052631578947,5,19
CD012454,8,16,We found insufficient evidence to determine whether administration of propofol would improve the quality and quantity of sleep in adults in the ICU.,rephrase,"['We were unable to collect sufficient evidence to determine whether propofol given at night to adults in the ICU improves quality and quantity of their sleep, as a way of helping recovery.']",14,0.8947368421052632,5,19
CD012454,8,17,"We noted differences in study designs, methodology, comparative agents and illness severity amongst study participants.",rephrase,['We noted differences in illness severity of participants and the medicines that were compared with propofol in the included studies.'],15,0.9473684210526315,5,19
CD012454,8,18,We did not pool data and we used the GRADE approach to downgrade the certainty of our evidence to very low.,delete,[],16,1.0,5,19
CD011559,0,0,"Four studies were identified that met pre-determined eligibility criteria, evaluating a total of 342 adults.",rephrase,['The review includes four studies involving 342 adults who had received radiotherapy for the treatment of head and neck cancer.'],0,0.1111111111111111,1,9
CD011559,0,1,"From the four studies, all assessed as at high risk of bias, three broad interventions were identified that may potentially reduce the risk of ORN development: one study showed no reduction in ORN when using platelet-rich plasma placed in the extraction sockets of prophylactically removed healthy mandibular molar teeth prior to radiotherapy (odds ratio (OR) 3.32, 95% confidence interval (CI) 0.58 to 19.09; one trial, 44 participants; very low-certainty evidence).",rephrase,['One study showed no reduction in ORN when using platelet-rich plasma in bone after the removal of healthy teeth.'],1,0.2222222222222222,2,9
CD011559,0,2,"Another study involved comparing fluoride gel and high-content fluoride toothpaste (1350 parts per million (ppm)) in prevention of post-radiation caries, and found no difference between their use as no cases of ORN were reported (one trial, 220 participants; very low-certainty evidence).",rephrase,['Another study found no difference between fluoride gel and toothpaste with a higher level of fluoride than normal as no cases of ORN were reported.'],2,0.3333333333333333,2,9
CD011559,0,3,The other two studies involved the use of perioperative hyperbaric oxygen (HBO) therapy and antibiotics.,rephrase,['Two studies compared the use of hyperbaric oxygen therapy for taking out teeth or placing dental implants with antibiotics.'],3,0.4444444444444444,3,9
CD011559,0,4,"One study showed that treatment with HBO caused a reduction in the development of ORN in comparison to patients treated with antibiotics following dental extractions (risk ratio (RR) 0.18, 95% CI 0.43 to 0.76; one trial, 74 participants; very low-certainty evidence).",rephrase,['A third study showed that treatment with hyperbaric oxygen therapy caused a reduction in the development of ORN in comparison to patients treated with antibiotics following the removal of teeth.'],4,0.5555555555555556,3,9
CD011559,0,5,"Another study found no difference between combined HBO and antibiotics compared to antibiotics alone prior to dental implant placement (RR 3.00, 95% CI 0.14 to 65.16; one trial, 26 participants; very low-certainty evidence).",rephrase,['The fourth study found no difference between combined hyperbaric oxygen therapy and antibiotics compared to antibiotics alone.'],5,0.6666666666666666,4,9
CD011559,1,6,Adverse effects of the different interventions were not reported clearly or were not important.,ignore,['Harmful effects of the different interventions were not reported clearly or were not important.'],6,0.7777777777777778,4,9
CD011559,2,7,"Given the suboptimal reporting and inadequate sample sizes of the included studies, evidence regarding the interventions evaluated by the trials included in this review is uncertain.",delete,[],7,0.8888888888888888,5,9
CD011559,2,8,More well-designed RCTs with larger samples are required to make conclusive statements regarding the efficacy of these interventions.,delete,[],7,1.0,5,9
CD013276,0,0,"We included two studies, a parallel RCT involving 700 women and a stepped-wedge cluster trial involving 536,233 women.",rephrase,"[""One study was a single-centre study involving 700 women and the second was a stepped-wedge cluster trial (multiple centres grouped into 'clusters') involving 536,233 women.""]",0,0.07142857142857142,1,14
CD013276,0,1,"Both studies were published in 2019, and both were conducted in low-resource settings.",rephrase,['Both studies were carried out in low-resource healthcare settings.'],1,0.14285714285714285,1,14
CD013276,0,2,"The interventions were the 'Saving Mothers Score' (SMS) and the CRADLE Vital Sign Alert (VSA) device, and both interventions were compared with standard care.",rephrase,"[""The tools were called the 'Saving Mothers Score' (SMS) and the CRADLE Vital Sign Alert (VSA) device.""]",2,0.21428571428571427,2,14
CD013276,0,3,Both studies had low or unclear risk of bias on all seven risk of bias criteria.,rephrase,['Risk of bias in the two studies was low or unclear.'],3,0.2857142857142857,2,14
CD013276,0,4,"Evidence certainty, assessed using GRADE, ranged from very low to moderate certainty, mainly due to other bias as well as inconsistency and imprecision.",delete,[],4,0.35714285714285715,2,14
CD013276,1,5,"For women randomised to TTS/EWS compared to standard care there is probably little to no difference in maternal death (OR 0.80, 95% CI 0.30 to 2.11; 1 study, 536,233 participants; moderate-certainty evidence).",merge,[],4,0.42857142857142855,3,14
CD013276,1,6,"Use of TTS/EWS compared to standard care may reduce total haemorrhage (OR 0.36, 95% CI 0.19 to 0.69; 1 study, 700 participants; low-certainty evidence).",none,['Use of the tools probably reduces the time a woman stays in hospital (moderate-certainty evidence).'],4,0.5,3,14
CD013276,1,7,"For women randomised to TTS/EWS compared to standard care there may be little to no difference in sepsis (OR 0.21, 95% CI 0.02 to 1.80; 1 study, 700 participants; low-certainty evidence), eclampsia (OR 1.50, 95% CI 0.74 to 3.03; 2 studies, 536,933 participants; low-certainty evidence) and HELLP (OR 0.21, 95% CI 0.01 to 4.40; 1 study, 700 participants; very low-certainty evidence), and probably little to no difference in maternal admission to the intensive care unit (ICU) (OR 0.78, 95% CI  0.53 to 1.15; 2 studies, 536,933 participants; moderate-certainty evidence).",delete,[],5,0.5714285714285714,3,14
CD013276,1,8,"Use of TTS/EWS compared to standard care may reduce a woman's length of hospital stay (MD -1.21, 95% CI -1.78 to -0.64; 1 study, 700 participants; low-certainty evidence) but may result in little to no difference in neonatal death (OR 1.06, 95% CI 0.62 to 1.84; 1 study, 700 participants; low-certainty evidence).",delete,[],5,0.6428571428571429,4,14
CD013276,1,9,Cost-effectiveness measures were not measured in either of the two studies.,rephrase,['Neither of the two included studies reported cost outcomes.'],5,0.7142857142857143,4,14
CD013276,2,10,"Use of TTS/EWS in maternity care may be helpful in reducing some maternal outcomes such as haemorrhage and maternal length of hospital stay, possibly through early identification of clinical deterioration and escalation of care.",rephrase,['Use of early warning tools for women in maternity care in low-resource settings\xa0may reduce serious bleeding and probably reduces the number of days a woman stays in the hospital but may not reduce maternal or infant deaths.'],6,0.7857142857142857,4,14
CD013276,2,11,The evidence suggests that the use of TTS/EWS compared to standard care probably results in little to no difference in maternal death and may result in little to no difference in neonatal death.,delete,[],7,0.8571428571428571,5,14
CD013276,2,12,Both of the included studies were conducted in low-resource settings where the use of TTS/EWS might potentially confer a different effect to TTS/EWS use in high-resource settings.,rephrase,['More studies are required on the different early warning systems in low-resource settings.'],7,0.9285714285714286,5,14
CD013276,2,13,"Further high-quality trials in high- and middle-resource settings, as well as in discrete populations of high- and low-risk women, are required.",rephrase,"['Studies are also needed in middle- and high-resource settings, and in high- and low-risk pregnant women.']",8,1.0,5,14
CD012010,0,0,Ten studies including 5056 participants met the inclusion criteria for this review and assessed the diagnostic accuracy of the index tests in people presenting to the emergency department with acute abdominal pain.,rephrase,['We identified 10 studies reporting information on 5056 people with abdominal pain that started suddenly.'],0,0.1,1,10
CD012010,0,1,The risk of bias was unclear or high for all of the included studies.,rephrase,"['All of the studies were of unclear or low methodological quality, which may result in arriving at false conclusions.']",1,0.2,1,10
CD012010,0,2,The study that contributed approximately two-thirds of the participants included in this review was excluded from the results of the analysis presented below due to major concerns about the participants included in the study.,merge,['We excluded the study that contributed approximately two-thirds of the participants included in this review from the results of the analysis presented below due to concerns about whether the participants included in the study are typical of those seen in the emergency department.'],2,0.3,2,10
CD012010,0,3,We have presented only the results where at least two studies were included in the analysis.,none,[],2,0.4,2,10
CD012010,1,4,"Serum amylase, serum lipase, and urinary trypsinogen-2 at the standard threshold levels of more than three times normal for serum amylase and serum lipase, and a threshold of 50 ng/mL for urinary trypsinogen-2 appear to have similar sensitivities (0.72 (95% CI 0.59 to 0.82); 0.79 (95% CI 0.54 to 0.92); and 0.72 (95% CI 0.56 to 0.84), respectively) and specificities (0.93 (95% CI 0.66 to 0.99); 0.89 (95% CI 0.46 to 0.99); and 0.90 (95% CI 0.85 to 0.93), respectively).",merge,"['The accuracy of serum amylase, serum lipase, and urinary trypsinogen-2 in making the diagnosis of acute pancreatitis was similar.']",3,0.5,3,10
CD012010,1,5,"At the median prevalence of 22.6% of acute pancreatitis in the studies, out of 100 people with positive test, serum amylase (more than three times normal), serum lipase (more than three times normal), and urinary trypsinogen (more than 50 ng/mL), 74 (95% CI 33 to 94); 68 (95% CI 21 to 94); and 67 (95% CI 57 to 76) people have acute pancreatitis, respectively; out of 100 people with negative test, serum amylase (more than three times normal), serum lipase (more than three times normal), and urinary trypsinogen (more than 50 ng/mL), 8 (95% CI 5 to 12); 7 (95% CI 3 to 15); and 8 (95% CI 5 to 13) people have acute pancreatitis, respectively.",none,[],3,0.6,3,10
CD012010,1,6,We were not able to compare these tests formally because of sparse data.,delete,[],4,0.7,4,10
CD012010,2,7,"As about a quarter of people with acute pancreatitis fail to be diagnosed as having acute pancreatitis with the evaluated tests, one should have a low threshold to admit the patient and treat them for acute pancreatitis if the symptoms are suggestive of acute pancreatitis, even if these tests are normal.",split,"['About a quarter of people with acute pancreatitis fail to be diagnosed as having acute pancreatitis with these tests.', 'The patient should be admitted and treated as having acute pancreatitis, even if these tests are normal, if there is a suspicion of acute pancreatitis.']",4,0.8,4,10
CD012010,2,8,"About 1 in 10 patients without acute pancreatitis may be wrongly diagnosed as having acute pancreatitis with these tests, therefore it is important to consider other conditions that require urgent surgical intervention, such as perforated viscus, even if these tests are abnormal.",rephrase,"['As about 1 in 10 patients without acute pancreatitis may be wrongly diagnosed as having acute pancreatitis with these tests, it is important to consider other conditions that require urgent surgery, even if these tests are abnormal.']",6,0.9,5,10
CD012010,3,9,"The diagnostic performance of these tests decreases even further with the progression of time, and one should have an even lower threshold to perform additional investigations if the symptoms are suggestive of acute pancreatitis.",rephrase,"['The diagnostic performance of these tests decreases even further with the progression of time, and additional investigations should be performed if there is a suspicion of acute pancreatitis.']",7,1.0,5,10
CD012112,0,0,We included five RCTs involving a total of 1231 participants with NMIBC in this review.,rephrase,['We included five studies with a total of 1231 participants with non-muscle-invasive bladder cancer.'],0,0.07142857142857142,1,14
CD012112,0,1,"Due to poor reporting, the risk of bias in the included studies was often unclear.",rephrase,"['As the included studies were often poorly conducted or reported, we rated the quality of the evidence as low overall.']",1,0.14285714285714285,1,14
CD012112,0,2,"We assessed the studies under two main comparisons: intravesical BCG plus IFN-α versus intravesical BCG alone (four RCTs), and intravesical BCG alternating with IFN-α versus intravesical BCG alone (one RCT).",split,"['Four studies compared BCG given together with IFN-α versus BCG alone.', 'One study compared BCG alternating with IFN-α versus BCG alone.']",2,0.21428571428571427,2,14
CD012112,1,3,"Intravesical BCG plus IFN-α versus intravesical BCG alone (four RCTs): We observed no clear difference between BCG plus IFN-α and BCG alone for recurrence (average risk ratio (RR) 0.76, 95% confidence interval (CI) 0.44 to 1.32; 4 RCTs; 925 participants; very low-quality evidence) or progression (average RR 0.26, 95% CI 0.04 to 1.87; 2 RCTs; 219 participants; low-quality evidence).",rephrase,['BCG combined with IFN-α (four studies):We found very low-quality evidence showing no clear difference in recurrence (four studies involving 925 participants) or progression (two studies involving 219 participants) between participants who received BCG combined with IFN-α and those who received BCG alone.'],4,0.2857142857142857,2,14
CD012112,1,4,"The included RCTs did not report on the other primary outcome of this review, discontinuation of therapy due to adverse events.",rephrase,['None of the studies reported on the important outcome of stopping treatment due to adverse events.'],5,0.35714285714285715,2,14
CD012112,1,5,"Regarding secondary outcomes, we observed no clear difference for disease-specific mortality (RR 0.38, 95% CI 0.05 to 3.05; 1 RCT; 99 participants; very low-quality evidence).",rephrase,"['There was also very low-quality evidence showing no clear difference between groups for cancer-specific mortality (one study, 99 participants).']",6,0.42857142857142855,3,14
CD012112,1,6,Two RCTs reporting contradictory findings for adverse events could not be pooled due to variation in definitions.,delete,[],7,0.5,3,14
CD012112,1,7,There were no data from the included RCTs on time-to-death or disease-specific quality of life.,delete,[],7,0.5714285714285714,3,14
CD012112,2,8,"Intravesical BCG alternating with IFN-α versus intravesical BCG alone (one RCT): We observed shorter time-to-recurrence for participants in the BCG alternating with IFN-α group compared with the BCG alone group (hazard ratio (HR) 2.86, 95% CI 1.98 to 4.13; 1 RCT; 205 participants; low-quality evidence), but no clear differences in time-to-progression (HR 2.39, 95% CI 0.92 to 6.21; 1 RCT; 205 participants; low-quality evidence) and discontinuation of therapy due to adverse events (RR 2.97, 95% CI 0.31 to 28.09; 1 RCT; 205 participants; low-quality evidence).",delete,[],7,0.6428571428571429,4,14
CD012112,2,9,"Regarding secondary outcomes, there were no clear differences between the BCG alternating with IFN-α and BCG alone groups for disease-specific mortality (HR 2.74, 95% CI 0.73 to 10.28; 1 RCT; 205 participants; low-quality evidence), time-to-death (overall survival) (HR 1.00, 95% CI 0.68 to 1.47; 1 RCT; 205 participants; low-quality evidence), or systemic or local adverse events (RR 1.65, 95% CI 0.41 to 6.73; 1 RCT; 205 participants; low-quality evidence).",split,"['BCG alternating with IFN-α (one study):We found low-quality evidence showing a higher probability of recurrence when BCG was alternated with IFN-α compared with BCG alone (study involving 205 participants).', 'There was also no clear difference between groups for overall survival or adverse events (one study involving 205 participants).']",7,0.7142857142857143,4,14
CD012112,2,10,There were no data on disease-specific quality of life.,delete,[],9,0.7857142857142857,4,14
CD012112,3,11,We found low- to very low-quality evidence suggesting no clear differences in recurrence or progression with BCG plus IFN-α compared with BCG alone for people with NMIBC; there was no information to determine the effect on discontinuation of therapy due to adverse events.,rephrase,"['We also found low-quality evidence that showed no clear difference in the probability of progression, risk of stopping treatment due to adverse events, and cancer-specific mortality between those participants receiving BCG alternating with IFN-α and those receiving BCG alone (one study involving 205 participants).']",9,0.8571428571428571,5,14
CD012112,3,12,"Low-quality evidence suggests BCG alternating with IFN-α compared with BCG alone may increase time-to-recurrence, however low-quality evidence also suggests no clear differences for time-to-progression or discontinuation of therapy due to adverse events.",delete,[],10,0.9285714285714286,5,14
CD012112,4,13,"Additional high-quality, adequately powered trials using standardised instillation regimens and doses of both BCG and IFN-α, reporting outcomes in subgroups stratified by patient and tumour characteristics, and on long-term outcomes related not only to recurrence but also to progression, discontinuation due to adverse events, and mortality may help to clarify the ideal treatment strategy and provide a more definitive result.",delete,[],10,1.0,5,14
CD001338,0,0,"Overall, there were 75 trials (13,793 women); these were of mixed quality.",rephrase,"['This review of 75 randomised controlled trials (13,793 women) found that oral misoprostol appears to be at least as effective as current methods of induction.']",0,0.05,1,20
CD001338,1,1,"In nine trials comparing oral misoprostol with placebo (1109 women), women using oral misoprostol were more likely to give birth vaginally within 24 hours (risk ratio (RR) 0.16, 95% confidence interval (CI) 0.05 to 0.49; one trial; 96 women) and less likely to undergo caesarean birth (RR 0.72, 95% CI 0.54 to 0.95; 8 trials; 1029 women).",rephrase,"['Women in the oral misoprostol group were more likely to have vaginal birth within 24 hours, and less likely to have a caesarean section.']",1,0.1,1,20
CD001338,1,2,"Differences in ‘uterine hyperstimulation with fetal heart rate changes’ were compatible with no effect (RR 2.71, 95% CI 0.84 to 8.68; 7 trials; 669 women).",delete,[],2,0.15,1,20
CD001338,2,3,"Ten trials compared oral misoprostol with vaginal prostaglandin (dinoprostone) (3,240 women).",rephrase,"[""In 10 trials (3,240 women) comparing oral misoprostol with a vaginal prostaglandin (dinoprost), there was little difference in the frequency of vaginal birth within 24 hours, uterine hyperstimulation with changes to the baby's heart rate, or caesarean section.""]",2,0.2,1,20
CD001338,2,4,"There was little difference in the frequency of: vaginal birth within 24 hours (RR 1.10, 95% CI 0.99 to 1.22; 5 trials; 2,128 women), uterine hyperstimulation with fetal heart rate changes (RR 0.95, 95% CI 0.59 to 1.53; 7 trials; 2,352 women), and caesarean birth (RR 0.92, 95% CI 0.81 to 1.04; 10 trials; 3240 women).",rephrase,"[""There was little difference between groups in terms of the number of women who experienced uterine hyperstimulation with changes to the baby's heart rate.""]",3,0.25,2,20
CD001338,3,5,Five trials compared administration of oral misoprostol with intracervical prostaglandin E2 (681 women).,rephrase,['Five trials compared oral misoprostol with intracervical (inserted into the entrance of the womb) prostaglandin E2 (681 women).'],4,0.3,2,20
CD001338,3,6,"Oral misoprostol was associated with fewer instances of failure to achieve vaginal birth within 24 hours (RR 0.78, 95% CI 0.63 to 0.97; 3 trials; 452 women) but more frequent uterine hyperstimulation with fetal heart rate changes (RR 3.57, 95% CI 1.11 to 11.54; 3 trials; 490 women).",rephrase,"[""Oral misoprostol was associated with fewer instances of failure to achieve vaginal birth within 24 hours but more frequent uterine hyperstimulation with changes to the baby's heart rate.""]",5,0.35,2,20
CD001338,3,7,"The available data for this comparison were however limited and the differences in caesarean birth were small (RR 0.85, 95% CI 0.63 to 1.16; 5 trials; 742 women).",rephrase,['The available data for this comparison was limited and the differences in caesarean birth were small.'],6,0.4,2,20
CD001338,4,8,Nine trials compared oral misoprostol with intravenous oxytocin (1282 women).,delete,[],7,0.45,3,20
CD001338,4,9,"There were no obvious differences in the frequency of: vaginal birth within 24 hours (RR 0.79, 95% CI 0.59 to 1.05; 6 trials; 789 women), or uterine hyperstimulation with fetal heart rate changes (RR 1.30, 95% CI 0.43 to 3.91; 7 trials; 947 women).",delete,[],7,0.5,3,20
CD001338,4,10,"There were, however, fewer caesarean births with oral misoprostol (RR 0.77, 95% CI 0.60 to 0.98; 9 trials; 1282 women).",delete,[],7,0.55,3,20
CD001338,5,11,Thirty-seven trials compared oral misoprostol with vaginal misoprostol (6417 women).,delete,[],7,0.6,3,20
CD001338,5,12,"There was little difference in the frequency of: vaginal birth within 24 hours (RR 1.08, 95% CI 0.86 to 1.36; 14 trials; 2,448 women), uterine hyperstimulation with fetal heart rate changes (RR 0.71, 95% CI 0.47 to 1.08; 29 trials; 5,503 women), and caesarean birth (RR 0.93, 95% CI 0.81 to 1.07; 35 trials; 6,326 women).",delete,[],7,0.65,4,20
CD001338,6,13,The incidence of serious neonatal or maternal morbidity or death was rare and no meaningful results were available for any of the comparisons.,rephrase,"['Overall, the incidence of serious illness or death of the mother or her baby was rare and no meaningful results were available for any of the comparisons in this review.']",7,0.7,4,20
CD001338,7,14,Oral misoprostol as an induction agent is effective at achieving vaginal birth.,rephrase,['Using oral misoprostol to induce labour is effective at achieving vaginal birth.'],8,0.75,4,20
CD001338,7,15,"It is more effective than placebo, as effective as vaginal misoprostol and vaginal dinoprostone, and results in fewer caesarean sections than oxytocin alone.",ignore,"['It is more effective than placebo, as effective as vaginal misoprostol and vaginal dinoprostone, and results in fewer caesarean sections than using oxytocin alone.']",9,0.8,4,20
CD001338,8,16,"Where misoprostol remains unlicensed for the induction of labour, many practitioners will prefer to use a licensed product like dinoprostone.",rephrase,"['In some countries where misoprostol is not licenced for the purpose of inducing labour, many clinicians may prefer to use some other licensed product such as dinoprostone.']",10,0.85,5,20
CD001338,8,17,"If using oral misoprostol, the evidence suggests that the dose should be 20 to 25 mcg in solution.",rephrase,"['Where oral misoprostol is used, evidence suggests that an appropriate dose may be 20 to 25 mcg in solution.']",11,0.9,5,20
CD001338,8,18,"Given that safety is the primary concern, the evidence supports the use of oral regimens over vaginal regimens.",ignore,"['Given that safety is the primary concern, the evidence supports the use of oral regimens over vaginal regimens.']",12,0.95,5,20
CD001338,8,19,This is especially important in situations where the risk of ascending infection is high and the lack of staff means that women cannot be intensely monitored.,rephrase,['This is particularly important in settings where the mother is at a higher risk of infection and where there may be insufficient staff to closely monitor the mother and her baby.'],13,1.0,5,20
CD013638,0,0,"From 902 results identified in the search, 29 studies met our inclusion criteria.",rephrase,['We included 29 studies in our analysis.'],0,0.05,1,20
CD013638,0,1,"The studies covered a broad range of countries in Africa, South-East Asia, and South America, and explored the views and experiences of community members and community drug distributors in low-income countries endemic for lymphatic filariasis.",split,"['The studies covered a broad range of countries in Africa, South-East Asia, and South America, although most were conducted in India.', 'These studies primarily explored the views and experiences of community members and those distributing the medicines in low-income countries where lymphatic filariasis is considered a problem.']",1,0.1,1,20
CD013638,0,2,Four themes emerged.,rephrase,"['From the data, four themes emerged.']",3,0.15,1,20
CD013638,1,3,People weigh up benefits and harms before participating.,ignore,['People weigh up benefits and harms before participating.'],4,0.2,1,20
CD013638,1,4,"People understand the potential benefits in terms of relief of suffering, stigma, and avoiding costs (high confidence); however, these theoretical benefits do not always mesh with their experiences (high confidence).",rephrase,"['People understand they can reduce the suffering, stigma and costs of developing the disease (high confidence); however, these benefits do not always mesh with their experiences (high confidence).']",5,0.25,2,20
CD013638,1,5,"In particular, adverse effects are frightening and unwelcome (high confidence); and these effects are amplified through rumour and social media (moderate confidence).",ignore,"['In particular, side effects are frightening and unwelcome (high confidence); and these effects are amplified through rumour and social media (moderate confidence).']",6,0.3,2,20
CD013638,2,6,Many people are suspicious of MDA programmes.,ignore,['Many people are suspicious of MDA programmes.'],7,0.35,2,20
CD013638,2,7,"When people lack a scientific explanation for the programme and their experiences of it, they often develop social explanations instead.",merge,"['When people lack a detailed explanation for the programme and their experiences of it, they often develop explanations based on the historical backdrop and level of trust people have in relevant authority figures (high confidence), although some have unwavering faith in their government and by extension the programme (moderate confidence).']",8,0.4,2,20
CD013638,2,8,"These are largely shaped on the historical backdrop and level of trust people have in relevant authority figures (high confidence), although some have unwavering faith in their government and, by extension, the programme (moderate confidence).",none,[],8,0.45,3,20
CD013638,3,9,"Programmes expect compliance, and this can become coercive and blaming.",ignore,"['Programmes expect compliance, and this can become coercive and blaming.']",9,0.5,3,20
CD013638,3,10,"Health workers and community members stigmatize non-compliance, which can become coercive (moderate confidence), so communities may appear to comply publicly, but privately reject treatment (moderate confidence).",ignore,"['Health workers and community members stigmatize non-compliance, which can become coercive (moderate confidence), so communities may appear to comply publicly, but privately reject treatment (moderate confidence).']",10,0.55,3,20
CD013638,4,11,Community distributors are often not respected or valued.,ignore,['Community distributors are often not respected or valued.'],11,0.6,3,20
CD013638,4,12,"They have little authority (moderate confidence), and the behaviour of some distributors damages the MDA programme's reputation (high confidence).",ignore,"[""They have little authority (moderate confidence), and the behaviour of some damages the MDA programme's reputation (high confidence).""]",12,0.65,4,20
CD013638,4,13,"Communities want information about programmes to help make decisions about participation, but drug distributors are not sufficiently informed, or skilled in this communication (high confidence).",ignore,"['Communities want information about programmes to help make decisions about participation, but drug distributors are not sufficiently informed, or skilled in this communication (high confidence).']",13,0.7,4,20
CD013638,5,14,We intended to assess whether programme designs influenced communities' perceptions of the programme and decision to adhere but were unable to do so as few studies adequately reported the design and implementation of the local programme.,rephrase,"[""We were unable to assess the impact of programme design on communities' perception of the programme and decision to adhere as these aspects were too similar across all studies.""]",14,0.75,4,20
CD013638,6,15,We have moderate to high confidence in the evidence contributing to the review themes and subthemes.,delete,[],15,0.8,4,20
CD013638,7,16,Adherence with MDA for filariasis is influenced by individual direct experience of benefit and harm; social influences in the community; political influences and their relationship to government; and historical influences.,delete,[],15,0.85,5,20
CD013638,7,17,Fear of adverse effects was frequently described and this appears to be particularly important for communities.,delete,[],15,0.9,5,20
CD013638,7,18,"When views were negative, we were surprised by the strength of feeling expressed.",delete,[],15,0.95,5,20
CD013638,7,19,Enthusiasm for these schemes as a strategy in global policy needs debate in the light of these findings.,delete,[],15,1.0,5,20
CD006089,0,0,We included 15 trials involving 3057 participants.,split,"['We included 15 studies in which adults with short-duration sinus infection, whether or not confirmed by imaging, randomly received antibiotics, or a dummy drug or no treatment, in ambulatory care settings.', 'The studies included a total of 3057 adults whose average age was 36 years; about 60% were female.']",0,0.07142857142857142,1,14
CD006089,0,1,"Of the 15 included trials, 10 appeared in our 2012 review, and five (631 participants) are legacy trials from merging two reviews.",delete,[],2,0.14285714285714285,1,14
CD006089,0,2,No new studies were included from searches for this update.,delete,[],2,0.21428571428571427,2,14
CD006089,0,3,"Overall, risk of bias was low.",delete,[],2,0.2857142857142857,2,14
CD006089,0,4,"Without antibiotics, 46% of participants with rhinosinusitis, whether or not confirmed by radiography, were cured after 1 week and 64% after 14 days.",rephrase,"['Without antibiotics, almost half of all participants were cured after one week, and two out of three were cured after 14 days.']",2,0.35714285714285715,2,14
CD006089,0,5,"Antibiotics can shorten time to cure, but only 5 to 11 more people per 100 will be cured faster if they receive antibiotics instead of placebo or no treatment: clinical diagnosis (odds ratio (OR) 1.25, 95% confidence interval (CI) 1.02 to 1.54; number needed to treat for an additional beneficial outcome (NNTB) 19, 95% CI 10 to 205; I² = 0%; 8 trials; high-quality evidence) and diagnosis confirmed by radiography (OR 1.57, 95% CI 1.03 to 2.39; NNTB 10, 95% CI 5 to 136; I² = 0%; 3 trials; moderate-quality evidence).",rephrase,['Five (diagnosis based on symptoms described to a doctor) to 11 (diagnosis confirmed by x-ray) more people per 100 were cured faster with antibiotics.'],3,0.42857142857142855,3,14
CD006089,0,6,"Cure rates with antibiotics were higher when a fluid level or total opacification in any sinus was found on computed tomography (OR 4.89, 95% CI 1.75 to 13.72; NNTB 4, 95% CI 2 to 15; 1 trial; moderate-quality evidence).",delete,[],4,0.5,3,14
CD006089,0,7,"Purulent secretion resolved faster with antibiotics (OR 1.58, 95% CI 1.13 to 2.22; NNTB 10, 95% CI 6 to 35; I² = 0%; 3 trials; high-quality evidence).",delete,[],4,0.5714285714285714,3,14
CD006089,0,8,"However, 13 more people experienced side effects with antibiotics compared to placebo or no treatment (OR 2.21, 95% CI 1.74 to 2.82; number needed to treat for an additional harmful outcome (NNTH) 8, 95% CI 6 to 12; I² = 16%; 10 trials; high-quality evidence).",rephrase,['Thirteen more people per 100 experienced side effects (mostly concerning stomach or intestines) with antibiotics compared to a dummy drug or no treatment.'],4,0.6428571428571429,4,14
CD006089,0,9,"Five fewer people per 100 will experience clinical failure if they receive antibiotics instead of placebo or no treatment (Peto OR 0.48, 95% CI 0.36 to 0.63; NNTH 19, 95% CI 15 to 27; I² = 21%; 12 trials; high-quality evidence).",rephrase,"['Compared with people who initially started antibiotics, five more people per 100 in the dummy drug or no treatment group had to start antibiotics because their condition worsened.']",5,0.7142857142857143,4,14
CD006089,0,10,"A disease-related complication (brain abscess) occurred in one participant (of 3057) one week after receiving open antibiotic therapy (clinical failure, control group).",delete,[],6,0.7857142857142857,4,14
CD006089,1,11,"The potential benefit of antibiotics to treat acute rhinosinusitis diagnosed either clinically (low risk of bias, high-quality evidence) or confirmed by imaging (low to unclear risk of bias, moderate-quality evidence) is marginal and needs to be seen in the context of the risk of adverse effects.",delete,[],6,0.8571428571428571,5,14
CD006089,1,12,"Considering antibiotic resistance, and the very low incidence of serious complications, we conclude there is no place for antibiotics for people with uncomplicated acute rhinosinusitis.",rephrase,['We found that antibiotics are not a first-choice treatment for adults with short-duration sinus infection.'],6,0.9285714285714286,5,14
CD006089,1,13,"We could not draw conclusions about children, people with suppressed immune systems, and those with severe sinusitis, because these populations were not included in the available trials.",rephrase,"['We found no evidence relating to adults with severe sinusitis or with reduced immunity, or to children.']",7,1.0,5,14
CD000341,0,0,One randomised trial involving 14 preterm infants was included.,rephrase,['We included one trial with very low-quality evidence and involving 14 preterm infants.'],0,0.14285714285714285,1,7
CD000341,0,1,This risk of bias was unclear for all methodological domains.,delete,[],1,0.2857142857142857,2,7
CD000341,0,2,"Very low-quality evidence means that there is uncertainty about the effect of fat supplemention on in-hospital rates of growth in weight (MD 0.6 g/kg/day, 95% CI −2.4 to 3.6; 1 RCT, n = 14 infants,), length (MD 0.1 cm/week, 95% CI −0.08 to 0.3; 1 RCT, n = 14 infants) and head circumference (MD 0.2 cm/week, 95% CI −0.07 to 0.4; 1 RCT n = 14 infants), and on the risk of feeding intolerance (RR 3.0, 95% CI 0.1 to 64.3; 1 RCT, n = 16 infants).",delete,[],1,0.42857142857142855,3,7
CD000341,0,3,No data were available regarding the effects of fat supplementation on the risk of necrotising enterocolitis or neurodevelopmental outcomes.,rephrase,"['No data were available regarding the effects of addition of extra fat on long-term growth, body fat, obesity, high blood sugar, or brain development.']",1,0.5714285714285714,3,7
CD000341,1,4,The one included trial suggests no evidence of an effect of fat supplementation of human milk on short-term growth and feeding intolerance in preterm infants.,split,"['Addition of extra fat to human milk for preterm infants showed no clear benefits with regards to short-term rates of weight gain, length gain, and head growth.', 'There was no evidence that the extra fat increased the risk of feeding intolerance.']",2,0.7142857142857143,4,7
CD000341,1,5,"However, the very low-quality evidence, small sample size, few events, and low precision diminishes our confidence that these results reflect the true effect of fat supplementation of human milk in preterm infants, and no long-term outcomes were reported.",rephrase,"['There was insufficient high-quality evidence on the benefits and harms of the addition of extra fat to human milk in preterm infants, and no long-term outcomes have been reported.']",4,0.8571428571428571,5,7
CD000341,1,6,"Further high-quality research should evaluate the effect on growth, neurodevelopmental and cardio-metabolic outcomes in the context of the development of multicomponent fortifiers.",delete,[],5,1.0,5,7
CD009955,0,0,"Along with the three RCTs included in the original version of this review (2013), we identified an additional five RCTs in this update, resulting in a total of eight RCTs involving 450 participants (180 (40%) females).",rephrase,"['We included three studies from the 2013 review and an additional five new studies from the current review, for a total of eight studies with 450 participants (180 women).']",0,0.08333333333333333,1,12
CD009955,0,1,The risk of selection bias in the included studies was low and the risk of performance bias high.,rephrase,['The number of participants in the included studies ranged between 17 and 131; the mean age of participants was between 63 and 71 years.'],1,0.16666666666666666,1,12
CD009955,0,2,"Six studies explored the effects of combined aerobic and resistance training; one explored the effects of combined aerobic and inspiratory muscle training; and one explored the effects of combined aerobic, resistance, inspiratory muscle training and balance training.",rephrase,"['Six studies explored the effects of combined aerobic and strengthening exercises; one explored the effects of combined aerobic exercise and inspiratory muscle training; and one explored the effects of combined aerobic exercise, strengthening exercise inspiratory muscle training and balance training.']",2,0.25,2,12
CD009955,0,3,"On completion of the intervention period, compared to the control group, exercise capacity expressed as the peak rate of oxygen uptake (VO2peak) and six-minute walk distance (6MWD) was greater in the intervention group (VO2peak: MD 2.97 mL/kg/min, 95% confidence interval (CI) 1.93 to 4.02 mL/kg/min, 4 studies, 135 participants, moderate-certainty evidence; 6MWD: MD 57 m, 95% CI 34 to 80 m, 5 studies, 182 participants, high-certainty evidence).",delete,[],3,0.3333333333333333,2,12
CD009955,0,4,One adverse event (hip fracture) related to the intervention was reported in one of the included studies.,rephrase,['One adverse event (hip fracture) related to the intervention was reported in one study.'],3,0.4166666666666667,3,12
CD009955,0,5,"The intervention group also achieved greater improvements in the physical component of general HRQoL (MD 5.0 points, 95% CI 2.3 to 7.7 points, 4 studies, 208 participants, low-certainty evidence); improved force-generating capacity of the quadriceps muscle (SMD 0.75, 95% CI 0.4 to 1.1, 4 studies, 133 participants, moderate-certainty evidence); and less dyspnoea (SMD −0.43, 95% CI −0.81 to −0.05, 3 studies, 110 participants, very low-certainty evidence).",delete,[],4,0.5,3,12
CD009955,0,6,"We observed uncertain effects on the mental component of general HRQoL, disease-specific HRQoL, handgrip force, fatigue, and lung function.",rephrase,"['The effect of exercise training after lung surgery on grip strength, fatigue, and lung function was uncertain.']",4,0.5833333333333334,3,12
CD009955,0,7,There were insufficient data to comment on the effect of exercise training on maximal inspiratory and expiratory pressures and feelings of anxiety and depression.,rephrase,['We found insufficient evidence for improvements in the strength of breathing muscles or feelings of anxiety and depression.'],5,0.6666666666666666,4,12
CD009955,0,8,Mortality was not reported in the included studies.,delete,[],6,0.75,4,12
CD009955,1,9,Exercise training increased exercise capacity and quadriceps muscle force of people following lung resection for NSCLC.,delete,[],6,0.8333333333333334,5,12
CD009955,1,10,Our findings also suggest improvements on the physical component score of general HRQoL and decreased dyspnoea.,delete,[],6,0.9166666666666666,5,12
CD009955,1,11,This systematic review emphasises the importance of exercise training as part of the postoperative management of people with NSCLC.,delete,[],6,1.0,5,12
CD013274,0,0,We found 182 studies that were eligible for inclusion.,delete,[],0,0.047619047619047616,1,21
CD013274,0,1,"From this group, we selected 33 studies to include in the final synthesis.",rephrase,['From these searches we selected 33 studies for in-depth analysis.'],0,0.09523809523809523,1,21
CD013274,0,2,These studies came from a wide range of countries including 28 from high-income countries and five from low- or middle-income countries (LMICs).,delete,[],1,0.14285714285714285,1,21
CD013274,1,3,Each of the studies included the experiences and views of consumers and/or health providers of partnering in formal group formats.,rephrase,"[""We searched databases for qualitative studies that explored consumers’ and health providers' views and experiences of partnering in formal group formats.""]",1,0.19047619047619047,1,21
CD013274,1,4,The results were divided into the following categories.,rephrase,['We grouped the findings into categories.'],2,0.23809523809523808,2,21
CD013274,2,5,"Contextual factors influencing partnerships: government policy, policy implementation processes and funding, as well as the organisational context of the health service, could facilitate or impede partnering (moderate level of confidence).",rephrase,"['government policy, processes, funding, and the organisational context of the health service influenced partnering.']",3,0.2857142857142857,2,21
CD013274,3,6,Consumer recruitment: consumer recruitment occurred in different ways and consumers managed the recruitment process in a minority of studies only (high level of confidence).,split,"['consumer recruitment occurred in various ways.', 'In a few studies consumers managed the recruitment process.']",4,0.3333333333333333,2,21
CD013274,3,7,"Recruiting a range of consumers who were reflective of the clinic's demographic population was considered desirable, particularly by health providers (high level of confidence).",rephrase,['Some people (particularly health providers) felt consumers should reflect the range of people who used the health service.'],6,0.38095238095238093,2,21
CD013274,3,8,Some health providers perceived that individual consumers' experiences were not generalisable to the broader population whereas consumers perceived it could be problematic to aim to represent a broad range of community views (high level of confidence).,split,"['Some health providers thought that the experience of some consumers did not reflect the broader population.', 'Consumers sometimes found it difficult to represent a broad range of community views.']",7,0.42857142857142855,3,21
CD013274,4,9,Partnership dynamics and processes: positive interpersonal dynamics between health providers and consumers facilitated partnerships (high level of confidence).,rephrase,['positive relationships between health providers and consumers improved \xa0partnerships.'],9,0.47619047619047616,3,21
CD013274,4,10,"However, formal meeting formats and lack of clarity about the consumer role could constrain consumers’ involvement (high level of confidence).",rephrase,['Formal meetings and being unclear about the consumer role could limit consumers’ involvement.'],10,0.5238095238095238,3,21
CD013274,4,11,"Health providers’ professional status, technical knowledge and use of jargon were intimidating for some consumers (high level of confidence) and consumers could feel their experiential knowledge was not valued (moderate level of confidence).",split,"['Health providers’ professional status, technical knowledge, and use of jargon could be intimidating for consumers.', 'Consumers sometimes felt their knowledge was not valued.']",11,0.5714285714285714,3,21
CD013274,4,12,"Consumers could also become frustrated when health providers dominated the meeting agenda (moderate level of confidence) and when they experienced token involvement, such as a lack of decision-making power (high level of confidence)
Perceived impacts on partnership participants: partnering could affect health provider and consumer participants in both positive and negative ways (high level of confidence).",rephrase,"['Consumers could become frustrated when they lacked decision-making power, and when health providers dominated the meeting agenda.']",13,0.6190476190476191,4,21
CD013274,5,13,"Perceived impacts on health service planning, delivery and evaluation: partnering was perceived to improve the person-centredness of health service culture (high level of confidence), improve the built environment of the health service (high level of confidence), improve health service design and delivery e.g. facilitate 'out of hours' services or treatment closer to home (high level of confidence), enhance community ownership of health services, particularly in LMICs (moderate level of confidence), and improve consumer involvement in strategic decision-making, under certain conditions (moderate level of confidence).",delete,[],14,0.6666666666666666,4,21
CD013274,5,14,There was limited evidence suggesting partnering may improve health service evaluation (very low level of confidence).,rephrase,"['However, one finding that showed people perceived formal partnerships improved health service evaluation, was rated as ""very low"" confidence because it was based on weaker evidence.']",14,0.7142857142857143,4,21
CD013274,6,15,Best practice principles for formal partnering to promote person-centred care were developed from these findings.,rephrase,['Best practice principles for partnering in formal group formats were developed from the findings.'],15,0.7619047619047619,4,21
CD013274,6,16,The principles were developed collaboratively with the Stakeholder Panel and included leadership and health service culture; diversity; equity; mutual respect; shared vision and regular communication; shared agendas and decision-making; influence and sustainability.,rephrase,['Principles included leadership and health service culture; diversity; equity; mutual respect; shared vision and regular communication; shared agendas and decision-making; influence and sustainability.'],16,0.8095238095238095,5,21
CD013274,7,17,Successful formal group partnerships with consumers require health providers to continually reflect and address power imbalances that may constrain consumers' participation.,delete,[],17,0.8571428571428571,5,21
CD013274,7,18,"Such imbalances may be particularly acute in recruitment procedures, meeting structure and content and decision-making processes.",delete,[],17,0.9047619047619048,5,21
CD013274,7,19,"Formal group partnerships were perceived to improve the physical environment of health services, the person-centredness of health service culture and health service design and delivery.",delete,[],17,0.9523809523809523,5,21
CD013274,7,20,"Implementing the best practice principles may help to address power imbalances, strengthen formal partnering, improve the experiences of consumers and health providers and positively affect partnership outcomes.",delete,[],17,1.0,5,21
CD011240,0,0,We identified 4245 possible studies from the initial search.,delete,[],0,0.0625,1,16
CD011240,0,1,"Of those studies, four studies (256 participants) met the inclusion criteria.",rephrase,['Four randomized controlled studies met the inclusion criteria for this review (involving 256 adults).'],0,0.125,1,16
CD011240,0,2,One more study is awaiting classification.,ignore,['One more study is awaiting classification.'],1,0.1875,1,16
CD011240,0,3,"Studies were, conducted in single-centre surgical and mixed medical-surgical ICUs.",rephrase,"['These studies were conducted in adult surgical and mixed medical-surgical ICUs, and compared BIS monitoring with various measures for CA.']",2,0.25,2,16
CD011240,0,4,BIS monitor was used to assess the level of sedation in the intervention arm in all the studies.,rephrase,"['For one study, the BIS monitoring devices manufacturer provided equipment.']",3,0.3125,2,16
CD011240,0,5,"In the control arm, the sedation assessment tools for CA included the Sedation-Agitation Scale (SAS), Ramsay Sedation Scale (RSS) or subjective CA utilizing traditional clinical signs (heart rate, blood pressure, conscious level and pupillary size).",delete,[],4,0.375,2,16
CD011240,0,6,"Only one study was classified as low risk of bias, the other three studies were classified as high risk.",delete,[],4,0.4375,3,16
CD011240,1,7,There was no evidence of a difference in one study (N = 50) that measured ICU LOS (Median (Interquartile Range IQR) 8 (4 to 14) in the CA group; 12 (6 to 18) in the BIS group; low-quality evidence).There was little or no effect on the duration of mechanical ventilation (MD -0.02 days (95% CI -0.13 to 0.09; 2 studies; N = 155; I2 = 0%; low-quality evidence)).,rephrase,"['With BIS monitoring, we found no significant differences in ICU length of stay (one study, 50 adults), duration of ventilation (two studies, 155 adults) and the risk of adverse events (one study, 105 adults) compared with CA.']",4,0.5,3,16
CD011240,1,8,"Adverse events were reported in one study (N = 105) and the effects on restlessness after suction, endotracheal tube resistance, pain tolerance during sedation or delirium after extubation were uncertain due to very low-quality evidence.",delete,[],5,0.5625,3,16
CD011240,1,9,Clinically relevant adverse events such as self-extubation were not reported in any study.,split,"['Clinically relevant adverse events, for example, accidental self-removal of the breathing tube, were not reported.', 'were reported in any of the studies.']",5,0.625,4,16
CD011240,1,10,Three studies reported the amount of sedative agents used.,delete,[],7,0.6875,4,16
CD011240,1,11,We could not measure combined difference in the amount of sedative agents used because of different sedation protocols and sedative agents used in the studies.,rephrase,['We could not measure combined difference in amount of sedative use because of the different sedation protocols and sedatives used.'],7,0.75,4,16
CD011240,1,12,GRADE quality of evidence was very low.,rephrase,"[""The findings of our review are from a limited number of studies which provided 'low to very low' GRADE quality of evidence.""]",8,0.8125,5,16
CD011240,1,13,No study reported other secondary outcomes of interest for the review.,rephrase,"['None of the other outcomes of interest for the review, for example, death, ventilator-associated pneumonia, quality of life etc.']",9,0.875,5,16
CD011240,2,14,We found insufficient evidence about the effects of BIS monitoring for sedation in critically ill mechanically ventilated adults on clinical outcomes or resource utilization.,rephrase,['The authors of this review conclude that we found insufficient evidence about the effects of BIS monitoring compared with CA of sedation in critically ill adults who were on a ventilator.'],10,0.9375,5,16
CD011240,2,15,The findings are uncertain due to the low- and very low-quality evidence derived from a limited number of studies.,delete,[],11,1.0,5,16
CD007210,0,0,We included two trials involving 189 participants.,rephrase,"['The review authors searched the literature and identified two controlled trials from the USA that involved 187 heroin addicts, aged 14 to 21 years; the participants were treated as outpatients.']",0,0.058823529411764705,1,17
CD007210,0,1,"One study, with 35 participants, compared methadone with levo-alpha-acetylmethadol (LAAM) for maintenance treatment lasting 16 weeks, after which patients were detoxified.",split,"['One study of 37 participants compared methadone with levo-alpha-acetylmethadol (LAAM) for maintenance treatment.', 'After 16 weeks of maintenance treatment the adolescents were detoxified.']",1,0.11764705882352941,1,17
CD007210,0,2,"The other study, with 154 participants, compared maintenance treatment with buprenorphine-naloxone and detoxification with buprenorphine.",rephrase,['The second trial of 150 adolescents compared buprenorphine and naloxone as maintenance treatment for nine weeks followed by tapered doses for up to 12 weeks with buprenorphine detoxification over 14 days.'],3,0.17647058823529413,1,17
CD007210,0,3,We did not perform meta-analysis because the two studies assessed different comparisons.,delete,[],4,0.23529411764705882,2,17
CD007210,1,4,"In the study comparing methadone and LAAM, the authors declared that there was no difference in the use of a substance of abuse or social functioning (data not shown).",rephrase,['In the first trial methadone and LAAM led to similar improvements in social functioning.'],4,0.29411764705882354,2,17
CD007210,1,5,The quality of the evidence was very low.,rephrase,['The quality of the evidence was very low for the comparison between methadone and LAAM and low for the comparison between buprenorphine detoxification and buprenorphine maintenance.'],5,0.35294117647058826,2,17
CD007210,1,6,"No side effects, such as nausea, vomiting, constipation, weakness or fatigue, were reported by study participants.",rephrase,['No side effects were reported.'],6,0.4117647058823529,3,17
CD007210,2,7,"In the comparison between buprenorphine maintenance and buprenorphine detoxification, maintenance treatment appeared to be more efficacious in retaining patients in treatment (drop-out risk ratio (RR) 0.37; 95% confidence interval (CI) 0.26 to 0.54), but not in reducing the number of patients with a positive urine test at the end of the study (RR 0.97; 95% CI 0.78 to 1.22).",rephrase,['In the second trial the maintenance treatment seemed to be more effective in retaining patients in treatment but not in reducing the use of drugs of abuse.'],7,0.47058823529411764,3,17
CD007210,2,8,"Self reported opioid use at one-year follow-up was significantly lower in the maintenance group, even though both groups reported a high level of opioid use (RR 0.73; 95% CI 0.57 to 0.95).",merge,"['At one-year follow-up, self reported opioid use was clearly less in the maintenance group and more adolescents were enrolled in other addiction programmes.']",8,0.5294117647058824,3,17
CD007210,2,9,More patients in the maintenance group were enrolled in other addiction treatment programmes at 12-month follow-up (RR 1.33; 95% CI 0.94 to 1.88).,none,[],8,0.5882352941176471,3,17
CD007210,2,10,The quality of the evidence was low.,delete,[],9,0.6470588235294118,4,17
CD007210,2,11,No serious side effects attributable to buprenorphine-naloxone were reported by study participants and no patients were removed from the study due to side effects.,rephrase,['No participants left the study because of side effects.'],9,0.7058823529411765,4,17
CD007210,2,12,"The most common side effect was headache, which was reported by 16% to 21% of patients in both groups",rephrase,['The most common side effect in both groups was headache.'],10,0.7647058823529411,4,17
CD007210,3,13,It is difficult to draft conclusions on the basis of only two trials.,rephrase,['It is difficult to draw conclusions about the use of maintenance pharmacological interventions from only two trials.'],11,0.8235294117647058,5,17
CD007210,3,14,One of the possible reasons for the lack of evidence could be the difficulty of conducting trials with young people for practical and ethical reasons.,rephrase,['Conducting trials with young people may be difficult for both practical and ethical reasons.'],12,0.8823529411764706,5,17
CD007210,4,15,There is an urgent need for further randomised controlled trials comparing maintenance treatment with detoxification treatment or psychosocial treatment alone before carrying out studies that compare different pharmacological maintenance treatments.,delete,[],13,0.9411764705882353,5,17
CD007210,4,16,"These studies should have long follow-up and measure relapse rates after the end of treatment and social functioning (integration at school or at work, family relationships).",delete,[],13,1.0,5,17
CD005077,0,0,Included are three randomised controlled trials involving 184 people (predominantly active young men) with unidirectional anterior shoulder instability generally following a traumatic event.,rephrase,"['Only three randomised controlled trials, involving a total of 184 people with anterior shoulder instability that usually followed a traumatic event, are included in the review.']",0,0.125,1,8
CD005077,0,1,"All three trials compared arthroscopic versus open surgery, generally involving the repair of Bankart lesions.",rephrase,"['All three trials compared arthroscopic (key hole) surgery with open surgery, generally involving the repair of Bankart lesions.']",1,0.25,2,8
CD005077,0,2,The three trials were inadequately reported but appeared well-conducted with minimum follow-ups of two years.,ignore,['All three trials were inadequately reported but appeared well-conducted with minimum follow-ups of two years.'],2,0.375,2,8
CD005077,1,3,"Pooled results showed no statistically significant difference between the two groups in recurrent instability or re-injury (7/92 versus 5/85, risk ratio (RR) 0.89, 95% confidence interval (CI) 0.09 to 8.72; random-effects model), in subsequent instability-related surgery (RR 0.66, 95% CI 0.05 to 8.97; random-effects model) or surgery for all reasons (RR 0.55, 95% CI 0.04 to 7.18; random-effects model).",rephrase,"['The limited data available showed no statistically significant differences between the two groups in recurrent instability or re-injury, in subsequent instability-related surgery or surgery for all reasons.']",3,0.5,3,8
CD005077,1,4,"For other outcomes, including shoulder function, there were either no statistically significant differences between the two groups or the differences were clinically insignificant where statistically significant differences occurred.",rephrase,"['Data for other outcomes, including shoulder function, also showed no significance differences between the two groups.']",4,0.625,4,8
CD005077,2,5,There is insufficient evidence from randomised trials comparing arthroscopic with open surgery for treating anterior shoulder instability.,rephrase,['In all the available evidence was insufficient to draw conclusions and further well designed randomised controlled trials are required.'],5,0.75,4,8
CD005077,2,6,Further research is needed on this subject and for other surgical interventions.,delete,[],6,0.875,5,8
CD005077,2,7,"Sufficiently powered, good quality, well reported randomised controlled trials with validated outcome measures and long-term follow up are required.",delete,[],6,1.0,5,8
CD005494,0,0,"For this update, we identified two additional studies, for a total of five eligible trials that enrolled 166 infants.",split,"['We identified five studies that evaluated effects of sildenafil: three studies that compared sildenafil with placebo (no sildenafil); one that compared sildenafil with other medication (magnesium sulphate); and one that used sildenafil in combination with another medicine (nitric oxide).', 'These studies included 166 newborns and were conducted in Colombia, Mexico, Turkey, and Qatar.']",0,0.09090909090909091,1,11
CD005494,0,1,The methodological quality of these studies ranged from low to high risk of bias.,delete,[],2,0.18181818181818182,1,11
CD005494,0,2,"Three studies were performed in resource-limited settings, where iNO and high-frequency ventilation were not available at the time of the study.",delete,[],2,0.2727272727272727,2,11
CD005494,0,3,"One study compared sildenafil versus active controls, and another study evaluated sildenafil as adjuvant therapy to iNO.",delete,[],2,0.36363636363636365,2,11
CD005494,0,4,"When comparing sildenafil with placebo, investigators noted significant reduction in mortality in the sildenafil alone group (three studies, 77 participants; typical RR 0.20, 95% confidence interval (CI) 0.07 to 0.56; I2 = 0% - none; typical RR -0.36, 95% CI -0.53 to -0.18; number needed to treat for an additional beneficial outcome 3, 95% CI 2 to 6; I2 = 39% - low).",split,"['Three studies that compared sildenafil and placebo (no sildenafil) reported that sildenafil reduced the number of deaths.', 'Studies that compared sildenafil against another medication or that used another treatment with sildenafil described no significant reduction in the number of deaths.']",2,0.45454545454545453,3,11
CD005494,0,5,"Trials reported no significant differences in mortality upon comparison of the sildenafil group versus the active control group (one study, 65 participants; typical RR 0.55, 95% CI 0.05 to 5.75), or when iNO was administered to both groups (one study, 24 participants; typical RR 1.27, 95% CI 0.26 to 6.28).",delete,[],4,0.5454545454545454,3,11
CD005494,0,6,"Physiological parameters of oxygenation (oxygenation index, partial pressure of oxygen in arterial blood (PaO2)) suggested steady improvement after the first dose of sildenafil.",delete,[],4,0.6363636363636364,4,11
CD005494,0,7,None of the included trials identified any clinically important side effects.,rephrase,['None of the five included studies reported safety concerns.'],4,0.7272727272727273,4,11
CD005494,0,8,We rated the quality of evidence as low to very low owing to imprecision related to small sample size and unclear methodological features.,split,"['The quality of evidence for reducing mortality or improving respiratory parameters was low owing to the small number of included studies and the small number of babies evaluated.', 'Some of the included studies have methodological issues, resulting in low to very low quality of evidence.']",5,0.8181818181818182,5,11
CD005494,1,9,"Sildenafil used for treatment of pulmonary hypertension has potential for reducing mortality and improving oxygenation in neonates, especially in resource-limited settings where iNO is not available.",rephrase,['Sildenafil may be useful in settings where other treatment approaches are not available.'],7,0.9090909090909091,5,11
CD005494,1,10,"However, large-scale randomised trials comparing sildenafil versus active controls (other pulmonary vasodilators) and providing follow-up for survivors are needed to assess the comparative effectiveness and long-term safety of sildenafil versus other pulmonary vasodilators.",rephrase,"['However, additional studies are needed to compare sildenafil against existing treatment in a resourceful environment to assess its effectiveness and safety.']",8,1.0,5,11
CD012920,0,0,We identified one ongoing study and two unpublished studies that met the inclusion criteria for the review.,ignore,"['We identified one ongoing study and two unpublished studies, which met the inclusion criteria for the review.']",0,0.14285714285714285,1,7
CD012920,0,1,"Due to a lack of study data, we could not compare the outcomes of hybrid repair to conventional open repair for aortic arch dissection.",split,"['We searched medical databases for clinical trials that compared the use of a hybrid technique versus open surgical technique for people who suffered from arterial dissection of the aortic arch (last search February 2021).', 'However, due to a lack of published study data, we could not compare the outcomes of hybrid repair to conventional open repair for aortic arch dissection.']",1,0.2857142857142857,2,7
CD012920,1,2,This review revealed one ongoing RCT and two unpublished RCTs evaluating hybrid versus conventional open repair for aortic arch surgery.,delete,[],3,0.42857142857142855,3,7
CD012920,1,3,"Observational data suggest that hybrid repair for aortic arch dissection could potentially be favourable, but conclusions can not be drawn from these studies, which are highly selective, and are based on the clinical status of the patient, the presence of comorbidities and the skills of the operators.",delete,[],3,0.5714285714285714,3,7
CD012920,1,4,"However, a conclusion about its definitive benefit over conventional open surgical repair cannot be made from this review without published RCTs or CCTs.",delete,[],3,0.7142857142857143,4,7
CD012920,2,5,"Future RCTs or CCTs need to have adequate sample sizes and follow-up, and assess clinically-relevant outcomes, in order to determine the optimal treatment for people with aortic arch dissection.",ignore,"['Future studies need to have adequate sample sizes and follow-up, and assess clinically relevant outcomes, in order to determine the best treatment for people with aortic arch dissection.']",3,0.8571428571428571,5,7
CD012920,2,6,"It must be noted that this may not be feasible, due to the reasons mentioned.",ignore,['It must be noted that this may not be feasible due to the reasons mentioned.'],4,1.0,5,7
CD007614,0,0,"We included 15 trials, with a total of 755 participants for analysis in the review.",rephrase,['We searched scientific sources to identify eligible trials and found 15 studies with 755 patients.'],0,0.05,1,20
CD007614,0,1,Fourteen trials compared prophylactic use of FFP against no FFP.,merge,"['Fourteen studies compared prophylactic FFP against no FFP and one study compared two types of FFP, both used therapeutically.']",1,0.1,1,20
CD007614,0,2,One study compared therapeutic use of two types of plasma.,none,[],1,0.15,1,20
CD007614,0,3,"The timing of intervention varied, including FFP transfusion at the time of heparin neutralisation and stopping cardiopulmonary bypass (CPB) (seven trials), with CPB priming (four trials), after anaesthesia induction (one trial) and postoperatively (two trials).",delete,[],2,0.2,1,20
CD007614,0,4,Twelve trials excluded patients having emergency surgery and nine excluded patients with coagulopathies.,delete,[],2,0.25,2,20
CD007614,1,5,"Overall the trials were small, with only four reporting an a priori sample size calculation.",delete,[],2,0.3,2,20
CD007614,1,6,No trial was powered to determine changes in mortality as a primary outcome.,rephrase,['Our primary outcome was death within 30 days after surgery.'],2,0.35,2,20
CD007614,1,7,"There was either high risk of bias, or unclear risk, in the majority of trials included in this review.",ignore,"['There was either high risk of bias, or unclear risk, in the majority of trials included in this review.']",3,0.4,2,20
CD007614,2,8,There was no difference in the number of deaths between the intervention arms in the six trials (with 287 patients) reporting mortality (very low quality evidence).,rephrase,['Six trials (with 287 patients) looked at this outcome and found no clear difference in mortality between the treatment arms but the quality of the evidence was very low.'],4,0.45,3,20
CD007614,2,9,There was also no difference in blood loss in the first 24 hours for neonatal/paediatric patients (four trials with 138 patients; low quality evidence): mean difference (MD) -1.46 ml/kg (95% confidence interval (CI) -4.7 to 1.78 ml/kg); or adult patients (one trial with 120 patients): MD -12.00 ml (95% CI -101.16 to 77.16 ml).,rephrase,"['There was also no difference in the amount of blood lost in the first 24 hours following surgery (measured in five trials; low quality evidence), or the risk of returning to theatre for a reoperation (measured in eight trials; moderate quality evidence).']",5,0.5,3,20
CD007614,3,10,Transfusion with FFP was inferior to control for preventing patients receiving any red cell transfusion: Peto odds ratio (OR) 2.57 (95% CI 1.30 to 5.08; moderate quality evidence).,rephrase,"['Patients who had FFP received significantly more red blood cells, suggesting that FFP may not be effective in this setting (moderate quality evidence).']",6,0.55,3,20
CD007614,3,11,There was a difference in prothrombin time within two hours of FFP transfusion in eight trials (with 210 patients; moderate quality evidence) favouring the FFP arm: MD -0.71 seconds (95% CI -1.28 to -0.13 seconds).,rephrase,['Measurement of a blood test used to assess blood clotting (prothrombin time) was reported in eight trials and showed that clotting was improved by the use of prophylactic FFP (moderate quality evidence).'],7,0.6,3,20
CD007614,3,12,There was no difference in the risk of returning to theatre for reoperation (eight trials with 398 patients; moderate quality evidence): Peto OR 0.81 (95% CI 0.26 to 2.57).,delete,[],8,0.65,4,20
CD007614,3,13,Only one included study reported adverse events as an outcome and reported no significant adverse events following FFP transfusion.,rephrase,['Only one included study reported adverse events as an outcome and reported no adverse events due to FFP transfusion.'],8,0.7,4,20
CD007614,4,14,This review has found no evidence to support the prophylactic administration of FFP to patients without coagulopathy undergoing elective cardiac surgery.,rephrase,['The review found no evidence for the efficacy of FFP for the prevention of bleeding in heart surgery and it found some evidence of an increased overall need for red cell transfusion in those treated with FFP.'],9,0.75,4,20
CD007614,4,15,There was insufficient evidence about treatment of patients with coagulopathies or those who are undergoing emergency surgery.,delete,[],10,0.8,4,20
CD007614,4,16,"There were no reported adverse events attributable to FFP transfusion, although there was a significant increase in the number of patients requiring red cell transfusion who were randomised to FFP.",rephrase,['There were no reported adverse events due to FFP transfusion.'],10,0.85,5,20
CD007614,4,17,"Variability in outcome reporting between trials precluded meta-analysis for many outcomes across all trials, and there was evidence of a high risk of bias in most of the studies.",delete,[],11,0.9,5,20
CD007614,4,18,"Further adequately powered studies of FFP, or comparable pro-haemostatic agents, are required to assess whether larger reductions in prothrombin time translate into clinical benefits.",delete,[],11,0.95,5,20
CD007614,4,19,Overall the evidence from randomised controlled trials for the safety and efficacy of prophylactic transfusion of FFP for cardiac surgery is insufficient.,rephrase,['Overall the evidence for the safety and efficacy of prophylactic FFP for cardiac surgery is insufficient.'],11,1.0,5,20
CD009211,0,0,Of the 556 potentially relevant studies only two met the inclusion criteria.,delete,[],0,0.07142857142857142,1,14
CD009211,0,1,One of those was excluded as the trial was abandoned prematurely and reported only preliminary results.,delete,[],0,0.14285714285714285,1,14
CD009211,0,2,The only analysed trial enrolled 551 participants receiving first-line chemotherapy (methotrexate) followed by whole brain radiotherapy (WBR) or receiving chemotherapy only (methotrexate followed by cytarabine in case of incomplete response).,rephrase,"['We included only one study that enrolled 551 participants and treated one half with methotrexate followed by WBR, and the other half with methotrexate alone.']",0,0.21428571428571427,2,14
CD009211,0,3,"In this non-inferiority trial, the intention-to-treat (ITT) population consisted of 411 participants and the per-protocol (PP) population of 318 participants.",delete,[],1,0.2857142857142857,2,14
CD009211,0,4,We judged the potential for risk of bias in this open-label study as moderate.,rephrase,"['We consider the quality of the evidence body as moderate to low, as we included only one trial with a small number of participants.']",1,0.35714285714285715,2,14
CD009211,1,5,The estimated effect of chemotherapy plus WBR on survival was similar to that with chemotherapy alone but due to a wide CI we could not rule out the superiority of either therapy.,rephrase,"['When we analysed the data regarding the effect of chemotherapy plus WBR or chemotherapy alone on overall survival, the results were imprecise and either treatment could have been superior to the other.']",2,0.42857142857142855,3,14
CD009211,1,6,"This applied to both the ITT population (HR 1.01, 95% CI 0.79 to 1.30; P = 0.94) and the PP population (HR 1.06, 95% CI 0.80 to 1.40; P = 0.71) (moderate-quality evidence).",delete,[],3,0.5,3,14
CD009211,1,7,"Due to the low number of participants and a risk of detection bias we found low-quality evidence for an improvement in progression-free survival in participants in the ITT population receiving WBR in addition to chemotherapy (HR 0.79, 95% CI 0.63 to 0.99; P = 0.041).",delete,[],3,0.5714285714285714,3,14
CD009211,1,8,"An improvement in PFS was also observed with WBR plus chemotherapy in participants in the PP population, but the CI was slightly wider and the result not significant (HR 0.82,95% CI 0.64 to 1.07; P = 0.14).",delete,[],3,0.6428571428571429,4,14
CD009211,1,9,Treatment-related mortality and health-related quality of life were not evaluated.,rephrase,['The authors did not analyse treatment-related mortality.We also looked at whether treatment resulted in any damage to healthy brain tissue during treatment.'],3,0.7142857142857143,4,14
CD009211,1,10,"Treatment-related neurotoxicity was assessed clinically in 79 participants, revealing signs of neurotoxicity in 49% of those receiving chemotherapy plus radiotherapy and in 26% of those receiving chemotherapy only (RR 1.85, 95% CI 0.98 to 3.48; P = 0.054) (very-low-quality evidence).",delete,[],4,0.7857142857142857,4,14
CD009211,2,11,"In summary, the currently available evidence (one RCT) is not sufficient to conclude that WBR plus chemotherapy and chemotherapy alone have similar effects on overall survival in people with PCNSL.",ignore,"['In summary, the currently available evidence (one randomised controlled trial) is not sufficient to conclude that WBR plus chemotherapy and chemotherapy alone have similar effects on overall survival in people with PCNSL.']",4,0.8571428571428571,5,14
CD009211,2,12,"The findings suggest that the addition of radiotherapy (WBR) to chemotherapy may increase progression-free survival, but may also increase the incidence of neurotoxicity compared to chemotherapy only (methotrexate monotherapy).",rephrase,"['The addition of WBR to chemotherapy may increase progression-free survival, but could possibly also increase levels of toxic effects on the brain.']",5,0.9285714285714286,5,14
CD009211,2,13,"As the role of chemoradiotherapy in the treatment of PCNSL remains unclear, further prospective, randomised trials are needed before definitive conclusions can be drawn.",rephrase,['Further prospective randomised trials are needed before definitive conclusions can be drawn about the role of adding radiotherapy to chemotherapy in the treatment of PCNSL.'],6,1.0,5,14
CD001505,0,0,The searches identified 17 trials; four are included (287 participants aged five to 39 years; maximum follow-up of four years) and one is currently awaiting classification pending publication of the full trial report and two are ongoing.,rephrase,['We found 17 trials and included four of these with a total of 287 people aged five to 39 years; one further trial has not yet been published in full and two are still ongoing; we will assess these when we have more information.'],0,0.07142857142857142,1,14
CD001505,0,1,Three trials compared ibuprofen to placebo (two from the same center with some of the same participants); one trial assessed piroxicam versus placebo.,split,"['Three of the four included trials compared ibuprofen to a placebo; two of these trials were run in the same center and used some of the same people.', 'One trial compared a drug called piroxicam to placebo.']",1,0.14285714285714285,1,14
CD001505,1,2,"The three ibuprofen trials were deemed to have good or adequate methodological quality, but used various outcomes and summary measures.",rephrase,"['We thought the three ibuprofen trials had a good or adequate level of methodological quality with little risk of bias to the results, but used a range of different outcomes and summary measures.']",3,0.21428571428571427,2,14
CD001505,1,3,"Reviewers considered measures of lung function, nutritional status, radiological assessment of pulmonary involvement, intravenous antibiotic usage, hospital admissions, survival and adverse effects.",rephrase,"['We aimed to report on lung function, nutritional status, lung x-rays, how often intravenous antibiotics were needed, details about hospital admissions, survival and side effects.']",4,0.2857142857142857,2,14
CD001505,1,4,"Combined data from the two largest ibuprofen trials showed a lower annual rate of decline for lung function, % predicted forced expiratory volume in one second (FEV1), mean difference (MD) 1.32 (95% confidence interval (CI) 0.21 to 2.42) (moderate-quality evidence); forced vital capacity (FVC), MD 1.27 (95% CI 0.26 to 2.28) (moderate-quality evidence); forced expiratory flow (FEF25%-75%), MD 1.80 (95% CI 0.15 to 3.45).",rephrase,['We combined results from the two largest ibuprofen trials and showed that those taking ibuprofen had a lower annual rate of decline in lung function which was consistent across three lung function measurements.'],5,0.35714285714285715,2,14
CD001505,1,5,"The post hoc analysis of data from two trials split by age showed a slower rate of annual decline of FEV1 % predicted and FVC in the ibuprofen group in younger children, MD 1.41% (95% CI 0.03 to 2.80) (moderate-quality evidence) and MD 1.32% (95% CI 0.04 to 2.60) (moderate-quality evidence) respectively.",rephrase,['We then looked at these results split by age (even though we did not originally plan to do this) and found that two of the measurements showed a slower rate of annual decline in lung function in younger children.'],6,0.42857142857142855,3,14
CD001505,1,6,"Data from four trials demonstrated the proportion of participants with at least one hospitalization may be slightly lower in the ibuprofen group compared to placebo, Peto odds ratio 0.61 (95% CI 0.37 to 1.01) (moderate-quality evidence).",rephrase,"['Results from four trials showed that fewer participants in the ibuprofen group were admitted to hospital at least once compared to placebo, although it was not clear if the difference was just chance or not.']",7,0.5,3,14
CD001505,1,7,"In one trial, long-term use of high-dose ibuprofen was associated with reduced intravenous antibiotic usage, improved nutritional and radiological pulmonary status.",rephrase,"['In one trial, people taking a long-term high dose of ibuprofen were less likely to need intravenous antibiotics, had better nutritional status and healthier lungs as seen by X-ray.']",8,0.5714285714285714,3,14
CD001505,1,8,"No major adverse effects were reported, but the power of the trials to identify clinically important differences in the incidence of adverse effects was low.",rephrase,"['No major side effects were reported in the trials, but they had not been designed to show differences in the rates of side effects.']",9,0.6428571428571429,4,14
CD001505,2,9,We did not have any concerns with regards to risk of bias for the trial comparing piroxicam to placebo.,ignore,['We did not have any concerns with regards to risks of bias for the trial comparing piroxicam to placebo.'],10,0.7142857142857143,4,14
CD001505,2,10,"However, the trial did not report many data in a form that we could analyze in this review.",rephrase,['The trial of the drug piroxicam did not report many results in a form that we could analyse in the review.'],11,0.7857142857142857,4,14
CD001505,2,11,No data were available for the review's primary outcome of lung function; available data for hospital admissions showed no difference between the groups.,split,"['We did not have any results for our main outcome of lung function.', 'The only results we had reported no difference between the piroxicam group and the placebo group for the number of hospital admissions.']",12,0.8571428571428571,5,14
CD001505,2,12,No analyzable data were available for any other review outcome.,delete,[],14,0.9285714285714286,5,14
CD001505,3,13,"High-dose ibuprofen can slow the progression of lung disease in people with cystic fibrosis, especially in children, which suggests that strategies to modulate lung inflammation can be beneficial for people with cystic fibrosis.",rephrase,"['To summarize, we found evidence showing that a high dose of a non-steroidal anti-inflammatory drug, most notably ibuprofen, may slow the progression of lung damage in people with cystic fibrosis, especially in younger people.']",14,1.0,5,14
CD007383,0,0,"Two studies are included, which involved a total of 114 people with penetrating abdominal injuries.",rephrase,"['Both studies included people with penetrating abdominal injuries, from having been stabbed.']",0,0.08333333333333333,1,12
CD007383,0,1,"Both studies are at moderate risk of bias because the randomisation methods are not fully described, and the original study protocols are no longer available.",rephrase,"['The review authors considered both studies to be at moderate risk of bias, since only part of the randomisation process was described and the study protocols were not available to enable full assessment of overall quality.']",1,0.16666666666666666,1,12
CD007383,0,2,"The studies were undertaken in Finland between 1992 and 2002, by the same two researchers.",delete,[],2,0.25,2,12
CD007383,1,3,"In one study, 51 people were randomised to surgery or an observation protocol.",rephrase,['In one study (1992-1994) people received either an observation protocol or mandatory surgery.'],2,0.3333333333333333,2,12
CD007383,1,4,None of the participants in the study died.,rephrase,"['None of the people in the study died, and there was no difference in the number of people with medical complications between the study groups.']",3,0.4166666666666667,3,12
CD007383,1,5,Seven people had complications: 5 (18.5%) in the surgical group and 2 (8.3%) in the observation group; the difference was not statistically significant (P = 0.42; Fischer's exact).,delete,[],4,0.5,3,12
CD007383,1,6,"Among the 27 people who had surgery, 6 (22.2%) surgeries were negative laparotomies, and 15 (55.6%) were non-therapeutic.",delete,[],4,0.5833333333333334,3,12
CD007383,2,7,"In the other study, 63 people were randomised to diagnostic laparoscopy (surgery) or an observation protocol.",rephrase,['In the other study (1997-2002) people received an observation protocol or diagnostic laparoscopy (minimal surgery).'],4,0.6666666666666666,4,12
CD007383,2,8,There were no deaths and no unnecessary surgeries in either group.,split,"['No one died in either group, and there were no differences between the groups in the number of surgeries needed.', 'There were no unnecessary surgeries in either group.']",5,0.75,4,12
CD007383,2,9,Four people did not receive the intervention they were assigned.,delete,[],7,0.8333333333333334,5,12
CD007383,2,10,There was no difference in therapeutic operations between the two groups: 3 of 28 in the diagnostic laparoscopy group versus 1 of 31 in the observation protocol group (P = 0.337).,delete,[],7,0.9166666666666666,5,12
CD007383,3,11,"Based on the findings of 2 studies involving a total of 114 people, there is no evidence to support the use of surgery over an observation protocol for people with penetrating abdominal trauma who have no signs of peritonitis and are stable.",rephrase,"['Based on the findings of these two small studies, there is no evidence to support the use of surgical management over an observation protocol for people with abdominal trauma showing no signs of bleeding or infection.']",7,1.0,5,12
CD010010,0,0,We identified six placebo-controlled randomised controlled trials with a total of 557 participants.,split,"['We identified six studies with a total of 557 participants.', 'The studies were blinded, placebo-controlled randomised trials that tested how effective the NTHi vaccine is in preventing infections in people over 18 years of age with COPD or chronic bronchitis.']",0,0.058823529411764705,1,17
CD010010,0,1,"These trials investigated the efficacy of enteric-coated, killed preparations of H influenzae in populations prone to recurrent acute exacerbations of chronic bronchitis or COPD.",delete,[],2,0.11764705882352941,1,17
CD010010,0,2,"The vaccine preparation and immunisation regimen in all trials consisted of at least three courses of formalin-killed H influenzae in enteric-coated tablets taken at intervals (e.g. days 0, 28, and 56).",rephrase,"['In all six trials, both the vaccine and placebo group were given at least three courses of tablets at regular intervals over a period of three to 12 months.']",2,0.17647058823529413,1,17
CD010010,0,3,Each course generally consisted of two tablets taken after breakfast over three consecutive days.,delete,[],3,0.23529411764705882,2,17
CD010010,0,4,In all cases the placebo groups took enteric-coated tablets containing glucose.,delete,[],3,0.29411764705882354,2,17
CD010010,0,5,"Risk of bias was moderate across the studies, namely due to the lack of information provided about methods and inadequate presentation of results.",rephrase,['The studies were well conducted with moderate risk of bias.'],3,0.35294117647058826,2,17
CD010010,1,6,"Meta-analysis of the oral NTHi vaccine showed a small, non-statistically significant reduction in the incidence of acute exacerbations of chronic bronchitis or COPD (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.57 to 1.10; P = 0.16).",rephrase,['The NTHi vaccine had no significant impact on reducing the number of acute exacerbations experienced by people with COPD.'],4,0.4117647058823529,3,17
CD010010,1,7,"There was no significant difference in mortality rate between the vaccine and placebo groups (odds ratio (OR) 1.62, 95% CI 0.63 to 4.12; P = 0.31).",rephrase,"['There was no significant difference in mortality rate between the vaccine and placebo groups, and the reported deaths in the vaccinated group were not attributed to the vaccine.']",5,0.47058823529411764,3,17
CD010010,2,8,We were unable to meta-analyse the carriage levels of NTHi in participants as each trial reported this result using different units and tools of measurement.,rephrase,"['Due to inconsistencies of measurement between the trials, we were not able to compare the studies against one another.']",6,0.5294117647058824,3,17
CD010010,2,9,"Four trials showed no significant difference in carriage levels, while two trials showed a significant decrease in carriage levels in the vaccinated group compared with the placebo group.",delete,[],7,0.5882352941176471,3,17
CD010010,3,10,Four trials assessed severity of exacerbations measured by requirement for antibiotics.,delete,[],7,0.6470588235294118,4,17
CD010010,3,11,"Three of these trials were comparable and when meta-analysed showed a statistically significant 80% increase in antibiotic courses per person in the placebo group (RR 1.81, 95% CI 1.35 to 2.44; P < 0.001).",delete,[],7,0.7058823529411765,4,17
CD010010,3,12,"There was no significant difference between the groups with regard to hospital admission rates (OR 0.96, 95% CI 0.13 to 7.04; P = 0.97).",delete,[],7,0.7647058823529411,4,17
CD010010,3,13,"Adverse events were reported in five trials but were not necessarily related to the vaccine; a point estimate is suggestive that they occurred more frequently in the vaccine group, however this result was not statistically significant (RR 1.43, 95% CI 0.70 to 2.92; P = 0.87).",rephrase,"['Five trials reported adverse effects, but there was no particular association with either the vaccine or placebo group.']",7,0.8235294117647058,5,17
CD010010,3,14,"Quality of life was not meta-analysed but was reported in two trials, with results at six months showing an improvement in quality of life in the vaccinated group (scoring at least two points better than placebo).",rephrase,"['Two trials studying quality of life found that vaccinated participants generally had a better quality of life, but these results were measured differently and so could not be compared.']",8,0.8823529411764706,5,17
CD010010,4,15,Analyses demonstrate that NTHi oral vaccination of people with recurrent exacerbations of chronic bronchitis or COPD does not yield a significant reduction in the number and severity of exacerbations.,rephrase,['We concluded after reviewing the relevant studies that the H influenzae vaccine taken orally in people with chronic bronchitis and COPD does not have a significant reduction in the number and severity of acute exacerbations.'],9,0.9411764705882353,5,17
CD010010,4,16,"Evidence was mixed, and the individual trials that showed a significant benefit of the vaccine are too small to advocate widespread oral vaccination of people with COPD.",delete,[],10,1.0,5,17
CD009933,0,0,A total of 431 participants undergoing elective laparoscopic cholecystectomy were randomised to formal patient education (215 participants) versus standard care (216 participants) in four trials.,split,"['We found four trials including 431 patients undergoing elective laparoscopic cholecystectomy who received either formal patient education (215 participants) or standard care (216 participants).', 'The choice of whether the patient received formal patient education or standard care was determined by a method similar to the toss of a coin in order to create comparable groups of patients.']",0,0.08333333333333333,1,12
CD009933,0,1,"The patient education included verbal education, multimedia DVD programme, computer-based multimedia programme, and PowerPoint presentation in the four trials.",rephrase,['The patient education included providing information by just talking to the patient but in a more formal way or by using various method of presentation.'],2,0.16666666666666666,1,12
CD009933,0,2,All the trials were of high risk of bias.,rephrase,['All the trials were of high risk of bias (faults in study design that can result in erroneous conclusions).'],3,0.25,2,12
CD009933,0,3,One trial including 212 patients reported mortality.,rephrase,['Only one trial including 212 participants reported deaths after surgery.'],4,0.3333333333333333,2,12
CD009933,0,4,There was no mortality in either group in this trial.,rephrase,['There were no deaths in either group in this trial.'],5,0.4166666666666667,3,12
CD009933,0,5,"None of the trials reported surgery-related morbidity, quality of life, proportion of patients discharged as day-procedure laparoscopic cholecystectomy, the length of hospital stay, return to work, or the number of unplanned visits to the doctor.",rephrase,"['None of the trials reported surgical complications, quality of life, percentage of patients discharged as day-procedure laparoscopic cholecystectomy, length of hospital stay, return to work, or the number of unplanned visits to the doctor.']",6,0.5,3,12
CD009933,0,6,"There were insufficient details to calculate the mean difference and 95% CI for the difference in pain scores at 9 to 24 hours (1 trial; 93 patients); and we did not identify clear evidence of an effect on patient knowledge (3 trials; 338 participants; SMD 0.19; 95% CI -0.02 to 0.41; very low quality evidence), patient satisfaction (2 trials; 305 patients; SMD 0.48; 95% CI -0.42 to 1.37; very low quality evidence), or patient anxiety (1 trial; 76 participants; SMD -0.37; 95% CI -0.82 to 0.09; very low quality evidence) between the two groups.",rephrase,"['There was no clear evidence of an effect on pain scores at 9 to 24 hours, patient knowledge, patient satisfaction, or patient anxiety associated with education.']",7,0.5833333333333334,3,12
CD009933,1,7,A total of 173 participants undergoing elective laparoscopic cholecystectomy were randomised to electronic consent with repeat-back (patients repeating back the information provided) (92 participants) versus electronic consent without repeat-back (81 participants) in one trial of high risk of bias.,rephrase,['A total of 173 participants undergoing elective laparoscopic cholecystectomy underwent patient education with repeat-back (patients repeating back the information provided) (92 participants) or patient education without repeat-back (81 participants) in one trial of high risk of bias.'],8,0.6666666666666666,4,12
CD009933,1,8,The only outcome reported in this trial was patient knowledge.,ignore,['The only outcome reported in this trial was patient knowledge.'],9,0.75,4,12
CD009933,1,9,The effect on patient knowledge between the patient education with repeat-back versus patient education without repeat-back groups was imprecise and based on 1 trial of 173 participants; SMD 0.07; 95% CI -0.22 to 0.37; very low quality evidence).,rephrase,['The results we found for the effect onpatient knowledge between the patient education with repeat-back and patient education without repeat-back groups were uncertain and we could not exclude possible benefits of either education or control.'],10,0.8333333333333334,5,12
CD009933,2,10,"Due to the very low quality of the current evidence, the effects of formal patient education provided in addition to the standard information provided by doctors to patients compared with standard care remain uncertain.",rephrase,"['Due to the very low quality of the current evidence, we are uncertain as to whether formal patient education provided in addition to the standard information provided by doctors has any benefit to patients.']",11,0.9166666666666666,5,12
CD009933,2,11,Further well-designed randomised clinical trials of low risk of bias are necessary.,rephrase,['Further well-designed randomised clinical trials are necessary.'],12,1.0,5,12
CD009400,0,0,Two RCTs (90 participants) were included.,delete,[],0,0.043478260869565216,1,23
CD009400,0,1,One trial assessed the efficacy and safety of Trichuris suis (T. suis) ova in patients with UC (n = 54).,delete,[],0,0.08695652173913043,1,23
CD009400,0,2,The other RCT was a phase one that assessed the safety and tolerability of T. suis ova in patients with CD (n = 36).,delete,[],0,0.13043478260869565,1,23
CD009400,0,3,The risk of bias in both studies was judged to be low.,delete,[],0,0.17391304347826086,1,23
CD009400,0,4,"In the UC study, during the 12-week study period, participants in the active arm received 2-weekly aliquots of 2500 T. suis eggs, added to 0.8 mL of saline; those in the placebo arm received 0.8 mL saline only.",rephrase,['One study compared twice weekly treatment with helminths (an 0.8 mL solution containing 2500 live eggs of the helminth Trichuris suis) for 12 weeks to a matching placebo (an 0.8 ml identical looking solution with no Trichuris suis eggs) in 54 patients with active ulcerative colitis.'],0,0.21739130434782608,2,23
CD009400,0,5,There were sparse data available for the outcomes clinical remission and clinical improvement.,delete,[],1,0.2608695652173913,2,23
CD009400,0,6,"Ten per cent (3/30) of patients in the T. suis arm entered remission compared to 4% (1/24) of patients in the placebo arm (RR 2.40, 95% CI 0.27 to 21.63).",rephrase,['Ten per cent (3/30) of patients in the helminth group achieved remission compared to four per cent (1/24) of placebo patients.'],1,0.30434782608695654,2,23
CD009400,0,7,"Forty-three per cent (13/30) of patients in the T. suis group achieved clinical improvement compared to 17% (4/24) of placebo patients (RR 2.60, 95% CI 0.97 to 6.95).",rephrase,['A higher proportion of patients in the helminth group (43% or 13/30) improved clinically compared to the placebo group (17% or 4/24).'],2,0.34782608695652173,2,23
CD009400,0,8,"The mean ulcerative colitis disease activity index (UCDAI) score was lower in the T. suis group (6.1 +/- 0.61) compared to the placebo group (7.5 +/- 0.66) after 12 weeks of treatment (MD -1.40, 95% CI -1.75 to -1.05).",delete,[],3,0.391304347826087,2,23
CD009400,0,9,There was only limited evidence relating to the proportion of patients who experienced an adverse event.,rephrase,['We could not determine whether the proportion of patients who had a side effect was higher in either group.'],3,0.43478260869565216,3,23
CD009400,0,10,"Three per cent (1/30) of patients in the T. suis group experienced at least one adverse event compared to 12% (3/24) of placebo patients (RR 0.27, 95% CI 0.03 to 2.40).",delete,[],4,0.4782608695652174,3,23
CD009400,0,11,None of the adverse events reported in this study were judged to be related to the study treatment.,rephrase,['No observed side effects were thought to be related to treatment were reported in this study.'],4,0.5217391304347826,3,23
CD009400,0,12,GRADE analyses rated the overall quality of the evidence for the primary and secondary outcomes (i.e. clinical remission and improvement) as low due to serious imprecision.,delete,[],5,0.5652173913043478,3,23
CD009400,0,13,"In the CD study, participants received a single treatment of T. suis ova at a dosage of 500 (n = 9), 2500 (n = 9), or 7500 (n = 9) embryonated eggs or matching placebo (n = 9).",rephrase,"[""The other study compared one treatment with various doses of helminths (a solution of 500, 2500 or 7500 Trichuris suis eggs) to a matching placebo in 36 patients with Crohn's disease.""]",5,0.6086956521739131,4,23
CD009400,0,14,The CD study did not assess clinical remission or improvement as outcomes.,rephrase,['This study was designed to assess side effects and did not measure clinical remission or improvement.'],6,0.6521739130434783,4,23
CD009400,0,15,There were sparse data on adverse events at two weeks.,rephrase,['There amount of information available on side-effects at two weeks was limited and the results were uncertain due to the small number of participants in the study.'],7,0.6956521739130435,4,23
CD009400,0,16,"Thirty-seven per cent (10/27) of patients in the T. suis group experienced at least one adverse event compared to 44% (4/9) of placebo patients (RR 0.83, 95% CI 0.35 to 2.01).",delete,[],8,0.7391304347826086,4,23
CD009400,0,17,Only one adverse event (dysgeusia) was judged to be possibly related to treatment in this study.,rephrase,['The only side effect that was judged to be possibly related to the study treatment was dysgeusia (a distortion of the sense of taste).'],8,0.782608695652174,4,23
CD009400,0,18,Dysgeusia was reported in one patient in the T. suis group and in one patient in the placebo group.,rephrase,['This was reported in one patient in the helminth group and in one patient in the placebo group.'],9,0.8260869565217391,5,23
CD009400,1,19,"Currently, there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of helminths used to treat patients with IBD.",ignore,"['Currently, there is insufficient evidence to allow any firm conclusions regarding the effectiveness and safety of helminths used to treat patients with IBD.']",10,0.8695652173913043,5,23
CD009400,1,20,The evidence for our primary efficacy outcomes in this review comes from one small study and is of low quality due to serious imprecision.,rephrase,['The only information available relating to clinical improvement in patients with active ulcerative colitis comes from one small study.'],11,0.9130434782608695,5,23
CD009400,1,21,We do not have enough evidence to determine whether helminths are safe when used in patients with UC and CD.,rephrase,"[""We do not know how safe helminths are when used in patients with ulcerative colitis and Crohn's disease.""]",12,0.9565217391304348,5,23
CD009400,1,22,Further RCTs are required to assess the efficacy and safety of helminth therapy in IBD.,split,"['The purpose of this systematic review was to examine the effectiveness and safety of helminth therapy for inducing remission in people with IBD.', 'Further randomised controlled trials are required to assess the efficacy and safety of helminth therapy in IBD.']",13,1.0,5,23
CD003075,0,0,Eight RCTs were included with a total of 3610 PAD patients.,rephrase,['We identified eight RCTs with a total of 3610 people with symptomatic PAD where participants were randomised to receive an anti-hypertensive treatment for at least one month or placebo or no treatment.'],0,0.06666666666666667,1,15
CD003075,0,1,Four studies compared a recognised class of anti-hypertensive treatment with placebo and four studies compared two anti-hypertensive treatments with each other.,ignore,['Four studies compared an anti-hypertensive treatment with placebo and four studies compared two anti-hypertensive treatments with each other.'],1,0.13333333333333333,1,15
CD003075,0,2,Studies were not pooled due to the variation of the comparisons and the outcomes presented.,rephrase,['The studies were not combined due to the variation of comparisons and the outcomes presented.'],2,0.2,1,15
CD003075,0,3,"Overall the quality of the available evidence was unclear, primarily as a result of a lack of detail in the study reports on the randomisation and blinding procedures and incomplete outcome data.",delete,[],3,0.26666666666666666,2,15
CD003075,0,4,Two studies compared angiotensin converting enzyme (ACE) inhibitors against placebo.,merge,['One trial with 1725 participants showed that the angiotensin converting enzyme (ACE) inhibitor ramipril was effective in reducing the number of cardiovascular events by 28% compared to placebo.'],3,0.3333333333333333,2,15
CD003075,0,5,"In one study there was a significant reduction in the number of cardiovascular events in patients receiving ramipril (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.91; n = 1725).",none,[],3,0.4,2,15
CD003075,0,6,In the second trial using perindopril (n = 52) there was a marginal increase in claudication distance but no change in ABI and a reduction in maximum walking distance.,rephrase,['In one other study using an ACE inhibitor (n = 52) the perindopril group showed a small increase in claudication distance but no change in ABI and a reduction in maximal walking distance (MWD).'],4,0.4666666666666667,3,15
CD003075,0,7,"A trial comparing the calcium antagonist verapamil versus placebo in patients undergoing angioplasty (n = 96) suggested that verapamil reduced restenosis (per cent diameter stenosis (± SD) 48.0% ± 11.5 versus 69.6% ± 12.2; P < 0.01), although this was not reflected in the maintenance of a high ABI (0.76 ± 0.10 versus 0.72 ± 0.08 for verapamil versus placebo).",rephrase,['In patients undergoing peripheral arterial angioplasty (a procedure to open narrowed or blocked blood vessels) the results from a trial with 96 participants suggested that the calcium channel blocker verapamil reduced restenosis (new blockage of the artery) at six months.'],5,0.5333333333333333,3,15
CD003075,0,8,"Another study (n = 80) demonstrated no significant difference in arterial intima-media thickness (IMT) in men receiving the thiazide diuretic hydrochlorothiazide (HCTZ) compared to those receiving the alpha-adrenoreceptor blocker doxazosin (-0.12 ± 0.14 mm and -0.08 ± 0.13 mm, respectively; P = 0.66).",rephrase,['In one small study (n = 80) peripheral arterial wall thickness was similar whether men received the thiazide diuretic hydrochlorothiazide (HCTZ) or the alpha-adrenoreceptor blocker doxazosin.'],6,0.6,3,15
CD003075,0,9,A study (n = 36) comparing telmisartan to placebo found a significant improvement in maximum walking distance at 12 months with telmisartan (median (interquartile range (IQR)) 191 m (157 to 226) versus 103 m (76 to 164); P < 0.001) but no differences in ABI (median (IQR) 0.60 (0.60 to 0.77) versus 0.52 (0.48 to 0.67)) or arterial IMT (median (IQR) 0.08 cm (0.07 to 0.09) versus 0.09 cm (0.08 to 0.10)).,rephrase,['In another small study (n = 36) MWD was improved at 12 months in the angiotensin-II receptor antagonist telmisartan group compared to the placebo group but there were no significant differences in ABI or arterial wall thickness.'],7,0.6666666666666666,4,15
CD003075,0,10,Two studies compared the beta-adrenoreceptor blocker nebivolol with either the thiazide diuretic HCTZ or with metoprolol.,rephrase,"['A study comparing two beta-adrenoreceptor blockers, nebivolol and metoprolol, found no clear differences in intermittent or absolute claudication distance, ABI, all-cause mortality or revascularisation after 36 weeks of treatment.']",8,0.7333333333333333,4,15
CD003075,0,11,"Both studies found no significant differences in intermittent or absolute claudication distance, ABI, or all-cause mortality between the anti-hypertensives.",rephrase,"['Another study (n = 163) found no significant differences in intermittent or absolute claudication distance, ABI, all-cause mortality or non-fatal cardiovascular events after 24 weeks of treatment in the beta-adrenoreceptor blocker nebivolol group and the HCTZ group.']",9,0.8,4,15
CD003075,0,12,"A subgroup analysis of PAD patients (n = 2699) in a study which compared a calcium antagonist-based strategy (verapamil slow release (SR) ± trandolapril) to a beta-adrenoreceptor blocker-based strategy (atenolol ± hydrochlorothiazide) found no significant differences in the composite endpoints of death, non-fatal myocardial infarction or non-fatal stroke with or without revascularisation (OR 0.90, 95% CI 0.76 to 1.07 and OR 0.96, 95% CI 0.82 to 1.13, respectively).",rephrase,"['A subgroup analysis of PAD patients (n = 2699) in the final study revealed no significant differences in the combined endpoints of death, non-fatal myocardial infarction or non-fatal stroke with or without revascularisation between the calcium antagonist-based strategy (verapamil slow release (SR) with or without trandolapril) compared to the beta-adrenoreceptor blocker strategy (atenolol with or without HCTZ).']",10,0.8666666666666667,5,15
CD003075,1,13,Evidence on the use of various anti-hypertensive drugs in people with PAD is poor so that it is unknown whether significant benefits or risks accrue.,ignore,['The evidence on the use of various anti-hypertensive drugs in people with PAD is poor so that it is not known whether significant benefits or risks accrue.'],11,0.9333333333333333,5,15
CD003075,1,14,"However, lack of data specifically examining outcomes in PAD patients should not detract from the overwhelming evidence on the benefit of treating hypertension and lowering blood pressure.",ignore,"['However, lack of data specifically examining outcomes in hypertensive PAD patients should not detract from the overwhelming evidence on the benefit of treating hypertension and lowering blood pressure.']",12,1.0,5,15
CD003426,0,0,"Of the 51 studies identified, three met the inclusion criteria, including 524 people with sickle cell disease aged between 12 and 65 years of age.",rephrase,['The review included three studies with 524 people with sickle cell disease aged between 12 and 65 years of age.'],0,0.07142857142857142,1,14
CD003426,0,1,One study tested the effectiveness of zinc sulphate as compared to placebo and the remaining two assessed senicapoc versus placebo.,rephrase,['The intervention in one study was zinc sulphate and in two studies was senicapoc.'],1,0.14285714285714285,1,14
CD003426,0,2,No deaths were seen in any of the studies (low-quality evidence).,delete,[],2,0.21428571428571427,2,14
CD003426,0,3,"The zinc sulphate study showed a significant reduction in painful crises (in a total of 145 participants) over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15) (moderate-quality evidence).",split,"['The study with zinc sulphate showed that this drug may be able to reduce the number of sickle cell crises without causing toxic effects (low-quality evidence).', 'There were 145 participants in this study and results showed a significant reduction in the total number of serious sickle-related crises over one and a half years, mean difference -2.83 (95% confidence interval -3.51 to -2.15) (moderate-quality evidence).']",2,0.2857142857142857,2,14
CD003426,0,4,"However, analysis was restricted due to limited statistical data.",rephrase,"['However, our analysis was limited since not all data were reported.']",4,0.35714285714285715,2,14
CD003426,0,5,Changes to red blood cell parameters and blood counts were inconsistent (very low-quality evidence).,split,"['Changes to red blood cell measurements and blood counts were not consistent (very low-quality evidence).', 'But these changes in the red blood cells did not translate into positive clinical outcomes in terms of reduction in the number of sickle cell crises (low-quality evidence).']",5,0.42857142857142855,3,14
CD003426,0,6,No serious adverse events were noted in the study.,ignore,['No serious adverse events were noted in the study.'],7,0.5,3,14
CD003426,0,7,"The Phase II dose-finding study of senicapoc (a Gardos channel blocker) compared to placebo showed that the high dose senicapoc showed significant improvement in change in hemoglobin level, the number and proportion of dense red blood cells, red blood cell count and indices and hematocrit value (very low-quality evidence).",rephrase,['The two studies with senicapoc demonstrated that this drug increases the red blood survival and has a role in preventing red blood cell dehydration in people with sickle cell disease (very low-quality evidence).'],8,0.5714285714285714,3,14
CD003426,0,8,The results with low-dose senicapoc were similar to the high-dose senicapoc group but of lesser magnitude.,delete,[],9,0.6428571428571429,4,14
CD003426,0,9,There was no difference in the frequency of painful crises between the three groups (low-quality evidence).,delete,[],9,0.7142857142857143,4,14
CD003426,0,10,A subsequent Phase III study of senicapoc was terminated early since there was no difference observed between the treatment and control groups in the primary end point of painful crises.,delete,[],9,0.7857142857142857,4,14
CD003426,1,11,"While the results of zinc for reducing sickle-related crises are encouraging, larger and longer-term multicenter studies are needed to evaluate the effectiveness of this therapy for people with sickle cell disease.",delete,[],9,0.8571428571428571,5,14
CD003426,2,12,"While the Phase II and the prematurely terminated phase III studies of senicapoc showed that the drug improved red blood cell survival (depending on dose), this did not lead to fewer painful crises.",delete,[],9,0.9285714285714286,5,14
CD003426,3,13,"Given this is no longer an active area of research, this review will no longer be regularly updated.",ignore,"['Given this is no longer an active area of research, this review will no longer be regularly updated.']",9,1.0,5,14
CD007714,0,0,Six studies involving 126 participants who completed the study protocols were included.,rephrase,['We included six studies involving 126 participants who completed the study protocols.'],0,0.0625,1,16
CD007714,0,1,Most studies recruited participants with severe to very severe COPD (mean forced expiratory volume in one second (FEV1) ranged from 26% to 48% predicted).,rephrase,['Most studies recruited participants with severe to very severe COPD.'],1,0.125,1,16
CD007714,0,2,"There was an increase in percentage change peak and endurance exercise capacity with NIV during training (mean difference in peak exercise capacity 17%, 95% confidence interval (CI) 7% to 27%, 60 participants, low-quality evidence; mean difference in endurance exercise capacity 59%, 95% CI 4% to 114%, 48 participants, low-quality evidence).",rephrase,"['The percentage change in peak exercise capacity increased by an average of 17% in three studies, and the percentage change in endurance exercise capacity by an average of 59% in two studies that provided NIV during training compared with training without NIV or training with sham NIV.']",2,0.1875,1,16
CD007714,0,3,"However, there was no clear evidence of a difference between interventions for all other measures of exercise capacity.",rephrase,"['However, these improvements in exercise capacity were not consistent findings as there was no clear evidence that NIV improved all other measures of exercise capacity.']",3,0.25,2,16
CD007714,0,4,"The results for HRQL assessed using the St George's Respiratory Questionnaire do not rule out an effect of NIV (total score mean 2.5 points, 95% CI -2.3 to 7.2, 48 participants, moderate-quality evidence).",delete,[],4,0.3125,2,16
CD007714,0,5,Physical activity was not assessed in any study.,rephrase,['Physical activity was not assessed in any of the studies.'],4,0.375,2,16
CD007714,0,6,"There was an increase in training intensity with NIV during training of 13% (95% CI 1% to 27%, 67 participants, moderate-quality evidence), and isoload lactate was lower with NIV (mean difference -0.97 mmol/L, 95% CI -1.58mmol/L to -0.36 mmol/L, 37 participants, moderate-quality evidence).",rephrase,"['Non-invasive ventilation allowed participants to exercise at a higher training intensity (average of 13% higher) in three studies, and evidence of a greater training effect on the muscles was found in two studies, as a marker in the blood (isoload blood lactate) was significantly lower by an average of 0.97 mmol/L.']",5,0.4375,3,16
CD007714,0,7,"The effect of NIV on dyspnoea or the number of dropouts between interventions was uncertain, although again results were imprecise.",rephrase,"['Consequently, the effect of NIV during exercise training on exercise capacity is uncertain.']",6,0.5,3,16
CD007714,0,8,No adverse events and no information regarding cost were reported.,rephrase,['No information regarding adverse events or cost was reported.'],7,0.5625,3,16
CD007714,0,9,"Only one study blinded participants, whereas three studies used blinded assessors.",delete,[],8,0.625,4,16
CD007714,0,10,Adequate allocation concealment was reported in four studies.,delete,[],8,0.6875,4,16
CD007714,1,11,"The small number of included studies with small numbers of participants, as well as the high risk of bias within some of the included studies, limited our ability to draw strong evidence-based conclusions.",delete,[],8,0.75,4,16
CD007714,1,12,"Although NIV during lower limb exercise training may allow people with COPD to exercise at a higher training intensity and to achieve a greater physiological training effect compared with exercise training alone or exercise training with sham NIV, the effect on exercise capacity is unclear.",delete,[],8,0.8125,5,16
CD007714,1,13,"Some evidence suggests that NIV during exercise training improves the percentage change in peak and endurance exercise capacity; however, these findings are not consistent across other measures of exercise capacity.",delete,[],8,0.875,5,16
CD007714,1,14,There is no clear evidence that HRQL is better or worse with NIV during training.,delete,[],8,0.9375,5,16
CD007714,1,15,It is currently unknown whether the demonstrated benefits of NIV during exercise training are clinically worthwhile or cost-effective.,ignore,['It is currently unknown whether demonstrated benefits of NIV during exercise training are clinically worthwhile or cost-effective.'],8,1.0,5,16
CD009366,0,0,We included a single study in this review comparing lumbar sympathectomy with prostanoids for the treatment of CLI in people with non-reconstructable PAD.,merge,[],0,0.05555555555555555,1,18
CD009366,0,1,"The single study included 200 participants with Buerger's disease, a form of PAD, 100 in each treatment group, but only 162 were actually included in the analyses.",merge,[],0,0.1111111111111111,1,18
CD009366,0,2,"The study compared an open surgical technique for lumbar sympathectomy with the prostanoid, iloprost, and followed participants for 24 weeks.",none,"[""This study randomised 200 participants (162 included in analysis) and compared surgical lumbar sympathectomy with the prostaglandin, iloprost, in people with Buerger's disease, a form of PAD, and followed participants for 24 weeks.""]",0,0.16666666666666666,1,18
CD009366,1,3,Risk of bias was low for most evaluated domains.,rephrase,"['Overall, the study had little risk of bias due to design.']",1,0.2222222222222222,2,18
CD009366,1,4,"Due to the nature of the treatment, blinding of the participants and those providing the treatment would be impossible as a surgical procedure was compared with intravenous injections.",rephrase,"['Blinding of the participants and those that administered the treatment would be impossible, but there was no mention of blinding of the people who evaluated the outcomes, which would have been a possibility.']",2,0.2777777777777778,2,18
CD009366,1,5,"It was not mentioned if blinded assessors evaluated the study outcomes, therefore, we judged subjective outcomes (i.e. pain reduction) to be at unclear risk of detection bias and objective outcomes (i.e. ulcer healing, amputation and mortality) at low risk of detection bias.",rephrase,"['Due to this, we rated the outcomes that had subjective measures (measures that can be influenced by or based on personal beliefs or feelings), such as relief of rest pain as unclear risk of bias, but the outcomes that had objective measures (measures that are not influenced by or based on personal beliefs or feelings) such as ulcer healing, amputation and mortality as low risk of bias.']",3,0.3333333333333333,2,18
CD009366,1,6,We also rated the risk of attrition bias as unclear; 38 out of 200 (19%) participants were not included in the analysis without clear explanation (16 of 100 in the iloprost arm and 22 of 100 in the sympathectomy arm).,rephrase,"['Also, there was a large number of participants not included in the analysis (38 of the 200, 19%), in both groups, with inadequate reasons as to why, so we rated bias due to incomplete outcome data as unclear.']",4,0.3888888888888889,2,18
CD009366,1,7,The quality of evidence was low due to serious imprecision because the study numbers were low and there was only one study included.,rephrase,"['The quality of the evidence, therefore, was low for the outcomes evaluated as the number of participants included was low and only a single study reported evidence.']",5,0.4444444444444444,3,18
CD009366,2,8,"The single included study reported on the outcome of complete healing without pain or major amputation, which fell under three separate outcomes for our review: relief of rest pain, complete ulcer healing and avoidance of major amputation.",delete,[],6,0.5,3,18
CD009366,2,9,"We chose to keep the outcome as a singularly reported outcome in order to not introduce bias into the outcomes, which may have been the case if reported separately.",delete,[],6,0.5555555555555556,3,18
CD009366,2,10,"The limited evidence suggests participants who received prostaglandins had improved complete ulcer healing without rest pain or major amputation when compared with those who received lumbar sympathectomy (RR 1.63, 95% CI 1.30 to 2.05), but as it was the only included study, we rated the data as low-quality and could not draw any overall conclusions.",rephrase,['This study found evidence of increased complete ulcer healing without rest pain or major amputation in the participants who received intravenous prostaglandin compared with those that received surgical lumbar sympathectomy.'],6,0.6111111111111112,4,18
CD009366,2,11,"The study authors stated that more participants who received prostaglandins reported adverse effects, such as headache, flushing, nausea and abdominal discomfort, but only one participant experienced severe enough adverse effects to drop out.",rephrase,"['However, those who received prostaglandins were more likely to report adverse events such as headache, flushing, nausea and abdominal discomfort.']",7,0.6666666666666666,4,18
CD009366,2,12,Five participants who underwent lumbar sympathectomy reported minor wound infection (low-quality evidence).,delete,[],8,0.7222222222222222,4,18
CD009366,2,13,There was no reported mortality in either of the treatment groups (low-quality evidence).,rephrase,['There were no reported deaths in either treatment group.'],8,0.7777777777777778,4,18
CD009366,3,14,"The included study did not report on claudication distances, quality of life or functional status, ankle brachial pressure index (ABPI), tissue oxygenation or toe pressures, or progression to minor amputation, complications or provide any cost-effectiveness data.",rephrase,['The single included study did not report on other planned outcomes for this review such as walking distances and quality of life or functional status.'],9,0.8333333333333334,5,18
CD009366,4,15,"Low-quality evidence from a single study in a select group of participants (people with Buerger's disease) suggests that prostaglandins are superior to open surgical lumbar sympathectomy for complete ulcer healing without rest pain or major amputation, but possibly incur more adverse effects.",delete,[],10,0.8888888888888888,5,18
CD009366,4,16,Further studies are needed to better understand if prostaglandins truly are more efficacious than open surgical lumbar sympathectomy and if there are any concerns with adverse effects.,delete,[],10,0.9444444444444444,5,18
CD009366,4,17,"It would be of great importance for future studies to include other forms of PAD (as Buerger's disease is a select type of PAD), other methods of sympathectomy as well as data on quality of life, complications and cost-effectiveness.",delete,[],10,1.0,5,18
CD007529,0,0,"Nineteen trials involving 10,667 women were included.",rephrase,"['We found 19 trials involving over 10,000 women.']",0,0.058823529411764705,1,17
CD007529,0,1,Risk of bias in trials was difficult to assess accurately due to incomplete reporting.,rephrase,"['Evidence from included studies was assessed as moderate to very low-quality due to incomplete reporting of methods and uncertainty of findings; when the strength of the evidence is low or very low, this means future research may change the results and we cannot be certain about them.']",1,0.11764705882352941,1,17
CD007529,0,2,None of the evidence relating to our main outcomes was graded as high quality.,delete,[],2,0.17647058823529413,1,17
CD007529,0,3,"The quality of evidence was downgraded due to missing information on trial methods, imprecision in risk estimates and heterogeneity.",delete,[],2,0.23529411764705882,2,17
CD007529,0,4,Eighteen of these studies compared the use of Doppler ultrasound of the umbilical artery of the unborn baby with no Doppler or with cardiotocography (CTG).,rephrase,"['Eighteen of these studies compared the use of Doppler ultrasound of the umbilical artery of the unborn baby with no Doppler or with cardiotocography (CTG, sometimes called electronic fetal monitoring).']",2,0.29411764705882354,2,17
CD007529,0,5,One more recent trial compared Doppler examination of other fetal blood vessels (ductus venosus) with computerised CTG.,rephrase,['One more recent trial compared Doppler examination of other fetal blood vessels (ductus venosus) with computerised CTG (short-term variation).'],3,0.35294117647058826,2,17
CD007529,1,6,"The use of Doppler ultrasound of the umbilical artery in high-risk pregnancy was associated with fewer perinatal deaths (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.52 to 0.98, 16 studies, 10,225 babies, 1.2% versus 1.7 %, number needed to treat (NNT) = 203; 95% CI 103 to 4352, evidence graded moderate).",delete,[],4,0.4117647058823529,3,17
CD007529,1,7,"The results for stillbirths were consistent with the overall rate of perinatal deaths, although there was no clear difference between groups for this outcome (RR 0.65, 95% CI 0.41 to 1.04; 15 studies, 9560 babies, evidence graded low).",delete,[],4,0.47058823529411764,3,17
CD007529,1,8,"Where Doppler ultrasound was used, there were fewer inductions of labour (average RR 0.89, 95% CI 0.80 to 0.99, 10 studies, 5633 women, random-effects, evidence graded moderate) and fewer caesarean sections (RR 0.90, 95% CI 0.84 to 0.97, 14 studies, 7918 women, evidence graded moderate).",delete,[],4,0.5294117647058824,3,17
CD007529,1,9,There was no comparative long-term follow-up of babies exposed to Doppler ultrasound in pregnancy in women at increased risk of complications.,delete,[],4,0.5882352941176471,3,17
CD007529,2,10,"No difference was found in operative vaginal births (RR 0.95, 95% CI 0.80 to 1.14, four studies, 2813 women), nor in Apgar scores less than seven at five minutes (RR 0.92, 95% CI 0.69 to 1.24, seven studies, 6321 babies, evidence graded low).",rephrase,"['There was no clear difference in the number of stillbirths, births using forceps or ventouse, or babies with a low Apgar score five minutes after birth.']",4,0.6470588235294118,4,17
CD007529,2,11,Data for serious neonatal morbidity were not pooled due to high heterogeneity between the three studies that reported it (1098 babies) (evidence graded very low).,rephrase,['Findings for serious problems in the neonate were not consistent in different studies.'],5,0.7058823529411765,4,17
CD007529,3,12,The use of Doppler to evaluate early and late changes in ductus venosus in early fetal growth restriction was not associated with significant differences in any perinatal death after randomisation.,delete,[],6,0.7647058823529411,4,17
CD007529,3,13,"However, there was an improvement in long-term neurological outcome in the cohort of babies in whom the trigger for delivery was either late changes in ductus venosus or abnormalities seen on computerised CTG.",rephrase,"['In babies with growth restriction, when the decision to deliver was based on late ductus venosus changes or abnormalities on computerised CTG, this appeared to improve long-term (two-year) developmental outcome.']",6,0.8235294117647058,5,17
CD007529,4,14,Current evidence suggests that the use of Doppler ultrasound on the umbilical artery in high-risk pregnancies reduces the risk of perinatal deaths and may result in fewer obstetric interventions.,rephrase,"['Doppler ultrasound in high-risk pregnancies appears to reduce the number of babies who die, and may also lead to fewer obstetric interventions.']",7,0.8823529411764706,5,17
CD007529,4,15,"The results should be interpreted with caution, as the evidence is not of high quality.",rephrase,"['However, the evidence was of moderate to very low-quality.']",8,0.9411764705882353,5,17
CD007529,4,16,"Serial monitoring of Doppler changes in ductus venosus may be beneficial, but more studies of high quality with follow-up including neurological development are needed for evidence to be conclusive.",rephrase,['Further studies of high-quality with long-term follow-up would help us to be more certain.'],9,1.0,5,17
CD012004,0,0,We included 29 trials (n = 2431) in this review.,rephrase,"['In total, 2431 participants were enrolled in 29 trials.']",0,0.07692307692307693,1,13
CD012004,0,1,The study sample sizes ranged from 20 to 323 participants.,rephrase,"['The study sample sizes ranged from 20 to 323 participants, and most of them were middle-aged people recruited from primary or tertiary care.']",1,0.15384615384615385,1,13
CD012004,0,2,"We considered a total of 76.6% of the included trials to have a low risk of bias, representing 86% of all participants.",delete,[],2,0.23076923076923078,2,13
CD012004,0,3,There is low to high quality evidence that MCE is not clinically more effective than other exercises for all follow-up periods and outcomes tested.,delete,[],2,0.3076923076923077,2,13
CD012004,0,4,"When compared with minimal intervention, there is low to moderate quality evidence that MCE is effective for improving pain at short, intermediate and long-term follow-up with medium effect sizes (long-term, MD –12.97; 95% CI –18.51 to –7.42).",merge,[],2,0.38461538461538464,2,13
CD012004,0,5,There was also a clinically important difference for the outcomes function and global impression of recovery compared with minimal intervention.,none,"['MCE probably provides better improvements in pain, function and global impression of recovery than minimal intervention at all follow-up periods.']",2,0.46153846153846156,3,13
CD012004,0,6,There is moderate to high quality evidence that there is no clinically important difference between MCE and manual therapy for all follow-up periods and outcomes tested.,rephrase,['There is probably little or no difference between MCE and manual therapy for all outcomes and follow-up periods.'],3,0.5384615384615384,3,13
CD012004,0,7,"Finally, there is very low to low quality evidence that MCE is clinically more effective than exercise and electrophysical agents (EPA) for pain, disability, global impression of recovery and quality of life with medium to large effect sizes (pain at short term, MD –30.18; 95% CI –35.32 to –25.05).",rephrase,"['MCE may provide slightly better improvements than exercise and electrophysical agents for pain, disability, global impression of recovery and the physical component of quality of life in the short and intermediate term.']",4,0.6153846153846154,4,13
CD012004,0,8,Minor or no adverse events were reported in the included trials.,delete,[],5,0.6923076923076923,4,13
CD012004,1,9,There is very low to moderate quality evidence that MCE has a clinically important effect compared with a minimal intervention for chronic low back pain.,delete,[],5,0.7692307692307693,4,13
CD012004,1,10,There is very low to low quality evidence that MCE has a clinically important effect compared with exercise plus EPA.,merge,[],5,0.8461538461538461,5,13
CD012004,1,11,There is moderate to high quality evidence that MCE provides similar outcomes to manual therapies and low to moderate quality evidence that it provides similar outcomes to other forms of exercises.,none,['Little or no difference is observed between MCE and other forms of exercise.'],5,0.9230769230769231,5,13
CD012004,1,12,"Given the evidence that MCE is not superior to other forms of exercise, the choice of exercise for chronic LBP should probably depend on patient or therapist preferences, therapist training, costs and safety.",ignore,"['Given the minimal evidence that MCE is superior to other forms of exercise, the choice of exercise for chronic LBP should probably depend on patient or therapist preferences, therapist training, costs and safety.']",6,1.0,5,13
CD010211,0,0,No eligible published trials were identified.,delete,[],0,0.14285714285714285,1,7
CD010211,0,1,"We identified a completed randomised controlled trial that was designed to evaluate the effects of a diet and exercise intervention compared with standard care in women with a history of GDM, however to date, it has only published results on women who were pregnant at randomisation (and not women in the interconception period).",merge,"['We searched for trials which looked at the health outcomes for women and babies after specific interconception care, and compared the outcomes for standard care (with no interconception care of this type).']",0,0.2857142857142857,2,7
CD010211,0,2,"We also identified an ongoing trial, in obese women with a history of GDM planning a subsequent pregnancy, which is assessing the effects of an intensive lifestyle intervention, supported with liraglutide treatment, compared with usual care.",none,[],0,0.42857142857142855,3,7
CD010211,0,3,"We also identified a trial that was designed to evaluate the effects of a weight loss and exercise intervention compared with lifestyle education also in obese women with a history of GDM planning a subsequent pregnancy, however it has not yet been published.",rephrase,"['Our search identified one trial which has yet to issue a full set of results, plus two further trials; one of these is still underway and the other has yet to be published.']",1,0.5714285714285714,3,7
CD010211,0,4,These trials will be re-considered for inclusion in the next review update.,delete,[],2,0.7142857142857143,4,7
CD010211,1,5,The role of interconception care for women with a history of GDM remains unclear.,rephrase,"['Because there are no studies currently available, there is not enough evidence at present to say if interconception care for women with a history of GDM can help to improve the health of mothers and their infants.']",2,0.8571428571428571,5,7
CD010211,1,6,"Randomised controlled trials are required evaluating different forms and protocols of interconception care for these women on perinatal and long-term maternal and infant health outcomes, acceptability of such interventions and cost-effectiveness.",rephrase,"['More high-quality studies are needed, which assess both short- and long-term health outcomes for women and their babies, as well as evaluating the impact on the health services.']",3,1.0,5,7
CD000188,0,0,"Four trials appeared to meet the inclusion criteria, but one was excluded because of poor methodology.",rephrase,"['Although four randomised controlled trials met the inclusion criteria, one was excluded because of poor methodology.']",0,0.125,1,8
CD000188,0,1,The three remaining trials compared testosterone treatment with placebo in a total of 109 subjects with intermittent claudication or critical leg ischaemia.,rephrase,"['The three remaining trials compared testosterone treatment with placebo in a total of 109 middle-aged to elderly people, predominantly men.']",1,0.25,2,8
CD000188,0,2,The most recent trial to meet the inclusion criteria dated from 1971.,delete,[],2,0.375,2,8
CD000188,0,3,No trials were available which investigated the potentially beneficial effects of oestrogenic hormones in women with lower limb atherosclerosis.,rephrase,['No trials investigated oestrogens in women with lower limb atherosclerosis.'],2,0.5,3,8
CD000188,1,4,"Testosterone therapy produced no significant improvement in tests of walking distance or in a variety of other objective tests for peripheral arterial disease, including venous filling time, muscle blood flow and plethysmography.",rephrase,"['Testosterone did not provide any clear improvement in the symptoms reported by the participants, walking distance or other objective tests for peripheral arterial disease including leg muscle blood flow.']",3,0.625,4,8
CD000188,1,5,"The relative risk for subjective improvement in symptoms using the combined trial results was also non-significant (relative risk (RR) 1.10, 95% confidence interval (CI) 0.81 to 1.48).",delete,[],4,0.75,4,8
CD000188,2,6,There is no evidence to date that short-term testosterone treatment is beneficial in subjects with lower limb atherosclerosis.,delete,[],4,0.875,5,8
CD000188,2,7,"However, this might reflect limited data rather than the lack of a real effect.",delete,[],4,1.0,5,8
CD001711,0,0,Four RCTs (n = 607) of user-held records versus treatment as usual met the inclusion criteria.,delete,[],0,0.1111111111111111,1,9
CD001711,0,1,"When the effect of user-held records on psychiatric hospital admissions was compared with treatment as usual in four studies, the pooled treatment effect showed no significant impact of the intervention and was of very low magnitude (n = 597, 4 RCTs, RR 0.99 CI 0.71 to 1.38, moderate quality evidence).",delete,[],0,0.2222222222222222,2,9
CD001711,0,2,"Similarly, there was no significant effect of the intervention in three studies which investigated compulsory psychiatric hospital admissions (n = 507, 4 RCTs, RR 0.64 CI 0.37 to 1.10, moderate quality evidence).",delete,[],0,0.3333333333333333,2,9
CD001711,0,3,"Other outcomes including satisfaction and mental state were investigated but pooled estimates were not obtainable due to skewed or poorly reported data, or only being investigated by one study.",rephrase,"['Other important outcomes, such as satisfaction with care, costs and effect on mental health, were not available due to the limited quality of the four studies.']",0,0.4444444444444444,3,9
CD001711,0,4,Two outcomes (violence and death) were not investigated by the included studies.,delete,[],1,0.5555555555555556,3,9
CD001711,0,5,Two important randomised studies are ongoing.,rephrase,['Two important randomised studies are currently taking place.'],1,0.6666666666666666,4,9
CD001711,1,6,"The evidence gap remains regarding user-held, personalised, accessible clinical information for people with psychotic illnesses for many of the outcomes of interest.",split,"['There is therefore a gap in knowledge and evidence regarding user-held information for people with severe mental health problems.', 'Large-scale, well-conducted and well-reported studies are required to assess the effects of user-held information for people with mental illness.', 'For the present, despite a gap in evidence, user-held information is low cost and acceptable to patients, so its use is likely to grow.']",2,0.7777777777777778,4,9
CD001711,1,7,"However, based on moderate quality evidence, this review suggests that there is no effect of the intervention on hospital or outpatient appointment use for individuals with psychotic disorders.",rephrase,"['Based on moderate quality evidence, the review found that user-held information did not decrease hospital admissions, and did not decrease compulsory admissions or encourage people with severe mental illness to attend appointments (when compared to treatment as usual).']",5,0.8888888888888888,5,9
CD001711,1,8,"The number of studies is low, however, and further evidence is required to ascertain whether these results are mediated by the type of intervention, such as involvement of a clinical team or the type of information included.",split,"['In the main, the number of relevant studies is low, with poor reporting of some outcomes.', 'Further evidence is also required on the different types of user-held information (for example, if it involves the mental health team and what type of information is included in the record).']",6,1.0,5,9
CD009517,0,0,"Endometrial injury versus control (no procedure or a sham procedure)
A total of 37 studies (8786 women) were included in this comparison.",rephrase,['We included 38 clinical trials (8915 women) which had tested the effects of endometrial injury on the outcomes of IVF.'],0,0.047619047619047616,1,21
CD009517,0,1,Most studies performed endometrial injury by pipelle biopsy in the luteal phase of the cycle before the IVF cycle.,rephrase,"['The studies were conducted in different populations of women, and the way the endometrial injury was conducted also differed between studies in terms of the instrument used and the timing of the procedure in relation to the IVF cycle.']",1,0.09523809523809523,1,21
CD009517,0,2,"The primary analysis was restricted to studies at low risk of bias, and included eight studies.",split,"['Many of the studies were poor quality and at high risk of bias, and therefore we performed the main analyses only including studies that were not at high risk of bias.', 'Of the 38 included studies, only eight were included in the primary analyses.']",2,0.14285714285714285,1,21
CD009517,0,3,"The effect of endometrial injury on live birth is unclear as the result is consistent with no effect, or a small reduction, or an improvement (odds ratio (OR) 1.12, 95% confidence interval (CI) 0.98 to 1.28; participants = 4402; studies = 8; I2 = 15%, moderate-certainty evidence).",rephrase,['It is unclear whether endometrial injury affects the chance having a baby from IVF.'],4,0.19047619047619047,1,21
CD009517,0,4,"This suggests that if the chance of live birth with IVF is usually 27%, then the chance when using endometrial injury would be somewhere between < 27% and 32%.",rephrase,"['The results suggest that, if the chance of having a baby from IVF is usually about 27%, then the chance of having a baby when using endometrial injury before IVF would be somewhere between less than 27% and 32%.']",5,0.23809523809523808,2,21
CD009517,1,5,"Similarly, the effect of endometrial injury on clinical pregnancy is unclear (OR 1.08, 95% CI 0.95 to 1.23; participants = 4402; studies = 8; I2 = 0%, moderate-certainty evidence).",delete,[],6,0.2857142857142857,2,21
CD009517,1,6,"This suggests that if the chance of clinical pregnancy from IVF is normally 32%, then the chance when using endometrial injury before IVF is between 31% and 37%.",rephrase,"['Similarly, for the outcome of pregnancy, if the chance of getting pregnant from IVF is assumed to be about 32%, then the chance of pregnancy when using endometrial injury before IVF is somewhere between 31% and 37%.']",6,0.3333333333333333,2,21
CD009517,1,7,"When all studies were included in the sensitivity analysis, we were unable to conduct meta-analysis for the outcomes of live birth and clinical pregnancy due to high risk of bias and statistical heterogeneity.",delete,[],7,0.38095238095238093,2,21
CD009517,2,8,"Endometrial injury probably results in little to no difference in chance of miscarriage (OR 0.88, 95% CI 0.68 to 1.13; participants = 4402; studies = 8; I2 = 0%, moderate-certainty evidence), and this result was similar in the sensitivity analysis that included all studies.",delete,[],7,0.42857142857142855,3,21
CD009517,2,9,"The result suggests that if the chance of miscarriage with IVF is usually 6.0%, then when using endometrial injury it would be somewhere between 4.2% and 6.8%.",rephrase,['Endometrial injury does not appear to affect the chance of having a miscarriage from IVF.'],7,0.47619047619047616,3,21
CD009517,3,10,"Endometrial injury was associated with mild to moderate pain (approximately 4 out of 10), and was generally associated with some minimal bleeding.",rephrase,"['The endometrial injury procedure causes mild to moderate pain and a small amount of vaginal bleeding, although this is short-lived.']",8,0.5238095238095238,3,21
CD009517,4,11,The evidence was downgraded for imprecision due to wide confidence intervals and therefore all primary analyses were graded as moderate certainty.,split,"['For the primary analyses, the evidence is of moderate certainty.', 'The evidence was reduced because the results were imprecise, and consistent with endometrial injury having no effect, being beneficial, and being harmful to the chance of getting pregnant or having a baby.']",9,0.5714285714285714,3,21
CD009517,5,12,"Higher versus lower degree of injury
Only one small study was included in this comparison (participants = 129), which compared endometrial injury using two different instruments in the cycle prior to the IVF cycle: a pipelle catheter and a Shepard catheter.",rephrase,['One small study compared endometrial injury using two different instruments in the cycle prior to the IVF cycle.'],11,0.6190476190476191,4,21
CD009517,5,13,This trial was excluded from the primary analysis due to risk of bias.,merge,[],12,0.6666666666666666,4,21
CD009517,5,14,"In the sensitivity analysis, all outcomes reported for this study were graded as very-low certainty due to risk of bias, and as such we were not able to interpret the study results.",none,"['All outcomes reported for this study were graded as very-low certainty due to risk of bias, and as such we were not able to interpret the study results.']",12,0.7142857142857143,4,21
CD009517,6,15,The effect of endometrial injury on live birth and clinical pregnancy among women undergoing IVF is unclear.,rephrase,['This evidence does not support the routine use of endometrial injury for women undergoing IVF.'],13,0.7619047619047619,4,21
CD009517,6,16,"The results of the meta-analyses are consistent with an increased chance, no effect and a small reduction in these outcomes.",delete,[],14,0.8095238095238095,5,21
CD009517,6,17,We are therefore uncertain whether endometrial injury improves the chance of live birth or clinical pregnancy in women undergoing IVF.,delete,[],14,0.8571428571428571,5,21
CD009517,6,18,Endometrial injury does not appear to affect the chance of miscarriage.,delete,[],14,0.9047619047619048,5,21
CD009517,6,19,It is a somewhat painful procedure associated with a small amount of bleeding.,delete,[],14,0.9523809523809523,5,21
CD009517,6,20,"In conclusion, current evidence does not support the routine use of endometrial injury for women undergoing IVF.",delete,[],14,1.0,5,21
CD008251,0,0,Three small RCTs met our inclusion criteria and included a total of 148 participants.,rephrase,['We found three small RCTs that included a total of 148 people with pressure ulcers.'],0,0.05555555555555555,1,18
CD008251,0,1,"These compared three treatments with topical phenytoin: hydrocolloid dressings, triple antibiotic ointment and simple dressings.",delete,[],1,0.1111111111111111,1,18
CD008251,0,2,"In the three RCTs, 79% of participants had grade II ulcers, and 21% of participants had grade I ulcers; no participants had grade III or IV ulcers.",split,"['Twenty-one per cent of participants had grade I ulcers (the least severe type, with swollen but unbroken skin) and 79% had grade II ulcers (slightly more severe).', 'No one had grade III or IV ulcers (the most severe types).']",1,0.16666666666666666,1,18
CD008251,0,3,Two RCTs had a high risk of bias overall and the other RCT was at unclear risk of bias due to poor reporting.,delete,[],3,0.2222222222222222,2,18
CD008251,0,4,Two RCTs had three intervention arms and the other had two intervention arms.,delete,[],3,0.2777777777777778,2,18
CD008251,1,5,Two studies compared topical phenytoin with hydrocolloid dressing (84 participants analysed).,rephrase,"['The trials compared topical phenytoin with three other treatments for pressure ulcers: hydrocolloid dressings, triple antibiotic ointment, and simple dressings.']",3,0.3333333333333333,2,18
CD008251,1,6,"The available data suggest that hydrocolloid dressings may improve ulcer healing compared to topical phenytoin (39.3% ulcers healed for phenytoin versus 71.4% ulcers healed for hydrocolloid dressings (RR 0.55, 95% CI 0.33 to 0.92; 56 participants, 1 study; low quality evidence).",rephrase,['The results of one study suggested that hydrocolloid dressings may slightly improve ulcer healing compared to topical phenytoin.'],4,0.3888888888888889,2,18
CD008251,1,7,We downgraded the evidence twice: once due to serious limitations (high risk of bias) and once due to the small sample size and small number of events.,delete,[],5,0.4444444444444444,3,18
CD008251,1,8,Two studies compared topical phenytoin with simple dressings (81 participants analysed).,delete,[],5,0.5,3,18
CD008251,1,9,"From the available data, we are uncertain whether topical phenytoin improves ulcer healing compared to simple dressings (39.3% ulcers healed for phenytoin versus 29.6% ulcers healed for the simple dressing (RR 1.33, 95% CI 0.63 to 2.78; 55 participants, 1 study; very low quality evidence).",rephrase,"['However, we are uncertain whether topical phenytoin improves ulcer healing compared to simple dressings.']",5,0.5555555555555556,3,18
CD008251,1,10,This evidence was downgraded once due to serious limitations (high risk of bias) and twice due to the low number of outcome events and resulting wide CI which included the possibility of both increased healing and reduced healing.,delete,[],6,0.6111111111111112,4,18
CD008251,1,11,We therefore considered it to be insufficient to determine the effect of topical phenytoin on ulcer healing.,delete,[],6,0.6666666666666666,4,18
CD008251,1,12,"One study compared topical phenytoin with triple antibiotic ointment, however, none of the outcomes of interest to this review were reported.",rephrase,['The study which compared topical phenytoin with triple antibiotic ointment did not report any outcomes of interest to this review.'],6,0.7222222222222222,4,18
CD008251,1,13,No adverse drug reactions or interactions were detected in any of the three RCTs.,delete,[],7,0.7777777777777778,4,18
CD008251,1,14,Minimal pain was reported in all groups in one trial that compared topical phenytoin with hydrocolloid dressings and triple antibiotic ointment.,delete,[],7,0.8333333333333334,5,18
CD008251,2,15,This review has considered the available evidence and the result shows that it is uncertain whether topical phenytoin improves ulcer healing for patients with grade I and II pressure ulcers.,rephrase,['It is uncertain whether topical phenytoin improves ulcer healing for patients with grade I and II pressure ulcers.'],7,0.8888888888888888,5,18
CD008251,2,16,No adverse events were reported from three small trials and minimal pain was reported in one trial.,ignore,['No adverse events were reported from three small trials and minimal pain was reported in one trial.'],8,0.9444444444444444,5,18
CD008251,2,17,"Therefore, further rigorous, adequately powered RCTs examining the effects of topical phenytoin for treating pressure ulcers, and to report on adverse events, quality of life and costs are necessary.",rephrase,"['Further rigorous, adequately powered RCTs are needed to find whether topical phenytoin is a helpful medication for treating pressure ulcers.']",9,1.0,5,18
CD009065,0,0,We included a total of 20 heterogeneous studies (2012 participants with acute ankle sprains); three of which included more than one comparison.,rephrase,['Our review includes 20 studies involving 2012 people with ankle sprains.'],0,0.058823529411764705,1,17
CD009065,0,1,Seventeen trials were conducted in China.,delete,[],1,0.11764705882352941,1,17
CD009065,0,2,All of the studies had a high risk of bias due to lack of blinding.,delete,[],1,0.17647058823529413,1,17
CD009065,0,3,"The results may also have been affected by selection bias, particularly as five studies were quasi-randomised controlled trials and 12 studies gave no information on their method of randomisation.",delete,[],1,0.23529411764705882,2,17
CD009065,0,4,"Of our three prespecified primary outcomes, only cure rate was reported by the majority of studies.",rephrase,"[""Most studies reported only the 'cure rate' - the number of participants who had recovered at a set time.""]",1,0.29411764705882354,2,17
CD009065,0,5,No study reported on patient-reported assessment of function and only one reported on adverse events (in which three participants receiving a control intervention experienced skin problems from over-the-counter Chinese herbal patches).,split,"['No study reported on patient-reported assessment of function.', 'Only one study reported on adverse events and found skin problems in individuals receiving over-the-counter traditional Chinese herbal patches as a control intervention.']",2,0.35294117647058826,2,17
CD009065,0,6,The other 19 studies did not record or report on adverse events.,delete,[],4,0.4117647058823529,3,17
CD009065,0,7,"We assessed the quality of evidence for cure rates as very low for all comparisons, which means we are very uncertain about the reliability of any of the estimates.",delete,[],4,0.47058823529411764,3,17
CD009065,1,8,"The single study comparing acupuncture treatment with no treatment found acupuncture to be more effective with regard to cure rate at five days (31/31 versus 1/30; RR 20.34, 95% CI 4.27 to 96.68).",rephrase,"['One study, which compared acupuncture with no treatment, found more people were cured with acupuncture.']",4,0.5294117647058824,3,17
CD009065,1,9,Acupuncture plus another standard treatment versus that standard treatment alone was tested in eight studies; with cure rate data available for seven.,rephrase,['Most of the eight studies comparing acupuncture plus another standard treatment versus that standard treatment alone found higher cure rates in the acupuncture group.'],5,0.5882352941176471,3,17
CD009065,1,10,Most of these studies reported higher cure rates in the acupuncture plus another standard treatment group than in the standard treatment alone group.,rephrase,"['However, we found that pooling these results did not provide conclusive evidence that acupuncture resulted in a better cure rate.']",6,0.6470588235294118,4,17
CD009065,1,11,"However, while the results of an exploratory meta-analysis of cure rate data from eight trials testing acupuncture versus no acupuncture tended to favour acupuncture, the results were very inconsistent across the studies and the estimated effect was very imprecise (383/396 versus 272/355; RR 1.32, 95% CI 0.95 to 1.84; P value = 0.1; I2 = 98%).",delete,[],7,0.7058823529411765,4,17
CD009065,2,12,"Fourteen studies compared acupuncture with a variety of other non-surgical treatments, such as Chinese drug patches, hot and cold water, ice packs, oral Chinese herbal medicine and elastic bandage.",ignore,"['Fourteen studies compared acupuncture with a variety of other non-surgical treatments, such as Chinese herbal patches, hot and cold water, ice packs, Chinese oral herbal medicine and elastic bandages.']",7,0.7647058823529411,4,17
CD009065,2,13,"Some studies found in favour of acupuncture, some in favour of the other treatment and some found a lack of evidence for a difference between the two interventions under test.",ignore,"['Some studies found in favour of acupuncture, some in favour of the other treatment and some found a lack of evidence for a difference between the two interventions under test.']",8,0.8235294117647058,5,17
CD009065,2,14,"The results of an exploratory meta-analysis of cure rate data from 11 trials testing acupuncture versus another non-surgical intervention tended to slightly favour acupuncture, but these were not statistically significant and the data were very heterogeneous (404/509 versus 416/497; RR 1.07, 95% CI 0.94 to 1.22; P value = 0.30; I2 = 92%).",rephrase,"['The pooled results from 11 studies comparing acupuncture versus another non-surgical intervention tended to favour acupuncture, but this evidence was not conclusive.']",9,0.8823529411764706,5,17
CD009065,3,15,"The currently available evidence from a very heterogeneous group of randomised and quasi-randomised controlled trials evaluating the effects of acupuncture for the treatment of acute ankle sprains does not provide reliable support for either the effectiveness or safety of acupuncture treatments, alone or in combination with other non-surgical interventions; or in comparison with other non-surgical interventions.",rephrase,"['Currently, we are unable to conclude whether or not acupuncture is more effective than other standard methods for the treatment of ankle sprains in adults because of the very low quality of the available evidence.']",10,0.9411764705882353,5,17
CD009065,3,16,Future rigorous randomised clinical trials with larger sample sizes will be necessary to establish robust clinical evidence concerning the effectiveness and safety of acupuncture treatment for acute ankle sprains.,rephrase,"['Large, high quality studies of acupuncture for sudden-onset ankle sprains in adults are needed.']",11,1.0,5,17
CD009708,0,0,"We included 14 studies (in 18 trial reports), involving 1047 pregnant women at risk of preterm birth with 1077 newborns.",rephrase,"['The review identified 14 small studies involving a total of 1047 women (and their 1077 newborns), that compared ambroxol with corticosteroid (betamethasone), or to placebo/no treatment.']",0,0.06666666666666667,1,15
CD009708,0,1,"However, three of the included studies did not report on this review's outcomes of interest.",rephrase,['Three of the studies did not report on the outcomes of interest for this review.'],1,0.13333333333333333,1,15
CD009708,0,2,We carried out two main comparisons: ambroxol versus antenatal corticosteroids (betamethasone); and ambroxol versus placebo or no treatment.,merge,"['Nor did we identify any trials comparing ambroxol combined with corticosteroid versus corticosteroid alone, or placebo/no treatment.']",2,0.2,1,15
CD009708,0,3,Seven RCTs provided data for our comparison of ambroxol versus corticosteroid (betamethasone) and two trials contributed data to our comparison of ambroxol compared to placebo or no treatment.,none,[],2,0.26666666666666666,2,15
CD009708,1,4,"The included studies were generally judged as having either 'low' risk of bias or 'unclear' risk of bias (because the trial reports provided insufficient details about methods of sequence generation, allocation concealment and blinding).",delete,[],3,0.3333333333333333,2,15
CD009708,2,5,"Primary outcomes
There was no clear evidence of a difference in the incidence of RDS among newborns born to women who received ambroxol when compared to newborns of women who were given the corticosteroid, betamethasone (risk ratio (RR) 0.79, 95% confidence interval (CI) 0.59 to 1.07, seven RCTs, 728 women/758 newborns, moderate quality evidence) or placebo/no treatment (average RR 0.74; 95% CI 0.46 to 1.20, two studies, 204 women/204 newborns,T2= 0.07; I2= 53%, low-quality evidence).",delete,[],3,0.4,2,15
CD009708,2,6,Results were imprecise and consistent with appreciable benefit as well as negligible effect.,delete,[],3,0.4666666666666667,3,15
CD009708,3,7,"Similarly, there was no clear evidence of a difference in the rates of perinatal mortality between the group of women who received ambroxol and women in the corticosteroid (betamethasone) group (RR 0.51, 95% CI 0.23 to 1.12, six studies, 648 women/657 newborns, moderate quality evidence) or the placebo/no treatment group (RR 0.61; 95% CI 0.19 to 1.98, one study, 116 women/116 newborns, low-quality evidence).",rephrase,['There were no clear evidence of differences in the incidence of RDS or perinatal mortality in newborns of women who were given ambroxol when compared with newborns of women who received either a corticosteroid (betamethasone) or placebo/no treatment.'],3,0.5333333333333333,3,15
CD009708,4,8,"In terms of maternal adverse effects, there was no clear differences (in nausea or vomiting) between those women who received ambroxol compared to either those women who received corticosteroids (betamethasone) (average RR 3.45; 95% CI 0.34 to 35.51, three studies, 305 women, T2= 2.82; I2= 67%, very low-quality evidence), or women who received placebo or no treatment (RR 1.79; 95% CI 0.45 to 7.13, one study, 116 women, low-quality evidence).",rephrase,"['Similarly, there was no clear difference between groups in terms of nausea and vomiting (the only maternal adverse effects that were reported).']",4,0.6,3,15
CD009708,4,9,"No other adverse effects (e.g. diarrhoea, gastric irritation and headache) were reported in the included studies.",delete,[],5,0.6666666666666666,4,15
CD009708,5,10,"Secondary outcomes
For the review's secondary outcomes, none of the included studies reported on the incidence of bronchopulmonary dysplasia, periventricular haemorrhage, necrotising enterocolitis or rate of maternal mortality.",ignore,"[""For the review's secondary outcomes, none of the included studies reported on the incidence of bronchopulmonary dysplasia, periventricular haemorrhage, necrotising enterocolitis or rate of maternal mortality.""]",5,0.7333333333333333,4,15
CD009708,6,11,"One small trial (involving 88 women) comparing ambroxol with placebo or no treatment, reported no difference between groups in terms of the need for mechanical ventilation in the neonate (RR 0.94; 95% CI 0.73 to 1.21, 88 women/88 babies, low-quality evidence) or the administration of pulmonary surfactant (RR 1.19; 95% CI 0.61 to 2.30, one RCT, 88 women/88 babies, low-quality evidence).",rephrase,"[""One small study (comparing ambroxol with placebo/no treatment) found no difference between groups for the neonatal outcomes of 'need for mechanical ventilation' or 'administration of pulmonary surfactant'.""]",6,0.8,4,15
CD009708,7,12,This review is based on very low to moderate quality evidence from 14 small trials (many are published in the form of conference abstracts with minimal methodological details provided).,delete,[],7,0.8666666666666667,5,15
CD009708,7,13,"There is insufficient evidence to support or refute the practice of giving ambroxol to women at risk of preterm birth for preventing neonatal RDS, perinatal mortality and adverse effects.",rephrase,['There is insufficient evidence to support or refute the practice of giving ambroxol to pregnant women at risk of preterm birth for preventing neonatal RDS.'],7,0.9333333333333333,5,15
CD009708,7,14,More research is needed in order to fully evaluate the benefits and risks of this intervention.,rephrase,['More research in this area is necessary in order to evaluate the effectiveness and safety of this intervention.'],8,1.0,5,15
CD006370,0,0,"Twelve studies, with a total of 343 participants, met our inclusion criteria (four RCTs and eight before and after non-controlled studies).",delete,[],0,0.1,1,10
CD006370,0,1,"Of the four RCTs, one examined patients with non-epileptic seizures and three had a mixed diagnosis (pseudoseizures, conversion disorder and somatisation disorder).",delete,[],0,0.2,1,10
CD006370,0,2,Most of the non-randomised studies used non-epileptic seizure patients exclusively.,split,"['We reviewed the existing studies treating people having non-epileptic attacks.', 'Most of the non-randomised studies included patients with mainly non-epileptic attacks.']",0,0.3,2,10
CD006370,0,3,"Overall, five studies examined the effectiveness of psychotherapy, three examined CBT, two investigated hypnosis, one assessed paradoxical intention and one had a mixed intervention design.",delete,[],2,0.4,2,10
CD006370,0,4,"We classified two included studies as low risk of bias, one as unclear and nine as high risk of bias.",rephrase,['Many of the studies did not use satisfactory methods which meant that the evidence was rated as high risk of bias.'],2,0.5,3,10
CD006370,0,5,Meta-analysis could not be undertaken due to the heterogeneity of design and interventions.,delete,[],3,0.6,3,10
CD006370,0,6,Most included studies reported improved outcomes for the intervention under investigation.,rephrase,['Most included studies reported improved outcomes for the treatment they were investigating.'],3,0.7,4,10
CD006370,0,7,One RCT investigating the effectiveness of CBT in this patient group found a significant reduction in seizure frequency compared to controls (P < 0.001).,delete,[],4,0.8,4,10
CD006370,1,8,"There is little reliable evidence to support the use of any treatment, including CBT, in the treatment of non-epileptic seizures.",split,"['The overall evidence for the main outcome of reducing seizures as a result of treatment is not considered reliable except in one study.', 'Our conclusion is there is little reliable evidence to support the use of any treatment for people with non-epileptic attacks.']",4,0.9,5,10
CD006370,1,9,Further randomised controlled trials of CBT and other interventions are needed.,rephrase,"['Four studies were randomised controlled trials, and 8 were non-randomised studies.']",6,1.0,5,10
CD007945,0,0,Five studies met our inclusion criteria; all were retrospective observational studies and therefore at high risk of bias.,delete,[],0,0.08333333333333333,1,12
CD007945,1,1,"Meta-analysis of three studies assessing over 9000 women suggested that institutions with gynaecologic oncologists on site may prolong survival in women with ovarian cancer, compared to community or general hospitals: hazard ratio (HR) of death was 0.90 (95% confidence interval (CI) 0.82 to 0.99).",rephrase,"['We used a set of tests to ensure that the evidence the five studies identified reached the quality standard for our analysis.The analysis of three studies combined (meta-analysis), assessing over 9000 women, suggested that institutions with gynaecologic oncologists (specialists in the field of gynaecological cancer treatment) on site may prolong the lives of women with ovarian cancer compared to community or general hospitals.']",0,0.16666666666666666,1,12
CD007945,1,2,"Similarly, another meta-analysis of three studies assessing over 50,000 women, found that teaching centres or regional cancer centres may prolong survival in women with any gynaecological cancer compared to community or general hospitals (HR 0.91; 95% CI 0.84 to 0.99).",rephrase,"['Similarly, another meta-analysis of three studies which assessed well over 50,000 women, found evidence to suggest that teaching centres or regional cancer centres (specialised centres) may prolong the lives of women with gynaecological cancer compared to community or general hospitals.']",1,0.25,2,12
CD007945,1,3,"The largest of these studies included all gynaecological malignancies and assessed 48,981 women, so the findings extend beyond ovarian cancer.",rephrase,"['The largest study in this meta-analysis assessed all gynaecological cancers in 48,981 women, so it had major influence on the final result; this means that our findings are likely to be relevant to other gynaecological cancers, besides ovarian cancer.']",2,0.3333333333333333,2,12
CD007945,1,4,One study compared community hospitals with semi-specialised gynaecologists versus general hospitals and reported non-significantly better disease-specific survival in women with ovarian cancer (HR 0.89; 95% CI 0.78 to 1.01).,delete,[],3,0.4166666666666667,3,12
CD007945,1,5,The findings of included studies were highly consistent.,delete,[],3,0.5,3,12
CD007945,1,6,Adverse event data were not reported in any of the studies.,delete,[],3,0.5833333333333334,3,12
CD007945,2,7,"We found low quality, but consistent evidence to suggest that women with gynaecological cancer who received treatment in specialised centres had longer survival than those managed elsewhere.",delete,[],3,0.6666666666666666,4,12
CD007945,2,8,The evidence was stronger for ovarian cancer than for other gynaecological cancers.,rephrase,['Another weakness of the review is that only one of the studies included women with gynaecological cancers other than ovarian cancer.'],3,0.75,4,12
CD007945,3,9,"Further studies of survival are needed, with more robust designs than retrospective observational studies.",rephrase,"['Ideally, further studies in this area are needed.']",4,0.8333333333333334,5,12
CD007945,3,10,Research should also assess the quality of life associated with centralisation of gynaecological cancer care.,rephrase,"['Additionally, studies should assess the impact of centralisation of care on the quality of life of patients.']",5,0.9166666666666666,5,12
CD007945,3,11,Most of the available evidence addresses ovarian cancer in developed countries; future studies should be extended to other gynaecological cancers within different healthcare systems.,rephrase,['Most of the available evidence was about ovarian cancer in developed countries;\xa0future studies should be extended to other gynaecological cancers and to less developed countries.'],6,1.0,5,12
CD002190,0,0,We did not identify any new RCTs for inclusion in this update.,ignore,['We did not identify any new trials for inclusion in this update.'],0,0.09090909090909091,1,11
CD002190,0,1,This review includes one RCT conducted in 1965 with an overall high risk of bias.,rephrase,['This review includes one previously identified randomised controlled trial (a type of study where participants are randomly assigned to one of two or more treatment groups) performed in 1965.'],1,0.18181818181818182,1,11
CD002190,0,2,"The RCT included 2307 healthy young men in a military facility, all of whom were included in the analyses, and compared the effect of three adenovirus vaccines (live, inactivated type 4, and inactivated type 4 and 7) against a placebo (injection of physiological saline or gelatin capsule).",rephrase,"['This study involved 2307 young, healthy military men at a training facility in the United States Navy, and evaluated the effects of a live attenuated (weakened) adenovirus vaccine, an inactivated type 4, and an inactivated type 4 and 7 vaccines compared to a placebo (fake vaccine).']",2,0.2727272727272727,2,11
CD002190,0,3,"There were 13 (1.14%) events in 1139 participants in the vaccine group, and 14 (1.19%) events in 1168 participants in the placebo group.",delete,[],3,0.36363636363636365,2,11
CD002190,0,4,"Overall, we do not know if there is a difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold (risk ratio 0.95, 95% confidence interval 0.45 to 2.02; very low-certainty evidence).",delete,[],3,0.45454545454545453,3,11
CD002190,0,5,"Furthermore, no difference in adverse events when comparing live vaccine preparation with placebo was reported.",split,"['There were no differences in the frequency of occurrence of the common cold between those who received a\xa0live attenuated adenovirus vaccine compared to those who received a placebo.', 'There were no differences between groups in adverse events.']",3,0.5454545454545454,3,11
CD002190,0,6,"We downgraded the certainty of the evidence to very low due to unclear risk of bias, indirectness because the population of this study was only young men, and imprecision because confidence intervals were wide and the number of events was low.",rephrase,['We assessed the certainty of the evidence as very low due to high risk of bias; because the study population was only young men; and due to the small number of people included in the study and low numbers of colds.'],5,0.6363636363636364,4,11
CD002190,0,7,The included study did not assess vaccine-related or all-cause mortality.,delete,[],6,0.7272727272727273,4,11
CD002190,1,8,"This Cochrane Review was based on one study with very low-certainty evidence, which showed that there may be no difference between the adenovirus vaccine and placebo in reducing the incidence of the common cold.",delete,[],6,0.8181818181818182,5,11
CD002190,1,9,"We identified a need for well-designed, adequately powered RCTs to investigate vaccines for the common cold in healthy people.",rephrase,"['Further research is needed to find out if vaccines can prevent the common cold, as the current evidence does not support the use of the adenovirus vaccine to prevent the common cold in healthy people.']",6,0.9090909090909091,5,11
CD002190,1,10,"Future trials on interventions for preventing the common cold should assess a variety of virus vaccines for this condition, and should measure such outcomes as common cold incidence, vaccine safety, and mortality (all-cause and related to the vaccine).",delete,[],7,1.0,5,11
CD008185,0,0,"One study (96 male participants) met the inclusion criteria, although the primary outcome of this review - z score for height and weight, was not assessed in the study.",rephrase,['The review included one study with 96 males with Hunter syndrome aged between 4.9 and 30.9 years of age.'],0,0.07142857142857142,1,14
CD008185,0,1,This trial was considered to be of overall good quality.,delete,[],1,0.14285714285714285,1,14
CD008185,0,2,"Following 53 weeks of treatment, participants in the weekly idursulfase 0.5 mg/kg group demonstrated a significant improvement rate compared with placebo for the primary outcome: distance walked in six minutes on the basis of the sum of ranks of change from baseline, mean difference 37.00 (95% confidence interval 6.52 to 67.48).",rephrase,"['The trial compared idursulfase 0.5 mg/kg given either weekly or every-other week, or weekly infusions of placebo (a substance which contains no medication) and people were selected for one treatment or the other randomly.']",1,0.21428571428571427,2,14
CD008185,0,3,"The every-other-week idursulfase 0.5 mg/kg group also showed an improvement, which was not significant compared with placebo, mean difference 23.00 (95% confidence interval -4.49 to 50.49).",delete,[],2,0.2857142857142857,2,14
CD008185,0,4,"After 53 weeks, there was no statistical significance difference in per cent predicted forced vital capacity between the three groups and absolute forced vital capacity was significantly increased from baseline in the weekly dosing group compared to placebo, mean difference 0.16 (95% confidence interval CI 0.05 to 0.27).",rephrase,['The study lasted 53 weeks.'],2,0.35714285714285715,2,14
CD008185,0,5,No difference was observed between the every-other-week idursulfase 0.5 mg/kg group and placebo.,delete,[],3,0.42857142857142855,3,14
CD008185,1,6,"In addition, liver and spleen volumes and urine glycosaminoglycan excretion were significantly reduced from baseline by both idursulfase dosing regimens.",delete,[],3,0.5,3,14
CD008185,1,7,"Idursulfase was generally well tolerated, but infusion reactions did occur.",delete,[],3,0.5714285714285714,3,14
CD008185,1,8,Idursulfase antibodies were detected in 31.7% of participants at the end of the study and they were related to a smaller reduction in urine glycosaminoglycan levels.,delete,[],3,0.6428571428571429,4,14
CD008185,2,9,The current evidence is limited.,rephrase,['Current evidence is limited given there was only one randomised clinical trial found in the medical literature.'],3,0.7142857142857143,4,14
CD008185,2,10,"While the randomised clinical trial identified was considered to be of good quality, it failed to describe important outcomes.",rephrase,['This trial was considered to be of overall good quality.'],4,0.7857142857142857,4,14
CD008185,2,11,"It has been demonstrated that enzyme replacement therapy with idursulfase is effective in relation to functional capacity (distance walked in six minutes and forced vital capacity), liver and spleen volumes and urine glycosaminoglycan excretion in people with mucopolysaccharidosis type II compared with placebo.",rephrase,"[""As compared with placebo, enzyme replacement therapy with idursulfase in people with Hunter syndrome, led to some improvement in the individuals' ability to walk and a reduction in the excretion of abnormal mucopolysaccharides in the urine.""]",5,0.8571428571428571,5,14
CD008185,2,12,"There is no available evidence in the included study and in the literature on outcomes such as improvement in growth, sleep apnoea, cardiac function, quality of life and mortality.",rephrase,['To date there is no evidence available in the literature showing that treatment reduces complications of the disease related to quality of life and mortality.'],6,0.9285714285714286,5,14
CD008185,2,13,More studies are needed to obtain more information on the long-term effectiveness and safety of enzyme replacement therapy.,delete,[],7,1.0,5,14
MR000027,0,0,Six studies met the inclusion criteria; two were randomised studies and four were observational comparative studies evaluating different methods for obtaining missing data.,ignore,"['Six studies met the inclusion criteria, two were randomised studies and four were observational comparative studies evaluating different methods for obtaining missing data.']",0,0.08333333333333333,1,12
MR000027,1,1,"Methods to obtain missing data
Five studies, two randomised studies and three observational comparative studies, assessed methods for obtaining missing data (i.e. data available to the original researchers but not reported in the published study).",rephrase,['Five studies assessed methods for obtaining missing data (i.e. data available to the original researchers but not reported in the published study).'],1,0.16666666666666666,1,12
MR000027,2,2,Two studies found that correspondence with study authors by e-mail resulted in the greatest response rate with the fewest attempts and shortest time to respond.,ignore,['Two studies found that correspondence with study authors by e-mail resulted in the greatest response rate with the fewest attempts and shortest time to respond.'],2,0.25,2,12
MR000027,2,3,"The difference between the effect of a single request for missing information (by e-mail or surface mail) versus a multistage approach (pre-notification, request for missing information and active follow-up) was not significant for response rate and completeness of information retrieved (one study).",ignore,"['The difference between the effect of a single request for missing information (by e-mail or surface mail) versus a multistage approach (pre-notification, request for missing information and active follow-up) was not significant for response rate and completeness of information retrieved (one study).']",3,0.3333333333333333,2,12
MR000027,2,4,Requests for clarification of methods (one study) resulted in a greater response than requests for missing data.,ignore,['Requests for clarification of methods (one study) resulted in a greater response than requests for missing data.'],4,0.4166666666666667,3,12
MR000027,2,5,A well-known signatory had no significant effect on the likelihood of authors responding to a request for unpublished information (one study).,ignore,['A well-known signatory had no significant effect on the likelihood of authors responding to a request for unpublished information (one study).'],5,0.5,3,12
MR000027,2,6,One study assessed the number of attempts made to obtain missing data and found that the number of items requested did not influence the probability of response.,ignore,['One study assessed the number of attempts made to obtain missing data and found that the number of items requested did not influence the probability of response.'],6,0.5833333333333334,3,12
MR000027,2,7,"In addition, multiple attempts using the same methods did not increase the likelihood of response.",ignore,"['In addition, multiple attempts using the same methods did not increase the likelihood of response.']",7,0.6666666666666666,4,12
MR000027,3,8,"Methods to obtain unpublished studies
One observational comparative study assessed methods to obtain unpublished studies (i.e. data for studies that have never been published).",rephrase,['One study assessed methods to obtain unpublished studies (i.e. data for studies that have never been published).'],8,0.75,4,12
MR000027,3,9,Identifying unpublished studies ahead of time and then asking the drug industry to provide further specific detail proved to be more fruitful than sending of a non-specific request.,ignore,['Identifying unpublished studies ahead of time and then asking the drug industry to provide further specific detail proved to be more fruitful than sending of a non-specific request.'],9,0.8333333333333334,5,12
MR000027,4,10,"Those carrying out systematic reviews should continue to contact authors for missing data, recognising that this might not always be successful, particularly for older studies.",ignore,"['Those carrying out systematic reviews should continue to contact authors for missing data, recognising that this might not always be successful, particularly for older studies.']",10,0.9166666666666666,5,12
MR000027,4,11,Contacting authors by e-mail results in the greatest response rate with the fewest number of attempts and the shortest time to respond.,ignore,['Contacting authors by e-mail results in the greatest response rate with the fewest number of attempts and the shortest time to respond.'],11,1.0,5,12
CD004931,0,0,Nine randomised controlled trials involving 395 patients were included.,ignore,['Nine randomised controlled trials involving 395 patients were evaluated.'],0,0.09090909090909091,1,11
CD004931,0,1,"Six out of nine studies had a follow-up of less than one year, the longest study duration was 24 months.",ignore,"['Six out of nine studies had a follow-up of less than one year, the longest study duration was 24 months.']",1,0.18181818181818182,1,11
CD004931,0,2,Only a third of the analysed studies revealed a low risk of bias.,rephrase,"['The overall quality of trials was variable, only a third of the analysed studies showed a low risk of bias.']",2,0.2727272727272727,2,11
CD004931,0,3,"No information was available on quality of life, all-cause mortality and morbidity.",ignore,"['No information was available on quality of life, all-cause mortality and morbidity.']",3,0.36363636363636365,2,11
CD004931,0,4,"Compared with conventional management, IGB did not show convincing evidence of a greater weight loss.",ignore,"['Compared with conventional management, IGB did not show convincing evidence of a greater weight loss.']",4,0.45454545454545453,3,11
CD004931,0,5,"On the other hand, complications of intragastric balloon placement occurred, however few of a serious nature.",delete,[],5,0.5454545454545454,3,11
CD004931,0,6,The relative risks for minor complications like gastric ulcers and erosions were significantly raised.,ignore,"['The relative risks for minor complications, for example gastric ulcers and erosions were significantly raised.']",5,0.6363636363636364,4,11
CD004931,1,7,"Evidence from this review is limited for decision making, since there was large heterogeneity in IGB trials, regarding both methodological and clinical aspects.",delete,[],6,0.7272727272727273,4,11
CD004931,1,8,"However, a co-adjuvant factor described by some authors in the loss and maintenance of weight has been the motivation and the encouragement to changing eating habits following a well-organized diet and a program of behavioural modification.",delete,[],6,0.8181818181818182,5,11
CD004931,1,9,The IGB alone and the technique of positioning appear to be safe.,delete,[],6,0.9090909090909091,5,11
CD004931,1,10,"Despite the evidence for little additional benefit of the intragastric balloon in the loss of weight, its cost should be considered against a program of eating and behavioural modification.",delete,[],6,1.0,5,11
CD002052,0,0,We included in the review three trials enrolling 148 neonates.,merge,['We included three clinical trials in this review.'],0,0.09090909090909091,1,11
CD002052,0,1,We identified no new trials for this update.,none,[],0,0.18181818181818182,1,11
CD002052,0,2,"Using different sedation scales, each study showed a statistically significantly higher sedation level in the midazolam group compared with the placebo group.",rephrase,"['Using different scales to measure level of sedation, each study showed that midazolam was effective in providing sedation to babies.']",1,0.2727272727272727,2,11
CD002052,0,3,"However, none of the sedation scales used have been validated in preterm infants; therefore, we could not ascertain the effectiveness of midazolam in this population.",rephrase,"['However, the validity of the sedation scales used in these studies has not been proven in babies; therefore, we cannot be certain that midazolam is, in fact, an effective sedative for babies.']",2,0.36363636363636365,2,11
CD002052,0,4,"Duration of NICU stay was significantly longer in the midazolam group than in the placebo group (WMD 5.4 days, 95% CI 0.40 to 10.5; I2 = 0%; two studies, 89 infants).",delete,[],3,0.45454545454545453,3,11
CD002052,0,5,"One study (43 infants) reported significantly lower Premature Infant Pain Profile (PIPP) scores during midazolam infusion than during dextrose (placebo) infusion (MD -3.80, 95% CI -5.93 to -1.67).",delete,[],3,0.5454545454545454,3,11
CD002052,0,6,"Another study (46 infants) observed a higher incidence of adverse neurological events at 28 days' postnatal age (death, grade III or IV IVH or PVL) in the midazolam group compared with the morphine group (RR 7.64, 95% CI 1.02 to 57.21; RD 0.28, 95% CI 0.07 to 0.49; NNTH 4, 95% CI 2 to 14) (tests for heterogeneity not applicable).",delete,[],3,0.6363636363636364,4,11
CD002052,0,7,"We considered these trials to be of moderate quality according to GRADE assessment based on the following outcomes: mortality during hospital stay, length of NICU stay, adequacy of analgesia according to PIPP scores and poor neurological outcomes by 28 days' postnatal age.",rephrase,"['We assessed the quality of the evidence on the outcomes of mortality during hospital stay, length of stay in the NICU, pain, and neurological outcomes at 28 days of life and found the evidence to be of moderate quality, as there was not enough evidence available.']",3,0.7272727272727273,4,11
CD002052,1,8,Data are insufficient to promote the use of intravenous midazolam infusion as a sedative for neonates undergoing intensive care.,rephrase,"['Therefore, we conclude there is not enough evidence to support the use of midazolam as a sedative for babies undergoing intensive care.']",4,0.8181818181818182,5,11
CD002052,1,9,This review raises concerns about the safety of midazolam in neonates.,merge,[],5,0.9090909090909091,5,11
CD002052,1,10,Further research on the effectiveness and safety of midazolam in neonates is needed.,none,['Additional research is needed to address the safety and effectiveness of midazolam in this population.'],5,1.0,5,11
CD012089,0,0,We included three studies involving 45 children aged between 29 months and six years with Down syndrome.,rephrase,['We found three studies involving 45 children aged between 29 months and six years.'],0,0.034482758620689655,1,29
CD012089,0,1,Two studies compared parent-mediated interventions versus TAU; the third compared a parent-mediated plus clinician-mediated intervention versus a clinician-mediated intervention alone.,split,"['Two studies compared parent-mediated intervention to treatment as usual.', 'A third study compared a parent- and clinician-mediated intervention to a clinician-only-mediated intervention.']",1,0.06896551724137931,1,29
CD012089,0,2,Treatment duration varied from 12 weeks to six months.,delete,[],3,0.10344827586206896,1,29
CD012089,0,3,One study provided nine group sessions and four individualised home-based sessions over a 13-week period.,split,"['One of these lasted for 13 weeks, and parents in the intervention group received nine, weekly group sessions and four individual sessions in the home.', 'In this study the parents in the intervention group took part in a two- to three-hour interactive workshop plus three individualised sessions (two clinic-based and one home-based) every week for 12 weeks.']",3,0.13793103448275862,1,29
CD012089,0,4,"Another study provided weekly, individual clinic-based or home-based sessions lasting 1.5 to 2 hours, over a six-month period.",merge,"['A second study lasted for six months, and parents received weekly, 1.5- to 2-hour clinic or home-based, individualised, parent-child sessions.']",5,0.1724137931034483,1,29
CD012089,0,5,"The third study provided one 2- to 3-hour group session followed by bi-weekly, individual clinic-based sessions plus once-weekly home-based sessions for 12 weeks.",none,[],5,0.20689655172413793,2,29
CD012089,0,6,"Because of the different study designs and outcome measures used, we were unable to conduct a meta-analysis.",delete,[],6,0.2413793103448276,2,29
CD012089,1,7,"We judged all three studies to be at high risk of bias in relation to blinding of participants (not possible due to the nature of the intervention) and blinding of outcome assessors, and at an unclear risk of bias for allocation concealment.",delete,[],6,0.27586206896551724,2,29
CD012089,1,8,"We judged one study to be at unclear risk of selection bias, as authors did not report the methods used to generate the random sequence; at high risk of reporting bias, as they did not report on one assessed outcome; and at high risk of detection bias, as the control group had a cointervention and only parents in the intervention group were made aware of the target words for their children.",delete,[],6,0.3103448275862069,2,29
CD012089,1,9,"The sample sizes of each included study were very small, meaning that they are unlikely to be representative of the target population.",delete,[],6,0.3448275862068966,2,29
CD012089,2,10,The findings from the three included studies were inconsistent.,merge,[],6,0.3793103448275862,2,29
CD012089,2,11,"Two studies found no differences in expressive or receptive language abilities between the groups, whether measured by direct assessment or parent reports.",none,"[""Two of the three studies found no differences in children's language ability after parent training.""]",6,0.41379310344827586,3,29
CD012089,2,12,"However, they did find that children in the intervention group could use more targeted vocabulary items or utterances with language targets in certain contexts postintervention, compared to those in the control group; this was not maintained 12 months later.",rephrase,"['However, these same two studies found that children in the intervention group used more words that had been specifically targeted, postintervention; this was not maintained 12 months later.']",7,0.4482758620689655,3,29
CD012089,2,13,The third study found gains for the intervention group on total-language measures immediately postintervention.,rephrase,['The study that gave parents the largest amount of intervention reported gains on general measures of overall language ability for children in the intervention group.'],8,0.4827586206896552,3,29
CD012089,3,14,One study did not find any differences in parental stress scores between the groups at any time point up to 12 months postintervention.,rephrase,['One study did not find any changes in levels of parental stress immediately or up to 12 months postintervention in either group.'],9,0.5172413793103449,3,29
CD012089,3,15,"All three studies noted differences in most measures of how the parents talked to and interacted with their children postintervention, and in one study most strategies were maintained in the intervention group at 12 months postintervention.",rephrase,"['All three studies noted changes in how parents talked to and interacted with their children immediately postintervention, and most strategies were retained by the intervention group 12 months later.']",10,0.5517241379310345,3,29
CD012089,3,16,"No study reported evidence of language attrition following the intervention in either group, while one study found positive outcomes on children's socialisation skills in the intervention group.",split,"['One study reported increases in the socialisation skills of children who received the intervention.', 'No study reported language attrition in either group postintervention.']",11,0.5862068965517241,3,29
CD012089,3,17,"One study looked at adherence to the treatment through attendance data, finding that mothers in the intervention group attended seven out of nine group sessions and were present for four home visits.",delete,[],13,0.6206896551724138,4,29
CD012089,3,18,No study measured parental use of the strategies outside of the intervention sessions.,delete,[],13,0.6551724137931034,4,29
CD012089,4,19,"A grant from the Hospital for Sick Children Foundation (Toronto, Ontario, Canada) funded one study.",ignore,"['A grant from the Hospital for Sick Children Foundation (Toronto, Ontario, Canada) funded one study.']",13,0.6896551724137931,4,29
CD012089,4,20,Another received partial funding from the National Institute of Child Health and Human Development and the Department of Education in the USA.,ignore,['Another received partial funding from the National Institute of Child Health and Human Development and the Department of Education in the USA.'],14,0.7241379310344828,4,29
CD012089,4,21,The remaining study did not specify any funding sources.,ignore,['The remaining study did not specify any funding sources.'],15,0.7586206896551724,4,29
CD012089,5,22,"In light of the serious limitations in methodology, and the small number of studies included, we considered the overall quality of the evidence, as assessed by GRADE, to be very low.",rephrase,"['We rated the quality of the evidence in this review as very low, as only three studies fulfilled the criteria for inclusion, and all had small sizes and serious methodological limitations.']",16,0.7931034482758621,4,29
CD012089,5,23,"This means that we have very little confidence in the results, and further research is very likely to have an important impact on our confidence in the estimate of treatment effect.",delete,[],17,0.8275862068965517,5,29
CD012089,6,24,There is currently insufficient evidence to determine the effects of parent-mediated interventions for improving the language and communication of children with Down syndrome.,rephrase,['There is currently insufficient evidence to determine the effect of parent-mediated interventions for improving the communication and language development in young children with Down syndrome.'],17,0.8620689655172413,5,29
CD012089,6,25,We found only three small studies of very low quality.,delete,[],18,0.896551724137931,5,29
CD012089,6,26,"This review highlights the need for well-designed studies, including RCTs, to evaluate the effectiveness of parent-mediated interventions.",delete,[],18,0.9310344827586207,5,29
CD012089,6,27,"Trials should use valid, reliable and similar measures of language development, and they should include measures of secondary outcomes more distal to the intervention, such as family well-being.",delete,[],18,0.9655172413793104,5,29
CD012089,6,28,"Treatment fidelity, in particular parental dosage of the intervention outside of prescribed sessions, also needs to be documented.",delete,[],18,1.0,5,29
CD003643,0,0,The review authors identified 14 relevant RCTs.,delete,[],0,0.08333333333333333,1,12
CD003643,0,1,They excluded four trials.,delete,[],0,0.16666666666666666,1,12
CD003643,1,2,"The 10 included studies, four of which have been added in this update, included a total of 258 participants.",delete,[],0,0.25,2,12
CD003643,1,3,"Six studies compared an immunosuppressant or immunomodulator with placebo control, and four studies compared two immunosuppressant regimes with each other.",delete,[],0,0.3333333333333333,2,12
CD003643,1,4,Most of the studies were small (the largest had 62 participants) and many of the reports contained insufficient information to assess risk of bias.,ignore,['Most of the studies were small (the largest had 62 participants) and many of the reports contained insufficient information to assess risk of bias.'],0,0.4166666666666667,3,12
CD003643,2,5,"Amongst the six studies comparing immunosuppressant with placebo, one study, investigating intravenous immunoglobulin (IVIg), showed statistically significant improvement in scores of muscle strength in the IVIg group over three months.",ignore,"['Amongst the six studies comparing immunosuppressant with placebo, one study, investigating intravenous immunoglobulin (IVIg), showed statistically significant improvement in scores of muscle strength in the IVIg group over three months.']",1,0.5,3,12
CD003643,2,6,"Another study investigating etanercept showed some evidence of a longer median time to relapse in the etanercept group, a secondary outcome in this review, but no improvement in other assessed outcomes.",ignore,"['Another study investigating etanercept showed some evidence of a longer median time to relapse in the etanercept group, a secondary outcome in this review, but no improvement in other assessed outcomes.']",2,0.5833333333333334,3,12
CD003643,2,7,"The other four randomised placebo-controlled trials assessed either plasma exchange and leukapheresis, eculizumab, infliximab or azathioprine against placebo and all produced negative results.",ignore,"['The other four randomised placebo-controlled trials assessed either plasma exchange and leukapheresis, eculizumab, infliximab or azathioprine against placebo and all produced negative results.']",3,0.6666666666666666,4,12
CD003643,3,8,"Three of the four studies comparing two immunosuppressant regimes (azathioprine with methotrexate, ciclosporin with methotrexate, and intramuscular methotrexate with oral methotrexate plus azathioprine) showed no statistically significant difference in efficacy between the treatment regimes.",ignore,"['Three of the four studies comparing two immunosuppressant regimes (azathioprine with methotrexate, ciclosporin with methotrexate, and intramuscular methotrexate with oral methotrexate plus azathioprine) showed no statistically significant difference in efficacy between the treatment regimes.']",4,0.75,4,12
CD003643,3,9,The fourth study comparing pulsed oral dexamethasone with daily oral prednisolone and found that the dexamethasone regime had a shorter median time to relapse but fewer side effects.,ignore,['The fourth study comparing pulsed oral dexamethasone with daily oral prednisolone and found that the dexamethasone regime had a shorter median time to relapse but fewer side effects.'],5,0.8333333333333334,5,12
CD003643,4,10,Immunosuppressants were associated with significant side effects.,ignore,['Immunosuppressants were associated with significant side effects.'],6,0.9166666666666666,5,12
CD003643,5,11,This systematic review highlights the lack of high quality RCTs that assess the efficacy and toxicity of immunosuppressants in inflammatory myositis.,rephrase,['The small number of RCTs of immunosuppressants and immunomodulatory therapies are inadequate to decide whether these agents are beneficial in dermatomyositis and polymyositis.'],7,1.0,5,12
CD009546,0,0,"The search resulted in four potential studies; after inspection, all were excluded.",rephrase,"['The search was carried out 15 November 2012 and resulted in identification of four potential studies, but none could be included.']",0,0.09090909090909091,1,11
CD009546,0,1,Three studies were excluded because they involved people with clozapine-induced hypersalivation - a topic covered in another Cochrane review.,rephrase,['Three of these were excluded because they involved clozapine-related hypersalivation.'],1,0.18181818181818182,1,11
CD009546,0,2,"The fourth study was excluded because it involved people with schizophrenia, mood disorders or other mental disorders who were suffering from clozapine- and non-clozapine induced hypersalivation and were treated with Chinese medicines with unknown anticholinergic properties.",rephrase,['The fourth study was excluded because it involved people with mood or other mental disorders and Chinese medicines.'],2,0.2727272727272727,2,11
CD009546,0,3,People in the control group received an anticholinergic drug (artane) or an antihistamine (phenergan).,delete,[],3,0.36363636363636365,2,11
CD009546,0,4,"It was not possible to separate clozapine- from non-clozapine-treated people in the intervention group, or to separate artane-treated people from phenergan-treated people in the control group.",delete,[],3,0.45454545454545453,3,11
CD009546,1,5,We have been unable to locate any studies addressing the question raised in this review.,delete,[],3,0.5454545454545454,3,11
CD009546,1,6,"Accordingly, this empty review points out an important clinical problem that needs to be investigated via well-designed and well-conducted randomised trials.",rephrase,['Dribbling or hypersalivation is an important problem that needs to be investigated via well-designed research and randomised trials.'],3,0.6363636363636364,4,11
CD009546,1,7,Clinicians and patients are likely to continue with their current dependence on clinical judgement and personal experience.,rephrase,"['Until such time, psychiatrists and patients are likely to continue their treatment of hypersalivation on the basis of daily clinical judgement and personal experience rather than hard evidence.']",4,0.7272727272727273,4,11
CD009546,1,8,Policy makers have no trial-based evidence upon which to base guidelines for the treatment of hypersalivation induced by neuroleptics other than clozapine.,rephrase,['Treatment of hypersalivation caused by antipsychotics or neuroleptics other than clozapine does not seem to have received adequate research attention to help guide practice.'],5,0.8181818181818182,5,11
CD009546,1,9,They are likely to continue to rely on opinion and habit when making recommendations.,delete,[],6,0.9090909090909091,5,11
CD009546,1,10,Funders of studies may wish to make this important subgroup of people a priority in future research.,delete,[],6,1.0,5,11
CD006774,0,0,Five studies were eligible for inclusion (329 patients).,rephrase,['The researchers identified five studies that included a total of 329 patients.'],0,0.05555555555555555,1,18
CD006774,0,1,"Three studies (270 patients) compared low molecular weight heparin to placebo, one study (34 patients) compared LMWH in addition to standard therapy, and one study (25 patients) compared UFH to corticosteroids.",rephrase,"['Three studies (270 patients) compared low molecular weight heparin to placebo (e.g. a sugar pill), one study (34 patients) compared low molecular weight heparin in addition to standard therapy, and one study (25 patients) compared unfractionated heparin to steroids.']",1,0.1111111111111111,1,18
CD006774,0,2,The study comparing UFH to corticosteroids was rated at high risk of bias due to a single-blind design.,delete,[],2,0.16666666666666666,1,18
CD006774,0,3,The study that compared the addition of LMWH to standard therapy to standard therapy alone was rated at high risk of bias due to open-label design.,rephrase,['The study comparing unfractionated heparin to steroids and the study that compared the addition of low molecular weight heparin to standard therapy to standard therapy alone was judged to be of low quality.'],2,0.2222222222222222,2,18
CD006774,0,4,The other three studies were rated as low risk of bias.,rephrase,['The three placebo-controlled studies were judged to be of high quality.'],3,0.2777777777777778,2,18
CD006774,0,5,"LMWH administered subcutaneously showed no benefit over placebo for any outcome, including clinical remission (very low quality of evidence), and clinical, endoscopic, or histological improvement.",rephrase,"['Low molecular weight heparin administered by injection showed no benefit over placebo for any outcome, including clinical remission (very low quality of evidence), clinical improvement and endoscopic improvement (i.e. healing of inflammation).']",4,0.3333333333333333,2,18
CD006774,0,6,"High dose LMWH administered via an extended colon-release tablet demonstrated benefit over placebo for clinical remission (RR 1.39; 95% CI 1.09 to 1.77 ; P = 0.008; very low quality of evidence), clinical improvement (RR 1.28; 95% CI 1.06 to 1.55; P = 0.01; very low quality of evidence), and endoscopic improvement (RR 1.21; 95% CI 1.00 to 1.47 ; P = 0.05) but not endoscopic remission or histologic improvement.",rephrase,"['High dose low molecular weight heparin administered via an extended colon-release tablet demonstrated benefit over placebo for clinical remission, clinical improvement.']",5,0.3888888888888889,2,18
CD006774,0,7,"LMWH was not beneficial when added to standard therapy for clinical remission, clinical improvement, endoscopic remission or endoscopic improvement.",rephrase,['and endoscopic improvement.'],6,0.4444444444444444,3,18
CD006774,0,8,LMWH was well-tolerated but provided no significant benefit for quality of life.,delete,[],7,0.5,3,18
CD006774,0,9,One study examining UFH versus corticosteroids for the treatment of severe UC demonstrated the inferiority of UFH for clinical improvement.,delete,[],7,0.5555555555555556,3,18
CD006774,0,10,More patients assigned to UFH had rectal hemorrhage as an adverse event.,delete,[],7,0.6111111111111112,4,18
CD006774,1,11,There is evidence to suggest that LMWH may be effective for the treatment of active UC.,rephrase,['This result suggests that high dose low molecular weight heparin administered by extended-release capsules may be effective for the treatment of active ulcerative colitis.'],7,0.6666666666666666,4,18
CD006774,1,12,"When administered by extended colon-release tablets, LMWH was more effective than placebo for treating outpatients with mild to moderate disease.",delete,[],8,0.7222222222222222,4,18
CD006774,1,13,This benefit needs to be confirmed by further randomized controlled studies.,rephrase,"['However, this result needs to be verified by future clinical trials.']",8,0.7777777777777778,4,18
CD006774,1,14,The same benefits were not seen when LMWH was administered subcutaneously at lower doses.,delete,[],9,0.8333333333333334,5,18
CD006774,1,15,There is no evidence to support the use of UFH for the treatment of active UC.,delete,[],9,0.8888888888888888,5,18
CD006774,1,16,A further trial of UFH in patients with mild disease may also be justified.,delete,[],9,0.9444444444444444,5,18
CD006774,1,17,Any benefit found would need to be weighed against a possible increased risk of rectal bleeding in patients with active UC.,delete,[],9,1.0,5,18
CD002259,0,0,"One randomised controlled trial has compared pramipexole with bromocriptine using a double-blind, parallel group, multicentre design.",rephrase,['One trial compared pramipexole with bromocriptine but this was not designed to examine differences between the two treatments as there were too few patients included.'],0,0.09090909090909091,1,11
CD002259,0,1,It was not powered to examine differences between active treatment arms.,delete,[],1,0.18181818181818182,1,11
CD002259,0,2,"There was a larger reduction in off time with pramipexole therapy compared with bromocriptine (weighted mean difference 1.4 hours; 0, 2.8, 95% CI).",rephrase,"['However, there was a larger reduction in the time patients spent in the immobile off state with pramipexole therapy compared with bromocriptine by an average of 1.4 hours.']",1,0.2727272727272727,2,11
CD002259,0,3,"No differences occurred in dyskinesia rating scale, dyskinesia as an adverse event or UPDRS complication score.",rephrase,"[""No differences occurred in dyskinesia rating scale, dyskinesia as a side effect or Unified Parkinson's Disease Rating Scale (UPDRS) complication score.""]",2,0.36363636363636365,2,11
CD002259,0,4,The UPDRS ADL and motor scores showed similar improvements compared to placebo with both agonists.,rephrase,['The UPDRS activities of daily living and motor scores showed similar improvements compared to placebo with both agonists.'],3,0.45454545454545453,3,11
CD002259,0,5,Levodopa dose reduction was similar with both agonists.,ignore,['Levodopa dose reduction was similar with both agonists.'],4,0.5454545454545454,3,11
CD002259,0,6,Subscales of the Functional Status Questionnaire showed significant improvements compared to placebo with both agonists.,rephrase,"['Subscales of a quality of life measure, the Functional Status Questionnaire, showed significant improvements compared to placebo with both agonists.']",5,0.6363636363636364,4,11
CD002259,0,7,The finding that the EuroQol improved significantly compared with placebo with pramipexole but not bromocriptine should be treated with caution.,rephrase,"['The finding that another quality of life scale, the EuroQol, improved significantly compared with placebo with pramipexole but not bromocriptine should be treated with caution.']",6,0.7272727272727273,4,11
CD002259,0,8,"Dopaminergic adverse events were similar with each agonist, as was the all cause withdrawal rate.",rephrase,"['Side effects such as nausea, vomiting, and faintness were similar with each agonist, as was the withdrawal from treatment rate.']",7,0.8181818181818182,5,11
CD002259,1,9,"Although pramipexole and bromocriptine improved off time and reduced parkinsonian motor impairments and disability compared with placebo, no conclusions regarding their comparative effectiveness and safety can be drawn as this single trial did not have adequate power to assess such differences.",rephrase,['No conclusions regarding the comparative effectiveness and safety of pramipexole versus bromocriptine can be drawn as this single trial did not have adequate numbers of patients to assess such differences.'],8,0.9090909090909091,5,11
CD002259,1,10,Further larger trials are required to examine this issue in the future.,ignore,['Further larger trials are required to examine this issue in the future.'],9,1.0,5,11
CD006780,0,0,Our search strategy identified 18 reports of 14 studies for consideration.,delete,[],0,0.16666666666666666,1,6
CD006780,0,1,"The original review included five studies (484 women) which met the inclusion criteria, with a further five studies included in the updated review, involving an additional 655 women.",rephrase,['Ten randomised trials involving 1139 women met the inclusion criteria for the review.'],0,0.3333333333333333,2,6
CD006780,0,2,The overall quality of the included trials was considered fair to good.,delete,[],1,0.5,3,6
CD006780,1,3,Nine studies compared heparin (alone or in combination with dipyridamole or low-dose aspirin) with no treatment; and one compared trapidil (triazolopyrimidine).,rephrase,['Nine studies compared heparin (alone or in combination with dipyridamole) with no treatment; and one compared triazolopyrimidine with placebo.'],1,0.6666666666666666,4,6
CD006780,2,4,"While this review identified the use of heparin to be associated with a statistically significant reduction in risk of perinatal mortality (six studies; 653 women; risk ratio (RR) 0.40; 95% confidence intervals (CI) 0.20 to 0.78), preterm birth before 34 (three studies; 494 women; RR 0.46; 95% CI 0.29 to 0.73) and 37 (five studies; 621 women; RR 0.72; 95% CI 0.58 to 0.90) weeks' gestation, and infant birthweight below the 10th centile for gestational age (seven studies; 710 infants; RR 0.41; 95% CI 0.27 to 0.61), there is a lack of reliable information available related to clinically relevant, serious adverse infant health outcomes, which have not been reported to date.",delete,[],2,0.8333333333333334,5,6
CD006780,3,5,"While treatment with heparin for women considered to be at particularly high risk of adverse pregnancy complications secondary to placental insufficiency was associated with a statistically significant reduction in risk of perinatal mortality, preterm birth before 34 and 37 weeks' gestation, and infant birthweight below the 10th centile for gestational age when compared with no treatment for women considered at increased risk of placental dysfunction, to date, important information about serious adverse infant and long-term childhood outcomes is unavailable.",rephrase,"['To date, important information about serious adverse infant and long-term childhood outcomes with using anti-clotting medications is unavailable.']",2,1.0,5,6
CD006755,0,0,We included four studies with 166 participants.,rephrase,"['This review of four studies with 166 relevant participants, looked at whether participating in home-based therapy programmes, targeted at the upper limb, could improve performance in activities of daily living (ADL), functional movement of the upper limb, performance in extended ADL and arm motor impairment.']",0,0.14285714285714285,1,7
CD006755,0,1,No studies compared the effects of home-based upper limb therapy programmes with placebo or no intervention.,rephrase,['Further research is needed to determine the effects of home-based therapy programmes.'],1,0.2857142857142857,2,7
CD006755,0,2,Three studies compared the effects of home-based upper limb therapy programmes with usual care.,rephrase,"['In comparison with usual care, home-based upper limb programmes had no difference in effect on any of the outcomes.']",2,0.42857142857142855,3,7
CD006755,0,3,Primary outcomes: we found no statistically significant result for performance of ADL (mean difference (MD) 2.85; 95% confidence interval (CI) -1.43 to 7.14) or functional movement of the upper limb (MD 2.25; 95% CI -0.24 to 4.73)).,delete,[],3,0.5714285714285714,3,7
CD006755,0,4,Secondary outcomes: no statistically significant results for extended ADL (MD 0.83; 95% CI -0.51 to 2.17)) or upper limb motor impairment (MD 1.46; 95% CI -0.58 to 3.51).,delete,[],3,0.7142857142857143,4,7
CD006755,0,5,"One study compared the effects of a home-based upper limb programme with the same upper limb programme based in hospital, measuring upper limb motor impairment only; we found no statistically significant difference between groups (MD 0.60; 95% CI -8.94 to 10.14).",rephrase,"['In comparison with an upper limb programme based in hospital, we found home-based upper limb programmes to be no more or no less effective for arm motor impairment outcomes.']",3,0.8571428571428571,5,7
CD006755,1,6,"There is insufficient good quality evidence to make recommendations about the relative effect of home-based therapy programmes compared with placebo, no intervention or usual care.",delete,[],4,1.0,5,7
CD004726,0,0,Two studies met the inclusion criteria.,rephrase,['Two studies were included in this review.'],0,0.09090909090909091,1,11
CD004726,0,1,No study looked at our main outcome: dog bite rates.,delete,[],1,0.18181818181818182,1,11
CD004726,0,2,The included studies were randomised controlled trials conducted in kindergarten and primary schools.,delete,[],1,0.2727272727272727,2,11
CD004726,0,3,Their methodology was of moderate quality.,rephrase,['Both were of moderate methodological quality and evaluated the effectiveness of educating children on preventing dog bite injuries.'],1,0.36363636363636365,2,11
CD004726,0,4,One study showed that the intervention group showed less 'inappropriate behaviour' when observed in the presence of a dog after a 30-minute educational intervention.,rephrase,['Both studies involved a 30-minute lesson.'],2,0.45454545454545453,3,11
CD004726,0,5,Another study showed an increase in knowledge and in caution after an information programme.,delete,[],3,0.5454545454545454,3,11
CD004726,1,6,There is no direct evidence that educational programmes can reduce dog bite rates in children and adolescents.,rephrase,['It is unclear from this review whether educating children can reduce dog bite injuries as dog bite rates were not reported as an outcome in either of the included studies.'],3,0.6363636363636364,4,11
CD004726,1,7,"Educating children who are less than 10 years old in school settings could improve their knowledge, attitude and behaviour towards dogs.",merge,[],4,0.7272727272727273,4,11
CD004726,1,8,Educating children and adolescents in settings other than schools should also be evaluated.,none,['The effect of educating children and adolescents in settings other than schools has not been evaluated.'],4,0.8181818181818182,5,11
CD004726,1,9,There is a need for high quality studies that measure dog bite rates as an outcome.,delete,[],5,0.9090909090909091,5,11
CD004726,1,10,"To date, evidence does not suggest that educating children and adolescents is effective as a unique public health strategy to reduce dog bite injuries and their consequences.",split,"['There is a general lack of evidence about the impact of education\xa0to prevent dog bites in children and adolescents, therefore further studies that look at dog bite rates after an intervention are recommended.', 'Education of children and adolescents should not be the only public health strategy to reduce dog bites and their dramatic consequences.']",5,1.0,5,11
CD001877,0,0,Eight eligible trials were identified.,delete,[],0,0.07692307692307693,1,13
CD001877,0,1,"We excluded a trial because the randomisation had failed to produce comparable groups.The eligible trials included 600,000 women in the analyses in the age range 39 to 74 years.",rephrase,"['The review includes seven trials that involved 600,000 women in the age range 39 to 74 years who were randomly assigned to receive screening mammograms or not.']",0,0.15384615384615385,1,13
CD001877,0,2,"Three trials with adequate randomisation did not show a statistically significant reduction in breast cancer mortality at 13 years (relative risk (RR) 0.90, 95% confidence interval (CI) 0.79 to 1.02); four trials with suboptimal randomisation showed a significant reduction in breast cancer mortality with an RR of 0.75 (95% CI 0.67 to 0.83).",delete,[],1,0.23076923076923078,2,13
CD001877,0,3,The RR for all seven trials combined was 0.81 (95% CI 0.74 to 0.87).,delete,[],1,0.3076923076923077,2,13
CD001877,1,4,"We found that breast cancer mortality was an unreliable outcome that was biased in favour of screening, mainly because of differential misclassification of cause of death.",split,"['The studies which provided the most reliable information showed that screening did not reduce breast cancer mortality.', 'Studies that were potentially more biased (less carefully done) found that screening reduced breast cancer mortality.']",1,0.38461538461538464,2,13
CD001877,1,5,"The trials with adequate randomisation did not find an effect of screening on total cancer mortality, including breast cancer, after 10 years (RR 1.02, 95% CI 0.95 to 1.10) or on all-cause mortality after 13 years (RR 0.99, 95% CI 0.95 to 1.03).",delete,[],3,0.46153846153846156,3,13
CD001877,2,6,"Total numbers of lumpectomies and mastectomies were significantly larger in the screened groups (RR 1.31, 95% CI 1.22 to 1.42), as were number of mastectomies (RR 1.20, 95% CI 1.08 to 1.32).",delete,[],3,0.5384615384615384,3,13
CD001877,2,7,The use of radiotherapy was similarly increased whereas there was no difference in the use of chemotherapy (data available in only two trials).,delete,[],3,0.6153846153846154,4,13
CD001877,3,8,"If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and overtreatment is at 30%, it means that for every 2000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily.",ignore,"['If we assume that screening reduces breast cancer mortality by 15% after 13 years of follow-up and that overdiagnosis and overtreatment is at 30%, it means that for every 2000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily.']",3,0.6923076923076923,4,13
CD001877,3,9,"Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings.",ignore,"['Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings.']",4,0.7692307692307693,4,13
CD001877,3,10,"To help ensure that the women are fully informed before they decide whether or not to attend screening, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.",rephrase,"['To help ensure that the requirements for informed choice for women contemplating whether or not to attend a screening programme can be met, we have written an evidence-based leaflet for lay people that is available in several languages on www.cochrane.dk.']",5,0.8461538461538461,5,13
CD001877,3,11,"Because of substantial advances in treatment and greater breast cancer awareness since the trials were carried out, it is likely that the absolute effect of screening today is smaller than in the trials.",ignore,"['Because of substantial advances in treatment and greater breast cancer awareness since the trials were carried out, it is likely that the absolute effect of screening today is smaller than in the trials.']",6,0.9230769230769231,5,13
CD001877,3,12,Recent observational studies show more overdiagnosis than in the trials and very little or no reduction in the incidence of advanced cancers with screening.,ignore,['Recent observational studies show more overdiagnosis than in the trials and very little or no reduction in the incidence of advanced cancers with screening.'],7,1.0,5,13
CD011859,0,0,We identified 15 studies described in 27 articles that met our inclusion criteria.,rephrase,['We found 15 studies that provided the information we were looking for in conducting this review.'],0,0.0625,1,16
CD011859,0,1,These 15 included studies randomised a total of 3062 participants (PAAP vs no PAAP: 2602 participants; PAAP plus education vs education alone: 460 participants).,rephrase,"['A total of 3062 people had taken part in these studies; 2602 people took part in 11 studies looking at PAAP versus no PAAP, and 460 people were included in four studies looking at PAAP and education versus just education.']",1,0.125,1,16
CD011859,0,2,Ten studies (eight PAAP vs no PAAP; two PAAP plus education vs education alone) provided outcome data that contributed to quantitative analyses.,delete,[],2,0.1875,1,16
CD011859,0,3,The overall quality of evidence was rated as low or very low.,rephrase,"['We rated the quality of the 15 included studies as low or very low because the few studies included in this review had problems with study design, including how to enrol people into the study and how to handle missing data for some people.']",2,0.25,2,16
CD011859,1,4,"Fourteen studies lasted six months or longer, and the remaining study lasted for 14 weeks.",rephrase,['Fourteen studies lasted six months or longer.'],3,0.3125,2,16
CD011859,1,5,"When reported, mean age ranged from 22 to 49 years and asthma severity ranged from mild to severe/high risk.",split,"['The average age of people in these studies ranged from 22 to 49 years.', 'Asthma severity ranged from mild to severe.']",4,0.375,2,16
CD011859,2,6,"PAAP alone compared with no PAAP
Results showed no clear benefit or harm associated with PAAPs in terms of the number of participants requiring an ED visit or hospitalisation for an exacerbation (odds ratio (OR) 0.75, 95% confidence interval (CI) 0.45 to 1.24; 1385 participants; five studies; low-quality evidence), change from baseline in asthma symptoms (mean difference (MD) -0.16, 95% CI -0.25 to - 0.07; 141 participants; one study; low-quality evidence) or the number of serious adverse events, including death (OR 3.26, 95% CI 0.33 to 32.21; 125 participants; one study; very low-quality evidence).",rephrase,['PAAP alone compared with no PAAP: People using a PAAP did not show any difference (good or bad) in terms of having to go to the hospital because their asthma worsened compared with people not using a PAAP.'],6,0.4375,3,16
CD011859,2,7,"Data revealed a statistically significant improvement in quality of life scores for those receiving PAAP compared with no PAAP (MD 0.18, 95% CI 0.05 to 0.30; 441 participants; three studies; low-quality evidence), but this was below the threshold for a minimum clinically important difference (MCID).",rephrase,"['People with a PAAP showed no improvement in their quality of life compared with those without a PAAP, but the difference was not large enough to be meaningful.']",7,0.5,3,16
CD011859,2,8,"Results also showed no clear benefit or harm associated with PAAPs on the number of participants reporting at least one exacerbation requiring oral corticosteroids (OR 1.45, 95% CI 0.84 to 2.48; 1136 participants; three studies; very low-quality evidence) nor on respiratory function (change from baseline forced expiratory volume in one second (FEV1): MD -0.04 L, 95% CI -0.25L to 0.17 L; 392 participants; three studies; low-quality evidence).",delete,[],8,0.5625,3,16
CD011859,2,9,"In one study, PAAPs were associated with significantly fewer days lost from work or study (MD -6.20, 95% CI -7.32 to - 5.08; 74 participants; low-quality evidence).",delete,[],8,0.625,4,16
CD011859,3,10,"PAAP plus education compared with education alone
Results showed no clear benefit or harm associated with adding a PAAP to education in terms of the number of participants requiring an ED visit or hospitalisation for an exacerbation (OR 1.08, 95% CI 0.27 to 4.32; 70 participants; one study; very low-quality evidence), change from baseline in asthma symptoms (MD -0.10, 95% CI -0.54 to 0.34; 70 participants; one study; low-quality evidence), change in quality of life scores from baseline (MD 0.13, 95% CI -0.13 to 0.39; 174 participants; one study; low-quality evidence) and number of participants requiring oral corticosteroids for an exacerbation (OR 0.28, 95% CI 0.07 to 1.12; 70 participants; one study; very low-quality evidence).",rephrase,['PAAP plus education compared with education alone: Review authors found no real difference - good or bad - between people using a PAAP and education and those just receiving education.'],8,0.6875,4,16
CD011859,3,11,"No studies reported serious adverse events, respiratory function or days lost from work or study.",delete,[],9,0.75,4,16
CD011859,4,12,"Analysis of available studies was limited by variable reporting of primary and secondary outcomes; therefore, it is difficult to draw firm conclusions related to the effectiveness of PAAPs in the management of adult asthma.",delete,[],9,0.8125,5,16
CD011859,4,13,"We found no evidence from randomised controlled trials of additional benefit or harm associated with use of PAAP versus no PAAP, or PAAP plus education versus education alone, but we considered the quality of the evidence to be low or very low, meaning that we cannot be confident in the magnitude or direction of reported treatment effects.",delete,[],9,0.875,5,16
CD011859,4,14,"In the context of this caveat, we found no observable effect on the primary outcomes of hospital attendance with an asthma exacerbation, asthma symptom scores or adverse events.",delete,[],9,0.9375,5,16
CD011859,4,15,"We recommend further research with a particular focus on key patient-relevant outcomes, including exacerbation frequency and quality of life, in a broad spectrum of adults, including those over 60 years of age.",delete,[],9,1.0,5,16
CD012326,0,0,"We included three randomised controlled trials (351 participants) investigating immediate versus delayed chemotherapy in people diagnosed with asymptomatic, metastatic, incurable colorectal cancer.",split,"['We included three randomised clinical trials.', 'In these trials, people with metastatic and incurable colorectal cancer, without symptoms, received chemotherapy straight away (standard group) or their chemotherapy was delayed (intervention group).']",0,0.16666666666666666,1,6
CD012326,0,1,"Giving immediate versus delayed chemotherapy may make little or no difference to overall survival (hazard ratio (HR) 1.17, 95% confidence interval (CI) 0.93 to 1.46; 3 studies, 351 persons; low-quality evidence).",delete,[],2,0.3333333333333333,2,6
CD012326,0,2,"For toxicity, giving immediate versus delayed chemotherapy may make little or no difference to the risk of grade 3 or 4 nausea and vomiting (risk ratio (RR) 0.84, 95% CI 0.31 to 2.25; 2 studies, 140 persons; very low-quality evidence), stomatitis (RR 1.10, 95% CI 0.47 to 2.55; 2 studies, 140 persons; very low-quality evidence), or diarrhoea (RR 0.69, 95% CI 0.34 to 1.40; 2 studies, 140 persons, very low-quality evidence).",delete,[],2,0.5,3,6
CD012326,0,3,"We are uncertain whether delayed chemotherapy made a difference to quality of life (very low-quality evidence), progression-free survival (low-quality evidence), or compliance with chemotherapy (low-quality evidence), as we had insufficient data to pool for these outcomes.",rephrase,"['There were insufficient data to compare other outcomes of interest, such as quality of life, progression-free survival (the length of time during and after treatment that a person lives with the disease, but it does not get worse), and compliance with chemotherapy (whether a participant was able to complete the chemotherapy regimen).']",2,0.6666666666666666,4,6
CD012326,1,4,"Based on a limited number of trials, very sparse data, and uncertainty of the evidence, this review was unable to establish whether there was a difference in overall survival or other clinically relevant outcomes, between immediate or delayed chemotherapy in persons with metastatic, incurable, colorectal cancer.",rephrase,"['Based on very sparse data and uncertainty of the evidence, we were unable to establish whether there was a difference in overall survival and other important outcomes in people with metastatic, incurable, colorectal cancer, who received chemotherapy either straight away or waited until after symptoms had appeared.']",3,0.8333333333333334,5,6
CD012326,1,5,The results should be interpreted with caution.,delete,[],4,1.0,5,6
CD004085,0,0,We include 10 RCTs (n = 1850); almost all participants had moderate or severe ARDS.,rephrase,['We included 10 randomized controlled trials (RCTs) enrolling 1850 participants in this updated review.'],0,0.14285714285714285,1,7
CD004085,0,1,"For the primary analysis, the risk of bias was low in three studies and unclear in five studies; the overall quality of evidence was very low due to imprecision, inconsistency, indirectness and methodologic limitations.",delete,[],1,0.2857142857142857,2,7
CD004085,0,2,"In participants randomized to HFO, there was no significant difference in hospital or 30-day mortality (risk ratio (RR) 0.92, 95% confidence interval (CI) 0.72 to 1.16; P = 0.46, I² = 66%; 8 trials, 1779 participants, 807 deaths) compared with conventional ventilation.",rephrase,['HFO did not reduce the risk of death in hospital in eight trials enrolling 1779 participants.'],1,0.42857142857142855,3,7
CD004085,0,3,"One large multicentre RCT was terminated early because of increased mortality in participants randomized to HFO compared to mechanical ventilation with low tidal volume and high positive end expiratory pressure, with HFO reserved only as a rescue therapy.",rephrase,['One large trial was stopped early because of increased deaths among participants who were randomized to HFO.'],2,0.5714285714285714,3,7
CD004085,0,4,"We found substantial between-trial statistical heterogeneity (I² = 0% to 66%) for clinical outcomes, including mortality.",rephrase,['We found substantial inconsistency among clinical trials which reported the effect of HFO on the risk of death in participants with ARDS.'],3,0.7142857142857143,4,7
CD004085,1,5,The findings of this systematic review suggest that HFO does not reduce hospital and 30-day mortality due to ARDS; the quality of evidence was very low.,rephrase,['The quality of evidence is very low for outcomes that would be most important to patients.'],4,0.8571428571428571,5,7
CD004085,1,6,Our findings do not support the use of HFO as a first-line strategy in people undergoing mechanical ventilation for ARDS.,delete,[],5,1.0,5,7
CD000530,0,0,Twenty-four double-blind trials with 4631 participants including a total of 33 comparisons of Echinacea preparations and placebo met the inclusion criteria.,rephrase,['We reviewed 24 controlled clinical trials with 4631 participants investigating the effectiveness of several different Echinacea preparations for preventing and treating common colds or induced rhinovirus infections.'],0,0.08333333333333333,1,12
CD000530,0,1,A variety of different Echinacea preparations based on different species and parts of plant were used.,rephrase,"['Our review shows that a variety of products prepared from different Echinacea species, different plant parts and in a different form have been compared to placebo in randomized trials.']",1,0.16666666666666666,1,12
CD000530,0,2,Evidence from seven trials was available for preparations based on the aerial parts of Echinacea purpurea.,delete,[],2,0.25,2,12
CD000530,1,3,"Ten trials were considered to have a low risk of bias, six to have an unclear risk of bias and eight to have a high risk of bias.",split,"[""Five trials were rated as having a low risk of bias in all five categories of the Cochrane 'Risk of bias' tool."", 'Five more trials were rated as low risk of bias, having an unclear risk of bias in only one category.', 'Eight trials were rated as having a high risk of bias in at least one category and the remaining six as having an unclear risk of bias.']",2,0.3333333333333333,2,12
CD000530,1,4,Ten trials with 13 comparisons investigated prevention and 15 trials with 20 comparisons investigated treatment of colds (one trial addressed both prevention and treatment).,delete,[],5,0.4166666666666667,3,12
CD000530,2,5,Due to the strong clinical heterogeneity of the studies we refrained from pooling for the main analysis.,delete,[],5,0.5,3,12
CD000530,2,6,None of the 12 prevention comparisons reporting the number of patients with at least one cold episode found a statistically significant difference.,delete,[],5,0.5833333333333334,3,12
CD000530,2,7,"However a post hoc pooling of their results, suggests a relative risk reduction of 10% to 20%.",delete,[],5,0.6666666666666666,4,12
CD000530,2,8,"Of the six treatment trials reporting data on the duration of colds, only two showed a significant effect of Echinacea over placebo.",rephrase,"['The majority of trials investigated whether taking Echinacea preparations after the onset of cold symptoms shortens the duration, compared with placebo.']",5,0.75,4,12
CD000530,2,9,The number of patients dropping out or reporting adverse effects did not differ significantly between treatment and control groups in prevention and treatment trials.,ignore,['The number of patients dropping out or reporting adverse effects did not differ significantly between treatment and control groups in prevention and treatment trials.'],6,0.8333333333333334,5,12
CD000530,2,10,"However, in prevention trials there was a trend towards a larger number of patients dropping out due to adverse events in the treatment groups.",ignore,"['However, in prevention trials there was a trend towards a larger number of patients dropping out due to adverse events in the treatment groups.']",7,0.9166666666666666,5,12
CD000530,3,11,"Echinacea products have not here been shown to provide benefits for treating colds, although, it is possible there is a weak benefit from some Echinacea products: the results of individual prophylaxis trials consistently show positive (if non-significant) trends, although potential effects are of questionable clinical relevance.",rephrase,"['Although it seems possible that some Echinacea products are more effective than a placebo for treating colds, the overall evidence for clinically relevant treatment effects is weak.']",8,1.0,5,12
CD006553,0,0,We included two trials comparing planned caesarean section versus planned vaginal birth for twin pregnancies.,rephrase,['In this review we included two randomised trials comparing planned caesarean versus planned vaginal birth for twin pregnancies which together included 2864 women.'],0,0.05555555555555555,1,18
CD006553,1,1,Most of the data included in the review were from a multicentre trial where 2804 women were randomised in 106 centres in 25 countries.,delete,[],1,0.1111111111111111,1,18
CD006553,1,2,"All centres had facilities to perform emergency caesarean section and had anaesthetic, obstetrical, and nursing staff available in the hospital at the time of planned vaginal delivery.",delete,[],1,0.16666666666666666,1,18
CD006553,1,3,"In the second trial carried out in Israel, 60 women were randomised.",delete,[],1,0.2222222222222222,2,18
CD006553,1,4,We judged the risk of bias to be low for all categories except performance (high) and outcome assessment bias (unclear).,delete,[],1,0.2777777777777778,2,18
CD006553,2,5,"There was no clear evidence of differences between women randomised to planned caesarean section or planned vaginal birth for maternal death or serious morbidity (risk ratio (RR) 0.86, 95% confidence interval (CI) 0.67 to 1.11; 2844 women; two studies; moderate quality evidence).",merge,['There was no clear evidence of differences between women randomised to planned caesarean or planned vaginal birth for death or serous illness in either the mothers or babies.'],1,0.3333333333333333,2,18
CD006553,2,6,"There was no significant difference between groups for perinatal or neonatal death or serious neonatal morbidity (RR 1.15, 95% CI 0.80 to 1.67; data for 5565 babies, one study, moderate quality evidence).",none,[],1,0.3888888888888889,2,18
CD006553,2,7,No studies reported childhood disability.,ignore,['No studies reported childhood disability.'],2,0.4444444444444444,3,18
CD006553,3,8,"For secondary outcomes there was no clear evidence of differences between groups for perinatal or neonatal mortality (RR 1.41, 95% CI 0.76 to 2.62; 5685 babies; two studies, moderate quality evidence), serious neonatal morbidity (RR 1.03, 95% CI 0.65 to 1.64; 5644 babies; two studies, moderate quality evidence) or any of the other neonatal outcomes reported.",delete,[],3,0.5,3,18
CD006553,4,9,The number of women undergoing caesarean section was reported in both trials.,ignore,['The number of women undergoing caesarean section was reported in both trials.'],3,0.5555555555555556,3,18
CD006553,4,10,"Most women in the planned caesarean group had treatment as planned (90.9% underwent caesarean section), whereas in the planned vaginal birth group 42.9% had caesarean section for at least one twin.",ignore,"['Most women in the planned caesarean group had treatment as planned (90.9%), whereas in the planned vaginal birth group 42.9% had caesarean section for at least one twin.']",4,0.6111111111111112,4,18
CD006553,4,11,For maternal mortality; no events were reported in one trial and two deaths (one in each group) in the other.,ignore,['For maternal mortality no events were reported in one trial and two deaths (one in each group) in the other.'],5,0.6666666666666666,4,18
CD006553,4,12,"There were no significant differences between groups for serious maternal morbidity overall (RR 0.86, 95% CI 0.67 to 1.11; 2844 women; two studies) or for different types of short-term morbidity.",merge,[],6,0.7222222222222222,4,18
CD006553,4,13,"There were no significant differences between groups for failure to breastfeed (RR 1.14, 95% CI 0.95 to 1.38; 2570 women, one study; moderate quality evidence) or the number of women with scores greater than 12 on the Edinbugh postnatal depression scale (RR 0.95, 95% CI 0.78 to 1.14; 2570 women, one study; moderate quality evidence).",none,['There were no significant differences between groups for failure to breastfeed or for postnatal depression.'],6,0.7777777777777778,4,18
CD006553,5,14,"Data mainly from one large, multicentre study found no clear evidence of benefit from planned caesarean section for term twin pregnancies with leading cephalic presentation.",rephrase,['There is very little clear research evidence to provide guidance on the method of birth for twin pregnancies.'],7,0.8333333333333334,5,18
CD006553,5,15,Data on long-term infant outcomes are awaited.,delete,[],8,0.8888888888888888,5,18
CD006553,5,16,Women should be informed of possible risks and benefits of labour and vaginal birth pertinent to their specific clinical presentation and the current and long-term effects of caesarean section for both mother and babies.,rephrase,"['The benefits and risks should be made available to women, including short-term and long-term consequences for both mother and babies.']",8,0.9444444444444444,5,18
CD006553,5,17,"There is insufficient evidence to support the routine use of planned caesarean section for term twin pregnancy with leading cephalic presentation, except in the context of further randomised trials.",delete,[],9,1.0,5,18
CD013573,0,0,"We included 34 RCTs with 11,571 participants.",delete,[],0,0.058823529411764705,1,17
CD013573,0,1,Data for meta-analysis were available from only 22 studies with 6887 participants.,rephrase,['These 22 studies involved a total of 6887 people with asymptomatic carotid stenosis.'],0,0.11764705882352941,1,17
CD013573,0,2,The mean follow-up period was 2.5 years.,rephrase,['The average follow-up period was under three years.'],1,0.17647058823529413,1,17
CD013573,0,3,None of the 34 included studies assessed neurological impairment and quality of life.,rephrase,"[""None of the studies assessed participants for neurological (i.e. brain) damage, and none measured changes in people's quality of life.""]",2,0.23529411764705882,2,17
CD013573,1,4,"Antiplatelet agent (acetylsalicylic acid) versus placebo
Acetylsalicylic acid (1 study, 372 participants) may result in little to no difference in ipsilateral major or disabling stroke (risk ratio (RR) 1.08, 95% confidence interval (CI) 0.47 to 2.47), stroke-related mortality (RR 1.40, 95% CI 0.54 to 3.59), progression of carotid stenosis (RR 1.16, 95% CI 0.79 to 1.71), and adverse events (RR 0.81, 95% CI 0.41 to 1.59), compared to placebo (all low-certainty evidence).",rephrase,"['Aspirin (1 study; 372 participants) may not prevent stroke, stroke-related death, progression of carotid narrowing, or increase side effects compared to placebo.']",3,0.29411764705882354,2,17
CD013573,1,5,"The effect of acetylsalicylic acid on major bleeding is very uncertain (RR 0.98, 95% CI 0.06 to 15.53; very low-certainty evidence).",rephrase,['We are very uncertain about the effect of aspirin on large bleeding events.'],4,0.35294117647058826,2,17
CD013573,1,6,The study did not measure neurological impairment or quality of life.,delete,[],5,0.4117647058823529,3,17
CD013573,2,7,"Antihypertensive agents (metoprolol and chlorthalidone) versus placebo
The antihypertensive agent, metoprolol, may result in no difference in ipsilateral major or disabling stroke (RR 0.14, 95% CI 0.02 to1.16; 1 study, 793 participants) and stroke-related mortality (RR 0.57, 95% CI 0.17 to 1.94; 1 study, 793 participants) compared to placebo (both low-certainty evidence).",rephrase,"['It is uncertain if metoprolol (1 study, 793 participants) may prevent stroke or stroke-related death.']",5,0.47058823529411764,3,17
CD013573,2,8,"However, chlorthalidone may slow the progression of carotid stenosis (RR 0.45, 95% CI 0.23 to 0.91; 1 study, 129 participants; low-certainty evidence) compared to placebo.",rephrase,"['However, chlorthalidone (1 study, 129 participants) may slow the progression of carotid narrowing compared to placebo.']",6,0.5294117647058824,3,17
CD013573,2,9,"Neither study measured neurological impairment, major bleeding, adverse events, or quality of life.",rephrase,['Neither study measured large bleeding events or side effects.'],7,0.5882352941176471,3,17
CD013573,3,10,"Anticoagulant agent (warfarin) versus placebo
The evidence is very uncertain about the effects of warfarin (1 study, 919 participants) on major bleeding (RR 1.19, 95% CI 0.97 to 1.46; very low-certainty evidence), but it may reduce adverse events (RR 0.89, 95% CI 0.81 to 0.99; low-certainty evidence) compared to placebo.",rephrase,"['It is uncertain whether warfarin (1 study, 919 participants) increases large bleeding events compared to placebo.']",8,0.6470588235294118,4,17
CD013573,3,11,"The study did not measure neurological impairment, ipsilateral major or disabling stroke, stroke-related mortality, progression of carotid stenosis, or quality of life.",rephrase,"['The study did not measure stroke, stroke-related death, or progression of carotid stenosis.']",9,0.7058823529411765,4,17
CD013573,4,12,"Lipid-lowering agents (atorvastatin, fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin) versus placebo or no treatment
Lipid-lowering agents may result in little to no difference in ipsilateral major or disabling stroke (atorvastatin, lovastatin, pravastatin, and rosuvastatin; RR 0.36, 95% CI 0.09 to 1.53; 5 studies, 2235 participants) stroke-related mortality (lovastatin and pravastatin; RR 0.25, 95% CI 0.03 to 2.29; 2 studies, 1366 participants), and adverse events (fluvastatin, lovastatin, pravastatin, probucol, and rosuvastatin; RR 0.76, 95% CI 0.53 to1.10; 7 studies, 3726 participants) compared to placebo or no treatment (all low-certainty evidence).",delete,[],10,0.7647058823529411,4,17
CD013573,4,13,"The studies did not measure neurological impairment, major bleeding, progression of carotid stenosis, or quality of life.",rephrase,['The studies did not measure large bleeding events or progression of carotid stenosis.'],10,0.8235294117647058,5,17
CD013573,5,14,"Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality.",delete,[],11,0.8823529411764706,5,17
CD013573,5,15,High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis.,delete,[],11,0.9411764705882353,5,17
CD013573,5,16,"In the interim, clinicians will have to use other sources of information.",delete,[],11,1.0,5,17
CD007477,0,0,"Two studies (with 203 and 212 people) comparing the efficacy and safety of deferasirox and deferoxamine after 12 months and 24 weeks, respectively, were included.",split,"['Two randomised studies, with moderate overall quality of evidence, comparing deferasirox to deferoxamine were identified.', 'The studies with 203 and 212 participants lasted for 12 months and 24 weeks, respectively.']",0,0.06666666666666667,1,15
CD007477,0,1,"The overall quality, according to GRADE, for the main outcomes was moderate to low.",rephrase,['The overall quality of evidence rated according to the GRADE criteria was moderate due to issues with study design.'],2,0.13333333333333333,1,15
CD007477,0,2,"Only limited data were available on mortality and end-organ damage, although one study did assess mortality, relative risk 1.26 (95% confidence interval 0.05 to 30.41), the 24-week follow up was too short to allow us to draw firm conclusions.",rephrase,['Only little data on patient-important outcomes such as mortality (limited by a short study follow up) and end-organ damage (incidence of diabetes mellitus) were available.'],3,0.2,1,15
CD007477,0,3,One study reported a relative risk of 1.26 for the incidence of type 2 diabetes mellitus (95% confidence interval 0.05 to 30.41).,delete,[],4,0.26666666666666666,2,15
CD007477,0,4,"Serum ferritin reduction was significantly greater with deferoxamine, mean difference of change of 440.69 µg/l (95% confidence interval 11.73 to 869.64).",rephrase,"['Iron removal, as measured by the surrogate marker serum ferritin was significantly greater with deferoxamine.']",4,0.3333333333333333,2,15
CD007477,0,5,"Liver iron concentration (reported in one study) measured by superconduction quantum interference device showed no significant difference for the overall group of patients adjusted for transfusion category, mean difference -0.20 mg Fe/g dry weight (95% confidence interval -3.15 to 2.75).",delete,[],5,0.4,2,15
CD007477,1,6,The occurrence of serious adverse events did not differ between drugs.,delete,[],5,0.4666666666666667,3,15
CD007477,1,7,"Nausea, diarrhoea and rash occurred significantly more often in people treated with deferasirox, while adverse events of any kind were more often reported for patients treated with deferoxamine (one study).",delete,[],5,0.5333333333333333,3,15
CD007477,1,8,"The mean increase of creatinine was also significantly higher with deferasirox, mean difference 3.24 (95% confidence interval 0.45 to 6.03).",delete,[],5,0.6,3,15
CD007477,1,9,Long-term adverse events could not be measured in the included studies (follow up 52 weeks and 24 weeks).,delete,[],5,0.6666666666666666,4,15
CD007477,1,10,"Patient satisfaction and the likelihood of continuing treatment, were significantly better with deferasirox.",rephrase,['Patient satisfaction and compliance with therapy was significantly greater with deferasirox.'],5,0.7333333333333333,4,15
CD007477,2,11,Deferasirox appears to be of similar efficacy to deferoxamine depending on depending on the appropriate ratio of doses of deferoxamine and deferasirox being compared.,rephrase,"['In summary, the evidence from the two included studies suggests that deferasirox is similarly effective as deferoxamine depending on the appropriate ratio of doses of deferoxamine and deferasirox being compared.']",6,0.8,4,15
CD007477,2,12,"However, only limited evidence is available assessing the efficacy regarding patient-important outcomes.",rephrase,['Further data on long-term efficacy on patient-relevant outcomes and long-term adverse effects are needed to decide whether deferasirox should be used as alternative to the first-line option of deferoxamine.'],7,0.8666666666666667,5,15
CD007477,2,13,"The short-term safety of deferasirox seems to be acceptable, however, follow up in the available studies was too short to assess long-term side effects.",merge,"['In the short term, deferasirox appears to have an acceptable safety profile, but there are no comparative data based on randomised controlled trials available looking at long-term safety.']",8,0.9333333333333333,5,15
CD007477,2,14,"Long-term safety and efficacy data are available from a non-controlled extension phase not included in our review; however, no valid comparative conclusions can be drawn and future studies should assess comparatively long-term outcomes both for safety and efficacy.",none,[],8,1.0,5,15
CD013106,0,0,We included 10 randomised clinical trials with 898 participants.,rephrase,['We included 10 randomised clinical trials (clinical studies where people are randomly put into one of two or more treatment groups) with 898 participants.'],0,0.05555555555555555,1,18
CD013106,0,1,We judged all trials at high risk of bias.,rephrase,['All the trials were at high risk of bias.'],1,0.1111111111111111,1,18
CD013106,0,2,"The trials covered oral capsules, intravenous infusion, intramuscular injection, and acupoint (a specifically chosen site of acupuncture) injection of Radix Sophorae flavescentis with a follow-up period from 1 to 12 months.",rephrase,"['The trials covered oral capsules, intravenous (into a vein) infusion, intramuscular (into a muscle) injection, and acupoint (a specifically chosen site of acupuncture) injection of Radix Sophorae flavescentis with treatment duration from 1 month to 12 months.']",2,0.16666666666666666,1,18
CD013106,0,3,"The drugs being used as a comparator were lamivudine, adefovir, interferon, tiopronin, thymosin, or other Chinese herbs.",rephrase,"['Radix Sophorae flavescentis was compared with lamivudine, adefovir, interferon, tiopronin, thymosin, and other Chinese herbs.']",3,0.2222222222222222,2,18
CD013106,0,4,Two trials included children up to 14 years old.,ignore,['Two trials included children up to 14 years old.'],4,0.2777777777777778,2,18
CD013106,0,5,Participants in one trial had cirrhosis in chronic hepatitis B.,rephrase,['Participants in one trial had cirrhosis (late stage of scarring of the liver) in chronic hepatitis B.'],5,0.3333333333333333,2,18
CD013106,0,6,"None of the trials reported all-cause mortality, health-related quality of life, serious adverse events, hepatitis B-related mortality, or morbidity.",delete,[],6,0.3888888888888889,2,18
CD013106,0,7,"We are uncertain as to whether Radix Sophorae flavescentis has a beneficial or harmful effect on adverse events considered 'not to be serious' (RR 0.86, 95% CI 0.42 to 1.75; I2 = 0%; 2 trials, 163 participants; very low-certainty evidence), as well as if it decreases or increases the proportion of participants with detectable HBV-DNA (RR 1.14, 95% CI 0.81 to 1.63; I2 = 92%; 8 trials, 719 participants; very low-certainty evidence).",delete,[],6,0.4444444444444444,3,18
CD013106,0,8,"Radix Sophorae flavescentis showed a reduction in the proportion of participants with detectable hepatitis B virus e-antigen (HBeAg) (RR 0.86, 95% CI 0.75 to 0.98; I2 = 43%; 7 trials, 588 participants; very low-certainty evidence).",delete,[],6,0.5,3,18
CD013106,1,9,"Two of the 10 trials were not funded, and one received academic funding.",rephrase,"['Two of the 10 trials were not funded, and one received governmental funding.']",6,0.5555555555555556,3,18
CD013106,1,10,The remaining seven trials provided no information on funding.,ignore,['The remaining seven trials provided no information on funding.'],7,0.6111111111111112,4,18
CD013106,2,11,The randomisation process in another 109 trials was insufficiently reported to ensure the inclusion of any of these studies in our review.,rephrase,['We identified 109 trials that not be included because of lack of information required for the conduct of this review.'],8,0.6666666666666666,4,18
CD013106,3,12,"The included trials lacked data on all-cause mortality, health-related quality of life, serious adverse events, hepatitis-B related mortality, and hepatitis-B related morbidity.",rephrase,"[""None of the trials reported health-related quality of life (a measure of a person's satisfaction with their life and health), or followed people who have died from any reason or died from hepatitis B, or who were at risk of dying because of hepatitis B.""]",9,0.7222222222222222,4,18
CD013106,3,13,The evidence on the effect of Radix Sophorae flavescentis on the proportion of participants with adverse events considered 'not to be serious' and on the proportion of participants with detectable HBV-DNA is still unclear.,rephrase,"['The certainty of the evidence on the use of Radix Sophorae flavescentis in people with chronic HBV in terms of its beneficial or harmful effects on death, health-related quality of life, risk of dying due to HBV infection, and serious side effects cannot be determined as none of the trials reported patient-relevant outcomes.']",10,0.7777777777777778,4,18
CD013106,3,14,"We advise caution regarding the results of Radix Sophorae flavescentis showing a reduction in the proportion of people with detectable HBeAg because the trials were at high risk of bias, because it is a non-validated surrogate outcome, and because of the very low certainty in the evidence.",split,"[""Our certainty in the evidence that Radix Sophorae flavescentis, when compared with other medicines or herbs, would decrease or increase side effects considered 'not to be serious' and number of people with detectable HBV-DNA is very low."", 'Our certainty in the evidence that Radix Sophorae flavescentis decreases the number of people with detectable HBeAg is also very low.']",11,0.8333333333333334,5,18
CD013106,3,15,"As we were unable to obtain information on a large number of studies regarding their trial design, we were deterred from including them in our review.",delete,[],13,0.8888888888888888,5,18
CD013106,3,16,Undisclosed funding may have influence on trial results and lead to poor design of the trial.,ignore,['Undisclosed funding may have influence on trial results and lead to poor design of the trial.'],13,0.9444444444444444,5,18
CD013106,3,17,"In view of the wide usage of Radix Sophorae flavescentis, we need large, unbiased, high-quality placebo-controlled randomised trials assessing patient-centred outcomes.",delete,[],14,1.0,5,18
CD011364,0,0,We included nine RCTs reporting 748 arterial cannulations in children and adolescents (under 18 years of age) undergoing different surgical procedures.,delete,[],0,0.07142857142857142,1,14
CD011364,0,1,"Eight RCTs compared ultrasound with palpation, and one compared ultrasound with Doppler auditory assistance.",rephrase,['We found nine eligible studies: eight\xa0comparing ultrasound with palpation and one comparing ultrasound with Doppler auditory assistance.'],0,0.14285714285714285,1,14
CD011364,0,2,Five studies reported the incidence of haematomas.,rephrase,['The occurrence of complications such as haematoma and injury caused by reduced blood flow\n3.'],1,0.21428571428571427,2,14
CD011364,0,3,Seven involved radial artery cannulation and two involved femoral artery cannulation.,rephrase,['Seven studies were of radial artery cannulation and two studies were of femoral artery cannulation.'],2,0.2857142857142857,2,14
CD011364,1,4,The people performing arterial cannulation were physicians with different levels of experience.,delete,[],3,0.35714285714285715,2,14
CD011364,1,5,"The risk of bias varied across studies, with some studies lacking details of allocation concealment.",delete,[],3,0.42857142857142855,3,14
CD011364,1,6,It was not possible to blind practitioners in any case; this adds a performance bias that is inherent to the type of intervention studied in our review.,delete,[],3,0.5,3,14
CD011364,2,7,"Compared to traditional methods, ultrasound guidance probably causes a large increase in first-attempt success rates (risk ratio (RR) 2.01, 95% confidence interval (CI) 1.64 to 2.46; 8 RCTs, 708 participants; moderate-certainty evidence) and probably causes a large reduction in the risk of complications such as haematoma formation (RR 0.26, 95% CI 0.14 to 0.47; 5 RCTs, 420 participants; moderate-certainty evidence).",delete,[],3,0.5714285714285714,3,14
CD011364,2,8,No studies reported data about ischaemic damage.,delete,[],3,0.6428571428571429,4,14
CD011364,2,9,"Ultrasound guidance probably improves success rates within two attempts (RR 1.78, 95% CI 1.25 to 2.51; 2 RCTs, 134 participants; moderate-certainty evidence) and overall rate of successful cannulation (RR 1.32, 95% CI 1.10 to 1.59; 6 RCTs, 374 participants; moderate-certainty evidence).",rephrase,"['We found that ultrasound guidance compared with traditional methods probably increases the rate of successful cannulation on first attempt, within the first two attempts, and after several attempts.']",3,0.7142857142857143,4,14
CD011364,2,10,"In addition, ultrasound guidance probably reduces the number of attempts to successful cannulation (mean difference (MD) −0.99 attempts, 95% CI −1.15 to −0.83; 5 RCTs, 368 participants; moderate-certainty evidence) and duration of the cannulation procedure (MD −98.77 seconds, 95% CI −150.02 to −47.52, 5 RCTs, 402 participants; moderate-certainty evidence).",rephrase,"['Ultrasound guidance probably reduces the occurrence of haematoma, the number of attempts needed to successfully place an arterial catheter, and the time needed to perform successful cannulation.']",4,0.7857142857142857,4,14
CD011364,3,11,More studies are needed to confirm whether the improvement in first-attempt success rates is more pronounced in neonates and younger children compared to older children and adolescents.,delete,[],5,0.8571428571428571,5,14
CD011364,4,12,"We identified moderate-certainty evidence that ultrasound guidance for arterial cannulation compared with palpation or Doppler auditory assistance improves first-attempt success rate, second-attempt success rate and overall success rate.",rephrase,['We aimed to find out whether ultrasound offers any advantages over palpation of the artery or Doppler auditory assistance.'],5,0.9285714285714286,5,14
CD011364,4,13,"We also found moderate-certainty evidence that ultrasound guidance reduces the incidence of complications, the number of attempts to successful cannulation and the duration of the cannulation procedure.",rephrase,"['Our confidence in the evidence is only moderate because it was impossible to mask the doctors performing the cannulation (they knew which children had ultrasound-assisted cannulation), and because the studies included few children and reported few events.']",6,1.0,5,14
CD013385,0,0,"Out of 12,984 citations screened, we included 28 studies of decision coaching interventions alone or in combination with evidence-based information, involving 5509 adult participants (aged 18 to 85 years; 64% female, 52% white, 33% African-American/Black; 68% post-secondary education).",rephrase,['We found 28 studies about decision coaching used alone or with high-quality patient information based on research (called ‘evidence-based information’).'],0,0.06666666666666667,1,15
CD013385,0,1,"The studies evaluated decision coaching used for a range of healthcare decisions (e.g. treatment decisions for cancer, menopause, mental illness, advancing kidney disease; screening decisions for cancer, genetic testing).",rephrase,"['The studies tested decision coaching with a range of healthcare decisions such as treatment decisions related to cancer, menopause, or mental illness; cancer screening decisions, and genetic testing.']",1,0.13333333333333333,1,15
CD013385,0,2,Four of the 28 studies included three comparator arms.,delete,[],2,0.2,1,15
CD013385,1,3,"For decision coaching compared with usual care (n = 4 studies), we are uncertain if decision coaching compared with usual care improves any outcomes (i.e. preparation for decision making, decision self-confidence, knowledge, decision regret, anxiety) as the certainty of the evidence was very low.",delete,[],2,0.26666666666666666,2,15
CD013385,2,4,"For decision coaching compared with evidence-based information only (n = 4 studies), there is low certainty-evidence that participants exposed to decision coaching may have little or no change in knowledge (SMD -0.23, 95% CI: -0.50 to 0.04; 3 studies, 406 participants).",rephrase,"['Some of the studies looked at decision coaching with, or compared to,\xa0disease-specific information or evidence-based information such as\xa0patient decision aids (booklets, videos, online tools that: make the decision clear, provide options and the pros and cons, and help people be clear on what matters to them).']",2,0.3333333333333333,2,15
CD013385,2,5,"There is low certainty-evidence that participants exposed to decision coaching may have little or no change in anxiety, compared with evidence-based information.",rephrase,['We have low confidence that decision coaching may have little or no effect on knowledge and anxiety compared to evidence-based information.'],3,0.4,2,15
CD013385,2,6,"We are uncertain if decision coaching compared with evidence-based information improves other outcomes (i.e. decision self-confidence, feeling uninformed) as the certainty of the evidence was very low.",rephrase,"['We are less confident about our other findings, as the certainty of the evidence is very low\xa0and there were important outcomes that were not reported by the included studies.']",4,0.4666666666666667,3,15
CD013385,3,7,"For decision coaching plus evidence-based information compared with usual care (n = 17 studies), there is low certainty-evidence that participants may have improved knowledge (SMD 9.3, 95% CI: 6.6 to 12.1; 5 studies, 1073 participants).",rephrase,"['People who received decision coaching plus evidence-based information compared with usual care:\n-may have improved knowledge (1073 patients, 5 studies)']",5,0.5333333333333333,3,15
CD013385,3,8,"We are uncertain if decision coaching plus evidence-based information compared with usual care improves other outcomes (i.e. preparation for decision making, decision self-confidence, feeling uninformed, unclear values, feeling unsupported, decision regret, anxiety) as the certainty of the evidence was very low.",rephrase,['We have low confidence that decision coaching plus evidence-based information improves people’s knowledge compared to usual care.'],6,0.6,3,15
CD013385,4,9,"For decision coaching plus evidence-based information compared with evidence-based information only (n = 7 studies), we are uncertain if decision coaching plus evidence-based information compared with evidence-based information only improves any outcomes (i.e. feeling uninformed, unclear values, feeling unsupported, knowledge, anxiety) as the certainty of the evidence was very low.",delete,[],7,0.6666666666666666,4,15
CD013385,5,10,Decision coaching may improve participants’ knowledge when used with evidence-based information.,rephrase,['Decision coaching may improve peoples’ knowledge to help them prepare to make healthcare decisions when used with\xa0evidence-based information.'],7,0.7333333333333333,4,15
CD013385,5,11,"Our findings do not indicate any significant adverse effects (e.g. decision regret, anxiety) with the use of decision coaching.",rephrase,['The review did not detect any adverse effects with the use of decision coaching.'],8,0.8,4,15
CD013385,5,12,It is not possible to establish strong conclusions for other outcomes.,delete,[],9,0.8666666666666667,5,15
CD013385,5,13,It is unclear if decision coaching always needs to be paired with evidence-informed information.,delete,[],9,0.9333333333333333,5,15
CD013385,5,14,Further research is needed to establish the effectiveness of decision coaching for a broader range of outcomes.,delete,[],9,1.0,5,15
CD010704,0,0,We included one small RCT (80 male student participants conducted in the Netherlands and published in 2009) and three ITS studies (general population studies in Canadian provinces conducted in the 1970s and 80s).,delete,[],0,0.058823529411764705,1,17
CD010704,1,1,"The RCT found that young men exposed to movies with a low-alcohol content drank less than men exposed to movies with a high-alcohol content (mean difference (MD) -0.65 drinks; 95% CI -1.2, -0.07; p value = 0.03, very-low-quality evidence).",rephrase,"['In the RCT, young men who watched movies with a low-alcohol content drank less than men who watched movies with a high-alcohol content.']",0,0.11764705882352941,1,17
CD010704,1,2,"Young men exposed to commercials with a neutral content compared with those exposed to commercials for alcohol drank less (MD -0.73 drinks; 95% CI -1.30, -0.16; p value = 0.01, very-low-quality evidence).",rephrase,['Young men exposed to commercials with a neutral content compared with those exposed to commercials for alcohol drank less.'],1,0.17647058823529413,1,17
CD010704,1,3,"Outcomes were assessed immediately after the end of the intervention (lasting 1.5 hours), so no follow-up data were available.",delete,[],2,0.23529411764705882,2,17
CD010704,1,4,"Using the Grading of Recommendations Assessment, Development and Evaluation approach, the quality of the evidence was rated as very low due to a serious risk of bias, serious indirectness of the included population and serious level of imprecision.",delete,[],2,0.29411764705882354,2,17
CD010704,2,5,Two of the ITS studies evaluated the implementation of an advertising ban and one study evaluated the lifting of such a ban.,split,"['We found four studies that evaluated the restriction or banning of alcohol advertising via any format.', 'Two of the three ITS studies evaluated what happened after an advertising ban was introduced by two different Canadian provincial governments.', 'The third ITS study evaluated what happened after a ban was lifted after being in place for 50 years in another Canadian province.']",2,0.35294117647058826,2,17
CD010704,2,6,Each of the three ITS studies evaluated a different type of ban (partial or full) compared with different degrees of restrictions or no restrictions during the control period.,rephrase,['Each study evaluated a different category of ban (either partial or full).'],5,0.4117647058823529,3,17
CD010704,2,7,The results from the three ITS studies were inconsistent.,ignore,['The results from the three ITS studies were inconsistent.'],6,0.47058823529411764,3,17
CD010704,2,8,"A meta-analysis of the two studies that evaluated the implementation of a ban showed an overall mean non-significant increase in beer consumption in the general population of 1.10% following the ban (95% CI -5.26, 7.47; p value = 0.43; I2 = 83%, very-low-quality evidence).",rephrase,['We statistically combined the results of the two studies that assessed what happened after a ban was introduced.'],7,0.5294117647058824,3,17
CD010704,2,9,"This finding is consistent with an increase, no difference, or a decrease in alcohol consumption.",rephrase,"['This showed an overall increase in beer consumption in the general population following the introduction of the ban, but the results were uncertain and could also be consistent with no difference or an overall decrease in alcohol consumption.']",8,0.5882352941176471,3,17
CD010704,2,10,"In the study evaluating the lifting of a total ban on all forms of alcohol advertising to a partial ban on spirits advertising only, which utilised an Abrupt Auto-regressive Integrated Moving Average model, the volume of all forms of alcohol sales decreased by 11.11 kilolitres (95% CI -27.56, 5.34; p value = 0.19) per month after the ban was lifted.",rephrase,"['The third ITS study, which evaluated the lifting of a total ban on all forms of alcohol advertising to a ban on spirits advertising only, also found uncertain results.']",9,0.6470588235294118,4,17
CD010704,2,11,"In this model, beer and wine sales increased per month by 14.89 kilolitres (95% CI 0.39, 29.39; p value = 0.04) and 1.15 kilolitres (95% CI -0.91, 3.21; p value = 0.27), respectively, and spirits sales decreased statistically significantly by 22.49 kilolitres (95% CI -36.83, -8.15; p value = 0.002).",delete,[],10,0.7058823529411765,4,17
CD010704,2,12,"Using the GRADE approach, the evidence from the ITS studies was rated as very low due to a high risk of bias arising from a lack of randomisation and imprecision in the results.",split,"['Overall we judged the quality of evidence to be very low in the RCT.', 'In the ITS studies, the quality was also judged to be very low due to problems with the study methodology and the results not being precise.']",10,0.7647058823529411,4,17
CD010704,3,13,No other prespecified outcomes (including economic loss or hardship due to decreased alcohol sales) were addressed in the included studies and no adverse effects were reported in any of the studies.,delete,[],12,0.8235294117647058,5,17
CD010704,3,14,None of the studies were funded by the alcohol or advertising industries.,ignore,['None of the above studies were funded by the alcohol or advertising industries.'],12,0.8823529411764706,5,17
CD010704,4,15,There is a lack of robust evidence for or against recommending the implementation of alcohol advertising restrictions.,rephrase,['The review cannot recommend for or against banning alcohol advertising.'],13,0.9411764705882353,5,17
CD010704,4,16,"Advertising restrictions should be implemented within a high-quality, well-monitored research programme to ensure the evaluation over time of all relevant outcomes in order to build the evidence base.",rephrase,['Governments that are considering implementing alcohol advertising bans would be advised to implement the ban in a research environment and monitor the effects over time to build the evidence base.'],14,1.0,5,17
CD010947,0,0,"We included 15 studies in the review, comprising a total of 1822 adult participants.",rephrase,['We included 15 completed randomized controlled trials involving 1822 participants.'],0,0.05263157894736842,1,19
CD010947,0,1,"There are 12 studies awaiting classification, and eight ongoing studies.",rephrase,['There are 8 ongoing studies and 12 waiting further assessment.'],1,0.10526315789473684,1,19
CD010947,1,2,None of the 15 included studies considered the paediatric population.,rephrase,['None of the completed studies included infants or children.'],2,0.15789473684210525,1,19
CD010947,1,3,"Four studies were conducted in the abdominal and orthopaedic surgery setting (lumbar spine, or knee and hip replacement), one study in the carotid endarterectomy setting, and the remaining 10 studies in the aortic or cardiac surgery setting.",rephrase,"['In four studies participants were undergoing abdominal or orthopaedic surgery, one study included participants undergoing a procedure to restore proper blood flow to the brain, and in the remaining 10 studies participants were undergoing large blood vessel or heart surgery with or without heart bypass.']",3,0.21052631578947367,2,19
CD010947,1,4,"The main sources of bias in the included studies related to potential conflict of interest from industry sponsorship, unclear blinding status or missing participant data.",rephrase,['Some studies had potential conflicts of interest from industry sponsorship.'],4,0.2631578947368421,2,19
CD010947,2,5,"Two studies with 312 participants considered postoperative neurological injury, however no pooled effect estimate could be calculated due to discordant direction of effect between studies (low-quality evidence).",delete,[],5,0.3157894736842105,2,19
CD010947,2,6,One study (N = 126) in participants undergoing major abdominal surgery reported that 4/66 participants experienced neurological injury with blinded monitoring versus 0/56 in the active monitoring group.,rephrase,"['One study with 126 participants having major abdominal surgery reported that 4/66 versus 0/56 participants experienced neurological injury with blinded and active monitoring, respectively.']",5,0.3684210526315789,2,19
CD010947,2,7,A second study (N = 195) in participants having coronary artery bypass surgery reported that 1/96 participants experienced neurological injury in the blinded monitoring group compared with 4/94 participants in the active monitoring group.,rephrase,"['A second study with 195 participants undergoing coronary artery bypass surgery reported that 1/96 versus 4/94 participants suffered neurological injury in the blinded (masked) and active (with active treatments) monitoring groups, respectively.']",6,0.42105263157894735,3,19
CD010947,3,8,"We are uncertain whether active cerebral NIRS monitoring has an important effect on the risk of postoperative stroke because of the low number of events and wide confidence interval (RR 0.25, 95% CI 0.03 to 2.20; 2 studies, 240 participants; low-quality evidence).",rephrase,"['We are unsure whether active NIRS monitoring has an important effect on the risk of postoperative stroke and delirium because there was a low number of events and the result was not precise (2 studies, 240 participants; 1 study, 190 participants, respectively; low-quality evidence).']",7,0.47368421052631576,3,19
CD010947,4,9,"We are uncertain whether active cerebral NIRS monitoring has an important effect on postoperative delirium because of the wide confidence interval (RR 0.63, 95% CI 0.27 to 1.45; 1 study, 190 participants; low-quality evidence).",delete,[],8,0.5263157894736842,3,19
CD010947,5,10,"Two studies with 126 participants showed that active cerebral NIRS monitoring may reduce the incidence of mild postoperative cognitive dysfunction (POCD) as defined by the original studies at one week after surgery (RR 0.53, 95% CI 0.30 to 0.95, I2 = 49%, low-quality evidence).",rephrase,"['Based on two studies with 126 participants, we found low-quality evidence that cerebral NIRS monitoring may reduce the number of participants with mild cognitive impairment at one week after surgery.']",8,0.5789473684210527,3,19
CD010947,6,11,"Based on six studies with 962 participants, there was moderate-quality evidence that active cerebral oxygenation monitoring probably does not decrease the occurrence of POCD (decline in cognitive function) at one week after surgery (RR 0.62, 95% CI 0.37 to 1.04, I2 = 80%).",rephrase,"['Based on six studies with 962 participants, we found moderate-quality evidence that monitoring with cerebral NIRS probably leads to little or no decrease in the number of participants with a decline in cognitive function one week after surgery.']",9,0.631578947368421,4,19
CD010947,6,12,The different type of monitoring equipment in one study could potentially be the cause of the heterogeneity.,delete,[],10,0.6842105263157895,4,19
CD010947,7,13,"We are uncertain whether active cerebral NIRS monitoring has an important effect on intraoperative mortality or postoperative mortality because of the low number of events and wide confidence interval (RR 0.63, 95% CI 0.08 to 5.03, I2= 0%; 3 studies, 390 participants; low-quality evidence).",rephrase,"['We are uncertain whether active cerebral oxygenation monitoring has a crucial effect on intraoperative or postoperative deaths because there was a low number of events and the result was not precise (3 studies, 390 participants; low-quality evidence).']",10,0.7368421052631579,4,19
CD010947,7,14,There was no evidence to determine whether routine use of NIRS-based cerebral oxygenation monitoring causes adverse effects.,rephrase,['We did not find any detrimental effects of the routine use of NIRS-based brain oxygenation monitoring.'],11,0.7894736842105263,4,19
CD010947,8,15,"The effects of perioperative active cerebral NIRS monitoring of brain oxygenation in adults for reducing the occurrence of short-term, mild POCD are uncertain due to the low quality of the evidence.",delete,[],12,0.8421052631578947,5,19
CD010947,8,16,"There is uncertainty as to whether active cerebral NIRS monitoring has an important effect on postoperative stroke, delirium or death because of the low number of events and wide confidence intervals.",split,"['Overall, it is uncertain whether active NIRS monitoring has a crucial effect on postoperative stroke, delirium or death because of the imprecision of the results (low-quality evidence).', 'Therefore, the effects of active cerebral NIRS monitoring on postoperative nervous system injury, delirium, decline in cognitive function and death are uncertain.']",12,0.8947368421052632,5,19
CD010947,8,17,The conclusions of this review may change when the eight ongoing studies are published and the 12 studies awaiting assessment are classified.,delete,[],14,0.9473684210526315,5,19
CD010947,8,18,"More RCTs performed in the paediatric population and high-risk patients undergoing non-cardiac surgery (e.g. neurosurgery, carotid endarterectomy and other surgery) are needed.",delete,[],14,1.0,5,19
CD011739,0,0,There are no included trials.,delete,[],0,0.16666666666666666,1,6
CD011739,1,1,We found no randomised controlled trials that assessed the effect of antenatal fetal surveillance regimens of a suspected LGA fetus on important health outcomes for the mother and baby.,rephrase,['We searched for studies on 10 August 2015 but did not find any randomised controlled trials looking at the effects of performing extra tests on health outcomes in pregnant women with overgrowth of the baby after 20 weeks gestation.'],0,0.3333333333333333,2,6
CD011739,2,2,There has been a rise in the prevalence of LGA babies over the past few decades in many countries.,delete,[],1,0.5,3,6
CD011739,2,3,"Research is therefore required on regimens of antenatal surveillance of suspected LGA infants, in order to guide practice and improve the health outcomes for the mother and infant.",delete,[],1,0.6666666666666666,4,6
CD011739,2,4,"In particular, randomised control trials to investigate whether serial antenatal clinic and ultrasound assessments of suspected LGA infants (including liquor volume and markers of fetal adiposity) would be useful, to assess whether surveillance methods improve health outcomes.",rephrase,"['There is a need for randomised controlled trials in this area in order to inform clinical practice when large babies are identified during a pregnancy, to assess if extra tests or surveillance can improve the health of these women and their babies.']",1,0.8333333333333334,5,6
CD011739,2,5,"In addition, as there are concerns that identifying suspected LGA fetuses may lead to unnecessary maternal anxiety, investigations and interventions, any such trial would need to assess the risks as well as benefits of regimens of fetal surveillance for suspected LGA fetuses.",rephrase,"['It is also important to identify any harms associated with extra tests and surveillance, as identifying women with suspected large babies may lead to unnecessary maternal anxiety with additional investigations and interventions, including induction of labour or caesarean section.']",2,1.0,5,6
CD007066,0,0,12 studies (mean duration of eight weeks) in 7439 mostly Caucasian patients (mean age 54 years) with mild-to-moderate uncomplicated hypertension were eligible for inclusion in the review.,rephrase,"['We found 12 studies, eight weeks in duration, that randomly assigned 7439 adult people with uncomplicated mild-to-moderate hypertension to aliskiren at doses ranging from 75 mg to 600 mg or placebo.']",0,0.0625,1,16
CD007066,0,1,Aliskiren was the only renin inhibitor evaluated.,delete,[],1,0.125,1,16
CD007066,0,2,"All included studies were assessed to have high likelihood of attrition, reporting and funding bias.",rephrase,['The decrease in blood pressure at the recommended dose was rated as moderate-quality evidence and adverse event data was graded as low-quality evidence as included studies were assessed to have high likelihood of reporting and funding bias.'],1,0.1875,1,16
CD007066,1,3,"Aliskiren has a dose-related systolic/diastolic blood pressure (SBP/DBP) lowering effect as compared with placebo MD with 95% CI: aliskiren 75 mg (MD -2.97, 95% CI -4.76 to -1.18)/(MD -2.05, 95% CI -3.13 to -0.96) mm Hg (moderate-quality evidence), aliskiren 150 mg (MD -5.95, 95% CI -6.85 to -5.06)/ (MD -3.16, 95% CI -3.74 to -2.58) mm Hg (moderate-quality evidence), aliskiren 300 mg (MD -7.88, 95% CI -8.94 to -6.82)/ (MD -4.49, 95% CI -5.17 to -3.82) mm Hg (moderate-quality evidence), aliskiren 600 mg (MD -11.35, 95% CI -14.43 to -8.27)/ (MD -5.86, 95% CI -7.73 to -3.99) mm Hg (low-quality evidence).",delete,[],2,0.25,2,16
CD007066,1,4,"There was a dose-dependent decrease in blood pressure for aliskiren 75 mg, 150 mg and 300 mg.",rephrase,"['We concluded that aliskiren is better than placebo at lowering blood pressure and that the magnitude of this effect could be similar to other classes of drugs when 300 mg, which is the maximum recommended dose, is used.']",2,0.3125,2,16
CD007066,1,5,"The blood pressure lowering effect of aliskiren 600 mg was not different from 300 mg (MD -0.61, 95% CI -2.78 to 1.56)/(MD -0.68, 95% CI -2.03 to 0.67).",rephrase,['Aliskiren 300 mg reduced blood pressure by eight points in the upper number (called systolic blood pressure) and five points in the lower number (called diastolic blood pressure).'],3,0.375,2,16
CD007066,1,6,Aliskiren had no effect on blood pressure variability.,ignore,['Aliskiren had no effect on blood pressure changeability.'],4,0.4375,3,16
CD007066,1,7,"Due to very limited information available regarding change in heart rate and pulse pressure, it was not possible to meta-analyze these outcomes.",rephrase,['Due to very limited information regarding change in heart rate and pulse pressure (difference between upper and lower number) it was not possible to analyze these outcomes.'],5,0.5,3,16
CD007066,2,8,Mortality and non-fatal serious adverse events were not increased.,merge,"['Aliskiren did not increase death, non-fatal serious adverse events or withdrawal due to side effects.']",6,0.5625,3,16
CD007066,2,9,This review found that in studies of eight week duration aliskiren may not increase withdrawal due to adverse events (low-quality evidence).,none,[],6,0.625,4,16
CD007066,2,10,"Diarrhoea was increased in a dose-dependent manner (RR 7.00, 95% CI 2.48 to 19.72) with aliskiren 600 mg (low-quality evidence).",rephrase,['Diarrhoea was considerably increased with aliskiren 600 mg as compared to placebo.'],7,0.6875,4,16
CD007066,2,11,"The most frequent adverse events reported were headache, nasopharyngitis, diarrhoea, dizziness and fatigue.",rephrase,"['The most common adverse events observed were headache, diarrhoea, dizziness and fatigue.']",8,0.75,4,16
CD007066,3,12,"Compared to placebo, aliskiren lowered BP and this effect is dose-dependent.",delete,[],9,0.8125,5,16
CD007066,3,13,This magnitude of BP lowering effect is similar to that for angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs).,delete,[],9,0.875,5,16
CD007066,3,14,"There is no difference in mortality, nonfatal serious adverse events or withdrawal due to adverse effects with short term aliskiren monotherapy.",delete,[],9,0.9375,5,16
CD007066,3,15,Diarrhoea was considerably increased with aliskiren 600 mg.,delete,[],9,1.0,5,16
CD003577,0,0,The two methods of skin closure for caesarean that have been most often compared are non-absorbable staples and absorbable subcutaneous sutures.,rephrase,['The most commonly studied methods of skin closure were non-absorbable staples compared with absorbable subcutaneous sutures.'],0,0.1111111111111111,1,9
CD003577,0,1,"Compared with absorbable subcutaneous sutures, non-absorbable staples are associated with similar incidences of wound infection.",rephrase,"['Staples were associated with similar outcomes in terms of wound infection, pain and appearance compared with sutures.']",1,0.2222222222222222,2,9
CD003577,0,2,"Other important secondary outcomes, such as wound complications, were also similar between the groups in women with Pfannenstiel incisions.",delete,[],2,0.3333333333333333,2,9
CD003577,0,3,"However, it is important to note, that for both of these outcomes (wound infection and wound complication), staples may have a differential effect depending on the type of skin incision, i.e., Pfannenstiel or vertical.",delete,[],2,0.4444444444444444,3,9
CD003577,0,4,"Compared with absorbable subcutaneous sutures, non-absorbable staples are associated with an increased risk of skin separation, and therefore, reclosure.",rephrase,"['Non-absorbable staples had an increased risk of skin separation and, therefore, reclosure.']",2,0.5555555555555556,3,9
CD003577,0,5,"However, skin separation was variably defined across trials, and most staples were removed before four days postpartum.",rephrase,['Skin separation was defined differently across trials and removal of staples varied from about day three to day seven postoperatively.'],3,0.6666666666666666,4,9
CD003577,1,6,There is currently no conclusive evidence about how the skin should be closed after caesarean section.,rephrase,['There is not enough evidence from the included studies to say which method of closing the caesarean skin incision is superior.'],4,0.7777777777777778,4,9
CD003577,1,7,"Staples are associated with similar outcomes in terms of wound infection, pain and cosmesis compared with sutures, and these two are the most commonly studied methods for skin closure after caesarean section.",delete,[],5,0.8888888888888888,5,9
CD003577,1,8,"If staples are removed on day three, there is an increased incidence of skin separation and the need for reclosure compared with absorbable sutures.",delete,[],5,1.0,5,9
CD010094,0,0,We included two RCTs involving 425 adult participants with Graves' disease in this review.,rephrase,"[""We identified two randomised controlled trials (RCTs) enrolling 425 adult participants with Graves' disease.""]",0,0.05,1,20
CD010094,0,1,Altogether 204 participants were randomised to radioiodine therapy and 221 to methimazole therapy.,rephrase,['Altogether 204 participants were randomised to treatment with radioiodine and 221 to methimazole.'],1,0.1,1,20
CD010094,0,2,A single dose of radioiodine was administered.,delete,[],2,0.15,1,20
CD010094,0,3,The duration of methimazole medication was 18 months.,delete,[],2,0.2,1,20
CD010094,0,4,"The period of follow-up was at least two years, depending on the outcome measured.",rephrase,['Follow-up in the included studies was from 2 to 21 years depending on which outcome was investigated.'],2,0.25,2,20
CD010094,0,5,For most outcome measures risk of bias was low; for the outcomes health-related quality of life as well as development and worsening of Graves' ophthalmopathy risks of performance bias and detection bias were high in at least one of the two RCTs.,delete,[],3,0.3,2,20
CD010094,1,6,"Health-related quality of life appeared to be similar in the radioiodine and methimazole treatment groups, however no quantitative data were reported (425 participants; 2 trials; low quality evidence).",rephrase,"['Study authors reported health-related quality of life to be similar in the radioiodine and methimazole treatment groups, however exact data were not published.']",3,0.35,2,20
CD010094,1,7,The development and worsening of Graves' ophthalmopathy was observed in 76 of 202 radioiodine-treated participants (38%) and in 40 of 215 methimazole-treated participants (19%): risk ratio (RR) 1.94 (95% confidence interval (CI) 1.40 to 2.70); 417 participants; 2 trials; low quality evidence.,rephrase,"[""The development and worsening of Graves' opthalmopathy, which is a serious eye disease that happens in some people with Graves' disease, was observed in 361 of 1000 radioiodine-treated persons compared with 186 of 1000 methimazole-treated persons.""]",4,0.4,2,20
CD010094,1,8,"A total of 35% to 56% of radioiodine-treated participants and 42% of participants treated with methimazole were smokers, which is associated with the risk of worsening or development of Graves' ophthalmopathy.",rephrase,"[""A high percentage of the study participants were smokers, which is related to the risk of worsening or development of Graves' opthalmopathy.""]",5,0.45,3,20
CD010094,1,9,Euthyroidism was not achieved by any participant being treated with radioiodine compared with 64/68 (94%) of participants after methimazole treatment (112 participants; 1 trial).,rephrase,['A normal thyroid gland function (euthyroidism) was not achieved by any participant who was treated with radioiodine compared with 64 of 68 participants (94%) after methimazole treatment.'],6,0.5,3,20
CD010094,1,10,In this trial thyroxine therapy was not introduced early in both treatment arms to avoid hypothyroidism.,rephrase,['In this study thyroid hormone (thyroxine) therapy was not started early in both treatment arms to accomplish euthyroidism.'],7,0.55,3,20
CD010094,1,11,Recurrence of hyperthyroidism (relapse) in favour of radioiodine treatment showed a RR of 0.20 (95% CI 0.01 to 2.66); P value = 0.22; 417 participants; 2 trials; very low quality evidence.,rephrase,"['A recurrence of hyperthyroidism (relapse of the disease) was seen more often after methimazole treatment, however the size of the effect is unclear because of big differences between the two included studies.']",8,0.6,3,20
CD010094,1,12,Heterogeneity was high (I² = 91%) and the RRs were 0.61 or 0.06 with non-overlapping CIs.,delete,[],9,0.65,4,20
CD010094,1,13,"Adverse events other than development of worsening of Graves' ophthalmopathy for radioiodine therapy were hypothyroidism (39 of 41 participants (95%) compared with 0% of participants receiving methimazole, however thyroxine treatment to avoid hypothyroidism was not introduced early in the radioiodine group - 104 participants; 1 trial; very low quality evidence) and drug-related adverse events for methimazole treatment (23 of 215 participants (11%) reported adverse effects likely related to methimazole therapy - 215 participants; 2 trials; very low quality evidence).",split,"['A side effect related to radioiodine therapy was an underactive thyroid gland (hypothyroidism), which was seen in 39 of 41 participants (95%) compared with 0% of participants receiving methimazole.', 'Side effects related to methimazole treatment were seen in 23 of 215 participants (11%).']",9,0.7,4,20
CD010094,1,14,The outcome measures all-cause mortality and bone mineral density were not reported in the included trials.,rephrase,['The outcomes death from any cause and bone mineral density were not reported in the included studies.'],11,0.75,4,20
CD010094,1,15,One trial (174 participants) reported socioeconomic effects: costs based on the official hospital reimbursement system in Sweden for patients without relapse and methimazole treatment were USD 1126/1164 (young/older methimazole group) and for radioiodine treatment USD 1862.,rephrase,"['One study reported socioeconomic effects: costs based on the official hospital reimbursement system in Sweden for people without relapse and methimazole treatment were between USD 1126 and USD 1164, and for radioiodine treatment USD 1862.']",12,0.8,4,20
CD010094,1,16,Costs for patients with relapse and methimazole treatment were USD 2284/1972 (young/older methimazole group) and for radioiodine treatment USD 2760.,rephrase,"['Costs for people with relapse and methimazole treatment were between USD 1972 and USD 2284, and for radioiodine treatment USD 2760.']",13,0.85,5,20
CD010094,2,17,"The only antithyroid drug investigated in the two included trials was methimazole, which might limit the applicability of our findings with regard to other compounds such as propylthiouracil.",rephrase,"['Another limitation is that among antithyroid medications only methimazole was investigated, which might limit the applicability of our findings with regard to other medications such as propylthiouracil.']",14,0.9,5,20
CD010094,2,18,Results from two RCTs suggest that radioiodine treatment is associated with an increased risk of Graves' ophthalmopathy.,delete,[],15,0.95,5,20
CD010094,2,19,Our findings suggest some benefit from radioiodine treatment for recurrence of hyperthyroidism (relapse) but there is uncertainty about the magnitude of the effect size.,delete,[],15,1.0,5,20
CD003882,0,0,Six trials were included; three of these trials are new to this update.,rephrase,['Six trials were included.'],0,0.058823529411764705,1,17
CD003882,0,1,Four trials were small (less than 25 women per arm) and two had moderate to high risk of bias.,delete,[],1,0.11764705882352941,1,17
CD003882,0,2,Four trials compared PFMT as a treatment for prolapse against a control group (n = 857 women); two trials included women having surgery for prolapse and compared PFMT as an adjunct to surgery versus surgery alone (n = 118 women).,rephrase,"['Four trials compared pelvic floor muscle training (PFMT) with no intervention, and two trials compared pelvic floor muscle training plus surgery to surgery alone.']",1,0.17647058823529413,1,17
CD003882,1,3,"PFMT versus control
There was a significant risk of bias in two out four trials in this comparison.",delete,[],2,0.23529411764705882,2,17
CD003882,1,4,Prolapse symptoms and women's reports of treatment outcomes (primary outcomes) were measured differently in the three trials where this was reported: all three indicated greater improvement in symptoms in the PFMT group compared to the control group.,rephrase,"['PFMT compared to no intervention was found in individual trials to improve prolapse symptoms, but data could not be combined.']",2,0.29411764705882354,2,17
CD003882,1,5,Pooling data on severity of prolapse from two trials indicated that PFMT increases the chance of an improvement in prolapse stage by 17% compared to no PFMT.,rephrase,['Data on prolapse severity was combined from two trials and results indicated that PFMT increases the chance of improvement in prolapse stage by 17% compared to no treatment.'],3,0.35294117647058826,2,17
CD003882,1,6,The two trials which measured pelvic floor muscle function found better function (or improvement in function) in the PFMT group compared to the control group; measurements were not known to be blinded.,rephrase,['Pelvic floor muscle function appeared to be improved in women who received PFMT in the two trials which measured this.'],4,0.4117647058823529,3,17
CD003882,1,7,"Two out of three trials which measured urinary outcomes (urodynamics, frequency and bother of symptoms, or symptom score) reported differences between groups in favour of the PFMT group.",rephrase,"['Bladder symptoms were improved with PFMT in two out of three trials measuring this; bowel symptoms were measured in one trial, and an improvement with PFMT was found.']",5,0.47058823529411764,3,17
CD003882,1,8,"One trial reported bowel outcomes, showing less frequency and bother with symptoms in the PFMT group compared to the control group.",delete,[],6,0.5294117647058824,3,17
CD003882,2,9,"PFMT supplementing surgery versus surgery alone
Both trials were small and neither measured prolapse-specific outcomes.",rephrase,"['The two trials which looked at the benefit of PFMT in addition to surgery, were small but of good quality.']",6,0.5882352941176471,3,17
CD003882,2,10,"Pelvic floor muscle function findings differed between the trials: one found no difference between trial groups in muscle strength, whilst the other found a benefit for the PFMT group in terms of stronger muscles.",merge,[],7,0.6470588235294118,4,17
CD003882,2,11,"Similarly findings relating to urinary outcomes were contradictory: one trial found no difference in symptom score change between groups, whilst the other found more improvement in urinary symptoms and a reduction in diurnal frequency in the PFMT group compared to the control group.",none,"['Findings were contradictory: women benefited from PFMT, in terms of urinary symptoms and pelvic floor muscle strength, in one trial but not the other.']",7,0.7058823529411765,4,17
CD003882,3,12,There is now some evidence available indicating a positive effect of PFMT for prolapse symptoms and severity.,rephrase,"['The evidence from the trials suggests there is some benefit from conservative treatment of prolapse, specifically for PFMT as compared to no intervention.']",8,0.7647058823529411,4,17
CD003882,3,13,The largest most rigorous trial to date suggests that six months of supervised PFMT has benefits in terms of anatomical and symptom improvement (if symptomatic) immediately post-intervention.,delete,[],9,0.8235294117647058,5,17
CD003882,3,14,"Further evidence relating to effectiveness and cost-effectiveness of PFMT, of different intensities, for symptomatic prolapse in the medium and long term is needed.",rephrase,"['More randomised controlled trials are still needed to look at different regimens of PFMT, the cost in relation to benefit, and the long-term effects.']",9,0.8823529411764706,5,17
CD003882,3,15,A large trial of PFMT supplementing surgery is needed to give clear evidence about the usefulness of combining these treatments.,rephrase,['The combination of PFMT and surgery requires to be evaluated in a large randomised trial.'],10,0.9411764705882353,5,17
CD003882,3,16,"Other comparisons which have not been addressed in trials to date and warrant consideration include those involving lifestyle change interventions, and trials aimed at prolapse prevention.",rephrase,"['There is a dearth of trials addressing lifestyle changes as a treatment for prolapse, and trials aimed at prevention of prolapse.']",11,1.0,5,17
CD001511,0,0,Sixteen trials fulfilled our inclusion criteria.,delete,[],0,0.07142857142857142,1,14
CD001511,0,1,All trials but one were at overall high risk of bias.,rephrase,"['All trials but one were at overall high risk of bias, which means that there is possibility of drawing wrong conclusions, exaggerating benefits, or underestimating harms of glucocorticosteroids because of the way the trials were conducted and analysed.']",0,0.14285714285714285,1,14
CD001511,0,2,Fifteen trials (one of which was an abstract) provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no intervention).,split,"['Sixteen randomised clinical trials compared glucocorticosteroids with placebo or no intervention in people with alcoholic hepatitis.', 'Fifteen trials provided data for analysis (927 participants received glucocorticosteroids and 934 participants received placebo or no intervention).']",1,0.21428571428571427,2,14
CD001511,0,3,Glucocorticosteroids were administered orally or parenterally for a median 28 days (range 3 days to 12 weeks).,rephrase,['Glucocorticosteroids were administered orally or as an injection for a median of 28 days (range 3 days to 12 weeks).'],3,0.2857142857142857,2,14
CD001511,0,4,"The participants were between 25 and 70 years old, had different stages of alcoholic liver disease, and 65% were men.",rephrase,"['The trial participants were between 25 and 70 years old, 65% were men, and had different stages of alcoholic liver disease.']",4,0.35714285714285715,2,14
CD001511,0,5,"Follow-up, when reported, was up to the moment of discharge from the hospital, until they died (median of 63 days), or for at least one year.",rephrase,"['Trial participants were followed up to the moment of discharge from the hospital, or until they died (a median of 63 days), or for at least one year.']",5,0.42857142857142855,3,14
CD001511,0,6,"There was no evidence of effect of glucocorticosteroids on all-cause mortality up to three months following randomisation (random-effects RR 0.90, 95% CI 0.70 to 1.15; participants = 1861; trials = 15; very low-certainty evidence) or on health-related quality of life up to three months, measured with the European Quality of Life – 5 Dimensions – 3 Levels scale (MD –0.04 points, 95% CI –0.11 to 0.03; participants = 377; trial = 1; low-certainty evidence).",delete,[],6,0.5,3,14
CD001511,0,7,"There was no evidence of effect on the occurrence of serious adverse events during treatment (random-effects RR 1.05, 95% CI 0.85 to 1.29; participants = 1861; trials = 15; very low-certainty evidence), liver-related mortality up to three months following randomisation (random-effects RR 0.89, 95% CI 0.69 to 1.14; participants = 1861; trials = 15; very low-certainty evidence), number of participants with any complications up to three months following randomisation (random-effects RR 1.04, 95% CI 0.86 to 1.27; participants = 1861; very low-certainty evidence), and number of participants of non-serious adverse events up to three months' follow-up after end of treatment (random-effects RR 1.99, 95% CI 0.72 to 5.48; participants = 160; trials = 4; very low-certainty evidence).",delete,[],6,0.5714285714285714,3,14
CD001511,0,8,"Based on the information that we collected from the published trial reports, only one of the trials seems not to be industry-funded, and the remaining 15 trials did not report clearly whether they were partly or completely funded by the industry.",ignore,"['Based on the information that we collected from the published trial reports, only one of the trials seems not to be industry-funded, and the remaining 15 trials did not report clearly whether they were partly or completely funded by the industry.']",6,0.6428571428571429,4,14
CD001511,1,9,"We are very uncertain about the effect estimate of no difference between glucocorticosteroids and placebo or no intervention on all-cause mortality and serious adverse events during treatment because the certainty of evidence was very low, and low for health-related quality of life.",split,"['Despite available data on outcomes which included mortality, health-related quality of life, and serious complications, we were unable to draw firm conclusions mainly because available data were still insufficient to produce robust results, trials were small, and the included participants differed in severity of disease.', 'Therefore, we have very little confidence in our conclusions.']",7,0.7142857142857143,4,14
CD001511,1,10,"Due to inadequate reporting, we cannot exclude increases in adverse events.",delete,[],9,0.7857142857142857,4,14
CD001511,1,11,"As the CIs were wide, we cannot rule out significant benefits or harms of glucocorticosteroids.",delete,[],9,0.8571428571428571,5,14
CD001511,1,12,"Therefore, we need placebo-controlled randomised clinical trials, designed according to the SPIRIT guidelines and reported according to the CONSORT guidelines.",delete,[],9,0.9285714285714286,5,14
CD001511,1,13,"Future trials ought to report depersonalised individual participant data, so that proper individual participant data meta-analyses of the effects of glucocorticosteroids in subgroups can be conducted.",delete,[],9,1.0,5,14
CD009259,0,0,"We identified nine studies comprising 338,467 individuals randomised to screening and 405,919 individuals to the control groups.",merge,[],0,0.08333333333333333,1,12
CD009259,0,1,Five studies compared flexible sigmoidoscopy to no screening and four studies compared repetitive guaiac-based FOBT (annually and biennially) to no screening.,none,['We identified four trials which compared FOBT to no screening and five trials which compared flexible sigmoidoscopy to no screening.'],0,0.16666666666666666,1,12
CD009259,0,2,We did not consider that study risk of bias reduced our confidence in our results.,delete,[],1,0.25,2,12
CD009259,0,3,We did not identify any studies comparing the two screening methods directly.,split,"['No studies compared the two methods directly.', 'When we compared the two methods, we could not conclude that one was better than the other.']",1,0.3333333333333333,2,12
CD009259,0,4,"When compared with no screening, colorectal cancer mortality was lower with flexible sigmoidoscopy (relative risk 0.72; 95% CI 0.65 to 0.79, high quality evidence) and FOBT (relative risk 0.86; 95% CI 0.80 to 0.92, high quality evidence).",merge,['Mortality from colorectal cancer was reduced with FOBT screening and screening with flexible sigmoidoscopy.'],3,0.4166666666666667,3,12
CD009259,0,5,"In the analyses based on indirect comparison of the two screening methods, the relative risk of dying from colorectal cancer was 0.85 (95% credibility interval 0.72 to 1.01, low quality evidence) for flexible sigmoidoscopy screening compared to FOBT.",none,[],3,0.5,3,12
CD009259,0,6,"No complications occurred after the FOBT test itself, but 0.03% of participants suffered a major complication after follow-up.",ignore,"['No complications occurred after the FOBT test itself, but 0.03% of participants suffered a major complication after follow-up.']",4,0.5833333333333334,3,12
CD009259,0,7,"Among more than 60,000 flexible sigmoidoscopy screening procedures and almost 6000 work-up colonoscopies, a major complication was recorded in 0.08% of participants.",ignore,"['Among more than 60,000 flexible sigmoidoscopy screening procedures and almost 6000 work-up colonoscopies, a major complication was recorded in 0.08% of participants.']",5,0.6666666666666666,4,12
CD009259,0,8,Adverse event data should be interpreted with caution as the reporting of adverse effects was incomplete.,rephrase,['These findings should be interpreted with caution as the reporting of adverse effects was incomplete.'],6,0.75,4,12
CD009259,1,9,There is high quality evidence that both flexible sigmoidoscopy and faecal occult blood testing reduce colorectal cancer mortality when applied as screening tools.,delete,[],7,0.8333333333333334,5,12
CD009259,1,10,There is low quality indirect evidence that screening with either approach reduces colorectal cancer deaths more than the other.,delete,[],7,0.9166666666666666,5,12
CD009259,1,11,Major complications associated with screening require validation from studies with more complete reporting of harms.,delete,[],7,1.0,5,12
CD010648,0,0,We included two randomised trials with a total of 581 women each comparing different regimens of titrated oral misoprostol with intravenous oxytocin.,rephrase,"['We identified two randomised controlled trials with 581 women requiring augmentation, each looking at different doses of oral misoprostol compared with oxytocin.']",0,0.058823529411764705,1,17
CD010648,0,1,"One study compared 20 mcg doses of misoprostol dissolved in water (repeated every hour up to four hours, after which the dose was increased to 40 mcg per hour up to a maximum total dose of 1600 mcg), while the second study gave women 75 mcg doses (repeated after four hours provided there were no adverse effects observed).",rephrase,"['One study gave 20 mcg doses of misoprostol every hour up to four hours, after which the dose was increased; the second gave women 75 mcg doses, repeated after four hours provided there were no adverse effects observed.']",1,0.11764705882352941,1,17
CD010648,1,2,"Neither trial reported maternal death, severe maternal morbidity, or fetal/neonatal mortality outcomes, and only a few fetal/neonatal morbidity outcomes were considered, none of which were significantly different between groups.",rephrase,"['Neither trial reported on the important safety outcomes of maternal or neonatal deaths, or severe maternal ill health.']",2,0.17647058823529413,1,17
CD010648,1,3,"For several outcomes (such as maternal side-effects, instrumental birth, maternal blood transfusion for hypovolaemia and epidural analgesia), the number of events was generally too low for sufficient statistical power to be achieved.",delete,[],3,0.23529411764705882,2,17
CD010648,1,4,Maternal satisfaction was not reported in either trial.,ignore,['Maternal satisfaction was not reported in either trial.'],3,0.29411764705882354,2,17
CD010648,1,5,One trial reported a slight reduction in the median duration of labour from the start of augmentation to vaginal delivery in the oxytocin group.,rephrase,"['One trial measured duration of labour from the start of augmentation, which was slightly shorter with intravenous oxytocin (5.20 hours compared with 5.22 hours).']",4,0.35294117647058826,2,17
CD010648,2,6,Neither trial reported significantly higher rates of caesarean section (CS) in the oral misoprostol group.,delete,[],5,0.4117647058823529,3,17
CD010648,2,7,Rates of vaginal delivery within 12 and 24 hours of commencing augmentation were not significantly different in the trial using a 20 mcg misoprostol dose.,rephrase,"['The number of vaginal deliveries within 12 and 24 hours, and caesarean section rates were similar.']",5,0.47058823529411764,3,17
CD010648,2,8,Neither trial had significantly higher rates of uterine hyperstimulation with fetal heart rate changes in the titrated oral misoprostol group.,rephrase,['Neither trial reported clearly higher rates of uterine hyperstimulation with worrying fetal heart rate changes in the titrated oral misoprostol group.'],6,0.5294117647058824,3,17
CD010648,2,9,"However, the rates of this outcome varied so greatly between the two studies as to suggest that other factors were at play.",rephrase,['The rates of this outcome in the two studies varied greatly however.'],7,0.5882352941176471,3,17
CD010648,2,10,"The only significant differences between groups related to uterine hyperstimulation (without fetal heart rate changes), and results were not consistent in the two trials.",rephrase,['The evidence on uterine hyperstimulation without fetal heart rate changes was not consistent.'],8,0.6470588235294118,4,17
CD010648,2,11,"In the trial examining the higher dose of misoprostol, more women in the misoprostol group experienced hyperstimulation of labour measured over a 10-minute period compared with those receiving oxytocin (risk ratio (RR) 1.17, 95% confidence interval (CI) 1.02 to 1.35, 350 women).",delete,[],9,0.7058823529411765,4,17
CD010648,2,12,"In the study examining the lower titrated dose of misoprostol, there was a lower incidence of tachysystole when labour was augmented with titrated oral misoprostol than with oxytocin (RR 0.39, 95% CI 0.17 to 0.91, 231 women) with no occurrences of hypertonus in either group of women.",delete,[],9,0.7647058823529411,4,17
CD010648,3,13,Important uncertainties still exist on the safety and acceptability of titrated oral misoprostol compared with intravenous oxytocin regimens in women with dystocia following spontaneous onset of labour.,rephrase,"['Important uncertainties still exist on the safety and acceptability of titrated oral misoprostol for labour dystocia, and further research is needed before it can be recommended as an alternative to oxytocin.']",9,0.8235294117647058,5,17
CD010648,3,14,"Although in facilities where electronic oxytocin infusion is not available, low-dose titrated misoprostol may offer a better alternative to an uncontrolled oxytocin infusion to avoid hyperstimulation.",rephrase,"['However, in facilities that do not have access to electronic oxytocin infusion, lower doses of titrated misoprostol may be a better alternative to avoid hyperstimulation.']",10,0.8823529411764706,5,17
CD010648,3,15,"Further research is needed in both high- and low-resource settings More trials should be conducted to evaluate the effect of a standard titration oral misoprostol regimen, both following spontaneous labour and labour induction.",delete,[],11,0.9411764705882353,5,17
CD010648,3,16,"Comparisons with other augmentation methods are also warranted, as are any effects on women's birth experiences.",delete,[],11,1.0,5,17
CD014874,0,0,We included evidence from 1925 participants in 15 RCTs that investigated the effect of 17 interventions.,rephrase,['We found 15 studies that involved 1925 parents who had experienced childhood maltreatment and/or who had CPTSD or PTSD symptoms.'],0,0.04,1,25
CD014874,0,1,All included studies were published after 2005.,delete,[],1,0.08,1,25
CD014874,0,2,"Interventions included seven parenting interventions, eight psychological interventions and two service system approaches.",delete,[],1,0.12,1,25
CD014874,0,3,"The studies were funded by major research councils, government departments and philanthropic/charitable organisations.",ignore,"['Most studies were funded by major research councils, government departments and philanthropic/charitable organisations.']",1,0.16,1,25
CD014874,0,4,All evidence was of low or very low certainty.,delete,[],2,0.2,1,25
CD014874,1,5,"Parenting interventions
Evidence was very uncertain from a study (33 participants) assessing the effects of a parenting intervention compared to attention control on trauma-related symptoms, and psychological wellbeing symptoms (postpartum depression), in mothers who had experienced childhood maltreatment and were experiencing current parenting risk factors.",rephrase,"['Parenting interventions\nEvidence was very uncertain from a study of a parenting intervention compared to a control on trauma-related symptoms, and psychological wellbeing symptoms (postnatal depression), in mothers who had experienced childhood maltreatment and were experiencing current parenting risk factors.']",2,0.24,2,25
CD014874,1,6,"Evidence suggested that parenting interventions may improve parent-child relationships slightly compared to usual service provision (SMD 0.45, 95% CI -0.06 to 0.96; I2 = 60%; 2 studies, 153 participants; low-certainty evidence).",rephrase,['Two studies found that parenting interventions may slightly improve the relationship between mothers and their child compared to usual care.'],3,0.28,2,25
CD014874,1,7,"There may be little or no difference between parenting interventions and usual perinatal service in parenting skills including nurturance, supportive presence and reciprocity (SMD 0.25, 95% CI -0.07 to 0.58; I2 = 0%; 4 studies, 149 participants; low-certainty evidence).",rephrase,['Four studies found little to no difference between a parenting intervention and usual care in parenting skills.'],4,0.32,2,25
CD014874,1,8,"No studies assessed the effects of parenting interventions on parents' substance use, relationship quality or self-harm.",ignore,"[""No studies assessed the effects of parenting interventions on parent's substance use, relationship quality or self-harm.""]",5,0.36,2,25
CD014874,2,9,"Psychological interventions
Psychological interventions may result in little or no difference in trauma-related symptoms compared to usual care (SMD -0.05, 95% CI -0.40 to 0.31; I2 = 39%; 4 studies, 247 participants; low-certainty evidence).",rephrase,['Psychological interventions\nFour studies found little or no difference in trauma-related symptoms from a psychological intervention compared to usual care.'],6,0.4,2,25
CD014874,2,10,"Psychological interventions may make little or no difference compared to usual care to depression symptom severity (8 studies, 507 participants, low-certainty evidence, SMD -0.34, 95% CI -0.66 to -0.03; I2 = 63%).",rephrase,['Eight studies found little or no difference between a psychological intervention and usual care in parents psychological wellbeing (depression).'],7,0.44,3,25
CD014874,2,11,"An interpersonally focused cognitive behavioural analysis system of psychotherapy may slightly increase the number of pregnant women who quit smoking compared to usual smoking cessation therapy and prenatal care (189 participants, low-certainty evidence).",rephrase,['Another study showed that the addition of a psychological intervention may help slightly more women quit smoking in pregnancy than usual prenatal care and smoking cessation counselling.'],8,0.48,3,25
CD014874,2,12,"A psychological intervention may slightly improve parents' relationship quality compared to usual care (1 study, 67 participants, low-certainty evidence).",split,"[""Another found that a psychological intervention may help parents' relationship quality slightly."", 'Another study found that there may be small improvements in parenting skills when parents received a psychological intervention compared to usual care.']",9,0.52,3,25
CD014874,2,13,"Benefits for parent-child relationships were very uncertain (26 participants, very low-certainty evidence), while there may be a slight improvement in parenting skills compared to usual care (66 participants, low-certainty evidence).",rephrase,['The evidence from one study was very uncertain about whether a psychological intervention made any difference to parent-child relationships compared to usual care.'],11,0.56,3,25
CD014874,2,14,No studies assessed the effects of psychological interventions on parents' self-harm.,ignore,"[""No studies assessed the effects of psychological interventions on parents' self-harm.""]",12,0.6,3,25
CD014874,3,15,"Service system approaches
One service system approach assessed the effect of a financial empowerment education programme, with and without trauma-informed peer support, compared to usual care for parents with low incomes.",rephrase,['Service system approaches\nOne financial education programme for parents with low incomes and childhood maltreatment histories increased depression symptoms slightly compared to usual care.'],13,0.64,4,25
CD014874,3,16,"The interventions increased depression slightly (52 participants, low-certainty evidence).",delete,[],14,0.68,4,25
CD014874,3,17,"No studies assessed the effects of service system interventions on parents' trauma-related symptoms, substance use, relationship quality, self-harm, parent-child relationships or parenting skills.",ignore,"[""No studies assessed the effects of service system interventions on parents' trauma-related symptoms, substance use, relationship quality, self-harm, parent-child relationships or parenting skills.""]",14,0.72,4,25
CD014874,4,18,There is currently a lack of high-quality evidence regarding the effectiveness of interventions to improve parenting capacity or parental psychological or socio-emotional wellbeing in parents experiencing CPTSD symptoms or who have experienced childhood maltreatment (or both).,rephrase,['We wanted to find out which of these supports helped improve parenting capacity and wellbeing in parents who had experienced childhood maltreatment or CPTSD.'],15,0.76,4,25
CD014874,4,19,This lack of methodological rigour and high risk of bias made it difficult to interpret the findings of this review.,delete,[],16,0.8,4,25
CD014874,4,20,"Overall, results suggest that parenting interventions may slightly improve parent-child relationships but have a small, unimportant effect on parenting skills.",delete,[],16,0.84,5,25
CD014874,4,21,"Psychological interventions may help some women stop smoking in pregnancy, and may have small benefits on parents' relationships and parenting skills.",delete,[],16,0.88,5,25
CD014874,4,22,A financial empowerment programme may slightly worsen depression symptoms.,delete,[],16,0.92,5,25
CD014874,4,23,"While potential beneficial effects were small, the importance of a positive effect in a small number of parents must be considered when making treatment and care decisions.",delete,[],16,0.96,5,25
CD014874,4,24,There is a need for further high-quality research into effective strategies for this population.,delete,[],16,1.0,5,25
CD006691,0,0,Only two trials (60 participants) investigating the effect of metformin added to insulin therapy for three months in adolescents with poorly controlled type 1 diabetes could be included.,rephrase,"['Only two trials (60 participants, three months treatment) could be included.']",0,0.125,1,8
CD006691,0,1,Meta-analysis was not possible due to the clinical and methodological heterogeneity of data.,delete,[],1,0.25,2,8
CD006691,0,2,Both studies suggested that metformin treatment lowered glycosylated haemoglobin A1c (HbA1c) in adolescents with type 1 diabetes and poor metabolic control.,rephrase,['Both studies suggested that metformin plus insulin treatment lowered HbA1c somewhat more than placebo plus insulin.'],1,0.375,2,8
CD006691,0,3,"Improvements in insulin sensitivity, body composition or serum lipids were not documented in either study, however, one study showed a decrease in insulin dosage by 10%.",split,"['Improvement in insulin sensitivity, body weight or serum lipids were not seen in either study.', 'However, one study showed a small decrease in insulin dosage by 10%.']",2,0.5,3,8
CD006691,0,4,Adverse effects were mainly gastrointestinal in both studies and hypoglycaemia in one study.,rephrase,['Side effects were mainly gastrointestinal upset in both studies and hypoglycaemia (low blood sugar) in one study.'],4,0.625,4,8
CD006691,0,5,"No data on health-related quality of life, all-cause mortality or morbidity are currently available.",rephrase,"['There was no information on health-related quality of life, costs, morbidity or mortality in either study.']",5,0.75,4,8
CD006691,1,6,"There is some evidence suggesting improvement of metabolic control in poorly controlled adolescents with type 1 diabetes, on addition of metformin to insulin therapy.",delete,[],6,0.875,5,8
CD006691,1,7,"Stronger evidence is required from larger studies, carried out over longer time periods to document the long-term effects on metabolic control, health-related quality of life as well as morbidity and mortality in those patients.",delete,[],6,1.0,5,8
CD002100,0,0,"Of the 908 participants enrolled (three RCTs), 454 were allocated for drainage and 454 for no drainage.",delete,[],0,0.125,1,8
CD002100,0,1,We found no new RCTs for this review update.,rephrase,['We found no new evidence since the previous version of our systematic review of 2004.'],0,0.25,2,8
CD002100,0,2,Two trials reported the primary outcome measure of anastomotic dehiscence.,delete,[],1,0.375,2,8
CD002100,0,3,"There was no statistically significant difference in anastomotic dehiscence in participants treated with intra-abdominal drainage routinely compared to no treatment (risk ratio (RR) 1.40, 95% confidence intervals (CI) 0.45 to 4.40; I2 = 0%; 2 RCTs; 809 participants).",delete,[],1,0.5,3,8
CD002100,0,4,"There was no statistically significant difference in mortality (RR 0.77, 95% CI 0.41 to 1.45; I2 = 0%; 3 RCTs; 908 participants); surgical re-intervention (RR 1.11, 95% CI 0.67 to 1.82; I2 = 29%; 3 RCTs; 908 participants); radiological dehiscence (RR 0.85, 95% CI 0.39 to 1.83; I2 = 0%; 2 RCTs; 809 participants) and wound infection (RR 0.82, 95% CI 0.45 to 1.51; I2 = 0%; 3 RCTs; 908 participants) in participants treated with routine prophylactic drainage compared to no treatment undergoing elective colorectal surgery.",delete,[],1,0.625,4,8
CD002100,0,5,The quality of evidence was low according to GRADE method assessment.,rephrase,"['The quality of the evidence was low, making it impossible to draw firm conclusions about the use of routine prophylactic drains after elective colorectal anastomosis.']",1,0.75,4,8
CD002100,1,6,There was insufficient evidence for the use of prophylactic drains after elective colorectal anastomoses.,rephrase,['We found insufficient evidence to support the use of routine prophylactic drains after elective colorectal anastomosis.'],2,0.875,5,8
CD002100,1,7,The conclusions of this review were limited due to the nature of the available clinical data; The three included RCTs performed different interventions with relatively small sample sizes of eligible participants.,rephrase,['We based our conclusion on limited evidence with relatively small numbers of participants; this means that it is difficult to detect differences between treatment groups that may be present.'],3,1.0,5,8
CD012970,0,0,Nine RCTs (695 pregnant women with GDM) comparing probiotics versus placebo were identified.,rephrase,"['We identified nine studies, involving 695 women with GDM.']",0,0.043478260869565216,1,23
CD012970,0,1,The overall risk of bias in the nine RCTs was low to unclear and the evidence was downgraded for imprecision due to the small numbers of women participating in the trials.,rephrase,['The overall risk of bias was low to unclear.'],1,0.08695652173913043,1,23
CD012970,0,2,"The trials were carried out in hospitals and universities in Iran (seven trials), Thailand (one trial) and Ireland (one trial).",split,"['Seven trials were conducted in Iran; one in Thailand, and one in Ireland.', 'Trials took place in hospitals and universities.']",2,0.13043478260869565,1,23
CD012970,0,3,All trials compared probiotics with placebo.,ignore,['All trials compared probiotics with placebo.'],4,0.17391304347826086,1,23
CD012970,1,4,"Maternal outcomes
We are uncertain if probiotics have any effect compared with placebo on hypertensive disorders of pregnancy, (risk ratio (RR) 1.50, 95% confidence interval (CI) 0.64 to 3.53; participants = 256; studies = 3; low-certainty evidence) and mode of birth as caesareans (average RR 0.64, 95% CI 0.30 to 1.35; participants = 267; studies = 3; low-certainty evidence) because the certainty of evidence is low and the 95% CIs span possible benefit and possible harm.",rephrase,"['We are uncertain if there is any difference between probiotic and placebo in rates of: high blood-pressure disorders (three studies, 256 participants, low-certainty evidence); caesarean section (three studies, 267 women, low-certainty evidence); and large-for-gestational-age babies (two studies, 174 participants, low-certainty evidence).']",5,0.21739130434782608,2,23
CD012970,2,5,No trials reported primary outcomes of: mode of birth as vaginal/assisted and subsequent development of type 2 diabetes.,delete,[],6,0.2608695652173913,2,23
CD012970,3,6,"We are uncertain if probiotics have any effect compared with placebo on induction of labour (RR 1.33, 95% CI 0.74 to 2.37; participants = 127; studies = 1; very low-certainty evidence).",rephrase,"['We are uncertain if there is any difference between probiotic and placebo for induction of labour (one study, 127 participants, very low-certainty evidence) and low blood glucose levels in the newborn (three studies, 177 participants, low-certainty evidence).']",6,0.30434782608695654,2,23
CD012970,4,7,"For other secondary maternal outcomes, we are uncertain if there are differences between probiotics and placebo for: postpartum haemorrhage; weight gain during pregnancy intervention and total gestational weight gain; fasting plasma glucose and need for extra pharmacotherapy (insulin).",rephrase,"['We are also uncertain if there is any difference between probiotics and placebo for heavy bleeding immediately after birth, weight gain during pregnancy or total gestational weight gain.']",7,0.34782608695652173,2,23
CD012970,4,8,Probiotics may be associated with a slight reduction in triglycerides and total cholesterol.,rephrase,"['Probiotics may be assoicated with a slight reduction in triglycerides and total cholesterol (four studies, 320 participants).']",8,0.391304347826087,2,23
CD012970,5,9,"In probiotics compared with placebo, there was evidence of reduction in markers for insulin resistance (HOMA-IR) and HOMA-B; and insulin secretion.",rephrase,"['There was reduction in insulin secretion with probiotics (seven studies, 505 participants).']",9,0.43478260869565216,3,23
CD012970,5,10,There was also an increase in quantitative insulin sensitivity check index (QUICKI).,rephrase,"['Quantitative insulin sensitivity check index (QUICKI) increased (four studies, 276 participants) with probiotics.']",10,0.4782608695652174,3,23
CD012970,6,11,"Probiotics were associated with minor benefits in relevant bio-markers with evidence of a reduction in inflammatory markers high-sensitivity C-reactive protein (hs-CRP), interleukin 6 (IL-6), and marker of oxidative stress malondialdehyde; and an increase in antioxidant total glutathione, but we are uncertain if there is any difference in total antioxidant capacity.",split,"['Inflammatory markers, hs-CRP (four studies, 248 participants) and interleukin 6 (two studies, 128 participants) were reduced with probiotics.', 'Antioxidant total glutathione was increased (two studies, 120 participants) and the oxidative stress biomarker malondialdehyde was reduced with probiotics (three studies, 176 participants).', 'We are uncertain if there is any difference in total antioxidant capacity (four studies 266 participants).']",11,0.5217391304347826,3,23
CD012970,7,12,"No trials reported secondary outcomes: perineal trauma, postnatal weight retention or return to pre-pregnancy weight and postnatal depression.",delete,[],14,0.5652173913043478,3,23
CD012970,8,13,"Infant/child/adult outcomes
We are uncertain if probiotics have any effect, compared with placebo, on the risk of large-for-gestational-age babies (RR 0.73, 95% CI 0.35 to 1.52; participants = 174; studies = 2; low-certainty evidence) or infant hypoglycaemia (RR 0.85, 95% CI 0.39 to 1.84; participants = 177; studies = 3; low-certainty evidence) because the certainty of evidence is low and the 95% CIs span possible benefit and possible harm.",delete,[],14,0.6086956521739131,4,23
CD012970,9,14,No trials reported primary outcomes of: perinatal (fetal/neonatal) mortality; or neurosensory disability.,delete,[],14,0.6521739130434783,4,23
CD012970,10,15,"For other secondary outcomes, we are uncertain if there is any difference between probiotics and placebo in gestational age at birth, preterm birth, macrosomia, birthweight, head circumference, length, infant hypoglycaemia, and neonatal intensive care unit (NICU) admissions.",rephrase,"['For the newborn baby, we are uncertain if there is any difference between groups for: birthweight, gestational age at birth, preterm births, large babies, head circumference and length scores, or need for admission to the neonatal intensive care unit.']",14,0.6956521739130435,4,23
CD012970,11,16,There was evidence of a reduction in infant hyperbilirubinaemia with probiotics compared with placebo.,rephrase,['The number of babies with high levels of bilirubin was reduced with probiotics.'],15,0.7391304347826086,4,23
CD012970,12,17,"No trials reported secondary outcomes: infant adiposity, and later childhood adiposity.",delete,[],16,0.782608695652174,4,23
CD012970,13,18,There were no adverse events reported by any of the trials.,rephrase,['No adverse events were reported by the trials.'],16,0.8260869565217391,5,23
CD012970,14,19,"Low-certainty evidence means we are not certain if there is any difference between probiotic and placebo groups in maternal hypertensive disorders of pregnancy, caesareans; and large-for-gestational-age babies.",delete,[],17,0.8695652173913043,5,23
CD012970,15,20,There were no adverse events reported by the trials.,delete,[],17,0.9130434782608695,5,23
CD012970,16,21,"Due to the variability of probiotics used and small sample sizes of trials, evidence from this review has limited ability to inform practice.",rephrase,"['Based on the clinical trials available, the evidence is limited to support the use of probiotics as treatment for women with GDM to improve pregnancy outcomes for mothers and their babies.']",17,0.9565217391304348,5,23
CD012970,16,22,Well-designed adequately-powered trials are needed to identify whether probiotics may improve maternal blood glucose levels and/or infant/child/adult outcomes; and whether they can be used to treat GDM.,rephrase,"['Larger well-designed randomised controlled trials are needed to assess the effects of probiotics on management of glucose levels and when available, they can be included in the update of this review.']",18,1.0,5,23
CD010200,0,0,We included five studies involving 266 participants (136 intervention; 130 control).,rephrase,['We included five studies with a total of 266 participants.'],0,0.1,1,10
CD010200,0,1,"All participants were adult stroke survivors, living in the community or a care home.",ignore,['All participants were adult stroke survivors who lived in the community or a care home.'],1,0.2,1,10
CD010200,0,2,"Programmes to improve community ambulation consisted of walking practice in a variety of settings and environments in the community, or an indoor activity that mimicked community walking (including virtual reality or mental imagery).",rephrase,"['Programmes to improve community ambulation consisted of walking practice in a variety of settings and environments in the community (three studies), or an activity indoors that mimicked community walking (three studies).']",2,0.3,2,10
CD010200,0,3,"Three studies were funded by government agencies, and two had no funding.",ignore,"['Three studies were funded by government agencies, and two had no funding.']",3,0.4,2,10
CD010200,1,4,"From two studies of 198 people there was low quality evidence for the effect of intervention on participation compared with control (SMD, 0.08, 95% confidence interval (CI) -0.20 to 0.35 (using inverse variance).",delete,[],4,0.5,3,10
CD010200,1,5,"The CI for the effect of the intervention on gait speed was wide and does not exclude no difference (MD 0.12, 95% CI -0.01 to 0.24; four studies, 98 participants, low quality evidence).",delete,[],4,0.6,3,10
CD010200,1,6,"We considered the quality of the evidence to be low for all the remaining outcomes in our review: Community Walk Test (MD -6.35, 95% CI -21.59 to 8.88); Walking Ability Questionnaire (MD 0.53, 95% CI -5.59 to 6.66); Six-Minute Walk Test (MD 39.62 metres, 95% CI -8.26 to 87.51) and self-efficacy (SMD 0.32, 95% CI -0.09 to 0.72).",merge,['We considered the quality of the evidence to be low across the studies for both the participation and walking speed outcomes.'],4,0.7,4,10
CD010200,1,7,We downgraded the quality of the evidence because of a high risk of bias and imprecision.,none,[],4,0.8,4,10
CD010200,2,8,There is currently insufficient evidence to establish the effect of community ambulation interventions or to support a change in clinical practice.,ignore,['There is currently insufficient evidence to establish the effect of community ambulation interventions or to support a change in clinical practice.'],5,0.9,5,10
CD010200,2,9,More research is needed to determine if practicing outdoor or community walking will improve participation and community ambulation skills for stroke survivors living in the community.,rephrase,['More research is needed in this area.'],6,1.0,5,10
CD001706,0,0,Twenty-three trials involving 2861 older and mainly female patients with proximal femoral fractures are included.,rephrase,['Twenty-three trials involving 2861 older and mainly female patients with hip fractures are included in this review.'],0,0.08333333333333333,1,12
CD001706,0,1,"Cemented prostheses, when compared with uncemented prostheses (6 trials, 899 participants) were associated with a less pain at a year or later and improved mobility.",delete,[],1,0.16666666666666666,1,12
CD001706,0,2,No significant difference in surgical complications was found.,delete,[],1,0.25,2,12
CD001706,0,3,One trial of 220 participants compared a hydroxyapatite coated hemiarthroplasty with a cemented prosthesis and reported no notable differences between the two prosthesis.,delete,[],1,0.3333333333333333,2,12
CD001706,0,4,"Comparison of unipolar hemiarthroplasty with bipolar hemiarthroplasty (7 trials, 857 participants, 863 fractures) showed no significant differences between the two types of implant.",rephrase,['No notable differences between these two types of implant were demonstrated.'],1,0.4166666666666667,3,12
CD001706,0,5,Seven trials involving 734 participants compared hemiarthroplasty with a total hip replacement (THR).,split,"['Six studies involving 899 participants compared a press fit arthroplasty with one that was secured in place with bone cement.', 'Seven trials involving 857 participants compared those implants which have a second joint built into them (bipolar hemiarthroplasties) with those without this additional joint (unipolar hemiarthroplasties).', 'Seven studies of 734 participants compared different types of hemiarthroplasty with a total hip replacement.']",2,0.5,3,12
CD001706,0,6,Most studies involved cemented implants.,rephrase,['Most implants had been cemented in place.'],5,0.5833333333333334,3,12
CD001706,0,7,Dislocation of the prosthesis was more common with the THR but there was a general trend within these studies to better functional outcome scores for those treated with the THR.,rephrase,"['There was a trend to better functional outcomes after total hip replacement, but firm conclusions could not be made because of the lack of patient numbers.']",6,0.6666666666666666,4,12
CD001706,1,8,There is good evidence that cementing the prostheses in place will reduce post-operative pain and lead to better mobility.,rephrase,"['There is good evidence that people with arthroplasties that are cemented in place have less pain and better mobility after the operation than those, which are inserted as a press fit.']",7,0.75,4,12
CD001706,1,9,From the trials to date there is no evidence of any difference in outcome between bipolar and unipolar prosthesis.,delete,[],8,0.8333333333333334,5,12
CD001706,1,10,There is some evidence that a total hip replacement leads to better functional outcome than a hemiarthroplasty.,ignore,['There is limited evidence that a total hip replacement leads to better functional outcome than a hemiarthroplasty.'],8,0.9166666666666666,5,12
CD001706,1,11,Further well-conducted randomised trials are required.,delete,[],9,1.0,5,12
CD011274,0,0,We identified 26 studies (8835 participants).,rephrase,['We identified 26 studies studying 8835 participants.'],0,0.05555555555555555,1,18
CD011274,0,1,"Risk of bias was high in 17, unclear in 6and low in three studies.",merge,"['Risk of bias was high in 17, unclear in six studies and low in three studies.']",1,0.1111111111111111,1,18
CD011274,0,2,There was high risk of attrition bias in six studies.,none,[],1,0.16666666666666666,1,18
CD011274,1,3,Only two studies measured AKI.,merge,[],2,0.2222222222222222,2,18
CD011274,1,4,"The use of NSAIDs had uncertain effects on the incidence of AKI compared to placebo (7066 participants: RR 1.79, 95% CI 0.40 to 7.96; I2 = 59%; very low certainty evidence).",none,['The use NSAIDs had uncertain effects on the incidence of AKI compared to placebo.'],2,0.2777777777777778,2,18
CD011274,1,5,One study was stopped early by the data monitoring committee due to increased rates of AKI in the NSAID group.,merge,['One study was stopped early by the data monitoring committee due to increased rates of AKI in the NSAID group and both of these studies examined much lower doses of NSAIDs than would usually be used for pain relief.'],3,0.3333333333333333,2,18
CD011274,1,6,"Moreover, both of these studies were examining NSAIDs for indications other than analgesia and therefore utilised relatively low doses.",none,[],3,0.3888888888888889,2,18
CD011274,2,7,"Compared to placebo, NSAIDs may slightly increase serum SCr (15 studies, 794 participants: MD 3.23 μmol/L, 95% CI -0.80 to 7.26; I2 = 63%; low certainty evidence).",rephrase,['NSAIDs may slightly increase serum creatinine (a marker of kidney function which rises in kidney failure) compared with placebo.'],4,0.4444444444444444,3,18
CD011274,2,8,Studies displayed moderate to high heterogeneity and had multiple exclusion criteria including age and so were not representative of patients undergoing surgery.,delete,[],5,0.5,3,18
CD011274,2,9,Three of these studies excluded patients if their creatinine rose post-operatively.,rephrase,"['These studies only included fit, healthy patients.']",5,0.5555555555555556,3,18
CD011274,3,10,"NSAIDs may make little or no difference to post-operative urine output compared to placebo (6 studies, 149 participants: SMD -0.02, 95% CI -0.31 to 0.27).",delete,[],6,0.6111111111111112,4,18
CD011274,3,11,No reliable conclusions could be drawn from these studies due to the differing units of measurements and measurement time points.,rephrase,['No reliable conclusions could be drawn from the studies examining urine output due to the different methods of measuring this.'],6,0.6666666666666666,4,18
CD011274,4,12,"It is uncertain whether NSAIDs leads to the need for RRT because the certainty of this evidence is very low (2 studies, 7056 participants: RR 1.57, 95% CI 0.49 to 5.07; I2 = 26%); there were few events and the results were inconsistent.",delete,[],7,0.7222222222222222,4,18
CD011274,5,13,"It is uncertain whether NSAIDs lead to more deaths (2 studies, 312 participants: RR 1.44, 95% CI 0.19 to 11.12; I2 = 38%) or increased the length of hospital stay (3 studies, 410 participants: MD 0.12 days, 95% CI -0.48 to 0.72; I2 = 24%).",rephrase,"['It is uncertain whether the use of NSAIDs leads to an increased need for renal replacement therapy (dialysis), more deaths, or increased length of hospital stay.']",7,0.7777777777777778,4,18
CD011274,6,14,"Overall NSAIDs had uncertain effects on the risk of post-operative AKI, may slightly increase post-operative SCr, and it is uncertain whether NSAIDs lead to the need for RRT, death or increases the length of hospital stay.",split,"['NSAIDs have uncertain effects on the rates of AKI when used in patients with normal kidney function following surgery.', 'It is uncertain whether NSAIDs increase the need for dialysis.']",8,0.8333333333333334,5,18
CD011274,6,15,The available data therefore does not confirm the safety of NSAIDs in patients undergoing surgery.,ignore,['The available data therefore does not confirm the safety of NSAIDs in patients undergoing surgery.'],10,0.8888888888888888,5,18
CD011274,6,16,Further larger studies using the Kidney Disease Improving Global Outcomes definition for AKI including patients with co-morbidities are required to confirm these findings.,rephrase,['Further studies including patients with other health problems are required.'],11,0.9444444444444444,5,18
CD011274,6,17,.,delete,[],12,1.0,5,18
CD010478,0,0,We identified eight trials that met the inclusion criteria.,delete,[],0,0.043478260869565216,1,23
CD010478,0,1,One trial including 17 surgical trainees did not contribute to the meta-analysis.,rephrase,['Three trials including 168 trainees reported the complications that the patients developed during or immediately after the operation.'],0,0.08695652173913043,1,23
CD010478,0,2,We included seven trials (249 surgical trainees belonging to various postgraduate years ranging from year one to four) in which the participants were randomised to supplementary box model training (122 trainees) versus standard training (127 trainees).,split,"['We identified and included seven trials in which 249 surgical trainees with limited previous laparoscopic experience received either box model training in addition to their standard apprenticeship training (122 trainees) versus standard apprenticeship training alone (127 trainees).', 'The choice of whether the trainees received supplementary box model training was made in a random method similar to the toss of a coin.']",1,0.13043478260869565,1,23
CD010478,0,3,Only one trial (50 trainees) was at low risk of bias.,delete,[],3,0.17391304347826086,1,23
CD010478,0,4,The box trainers used in all the seven trials were video trainers.,delete,[],3,0.21739130434782608,2,23
CD010478,0,5,Six trials were conducted in USA and one trial in Canada.,ignore,['Six trials were conducted in USA and one trial in Canada.'],3,0.2608695652173913,2,23
CD010478,0,6,"The surgeries in which the final assessments were made included laparoscopic total extraperitoneal hernia repairs, laparoscopic cholecystectomy, laparoscopic tubal ligation, laparoscopic partial salpingectomy, and laparoscopic bilateral mid-segment salpingectomy.",delete,[],4,0.30434782608695654,2,23
CD010478,0,7,The final assessments were made on a single operative procedure.,delete,[],4,0.34782608695652173,2,23
CD010478,1,8,There were no deaths in three trials (0/82 (0%) supplementary box model training versus 0/86 (0%) standard training; RR not estimable; very low quality evidence).,rephrase,['There were no deaths in either group in 168 operations performed by 168 trainees and we could not tell whether laparoscopic box model training led to major complications (one major complication in one patient operated by a trainee who underwent standard training out of 86 operations performed by trainees who underwent standard training as compared with no major complications in 82 operations performed by trainees who underwent box model training).'],4,0.391304347826087,2,23
CD010478,1,9,The other trials did not report mortality.,delete,[],5,0.43478260869565216,3,23
CD010478,1,10,The estimated effect on serious adverse events was compatible with benefit and harm (three trials; 168 patients; 0/82 (0%) supplementary box model training versus 1/86 (1.1%) standard training; RR 0.36; 95% CI 0.02 to 8.43; very low quality evidence).,delete,[],5,0.4782608695652174,3,23
CD010478,1,11,None of the trials reported patient quality of life.,ignore,['None of the trials reported patient quality of life.'],5,0.5217391304347826,3,23
CD010478,1,12,The operating time was significantly shorter in the supplementary box model training group versus the standard training group (1 trial; 50 patients; MD -6.50 minutes; 95% CI -10.85 to -2.15).,rephrase,['One trial reported a small reduction in operating time of just over six minutes in the supplementary box model training group.'],6,0.5652173913043478,3,23
CD010478,1,13,The proportion of patients who were discharged as day-surgery was significantly higher in the supplementary box model training group versus the standard training group (1 trial; 50 patients; 24/24 (100%) supplementary box model training versus 15/26 (57.7%) standard training; RR 1.71; 95% CI 1.23 to 2.37).,rephrase,"['In one trial, the proportion of patients who were discharged as day-surgery was significantly higher in the supplementary box model training group (24/24 (100%)) compared with the standard training group (15/26 (57.7%)).']",7,0.6086956521739131,4,23
CD010478,1,14,None of the trials reported trainee satisfaction.,split,"['The remaining trials did not report operating time.', 'None of the trials reported trainee satisfaction.']",8,0.6521739130434783,4,23
CD010478,1,15,The operating performance was significantly better in the supplementary box model training group versus the standard training group (seven trials; 249 trainees; SMD 0.84; 95% CI 0.57 to 1.10).,rephrase,['The operating performance as assessed by surgical experts was significantly better in the supplementary box model training group compared with the standard training group.'],10,0.6956521739130435,4,23
CD010478,2,16,None of the trials compared box model training versus animal model training or versus different methods of box model training.,rephrase,['None of the trials compared box model training compared with animal model training or compared with different methods of box model training.'],11,0.7391304347826086,4,23
CD010478,3,17,There is insufficient evidence to determine whether laparoscopic box model training reduces mortality or morbidity.,merge,[],12,0.782608695652174,4,23
CD010478,3,18,There is very low quality evidence that it improves technical skills compared with standard surgical training in trainees with limited previous laparoscopic experience.,none,['Laparoscopic box model training appears to improve technical skills compared with standard surgical training in trainees with limited previous laparoscopic experience.'],12,0.8260869565217391,5,23
CD010478,3,19,It may also decrease operating time and increase the proportion of patients who were discharged as day-surgery in the first total extraperitoneal hernia repair after box model training.,rephrase,['It may also decrease operating time and decrease the proportion of patients who require overnight stay in the first hernia repair operation that the trainee performed after box model training.'],13,0.8695652173913043,5,23
CD010478,3,20,"However, the duration of the benefit of box model training is unknown.",rephrase,"['However, the duration of the benefit of box model training (ie, whether such benefit continues in subsequent operations) is unknown.']",14,0.9130434782608695,5,23
CD010478,3,21,Further well-designed trials of low risk of bias and random errors are necessary.,rephrase,['Further well-designed trials with less risk of bias because of poor study design or because of chance are necessary.'],15,0.9565217391304348,5,23
CD010478,3,22,Such trials should assess the long-term impact of box model training on clinical outcomes and compare box training with other forms of training.,rephrase,['Such trials should assess the long-term impact of box model training on clinical outcomes.'],16,1.0,5,23
CD011539,0,0,"We found no trials comparing the effectiveness and safety of enzyme replacement therapy to another intervention, no intervention or placebo.",split,"['We searched medical databases for clinical trials of enzyme replacement therapy in children with Pompe disease.', ""We found no randomised trials (where people taking part in the trial have equal chances of being in the treatment or the control group) comparing the effectiveness and safety of enzyme replacement therapy to another intervention, no intervention or placebo (a 'dummy' drug).""]",0,0.07142857142857142,1,14
CD011539,1,1,"We found one trial (18 participants) that fulfilled the selection criteria, comparing different doses of alglucosidase alfa.",rephrase,['We found one trial (18 children) that compared two doses of recombinant human alglucosidase alfa (an enzyme replacement therapy): 20 mg/kg every two weeks (low dose) and 40 mg/kg every two weeks (high dose).'],2,0.14285714285714285,1,14
CD011539,1,2,"The trial provided low-quality evidence (this was a small trial, there were no numerical results available by dose group, random sequence generation and allocation concealment were unclear, and there was a lack of blinding).",rephrase,"['There were very limited numerical results available by dose group, the trial showed no evidence in favour of a high dose as opposed to a low dose.']",3,0.21428571428571427,2,14
CD011539,1,3,"The duration of alglucosidase alfa treatment ranged from 52 weeks (the length of the original study) to up to three years (including the extended phase of the trial), with a median duration of treatment being 2.3 years.",rephrase,"['The duration of treatment ranged from 52 weeks (the length of the original study) to up to three years (including the extension phase of the study), with a median (the middle number) duration of treatment being 2.3 years.']",4,0.2857142857142857,2,14
CD011539,2,4,"The trial only reported that clinical responses including cardiac function and motor development, as well as the proportion of children that were free of invasive ventilation, were similar in the 20 mg/kg every two weeks and the 40 mg/kg every two weeks groups (low-quality evidence).",rephrase,"[""It described that the clinical responses including cardiac function, motor development (development of a child's muscles and their ability to move around and manipulate their environment), as well as the proportion of children that were free of invasive ventilation,were similar in the two groups (low-quality evidence).""]",5,0.35714285714285715,2,14
CD011539,2,5,Long-term alglucosidase alfa treatment markedly extended survival as well as ventilation-free survival and improved cardiomyopathy (low-quality evidence).,rephrase,['Long-term alglucosidase alfa treatment markedly extended survival as well as ventilation-free survival (time without requiring a machine to help with breathing) and improved cardiomyopathy (heart disease) (low-quality evidence).'],6,0.42857142857142855,3,14
CD011539,2,6,"In relation to the number of children experiencing one or more infusion-related events, there was no significant difference between dose groups, risk ratio 0.83 (95% confidence interval 0.40 to 1.76) (low-quality of evidence).",merge,"['In relation to the number of children experiencing one or more infusion-related events, there was no significant difference between the different dose groups (low-quality evidence), although, of note, at 52 weeks, five children in the low-dose group experienced a total of 41 mild or moderate (none were severe) infusion-related events and the six children in the high dose-group experienced a total of 123 infusion-related events.']",7,0.5,3,14
CD011539,2,7,"However, of note, at 52 weeks, five children in the 20 mg/kg every two weeks dose group experienced a total of 41 mild or moderate (none severe) infusion-related events and the six children in the 40 mg/kg every two weeks dose group experienced a total of 123 infusion-related events.",none,[],7,0.5714285714285714,3,14
CD011539,2,8,"By the end of the extended phase of the trial, five children in the 20 mg/kg every two weeks dose group experienced a total of 47 infusion-related events and the six children in the 40 mg/kg every two weeks dose group experienced a total of 177 infusion-related events.",rephrase,"['By the end of the extension phase, five children in the low-dose group experienced a total of 47 infusion-related events and the six children in the high-dose group experienced a total of 177 infusion-related events.']",8,0.6428571428571429,4,14
CD011539,2,9,The trial was supported by the Genzyme Corporation.,ignore,['The trial was supported by the Genzyme Corporation.'],9,0.7142857142857143,4,14
CD011539,3,10,"The search found no trials comparing the effectiveness and safety of enzyme replacement therapy to another intervention, no intervention or placebo.",delete,[],10,0.7857142857142857,4,14
CD011539,3,11,One small randomized controlled trial provided no robust evidence for which dosing schedule of alglucosidase alfa was more effective to treat infantile-onset Pompe disease.,delete,[],10,0.8571428571428571,5,14
CD011539,3,12,"It is not deemed ethical to proceed with new placebo-controlled trials, therefore a randomized controlled trial with a large sample size comparing different dosing schedules of enzyme replacement therapy is needed.",delete,[],10,0.9285714285714286,5,14
CD011539,3,13,"The main clinical outcomes (i.e. cardiac function, invasive ventilation, survival, motor development, adverse events (e.g. the development of antibodies)) should be standardized when evaluated and reported.",rephrase,"['The main clinical outcomes (i.e. cardiac function, time to ventilation, survival, motor development and side effects) should be standardized when evaluated and reported.']",10,1.0,5,14
CD008623,0,0,"When the described search method was used and the eligibility criteria of the search results were applied, 653 records were found.",delete,[],0,0.05263157894736842,1,19
CD008623,0,1,Only two of these were randomised clinical trials that were considered eligible for inclusion.,rephrase,['This systematic review identified two randomised clinical trials with very small numbers of participants.'],0,0.10526315789473684,1,19
CD008623,0,2,We assessed both trials as trials with high risk of bias.,rephrase,"['Both trials were at high risk of bias (that is, overestimation of benefits and underestimation of harms).']",1,0.15789473684210525,1,19
CD008623,0,3,One of the trials was a pilot trial in which 16 participants with biopsy-proven NASH were randomised to receive simvastatin 40 mg (n = 10) or placebo (n = 6) once daily for 12 months.,rephrase,"['One of the trials was a pilot trial and compared simvastatin with placebo, and the other trial assessed atorvastatin versus fenofibrate versus a combination of the two.']",2,0.21052631578947367,2,19
CD008623,0,4,No statistically significant improvement in the aminotransferase level was seen in the simvastatin group compared with the placebo group.,delete,[],3,0.2631578947368421,2,19
CD008623,0,5,Liver histology was not significantly affected by simvastatin.,rephrase,['The small pilot trial (n = 16 patients) assessing simvastatin versus placebo in NASH patients did not show significant effects on liver enzyme activities or liver histology.'],3,0.3157894736842105,2,19
CD008623,1,6,The other trial had three arms.,delete,[],4,0.3684210526315789,2,19
CD008623,1,7,The trial compared atorvastatin 20 mg daily (n = 63) versus fenofibrate 200 mg daily (n = 62) versus a group treated with a combination of the two interventions (n = 61).,rephrase,['The other trial compared atorvastatin versus fenofibrate versus a group receiving both interventions in 186 patients with NAFLD.'],4,0.42105263157894735,3,19
CD008623,1,8,"There were no statistically significant differences between any of the three intervention groups regarding the week 54 mean activity levels of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, and alkaline phosphatase.",rephrase,"['There were no statistically significant differences between any of the three intervention groups regarding the 54 week mean activities of aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpeptidase, or alkaline phosphatases (liver enzymes) in the blood.']",5,0.47368421052631576,3,19
CD008623,1,9,The triglyceride levels seemed higher in the fenofibrate group compared with the atorvastatin group.,ignore,['The triglyceride levels seemed higher in the fenofibrate group compared with the atorvastatin group.'],6,0.5263157894736842,3,19
CD008623,1,10,Liver histology was not assessed in this trial.,ignore,['Liver histology was not assessed in this trial.'],7,0.5789473684210527,3,19
CD008623,1,11,The presence of biochemical and ultrasonographic evidence of NAFLD seemed to be higher in the fenofibrate group compared with the atorvastatin group (58% versus 33%).,rephrase,['The presence of biochemical and ultrasonographic evidence of NAFLD seemed higher in the fenofibrate group compared with the other two intervention groups.'],8,0.631578947368421,4,19
CD008623,1,12,Three patients discontinued treatment due to myalgia and elevated serum creatine kinase activity; one from the atorvastatin group and two from the combination group.,ignore,"['Three patients discontinued treatment due to myalgia and elevated serum creatine kinase activity, one from the atorvastatin group and two from the combination group.']",9,0.6842105263157895,4,19
CD008623,1,13,Another patient from the atorvastatin group discontinued treatment due to alanine aminotransferase activity that was over three times the upper normal limit.,ignore,"['Another patient from the atorvastatin group discontinued treatment due to raised alanine aminotransferase activity, over three times the upper normal limit.']",10,0.7368421052631579,4,19
CD008623,2,14,No data for all-cause mortality and hepatic-related mortality were reported in the included trials.,delete,[],11,0.7894736842105263,4,19
CD008623,3,15,"Based on the findings of this review, which included two trials with high risk of bias and a small numbers of participants, it seems possible that statins may improve serum aminotransferase levels as well as ultrasound findings.",delete,[],11,0.8421052631578947,5,19
CD008623,3,16,"Neither of the trials reported on possible histological changes, liver-related morbidity or mortality.",delete,[],11,0.8947368421052632,5,19
CD008623,3,17,Trials with larger sample sizes and low risk of bias are necessary before we may suggest statins as an effective treatment for patients with NASH.,delete,[],11,0.9473684210526315,5,19
CD008623,3,18,"However, as statins can improve the adverse outcomes of other conditions commonly associated with NASH (for example, hyperlipidaemia, diabetes mellitus, metabolic syndrome), their use in patients with non-alcoholic steatohepatitis may be justified.",delete,[],11,1.0,5,19
CD004371,0,0,"For this updated review, we added 24 new studies meeting the eligibility criteria to the 11 studies from prior updates.",delete,[],0,0.07142857142857142,1,14
CD004371,0,1,"We have therefore included 35 studies, randomising 925,171 participants.",rephrase,"['We now include 35 studies covering 925,171 participants in this review.']",0,0.14285714285714285,1,14
CD004371,0,2,"Seven studies including 11,204 individuals compared adherence rates of those in an intensification of a patient care intervention (e.g. electronic reminders, pharmacist-led interventions, healthcare professional education of patients) versus usual care over the short term (six months or less), and were pooled in a meta-analysis.",rephrase,"['These interventions included electronic reminders, pharmacist-led interventions, and healthcare professional education to help people better remember to take their medications.']",1,0.21428571428571427,2,14
CD004371,0,3,"Participants in the intervention group had better adherence than those receiving usual care (odds ratio (OR) 1.93, 95% confidence interval (CI) 1.29 to 2.88; 7 studies; 11,204 participants; moderate-quality evidence).",delete,[],2,0.2857142857142857,2,14
CD004371,0,4,"A separate analysis also showed improvements in long-term adherence rates (more than six months) using intensification of care (OR 2.87, 95% CI 1.91 to 4.29; 3 studies; 663 participants; high-quality evidence).",rephrase,['These types of interventions when compared to standard care demonstrated significantly better adherence rates both over the short term (up to and including six months) as well as the long term (longer than six months).'],2,0.35714285714285715,2,14
CD004371,0,5,Analyses of the effect on total cholesterol and LDL-cholesterol levels also showed a positive effect of intensified interventions over both short- and long-term follow-up.,rephrase,"['Additionally, cholesterol levels were better over both long- and short-term periods in those offered the intervention, compared to those receiving usual care.']",3,0.42857142857142855,3,14
CD004371,0,6,"Over the short term, total cholesterol decreased by a mean of 17.15 mg/dL (95% CI 1.17 to 33.14; 4 studies; 430 participants; low-quality evidence) and LDL-cholesterol decreased by a mean of 19.51 mg/dL (95% CI 8.51 to 30.51; 3 studies; 333 participants; moderate-quality evidence).",delete,[],4,0.5,3,14
CD004371,0,7,Over the long term (more than six months) total cholesterol decreased by a mean of 17.57 mg/dL (95% CI 14.95 to 20.19; 2 studies; 127 participants; high-quality evidence).,rephrase,"['For the outcome total cholesterol levels at less than six months follow-up, we downgraded the evidence to low quality.']",4,0.5714285714285714,3,14
CD004371,0,8,"Included studies did not report usable data for health outcome indications, adverse effects or costs/resource use, so we could not pool these outcomes.",delete,[],5,0.6428571428571429,4,14
CD004371,0,9,We assessed each included study for bias using methods described in the Cochrane Handbook for Systematic Reviews of Interventions.,delete,[],5,0.7142857142857143,4,14
CD004371,0,10,"In general, the risk of bias assessment revealed a low risk of selection bias, attrition bias, and reporting bias.",delete,[],5,0.7857142857142857,4,14
CD004371,0,11,There was unclear risk of bias relating to blinding for most studies.,rephrase,"['However, analysis of other forms of bias indicated that generally the studies were at low risk of bias.']",5,0.8571428571428571,5,14
CD004371,1,12,"The evidence in our review demonstrates that intensification of patient care interventions improves short- and long-term medication adherence, as well as total cholesterol and LDL-cholesterol levels.",rephrase,"['We assessed the evidence for the outcomes using the GRADE system, and rated it as high quality for long-term adherence (more than six months) and for reduction in total cholesterol, and moderate quality for short-term medication adherence (up to six months) and for LDL-cholesterol levels.']",6,0.9285714285714286,5,14
CD004371,1,13,Healthcare systems which can implement team-based intensification of patient care interventions may be successful in improving patient adherence rates to lipid-lowering medicines.,delete,[],7,1.0,5,14
CD006178,0,0,One study (4155 women at less than 20 weeks' gestation) met the inclusion criteria.,merge,[],0,0.125,1,8
CD006178,0,1,"The intervention group (2058 women) received infection screening and treatment for bacterial vaginosis, trichomonas vaginalis and candidiasis; the control group (2097 women) also received screening, but the results of the screening program were not revealed and women received routine antenatal care.",none,"['The study reported on 4155 women randomly assigned either to an intervention group (2058 women received infection screening and treatment for bacterial vaginosis, trichomonas vaginalis and candidiasis) or a control group (2097 women received screening, but the results of the screening program were not revealed).']",0,0.25,2,8
CD006178,0,2,The rate of preterm birth before 37 weeks' gestation was significantly lower in the intervention group (3% versus 5% in the control group) with a risk ratio (RR) of 0.55 (95% confidence interval (CI) 0.41 to 0.75; the evidence for this outcome was graded as of moderate quality).,delete,[],1,0.375,2,8
CD006178,0,3,"The incidence of preterm birth for infants with a weight equal to or below 2500 g (low birthweight) and infants with a weight equal to or below 1500 g (very low birthweight) were significantly lower in the intervention group than in the control group (RR 0.48, 95% CI 0.34 to 0.66 and RR 0.34; 95% CI 0.15 to 0.75, respectively; both graded as moderate quality evidence).",rephrase,['The number of low birthweight preterm infants and very low birthweight preterm infants were significantly lower in the intervention group than in the control group.'],1,0.5,3,8
CD006178,0,4,"Based on a subset of costs for preterm births of < 1900 g, the authors reported that for each of those preterm births averted, EUR 60,262 would be saved.",delete,[],2,0.625,4,8
CD006178,1,5,There is evidence from one trial that infection screening and treatment programs for pregnant women before 20 weeks' gestation reduce preterm birth and preterm low birthweight.,rephrase,['The present systematic review found that a simple infection screening and treatment program during routine antenatal care may reduce preterm births and preterm low (below 2500 g) and very low (below 1500 g) birthweight.'],2,0.75,4,8
CD006178,1,6,Infection screening and treatment programs are associated with cost savings when used for the prevention of preterm birth.,split,"['The simple infection screening reduced preterm births from 5% of women in the control group to 3% in the intervention group.', 'Moreover, an infection screening and treatment program during routine antenatal care is likely to save over EUR 60,000 for each preterm birth averted.']",3,0.875,5,8
CD006178,1,7,Future trials should evaluate the effects of different types of infection screening programs.,delete,[],5,1.0,5,8
CD004873,0,0,Our update of the searches dated 20 April 2022 identified five new RCTs with 430 participants.,delete,[],0,0.041666666666666664,1,24
CD004873,0,1,We included a total of 17 RCTs (1679 participants) comparing chest physiotherapy with no intervention or comparing different types of physiotherapy.,rephrase,['We included 17 trials with a total of 1679 infants.'],0,0.08333333333333333,1,24
CD004873,1,2,"Five trials (246 participants) assessed percussion and vibration techniques plus postural drainage (conventional chest physiotherapy), and 12 trials (1433 participants) assessed different passive flow-oriented expiratory techniques, of which three trials (628 participants) assessed forced expiratory techniques, and nine trials (805 participants) assessed slow expiratory techniques.",rephrase,['Five trials (246 infants) tested vibration and percussion techniques (conventional chest physiotherapy); three trials (628 infants) tested forced expiratory techniques; and nine trials (805 infants) tested slow expiratory techniques.'],1,0.125,1,24
CD004873,1,3,"In the slow expiratory subgroup, two trials (78 participants) compared the technique with instrumental physiotherapy techniques, and two recent trials (116 participants) combined slow expiratory techniques with rhinopharyngeal retrograde technique (RRT).",rephrase,"['Two trials (80 infants) tested instrumental physiotherapy techniques, and three trials (216 infants) tested the rhinopharyngeal retrograde clearance technique (two combined with slow expiratory technique in 116 infants).']",2,0.16666666666666666,1,24
CD004873,1,4,One trial used RRT alone as the main component of the physiotherapy intervention.,delete,[],3,0.20833333333333334,2,24
CD004873,1,5,"Clinical severity was mild in one trial, severe in four trials, moderate in six trials, and mild to moderate in five trials.",rephrase,"['Disease severity of infants was mild in one trial, severe in four trials, moderate in six trials, and a mix of mild to moderate in five trials.']",3,0.25,2,24
CD004873,1,6,One study did not report clinical severity.,rephrase,['One trial did not report disease severity of infants.'],4,0.2916666666666667,2,24
CD004873,1,7,Two trials were performed on non-hospitalised participants.,rephrase,"['Two trials were performed in ambulatory (non-hospitalised) infants, and the rest were performed in hospitalised infants.']",5,0.3333333333333333,2,24
CD004873,2,8,"Overall risk of bias was high in six trials, unclear in five, and low in six trials.",delete,[],6,0.375,2,24
CD004873,3,9,"The analyses showed no effects of conventional techniques on change in bronchiolitis severity status, respiratory parameters, hours with oxygen supplementation, or length of hospital stay (5 trials, 246 participants).",rephrase,['We found no effect of conventional physiotherapy on disease severity of infants with moderate bronchiolitis.'],6,0.4166666666666667,3,24
CD004873,4,10,"Regarding instrumental techniques (2 trials, 80 participants), one trial observed similar results in bronchiolitis severity status when comparing slow expiration to instrumental techniques (mean difference 0.10, 95% confidence interval (C) −0.17 to 0.37).",delete,[],7,0.4583333333333333,3,24
CD004873,5,11,"Forced passive expiratory techniques failed to show an effect on bronchiolitis severity in time to recovery (2 trials, 509 participants; high-certainty evidence) and time to clinical stability (1 trial, 99 participants; high-certainty evidence) in infants with severe bronchiolitis.",merge,"['Forced expiratory techniques also failed to show an effect on bronchiolitis severity in infants with severe disease, while important adverse effects were reported.']",7,0.5,3,24
CD004873,5,12,Important adverse effects were reported with the use of forced expiratory techniques.,none,[],7,0.5416666666666666,3,24
CD004873,6,13,"Regarding slow expiratory techniques, a mild to moderate improvement was observed in bronchiolitis severity score (standardised mean difference −0.43, 95% CI −0.73 to −0.13; I2 = 55%; 7 trials, 434 participants; low-certainty evidence).",rephrase,"['Slow expiratory techniques showed a mild to moderate improvement in bronchiolitis severity, mostly in infants with moderate bronchiolitis, based on low-certainty evidence (future studies may challenge this result).']",8,0.5833333333333334,3,24
CD004873,6,14,"Also, in one trial an improvement in time to recovery was observed with the use of slow expiratory techniques.",rephrase,"['Also, one study showed an improvement in time to recovery with slow expiratory techniques in infants with moderate bronchiolitis.']",9,0.625,4,24
CD004873,6,15,"No benefit was observed in length of hospital stay, except for one trial which showed a one-day reduction.",merge,[],10,0.6666666666666666,4,24
CD004873,6,16,"No effects were shown or reported for other clinical outcomes such as duration on oxygen supplementation, use of bronchodilators, or parents' impression of physiotherapy benefit.",none,"[""No effects were shown or reported for other clinical outcomes such as length of hospital stay, duration of oxygen supplementation, use of bronchodilators, or parents' impression of a benefit from the physiotherapy.""]",10,0.7083333333333334,4,24
CD004873,7,17,We found low-certainty evidence that passive slow expiratory technique may result in a mild to moderate improvement in bronchiolitis severity when compared to control.,delete,[],11,0.75,4,24
CD004873,7,18,This evidence comes mostly from infants with moderately acute bronchiolitis treated in hospital.,delete,[],11,0.7916666666666666,4,24
CD004873,7,19,The evidence was limited with regard to infants with severe bronchiolitis and those with moderately severe bronchiolitis treated in ambulatory settings.,delete,[],11,0.8333333333333334,5,24
CD004873,8,20,We found high-certainty evidence that conventional techniques and forced expiratory techniques result in no difference in bronchiolitis severity or any other outcome.,merge,[],11,0.875,5,24
CD004873,8,21,We found high-certainty evidence that forced expiratory techniques in infants with severe bronchiolitis do not improve their health status and can lead to severe adverse effects.,none,"['For some techniques, the evidence for the effect is of low certainty.']",11,0.9166666666666666,5,24
CD004873,9,22,"Currently, the evidence regarding new physiotherapy techniques such as RRT or instrumental physiotherapy is scarce, and further trials are needed to determine their effects and potential for use in infants with moderate bronchiolitis, as well as the potential additional effect of RRT when combined with slow passive expiratory techniques.",split,"['The evidence is robust for the older or more established types of physiotherapy (vibration and percussion and forced expiratory techniques) administered to hospitalised infants.', 'The evidence is limited for slow expiratory techniques, and only anecdotal for the newest techniques (rhinopharyngeal retrograde clearance and instrumental clearance techniques), which have been explored in few trials.']",12,0.9583333333333334,5,24
CD004873,9,23,"Finally, the effectiveness of combining chest physiotherapy with hypertonic saline should also be investigated.",rephrase,['There is little evidence on the effectiveness of chest physiotherapy in non-hospitalised infants.'],14,1.0,5,24
CD004845,0,0,Eight controlled trials (seven placebo controlled and one trial against an active treatment) with a total of 664 participants met the inclusion criteria.,rephrase,['Eight studies with a total of 664 participants were included in this review.'],0,0.1111111111111111,1,9
CD004845,0,1,"Three studied adverse effects of radiotherapy, three studied adverse effects of chemotherapy and two studied menopausal symptoms associated with breast cancer treatment.",ignore,"['Three studied adverse effects of radiotherapy, three studied adverse effects of chemotherapy and two studied menopausal symptoms associated with breast cancer treatment.']",1,0.2222222222222222,2,9
CD004845,1,2,"Two studies with low risk of bias demonstrated benefit: one with 254 participants demonstrated superiority of topical calendula over trolamine (a topical agent not containing corticosteroids) for prevention of radiotherapy-induced dermatitis, and another with 32 participants demonstrated superiority of Traumeel S (a proprietary complex homeopathic medicine) over placebo as a mouthwash for chemotherapy-induced stomatitis.",rephrase,"['Two studies with low risk of bias demonstrated benefit: one with 254 participants demonstrated benefits from calendula ointment in the prevention of radiotherapy-induced dermatitis, and another with 32 participants demonstrated benefits from Traumeel S (a complex homeopathic medicine) over placebo as a mouthwash for chemotherapy-induced stomatitis.']",2,0.3333333333333333,2,9
CD004845,1,3,"Two other studies reported positive results, although the risk of bias was unclear, and four further studies reported negative results.",ignore,"['Two other studies reported positive results, although the risk of bias was unclear, and four further studies reported negative results.']",3,0.4444444444444444,3,9
CD004845,2,4,No serious adverse effects or interactions were reported attributable to the homeopathic medicines used.,rephrase,['The homeopathic medicines used in all eight studies did not seem to cause any serious adverse effects or interact with conventional treatment.'],4,0.5555555555555556,3,9
CD004845,3,5,This review found preliminary data in support of the efficacy of topical calendula for prophylaxis of acute dermatitis during radiotherapy and Traumeel S mouthwash in the treatment of chemotherapy-induced stomatitis.,delete,[],5,0.6666666666666666,4,9
CD004845,3,6,These trials need replicating.,ignore,['These trials need replicating.'],5,0.7777777777777778,4,9
CD004845,3,7,There is no convincing evidence for the efficacy of homeopathic medicines for other adverse effects of cancer treatments.,delete,[],6,0.8888888888888888,5,9
CD004845,3,8,Further research is required.,delete,[],6,1.0,5,9
CD009609,0,0,We included one RCT which was a pilot study with 19 participants that compared HFNC therapy with oxygen delivery via a head box.,rephrase,['One study (19 participants) met our inclusion criteria.'],0,0.08333333333333333,1,12
CD009609,0,1,"In this study, we judged the risk of selection, attrition and reporting bias to be low, and we judged the risk of performance and detection bias to be unclear due to lack of blinding.",delete,[],1,0.16666666666666666,1,12
CD009609,0,2,"The median oxygen saturation (SpO2) was higher in the HFNC group at eight hours (100% versus 96%, P = 0.04) and at 12 hours (99% versus 96%, P = 0.04) but similar at 24 hours.",rephrase,"['Oxygen saturations (blood oxygen levels) were better at eight and 12 hours in participants receiving high-flow nasal cannula therapy than in those receiving oxygen therapy via a head box, but were similar between groups at 24 hours, although this may have been due to higher oxygen flow rates in the high-flow nasal cannula group.']",1,0.25,2,12
CD009609,0,3,"There was no clear evidence of a difference in total duration of oxygen therapy, time to discharge or total length of stay between groups.",rephrase,"['There was no clear evidence of a difference between the two groups in the duration of oxygen therapy, length of hospitalisation and time to discharge.']",2,0.3333333333333333,2,12
CD009609,0,4,No adverse events were reported in either group and no participants in either group required further respiratory support.,rephrase,['No adverse events were reported in either group.'],3,0.4166666666666667,3,12
CD009609,0,5,Five ongoing trials were identified but no data were available in May 2013.,rephrase,['The evidence is current to May 2013.'],4,0.5,3,12
CD009609,0,6,We were not able to perform a meta-analysis.,delete,[],5,0.5833333333333334,3,12
CD009609,1,7,There is insufficient evidence to determine the effectiveness of HFNC therapy for treating infants with bronchiolitis.,rephrase,['There is insufficient evidence to determine the effectiveness of high-flow nasal cannula therapy for treating bronchiolitis in infants.'],5,0.6666666666666666,4,12
CD009609,1,8,"The current evidence in this review is of low quality, from one small study with uncertainty about the estimates of effect and an unclear risk of performance and detection bias.",rephrase,"['However, our evidence is based on one low-quality, small study with uncertainty about the effects and some possibility of bias arising from the study methods.']",6,0.75,4,12
CD009609,1,9,The included study provides some indication that HFNC therapy is feasible and well tolerated.,ignore,['The included study provides some indication that HFNC therapy is feasible and well tolerated.'],7,0.8333333333333334,5,12
CD009609,1,10,Further research is required to determine the role of HFNC in the management of bronchiolitis in infants.,rephrase,['Further research is required to determine the role of high-flow nasal cannula therapy in the management of bronchiolitis in infants.'],8,0.9166666666666666,5,12
CD009609,1,11,The results of the ongoing studies identified will contribute to the evidence in future updates of this review.,ignore,['The results of six ongoing studies identified will contribute to the evidence in future updates of this review.'],9,1.0,5,12
CD003540,0,0,Five studies met the inclusion criteria.,delete,[],0,0.125,1,8
CD003540,0,1,"All were conducted in the UK, and tested short-term changes in the consultation time allocated to each patient.",rephrase,['All studies tested short-term changes in the consultation time allocated to each patient.'],0,0.25,2,8
CD003540,0,2,"Overall, our confidence in the results was very low; most studies had a high risk of bias, particularly due to non-random allocation of participants and the absence of data on participants' characteristics and small sample sizes.",rephrase,['Our confidence in the results of these studies is very low.'],1,0.375,2,8
CD003540,0,3,"We are uncertain whether altering appointment length increases primary care consultation length, number of referrals and investigations, prescriptions, or patient satisfaction based on very low-certainty evidence.",split,"['Consequently, we are not certain whether changing appointment slots leads to an actual increase of the length of the consultation, number of referrals and investigations requested by the doctor, and number of medications prescribed.', 'Likewise, it is unclear whether patients are more satisfied with the health care they receive when appointments are longer.']",2,0.5,3,8
CD003540,0,4,None of the studies reported on the effects of altering the length of consultation on resources used.,rephrase,['None of the studies reported on the resources associated with lengthening appointments.'],4,0.625,4,8
CD003540,1,5,We did not find sufficient evidence to support or refute a policy of altering the lengths of primary care physicians' consultations.,rephrase,['There is currently not enough evidence to say whether altering the amount of time that doctors consult with patients provides benefits or not.'],5,0.75,4,8
CD003540,1,6,It is possible that these findings may change if high-quality trials are reported in the future.,delete,[],6,0.875,5,8
CD003540,1,7,Further trials are needed that focus on health outcomes and cost-effectiveness.,delete,[],6,1.0,5,8
CD009257,0,0,We did not identify any randomised controlled trials that evaluated the effectiveness of sleep positioning systems on hip migration.,rephrase,['No randomised controlled trials were found that evaluated the effectiveness of sleep positioning systems to reduce or prevent hip migration.'],0,0.1111111111111111,1,9
CD009257,1,1,We did find two randomised cross-over trials that met the inclusion criteria in respect of secondary objectives relating to sleep quality and pain.,rephrase,['These were cross-over trials (see Cochrane Glossary).'],1,0.2222222222222222,2,9
CD009257,1,2,"Neither study reported any important difference between sleeping in sleep positioning systems and not for sleep patterns or sleep quality (two studies, 21 children, very low quality evidence) and pain (one study, 11 children, very low quality evidence).",rephrase,['Neither study reported any differences in quality of sleep or pain whether using or not using their sleep positioning system.'],2,0.3333333333333333,2,9
CD009257,1,3,These were small studies with established users of sleep positioning systems and were judged to have high risk of bias.,rephrase,"['The children in these studies spent a few nights using their sleep positioning system and then a few nights not using it, or the other way round.']",3,0.4444444444444444,3,9
CD009257,2,4,"We found no eligible trials that explored the other secondary objectives (number or frequency of hip problems, quality of life of the child and family, physical functioning, and adverse effects).",delete,[],4,0.5555555555555556,3,9
CD009257,3,5,We found no randomised trials that evaluated the effectiveness of sleep positioning systems to reduce or prevent hip migration in children with cerebral palsy.,rephrase,['The quality of the current evidence regarding the effectiveness of sleep positioning systems for children with cerebral palsy is very low and more robust research is needed to help families and professionals make informed decisions about whether to use this intervention.'],4,0.6666666666666666,4,9
CD009257,3,6,"Nor did we find any randomised trials that evaluated the effect of sleep positioning systems on the number or frequency of hip problems, quality of life of the child and family or on physical functioning.",delete,[],5,0.7777777777777778,4,9
CD009257,4,7,"Limited data from two randomised trials, which evaluated the effectiveness of sleep positioning systems on sleep quality and pain for children with cerebral palsy, showed no significant differences in these aspects of health when children were using and not using a sleep positioning system.",delete,[],5,0.8888888888888888,5,9
CD009257,5,8,"In order to inform clinical decision-making and the prescription of sleep positioning systems, more rigorous research is needed to determine effectiveness, cost-effectiveness, and the likelihood of adverse effects.",delete,[],5,1.0,5,9
CD011672,0,0,We included 16 studies (18 publications; 2164 neonates) in this review.,delete,[],0,0.08333333333333333,1,12
CD011672,0,1,"These studies compared surfactant administration via thin catheter with surfactant administration through an ETT with early extubation (Intubate, Surfactant, Extubate technique - InSurE) (12 studies) or with delayed extubation (2 studies), or with continuation of continuous positive airway pressure (CPAP) and rescue surfactant administration at pre-specified criteria (1 study), or compared different strategies of surfactant administration via thin catheter (1 study).",delete,[],0,0.16666666666666666,1,12
CD011672,0,2,Two trials reported neurosensory outcomes of of surviving participants at two years of age.,delete,[],0,0.25,2,12
CD011672,0,3,"Eight studies were of moderate certainty with low risk of bias, and eight studies were of lower certainty with unclear risk of bias.",delete,[],0,0.3333333333333333,2,12
CD011672,1,4,"S-TC versus S-ETT in preterm infants with or at risk of RDS
Meta-analyses of 14 studies in which S-TC was compared with S-ETT as a control demonstrated a significant decrease in risk of the composite outcome of death or bronchopulmonary dysplasia (BPD) at 36 weeks' postmenstrual age (risk ratio (RR) 0.59, 95% confidence interval (CI) 0.48 to 0.73; risk difference (RD) -0.11, 95% CI -0.15 to -0.07; number needed to treat for an additional beneficial outcome (NNTB) 9, 95% CI 7 to 16; 10 studies; 1324 infants; moderate-certainty evidence); the need for intubation within 72 hours (RR 0.63, 95% CI 0.54 to 0.74; RD -0.14, 95% CI -0.18 to -0.09; NNTB 8, 95% CI; 6 to 12; 12 studies, 1422 infants; moderate-certainty evidence); severe intraventricular haemorrhage (RR 0.63, 95% CI 0.42 to 0.96; RD -0.04, 95% CI -0.08 to -0.00; NNTB 22, 95% CI 12 to 193; 5 studies, 857 infants; low-certainty evidence); death during first hospitalisation (RR 0.63, 95% CI 0.47 to 0.84; RD -0.02, 95% CI -0.10 to 0.06; NNTB 20, 95% CI 12 to 58; 11 studies, 1424 infants; low-certainty evidence); and BPD among survivors (RR 0.57, 95% CI 0.45 to 0.74; RD -0.08, 95% CI -0.11 to -0.04; NNTB 13, 95% CI 9 to 24; 11 studies, 1567 infants; moderate-certainty evidence).",delete,[],0,0.4166666666666667,3,12
CD011672,1,5,"There was no significant difference in risk of air leak requiring drainage (RR 0.58, 95% CI 0.33 to 1.02; RD -0.03, 95% CI -0.05 to 0.00; 6 studies, 1036 infants; low-certainty evidence).",delete,[],0,0.5,3,12
CD011672,1,6,None of the studies reported on the outcome of death or survival with neurosensory disability.,ignore,['None of the studies reported on the outcome of death or survival with disability.'],0,0.5833333333333334,3,12
CD011672,2,7,"Only one trial compared surfactant delivery via thin catheter with continuation of CPAP, and one trial compared different strategies of surfactant delivery via thin catheter, precluding meta-analysis.",rephrase,['These trials involved delivery of surfactant via a thin catheter.'],1,0.6666666666666666,4,12
CD011672,3,8,"Administration of surfactant via thin catheter compared with administration via an ETT is associated with reduced risk of death or BPD, less intubation in the first 72 hours, and reduced incidence of major complications and in-hospital mortality.",rephrase,"['Surfactant delivery via a thin catheter to spontaneously breathing preterm infants compared with surfactant administration through an ETT was associated with a decrease in the following: risk of death or BPD, need for assisted breathing in the first 72 hours of life, severe brain bleeding, death during first hospitalisation, and BPD among survivors.']",2,0.75,4,12
CD011672,3,9,This procedure had a similar rate of adverse effects as surfactant administration through an ETT.,rephrase,['The procedure had rates of adverse effects similar to surfactant administration through an ETT.'],3,0.8333333333333334,5,12
CD011672,3,10,Data suggest that treatment with surfactant via thin catheter may be preferable to surfactant therapy by ETT.,rephrase,['These data suggest that treatment with surfactant via a thin catheter is preferable to surfactant therapy through an ETT.'],4,0.9166666666666666,5,12
CD011672,3,11,"Further well-designed studies of adequate size and power, as well as ongoing studies, will help confirm and refine these findings, clarify whether surfactant therapy via thin tracheal catheter provides benefits over continuation of non-invasive respiratory support without surfactant, address uncertainties within important subgroups, and clarify the role of sedation.",rephrase,"['Further well-designed studies of adequate size and power, as well as ongoing studies, are required to confirm and refine these findings, and to clarify whether surfactant therapy via a thin catheter provides benefits over continuation of non-invasive respiratory support without surfactant.']",5,1.0,5,12
CD005293,0,0,"Two studies assessed as at high risk of bias, reporting data from 26 analysed participants were included in this review.",delete,[],0,0.09090909090909091,1,11
CD005293,0,1,The age range of participants was from 17 to 55 years.,rephrase,"['There were 15 participants in one study and 16 in the other, their ages ranging from 17 to 55 years.']",0,0.18181818181818182,1,11
CD005293,0,2,Both trials investigated the effectiveness of low-level laser treatment compared to placebo laser therapy on inferior alveolar sensory deficit as a result of iatrogenic injury.,rephrase,['Low-level laser therapy was the only treatment to be evaluated in the included studies and this was compared to fake or placebo laser therapy.'],1,0.2727272727272727,2,11
CD005293,1,3,Patient-reported altered sensation was partially reported in one study and fully reported in another.,delete,[],2,0.36363636363636365,2,11
CD005293,1,4,"Following treatment with laser therapy, there was some evidence of an improvement in the subjective assessment of neurosensory deficit in the lip and chin areas compared to placebo, though the estimates were imprecise: a difference in mean change in neurosensory deficit of the chin of 8.40 cm (95% confidence interval (CI) 3.67 to 13.13) and a difference in mean change in neurosensory deficit of the lip of 21.79 cm (95% CI 5.29 to 38.29).",rephrase,['There was some evidence of an improvement when participants reported whether or not sensation was better in the lip and chin areas with low-level laser therapy.'],2,0.45454545454545453,3,11
CD005293,1,5,"The overall quality of the evidence for this outcome was very low; the outcome data were fully reported in one small study of 13 patients, with differential drop-out in the control group, and patients suffered only partial loss of sensation.",delete,[],3,0.5454545454545454,3,11
CD005293,1,6,"No studies reported on the effects of the intervention on the remaining primary outcomes of pain, difficulty eating or speaking or taste.",rephrase,"['No studies reported on the effects of the treatment on other outcomes such as pain, difficulty eating or speaking or taste.']",3,0.6363636363636364,4,11
CD005293,1,7,No studies reported on quality of life or adverse events.,rephrase,['No studies reported on quality of life or harm.'],4,0.7272727272727273,4,11
CD005293,2,8,"The overall quality of the evidence was very low as a result of limitations in the conduct and reporting of the studies, indirectness of the evidence and the imprecision of the results.",rephrase,"['The overall quality of the evidence is very low as a result of limitations in the conduct and reporting of the two included studies and the low number of participants, and evidence from participants with only partial sensory loss.']",5,0.8181818181818182,5,11
CD005293,3,9,"There is clearly a need for randomised controlled clinical trials to investigate the effectiveness of surgical, medical and psychological interventions for iatrogenic inferior alveolar and lingual nerve injuries.",delete,[],6,0.9090909090909091,5,11
CD005293,3,10,"Primary outcomes of this research should include: patient-focused morbidity measures including altered sensation and pain, pain, quantitative sensory testing and the effects of delayed treatment.",delete,[],6,1.0,5,11
CD009221,0,0,"Only four studies met the criteria for inclusion, with a total of 274 participants.",rephrase,['Results: We identified only four trials for inclusion.'],0,0.06666666666666667,1,15
CD009221,0,1,"Four pharmacological agents were investigated: modafinil (51 participants); (−)-OSU6162, a monoamine stabiliser (12 participants of which six had a TBI); atomoxetine (60 participants); and rivastigmine (157 participants).",rephrase,['These investigated four different drugs—modafinil; the experimental drug (−)-OSU6162; atomoxetine; and rivastigmine—against placebo.'],1,0.13333333333333333,1,15
CD009221,0,2,A meta-analysis could not be performed due to the small number and heterogeneity of the studies.,delete,[],2,0.2,1,15
CD009221,1,3,"All studies examined cognitive performance, with the majority of the psychometric sub-tests showing no difference between treatment and placebo (n = 274, very low quality evidence).",delete,[],2,0.26666666666666666,2,15
CD009221,1,4,"For (−)-OSU6162 modest superiority over placebo was demonstrated on three measures, but markedly inferior performance on another.",split,"['The experimental drug called (−)-OSU6162 was better than placebo on three cognitive measures, although this was a small study with only six participants with TBI.', 'In the study of (−)-OSU6162, one participant of three given placebo experienced adverse effects requiring a dose reduction, with no drop-outs reported.']",2,0.3333333333333333,2,15
CD009221,1,5,"Rivastigmine was better than placebo on one primary measure, and a single cognitive outcome in a secondary analysis of a subgroup with more severe memory impairment at baseline.",rephrase,"['Modafinil, atomoxetine and rivastigmine were not found to be better than placebo.']",4,0.4,2,15
CD009221,1,6,"The study of modafinil assessed clinical global improvement (n = 51, low quality evidence), and did not find any difference between treatment and placebo.",rephrase,['No difference between modafinil and placebo was found on assessment of clinical global improvement.'],5,0.4666666666666667,3,15
CD009221,1,7,"Safety, as measured by adverse events, was reported by all studies (n = 274, very low quality evidence), with significantly more nausea reported by participants who received rivastigmine compared to placebo.",delete,[],6,0.5333333333333333,3,15
CD009221,1,8,There were no other differences in safety between treatment and placebo.,rephrase,['On most measures there was no difference between treatment and placebo.'],6,0.6,3,15
CD009221,1,9,No studies reported any deaths.,ignore,['No studies reported any deaths.'],7,0.6666666666666666,4,15
CD009221,2,10,There is insufficient evidence to determine whether pharmacological treatment is effective in chronic cognitive impairment in TBI.,rephrase,"['Conclusion: Recommendations for, or against, drug treatment of chronic cognitive impairment in TBI cannot be made on the basis of current evidence.']",8,0.7333333333333333,4,15
CD009221,2,11,"Whilst there is a positive finding for rivastigmine on one primary measure, all other primary measures were not better than placebo.",delete,[],9,0.8,4,15
CD009221,2,12,The positive findings for (−)-OSU6162 are interpreted cautiously as the study was small (n = 6).,delete,[],9,0.8666666666666667,5,15
CD009221,2,13,For modafinil and atomoxetine no positive effects were found.,rephrase,"['More people taking modafinil, atomoxetine and rivastigmine experienced adverse effects than those on placebo, although the difference is most likely due to chance.']",9,0.9333333333333333,5,15
CD009221,2,14,"All four drugs appear to be relatively well tolerated, although evidence is sparse.",delete,[],10,1.0,5,15
CD010922,0,0,We included one trial with a total of 60 children with a diagnosis of ASD who randomly received hyperbaric oxygen therapy or a sham treatment.,rephrase,"['We found a single, small study of 60 children that evaluated high-pressure oxygen therapy for ASD.']",0,0.1111111111111111,1,9
CD010922,0,1,"Using GRADE criteria, we rated the quality of the evidence as low because of the small sample size and wide confidence intervals (CIs).",rephrase,['The quality of the evidence is low.'],1,0.2222222222222222,2,9
CD010922,0,2,Other problems included selection bias and short duration or follow-up.,delete,[],2,0.3333333333333333,2,9
CD010922,1,3,"Overall, study authors reported no improvement in social interaction and communication, behavioral problems, communication and linguistic abilities, or cognitive function.",rephrase,"['There was no evidence that high-pressure oxygen therapy improved social interaction, behavioral problems, speech or language communication, or mental function in children with ASD.']",2,0.4444444444444444,3,9
CD010922,1,4,"With regard to the safety of hyperbaric oxygen therapy (adverse events), they reported minor-grade ear barotrauma events.",rephrase,"['However, children who received high-pressure (hyperbaric) oxygen therapy showed an increased occurrence of ear barotrauma events when compared with those in the control group.']",3,0.5555555555555556,3,9
CD010922,1,5,"Investigators found significant differences between groups in total number of side effect events (Peto odds ratio (OR) 3.87, 95% CI 1.53 to 9.82) and in the number of children who experienced side effects (Peto OR 4.40, 95% CI 1.33 to 14.48).",delete,[],4,0.6666666666666666,4,9
CD010922,2,6,"To date, there is no evidence that hyperbaric oxygen therapy improves core symptoms and associated symptoms of ASD.",rephrase,['Evidence is insufficient to confirm that high-pressure oxygen is an effective treatment for individuals with ASD.'],4,0.7777777777777778,4,9
CD010922,2,7,It is important to note that adverse effects (minor-grade ear barotrauma events) can occur.,delete,[],5,0.8888888888888888,5,9
CD010922,2,8,"Given the absence of evidence of effectiveness and the limited biological plausibility and possible adverse effects, the need for future RCTs of hyperbaric oxygen therapy must be carefully considered.",delete,[],5,1.0,5,9
CD007724,0,0,"We identified six RCTs (707 women), eligible for inclusion in this updated review, however, three RCTs had mixed populations (that is, they included pregnant women with gestational diabetes) and did not report data separately for the relevant subset of women for this review.",split,"['We searched for evidence from randomised controlled trials (RCTs) on 31 October 2016 and included six RCTs (707 women).', 'Three RCTs included women with current gestational diabetes and did not report data separately for the population of women relevant to this review.']",0,0.05263157894736842,1,19
CD007724,0,1,Therefore we have only included outcome data from three RCTs; data were available for 241 women and their infants.,rephrase,"['Therefore we have only included outcome data from three RCTs, involving 241 pregnant women and their infants.']",2,0.10526315789473684,1,19
CD007724,0,2,The three RCTs all compared an oral anti-diabetic agent (metformin) with insulin.,merge,['The three RCTs all compared an oral anti-diabetic agent (metformin) with insulin in pregnant women with pre-existing (type 2) diabetes.'],3,0.15789473684210525,1,19
CD007724,0,3,The women in the RCTs that contributed data had type 2 diabetes diagnosed before or during their pregnancy.,none,[],3,0.21052631578947367,2,19
CD007724,0,4,"Overall, the RCTs were judged to be at varying risk of bias.",merge,['The quality of the evidence was assessed as being low or very low and the overall risk of bias of the RCTs was varied.'],4,0.2631578947368421,2,19
CD007724,0,5,"We assessed the quality of the evidence for selected important outcomes using GRADE; the evidence was low- or very low-quality, due to downgrading because of design limitations (risk of bias) and imprecise effect estimates (for many outcomes only one or two RCTs contributed data).",none,[],4,0.3157894736842105,2,19
CD007724,1,6,"For our primary outcomes there was no clear difference between metformin and insulin groups for pre-eclampsia (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.33 to 1.20; RCTs = 2; participants = 227; very low-quality evidence) although in one RCT women receiving metformin were less likely to have pregnancy-induced hypertension (RR 0.58, 95% CI 0.37 to 0.91; RCTs = 1; participants = 206; low-quality evidence).",rephrase,"['There was no clear difference in the development of pre-eclampsia (high blood pressure and protein in the urine) for women who received metformin compared with insulin (2 RCTs; 227 women; very low-quality evidence), though women receiving metformin were less likely to have pregnancy-induced high blood pressure in one RCT (206 women; low-quality evidence).']",5,0.3684210526315789,2,19
CD007724,1,7,"Women receiving metformin were less likely to have a caesarean section compared with those receiving insulin (RR 0.73, 95% CI 0.61 to 0.88; RCTs = 3; participants = 241; low-quality evidence).",rephrase,"['Women who received metformin were less likely to have a caesarean section birth (3 RCTs; 241 women; low-quality evidence), though no difference was observed in induction of labour (2 RCTs; 35 women; very low-quality evidence).']",6,0.42105263157894735,3,19
CD007724,1,8,"In one RCT there was no clear difference between groups for large-for-gestational-age infants (RR 1.12, 95% CI 0.73 to 1.72; RCTs = 1; participants = 206; very low-quality evidence).",rephrase,"['There was no clear difference between groups of infants born to mothers who received metformin or insulin for being large-for-gestational age (1 RCT; 206 infants; very low-quality evidence), though infants born to mothers who received metformin were less likely to have low blood sugar (hypoglycaemia) (3 RCTs; 241 infants; very low-quality evidence).']",7,0.47368421052631576,3,19
CD007724,1,9,There were no perinatal deaths in two RCTs (very low-quality evidence).,rephrase,['There were no infant deaths (before birth or shortly afterwards) (2 RCTs; very low-quality evidence).'],8,0.5263157894736842,3,19
CD007724,1,10,Neonatal mortality or morbidity composite outcome and childhood/adulthood neurosensory disability were not reported.,delete,[],9,0.5789473684210527,3,19
CD007724,2,11,"For other secondary outcomes we assessed using GRADE, there were no clear differences between metformin and insulin groups for induction of labour (RR 1.42, 95% CI 0.62 to 3.28; RCTs = 2; participants = 35; very low-quality evidence), though infant hypoglycaemia was reduced in the metformin group (RR 0.34, 95% CI 0.18 to 0.62; RCTs = 3; infants = 241; very low-quality evidence).",delete,[],9,0.631578947368421,4,19
CD007724,2,12,"Perineal trauma, maternal postnatal depression and postnatal weight retention, and childhood/adulthood adiposity and diabetes were not reported.",rephrase,"['The RCTs did not report on many important short- and long-term outcomes, including perineal trauma and a combined outcome of infant death or morbidity, postnatal depression and weight retention for mothers, and adiposity or disability in childhood or adulthood for infants.']",9,0.6842105263157895,4,19
CD007724,3,13,"There are insufficient RCT data to evaluate the use of oral anti-diabetic agents in women with established diabetes, impaired glucose tolerance or previous gestational diabetes who are planning a pregnancy, or in pregnant women with pre-existing diabetes.",rephrase,"['There is not enough evidence to guide us on the effects of oral anti-diabetic agents in women with established diabetes, impaired glucose tolerance or previous gestational diabetes who are planning a pregnancy, or pregnant women with pre-existing diabetes.']",10,0.7368421052631579,4,19
CD007724,3,14,"Low to very low-quality evidence suggests possible reductions in pregnancy-induced hypertension, caesarean section birth and neonatal hypoglycaemia with metformin compared with insulin for women with type 2 diabetes diagnosed before or during their pregnancy, and no clear differences in pre-eclampsia, induction of labour and babies that are large-for-gestational age.",delete,[],11,0.7894736842105263,4,19
CD007724,3,15,"Further high-quality RCTs that compare any combination of oral anti-diabetic agent, insulin and dietary and lifestyle advice for these women are needed.",delete,[],11,0.8421052631578947,5,19
CD007724,3,16,Future RCTs could be powered to evaluate effects on short- and long-term clinical outcomes; such RCTs could attempt to collect and report on the standard outcomes suggested in this review.,rephrase,"['Further large, well-designed, RCTs are required and could assess and report on the outcomes suggested in this review, including both short- and long-term outcomes for mothers and their infants.']",11,0.8947368421052632,5,19
CD007724,3,17,We have identified three ongoing studies and four are awaiting classification.,delete,[],12,0.9473684210526315,5,19
CD007724,3,18,We will consider these when this review is updated.,delete,[],12,1.0,5,19
CD009215,0,0,We included two trials (535 women) in the review.,rephrase,"['One trial involving 513 women compared one of Roman chamomile, clary sage, frankincense, lavender or mandarin essentials oils with standard care.']",0,0.16666666666666666,1,6
CD009215,0,1,"The trials found no difference between groups for the primary outcomes of pain intensity, assisted vaginal birth (risk ratio (RR) 1.04, 95% confidence interval (CI) 0.48 to 2.28, one trial, 513 women; RR 0.83, 95% CI 0.06 to 11.70, one trial, 22 women), and caesarean section (RR 0.98, 95% CI 0.49 to 1.94, one trial, 513 women; RR 2.54, 95% CI 0.11 to 56.25, one trial, 22 women); there were more babies admitted to neonatal intensive care in the control group of one trial (RR 0.08, 95% CI 0.00 to 1.42, one trial, 513 women) but this difference did not reach statistical significance.",merge,[],1,0.3333333333333333,2,6
CD009215,0,2,"The trials found no differences between groups for the secondary outcomes of use of pharmacological pain relief (RR 0.35, 95% CI 0.04 to 3.32, one trial, 513 women; RR 2.50, 95% CI 0.31 to 20.45, one trial, 22 women), spontaneous vaginal delivery (RR 1.00, 95% CI 0.94 to 1.06, one trial, 513 women; RR 0.93, 95% CI 0.67 to 1.28, one trial, 22 women) or length of labour and augmentation (RR 1.14, 95% CI 0.90 to 1.45, one trial, 513 women).",none,"['The trials found no difference between groups for pain intensity, assisted vaginal birth, caesarean section or the use of pharmacological pain relief (epidural).']",1,0.5,3,6
CD009215,0,3,The risk of bias was low in the trials.,delete,[],2,0.6666666666666666,4,6
CD009215,1,4,There is a lack of studies evaluating the role of aromatherapy for pain management in labour.,rephrase,"['Overall, there is insufficient evidence from randomised controlled trials about the benefits of aromatherapy on pain management in labour.']",2,0.8333333333333334,5,6
CD009215,1,5,Further research is needed before recommendations can be made for clinical practice.,rephrase,['More research is needed.'],3,1.0,5,6
CD003518,0,0,We included seven trials with 1521 participants in this review.,rephrase,['Seven trials with 1521 women looked at waiting versus surgery for miscarriage.'],0,0.0625,1,16
CD003518,0,1,The expectant-care group was more likely to have an incomplete miscarriage by two weeks (RR 3.98; 95% CI 2.94 to 5.38) or by six to eight weeks (RR 2.56; 95% CI 1.15 to 5.69).,delete,[],1,0.125,1,16
CD003518,0,2,The need for unplanned surgical treatment was greater for the expectant-care group (RR 7.35; 95% CI 5.04 to 10.72).,delete,[],1,0.1875,1,16
CD003518,0,3,"The mean percentage needing surgical management in the expectant-care group was 28%, while 4% of the surgical-treatment group needed additional surgery.",delete,[],1,0.25,2,16
CD003518,0,4,The expectant-care group had more days of bleeding (MD 1.59; 95% CI 0.74 to 2.45).,rephrase,['These women also had more days of bleeding.'],1,0.3125,2,16
CD003518,0,5,"Further, more of the expectant-care group needed transfusion (RR 6.45; 95% CI 1.21 to 34.42).",delete,[],2,0.375,2,16
CD003518,0,6,The mean percentage needing blood transfusion was 1.4% for expectant care compared with none for surgical management.,delete,[],2,0.4375,3,16
CD003518,0,7,Results were mixed for pain.,ignore,['Results were mixed for pain.'],2,0.5,3,16
CD003518,0,8,"Diagnosis of infection was similar for the two groups (RR 0.63; 95% CI 0.36 to 1.12), as were results for various psychological outcomes.",delete,[],3,0.5625,3,16
CD003518,0,9,Pregnancy data were limited.,rephrase,['Information was limited on future pregnancy.'],3,0.625,4,16
CD003518,0,10,Costs were lower for the expectant-care group (MD -499.10; 95% CI -613.04 to -385.16; in UK pounds sterling).,delete,[],4,0.6875,4,16
CD003518,1,11,"Expectant management led to a higher risk of incomplete miscarriage, need for unplanned (or additional) surgical emptying of the uterus, bleeding and need for transfusion.",delete,[],4,0.75,4,16
CD003518,1,12,Risk of infection and psychological outcomes were similar for both groups.,rephrase,['Both groups had about the same numbers of infections.'],4,0.8125,5,16
CD003518,1,13,Costs were lower for expectant management.,rephrase,['Costs were lower for waiting than for surgery.'],5,0.875,5,16
CD003518,1,14,"Given the lack of clear superiority of either approach, the woman's preference should be important in decision making.",rephrase,['What the woman prefers should be the major concern.'],6,0.9375,5,16
CD003518,1,15,Pharmacological ('medical') management has added choices for women and their clinicians and has been examined in other reviews.,rephrase,"['Drug treatment (such as with misoprostol and mifepristone) has added choices for women and their clinicians, and has been studied in other reviews.']",7,1.0,5,16
CD012735,0,0,Forty-seven studies (five RCTs and 42 before-and-after studies) evaluated the dose-related efficacy of pitavastatin in 5436 participants.,rephrase,['We looked for high-quality randomised trials (RCTs) and before-and-after studies with pitavastatin in\xa0different dose sizes\xa0.'],0,0.08333333333333333,1,12
CD012735,0,1,"The participants were of any age with and without cardiovascular disease, and pitavastatin effects were studied within a treatment period of three to 12 weeks.",rephrase,"['Participants in the trials could be of any age and gender, with or without cardiovascular disease.']",1,0.16666666666666666,1,12
CD012735,0,2,Log dose-response data over doses of 1 mg to 16 mg revealed strong linear dose-related effects on blood total cholesterol and LDL cholesterol and triglycerides.,delete,[],2,0.25,2,12
CD012735,0,3,"There was no dose-related effect of pitavastatin on blood HDL cholesterol, which was increased by 4% on average by pitavastatin.",rephrase,['The average increase in HDL cholesterol for all doses was\xa04%.'],2,0.3333333333333333,2,12
CD012735,0,4,"Pitavastatin 1 mg/day to 16 mg/day reduced LDL cholesterol by 33.3% to 54.7%, total cholesterol by 23.3% to 39.0% and triglycerides by 13.0% to 28.1%.",rephrase,['People taking 1\xa0mg\xa0to 16 mg\xa0of pitavastatin per day lowered their LDL cholesterol by 33.3% to 54.7%.'],3,0.4166666666666667,3,12
CD012735,0,5,"For every two-fold dose increase, there was a 5.35% (95% CI 3.32 to 7.38) decrease in blood LDL cholesterol, a 3.93% (95% CI 2.35 to 5.50) decrease in blood total cholesterol and a 3.76% (95% CI 1.03 to 6.48) decrease in blood triglycerides.",delete,[],4,0.5,3,12
CD012735,0,6,The certainty of evidence for these effects was judged to be high.,delete,[],4,0.5833333333333334,3,12
CD012735,0,7,"When compared to other statins for its effect to reduce LDL cholesterol, pitavastatin is about 6-fold more potent than atorvastatin, 1.7-fold more potent than rosuvastatin, 77-fold more potent than fluvastatin and 3.3-fold less potent than cerivastatin.",rephrase,"['For lowering\xa0LDL cholesterol,\xa0 pitavastatin is 6-times stronger than atorvastatin, 1.7-times stronger than rosuvastatin, 77-times stronger than fluvastatin and 3.3-times weaker than cerivastatin.']",4,0.6666666666666666,4,12
CD012735,0,8,"For the placebo group, there were no participants who withdrew due to an adverse effect per 109 subjects and for all doses of pitavastatin, there were three participants who withdrew due to an adverse effect per 262 subjects.",rephrase,"['In the RCTS, no person out of 109 in the placebo group and three out of 262 people in the pitavastatin group dropped out due to\xa0adverse effects.']",5,0.75,4,12
CD012735,1,9,"Pitavastatin lowers blood total cholesterol, LDL cholesterol and triglyceride in a dose-dependent linear fashion.",rephrase,"['There is a high level of trust\xa0around the effects of pitavastatin on total cholesterol,\xa0LDL cholesterol and triglycerides.']",6,0.8333333333333334,5,12
CD012735,1,10,"Based on the effect on LDL cholesterol, pitavastatin is about 6-fold more potent than atorvastatin, 1.7-fold more potent than rosuvastatin, 77-fold more potent than fluvastatin and 3.3-fold less potent than cerivastatin.",delete,[],7,0.9166666666666666,5,12
CD012735,1,11,There were not enough data to determine risk of withdrawal due to adverse effects due to pitavastatin.,delete,[],7,1.0,5,12
CD007512,0,0,We included six trials involving 418 patients for this review.,ignore,['We included six trials involving 418 patients for this review.'],0,0.0625,1,16
CD007512,0,1,The sample size in the trials varied from 30 to 131 patients.,rephrase,['The number of patients included in the trials varied from 30 to 131.'],1,0.125,1,16
CD007512,0,2,Only one trial involving 131 patients was of low risk of bias for mortality.,delete,[],2,0.1875,1,16
CD007512,0,3,This trial was at high risk of bias for other outcomes.,rephrase,"['Most of the trials were at high risk of systematic errors (ie, there was a potential to arrive at wrong conclusions because of the way the trial was conducted) and random errors (there was a potential to arrive at the wrong conclusions because of the play of chance).']",2,0.25,2,16
CD007512,0,4,Four trials excluded patients who underwent liver transplantation for acute liver failure.,delete,[],3,0.3125,2,16
CD007512,0,5,All the trials included livers obtained from cadaveric donors.,delete,[],3,0.375,2,16
CD007512,0,6,The remaining five trials were of high risk of bias for all outcomes.,delete,[],3,0.4375,3,16
CD007512,0,7,Liver transplantation was performed by the conventional method (caval replacement) in two trials and piggy-back method (caval preservation) in one trial.,delete,[],3,0.5,3,16
CD007512,0,8,The method of liver transplantation was not available in the remaining three trials.,delete,[],3,0.5625,3,16
CD007512,0,9,The comparisons performed included an initial hepatic artery flush versus initial portal vein flush; blood venting via inferior vena cava in addition to venting of storage fluid versus no blood venting; initial hepatic artery reperfusion versus initial portal vein reperfusion; simultaneous hepatic artery and portal vein reperfusion versus initial portal vein reperfusion; and retrograde inferior vena cava reperfusion versus simultaneous hepatic artery and portal vein reperfusion.,ignore,['The comparisons performed included initial hepatic artery flush versus initial portal vein flush; blood venting via the inferior vena cava in addition to venting of storage fluid versus no blood venting; initial hepatic artery reperfusion versus initial portal vein reperfusion; simultaneous hepatic artery and portal vein reperfusion versus initial portal vein reperfusion; and retrograde inferior vena cava reperfusion versus simultaneous hepatic artery and portal vein reperfusion.'],3,0.625,4,16
CD007512,0,10,Only one or two trials could be included under each comparison.,delete,[],4,0.6875,4,16
CD007512,0,11,"There was no significant difference in mortality, graft survival, or severe morbidity rates in any of the comparisons.",split,"['There were no significant differences in the risk of death or graft loss, or in the major complication rates, between the compared groups in any of the comparisons.', 'There were no significant differences in the transfusion requirements, intensive therapy unit stay, or hospital stay between the compared groups in any of the comparisons.']",4,0.75,4,16
CD007512,0,12,Quality of life was not reported in any of the trials.,ignore,['Quality of life was not reported in any of the trials.'],6,0.8125,5,16
CD007512,1,13,There is currently no evidence to support or refute the use of any specific technique of flushing or reperfusion during liver transplantation.,rephrase,['We are unable to advocate or refute any technique of flushing and reperfusion in patients undergoing liver transplantation.'],7,0.875,5,16
CD007512,1,14,"Due to the paucity of data, absence of evidence should not be confused with evidence of absence of any differences.",delete,[],8,0.9375,5,16
CD007512,1,15,Further well designed trials with low risk of systematic error and low risk of random errors are necessary.,ignore,['Further well designed trials with low risk of systematic error and low risk of random errors are necessary.'],8,1.0,5,16
CD008347,0,0,We included four RCTs involving a total of 176 participants with a clinical diagnosis of CLI.,rephrase,['We found four studies with a combined total of 176 participants testing the safety and effectiveness of this treatment.'],0,0.05555555555555555,1,18
CD008347,0,1,Participants were randomised to receive either intramuscular cell implantation of BMMNCs or control.,delete,[],1,0.1111111111111111,1,18
CD008347,0,2,"The control arms varied between studies, and included conventional therapy, diluted autologous peripheral blood, and saline.",delete,[],1,0.16666666666666666,1,18
CD008347,0,3,"There was no clear evidence of an effect on mortality related to the administration of BMMNCs compared to control (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.15 to 6.63; 3 studies, 123 participants; very low-certainty evidence).",delete,[],1,0.2222222222222222,2,18
CD008347,0,4,"All trials assessed changes in pain severity, but the trials used different forms of pain assessment tools, so we were unable to pool data.",rephrase,"['The studies measured pain in different ways, and not all information was reported, so we were unable to pool the data.']",1,0.2777777777777778,2,18
CD008347,0,5,Three studies individually reported that no differences in pain reduction were observed between the BMMNC and control groups.,rephrase,"['Individually, three studies did not find any difference in the reduction of pain between the therapy and control groups.']",2,0.3333333333333333,2,18
CD008347,0,6,One study reported that reduction in rest pain was greater in the BMMNC group compared to the control group (very low-certainty evidence).,rephrase,['One study reported that pain was reduced more in the cell therapy group than in the control group.'],3,0.3888888888888889,2,18
CD008347,0,7,All four trials reported the rate of amputation at the end of the study period.,merge,"['Pooling data from all four studies showed that cell therapy might reduce amputations, but we are not certain about this because the possible benefit was lost when we redid the analysis excluding data from studies we had concerns about.']",4,0.4444444444444444,3,18
CD008347,0,8,"We are uncertain if amputations were reduced in the BMMNC group compared to the control group, as a possible small effect (RR 0.52, 95% CI 0.27 to 0.99; 4 studies, 176 participants; very low-certainty evidence) was lost after undertaking sensitivity analysis (RR 0.52, 95% CI 0.19 to 1.39; 2 studies, 89 participants).",none,[],4,0.5,3,18
CD008347,0,9,None of the included studies reported any angiographic analysis.,delete,[],5,0.5555555555555556,3,18
CD008347,0,10,"Ankle-brachial index was reported differently by each study, so we were not able to pool the data.",delete,[],5,0.6111111111111112,4,18
CD008347,0,11,"Three studies reported no changes between groups, and one study reported greater improvement in ABI (as haemodynamic improvement) in the BMMNC group compared to the control group (very low-certainty evidence).",rephrase,"['Three studies reported no improvements in the ankle-brachial index (a way to measure the blood flow in the leg), whilst one study reported a greater improvement in the ankle-brachial index in the cell therapy group compared to the control group.']",5,0.6666666666666666,4,18
CD008347,0,12,"One study reported pain-free walking distance, finding no clear difference between BMMNC and control groups (low-certainty evidence).",rephrase,['No improvements were seen in pain-free walking distance between groups.'],6,0.7222222222222222,4,18
CD008347,0,13,"We pooled the data for side effects reported during the follow-up, and this did not show any clear difference between BMMNC and control groups (RR 2.13, 95% CI 0.50 to 8.97; 4 studies, 176 participants; very low-certainty evidence).",rephrase,['No clear difference was seen in side effects between groups.'],7,0.7777777777777778,4,18
CD008347,0,14,"We downgraded the certainty of the evidence due to the concerns about risk of bias, imprecision, and inconsistency.",rephrase,['Our confidence in the evidence was very low because of concerns about how the studies were carried out.'],8,0.8333333333333334,5,18
CD008347,1,15,"We identified a small number of studies that met our inclusion criteria, and these differed in the controls they used and how they measured important outcomes.",rephrase,['The four included studies differed from each other in how they measured effects at different time points; they used different controls; there were small numbers of events and participants overall; and there were differences in individual study results.'],9,0.8888888888888888,5,18
CD008347,1,16,"Limited data from these trials provide very low- to low-certainty evidence, and we are unable to draw conclusions to support the use of local intramuscular transplantation of BMMNC for improving clinical outcomes in people with CLI.",delete,[],10,0.9444444444444444,5,18
CD008347,1,17,Evidence from larger RCTs is needed in order to provide adequate statistical power to assess the role of this procedure.,delete,[],10,1.0,5,18
CD012556,0,0,Our search found 782 potentially relevant references.,delete,[],0,0.038461538461538464,1,26
CD012556,0,1,"From these, we included three trials without a control group, with 283 participants.",rephrase,['Our search led to the inclusion of three studies involving 283 participants and 14 ongoing trials.'],0,0.07692307692307693,1,26
CD012556,0,2,"In addition, we identified 14 ongoing trials evaluating nivolumab, of which two are randomised.",rephrase,['We searched important medical databases for clinical trials assessing the benefits and harms of nivolumab in adults with HL.'],1,0.11538461538461539,1,26
CD012556,0,3,Risk of bias of the three included studies was moderate to high.,delete,[],2,0.15384615384615385,1,26
CD012556,0,4,"All of the participants were in relapsed stage, most of them were heavily pretreated and had received at least two previous treatments, most of them had also undergone ASCT.",delete,[],2,0.19230769230769232,1,26
CD012556,0,5,"As we did not identify any RCTs, we could not use the software RobotReviewer to assess risk of bias.",delete,[],2,0.23076923076923078,2,26
CD012556,0,6,"The software identified correctly that one study was not an RCT and did not extract any trial data, but extracted characteristics of the other two studies (although also not RCTs) in a sufficient way.",delete,[],2,0.2692307692307692,2,26
CD012556,1,7,Two studies with 260 participants evaluated OS.,rephrase,['Two studies with 260 participants evaluated survival.'],2,0.3076923076923077,2,26
CD012556,1,8,"After six months, OS was 100% in one study and median OS (the timepoint when only 50% of participants were alive) was not reached in the other trial after a median follow-up of 18 months (interquartile range (IQR) 15 to 22 months) (very low certainty evidence, due to observational trial design, heterogenous patient population in terms of pretreatments and various follow-up times (downgrading by 1 point)).",rephrase,"['After six months, all participants were alive in one trial (17 participants).']",3,0.34615384615384615,2,26
CD012556,1,9,"In one study, one out of three cohorts reported quality of life.",rephrase,['One trial reported quality of life for a subgroup of participants using a questionnaire but not all follow-up data were available.'],4,0.38461538461538464,2,26
CD012556,1,10,It was unclear whether there was an effect on quality of life as only a subset of participants filled out the follow-up questionnaire (very low certainty evidence).,rephrase,"['Although it seemed that the participants answering the questionnaire might have had a benefit, it was unclear whether this applied to all the participants.']",5,0.4230769230769231,3,26
CD012556,1,11,Three trials (283 participants) evaluated progression-free survival (PFS) (very low certainty evidence).,delete,[],6,0.46153846153846156,3,26
CD012556,1,12,"Six-month PFS ranged between 60% and 86%, and median PFS ranged between 12 and 18 months.",delete,[],6,0.5,3,26
CD012556,1,13,"All three trials (283 participants) reported complete response rates, ranging from 12% to 29%, depending on inclusion criteria and participants' previous treatments (very low certainty evidence).",delete,[],6,0.5384615384615384,3,26
CD012556,2,14,"One trial (243 participants) reported drug-related grade 3 or 4 adverse events (AEs) only after a median follow-up of 18 months (IQR 15 to 22 months); these were fatigue (23%), diarrhoea (15%), infusion reactions (14%) and rash (12%).",rephrase,"['The most commonly reported side effects were fatigue (tiredness), diarrhoea (loose stools), infusion reactions (during or shortly after giving the medicine by a vein) and rash.']",6,0.5769230769230769,3,26
CD012556,2,15,The other two trials (40 participants) reported 23% to 52% grade 3 or 4 AEs after six months' follow-up (very low certainty evidence).,delete,[],7,0.6153846153846154,4,26
CD012556,2,16,Only one trial (243 participants) reported drug-related serious AEs; 2% of participants developed infusion reactions and 1% pneumonitis (very low certainty evidence).,delete,[],7,0.6538461538461539,4,26
CD012556,3,17,None of the studies reported treatment-related mortality.,split,"['Only one study reported medicine-related serious side effects.', 'Deaths related to the medicine were not reported.']",7,0.6923076923076923,4,26
CD012556,4,18,"To date, data on OS, quality of life, PFS, response rate, or short- and long-term AEs are available from small uncontrolled trials only.",rephrase,"['Data on survival, quality of life, tumour response and side effects were available from small trials only.']",9,0.7307692307692307,4,26
CD012556,4,19,"The three trials included heavily pretreated participants, which had previously undergone regimens of BV or ASCT.",rephrase,"['The three trials included only people different previous treatment options, very often also with a previous stem cell transplantation.']",10,0.7692307692307693,4,26
CD012556,4,20,"For these participants, median OS was not reached after follow-up times of at least 16 months (more than 50% of participants with a limited life expectancy were alive at this timepoint).",delete,[],11,0.8076923076923077,5,26
CD012556,4,21,"Only one cohort out of three only reported quality of life, with limited follow-up data so that meaningful conclusions were not possible.",rephrase,"['Quality of life data were not reported for all the included participants; moreover, data after a long period of treatment were not available for all evaluated participants, therefore meaningful conclusions were not possible.']",11,0.8461538461538461,5,26
CD012556,4,22,Serious adverse events occurred rarely.,rephrase,['Serious side effects occurred rarely.'],12,0.8846153846153846,5,26
CD012556,4,23,"Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for heavily pretreated people, which had previously undergone regimens of BV or ASCT.",rephrase,"['Currently, data are too sparse to make a clear statement on nivolumab for people with relapsed or refractory HL except for those who had received several treatments before.']",13,0.9230769230769231,5,26
CD012556,4,24,"When interpreting these results, it is important to consider that proper RCTs should confirm these findings.",delete,[],14,0.9615384615384616,5,26
CD012556,5,25,"As there are 14 ongoing trials evaluating nivolumab, of which two are RCTs, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.",ignore,"['As there are currently 14 ongoing trials evaluating nivolumab, of which two are well designed, it is possible that an update of this review will be published in the near future and that this update will show different results to those reported here.']",14,1.0,5,26
CD006929,0,0,Eighteen trials are included in the review.,delete,[],0,0.1,1,10
CD006929,0,1,The majority were in family care settings.,rephrase,['The majority were in family care settings and there were surprisingly few care home based studies.'],0,0.2,1,10
CD006929,0,2,"For fourteen studies, FA was just one aspect of a broad multi-component programme of care.",merge,"['Most evaluated broad programmes of care, where FA was just one component of a wide range of other interventions.']",1,0.3,2,10
CD006929,0,3,Assessing the effect of FA was compromised by ill-defined protocols for the duration of component parts of these programmes (i.e. frequency of the intervention or actual time spent).,none,[],1,0.4,2,10
CD006929,0,4,"Therefore, establishing the real effect of the FA component was not possible.",rephrase,['This made it hard to determine the real effect of FA for the management of challenging behaviour in dementia.'],2,0.5,3,10
CD006929,1,5,"Overall, positive effects were noted at post-intervention for the frequency of reported challenging behaviour (but not for incidence or severity) and for caregiver reaction (but not burden or depression).",split,"['However, positive results were noted in the frequency of the person’s reported problem behaviours and the caregiver’s reaction to them.', 'No significant effects were found for incidence or severity of mood and other problem behaviours.', 'Similarly, no significant effects were found for caregiver mood or burden.']",3,0.6,3,10
CD006929,1,6,These effects were not seen at follow-up.,delete,[],6,0.7,4,10
CD006929,2,7,"The delivery of FA has been incorporated within wide ranging multi-component programmes and study designs have varied according to setting - i.e. family care, care homes and hospital, with surprisingly few studies located in care homes.",delete,[],6,0.8,4,10
CD006929,2,8,"Our findings suggest potential beneficial effects of multi-component interventions, which utilise FA.",merge,[],6,0.9,5,10
CD006929,2,9,"Whilst functional analysis for challenging behaviour in dementia care shows promise, it is too early to draw conclusions about its efficacy.",none,"['Whilst it is too early to reach a firm conclusion on the evidence for FA in the management of challenging behaviour in dementia, we note emerging beneficial effects on challenging behaviour where multi-component psychosocial interventions have used FA as part of the programme of care.']",6,1.0,5,10
CD006096,0,0,Five RCTs (149 participants) met the inclusion criteria.,rephrase,['Five studies including 149 participants were identified.'],0,0.043478260869565216,1,23
CD006096,0,1,"These studies assessed bismuth subsalicylate versus placebo, budesonide versus placebo, mesalazine versus mesalazine plus cholestyramine and beclometasone dipropionate versus mesalazine.",rephrase,"['These studies assessed budesonide versus placebo (e.g. a sugar pill), mesalazine versus mesalazine plus cholestyramine and beclometasone dipropionate versus mesalazine and Pepto-Bismol® versus placebo.']",1,0.08695652173913043,1,23
CD006096,0,2,The study which assessed mesalazine versus mesalazine plus cholestyramine and the study which assessed beclometasone dipropionate versus mesalazine were judged to be at high risk of bias due to lack of blinding.,rephrase,['The study which compared mesalazine to mesalazine plus cholestyramine and the study which compared beclometasone dipropionate to mesalazine were judged to be of low quality.'],2,0.13043478260869565,1,23
CD006096,0,3,The study which compared bismuth subsalicylate versus us placebo was judged as low quality due to a very small sample size and limited data.,rephrase,['The study which compared Pepto-Bismol® bismuth subsalicylate to a placebo was judged as low quality due to a very small sample size (5 participants) and limited data.'],3,0.17391304347826086,1,23
CD006096,0,4,The other 3 studies were judged to be at low risk of bias.,rephrase,['The other three studies were judged to be high quality.'],4,0.21739130434782608,2,23
CD006096,0,5,Budesonide (9 mg/day for 6 to 8 weeks) was significantly more effective than placebo for induction of clinical and histological response.,rephrase,['A pooled analysis of two studies (57 participants) showed that budesonide (9 mg/day for 6 to 8 weeks) was superior to placebo for improvement of diarrhea and improvement of microscopic inflammation of the bowel.'],5,0.2608695652173913,2,23
CD006096,0,6,"Clinical response was noted in 88% of budesonide patients compared to 38% of placebo patients (2 studies; 57 participants; RR 2.03, 95% CI 1.25 to 3.33; GRADE = low).",rephrase,['Improvement in diarrhea was noted in 88% of budesonide participants compared to 38% of placebo participants.'],6,0.30434782608695654,2,23
CD006096,0,7,"Histological response was noted in 78% of budesonide patients compared to 33% of placebo patients (2 studies; 39 patients; RR 2.44, 95% CI 1.13 to 5.28; GRADE = low).",rephrase,['Improvement in microscopic inflammation was reported in 78% of budesonide participants compared to 33% of placebo participants.'],7,0.34782608695652173,2,23
CD006096,0,8,Forty-one patients were enrolled in the study assessing mesalazine (2.4 g/day) versus mesalazine plus cholestyramine (4 g/day).,rephrase,['Forty-one participants were enrolled in the study that compared mesalazine (2.4. g/day) to mesalazine plus cholestyramine (4 g/day).'],8,0.391304347826087,2,23
CD006096,0,9,"Clinical response was noted in 85% of patients in the mesalazine group compared to 86% of patients in the mesalazine plus cholestyramine group (RR 0.99, 95% CI 0.77 to 1.28; GRADE = low).",rephrase,['Improvement in diarrhea was noted in 85% of participants in the mesalazine group compared to 86% of participants in the mesalazine plus cholestyramine group.'],9,0.43478260869565216,3,23
CD006096,0,10,Five patients were enrolled in the trial studying bismuth subsalicylate (nine 262 mg tablets daily for 8 weeks versus placebo).,rephrase,['Five patients were enrolled in the trial studying Pepto-Bismol® (nine 262 mg tablets daily for 8 weeks versus placebo).'],10,0.4782608695652174,3,23
CD006096,0,11,There were no differences in clinical (P=0.10) or histological responses (P=0.71) in patients treated with bismuth subsalicylate compared with placebo (GRADE = very low).,delete,[],11,0.5217391304347826,3,23
CD006096,0,12,Forty-six patients were enrolled in the trial studying beclometasone dipropionate (5 mg/day or 10 mg/day) versus mesalazine (2.4 g/day).,ignore,['Forty-six participants were enrolled in the trial studying beclometasone dipropionate (5 mg/day or 10 mg/day) versus mesalazine (2.4 g/day).'],11,0.5652173913043478,3,23
CD006096,0,13,There were no differences in clinical remission at 8 weeks (RR 0.97; 95% CI 0.75 to 1.24; GRADE = low) and 12 months of treatment (RR 1.29; 95% CI 0.40 to 4.18; GRADE = very low).,delete,[],12,0.6086956521739131,4,23
CD006096,0,14,"Although patients receiving beclometasone dipropionate (84%) and mesalazine (86%) achieved clinical remission at 8 weeks, it was not maintained at 12 months (26% and 20%, respectively).",rephrase,"['Although participants receiving beclometasone dipropionate (84%) and mesalazine (86%) had improved diarrhea at 8 weeks, this improvement was not maintained at 12 months (26% and 20%, respectively).']",12,0.6521739130434783,4,23
CD006096,0,15,"Adverse events reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, hyperhidrosis and headache.",rephrase,"['Side effects reported in the budesonide studies include nausea, vomiting, neck pain, abdominal pain, excessive sweating and headache.']",13,0.6956521739130435,4,23
CD006096,0,16,Nausea and skin rash were reported as adverse events in the mesalazine study.,rephrase,['Side effects reported in the mesalazine plus cholestyramine study included nausea and skin rash.'],14,0.7391304347826086,4,23
CD006096,0,17,"Adverse events in the beclometasone dipropionate trial include nausea, sleepiness and change of mood.",ignore,"['Side effects in the beclometasone dipropionate trial included nausea, sleepiness and change of mood.']",15,0.782608695652174,4,23
CD006096,0,18,No adverse events were reported in the bismuth subsalicylate study.,rephrase,['No side effects were reported in the Pepto-Bismol® study.'],16,0.8260869565217391,5,23
CD006096,1,19,Low quality evidence suggests that budesonide may be effective for the treatment of active lymphocytic colitis.,ignore,['Low quality evidence suggests that budesonide may be an effective therapy for the treatment of lymphocytic colitis.'],17,0.8695652173913043,5,23
CD006096,1,20,This benefit needs to be confirmed by a large placebo -controlled trial.,rephrase,"['In the future, researchers should consider further large placebo-controlled trials of budesonide to confirm the suggested benefit and safety of this therapy.']",18,0.9130434782608695,5,23
CD006096,1,21,"Low quality evidence also suggests that mesalazine with or without cholestyramine and beclometasone dipropionate may be effective for the treatment of lymphocytic colitis, however this needs to be confirmed by large placebo-controlled studies.",split,"['Low quality evidence also suggests that mesalazine with or without cholestyramine and beclometasone dipropionate may be effective for treatment of lymphocytic colitis.', 'The effectiveness and safety of mesalazine with or without cholestyramine, and beclometasone dipropionate need to be investigated in a large placebo-controlled studies.']",19,0.9565217391304348,5,23
CD006096,1,22,"No conclusions can be made regarding bismuth subsalicylate due to the very small number of patients in the study, Further trials studying interventions for lymphocytic colitis are warranted.",split,"['No conclusions can be made regarding bismuth subsalicylate due to the very small number of participants in the study.', 'Bismuth subsalicylate, which has less potential for toxicity than budesonide, also warrants further study.']",21,1.0,5,23
CD006782,0,0,Seven randomised controlled trials involving 1919 participants were included.,ignore,['Seven randomised controlled trials involving a total of 1919 participants were included.'],0,0.1,1,10
CD006782,0,1,"All trials involved people, predominantly young adults, participating in regular sporting activities.",ignore,"['All trials involved people, predominantly young adults, participating in regular sporting activities.']",1,0.2,1,10
CD006782,0,2,"Some trials were compromised by poor methodology, including lack of blinding and incomplete outcome data.",ignore,"['Some trials were compromised by poor methodology, including lack of blinding and incomplete outcome data.']",2,0.3,2,10
CD006782,1,3,"Four trials, including 287 participants, examined interventions directly targeted at preventing hamstring injuries.",ignore,"['Four trials, including 287 participants, examined interventions directly targeted at preventing hamstring injuries.']",3,0.4,2,10
CD006782,1,4,"Three of these trials, which tested hamstring strengthening protocols, had contradictory findings, with one small trial showing benefit (although the control rate of mainly minor hamstring injury was unusually high).",rephrase,"['Three of these trials, which tested hamstring strengthening protocols, had contradictory findings and we could not conclude whether strengthening exercises of the hamstrings was beneficial or not.']",4,0.5,3,10
CD006782,1,5,"The other two trials found no benefit, with a greater incidence of hamstring injury in the intervention group.",delete,[],5,0.6,3,10
CD006782,1,6,"One unpublished and underpowered trial provided some evidence that manual therapy may prevent lower-limb muscle strain (RR 0.13, 95% CI 0.02 to 0.97), although the finding for hamstring injury did not reach statistical significance (RR 0.21, 95% CI 0.03 to 1.66).",rephrase,"['One small trial found that manual therapy (involving manipulation, massage and specific stretches to joints and muscles of the spine and leg) may prevent injuries of leg muscles, including the hamstrings.']",5,0.7,4,10
CD006782,2,7,Three trials testing interventions for preventing lower limb injuries for which data for hamstring injury were available found no statistically significant effect for hamstring injury for either proprioceptive protocols (two cluster randomised trials) or a warm up/cool down and stretching protocol (one trial).,split,"['Three inconclusive trials tested interventions for preventing all leg injuries for which data for hamstring injury were available.', 'Two trials found no evidence for an effect for balance training on a wobble board (proprioceptive protocol).', 'One trial found no evidence for a warm up/cool down and stretching protocol for distance runners.']",6,0.8,4,10
CD006782,3,8,There is insufficient evidence from randomised controlled trials to draw conclusions on the effectiveness of interventions used to prevent hamstring injuries in people participating in football or other high risk activities for these injuries.,rephrase,"['Based on currently available research findings, no specific intervention can be recommended for decreasing the risk of incurring hamstring injuries.']",9,0.9,5,10
CD006782,3,9,The findings for manual therapy need confirmation.,delete,[],10,1.0,5,10
CD013627,0,0,We found no completed studies to include in this review.,ignore,['We found no completed studies to include in this review.'],0,0.1,1,10
CD013627,0,1,"We identified 16 ongoing studies (including 14 RCTs), which aim to enrol nearly 1250 participants.",rephrase,['We found 16 studies currently in progress that aim to enrol nearly 1250 participants.'],1,0.2,1,10
CD013627,0,2,"The interventions included in these trials are ArtemiC (artemisinin, curcumin, frankincense and vitamin C), Citrox (a bioflavonoid), cetylpyridinium chloride, chlorhexidine, chlorine dioxide, essential oils, hydrogen peroxide, hypertonic saline, Kerecis spray (omega 3 viruxide – containing neem oil and St John's wort), neem extract, nitric oxide releasing solution, povidone iodine and saline with baby shampoo.",delete,[],2,0.3,2,10
CD013627,1,3,We identified no studies for inclusion in this review.,delete,[],2,0.4,2,10
CD013627,1,4,This is not surprising given the relatively recent emergence of COVID-19 infection.,delete,[],2,0.5,3,10
CD013627,1,5,It is promising that the question posed in this review is being addressed by a number of RCTs and other studies.,delete,[],2,0.6,3,10
CD013627,1,6,"We are concerned that few of the ongoing studies specifically state that they will evaluate adverse events such as changes in the sense of smell or to the oral and nasal microbiota, and any consequences thereof.",rephrase,['Few of the ongoing studies we identified specifically state that they will investigate these.'],2,0.7,4,10
CD013627,2,7,Very few interventions have large and dramatic effect sizes.,rephrase,"['If future studies show a beneficial effect of mouthwashes and nasal sprays, it may not be a large effect (very few health interventions have large and dramatic effect sizes).']",3,0.8,4,10
CD013627,2,8,"If a positive treatment effect is demonstrated when studies are available for inclusion in this review, it may not be large.",delete,[],4,0.9,5,10
CD013627,2,9,In these circumstances in particular it may be a challenge to weigh up the benefits against the harms if the latter are of uncertain frequency and severity.,rephrase,['It will only be possible to weigh up potentially small benefits against risks if any adverse events that occur are reported in studies.'],4,1.0,5,10
CD004957,0,0,Five trials (619 participants) met the inclusion criteria; two addressed inpatient rehabilitation (261 participants) and three (358 participants) home-based settings.,ignore,['Five trials (619 participants) met the inclusion criteria; two addressed inpatient rehabilitation (261 participants) and three (358 participants) home-based settings.'],0,0.1,1,10
CD004957,0,1,There were no trials addressing outpatient centre-based programmes.,ignore,['There were no trials addressing outpatient centre-based programmes.'],1,0.2,1,10
CD004957,0,2,Pooling of data was not possible due to differences in study design and outcomes used.,ignore,['Pooling of data was not possible due to differences in study design and outcomes used.'],2,0.3,2,10
CD004957,0,3,Methodological assessment showed all trials were of low quality.,ignore,['Methodological assessment showed all trials were of low quality.'],3,0.4,2,10
CD004957,0,4,"For inpatient settings early commencement of rehabilitation and clinical pathways led to more rapid attainment of functional milestones (disability) (Functional Independence Measure (FIM) transfer WMD 0.5, 95% CI 0.15, 0.85, number needed to treat to benefit (NNTB) = 6, FIM ambulation WMD 1.55 (95%CI 0.96, 2.14), NNTB = 3), shorter hospital stay, fewer post-operative complications and reduced costs in the first three to four months.",ignore,"['For inpatient settings early commencement of rehabilitation and clinical pathways led to more rapid attainment of functional milestones (disability) (Functional Independence Measure (FIM) transfer WMD 0.5, 95% CI 0.15, 0.85, number needed to treat to benefit (NNTB) = 6, FIM ambulation WMD 1.55 (95%CI 0.96, 2.14), NNTB = 3), shorter hospital stay, fewer post-operative complications and reduced costs in the first three to four months.']",4,0.5,3,10
CD004957,0,5,"Home-based multidisciplinary care improved functional gain (Oxford Hip Score (OHS) WMD at 6 months -7.00 (95%CI -10.36, -3.64), NNT = 2 and quality of life (QoL) and reduced hospital stay in the medium term (six months).",ignore,"['Home-based multidisciplinary care improved functional gain (Oxford Hip Score (OHS) WMD at 6 months -7.00 (95%CI -10.36, -3.64), NNT = 2 and quality of life (QoL) and reduced hospital stay in the medium term (six months).']",5,0.6,3,10
CD004957,0,6,No trials addressed longer-term outcomes following hip replacement only.,ignore,['No trials addressed longer-term outcomes following hip replacement only.'],6,0.7,4,10
CD004957,1,7,"Based on the heterogeneity and the low quality of the included trials that precluded pooled meta-analysis, there is silver level evidence that following hip or knee joint replacement, early multidisciplinary rehabilitation can improve outcomes at the level of activity and participation.",ignore,"['Based on the heterogeneity and the low quality of the included trials that precluded pooled meta-analysis, there is silver level evidence that following hip or knee joint replacement, early multidisciplinary rehabilitation can improve outcomes at the level of activity and participation.']",7,0.8,4,10
CD004957,1,8,"The optimal intensity, frequency and effects of rehabilitation over a longer period and associated social costs need further study.",ignore,"['The optimal intensity, frequency and effects of rehabilitation over a longer period and associated social costs need further study.']",8,0.9,5,10
CD004957,1,9,"Future research should focus on improving methodological and scientific rigour of clinical trials, and use of standardised outcome measures, so that results can be pooled for statistical analysis.",ignore,"['Future research should focus on improving methodological and scientific rigour of clinical trials, and use of standardised outcome measures, so that results can be pooled for statistical analysis.']",9,1.0,5,10
CD008402,0,0,Two trials with a total of 210 participants were included.,rephrase,['We included two studies with a total of 210 participants in this review.'],0,0.09090909090909091,1,11
CD008402,0,1,Both trials were at some risk of performance bias.,merge,['Both trials were at some risk of bias because not enough care had been taken to ensure that groups received the same treatment other than the interventions being tested.'],1,0.18181818181818182,1,11
CD008402,0,2,One trial had four intervention groups and the other had three.,none,[],1,0.2727272727272727,2,11
CD008402,0,3,"One trial found that foot orthoses when compared with flat insoles (control group) had better results at six weeks in knee pain (participants with global improvement: risk ratio 1.48, 95% confidence interval 1.11 to 1.99), but not at one year follow-up.",rephrase,['One trial found some benefits from using foot orthoses over simple insoles at six weeks but not at one year.'],2,0.36363636363636365,2,11
CD008402,0,4,"Participants in the orthoses group reported significantly more minor adverse effects (e.g. rubbing, blistering) compared with the flat insole group (risk ratio 1.87, 95% confidence intervaI 1.21 to 2.91).",rephrase,"['Participants wearing orthoses were, however, more likely to report minor adverse effects (e.g. rubbing, blistering) and discomfort compared with those wearing insoles.']",3,0.45454545454545453,3,11
CD008402,0,5,Both trials in their comparisons of orthoses plus physiotherapy versus physiotherapy alone found no statistically significant differences between the two intervention groups in knee pain or function.,rephrase,['There were no important differences in knee pain and function in people given foot orthoses as well as physiotherapy when compared with people given physiotherapy only.'],4,0.5454545454545454,3,11
CD008402,0,6,Results for knee pain outcomes did not show significant differences between foot orthoses versus physiotherapy.,rephrase,['Results for knee pain and function did not show important differences between foot orthoses versus physiotherapy.'],5,0.6363636363636364,4,11
CD008402,0,7,"Although participants in the physiotherapy group had consistently better results for the functional index questionnaire, the clinical relevance of these results is uncertain.",delete,[],6,0.7272727272727273,4,11
CD008402,1,8,"While not robust, the available evidence does not reveal any clear advantage of foot orthoses over simple insoles or physiotherapy for patellofemoral pain.",rephrase,['On the basis of the available evidence we do not recommend foot orthoses for adults with pain around the knee cap.'],6,0.8181818181818182,5,11
CD008402,1,9,"While foot orthoses may help relieve knee pain over the short term, the benefit may be marginal.",delete,[],7,0.9090909090909091,5,11
CD008402,1,10,Patients treated with orthoses are more likely to complain of mild adverse effects and discomfort.,delete,[],7,1.0,5,11
CD003690,0,0,We did not identify any new trials for this update.,rephrase,['We did not identify any new studies in our search update.'],0,0.058823529411764705,1,17
CD003690,0,1,We included seven trials with a total of 239 participants.,rephrase,['We included 7 studies involving 239 people.'],1,0.11764705882352941,1,17
CD003690,0,2,"Two trials had a cross-over design, but outcome data were not available from the first phase (precross-over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT).",delete,[],2,0.17647058823529413,1,17
CD003690,0,3,"Thus, the results of the review are based on five trials with a total of 213 participants.",delete,[],2,0.23529411764705882,2,17
CD003690,0,4,"It is uncertain whether fluoxetine increases the number of people who have a 50% reduction in emotionalism when compared to placebo (risk ratio (RR) 0.26, 95% CI 0.09 to 0.77; P = 0.02; 1 trial, 19 participants) because the certainty of evidence is very low.",rephrase,"['It is uncertain whether antidepressants affect the number of people with at least a 50% reduction in emotional displays, tearfulness, and scores on the questionnaires that measure uncontrollable laughing or crying, but they had no effect on lability (frequency of mood changes) scores and whether a clinician thought there had been an improvement when compared to placebo.']",2,0.29411764705882354,2,17
CD003690,1,5,"Sertraline may lead to little to no difference in Center for Neurologic Study - Lability Scale (CNS-LS) scores and Clinician Interview-Based Impression of Change (CIBIC) scores when compared to placebo (RR 0.20, 95% CI 0.03 to 1.50; P = 0.12; 1 trial, 28 participants; low-certainty evidence).",delete,[],3,0.35294117647058826,2,17
CD003690,1,6,"Antidepressants probably increase the number of people who experience a reduction in tearfulness (RR 0.32, 95% CI 0.12 to 0.86; P = 0.02; 3 trials, 164 participants; moderate-certainty evidence).",delete,[],3,0.4117647058823529,3,17
CD003690,1,7,No trials were found that evaluated the impact of other pharmaceutical interventions.,rephrase,['No studies of other types of medicine were found.'],3,0.47058823529411764,3,17
CD003690,2,8,"Only two trial authors systematically recorded and reported adverse events, resulting in limited data on the potential harms of treatment.",delete,[],4,0.5294117647058824,3,17
CD003690,2,9,"Six trials reported death as an adverse event and found no difference between the groups (antidepressants versus placebo) in the number of deaths reported (RR 0.59, 95% CI 0.08 to 4.50; P = 0.61; 172 participants; moderate-certainty evidence).",rephrase,['Six studies reported death and found no differences between those who were on antidepressants and those who were not.'],4,0.5882352941176471,3,17
CD003690,3,10,This review provides very low- to moderate-certainty evidence that antidepressants may reduce the frequency and severity of emotionalism.,rephrase,"['Our confidence in the evidence is moderate to very low, and the results of further research could differ from the results of this review.']",5,0.6470588235294118,4,17
CD003690,3,11,The included trials were small and had some degree of bias.,rephrase,"['Our confidence is limited because the included studies were small, and there was no consistency in how emotionalism was measured across the studies.']",6,0.7058823529411765,4,17
CD003690,4,12,"Antidepressants may reduce the frequency and severity of crying or laughing episodes when compared to placebo, based on very low-certainty evidence.",rephrase,['It is uncertain whether antidepressant medicines reduce outbursts of crying or laughing.'],7,0.7647058823529411,4,17
CD003690,4,13,Our conclusions must be qualified by several methodological deficiencies in the trials and interpreted with caution despite the effect being very large.,delete,[],8,0.8235294117647058,5,17
CD003690,4,14,The effect does not seem specific to one drug or class of drugs.,delete,[],8,0.8823529411764706,5,17
CD003690,4,15,More reliable data are required before appropriate conclusions can be made about the treatment of post-stroke emotionalism.,rephrase,['More studies with systematic assessment and reporting of unwanted or harmful effects of a treatment are needed to ensure that any benefits outweigh the risks.'],8,0.9411764705882353,5,17
CD003690,4,16,"Future trialists investigating the effect of antidepressants in people with emotionalism after stroke should consider developing and using a standardised method to diagnose emotionalism, determine severity, and assess change over time; provide treatment for a sufficient duration and follow-up to better assess rates of relapse or maintenance; and include careful assessment and complete reporting of adverse events.",delete,[],9,1.0,5,17
CD001127,0,0,"The searches identified 74 trials, of which 19 (2565 participants) met our inclusion criteria.",delete,[],0,0.058823529411764705,1,17
CD001127,0,1,15 trials compared dornase alfa to placebo or no dornase alfa (2447 participants); two compared daily dornase to hypertonic saline (32 participants); one compared daily dornase alfa to hypertonic saline and alternate day dornase alfa (48 participants); one compared dornase alfa to mannitol and the combination of both drugs (38 participants).,rephrase,['We included 19 trials with 2565 people with cystic fibrosis; 15 trials (2447 people) compared dornase alfa to placebo (a dummy treatment with no active medication) or no dornase alfa treatment; two trials (32 people) compared daily dornase to hypertonic saline; one trial (48 people) compared daily dornase alfa with hypertonic saline and alternate day dornase alfa; and one trial (38 people) compared dornase alfa to mannitol and the combination of both drugs.'],0,0.11764705882352941,1,17
CD001127,0,2,Trial duration varied from six days to three years.,rephrase,['People from all age groups (infants through to adults) took part in the trials which lasted from six days to three years.'],1,0.17647058823529413,1,17
CD001127,1,3,"Dornase alfa compared to placebo or no treatment
Dornase alfa probably improved forced expiratory volume at one second (FEV1) at one month (four trials, 248 participants), three months (one trial, 320 participants; moderate-quality evidence), six months (one trial, 647 participants; high-quality evidence) and two years (one trial, 410 participants).",rephrase,['Dornase alfa compared to placebo or no treatment\nWe found that dornase alfa probably improves lung function within one month when compared to a placebo or no treatment and this improvement was also seen in longer trials lasting from six months to two years (eight trials; 1708 participants).'],2,0.23529411764705882,2,17
CD001127,1,4,Limited low-quality evidence showed treatment may make little or no difference  in quality of life.,delete,[],3,0.29411764705882354,2,17
CD001127,1,5,Dornase alfa probably reduced the number of pulmonary exacerbations in trials of up to two years (moderate-quality evidence).,rephrase,['There were also fewer pulmonary exacerbations (flare up of lung inflammation) in these longer trials.'],3,0.35294117647058826,2,17
CD001127,1,6,"One trial that examined the cost of care, including the cost of dornase alfa, found that the cost savings from dornase alfa offset 18% to 38% of the medication costs.",rephrase,['One trial found that the cost savings from dornase alfa offset 18% to 38% of the medication costs.'],4,0.4117647058823529,3,17
CD001127,2,7,"Dornase alfa: daily versus alternate day
One cross-over trial (43 children) found little or no difference between treatment regimens for lung function, quality of life or pulmonary exacerbations (low-quality evidence).",rephrase,"['Dornase alfa - daily versus alternate day\nOne trial (43 children) found no differences between treatment schedules for lung function, quality of life or pulmonary exacerbations.']",5,0.47058823529411764,3,17
CD001127,3,8,"Dornase alfa compared to other medications that improve airway clearance
Results for these comparisons were mixed.",rephrase,['Dornase alfa compared to other medications that improve airway clearance\nThe results from trials comparing dornase alfa to hypertonic saline or mannitol were mixed.'],6,0.5294117647058824,3,17
CD001127,3,9,"One trial (43 children) showed dornase alfa may lead to a greater improvement in FEV1 compared to hypertonic saline (low-quality evidence), and one trial (23 participants) reported little or no differences in lung function between dornase alfa and mannitol or dornase alfa and dornase alfa plus mannitol (low-quality evidence).",rephrase,['One trial (43 children) showed a greater improvement in lung function with dornase alfa compared to hypertonic saline and one trial (23 participants) reported no difference in lung function between dornase alfa and mannitol or dornase alfa and dornase alfa plus mannitol.'],7,0.5882352941176471,3,17
CD001127,3,10,One trial (23 participants) found dornase alfa may improve quality of life compared to dornase alfa plus mannitol (low-quality evidence); other comparisons found little or no difference in this outcome (low-quality evidence).,rephrase,['In one trial (23 participants) quality of life scores were better with dornase alfa alone than with dornase alfa plus mannitol; other drug comparisons found no difference between treatments for quality of life.'],8,0.6470588235294118,4,17
CD001127,3,11,No trials in any comparison reported any difference between groups in the number of pulmonary exacerbations (low-quality evidence).,rephrase,['No trials in any comparison of treatments reported any difference between groups in the number of pulmonary exacerbations.'],9,0.7058823529411765,4,17
CD001127,4,12,"When all comparisons are assessed, dornase alfa did not cause significantly more adverse effects than other treatments, except voice alteration and rash.",rephrase,"['Overall, no serious side effects were reported, with only rash and a change in voice seen more frequently in those people taking dornase alfa.']",10,0.7647058823529411,4,17
CD001127,5,13,"There is evidence to show that, compared with placebo, therapy with dornase alfa may improve lung function in people with cystic fibrosis in trials lasting from one month to two years.",delete,[],11,0.8235294117647058,5,17
CD001127,5,14,"There was a decrease in pulmonary exacerbations in trials of six months or longer, probably due to treatment.",delete,[],11,0.8823529411764706,5,17
CD001127,5,15,Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials.,delete,[],11,0.9411764705882353,5,17
CD001127,5,16,There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function.,delete,[],11,1.0,5,17
CD002817,0,0,We identified 39 trials with 1827 participants.,delete,[],0,0.07142857142857142,1,14
CD002817,0,1,We considered the trials to be at a mixed risk of bias as the result of unreported allocation concealment and probable detection bias.,delete,[],0,0.14285714285714285,1,14
CD002817,0,2,"Compared with no intervention, physiotherapy significantly improved the gait outcomes of speed (mean difference 0.04 m/s, 95% confidence interval (CI) 0.02 to 0.06, P = 0.0002); two- or six-minute walk test (13.37 m, 95% CI 0.55 to 26.20, P = 0.04) and Freezing of Gait questionnaire (-1.41, 95% CI -2.63 to -0.19, P = 0.02); functional mobility and balance outcomes of Timed Up & Go test (-0.63 s, 95% CI -1.05 to -0.21, P = 0.003), Functional Reach Test (2.16 cm, 95% CI 0.89 to 3.43, P = 0.0008), and Berg Balance Scale (3.71 points, 95% CI 2.30 to 5.11, P < 0.00001); and clinician-rated disability using the Unified Parkinson’s Disease Rating Scale (UPDRS) (total -6.15 points, 95% CI-8.57 to -3.73, P < 0.00001; activities of daily living: -1.36, 95% CI -2.41 to -0.30, P = 0.01; and motor: -5.01, 95% CI -6.30 to -3.72, P < 0.00001).",rephrase,"['Mobility and balance also improved with a physiotherapy intervention, with significant improvements reported in one test of mobility (the Timed Up & Go test, which times how long it takes a person to get up from a chair, walk a certain distance, then walk back to the chair and sit down) and in two tests of balance (one assessing how far a person can reach before he or she loses balance (Functional Reach Test) and another assessing multiple aspects of balance (Berg Balance Scale)).']",0,0.21428571428571427,2,14
CD002817,0,3,"No difference between arms was noted in falls (Falls Efficacy Scale: -1.91 points, 95% CI -4.76 to 0.94, P = 0.19) or patient-rated quality of life (PDQ-39 Summary Index: -0.38 points, 95% CI -2.58 to 1.81, P = 0.73).",rephrase,['No difference was observed between the two groups in falls or patient-rated quality of life.'],1,0.2857142857142857,2,14
CD002817,0,4,One study reported that adverse events were rare; no other studies reported data on this outcome.,ignore,['One study reported that adverse events were rare; no other studies reported data on this outcome.'],2,0.35714285714285715,2,14
CD002817,0,5,Indirect comparisons of the different physiotherapy interventions revealed no evidence that the treatment effect differed across physiotherapy interventions for any of the outcomes assessed.,rephrase,"['When the different physiotherapy interventions were compared, no evidence suggested that treatment effect differed across the physiotherapy interventions for any of the outcomes assessed.']",3,0.42857142857142855,3,14
CD002817,1,6,"Benefit for physiotherapy was found in most outcomes over the short term (i.e. < 3 months) but was significant only for speed, two- or six-minute walk test, Freezing of Gait questionnaire, Timed Up & Go, Functional Reach Test, Berg Balance Scale, and clinician-rated UPDRS.",merge,[],4,0.5,3,14
CD002817,1,7,Most of the observed differences between treatments were small.,merge,"['Although most observed differences were small, improvements in walking speed, balance with the Berg Balance Scale, and clinician-rated disability using the UPDRS were of a size that patients may consider them to be important.']",4,0.5714285714285714,3,14
CD002817,1,8,"However, for some outcomes (e.g. speed, Berg Balance Scale, UPDRS), the differences observed were at, or approaching, what are considered minimal clinically important changes.",none,[],4,0.6428571428571429,4,14
CD002817,1,9,These benefits should be interpreted with caution because the quality of most of the included trials was not high.,rephrase,"['These benefits should be interpreted with caution because of the quality of the included trials, and the lack of common assessment of treatment effects.']",5,0.7142857142857143,4,14
CD002817,1,10,Variation in measurements of outcome between studies meant that our analyses include a small proportion of the participants recruited.,delete,[],6,0.7857142857142857,4,14
CD002817,2,11,This review illustrates that a wide range of approaches are employed by physiotherapists to treat patients with PD.,rephrase,['This review provides evidence of the short-term benefit of physiotherapy for the treatment of PD.'],6,0.8571428571428571,5,14
CD002817,2,12,"However, no evidence of differences in treatment effect was noted between the different types of physiotherapy interventions being used, although this was based on indirect comparisons.",delete,[],7,0.9285714285714286,5,14
CD002817,2,13,"A consensus menu of 'best practice' physiotherapy is needed, as are large, well-designed randomised controlled trials undertaken to demonstrate the longer-term efficacy and cost-effectiveness of 'best practice' physiotherapy in PD.",delete,[],7,1.0,5,14
CD003533,0,0,A total of three studies involving 466 participants were included.,rephrase,['This review aimed to explore this question and included three studies with a total of 466 participants.'],0,0.16666666666666666,1,6
CD003533,0,1,"There was no statistically significant difference between the asthma clinic group and the control group for most outcomes (primary outcomes: asthma exacerbations leading to hospitalisation or accident and emergency (A&E) visit, use of reliever and preventer medication, quality of life; secondary outcomes: symptoms, time lost from work and withdrawals from the intervention or usual care).",rephrase,"['These studies did not find any overall difference between asthma clinic and usual clinical practice care by a general practitioner for the following outcomes: A&E department visits for asthma, use of reliever or preventer medication for asthma and quality of life measures, but there was considerable uncertainty about these results.']",1,0.3333333333333333,2,6
CD003533,0,2,"However, the confidence intervals were wide for all outcomes and there was substantial heterogeneity between the studies for both A&E visits and time lost from work.",delete,[],2,0.5,3,6
CD003533,0,3,One study (101 patients) looked at nocturnal awakenings due to asthma and found a statistically significant reduction in the number of patients reporting this symptom in the asthma clinic group compared to the usual care group (OR 0.31; 95% CI 0.12 to 0.77).,rephrase,['One study found that there was a reduction in nocturnal awakening due to asthma in the asthma clinic group compared to control but no difference in other symptom outcomes reported.'],2,0.6666666666666666,4,6
CD003533,0,4,There were no studies looking at the secondary outcome of exacerbations requiring oral steroids.,delete,[],3,0.8333333333333334,5,6
CD003533,1,5,"There is limited evidence of efficacy for primary care based asthma clinics, and firm conclusions cannot be formed until more good quality trials have been carried out.",rephrase,"['Given the limited evidence found in this review, we believe that there is a need for further evidence in order to assess the effectiveness of asthma clinics.']",3,1.0,5,6
CD012026,0,0,"We identified 120 studies (21,149 participants) which aimed to improve health literacy.",rephrase,"['We found 120 studies enrolling 21,149 patients.']",0,0.06666666666666667,1,15
CD012026,0,1,There were 107 RCTs and 13 non-randomised studies.,delete,[],1,0.13333333333333333,1,15
CD012026,0,2,No studies targeted low literacy populations.,delete,[],1,0.2,1,15
CD012026,0,3,"For the RCTs, selection bias was low or unclear in 94% of studies, performance bias was high in 86% of studies, detection bias was high in 86% of studies reporting subjective outcomes and low in 93% of studies reporting objective outcomes.",delete,[],1,0.26666666666666666,2,15
CD012026,0,4,"Attrition and other biases were low or unclear in 86% and 78% of studies, respectively.",delete,[],1,0.3333333333333333,2,15
CD012026,1,5,"Compared to usual care, low certainty evidence showed educational interventions may increase kidney-related knowledge (14 RCTs, 2632 participants: SMD 0.99, 95% CI 0.69 to 1.32; I² = 94%).",merge,"['Compared to usual care, educational interventions may increase kidney-related knowledge; however, information on self-care, self-efficacy, quality of life (QoL), death, kidney function, and hospitalisations could not be analysed or was not reported.']",1,0.4,2,15
CD012026,1,6,"Data for self-care, self-efficacy, quality of life (QoL), death, estimated glomerular filtration rate (eGFR) and hospitalisations could not be pooled or was not reported.",none,[],1,0.4666666666666667,3,15
CD012026,2,7,"Compared to usual care, low-certainty evidence showed self-management interventions may improve self-efficacy (5 RCTs, 417 participants: SMD 0.58, 95% CI 0.13 to 1.03; I² = 74%) and QoL physical component score (3 RCTs, 131 participants: MD 4.02, 95% CI 1.09 to 6.94; I² = 0%).",merge,['Self-management interventions may improve self-efficacy and one aspect of QoL (physical component score) but probably did not slow the decline in kidney function after one year.'],2,0.5333333333333333,3,15
CD012026,2,8,"There was moderate-certainty evidence that self-management interventions probably did not slow the decline in eGFR after one year (3 RCTs, 855 participants: MD 1.53 mL/min/1.73 m², 95% CI -1.41 to 4.46; I² = 33%).",none,[],2,0.6,3,15
CD012026,2,9,"Data for knowledge, self-care behaviour, death and hospitalisations could not be pooled or was not reported.",rephrase,"['Information on knowledge, self-care behaviour, death and hospitalisations could not be analysed or was not reported.']",3,0.6666666666666666,4,15
CD012026,3,10,"Compared to usual care, low-certainty evidence showed educational with self-management interventions may increase knowledge (15 RCTs, 2185 participants: SMD 0.65, 95% CI 0.36 to 0.93; I² = 90%), improve self-care behaviour scores (4 RCTs, 913 participants: SMD 0.91, 95% CI 0.00 to 1.82; I² =97%), self-efficacy (8 RCTs, 687 participants: SMD 0.50, 95% CI 0.10 to 0.89; I² = 82%), improve QoL physical component score (3 RCTs, 2771 participants: MD 2.56, 95% CI 1.73 to 3.38; I² = 0%) and may make little or no difference to slowing the decline of eGFR (4 RCTs, 618 participants: MD 4.28 mL/min/1.73 m², 95% CI -0.03 to 8.85; I² = 43%).",merge,"['Educational with self-management interventions may increase knowledge, improve self-care behaviour scores, self-efficacy, one aspect of QoL (physical component score), and probably decreases the risk of death, but may make little or no difference to slowing the decline in kidney function.']",4,0.7333333333333333,4,15
CD012026,3,11,"Moderate-certainty evidence shows educational with self-management interventions probably decreases the risk of death (any cause) (4 RCTs, 2801 participants: RR 0.73, 95% CI 0.53 to 1.02; I² = 0%).",none,[],4,0.8,4,15
CD012026,3,12,Data for hospitalisation could not be pooled.,rephrase,['Data for hospitalisation could not be analysed.'],5,0.8666666666666667,5,15
CD012026,4,13,"Interventions to improve aspects of health literacy are a very broad category, including educational interventions, self-management interventions and educational with self-management interventions.",ignore,"['Interventions to improve aspects of health literacy are a very broad category, including educational interventions, self-management interventions and educational with self-management interventions.']",6,0.9333333333333333,5,15
CD012026,4,14,"Overall, this type of health literacy intervention is probably beneficial in this cohort however, due to methodological limitations and high heterogeneity in interventions and outcomes, the evidence is of low certainty.",rephrase,"['Overall, this type of health literacy intervention is probably beneficial to patients with CKD however, due to limitations with the study methods and high variability in the interventions and outcomes make it difficult to give any recommendations.']",7,1.0,5,15
CD000280,0,0,"One unblinded, quasi-randomised controlled trial (RCT) assessing effects of carbohydrate supplementation of human milk in the form of a prebiotic in 75 preterm infants was eligible for inclusion in this review.",rephrase,['We found one trial involving 75 preterm infants with very low-quality evidence on the effects of adding extra prebiotics (a type of carbohydrate) to human milk in preterm infants.'],0,0.09090909090909091,1,11
CD000280,0,1,"We identified two publications of the same trial, which reported different methods regarding blinding and randomisation.",rephrase,['A second publication by the same study authors reported different methods regarding blinding and randomisation of the trial.'],1,0.18181818181818182,1,11
CD000280,0,2,"Study authors confirmed that these publications pertain to the same trial, but they have not yet clarified which method is correct.",rephrase,['Study authors confirmed that these publications describe the same trial but have not yet clarified which method is accurate.'],2,0.2727272727272727,2,11
CD000280,0,3,"Our analyses showed very low certainty evidence of an effect of carbohydrate supplementation on weight by 30 days of age age (MD 160.4 grams, 95% CI 12.4 to 308.4 grams), and no effect on risk of feeding intolerance (RR 0.64, 95% CI 0.36 to 1.15) or necrotising enterocolitis (NEC) (RR 0.2, 95% CI 0.02 to 1.3).",rephrase,['No evidence shows a clear difference in risk of feeding intolerance or necrotising enterocolitis between the prebiotic-supplemented and unsupplemented groups.'],3,0.36363636363636365,2,11
CD000280,0,4,Duration of hospital stay was shorter in the prebiotic group than in the control group (median difference 9 days).,rephrase,['Prebiotic carbohydrate supplementation increased the mean weight of preterm infants at day 30 and resulted in a shorter hospital stay compared with control.'],4,0.45454545454545453,3,11
CD000280,0,5,No data were available for assessing effects of carbohydrate supplementation on long-term growth and neurodevelopment.,rephrase,"['No other data were available to show the effects of adding extra carbohydrate to human milk on short- and long-term growth, body fat, obesity, brain development, and heart problems.']",5,0.5454545454545454,3,11
CD000280,1,6,We are uncertain whether carbohydrate supplementation of human milk affects any outcomes in preterm infants.,rephrase,['Evidence on the short- and long-term effects of adding extra carbohydrate to human milk in preterm infants is lacking.'],6,0.6363636363636364,4,11
CD000280,1,7,"The only trial included in this review presented very low-quality evidence, and study authors provided uncertain information about study methods and analysis.",rephrase,"['This systematic review found very low-quality evidence on the effects of adding prebiotic carbohydrate to human milk in preterm infants, along with uncertainties about methods and analysis.']",7,0.7272727272727273,4,11
CD000280,1,8,The evidence may be limited in its applicability because researchers included a small sample of preterm infants from a single centre.,rephrase,"['The single trial included a small sample of Iranian preterm infants, and so the evidence may be considered as not generalisable.']",8,0.8181818181818182,5,11
CD000280,1,9,Future trials could assess the safety and efficacy of different types and concentrations of carbohydrate supplementation for preterm infants fed human milk.,split,"['However, the outcomes assessed are common to all preterm infants, and the trial shows that adding prebiotic carbohydrate to human milk is possible in developing countries.', 'Further research is needed to assess the benefits and harms of different types and concentrations of carbohydrate supplementation for preterm infants fed human milk.']",9,0.9090909090909091,5,11
CD000280,1,10,"However, we do not envisage that further trials of digestible carbohydrates will be conducted, as this is currently done as a component of multi-nutrient human milk fortification.",rephrase,"['Currently, digestible carbohydrate supplementation in preterm infants is provided as a component of multi-nutrient human milk fortification.']",11,1.0,5,11
CD007884,0,0,We identified three eligible trials.,rephrase,['We performed a search in March 2014 and found three relevant randomised trials.'],0,0.08333333333333333,1,12
CD007884,0,1,Two trials compared endoscopic intervention with surgical intervention and included a total of 111 participants: 55 in the endoscopic group and 56 in the surgical group.,rephrase,"['Two comparing endoscopic versus surgical interventions (111 patients with durations of two and three years), while the third compared surgery to conservative treatment (i.e. no intervention) (32 patients with a duration of 16 months).']",1,0.16666666666666666,1,12
CD007884,0,2,"Compared with the endoscopic group, the surgical group had a higher proportion of participants with pain relief, both at middle/long-term follow-up (two to five years: risk ratio (RR) 1.62, 95% confidence interval (CI) 1.22 to 2.15) and long-term follow-up (≥ five years, RR 1.56, 95% CI 1.18 to 2.05).",rephrase,['We found that surgery achieved pain relief in a higher proportion of participants than endoscopy.'],2,0.25,2,12
CD007884,0,3,"Surgical intervention resulted in improved quality of life and improved preservation of exocrine pancreatic function at middle/long-term follow-up (two to five years), but not at long-term follow-up (≥ 5 years).",rephrase,"['Surgery also had other advantages like improved quality of life for the first two years after intervention, although this difference disappeared with time.']",3,0.3333333333333333,2,12
CD007884,0,4,"No differences were found in terms of major post-interventional complications or mortality, although the number of participants did not allow for this to be reliably evaluated.",rephrase,['The studies seemingly showed no difference between endoscopy and surgery in complications after interventions.'],4,0.4166666666666667,3,12
CD007884,0,5,"One trial, including 32 participants, compared surgical intervention with conservative treatment: 17 in the surgical group and 15 in the conservative group.",rephrase,['We also compared surgery with conservative treatment.'],5,0.5,3,12
CD007884,0,6,The trial showed that surgical intervention resulted in a higher percentage of participants with pain relief and better preservation of pancreatic function.,rephrase,['The results of one trial suggested that surgery early in the condition achieved better pain relief and preservation of pancreatic function.'],6,0.5833333333333334,3,12
CD007884,0,7,"The trial had methodological limitations, and the number of participants was relatively small.",delete,[],7,0.6666666666666666,4,12
CD007884,1,8,"For patients with obstructive chronic pancreatitis and dilated pancreatic duct, this review shows that surgery is superior to endoscopy in terms of pain relief.",rephrase,"['For endoscopy versus surgery, the quality of the evidence for pain relief, quality of life and pancreatic function was moderate (according to GRADE).']",7,0.75,4,12
CD007884,1,9,"Morbidity and mortality seem not to differ between the two intervention modalities, but the small trials identified do not provide sufficient power to detect the small differences expected in this outcome.",delete,[],8,0.8333333333333334,5,12
CD007884,2,10,"Regarding the comparison of surgical intervention versus conservative treatment, this review has shown that surgical intervention in an early stage of chronic pancreatitis is a promising approach in terms of pain relief and pancreatic function.",delete,[],8,0.9166666666666666,5,12
CD007884,2,11,Other trials need to confirm these results because of the methodological limitations and limited number of participants assessed in the present evidence.,delete,[],8,1.0,5,12
CD006740,0,0,"Two studies, enrolling 97 participants, met our inclusion criteria.",delete,[],0,0.07692307692307693,1,13
CD006740,0,1,"The studies differed significantly in terms of study populations, natural history of AKI (multifactorial AKI in patients with native kidneys versus delayed graft function associated with acute tubular necrosis in transplant recipients), and study interventions; hence, data were not meta-analysed.",rephrase,['These differences meant that we were unable to statistically evaluate (meta-analyse) study data.'],0,0.15384615384615385,1,13
CD006740,0,2,"One study reported a significant increase in the risk of all-cause mortality associated with thyroid hormone interventions compared with placebo (59 participants, RR 3.32, 95% CI 1.21 to 9.12); no deaths were reported in the other study.",rephrase,['We found that risk of death from any cause was much higher among people with AKI who received thyroid hormone therapy compared with those who received placebo in one study; no deaths were reported in the second study.'],1,0.23076923076923078,2,13
CD006740,0,3,Both studies reported no significant difference in the need for RRT associated with thyroid hormone therapy when compared to placebo.,split,"[""Thyroid hormone therapy was found to be no better or worse than placebo in changing patients' needs for kidney dialysis or transplant."", 'People with AKI who received thyroid hormone therapy needed dialysis for longer than those who received placebo in one study, but no differences in AKI and dialysis durations were noted in the other.', 'Lengths of stay in intensive care units and hospital were similar in both those who received thyroid hormone therapy and placebo in one study; but not reported in the other study.']",2,0.3076923076923077,2,13
CD006740,0,4,Neither study reported incidence of progression to ESKD.,rephrase,['Neither study reported if any participants progressed to end-stage kidney disease.'],5,0.38461538461538464,2,13
CD006740,0,5,"There was a significantly longer duration of AKI (MD 2.00 days, 95% CI 0.18 to 3.82) and RRT (5.00 days, 95% CI 2.05 to 7.95) associated with thyroid hormone therapy compared with placebo in one study; no differences in durations of AKI (MD 2.00 days, 95% CI -3.53 to 7.53) and RRT (MD 2.00 days, 95% CI -2.36 to 6.36) were noted in the other study.",delete,[],6,0.46153846153846156,3,13
CD006740,0,6,"One study reported similar lengths of stay in the intensive care unit and hospital in both intervention and control arms (MD -0.20 days, 95% CI -8.17 to 7.77); the other did not report this outcome.",delete,[],6,0.5384615384615384,3,13
CD006740,0,7,No adverse events were noted to be associated with thyroid hormone therapy in either study.,delete,[],6,0.6153846153846154,4,13
CD006740,0,8,Adequate data were not available to assess changes in kidney function or numbers of RRT sessions.,rephrase,"['We had planned to analyse changes in kidney function and numbers of dialysis sessions, but data reporting was insufficient to make assessments.']",6,0.6923076923076923,4,13
CD006740,0,9,Both included studies were small and methodological quality was suboptimal.,rephrase,"['The included studies were few in number, small in size, and low in methodological quality.']",7,0.7692307692307693,4,13
CD006740,1,10,"We found a paucity of large, high quality studies to inform analysis of thyroid hormone interventions for the treatment of people with AKI.",rephrase,['We searched the medical literature to investigate the benefits and harms of thyroid hormone therapy for adults with AKI of any cause who were in hospital and found two studies that involved 97 people.'],8,0.8461538461538461,5,13
CD006740,1,11,"Current evidence suggested that thyroid hormone therapy may be associated with worse outcomes for patients with established AKI; therefore, its use for these patients should be avoided.",merge,"['The available evidence suggested that use of thyroid hormone therapy was associated with worse outcomes in patients with established AKI, and therefore, use of these therapies should be avoided for these people.']",9,0.9230769230769231,5,13
CD006740,1,12,The role of thyroid hormone therapy in preventing AKI has not been adequately investigated and may be considered in future clinical studies.,none,[],9,1.0,5,13
CD007396,0,0,"We included 70 studies that compared an opioid with placebo or no treatment, another opioid administered intramuscularly or intravenously or compared with TENS applied to the back.",split,"['We included 70 studies though only 61 studies involving more than 8000 women contributed data to the review.', 'The trials compared an opioid (intramuscular or intravenous) with placebo (dummy treatment), no treatment, another opioid (or in three trials another medication or inhaled nitrous oxide) or transcutaneous electrical nerve stimulation (TENS) in 34 different comparisons.']",0,0.05263157894736842,1,19
CD007396,0,1,Sixty-one studies involving more than 8000 women contributed data to the review and these studies reported on 34 different comparisons; for many comparisons and outcomes only one study contributed data.,delete,[],2,0.10526315789473684,1,19
CD007396,0,2,"All of the studies were conducted in hospital settings, on healthy women with uncomplicated pregnancies at 37 to 42 weeks' gestation.",ignore,"[""All of the trials were conducted in hospital settings, on healthy women with uncomplicated pregnancies at 37 to 42 weeks' gestation.""]",2,0.15789473684210525,1,19
CD007396,0,3,We excluded studies focusing on women with pre-eclampsia or pre-existing conditions or with a compromised fetus.,delete,[],3,0.21052631578947367,2,19
CD007396,0,4,"Overall, the evidence was graded as low- or very low-quality regarding the analgesic effect of opioids and satisfaction with analgesia; evidence was downgraded because of study design limitations, and many of the studies were underpowered to detect differences between groups and so effect estimates were imprecise.",rephrase,['The quality of the evidence was mainly assessed as low or very low for the outcomes of pain in labour and satisfaction with analgesia.'],3,0.2631578947368421,2,19
CD007396,0,5,"Due to the large number of different comparisons, it was not possible to present GRADE findings for every comparison.",delete,[],4,0.3157894736842105,2,19
CD007396,1,6,"For the comparison of intramuscular pethidine (50 mg/100 mg) versus placebo, no clear differences were found in maternal satisfaction with analgesia measured during labour (number of women satisfied or very satisfied after 30 minutes: 50 women; 1 trial; risk ratio (RR) 7.00, 95% confidence interval (CI) 0.38 to 128.87, very low-quality evidence), or number of women requesting an epidural (50 women; 1 trial; RR 0.50, 95% CI 0.14 to 1.78; very low-quality evidence).",delete,[],4,0.3684210526315789,2,19
CD007396,1,7,"Pain scores (reduction in visual analogue scale (VAS) score of at least 40 mm: 50 women; 1 trial; RR 25, 95% CI 1.56 to 400, low-quality evidence) and pain measured in labour (women reporting pain relief to be ""good"" or ""fair"" within one hour of administration: 116 women; 1 trial; RR 1.75, 95% CI 1.24 to 2.47, low-quality evidence) were both reduced in the pethidine group, and fewer women requested any additional analgesia (50 women; 1 trial; RR 0.71, 95% CI 0.54 to 0.94, low-quality evidence).",delete,[],4,0.42105263157894735,3,19
CD007396,2,8,There was limited information on adverse effects and harm to women and babies.,delete,[],4,0.47368421052631576,3,19
CD007396,2,9,There were few results that clearly showed that one opioid was more effective than another.,delete,[],4,0.5263157894736842,3,19
CD007396,2,10,"Overall, findings indicated that parenteral opioids provided some pain relief and moderate satisfaction with analgesia in labour.",rephrase,"['Overall, our findings indicate that opioids provided some pain relief during labour, although substantial proportions of women still reported moderate or severe pain.']",4,0.5789473684210527,3,19
CD007396,2,11,"Opioid drugs were associated with maternal nausea, vomiting and drowsiness, although different opioid drugs were associated with different adverse effects.",rephrase,"['Opioid drugs were associated with nausea, vomiting and drowsiness, with different types of opioids causing different side effects.']",5,0.631578947368421,4,19
CD007396,2,12,There was no clear evidence of adverse effects of opioids on the newborn.,rephrase,['Nor did we find clear evidence of adverse effects of opioids on the newborn.'],6,0.6842105263157895,4,19
CD007396,2,13,We did not have sufficient evidence to assess which opioid drug provided the best pain relief with the least adverse effects.,split,"['We did not have sufficient evidence to assess which opioid drug provided the best pain relief with the least adverse effects.', 'We did not have sufficient evidence to assess which opioid drugs women were most satisfied with.']",7,0.7368421052631579,4,19
CD007396,3,14,"Though most evidence is of low- or very-low quality, for healthy women with an uncomplicated pregnancy who are giving birth at 37 to 42 weeks, parenteral opioids appear to provide some relief from pain in labour but are associated with drowsiness, nausea, and vomiting in the woman.",delete,[],9,0.7894736842105263,4,19
CD007396,3,15,Effects on the newborn are unclear.,delete,[],9,0.8421052631578947,5,19
CD007396,3,16,Maternal satisfaction with opioid analgesia was largely unreported.,rephrase,['Maternal satisfaction with opioid analgesia appeared moderate although it was often unreported or reported in different ways.'],9,0.8947368421052632,5,19
CD007396,3,17,The review needs to be examined alongside related Cochrane reviews.,ignore,['The review needs to be examined alongside related Cochrane reviews.'],10,0.9473684210526315,5,19
CD007396,3,18,"More research is needed to determine which analgesic intervention is most effective, and provides greatest satisfaction to women with acceptable adverse effects for mothers and their newborn.",rephrase,['As injected opioid drugs are so widely used it is important that more research is carried out so that women can make informed choices about pain relief.'],11,1.0,5,19
CD006867,0,0,"From the three small (total n=250) short included studies, we were unable to extract any data on many broad clinically important outcomes such as global state, use of services, and satisfaction with treatment.",delete,[],0,0.1111111111111111,1,9
CD006867,0,1,"When Ayurvedic herbs were compared with placebo, about 20% of people left the studies early (n=120, 2 RCTs, RR 0.77 CI 0.37 to 1.62).",rephrase,['When the ayurvedic herbs brahmyadiyoga and tagara were compared to placebo (2 trials) there was no significant difference between the two groups in acceptability of treatment or overall improvement.'],0,0.2222222222222222,2,9
CD006867,0,2,"Mental state ratings were mostly equivocal with the exception of the brahmyadiyoga group using Ayurvedic assessment (n=68, 1 RCT, RR not improved 0.56 CI 0.36 to 0.88, NNT 4 CI 3 to 12).",rephrase,"['The brahmyadiyoga group did, however, show some improvement when assessed ayurvedically (a combination of assessing aspects of the mind, decision, orientation, memory and habit, and looking for the absence of symptoms of illness).']",1,0.3333333333333333,2,9
CD006867,0,3,"Behaviour seemed unchanged (n=43, 1 RCT, WMD Fergus Falls Behaviour Rating 1.14 CI -1.63 to 3.91).",delete,[],2,0.4444444444444444,3,9
CD006867,0,4,"Nausea and vomiting were common in the brahmyadiyoga group (n=43, RR 13.13 CI 0.80 to 216.30).",rephrase,"['Brahmyadiyoga and tagara tended to have vomiting and nausea as an adverse effect, while chlorpromazine caused people to be sleepy.']",2,0.5555555555555556,3,9
CD006867,0,5,"When the Ayurvedic herbs were compared with antipsychotic drugs (chlorpromazine), again, equal numbers left the study early (n=120, 2 RCTs, RR for brahmyadiyoga 0.91 CI 0.42 to 1.97) but people allocated herbs were at greater risk of no improvement in mental state compared to those allocated chlorpromazine (n=45, RR 1.82 CI 1.11 to 2.98).",rephrase,"['When these two herbs were compared to groups of people taking the antipsychotic, chlorpromazine, again there was no difference in acceptability of treatment, but in one of the two trials there was an improvement in mental state in those taking chlorpromazine.']",3,0.6666666666666666,4,9
CD006867,0,6,"Again, nausea and vomiting were found with use of brahmyadiyoga (n=45, 1 RCT, RR 20.45 CI 1.09 to 383.97, NNH 2 CI 2 to 38).",delete,[],4,0.7777777777777778,4,9
CD006867,0,7,"Finally, when Ayurvedic treatment, in this case a complex mixture of many herbs, is compared with chlorpromazine in acutely ill people with schizophrenia, it is equally (˜10% attrition, n=36, RR 0.67 CI 0.13 to 3.53), but skewed data does seem to favour the chlorpromazine group.",delete,[],4,0.8888888888888888,5,9
CD006867,1,8,"Ayurvedic medication may have some effects for treatment of schizophrenia, but has been evaluated only in a few small pioneering trials.",split,"['This review examines randomised controlled trials which compare aspects of ayurvedic medicine with the use of antipsychotics for people with schizophrenia.', 'It may be possible that ayurvedic treatments could be used as adjuncts to antipsychotic medication.']",4,1.0,5,9
CD009957,0,0,"Of the 370 records that we identified as a result of the search (excluding duplicates), we regarded six abstracts and titles as potentially relevant studies.",delete,[],0,0.1,1,10
CD009957,0,1,"Of these six studies, three met the inclusion criteria involving 708 participants; most trials were at moderate or high risk of bias (risk mainly due to lack of blinding and high rate of incomplete data).",rephrase,['The three included studies involved 708 participants who had undergone excisional treatment to the cervix (known as laser or large loop excision of transformation zone (LLETZ) or loop electrosurgical excision procedure (LEEP)).'],0,0.2,1,10
CD009957,0,2,We did not identify any ongoing trials.,split,"['We searched the literature to May 2016 and found three published randomised trials that met the review inclusion criteria.', 'We did not identify any ongoing trials.']",1,0.3,2,10
CD009957,0,3,"Although all included studies had been published in peer-reviewed journals at the time of the search and data extraction, numerical data regarding the outcome measured in one trial involving 77 participants were insufficient for inclusion in a meta-analyses.",delete,[],3,0.4,2,10
CD009957,1,4,"The difference in the rates of prolonged vaginal discharge or presumed cervicitis (one study; 348 participants; risk ratio (RR), 1.29; 95% confidence interval (CI) 0.72 to 2.31; low-quality evidence) and severe vaginal bleeding (two studies; 638 participants; RR 1.21; 95% CI 0.52 to 2.82; very low-quality evidence) among the two comparison groups did not reach the level for clinically important effect.",delete,[],3,0.5,3,10
CD009957,1,5,"In addition, there was no difference in adverse events related to antibiotics i.e. nausea/vomiting, diarrhoea, and headache among the two comparison groups (two studies; 638 participants; RR 1.69; 95% CI 0.85 to 3.34; very low-quality evidence).",rephrase,"['The quality of the evidence regarding prophylactic antibiotics for preventing severe vaginal bleeding, fever, and adverse events was very low, with evidence from other comparisons being of low quality.']",3,0.6,3,10
CD009957,1,6,"There were no differences in the incidence of fever (RR, 2.23; 95% CI 0.20 to 24.36), lower abdominal pain (RR, 1.03; 95% CI 0.61 to 1.72), unscheduled medical consultation (RR 2.68, 95% CI 0.97 to 7.41), and additional self-medication (RR 1.22; 95% CI 0.56 to 2.67) between the two comparison groups (one study; 290 participants; low to very low-quality evidence).",rephrase,"['We found that there was no benefit to prophylactic antibiotics after LLETZ to reduce or prevent prolonged vaginal discharge, severe vaginal bleeding, fever, lower abdominal pain, unscheduled medical consultation, and additional self-medication.']",4,0.7,4,10
CD009957,2,7,"As only limited data are available from three trials with overall moderate to high risk of bias, there is insufficient evidence to support use of antibiotics to reduce infectious complications following excision of the cervical transformation zone.",rephrase,['The limited evidence available does not support routinely giving antibiotics for infection prevention after LLETZ.'],5,0.8,4,10
CD009957,2,8,"In addition, there were minimal data about antibiotic-related adverse events and no information on the risk of developing antibiotic resistance.",rephrase,['There was little information on antibiotic-related adverse effects.'],6,0.9,5,10
CD009957,2,9,"Antibiotics given for infection prevention after excision of the cervical transformation zone should only be used in the context of clinical research, to avoid unnecessary prescription of antibiotics and to prevent further increases in antibiotic resistance.",rephrase,"['As there are growing concerns with antibiotic resistance, antibiotics for infection prevention after excision of the cervical transformation zones should only be used in the context of clinical trials.']",7,1.0,5,10
CD006870,0,0,"Eighteen studies (14,303 patients) compared early statin treatment versus placebo or no treatment in patients with ACS.",rephrase,"['This review is an update of a review previously published in 2011 that included 18 studies, enrolling 14,303 patients.']",0,0.1,1,10
CD006870,0,1,The new search did not identify any new studies for inclusion.,rephrase,['The update of this review did not identify any new studies for inclusion.'],1,0.2,1,10
CD006870,0,2,There were some concerns about risk of bias and imprecision of summary estimates.,rephrase,['We had some concerns about risk of bias and imprecision of the results.'],2,0.3,2,10
CD006870,0,3,"Based on moderate quality evidence, early statin therapy did not decrease the combined primary outcome of death, non-fatal myocardial infarction, and stroke at one month (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.80 to 1.08) or four months (RR 0.93, 95% CI 0.81 to 1.06) of follow-up when compared to placebo or no treatment.",delete,[],3,0.4,2,10
CD006870,0,4,"There were no statistically significant risk reductions from statins for total death, total myocardial infarction, total stroke, cardiovascular death, revascularization procedures, and acute heart failure at one month or at four months, although there were favorable trends related to statin use for each of these endpoints.",rephrase,"['We did not find a significant risk reduction for all-cause mortality, heart attack, or stroke within the first four months.']",3,0.5,3,10
CD006870,0,5,"Moderate quality evidence suggests that the incidence of unstable angina was significantly reduced at four months following ACS (RR 0.76, 95% CI 0.59 to 0.96).",rephrase,['The risk of unstable angina was reduced by about 25% at four months following acute coronary syndrome.'],4,0.6,3,10
CD006870,0,6,There were nine individuals with myopathy (elevated creatinine kinase levels more than 10 times the upper limit of normal) in statin-treated patients (0.13%) versus one (0.015%) in the control groups.,delete,[],5,0.7,4,10
CD006870,0,7,Serious muscle toxicity was mostly limited to patients treated with simvastatin 80 mg.,rephrase,"['Serious side effects from early treatment with statins were rare (0.1%), and serious muscle toxicity was mostly observed with simvastatin 80 mg.']",5,0.8,4,10
CD006870,1,8,"Based on moderate quality evidence, due to concerns about risk of bias and imprecision, initiation of statin therapy within 14 days following ACS does not reduce death, myocardial infarction, or stroke up to four months, but reduces the occurrence of unstable angina at four months following ACS.",delete,[],6,0.9,5,10
CD006870,1,9,Serious side effects were rare.,delete,[],6,1.0,5,10
CD003687,0,0,"Of the two relevant studies that were identified in the literature, only one RCT met the inclusion criteria.",rephrase,"['A review of randomized (RCT) and controlled clinical trials (CCT), case-control and cohort studies of the use of ES in RA only identified two RCTs, only one of which met the criteria for retention.']",0,0.125,1,8
CD003687,0,1,"This RCT compared the effects of two electrostimulation (ES) protocols on hand function in general and on the performance of the first dorsal interosseous muscle in particular, in 15 patients with RA and secondary disuse atrophy of the first dorsal interosseous of the dominant hand.",rephrase,"['The results of this one RCT, involving 15 patients with RA affecting the hand, showed significant results that favoured the use of patterned ES derived from a fatigued motor unit from the first dorsal interosseous in a normal hand for all outcome measures: grip strength, pinch strength, and muscle function and endurance.']",1,0.25,2,8
CD003687,0,2,The results showed that ES had significant benefit when compared to a control no treatment group in terms of muscle strength and fatigue resistance of the first dorsal interosseous.,delete,[],2,0.375,2,8
CD003687,0,3,Most favourable results were obtained by using a patterned stimulation derived from a fatigued motor unit of the first dorsal interosseous in a normal hand rather than a fixed 10 Hz stimulation frequency.,rephrase,"['Electrical stimulation whether delivered at a fixed frequency of 10 Hz or at patterned frequency, had significant benefit when compared to a no treatment control group on two outcome measures: pinch strength and muscle endurance.']",2,0.5,3,8
CD003687,0,4,Side effects of the ES application were not reported.,delete,[],3,0.625,4,8
CD003687,1,5,ES was shown to have a clinically beneficial effect on grip strength and fatigue resistance for RA patients with muscle atrophy of the hand.,delete,[],3,0.75,4,8
CD003687,1,6,"However, these conclusions are limited by the low methodological quality of the trial included.",rephrase,['These conclusions however are limited by poor reporting of the characteristics of application of the ES and the poor methodological quality of the trial.'],3,0.875,5,8
CD003687,1,7,More well-designed studies are therefore needed to provide further evidence of the benefits of ES in the management of RA.,rephrase,['The reviewers therefore conclude that there is no clear evidence for the inclusion of ES in the management of RA at this time.'],4,1.0,5,8
CD010973,0,0,"This review included 16 studies with a total of 1024 participants aged between five and 18 years, all of whom were recruited from paediatric outpatient clinics.",split,"['The studies included a total of 1024 children aged between five and 18 years.', 'All children were recruited from outpatient clinics.']",0,0.09090909090909091,1,11
CD010973,0,1,"Studies were conducted in seven countries: seven in the USA, four in Iran, and one each in the UK, Switzerland, Turkey, Sri Lanka, and India.",rephrase,"['The trials were carried out in seven countries: seven in the USA, four in Iran, one in the UK, one in Switzerland, one in Turkey, one in Sri Lanka, and one in India.']",2,0.18181818181818182,1,11
CD010973,0,2,Follow-up ranged from two weeks to four months.,rephrase,['Follow-up lasted between two weeks and four months.'],3,0.2727272727272727,2,11
CD010973,0,3,"The studies examined the following interventions to treat RAP: tricyclic antidepressants, antibiotics, 5-HT4 receptor agonists, antispasmodics, antihistamines, H2 receptor antagonists, serotonin antagonists, selective serotonin re-uptake inhibitors, a dopamine receptor antagonist, and a hormone.",rephrase,"['We found 16 studies that met our criteria, examining antidepressants, antibiotics, antihistamines, antispasmodics, a dopamine receptor antagonist, and a hormone treatment.']",4,0.36363636363636365,2,11
CD010973,0,4,"Although some single studies reported that treatments were effective, all of these studies were either small or had key methodological weaknesses with a substantial risk of bias.",rephrase,"['Many of the studies had some weaknesses in their design and how they were reported, therefore the overall quality of the evidence for medications in RAP is low.']",5,0.45454545454545453,3,11
CD010973,0,5,None of these 'positive' results have been reproduced in subsequent studies.,rephrase,['The studies with better methods included few children and have not been reproduced by other researchers since.'],6,0.5454545454545454,3,11
CD010973,0,6,We judged the evidence of effectiveness to be of low quality.,delete,[],7,0.6363636363636364,4,11
CD010973,0,7,No adverse effects were reported in these studies.,delete,[],7,0.7272727272727273,4,11
CD010973,1,8,There is currently no convincing evidence to support the use of drugs to treat RAP in children.,delete,[],7,0.8181818181818182,5,11
CD010973,1,9,Well-conducted clinical trials are needed to evaluate any possible benefits and risks of pharmacological interventions.,delete,[],7,0.9090909090909091,5,11
CD010973,1,10,"In practice, if a clinician chooses to use a drug as a 'therapeutic trial', they and the patient need to be aware that RAP is a fluctuating condition and any 'response' may reflect the natural history of the condition or a placebo effect, rather than drug efficacy.",delete,[],7,1.0,5,11
CD013808,0,0,"Two trials, involving 377 women, met the inclusion criteria for this review.",rephrase,['We searched for evidence on 18 October 2022 and identified two eligible studies (involving 377 women).'],0,0.041666666666666664,1,24
CD013808,0,1,"Both trials were conducted in hospital settings and included women with singleton, term (37+0 weeks or more) pregnancies, a cephalic presentation, and abnormal CTG.",rephrase,['Both studies were conducted in hospitals and recruited women in labour at term with a single baby presenting head first.'],1,0.08333333333333333,1,24
CD013808,0,2,Follow-up was until hospital discharge after the birth.,delete,[],2,0.125,1,24
CD013808,0,3,A pilot trial of 50 women in a high-income country (Ireland) compared CTG and digital fetal scalp stimulation (dFSS) with CTG and fetal blood sampling (FBS).,rephrase,['A pilot study of 50 women in Ireland compared digital fetal scalp stimulation (dFSS) and CTG with fetal blood sampling (FBS) and CTG.'],2,0.16666666666666666,1,24
CD013808,0,4,A single-centre trial of 327 women in a lower middle-income country (India) compared CTG and manual fetal stimulation (abdominal or vaginal scalp stimulation) with CTG alone.,rephrase,['A study in India of 327 women compared manual fetal scalp stimulation (FSS) (abdominal side to side movement of the fetal head or vaginal pinching of the fetal scalp) and CTG with CTG alone.'],3,0.20833333333333334,2,24
CD013808,0,5,The two included studies were at moderate or unclear risk of bias.,rephrase,"['Overall, the included studies were at moderate or unclear risk of bias, and the certainty of the generated evidence was very low or unclear.']",4,0.25,2,24
CD013808,0,6,Both trials provided clear information on allocation concealment but it was not possible to blind participants or health professionals in relation to the intervention.,delete,[],5,0.2916666666666667,2,24
CD013808,0,7,"Although objective outcome measures were reported, outcome assessment was not blinded or blinding was unclear.",delete,[],5,0.3333333333333333,2,24
CD013808,1,8,"dFSS and CTG versus FBS and CTG
There were no perinatal deaths and data were not reported for neurodevelopmental disability at >/= 12 months.",rephrase,['dFSS and CTG versus FBS and CTG\nThere were no perinatal deaths and no data reported on disability in the babies at or after 12 months.'],5,0.375,2,24
CD013808,1,9,"The risk of caesarean section (CS) may be lower with dFSS compared to FBS (risk ratio (RR) 0.38, 95% confidence interval (CI) 0.16 to 0.92; 1 pilot trial, 50 women; very low-certainty evidence) but the evidence is very uncertain.",rephrase,"[""We found very low-certainty evidence that stimulation of the baby's scalp in addition to CTG may lower the risk of caesarean section compared to scalp blood sampling and CTG (1 pilot trial; 50 women).""]",6,0.4166666666666667,3,24
CD013808,1,10,There were no cases of neonatal encephalopathy reported.,delete,[],7,0.4583333333333333,3,24
CD013808,1,11,"The evidence was also very uncertain between dFSS and FBS for assisted vaginal birth (RR 1.44, 95% CI 0.76 to 2.75; very low-certainty evidence) and for the spontaneous vaginal birth rate (RR 2.33, 95% CI 0.68 to 8.01, very low-certainty evidence).",delete,[],7,0.5,3,24
CD013808,1,12,Maternal acceptability of the procedures was not reported.,rephrase,['The acceptability of the procedures to the mother was not reported.'],7,0.5416666666666666,3,24
CD013808,2,13,"FSS and CTG versus CTG alone
Manual stimulation of the fetus was performed either abdominally (92/164) or vaginally (72/164).",merge,[],8,0.5833333333333334,3,24
CD013808,2,14,There were no perinatal deaths and data were not reported for neurodevelopmental disability at >/= 12 months.,none,['FSS and CTG versus CTG alone\nThere were no perinatal deaths and no data reported on disability in the babies at or after 12 months.'],8,0.625,4,24
CD013808,2,15,"There may be little differences in the risk of CS on comparing manual fetal stimulation and CTG with CTG alone (RR 0.83, 95% CI 0.59 to 1.18; 1 trial, 327 women; very low-certainty evidence), but again the evidence was very uncertain.",rephrase,"[""We found that stimulation of the baby's scalp in addition to CTG had little or no difference in the risk of caesarean section compared to CTG alone (1 trial; 327 women).""]",9,0.6666666666666666,4,24
CD013808,2,16,There were no cases of neonatal encephalopathy reported.,delete,[],10,0.7083333333333334,4,24
CD013808,2,17,"There may be no differences in the risk of assisted vaginal birth (RR 1.43, 95% CI 0.78 to 2.60; very low-certainty evidence) or in the rates of spontaneous vaginal birth (RR 1.01, 95% CI 0.85 to 1.21, very low-certainty evidence), but again the evidence is very uncertain.",rephrase,"['There was no difference in the risk of assisted vaginal birth by vacuum or forceps, or in the rate of spontaneous vaginal birth.']",10,0.75,4,24
CD013808,2,18,Maternal acceptability of abdominal stimulation/FSS was not reported although 13 women withdrew consent after randomisation due to concerns about fetal well-being.,rephrase,['The acceptability of the procedures to the mother was not reported.'],11,0.7916666666666666,4,24
CD013808,3,19,There is very low-certainty evidence available which makes it unclear whether stimulating the fetal scalp is a safe and effective way to confirm fetal well-being in labour.,rephrase,"[""The evidence is unclear whether stimulating a baby's scalp in labour is a safe and effective way to confirm the baby's well-being in labour.""]",12,0.8333333333333334,5,24
CD013808,3,20,Evidence was downgraded based on limitations in study design and imprecision.,delete,[],13,0.875,5,24
CD013808,3,21,Further high-quality studies of adequate sample size are required to evaluate this research question.,rephrase,"['Further high-quality studies of adequate sample size, including a broad range of settings and eligibility criteria, are required to evaluate this research question.']",13,0.9166666666666666,5,24
CD013808,3,22,"In order to be generalisable, these trials should be conducted in different settings, including broad clinical criteria at both preterm and term gestational ages, and standardising the method of stimulation.",delete,[],14,0.9583333333333334,5,24
CD013808,3,23,There is an ongoing study (FIRSST) that will be incorporated into this review in a subsequent update.,delete,[],14,1.0,5,24
CD009853,0,0,"Two cluster-RCTs, with data from 503 dental practices, representing 821 dentists and 4771 patients, met the selection criteria.",rephrase,"['Our review identified two studies examining the effects of different methods of remuneration on the behaviour of 821 dentists from 503 dental practices, involving 4771 patients.']",0,0.07692307692307693,1,13
CD009853,0,1,"We judged the risk of bias to be high for both studies and the overall quality of the evidence was low/very low for all outcomes, as assessed using the GRADE approach.",delete,[],1,0.15384615384615385,1,13
CD009853,1,2,One study used a factorial design to investigate the impact of fee-for-service and an educational intervention on the placement of fissure sealants in permanent molar teeth.,rephrase,['One study investigated the impact of a fee-for-service payment and an educational intervention on the placement of fissure sealants in permanent molar teeth.'],1,0.23076923076923078,2,13
CD009853,1,3,The authors reported a statistically significant increase in clinical activity in the arm that was incentivised with a fee-for-service payment.,delete,[],2,0.3076923076923077,2,13
CD009853,1,4,"However, the study was conducted in the four most deprived areas of Scotland, so the applicability of the findings to other settings may be limited.",delete,[],2,0.38461538461538464,2,13
CD009853,1,5,The study did not report data on measures of health service utilisation or measures of patient outcomes.,delete,[],2,0.46153846153846156,3,13
CD009853,2,6,The second study used a parallel group design undertaken over a three-year period to compare the impact of capitation payments with fee-for-service payments on primary care dentists’ clinical activity.,rephrase,['The second study compared the impact of capitation payments and fee-for-service payments on primary care dentists’ clinical activity and the levels of dental decay that were experienced across the two payment systems.'],2,0.5384615384615384,3,13
CD009853,2,7,"The study reported on measures of clinical activity (mean percentage of children receiving active preventive advice, health service utilisation (mean number of visits), patient outcomes (mean number of filled teeth, mean percentage of children having one or more teeth extracted and the mean number of decayed teeth) and healthcare costs (mean expenditure).",delete,[],3,0.6153846153846154,4,13
CD009853,2,8,"Teeth were restored at a later stage in the disease process in the capitation system and the clinicians tended to see their patients less frequently and tended to carry out fewer fillings and extractions, but also tended to give more preventive advice.",split,"['In the second study, dentists working under capitation arrangements restored carious teeth at a later stage in the disease process than fee-for-service controls.', 'In the capitation arm, the dentists tended to see their patients less frequently and tended to carry out fewer fillings and extractions, but tended to give more preventive advice.']",3,0.6923076923076923,4,13
CD009853,3,9,There was insufficient information regarding the cost-effectiveness of the different remuneration methods.,ignore,['There was insufficient information regarding cost-effectiveness of the different remuneration methods.'],5,0.7692307692307693,4,13
CD009853,4,10,Financial incentives within remuneration systems may produce changes to clinical activity undertaken by primary care dentists.,ignore,['Financial incentives within remuneration systems may produce changes to clinical activity undertaken by primary care dentists.'],6,0.8461538461538461,5,13
CD009853,4,11,"However, the number of included studies is limited and the quality of the evidence from the two included studies was low/very low for all outcomes.",rephrase,"['However, the number of included studies is limited and the quality of the evidence is low/very low for all outcomes.']",7,0.9230769230769231,5,13
CD009853,4,12,"Further experimental research in this area is highly recommended given the potential impact of financial incentives on clinical activity, and particular attention should be paid to the impact this has on patient outcomes.",delete,[],8,1.0,5,13
CD005512,0,0,We included five studies that evaluated three comparisons.,rephrase,['We identified five relevant studies.'],0,0.047619047619047616,1,21
CD005512,0,1,"Four studies compared crowns with fillings; two of them compared conventional PMCs with open sandwich restorations, and two compared PMCs fitted using the Hall Technique with fillings.",split,"['Four studies compared crowns with fillings.', 'Two of them compared metal crowns fitted using the conventional method with fillings and two compared metal crowns fitted using the Hall Technique with fillings.']",1,0.09523809523809523,1,21
CD005512,0,2,"One of these studies included a third arm, which allowed the comparison of PMCs (fitted using the Hall Technique) versus non-restorative caries treatment.",rephrase,"[""One of the studies also compared the Hall Technique with 'non-restorative caries treatment' (not using either a filling or crown but opening the cavity to make it possible to clean with a toothbrush, sealing with fluoride varnish and encouraging toothbrushing).""]",3,0.14285714285714285,1,21
CD005512,0,3,"In the two studies using crowns fitted using the conventional method, all teeth had undergone pulpotomy prior to the crown being placed.",delete,[],4,0.19047619047619047,1,21
CD005512,0,4,The final study compared two different types of crowns: PMCs versus aesthetic stainless steel crowns with white veneers.,rephrase,['The final study compared crowns made of two different materials (stainless steel versus stainless steel with a white covering).'],4,0.23809523809523808,2,21
CD005512,0,5,No RCT evidence was found that compared different methods of fitting preformed metal crowns (i.e. Hall Technique versus conventional technique).,delete,[],5,0.2857142857142857,2,21
CD005512,1,6,"We considered outcomes reported at the dental appointment or within 24 hours of it, and in the short term (less than 12 months) or long term (12 months or more).",rephrase,"['We looked at what happened for each treatment at the time of the dental appointment or within 24 hours of treatment, in the short term (less than 12 months) and long term (12 months to 48 months).']",5,0.3333333333333333,2,21
CD005512,1,7,"Some of our outcomes of interest were not measured in the studies: time to restoration failure or retreatment, patient satisfaction and costs.",ignore,"['Some of our outcomes of interest were not measured in any of the studies: these included time to restoration failure or retreatment, patient satisfaction and costs.']",6,0.38095238095238093,2,21
CD005512,2,8,"Crowns versus fillings
All studies in this comparison used PMCs.",delete,[],7,0.42857142857142855,3,21
CD005512,2,9,One study reported outcomes in the short term and found no reports of major failure or pain in either group.,delete,[],7,0.47619047619047616,3,21
CD005512,2,10,"There was moderate quality evidence that the risk of major failure was lower in the crowns group in the long term (risk ratio (RR) 0.18, 95% confidence interval (CI) 0.06 to 0.56; 346 teeth in three studies, one conventional and two using Hall Technique).",merge,[],7,0.5238095238095238,3,21
CD005512,2,11,"Similarly, there was moderate quality evidence that the risk of pain was lower in the long term for the crown group (RR 0.15, 95% CI 0.04 to 0.67; 312 teeth in two studies).",none,['There is moderate quality evidence that crowns are more effective than fillings for managing decay in primary molar teeth.'],7,0.5714285714285714,3,21
CD005512,3,12,"Discomfort associated with the procedure was lower for crowns fitted using the Hall Technique than for fillings (RR 0.56, 95% CI 0.36 to 0.87; 381 teeth) (moderate quality evidence).",rephrase,['There is moderate quality evidence that crowns fitted using the Hall Technique are less likely to cause abscesses and pain than fillings.'],8,0.6190476190476191,4,21
CD005512,4,13,"It is uncertain whether there is a clinically important difference in the risk of gingival bleeding when using crowns rather than fillings, either in the short term (RR 1.69, 95% CI 0.61 to 4.66; 226 teeth) or long term (RR 1.74, 95% CI 0.99 to 3.06; 195 teeth, two studies using PMCs with conventional technique at 12 months) (low quality evidence).",delete,[],9,0.6666666666666666,4,21
CD005512,5,14,"Crowns versus non-restorative caries treatment
Only one study compared PMCs (fitted with the Hall Technique) with non-restorative caries treatment; the evidence quality was very low and we are therefore we are uncertain about the estimates.",rephrase,"['The evidence comparing preformed crowns with non-restorative caries management, and comparing preformed metal crowns with preformed white crowns, is very low quality so we do not know which is better.']",9,0.7142857142857143,4,21
CD005512,6,15,"Metal crowns versus aesthetic crowns
One split-mouth study (11 participants) compared PMCs versus aesthetic crowns (stainless steel with white veneers).",delete,[],10,0.7619047619047619,4,21
CD005512,6,16,It provided very low quality evidence so no conclusions could be drawn.,delete,[],10,0.8095238095238095,5,21
CD005512,7,17,"Crowns placed on primary molar teeth with carious lesions, or following pulp treatment, are likely to reduce the risk of major failure or pain in the long term compared to fillings.",rephrase,"['Crowns placed on primary molar teeth with decay, or that have had pulp treatment, are likely to reduce the risk of major failure or pain in the long term compared to fillings.']",10,0.8571428571428571,5,21
CD005512,7,18,Crowns fitted using the Hall Technique may reduce discomfort at the time of treatment compared to fillings.,ignore,['Crowns fitted using the Hall Technique may reduce discomfort at the time of treatment compared to fillings.'],11,0.9047619047619048,5,21
CD005512,7,19,"The amount and quality of evidence for crowns compared to non-restorative caries, and for metal compared with aesthetic crowns, is very low.",delete,[],12,0.9523809523809523,5,21
CD005512,7,20,There are no RCTs comparing crowns fitted conventionally versus using the Hall Technique.,delete,[],12,1.0,5,21
CD012258,0,0,No studies met the inclusion criteria for this review.,delete,[],0,0.1111111111111111,1,9
CD012258,0,1,We excluded one study and one other study is ongoing.,rephrase,['We excluded one study and one other study is not yet complete.'],0,0.2222222222222222,2,9
CD012258,1,2,"We set out to evaluate the RCT evidence pertaining to the impact of antenatal education on perineal wound healing in postnatal women who have birthed in a hospital setting, and who experienced a break in the skin of the perineum as a result of a tear or episiotomy, or both.",split,"['We cannot say whether or not antenatal education has an effect on perineal wound healing after childbirth among women who have birthed in a hospital setting.', 'More research is this area is needed to determine the impact of education delivered before childbirth on perineal wound healing in women who have birthed in a hospital setting.']",1,0.3333333333333333,2,9
CD012258,1,3,"However, no studies met the inclusion criteria.",delete,[],3,0.4444444444444444,3,9
CD012258,1,4,"There is a lack of evidence concerning whether or not antenatal education relating to perineal wound healing in this cohort of women will change the outcome for these women in relation to wound healing, infection rate, re-attendance or re-admission to hospital, pain, health-related quality of life, maternal bonding, and negative emotional experiences.",rephrase,"['Trials may also examine the outcome on related issues including infection rate, re-attendance or re-admission to hospital, pain, health-related quality of life, maternal bonding, and negative emotional experiences relating to a perineal wound.']",3,0.5555555555555556,3,9
CD012258,1,5,"Further study is warranted in this area given the significant physical, psychological and economic impact of perineal wounds, and the large proportion of childbearing women who have experienced a postnatal wound.",rephrase,"['A large proportion of childbearing women experience a perineal wound in childbirth, and these wounds are known to have a significant physical, psychological and economic impact.']",4,0.6666666666666666,4,9
CD012258,1,6,"The benefits of any future research in this field would be maximised by incorporating women in a range of socio-economic groups, and with a range of healthcare options.",merge,[],5,0.7777777777777778,4,9
CD012258,1,7,"This research could take both a qualitative and a quantitative approach and examine the outcomes identified in this review in order to assess fully the potential benefits of a tailored antenatal package, and to make recommendations for future practice.",merge,"['Future research could examine the potential benefits of a tailor-made education package to be delivered to this cohort of women, as there is currently no evidence to support this.']",5,0.8888888888888888,5,9
CD012258,1,8,There is currently no evidence to inform practice in this regard.,none,[],5,1.0,5,9
CD001446,0,0,"The review authors discovered no new trials in the new searches in June 2009, November 2011, or January 2016.",delete,[],0,0.1,1,10
CD001446,0,1,Six trials with 587 participants provided data for the primary outcome.,rephrase,"['Only six trials with altogether 587 participants gave information about the primary outcome measure for this review, which was change in a seven-point disability scale.']",0,0.2,1,10
CD001446,0,2,"According to moderate quality evidence, the disability grade change after four weeks in the corticosteroid groups was not significantly different from that in the control groups, mean difference (MD) 0.36 less improvement (95% confidence intervals (CI) 0.16 more to 0.88 less improvement).",delete,[],1,0.3,2,10
CD001446,0,3,"In four trials of oral corticosteroids with 120 participants in total, there was very low quality evidence of less improvement after four weeks with corticosteroids than without corticosteroids, MD 0.82 disability grades less improvement (95% CI 0.17 to 1.47 grades less).",rephrase,"['In four small trials of oral corticosteroids, with 120 participants, there was significantly less improvement after four weeks with corticosteroids than without corticosteroids but we considered the evidence quality very low.']",1,0.4,2,10
CD001446,0,4,"In two trials with a combined total of 467 participants, there was moderate quality evidence of no significant difference of a disability grade more improvement after four weeks with intravenous corticosteroids (MD 0.17, 95% CI -0.06 to 0.39).",rephrase,"['By contrast, according to moderate quality evidence, in two large trials of intravenous (injected into a vein) corticosteroids with a combined total of 467 participants, there was a slight improvement in disability after four weeks, but the results allowed for the possibility of no effect.']",2,0.5,3,10
CD001446,0,5,"According to moderate quality evidence, there was also no significant difference between the corticosteroid treated and control groups for improvement by one or more grades after four weeks (risk ratio (RR) 1.08, 95% CI 0.93 to 1.24) or for death or disability after one year (RR 1.51, 95% CI 0.91 to 2.5).",split,"['According to moderate quality evidence, when we pooled the results of the six trials with the necessary information there was no significant difference in change in disability grade after four weeks.', 'Also according to moderate quality evidence, there was no difference in the percentage of participants who died or were left disabled after one year.']",3,0.6,3,10
CD001446,0,6,"We found high quality evidence that the occurrence of diabetes was more common (RR 2.21, 95% CI 1.19 to 4.12) and hypertension less common (RR 0.15, 95% CI 0.05 to 0.41) in the corticosteroid-treated participants.",delete,[],5,0.7,4,10
CD001446,1,7,"According to moderate quality evidence, corticosteroids given alone do not significantly hasten recovery from GBS or affect the long-term outcome.",delete,[],5,0.8,4,10
CD001446,1,8,"According to very low quality evidence, oral corticosteroids delay recovery.",delete,[],5,0.9,5,10
CD001446,1,9,Diabetes requiring insulin was more common and hypertension less common with corticosteroids based on high quality evidence.,rephrase,['Corticosteroids were not associated with a significant increase in harm except that diabetes was significantly more common than with placebo or supportive treatment alone.'],5,1.0,5,10
CD007621,0,0,Three studies met the inclusion criteria.,rephrase,"['Among the pertinent literature, 3 studies met the inclusion criteria of methodological quality, comprising a total of 2223 participants.']",0,0.05,1,20
CD007621,0,1,"These included one placebo-controlled trial (942 patients) and two add-on placebo-controlled trials, i.e. one plus glatiramer acetate (110 patients) and the second plus interferon beta-1a (1171 patients).",delete,[],1,0.1,1,20
CD007621,1,2,"This review assessed the efficacy, tolerability and safety of NTZ in patients with RRMS.",merge,"['The Authors of this review evaluated the efficacy, tolerability and safety of NTZ in patients with RRMS.']",1,0.15,1,20
CD007621,1,3,"Data was conclusive with respect to efficacy and tolerability, but not safety.",merge,[],1,0.2,1,20
CD007621,1,4,"As far as efficacy is concerned, the results showed statistically significant evidence in favour of NTZ for all the primary outcomes and for the secondary ones where data was available.",none,[],1,0.25,2,20
CD007621,1,5,NTZ reduced the risk of experiencing at least one new exacerbation at 2 years by about 40% and of experiencing progression at 2 years by about 25% as compared to a control group.,delete,[],2,0.3,2,20
CD007621,1,6,MRI parameters showed statistical evidence in favour of participants receiving NTZ.,rephrase,['Also Magnetic Resonance scans show evidence of a beneficial effect of NTZ on disease activity.'],2,0.35,2,20
CD007621,1,7,"Infusion reactions, anxiety, sinus congestion, lower limb swelling, rigors, vaginitis and menstrual disorders were reported as adverse events (AEs) more frequently after NTZ treatment.",rephrase,"['Although information on adverse events (AEs) was limited, as\xa0most participants were followed up for 2 years only, infusion reactions, anxiety, sinus congestion, lower limb swelling, rigors, vaginal inflammation and menstrual disorders were found to be more frequent after NTZ treatment.']",3,0.4,2,20
CD007621,1,8,In this review NTZ was found to be well tolerated over a follow-up period of two years: the number of patients experiencing at least one AE (including severe and serious AEs) during this period did not differ between NTZ-treated patients and controls.,rephrase,"['However, the number of patients experiencing at least one AE (including severe or serious AEs) did not differ between NTZ and control groups.']",4,0.45,3,20
CD007621,1,9,Safety concerns have been raised about Progressive Multifocal Leukoencephalopathy (PML).,rephrase,"['On the contrary, significant safety concerns have been raised regarding Progressive Multifocal Leukoencephalopathy (PML), a rare and often fatal viral disease characterized by damage to the white matter of the brain.']",5,0.5,3,20
CD007621,1,10,"In the trials included in this review, two cases of PML were encountered: one in a patient who had received 29 doses of NTZ and a second fatal case of PML in another patient after 37 doses of NTZ.",rephrase,"['In the studies included in this review, PML was reported in 2 patients treated with NTZ for more than 2 years.']",6,0.55,3,20
CD007621,1,11,"Our protocol was insufficient to evaluate PML risk as well as other rare and long-term adverse events such as cancers and other opportunistic infections, which are very important issues in considering the risk/benefit ratio of NTZ.",rephrase,"['However, our protocol was insufficient to evaluate PML risk as well as other potential rare and long-term AEs (e.g. cancers and other infections) which are important issues in considering the risk/benefit ratio of NTZ.']",7,0.6,3,20
CD007621,2,12,"Although one trial did not contribute to efficacy results due to its duration, we found robust evidence in favour of a reduction in relapses and disability at 2 years in RRMS patients treated with NTZ.",delete,[],8,0.65,4,20
CD007621,2,13,The drug was well tolerated.,delete,[],8,0.7,4,20
CD007621,2,14,There are current significant safety concerns due to reporting of an increasing number of PML cases in patients treated with NTZ.,delete,[],8,0.75,4,20
CD007621,2,15,This review was unable to provide an up-to-date systematic assessment of the risk due to the maximum 2 year-duration of the trials included.,delete,[],8,0.8,4,20
CD007621,2,16,An independent systematic review of the safety profile of NTZ is warranted.,ignore,['An independent systematic review of the safety profile of NTZ is warranted.'],8,0.85,5,20
CD007621,2,17,NTZ should be used only by skilled neurologists in MS centres under surveillance programs.,ignore,['NTZ should be used only by skilled neurologists in MS centres under surveillance programs.'],9,0.9,5,20
CD007621,3,18,All the data in this review came from trials supported by the Pharmaceutical Industry.,ignore,['All the data in this review came from studies supported by the Pharmaceutical Industry.'],10,0.95,5,20
CD007621,3,19,"In agreement with the Cochrane Collaboration policy, this may be considered a potential source of bias.",ignore,"['In agreement with the Cochrane Collaboration policy, this may be considered a potential source of bias.']",11,1.0,5,20
CD002784,0,0,We identified no new studies for this update.,delete,[],0,0.0625,1,16
CD002784,0,1,We included five trials with a total of 1292 participants; agents used for thrombolysis were recombinant tissue plasminogen activator and urokinase.,split,"['Authors of the review identified five controlled trials with a total of 1292 participants who needed immediate care for reduced blood flow in the leg(s) (current until 7 May 2018).', 'The specific agents used to break up clots (thrombolytic agents) were called recombinant tissue plasminogen activator and urokinase.']",0,0.125,1,16
CD002784,0,2,Trials were generally of moderate methodological quality.,delete,[],2,0.1875,1,16
CD002784,0,3,"The quality of evidence according to GRADE was generally low owing to risk of bias (lack of blinding), imprecision in estimates, and heterogeneity.",delete,[],2,0.25,2,16
CD002784,1,4,"Trial results showed no clear differences in limb salvage, amputation, or death at 30 days (odds ratio (OR) 1.02, 95% confidence interval (CI) 0.41 to 2.55, 4 studies, 636 participants; OR 0.97, 95% CI 0.51 to 1.85, 3 studies, 616 participants; OR 0.59, 95% CI 0.31 to 1.14, 4 studies, 636 participants, respectively), and we rated the evidence as low, low, and moderate quality, respectively.",delete,[],2,0.3125,2,16
CD002784,1,5,Trial results show no clear differences for any of the three outcomes at six months or one year between initial surgery and initial thrombolysis.,rephrase,"['The included studies provided no clear evidence about which treatment - thrombolysis or surgery - was a better option for preventing limb amputation (limb salvage) and no clear evidence about which treatment was better for preventing death or improving amputation rates within one month, six months, or one year after initial treatment.']",2,0.375,2,16
CD002784,1,6,"A single study evaluated vessel patency, so no overall association could be determined (OR 0.46, 95% CI 0.08 to 2.76, 20 participants; very low-quality evidence).",delete,[],3,0.4375,3,16
CD002784,1,7,"Evidence of increased risk of major haemorrhage (OR 3.22, 95% CI 1.79 to 5.78, 4 studies, 1070 participants; low-quality evidence) and distal embolisation (OR 31.68, 95% CI 6.23 to 161.07, 3 studies, 678 participants; very low-quality evidence) was associated with thrombolysis treatment at 30 days, and there was no clear difference in stroke (OR 5.33, 95% CI 0.95 to 30.11, 5 studies, 1180 participants; low-quality evidence).",delete,[],3,0.5,3,16
CD002784,1,8,"Participants treated by initial thrombolysis had a greater reduction in the level of intervention required, compared with a pre-intervention prediction, at 30 days (OR 9.06, 95% CI 4.95 to 16.56, 2 studies, 502 participants).",rephrase,"['Although people receiving initial thrombolysis had increased risk of some complications, they showed greater reduction in the level of intervention required compared with that predicted before intervention.']",3,0.5625,3,16
CD002784,1,9,None of the included studies evaluated time to thrombolysis as an outcome.,rephrase,['None of the studies included in this review used methods to stop participants or researchers or outcome assessors from knowing what treatment they were assigned to.'],4,0.625,4,16
CD002784,2,10,"There is currently no evidence in favour of either initial thrombolysis or initial surgery as the preferred option in terms of limb salvage, amputation, or death at 30 days, six months, or one year.",rephrase,['This review found no evidence of a difference between thrombolysis and surgery for treatment of acute limb ischaemia for our outcomes of interest.'],5,0.6875,4,16
CD002784,2,11,Low-quality evidence suggests that thrombolysis may be associated with higher risk of haemorrhagic complications and ongoing limb ischaemia (distal embolisation).,rephrase,['Those receiving thrombolysis treatment may be at higher risk of complications such as bleeding.'],6,0.75,4,16
CD002784,2,12,The higher risk of complications must be balanced against risks of surgery in each individual case.,rephrase,['The higher risks of complications with thrombolysis have to be weighted against individual risks in surgery.'],7,0.8125,5,16
CD002784,2,13,"Trial results show no statistical difference in stroke, but the confidence interval is very wide, making it difficult to interpret whether this finding is clinically important.",delete,[],8,0.875,5,16
CD002784,2,14,We used GRADE criteria to assess the quality of the evidence as generally low.,rephrase,['The quality of the evidence was generally low.'],8,0.9375,5,16
CD002784,2,15,"We downgraded quality owing to risk of bias, imprecision, and heterogeneity between included studies.",rephrase,['We downgraded the quality owing to risk of bias.'],9,1.0,5,16
CD003842,0,0,We included one new trial involving 45 participants in this updated review.,delete,[],0,0.07142857142857142,1,14
CD003842,0,1,"In total we included 22 trials involving a total of 2193 participants who received regional anaesthesia for hand, wrist, forearm or elbow surgery.",rephrase,"['These trials involved a total of 2193 participants who were given regional anaesthesia for hand, wrist, forearm or elbow surgery.']",0,0.14285714285714285,1,14
CD003842,0,2,'Risk of bias' assessment indicated that trial design and conduct were generally adequate; the most common areas of weakness were in blinding and allocation concealment.,rephrase,['The trials used methods that were generally adequate and did not affect the validity of the findings.'],1,0.21428571428571427,2,14
CD003842,1,3,"Nine trials comparing double versus single injections showed a statistically significant decrease in primary anaesthesia failure (risk ratio (RR) 0.55, 95% confidence interval (CI) 0.34 to 0.89, high-quality evidence).",rephrase,['Nine trials compared double versus single injections.'],2,0.2857142857142857,2,14
CD003842,1,4,Subgroup analysis by method of nerve location showed that the effect size was greater when neurostimulation was used rather than the transarterial technique.,delete,[],3,0.35714285714285715,2,14
CD003842,2,5,"Nine trials comparing multiple with single injections showed a statistically significant decrease in primary anaesthesia failure (RR 0.25, 95% CI 0.14 to 0.42, high-quality evidence).",rephrase,"['In the nine trials comparing multiple with single injections, and the 12 trials comparing multiple with double injections, there were significant reductions in the chance of needing additional anaesthesia in the multiple-injection groups (75% and 73% reductions when compared to single and double injections respectively).']",3,0.42857142857142855,3,14
CD003842,2,6,"Pooled data from five trials also showed a significant decrease in incomplete motor block (RR 0.61, 95% CI 0.39 to 0.96, high-quality evidence) in the multiple-injection group.",delete,[],4,0.5,3,14
CD003842,3,7,"Twelve trials comparing multiple versus double injections showed a statistically significant decrease in primary anaesthesia failure (RR 0.27, 95% CI 0.19 to 0.39, high-quality evidence).",delete,[],4,0.5714285714285714,3,14
CD003842,3,8,"Pooled data from six trials also showed a significant decrease in incomplete motor block (RR 0.55, 95% CI 0.36 to 0.85, high-quality evidence) in the multiple injection group.",delete,[],4,0.6428571428571429,4,14
CD003842,4,9,"Tourniquet pain was significantly reduced with multiple injections compared with double injections (RR 0.53, 95% CI 0.33 to 0.84, high-quality evidence).",delete,[],4,0.7142857142857143,4,14
CD003842,4,10,"Otherwise there were no statistically significant differences between groups in any of the three comparisons on secondary analgesia failure, complications and patient discomfort.",rephrase,['There were no other statistically significant differences in complications or patient discomfort between the two groups for any of the three comparisons.'],4,0.7857142857142857,4,14
CD003842,4,11,"Compared with multiple injections, the time for block performance was significantly shorter for single injection (MD 3.33 minutes, 95% CI 2.76 to 3.90) and double injections (MD 1.54 minutes, 95% CI 0.80 to 2.29); however there was no difference in time to readiness for surgery.",rephrase,"['Single and double injections took less time to perform than multiple injections, but this did not reduce the total time required for adequate surgical anaesthesia to be established.']",5,0.8571428571428571,5,14
CD003842,5,12,This review provides evidence that multiple-injection techniques using nerve stimulation for axillary plexus block produce more effective anaesthesia than either double or single-injection techniques.,rephrase,"['Overall, there is high-quality evidence showing that multiple injections of anaesthetic close to three or four nerves in the armpit provide more complete anaesthesia for hand and forearm surgery than one or two injections.']",6,0.9285714285714286,5,14
CD003842,5,13,"However, there was insufficient evidence to draw any definitive conclusions regarding differences in other outcomes, including safety.",rephrase,"['There was, however, not enough evidence to determine if there was a significant difference in the other outcomes, including safety.']",7,1.0,5,14
CD009951,0,0,"In this update, we included seven trials with 1647 participants.",rephrase,['We searched for evidence from randomised controlled trials in March 2020 and identified seven studies with 1647 pregnant women comparing probiotics with inactive placebo (pretend treatment).'],0,0.043478260869565216,1,23
CD009951,0,1,"Two studies were in overweight and obese women, two in obese women and three did not exclude women based on their weight.",ignore,"['Two studies were in overweight and obese women, two in obese women\xa0and three did not exclude women based on their weight.']",1,0.08695652173913043,1,23
CD009951,0,2,All included studies compared probiotics with placebo.,delete,[],2,0.13043478260869565,1,23
CD009951,0,3,The included studies were at low risk of bias overall except for one study that had an unclear risk of bias.,rephrase,['The overall risk of bias was low\xa0except for one study where the risk of bias\xa0was unclear.'],2,0.17391304347826086,1,23
CD009951,0,4,"We excluded two studies, eight studies were ongoing and three studies are awaiting classification.",delete,[],3,0.21739130434782608,2,23
CD009951,1,5,Six included studies with 1440 participants evaluated the risk of GDM.,rephrase,"['GDMdue to the wide variation in the results of six studies\xa0(1440 women, low-quality evidence).']",3,0.2608695652173913,2,23
CD009951,1,6,"It is uncertain if probiotics have any effect on the risk of GDM compared to placebo (mean risk ratio (RR) 0.80, 95% confidence interval (CI) 0.54 to 1.20; 6 studies, 1440 women; low-certainty evidence).",delete,[],4,0.30434782608695654,2,23
CD009951,1,7,The evidence was low certainty due to substantial heterogeneity and wide CIs that included both appreciable benefit and appreciable harm.,delete,[],4,0.34782608695652173,2,23
CD009951,2,8,"Probiotics increase the risk of pre-eclampsia compared to placebo (RR 1.85, 95% CI 1.04 to 3.29; 4 studies, 955 women; high-certainty evidence) and may increase the risk of hypertensive disorders of pregnancy (RR 1.39, 95% CI 0.96 to 2.01, 4 studies, 955 women), although the CIs for hypertensive disorders of pregnancy also indicated probiotics may have no effect.",rephrase,"['Probiotics increase\xa0the risk of developingpre-eclampsia(4 studies, 955\xa0women;\xa0high-quality evidence).']",4,0.391304347826087,2,23
CD009951,3,9,There were few differences between groups for other primary outcomes.,delete,[],5,0.43478260869565216,3,23
CD009951,3,10,"Probiotics make little to no difference in the risk of caesarean section (RR 1.00, 95% CI 0.86 to 1.17; 6 studies, 1520 women; high-certainty evidence), and probably make little to no difference in maternalweight gain during pregnancy (MD 0.30 kg, 95% CI –0.67 to 1.26; 4 studies, 853 women; moderate-certainty evidence).",merge,"['Probiotics make little to no difference to\xa0the risk of needing acaesarean section(6 studies, 1520 women; high-quality evidence), and probably make little to no difference to weight gain during pregnancy (4 studies, 853 women; moderate-quality evidence) or to the risk of giving birth to abig baby(4 studies, 919 women; moderate-quality\xa0evidence).']",5,0.4782608695652174,3,23
CD009951,3,11,"Probiotics probably make little to no difference in the incidence of large-for-gestational age infants (RR 0.99, 95% CI 0.72 to 1.36; 4 studies, 919 infants; moderate-certainty evidence) and may make little to no difference in neonatal adiposity (2 studies, 320 infants; data not pooled; low-certainty evidence).",none,[],5,0.5217391304347826,3,23
CD009951,3,12,"One study reported adiposity as fat mass (MD –0.04 kg, 95% CI –0.12 to 0.04), and one study reported adiposity as percentage fat (MD –0.10%, 95% CI –1.19 to 0.99).",delete,[],6,0.5652173913043478,3,23
CD009951,3,13,"We do not know the effect of probiotics on perinatal mortality (RR 0.33, 95% CI 0.01 to 8.02; 3 studies, 709 infants; low-certainty evidence), a composite measure of neonatal morbidity (RR 0.69, 95% CI 0.36 to 1.35; 2 studies, 623 infants; low-certainty evidence), or neonatal hypoglycaemia (mean RR 1.15, 95% CI 0.69 to 1.92; 2 studies, 586 infants; low-certainty evidence).",rephrase,"['It is also uncertain how probiotics affectinfant death(either before birth or as a newborn)\xa0(3 studies, 709 infants; low-certainty evidence),low blood sugar(2 studies, 586 infants; low-certainty evidence) orbody fat(2 studies, 320 infants; low-certainty evidence).']",6,0.6086956521739131,4,23
CD009951,3,14,"No included studies reported on perineal trauma, postnatal depression, maternal and infant development of diabetes or neurosensory disability.",rephrase,"['None of the studies reported information about the risk of perineal trauma (tears duringvaginal birth or a surgical incision (episiotomy)), postnatal depression or developing subsequent diabetes.']",7,0.6521739130434783,4,23
CD009951,4,15,Low-certainty evidence from six trials has not clearly identified the effect of probiotics on the risk of GDM.,ignore,['Low-quality evidence from six trials has not clearly identified the effect of probiotics on the risk of GDM.'],8,0.6956521739130435,4,23
CD009951,4,16,"However, high-certainty evidence suggests there is an increased risk of pre-eclampsia with probiotic administration.",rephrase,"['However, high-quality evidence suggests that probiotics probably increase the risk of pre-eclampsia.']",9,0.7391304347826086,4,23
CD009951,4,17,There were no other clear differences between probiotics and placebo among the other primary outcomes.,delete,[],10,0.782608695652174,4,23
CD009951,4,18,"The certainty of evidence for this review's primary outcomes ranged from low to high, with downgrading due to concerns about substantial heterogeneity between studies, wide CIs and low event rates.",delete,[],10,0.8260869565217391,5,23
CD009951,5,19,"Given the risk of harm and little observed benefit, we urge caution in using probiotics during pregnancy.",rephrase,"['Therefore, there is currently evidence of possible harm with little observed benefit for widespread use of probiotics in pregnancy.']",10,0.8695652173913043,5,23
CD009951,6,20,The apparent effect of probiotics on pre-eclampsia warrants particular consideration.,delete,[],11,0.9130434782608695,5,23
CD009951,6,21,"Eight studies are currently ongoing, and we suggest that these studies take particular care in follow-up and examination of the effect on pre-eclampsia and hypertensive disorders of pregnancy.",rephrase,['There are eight studies currently ongoing that may help to provide more clarity on the effects of probiotics.'],11,0.9565217391304348,5,23
CD009951,6,22,"In addition, the underlying potential physiology of the relationship between probiotics and pre-eclampsia risk should be considered.",rephrase,['It is also important to explore the relationship between probiotics and pre-eclampsia further.'],12,1.0,5,23
CD010404,0,0,Four trials of HCV-related cryoglobulinemia fulfiled selection criteria and the review authors included three in quantitative synthesis.,rephrase,['All four trials in this review included participants with peripheral neuropathy and HCV-related cryoglobulinemia.'],0,0.1111111111111111,1,9
CD010404,0,1,All studies were at high risk of bias.,delete,[],1,0.2222222222222222,2,9
CD010404,0,2,No trial addressed the primary outcome of change in sensory impairment.,delete,[],1,0.3333333333333333,2,9
CD010404,0,3,"No trial addressed secondary outcomes of change in combined sensory and motor impairment, disability, or electrodiagnostic measures.",delete,[],1,0.4444444444444444,3,9
CD010404,0,4,"A single trial of HCV-related mixed cryoglobulinemia treated with pegylated interferon alfa (peginterferon alfa), ribavirin, and rituximab versus peginterferon alfa and ribavirin did not show a significant difference in the number of participants with improvement in neuropathy at 36 months post treatment (risk ratio (RR) 4.00, 95% confidence interval (CI) 0.27 to 59.31, n = 9).",rephrase,['One trial of HCV-related cryoglobulinemia treated with rituximab and antiviral therapy versus antiviral therapy alone did not demonstrate any significant difference in the number of participants with improvement in neuropathy at 36 months post treatment.'],1,0.5555555555555556,3,9
CD010404,0,5,One study of interferon alfa (n = 22) and two studies of rituximab (n = 61) provided adverse event data.,rephrase,['Two studies of rituximab (61 participants) and one of interferon alfa (22 participants) provided information on adverse events.'],2,0.6666666666666666,4,9
CD010404,0,6,"Severe adverse events were no more common with interferon alfa (RR 7.00, 95% CI 0.38 to 128.02) or rituximab (RR 3.00, 95% CI 0.13 to 67.06) compared to the control group.",rephrase,['Severe adverse events were no more common with interferon alfa or rituximab compared to the control group.'],3,0.7777777777777778,4,9
CD010404,1,7,There is a lack of RCTs and quasi-RCTs addressing the effects of interventions for peripheral neuropathy associated with HCV infection.,rephrase,['High-quality studies of HCV-related peripheral neuropathy treatment are lacking.'],4,0.8888888888888888,5,9
CD010404,1,8,"At present, there is insufficient evidence from RCTs and quasi-RCTs to make evidence-based decisions about treatment.",rephrase,['There is not enough evidence to make evidence-based decisions about treatment based on the results of this review.'],5,1.0,5,9
CD010683,0,0,We identified 67 randomised clinical trials involving a total of 6197 participants.,rephrase,['We identified 67 randomised clinical trials involving a total of 6197 participants that met our inclusion criteria.'],0,0.058823529411764705,1,17
CD010683,0,1,All the trials were at high risk of bias.,rephrase,"['All the trials were at high risk of bias, that is, investigators may have overestimated the benefits or underestimated the harms of one method or the other because of the way that the studies were conducted.']",1,0.11764705882352941,1,17
CD010683,0,2,A total of 5771 participants from 64 trials provided data for one or more outcomes included in this review.,rephrase,"['However, we were only able to include 5771 participants from 64 trials since investigators either did not include the remaining participants in the analysis or did not report any outcomes of interest.']",2,0.17647058823529413,1,17
CD010683,0,3,"There was no evidence of differences in most of the comparisons, and where there was, these differences were in single trials, mostly of small sample size.",ignore,"['There was no evidence of differences in most of the comparisons, and where there was, these differences were in single trials, mostly of small sample size.']",3,0.23529411764705882,2,17
CD010683,0,4,We summarise only the evidence that was available in more than one trial below.,rephrase,"['So, we mention only the evidence that was available in more than one trial.']",4,0.29411764705882354,2,17
CD010683,0,5,"Of the primary outcomes, the only one with evidence of a difference from more than one trial under the pair-wise comparison was in the number of adverse events (complications), which was higher with radiofrequency dissecting sealer than with the clamp-crush method (rate ratio 1.85, 95% CrI 1.07 to 3.26; 250 participants; 3 studies; very low-quality evidence).",rephrase,"['Of the primary outcomes, the only one where there was evidence of difference was in the number of adverse events, which was higher with radiofrequency dissecting sealer than with clamp-crush method.']",5,0.35294117647058826,2,17
CD010683,0,6,"Among the secondary outcomes, the only differences we found from more than one trial under the pair-wise comparison were the following: blood transfusion (proportion) was higher in the low central venous pressure group than in the acute normovolemic haemodilution plus low central venous pressure group (OR 3.19, 95% CrI 1.56 to 6.95; 208 participants; 2 studies; low-quality evidence); blood transfusion quantity (red blood cells) was lower in the fibrin sealant group than in the control (MD −0.53 units, 95% CrI −1.00 to −0.07; 122 participants; 2; very low-quality evidence); blood transfusion quantity (fresh frozen plasma) was higher in the oxidised cellulose group than in the fibrin sealant group (MD 0.53 units, 95% CrI 0.36 to 0.71; 80 participants; 2 studies; very low-quality evidence); blood loss (MD −0.34 L, 95% CrI −0.46 to −0.22; 237 participants; 4 studies; very low-quality evidence), total hospital stay (MD −2.42 days, 95% CrI −3.91 to −0.94; 197 participants; 3 studies; very low-quality evidence), and operating time (MD −15.32 minutes, 95% CrI −29.03 to −1.69; 192 participants; 4 studies; very low-quality evidence) were lower with low central venous pressure than with control.",rephrase,"['Among the secondary outcomes, the only evidence of difference was in the following:\nBlood transfusion (percentage): higher in the low central venous pressure group than in the acute normovolemic haemodilution (diluting the blood by giving fluids during operation) plus low central venous pressure group.']",6,0.4117647058823529,3,17
CD010683,0,7,"For the other comparisons, the evidence for difference was either based on single small trials or there was no evidence of differences.",ignore,"['For other comparisons, the evidence for difference was based on single small trials, or there was no evidence of differences.']",7,0.47058823529411764,3,17
CD010683,0,8,None of the trials reported health-related quality of life or time needed to return to work.,ignore,['None of the trials reported health-related quality of life or time needed to return to work.'],8,0.5294117647058824,3,17
CD010683,1,9,Paucity of data meant that we could not assess transitivity assumptions and inconsistency for most analyses.,delete,[],9,0.5882352941176471,3,17
CD010683,1,10,"When direct and indirect comparisons were available, network meta-analysis provided additional effect estimates for comparisons where there were no direct comparisons.",delete,[],9,0.6470588235294118,4,17
CD010683,1,11,"However, the paucity of data decreases the confidence in the results of the network meta-analysis.",delete,[],9,0.7058823529411765,4,17
CD010683,1,12,Low-quality evidence suggests that liver resection using a radiofrequency dissecting sealer may be associated with more adverse events than with the clamp-crush method.,delete,[],9,0.7647058823529411,4,17
CD010683,1,13,"Low-quality evidence also suggests that the proportion of people requiring a blood transfusion is higher with low central venous pressure than with acute normovolemic haemodilution plus low central venous pressure; very low-quality evidence suggests that blood transfusion quantity (red blood cells) was lower with fibrin sealant than control; blood transfusion quantity (fresh frozen plasma) was higher with oxidised cellulose than with fibrin sealant; and blood loss, total hospital stay, and operating time were lower with low central venous pressure than with control.",rephrase,"['Blood loss, total hospital stay, and operating time: lower with the low central venous pressure group than control.']",9,0.8235294117647058,5,17
CD010683,1,14,"There is no evidence to suggest that using special equipment for liver resection is of any benefit in decreasing the mortality, morbidity, or blood transfusion requirements (very low-quality evidence).",rephrase,['There is no evidence to suggest that using special equipment for liver resection is of any benefit.'],10,0.8823529411764706,5,17
CD010683,1,15,Radiofrequency dissecting sealer should not be used outside the clinical trial setting since there is low-quality evidence for increased harm without any evidence of benefits.,delete,[],11,0.9411764705882353,5,17
CD010683,1,16,"In addition, it should be noted that the sample size was small and the credible intervals were wide, and we cannot rule out considerable benefit or harm with a specific method of liver resection.",delete,[],11,1.0,5,17
CD003792,0,0,We included five studies involving 113 adults.,split,"['We found and included five studies in our review.', 'A total of 113 adults with asthma (46 male and 67 female) were included.']",0,0.07142857142857142,1,14
CD003792,0,1,Participants in four studies had mild to moderate asthma and the fifth study included participants independent of their asthma severity.,delete,[],2,0.14285714285714285,1,14
CD003792,0,2,"There were substantial differences between the studies, including the training protocol, duration of training sessions (10 to 30 minutes) and duration of the intervention (3 to 25 weeks).",ignore,"['There were substantial differences between the studies, including the training protocol, duration of training sessions (10 to 30 minutes) and duration of the intervention (over 3 to 25 weeks).']",2,0.21428571428571427,2,14
CD003792,0,3,Three clinical trials were produced by the same research group.,rephrase,"['Three studies were conducted by the same group of researchers in Israel (Weiner 2000; Weiner 2002; Weiner 2002a), one study (Sampaio 2002) was conducted in Brazil and one trial was conduced in the United Kingdom (McConnell 1998).']",3,0.2857142857142857,2,14
CD003792,0,4,Risk of bias in the included studies was difficult to ascertain accurately due to poor reporting of methods.,split,"['The methodological quality of the studies included in this update was difficult to accurately ascertain.', 'Study samples were small and the risk of bias was mostly unclear, due to inadequate reporting.']",4,0.35714285714285715,2,14
CD003792,1,5,"The included studies showed a statistically significant increase in inspiratory muscle strength, measured by maximal inspiratory pressure (PImax) (mean difference (MD) 13.34 cmH2O, 95% CI 4.70 to 21.98, 4 studies, 84 participants, low quality evidence).",rephrase,['The studies showed a significant improvement in inspiratory muscle strength (PImax).'],6,0.42857142857142855,3,14
CD003792,1,6,"Our other primary outcome, exacerbations requiring a course of oral or inhaled corticosteroids or emergency department visits, was not reported.",delete,[],7,0.5,3,14
CD003792,1,7,"For the secondary outcomes, results from one trial showed no statistically significant difference between the inspiratory muscle training group and the control group for maximal expiratory pressure, peak expiratory flow rate, forced expiratory volume in one second, forced vital capacity, sensation of dyspnoea and use of beta2-agonist.",rephrase,"['Results from one study showed no significant difference between the training group and the control group (no treatment or usual care) for expiratory muscle strength, lung function, sensation of dyspnoea (breathlessness) and use of reliever medication.']",7,0.5714285714285714,3,14
CD003792,1,8,"There were no studies describing inspiratory muscle endurance, hospital admissions or days off work or school.",rephrase,"['There were no studies describing exacerbation events that required use of reliever medication or emergency department visits, inspiratory muscle endurance, hospital admissions and days off work or school.']",8,0.6428571428571429,4,14
CD003792,2,9,There is no conclusive evidence in this review to support or refute inspiratory muscle training for asthma.,rephrase,"['Given the insufficient evidence found in this review, we believe that there is a need for more well conducted studies in order to assess the efficacy of IMT in people with asthma, including children.']",9,0.7142857142857143,4,14
CD003792,2,10,The evidence was limited by the small number of trials with few participants together with the risk of bias.,delete,[],10,0.7857142857142857,4,14
CD003792,2,11,More well conducted randomised controlled trials are needed.,delete,[],10,0.8571428571428571,5,14
CD003792,2,12,"Future trials should investigate the following outcomes: lung function, exacerbation rate, asthma symptoms, hospital admissions, use of medications and days off work or school.",delete,[],10,0.9285714285714286,5,14
CD003792,2,13,Inspiratory muscle training should also be assessed in people with more severe asthma and conducted in children with asthma.,delete,[],10,1.0,5,14
CD008962,0,0,Thirty-two trials (2281 participants) met our inclusion criteria.,rephrase,"['We included 32 trials (2281 participants), published up to November 2019.']",0,0.05,1,20
CD008962,0,1,"Most trials (25) included participants with rotator cuff disease and calcific deposits, five trials included participants with rotator cuff disease and no calcific deposits, and two trials included a mixed population of participants with and without calcific deposits.",delete,[],1,0.1,1,20
CD008962,1,2,"Twelve trials compared shock wave therapy to placebo, 11 trials compared high-dose shock wave therapy (0.2 mJ/mm² to 0.4 mJ/mm² and above) to low-dose shock wave therapy.",split,"['Twelve trials compared shock wave therapy to placebo.', 'Eleven trials compared high- and low-dose shock wave therapy, although dosages varied across trials.']",1,0.15,1,20
CD008962,1,3,"Single trials compared shock wave therapy to ultrasound-guided glucocorticoid needling, ultrasound-guided hyaluronic acid injection, transcutaneous electric nerve stimulation (TENS), no treatment or exercise; dual session shock wave therapy to single session therapy; and different delivery methods of shock wave therapy.",rephrase,"['Single trials compared shock wave therapy to other treatments including ultrasound-guided glucocorticoid needling, transcutaneous electric nerve stimulation (TENS), exercise, or no treatment; or different regimens of shock wave therapy.']",3,0.2,1,20
CD008962,1,4,Our main comparison was shock wave therapy versus placebo and results are reported for the 3 month follow up.,delete,[],4,0.25,2,20
CD008962,2,5,"All trials were susceptible to bias; including selection (74%), performance (62%), detection (62%), and selective reporting (45%) biases.",delete,[],4,0.3,2,20
CD008962,3,6,No trial measured participant-reported pain relief of 30%.,rephrase,['Participant-reported pain relief of 50% or greater (one trial):\n• four more people out of 100 reported pain relief of 50% or more (ranging from 19 fewer to 26 more).'],4,0.35,2,20
CD008962,3,7,"However, in one trial (74 participants), at 3 months follow up, 14/34 participants reported pain relief of 50% or greater with shock wave therapy compared with 15/40 with placebo (risk ratio (RR) 1.10, 95% confidence interval (CI) 0.62 to 1.94); low-quality evidence (downgraded for bias and imprecision).",rephrase,['42 out of 100 people reported pain relief of 50% or greater with shock wave therapy compared with 38 out of 100 with placebo.'],5,0.4,2,20
CD008962,3,8,"Mean pain (0 to 10 scale, higher scores indicate more pain) was 3.02 points in the placebo group and 0.78 points better (0.17 better to 1.4 better; clinically important change was 1.5 points) with shock wave therapy (9 trials, 608 participants), moderate-quality evidence (downgraded for bias).",rephrase,['Pain (higher scores mean more pain) (nine trials):\n• Improved pain by 8% (ranging from 2% better to 14% better) or 0.78 points better (ranging from 0.17 better to 1.4 better) on a 0- to 10-point scale.'],6,0.45,3,20
CD008962,3,9,"Mean function (scale 0 to 100, higher scores indicate better function) was 66 points with placebo and 7.9 points better (1.6 better to 14 better, clinically important difference 10 points) with shock wave therapy (9 trials, 612 participants), moderate-quality evidence (downgraded for bias).",rephrase,['People who had shock wave therapy rated their function as 74 points and people who had placebo rated their function as 66 points.'],7,0.5,3,20
CD008962,3,10,"Participant-reported success was reported by 58/150 people in shock wave therapy group compared with 35/137 people in placebo group (RR 1.59, 95% CI 0.87 to 2.91; 6 trials, 287 participants), low-quality evidence (downgraded for bias and imprecision).",rephrase,['Participant-reported success (six trials):\n• 15% (ranging from 3% fewer to 49% more) more people reported their treatment a success.'],8,0.55,3,20
CD008962,3,11,None of the trials measured quality of life.,delete,[],9,0.6,3,20
CD008962,4,12,"Withdrawal rate or adverse event rates may not differ between extracorporeal shock wave therapy and placebo, but we are uncertain due to the small number of events.",rephrase,['We are uncertain if withdrawals or side effects differed between groups due to small number of events.'],9,0.65,4,20
CD008962,4,13,"There were 11/34 withdrawals in the extracorporeal shock wave therapy group compared with 13/40 withdrawals in the placebo group (RR 0.75, 95% CI 0.43 to 1.31; 7 trials, 581 participants) low-quality evidence (downgraded for bias and imprecision); and 41/156 adverse events with extracorporeal shock wave therapy compared with 10/139 adverse events in the placebo group (RR 3.61, 95% CI 2.00 to 6.52; 5 trials, 295 participants) low-quality evidence (downgraded for bias and imprecision).",delete,[],10,0.7,4,20
CD008962,5,14,Subgroup analyses indicated that there were no between-group differences in pain and function outcomes in participants who did or did not have calcific deposits in the rotator cuff.,rephrase,['It did not appear to matter if participants had calcific deposits or not.'],10,0.75,4,20
CD008962,6,15,"Based upon the currently available low- to moderate-certainty evidence, there were very few clinically important benefits of shock wave therapy, and uncertainty regarding its safety.",rephrase,"['We are uncertain if higher doses of shock wave therapy have benefits with more side effects compared with lower doses, as there was only low- or very low-certainty evidence available, and we cannot recommend a particular treatment dose.']",11,0.8,4,20
CD008962,6,16,"Wide clinical diversity and varying treatment protocols means that we do not know whether or not some trials tested subtherapeutic doses, possibly underestimating any potential benefits.",delete,[],12,0.85,5,20
CD008962,7,17,Further trials of extracorporeal shock wave therapy for rotator cuff disease should be based upon a strong rationale and consideration of whether or not they would alter the conclusions of this review.,delete,[],12,0.9,5,20
CD008962,7,18,A standard dose and treatment protocol should be decided upon before further research is conducted.,delete,[],12,0.95,5,20
CD008962,7,19,Development of a core set of outcomes for trials of rotator cuff disease and other shoulder disorders would also facilitate our ability to synthesise the evidence.,delete,[],12,1.0,5,20
CD007507,0,0,"We included ten studies involving data from 944 adults, all male.",rephrase,"['We identified 10 relevant studies involving data from 944 adults, all male.']",0,0.05,1,20
CD007507,1,1,Five trials involved primarily cognitive behavioural interventions (CBT) (n = 664).,rephrase,['Five of the trials we found involved 664 men and used primarily cognitive behavioural interventions (CBT).'],1,0.1,1,20
CD007507,1,2,"Of these, four compared CBT with no treatment or wait list control, and one compared CBT with standard care.",delete,[],2,0.15,1,20
CD007507,1,3,Only one study collected data on the primary outcome.,split,"['Few of these studies provided information about the primary outcome of this review, which was reoffending.', 'This was usually because studies did not collect data for a sufficiently long period outside prison or the treatment setting.']",2,0.2,1,20
CD007507,1,4,The largest study (n = 484) involved the most complex intervention versus no treatment.,delete,[],4,0.25,2,20
CD007507,1,5,Long-term outcome data are reported for groups in which the mean years 'at risk' in the community are similar (8.3 years for treatment (n = 259) compared to 8.4 in the control group (n = 225)).,delete,[],4,0.3,2,20
CD007507,1,6,There was no difference between these groups in terms of the risk of reoffending as measured by reconviction for sexual offences (risk ratio (RR) 1.10; 95% CI 0.78 to 1.56).,delete,[],4,0.35,2,20
CD007507,2,7,Four trials (n = 70) compared one behavioural programme with an alternative behavioural programme or with wait list control.,rephrase,['Behavioural programmes were looked at in four trials involving 70 men.'],4,0.4,2,20
CD007507,2,8,No meta-analysis was possible for this comparison.,delete,[],5,0.45,3,20
CD007507,2,9,"For two studies (both cross-over, n = 29) no disaggregated data were available.",rephrase,"['For two studies, not enough data were reported to assess the effectiveness of treatment.']",5,0.5,3,20
CD007507,2,10,"The remaining two behavioural studies compared imaginal desensitisation with either covert sensitisation or as part of adjunctive drug therapy (n = 20 and 21, respectively).",delete,[],6,0.55,3,20
CD007507,2,11,"In these two studies, results for the primary outcome (being 'charged with anomalous behaviour') were encouraging, with only one new charge for the treated groups over one year in the former study, and in the latter study, only one new charge (in the drug-only group) over two years.",rephrase,"['For the remaining two, encouraging results with regards to reconvictions and self-reported urges have to be treated with caution as the studies are relatively old, meaning that many participants would not now seek or be offered treatment, as some of the targeted behaviours have been decriminalised.']",6,0.6,3,20
CD007507,3,12,One study compared psychodynamic intervention with probation.,merge,"['One study, involving 231 men, compared psychodynamic intervention with standard care, which was probation, and suggested that probation was mildly superior in terms of reducing reoffending.']",7,0.65,4,20
CD007507,3,13,Results for this study (n = 231) indicate a slight trend in favour of the control group (probation) over the intervention (group therapy) in terms of sexual offending as measured by rearrest (RR 1.87; 95% CI 0.78 to 4.47) at 10-year follow-up.,none,[],7,0.7,4,20
CD007507,4,14,"Data for adverse events, 'sexually anomalous urges' and for secondary outcomes thought to be 'dynamic' risk factors for reoffending, including anger and cognitive distortions, were limited.",ignore,"[""Data for adverse events, 'sexually anomalous urges' and for secondary outcomes thought to be 'dynamic' risk factors for reoffending, including anger and cognitive distortions, were limited.""]",8,0.75,4,20
CD007507,5,15,The inescapable conclusion of this review is the need for further randomised controlled trials.,merge,"['We concluded that further randomised controlled trials are urgently needed in this area, so that society is not lured into a false sense of security in the belief that once the individual has been treated, then their risk of reoffending is reduced.']",9,0.8,4,20
CD007507,5,16,"While we recognise that randomisation is considered by some to be unethical or politically unacceptable (both of which are based on the faulty premise that the experimental treatment is superior to the control – this being the point of the trial to begin with), without such evidence, the area will fail to progress.",merge,[],9,0.85,5,20
CD007507,5,17,"Not only could this result in the continued use of ineffective (and potentially harmful) interventions, but it also means that society is lured into a false sense of security in the belief that once the individual has been treated, their risk of reoffending is reduced.",none,[],9,0.9,5,20
CD007507,5,18,Current available evidence does not support this belief.,rephrase,"['Currently, the evidence does not support this belief.']",10,0.95,5,20
CD007507,5,19,"Future trials should concentrate on minimising risk of bias, maximising quality of reporting and including follow-up for a minimum of five years 'at risk' in the community.",delete,[],11,1.0,5,20
CD001394,0,0,"Three studies were identified that met the inclusion criteria (Peoples 1982; Robb 1986; Toseland 1997) incorporating data on a total of 116 patients (42 in experimental groups, and 74 in the control groups (usual care 43 and social contact 21, 10 in reality orientation).",rephrase,['Three studies were identified that met the inclusion criteria.'],0,0.1111111111111111,1,9
CD001394,0,1,"It was not possible to pool the data from the 3 included studies, either because of the different lengths of treatment or choice of different control treatments, or because the outcome measures were not comparable.",ignore,"['It was not possible to pool the data from the 3 included studies, either because of the different lengths of treatment or choice of different control treatments, or because the outcome measures were not comparable.']",1,0.2222222222222222,2,9
CD001394,1,2,"Two significant results were found: 
Peoples 1982 - Validation versus usual care.",delete,[],2,0.3333333333333333,2,9
CD001394,1,3,"Behaviour at 6 weeks [MD --5.97, 95% CI (-9.43 to -2.51) P=0.0007, completers analysis] favours validation therapy.",delete,[],2,0.4444444444444444,3,9
CD001394,2,4,Toseland 1997 - Validation versus social contact.,delete,[],2,0.5555555555555556,3,9
CD001394,2,5,"Depression at 12 months (MOSES) [MD -4.01, 95% CI (-7.74 to - 0.28) P=0.04, completers analysis] favours validation.",delete,[],2,0.6666666666666666,4,9
CD001394,2,6,There were no statistically significant differences between validation and social contact or between validation and usual therapy.,rephrase,['Two significant results were found but there were no statistically significant differences between validation and social contact or between validation and usual therapy.'],2,0.7777777777777778,4,9
CD001394,2,7,There were no assessments of carers.,ignore,['There were no assessments of carers.'],3,0.8888888888888888,5,9
CD001394,3,8,There is insufficient evidence from randomised trials to allow any conclusion about the efficacy of validation therapy for people with dementia or cognitive impairment.,ignore,['All in all there is insufficient evidence from randomised trials to allow any conclusion about the efficacy of validation therapy for people with dementia or cognitive impairment.'],4,1.0,5,9
CD010764,0,0,We only identified one trial that met the inclusion criteria but this trial did not have any results so we could not perform the planned subgroup and sensitivity analyses in the absence of data.,delete,[],0,0.125,1,8
CD010764,0,1,Two ongoing trials were identified which may provide data for analyses in a later version of this review.,delete,[],0,0.25,2,8
CD010764,0,2,The completion date of these trials is currently unknown.,rephrase,['We believe there are currently two trials underway which may provide some evidence on this topic once completed.'],0,0.375,2,8
CD010764,1,3,The current review failed to find any completed randomised clinical trials with results.,rephrase,['We did not find any trials which have been completed on this topic with available results.'],1,0.5,3,8
CD010764,1,4,Therefore we are unable to conclude whether intensive glycaemic control when compared to conventional glycaemic control has a positive or detrimental effect on the treatment of foot ulcers in people with diabetes.,rephrase,['Therefore we cannot be sure whether controlling blood glucose intensively when people have diabetic foot ulcers is beneficial or harmful.'],2,0.625,4,8
CD010764,1,5,Previous evidence has however highlighted a reduction in risk of limb amputation (from various causes) in people with type 2 diabetes with intensive glycaemic control.,rephrase,['The lack of evidence however should not deter efforts to achieve optimal glycaemic control in people with diabetic foot ulcers to encourage healing as is current practice.'],3,0.75,4,8
CD010764,1,6,Whether this applies to people with foot ulcers in particular is unknown.,delete,[],4,0.875,5,8
CD010764,1,7,The exact role that intensive glycaemic control has in treating foot ulcers in multidisciplinary care (alongside other interventions targeted at treating foot ulcers) requires further investigation.,delete,[],4,1.0,5,8
CD006133,0,0,We found 31 trials that met the inclusion criteria.,rephrase,['We included 31 trials.'],0,0.04,1,25
CD006133,0,1,No new trials were eligible in 2014.,delete,[],1,0.08,1,25
CD006133,0,2,"Twenty-one trials compared combined oral contraceptives (COCs); others examined different COC regimens, progestin-only pills, injectables, a vaginal ring, and implants.",delete,[],1,0.12,1,25
CD006133,0,3,None included a placebo.,rephrase,['None had a placebo.'],1,0.16,1,25
CD006133,0,4,"Of 34 comparisons, eight had any notable difference between the study groups in an outcome.",rephrase,"['Of 34 pairs of birth control methods compared, eight showed some difference by study groups.']",2,0.2,1,25
CD006133,1,5,"Twelve trials studied desogestrel-containing COCs, and the few differences from levonorgestrel COCs were inconsistent.",split,"['Twelve trials studied pills with desogestrel.', 'The few differences were not consistent.']",3,0.24,2,25
CD006133,1,6,A meta-analysis of two studies showed the desogestrel group had a higher mean fasting glucose (MD 0.20; 95% CI 0.00 to 0.41).,delete,[],5,0.28,2,25
CD006133,1,7,"Where data could not be combined, single studies showed lower mean fasting glucose (MD -0.40; 95% CI -0.72 to -0.08) and higher means for two-hour glucose response (MD 1.08; 95% CI 0.45 to 1.71) and insulin area under the curve (AUC) (MD 20.30; 95% CI 4.24 to 36.36).",delete,[],5,0.32,2,25
CD006133,2,8,Three trials examined the etonogestrel vaginal ring and one examined an etonogestrel implant.,rephrase,['Three trials looked at the etonogestrel ring.'],5,0.36,2,25
CD006133,2,9,One trial showed the ring group had lower mean AUC insulin than the levonorgestrel-COC group (MD -204.51; 95% CI -389.64 to -19.38).,rephrase,['One showed the ring group had lower insulin than the pill group.'],6,0.4,2,25
CD006133,3,10,"Of eight trials of norethisterone preparations, five compared COCs and three compared injectables.",rephrase,['Eight trials looked at the progestin norethisterone.'],7,0.44,3,25
CD006133,3,11,"In a COC trial, a norethisterone group had smaller mean change in glucose two-hour response than a levonorgestrel-COC group (MD -0.30; 95% CI -0.54 to -0.06).",delete,[],8,0.48,3,25
CD006133,3,12,"In an injectable study, a group using depot medroxyprogesterone acetate had higher means than the group using norethisterone enanthate for fasting glucose (MD 10.05; 95% CI 3.16 to 16.94), glucose two-hour response (MD 17.00; 95% CI 5.67 to 28.33), and fasting insulin (MD 3.40; 95% CI 2.07 to 4.73).",rephrase,"['In another study, a group using the injectable ‘depo’ (depot medroxyprogesterone acetate) had higher glucose and insulin than the group using another injectable.']",8,0.52,3,25
CD006133,4,13,"Among five recent trials, two examined newer COCs with different estrogen types.",rephrase,"['Of five new trials, two used different estrogen types.']",9,0.56,3,25
CD006133,4,14,One showed the group with nomegestrel acetate plus 17β-estradiol had lower means than the levonorgestrel group for incremental AUC glucose (MD -1.43; 95% CI -2.55 to -0.31) and glycosylated hemoglobin (HbA1c) (MD -0.10; 95% CI -0.18 to -0.02).,delete,[],10,0.6,3,25
CD006133,4,15,Two trials compared extended versus conventional (cyclic) regimens.,rephrase,['Two other trials compared taking pills for several cycles without stopping (extended use) versus usual use.'],10,0.64,4,25
CD006133,4,16,"With a dienogest COC, an extended-use group had greater mean change in AUC glucose (MD 82.00; 95% CI 10.72 to 153.28).",rephrase,"['In one using a dienogest pill, the extended-use group had more glucose change.']",11,0.68,4,25
CD006133,4,17,"In a small trial using two levonorgestrel COCs, the lower-dose group showed smaller mean change in fasting glucose (MD -3.00; 95% CI -5.89 to -0.11), but the obese and normal weight women did not differ significantly.",rephrase,"['A small trial used two levonorgestrel pills, and looked at obese and normal weight women.']",12,0.72,4,25
CD006133,5,18,Current evidence suggests no major differences in carbohydrate metabolism between different hormonal contraceptives in women without diabetes.,rephrase,"[""In women without diabetes, hormone contraceptives have little effect on the body's carbohydrate use.""]",13,0.76,4,25
CD006133,5,19,We cannot make strong statements due to having few studies that compared the same types of contraceptives.,split,"['Few studies compared the same types of birth control.', 'Therefore, we cannot make strong statements.']",14,0.8,4,25
CD006133,5,20,Many trials had small numbers of participants and some had large losses.,split,"['Many trials had small numbers of women, and many women dropped out.', 'Many trials did not include overweight women.']",16,0.84,5,25
CD006133,5,21,Many of the earlier studies had limited reporting of methods.,rephrase,['Older trials often did not report all the study methods.'],18,0.88,5,25
CD006133,6,22,We still know very little about women at risk for metabolic problems due to being overweight.,delete,[],19,0.92,5,25
CD006133,6,23,More than half of the trials had weight restrictions as inclusion criteria.,delete,[],19,0.96,5,25
CD006133,6,24,Only one small trial stratified the groups by body mass index (obese versus normal).,delete,[],19,1.0,5,25
CD009543,0,0,Only one quasi-randomized controlled study with 121 study participants comparing two types of IPC devices met the inclusion criteria.,split,"['We looked for randomized controlled trials which compared different types of IPC devices for preventing venous thromboembolism in patients after THR.', 'We found one study with 121 participants comparing a calf-thigh compression device with a foot (plantar) compression device.']",0,0.14285714285714285,1,7
CD009543,0,1,The authors found no cases of symptomatic DVT or PE in either the calf-thigh compression group or the plantar compression group during the first three weeks after the THR.,rephrase,['There were no cases of symptomatic DVT or PE either in the calf-thigh compression group or the plantar compression group in the first three weeks after the THR.'],2,0.2857142857142857,2,7
CD009543,0,2,The calf-thigh pneumatic compression was more effective than plantar compression for reducing thigh swelling during the early postoperative stage.,split,"['The calf-thigh pneumatic compression was more effective than plantar compression for reducing thigh swelling one week following surgery.', 'The postoperative swelling in the calf-thigh pump group was reduced earlier than in the plantar pump group.']",3,0.42857142857142855,3,7
CD009543,0,3,The strength of the evidence in this review is weak as only one trial was included and it was classified as having a high risk of bias.,delete,[],5,0.5714285714285714,3,7
CD009543,1,4,There is a lack of evidence from randomized controlled trials to make an informed choice of IPC device for preventing venous thromboembolism (VTE) following total hip replacement.,merge,['We therefore suggest that more primary research is required to allow an informed choice of IPC device for preventing venous thromboembolism following THR.'],5,0.7142857142857143,4,7
CD009543,1,5,"More research is urgently required, ideally a multicenter, properly designed RCT including a sufficient number of participants.",none,[],5,0.8571428571428571,5,7
CD009543,1,6,"Clinically relevant outcomes such as mortality, imaging-diagnosed asymptomatic VTE and major complications must be considered.",rephrase,"['However, other outcomes such as imaging-diagnosed asymptomatic VTE were not determined and it is not possible to draw reliable conclusions from this single study with a high risk of bias.']",6,1.0,5,7
CD006008,0,0,"We included 23 trials (1339 randomised participants), including twelve RCTs and eleven cross-over trials.",rephrase,['We found 23 trials (involving a total of 1339 children and adults using intermittent catheterisation for bladder emptying) comparing different catheterisation techniques and catheter designs.'],0,0.05263157894736842,1,19
CD006008,0,1,"Most were small (fewer than 60 participants completed), although three trials had more than 100 participants.",delete,[],1,0.10526315789473684,1,19
CD006008,0,2,Length of follow-up ranged from one month to 12 months and there was considerable variation in definitions of UTI.,delete,[],1,0.15789473684210525,1,19
CD006008,0,3,Most of the data from cross-over trials were not presented in a useable form for this review.,delete,[],1,0.21052631578947367,2,19
CD006008,1,4,Risk of bias was unclear in many domains due to insufficient information in the trial reports and several trials were judged to have a high risk of performance bias due to lack of blinding and a high risk of attrition bias.,delete,[],1,0.2631578947368421,2,19
CD006008,1,5,"The certainty of evidence was downgraded for risk of bias, and imprecision due to low numbers of participants.",delete,[],1,0.3157894736842105,2,19
CD006008,2,6,"Aseptic versus clean technique
We are uncertain if there is any difference between aseptic and clean techniques in the risk of symptomatic UTI because the evidence is low-certainty and the 95% confidence interval (CI) is consistent with possible benefit and possible harm (RR 1.20 95% CI 0.54 to 2.66; one study; 36 participants).",rephrase,['We are uncertain if there is any difference between aseptic and clean techniques in the risk of symptomatic UTI.'],1,0.3684210526315789,2,19
CD006008,2,7,We identified no data relating to the risk of adverse events comparing aseptic and clean techniques or participant satisfaction or preference.,rephrase,['We identified no data relating to the risk of adverse events.'],2,0.42105263157894735,3,19
CD006008,3,8,"Single-use (sterile) catheter versus multiple-use (clean)
We are uncertain if there is any difference between single-use and multiple-use catheters in terms of the risk of symptomatic UTI because the certainty of evidence is low and the 95% CI is consistent with possible benefit and possible harm (RR 0.98, 95% CI 0.55, 1.74; two studies; 97 participants).",rephrase,['We are uncertain if there is any difference between single-use and multiple-use catheters in the risk of symptomatic UTI because the certainty of evidence is low.'],3,0.47368421052631576,3,19
CD006008,3,9,One study comparing single-use catheters to multiple-use catheters reported zero adverse events in either group; no other adverse event data were reported for this comparison.,rephrase,['One study comparing these interventions reported zero adverse events in either group and no other adverse event data were reported.'],4,0.5263157894736842,3,19
CD006008,3,10,We identified no data for participant satisfaction or preference.,rephrase,['We identified no useable evidence relating to cost-effectiveness for any of the comparisons.'],5,0.5789473684210527,3,19
CD006008,4,11,"Hydrophilic-coated catheters versus uncoated catheters
We are uncertain if there is any difference between hydrophilic and uncoated catheters in terms of the number of people with symptomatic UTI because the certainty of evidence is low and the 95% CI is consistent with possible benefit and possible harm (RR 0.89, 95% CI 0.69 to 1.14; two studies; 98 participants).",split,"['We are uncertain if there is any difference between hydrophilic and uncoated catheters in the number of people with symptomatic UTI.', 'We are uncertain if there is any difference in patient satisfaction or preference.']",6,0.631578947368421,4,19
CD006008,4,12,"Uncoated catheters probably slightly reduce the risk of urethral trauma and bleeding compared to hydrophilic-coated catheters (RR 1.37, 95% CI 1.01 to 1.87; moderate-certainty evidence).",rephrase,['Uncoated catheters probably slightly reduce the risk of urethral trauma and bleeding compared to hydrophilic-coated catheters.'],8,0.6842105263157895,4,19
CD006008,4,13,"The evidence is uncertain if hydrophilic-coated catheters compared with uncoated catheters has any effect on participant satisfaction measured on a 0-10 scale (MD 0.7 higher, 95% CI 0.19 to 1.21; very low-certainty evidence; one study; 114 participants).",delete,[],9,0.7368421052631579,4,19
CD006008,4,14,"Due to the paucity of data, we could not assess the certainty of evidence relating to participant preference (one cross-over trial of 29 participants reported greater preference for a hydrophilic-coated catheter (19/29) compared to an uncoated catheter (10/29)).",delete,[],9,0.7894736842105263,4,19
CD006008,5,15,"Despite a total of 23 trials, the paucity of useable data and uncertainty of the evidence means that it remains unclear whether the incidence of UTI or other complications is affected by use of aseptic or clean technique, single (sterile) or multiple-use (clean) catheters, coated or uncoated catheters or different catheter lengths.",delete,[],9,0.8421052631578947,5,19
CD006008,5,16,The current research evidence is uncertain and design and reporting issues are significant.,ignore,['The current research evidence is uncertain and design and reporting issues are significant.'],9,0.8947368421052632,5,19
CD006008,5,17,More well-designed trials are needed.,ignore,['More well-designed trials are needed.'],10,0.9473684210526315,5,19
CD006008,5,18,"Such trials should include analysis of cost-effectiveness because there are likely to be substantial differences associated with the use of different catheterisation techniques and strategies, and catheter designs.",rephrase,"['Such trials should include analysis of cost-effectiveness because there are likely to be substantial differences associated with the use of different catheter designs, catheterisation techniques and strategies.']",11,1.0,5,19
CD015331,0,0,"We included 28 studies, of which 26 provided data on 2407 participants (average age 24 years).",rephrase,"['We found 28 studies, of which 26 had usable data on 2407 participants with recent-onset or first-episode schizophrenia.']",0,0.125,1,8
CD015331,0,1,The mean sample size in the included studies was 92 participants (ranging from 19 to 444) and duration ranged between 26 and 52 weeks.,rephrase,"['The studies had a duration of between 26 and 52 weeks for the intervention phase and, in 18 studies, participants were contacted again to collect further data after the end of the treatment.']",1,0.25,2,8
CD015331,1,2,"When looking at the results at combined time points (mainly up to one year after start of the intervention), CBT added to standard care was associated with a greater reduction in overall symptoms of schizophrenia (standardised mean difference (SMD) -0.27, 95% confidence interval (CI) -0.47 to -0.08, 20 RCTs, n = 1508, I2 = 68%, substantial heterogeneity, low certainty of the evidence), and also with a greater reduction in positive (SMD -0.22, 95% CI -0.38 to -0.06, 22 RCTs, n = 1565, I² = 52%, moderate heterogeneity), negative (SMD -0.20, 95% CI -0.30 to -0.11, 22 RCTs, n = 1651, I² = 0%) and depressive symptoms (SMD -0.13, 95% CI -0.24 to -0.01, 18 RCTs, n = 1182, I² = 0%) than control.",rephrase,"['When looking at the results about one year after the start of the intervention, we found that CBT added to standard care:\n- is more effective than control conditions in reducing the overall symptoms of schizophrenia\n- is more effective than control conditions in reducing positive symptoms of schizophrenia (e.g. hearing voices)\n- is more effective than control conditions in reducing negative symptoms of schizophrenia (e.g. apathy, loss of interest and motivation, lack of concentration)\n- is more effective than control conditions in reducing depressive symptoms of schizophrenia\n- is more effective than control conditions in improving the global state (number of participants with symptoms improvement, number of participants with symptoms worsening, scores on scales that measure the general level of symptoms of the participants)\n- is more effective than control conditions in improving functioning (e.g. participating in social life, taking part in everyday activities).']",2,0.375,2,8
CD015331,1,3,"CBT added to standard care was also associated with a greater improvement in the global state (SMD -0.34, 95% CI -0.67 to -0.01, 4 RCTs, n = 329, I² = 47%, moderate heterogeneity) and in functioning (SMD -0.23, 95% CI -0.42 to -0.05, 18 RCTs, n = 1241, I² = 53%, moderate heterogeneity, moderate certainty of the evidence) than control.",delete,[],3,0.5,3,8
CD015331,2,4,"We did not find a difference between CBT added to standard care and control in terms of number of participants with relapse (relative risk (RR) 0.82, 95% CI 0.57 to 1.18, 7 RCTs, n = 693, I² = 48%, low certainty of the evidence), leaving the study early for any reason (RR 0.87, 95% CI 0.72 to 1.05, 25 RCTs, n = 2242, I² = 12%, moderate certainty of the evidence), adverse events (RR 1.29, 95% CI 0.85 to 1.97, 1 RCT, n = 43, very low certainty of the evidence) and the other investigated outcomes.",delete,[],3,0.625,4,8
CD015331,3,5,This review synthesised the latest evidence on CBT added to standard care for people with a first-episode or recent-onset psychosis.,rephrase,['We wanted to find out the effects of cognitive behavioural therapy added to standard care for people with a first episode or recent onset of schizophrenia.'],3,0.75,4,8
CD015331,4,6,"The evidence identified by this review suggests that people with a first-episode or recent-onset psychosis may benefit from CBT additionally to standard care for multiple outcomes (overall, positive, negative and depressive symptoms of schizophrenia, global state and functioning).",delete,[],4,0.875,5,8
CD015331,5,7,"Future studies should better define this population, for which often heterogeneous definitions are used.",delete,[],4,1.0,5,8
CD007114,0,0,We obtained full-text copies of nine potential studies and included five trials with a total of 244 participants in this review.,rephrase,['This review included five randomised controlled trials involving 244 participants.'],0,0.1,1,10
CD007114,0,1,"Orbital radiotherapy was compared to sham radiotherapy in two studies and to glucocorticoids in three studies, as a monotherapy or combination therapy.",delete,[],1,0.2,1,10
CD007114,0,2,There was heterogeneity (as defined in our protocol) of trial outcome measures.,delete,[],1,0.3,2,10
CD007114,0,3,Our primary outcome of a composite score was used in the two trials comparing radiotherapy versus sham radiotherapy and showed a risk ratio of success of 1.92 (95% confidence interval (CI) 1.27 to 2.91) in favour of orbital radiotherapy.,rephrase,"[""A combined analysis of trials using our primary outcome showed that the 'risk' of success in a patient who received radiotherapy was 1.92 times that of a patient who did not receive radiotherapy.""]",1,0.4,2,10
CD007114,0,4,The primary outcome was not used in the other three trials.,delete,[],2,0.5,3,10
CD007114,1,5,This review found that orbital radiotherapy is more effective than sham radiotherapy for the treatment of mild-to-moderate thyroid eye disease.,merge,[],2,0.6,3,10
CD007114,1,6,In a single trial no difference between radiotherapy and steroid monotherapy was found.,merge,['Single studies suggested that orbital radiotherapy in combination with steroids had a better outcome than steroids alone.'],2,0.7,4,10
CD007114,1,7,A meta-analysis of our secondary outcome of disease severity was not possible but results from individual trials suggest a better outcome with combination treatment with steroids versus steroids alone.,none,[],2,0.8,4,10
CD007114,1,8,No significant changes in quality-of-life scores following treatment with radiotherapy versus alternative treatments were found.,rephrase,['There was no significant change in quality-of-life information collected in the orbital radiotherapy groups compared to the other groups.'],3,0.9,5,10
CD007114,1,9,Short-term adverse events related to radiotherapy that were reported were local and mild but long-term data were lacking and development of retinal changes following radiotherapy was not reported on.,split,"['The short-term adverse events reported in the trials were mild and localised to the area of treatment (redness of skin and temporal hair loss).', 'Some studies did not report on retinal changes at all.']",4,1.0,5,10
CD008474,0,0,Three studies (212 participants) were included in this review.,rephrase,"['The review authors searched the medical literature up to March 3 2015, and identified three relevant clinical trials (212 participants) that investigated ozone therapy for the treatment of foot ulcers in people with diabetes.']",0,0.1111111111111111,1,9
CD008474,0,1,The overall risk of bias was high for two trials and unclear for one.,delete,[],1,0.2222222222222222,2,9
CD008474,1,2,One trial (101 participants) compared ozone treatment with antibiotics for foot ulcers in people with DM.,merge,"['One trial, with 101 participants, compared ozone treatment with antibiotics and followed up for 20 days.']",1,0.3333333333333333,2,9
CD008474,1,3,The study had a follow-up period of 20 days.,none,[],1,0.4444444444444444,3,9
CD008474,1,4,"This study showed that ozone treatment was associated with a greater reduction in ulcer area from baseline to the end of the study than treatment with antibiotics (MD -20.54 cm2, 95% CI -20.61 to -20.47), and a shorter duration of hospitalisation (MD -8.00 days, 95% CI -14.17 to -1.83), but did not appear to affect the number of ulcers healed over 20 days (RR 1.10, 95% CI 0.87 to 1.40).",rephrase,"['The results of this study showed that the reduction in ulcer size was greater, and also the length of hospital stay was shorter, in those receiving ozone treatment, but there was no apparent benefit in terms of the number of foot ulcers healed.']",2,0.5555555555555556,3,9
CD008474,1,5,No side effects were observed in either group.,rephrase,['No adverse effects (side effects or harms) were observed with either treatment.'],3,0.6666666666666666,4,9
CD008474,2,6,The other two trials (111 participants) compared ozone treatment plus usual care with usual care for foot ulcers in people with DM.,rephrase,['The other two trials (111 participants) compared ozone treatment plus usual care with usual care.'],4,0.7777777777777778,4,9
CD008474,2,7,"The meta-analysis results did not show evidence of a difference between groups for the outcomes of reduction of ulcer area (MD -2.11 cm2, 95% CI -5.29 to 1.07), the number of ulcers healed (RR 1.69, 95% CI 0.90 to 3.17), adverse events (RR 2.27, 95% CI 0.48 to 10.79), or amputation rate (RR 2.73, 95%CI 0.12, 64.42).",rephrase,"['The results of these two studies showed that there were no apparent differences between the groups for reduction in ulcer size,the number of foot ulcers healed, or occurrence of adverse events and amputation rates.']",5,0.8888888888888888,5,9
CD008474,3,8,"The available evidence was three small RCTs with unclear methodology, so we are unable to draw any firm conclusions regarding the effectiveness of ozone therapy for foot ulcers in people with DM.",rephrase,"['On the basis of the limited and poor quality information available, the review authors were unable to draw any conclusions about the effectiveness of ozone therapy for treating foot ulcers in people with DM.']",6,1.0,5,9
CD011056,0,0,We included 77 studies with 5619 randomised participants.,rephrase,"['This review identified 77 studies with over 5,000 people who received various treatments.']",0,0.08333333333333333,1,12
CD011056,0,1,"There was potential bias in most studies, with small size being the most common; individual treatment groups had fewer than 50 participants in 60 studies.",delete,[],1,0.16666666666666666,1,12
CD011056,0,2,"Participants were relatively young, with mean age in the studies typically between 50 and 70 years.",rephrase,['The population in these trials was mainly aged between 50 and 70 years.'],1,0.25,2,12
CD011056,0,3,"Multiple major problems with adverse event reporting were found, including failing to report adverse events in all participants who received medication, all adverse events experienced, how adverse events were collected, and not defining adverse event terminology or whether a reporting system was used.",rephrase,"['Known problems with adverse event measurement, recording, and reporting made assessment even more difficult.']",2,0.3333333333333333,2,12
CD011056,1,4,"Direct measures of patient consciousness, patient appetite, or thirst were not apparent.",delete,[],3,0.4166666666666667,3,12
CD011056,1,5,"For opioids used to treat cancer pain adverse event incidence rates were 25% for constipation, 23% for somnolence, 21% for nausea, 17% for dry mouth, and 13% for vomiting, anorexia, and dizziness.",rephrase,"['For all four opioids together, 1 in 4 people experienced constipation and somnolence (sleepiness, drowsiness), 1 in 5 experienced nausea and dry mouth, and 1 in 8 experienced vomiting, loss of appetite, and dizziness.']",3,0.5,3,12
CD011056,1,6,"Asthenia, diarrhoea, insomnia, mood change, hallucinations and dehydration occurred at incidence rates of 5% and below.",rephrase,"['Weakness, diarrhoea, insomnia (difficulty in sleeping), mood change, hallucinations and dehydration occurred at rates of 1 in 20 people and below.']",4,0.5833333333333334,3,12
CD011056,2,7,"We found no direct evidence that opioids affected patient consciousness, appetite or thirst when used to treat cancer pain.",rephrase,"['These results may contribute to understanding the effects of opioids on consciousness, appetite, and thirst in end-of-life care in all patients deemed to be people who are dying.']",5,0.6666666666666666,4,12
CD011056,2,8,"However, somnolence, dry mouth, and anorexia were common adverse events in people with cancer pain treated with morphine, fentanyl, oxycodone, or codeine.",delete,[],6,0.75,4,12
CD011056,3,9,"We are aware that there is an important literature concerning the problems that exist with adverse event measurement, reporting, and attribution.",delete,[],6,0.8333333333333334,5,12
CD011056,3,10,"Together with the known complications concerning concomitant medication, data collection and reporting, and nomenclature, this means that these adverse events cannot always be attributed unequivocally to the use of opioids, and so they provide only a broad picture of adverse events with opioids in cancer pain.",delete,[],6,0.9166666666666666,5,12
CD011056,3,11,"The research agenda includes developing definitions for adverse events that have a spectrum of severity or importance, and the development of appropriate measurement tools for recording such events to aid clinical practice and clinical research.",delete,[],6,1.0,5,12
CD001467,0,0,"There are now 30 studies involving 6334 participants (6339 fractures) included in this review, which was published in 2011.",rephrase,['This review of randomised controlled trials included 30 studies involving more than 6000 participants.'],0,0.09090909090909091,1,11
CD001467,0,1,There was considerable variation in the quality of trial methodology and generally inadequate reporting of methods and trial findings.,delete,[],1,0.18181818181818182,1,11
CD001467,0,2,Allocation concealment was confirmed in one trial only.,delete,[],1,0.2727272727272727,2,11
CD001467,0,3,"The main outcome measures reported were fracture healing complications, re-operations and mortality.",delete,[],1,0.36363636363636365,2,11
CD001467,0,4,The reporting of functional outcomes was particularly poor.,delete,[],1,0.45454545454545453,3,11
CD001467,1,5,Few trials tested the same comparison.,ignore,['Few trials tested the same comparison.'],1,0.5454545454545454,3,11
CD001467,1,6,"Most of the results for the 25 separate comparisons, frequently tested within one trial only, showed no statistically significant differences between the two implants under test.",rephrase,"['Most of the results for the 25 separate comparisons, frequently tested within one trial only, failed to show that one implant was better than the other under comparison.']",2,0.6363636363636364,4,11
CD001467,1,7,It was noted that the more rare findings of favourable results were often for implants developed within the same institutions as the trial.,rephrase,['This review found no evidence from trials undertaken so far that there were any major differences between different implants in patient survival or complications related to the operation.'],3,0.7272727272727273,4,11
CD001467,1,8,There was a consistent finding of less avascular necrosis with the sliding hip screw in comparison with five different types of cancellous screws but there was no significant difference found for re-operations.,rephrase,['There was a consistent finding of one serious complication (avascular necrosis) with the sliding hip screw in comparison with five different types of cancellous screws.'],4,0.8181818181818182,5,11
CD001467,1,9,"Additionally, the sliding hip screw was found to take longer to insert and to have an increased operative blood loss compared with multiple screws or pins.",ignore,"['Additionally, the sliding hip screw was found to take longer to insert and to have an increased operative blood loss compared with multiple screws or pins.']",5,0.9090909090909091,5,11
CD001467,2,10,No clear conclusions can be made on the choice of implant for internal fixation of intracapsular fractures from the available evidence within randomised trials.,delete,[],6,1.0,5,11
CD009557,0,0,The search of four standard electronic databases yielded 119 potentially relevant studies but only 18 RCTs involving 1252 people were found suitable for statistical analysis.,delete,[],0,0.14285714285714285,1,7
CD009557,0,1,There was significant heterogeneity among trials and the majority of trials were of poor quality.,rephrase,"['Although this conclusion is based on the combined analysis of 18 trials, the majority of these were of poor quality due to flaws in trial methods.']",0,0.2857142857142857,2,7
CD009557,0,2,"The use of FG under skin flaps following breast and axillary surgery failed to reduce the incidence of postoperative seroma (risk ratio (RR) 1.02; 95% Confidence Interval (CI) 0.90 to 1.16, P value = 0.73), mean volume of seroma (standardised mean difference (SMD) -0.25; 95% CI -0.92 to 0.42, P value = 0.46), wound infection (RR 1.05; 95% CI 0.63 to 1.77, P value = 0.84), postoperative complications (RR 1.13; 95% CI 0.63 to 2.04, P value = 0.68) and length of hospital stay (SMD -0.2; 95% CI -0.78 to 0.39, P value = 0.51).",delete,[],1,0.42857142857142855,3,7
CD009557,0,3,"FG reduced the total volume of drained seroma (SMD -0.75, 95% CI -1.24 to -0.26, P value = 0.003) and duration of persistent seromas requiring frequent aspirations (SMD -0.59; CI 95% -0.95 to -0.23, P value = 0.001).",rephrase,['FG reduced the total volume of drained seroma and the duration of persistent seroma requiring frequent aspirations.'],1,0.5714285714285714,3,7
CD009557,1,4,"FG did not influence the incidence of postoperative seroma, the mean volume of seroma, wound infections, complications and the length of hospital stays in people undergoing breast cancer surgery.",rephrase,"['The use of FG following breast and axillary surgery did not reduce the incidence of postoperative seroma, mean volume of seroma, wound infections, postoperative complications and the length of hospital stays.']",2,0.7142857142857143,4,7
CD009557,1,5,Due to significant methodological and clinical diversity among the included studies this conclusion may be considered weak and biased.,rephrase,['There were significant clinical and methodological differences among the included trials.'],3,0.8571428571428571,5,7
CD009557,1,6,"Therefore, a major multicentre and high-quality RCT is required to validate these findings.",rephrase,"['Therefore, this conclusion should be taken cautiously and a major, multicentre, high-quality randomised controlled trial on people undergoing breast and axillary surgery for breast cancer is required to corroborate this conclusion.']",4,1.0,5,7
CD009959,0,0,We identified no RCTs or quasi-RCTs that fulfilled the inclusion criteria.,rephrase,"['Despite extensive searching, we were unable to identify any studies that met our inclusion criteria.']",0,0.125,1,8
CD009959,0,1,"Our searches retrieved eight potentially relevant studies, but after assessment of the full-text reports we excluded all of them due to the absence of randomisation or because the patients did not have Frey's syndrome.",merge,[],1,0.25,2,8
CD009959,0,2,We excluded one randomised controlled trial that compared two different doses of botulinum toxin in patients with Frey's syndrome because the comparator was not an alternative treatment.,none,"[""We carried out a comprehensive search for randomised controlled trials (RCTs) in participants diagnosed with Frey's syndrome.""]",1,0.375,2,8
CD009959,1,3,We are unable to establish the efficacy and safety of the different methods used for the treatment of Frey's syndrome.,rephrase,"[""There is no high-quality evidence to establish which type of treatment is most effective for the treatment of Frey's syndrome.""]",2,0.5,3,8
CD009959,2,4,RCTs are urgently needed to assess the effectiveness of interventions for the treatment of Frey's syndrome.,delete,[],3,0.625,4,8
CD009959,2,5,Future RCTs should include patients with Frey's syndrome of different ranges of severity and report these patients separately.,delete,[],3,0.75,4,8
CD009959,2,6,"Studies should investigate all possibly effective treatments (such as anticholinergics, antiperspirants and botulinum toxin) compared to control groups using different treatments or placebo.",ignore,"['Studies should investigate all possibly effective treatments (such as anticholinergics, antiperspirants and botulinum toxin) compared to control groups using different treatments or placebo.']",3,0.875,5,8
CD009959,2,7,Subjective assessment of Frey's syndrome should be considered as one of the outcome measures.,rephrase,"[""Subjective (patient) assessment of Frey's syndrome should be one of the outcome measures used.""]",4,1.0,5,8
CD003743,0,0,We included in the review data from one quasi-randomised trial with 88 infants from 75 families.,rephrase,['Data from one quasi-randomised trial with 88 infants from 75 families were included in the review.'],0,0.16666666666666666,1,6
CD003743,0,1,"Infants in the early discharge programme with home gavage feeding had a mean hospital stay that was 9.3 days shorter (mean difference (MD) -9.3, 95% confidence interval (CI) -18.49 to -0.11) than that of infants in the control group.",rephrase,['Infants in the early discharge programme with home gavage feeds had a mean hospital stay that was approximately nine days shorter than that of infants in the control group.'],1,0.3333333333333333,2,6
CD003743,0,2,"Infants in the early discharge programme also had lower risk of clinical infection during the home gavage period compared with those in the control group spending corresponding time in hospital (risk ratio 0.35, 95% CI 0.17 to 0.69).",rephrase,['Infants in the early discharge programme also had lower risk of clinical infection during the home gavage period compared with infants in the control group during the corresponding time in hospital.'],2,0.5,3,6
CD003743,0,3,"No significant differences were noted between groups in duration and extent of breast feeding, weight gain, re-admission within the first 12 months post discharge from the home gavage programme or from hospital, scores reflecting parental satisfaction or overall health service use.",ignore,"['No significant differences were observed between groups in duration and extent of breast feeding, weight gain, re-admission within the first 12 months post discharge from the home gavage programme or from hospital, scores reflecting parental satisfaction or health service use.']",3,0.6666666666666666,4,6
CD003743,1,4,Experimental evidence on the benefits and risks for preterm infants of early discharge from hospital with home gavage feeding compared with later discharge upon attainment of full sucking feeds is limited to the results of one small quasi-randomised controlled trial.,rephrase,['Evidence is needed regarding the effects of early home discharge for preterm babies who are stable but still need gavage (tube) feeds.'],4,0.8333333333333334,5,6
CD003743,1,5,"High-quality trials with concealed allocation, complete follow-up of all randomly assigned infants and adequate sample size are needed before practice recommendations can be made.",delete,[],5,1.0,5,6
CD011407,0,0,Information was available from 39 Cochrane reviews for 41 different analgesics or analgesic combinations (51 drug/dose/formulations) tested in single oral doses in participants with moderate or severe postoperative pain.,delete,[],0,0.1111111111111111,1,9
CD011407,0,1,"This involved around 350 unique studies involving about 35,000 participants.",rephrase,"['In this overview, we used information from about 35,000 participants in about 350 studies to look specifically at the adverse events (unwanted effects) experienced with painkillers, and compared the results with those for placebo (dummy pill).']",0,0.2222222222222222,2,9
CD011407,0,2,Most studies involved younger participants with pain following removal of molar teeth.,rephrase,"['Most people in the studies had wisdom teeth removed, were relatively young and fit, and were likely to take occasional painkillers.']",1,0.3333333333333333,2,9
CD011407,1,3,"For most nonsteroidal anti-inflammatory drugs (NSAIDs), paracetamol, and combinations not containing opioids, there were few examples where participants experienced significantly more or fewer adverse events than with placebo.",rephrase,"['The results we have showed that for most nonsteroidal anti-inflammatory drugs (painkillers like aspirin, ibuprofen, or diclofenac), paracetamol, and combinations of different painkillers that do not contain opioids (drugs like codeine), adverse events happened to the same proportion of people with painkillers and placebo.']",2,0.4444444444444444,3,9
CD011407,1,4,"For aspirin 1000 mg and diflunisal 1000 mg, opioids, or fixed-dose combination drugs containing opioids, participants typically experienced significantly more adverse events than with placebo.",rephrase,"['With aspirin 1000 mg, opioids, or fixed dose combinations containing opioids, people typically experienced significantly more adverse events than with placebo.']",3,0.5555555555555556,3,9
CD011407,1,5,Studies of combinations of ibuprofen and paracetamol reported significantly fewer adverse events.,rephrase,['A combination of ibuprofen and paracetamol resulted in significantly fewer adverse events than placebo.'],4,0.6666666666666666,4,9
CD011407,2,6,"Serious adverse events were rare, occurring a rate of about 1 in 3200 participants.",rephrase,"['Serious adverse events were rare, occurring a rate of about 1 in 3200 people.']",5,0.7777777777777778,4,9
CD011407,3,7,Most reviews did not report specific adverse events.,delete,[],6,0.8888888888888888,5,9
CD011407,4,8,"Despite ongoing problems with the measurement, recording, and reporting of adverse events in clinical trials and in systematic reviews, the large amount of information available for single oral doses of analgesics provides evidence that adverse events rates are generally similar with active drug and placebo in these circumstances, except at higher doses of some drugs, and in combinations including opioids.",delete,[],6,1.0,5,9
CD007991,0,0,We included 13 trials in this review.,rephrase,['We found 13 relevant studies.'],0,0.1,1,10
CD007991,1,1,Eight studies reported data on the Bayley Scales of Infant Development (BSID) in 2134 participants.,merge,['Eight studies measured development using the Mental Development Index and the Psychomotor Development Index of the Bayley Scales of Infant Development.'],1,0.2,1,10
CD007991,1,2,We combined the data in a meta-analysis to assess the effect on development as measured by the Mental Development Index (MDI) and Psychomotor Development Index (PDI).,none,[],1,0.3,2,10
CD007991,1,3,There was no significant effect of zinc supplementation: the mean difference between the zinc supplementation and placebo groups on the MDI was -0.50 (95% confidence interval (CI) -2.06 to 1.06; P = 0.53; I2 = 70%) and the mean difference between the groups for the PDI was 1.54 (95% CI -2.26 to 5.34; P = 0.43; I2 = 93%).,delete,[],2,0.4,2,10
CD007991,1,4,"Most studies had low or unclear risk of bias but there was significant heterogeneity, which was not adequately explained by our subgroup analyses.",delete,[],2,0.5,3,10
CD007991,1,5,The overall quality of evidence was considered 'moderate'.,delete,[],2,0.6,3,10
CD007991,2,6,Two trials provided data on motor milestone attainment.,rephrase,"[""Two studies measured children's attainment of motor milestones.""]",2,0.7,4,10
CD007991,2,7,There was no significant difference in the time to attainment of milestones between the placebo group and the zinc supplementation group in either of the studies.,split,"['We found no difference between the results for those who had taken zinc supplements and those who had taken a placebo.', 'Again, no difference as found whether zinc supplements were taken or not.']",3,0.8,4,10
CD007991,3,8,No study provided data on cognition score or intelligence quotient (IQ) or on adverse effects of zinc supplementation.,rephrase,"['No study measured possible side effects of zinc supplementation such as vomiting, diarrhea or anemia.']",5,0.9,5,10
CD007991,4,9,There is no convincing evidence that zinc supplementation to infants or children results in improved motor or mental development.,rephrase,"['Overall, the results of the studies provided no convincing evidence that zinc supplements had any beneficial effect on mental and motor development in infants and children.']",6,1.0,5,10
CD004267,0,0,We included 12 studies with 3571 participants.,rephrase,['We analysed 12 studies with 3571 participants.'],0,0.058823529411764705,1,17
CD004267,0,1,"All included studies examined the empiric use of one antimicrobial regimen versus another for the treatment of adults with VAP, but the particular drug regimens examined by each study varied.",rephrase,"['All included studies looked at the use of one antibiotic treatment plan versus another, but these varied among studies.']",1,0.11764705882352941,1,17
CD004267,0,2,There was potential for bias because some studies did not report outcomes for all participants.,merge,"['There was potential for bias because some studies did not report outcomes for all participants, and funding for many was provided by pharmaceutical companies and study authors were affiliated with these companies.']",2,0.17647058823529413,1,17
CD004267,0,3,All but one study reported sources of funding or author affiliations with pharmaceutical companies.,none,[],2,0.23529411764705882,2,17
CD004267,1,4,"We found no statistical difference in all-cause mortality between monotherapy and combination therapy (N = 4; odds ratio (OR) monotherapy versus combination 0.97, 95% confidence interval (CI) 0.73 to 1.30), clinical cure (N = 2; OR monotherapy versus combination 0.88, 95% CI 0.56 to 1.36), length of stay in ICU (mean difference (MD) 0.65, 95% CI 0.07 to 1.23) or adverse events (N = 2; OR monotherapy versus combination 0.93, 95% CI 0.68 to 1.26).",delete,[],3,0.29411764705882354,2,17
CD004267,1,5,"We downgraded the quality of evidence for all-cause mortality, adverse events, and length of ICU stay to moderate for this comparison.",delete,[],3,0.35294117647058826,2,17
CD004267,1,6,We determined clinical cure for this comparison to be of very low-quality evidence.,delete,[],3,0.4117647058823529,3,17
CD004267,2,7,For our second comparison of combination therapy with optional adjunctives only one meta-analysis could be performed due to a lack of trials comparing the same antibiotic regimens.,merge,['For our comparison of combination therapies with optional adjunctives we were only able to analyse clinical cure for one the antibiotics Tigecycline and imipenem-cilastatin for which imipenem-cilastatin was found to have higher clinica cure.'],3,0.47058823529411764,3,17
CD004267,2,8,"Two studies compared tigecycline versus imipenem-cilastatin for clinical cure in the clinically evaluable population and there was a statistically significant increase in clinical cure for imipenem-cilastatin (N = 2; OR tigecycline versus imipenem-cilastatin 0.44, 95% CI 0.23 to 0.84).",none,[],3,0.5294117647058824,3,17
CD004267,2,9,"Of importance, this effect was due to a single study.",delete,[],4,0.5882352941176471,3,17
CD004267,3,10,"We found no statistical difference in all-cause mortality between carbapenem and non-carbapenem therapies (N = 1; OR carbapenem versus non-carbapenem 0.59, 95% CI 0.30 to 1.19) or adverse events (N = 3; OR carbapenem versus non-carbapenem 0.78, 95% CI 0.56 to 1.09), but we found that carbapenems are associated with a statistically significant increase in the clinical cure (N = 3; OR carbapenem versus non-carbapenem 1.53, 95% CI 1.11 to 2.12 for intention-to-treat (ITT) analysis and N = 2; OR carbapenem versus non-carbapenem 2.29, 95% CI 1.19 to 4.43 for clinically evaluable patients analysis).",rephrase,"['We also looked at carbapenem (antibiotics used to treat infections caused by multidrug-resistant bacteria) versus non-carbapenem treatment; we found no difference in death rate or adverse effects, but we found that carbapenems are associated with an increase in clinical cure.']",4,0.6470588235294118,4,17
CD004267,3,11,"For this comparison we downgraded the quality of evidence for mortality, and clinical cure (ITT and clinically evaluable populations) to moderate.",rephrase,"['We assessed evidence quality as moderate for most outcomes, and very low for clinical cure when single-antibiotic treatment was compared with multiple antibiotic therapy.']",5,0.7058823529411765,4,17
CD004267,3,12,We determined the quality of evidence for adverse events to be low.,rephrase,['We also found that evidence quality was low for adverse events when carbapenem was compared with non-carbapenem treatment.'],6,0.7647058823529411,4,17
CD004267,4,13,We did not find a difference between monotherapy and combination therapy for the treatment of people with VAP.,rephrase,"['We did not find differences between single and combination therapy, lending support to use of a single-antibiotic treatment plan for people with ventilator-associated pneumonia.']",7,0.8235294117647058,5,17
CD004267,4,14,"Since studies did not identify patients with increased risk for multidrug-resistant bacteria, these data may not be generalisable to all patient groups.",rephrase,['This may not be applicable to all patients because studies did not identify patients who are at risk of exposure to harmful types of bacteria.'],8,0.8823529411764706,5,17
CD004267,4,15,"However, this is the largest meta-analysis comparing monotherapy to multiple antibiotic therapies for VAP and contributes further evidence to the safety of using effective monotherapy for the empiric treatment of VAP.",delete,[],9,0.9411764705882353,5,17
CD004267,5,16,"Due to lack of studies, we could not evaluate the best antibiotic choice for VAP, but carbapenems as a class may result in better clinical cure than other tested antibiotics.",rephrase,"['We could not evaluate the best single-antibiotic choice to treat people with ventilator-associated pneumonia because there were too few studies, but carbapenems may achieve better cure rates than other tested antibiotics.']",9,1.0,5,17
CD013293,0,0,Our search strategy identified 14 eligible studies (1176 randomised participants) for inclusion in this review.,rephrase,['We included 14 studies randomising 1176 people with thrombosed haemodialysis access.'],0,0.08333333333333333,1,12
CD013293,0,1,"We included three types of interventions for the treatment of thrombosed AVF and AVG: (1) types of thrombectomy, (2) types of thrombolysis and (3) surgical procedures.",rephrase,"['We included three types of interventions for the treatment of thrombosed AVF and AVG: (1) types of thrombectomy (thrombus removal), (2) types of thrombolysis (thrombus dissolution) and (3) surgical procedures.']",1,0.16666666666666666,1,12
CD013293,0,2,"Most of the included studies had a high risk of bias due to a poor study design, a low number of patients and industry involvement.",rephrase,"['Most of the included studies had poor study design, low numbers of patients, and some had pharmaceutical industry funding.']",2,0.25,2,12
CD013293,0,3,"Overall, there was insufficient evidence to suggest that a specific intervention was better than another for the outcomes of failure, primary patency at 30 days, technical success and adverse events (both major and minor).",split,"['There is insufficient evidence to suggest that a specific intervention is better to ensure adequate dialysis.', 'There is insufficient evidence of which interventions have a lower risk of complications.']",3,0.3333333333333333,2,12
CD013293,0,4,"Primary patency at 30 days may improve with surgical compared to mechanical thrombectomy (3 studies, 404 participants: RR 1.36, 95% CI 1.07 to 1.67); however, the evidence is very uncertain.",rephrase,['The surgical procedure in thrombosed AVF may be associated with better results at 30 days.'],5,0.4166666666666667,3,12
CD013293,0,5,"Death, access dysfunction, successful dialysis, and SONG (Standards Outcomes in Nephrology) outcomes were rarely reported.",delete,[],6,0.5,3,12
CD013293,0,6,The current review is limited by the small number of available studies with a limited number of patients enrolled.,rephrase,['The small number of studies per comparison and the small size of the studies were limitations in this review.'],6,0.5833333333333334,3,12
CD013293,0,7,Most of the studies included in this review have a high risk of bias and a low or very low certainty of evidence.,delete,[],7,0.6666666666666666,4,12
CD013293,0,8,Further research is required to define the most effective and clinically appropriate technique for access dysfunction.,delete,[],7,0.75,4,12
CD013293,1,9,It remains unclear whether any intervention therapy affects the patency at 30 days or failure in any thrombosed HD AV access (very low certainty of evidence).,delete,[],7,0.8333333333333334,5,12
CD013293,1,10,Future research will very likely change the evidence base.,delete,[],7,0.9166666666666666,5,12
CD013293,1,11,"Based on the importance of HD access to these patients, future studies of these interventions among people receiving HD should be a priority.",delete,[],7,1.0,5,12
CD011522,0,0,"Only one study, funded by Pfizer, met the inclusion criteria for the review.",rephrase,['We only found one study funded by Pfizer that met our inclusion criteria.'],0,0.07142857142857142,1,14
CD011522,0,1,A total of 64 participants (with chronic pain due to chronic pancreatitis) were randomly assigned to receive escalating doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (30 participants).,rephrase,['A total of 64 participants with chronic pain due to chronic pancreatitis received either increasing doses of pregabalin (150 mg per day to 600 mg per day; 34 participants) or matching placebo (sham treatment; 30 participants) on an outpatient basis.'],1,0.14285714285714285,1,14
CD011522,0,2,Participants received pregabalin or placebo for three weeks on an outpatient basis; the outcomes were measured at the end of the treatment (i.e. three weeks from commencement of treatment).,split,"['The decision about whether a participant received pregabalin or placebo was made using methods similar to toss of a coin, to ensure that the participants in the two groups were similar.', 'Participants received pregabalin or placebo for three weeks, then the outcomes were measured.']",2,0.21428571428571427,2,14
CD011522,0,3,Potential participants taking concomitant analgesic medication and expected to stay on a stable regime during the trial were allowed to enter the study.,rephrase,['Potential participants taking other pain-killers were allowed to take part in the study.'],4,0.2857142857142857,2,14
CD011522,0,4,This trial was at low risk of bias.,delete,[],5,0.35714285714285715,2,14
CD011522,0,5,The overall quality of evidence was low or moderate.,rephrase,['The quality of evidence was low or moderate.'],5,0.42857142857142855,3,14
CD011522,1,6,Only the short-term outcomes were available in this trial.,ignore,['Only the short-term outcomes were available in this trial.'],6,0.5,3,14
CD011522,1,7,"The medium and long-term outcomes, number of work days lost, and length of hospital stay due to admissions for pain control were not available.",rephrase,"['Medium- and long-term outcomes, number of work days lost, and length of hospital stay were not available in this trial.']",7,0.5714285714285714,3,14
CD011522,1,8,"This trial found that the changes in opiate use (MD -26.00 mg; 95% CI -47.36 to -4.64; participants = 64; moderate-quality evidence), and pain score percentage changes from baseline (MD -12.00; 95% CI -21.82 to -2.18; participants = 64; moderate-quality evidence) were better in participants taking pregabalin compared to those taking placebo.",rephrase,"['This trial found that the changes in opiate use (drugs similar to morphine), and pain scores from baseline were better in participants taking pregabalin compared to those taking placebo.']",8,0.6428571428571429,4,14
CD011522,1,9,This trial also found that there were more adverse events in participants taking pregabalin compared to those taking placebo (RR 1.71; 95% CI 1.20 to 2.43; participants = 64).,rephrase,['It was not clear whether these changes had a significant impact on the life of the participants.This trial also found that there were more side-effects in participants taking pregabalin compared to those taking placebo.'],9,0.7142857142857143,4,14
CD011522,1,10,"The differences between pregabalin and placebo were imprecise for short-term health-related quality of life measured with the EORTC CLQ-30 questionnaire (MD 11.40; 95% CI -3.28 to 26.08; participants = 64; moderate-quality evidence), proportion of people with serious adverse events (RR 1.76; 95% CI 0.35 to 8.96; participants = 64; low-quality evidence), and proportion of people requiring hospital admissions (RR 0.44; 95% CI 0.04 to 4.62; participants = 64; low quality evidence).",rephrase,"['The differences between pregabalin and placebo were imprecise for short-term health-related quality of life, percentage of people with serious side-effects, and percentage of people requiring hospital admissions.']",10,0.7857142857142857,4,14
CD011522,2,11,"Based on low- to moderate-quality evidence, short-term use of pregabalin decreases short-term opiate use, and short-term pain scores, but increases the adverse events compared to placebo, in people with chronic pain due to chronic pancreatitis.",delete,[],11,0.8571428571428571,5,14
CD011522,2,12,The clinical implication of the decreases in short-term opiate use and short-term pain scores is not known.,delete,[],11,0.9285714285714286,5,14
CD011522,3,13,"Future trials assessing the role of pregabalin in decreasing chronic pain in chronic pancreatitis should assess the medium- or long-term effects of pregabalin and should include outcomes such as, quality of life, treatment-related adverse events, number of work days lost, number of hospital admissions, and the length of hospital stay, in addition to pain scores, to assess the clinical and socioeconomic impact.",delete,[],11,1.0,5,14
CD007845,0,0,Four randomised controlled trials with up to three months duration and investigating 479 participants met the inclusion criteria.,delete,[],0,0.1,1,10
CD007845,0,1,Risk of bias of these trials (only two studies were published as a full peer-reviewed publication) was generally high.,rephrase,['This review of trials found only four studies which had an overall low quality.'],0,0.2,1,10
CD007845,0,2,Two RCTs compared the effects of preparations from different parts of the momordica charantia plant with placebo on glycaemic control in type 2 diabetes mellitus.,delete,[],1,0.3,2,10
CD007845,0,3,There was no statistically significant difference in the glycaemic control with momordica charantia preparations compared to placebo.,merge,['Three trials showed no significant differences between momordica charantia and placebo or antidiabetic drugs (glibenclamide and metformin) in the blood sugar response.'],1,0.4,2,10
CD007845,0,4,"When momordica charantia was compared to metformin or glibenclamide, there was also no significant change in reliable parameters of glycaemic control.",none,[],1,0.5,3,10
CD007845,0,5,No serious adverse effects were reported in any trial.,split,"['Adverse effects were mostly moderate, including diarrhoea and abdominal pain.', 'However, reporting of adverse effects was incomplete in the included studies.']",2,0.6,3,10
CD007845,0,6,"No trial investigated death from any cause, morbidity, health-related quality of life or costs.",ignore,"['No trial investigated death from any cause, morbidity, health-related quality of life or costs.']",4,0.7,4,10
CD007845,1,7,There is insufficient evidence on the effects of momordica charantia for type 2 diabetes mellitus.,delete,[],5,0.8,4,10
CD007845,1,8,Further studies are therefore required to address the issues of standardization and the quality control of preparations.,merge,['Further studies are needed to assess the quality of the various momordica charantia preparations as well as to further evaluate its use in the diet of diabetic people.'],5,0.9,5,10
CD007845,1,9,"For medical nutritional therapy, further observational trials evaluating the effects of momordica charantia are needed before RCTs are established to guide any recommendations in clinical practice.",none,[],5,1.0,5,10
CD004479,0,0,"Of 2332 publications obtained through the search strategy, seven studies met the inclusion criteria; one study was ongoing and six studies of 435 participants were eligible for inclusion in the updated review.",rephrase,['We searched the medical literature (January 2017) and identified seven studies that met the inclusion criteria; one study was ongoing and six studies were eligible for inclusion in the updated review.'],0,0.1111111111111111,1,9
CD004479,0,1,"Data show a significant difference in immediate success rates of procedures favouring tube drainage over simple aspiration for management of primary spontaneous pneumothorax (risk ratio (RR) 0.78, 95% confidence interval (CI) 0.69 to 0.89; 435 participants, 6 studies; moderate-quality evidence).",rephrase,['The six included studies comprised a total of 435 participants with primary spontaneous pneumothorax; 208 of these underwent simple aspiration and 227 underwent intercostal tube drainage.'],1,0.2222222222222222,2,9
CD004479,0,2,"Duration of hospitalization however was significantly less for patients treated by simple aspiration (mean difference (MD) -1.66, 95% CI -2.28 to -1.04; 387 participants, 5 studies; moderate-quality evidence).",delete,[],2,0.3333333333333333,2,9
CD004479,0,3,"A narrative synthesis of evidence revealed that simple aspiration led to fewer adverse events (245 participants, 3 studies; low-quality evidence), but data suggest no differences between groups in terms of one-year success rate (RR 1.07, 95% CI 0.96 to 1.18; 318 participants, 4 studies; moderate-quality evidence), hospitalization rate (RR 0.60, 95% CI 0.25 to 1.47; 245 participants, 3 studies; very low-quality evidence), and patient satisfaction (median between-group difference of 0.5 on a scale from 1 to 10; 48 participants, 1 study; low-quality evidence).",delete,[],2,0.4444444444444444,3,9
CD004479,0,4,No studies provided data on cost-effectiveness.,delete,[],2,0.5555555555555556,3,9
CD004479,1,5,"Available trials showed low to moderate-quality evidence that intercostal tube drainage produced higher rates of immediate success, while simple aspiration resulted in a shorter duration of hospitalization.",split,"['Study results show that tube drainage produced a better rate of immediate treatment success when compared with simple aspiration for primary spontaneous pneumothorax.', 'However, simple aspiration was associated with shorter duration of hospitalization and may have led to fewer adverse events.']",2,0.6666666666666666,4,9
CD004479,1,6,"Although adverse events were reported more commonly for patients treated with tube drainage, the low quality of the evidence warrants caution in interpreting these findings.",delete,[],4,0.7777777777777778,4,9
CD004479,1,7,"Similarly, although this review observed no differences between groups when early failure rate, one-year success rate, or hospital admission rate was evaluated, this too needs to be put into the perspective of the quality of evidence, specifically, for evidence of very low and low quality for hospitalization rate and patient satisfaction, respectively.",rephrase,"['Researchers noted no significant differences between the two treatments with regard to hospitalization rate, early failure rate, one-year success rate, or patient satisfaction.']",4,0.8888888888888888,5,9
CD004479,1,8,Future adequately powered research is needed to strengthen the evidence presented in this review.,rephrase,"['The overall quality of evidence ranges from very low to moderate, and future research is needed to strengthen the evidence presented in this review.']",5,1.0,5,9
CD005229,0,0,"We identified two randomised controlled trials that met our inclusion criteria, and we found no new trials when we updated the searches in 2012.",rephrase,['We found no new trials when we updated the searches in 2012.'],0,0.1111111111111111,1,9
CD005229,0,1,"The first, a study with overall unclear risk of bias, examined the effects of a twice-daily exercise program of moderate load endurance exercise versus ""usual activities"" in 25 people with ALS.",delete,[],1,0.2222222222222222,2,9
CD005229,0,2,"The second, a study with overall low risk of bias, examined the effects of thrice weekly moderate load and moderate intensity resistance exercises compared to usual care (stretching exercises) in 27 people with ALS.",rephrase,['The trials compared an exercise program with usual care (stretching exercises).'],1,0.3333333333333333,2,9
CD005229,0,3,"After three months, when the results of the two trials were combined (43 participants), there was a significant mean improvement in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) measure of function in favour of the exercise groups (mean difference 3.21, 95% confidence interval 0.46 to 5.96).",rephrase,"['Combining the results from the two trials (43 participants), exercise produced a greater average improvement in function (measured using an ALS-specific measurement scale) than usual care.']",2,0.4444444444444444,3,9
CD005229,0,4,"No statistically significant differences in quality of life, fatigue or muscle strength were found.",delete,[],3,0.5555555555555556,3,9
CD005229,0,5,"In both trials adverse effects, investigators reported no adverse effects such as increased muscle cramping, muscle soreness or fatigue",delete,[],3,0.6666666666666666,4,9
CD005229,1,6,"The included studies were too small to determine to what extent strengthening exercises for people with ALS are beneficial, or whether exercise is harmful.",rephrase,['The studies were too small to determine to what extent exercise for people with ALS is beneficial or whether exercise is harmful.'],3,0.7777777777777778,4,9
CD005229,1,7,There is a complete lack of randomised or quasi-randomised clinical trials examining aerobic exercise in this population.,delete,[],4,0.8888888888888888,5,9
CD005229,1,8,More research is needed.,ignore,['More research is needed.'],4,1.0,5,9
CD004363,0,0,Two trials including a total of 81 participants fulfilled the inclusion criteria for this review.,delete,[],0,0.05,1,20
CD004363,0,1,All participants in both studies had a history of postnatal depression and were not taking antidepressant medication at baseline.,rephrase,"['All the women in these trials had a history of postnatal depression, but were not depressed or using antidepressants at the beginning of the studies.']",0,0.1,1,20
CD004363,0,2,Both trials were conducted by the same research group.,rephrase,"['We could only identify two relevant studies, which had small numbers of participants and inconsistent findings, and were conducted by the same research group.']",1,0.15,1,20
CD004363,0,3,Risk of bias was low or unclear in most domains for both studies.,delete,[],2,0.2,1,20
CD004363,0,4,We were unable to perform a meta-analysis due to the small number of studies.,delete,[],2,0.25,2,20
CD004363,1,5,One study compared nortriptyline with placebo and did not find any evidence that nortriptyline was effective in preventing postnatal depression.,rephrase,['Both studies compared antidepressant medicine with placebo.'],2,0.3,2,20
CD004363,1,6,"In this study, 23% (6/26) of women who took nortriptyline and 24% (6/25) of women who took placebo experienced postnatal depression (RR 0.96, 95% CI 0.36 to 2.59, very low quality evidence) in the first 17 weeks postpartum.",rephrase,"['During the 17-week treatment period, 6 of the 26 women taking nortriptyline experienced postnatal depression compared with 6 of the 25 women taking placebo.']",3,0.35,2,20
CD004363,1,7,"One woman taking nortriptyline developed mania; and one side effect, constipation, was more common among women taking nortriptyline than those taking placebo.",rephrase,"['One woman taking nortriptyline developed mania (a state of abnormally high arousal and energy level), and constipation was more common among women taking nortriptyline, but other unwanted, or harmful, effects did not differ between groups.']",4,0.4,2,20
CD004363,2,8,The second study compared sertraline with placebo.,delete,[],5,0.45,3,20
CD004363,2,9,"In this study, 7% (1/14) of women who took sertraline developed postnatal depression in the first 17 weeks postpartum compared with 50% (4/8) of women who took placebo.",split,"['In the sertraline study, 1 of the 14 women taking sertraline developed postnatal depression compared with 4 of the 8 women taking placebo (during the 17-week treatment period).', ""This study was very small, so we can't be sure whether the difference between sertraline and placebo is due to chance, or whether sertraline does prevent postnatal depression among women with a history of postnatal depression.""]",5,0.5,3,20
CD004363,2,10,"It is uncertain whether sertraline reduces the risk of postnatal depression (RR 0.14, 95% CI 0.02 to 1.07, very low quality evidence).",delete,[],7,0.55,3,20
CD004363,2,11,One woman taking sertraline had a hypomanic episode.,merge,['One woman taking sertraline experienced a hypomanic episode (a state like mania but less severe); and dizziness and drowsiness were more common among women taking sertraline than women taking placebo.'],7,0.6,3,20
CD004363,2,12,Two side effects (dizziness and drowsiness) were more common among women taking sertraline than women taking placebo.,none,[],7,0.65,4,20
CD004363,3,13,"Conclusions are limited by the small number of studies, small sample sizes and incomplete outcome data due to study drop-out which may have led to bias in the results.",delete,[],8,0.7,4,20
CD004363,3,14,"We have assessed the certainty of the evidence as very low, based on the GRADE system.",delete,[],8,0.75,4,20
CD004363,3,15,"No data were available on secondary outcomes of interest including child development, the mother‒infant relationship, breastfeeding, maternal daily functioning, family relationships or maternal satisfaction.",delete,[],8,0.8,4,20
CD004363,4,16,"Due to the limitations of the current evidence base, such as the low statistical power of the included studies, it is not possible to draw any clear conclusions about the effectiveness of antidepressants for the prevention of postnatal depression.",rephrase,['Further studies with larger samples are needed before we can know whether antidepressants can prevent postnatal depression.'],8,0.85,5,20
CD004363,4,17,It is striking that no new eligible trials have been completed in the period of over a decade since the last published version of this review.,rephrase,['It is worth noting that no new relevant trials have been completed in the 10 years since we last examined this evidence.'],9,0.9,5,20
CD004363,4,18,"Larger trials are needed which include comparisons of antidepressant drugs with other prophylactic treatments (e.g. psychological interventions), and examine adverse effects for the fetus or infant.",rephrase,['We also need studies which have longer follow-ups periods; examine outcomes and side effects for both the mother and fetus or breastfeeding infant; and compare antidepressants with other preventative interventions (such as psychological therapies).'],10,0.95,5,20
CD004363,4,19,"Future reviews in this area may benefit from broadening their focus to examine the effectiveness of antidepressants for the prevention of perinatal (i.e. antenatal or postnatal) depression, which could include studies comparing antidepressant discontinuation with continuation for the prevention of relapse of depression during pregnancy and the postnatal period.",rephrase,['It may be useful for future medical studies to investigate whether antidepressants can prevent depression during pregnancy as well as during the postnatal period; and whether women who continue to take antidepressants during pregnancy (compared with stopping medication) are less likely to have a relapse of depression at this time.'],11,1.0,5,20
CD007109,0,0,We found nine trials with 855 participants that randomised participants to fewer-than-four-ports laparoscopic cholecystectomy (n = 427) versus four-port laparoscopic cholecystectomy (n = 428).,split,"['We identified nine trials that compared fewer-than-four-ports laparoscopic cholecystectomy with four-port laparoscopic cholecystectomy.', 'In these nine studies, 855 participants were included.']",0,0.06666666666666667,1,15
CD007109,0,1,Most trials included low anaesthetic risk participants undergoing elective laparoscopic cholecystectomy.,rephrase,['Most of these studies included low anaesthetic risk patients undergoing planned laparoscopic cholecystectomy.'],2,0.13333333333333333,1,15
CD007109,0,2,Seven of the nine trials used a single port laparoscopic cholecystectomy and the remaining two trials used three-port laparoscopic cholecystectomy as the experimental intervention.,delete,[],3,0.2,1,15
CD007109,0,3,Only one trial including 70 participants had low risk of bias.,delete,[],3,0.26666666666666666,2,15
CD007109,0,4,Fewer-than-four-ports laparoscopic cholecystectomy could be completed successfully in more than 90% of participants in most trials.,ignore,['Fewer-than-four-ports laparoscopic cholecystectomy could be completed successfully in more than 90% of participants in most of the trials.'],3,0.3333333333333333,2,15
CD007109,0,5,The remaining participants were mostly converted to four-port laparoscopic cholecystectomy but some participants had to undergo open cholecystectomy.,rephrase,['The remaining participants were mostly converted to four-port laparoscopic cholecystectomy but some participants had to undergo open cholecystectomy (through a large incision in the abdomen).'],4,0.4,2,15
CD007109,1,6,There was no mortality in either group in the seven trials that reported mortality (318 participants in fewer-than-four-ports laparoscopic cholecystectomy group and 316 participants in four-port laparoscopic cholecystectomy group).,rephrase,['There was no mortality in either group in the seven trials that reported mortality (634 participants in the two groups).'],5,0.4666666666666667,3,15
CD007109,1,7,The proportion of participants with serious adverse events was low in both treatment groups and the estimated RR was compatible with a reduction and substantial increased risk with the fewer-than-four-ports group (6/318 (1.9%)) and four-port laparoscopic cholecystectomy group (0/316 (0%)) (RR 3.93; 95% CI 0.86 to 18.04; 7 trials; 634 participants; very low quality evidence).,delete,[],6,0.5333333333333333,3,15
CD007109,1,8,"The estimated difference in the quality of life (measured between 10 and 30 days) was imprecise (standardised mean difference (SMD) 0.18; 95% CI -0.05 to 0.42; 4 trials; 510 participants; very low quality evidence), as was the proportion of participants in whom the laparoscopic cholecystectomy had to be converted to open cholecystectomy between the groups (fewer-than-four ports 3/289 (adjusted proportion 1.2%) versus four port: 5/292 (1.7%); RR 0.68; 95% CI 0.19 to 2.35; 5 trials; 581 participants; very low quality evidence).",rephrase,"['There was no significant difference in the proportion of participants who developed serious complications, quality of life between 10 and 30 days after operation, proportion of participants in whom the laparoscopic operation had to be converted to open cholecystectomy, or in the length of hospital stay between the groups.']",6,0.6,3,15
CD007109,1,9,The fewer-than-four-ports laparoscopic cholecystectomy took 14 minutes longer to complete (MD 14.44 minutes; 95% CI 5.95 to 22.93; 9 trials; 855 participants; very low quality evidence).,rephrase,['Fewer-than-four-ports laparoscopic cholecystectomy took about 15 minutes longer to complete than four-port laparoscopic cholecystectomy.'],7,0.6666666666666666,4,15
CD007109,1,10,There was no clear difference in hospital stay between the groups (MD -0.01 days; 95% CI -0.28 to 0.26; 6 trials; 731 participants) or in the proportion of participants discharged as day surgery (RR 0.92; 95% CI 0.70 to 1.22; 1 trial; 50 participants; very low quality evidence) between the two groups.,delete,[],8,0.7333333333333333,4,15
CD007109,1,11,The times taken to return to normal activity and work were shorter by two days in the fewer-than-four-ports group compared with four-port laparoscopic cholecystectomy (return to normal activity: MD -1.20 days; 95% CI -1.58 to -0.81; 2 trials; 325 participants; very low quality evidence; return to work: MD -2.00 days; 95% CI -3.31 to -0.69; 1 trial; 150 participants; very low quality evidence).,rephrase,['The time taken to return to normal activity was one day shorter and time taken to return to work two days shorter in the fewer-than-four-ports group compared with four-port laparoscopic cholecystectomy.'],8,0.8,4,15
CD007109,1,12,There was no significant difference in cosmesis scores at 6 to 12 months between the two groups (SMD 0.37; 95% CI -0.10 to 0.84; 2 trials; 317 participants; very low quality evidence).,rephrase,['There was no significant difference in the cosmetic appearance between the two groups at 6 to 12 months after surgery.'],9,0.8666666666666667,5,15
CD007109,2,13,There is very low quality evidence that is insufficient to determine whether there is any significant clinical benefit in using fewer-than-four-ports laparoscopic cholecystectomy compared with four-port laparoscopic cholecystectomy.,rephrase,['The overall quality of evidence was very low.'],10,0.9333333333333333,5,15
CD007109,2,14,The safety profile of using fewer-than-four ports is yet to be established and fewer-than-four-ports laparoscopic cholecystectomy should be reserved for well-designed randomised clinical trials.,split,"['In contrast, the safety of fewer-than-four port laparoscopic cholecystectomy is yet to be established.', 'Fewer-than-four-ports laparoscopic cholecystectomy cannot be recommended routinely outside well-designed clinical trials.']",11,1.0,5,15
CD010173,0,0,"We included 18 studies, recruiting 72,202 participants, published between 1986 and 2019.",ignore,"['We included 18 studies recruiting 72,202 participants, published between 1986 and 2019.']",0,0.07142857142857142,1,14
CD010173,0,1,"These studies evaluated the diagnostic test accuracy of conventional oral examination (10 studies, none new to this update), mouth self-examination (four studies, two new to this update), and remote screening (three studies, all new to this update).",rephrase,"['These studies evaluated a conventional oral examination (COE) or visual inspection (10 studies), mouth self-examination (four studies), and remote screening (three studies).']",1,0.14285714285714285,1,14
CD010173,0,2,One randomised controlled trial of test accuracy directly evaluated conventional oral examination plus vital rinsing versus conventional oral examination alone.,ignore,['One randomised controlled trial of test accuracy directly compared conventional oral examination plus vital rinsing with conventional oral examination alone.'],2,0.21428571428571427,2,14
CD010173,0,3,There were no eligible studies evaluating light-based detection or blood or salivary sample analysis (which tests for the presence of biomarkers for OPMD and OSCC).,rephrase,['No eligible studies evaluated the accuracy of tests of blood or saliva.'],3,0.2857142857142857,2,14
CD010173,0,4,Only one study of conventional oral examination was judged as at overall low risk of bias and overall low concern regarding applicability.,delete,[],4,0.35714285714285715,2,14
CD010173,1,5,"Given the clinical heterogeneity of the included studies in terms of the participants recruited, setting, prevalence of the target condition, the application of the index test and reference standard, and the flow and timing of the process, the data could not be pooled within the broader categories of index test.",delete,[],4,0.42857142857142855,3,14
CD010173,1,6,"For conventional oral examination (10 studies, 25,568 participants), prevalence in the test accuracy sample ranged from 1% to 51%.",split,"['- Most studies evaluated the accuracy of the different COEs (10 studies, 25,568 participants).', 'The prevalence of mouth cancer or OPMDs in these studies ranged from 1% to 51%.']",4,0.5,3,14
CD010173,1,7,"For the seven studies with prevalence of 10% or lower, a prevalence more comparable to the general population, the sensitivity estimates were variable, and ranged from 0.50 (95% confidence interval (CI) 0.07 to 0.93) to 0.99 (95% CI 0.97 to 1.00); the specificity estimates were more consistent and ranged from 0.94 (95% CI 0.88 to 0.97) to 0.99 (95% CI 0.98 to 1.00).",rephrase,"['For the seven COE studies with a prevalence of 10% or lower, a prevalence more comparable to the general population, the sensitivity estimates (proportion of true positives) ranged from 0.50 to 0.99 with specificity estimates (proportion of true negatives) from 0.94 to 0.99.']",6,0.5714285714285714,3,14
CD010173,1,8,"We judged the overall certainty of the evidence to be low, and downgraded for inconsistency and indirectness.",delete,[],7,0.6428571428571429,4,14
CD010173,2,9,Evidence for mouth self-examination and remote screening was more limited.,rephrase,"['- Evidence for mouth self-examination (4 studies, 35,059 participants) and remote screening (3 studies, 3600 participants) was more limited.']",7,0.7142857142857143,4,14
CD010173,2,10,"We judged the overall certainty of the evidence for these index tests to be very low, and downgraded for imprecision, inconsistency, and indirectness.",split,"['We judged the overall certainty of the evidence for COE to be low and downgraded for the variation across studies and applicability of the study samples.', 'We judged the overall certainty of the evidence for mouth self-examination and remote screening to be very low, and downgraded for variation across studies, applicability of the study samples, and imprecise accuracy estimates.']",8,0.7857142857142857,4,14
CD010173,2,11,"We judged the evidence for vital rinsing (toluidine blue) as an adjunct to conventional oral examination compared to conventional oral examination to be moderate, and downgraded for indirectness as the trial was undertaken in a high-risk population.",delete,[],10,0.8571428571428571,5,14
CD010173,3,12,There is a lack of high-certainty evidence to support the use of screening programmes for oral cavity cancer and OPMD in the general population.,delete,[],10,0.9285714285714286,5,14
CD010173,3,13,"Frontline screeners such as general dentists, dental hygienists, other allied professionals, and community healthcare workers should remain vigilant for signs of OPMD and OSCC.",delete,[],10,1.0,5,14
CD011458,0,0,"We obtained and scrutinised 41 potentially relevant records, and from these we could include only six trials (n = 1835).",rephrase,['The review includes six trials with 1835 people.'],0,0.1,1,10
CD011458,0,1,Five of the six trials had high risk of attrition bias and all trials were sponsored by pharmaceutical companies.,rephrase,['Five of these trials had high rates of people leaving early and were sponsored by pharmaceutical companies.'],1,0.2,1,10
CD011458,0,2,"Results showed a clinically important change in global state (1 RCT, n = 336, RR 0.81, 95% CI 0.68 to 0.97, low-quality evidence) and mental state (1 RCT, n = 336, RR 0.72, 95% CI 0.59 to 0.86, very low-quality evidence) at short-term amongst people receiving asenapine.",delete,[],2,0.3,2,10
CD011458,0,3,"People receiving asenapine demonstrated significant reductions in negative symptoms (1 RCT, n = 336, MD -1.10, 95% CI -2.29 to 0.09, very low-quality evidence) at short-term.",delete,[],2,0.4,2,10
CD011458,0,4,"Individuals receiving asenapine demonstrated significantly fewer incidents of serious adverse effects (1 RCT, n = 386, RR 0.29, 95% CI 0.14 to 0.63, very low-quality evidence) at medium-term.",delete,[],2,0.5,3,10
CD011458,0,5,"There was no clear difference in people discontinuing the study for any reason between asenapine and placebo at short-term (5 RCTs, n = 1046, RR 0.91, 95% CI 0.80 to 1.04, very low-quality evidence).",delete,[],2,0.6,3,10
CD011458,0,6,No trial reported data for extrapyramidal symptoms or costs.,delete,[],2,0.7,4,10
CD011458,1,7,"There is some, albeit preliminary, evidence that asenapine provides an improvement in positive, negative, and depressive symptoms, whilst minimising the risk of adverse effects.",rephrase,"['There is some evidence that asenapine, when compared to placebo, improves the positive, negative and depressive symptoms of schizophrenia while having less risk of debilitating side effects.']",2,0.8,4,10
CD011458,1,8,"However due to the low-quality and limited quantity of evidence, it remains difficult to recommend the use of asenapine for people with schizophrenia.",rephrase,"['However, due to the low quantity and limited quality of evidence currently available, it remains difficult to recommend the use of asenapine for schizophrenia.']",3,0.9,5,10
CD011458,1,9,"We identify a need for large-scale, longer-term, better-designed and conducted randomised controlled trials investigating the clinical effects and safety of asenapine.",rephrase,"['There is a need for large-scale, longer-term follow up, and bias-free randomised controlled trials investigating the effects and safety of asenapine.']",4,1.0,5,10
CD010471,0,0,We found 13 eligible systematic reviews relevant to this overview that contained a total of 17 relevant RCTs.,rephrase,['This overview drew together and summarised evidence from 13 systematic reviews that contained 17 relevant randomised controlled trials (the best type of study for this type of question) published up to 2013.'],0,0.14285714285714285,1,7
CD010471,0,1,"One review reported the results of a network meta-analysis and so presented information on indirect, as well as direct, treatment effects.",delete,[],1,0.2857142857142857,2,7
CD010471,0,2,Collectively the reviews reported findings for 11 different comparisons supported by direct data and 26 comparisons supported by indirect data only.,rephrase,"['Collectively, these trials compared 10 different types of wound dressings against each other, making a total of 37 separate comparisons.']",1,0.42857142857142855,3,7
CD010471,0,3,"Only four comparisons informed by direct data found evidence of a difference in wound healing between dressing types, but the evidence was assessed as being of low or very low quality (in one case data could not be located and checked).",rephrase,"['Only four of the comparisons informed by direct data found evidence of a difference in ulcer healing between dressings, but these results were classed as low quality evidence.']",2,0.5714285714285714,3,7
CD010471,0,4,There was also no robust evidence of a difference between dressing types for any secondary outcomes assessed.,rephrase,"[""There was no clear evidence that any of the 'advanced' wound dressings types were any better than basic wound contact dressings for healing foot ulcers.""]",3,0.7142857142857143,4,7
CD010471,1,5,There is currently no robust evidence for differences between wound dressings for any outcome in foot ulcers in people with diabetes (treated in any setting).,rephrase,"['Until there is a clear answer about which type of dressing performs best for healing foot ulcers in people with diabetes, other factors, such as clinical management of the wound, cost, and patient preference and comfort, should influence the choice of dressing.']",4,0.8571428571428571,5,7
CD010471,1,6,"Practitioners may want to consider the unit cost of dressings, their management properties and patient preference when choosing dressings.",delete,[],5,1.0,5,7
CD001187,0,0,We included 55 trials (3121 patients).,rephrase,['We included 55 randomised trials on 3121 people with asthma.'],0,0.1111111111111111,1,9
CD001187,0,1,"Thirty-seven trials assessed physical methods, including 26 trials employing mattress encasings.",rephrase,['There are both chemical (10 trials) and physical methods such as mattress encasings (37 trials) of reducing mite allergen levels and we included both types in this review.'],1,0.2222222222222222,2,9
CD001187,0,2,Ten trials involved chemical methods and eight trials involved a combination of chemical and physical methods.,rephrase,['There were also eight trials that used both physical and chemical methods.'],2,0.3333333333333333,2,9
CD001187,0,3,"Despite the fact that many trials were of poor quality and would be expected to exaggerate the reported effect, we did not find an effect of the interventions.",rephrase,"['Many trials were of poor quality and would therefore be expected to exaggerate the reported effect, but we did not find an effect of the interventions.']",3,0.4444444444444444,3,9
CD001187,0,4,"For the most frequently reported outcome, peak flow in the morning (1665 patients), the standardised mean difference (SMD) was 0.01 (95% confidence interval (CI) -0.08 to 0.11).",delete,[],4,0.5555555555555556,3,9
CD001187,0,5,"There were no statistically significant differences either in number of patients improved (risk ratio 1.01, 95% CI 0.80 to 1.27), asthma symptom scores (SMD -0.06, 95% CI -0.16 to 0.05), or in medication usage (SMD -0.05, 95% CI -0.17 to 0.07).",rephrase,"['There was no difference in peak flow (a measure of lung function), asthma symptoms and medication scores, or the number of patients reporting an improvement in their asthma symptoms.']",4,0.6666666666666666,4,9
CD001187,1,6,Chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended.,rephrase,"['While reducing exposure to house dust mites is recommended in guidelines, we did not find an effect of control measures to reduce the exposure to mites or their products.']",5,0.7777777777777778,4,9
CD001187,1,7,"It is doubtful whether further studies, similar to the ones in our review, are worthwhile.",delete,[],6,0.8888888888888888,5,9
CD001187,1,8,"If other types of studies are considered, they should be methodologically rigorous and use other methods than those used so far, with careful monitoring of mite exposure and relevant clinical outcomes.",delete,[],6,1.0,5,9
CD004958,0,0,Thirty-three small studies ( 2267 patients) compared different fusion techniques.,rephrase,['This review of 33 small studies (2267 participants) evaluated fusion techniques used to treat degenerative disc disease.'],0,0.125,1,8
CD004958,0,1,"The major treatments were discectomy alone, addition of an interbody fusion procedure (autograft, allograft, cement, or cage), and addition of anterior plates.",rephrase,"['The major treatments were discectomy (removal of the damaged disc) alone, addition of a fusion procedure (bone transplanted from another part of the body, cement, or cage), and addition of a plate.']",1,0.25,2,8
CD004958,0,2,Eight studies had a low risk of bias.,delete,[],2,0.375,2,8
CD004958,0,3,"Few studies reported on pain, therefore, at best, there was very low quality evidence of little or no difference in pain relief between the different techniques.",delete,[],2,0.5,3,8
CD004958,0,4,"We found moderate quality evidence for these secondary outcomes: no statistically significant difference in Odom's criteria between iliac crest autograft and a metal cage (6 studies, RR 1.11 (95% CI 0.99 to1.24)); bone graft produced more effective fusion than discectomy alone (5 studies, RR 0.22 (95% CI 0.17 to 0.48)); no statistically significant difference in complication rates between discectomy alone and iliac crest autograft (7 studies, RR 1.56 (95% CI 0.71 to 3.43)); and low quality evidence that iliac crest autograft results in better fusion than a cage (5 studies, RR 1.87 (95% CI 1.10 to 3.17)); but more complications (7 studies, RR 0.33 (95% CI 0.12 to 0.92)).",rephrase,['There is moderate quality evidence that there was little or no difference in Odom’s criteria (a tool that measures the success of the surgery at relieving the symptoms that were troublesome prior to the surgery) between those who received a bone transplant from the hip and a metal cage to help with fusion.'],2,0.625,4,8
CD004958,1,5,"When the working mechanism for pain relief and functional improvement is fusion of the motion segment, there is low quality evidence that iliac crest autograft appears to be the better technique.",merge,"['There is low quality evidence that transplanting bone from the iliac crest is more effective in achieving fusion than using a cage, while cages are more effective in preventing complications.']",3,0.75,4,8
CD004958,1,6,"When ignoring fusion rates and looking at complication rates, a cage has a weak evidence base over iliac crest autograft, but not over discectomy alone.",none,[],3,0.875,5,8
CD004958,1,7,"Future research should compare additional instrumentation such as screws, plates, and cages against discectomy with or without autograft.",delete,[],4,1.0,5,8
CD008019,0,0,We included eight studies with a total of 2227 women undergoing elective caesarean section.,rephrase,['We identified eight studies with a total of 2227 women undergoing elective (planned) caesarean section before the onset of labour.'],0,0.09090909090909091,1,11
CD008019,0,1,"Of these, 1097 underwent intraoperative cervical dilatation with a double-gloved index finger or Hegar dilator inserted into the cervical canal to dilate, and 1130 did not undergo intraoperative cervical dilatation.",rephrase,"['Of these women, 1097 underwent cervical dilatation with a double-gloved index finger, or in one study with a Hegar dilator, during surgery, while 1130 did not undergo cervical dilatation during surgery.']",1,0.18181818181818182,1,11
CD008019,0,2,Six of the eight included trials had high risk of bias for some of the risk of bias domains.,delete,[],2,0.2727272727272727,2,11
CD008019,1,3,"Very low-quality evidence suggested it was unclear whether cervical dilatation had any impact on postpartum haemorrhage (estimated blood loss greater than 1000 mL; risk ratio (RR) 1.97, 95% confidence interval (CI) 0.48 to 8.13; 5/205 versus 3/242; one study, 447 women).",rephrase,"['Low- or very low-quality evidence suggested it was unclear whether cervical dilatation had any impact on postpartum haemorrhage (estimated blood loss greater than 1000 mL), the need for blood transfusion, and other measures of blood loss, postpartum haemorrhage within six weeks, febrile morbidity (infection indicated by increased temperature over a defined time period), endometritis (infection of the lining of the womb), or uterine subinvolution (uterus not returning to its normal size after childbirth).']",2,0.36363636363636365,2,11
CD008019,2,4,"Low- or very low-quality evidence showed no clear difference for the need for blood transfusion (RR 3.54, 95% CI 0.37 to 33.79; two studies, 847 women); postoperative haemoglobin (mean difference (MD -0.05, 95% CI -0.15 to 0.06; three studies, 749 women), or haematocrit (MD 0.01%, 95% CI -0.18 to 0.20; one study, 400 women); the incidence of drop from baseline haemoglobin above 0.5 g/dL (RR 0.92, 95% CI 0.64 to 1.31; two studies, 722 women), or amount of haemoglobin drop (MD -0.01 g/dL, 95% -0.14 to 0.13; three studies, 796 women); the incidence of secondary postpartum haemorrhage within six weeks (RR 1.18, 95% CI 0.07 to 18.76; one study, 447 women); febrile morbidity (RR 1.18, 95% CI 0.76 to 1.85; seven studies, 2126 women); endometritis (RR 0.94, 95% CI 0.35 to 2.52; four studies, 1536 women); or uterine subinvolution (RR 0.34, 95% CI 0.08 to 1.36; two studies, 654 women); the results crossed the line of no effect for all of the outcomes.",delete,[],3,0.45454545454545453,3,11
CD008019,2,5,There were no data for cervical trauma.,ignore,['There were no data for cervical trauma.'],3,0.5454545454545454,3,11
CD008019,3,6,"We found a slight improvement with mechanical dilatation for these secondary outcomes, not prespecified in the protocol: mean blood loss, endometrial cavity thickness, retained products of conception, distortion of uterine incision, and healing ratio.",merge,"['We found a slight improvement with mechanical dilatation for some outcomes that had not been specified in our original protocol, but the evidence for these outcomes was based on one or two studies (mean blood loss, endometrial cavity thickness, retained products of conception, distortion of uterine incision, and healing ratio).']",4,0.6363636363636364,4,11
CD008019,3,7,The evidence for these outcomes was based on one or two studies.,none,[],4,0.7272727272727273,4,11
CD008019,3,8,"Cervical dilatation did not have a clear effect on these secondary outcomes, not prespecified in the protocol: wound infection, urinary tract infection, operative time, infectious morbidity, and integrity of uterine scar.",ignore,"['Cervical dilatation did not have a clear effect on other secondary outcomes, (again not specified in our original protocol): wound infection, urinary tract infection, operative time, infectious morbidity, and integrity of uterine scar.']",5,0.8181818181818182,5,11
CD008019,4,9,"At this time, the evidence does not support or refute the use of mechanical dilatation of the cervix during elective caesarean section for reducing postoperative morbidity.",split,"['It is uncertain whether cervical dilatation has any impact on reducing postoperative problems after caesarean section.', 'This means there is insufficient evidence to encourage or discourage the use of mechanical dilatation of the cervix at elective caesarean section for reducing postoperative ill-health.']",6,0.9090909090909091,5,11
CD008019,5,10,"Further large, well-designed studies are required to compare the effect of intraoperative mechanical dilatation of the cervix with no intraoperative mechanical cervical dilatation for reducing postoperative morbidity.",delete,[],8,1.0,5,11
CD008935,0,0,None of the 1328 studies that were identified satisfied the inclusion criteria.,delete,[],0,0.14285714285714285,1,7
CD008935,1,1,"Based on this review, we cannot make any new recommendations on the effectiveness of adrenaline auto-injectors for the treatment of anaphylaxis.",split,"['Our searches found many studies relating to anaphylaxis and adrenaline auto-injector use but no randomized controlled trials on this subject.', 'We concluded that the use of adrenaline auto-injectors in anaphylaxis is based on the best available information at present.']",0,0.2857142857142857,2,7
CD008935,1,2,"Although randomized, double-blind, placebo-controlled clinical trials of high methodological quality are necessary to define the true extent of benefits from the administration of adrenaline in anaphylaxis via an auto-injector, such trials are unlikely to be performed in individuals experiencing anaphylaxis because of ethical concerns associated with randomization to placebo.",rephrase,['There is no evidence from randomized controlled trials for the effectiveness of adrenaline auto-injectors in the emergency treatment of anaphylaxis in the community.'],2,0.42857142857142855,3,7
CD008935,1,3,"There is, however, a need to consider trials in which, for example, auto-injectors of different doses of adrenaline and differing devices are compared in order to provide greater clarity on the dose and device of choice.",delete,[],3,0.5714285714285714,3,7
CD008935,1,4,Such trials would be practically challenging to conduct.,rephrase,"['Such trials would ideally involve comparison of adrenaline with placebo; however, use of a placebo in anaphylaxis treatment would be unethical.']",3,0.7142857142857143,4,7
CD008935,1,5,"In the absence of appropriate trials, we recommend that adrenaline administration by auto-injector should still be regarded as the most effective first-line treatment for the management of anaphylaxis in the community.",split,"['We therefore conducted a systematic review of the literature, searching key databases for high quality published and unpublished material on the use of adrenaline auto-injectors during episodes of anaphylaxis in the community.', 'We therefore recommend that auto-injectors remain the medication of first choice in the treatment of anaphylaxis in the community.']",4,0.8571428571428571,5,7
CD008935,1,6,"In countries where auto-injectors are not commonly used, it may be possible to conduct trials to compare administration of adrenaline via auto-injector with adrenaline administered by syringe and ampoule, or comparing the effectiveness of two different types of auto-injector.",delete,[],6,1.0,5,7
CD002996,0,0,Eleven studies met the inclusion criteria of the review (1021 participants).,rephrase,['We found 11 randomised controlled trials on 1021 participants that compared inhaled hyperosmolar agents versus no mucolytic treatment.'],0,0.0625,1,16
CD002996,1,1,Five studies on 833 participants compared inhaled mannitol with placebo but poor outcome reporting meant we could pool very little data and most outcomes were reported by only one study.,rephrase,['Five studies compared inhaled mannitol versus placebo (with a total of 883 participants) and two very small studies (with a total of just 25 participants) compared inhaled mannitol with no treatment.'],1,0.125,1,16
CD002996,1,2,"One 12-month trial on 461 participants provided results for exacerbations and demonstrated an advantage for mannitol in terms of time to first exacerbation (median time to exacerbation 165 versus 124 days for mannitol and placebo respectively (hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.63 to 0.96, P = 0.022) and number of days on antibiotics for bronchiectasis exacerbations was significantly better with mannitol (risk ratio (RR) 0.76, 95%CI 0.58 to 1.00, P = 0.0496).",rephrase,['For the comparison between mannitol and placebo only one study (a 12-month trial with 461 participants) provided information on the number of people who had an exacerbation (or flare up) over the course of a year.'],2,0.1875,1,16
CD002996,1,3,"However, exacerbation rate per year was not significantly different between mannitol and placebo (RR 0.92 95% CI 0.78 to 1.08).",rephrase,['This study showed that people who were treated with mannitol had 8% fewer exacerbations on average compared with placebo.'],3,0.25,2,16
CD002996,1,4,The quality of this evidence was rated as moderate.,rephrase,"['Taking this into account, the quality of evidence was generally regarded as moderate both for the mannitol and hypertonic saline studies.']",4,0.3125,2,16
CD002996,1,5,"There was also an indication, from only three trials, again based on moderate quality evidence, that mannitol improves health-related quality of life (mean difference (MD) -2.05; 95% CI -3.69 to -0.40).",rephrase,"['Three trials assessed the effect of mannitol on health-related quality of life, and again the quality of the evidence was rated as moderate.']",5,0.375,2,16
CD002996,1,6,"An analysis of adverse events data, also based on moderate quality evidence, revealed no difference between mannitol and placebo (OR 0.96; 95% CI 0.61 to 1.51).",split,"['An analysis of adverse events data, also based on moderate quality evidence, revealed no difference between mannitol and placebo\nThe trials comparing hypertonic saline with isotonic saline had conflicting results for most of the outcomes of interest.', 'Our analysis of adverse events between hypertonic saline versus isotonic saline showed no significant difference however this was based on a single study and the quality of the evidence was moderate.']",6,0.4375,3,16
CD002996,1,7,Two additional small trials on 25 participants compared mannitol versus no treatment and the data from these studies were inconclusive.,delete,[],8,0.5,3,16
CD002996,2,8,Four studies (combined N = 113) compared hypertonic saline versus isotonic saline.,delete,[],8,0.5625,3,16
CD002996,2,9,On most outcomes there were conflicting results and the opportunities for the statistical aggregation of data from studies was very limited.,delete,[],8,0.625,4,16
CD002996,2,10,It is not possible to draw robust conclusions for this comparison and judgments should be reserved until further data are available.,rephrase,"['Because we were unable to combine the data, it is not possible to draw robust conclusions for this comparison and judgments should be reserved until further data are available.']",8,0.6875,4,16
CD002996,3,11,"There is an indication from a single, large, unpublished study that inhaled mannitol increases time to first exacerbation in patients with bronchiectasis.",delete,[],9,0.75,4,16
CD002996,3,12,"In patients with near normal lung function, spirometry does not change dramatically with mannitol and adverse events are not more frequent than placebo.",delete,[],9,0.8125,5,16
CD002996,3,13,Further investigation is required in a patient population with impaired lung function.,delete,[],9,0.875,5,16
CD002996,4,14,"It is not possible to draw firm conclusions regarding the effect of nebulised hypertonic saline due to significant differences in the methodology, patient groups, and findings amongst the limited data available.",delete,[],9,0.9375,5,16
CD002996,4,15,"The data suggest that it is unlikely to have benefit over isotonic saline in patients with milder disease, and hence future studies should test its use in those with more severe disease",delete,[],9,1.0,5,16
CD004396,0,0,"Four trials are now included in the review, with 753 participants.",rephrase,['Four studies with 753 participants were included in this review.'],0,0.1111111111111111,1,9
CD004396,0,1,"They were different in many ways including the intervention, duration, outcomes and control group so pooling of data was not possible.",rephrase,['We were not able to pool the results of the studies as there were so few studies and they measured the outcomes in different ways.'],1,0.2222222222222222,2,9
CD004396,0,2,"Overall, the quality of the evidence was rated as very low.",delete,[],2,0.3333333333333333,2,9
CD004396,0,3,Re-analysis of outcomes using data from the published studies found no significant effects of respite care compared to no respite care on any caregiver variable.,delete,[],2,0.4444444444444444,3,9
CD004396,0,4,"When respite care was compared to polarity therapy a significant effect was found in favour of polarity therapy for caregiver perceived stress (n = 38, MD 5.80, 95% CI 1.43 to 10.17), but not for other measures of psychological health and other caregiver outcomes.",rephrase,['The study that compared respite care to polarity therapy found that polarity therapy decreased caregiver perceived stress but that there was no difference between polarity therapy and respite care for other measures of psychological health and other caregiver outcomes.'],2,0.5555555555555556,3,9
CD004396,0,5,No studies reported evaluable data on outcomes related to the people with dementia.,split,"['All studies included people with dementia and their caregivers.', 'All the studies reported outcomes for the caregiver, but only one reported outcomes for the person with dementia.']",3,0.6666666666666666,4,9
CD004396,1,6,Current evidence does not demonstrate any benefits or adverse effects from the use of respite care for people with dementia or their caregivers.,rephrase,"['The three studies that compared respite care to no respite care found no evidence of any benefit of respite care for people with dementia or for their caregivers for any outcome, including rates of institutionalisation and caregiver burden.']",5,0.7777777777777778,4,9
CD004396,1,7,"These results should be treated with caution, however, as they may reflect the lack of high quality research in this area rather than an actual lack of benefit.",delete,[],6,0.8888888888888888,5,9
CD004396,1,8,"Given the frequency with which respite care is advocated and provided, well-designed trials are needed in this area.",delete,[],6,1.0,5,9
CD009255,0,0,We identified four reviews reporting on 32 studies.,ignore,['We identified four reviews reporting on 32 studies.'],0,0.1111111111111111,1,9
CD009255,0,1,"Two reviews scored 7 on the AMSTAR criteria (moderate, score 5 to 7, quality) and two scored 9 (high, score 8 to 11, quality).",rephrase,['Two reviews were of moderate quality and two were of high quality.'],1,0.2222222222222222,2,9
CD009255,0,2,"The reported quality of the included studies was, by a variety of methods, low to moderate.",rephrase,['The studies that the reviews reported on were of low to moderate quality.'],2,0.3333333333333333,2,9
CD009255,0,3,"Payment for working for a specified time period was generally ineffective, improving 3/11 outcomes from one study reported in one review.",rephrase,['Payment for working for a specified time period was generally ineffective.'],3,0.4444444444444444,3,9
CD009255,0,4,"Payment for each service, episode or visit was generally effective, improving 7/10 outcomes from five studies reported in three reviews; payment for providing care for a patient or specific population was generally effective, improving 48/69 outcomes from 13 studies reported in two reviews; payment for providing a pre-specified level or providing a change in activity or quality of care was generally effective, improving 17/20 reported outcomes from 10 studies reported in two reviews; and mixed and other systems were of mixed effectiveness, improving 20/31 reported outcomes from seven studies reported in three reviews.",split,"['We grouped financial incentives into five groups: payment for working for a specified time period; payment for each service, episode or visit; payment for providing care for a patient or specific population; payment for providing a pre-specified level or providing a change in activity or quality of care; and mixed or other systems.', 'Payment for each service, episode or visit was generally effective, as were payment for providing care for a patient or specific population and payment for providing a pre-specified level or providing a change in activity or quality of care; mixed and other systems were of mixed effectiveness.']",4,0.5555555555555556,3,9
CD009255,0,5,"When looking at the effect of financial incentives overall across categories of outcomes, they were of mixed effectiveness on consultation or visit rates (improving 10/17 outcomes from three studies in two reviews); generally effective in improving processes of care (improving 41/57 outcomes from 19 studies in three reviews); generally effective in improving referrals and admissions (improving 11/16 outcomes from 11 studies in four reviews); generally ineffective in improving compliance with guidelines outcomes (improving 5/17 outcomes from five studies in two reviews); and generally effective in improving prescribing costs outcomes (improving 28/34 outcomes from 10 studies in one review).",rephrase,"['When looking at the effect of financial incentives overall across different outcomes, they were of mixed effectiveness on consultation or visit rates; generally effective in improving processes of care, referrals and admissions, and prescribing costs; and generally ineffective in improving compliance with guidelines outcomes.']",6,0.6666666666666666,4,9
CD009255,1,6,Financial incentives may be effective in changing healthcare professional practice.,rephrase,"['On the basis of these findings, we concluded that financial incentives may be effective in changing healthcare professional practice.']",7,0.7777777777777778,4,9
CD009255,1,7,The evidence has serious methodological limitations and is also very limited in its completeness and generalisability.,ignore,['The evidence has serious methodological limitations and is also very limited in its completeness and generalisability.'],8,0.8888888888888888,5,9
CD009255,1,8,We found no evidence from reviews that examined the effect of financial incentives on patient outcomes.,split,"[""Since there are several reviews describing the effects of different types of financial incentives, it is important to bring this together in an overview to examine which are best at changing healthcare professionals' behaviours and what happens to patients."", 'We therefore conducted an overview of systematic reviews that evaluated the impact of financial incentives on healthcare professional behaviour and patient outcomes.', 'We included systematic reviews of studies evaluating the effectiveness of any type of financial incentive.', 'We found no evidence that financial incentives can improve patient outcomes.']",9,1.0,5,9
CD013028,0,0,"Two randomized controlled trials had already been included in the previous version of the review, with a total of 115 participants.",delete,[],0,0.06666666666666667,1,15
CD013028,0,1,One study compared clonazepam to carbamazepine as monotherapy for participants with newly diagnosed psychomotor epilepsy (a condition corresponding to what is now termed mesial temporal lobe epilepsy).,split,"['We identified only two small trials comparing clonazepam with a different drug in two different epileptic syndromes, mesial temporal lobe epilepsy (the most common and well-defined focal epilepsy, with seizures originating in the internal part of the temporal lobe of the brain) and absence seizures (generalized seizures causing lapses of awareness).', 'In the study conducted in mesial temporal lobe epilepsy, clonazepam was compared to carbamazepine (an antiepileptic drug used to treat focal epilepsy).']",0,0.13333333333333333,1,15
CD013028,0,2,One study (published as an abstract) compared clonazepam to ethosuximide as monotherapy for children with absence seizures.,rephrase,"['In the study on absence seizures, clonazepam was compared to ethosuximide (a medication used to treat absence seizures).']",2,0.2,1,15
CD013028,0,3,"Based on the available data and the details on methodology provided, we judged both studies as being at unclear or high risk of bias for the domains assessed (apart from the selective reporting (reporting bias) domain - we judged one study as being at low risk of bias and the other study at high risk of bias).",rephrase,['We judged both studies as being of poor quality.'],3,0.26666666666666666,2,15
CD013028,1,4,"In the study comparing clonazepam to carbamazepine, no difference was found between the groups regarding the proportion of participants who were seizure-free at one month after randomization (risk ratio (RR) 1.97, 95% confidence interval (CI) 0.99 to 3.94; 30 participants; very low-certainty evidence), three months after randomization (RR 1.19, 95% CI 0.62 to 2.29; 26 participants; very low-certainty evidence), and six months after randomization (RR 0.50, 95% CI 0.09 to 2.73; 9 participants; very low-certainty evidence).",merge,[],4,0.3333333333333333,2,15
CD013028,1,5,"No statistical difference was found between clonazepam and carbamazepine in terms of proportion of participants with TEAEs leading to discontinuation (RR 2.61, 95% CI 0.80 to 8.52; 36 participants; very low-certainty evidence) and in terms of dropouts/withdrawals due to side effects, lack of efficacy or other reasons (RR 1.56, 95% CI 0.61 to 4.02; 36 participants; very low-certainty evidence).",none,"['No differences were found between clonazepam and carbamazepine in the proportion of seizure-free participants; however, this does not mean that clonazepam and carbamazepine have the same effect in controlling seizures, as the lack of difference can be due to the small number of people included.']",4,0.4,2,15
CD013028,1,6,The study did not provide any information on our other prespecified outcomes of interest.,delete,[],5,0.4666666666666667,3,15
CD013028,2,7,The study comparing clonazepam to ethosuximide did not provide any data on efficacy.,rephrase,['The study comparing clonazepam with ethosuximide provided no results on the effect in controlling seizures.'],5,0.5333333333333333,3,15
CD013028,2,8,"The proportion of dropouts/withdrawal was higher in the group receiving clonazepam compared to the group receiving ethosuximide (RR 3.63, 95% CI 1.12 to 11.74; 79 participants; very low-certainty evidence).",rephrase,"['However, the proportion of people who dropped out or withdrew from the study due to side effects, lack of efficacy or other reasons was higher in the clonazepam group compared to the ethosuximide group.']",6,0.6,3,15
CD013028,2,9,No information on other outcomes of interest was provided in this study.,delete,[],7,0.6666666666666666,4,15
CD013028,3,10,We did not find any new studies since the last version of this review.,delete,[],7,0.7333333333333333,4,15
CD013028,3,11,There is only limited and very low-certainty evidence from randomized controlled trials on the efficacy and tolerability of clonazepam used in monotherapy for the treatment of epilepsy.,rephrase,"['So far, the evidence on the effect in controlling seizures and the tolerability of clonazepam used as a single antiepileptic drug for the treatment of epilepsy is scarce and of very low-certainty.']",7,0.8,4,15
CD013028,3,12,No difference in efficacy and tolerability was found in a small trial comparing clonazepam to carbamazepine for the treatment of mesial temporal lobe epilepsy.,rephrase,['No differences were found between the two medications in terms of tolerability.'],8,0.8666666666666667,5,15
CD013028,3,13,"Clonazepam was less well tolerated than ethosuximide in a trial of children with absence seizures, however no comparative data on efficacy were provided.",delete,[],9,0.9333333333333333,5,15
CD013028,3,14,There is currently insufficient evidence to support the use of clonazepam as monotherapy treatment for epilepsy.,rephrase,['There is therefore insufficient information on which to base decisions on the use of clonazepam in monotherapy.'],9,1.0,5,15
CD010403,0,0,We found six publications involving a total of 47 participants requiring maxillary advancement of 4 mm to 10 mm.,rephrase,['We found six relevant articles to include in this review.'],0,0.0625,1,16
CD010403,0,1,"All of them related to a single trial performed between 2002 and 2008 at the University of Hong Kong, but not all of the publications reported outcomes from all 47 participants.",rephrase,['All are related to one single study conducted in Hong Kong between 2002 and 2008.'],1,0.125,1,16
CD010403,0,2,"The study compared maxillary distraction osteogenesis with orthognathic surgery, and included participants from 13 to 45 years of age.",rephrase,['The study involved 47 participants aged 13 to 45 years of age.'],2,0.1875,1,16
CD010403,1,3,"Results and conclusions should be interpreted with caution given the fact that this was a single trial at high risk of bias, with a small sample size.",delete,[],3,0.25,2,16
CD010403,2,4,"The main outcomes assessed were hard and soft tissue changes, skeletal relapse, effects on speech and velopharyngeal function, psychological status, and clinical morbidities.",rephrase,"['It investigated the effects of the two surgical procedures on alteration of face morphology, stability of upper jaw after surgery, speech and velopharyngeal function (ability to close the gap between the soft palate and nasal cavity to produce sound), psychological status of the participants and clinical side effects.']",3,0.3125,2,16
CD010403,3,5,Both interventions produced notable hard and soft tissue improvements.,delete,[],4,0.375,2,16
CD010403,3,6,"Nevertheless, the distraction group demonstrated a greater maxillary advancement, evaluated as the advancement of Subspinale A-point: a mean difference of 4.40 mm (95% CI 0.24 to 8.56) was recorded two years postoperatively.",delete,[],4,0.4375,3,16
CD010403,4,7,Horizontal relapse of the maxilla was significantly less in the distraction osteogenesis group five years after surgery.,rephrase,['Upper jaw was more stable in the distraction osteogenesis group than the conventional osteotomy group five years after surgery.'],4,0.5,3,16
CD010403,4,8,"A total forward movement of A-point of 2.27 mm was noted for the distraction group, whereas a backward movement of 2.53 mm was recorded for the osteotomy group (mean difference 4.8 mm, 95% CI 0.41 to 9.19).",delete,[],5,0.5625,3,16
CD010403,5,9,"No statistically significant differences could be detected between the groups in speech outcomes, when evaluated through resonance (hypernasality) at 17 months postoperatively (RR 0.11, 95% CI 0.01 to 1.85) and nasal emissions at 17 months postoperatively (RR 3.00, 95% CI 0.14 to 66.53), or in velopharyngeal function at the same time point (RR 1.28, 95% CI 0.65 to 2.52).",delete,[],5,0.625,4,16
CD010403,6,10,"Maxillary distraction initially lowered social self-esteem at least until the distractors were removed, at three months postoperatively, compared to the osteotomy group, but this improved over time and the distraction group had higher satisfaction with life in the long term (two years after surgery) (MD 2.95, 95% CI 014 to 5.76).",rephrase,"['Social self esteem in the maxillary distraction group initially seemed to be lower than in the conventional surgery group, but this improved over time and the distraction group had higher satisfaction with life two years after surgery.']",5,0.6875,4,16
CD010403,7,11,"Adverse effects, in terms of clinical morbidities, included mainly occlusal relapse and mucosal infection, with the frequency being similar between groups (3/15 participants in the distraction osteogenesis group and 3/14 participants in the osteotomy group).",delete,[],6,0.75,4,16
CD010403,7,12,There was no severe harm to any participant.,ignore,['There was no severe harm to any participant.'],6,0.8125,5,16
CD010403,8,13,This review found only one small randomised controlled trial concerning the effectiveness of distraction osteogenesis compared to conventional orthognathic surgery.,delete,[],7,0.875,5,16
CD010403,8,14,"The available evidence is of very low quality, which indicates that further research is likely to change the estimate of the effect.",rephrase,['We judged the quality of the evidence to be very low.'],7,0.9375,5,16
CD010403,8,15,"Based on measured outcomes, distraction osteogenesis may produce more satisfactory results; however, further prospective research comprising assessment of a larger sample size with participants with different facial characteristics is required to confirm possible true differences between interventions.",delete,[],8,1.0,5,16
CD012876,0,0,We found 13 relevant studies.,rephrase,['We included\xa013 relevant studies.'],0,0.03571428571428571,1,28
CD012876,0,1,Twelve were from the USA and one was from Canada.,ignore,['Twelve were from the USA and one was from Canada.'],1,0.07142857142857142,1,28
CD012876,0,2,"Where we judged the North American focus of the studies to be a concern for a finding’s relevance, we have reflected this in our assessment of confidence in the finding.",ignore,"['Where we judged the North American focus of the studies to be a concern for a finding’s relevance, we have reflected this in our assessment of confidence in the finding.']",2,0.10714285714285714,1,28
CD012876,0,3,"The studies explored the views and experiences of bedside and hub critical care personnel; administrative, technical, information technology, and managerial staff; and family members.",ignore,"['The studies explored the views and experiences of bedside and hub critical care personnel; administrative, technical, information technology, and managerial staff, and family members.']",3,0.14285714285714285,1,28
CD012876,0,4,The intensive care units (ICUs) were from tertiary hospitals in urban and rural areas.,rephrase,['The ICUs were from hospitals in both urban and rural areas.'],4,0.17857142857142858,1,28
CD012876,1,5,We identified several factors that could influence the implementation of CCT.,rephrase,['We identified\xa0several factors that could influence the acceptance and use of CCT.'],5,0.21428571428571427,2,28
CD012876,1,6,"We had high confidence in the following findings:
Hospital staff and family members described several advantages of CCT.",ignore,['We had high confidence in the following findings:\nHospital staff and family members described several advantages of CCT.'],6,0.25,2,28
CD012876,1,7,Bedside and hub staff strongly believed that the main advantage of CCT was having access to experts when bedside physicians were not available.,ignore,['Bedside\xa0and\xa0hub staff strongly believed that the main advantage\xa0of CCT was having access to experts when bedside doctors were not available.'],7,0.2857142857142857,2,28
CD012876,1,8,Families also valued having access to critical care experts.,ignore,['Families also valued having access to critical care experts.'],8,0.32142857142857145,2,28
CD012876,1,9,"In addition, hospital staff described how CCT could support clinical decision-making and mentoring of junior staff.",rephrase,['Hospital staff also described how CCT could support clinical decision-making and mentoring of junior\xa0staff.'],9,0.35714285714285715,2,28
CD012876,2,10,Hospital staff greatly valued the nature and quality of social networks between the bedside and CCT hub teams.,ignore,['Hospital staff greatly valued the nature and quality of social networks between the bedside and CCT hub teams.'],10,0.39285714285714285,2,28
CD012876,2,11,"Key issues for them were trust, acceptance, teamness, familiarity and effective communication between the two teams.",rephrase,"['Key issues for them were trust, acceptance, being part of a team, familiarity and effective communication between the two teams.']",11,0.42857142857142855,3,28
CD012876,3,12,"Interactions between some bedside and CCT hub staff were featured with tension, frustration and conflict.",ignore,"['Interactions between some bedside and CCT hub staff were featured with tension, frustration and conflict.']",12,0.4642857142857143,3,28
CD012876,3,13,"Staff on both sides commonly described disrespect of their expertise, resistance and animosity.",ignore,"['Staff on both sides commonly described disrespect of expertise, resistance and animosity.']",13,0.5,3,28
CD012876,4,14,Hospital staff thought it was important to promote and offer training in the use of CCT before its implementation.,ignore,['Hospital staff thought it was important to promote and offer training in the use of CCT before its implementation.'],14,0.5357142857142857,3,28
CD012876,4,15,"This included rehearsing every step in the process, offering staff opportunities to ask questions and disseminating learning resources.",ignore,"['This included rehearsing every step in the process, offering staff opportunities to ask questions and disseminating learning resources.']",15,0.5714285714285714,3,28
CD012876,4,16,Some also complained that experienced staff were taken away from bedside care and re-allocated to the CCT hub team.,ignore,['Some also complained that experienced staff were taken away from bedside care and re-allocated to the CCT hub team.'],16,0.6071428571428571,4,28
CD012876,5,17,"Hospital staff's attitudes towards, knowledge about and value placed on CCT influenced acceptance of CCT.",ignore,"[""Hospital staff's attitudes towards, knowledge about and value placed on CCT influenced acceptance of CCT.""]",17,0.6428571428571429,4,28
CD012876,5,18,Staff were positive towards CCT because of its several advantages.,ignore,['Staff were positive towards CCT because of its several advantages.'],18,0.6785714285714286,4,28
CD012876,5,19,But some were concerned that the CCT hub staff were not able to understand the patient’s situation through the camera.,ignore,['But some were concerned that the hub staff were not able to understand the patient’s situation through the camera.'],19,0.7142857142857143,4,28
CD012876,5,20,Some were also concerned about confidentiality of patient data.,ignore,['Some were also concerned about confidentiality of patient data.'],20,0.75,4,28
CD012876,6,21,"We also identified other factors that could influence the implementation of CCT, although our confidence in these findings is moderate or low.",rephrase,"['We also identified other factors that could influence the acceptance and use of CCT, although our confidence in these findings is moderate or low.']",21,0.7857142857142857,4,28
CD012876,6,22,"These factors included the extent to which telemedicine software was adaptable to local needs, and hub staff were aware of local norms; concerns about additional administrative work and cost; patients' and families’ desire to stay close to their local community; the type of hospital setting; the extent to which there was support from senior leadership; staff access to information about policies and procedures; individuals' stage of change; staff motivation, competence and values; clear strategies for staff engagement; feedback about progress; and the impact of CCT on staffing levels.",ignore,"[""These factors include the extent to which telemedicine software was adaptable to local needs, and hub staff were aware of local norms; concerns about additional administrative work and cost; patients'\xa0and families’ desire to stay close to their local community; the type of hospital setting; the extent to which there was support from senior leadership; staff access to information about policies and procedures; individuals'\xa0readiness to change; staff motivation, competence and values; clear strategies for staff engagement; feedback about progress; and the impact of CCT on staffing levels.""]",22,0.8214285714285714,5,28
CD012876,7,23,Our review identified several factors that could influence the acceptance and use of telemedicine in critical care.,delete,[],23,0.8571428571428571,5,28
CD012876,7,24,"These include the value that hospital staff and family members place on having access to critical care experts, staff access to sufficient training, and the extent to which healthcare providers at the bedside and the critical care experts supporting them from a distance acknowledge and respect each other’s expertise.",delete,[],23,0.8928571428571429,5,28
CD012876,7,25,"Further research, especially in contexts other than North America, with different cultures, norms and practices will strengthen the evidence base for the implementation of CCT internationally and our confidence in these findings.",delete,[],23,0.9285714285714286,5,28
CD012876,7,26,"Implementation of CCT appears to be growing in importance in the context of global pandemic management, especially in countries with wide geographical dispersion and limited access to critical care expertise.",delete,[],23,0.9642857142857143,5,28
CD012876,7,27,"For successful implementation, policymakers and other stakeholders should consider pre-empting and addressing factors that may affect implementation, including strengthening teamness between bedside and hub teams; engaging and supporting frontline staff; training ICU clinicians on the use of CCT prior to its implementation; and ensuring staff have access to information and knowledge about when, why and how to use CCT for maximum benefit.",delete,[],23,1.0,5,28
CD013871,0,0,We included six studies with 320 participants.,rephrase,['We found six clinical trials of 320 adults that met criteria for inclusion in this review that assessed the efficacy and safety of stool transplantation for the treatment of repeated C difficile infection.'],0,0.05555555555555555,1,18
CD013871,0,1,"Two studies were conducted in Denmark, and one each in the Netherlands, Canada, Italy, and the US.",ignore,"['Two studies were conducted in Denmark, and one each in the Netherlands, Italy, Canada, and the US.']",1,0.1111111111111111,1,18
CD013871,0,2,Four were single-center and two were multicenter studies.,delete,[],2,0.16666666666666666,1,18
CD013871,0,3,All studies included only adults.,delete,[],2,0.2222222222222222,2,18
CD013871,0,4,"Five studies excluded people who were severely immunocompromised, with only one study including 10 participants who were receiving immunosuppressive therapy out of the 64 enrolled; these were similarly distributed between the FMT arm (4/24 or 17%) and comparison arms (6/40 or 15%).",rephrase,['Five studies excluded people who had weak immune systems (immunocompromised people); one study included people with weak immune systems and apparently normal immune systems (immunocompetent people).'],2,0.2777777777777778,2,18
CD013871,0,5,"The route of administration was the upper gastrointestinal tract via a nasoduodenal tube in one study, two studies used enema only, two used colonoscopic only delivery, and one used either nasojejunal or colonoscopic delivery, depending on a clinical determination of whether the recipient could tolerate a colonoscopy.",delete,[],3,0.3333333333333333,2,18
CD013871,0,6,Five studies had at least one comparison group that received vancomycin.,delete,[],3,0.3888888888888889,2,18
CD013871,0,7,The risk of bias (RoB 2) assessments did not find an overall high risk of bias for any outcome.,delete,[],3,0.4444444444444444,3,18
CD013871,1,8,All six studies assessed the efficacy and safety of FMT for the treatment of rCDI.,rephrase,['These same studies looked at the rate of serious side effects and risk of death from FMT.'],3,0.5,3,18
CD013871,2,9,"Pooled results from six studies showed that the use of FMT in immunocompetent participants with rCDI likely leads to a large increase in resolution of rCDI in the FMT group compared to control (risk ratio (RR) 1.92, 95% confidence interval (CI) 1.36 to 2.71; P = 0.02, I2 = 63%; 6 studies, 320 participants; number needed to treat for an additional beneficial outcome (NNTB) 3; moderate-certainty evidence).",delete,[],4,0.5555555555555556,3,18
CD013871,2,10,"Fecal microbiota transplantation probably results in a slight reduction in serious adverse events; however, the CIs around the summary estimate were wide (RR 0.73, 95% CI 0.38 to 1.41; P = 0.24, I² = 26%; 6 studies, 320 participants; NNTB 12; moderate-certainty evidence).",rephrase,"['Fecal microbiota transplantation likely leads to a small decrease in serious side effects; however, these effects were few.']",4,0.6111111111111112,4,18
CD013871,2,11,"Fecal microbiota transplantation may result in a reduction in all-cause mortality; however, the number of events was small, and the CIs of the summary estimate were wide (RR 0.57, 95% CI 0.22 to 1.45; P = 0.48, I2 = 0%; 6 studies, 320 participants; NNTB 20; low-certainty evidence).",rephrase,"['Fecal microbiota transplantation may decrease the risk of death in people with rCDI; however, there were few deaths in either group.']",5,0.6666666666666666,4,18
CD013871,2,12,None of the included studies reported colectomy rates.,rephrase,['None of the included studies was funded by a drug manufacturer or an agency that had a commercial interest in FMT.'],6,0.7222222222222222,4,18
CD013871,3,13,"In immunocompetent adults with rCDI, FMT likely leads to a large increase in the resolution of recurrent Clostridioides difficile infection compared to alternative treatments such as antibiotics.",rephrase,['Stool transplantation probably leads to a larger increase in resolution of repeated infections of C difficile than the other treatments studied.'],7,0.7777777777777778,4,18
CD013871,3,14,There was no conclusive evidence regarding the safety of FMT for the treatment of rCDI as the number of events was small for serious adverse events and all-cause mortality.,delete,[],8,0.8333333333333334,5,18
CD013871,3,15,Additional data from large national registry databases might be required to assess any short-term or long-term risks with using FMT for the treatment of rCDI.,delete,[],8,0.8888888888888888,5,18
CD013871,3,16,Elimination of the single study that included some immunocompromised people did not alter these conclusions.,merge,"['Elimination of one study that included some immunocompromised people did not alter these conclusions, but, based on the low number of immunocompromised people enrolled in the included studies, conclusions could not be drawn about the benefits or harms of FMT for rCDI in the immunocompromised population at this time.']",8,0.9444444444444444,5,18
CD013871,3,17,"Due to the low number of immunocompromised participants enrolled, conclusions cannot be drawn about the risks or benefits of FMT for rCDI in the immunocompromised population.",none,[],8,1.0,5,18
CD011545,0,0,"We included eight RCTs, six of which were cluster-randomised trials, involving more than 1000 training participants and more than 200,000 pregnancies/births.",split,"['We identified eight randomised studies.', 'Six cluster-randomised studies compared simulation-based obstetric team training with no training.']",0,0.09090909090909091,1,11
CD011545,0,1,"Four studies reported on outcome measures on Kirkpatrick level 4 (patient outcome), three studies on Kirkpatrick level 3 (performance in practice), two studies on Kitkpatrick level 2 (performance in educational settings), and none on Kirkpatrick level 1 (trainees' experience).",delete,[],2,0.18181818181818182,1,11
CD011545,0,2,"The included studies were from Mexico, the Netherlands, the UK and the USA, all middle- and high-income countries.",delete,[],2,0.2727272727272727,2,11
CD011545,1,3,"Kirkpatrick level 4 (patient outcome)
Simulation-based obstetric team training may make little or no difference for composite outcomes of maternal and/or perinatal adverse events compared with no training (3 studies; n = 28,731, low-certainty evidence, data not pooled due to different composite outcome definitions).",rephrase,['simulation-based obstetric team training may make little or no difference for a combination of adverse events in the mother or the infant.'],2,0.36363636363636365,2,11
CD011545,1,4,"We are uncertain whether simulation-based obstetric team training affects maternal mortality compared with no training (2 studies; 79,246 women; very low-certainty evidence).",rephrase,['We are uncertain whether simulation-based obstetric team training affects the risk of death for the mother.'],3,0.45454545454545453,3,11
CD011545,1,5,"However, it may reduce neonatal mortality (RR 0.70, 95% CI 0.48 to 1.01; 2 studies, 79,246 pregnancies/births, low-certainty evidence).",rephrase,"['However, it may reduce the risk of death for the newborn baby.']",4,0.5454545454545454,3,11
CD011545,1,6,"Simulation-based obstetric team training may have little to no effect on low Apgar score compared with no training (RR 0.99, 95% 0.85 to 1.15; 2 studies; 115,171 infants; low-certainty evidence), but it probably reduces trauma after shoulder dystocia (RR 0.50, 95% CI 0.25 to 0.99; 1 study; moderate-certainty evidence) and probably slightly reduces the number of caesarean deliveries (RR 0.79, 95% CI 0.67 to 0.93; 1 study; n = 50,589; moderate-certainty evidence)
Kirkpatrick level 3 (performance in practice)
We found that simulation-based obstetric team training probably improves the performance of the obstetric teams in practice, compared with no training (3 studies; 2398 obstetric staff members, moderate-certainty evidence, data not pooled due to different outcome definitions).",rephrase,['Simulation-based obstetric team training may have little to no effect on low Apgar score but it probably reduces trauma after shoulder dystocia and probably slightly reduces the number of caesarean deliveries.'],5,0.6363636363636364,4,11
CD011545,2,7,"Simulation-based obstetric team training may help to improve team performance of obstetric teams, and it might contribute to improvement of specific maternal and perinatal outcomes, compared with no training.",rephrase,['Simulation-based obstetric team training might be helpful for the improvement of team performance and specific maternal and perinatal outcomes.'],6,0.7272727272727273,4,11
CD011545,2,8,"However, high-certainty evidence is lacking due to serious risk of bias and imprecision, and the effect cannot be generalised for all outcomes.",rephrase,['High-certainty evidence was lacking due to limitations in the way the studies were designed and conducted.'],7,0.8181818181818182,5,11
CD011545,2,9,Future studies investigating simulation-based obstetric team training compared to training courses with a different instructional design should carefully consider how and when to measure outcomes.,rephrase,['Future studies investigating simulation-based obstetric team training compared to different designs of training courses should carefully consider how and when to measure the effects of the interventions.'],8,0.9090909090909091,5,11
CD011545,2,10,"Particular attention should be paid to effect measurement at the level of patient outcome, taking into consideration the low incidence of adverse maternal and perinatal events.",delete,[],9,1.0,5,11
CD010568,0,0,We included nine randomised clinical trials (involving 861 women).,delete,[],0,0.041666666666666664,1,24
CD010568,0,1,"The trials compared Chinese herbal medicines (various formulations) either alone (one trial), or in combination with other pharmaceuticals (seven trials) versus other pharmaceuticals alone.",merge,[],0,0.08333333333333333,1,24
CD010568,0,2,One study compared Chinese herbal medicines and other pharmaceuticals versus psychotherapy.,none,['One trial studied the effectiveness of psychotherapy compared with Chinese herbs.'],0,0.125,1,24
CD010568,0,3,"We did not identify any trials comparing Chinese herbal medicines with placebo or no treatment, including bed rest.",rephrase,"['No trial used placebo, no treatment or bed rest as a control intervention.']",1,0.16666666666666666,1,24
CD010568,1,4,Various Chinese herbal medicines were used in the different trials (and some of the classical the formulations were modified in the trials).,rephrase,"['Different Chinese herbal medicine formulae (Shou Tai Pill, Yangxi Zaitai Decoction, Bushen Antai Decoction and some modified formulae) were used in the trials.']",2,0.20833333333333334,2,24
CD010568,1,5,"The Western pharmaceutical medicines included tocolytic drugs such as salbutamol and magnesium sulphate; hormonal supplementation with human chorionic gonadotrophin (HCG), progesterone or dydrogesterone; and supportive supplements such as vitamin E, vitamin K and folic acid.",ignore,"['Western pharmaceutical medicines included tocolytic drugs such as salbutamol and magnesium sulphate, hormonal supplementation with human chorionic gonadotrophin, progesterone or dydrogesterone, and supportive supplements such as vitamin E, vitamin K and folic acid.']",3,0.25,2,24
CD010568,2,6,"Overall, the methodological quality of the included studies was poor with unclear risk of bias for nearly all the 'Risk of bias' domains assessed.",rephrase,['All trials were methodologically poor and at an unclear risk of bias overall.'],4,0.2916666666666667,2,24
CD010568,3,7,"Chinese herbal medicines alone versus other pharmaceuticals alone - the live birth rate was no different between the two groups (risk ratio (RR) 1.05; 95% confidence interval (CI) 0.67 to 1.65; one trial, 80 women).",split,"['When Chinese herbal medicines were given in combination with other pharmaceuticals they were associated with higher rates of continuous pregnancy beyond 20 weeks (92.1% versus 72.0%, from two trials, involving 189 women) and live births (79.7% versus 44.2% from six trials, involving 601 women) compared to the other pharmaceuticals alone.', 'Live birth rate was not different when comparing Chinese herbal medicines alone and other pharmaceuticals alone (in one trial, involving 80 women).']",5,0.3333333333333333,2,24
CD010568,3,8,No data were available for the outcome of pregnancy rate (continuation of pregnancy after 20 weeks of gestation).,delete,[],7,0.375,2,24
CD010568,4,9,"In contrast, the continuing pregnancy rate (RR 1.27 95% CI 1.10 to 1.48, two trials, 189 women) and live birth rate (average RR 1.55; 95% CI 1.14 to 2.10; six trials, 601 women, Tau² = 0.10; I² = 73%) were higher among the group of women who received a combination of Chinese herbal medicines and other pharmaceuticals when compared with women who received other pharmaceuticals alone.",delete,[],7,0.4166666666666667,3,24
CD010568,5,10,"For Chinese herbal medicines and psychotherapy versus psychotherapy alone (one study) - there was a higher live birth rate (RR 1.32; 95% CI 1.07 to 1.64; one trial, 90 women) in the group of women who received a combination of Chinese herbal medicines and psychotherapy compared to those women who received psychotherapy alone.",rephrase,"['Compared with psychotherapy alone, the live birth rate was higher in the group of women who received a combination of Chinese herbal medicine and psychotherapy (91.1% versus 68.9%).']",7,0.4583333333333333,3,24
CD010568,5,11,No data were available on the continuing pregnancy rate for this comparison.,rephrase,['A comparison of continuing pregnancy rate was not available in this trial.'],8,0.5,3,24
CD010568,6,12,Other primary outcomes (maternal adverse effect and toxicity rate and the perinatal adverse effect and toxicity rate) were not reported in most of the included studies.,rephrase,['The majority of studies did not report any information about adverse effects for the mothers or the babies.'],9,0.5416666666666666,3,24
CD010568,6,13,"Two trials (341 women) reported that no maternal adverse effects were found (one trial compared (combined) medicines with other pharmaceuticals, and one trial compared combined Chinese herbal medicine alone versus other pharmaceuticals).",ignore,['Only two trials (involving 341 women) reported that no maternal adverse effects were found (one trial comparing (combined) medicines with other pharmaceuticals and one trial comparing combined Chinese herbal medicine alone versus other pharmaceuticals alone).'],10,0.5833333333333334,3,24
CD010568,6,14,One trial (Chinese herbal medicine alone versus other pharmaceuticals alone) reported that there were no abnormal fetuses (ultrasound) or after delivery.,rephrase,['Only one trial (comparing Chinese herbal medicine alone versus other pharmaceuticals alone) reported that there were no abnormal babies either before or after delivery.'],11,0.625,4,24
CD010568,7,15,There were no data reported for any of this review's secondary outcomes.,delete,[],12,0.6666666666666666,4,24
CD010568,8,16,We found limited evidence (from nine studies with small sample sizes and unclear risk of bias) to assess the effectiveness of Chinese herbal medicines for treating unexplained recurrent miscarriage; no data were available to assess the safety of the intervention for the mother or her baby.,rephrase,['We found no data to evaluate the safety and toxicity of this intervention for women and their babies and no data for all of our other maternal and infant outcomes.'],12,0.7083333333333334,4,24
CD010568,8,17,There were no data relating to any of this review's secondary outcomes.,delete,[],13,0.75,4,24
CD010568,8,18,"From the limited data we found, a combination of Chinese herbal medicines and other pharmaceuticals (mainly Western medicines) may be more effective than Western medicines alone in terms of the rate of continuing pregnancy and the rate of live births.",rephrase,['It is unclear which Chinese herbal medicines or their combinations are effective.'],13,0.7916666666666666,4,24
CD010568,8,19,"However, the methodological quality of the included studies was generally poor.",delete,[],14,0.8333333333333334,5,24
CD010568,9,20,A comparison of Chinese herbal medicines alone versus placebo or no treatment (including bed rest) was not possible as no relevant trials were identified.,delete,[],14,0.875,5,24
CD010568,10,21,More high-quality studies are needed to further evaluate the effectiveness and safety of Chinese herbal medicines for unexplained recurrent miscarriage.,merge,['More high-quality studies are necessary to fully evaluate the utility of Chinese herbal medicines for unexplained recurrent miscarriage.'],14,0.9166666666666666,5,24
CD010568,10,22,"In addition to assessing the effect of Chinese herbal medicines on pregnancy rate and the rate of live births, future studies should also consider safety issues (adverse effects and toxicity for the mother and her baby) as well as the secondary outcomes listed in this review.",none,[],14,0.9583333333333334,5,24
CD010568,10,23,"This review would provide more valuable information if the included studies could overcome the problems in their designs, such as lacking of qualified placebo-controlled trials, applying adequate randomisation methods and avoiding potential bias.",delete,[],15,1.0,5,24
CD008258,0,0,Two trials randomised in total 106 patients to piggy-back method (n = 53) versus conventional method with veno-venous bypass (n = 53).,rephrase,['Two clinical trials randomised 106 patients to the piggy-back method (53 patients) versus the standard method (53 patients).'],0,0.07692307692307693,1,13
CD008258,0,1,Both trials were at high risk of bias.,rephrase,['Both trials were at high risk of systematic errors.'],1,0.15384615384615385,1,13
CD008258,0,2,"There was no significant difference in post-operative mortality, primary graft non-function, vascular complications, renal failure, transfusion requirements, intensive therapy unit (ITU) stay, or hospital stay between the two groups.",rephrase,"['There was no significant difference in post-operative death, primary graft non-function (the liver graft does not start functioning at all), complications related to the blood vessels, kidney failure, blood transfusion requirements, intensive therapy unit (ITU) stay, or hospital stay between the two groups.']",2,0.23076923076923078,2,13
CD008258,0,3,The warm ischaemic time was significantly shorter in the piggy-back method than the conventional method (MD -11.50 minutes; 95% CI -19.35 to -3.65; P < 0.01).,delete,[],3,0.3076923076923077,2,13
CD008258,0,4,The proportion of patients who developed chest complications were significantly higher in the the piggy-back method than the conventional method (75.8% versus 44.1%; P = 0.01).,rephrase,['The proportion of patients who developed chest complications were significantly higher with the piggy-back method than with the conventional method (76% in piggy-back method versus 44% in conventional method; statistically significant).'],3,0.38461538461538464,2,13
CD008258,1,5,One trial randomised 80 patients to piggy-back with porto-caval bypass (n = 40) versus piggy-back without porto-caval bypass (n = 40).,rephrase,['One trial randomised 80 patients to a variant of piggy-back (in which blood from the intestines is temporarily diverted; 40 patients) versus standard piggy-back method (in which blood from the intestines is blocked; 40 patients).'],4,0.46153846153846156,3,13
CD008258,1,6,This trial was at high risk of bias.,rephrase,['This trial was at high risk of systematic error.'],5,0.5384615384615384,3,13
CD008258,1,7,"There was no significant difference in post-operative mortality, re-transplantation due to primary graft non-function, vascular complications, renal failure, or hospital stay between the two groups.",rephrase,"['There was no significant difference in post-operative death, re-transplantation due to primary graft non-function (liver graft does not start functioning at all), vascular complications, kidney failure, or hospital stay between the two groups.']",6,0.6153846153846154,4,13
CD008258,1,8,Fewer patients required blood transfusion in the piggy-back with porto-caval bypass group (55%) than the piggy-back without porto-caval bypass group (75%) (P = 0.02).,rephrase,['Significantly fewer patients required blood transfusion with the variant piggy-back method (55%) than with the standard piggy-back method (75%).'],7,0.6923076923076923,4,13
CD008258,1,9,There was no significant difference in the mean amount of blood transfused between the groups (MD -1.00 unit; 95% CI -2.19 to 0.19; P = 0.10).,delete,[],8,0.7692307692307693,4,13
CD008258,1,10,The ITU stay was significantly shorter in the piggy-back with porto-caval bypass group (2.9 days) than the piggy-back without porto-caval bypass group (4.9 days; MD -2.00 days; 95% CI -3.82 to -0.18; P = 0.03).,rephrase,['The ITU stay was significantly shorter in the variant (2.9 days) than with the standard piggy-back method (4.9 days).'],8,0.8461538461538461,5,13
CD008258,2,11,There were no trials comparing piggy-back method with conventional method without veno-venous bypass or different techniques of piggy-back method.,rephrase,['There were no trials comparing piggy-back method and standard method of liver transplantation without diversion of venous blood or different techniques of piggy-back method.'],9,0.9230769230769231,5,13
CD008258,3,12,There is currently no evidence to recommend or refute the use of piggy-back method of liver transplantation.,rephrase,['We conclude that there is currently no evidence to recommend or refute the use of piggy-back method of liver transplantation.'],10,1.0,5,13
CD011523,0,0,We included only one non-randomised study published 30 years ago in the review.,rephrase,"['We found no randomised controlled trials, and identified only one non-randomised study published 30 years ago, on this topic.']",0,0.06666666666666667,1,15
CD011523,0,1,"This study included 77 participants who had gastric ulcer and in whom medical therapy (histamine H2 receptor blockers, antacids, and diet) had failed after an average duration of treatment of 29 months.",split,"['This study included 77 participants who had stomach ulcer and in whom medical therapy had failed after an average treatment duration of 29 months.', 'Medical therapy included histamine H2 receptor blockers (medicines that block the action of the chemical histamine, resulting in a decreased production of stomach acid, such as ranitidine), antacids, and diet.']",1,0.13333333333333333,1,15
CD011523,0,2,The authors do not state whether these were recurrent or refractory ulcers.,ignore,['The authors do not state whether these were recurrent or refractory ulcers.'],3,0.2,1,15
CD011523,0,3,It appears that the participants did not have previous complications such as bleeding or perforation.,delete,[],4,0.26666666666666666,2,15
CD011523,0,4,"Of the 77 included participants, 37 participants continued to have medical therapy while 40 participants received surgical therapy (antrectomy with or without vagotomy; subtotal gastrectomy with or without vagotomy; vagotomy; pyloroplasty and suture of the ulcer; suture or closure of ulcer without vagotomy or excision of the ulcer; proximal gastric or parietal cell vagotomy alone; suture or closure of the ulcer with proximal gastric or parietal cell vagotomy).",rephrase,"['Of the 77 included participants, 37 participants continued to have medical therapy, while 40 participants received surgical therapy.']",4,0.3333333333333333,2,15
CD011523,0,5,Whether to use medical or surgical treatment was determined by participant's or treating physician's preference.,ignore,"[""Whether to use medical or surgical treatment was determined by participant's or treating physician's preference.""]",5,0.4,2,15
CD011523,1,6,"The study authors reported that two participants in the medical treatment group (2 out of 37; 5.4%) had gastric cancer, which was identified by repeated biopsy.",rephrase,"['The study authors reported that two participants in the medical treatment group (5%) had stomach cancer, which was identified after repeated examinations using a camera to look inside the body (an endoscope), in this case, the stomach and small intestine.']",6,0.4666666666666667,3,15
CD011523,1,7,They did not report the proportion of participants who had gastric cancer in the surgical treatment group.,rephrase,['They did not report the percentage of participants who had stomach cancer in the surgical treatment group.'],7,0.5333333333333333,3,15
CD011523,1,8,They also did not report the implications of the delayed diagnosis of gastric cancer in the medical treatment group.,ignore,['They also did not report the implications of the delayed diagnosis of stomach cancer in the medical treatment group.'],8,0.6,3,15
CD011523,1,9,"They did not report any other outcomes of interest for this review (that is health-related quality of life (using any validated scale), adverse events and serious adverse events, peptic ulcer bleeding, peptic ulcer perforation, abdominal pain, and long-term mortality).",rephrase,"['They did not report any other outcomes of interest (measures by which one treatment can be considered better than another) for this review (that is health-related quality of life, treatment-related complications, peptic ulcer-related complications, abdominal pain, and long-term deaths).']",9,0.6666666666666666,4,15
CD011523,2,10,We found no studies that provide the relative benefits and harms of medical versus surgical treatment for recurrent or refractory peptic ulcers.,ignore,['There is thus no study that provides the relative benefits and harms of medical versus surgical treatment for recurrent or refractory peptic ulcers.'],10,0.7333333333333333,4,15
CD011523,2,11,Studies that evaluate the natural history of recurrent and refractory peptic ulcers are urgently required to determine whether randomised controlled trials comparing medical versus surgical management in patients with recurrent or refractory peptic ulcers or both are necessary.,rephrase,['Studies on this topic are urgently required.'],11,0.8,4,15
CD011523,2,12,Such studies will also provide information for the design of such randomised controlled trials.,delete,[],12,0.8666666666666667,5,15
CD011523,2,13,A minimum follow-up of two to three years will allow the calculation of the incidence of complications and gastric cancer (in gastric ulcers only) in recurrent and refractory peptic ulcers.,delete,[],12,0.9333333333333333,5,15
CD011523,2,14,"In addition to complications related to treatment and disease, health-related quality of life and loss of productivity should also be measured.",delete,[],12,1.0,5,15
CD006247,0,0,"In the original version of this review, we identified three RCTs that assessed different intervention and control diets in 192 participants (97 randomised to intervention diet; 95 to control diet) with different types of malignancies.",rephrase,['Review authors identified three randomised studies comparing different diets in 192 children and adults with different types of cancer.'],0,0.058823529411764705,1,17
CD006247,0,1,"For the update, we identified no eligible new studies.",delete,[],1,0.11764705882352941,1,17
CD006247,0,2,"Co-interventions (e.g. protective environment, antimicrobial prophylaxis, central venous catheter care, oral care, hygiene practices, colony-stimulating factors) and outcome definitions also differed between studies.",rephrase,"['Other interventions, such as antimicrobial prophylaxis (i.e. prevention of infection via antimicrobial therapy such as antibiotics) and hygiene practices, and definitions of study outcomes also differed between studies, and very limited information on anticancer treatment was given.']",1,0.17647058823529413,1,17
CD006247,0,3,"In all included studies, it was standard policy to give empirical antibiotics (and sometimes also antimycotics) to (some of) the participants diagnosed with an infection.",delete,[],2,0.23529411764705882,2,17
CD006247,0,4,Two studies included adults and one study included children.,delete,[],2,0.29411764705882354,2,17
CD006247,0,5,"In all studies, only a scant description of treatment regimens was provided.",merge,[],2,0.35294117647058826,2,17
CD006247,0,6,All studies had methodological limitations.,none,['All studies had methodological problems.'],2,0.4117647058823529,3,17
CD006247,0,7,Pooling of results of included studies was not possible.,rephrase,"['Unfortunately, combining the results of included studies was not possible, but at the moment, no evidence from individual studies suggests that a low bacterial diet prevents infection.']",3,0.47058823529411764,3,17
CD006247,0,8,"In two individual studies, no statistically significant differences in infection rate were identified between intervention and control diets; another study showed no significant differences between treatment groups in the number of chemotherapy cycles with an infection.",delete,[],4,0.5294117647058824,3,17
CD006247,0,9,"None of the studies mentioned infection-related mortality, but in one study, no significant difference in overall survival was observed between treatment groups.",rephrase,['None of the studies evaluated infection-related mortality.'],4,0.5882352941176471,3,17
CD006247,0,10,"Time from onset of neutropenia to fever, duration of empirical antibiotics and antimycotics, diet acceptability (i.e. following the diet easily and following the diet throughout all chemotherapy cycles) and quality of life were all evaluated by only one study; for all outcomes, no statistically significant differences between treatment arms were identified.",rephrase,"['Data on survival, time from onset of neutropenia to start of fever, duration of empirical (i.e. start of treatment before determination of a definitive diagnosis) antibiotics and antimycotics (i.e. agents that target fungal infection), diet acceptability and quality of life all were evaluated by only one study; for all outcomes, no statistically significant differences between treatment groups were observed.']",5,0.6470588235294118,4,17
CD006247,1,11,"At the moment, no evidence from individual RCTs in children and adults with different malignancies underscores use of an LBD for prevention of infection and related outcomes.",delete,[],6,0.7058823529411765,4,17
CD006247,1,12,"All studies differed with regard to co-interventions, outcome definitions and intervention and control diets.",delete,[],6,0.7647058823529411,4,17
CD006247,1,13,"As pooling of results was not possible, and as all studies had serious methodological limitations, we could reach no definitive conclusions.",delete,[],6,0.8235294117647058,5,17
CD006247,1,14,"It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'.",ignore,"[""It should be noted that 'no evidence of effect', as identified in this review, is not the same as 'evidence of no effect'.""]",6,0.8823529411764706,5,17
CD006247,1,15,"On the basis of currently available evidence, we are not able to provide recommendations for clinical practice.",rephrase,"['On the basis of currently available evidence, the review authors were not able to give recommendations for clinical practice.']",7,0.9411764705882353,5,17
CD006247,1,16,Additional high-quality research is needed.,ignore,['Additional high-quality research is needed.'],8,1.0,5,17
CD004248,0,0,Seven studies met the inclusion criteria for this systematic review.,ignore,['Seven studies met the inclusion criteria for this systematic review.'],0,0.09090909090909091,1,11
CD004248,0,1,"Meta-analysis was limited due to the following differences among the studies: types of exercise interventions, inclusion of co-intervention groups, level of exercise supervision, baseline body composition and testosterone levels of participants, types of outcomes assessed, and methodological quality of the individual studies.",delete,[],1,0.18181818181818182,1,11
CD004248,1,2,Main results indicated that performing progressive resistive exercise or a combination of progressive resistive exercise and aerobic exercise at least three times a week for at least four weeks appears to be safe and may lead to statistically and possibly clinically important increases in body weight and composition.,delete,[],1,0.2727272727272727,2,11
CD004248,1,3,Results also indicate exercise interventions may lead to clinically important improvements in cardiopulmonary fitness.,delete,[],1,0.36363636363636365,2,11
CD004248,1,4,Individual studies included in this review suggest that progressive resistive exercise interventions with or without aerobic exercise also contribute to improvements in strength and psychological status for adults living with HIV/AIDS.,rephrase,"['In this review, we included studies that were randomized controlled trials (RCTs) comparing progressive resistive exercise interventions with no progressive resistive exercise or another exercise or treatment modality, performed at least three times per week, and lasting at least four weeks among adults (18 years of age or older) living with HIV/AIDS.']",1,0.45454545454545453,3,11
CD004248,1,5,Individual studies indicate that progressive resistive exercise or a combination of progressive resistive and aerobic exercise appears to be safe for adults living with HIV/AIDS who are medically stable as a result of no change seen in immunological/virological status.,delete,[],2,0.5454545454545454,3,11
CD004248,1,6,These results are limited to those who continued to exercise and for whom there were adequate follow-up data.,delete,[],2,0.6363636363636364,4,11
CD004248,2,7,Progressive resistive exercise or a combination of progressive resistive exercise and aerobic exercise appear to be safe and may be beneficial for adults living with HIV/AIDS.,ignore,['Progressive resistive exercise or a combination of progressive resistive exercise and aerobic exercise appear to be safe and may be beneficial for adults living with HIV/AIDS.'],2,0.7272727272727273,4,11
CD004248,2,8,"These findings are limited by the small number of studies that could be included in meta-analyses, small sample sizes and variable participant withdrawal rates among included studies.",ignore,"['These findings are limited by the small number of studies that could be included in meta-analyses, small sample sizes and variable participant withdrawal rates among included studies.']",3,0.8181818181818182,5,11
CD004248,2,9,"Future research would benefit from including participants at various stages of HIV infection, a greater proportion of female participants, and participants in a variety of age groups to increase the generalizability of results.",ignore,"['Future research would benefit from including participants at various stages of HIV infection, a greater proportion of female participants, and participants in a variety of age groups to increase the generalizability of results.']",4,0.9090909090909091,5,11
CD004248,2,10,"Furthermore, future research would benefit from studies with larger sample sizes that conduct an ""intention-to-treat"" analysis (analysis of participants based on the groups to which they were originally allocated) to better understand outcomes of participants that withdraw from exercise interventions.",ignore,"['Furthermore, future research would benefit from studies with larger sample sizes that conduct an ""intention-to-treat"" analysis (analysis of participants based on the groups to which they were originally allocated) to better understand outcomes of participants that withdraw from exercise interventions.']",5,1.0,5,11
CD008959,0,0,"We included 29 studies (33,147 children) conducted in low- and middle-income countries in Asia, Africa, Latin America, and the Caribbean, where anaemia is a public health problem.",rephrase,"['We included 29 studies that involved 33,147 infants and young children from low- and middle-income countries in Asia, Africa, Latin America, and the Caribbean.']",0,0.043478260869565216,1,23
CD008959,0,1,"Twenty-six studies with 27,051 children contributed data.",ignore,"['Twenty-six studies with 27,051 children contributed data.']",1,0.08695652173913043,1,23
CD008959,0,2,"The interventions lasted between 2 and 44 months, and the powder formulations contained between 5 and 22 nutrients.",rephrase,['We found that a variety of MNP formulations containing between 5 and 22 vitamins and minerals were given for 2 to 44 months to infants and young children aged 6 to 23 months.'],2,0.13043478260869565,1,23
CD008959,0,3,"Among the 26 studies contributing data, 24 studies (26,486 children) compared the use of MNP versus no intervention or placebo; the two remaining studies compared the use of MNP versus an iron-only supplement (iron drops) given daily.",rephrase,"['Of these 26 studies, 24 compared the use of MNP versus no intervention or placebo, and 2 compared the use of MNP versus an iron-only supplement (iron drops) given daily.']",3,0.17391304347826086,1,23
CD008959,0,4,The main outcomes of interest were related to anaemia and iron status.,delete,[],4,0.21739130434782608,2,23
CD008959,0,5,We assessed most of the included studies at low risk of selection and attrition bias.,delete,[],4,0.2608695652173913,2,23
CD008959,0,6,We considered some studies to be at high risk of performance and detection bias due to lack of blinding.,delete,[],4,0.30434782608695654,2,23
CD008959,0,7,Most studies were funded by government programmes or foundations; only two were funded by industry.,ignore,['Most studies were funded by government programmes or foundations; only 2 were funded by industry.'],4,0.34782608695652173,2,23
CD008959,1,8,"Home fortification with MNP, compared with no intervention or placebo, reduced the risk of anaemia in infants and young children by 18% (RR 0.82, 95% CI 0.76 to 0.90; 16 studies; 9927 children; moderate-certainty evidence) and iron deficiency by 53% (RR 0.47, 95% CI 0.39 to 0.56; 7 studies; 1634 children; high-certainty evidence).",rephrase,"['The use of MNP containing at least iron, zinc, and vitamin A for home fortification of foods was associated with reduced risk of anaemia of 18% and iron deficiency of 53% in children aged six months to two years compared with no intervention.']",5,0.391304347826087,2,23
CD008959,1,9,"Children receiving MNP had higher haemoglobin concentrations (MD 2.74 g/L, 95% CI 1.95 to 3.53; 20 studies; 10,509 children; low-certainty evidence) and higher iron status (MD 12.93 μg/L, 95% CI 7.41 to 18.45; 7 studies; 2612 children; moderate-certainty evidence) at follow-up compared with children receiving the control intervention.",delete,[],6,0.43478260869565216,3,23
CD008959,1,10,"We did not find an effect on weight-for-age (MD 0.02, 95% CI −0.03 to 0.07; 10 studies; 9287 children; moderate-certainty evidence).",rephrase,['Studies did not find any effects on growth.'],6,0.4782608695652174,3,23
CD008959,1,11,"Few studies reported morbidity outcomes (three to five studies each outcome) and definitions varied, but MNP did not increase diarrhoea, upper respiratory infection, malaria, or all-cause morbidity.",delete,[],7,0.5217391304347826,3,23
CD008959,2,12,"In comparison with daily iron supplementation, the use of MNP produced similar results for anaemia (RR 0.89, 95% CI 0.58 to 1.39; 1 study; 145 children; low-certainty evidence) and haemoglobin concentrations (MD −2.81 g/L, 95% CI −10.84 to 5.22; 2 studies; 278 children; very low-certainty evidence) but less diarrhoea (RR 0.52, 95% CI 0.38 to 0.72; 1 study; 262 children; low-certainty of evidence).",rephrase,"['Two trials that compared the use of MNP versus iron supplement showed similar effects on anaemia and haemoglobin but less diarrhoea; however, we judged the certainty of evidence as low for anaemia and very low for haemoglobin concentration due to the small number of study participants.']",7,0.5652173913043478,3,23
CD008959,2,13,"However, given the limited quantity of data, these results should be interpreted cautiously.",delete,[],8,0.6086956521739131,4,23
CD008959,3,14,"Reporting of death was infrequent, although no trials reported deaths attributable to the intervention.",rephrase,['No trials reported death attributable to the intervention.'],8,0.6521739130434783,4,23
CD008959,3,15,"Information on side effects and morbidity, including malaria and diarrhoea, was scarce.",ignore,"['Information on deaths, side effects, and morbidity, including malaria and diarrhoea, was scarce.']",9,0.6956521739130435,4,23
CD008959,4,16,"It appears that use of MNP is efficacious among infants and young children aged 6 to 23 months who are living in settings with different prevalences of anaemia and malaria endemicity, regardless of intervention duration.",rephrase,"['The use of MNP was beneficial for young children 6 to 23 months of age, independent of whether they lived in settings with different anaemia and malaria backgrounds and regardless of the length of the intervention.']",10,0.7391304347826086,4,23
CD008959,5,17,MNP intake adherence was variable and in some cases comparable to that achieved in infants and young children receiving standard iron supplements as drops or syrups.,ignore,['MNP intake adherence was variable and in some cases comparable to that achieved in infants and young children receiving standard iron supplements as drops or syrups.'],11,0.782608695652174,4,23
CD008959,6,18,Home fortification of foods with MNP is an effective intervention for reducing anaemia and iron deficiency in children younger than two years of age.,delete,[],12,0.8260869565217391,5,23
CD008959,6,19,Providing MNP is better than providing no intervention or placebo and may be comparable to using daily iron supplementation.,merge,"['MNP is better than no intervention or placebo and may be comparable to daily iron supplementation.The benefits of this intervention as a child survival strategy or for developmental outcomes are still unclear, and further investigation is required.']",12,0.8695652173913043,5,23
CD008959,6,20,The benefits of this intervention as a child survival strategy or for developmental outcomes are unclear.,none,[],12,0.9130434782608695,5,23
CD008959,6,21,"Further investigation of morbidity outcomes, including malaria and diarrhoea, is needed.",delete,[],13,0.9565217391304348,5,23
CD008959,6,22,MNP intake adherence was variable and in some cases comparable to that achieved in infants and young children receiving standard iron supplements as drops or syrups.,delete,[],13,1.0,5,23
CD012257,0,0,We included 10 RCTs that enrolled a total of 1629 participants.,rephrase,['We included 10 randomized controlled studies (1629 participants) that compared PJ and PG in people undergoing Whipple surgery.'],0,0.07142857142857142,1,14
CD012257,0,1,The characteristics of all studies matched the requirements to compare the two types of surgical reconstruction following pancreatoduodenectomy.,rephrase,"[""The studies' features were adequate to make feasible and the planned comparison between the two surgical techniques.""]",1,0.14285714285714285,1,14
CD012257,0,2,All studies reported incidence of postoperative pancreatic fistula (the main complication) and postoperative mortality.,delete,[],2,0.21428571428571427,2,14
CD012257,1,3,"Overall, the risk of bias in included studies was high; only one included study was assessed at low risk of bias.",rephrase,"['Overall, the quality of evidence was low.']",2,0.2857142857142857,2,14
CD012257,2,4,"There was little or no difference between PJ and PG in overall risk of postoperative pancreatic fistula (PJ 24.3%; PG 21.4%; RR 1.19, 95% CI 0.88 to 1.62; 7 studies; low-quality evidence).",rephrase,"['PJ may have little or no difference from PG in overall postoperative pancreatic fistula rate (PJ 24.3%; PG 21.4%), duration of hospitalization, or need for surgical re-intervention (11.6% versus 10.3%).']",3,0.35714285714285715,2,14
CD012257,2,5,"Inclusion of studies that clearly distinguished clinically significant pancreatic fistula resulted in us being uncertain whether PJ improved the risk of pancreatic fistula when compared with PG (19.3% versus 12.8%; RR 1.51, 95% CI 0.92 to 2.47; very low-quality evidence).",split,"[""Only seven studies clearly distinguished clinically significant pancreatic fistula which required a change in the patient's management."", 'We are uncertain whether PJ improves the risk of clinically significant pancreatic fistula when compared with PG (19.3% versus 12.8%).']",4,0.42857142857142855,3,14
CD012257,2,6,"PJ probably has little or no difference from PG in risk of postoperative mortality (3.9% versus 4.8%; RR 0.84, 95% CI 0.53 to 1.34; moderate-quality evidence).",rephrase,['PJ probably has little or no difference from PG in rates of death (3.9% versus 4.8%) or complications (46.5% versus 44.5%).'],6,0.5,3,14
CD012257,3,7,"We found low-quality evidence that PJ may differ little from PG in length of hospital stay (MD 1.04 days, 95% CI -1.18 to 3.27; 4 studies, N = 502) or risk of surgical re-intervention (11.6% versus 10.3%; RR 1.18, 95% CI 0.86 to 1.61; 7 studies, N = 1263).",delete,[],7,0.5714285714285714,3,14
CD012257,3,8,"We found moderate-quality evidence suggesting little difference between PJ and PG in terms of risk of any surgical complication (46.5% versus 44.5%; RR 1.03, 95% CI 0.90 to 1.18; 9 studies, N = 1513).",delete,[],7,0.6428571428571429,4,14
CD012257,3,9,"PJ may slightly improve the risk of postoperative bleeding (9.3% versus 13.8%; RR 0.69, 95% CI: 0.51 to 0.93; low-quality evidence; 8 studies, N = 1386), but may slightly worsen the risk of developing intra-abdominal abscess (14.7% versus 8.0%; RR 1.77, 95% CI 1.11 to 2.81; 7 studies, N = 1121; low quality evidence).",rephrase,"['The risk of postoperative bleeding in participants undergoing PJ was slightly lower than those undergoing PG (9.3% versus 13.8%), but this benefit appeared to be balanced with a higher risk of developing an abdominal abscess in PJ participants (14.7% versus 8.0%).']",7,0.7142857142857143,4,14
CD012257,3,10,Only one study reported quality of life (N = 320); PG may improve some quality of life parameters over PJ (low-quality evidence).,rephrase,['Only one study reported quality of life; PG may be better than PJ in some quality of life parameters.'],8,0.7857142857142857,4,14
CD012257,3,11,No studies reported cost analysis data.,rephrase,['Cost data were not reported in any studies.'],9,0.8571428571428571,5,14
CD012257,4,12,There is no reliable evidence to support the use of pancreatojejunostomy over pancreatogastrostomy.,delete,[],10,0.9285714285714286,5,14
CD012257,4,13,Future large international studies may shed new light on this field of investigation.,delete,[],10,1.0,5,14
CD005598,0,0,We were unable to find any randomized controlled trials on antibiotic treatment approaches for community-acquired pneumonia in people with sickle cell disease.,rephrase,['We were not able to find any trials to include in this review.'],0,0.14285714285714285,1,7
CD005598,1,1,The updated review was unable to identify randomized controlled trials on efficacy and safety of the antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia.,delete,[],1,0.2857142857142857,2,7
CD005598,1,2,Randomized controlled trials are needed to establish the optimum antibiotic treatment for this condition.,delete,[],1,0.42857142857142855,3,7
CD005598,1,3,The trials regarding this issue should be structured and reported according to the CONSORT statement for improving the quality of reporting of efficacy and improved reports of harms in clinical research.,ignore,['Trials addressing this issue should be structured and reported according to the CONSORT statement for improving the quality of reporting of efficacy and improved reports of harms in clinical research.'],1,0.5714285714285714,3,7
CD005598,1,4,Triallists should consider including the following outcomes in new trials: number of days to become afebrile; mortality; onset of pain crisis or complications of sickle cell disease following community-acquired pneumonia; diagnosis; hospitalization (admission rate and length of hospital stay); respiratory failure rate; and number of participants receiving a blood transfusion.,ignore,"['Trial investigators should consider including the following outcomes in new trials: number of days to be free of fever, death, onset of pain crisis or complications of sickle cell disease following community-acquired pneumonia, diagnosis, hospitalization (admission rate and length of hospital stay), respiratory failure rate, and number of participants receiving a blood transfusion.']",2,0.7142857142857143,4,7
CD005598,2,5,There are no trials included in the review and we have not identified any relevant trials up to September 2016.,merge,"['Since no trials have been included in the review up until September 2016, we will still search for trials every two years, but will not publish an updated version of this review until any eligible trials are identified.']",3,0.8571428571428571,5,7
CD005598,2,6,We therefore do not plan to update this review until new trials are published.,none,[],3,1.0,5,7
CD013682,0,0,"We identified four eligible studies reporting on atopic outcomes, representing 7333 children.",rephrase,"['Investigation 1\nWe found four studies (7333 children) carried out in Sweden (one), Australia (two) and the UK (one) that looked at the effect of whooping cough vaccines on allergic diseases.']",0,0.06666666666666667,1,15
CD013682,0,1,"Based on a single trial, there was uncertain evidence on whether wP vaccines affected the risk of overall atopic disease (RR 0.85, 95% CI 0.62 to 1.17) or asthma only (RR 1.04, 95% CI 0.59 to 1.82; 497 children) by 2.5 years old.Three NRSIs were judged to be at serious or critical risk of bias due to confounding, missing data, or both, and were ineligible for inclusion in a narrative synthesis.",delete,[],1,0.13333333333333333,1,15
CD013682,1,2,"We identified 21 eligible studies (137,281 children) that reported the safety outcomes of interest.",delete,[],1,0.2,1,15
CD013682,1,3,"We judged seven studies to be at high risk of bias and those remaining, at unclear risk.",delete,[],1,0.26666666666666666,2,15
CD013682,2,4,"The pooled RR was 0.94 for all-cause SAEs (95% CI 0.78 to 1.15; I2 = 0%; 15 studies, 38,072 children).",rephrase,"['Investigations 2 & 3\nLow numbers of serious unwanted effects were reported for all\xa0groups (15 studies,\xa038,072 children).']",1,0.3333333333333333,2,15
CD013682,2,5,"For every 1000 children primed with a first dose of wP, 11 had an SAE.",rephrase,"['For every 1000 babies vaccinated with a first dose of wP, 11 had at least one serious unwanted effect.']",2,0.4,2,15
CD013682,2,6,The corresponding risk with aP was 12 children (95% CI 9 to 13).,rephrase,['The risk for those who received aP vaccines was 12 children.'],3,0.4666666666666667,3,15
CD013682,2,7,"The 95% CI around the risk difference ranged from three fewer to two more events per 1000 children, and the certainty of the evidence was judged as moderate (downgraded one level for imprecision).",delete,[],4,0.5333333333333333,3,15
CD013682,3,8,"No diagnoses of encephalopathy following vaccination were reported (95% CI around the risk difference - 5 to 12 per 100,000 children; seven primary series studies; 115,271 children).",rephrase,"['No cases of encephalopathy were identified in either group (seven studies, 115,271 children).']",4,0.6,3,15
CD013682,3,9,"The certainty of the evidence was judged as low, since this is a serious condition, and we could not exclude a clinically meaningful difference.",rephrase,"['Because this is a serious outcome, the certainty of the evidence was judged to be low.']",5,0.6666666666666666,4,15
CD013682,4,10,"There is very low-certainty evidence that a first dose of wP given early in infancy, compared to a first dose of aP, affects the risk of atopic diseases in children.",rephrase,"['We are uncertain whether there is a difference in the risk of serious unwanted effects in children vaccinated with a first dose of wP, compared with aP, but any difference is likely to be small.']",6,0.7333333333333333,4,15
CD013682,4,11,"The incidence of all-cause SAEs in wP and aP vaccinees was low, and no cases of encephalopathy were reported.",rephrase,['No\xa0cases of encephalopathy following vaccination were reported.'],7,0.8,4,15
CD013682,4,12,"The certainty of the evidence was judged as moderate for all-cause SAEs, and low for encephalopathy.",delete,[],8,0.8666666666666667,5,15
CD013682,5,13,"Future studies should use sensitive and specific endpoints of clinical relevance, and should be conducted in settings with high prevalence of IgE-mediated food allergy.",delete,[],8,0.9333333333333333,5,15
CD013682,5,14,"Safety endpoints should prioritise common vaccine reactions, parental acceptability, SAEs and their potential relatedness to the dose administered.",delete,[],8,1.0,5,15
CD011024,0,0,We included 26 trials with 2435 randomised participants aged between 2 and 16 years.,rephrase,['We included 26 studies with a total of 2435 children aged between 2 and 16 years.'],0,0.058823529411764705,1,17
CD011024,0,1,"Studies were carried out between 2002 and 2019 in dental clinics in the UK, USA, the Netherlands, Iran, India, France, Egypt, Saudi Arabia, Syria, Mexico, and Korea.",ignore,"['The studies were carried out between 2002 and 2019 in dental clinics in the UK, USA, the Netherlands, Iran, India, France, Egypt, Saudi Arabia, Syria, Mexico, and Korea.']",1,0.11764705882352941,1,17
CD011024,0,2,"Studies included equipment interventions (using several LA delivery devices for injection or audiovisual aids used immediately prior to or during LA delivery or both) and dentist interventions (psychological behaviour interventions delivered in advance of LA (video modelling), or immediately prior to or during delivery of LA or both (hypnosis, counter-stimulation).",rephrase,"['We included studies comparing the use of different equipment like audiovisual glasses or a computerised device for injection called the wand, or dentist interventions like hypnosis, counter-stimulation/distraction, video modelling, to increase the acceptance of delivery of local anaesthetic.']",2,0.17647058823529413,1,17
CD011024,1,3,We judged one study to be at low risk and the rest at high risk of bias.,delete,[],3,0.23529411764705882,2,17
CD011024,1,4,Clinical heterogeneity of the included studies rendered it impossible to pool data into meta-analyses.,delete,[],3,0.29411764705882354,2,17
CD011024,1,5,None of the studies reported on our primary outcome of acceptance of LA.,delete,[],3,0.35294117647058826,2,17
CD011024,1,6,"No studies reported on the following secondary outcomes: completion of dental treatment, successful LA/painless treatment, patient satisfaction, parent satisfaction, and adverse events.",delete,[],3,0.4117647058823529,3,17
CD011024,2,7,"Audiovisual distraction compared to conventional treatment: the evidence was uncertain for the outcome pain-related behaviour during delivery of LA with a reduction in negative behaviour when 3D video glasses where used in the audiovisual distraction group (risk ratio (RR) 0.13, 95% confidence interval (CI) 0.03 to 0.50; 1 trial, 60 participants; very low-certainty evidence).",rephrase,['The evidence was uncertain for audiovisual distraction (using 3D video glasses as distraction) compared to conventional treatment.'],3,0.47058823529411764,3,17
CD011024,3,8,The wand versus conventional treatment: the evidence was uncertain regarding the effect of the wand on pain-related behaviour during delivery of LA.,merge,['The evidence was uncertain when comparing the wand to conventional treatment.'],4,0.5294117647058824,3,17
CD011024,3,9,"Four studies reported a benefit in using the wand while the remaining studies results suggested no difference between the two methods of delivering LA (six trials, 704 participants; very low-certainty evidence).",none,[],4,0.5882352941176471,3,17
CD011024,4,10,"Counter-stimulation/distraction versus conventional treatment: the evidence was uncertain for the outcome pain experience during delivery of LA with children experiencing less pain when counter-stimulation was used (RR 0.12, 95% CI 0.04 to 0.34; 1 trial, 134 participants; very low-certainty evidence).",rephrase,['The evidence was also uncertain for counter-stimulation/distraction compared to conventional treatment and for hypnosis compared to conventional treatment.'],5,0.6470588235294118,4,17
CD011024,5,11,"Hypnosis versus conventional treatment: the evidence was uncertain for the outcome pain experience during delivery of LA with participants in the hypnosis group experiencing less pain (mean difference (MD) -1.79, 95% CI -3.01 to -0.57; 1 trial, 29 participants; very low-certainty evidence).",delete,[],6,0.7058823529411765,4,17
CD011024,6,12,"Other comparisons considered included pre-cooling of the injection site, the wand versus Sleeper One, the use of a camouflage syringe, use of an electrical counter-stimulation device, and video modelling acclimatisation, and had a single study each.",rephrase,"['Other comparisons considered included pre-cooling of the injection site, the wand versus another electronic system called Sleeper One, the use of a camouflage syringe, use of an electrical counter-stimulation device, and video modelling.']",6,0.7647058823529411,4,17
CD011024,6,13,"The findings from these other comparisons were insufficient to draw any affirmative conclusions about their effectiveness, and were considered to be very low-certainty evidence.",rephrase,['The findings from these other comparisons were not enough to be able to decide on their effectiveness.'],7,0.8235294117647058,5,17
CD011024,7,14,We did not find sufficient evidence to draw firm conclusions as to the best interventions to increase acceptance of LA in children due to variation in methodology and nature/timing of outcome measures.,rephrase,['We do not have enough evidence to say which intervention works better to increase acceptance of local anaesthetic in children and adolescents.'],8,0.8823529411764706,5,17
CD011024,7,15,"We recommend further parallel RCTs, reported in line with the CONSORT Statement.",delete,[],9,0.9411764705882353,5,17
CD011024,7,16,Care should be taken when choosing outcome measures.,delete,[],9,1.0,5,17
CD011876,0,0,We included 10 studies (1354 women).,rephrase,['We searched for evidence from randomised controlled trials on 6 January 2016 and found 10 studies (involving a total of 1354 women).'],0,0.05263157894736842,1,19
CD011876,0,1,The risk of bias was unclear or high in most of the included studies.,delete,[],1,0.10526315789473684,1,19
CD011876,1,2,All of the included trials involved women undergoing caesarean section whether elective or non-elective.,delete,[],1,0.15789473684210525,1,19
CD011876,2,3,"Intravenous antibiotics versus antibiotic irrigation (nine studies, 1274 women)
Nine studies (1274 women) compared the administration of intravenous antibiotics with antibiotic irrigation.",rephrase,['Nine studies (1274 women) compared intravenous antibiotic administration with antibiotic irrigation (washing with a saline solution containing antibiotics).'],1,0.21052631578947367,2,19
CD011876,2,4,"There were no clear differences between groups in terms of this review's maternal primary outcomes: endometritis (risk ratio (RR) 0.95, 95% confidence interval (CI) 0.70 to 1.29; eight studies (966 women) (low-quality evidence)); wound infection (RR 0.49, 95% CI 0.17 to 1.43; seven studies (859 women) (very low-quality evidence)).",delete,[],2,0.2631578947368421,2,19
CD011876,2,5,The outcome of infant sepsis was not reported in the included studies.,rephrase,['The studies did not report on blood infections in the newborn infant (sepsis).'],2,0.3157894736842105,2,19
CD011876,3,6,"In terms of this review's maternal secondary outcomes, there were no clear differences between intravenous antibiotic or irrigation antibiotic groups in terms of postpartum febrile morbidity (RR 0.87, 95% CI 0.48 to 1.60; three studies (264 women) (very low-quality evidence)); or urinary tract infection (RR 0.74, 95% CI 0.25 to 2.15; five studies (660 women) (very low-quality evidence)).",rephrase,"['The numbers of women who had urinary tract infection (very low-quality evidence), serious infectious complications (very low-quality evidence) or fever after birth (very low-quality evidence) also did not clearly differ between groups.']",3,0.3684210526315789,2,19
CD011876,3,7,"In terms of adverse effects of the treatment on the women, no drug allergic reactions were reported in three studies (284 women) (very low-quality evidence), and there were no cases of serious infectious complications reported (very low-quality evidence).",rephrase,['No women had allergic reactions to the antibiotics (very low-quality evidence) in the three studies that reported this outcome.'],4,0.42105263157894735,3,19
CD011876,3,8,"There was no clear difference between groups in terms of maternal length of hospital stay (mean difference (MD) 0.28 days, 95% CI -0.22 to 0.79 days, (random-effects analysis), four studies (512 women).",merge,['There was no clear difference between groups in terms of how long women spent in hospital and no data reported on the number of women who were readmitted to hospital.'],5,0.47368421052631576,3,19
CD011876,3,9,No data were reported for the number of women readmitted to hospital.,none,[],5,0.5263157894736842,3,19
CD011876,3,10,"For the baby, there were no data reported in relation to oral thrush, infant length of hospital stay or immediate adverse effects of the antibiotics on the infant.",rephrase,['None of the studies reported information about whether the babies had any immediate adverse reactions to the antibiotics.'],6,0.5789473684210527,3,19
CD011876,4,11,"Intravenous antibiotic prophylaxis versus oral antibiotic prophylaxis (one study, 80 women)
One study (80 women) compared an intravenous versus an oral route of administration of prophylactic antibiotics, but did not report any of this review's primary or secondary outcomes.",rephrase,"[""One study (involving 80 women) compared intravenous antibiotics with taking antibiotics orally but it did not report on any of this review's outcomes.""]",7,0.631578947368421,4,19
CD011876,5,12,There was no clear difference between irrigation and intravenous antibiotic prophylaxis in reducing the risk of post-caesarean endometritis.,delete,[],8,0.6842105263157895,4,19
CD011876,5,13,"For other outcomes, there is insufficient evidence regarding which route of administration of prophylactic antibiotics is most effective at preventing post-caesarean infections.",delete,[],8,0.7368421052631579,4,19
CD011876,5,14,"The quality of evidence was very low to low, mainly due to limitations in study design and imprecision.",rephrase,['This meant the evidence was of low quality.'],8,0.7894736842105263,4,19
CD011876,5,15,"Furthermore, most of the included studies were underpowered (small sample sizes with few events).",delete,[],9,0.8421052631578947,5,19
CD011876,5,16,"Therefore, we advise caution in the interpretation and generalisability of the results.",ignore,"['Therefore, we need to exercise caution in the interpretation and generalisability of the results.']",9,0.8947368421052632,5,19
CD011876,6,17,"For future research, there is a need for well-designed, properly-conducted, and clearly-reported RCTs.",delete,[],10,0.9473684210526315,5,19
CD011876,6,18,"Such studies should evaluate the more recently available antibiotics, elaborating on the various available routes of administration, and exploring potential neonatal side effects of such interventions.",rephrase,['Such studies should evaluate more recently available antibiotics and consider potential side effects that the intervention may have for the baby.'],10,1.0,5,19
CD013335,0,0,We included eight studies involving 1585 participants.,rephrase,"['We included findings from eight studies involving 1585 adults, with most being men (1019 men versus 506 women) with average ages 60 to 69 years.']",0,0.09090909090909091,1,11
CD013335,0,1,All studies were RCTs conducted in ICU settings.,rephrase,"['All studies were conducted in the ICU settings, and many people were severely ill and required mechanical ventilation and tube feeding for more than 48 hours.']",1,0.18181818181818182,1,11
CD013335,1,2,Two studies (417 participants) compared less-frequent (less than eight hours) monitoring of GRV against a regimen of more-frequent (eight hours or greater) monitoring.,rephrase,['Two studies (417 participants) compared less-frequent GRV monitoring with a more-frequent regimen.'],2,0.2727272727272727,2,11
CD013335,1,3,"The evidence is very uncertain about the effect of frequent monitoring of GRV on mortality rate (RR 0.91, 95% CI 0.60 to 1.37; I² = 8%; very low-certainty evidence), incidence of pneumonia (RR 1.08, 95% CI 0.64 to 1.83; heterogeneity not applicable; very low-certainty evidence), length of hospital stay (MD 2.00 days, 95% CI –2.15 to 6.15; heterogeneity not applicable; very low-certainty evidence), and incidence of vomiting (RR 0.14, 95% CI 0.02 to 1.09; heterogeneity not applicable; very low-certainty evidence).",delete,[],3,0.36363636363636365,2,11
CD013335,2,4,Two studies (500 participants) compared no GRV monitoring with frequent (12 hours or less) monitoring.,rephrase,['Two studies (500 participants) compared no GRV monitoring with frequent monitoring.'],3,0.45454545454545453,3,11
CD013335,2,5,"Similarly, the evidence is very uncertain about the effect of no monitoring of GRV on mortality rate (RR 0.87, 95% CI 0.62 to 1.23; I² = 51%; very low-certainty evidence), incidence of pneumonia (RR 0.70, 95% CI 0.43 to 1.13; heterogeneity not applicable; very low-certainty evidence), length of hospital stay (MD –1.53 days, 95% CI –4.47 to 1.40; I² = 0%; very low-certainty evidence), and incidence of vomiting (RR 1.47, 95% CI 1.13 to 1.93; I² = 0%; very low-certainty evidence).",delete,[],4,0.5454545454545454,3,11
CD013335,3,6,One study (322 participants) assessed the impact of GRV threshold (500 mL per six hours) on clinical outcomes.,rephrase,['One trial (329 participants) assessed the effects of GRV threshold by comparing a higher threshold at the time of aspiration against a lower threshold.'],4,0.6363636363636364,4,11
CD013335,3,7,"The evidence is very uncertain about the effect of the threshold for GRV at time of aspiration on mortality rate (RR 1.01, 95% CI 0.74 to 1.38; heterogeneity not applicable; very low-certainty evidence), incidence of pneumonia (RR 1.03, 95% CI 0.72 to 1.46; heterogeneity not applicable; very low-certainty evidence), and length of hospital stay (MD –0.90 days, 95% CI –2.60 to 4.40; heterogeneity not applicable; very low-certainty evidence).",delete,[],5,0.7272727272727273,4,11
CD013335,4,8,Two studies (140 participants) explored the effects of returning or discarding the aspirated/drained GRV.,rephrase,['Two studies (140 participants) compared the technique of returning versus discarding the aspirated/drained GRV.'],5,0.8181818181818182,5,11
CD013335,4,9,"The evidence is uncertain about the effect of discarding or returning the aspirated/drained GRV on the incidence of vomiting (RR 1.00, 95% CI 0.06 to 15.63; heterogeneity not applicable; very low-certainty evidence) and volume aspirated from the stomach (MD –7.30 mL, 95% CI –26.67 to 12.06, I² = 0%; very low-certainty evidence)
We found no studies comparing the effects of protocol-based EN strategies that included GRV-related criteria against strategies that did not include such criteria.",delete,[],6,0.9090909090909091,5,11
CD013335,5,10,"The evidence is very uncertain about the effect of GRV on clinical outcomes including mortality, pneumonia, vomiting, and length of hospital stay.",rephrase,"['We found that the evidence is uncertain about GRV monitoring (less frequent versus more frequent; no monitoring versus frequent monitoring) on mortality, pneumonia, vomiting, and length of hospital stay.']",6,1.0,5,11
CD011952,0,0,Six RCTs compared the effect of oral ascorbic acid (1 to 4 grams) and placebo treatment in CMT1A.,rephrase,"['We searched the medical literature for trials of vitamin C in CMT disease and found six trials - five in adults and one in children - on the treatment of CMT type 1A (CMT1A) with vitamin C. All compared vitamin C doses of 1 to 4 grams per day with a placebo (a dummy or sugar pill disguised as vitamin C), and lasted for 12 or 24 months.']",0,0.07692307692307693,1,13
CD011952,0,1,"In five trials involving adults with CMT1A, a total of 622 participants received ascorbic acid or placebo.",rephrase,['The trials in adults included a total of 622 people.'],1,0.15384615384615385,1,13
CD011952,0,2,Trials were largely at low risk of bias.,rephrase,"['The measures used for children in this study did not show benefit from vitamin C. The studies were largely at low risk of bias, meaning they were well designed and the results were not easily influenced by chance.']",2,0.23076923076923078,2,13
CD011952,0,3,"There is high-quality evidence that ascorbic acid does not improve the course of CMT1A in adults as measured by the CMT neuropathy score (0 to 36 scale) at 12 months (mean difference (MD) -0.37; 95% confidence intervals (CI) -0.83 to 0.09; five studies; N = 533), or at 24 months (MD -0.21; 95% CI -0.81 to 0.39; three studies; N = 388).",rephrase,['We found that ascorbic acid treatment did not improve impairment from CMT1A in adults as measured by the CMT neuropathy score (CMTNS).'],3,0.3076923076923077,2,13
CD011952,0,4,"Ascorbic acid treatment showed a positive effect on the nine-hole peg test versus placebo (MD -1.16 seconds; 95% CI -1.96 to -0.37), but the clinical significance of this result is probably small.",delete,[],4,0.38461538461538464,2,13
CD011952,0,5,Meta-analyses of other secondary outcome parameters showed no relevant benefit of ascorbic acid.,delete,[],4,0.46153846153846156,3,13
CD011952,0,6,"In one trial, 80 children with CMT1A received ascorbic acid or placebo.",rephrase,['The other trial included 80 children.'],4,0.5384615384615384,3,13
CD011952,0,7,The trial showed no clinical benefit of ascorbic acid treatment.,delete,[],5,0.6153846153846154,4,13
CD011952,0,8,Adverse effects did not differ in their nature or abundance between ascorbic acid and placebo.,rephrase,['Adverse events were similar in nature and number in vitamin C and placebo groups.'],5,0.6923076923076923,4,13
CD011952,1,9,High-quality evidence indicates that ascorbic acid does not improve the course of CMT1A in adults in terms of the outcome parameters used.,merge,['There is high-quality evidence for adults and low-quality evidence for children that vitamin C does not improve the course of CMT1A.'],6,0.7692307692307693,4,13
CD011952,1,10,"According to low-quality evidence, ascorbic acid does not improve the course of CMT1A in children.",none,[],6,0.8461538461538461,5,13
CD011952,1,11,"However, CMT1A is slowly progressive and the outcome parameters show only small change over time.",delete,[],7,0.9230769230769231,5,13
CD011952,1,12,"Longer study durations should be considered, and outcome parameters more sensitive to change over time should be designed and validated for future studies.",rephrase,"['Further research with longer study duration and more sensitive outcome parameters should be done, although any large effect in adults or children is unlikely.']",7,1.0,5,13
CD013700,0,0,"We identified 55 studies in 90 records in the qualitative analysis, reporting 39 primary RCTs and 16 subgroup analyses.",delete,[],0,0.125,1,8
CD013700,0,1,"We included 22 RCTs, with 4299 participants, that reported disease control and/or progression-free survival in the network meta-analysis.",rephrase,"['We included 22 randomised controlled trials (studies in which participants are randomly assigned to treatment groups), published before 11 December 2020, with a total of 4299 people.']",0,0.25,2,8
CD013700,0,2,"Precision-of-treatment estimates and estimated heterogeneity were limited, although the risk of bias was predominantly low.",delete,[],1,0.375,2,8
CD013700,1,3,"The network meta-analysis of progression-free survival found nine therapies for pancreatic NETs: everolimus (hazard ratio [HR], 0.36 [95% CI, 0.28 to 0.46]), interferon plus somatostatin analogue (HR, 0.34 [95% CI, 0.14 to 0.80]), everolimus plus somatostatin analogue (HR, 0.38 [95% CI, 0.26 to 0.57]), bevacizumab plus somatostatin analogue (HR, 0.36 [95% CI, 0.15 to 0.89]), interferon (HR, 0.41 [95% CI, 0.18 to 0.94]), sunitinib (HR, 0.42 [95% CI, 0.26 to 0.67]), everolimus plus bevacizumab plus somatostatin analogue (HR, 0.48 [95% CI, 0.28 to 0.83]), surufatinib (HR, 0.49 [95% CI, 0.32 to 0.76]), and somatostatin analogue (HR, 0.51 [95% CI, 0.34 to 0.77]); and six therapies for gastrointestinal NETs: 177-Lu-DOTATATE plus somatostatin analogue (HR, 0.07 [95% CI, 0.02 to 0.26]), everolimus plus somatostatin analogue (HR, 0.12 [95%CI, 0.03 to 0.54]), bevacizumab plus somatostatin analogue (HR, 0.18 [95% CI, 0.04 to 0.94]), interferon plus somatostatin analogue (HR, 0.23 [95% CI, 0.06 to 0.93]), surufatinib (HR, 0.33 [95%CI, 0.12 to 0.88]), and somatostatin analogue (HR, 0.34 [95% CI, 0.16 to 0.76]), with higher efficacy than placebo.",delete,[],1,0.5,3,8
CD013700,1,4,"Besides everolimus for pancreatic NETs, the results suggested an overall superiority of combination therapies, including somatostatin analogues.",split,"['This analysis suggests, in general, a superiority of combination therapies,\xa0including somatostatin-like medications, in both gastrointestinal and pancreatic NETs.', 'However, in pancreatic NETs, everolimus was the most effective therapy \xa0with the highest certainty of evidence compared to the other treatments.']",1,0.625,4,8
CD013700,2,5,"The results indicate that NET therapies have a broad range of risk for adverse events and effects on quality of life, but these were reported inconsistently.",rephrase,"['Furthermore, the results indicate that NET therapies have a broad range of risk for adverse events and effects on quality of life.']",3,0.75,4,8
CD013700,3,6,Evidence from this network meta-analysis (and underlying RCTs) does not support any particular therapy (or combinations of therapies) with respect to patient-centred outcomes (e.g. overall survival and quality of life).,ignore,['Evidence from this network meta-analysis (and underlying RCTs) does not support any particular therapy (or combinations of therapies) with respect to patient-centred outcomes\xa0(e.g. overall survival and quality of life).'],4,0.875,5,8
CD013700,4,7,The findings from this study suggest that a range of efficient therapies with different safety profiles is available for people with NETs.,delete,[],5,1.0,5,8
CD007338,0,0,Ten trials involving 617 patients satisfied the inclusion criteria.,delete,[],0,0.07692307692307693,1,13
CD007338,0,1,"The interventions included low central venous pressure (CVP), autologous blood donation, haemodilution, haemodilution with controlled hypotension, and hypoventilation.",rephrase,"[""The interventions included low central venous pressure (CVP; lowering the pressure in the major veins), autologous blood donation (using the patient's own blood obtained prior to liver resection), haemodilution (replacing blood with other fluids), haemodilution with controlled hypotension (lowering the blood pressure in addition to diluting the blood), and hypoventilation (decreasing the rate of artificial breathing).""]",0,0.15384615384615385,1,13
CD007338,0,2,Only one or two trials were included under most comparisons.,delete,[],1,0.23076923076923078,2,13
CD007338,0,3,All trials had a high risk of bias.,rephrase,"[""All trials had high risk of bias (with the possibility of overestimating the benefits and underestimating the harms of the treatment) and play of chance ('random error').""]",1,0.3076923076923077,2,13
CD007338,0,4,"There was no significant difference in the peri-operative mortality in any of the comparisons: low CVP versus no intervention (3 trials, 0/88 (0%) patients in the low CVP group versus 1/89 (1.1%) patients in the no intervention group); autologous blood donation versus no intervention (1 trial, 0/40 (0%) versus 0/39 (0%)); haemodilution versus no intervention (2 trials, 1/73 (1.4%) versus 3/77 (3.9%) in one of these trials); haemodilution with controlled hypotension versus no intervention (1 trial, 0/10 (0%) versus 0/10 (0%)); haemodilution with bovine haemoglobin (HBOC-201) versus haemodilution with hydroxy ethyl starch (HES) (1 trial, 1/6 (16.7%) versus 0/6 (0%)); hypoventilation versus no intervention (1 trial, 0/40 (0%) versus 0/39 (0%)).",rephrase,['There were no differences in the number of deaths or complications due to surgery in any of the comparisons.'],2,0.38461538461538464,2,13
CD007338,0,5,None of the trials reported long-term survival or quality of life.,rephrase,['Long-term survival was not reported in any of the trials.'],3,0.46153846153846156,3,13
CD007338,0,6,"The risk ratio of requiring allogeneic blood transfusion was significantly lower in the haemodilution versus no intervention groups (3 trials, 16/115 (weighted proportion = 14.2%) versus 41/118 (34.7%), RR 0.41 (95% CI 0.25 to 0.66), P = 0.0003); and for haemodilution with controlled hypotension versus no intervention (1 trial, 0/10 (0%) versus 10/10 (100%), P < 0.0001).",rephrase,['Fewer patients required transfusion of blood donated by others when haemodilution or haemodilution with controlled hypotension were compared with a control group.'],4,0.5384615384615384,3,13
CD007338,0,7,"There were no significant differences in the allogeneic transfusion requirements in the other comparisons which reported this outcome, such as low CVP versus no intervention, autologous blood donation versus control, and hypoventilation versus no intervention.",rephrase,['The other comparisons did not decrease the transfusion requirements.'],5,0.6153846153846154,4,13
CD007338,1,8,None of the interventions seemed to decrease peri-operative morbidity or offer any long-term survival benefit.,delete,[],6,0.6923076923076923,4,13
CD007338,1,9,Haemodilution shows promise in the reduction of blood transfusion requirements in liver resection surgery.,rephrase,['Haemodilution showed promise in the reduction of blood transfusion requirements in patients undergoing liver resections.'],6,0.7692307692307693,4,13
CD007338,1,10,"However, there is a high risk of type I (erroneously concluding that an intervention is beneficial when it is actually not beneficial) and type II errors (erroneously concluding that an intervention is not beneficial when it is actually beneficial) because of the few trials included, the small sample size in each trial, and the high risk of bias in the trials.",rephrase,"['However, there is a high risk of type I errors (erroneously concluding that an intervention is beneficial when it is actually not beneficial) and type II errors (erroneously concluding that an intervention is not beneficial when it is actually beneficial) because of the few trials included and the small sample size in each trial, as well as the inherent risk of bias (systematic errors which can result in overestimation of the benefits and underestimation of the harms of the intervention).']",7,0.8461538461538461,5,13
CD007338,1,11,Further randomised clinical trials with low risk of bias and random errors that assess clinically important outcomes such as peri-operative mortality are necessary to assess any cardiopulmonary interventions aimed at decreasing blood loss and blood transfusion requirements in patients undergoing liver resections.,split,"['This systematic review was aimed at determining whether any cardiopulmonary intervention (interventions that change the circulation or breathing during surgery) decreased blood loss or decreased allogeneic blood transfusion requirements in patients undergoing liver resections.', 'Further randomised clinical trials with low risk of bias (systematic errors) and low risk of play of chance (random errors) which assess clinically important outcomes (such as death and complications due to the operation) are necessary to assess cardiopulmonary interventions aimed at decreasing blood loss in liver resections.']",8,0.9230769230769231,5,13
CD007338,1,12,Trials need to be designed to assess the effect of a combination of different interventions in liver resections.,ignore,['Trials need to be designed to assess the effect of a combination of different interventions during liver resections.'],10,1.0,5,13
CD006032,0,0,"We included one study that met our selection criteria; a double-masked, placebo-controlled, randomised trial of high dose intravenous steroids in patients with indirect TON diagnosed within seven days of the initial injury.",rephrase,"['We found only one, relatively small, randomised controlled trial of steroids in TON, which included 31 participants within seven days of their initial injury.']",0,0.1111111111111111,1,9
CD006032,0,1,"A total of 31 eligible participants were randomised to receive either high dose intravenous steroids (n = 16) or placebo (n = 15), and they were all followed-up for three months.",rephrase,['These participants received either high dose intravenous steroids (n = 16) or placebo (n = 15).'],1,0.2222222222222222,2,9
CD006032,0,2,"Mean final best corrected visual acuity (BCVA) was 1.78±1.23 Logarithm of the Minimum Angle of Resolution (LogMAR) in the placebo group, and 1.11±1.14 LogMAR in the steroid group.",delete,[],2,0.3333333333333333,2,9
CD006032,0,3,"The mean difference in BCVA between the placebo and steroid groups was 0.67 LogMAR (95% confidence interval -1.54 to 0.20), and this difference was not statistically significant (P = 0.13).",delete,[],2,0.4444444444444444,3,9
CD006032,0,4,"At three months follow-up, an improvement in BCVA of 0.40 LogMAR occurred in eight eyes (8/15, 53.3%) in the placebo group, and in 11 eyes (11/16, 68.8%) in the treatment group.",rephrase,"['At three months follow-up, no significant difference in best corrected visual acuity was found between these two groups.']",2,0.5555555555555556,3,9
CD006032,0,5,This difference was not statistically significant (P = 0.38).,delete,[],3,0.6666666666666666,4,9
CD006032,1,6,There is a relatively high rate of spontaneous visual recovery in TON and there is no convincing data that steroids provide any additional visual benefit over observation alone.,ignore,['There is a relatively high rate of spontaneous visual recovery in TON and no convincing data that steroids provide any additional benefit over observation alone.'],3,0.7777777777777778,4,9
CD006032,1,7,Recent evidence also suggests a possible detrimental effect of steroids in TON and further studies are urgently needed to clarify this important issue.,rephrase,"['Furthermore, recent studies have highlighted possible detrimental effects of steroids when used in brain and spinal cord injuries and these new lines of evidence need to be considered seriously.']",4,0.8888888888888888,5,9
CD006032,1,8,Each case therefore needs to be assessed on an individual basis and proper informed consent is paramount.,rephrase,"['Each case needs to be assessed on an individual basis and the patient needs to be made fully aware of the possibility of a serious adverse reaction, although rare, to steroids.']",5,1.0,5,9
CD006325,0,0,We could not identify any studies in which the only difference between the treatment groups was the use of MTX.,rephrase,['The authors found that there were no studies in which the only difference between the intervention and control group was the use of MTX.'],0,0.07692307692307693,1,13
CD006325,1,1,We did identify a RCT comparing MTX with cisplatin (n=30 children).,rephrase,['They did identify a RCT comparing MTX with cisplatin.'],1,0.15384615384615385,1,13
CD006325,1,2,The risk of bias in this study was difficult to assess due to a lack of reporting.,ignore,['The risk of bias in this study was difficult to assess due to a lack of reporting.'],2,0.23076923076923078,2,13
CD006325,1,3,"Survival could not be evaluated, but no evidence of a significant difference in response rate between the treatment groups was identified (RR=0.44; 95% CI 0.17 to 1.13; P=0.09).",rephrase,"['Survival could not be evaluated, but no evidence of a significant difference in response rate between the treatment groups was identified.']",3,0.3076923076923077,2,13
CD006325,1,4,"A significant difference in the occurrence of toxicities in favour of MTX was identified, but with regard to quality of life treatment with cisplatin seemed to give better results.",rephrase,"['However, a significant difference in the occurrence of toxicities in favour of treatment with MTX was identified, but treatment with cisplatin seemed to give better results with regard to quality of life.']",4,0.38461538461538464,2,13
CD006325,2,5,For other combinations of treatment including and not including MTX no studies were identified.,delete,[],5,0.46153846153846156,3,13
CD006325,3,6,"Since no RCTs or CCTs in which only the use of MTX differed between the treatment groups were identified, no definitive conclusions can be made about the effects on antitumour efficacy, toxicities and quality of life of the addition of MTX to treatment of children and young adults with primary high-grade osteosarcoma.",merge,[],5,0.5384615384615384,3,13
CD006325,3,7,The same is true for combinations of treatment including and not including MTX other than treatment with MTX versus treatment with cisplatin.,merge,['For other combinations of treatment including and not including MTX no studies are available.'],5,0.6153846153846154,4,13
CD006325,3,8,"Only 1 RCT comparing MTX with cisplatin treatment was available and therefore, no definitive conclusions can be made about the effectiveness of these agents in children and young adults with primary high-grade osteosarcoma.",none,[],5,0.6923076923076923,4,13
CD006325,3,9,"Furthermore, this study was performed in a different treatment era.",rephrase,['It should be noted that this study was performed in a different treatment era.'],6,0.7692307692307693,4,13
CD006325,3,10,Nowadays single agent treatment of osteosarcoma is considered inadequate.,ignore,['Nowadays single agent treatment of osteosarcoma is considered inadequate.'],7,0.8461538461538461,5,13
CD006325,3,11,"Based on the currently available evidence, we are not able to give recommendations for the use of MTX in clinical practice.",delete,[],8,0.9230769230769231,5,13
CD006325,3,12,More high quality research is needed.,ignore,['More high quality research is needed.'],8,1.0,5,13
CD010615,0,0,We identified four RCTs fitting the inclusion criteria.,rephrase,['We searched several medical databases and identified four randomised controlled trials that met our inclusion criteria.'],0,0.058823529411764705,1,17
CD010615,0,1,"However, two of these closed prematurely due to low recruitment and did not report results.",rephrase,['Two of the four studies terminated early due to low recruitment (14 participants included) and did not release any results.'],1,0.11764705882352941,1,17
CD010615,0,2,The remaining two trials evaluated 600 participants with multiple myeloma or non-Hodgkin lymphoma.,rephrase,['The two published analysed trials included 600 participants with multiple myeloma and non-Hodgkin lymphoma.'],2,0.17647058823529413,1,17
CD010615,0,3,In both studies the experimental group received G-CSF plus plerixafor and the control group received G-CSF plus placebo.,ignore,"['In both studies, the experimental group received G-CSF plus plerixafor subcutaneously, and the control group received G-CSF plus placebo.']",3,0.23529411764705882,2,17
CD010615,1,4,"The meta-analysis showed no evidence for differences between plerixafor and placebo group regarding mortality at 12 months (600 participants; risk ratio (RR) 1.00, 95% confidence interval (CI) 0.59 to 1.69; P = 1.00; moderate-quality evidence) and adverse events during stem cell mobilisation and collection (593 participants; RR 1.02, 95% CI 0.99 to 1.06; P = 0.19; high-quality evidence).",rephrase,['We found no evidence for a difference between the plerixafor and placebo group for the outcomes mortality at 12 months and adverse events during stem cell mobilisation period.'],4,0.29411764705882354,2,17
CD010615,2,5,"Regarding the outcome successful stem cell collection, the meta-analysis showed an advantage for those participants randomised to the plerixafor group (600 participants; RR 2.42, 95% CI 1.98 to 2.96; P < 0.00001; high-quality evidence).",rephrase,['The meta-analysis showed an advantage for those participants randomised to plerixafor for the outcome successful stem cell collection.'],5,0.35294117647058826,2,17
CD010615,3,6,"As there was high heterogeneity between studies for the number of transplanted participants, we did not meta-analyse these data.",delete,[],6,0.4117647058823529,3,17
CD010615,3,7,"In the multiple myeloma study, 95.9% (142 participants) in the plerixafor arm and 88.3% (136 participants) in the placebo arm underwent transplantation (RR 1.09, 95% CI 1.02 to 1.16); in the non-Hodgkin lymphoma trial, 90% (135 participants) in the plerixafor group versus 55.4% (82 participants) in the placebo group could be transplanted (RR 1.62, 95% CI 1.39 to 1.89).",split,"['In the study that enrolled people with multiple myeloma, 95.9% of the participants in the plerixafor arm and 88.3% in the placebo arm underwent transplantation.', 'In the study that examined people with non-Hodgkin lymphoma, 90% of the participants in the plerixafor group and only 55.4% in the placebo group could be transplanted.']",6,0.47058823529411764,3,17
CD010615,3,8,In both trials there was no evidence for a difference between participants in the plerixafor and placebo group in terms of time to neutrophil and platelet engraftment in transplanted participants.,rephrase,"['It seems that especially people with non-Hodgkin lymphoma benefit from the addition of plerixafor in terms of successful transplantation, but there was no evidence for a difference for time to neutrophil and platelet engraftment in transplanted participants.']",8,0.5294117647058824,3,17
CD010615,4,9,None of the trials reported on the outcomes quality of life and progression-free survival.,rephrase,['None of the trials reported on quality of life or progression-free survival.'],9,0.5882352941176471,3,17
CD010615,5,10,The results of the analysed data suggest that additional plerixafor leads to increased stem cell collection in a shorter time.,delete,[],10,0.6470588235294118,4,17
CD010615,5,11,There was insufficient evidence to determine whether additional plerixafor affects survival or adverse events.,delete,[],10,0.7058823529411765,4,17
CD010615,6,12,"The two trials included in the meta-analysis, both of which were conducted by the Genzyme Corporation, the manufacturer of plerixafor, were published several times.",delete,[],10,0.7647058823529411,4,17
CD010615,6,13,Two more RCTs examining the addition of plerixafor to a G-CSF mobilisation regimen terminated early without publishing any outcome.,delete,[],10,0.8235294117647058,5,17
CD010615,6,14,"The trials included nine and five participants, respectively.",delete,[],10,0.8823529411764706,5,17
CD010615,6,15,"Another RCT with 100 participants was recently completed, but has not yet published outcomes.",delete,[],10,0.9411764705882353,5,17
CD010615,6,16,"Due to the unpublished RCTs, it is possible that our review is affected by publication bias, even though two trials failed to recruit a sufficient number of participants to analyse any data.",delete,[],10,1.0,5,17
CD001139,0,0,"We included 34 RCTs examining 5121 pregnant women, aged 16 to 45 years and, when reported, from 12 to 38 weeks’ gestation.",split,"['We included 34 randomised studies in this updated review, with 5121 pregnant women, aged 16 to 45 years.', 'Women were from 12 to 38 weeks’ pregnant.']",0,0.047619047619047616,1,21
CD001139,0,1,Fifteen RCTs examined women with low-back pain (participants = 1847); six examined pelvic pain (participants = 889); and 13 examined women with both low-back and pelvic pain (participants = 2385).,delete,[],2,0.09523809523809523,1,21
CD001139,0,2,"Two studies also investigated low-back pain prevention and four, low-back and pelvic pain prevention.",rephrase,"['Studies looked at different treatments for pregnant women with low-back pain, pelvic pain or both types of pain.']",2,0.14285714285714285,1,21
CD001139,0,3,Diagnoses ranged from self-reported symptoms to clinicians’ interpretation of specific tests.,rephrase,"[""Studies measured women's symptoms in different ways, ranging from self-reported pain and sick leave to the results of specific tests.""]",3,0.19047619047619047,1,21
CD001139,0,4,"All interventions were added to usual prenatal care and, unless noted, were compared with usual prenatal care.",rephrase,"['All treatments were added to usual prenatal care, and were compared with usual prenatal care alone in 23 studies.']",4,0.23809523809523808,2,21
CD001139,0,5,"The quality of the evidence ranged from moderate to low, raising concerns about the confidence we could put in the estimates of effect.",delete,[],5,0.2857142857142857,2,21
CD001139,1,6,"For low-back pain
Results from meta-analyses provided low-quality evidence (study design limitations, inconsistency) that any land-based exercise significantly reduced pain (standardised mean difference (SMD) -0.64; 95% confidence interval (CI) -1.03 to -0.25; participants = 645; studies = seven) and functional disability (SMD -0.56; 95% CI -0.89 to -0.23; participants = 146; studies = two).",delete,[],5,0.3333333333333333,2,21
CD001139,1,7,"Low-quality evidence (study design limitations, imprecision) also suggested no significant differences in the number of women reporting low-back pain between group exercise, added to information about managing pain, versus usual prenatal care (risk ratio (RR) 0.97; 95% CI 0.80 to 1.17; participants = 374; studies = two).",rephrase,"['However, two other studies (374 women) found that group exercise plus information was no better at preventing either pelvic or low-back pain than usual prenatal care.']",5,0.38095238095238093,2,21
CD001139,2,8,"For pelvic pain
Results from a meta-analysis provided low-quality evidence (study design limitations, imprecision) of no significant difference in the number of women reporting pelvic pain between group exercise, added to information about managing pain, and usual prenatal care (RR 0.97; 95% CI 0.77 to 1.23; participants = 374; studies = two).",rephrase,['Two studies found that women who participated in group exercise and received information about managing their pain reported no difference in their pelvic pain than women who received usual prenatal care.'],6,0.42857142857142855,3,21
CD001139,3,9,"For low-back and pelvic pain
Results from meta-analyses provided moderate-quality evidence (study design limitations) that: an eight- to 12-week exercise program reduced the number of women who reported low-back and pelvic pain (RR 0.66; 95% CI 0.45 to 0.97; participants = 1176; studies = four); land-based exercise, in a variety of formats, significantly reduced low-back and pelvic pain-related sick leave (RR 0.76; 95% CI 0.62 to 0.94; participants = 1062; studies = two).",split,"['The results of four studies combined (1176 women) showed that an eight- to 12-week exercise program reduced the number of women who reported low-back and pelvic pain.', 'Land-based exercise, in a variety of formats, also reduced low-back and pelvic pain-related sick leave in two studies (1062 women).']",7,0.47619047619047616,3,21
CD001139,4,10,"The results from a number of individual studies, incorporating various other interventions, could not be pooled due to clinical heterogeneity.",delete,[],9,0.5238095238095238,3,21
CD001139,4,11,"There was moderate-quality evidence (study design limitations or imprecision) from individual studies suggesting that osteomanipulative therapy significantly reduced low-back pain and functional disability, and acupuncture or craniosacral therapy improved pelvic pain more than usual prenatal care.",delete,[],9,0.5714285714285714,3,21
CD001139,4,12,"Evidence from individual studies was largely of low quality (study design limitations, imprecision), and suggested that pain and functional disability, but not sick leave, were significantly reduced following a multi-modal intervention (manual therapy, exercise and education) for low-back and pelvic pain.",delete,[],9,0.6190476190476191,4,21
CD001139,5,13,"When reported, adverse effects were minor and transient.",rephrase,"['When reported, there were no lasting side effects in any of the studies.']",9,0.6666666666666666,4,21
CD001139,6,14,"There is low-quality evidence that exercise (any exercise on land or in water), may reduce pregnancy-related low-back pain and moderate- to low-quality evidence suggesting that any exercise improves functional disability and reduces sick leave more than usual prenatal care.",rephrase,"['There is low-quality evidence suggesting that exercise improves pain and disability for women with low-back pain, and moderate-quality evidence that exercise results in less sick leave and fewer women reporting pain in those with both low-back and pelvic pain together.']",10,0.7142857142857143,4,21
CD001139,6,15,"Evidence from single studies suggests that acupuncture or craniosacral therapy improves pregnancy-related pelvic pain, and osteomanipulative therapy or a multi-modal intervention (manual therapy, exercise and education) may also be of benefit.",rephrase,"['Findings suggested that craniosacral therapy, osteomanipulative therapy or a multi-modal intervention (manual therapy, exercise and education) may be of benefit.']",11,0.7619047619047619,4,21
CD001139,7,16,Clinical heterogeneity precluded pooling of results in many cases.,delete,[],12,0.8095238095238095,5,21
CD001139,7,17,"Statistical heterogeneity was substantial in all but three meta-analyses, which did not improve following sensitivity analyses.",delete,[],12,0.8571428571428571,5,21
CD001139,7,18,Publication bias and selective reporting cannot be ruled out.,delete,[],12,0.9047619047619048,5,21
CD001139,8,19,Further evidence is very likely to have an important impact on our confidence in the estimates of effect and change the estimates.,rephrase,"['As a result, we believe that future studies are very likely to change our conclusions.']",12,0.9523809523809523,5,21
CD001139,8,20,"Studies would benefit from the introduction of an agreed classification system that can be used to categorise women according to their presenting symptoms, so that treatment can be tailored accordingly.",delete,[],13,1.0,5,21
CD010905,0,0,We included 25 studies of which 4 are awaiting assessment.,ignore,['We included 25 studies of which 4 studies are awaiting assessment.'],0,0.06666666666666667,1,15
CD010905,0,1,"The 21 studies that could be analysed were 1 RCT, 14 cRCTs and 6 CBAs with a total of at least 3479 employees in intervention and control groups.",rephrase,['The 21 studies that could be analysed included a total of 3479 employees.'],1,0.13333333333333333,1,15
CD010905,0,2,We judged 12 studies to have an unclear risk of bias and the remaining nine studies to have a high risk of bias.,delete,[],2,0.2,1,15
CD010905,0,3,"Sixteen studies focused on improving supervisor-employee interaction, whereas five studies aimed at improving the design of working environments by means of supervisor training.",split,"['Sixteen studies trained supervisor-employee interaction, either off-the-job (9 studies) or on-the job (7 studies).', 'Five studies trained the design of working environments, off-the-job in 2 studies and on-the job in 3 studies.']",2,0.26666666666666666,2,15
CD010905,1,4,"Training versus no intervention
We found very low-quality evidence that supervisor training does not reduce employees' stress levels (6 studies) or absenteeism (1 study) when compared to no intervention, regardless of intervention type or follow-up.",rephrase,"[""There is no considerable effect of supervisor training on employees' stress (6 studies) or absenteeism (1 study) when compared to no training.""]",4,0.3333333333333333,2,15
CD010905,1,5,"We found inconsistent, very low-quality evidence that supervisor training aimed at employee interaction may (2 studies) or may not (7 studies) improve employees' well-being when compared to no intervention.",rephrase,"[""There is inconsistent evidence that supervisor training may (2 studies) or may not (7 studies) improve employees' well-being when compared to no training.""]",5,0.4,2,15
CD010905,1,6,Effects from two studies were not estimable due to missing data.,rephrase,"['Data were missing from two studies, so we could not calculate the effects of training on employee well-being.']",6,0.4666666666666667,3,15
CD010905,2,7,"Training versus placebo
We found moderate-quality evidence (2 studies) that supervisor training off the job aimed at employee interaction does not reduce employees' stress levels more than a placebo training at mid-term follow-up.",delete,[],7,0.5333333333333333,3,15
CD010905,2,8,We found low-quality evidence in one study that supervisor training on the job aimed at employee interaction does not reduce employees' absenteeism more than placebo training at long-term follow-up.,rephrase,"[""There is no effect of supervisor training on employees' stress (2 studies) or absenteeism (1 study) when compared to a placebo training.""]",7,0.6,3,15
CD010905,2,9,Effects from one study were not estimable due to insufficient data.,rephrase,"['Data were missing from one study, so we could not calculate the effects of training on employee well-being.']",8,0.6666666666666666,4,15
CD010905,3,10,"Training versus other training
One study compared the effects of supervisor training off the job aimed at employee interaction on employees' stress levels to training off the job aimed at working conditions at long-term follow-up but due to insufficient data, effects were not estimable.",rephrase,"[""One study that evaluated supervisor training compared to another type of training to reduce employees' stress did not provide enough data to calculate its effects.""]",9,0.7333333333333333,4,15
CD010905,4,11,"Based on a small and heterogeneous sample of controlled intervention studies and in contrast to prevailing consensus that supervisor behaviour influences employees' health and well-being, we found inconsistent evidence that supervisor training may or may not improve employees' well-being when compared to no intervention.",delete,[],10,0.8,4,15
CD010905,4,12,"For all other types of interventions and outcomes, there was no evidence of a considerable effect.",delete,[],10,0.8666666666666667,5,15
CD010905,4,13,"However, due to the very low- to moderate-quality of the evidence base, clear conclusions are currently unwarranted.",rephrase,"['The quality of the evidence was very low for most outcomes due to risk of bias in the studies, inconsistent results, and imprecise effects.']",10,0.9333333333333333,5,15
CD010905,4,14,"Well-designed studies are needed to clarify effects of supervisor training on employees' stress, absenteeism, and well-being.",split,"['Overall, the data suggest that training of supervisors may not lead to reduced levels of stress and absenteeism, or improved levels of well-being in their employees.', ""The discrepancy between the apparent scientific consensus and the empirical evidence might be attributed to weak study designs.High quality studies are needed to clarify if supervisor training affects employees' stress, absenteeism, and well-being.""]",11,1.0,5,15
CD006616,0,0,We included 41 fully published studies (2768 patients).,rephrase,['This Cochrane review of 41 randomized controlled trials with 2768 critically ill adult patients found no evidence to support the theory that N-acetylcysteine might reduce the risk of death in adults with SIRS or sepsis.'],0,0.1111111111111111,1,9
CD006616,0,1,"Mortality was similar in the N-acetylcysteine group and the placebo group (RR 1.06, 95% CI 0.79 to 1.42; I2 = 0%).",delete,[],1,0.2222222222222222,2,9
CD006616,0,2,"Neither did N-acetylcysteine show any significant effect on length of stay, duration of mechanical ventilation or incidence of new organ failure.",rephrase,"['Intravenous N-acetylcysteine did not affect the length of stay in the intensive care unit, duration of mechanical ventilation, duration of support for the cardiovascular system or incidence of new organ failure.']",1,0.3333333333333333,2,9
CD006616,0,3,"Early application of N-acetylcysteine to prevent the development of an oxidato-inflammatory response did not affect the outcome, nor did late application that is after 24 hours of developing symptoms.",rephrase,"['The dosing of N-acetylcysteine, timing and duration of treatment, from a single intravenous dose to infusions up to seven days, varied.']",2,0.4444444444444444,3,9
CD006616,0,4,Late application was associated with cardiovascular instability.,delete,[],3,0.5555555555555556,3,9
CD006616,1,5,"Overall, this meta-analysis puts doubt on the safety and utility of intravenous N-acetylcysteine as an adjuvant therapy in SIRS and sepsis.",rephrase,['There is currently insufficient evidence to support the use of N-acetylcysteine in SIRS or sepsis.'],3,0.6666666666666666,4,9
CD006616,1,6,"At best, N-acetylcysteine is ineffective in reducing mortality and complications in this patient population.",delete,[],4,0.7777777777777778,4,9
CD006616,1,7,"At worst, it can be harmful, especially when administered later than 24 hours after the onset of symptoms, by causing cardiovascular depression.",rephrase,"['We also found that when N-acetylcysteine was administered more than 24 hours after the development of clinical signs of SIRS or sepsis it may even be harmful, by causing cardiovascular depression.']",4,0.8888888888888888,5,9
CD006616,1,8,"Unless future RCTs provide evidence of treatment effect, clinicians should not routinely use intravenous N-acetylcysteine in SIRS or sepsis and academics should not promote its use.",delete,[],5,1.0,5,9
CD007751,0,0,Six studies randomising 9379 participants with CKD stages 1 to 3 (without DM) met our inclusion criteria.,rephrase,"['We found six studies randomising a total of 9379 patients who have early CKD (stages 1 to 3 only, without diabetes).']",0,0.09090909090909091,1,11
CD007751,0,1,"Participants were adults with hypertension; 79% were male from China, Europe, Japan, and the USA.",rephrase,"['Patients were 18 to 75 years old, 79% were males, most had high blood pressure and were from China, Europe, Japan, and the USA.']",1,0.18181818181818182,1,11
CD007751,0,2,Treatment periods ranged from 12 weeks to three years.,delete,[],2,0.2727272727272727,2,11
CD007751,0,3,"Overall, studies were judged to be at unclear or high risk of bias across all domains, and the quality of the evidence was poor, with GRADE rated as low or very low certainty.",rephrase,['All six studies were considered to be at a high risk of bias.'],2,0.36363636363636365,2,11
CD007751,1,4,"In low certainty evidence, ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo may make little or no difference to death (any cause) (2 studies, 8873 participants): RR 2.00, 95% CI 0.26 to 15.37; I² = 76%), total cardiovascular events (2 studies, 8873 participants): RR 0.97, 95% CI 0.90 to 1.05; I² = 0%), cardiovascular-related death (2 studies, 8873 participants): RR 1.73, 95% CI 0.26 to 11.66; I² = 54%), stroke (2 studies, 8873 participants): RR 0.76, 95% CI 0.56 to 1.03; I² = 0%), myocardial infarction (2 studies, 8873 participants): RR 1.00, 95% CI 0.84 to 1.20; I² = 0%), and adverse events (2 studies, 8873 participants): RR 1.33, 95% CI 1.26 to 1.41; I² = 0%).",delete,[],3,0.45454545454545453,3,11
CD007751,2,5,"It is uncertain whether ACEi (benazepril 10 mg or trandolapril 2 mg) compared to placebo reduces congestive heart failure (1 study, 8290 participants): RR 0.75, 95% CI 0.59 to 0.95) or transient ischaemic attack (1 study, 583 participants): RR 0.94, 95% CI 0.06 to 15.01; I² = 0%) because the certainty of the evidence is very low.",rephrase,"['Benazepril or trandolapril may reduce the chance of death, having a stroke, myocardial infarction, and side effects, but may or may not reduce the chance of congestive heart failure or transient ischaemic attack.']",3,0.5454545454545454,3,11
CD007751,3,6,"It is uncertain whether ARB (losartan 50 mg) compared to placebo (1 study, 226 participants) reduces: death (any-cause) (no events), adverse events (RR 19.34, 95% CI 1.14 to 328.30), eGFR rate of decline (MD 5.00 mL/min/1.73 m2, 95% CI 3.03 to 6.97), presence of proteinuria (MD -0.65 g/24 hours, 95% CI -0.78 to -0.52), systolic blood pressure (MD -0.80 mm Hg, 95% CI -3.89 to 2.29), or diastolic blood pressure (MD -1.10 mm Hg, 95% CI -3.29 to 1.09) because the certainty of the evidence is very low.",delete,[],4,0.6363636363636364,4,11
CD007751,4,7,"It is uncertain whether ACEi (enalapril 20 mg, perindopril 2 mg or trandolapril 1 mg) compared to ARB (olmesartan 20 mg, losartan 25 mg or candesartan 4 mg) (1 study, 26 participants) reduces: proteinuria (MD -0.40, 95% CI -0.60 to -0.20), systolic blood pressure (MD -3.00 mm Hg, 95% CI -6.08 to 0.08) or diastolic blood pressure (MD -1.00 mm Hg, 95% CI -3.31 to 1.31) because the certainty of the evidence is very low.",rephrase,"['Enalapril, perindopril, or trandolapril may or may not be any better than olmesartan, losartan, or candesartan for proteinuria and blood pressure.']",4,0.7272727272727273,4,11
CD007751,5,8,There is currently insufficient evidence to determine the effectiveness of ACEi or ARB in patients with stage 1 to 3 CKD who do not have DM.,rephrase,['There is not enough evidence to know whether blood pressure-lowering medications work well in patients with early CKD (stages 1 to 3) who do not have diabetes.'],5,0.8181818181818182,5,11
CD007751,5,9,The available evidence is overall of very low certainty and high risk of bias.,split,"['The quality and certainty of the evidence is considered to be very low.', 'This is due to a high risk of bias in the studies, poorly conducted methods, and too little data from too few patients.']",6,0.9090909090909091,5,11
CD007751,5,10,We have identified an area of large uncertainty for a group of patients who account for most of those diagnosed as having CKD.,rephrase,['We have identified an area of large uncertainty for further research.'],8,1.0,5,11
CD014498,0,0,"We included a total of eight studies (679 women) in this review, all of which contributed to the data and analysis.",delete,[],0,0.04,1,25
CD014498,0,1,"The identified studies report on five different comparisons: sildenafil compared with placebo or no therapy, tadalafil compared with placebo or no therapy, L-arginine compared with placebo or no therapy, nitroglycerin compared with placebo or no therapy and sildenafil compared with nitroglycerin.",rephrase,"['Four different relevant drugs have been investigated (sildenafil, tadalafil, L-arginine, and nitroglycerin).']",0,0.08,1,25
CD014498,1,2,The risk of bias of included studies was judged as low or unclear.,delete,[],1,0.12,1,25
CD014498,1,3,In two studies the intervention was not blinded.,delete,[],1,0.16,1,25
CD014498,1,4,The certainty of evidence for our primary outcomes was judged as moderate for the intervention sildenafil and low for tadalafil and nitroglycerine (due to low number of participants and low number of events).,delete,[],1,0.2,1,25
CD014498,1,5,"For the intervention L-arginine, our primary outcomes were not reported.",delete,[],1,0.24,2,25
CD014498,2,6,"Sildenafil citrate compared to placebo or no therapy (5 studies, 516 women)
Five studies (Canada, Australia and New Zealand, the Netherlands, the UK and Brazil) involving 516 pregnant women with FGR were included.",rephrase,"['Five studies (Canada, Australia and New Zealand, the Netherlands, the UK, and Brazil) involving 516 pregnant women with fetal growth restriction.']",1,0.28,2,25
CD014498,2,7,We assessed the certainty of the evidence as moderate.,delete,[],2,0.32,2,25
CD014498,3,8,"Compared with placebo or no therapy, sildenafil probably has little or no effect on all-cause mortality (risk ratio (RR) 1.01, 95% confidence interval (CI) 0.80 to 1.27, 5 studies, 516 women); may reduce fetal mortality (RR 0.82, 95% CI 0.60 to 1.12, 5 studies, 516 women), and increase neonatal mortality (RR 1.45, 95% CI 0.90 to 2.33, 5 studies, 397 women), although the results are uncertain for fetal and neonatal mortality as 95% confidence intervals are wide crossing the line of no effect.",rephrase,"['Sildenafil compared with placebo or no therapy probably makes no difference to the incidence of all-cause mortality, fetal mortality, and neonatal mortality.']",2,0.36,2,25
CD014498,4,9,"Tadalafil compared with placebo or no therapy (1 study, 87 women)
One study (Japan) involving 87 pregnant women with FGR was included.",rephrase,['One study (Japan) involving 87 pregnant women with fetal growth restriction.'],3,0.4,2,25
CD014498,4,10,We assessed the certainty of the evidence as low.,delete,[],4,0.44,3,25
CD014498,5,11,"Compared with placebo or no therapy, tadalafil may have little or no effect on all-cause mortality (risk ratio 0.20, 95% CI 0.02 to 1.60, one study, 87 women); fetal mortality (RR 0.11, 95% CI 0.01 to 1.96, one study, 87 women); and neonatal mortality (RR 0.89, 95% CI 0.06 to 13.70, one study, 83 women).",rephrase,"['Tadalafil probably makes no difference to the incidence of all-cause mortality, fetal mortality, and neonatal mortality.']",4,0.48,3,25
CD014498,6,12,"L-Arginine compared with placebo or no therapy (1 study, 43 women)
One study (France) involving 43 pregnant women with FGR was included.",rephrase,['One study (France) involving 43 pregnant women with fetal growth restriction.'],5,0.52,3,25
CD014498,6,13,This study did not assess our primary outcomes.,ignore,['This study did not assess our primary outcomes.'],6,0.56,3,25
CD014498,7,14,"Nitroglycerin compared to placebo or no therapy (1 studies, 23 women)
One study (Brazil) involving 23 pregnant women with FGR was included.",rephrase,['One study (Brazil) involving 43 pregnant women with fetal growth restriction.'],7,0.6,3,25
CD014498,7,15,We assessed the certainty of the evidence as low.,delete,[],8,0.64,4,25
CD014498,7,16,The effect on the primary outcomes is not estimable due to no events in women participating in both groups.,rephrase,['The effect on the primary outcomes is not estimable since no fetal or neonatal mortality occurred in the women participating in both intervention groups.'],8,0.68,4,25
CD014498,8,17,"Sildenafil citrate compared to nitroglycerin (1 study, 23 women)
One study (Brazil) involving 23 pregnant women with FGR was included.",rephrase,['One study (Brazil) involving 23 pregnant women with fetal growth restriction.'],9,0.72,4,25
CD014498,8,18,We assessed the certainty of the evidence as low.,delete,[],10,0.76,4,25
CD014498,9,19,The effect on the primary outcomes is not estimable due to no events in women participating in both groups.,rephrase,['The effect on the primary outcomes is not estimable since no fetal or neonatal mortality occurred in the women participating in both intervention groups.'],10,0.8,4,25
CD014498,10,20,"Interventions affecting the nitric oxide pathway probably do not seem to influence all-cause (fetal and neonatal) mortality in pregnant women carrying a baby with FGR, although more evidence is needed.",delete,[],11,0.84,5,25
CD014498,10,21,The certainty of this evidence is moderate for sildenafil and low for tadalafil and nitroglycerin.,rephrase,"['For tadalafil, L-arginine, and nitroglycerin there are insufficient data to be able to form a judgement.']",11,0.88,5,25
CD014498,11,22,"For sildenafil a fair amount of data are available from randomised clinical trials, but with low numbers of participants.",delete,[],12,0.92,5,25
CD014498,11,23,"Therefore, the certainty of evidence is moderate.",rephrase,"['For sildenafil we are moderately certain that this is the case, but for the other treatments more studies are needed to provide enough information to answer this question.']",12,0.96,5,25
CD014498,11,24,"For the other interventions investigated in this review there are insufficient data, meaning we do not know whether these interventions improve perinatal and maternal outcomes in pregnant women with FGR.",delete,[],13,1.0,5,25
CD002800,0,0,"Combining the results of six randomised clinical trials with high risk of bias which included 710 patients demonstrated no significant effects of propylthiouracil versus placebo on all-cause mortality (risk ratio (RR) 0.93, 95% confidence interval (CI) 0.66 to 1.30), liver-related mortality (RR 0.90, 95% CI 0.58 to 1.40), or complications of the liver disease.",split,"['Six randomised clinical trials with a total of 710 patients were included in this systematic review.', 'The trials were generally with high risk of bias.']",0,0.14285714285714285,1,7
CD002800,0,1,"Although propylthiouracil was not associated with a significant increased risk of non-serious adverse events, there were occasional instances of serious adverse events such as leukopenia and generalised bullous eruption.",delete,[],2,0.2857142857142857,2,7
CD002800,1,2,"We could not demonstrate any significant beneficial effect of propylthiouracil on all-cause mortality, liver-related mortality, liver complications, or liver histology of patients with alcoholic liver disease.",ignore,"['We could not demonstrate any significant effect of propylthiouracil on all-cause mortality, liver-related mortality, liver complications, or liver histology of patients with alcoholic liver disease.']",2,0.42857142857142855,3,7
CD002800,1,3,Propylthiouracil was associated with adverse events.,rephrase,"['Although propylthiouracil was not associated with a significant increased risk of non-serious adverse events, there were occasional instances of serious adverse events (leukopenia, generalized bullous eruption).']",3,0.5714285714285714,3,7
CD002800,1,4,Confidence intervals were wide.,delete,[],4,0.7142857142857143,4,7
CD002800,1,5,"Thus, the risk of random errors and systematic errors was high.",rephrase,"['The trials included a small number of patients, and so, the risk of random error (error due to play of chance) is high.']",4,0.8571428571428571,5,7
CD002800,1,6,"Accordingly, there is no evidence for using propylthiouracil for alcoholic liver disease outside randomised clinical trials.",rephrase,['There seems to be no evidence for using propylthiouracil for alcoholic liver disease outside randomised clinical trials.'],5,1.0,5,7
CD009874,0,0,"We identified 10 trials with a total of 1730 participants randomised, and one ongoing trial.",rephrase,['We found 10 trials involving 1730 participants in which six examined the provision of fruit and vegetables to increase intake and four trials examined dietary advice to increase fruit and vegetable intake.'],0,0.1111111111111111,1,9
CD009874,0,1,"Six trials investigated the provision of fruit and vegetables, and four trials examined advice to increase fruit and vegetable consumption.The ongoing trial is examining the provision of an avocado-rich diet.The number and type of intervention components for provision, and the dietary advice provided differed between trials.",rephrase,['There were variations in the type of fruit and vegetable provided but all interventions investigating provision involved only one fruit or vegetable component.'],1,0.2222222222222222,2,9
CD009874,1,2,None of the trials reported clinical events as they were all relatively short term.,delete,[],2,0.3333333333333333,2,9
CD009874,1,3,"There was no strong evidence for effects of individual trials of provision of fruit and vegetables on cardiovascular risk factors, but trials were heterogeneous and short term.",split,"['None of the included trials were long enough to examine the effect of increased fruit and vegetable consumption on cardiovascular disease events such as heart attacks.', 'There was no strong evidence that provision of one type of fruit or vegetable had beneficial effects on blood pressure and lipid levels but most trials were short term.']",2,0.4444444444444444,3,9
CD009874,1,4,"Furthermore, five of the six trials only provided one fruit or vegetable.",delete,[],4,0.5555555555555556,3,9
CD009874,1,5,"Dietary advice showed some favourable effects on blood pressure (systolic blood pressure (SBP): mean difference (MD) -3.0 mmHg (95% confidence interval (CI) -4.92 to -1.09), diastolic blood pressure (DBP): MD -0.90 mmHg (95% CI -2.03 to 0.24)) and low-density lipoprotein (LDL) cholesterol but analyses were based on only two trials.",delete,[],4,0.6666666666666666,4,9
CD009874,1,6,"Three of the 10 included trials examined adverse effects, which included increased bowel movements, bad breath and body odour.",rephrase,"['Adverse effects were reported in three of the included trials and included increased bowel movements, bad breath and body odour.']",4,0.7777777777777778,4,9
CD009874,2,7,"There are very few studies to date examining provision of, or advice to increase the consumption of, fruit and vegetables in the absence of additional dietary interventions or other lifestyle interventions for the primary prevention of CVD.",rephrase,['This review assessed the effectiveness of increasing fruit and vegetable consumption as a single intervention without the influence of other dietary patterns or other lifestyle modifications in healthy adults and those at high risk of CVD for the prevention of CVD.'],5,0.8888888888888888,5,9
CD009874,2,8,The limited evidence suggests advice to increase fruit and vegetables as a single intervention has favourable effects on CVD risk factors but more trials are needed to confirm this.,split,"['There was some evidence to suggest beneficial effects of dietary advice to increase fruit and vegetable consumption but this is based on findings from two trials.', 'More trials are needed to confirm these findings.']",6,1.0,5,9
CD009776,0,0,We included 15 randomised placebo-controlled trials with 718 participants.,rephrase,['We included 15 trials with 718 participants.'],0,0.05,1,20
CD009776,0,1,Nine trials evaluated the effect of melatonin and two the effect of hypnotics for improving sleep problems.,merge,"['Trials evaluated the effect of melatonin and hypnotics on sleep after the shift and the effect of modafinil, armodafinil and caffeine plus naps on sleepiness during the shift.']",1,0.1,1,20
CD009776,0,2,"One trial assessed the effect of modafinil, two of armodafinil and one examined caffeine plus naps to decrease sleepiness or to increase alertness.",none,[],1,0.15,1,20
CD009776,1,3,"Melatonin (1 to 10 mg) after the night shift may increase sleep length during daytime sleep (mean difference (MD) 24 minutes, 95% confidence interval (CI) 9.8 to 38.9; seven trials, 263 participants, low quality evidence) and night-time sleep (MD 17 minutes, 95% CI 3.71 to 30.22; three trials, 234 participants, low quality evidence) compared to placebo.",rephrase,"['People who take melatonin may sleep for 24 minutes longer during the daytime after the night shift but there may be no effect on other sleep outcomes, such as time needed to fall asleep (low quality evidence).']",2,0.2,1,20
CD009776,1,4,We did not find a dose-response effect.,rephrase,['We did not find reports on their side effects in shift workers.'],3,0.25,2,20
CD009776,1,5,"Melatonin may lead to similar sleep latency times as placebo (MD 0.37minutes, 95% CI - 1.55 to 2.29; five trials, 74 participants, low quality evidence).",delete,[],4,0.3,2,20
CD009776,2,6,"Hypnotic medication, zopiclone, did not result in significantly longer daytime sleep length compared to placebo in one low quality trial and we could not use the data from the study on lormetazepam.",rephrase,"['For hypnotics (zopiclone), there is insufficient evidence to know whether or not they affect sleep length (very low quality evidence).']",4,0.35,2,20
CD009776,3,7,"Armodafinil taken before the night shift probably reduces sleepiness by one point on the Karolinska Sleepiness Scale (KSS) (MD -0.99, 95% CI -1.32 to -0.67; range 1 to 10; two trials, 572 participants, moderate quality evidence) and increases alertness by 50 ms in a simple reaction time test (MD -50.0, 95% CI -85.5 to -15.5) at three months' follow-up in shift work sleep disorder patients.",merge,"[""People that take modafinil and armodafinil probably have a small reduction in sleepiness and an increase in alertness during the night shift, based on evidence at three months' follow-up in people with shift work sleep disorder (moderate quality evidence).""]",5,0.4,2,20
CD009776,3,8,"Modafinil probably has similar effects on sleepiness (KSS) (MD -0.90, 95% CI -1.45 to -0.35; one trial, 183 participants, moderate quality evidence) and alertness in the psychomotor vigilance test in the same patient group.",none,[],5,0.45,3,20
CD009776,3,9,"Post-marketing, severe skin reactions have been reported.",rephrase,"['However, serious skin disorders have been reported since these drugs have come on the market.']",6,0.5,3,20
CD009776,3,10,"Adverse effects reported by trial participants were headache, nausea and a rise in blood pressure.",rephrase,['Headache and nausea were the most common side effects both in the short and long term follow-up.'],7,0.55,3,20
CD009776,3,11,There were no trials in non-patient shift workers.,rephrase,['We found no trials in shift workers without a diagnosis of shift work sleep disorder.'],8,0.6,3,20
CD009776,4,12,"Based on one trial, caffeine plus pre-shift naps taken before the night shift decreased sleepiness (KSS) (MD -0.63, 95% CI -1.09 to -0.17).",rephrase,['We found one trial which showed that people that took caffeine before the night shift in combination with a nap before the shift had increased alertness during the night shift.'],9,0.65,4,20
CD009776,5,13,We judged most trials to have a low risk of bias even though the randomisation method and allocation concealment were often not described.,delete,[],10,0.7,4,20
CD009776,6,14,There is low quality evidence that melatonin improves sleep length after a night shift but not other sleep quality parameters.,delete,[],10,0.75,4,20
CD009776,6,15,Both modafinil and armodafinil increase alertness and reduce sleepiness to some extent in employees who suffer from shift work sleep disorder but they are associated with adverse events.,delete,[],10,0.8,4,20
CD009776,6,16,"Caffeine plus naps reduces sleepiness during the night shift, but the quality of evidence is low.",delete,[],10,0.85,5,20
CD009776,6,17,"Based on one low quality trial, hypnotics did not improve sleep length and quality after a night shift.",delete,[],10,0.9,5,20
CD009776,7,18,We need more and better quality trials on the beneficial and adverse effects and costs of all pharmacological agents that induce sleep or promote alertness in shift workers both with and without a diagnosis of shift work sleep disorder.,split,"['Both sleep and alertness promoting agents have potentially serious adverse effects.', 'Therefore, we need more trials to determine the beneficial and harmful effects of these drugs.']",10,0.95,5,20
CD009776,7,19,We also need systematic reviews of their adverse effects.,delete,[],12,1.0,5,20
CD009953,0,0,We included a total of 984 participants from 12 studies (23 references) in this analysis.,merge,[],0,0.058823529411764705,1,17
CD009953,0,1,We included only those involved in Tai Chi and the control group (i.e. 811 participants) in the final analysis.,none,['We included a total of 811 participants from 12 studies in the final analysis of this review.'],0,0.11764705882352941,1,17
CD009953,0,2,"Study sample size ranged from 10 to 206, and mean age ranged from 61 to 74 years.",rephrase,"['The number of participants in each study ranged from 10 to 206, and mean age ranged from 61 to 74 years.']",1,0.17647058823529413,1,17
CD009953,0,3,Programmes lasted for six weeks to one year.,ignore,['The programme lasted for six weeks to one year.'],2,0.23529411764705882,2,17
CD009953,0,4,"All included studies were RCTs; three studies used allocation concealment, six reported blinded outcome assessors and three studies adopted an intention-to-treat approach to statistical analysis.",delete,[],3,0.29411764705882354,2,17
CD009953,0,5,No adverse events were reported.,rephrase,['No unwanted events or side effects were reported throughout the study period.'],3,0.35294117647058826,2,17
CD009953,0,6,Quality of evidence of the outcomes ranged from very low to moderate.,rephrase,['Quality of evidence of all outcomes of interest ranged from very low to moderate.'],4,0.4117647058823529,3,17
CD009953,1,7,Analysis was split into three comparisons: (1) Tai Chi versus usual care; (2) Tai Chi and breathing exercise versus breathing exercise alone; and (3) Tai Chi and exercise versus exercise alone.,delete,[],5,0.47058823529411764,3,17
CD009953,2,8,"Comparison of Tai Chi versus usual care revealed that Tai Chi demonstrated a longer six-minute walk distance (mean difference (MD) 29.64 metres, 95% confidence interval (CI) 10.52 to 48.77 metres; participants = 318; I2 = 59%) and better pulmonary function (i.e. forced expiratory volume in one second, MD 0.11 L, 95% CI 0.02 to 0.20 L; participants = 258; I2 = 0%) in post-programme data.",rephrase,"['Participants in the Tai Chi group walked farther, by 29.64 metres in six minutes, and had better pulmonary function, than those who received usual care.']",5,0.5294117647058824,3,17
CD009953,2,9,"However, the effects of Tai Chi in reducing dyspnoea level and improving quality of life remain inconclusive.",delete,[],6,0.5882352941176471,3,17
CD009953,2,10,"Data are currently insufficient for evaluating the impact of Tai Chi on maximal exercise capacity, balance and muscle strength in people with COPD.",delete,[],6,0.6470588235294118,4,17
CD009953,2,11,Comparison of Tai Chi and other interventions (i.e. breathing exercise or exercise) versus other interventions shows no superiority and no additional effects on symptom improvement nor on physical and psychosocial outcomes with Tai Chi.,delete,[],6,0.7058823529411765,4,17
CD009953,3,12,"No adverse events were reported, implying that Tai Chi is safe to practise in people with COPD.",delete,[],6,0.7647058823529411,4,17
CD009953,3,13,Evidence of very low to moderate quality suggests better functional capacity and pulmonary function in post-programme data for Tai Chi versus usual care.,delete,[],6,0.8235294117647058,5,17
CD009953,3,14,"When Tai Chi in addition to other interventions was compared with other interventions alone, Tai Chi did not show superiority and showed no additional effects on symptoms nor on physical and psychosocial function improvement in people with COPD.",rephrase,"['When the effect of Tai Chi used in addition to another intervention (i.e. breathing exercise or exercise) was examined, we did not find that Tai Chi offered additional benefit in terms of shortness of breath or functional and psychosocial well-being.']",6,0.8823529411764706,5,17
CD009953,3,15,"With the diverse style and number of forms being adopted in different studies, the most beneficial protocol of Tai Chi style and number of forms could not be commented upon.",rephrase,['Included studies adopted different styles and numerous forms of Tai Chi.'],7,0.9411764705882353,5,17
CD009953,3,16,"Hence, future studies are warranted to address these topics.",rephrase,['Future studies addressing these topics are warranted.'],8,1.0,5,17
CD011649,0,0,"Three randomised clinical trials, including 430 participants, met the inclusion criteria for this review; however, data from two trials with 412 participants could be included in only one primary outcome (i.e. mortality).",rephrase,"['Only three trials with 430 participants met our inclusion criteria; however, two of the trials (412 participants) only reported death and no other measures of how well the treatments worked.']",0,0.0625,1,16
CD011649,0,1,All three trials were at high risk of bias.,rephrase,"['The overall quality of evidence was low or very low and all the trials were at high risk of bias, which means that there is possibility of making the wrong conclusions, overestimating benefits, or underestimating harms of one treatment or the other because of the way that the trials were conducted.']",1,0.125,1,16
CD011649,0,2,All three trials included supportive care as cointervention.,rephrase,"['All three trials included supportive care (treatment to prevent, control, or relieve complications and side effects and improve comfort and quality of life) as a co-intervention.']",2,0.1875,1,16
CD011649,0,3,The comparisons included in the two trials reporting on mortality were: systemic chemotherapy with sorafenib versus no active intervention; and transarterial chemoembolisation plus systemic chemotherapy with sorafenib versus transarterial chemoembolisation alone.,rephrase,"['The trials assessed transarterial chemoembolisation (where anti-cancer drugs block the blood supply and treat the cancer through the vessels supplying the cancer), chemotherapy using sorafenib (a drug which blocks cancer growth), or a combination of transarterial chemoembolisation and sorafenib.']",3,0.25,2,16
CD011649,0,4,"The trials did not report the duration of follow-up; however, it appeared that the participants were followed up for a period of about 18 to 30 months.",rephrase,['It appeared that the trials followed participants for about 18 to 30 months from the initiation of treatment.'],4,0.3125,2,16
CD011649,0,5,The majority of the participants in the trials had cirrhotic livers.,delete,[],5,0.375,2,16
CD011649,0,6,The trials included participants with intermediate-stage hepatocellular carcinoma arising from viral and non-viral aetiologies.,delete,[],5,0.4375,3,16
CD011649,0,7,The trials did not report the portal hypertension status of the participants.,delete,[],5,0.5,3,16
CD011649,0,8,The mortality was 50% to 70% over a median follow-up period of 18 to 30 months.,rephrase,"['Over 18 to 30 months, 50% to 75% of participants died.']",5,0.5625,3,16
CD011649,0,9,"There was no evidence of difference in mortality at maximal follow-up between systemic chemotherapy versus no chemotherapy (hazard ratio 0.85, 95% CI 0.60 to 1.18; participants = 412; studies = 2; I2 = 0%; very low quality evidence).",rephrase,['There was no evidence of any difference between the people who received chemotherapy and those who did not receive chemotherapy.'],6,0.625,4,16
CD011649,0,10,A subgroup analysis performed by stratifying the analysis by the presence or absence of transarterial chemoembolisation as cointervention did not alter the results.,delete,[],7,0.6875,4,16
CD011649,0,11,"None of the trials reported on serious adverse events other than mortality, health-related quality of life, recurrence of hepatocellular carcinoma, or length of hospital stay.",rephrase,"[""None of the trials reported complications, health-related quality of life (a measure of a person's satisfaction with their life and health), cancer recurrence, or length of hospital stay.""]",7,0.75,4,16
CD011649,0,12,"One of the trials providing data was funded by the pharmaceutical industry, the other did not report the source of funding, and the trial with no data for the review was also funded by the pharmaceutical industry.",merge,['Two trials were funded by the pharmaceutical industry; one trial did not report the source of funding.'],8,0.8125,5,16
CD011649,0,13,We found two ongoing trials.,none,[],8,0.875,5,16
CD011649,1,14,"Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence).",rephrase,"['Overall, there is currently no evidence for benefit of any active treatment in addition to supportive treatment for intermediate-stage hepatocellular carcinoma.']",9,0.9375,5,16
CD011649,1,15,We need high-quality randomised clinical trials designed to measure differences in clinically important outcomes (e.g. all-cause mortality or health-related quality of life).,delete,[],10,1.0,5,16
CD013447,0,0,"We included 35 studies, from a wide range of countries on six continents.",rephrase,['We included 35 studies from around the world.'],0,0.04,1,25
CD013447,0,1,Nineteen studies were conducted in low- and middle-income settings and sixteen in high-income settings.,delete,[],1,0.08,1,25
CD013447,0,2,"Some of the studies explored the views of people who had experienced the interventions, whereas others were hypothetical in nature, asking what people felt they would like from a digital health intervention.",delete,[],1,0.12,1,25
CD013447,0,3,"The studies covered a range of digital targeted client communication, for example medication or appointment reminders, prenatal health information, support for smoking cessation while pregnant, or general sexual health information.",delete,[],1,0.16,1,25
CD013447,1,4,Our synthesis showed that clients' experiences of these types of programmes were mixed.,rephrase,"[""These studies showed that clients' experiences of these types of programmes were mixed.""]",1,0.2,1,25
CD013447,1,5,"Some felt that these programmes provided them with feelings of support and connectedness, as they felt that someone was taking the time to send them messages (moderate confidence in the evidence).",ignore,"['Some felt that these programmes provided them with feelings of support and connectedness, as they felt that someone was taking the time to send them messages (moderate confidence in the evidence).']",2,0.24,2,25
CD013447,1,6,They also described sharing the messages with their friends and family (moderate confidence).,ignore,['Others also described sharing the messages with their friends and family (moderate confidence).'],3,0.28,2,25
CD013447,2,7,"However, clients also pointed to problems when using these programmes.",ignore,"['However, clients also pointed to problems when using these programmes.']",4,0.32,2,25
CD013447,2,8,Some clients had poor access to cell networks and to the internet (high confidence).,ignore,['Some clients had poor access to cell networks and to the internet (high confidence).'],5,0.36,2,25
CD013447,2,9,"Others had no phone, had lost or broken their phone, could not afford airtime, or had changed their phone number (moderate confidence).",ignore,"['Others had no phone, had lost or broken their phone, could not afford airtime, or had changed their phone number (moderate confidence).']",6,0.4,2,25
CD013447,2,10,"Some clients, particularly women and teenagers, had their access to phones controlled by others (moderate confidence).",ignore,"['Some clients, particularly women and teenagers, had their access to phones controlled by others (moderate confidence).']",7,0.44,3,25
CD013447,2,11,"The cost of messages could also be a problem, and many thought that messages should be free of charge (high confidence).",ignore,"['The cost of messages could also be a problem, and many thought that messages should be free of charge (high confidence).']",8,0.48,3,25
CD013447,2,12,"Language issues as well as skills in reading, writing, and using mobile phones could also be a problem (moderate confidence).",ignore,"[""Languages issues as well as clients' skills in reading, writing, and using mobile phones could also be a problem (moderate confidence).""]",9,0.52,3,25
CD013447,3,13,"Clients dealing with stigmatised or personal health conditions such as HIV, family planning, or abortion care were also concerned about privacy and confidentiality (high confidence).",ignore,"['Clients dealing with stigmatised or personal health conditions such as HIV, family planning, or abortion care were concerned about privacy and confidentiality (high confidence).']",10,0.56,3,25
CD013447,3,14,"Some clients suggested strategies to deal with these issues, such as using neutral language and tailoring the content, timing, and frequency of messages (high confidence).",ignore,"['Some suggested strategies to deal with these issues, such as using neutral language and tailoring the content, timing, and frequency of messages (high confidence).']",11,0.6,3,25
CD013447,4,15,Clients wanted messages at a time and frequency that was convenient for them (moderate confidence).,ignore,['Clients wanted messages at a time and frequency that was convenient for them (moderate confidence).'],12,0.64,4,25
CD013447,4,16,They had preferences for different delivery channels (e.g. short message service (SMS) or interactive voice response) (moderate confidence).,ignore,['They had preferences for different delivery channels (e.g. short message service (SMS) or interactive voice response) (moderate confidence).'],13,0.68,4,25
CD013447,4,17,"They also had preferences about message content, including new knowledge, reminders, solutions, and suggestions about health issues (moderate confidence).",ignore,"['They also had preferences about message content, including new knowledge, reminders, solutions, and suggestions about health issues (moderate confidence).']",14,0.72,4,25
CD013447,4,18,Clients' views about who sent the digital health communication could influence their views of the programme (moderate confidence).,rephrase,"[""Clients' views about who sent the digital health communication could influence their views of the programme, and many people wanted a sender that they knew and trusted (moderate confidence).""]",15,0.76,4,25
CD013447,5,19,"For an overview of the findings and our confidence in the evidence, please see the 'Summary of qualitative findings' tables.",delete,[],16,0.8,4,25
CD013447,6,20,"Our matrix shows that many of the trials assessing these types of programmes did not try to address the problems we identified, although this may have been a reporting issue.",delete,[],16,0.84,5,25
CD013447,7,21,Our synthesis identified several factors that can influence the successful implementation of targeted client communication programmes using mobile devices.,delete,[],16,0.88,5,25
CD013447,7,22,These include barriers to use that have equity implications.,delete,[],16,0.92,5,25
CD013447,7,23,Programme planners should take these factors into account when designing and implementing programmes.,delete,[],16,0.96,5,25
CD013447,7,24,Future trial authors also need to actively address these factors and to report their efforts in their trial publications.,delete,[],16,1.0,5,25
CD013710,0,0,"We included two studies, involving 74 adults with open abdomen associated with various conditions, predominantly severe peritonitis (N = 55).",rephrase,"['We found one single-centre study conducted in Turkey, which included 40 adults with open abdomen.']",0,0.0625,1,16
CD013710,0,1,The mean age of the participants was 52.8 years; the mean proportion of women was 39.2%.,delete,[],1,0.125,1,16
CD013710,0,2,Both RCTs were carried out in single centres and were at high risk of bias.,delete,[],1,0.1875,1,16
CD013710,1,3,"Negative pressure wound therapy versus Bogota bag
We included one study (40 participants) comparing NPWT with Bogota bag.",delete,[],1,0.25,2,16
CD013710,1,4,"We are uncertain whether NPWT reduces time to primary fascial closure of the abdomen (NPWT: 16.9 days versus Bogota bag: 20.5 days (mean difference (MD) -3.60 days, 95% confidence interval (CI) -8.16 to 0.96); very low-certainty evidence) or adverse events (fistulae formation, NPWT: 10% versus Bogota: 5% (risk ratio (RR) 2.00, 95% CI 0.20 to 20.33); very low-certainty evidence) compared with the Bogota bag.",delete,[],1,0.3125,2,16
CD013710,1,5,"We are also uncertain whether NPWT reduces all-cause mortality (NPWT: 25% versus Bogota bag: 35% (RR 0.71, 95% CI 0.27 to 1.88); very low-certainty evidence) or length of hospital stay compared with the Bogota bag (NPWT mean: 28.5 days versus Bogota bag mean: 27.4 days (MD 1.10 days, 95% CI -13.39 to 15.59); very low-certainty evidence).",rephrase,"['We cannot tell from the results whether when compared to Bogota bag, NPWT reduces:\n-\xa0the time needed for wounds to completely close;\n-\xa0harmful or unwanted effects (bowel perforation);\n-\xa0death rate; or\n-\xa0length of hospital stay between the groups.']",1,0.375,2,16
CD013710,1,6,"The study did not report the proportion of participants with successful primary fascial closure of the abdomen, participant health-related quality of life, reoperation rate, wound infection, or pain.",rephrase,"['The study did not report the proportion of people with wounds that were successfully closed, participant health-related quality of life, reoperation rate, wound infection, or pain.']",2,0.4375,3,16
CD013710,2,7,"Negative pressure wound therapy versus any other type of temporary abdominal closure
There were no randomised controlled trials comparing NPWT with any other type of temporary abdominal closure.",rephrase,['We did not find any studies that compared NPWT with other types of temporary abdominal closure.'],3,0.5,3,16
CD013710,3,8,"Comparison of different negative pressure wound therapy devices
We included one study (34 participants) comparing different types of NPWT systems (Suprasorb CNP system versus ABThera system).",rephrase,['We also included studies that compared different types of NPWT systems for managing the open abdomen in non-trauma patients.'],4,0.5625,3,16
CD013710,3,9,"We are uncertain whether the Suprasorb CNP system increases the proportion of participants with successful primary fascial closure of the abdomen compared with the ABThera system (Suprasorb CNP system: 88.2% versus ABThera system: 70.6% (RR 0.80, 95% CI 0.56 to 1.14); very low-certainty evidence).",delete,[],5,0.625,4,16
CD013710,3,10,"We are also uncertain whether the Suprasorb CNP system reduces adverse events (fistulae formation, Suprasorb CNP system: 0% versus ABThera system: 23.5% (RR 0.11, 95% CI 0.01 to 1.92); very low-certainty evidence), all-cause mortality (Suprasorb CNP system: 5.9% versus ABThera system: 17.6% (RR 0.33, 95% CI 0.04 to 2.89); very low-certainty evidence), or reoperation rate compared with the ABThera system (Suprasorb CNP system: 100% versus ABThera system: 100% (RR 1.00, 95% CI 0.90 to 1.12); very low-certainty evidence).",delete,[],5,0.6875,4,16
CD013710,3,11,"The study did not report the time to primary fascial closure of the abdomen, participant health-related quality of life, length of hospital stay, wound infection, or pain.",rephrase,"['The study did not report the time needed for wounds to completely close, participant health-related quality of life, length of hospital stay, wound infection, or pain.']",5,0.75,4,16
CD013710,4,12,"Based on the available trial data, we are uncertain whether NPWT has any benefit in primary fascial closure of the abdomen, adverse events (fistulae formation), all-cause mortality, or length of hospital stay compared with the Bogota bag.",rephrase,"['We only found two relevant studies, so we are uncertain about the benefits or harms of using NPWT compared with using a Bogota bag or different types of NPWT systems.']",6,0.8125,5,16
CD013710,4,13,"We are also uncertain whether the Suprasorb CNP system has any benefit in primary fascial closure of the abdomen, adverse events, all-cause mortality, or reoperation rate compared with the ABThera system.",rephrase,"['We cannot tell from the results whether when compared to an ABThera system, a Suprasorb CNP system reduces:\n- the proportion of people with wounds that were successfully closed;\n- harmful or unwanted effects (bowel perforation);\n- death rate; or\n- reoperation rate between the groups.']",7,0.875,5,16
CD013710,4,14,"Further research evaluating these outcomes as well as participant health-related quality of life, wound infection, and pain outcomes is required.",delete,[],8,0.9375,5,16
CD013710,4,15,We will update this review when data from the large studies that are currently ongoing are available.,delete,[],8,1.0,5,16
CD005450,0,0,Thirteen relevant trials with 1770 participants were included.,ignore,['Thirteen relevant trials with 1770 participants were analysed.'],0,0.1,1,10
CD005450,0,1,All of them were of low quality.,ignore,['All of them were of low quality.'],1,0.2,1,10
CD005450,0,2,Fifty-two studies still need to be assessed because the original authors could not be interviewed.,delete,[],2,0.3,2,10
CD005450,0,3,"None of these trials analysed mortality, health related quality of life, economic outcomes or compliance.",ignore,"['None of these trials analysed mortality, health related quality of life, economic outcomes or compliance with treatments.']",2,0.4,2,10
CD005450,0,4,"Compared to antithyroid drugs alone the results showed that Chinese herbal medicines combined with antithyroid drugs may offer benefits in lowering relapse rates, reducing the incidence of adverse effects, relieving symptoms, improving thyroid antibody status and thyroid function.",rephrase,"['Some of these herbs may show benefits in improving symptoms, thyroid function and adverse effects.']",3,0.5,3,10
CD005450,0,5,"Two trials investigated Chinese herbal medicine versus radioiodine and reported improvements in anxiety, tachycardia and heat intolerance.",delete,[],4,0.6,3,10
CD005450,0,6,"However, thyroid function - with the exception of restored thyroid stimulating hormone (TSH) - was not significantly altered.",delete,[],4,0.7,4,10
CD005450,1,7,The results suggest that traditional Chinese herbal medicines added to other routine treatment have a therapeutic potential for people with hyperthyroidism.,delete,[],4,0.8,4,10
CD005450,1,8,"However, due to methodological limitations, we could not identify a well-designed trial to provide strong evidence for Chinese traditional herbal medicine in the treatment of hyperthyroidism.",delete,[],4,0.9,5,10
CD005450,1,9,"Thus, we currently cannot recommend any single preparation or formulation for clinical use.",rephrase,"['Unfortunately, we were unable to find reliable evidence to recommend a specific herbal preparation from 103 investigated formulations.']",4,1.0,5,10
CD009134,0,0,We included two trials involving 269 participants.,merge,['We included two trials involving 269 participants.The participants were mostly men (67%) and on average 65 years of age.'],0,0.07142857142857142,1,14
CD009134,0,1,The participants were mostly men (67%); the mean age was 65 years.,none,[],0,0.14285714285714285,1,14
CD009134,0,2,The trials were conducted in China and Italy (one was a multicentre trial).,delete,[],1,0.21428571428571427,2,14
CD009134,0,3,Both trials included adults with acute respiratory failure after upper abdominal surgery.,split,"['We searched scientific databases for clinical trials looking at the treatment of adults with acute respiratory failure following abdominal surgery.', 'Both trials included adults with acute respiratory failure after upper abdominal surgery.']",1,0.2857142857142857,2,14
CD009134,0,4,We judged both trials at high risk of bias.,delete,[],3,0.35714285714285715,2,14
CD009134,0,5,"Compared to oxygen therapy, CPAP or bilevel NPPV may reduce the rate of tracheal intubation (risk ratio (RR) 0.25; 95% confidence interval (CI) 0.08 to 0.83; low quality evidence) with a number needed to treat for an additional beneficial outcome of 11.",rephrase,"['Compared with oxygen therapy, NPPV decreased the rate of tracheal intubation.']",3,0.42857142857142855,3,14
CD009134,0,6,There was very low quality evidence that the intervention may also reduce ICU length of stay (mean difference (MD) -1.84 days; 95% CI -3.53 to -0.15).,rephrase,['The use of NPPV also reduced the length of stay in the ICU by almost two days when compared to oxygen therapy.'],4,0.5,3,14
CD009134,0,7,We found no differences for mortality (low quality evidence) and hospital length of stay.,rephrase,"['There was low quality evidence for hospital mortality, low quality of evidence for rate of tracheal intubation, and very low quality of evidence for ICU length of stay.']",5,0.5714285714285714,3,14
CD009134,0,8,"There was insufficient evidence to be certain that CPAP or NPPV had an effect on anastomotic leakage, pneumonia-related complications, and sepsis or infections.",rephrase,"['There was insufficient evidence to be certain that CPAP or NPPV had an effect on anastomotic (e.g. where two pieces of intestine are joined together) leakage, pneumonia related complications and sepsis (blood poisoning) or infections.']",6,0.6428571428571429,4,14
CD009134,0,9,"Findings from one trial of 60 participants suggested that bilevel NPPV, compared to oxygen therapy, may improve blood gas levels and blood pH one hour after the intervention (partial pressure of arterial oxygen (PaO2): MD 22.5 mm Hg; 95% CI 17.19 to 27.81; pH: MD 0.06; 95% CI 0.01 to 0.11; partial pressure of arterial carbon dioxide (PCO2) levels (MD -9.8 mm Hg; 95% CI -14.07 to -5.53).",rephrase,"['When compared to oxygen therapy, NPPV improved blood gas levels one hour after the intervention.']",7,0.7142857142857143,4,14
CD009134,0,10,"The trials included in this systematic review did not present data on the following outcomes that we intended to assess: gastric insufflation, fistulae, pneumothorax, bleeding, skin breakdown, eye irritation, sinus congestion, oronasal drying, and patient-ventilator asynchrony.",delete,[],8,0.7857142857142857,4,14
CD009134,1,11,The findings of this review indicate that CPAP or bilevel NPPV is an effective and safe intervention for the treatment of adults with acute respiratory failure after upper abdominal surgery.,rephrase,['The findings of this review showed that NPPV is an effective and safe treatment for adults with acute respiratory failure after upper abdominal surgery.'],8,0.8571428571428571,5,14
CD009134,1,12,"However, based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, the quality of the evidence was low or very low.",delete,[],9,0.9285714285714286,5,14
CD009134,1,13,More good quality studies are needed to confirm these findings.,rephrase,"['However, due to the low quality of the evidence, more good quality studies are needed to confirm these findings.']",9,1.0,5,14
CD011287,0,0,We included 25 RCTs involving 7259 participants including 977 (13.5%) men and 6282 (86.5%) women.,rephrase,['We identified 25 RCTs involving 27 different comparisons.'],0,0.05,1,20
CD011287,0,1,"Mean age reported ranged from 52.6 to 71 years, and range of age of included participants was 23 to 85 years.",delete,[],1,0.1,1,20
CD011287,0,2,"The trials reported 27 comparisons and included participants who had survived breast cancer (17 trials), colorectal cancer (2 trials), gynaecological cancer (1 trial), and cancer at mixed sites (5 trials).",delete,[],1,0.15,1,20
CD011287,1,3,"For overall survival, dietary intervention and control groups showed little or no difference in risk of mortality (hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.77 to 1.23; 1 study; 3107 participants; low-certainty evidence).",delete,[],1,0.2,1,20
CD011287,1,4,"For secondary malignancies, dietary interventions versus control trials reported little or no difference (risk ratio (RR) 0.99, 95% CI 0.84 to 1.15; 1 study; 3107 participants; low-certainty evidence).",delete,[],1,0.25,2,20
CD011287,1,5,Co-morbidities were not measured in any included trials.,delete,[],1,0.3,2,20
CD011287,2,6,"Subsequent outcomes reported after 12 months found that dietary interventions versus control probably make little or no difference in energy intake at 12 months (mean difference (MD) -59.13 kcal, 95% CI -159.05 to 37.79; 5 studies; 3283 participants; moderate-certainty evidence).",delete,[],1,0.35,2,20
CD011287,2,7,"Dietary interventions versus control probably led to slight increases in fruit and vegetable servings (MD 0.41 servings, 95% CI 0.10 to 0.71; 5 studies; 834 participants; moderate-certainty evidence); mixed results for fibre intake overall (MD 5.12 g, 95% CI 0.66 to 10.9; 2 studies; 3127 participants; very low-certainty evidence); and likely improvement in Diet Quality Index (MD 3.46, 95% CI 1.54 to 5.38; 747 participants; moderate-certainty evidence).",delete,[],1,0.4,2,20
CD011287,3,8,"For anthropometry, dietary intervention versus control probably led to a slightly decreased body mass index (BMI) (MD -0.79 kg/m², 95% CI -1.50 to -0.07; 4 studies; 777 participants; moderate-certainty evidence).",delete,[],1,0.45,3,20
CD011287,3,9,"Dietary interventions versus control probably had little or no effect on waist-to-hip ratio (MD -0.01, 95% CI -0.04 to 0.02; 2 studies; 106 participants; low-certainty evidence).",rephrase,['Included studies compared dietary interventions versus control or usual care.'],1,0.5,3,20
CD011287,4,10,"For QoL, there were mixed results; several different quality assessment tools were used and evidence was of low to very low-certainty.",rephrase,['The quality of evidence is generally low to very low.'],2,0.55,3,20
CD011287,4,11,No adverse events were reported in any of the included studies.,rephrase,['No adverse events were reported.'],3,0.6,3,20
CD011287,5,12,Evidence demonstrated little effects of dietary interventions on overall mortality and secondary cancers.,rephrase,"['Most studies did not evaluate dietary interventions for key review outcomes, particularly mortality and morbidity.']",4,0.65,4,20
CD011287,5,13,"For comorbidities, no evidence was identified.",rephrase,"['Gaps identified in the evidence involved the use of new technologies, comorbidities, and body composition data.']",5,0.7,4,20
CD011287,5,14,"For nutritional outcomes, there was probably little or no effect on energy intake, although probably a slight increase in fruit and vegetable intake and Diet Quality Index.",split,"['We found some evidence showing that dietary interventions probably did not modify energy intake; however, some evidence shows what is probably a slight increase in fruit and vegetable intake (moderate-certainty evidence).', 'Dietary interventions compared to control probably improved the Diet Quality Index (moderate-certainty evidence).']",6,0.75,4,20
CD011287,5,15,Results were mixed for fibre.,rephrase,['Evidence on dietary fibre was mixed for different advice on weight reducing or healthy eating.'],8,0.8,4,20
CD011287,5,16,"For anthropometry, there was probably a slight decrease in body mass index (BMI) but probably little or no effect on waist-to-hip ratio.",rephrase,"['For physical measurements, we found a probable reduction in body mass index (BMI) with dietary interventions compared to controls (moderate-certainty evidence) but little evidence showing any change in waist-to-hip ratio (low-certainty evidence).']",9,0.85,5,20
CD011287,5,17,"For QoL, results were highly varied.",rephrase,"['For quality of life (QoL), results were mixed due to the wide variety of tools used.']",10,0.9,5,20
CD011287,5,18,"Additional high-quality research is needed to examine the effects of dietary interventions for different cancer sites, and to evaluate important outcomes including comorbidities and body composition.",delete,[],11,0.95,5,20
CD011287,5,19,Evidence on new technologies used to deliver dietary interventions was limited.,delete,[],11,1.0,5,20
CD003383,0,0,Twelve double-blind RCTs (n=700) met the inclusion criteria.,rephrase,['Twelve trials met the inclusion criteria.'],0,0.1,1,10
CD003383,0,1,The meta-analysis was done on seven studies using the total score on the Hamilton Anxiety (HAM-A) scale as a common outcome measure.,merge,['The meta-analysis of seven trials suggests a significant treatment effect for the total score on the Hamilton Anxiety Scale in favour of kava extract.'],1,0.2,1,10
CD003383,0,2,"The result suggests a significant effect towards a reduction of the HAM-A total score in patients receiving kava extract compared with patients receiving placebo (weighted mean difference: 3.9, 95% confidence interval: 0.1 to 7.7; p = 0.05; n = 380).",none,[],1,0.3,2,10
CD003383,0,3,The results of the five studies that were not submitted to meta-analysis largely support these findings.,delete,[],2,0.4,2,10
CD003383,0,4,"Adverse events as reported in the reviewed trials were mild, transient and infrequent.",rephrase,"['Few adverse events were reported in the reviewed trials, which were all mild, transient and infrequent.']",2,0.5,3,10
CD003383,1,5,"Compared with placebo, kava extract is an effective symptomatic treatment for anxiety although, at present, the size of the effect seems small.",rephrase,"['These data imply that, compared with placebo, kava extract might be an effective symptomatic treatment for anxiety although, at present, the size of the effect seems to be small.']",3,0.6,3,10
CD003383,1,6,The effect lacks robustness and is based on a relatively small sample.,delete,[],4,0.7,4,10
CD003383,1,7,"The data available from the reviewed studies suggest that kava is relatively safe for short-term treatment (1 to 24 weeks), although more information is required.",delete,[],4,0.8,4,10
CD003383,1,8,Rigorous trials with large sample sizes are needed to clarify the existing uncertainties.,ignore,['Rigorous trials with large sample sizes are needed to clarify the existing uncertainties.'],4,0.9,5,10
CD003383,1,9,"Also, long-term safety studies of kava are required.",rephrase,['Particularly long-term safety studies of kava are needed.'],5,1.0,5,10
CD009336,0,0,Two studies conducted in rural Uganda met the inclusion criteria for this review.,rephrase,['We identified two studies from rural Uganda involving 3214 women who were randomised (assigned by chance) to receive and keep misoprostol tablets or receive standard care for preventing excessive bleeding after birth.'],0,0.07142857142857142,1,14
CD009336,0,1,One was a stepped-wedge cluster-randomised trial (involving 2466 women) which assessed the effectiveness and safety of misoprostol distribution to pregnant women compared with standard care for PPH prevention during non-facility births.,delete,[],1,0.14285714285714285,1,14
CD009336,0,2,"The other study (involving 748 women) was a pilot individually randomised placebo-controlled trial which assessed the logistics and feasibility of community antenatal distribution of misoprostol, as well as the effectiveness and safety of self-administration of misoprostol for PPH prevention.",delete,[],1,0.21428571428571427,2,14
CD009336,0,3,Only 271 (11%) of women in the cluster-randomised trial and 299 (40%) of the women in the individually randomised trial had non-facility births.,delete,[],1,0.2857142857142857,2,14
CD009336,0,4,Data from the two studies could not be meta-analysed as the data available from the stepped-wedge trial were not adjusted for the study design.,rephrase,['We were unable to analyse most of the information from one study as it was not separated out by birth setting (health facility versus non-facility) and not well adjusted for the type of study design.'],1,0.35714285714285715,2,14
CD009336,0,5,"Therefore, the analysed effects of advance misoprostol distribution on PPH prevention largely reflect the findings of the placebo-controlled trial.",rephrase,"['Therefore, the analysed information in our review largely reflects the findings of one study.']",2,0.42857142857142855,3,14
CD009336,0,6,Neither of the included studies addressed advance misoprostol distribution for the treatment of PPH.,delete,[],3,0.5,3,14
CD009336,1,7,"Primary outcomes
Severe PPH was not reported in the studies.",delete,[],3,0.5714285714285714,3,14
CD009336,1,8,"In both the intervention and standard care arms of the two studies, no cases of severe maternal morbidity or death were recorded among women who had a non-facility birth.",rephrase,['No serious maternal ill health or deaths were reported in the two studies.'],3,0.6428571428571429,4,14
CD009336,2,9,"Secondary outcomes
Compared with standard care, it is uncertain whether advance misoprostol distribution has any effect on blood transfusion (no events, 1 study, 299 women), the number of women not using misoprostol (2% in the advance distribution group versus 4% in the usual care group; risk ratio (RR) 0.50, 95% confidence interval (CI) 0.13 to 1.95, 1 study, 299 women), the number of women not using misoprostol correctly (RR 4.86, 95% CI 0.24 to 100.46, 1 study, 290 women), inappropriate use of misoprostol (RR 4.97, 95% CI 0.24 to 102.59, 1 study, 299 women) or maternal transfer or referral to a health facility (RR 0.66, 95% CI 0.11 to 3.91, 1 study, 299 women).",delete,[],4,0.7142857142857143,4,14
CD009336,2,10,"Compared with standard care, it is uncertain whether advance misoprostol provision increases the number of women experiencing minor adverse effects: shivering/chills (RR 1.84, CI 95% 1.35 to 2.50, 1 study, 299 women), fever (RR 1.87, 95% CI 1.16 to 3.00, 1 study, 299 women), or diarrhoea (RR 3.92, 95% CI 0.44 to 34.64, 1 study, 299 women); major adverse effects: placenta retention (RR 1.49, 95% CI 0.25 to 8.79, 1 study, 299 women) or hospital admission for longer than 24 hours (RR 0.99, 95% CI 0.66 to 15.73, 1 study, 299 women) after non-facility birth.",delete,[],4,0.7857142857142857,4,14
CD009336,2,11,"For all the outcomes included in the 'Summary of findings' table, we assessed the certainty of the evidence as very low, according to GRADE criteria.",rephrase,['The certainty of the evidence was very low and the findings were variable.'],4,0.8571428571428571,5,14
CD009336,3,12,"Whilst it might be considered reasonable and feasible to provide advance misoprostol to pregnant women where there are no suitable alternative options for the prevention or treatment of PPH, the evidence on the benefits and harms of this approach remains uncertain.",rephrase,"['Although this update supports the feasibility of a strategy of giving women misoprostol tablets to use after birth outside of a health facility, the evidence on the benefits of this approach remains uncertain.']",5,0.9285714285714286,5,14
CD009336,3,13,Expansion of uterotonic coverage through this strategy should be cautiously implemented either in the context of rigorous research or with targeted monitoring and evaluation of its impact.,rephrase,"['Efforts to scale up this strategy as part of reducing maternal deaths in remote regions should be done cautiously through targeted monitoring and evaluation, or with large-scale research to resolve the uncertainties.']",6,1.0,5,14
CD007630,0,0,We identified two randomised trials eligible for inclusion in the review.,rephrase,['Two eligible studies were included in the review.'],0,0.0625,1,16
CD007630,0,1,"There was significant variability between the trials for interventions, methodology and outcome measures and therefore meta-analysis was not performed.",rephrase,"['These studies vary significantly in interventions, methodology and reported outcomes.']",1,0.125,1,16
CD007630,0,2,"One study suggested that the transantral approach and endoscopic transnasal technique had similar effects in reducing exophthalmos but that the endoscopic approach may be safer, relating to fewer complications.",rephrase,['One study reported that removal of the inferior wall through the antrum and removal of the medial wall through the nose had similar effects in reducing exophthalmos but the latter had fewer complications.'],2,0.1875,1,16
CD007630,0,3,This study had short-term follow-up and lacked information on our primary outcome (success or failure of treatment).,rephrase,['This study was disadvantaged by short-term follow-up and did not report on our primary outcome measure (success or failure of treatment).'],3,0.25,2,16
CD007630,0,4,"The second study provided evidence that intravenous steroids may be superior to primary surgical decompression in the management of compressive optic neuropathy requiring less secondary surgical procedures, although it relates more frequently to transient side effects.",split,"['The second study suggested that intravenous corticosteroids achieve better visual recovery (56%) than surgical decompression (17%) as a first line treatment for optic neuropathy.', 'It suggested that fewer secondary surgical procedures were required when treated with intravenous corticosteroids but their use related more frequently to side effects with short duration.']",4,0.3125,2,16
CD007630,0,5,This study was weakened by a small sample size.,rephrase,['This study was weakened by the small number of participants involved.'],6,0.375,2,16
CD007630,0,6,Until more credible evidence is available recommendations as to best treatment cannot be reliably made.,rephrase,['Until more evidence is available we cannot recommend any particular intervention.'],7,0.4375,3,16
CD007630,1,7,"A single study showed that the transantral approach for orbital decompression was related to more complications than the endoscopic transnasal technique which is preferred by Ear, Nose and Throat (ENT) surgeons, usually as an adjunctive procedure.",delete,[],8,0.5,3,16
CD007630,1,8,Intravenous steroids were reported in a single trial to be the most efficient intervention for dysthyroid optic neuropathy.,delete,[],8,0.5625,3,16
CD007630,1,9,"The majority of published literature on orbital decompression for thyroid eye disease consists of retrospective, cohort, or case series studies.",delete,[],8,0.625,4,16
CD007630,1,10,"Although these provide useful descriptive information, clarification is required to show the relative effectiveness of each intervention for various indications.",delete,[],8,0.6875,4,16
CD007630,2,11,The two RCTs reviewed are not robust enough to provide credible evidence to our understanding of current decompressive surgery and to support recommendations for clinical practice.,delete,[],8,0.75,4,16
CD007630,2,12,There is evidence from currently available uncontrolled studies that removal of the medial and lateral wall (balanced decompression) with or without fat removal may be the most effective surgical method related to only a few complications.,delete,[],8,0.8125,5,16
CD007630,3,13,"There is a clear need for randomised studies evaluating the balanced two-wall, three-wall and orbital fat decompression techniques.",rephrase,"['These trials should review the balanced two-wall, three-wall and orbital fat decompression techniques.']",8,0.875,5,16
CD007630,3,14,Comparison with other surgical techniques for orbital decompression or with immunosuppression in cases of compressive optic neuropathy would also be important.,delete,[],9,0.9375,5,16
CD007630,3,15,"These studies should primarily address the reduction of exophthalmos, disease severity, complication rates, quality of life and cost of the intervention.",ignore,"['These studies should address the reduction of exophthalmos, disease severity, complication rates, quality of life and cost of the intervention.']",9,1.0,5,16
CD004159,0,0,We found no RCTs or quasi-RCTs in the original review or updates in 20011 and 2012.,rephrase,['We found no randomised controlled trials (RCTs) in the original review or when searches were updated in 2010 and 2012.'],0,0.125,1,8
CD004159,0,1,"Cure or improvement have been described in high quality observational studies: 
(1) A single study describes spontaneous improvement of meralgia paraesthetica in 20 (69%) of 29 cases.",rephrase,"['However, a single observational study also showed that meralgia paraesthetica improved spontaneously in the majority of cases.']",1,0.25,2,8
CD004159,1,2,(2) Four studies evaluating the injection of corticosteroid and local anaesthetic found cure or improvement in 130 (83%) out of a combined total of 157 cases.,rephrase,['Local injections of corticosteroid and surgical operations were found to be effective treatments in observational studies.'],2,0.375,2,8
CD004159,2,3,(3) Surgical treatments have been found to be beneficial in 264 (88%) out of 300 cases treated with decompression (nine studies); and 45 (94%) out of 48 cases treated with neurectomy (three studies).,delete,[],3,0.5,3,8
CD004159,3,4,(4) Ninety-nine (97%) out of 102 patients with iatrogenic meralgia paraesthetica recovered completely (three studies).,delete,[],3,0.625,4,8
CD004159,4,5,"In the absence of any published RCTs or quasi-RCTs, the objective evidence base for treatment choices in meralgia paraesthetica is weak.",rephrase,['RCTs of treatments for meralgia paraesthetica are needed.'],3,0.75,4,8
CD004159,4,6,High quality observational studies report comparable high improvement rates for meralgia paraesthetica following local injection of corticosteroid and surgical interventions (either nerve decompression or neurectomy).,delete,[],4,0.875,5,8
CD004159,4,7,"However, a similar outcome has been reported without any intervention in a single natural history study.",delete,[],4,1.0,5,8
CD007675,0,0,"We included 14 weight loss studies with a total of 2537 participants, and four weight maintenance studies with a total of 1603 participants.",ignore,"['We included 14 weight loss studies with a total of 2537 participants, and four weight maintenance studies with a total of 1603 participants.']",0,0.08333333333333333,1,12
CD007675,0,1,Treatment duration was between four weeks and 30 months.,rephrase,['The length of treatment ranged from four weeks to 30 months.'],1,0.16666666666666666,1,12
CD007675,0,2,"At six months, computer-based interventions led to greater weight loss than minimal interventions (mean difference (MD) -1.5 kg; 95% confidence interval (CI) -2.1 to -0.9; two trials) but less weight loss than in-person treatment (MD 2.1 kg; 95% CI 0.8 to 3.4; one trial).",ignore,"['At six months, computer-based interventions led to greater weight loss than minimal interventions (mean difference -1.5 kg; 95% confidence interval (CI) -2.1 to -0.9; two trials) but less than in-person treatment (mean difference 2.1 kg; 95% CI 0.8 to 3.4; one trial).']",2,0.25,2,12
CD007675,0,3,"At six months, computer-based interventions were superior to a minimal control intervention in limiting weight regain (MD -0.7 kg; 95% CI -1.2 to -0.2; two trials), but not superior to infrequent in-person treatment (MD 0.5 kg; 95% -0.5 to 1.6; two trials).",ignore,"['At six months, computer-based interventions were superior to a minimal control intervention in limiting weight regain (mean difference -0.7 kg; 95% CI -1.2 to -0.2; two trials), but not superior to infrequent in-person treatment (mean difference 0.5 kg; 95% -0.5 to 1.6; two trials).']",3,0.3333333333333333,2,12
CD007675,0,4,We did not observe consistent differences in dietary or physical activity behaviors between intervention and control groups in either weight loss or weight maintenance trials.,delete,[],4,0.4166666666666667,3,12
CD007675,0,5,"Three weight loss studies estimated the costs of computer-based interventions compared to usual care, however two of the studies were 11 and 28 years old, and recent advances in technology render these estimates unlikely to be applicable to current or future interventions, while the third study was conducted in active duty military personnel, and it is unclear whether the costs are relevant to other settings.",rephrase,"['Three weight loss studies estimated the costs of computer-based interventions compared to usual care, however two of the studies were 11 and 28 years old, and these estimates are probably not relevant to interventions using current technology, while the third study was carried out in active duty military personnel, and it is unclear whether costs would be similar in other settings.']",4,0.5,3,12
CD007675,0,6,"One weight loss study reported the cost-effectiveness ratio for a weekly in-person weight loss intervention relative to a computer-based intervention as USD 7177 (EUR 5678) per life year gained (80% CI USD 3055 to USD 60,291 (EUR 2417 to EUR 47,702)).",ignore,"['One weight loss study reported the cost-effectiveness ratio for a weekly in-person weight loss intervention relative to a computer-based intervention as USD 7177 (EUR 5678) per life year gained (80% CI USD 3055 to USD 60,291 (EUR 2417 to EUR 47,702)).']",5,0.5833333333333334,3,12
CD007675,0,7,It is unclear whether this could be extrapolated to other studies.,rephrase,['It is unclear whether this is relevant to other studies.'],6,0.6666666666666666,4,12
CD007675,0,8,"No data were identified on adverse events, morbidity, complications or health-related quality of life.",rephrase,"['No studies had information on health-related quality of life, morbidity, complications or adverse effects.']",7,0.75,4,12
CD007675,1,9,"Compared to no intervention or minimal interventions (pamphlets, usual care), interactive computer-based interventions are an effective intervention for weight loss and weight maintenance.",ignore,"['Compared to no intervention or minimal interventions (pamphlets, usual care), interactive computer-based interventions are an effective intervention for weight loss and weight maintenance.']",8,0.8333333333333334,5,12
CD007675,1,10,"Compared to in-person interventions, interactive computer-based interventions result in smaller weight losses and lower levels of weight maintenance.",ignore,"['Compared to in-person interventions, interactive computer-based interventions result in smaller weight losses and lower levels of weight maintenance.']",9,0.9166666666666666,5,12
CD007675,1,11,"The amount of additional weight loss, however, is relatively small and of brief duration, making the clinical significance of these differences unclear.",ignore,"['The amount of additional weight loss, however, is relatively small and of brief duration, making the clinical significance of these differences unclear.']",10,1.0,5,12
CD008146,0,0,"The review includes three trials, which were all at low risk of bias, involving 530 people with peripheral neuropathy.",rephrase,['The trials involved a total of 530 adults with peripheral neuropathy.'],0,0.07692307692307693,1,13
CD008146,0,1,"The effects of amantadine from one randomised, double-blind, placebo-controlled, cross-over trial comparing amantadine with placebo for the treatment of fatigue in 80 people with Guillain-Barré syndrome (GBS) were uncertain for the proportion of people achieving a favourable outcome six weeks post-intervention (odds ratio (OR) 0.56 (95% confidence interval (CI) 0.22 to 1.35, N = 74, P = 0.16).",delete,[],1,0.15384615384615385,1,13
CD008146,0,2,We assessed the quality of this evidence as low.,rephrase,"['We assessed the quality of this evidence as moderate because the results were imprecise, which means they do not rule out the possibility that the drugs could have an effect.']",1,0.23076923076923078,2,13
CD008146,0,3,"Two parallel-group randomised double-blind, placebo-controlled trials comparing the effects of two doses of ascorbic acid with placebo for reducing fatigue in adults with Charcot-Marie-Tooth disease type 1A (CMT1A) showed that the effects of ascorbic acid at either dose are probably small (standardised mean difference (SMD) -0.12 (95% CI -0.32 to 0.08, n = 404, P = 0.25)) for change in fatigue after 12 to 24 months (moderate quality evidence).",delete,[],2,0.3076923076923077,2,13
CD008146,0,4,"Neither ascorbic acid study measured fatigue at four to 12 weeks, which was our primary outcome measure.",rephrase,['We chose measures of fatigue at four to 12 weeks as our preferred measure of the effects of treatment.'],2,0.38461538461538464,2,13
CD008146,0,5,No serious adverse events were reported with amantadine.,delete,[],3,0.46153846153846156,3,13
CD008146,0,6,Serious adverse events were reported in the trials of ascorbic acid.,delete,[],3,0.5384615384615384,3,13
CD008146,0,7,"However,risk of serious adverse events was similar with ascorbic acid and placebo.",delete,[],3,0.6153846153846154,4,13
CD008146,1,8,One small imprecise study in people with GBS showed uncertain effects of amantadine on fatigue.,rephrase,['There was insufficient evidence to determine the effects of amantadine when compared with an inactive treatment (placebo) for fatigue.'],3,0.6923076923076923,4,13
CD008146,1,9,In two studies in people with CMT1A there is moderate-quality evidence that ascorbic acid has little meaningful benefit on fatigue.,rephrase,['We found evidence that ascorbic acid probably has little meaningful benefit for fatigue.'],4,0.7692307692307693,4,13
CD008146,1,10,"Information about adverse effects was limited, although both treatments appear to be well tolerated and safe in these conditions.",delete,[],5,0.8461538461538461,5,13
CD008146,2,11,"There was no evidence available from RCTs to evaluate the effect of other drugs or other interventions for fatigue in either GBS, CMT1A or other causes of peripheral neuropathy.",rephrase,['We found no evidence from RCTs on other medicines or treatments for fatigue in peripheral neuropathy.'],5,0.9230769230769231,5,13
CD008146,2,12,The cost effectiveness of different interventions should also be considered in future randomised clinical trials.,rephrase,['The cost effectiveness of different interventions should also be considered in future RCTs.'],6,1.0,5,13
CD005417,0,0,Ten studies randomised individuals and trial sizes varied from n=31 to n=549.,delete,[],0,0.07142857142857142,1,14
CD005417,0,1,"One study randomised 392 households and enrolled a total of 509 persons with HIV and 1,521 HIV-negative household members.",delete,[],0,0.14285714285714285,1,14
CD005417,0,2,Two ongoing studies were identified.,rephrase,['Eleven completed and two ongoing studies were identified.'],0,0.21428571428571427,2,14
CD005417,0,3,"Intensive home-based nursing significantly improved self-reported knowledge of HIV and medications, self-reported adherence and difference in pharmacy drug refill (1 study).",rephrase,"['Intensive home-based nursing significantly improved self-reported knowledge of HIV and medications, and self-reported adherence to medication.']",1,0.2857142857142857,2,14
CD005417,0,4,"Another study, comparing proportion of participants with greater than 90% adherence, found statistically significant differences over time but no significant change in CD4 counts and viral loads.",ignore,"['Another study, comparing proportion of participants with greater than 90% adherence, found statistically significant differences over time but no significant change in CD4 counts and viral loads.']",2,0.35714285714285715,2,14
CD005417,0,5,"A third study found significant differences in HIV stigma, worry and physical functioning but no differences in depressive symptoms, mood, general health, and overall functioning.",ignore,"['A third study found significant differences in HIV stigma, worry and physical functioning but no differences in depressive symptoms, mood, general health, and overall functioning.']",3,0.42857142857142855,3,14
CD005417,0,6,Comprehensive case management by trans-professional teams compared to usual care by primary care nurses had no significant difference in quality-of-life after 6-months of follow-up (n=57) and average length of time on service (n=549).,ignore,['Comprehensive case management by trans-professional teams compared to usual care by primary care nurses had no significant difference in quality-of-life after 6-months of follow-up and average length of time on service.'],4,0.5,3,14
CD005417,0,7,Home total parenteral nutrition had no significant impact on overall survival and rate of re-hospitalisation.,ignore,['Home total parenteral nutrition had no significant impact on overall survival and rate of re-hospitalisation.'],5,0.5714285714285714,3,14
CD005417,0,8,"Two trials comparing computers with brochures/nothing/standard medical care found no significant effect on health status, and decision-making confidence and skill, but a reduction in social isolation after controlling for depression.",ignore,"['Two trials comparing computers with brochures/nothing/standard medical care found no significant effect on health status, and decision-making confidence and skill, but a reduction in social isolation after controlling for depression.']",6,0.6428571428571429,4,14
CD005417,0,9,Two trials evaluating home exercise programmes found opposing results.,ignore,['Two trials evaluating home exercise programmes found opposing results.'],7,0.7142857142857143,4,14
CD005417,0,10,Home-based safe water systems reduced diarrhea frequency and severity among persons with HIV in Africa.,ignore,['Home-based safe water systems reduced diarrhea frequency and severity among persons with HIV in Africa.'],8,0.7857142857142857,4,14
CD005417,1,11,Studies were generally small and very few studies were done in developing countries.,ignore,['Studies were generally small and very few studies were done in developing countries.'],9,0.8571428571428571,5,14
CD005417,1,12,There was a lack of studies truly looking at the effect of home based care itself or looking at significant end points (death and progression to AIDS).,ignore,['There was a lack of studies truly looking at the effect of home based care itself or looking at significant end points (death and progression to AIDS).'],10,0.9285714285714286,5,14
CD005417,1,13,"However, the range of interventions and HBC models evaluated can assist in making evidence-based decisions about HIV care and support.",delete,[],11,1.0,5,14
CD002212,0,0,We included one study from the USA (re-analysed as an ITS) involving one hospital and an unknown number of nurses and patients.,rephrase,['We included one study from the USA which involved one hospital and for which the number of nurses was not reported.'],0,0.14285714285714285,1,7
CD002212,0,1,The study evaluated the effects of a standardised evidence-based nursing procedure on nursing care for patients at risk of developing healthcare-acquired pressure ulcers (HAPUs).,rephrase,"['The study evaluated the effects of a standardised evidence-based nursing procedure on improved nursing care for patients at risk of developing healthcare-acquired pressure ulcers (HAPUs), as measured by the HAPU rate.']",1,0.2857142857142857,2,7
CD002212,0,2,"If a patient's admission Braden score was below or equal to 18 (i.e. indicating a high risk of developing pressure ulcers), nurses were authorised to initiate a pressure ulcer prevention bundle (i.e. a set of evidence-based clinical interventions) without waiting for a physician order.",split,"[""If a patient's admission Braden score was lower than or equal to 18, nurses were authorised to initiate a prevention pressure ulcer care bundle, without a physician order."", ""The Braden scale is a tool used to assess a patient's risk of developing pressure ulcers."", 'An adult with a score below or equal to 18 is considered to have a high risk for developing a pressure ulcer.']",2,0.42857142857142855,3,7
CD002212,0,3,"Re-analysis of data as a time series showed that against a background trend of decreasing HAPU rates, if that trend was assumed to be real, there was no evidence of an intervention effect at three months (mean rate per quarter 0.7%; 95% confidence interval (CI) 1.7 to 3.3; P = 0.457).",rephrase,"['Re-analysis of the HAPU data, as an interrupted time series, was suggestive of a trend in rates prior to intervention and, if that trend was assumed to be real, there was no evidence of an intervention effect at three months (mean rate per quarter 0.7%; 95% confidence interval (CI) 1.7 to 3.3; P = 0.457).']",5,0.5714285714285714,3,7
CD002212,0,4,Given the small percentages post intervention it was not statistically possible to extrapolate effects beyond three months.,ignore,['Given the small percentages post intervention it was not statistically possible to extrapolate effects beyond three months.'],6,0.7142857142857143,4,7
CD002212,1,5,Despite extensive searching of published and unpublished research we identified only one low-quality study; we excluded many studies due to non-eligible study design.,delete,[],7,0.8571428571428571,5,7
CD002212,1,6,"If policy-makers and healthcare organisations wish to promote evidence-based nursing successfully at an organisational level, they must ensure the funding and conduct of well-designed studies to generate evidence to guide policy.",ignore,"['If policy-makers and healthcare organisations wish to promote evidence-based nursing at an organisational level successfully, they must ensure the funding and conduct of well-designed studies to generate evidence to guide policy.']",7,1.0,5,7
CD004492,0,0,"We found 41 trials (>33,000 participants) which met our inclusion criteria.",rephrase,"['We found 41 stage-based trials, covering more than 33,000 smokers, which measured quit rates at least six months after treatment.']",0,0.0625,1,16
CD004492,0,1,"Four trials, which directly compared the same intervention in stage-based and standard versions, found no clear advantage for the staging component.",rephrase,['Only four of the 41 trials directly compared the same intervention in a standard and a stage-based version.'],1,0.125,1,16
CD004492,0,2,Stage-based versus standard self-help materials (two trials) gave a relative risk (RR) of 0.93 (95% CI 0.62 to 1.39).,delete,[],2,0.1875,1,16
CD004492,0,3,Stage-based versus standard counselling (two trials) gave a relative risk of 1.00 (95% CI 0.82 to 1.22).,delete,[],2,0.25,2,16
CD004492,0,4,"Six trials of stage-based self-help systems versus any standard self-help support demonstrated a benefit for the staged groups, with an RR of 1.27 (95% CI 1.01 to 1.59).",delete,[],2,0.3125,2,16
CD004492,0,5,Twelve trials comparing stage-based self help with 'usual care' or assessment-only gave an RR of 1.32 (95% CI 1.17 to 1.48).,split,"[""In this review, we have compared stage-based programmes of smoking cessation with standard (unstaged) programmes, or with 'usual care', or with assessment only."", 'Eighteen trials which compared stage-based self-help programmes with any control condition showed better success rates for the intervention groups.']",2,0.375,2,16
CD004492,0,6,Thirteen trials of stage-based individual counselling versus any control condition gave an RR of 1.24 (95% CI 1.08 to 1.42).,rephrase,['Thirteen trials of stage-based individual counselling versus any control condition showed a similar benefit for the intervention groups.'],4,0.4375,3,16
CD004492,0,7,These findings are consistent with the proven effectiveness of these interventions in their non-stage-based versions.,rephrase,"['These findings confirm the known effectiveness of these interventions, whether staged or unstaged.']",5,0.5,3,16
CD004492,0,8,"The evidence was unclear for telephone counselling, interactive computer programmes or training of doctors or lay supporters.",rephrase,"['The evidence was less clear on the effects of stage-based telephone counselling, interactive computer programmes or training of doctors and helpers.']",6,0.5625,3,16
CD004492,0,9,This uncertainty may be due in part to smaller numbers of trials.,ignore,['This uncertainty may be due in part to smaller numbers of trials.'],7,0.625,4,16
CD004492,1,10,"Based on four trials using direct comparisons, stage-based self-help interventions (expert systems and/or tailored materials) and individual counselling were neither more nor less effective than their non-stage-based equivalents.",delete,[],8,0.6875,4,16
CD004492,1,11,Thirty-one trials of stage-based self help or counselling interventions versus any control condition demonstrated levels of effectiveness which were comparable with their non-stage-based counterparts.,delete,[],8,0.75,4,16
CD004492,1,12,Providing these forms of practical support to those trying to quit appears to be more productive than not intervening.,rephrase,"[""We find on the evidence from this review that providing self-help or counselling support to smokers trying to quit is more effective than 'usual care' or simple observation.""]",8,0.8125,5,16
CD004492,1,13,"However, the additional value of adapting the intervention to the smoker's stage of change is uncertain.",rephrase,"[""However, the extra value of fitting that support to the smoker's stage of change is currently unclear.""]",9,0.875,5,16
CD004492,1,14,"The evidence is not clear for other types of staged intervention, including telephone counselling, interactive computer programmes and training of physicians or lay supporters.",delete,[],10,0.9375,5,16
CD004492,1,15,The evidence does not support the restriction of quitting advice and encouragement only to those smokers perceived to be in the preparation and action stages.,delete,[],10,1.0,5,16
CD007495,0,0,Thirty studies met our inclusion criteria.,delete,[],0,0.058823529411764705,1,17
CD007495,1,1,"From 11 studies on osteoporosis, meta-analysis of five studies (high-certainty evidence) showed that a combination of a GP alerting system on a patient's increased risk of osteoporosis and a patient-directed intervention (including patient education and a reminder to see their GP) improves GP behaviour with regard to diagnostic bone mineral density (BMD) testing and osteoporosis medication prescribing (RR 4.44; (95% confidence interval (CI) 3.54 to 5.55; 3 studies; 3,386 participants)) for BMD and RR 1.71 (95% CI 1.50 to 1.94; 5 studies; 4,223 participants) for osteoporosis medication.",delete,[],0,0.11764705882352941,1,17
CD007495,1,2,"Meta-analysis of two studies showed that GP alerting on its own also probably improves osteoporosis guideline-consistent GP behaviour (RR 4.75 (95% CI 3.62 to 6.24; 3,047 participants)) for BMD and RR 1.52 (95% CI 1.26 to 1.84; 3.047 participants) for osteoporosis medication) and that adding the patient-directed component probably does not lead to a greater effect (RR 0.94 (95% CI 0.81 to 1.09; 2,995 participants)) for BMD and RR 0.93 (95% CI 0.79 to 1.10; 2,995 participants) for osteoporosis medication.",rephrase,['GP alerting on its own is also probably effective according to two studies and adding the patient-directed component probably does not lead to a greater effect.'],0,0.17647058823529413,1,17
CD007495,2,3,"Of the 10 studies on low back pain, seven showed that guideline dissemination and educational opportunities for GPs may lead to little or no improvement with regard to guideline-consistent GP behaviour.",rephrase,"[""Of the ten studies on low back pain, seven showed that GP education and distribution of guidelines may lead to little or no improvement with regards to GPs' clinical behaviour.""]",1,0.23529411764705882,2,17
CD007495,2,4,"Two studies showed that the combination of guidelines and GP feedback on the total number of investigations requested may have an effect on GP behaviour and result in a slight reduction in the number of tests, while one of these studies showed that the combination of guidelines and GP reminders attached to radiology reports may result in a small but sustained reduction in the number of investigation requests.",split,"['Two studies showed that providing GPs with guidelines and information on the total number of tests they request may have an effect on GP behaviour (resulting in a slight reduction in the number of tests).', 'One study showed that using a combination of guidelines and GP reminders attached to test reports may result in a small but sustained reduction in the number of tests.']",2,0.29411764705882354,2,17
CD007495,3,5,"Of the four studies on osteoarthritis, one study showed that using educationally influential physicians may result in improvement in guideline-consistent GP behaviour.",rephrase,"['Of the four studies on osteoarthritis, one found that GP behaviour may improve when prominent GPs are recruited to educate their colleagues.']",4,0.35294117647058826,2,17
CD007495,3,6,Another study showed slight improvements in patient outcomes (pain control) after training GPs on pain management.,ignore,['A second study showed slight improvements in patient outcomes (pain control) after training GPs on pain management.'],5,0.4117647058823529,3,17
CD007495,4,7,"Of three studies on shoulder pain, one study reported that there may be little or no improvement in patient outcomes (functional capacity) after GP education on shoulder pain and injection training.",ignore,"['Of the three studies on shoulder pain, one study showed that there may be little or no improvement in patient outcomes (functional capacity) after GP education on shoulder pain and injection training.']",6,0.47058823529411764,3,17
CD007495,5,8,"Of two studies on other musculoskeletal conditions, one study on pain management showed that there may be worse patient outcomes (pain control) after GP training on the use of validated assessment scales.",rephrase,"['Of the two studies on other musculoskeletal conditions, one study on pain management showed worse patient outcomes (pain control) after GP training on the use of tools to measure pain.']",7,0.5294117647058824,3,17
CD007495,6,9,The 12 remaining studies across all musculoskeletal conditions showed little or no improvement in GP behaviour and patient outcomes.,ignore,['The 12 remaining studies across all musculoskeletal conditions showed little or no improvement in GP behaviour and patient outcomes.'],8,0.5882352941176471,3,17
CD007495,7,10,The direction of the targeted behaviour (i.e. increasing or decreasing a behaviour) does not seem to affect the effectiveness of an intervention.,ignore,['The direction of the targeted behaviour (i.e. increasing or decreasing a behaviour) does not seem to affect the effectiveness of an intervention.'],9,0.6470588235294118,4,17
CD007495,7,11,The majority of the studies did not investigate the potential adverse effects of the interventions and only three studies included a cost-effectiveness analysis.,ignore,['The majority of the studies did not investigate the potential adverse effects of the interventions and only three studies included a cost-effectiveness analysis.'],10,0.7058823529411765,4,17
CD007495,8,12,"Overall, there were important methodological limitations in the body of evidence, with just a third of the studies reporting adequate allocation concealment and blinded outcome assessments.",rephrase,"['There were important limitations in how most of the remaining studies were conducted or reported, and we are less certain of the likely effects of these interventions to improve the management of musculoskeletal conditions.']",11,0.7647058823529411,4,17
CD007495,8,13,"While our confidence in the pooled effect estimate of interventions for improving diagnostic testing and medication prescribing in osteoporosis is high, our confidence in the reported effect estimates in the remaining studies is low.",rephrase,"['The certainty of the evidence was high from studies that examined the effectiveness of interventions to improve the management of osteoporosis by GPs, so we are confident in these findings.']",12,0.8235294117647058,5,17
CD007495,9,14,"There is good-quality evidence that a GP alerting system with or without patient-directed education on osteoporosis improves guideline-consistent GP behaviour, resulting in better diagnosis and treatment rates.",rephrase,"['Our findings suggest that alerting the GP that a patient is at risk of osteoporosis and educating the patient, reminding them to visit their GP, leads to improved GP behaviour (diagnostic testing and medication prescribing).']",13,0.8823529411764706,5,17
CD007495,10,15,"Interventions such as GP reminder messages and GP feedback on performance combined with guideline dissemination may lead to small improvements in guideline-consistent GP behaviour with regard to low back pain, while GP education on osteoarthritis pain and the use of educationally influential physicians may lead to slight improvement in patient outcomes and guideline-consistent behaviour respectively.",delete,[],14,0.9411764705882353,5,17
CD007495,10,16,"However, further studies are needed to ascertain the effectiveness of such interventions in improving GP behaviour and patient outcomes.",delete,[],14,1.0,5,17
CD006887,0,0,"We identified 41 randomised controlled trials (RCTs) involving 194,035 participants from 6422 reports.",rephrase,"['We identified 41 trials that included 194,035 participants.']",0,0.09090909090909091,1,11
CD006887,0,1,We assessed studies as having high or unclear risk of bias across multiple domains.,delete,[],1,0.18181818181818182,1,11
CD006887,0,2,"Low-quality evidence evidence suggests that providing CVD risk scores may have little or no effect on CVD events compared with usual care (5.4% versus 5.3%; RR 1.01, 95% confidence interval (CI) 0.95 to 1.08; I² = 25%; 3 trials, N = 99,070).",rephrase,['Low-quality evidence suggests that providing CVD risk scores had little or no effect on the number of people who develop heart disease or stroke.'],1,0.2727272727272727,2,11
CD006887,0,3,Providing CVD risk scores may reduce CVD risk factor levels by a small amount compared with usual care.,rephrase,"['Providing CVD risk scores may reduce CVD risk factor levels (like cholesterol, blood pressure, and multivariable CVD risk) by a small amount and may increase cholesterol-lowering and blood pressure-lowering medication prescribing in higher risk people.']",2,0.36363636363636365,2,11
CD006887,0,4,"Providing CVD risk scores reduced total cholesterol (MD −0.10 mmol/L, 95% CI −0.20 to 0.00; I² = 94%; 12 trials, N = 20,437, low-quality evidence), systolic blood pressure (MD −2.77 mmHg, 95% CI −4.16 to −1.38; I² = 93%; 16 trials, N = 32,954, low-quality evidence), and multivariable CVD risk (SMD −0.21, 95% CI −0.39 to −0.02; I² = 94%; 9 trials, N = 9549, low-quality evidence).",merge,[],3,0.45454545454545453,3,11
CD006887,0,5,"Providing CVD risk scores may reduce adverse events compared with usual care, but results were imprecise (1.9% versus 2.7%; RR 0.72, 95% CI 0.49 to 1.04; I² = 0%; 4 trials, N = 4630, low-quality evidence).",merge,"['Providing CVD risk scores may reduce harms, but the results were imprecise.']",3,0.5454545454545454,3,11
CD006887,0,6,"Compared with usual care, providing CVD risk scores may increase new or intensified lipid-lowering medications (15.7% versus 10.7%; RR 1.47, 95% CI 1.15 to 1.87; I² = 40%; 11 trials, N = 14,175, low-quality evidence) and increase new or increased antihypertensive medications (17.2% versus 11.4%; RR 1.51, 95% CI 1.08 to 2.11; I² = 53%; 8 trials, N = 13,255, low-quality evidence).",none,[],3,0.6363636363636364,4,11
CD006887,1,7,There is uncertainty whether current strategies for providing CVD risk scores affect CVD events.,delete,[],4,0.7272727272727273,4,11
CD006887,1,8,Providing CVD risk scores may slightly reduce CVD risk factor levels and may increase preventive medication prescribing in higher-risk people without evidence of harm.,rephrase,['There is low-quality evidence to guide the use of CVD risk scores in clinical practice.'],4,0.8181818181818182,5,11
CD006887,1,9,"There were multiple study limitations in the identified studies and substantial heterogeneity in the interventions, outcomes, and analyses, so readers should interpret results with caution.",rephrase,['Studies had multiple limitations and used different methods to provide CVD risk scores.'],5,0.9090909090909091,5,11
CD006887,1,10,New models for implementing and evaluating CVD risk scores in adequately powered studies are needed to define the role of applying CVD risk scores in primary CVD prevention.,delete,[],6,1.0,5,11
CD011148,0,0,We included only one small trial (60 participants randomised) which overall was judged to be at low risk of bias.,rephrase,['Only one small trial met our inclusion criteria.'],0,0.14285714285714285,1,7
CD011148,0,1,The study examined two doses of menaquinone (vitamin K2) over 3 months in healthy participants aged 40 to 65 years.,split,"['It included 60 participants aged 40 to 65 years.', 'This study looked at the effects of vitamin K2 supplements on CVD risk factors (blood pressure and lipid levels) over three months in healthy participants.']",1,0.2857142857142857,2,7
CD011148,0,2,"The primary focus of the trial was to examine the effects of menaquinone (subtype MK7) on different matrix Gla proteins (MGP - vitamin K dependent proteins in the vessel wall) at different doses, but the authors also reported blood pressure and lipid levels.",delete,[],3,0.42857142857142855,3,7
CD011148,0,3,"The trial did not report on our primary outcomes (cardiovascular disease clinical events) as it was small, short term and conducted in healthy participants.",rephrase,['The trial did not look at fatal and non-fatal cardiovascular endpoints as it was small and short term.'],3,0.5714285714285714,3,7
CD011148,1,4,"In terms of cardiovascular disease risk factors, no effects were seen for vitamin K2 on blood pressure or lipid levels, although the trial was small and findings are limited.",rephrase,"['No differences in these risk factors were seen between the comparison groups, but this was a small study and the findings are limited.']",4,0.7142857142857143,4,7
CD011148,1,5,The trial did not report any of our other secondary outcomes.,delete,[],5,0.8571428571428571,5,7
CD011148,2,6,"The very limited results of this review highlight the lack of evidence currently available to determine the effectiveness of vitamin K supplementation for the primary prevention of cardiovascular disease, and demonstrate the need for further high quality trials in this area.",rephrase,['The evidence is currently extremely limited and further high-quality trials are needed so that the effectiveness of vitamin K supplementation for CVD prevention can be determined.'],5,1.0,5,7
CD000052,0,0,This review includes a total of 1897 children and 729 adults in 39 trials.,rephrase,['We found 39 clinical trials involving 1897 children and 729 adults.'],0,0.07692307692307693,1,13
CD000052,0,1,"Thirty-three trials were conducted in the emergency room and equivalent community settings, and six trials were on inpatients with acute asthma (207 children and 28 adults).",rephrase,"[""Thirty-three of the trials were conducted in an emergency room (or emergency department) and community settings (such as a GP's surgery), and six trials were on inpatients (people in hospital) with acute asthma (207 children and 28 adults).""]",1,0.15384615384615385,1,13
CD000052,0,2,The method of delivery of beta₂-agonist did not show a significant difference in hospital admission rates.,rephrase,"['Taking beta-agonists through either a spacer or a nebuliser in the emergency department did not make a difference to the number of adults being admitted to hospital, whilst in children we can be fairly confident that nebulisers are not better than spacers at preventing admissions.']",2,0.23076923076923078,2,13
CD000052,0,3,"In adults, the risk ratio (RR) of admission for spacer versus nebuliser was 0.94 (95% CI 0.61 to 1.43).",delete,[],3,0.3076923076923077,2,13
CD000052,0,4,"The risk ratio for children was 0.71 (95% CI 0.47 to 1.08, moderate quality evidence).",delete,[],3,0.38461538461538464,2,13
CD000052,0,5,"In children, length of stay in the emergency department was significantly shorter when the spacer was used.",rephrase,"['In children, the length of stay in the emergency department was significantly shorter when the spacer was used instead of a nebuliser.']",3,0.46153846153846156,3,13
CD000052,0,6,"The mean duration in the emergency department for children given nebulised treatment was 103 minutes, and for children given treatment via spacers 33 minutes less (95% CI -43 to -24 minutes, moderate quality evidence).",split,"['The average stay in the emergency department for children given nebulised treatment was 103 minutes.', 'Children given treatment via spacers spent an average of 33 minutes less.']",4,0.5384615384615384,3,13
CD000052,0,7,Length of stay in the emergency department for adults was similar for the two delivery methods.,split,"['In adults, the length of stay in the emergency department was similar for the two delivery methods.', 'However the adult studies were conducted slightly differently which may have made it more difficult to show a difference in the length of stay in the emergency department.']",6,0.6153846153846154,4,13
CD000052,0,8,Peak flow and forced expiratory volume were also similar for the two delivery methods.,delete,[],8,0.6923076923076923,4,13
CD000052,0,9,"Pulse rate was lower for spacer in children, mean difference -5% baseline (95% CI -8% to -2%, moderate quality evidence), as was the risk of developing tremor (RR 0.64; 95% CI 0.44 to 0.95, moderate quality evidence).",rephrase,"['Pulse rate was lower in children taking beta-agonists through a spacer (mean difference -5% baseline), and there was a lower risk of developing tremor.']",8,0.7692307692307693,4,13
CD000052,1,10,"Nebuliser delivery produced outcomes that were not significantly better than metered-dose inhalers delivered by spacer in adults or children, in trials where treatments were repeated and titrated to the response of the participant.",merge,"['Metered-dose inhalers with a spacer can perform at least as well as wet nebulisation in delivering beta₂-agonists in children with acute asthma, but we are less certain about the results in adults.']",9,0.8461538461538461,5,13
CD000052,1,11,Spacers may have some advantages compared to nebulisers for children with acute asthma.,none,[],9,0.9230769230769231,5,13
CD000052,1,12,"The studies excluded people with life-threatening asthma; therefore, the results of this meta-analysis should not be extrapolated to this patient population.",delete,[],10,1.0,5,13
CD002063,0,0,Twelve trials were found to be eligible for inclusion in this review.,rephrase,['We found 12 trials.'],0,0.058823529411764705,1,17
CD002063,0,1,Seven trials with a variable risk of bias compared IVIg with PE in 623 severely affected participants.,rephrase,['- Seven trials compared IVIg with PE (in 623 participants with severe GBS).'],1,0.11764705882352941,1,17
CD002063,0,2,"In five trials with 536 participants for whom the outcome was available, the mean difference (MD) of change in a seven-grade disability scale after four weeks was not significantly different between the two treatments: MD of 0.02 of a grade more improvement in the intravenous immunoglobulin than the plasma exchange group; 95% confidence interval (CI) 0.25 to -0.20.",rephrase,['IVIg and PE produced a similar amount of improvement in disability in the 536 trial participants.'],2,0.17647058823529413,1,17
CD002063,0,3,There were also no statistically significant differences in the other measures considered.,delete,[],3,0.23529411764705882,2,17
CD002063,0,4,Three studies including a total of 75 children suggested that IVIg significantly hastens recovery compared with supportive care.,rephrase,['- Three compared IVIg with supportive care (in a total of 75 children).'],3,0.29411764705882354,2,17
CD002063,0,5,"The primary outcome for this review, available for only one trial with 21 mildly affected children, showed significantly more improvement in disability grade after four weeks with IVIg than supportive treatment alone, MD 1.42, 95% CI 2.57 to 0.27.",delete,[],4,0.35294117647058826,2,17
CD002063,1,6,"In one trial involving 249 participants comparing PE followed by IVIg with PE alone, the mean grade improvement was 0.2 (95% CI -0.14 to 0.54) more in the combined treatment group than in the PE alone group; not clinically significantly different, but not excluding the possibility of significant extra benefit.",rephrase,"['In one trial involving 249 participants who received PE or PE followed by IVIg, there was slightly more improvement from PE and IVIg together.']",4,0.4117647058823529,3,17
CD002063,1,7,Another trial with 34 participants comparing immunoabsorption followed by IVIg with immunoabsorption alone did not reveal significant extra benefit from the combined treatment.,rephrase,['- One compared IVIg plus immunoabsorption with immunoabsorption (in 34 participants).'],5,0.47058823529411764,3,17
CD002063,2,8,"Adverse events were not significantly more frequent with either treatment, but IVIg is significantly much more likely to be completed than PE.",rephrase,"['Harmful effects were no more frequent with PE or IVIg, but people were more likely to finish a course of IVIg.']",6,0.5294117647058824,3,17
CD002063,3,9,One trial in altogether 51 children showed no significant difference when the standard dose was given over two days rather than five days.,rephrase,"['In one small trial in children, the effect on disability appeared similar with a standard dose over two days rather than five days.']",7,0.5882352941176471,3,17
CD002063,4,10,A previous Cochrane review has shown that PE hastens recovery compared with supportive treatment alone.,delete,[],8,0.6470588235294118,4,17
CD002063,4,11,"There are no adequate comparisons of IVIg with placebo in adults, but this review provides moderate quality evidence that, in severe disease, IVIg started within two weeks from onset hastens recovery as much as PE.",delete,[],8,0.7058823529411765,4,17
CD002063,4,12,Adverse events were not significantly more frequent with either treatment but IVIg is significantly much more likely to be completed than PE.,delete,[],8,0.7647058823529411,4,17
CD002063,4,13,"Also, according to moderate quality evidence, giving IVIg after PE did not confer significant extra benefit.",rephrase,['This evidence was of moderate quality.'],8,0.8235294117647058,5,17
CD002063,4,14,"In children, according to low quality evidence, IVIg probably hastens recovery compared with supportive care alone.",split,"['Three studies in children suggested that IVIg speeds up recovery compared with supportive care.', 'They provided low quality evidence.']",9,0.8823529411764706,5,17
CD002063,4,15,More research is needed in mild disease and in patients whose treatment starts more than two weeks after onset.,merge,"['More research is needed to find the best dose of IVIg in adults and children, and one trial of giving a second dose to people who otherwise would be expected to do badly is in progress.']",11,0.9411764705882353,5,17
CD002063,4,16,Dose-ranging studies are also needed and one is in progress.,none,[],11,1.0,5,17
CD004156,0,0,We identified only one randomized controlled trial that met our inclusion criteria and no further trials were identified in subsequent updates.,rephrase,"['This review found only one randomized trial of treatment for spasticity in motor neuron disease, which involved 25 participants, and no further trials have been found in subsequent updates.']",0,0.14285714285714285,1,7
CD004156,0,1,"The included study was a trial of moderate intensity, endurance type exercise versus 'usual activities' in 25 patients with amyotrophic lateral sclerosis.",delete,[],1,0.2857142857142857,2,7
CD004156,0,2,The risk of bias was high and no adverse events were reported.,delete,[],1,0.42857142857142855,3,7
CD004156,0,3,"At three months patients performing the 15 minute twice daily exercises had significantly less spasticity overall (mean reduction of -0.43, 95% confidence interval (CI) -1.03 to +0.17 in the treatment group versus an increase of +0.25, 95% CI -0.46 to +0.96 in control) but the mean change between groups was not significant (-0.68, 95% CI -1.62 to +0.26), as measured by the Ashworth scale (possible scores 0 to 5, where higher is worse).",rephrase,"['At three months participants performing the 15 minute twice daily exercises had significantly less spasticity overall than control participants (mean reduction of -0.43, 95% confidence interval (CI) -1.03 to +0.17 in the treatment group versus an increase of +0.25, 95% CI -0.46 to +0.96 in control) but the mean change between groups was not significant, as measured by the Ashworth scale (a scale of spasticity, with a range of 0 to 5, where higher is worse).']",1,0.5714285714285714,3,7
CD004156,1,4,The single trial performed was too small to determine whether individualized moderate intensity endurance type exercises for the trunk and limbs are beneficial or harmful.,ignore,['The trial was too small to determine whether individualized moderate intensity endurance type exercises for the trunk and limbs are beneficial or harmful.'],2,0.7142857142857143,4,7
CD004156,1,5,"No other medical, surgical or alternative treatment and therapy has been evaluated in a randomized fashion in this patient population.",rephrase,['No other randomized trials of different treatments or therapies were found.'],3,0.8571428571428571,5,7
CD004156,1,6,More research is needed.,rephrase,['Further research is needed to determine if exercise or other therapies such as anti-spasticity medication are beneficial or harmful.'],4,1.0,5,7
CD002275,0,0,We identified four RCTs with 148 participants in total.,delete,[],0,0.1,1,10
CD002275,0,1,"In the first one, of 14 participants with moderate or severe myasthenia gravis, improvement after one month was not significantly greater for participants treated with plasma exchange and prednisone than for those treated with prednisone alone.",rephrase,"['In the first one, of 14 participants with moderate or severe myasthenia gravis, the myasthenic muscular score after one month was not significantly different for participants treated with plasma exchange and prednisone than for those treated with prednisone alone but there can be only low statistical confidence in the results of this study because of its small size.']",0,0.2,1,10
CD002275,0,2,A randomised controlled cross-over trial of 12 participants with moderate to severe myasthenia gravis found no statistically significant difference in the efficacy of plasma exchange or intravenous immunoglobulins after four weeks.,split,"['Four randomised controlled trials were identified.', 'A randomised controlled cross-over trial of only 12 participants reported the same efficacy, after four weeks, of plasma exchange or intravenous immunoglobulins for the treatment of moderate to severe myasthenia gravis, but because of bias and a very weak statistical power the data prevent any conclusion.']",1,0.3,2,10
CD002275,0,3,A trial including 87 participants with myasthenia gravis exacerbation found no statistically significant difference between plasma exchange and immunoglobulin after two weeks.,rephrase,"['The third, including 87 participants, showed the same efficacy, after two weeks, of plasma exchange or intravenous immunoglobulins for the treatment of myasthenia gravis exacerbation.']",3,0.4,2,10
CD002275,0,4,"The fourth RCT, with 35 participants, showed a statistically significant difference in favour of plasma exchange before thymectomy.",rephrase,['The fourth randomised controlled trial involving 35 participants reported a benefit from plasma exchange before thymectomy but this trial was heavily biased.'],4,0.5,3,10
CD002275,0,5,"However these trials, except the third, are at high risk of bias and have a weak statistical power.",delete,[],5,0.6,3,10
CD002275,1,6,No adequate RCTs have been performed to determine whether plasma exchange improves the short- or long-term outcome for chronic myasthenia gravis or myasthenia gravis exacerbation.,delete,[],5,0.7,4,10
CD002275,1,7,"However, many studies with case series report short-term benefit from plasma exchange in myasthenia gravis, especially in myasthenic crisis.",delete,[],5,0.8,4,10
CD002275,1,8,In severe exacerbations of myasthenia gravis one RCT did not show a significant difference between plasma exchange and intravenous immunoglobulin.,delete,[],5,0.9,5,10
CD002275,1,9,Further research is need to compare plasma exchange with alternative short-term treatments for myasthenic crisis or before thymectomy and to determine the value of long-term plasma exchange for treating myasthenia gravis.,rephrase,['Further research is needed to determine the value of long-term plasma exchange for treating myasthenia gravis and to compare plasma exchange with alternative short-term treatments for myasthenic crisis or before thymectomy in both types of autoimmune myasthenia.'],5,1.0,5,10
CD010527,0,0,We found no randomised trials for inclusion in this review.,rephrase,"[""We did not find any completed randomised controlled trials that assessed melatonin given to the mother during pregnancy to help protect the baby's brain.""]",0,0.14285714285714285,1,7
CD010527,0,1,One study is ongoing.,delete,[],1,0.2857142857142857,2,7
CD010527,1,2,"As we did not identify any randomised trials for inclusion in this review, we are unable to comment on implications for practice at this stage.",delete,[],1,0.42857142857142855,3,7
CD010527,2,3,"Although evidence from animals studies has supported a fetal neuroprotective role for melatonin when administered to the mother during pregnancy, no trials assessing melatonin for fetal neuroprotection in pregnant women have been completed to date.",delete,[],1,0.5714285714285714,3,7
CD010527,2,4,"However, there is currently one ongoing randomised controlled trial (with an estimated enrolment target of 60 pregnant women) which examines the dose of melatonin, administered to women at risk of imminent very preterm birth (less than 28 weeks' gestation) required to reduce brain damage in the white matter of the babies that were born very preterm.",split,"['One ongoing trial (planning to include 60 women) was identified.', 'This trial is designed to determine what dose of melatonin can reduce brain injury for babies when given to their mothers before very preterm birth (before 28 weeks of pregnancy).']",1,0.7142857142857143,4,7
CD010527,3,5,"Further high-quality research is needed and research efforts should directed towards trials comparing melatonin with either no intervention (no treatment or placebo), or with alternative agents aimed at providing fetal neuroprotection (such as magnesium sulphate for the very preterm infant).",rephrase,"[""Further studies are needed to establish whether melatonin given to the mother in pregnancy can protect the baby's brain against brain injury.""]",3,0.8571428571428571,5,7
CD010527,3,6,"Such trials should evaluate maternal and infant short- and longer-term outcomes (including neurosensory disabilities such as cerebral palsy), and consider the costs of care.",rephrase,"['The babies in these trials need to be followed up over a long period so that we can monitor the effects of melatonin on childhood development, including impairments or disabilities such as cerebral palsy.']",4,1.0,5,7
CD009810,0,0,We included one trial with a total of 23 participants.,rephrase,['We found one randomised controlled trial with a total of 23 participants for inclusion in this review.'],0,0.125,1,8
CD009810,0,1,This study was at high risk of bias.,delete,[],1,0.25,2,8
CD009810,0,2,"None of our primary outcomes and only one of our secondary outcomes (reduction in volume of disease, assessed endoscopically) was measured in the study.",rephrase,['It did measure the reduction in the volume of disease (assessed with an endoscope).'],1,0.375,2,8
CD009810,0,3,There was no significant difference between the groups (very low-quality evidence).,rephrase,['The overall quality of the evidence is very low: there was no blinding of treatment and a high rate of drop-out.'],2,0.5,3,8
CD009810,0,4,Adverse effects reported included airway swelling requiring intubation in a child with severe RRP a few hours after photodynamic therapy.,rephrase,"['Adverse effects reported included airway swelling in a child with severe disease a few hours after photodynamic therapy, which required insertion of a breathing tube and a prolonged stay in hospital.']",3,0.625,4,8
CD009810,1,5,There is insufficient evidence from high-quality randomised controlled trials to determine whether photodynamic therapy alters the course of disease or provides an added benefit to surgery in patients with recurrent respiratory papillomatosis.,rephrase,['We found insufficient evidence from the included study that photodynamic therapy has a benefit on its own or in combination with surgery in recurrent respiratory papillomatosis.'],4,0.75,4,8
CD009810,1,6,Multicentre randomised controlled trials with appropriate sample sizes and long-term follow-up are required to evaluate whether photodynamic therapy is of benefit.,delete,[],5,0.875,5,8
CD009810,1,7,Outcomes such as improvement in symptoms (respiratory function and voice quality) and quality of life should be measured in future trials.,rephrase,"['The study did not measure any of the outcomes important to patients (symptom improvement - respiratory distress/dyspnoea and voice quality, quality of life improvement and recurrence-free interval).']",5,1.0,5,8
CD009785,0,0,"Only one randomised trial met our inclusion criteria, despite our initial search yielding 141 citations.",rephrase,"['Authors found 141 citations in the search but only one trial, randomising 17 people, could be included in the review.']",0,0.07142857142857142,1,14
CD009785,0,1,"This was a small study, with 17 people completing a trial comparing CBT to an attention placebo (supportive psychotherapy) for people with delusional disorder.",rephrase,['The study compared the effectiveness of CBT with supportive psychotherapy for people with delusional disorder.'],1,0.14285714285714285,1,14
CD009785,0,2,Most participants were already taking medication and this was continued during the trial.,ignore,['Participants were already taking medication and this was continued during the trial.'],2,0.21428571428571427,2,14
CD009785,0,3,"We were not able to include any randomised trials on medications of any type due to poor data reporting, which left us with no usable data for these trials.",rephrase,['The review was not able to include any studies or trials involving medications of any type used to treat delusional disorder.'],3,0.2857142857142857,2,14
CD009785,0,4,"For the included study, usable data were limited, risk of bias varied and the numbers involved were small, making interpretation of data difficult.",rephrase,"['For the study that was included, there was limited information presented that we could use.']",4,0.35714285714285715,2,14
CD009785,0,5,"In particular there were no data on outcomes such as global state and behaviour, nor any information on possible adverse effects.",delete,[],5,0.42857142857142855,3,14
CD009785,1,6,"A positive effect for CBT was found for social self esteem using the Social Self-Esteem Inventory (1 RCT, n = 17, MD 30.5, CI 7.51 to 53.49, very low quality evidence), however this is only a measure of self worth in social situations and may thus not be well correlated to social function.",rephrase,"[""A positive effect for CBT was found for people's social self esteem, although again, this finding is limited by the low quantity and quality of the data and does not relate to people's social or everyday functioning.""]",5,0.5,3,14
CD009785,1,7,"More people left the study early if they were in the supportive psychotherapy group with 6/12 leaving early compared to 1/6 from the CBT group, but the difference was not significant (1 RCT, n = 17, RR 0.17, CI 0.02 to 1.18, moderate quality evidence).",rephrase,"['More people left the study early from the supportive psychotherapy group, but number of participants was small and the overall difference between the groups was not enough to conclude one treatment was better than the other.']",6,0.5714285714285714,3,14
CD009785,1,8,"For mental state outcomes the results were skewed making interpretation difficult, especially given the small sample.",delete,[],7,0.6428571428571429,4,14
CD009785,2,9,"Despite international recognition of this disorder in psychiatric classification systems such as ICD-10 and DSM-5, there is a paucity of high quality randomised trials on delusional disorder.",delete,[],7,0.7142857142857143,4,14
CD009785,2,10,There is currently insufficient evidence to make evidence-based recommendations for treatments of any type for people with delusional disorder.,rephrase,['Currently there is an overall lack of high quality evidence-based information about the treatment of delusional disorders and insufficient evidence to make recommendations for treatments of any type.'],7,0.7857142857142857,4,14
CD009785,2,11,The limited evidence that we found is not generalisable to the population of people with delusional disorder.,delete,[],8,0.8571428571428571,5,14
CD009785,2,12,"Until further evidence is found, it seems reasonable to offer treatments which have efficacy in other psychotic disorders.",rephrase,"['Until such evidence is found, the treatment of delusional disorders will most likely include those that are considered effective for other psychotic disorders and mental health problems.']",8,0.9285714285714286,5,14
CD009785,2,13,"Further research is needed in this area and could be enhanced in two ways: firstly, by conducting randomised trials specifically for people with delusional disorder and, secondly, by high quality reporting of results for people with delusional disorder who are often recruited into larger studies for people with a variety of psychoses.",split,"['Further large-scale and high quality research is needed in this area.', 'Research could be improved by conducting trials specifically for people with delusional disorder.']",9,1.0,5,14
CD008600,0,0,Eleven trials with a total of 2246 AF patients (ranging from 14 to 712 by study) were included within the review.,rephrase,['We searched scientific databases in February 2016 and found 11 randomised clinical trials including 2246 adults with atrial fibrillation who were taking oral anticoagulant medication.'],0,0.125,1,8
CD008600,0,1,"Studies included education, decision aids, and self-monitoring plus education interventions.",rephrase,"['The trials we found compared education, decision aids, and self-monitoring plus education to usual care, over any length of time.']",1,0.25,2,8
CD008600,0,2,"The effect of self-monitoring plus education on TTR was uncertain compared with usual care (MD 6.31, 95% CI -5.63 to 18.25, I2 = 0%, 2 trials, 69 participants, very low-quality evidence).",rephrase,['There was uncertainty about the effect of self-monitoring plus education on the percentage of time the INR was within the therapeutic range because the proportion or time in the therapeutic range was similar between individuals who received self-monitoring plus education and those who did not.'],2,0.375,2,8
CD008600,0,3,"We found small but positive effects of education on anxiety (MD -0.62, 95% CI -1.21 to -0.04, I2 = 0%, 2 trials, 587 participants, low-quality evidence) and depression (MD -0.74, 95% CI -1.34 to -0.14, I2 = 0%, 2 trials, 587 participants, low-quality evidence) compared with usual care.",split,"['There were small and positive effects on anxiety and depression in individuals who received education compared to those who received usual care.', 'There were small and negative effects on decision conflict in individuals who received decision aids compared to those who received usual care.']",3,0.5,3,8
CD008600,0,4,"The effect of decision aids on decision conflict favoured usual care (MD -0.1, 95% CI -0.17 to -0.02, I2 = 0%, 2 trials, 721 participants, low-quality evidence).",delete,[],5,0.625,4,8
CD008600,1,5,This review demonstrates that there is insufficient evidence to draw definitive conclusions regarding the impact of educational or behavioural interventions on TTR in AF patients receiving OAT.,delete,[],5,0.75,4,8
CD008600,1,6,"Thus, more trials are needed to examine the impact of interventions on anticoagulation control in AF patients and the mechanisms by which they are successful.",delete,[],5,0.875,5,8
CD008600,1,7,It is also important to explore the psychological implications for patients suffering from this long-term chronic condition.,delete,[],5,1.0,5,8
CD002070,0,0,"Treatment with naftidrofuryl tended to show reduction of pain evaluated by both analogue score and analgesic consumption, but the effect was statistically non-significant (mean difference (MD): 0.42; 95% confidence interval (CI)1.19 to 0.35).",rephrase,"['Treatment with naftidrofuryl tended to reduce pain, measured using a scale or with analgesic consumption, and improve rest pain and skin necrosis but the effects were not clear (statistically significant).']",0,0.14285714285714285,1,7
CD002070,0,1,"Similarly, improvement in rest pain or skin necrosis occurred, but these effects were also non-significant.",rephrase,['There was no clear indication that short-term intravenous naftidrofuryl significantly improves either symptoms of ischaemic rest pain or skin necrosis.'],1,0.2857142857142857,2,7
CD002070,0,2,The effect on mean ankle systolic pressure was inconclusive.,delete,[],2,0.42857142857142855,3,7
CD002070,1,3,"Based on the results of these trials, it cannot be confirmed that intravenous naftidrofuryl is effective in the treatment of people with critical limb ischaemia.",delete,[],2,0.5714285714285714,3,7
CD002070,1,4,"However, these results were based on trials of generally low methodological quality which had only a small number of participants, the duration of treatment was extremely short, and the methods varied between the trials.",split,"['The trials were generally of low methodological quality, included small numbers of predominantly elderly participants with varying levels of severity of critical limb ischaemia and used different measures of effect.', 'The duration of treatment was short, from three to 42 days, most often seven days.']",2,0.7142857142857143,4,7
CD002070,1,5,The wide range of endpoints effectively precluded any meaningful pooling of the results.,delete,[],4,0.8571428571428571,5,7
CD002070,1,6,Intravenous naftidrofuryl was withdrawn as a treatment for severe peripheral arterial disease in 1995 because of reported side effects.,ignore,['Intravenous naftidrofuryl was withdrawn as a treatment for severe peripheral arterial disease in 1995 because of reported side effects.'],4,1.0,5,7
